FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Andersen, SL
AF Andersen, SL
TI Changes in the second messenger cyclic AMP during development may
   underlie motoric symptoms in attention deficit/hyperactivity disorder
   (ADHD)
SO BEHAVIOURAL BRAIN RESEARCH
LA English
DT Article; Proceedings Paper
CT Symposium on Dopamine Hypothesis of ADHD
CY FEB 14-25, 2000
CL UNIV CASTILLA LA MANCHA, CASTILLA LA MANCHA, SPAIN
HO UNIV CASTILLA LA MANCHA
DE ADHD; adolescence; cAMP; D1; D2; dopamine; pruning
ID OPEN-FIELD BEHAVIOR; SEX-DIFFERENCES; DOPAMINE-RECEPTORS; ESTROUS-CYCLE;
   RATS; CORTEX; OVERPRODUCTION; PERIADOLESCENT; AMPHETAMINE; STRIATUM
AB The transitions that occur in the ascending dopamine systems between childhood and adulthood parallel the emergence, course, and severity of attention-deficit hyperactivity disorder (ADHD) symptoms. Behaviorally, rats are more active in open field during periadolescence, and activity levels decline by 50% in males by adulthood. This peak in behavior parallels a transient overproduction in D1 and D2 dopamine receptors that occurs at puberty in rat striatum (STR) and prefrontal cortex (PFC), followed by a decline in receptor density into adulthood. While tempting to speculate that receptor density plays a role in the waning of ADHD symptoms, receptor overproduction does not occur in the nucleus accumbens (NA), which demonstrates only a modest rise in receptor density (10-20%). Given the importance of the accumbens in locomotor activity, an alternative explanation for increased activity was sought. The second messenger system cyclic adenosine monophosphate (CAMP) has classically been associated with dopamine receptors. The results of these studies demonstrate that CAMP accumulation in the accumbens and the STR parallel the observed rise and fall in activity levels in rats. At puberty, basal CAMP levels are 35% higher relative to adulthood in male accumbens, while a modest 7% change was observed in STR. Forskolin-stimulated CAMP was 240 300% higher in STR and accumbens at puberty before declining with maturation. These findings suggest that, the adolescent dopamine system has a much higher 'tone' relative to adults, However, pharmacological responsiveness of CAMP to D1 or D2 stimulation demonstrates an overall blunted response during puberty relative to adulthood. This finding is consistent with a hyposensitivity to stress and pharmacological agents at puberty in animals that are in a hyperdopaminergic state. These findings of combined elevated CAMP accumulation and reduced CAMP sensitivity during adolescence have clinical implications for hypothesized mechanism and course of ADHD and its treatment. The maturational decline in CAMP activity may explain why this disorder recedes, while, simultaneously CAMP becomes more responsive to D1 and D2 receptor stimulation in adulthood. (C) 2002 Elsevier Science B.V. All rights reserved.
C1 Harvard Univ, Sch Med, Dept Psychiat, Belmont, MA 02478 USA.
   McLean Hosp, Lab Dev Psychopharmacol, Belmont, MA 02478 USA.
RP Andersen, SL (corresponding author), Harvard Univ, Sch Med, Dept Psychiat, Belmont, MA 02478 USA.
EM andersen@mclean.org
CR Andersen SL, 2000, NEUROSCI BIOBEHAV R, V24, P137, DOI 10.1016/S0149-7634(99)00044-5
   Andersen SL, 1997, NEUROREPORT, V8, P1495, DOI 10.1097/00001756-199704140-00034
   Andersen SL, 2000, SYNAPSE, V37, P167, DOI 10.1002/1098-2396(200008)37:2<167::AID-SYN11>3.0.CO;2-B
   ANDERSON SA, 1995, NEUROSCIENCE, V67, P7, DOI 10.1016/0306-4522(95)00051-J
   BECKER JB, 1982, EUR J PHARMACOL, V80, P65, DOI 10.1016/0014-2999(82)90178-9
   Biederman J, 1999, PEDIATRICS, V104, part. no., DOI 10.1542/peds.104.2.e20
   BIRD HR, 1988, ARCH GEN PSYCHIAT, V45, P1120
   Bolanos CA, 1998, DEV BRAIN RES, V111, P25, DOI 10.1016/S0165-3806(98)00116-3
   Chen ZJ, 1998, BIOCHEM BIOPH RES CO, V252, P639, DOI 10.1006/bbrc.1998.9716
   GELBARD HA, 1989, DEV BRAIN RES, V49, P123, DOI 10.1016/0165-3806(89)90065-5
   GOLDMANRAKIC PS, 1982, DEV BRAIN RES, V4, P339, DOI 10.1016/0165-3806(82)90146-8
   GORDON JH, 1983, BRAIN RES BULL, V10, P425, DOI 10.1016/0361-9230(83)90137-5
   HUTTENLOCHER PR, 1979, BRAIN RES, V163, P195
   KAZANDJIAN A, 1987, NEUROPHARMACOLOGY, V26, P1037, DOI 10.1016/0028-3908(87)90246-2
   LAVIOLA G, 1995, J PHARMACOL EXP THER, V275, P345
   Leckman James F., 1995, P1665
   LEVESQUE D, 1988, NEUROSCI LETT, V88, P113, DOI 10.1016/0304-3940(88)90324-2
   LIDOW MS, 1991, P NATL ACAD SCI USA, V88, P10218, DOI 10.1073/pnas.88.22.10218
   MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1
   SEEMAN P, 1987, SYNAPSE, V1, P399, DOI 10.1002/syn.890010503
   Seeman P, 1998, MOL PSYCHIATR, V3, P386, DOI 10.1038/sj.mp.4000421
   SPEAR LP, 1983, DEV PSYCHOBIOL, V16, P83, DOI 10.1002/dev.420160203
   STEVENS R, 1981, PHYSIOL BEHAV, V26, P551, DOI 10.1016/0031-9384(81)90188-8
   STEWART J, 1975, PHYSIOL BEHAV, V14, P291, DOI 10.1016/0031-9384(75)90036-0
   Stoof JC, 1981, NATURE, V294, P366, DOI 10.1038/294366a0
   TEICHER MH, 1995, DEV BRAIN RES, V89, P167, DOI 10.1016/0165-3806(95)00109-Q
   WILLIAMS DI, 1972, BRIT J PSYCHOL, V63, P593, DOI 10.1111/j.2044-8295.1972.tb01312.x
NR 27
TC 64
Z9 68
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-4328
EI 1872-7549
J9 BEHAV BRAIN RES
JI Behav. Brain Res.
PD MAR 10
PY 2002
VL 130
IS 1-2
SI SI
BP 197
EP 201
AR PII S0166-4328(01)00417-X
DI 10.1016/S0166-4328(01)00417-X
PG 5
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA 536VF
UT WOS:000174722000023
PM 11864735
DA 2021-08-04
ER

PT J
AU Benabou, R
AF Benabou, R
TI Tax and education policy in a heterogeneous-agent economy: What levels
   of redistribution maximize growth and efficiency?
SO ECONOMETRICA
LA English
DT Article
DE heterogeneous agents; income distribution; inequality; growth; education
   finance; redistribution
ID INCOME-DISTRIBUTION; TAXATION; CHOICE; TRANSFERS; MOBILITY; RETURNS;
   MODELS
AB This paper studies the effects of progressive income taxes and education finance in a dynamic heterogeneous-agent economy. Such redistributive policies entail distortions to labor supply and savings, but also serve as partial substitutes for missing credit and insurance markets. The resulting tradeoffs for growth and efficiency are explored, both theoretically and quantitatively, in a model that yields complete analytical solutions. Progressive education finance always leads to higher income growth than taxes and transfers, but at the cost of lower insurance. Overall efficiency is assessed using a new measure that properly reflects aggregate resources and idiosyncratic risks but, unlike a standard social welfare function, does not reward equality per se, Simulations using empirical parameter estimates show that the efficiency costs and benefits of redistribution are generally of the same order of magnitude, resulting in plausible values for the optimal rates. Aggregate income and aggregate welfare provide only crude lower and upper bounds around the true efficiency tradeoff.
C1 Princeton Univ, Woodrow Wilson Sch, Princeton, NJ 08544 USA.
   Princeton Univ, Dept Econ, Princeton, NJ 08544 USA.
   NBER, Cambridge, MA 02138 USA.
RP Benabou, R (corresponding author), Princeton Univ, Woodrow Wilson Sch, Princeton, NJ 08544 USA.
EM rbenabou@princeton.edu
CR Aghion P, 1997, REV ECON STUD, V64, P151, DOI 10.2307/2971707
   AIYAGARI SR, 1995, J POLIT ECON, V103, P1158, DOI 10.1086/601445
   ATKESON A, 1995, J ECON THEORY, V66, P64, DOI 10.1006/jeth.1995.1032
   BANERJEE AV, 1993, J POLIT ECON, V101, P274, DOI 10.1086/261876
   BARRO RJ, 1995, AM ECON REV, V85, P103
   Benabou R, 1996, AM ECON REV, V86, P584
   Benabou R, 2000, AM ECON REV, V90, P96, DOI 10.1257/aer.90.1.96
   Benabou R, 1996, NBER MACROECON ANNU, P11, DOI DOI 10.1086/654291
   BERGSTROM TC, 1982, ECONOMETRICA, V50, P1183, DOI 10.2307/1911869
   BISHOP JA, 1991, REV ECON STAT, V73, P134, DOI 10.2307/2109695
   BROWNING M, 1999, HDB MACROECONOMICS, pCH8
   CARD D, 1992, J POLIT ECON, V100, P1, DOI 10.1086/261805
   Cooper S.J., 1998, J ECON GROWTH, V3, P171
   Daveri F, 2000, ECON POLICY, P47
   DURLAUF S, 1996, J ECON GROWTH, V1, P75, DOI DOI 10.1007/BF00163343)
   EASTERLY W, 1993, EUR ECON REV, V37, P409, DOI 10.1016/0014-2921(93)90029-A
   ENGLUND P, 1982, J PUBLIC ECON, V19, P271, DOI 10.1016/0047-2727(82)90057-3
   EPSTEIN LG, 1989, ECONOMETRICA, V57, P937, DOI 10.2307/1913778
   FELDSTEIN MS, 1969, J POLIT ECON, V77, P755, DOI 10.1086/259560
   Fernandez R, 1998, AM ECON REV, V88, P813
   FERNANDEZ R, 1996, Q J ECON, V101, P35
   Floden M, 2001, J MONETARY ECON, V48, P81, DOI 10.1016/S0304-3932(01)00064-2
   GALOR O, 1993, REV ECON STUD, V60, P35, DOI 10.2307/2297811
   GLOMM G, 1992, J POLIT ECON, V100, P818, DOI 10.1086/261841
   GOTTSCHALK P, 2000, 495 BOST COLL
   GOUVEIA M, 1994, NATL TAX J       JUN, P337
   HANSEN GD, 1992, J POLIT ECON, V100, P118, DOI 10.1086/261809
   Heaton J, 1996, J POLIT ECON, V104, P443, DOI 10.1086/262030
   HECKMAN JJ, 1976, J POLIT ECON, V84, pS11, DOI 10.1086/260531
   Hendricks L, 1999, J MONETARY ECON, V43, P411, DOI 10.1016/S0304-3932(98)00058-0
   Hoxby CM, 1998, AM ECON REV, V88, P309
   JAKOBSSON U, 1976, J PUBLIC ECON, V5, P161, DOI 10.1016/0047-2727(76)90066-9
   JONES LE, 1993, J POLIT ECON, V101, P485, DOI 10.1086/261884
   KAKWANI NC, 1977, ECONOMETRICA, V45, P719, DOI 10.2307/1911684
   KILLINGSWORTH MR, 1986, HDB LABOR EC, V1, pCH2
   KREPS DM, 1979, ECONOMETRICA, V47, P91, DOI 10.2307/1912348
   Krusell P, 1998, J POLIT ECON, V106, P867, DOI 10.1086/250034
   LAITNER J, 1992, J ECON THEORY, V58, P135, DOI 10.1016/0022-0531(92)90051-I
   LOURY GC, 1981, ECONOMETRICA, V49, P843, DOI 10.2307/1912506
   Mulligan C., 1997, PARENTAL PRIORITIES, P186
   Pencavel John, 1986, HDB LABOR EC, V1, P3, DOI DOI 10.1016/S1573-4463(86)01004-0
   PERSSON M, 1983, J PUBLIC ECON, V22, P73, DOI 10.1016/0047-2727(83)90057-9
   Piketty T, 1997, REV ECON STUD, V64, P173, DOI 10.2307/2971708
   SHESHADRI A, 2000, EQUITY EFFICIENCY EF
   SOLON G, 1992, AM ECON REV, V82, P393
   STOKEY NL, 1995, J POLIT ECON, V103, P519, DOI 10.1086/261993
   Tamura R, 2001, J POLIT ECON, V109, P1021, DOI 10.1086/322830
   VARIAN HR, 1980, J PUBLIC ECON, V14, P49, DOI 10.1016/0047-2727(80)90004-3
   WEIL P, 1990, Q J ECON, V105, P29, DOI 10.2307/2937817
NR 49
TC 178
Z9 182
U1 5
U2 50
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0012-9682
EI 1468-0262
J9 ECONOMETRICA
JI Econometrica
PD MAR
PY 2002
VL 70
IS 2
BP 481
EP 517
DI 10.1111/1468-0262.00293
PG 37
WC Economics; Mathematics, Interdisciplinary Applications; Social Sciences,
   Mathematical Methods; Statistics & Probability
SC Business & Economics; Mathematics; Mathematical Methods In Social
   Sciences
GA 527QB
UT WOS:000174196600002
OA Green Submitted
DA 2021-08-04
ER

PT J
AU Blower, P
   Fligner, M
   Verducci, J
   Bjoraker, J
AF Blower, P
   Fligner, M
   Verducci, J
   Bjoraker, J
TI On combining recursive partitioning and simulated annealing to detect
   groups of biologically active compounds
SO JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES
LA English
DT Article
ID DESCRIPTORS; SETS
AB Statistical data mining methods have proven to be powerful tools for investigating correlations between molecular structure and biological activity. Recursive partitioning (RP), in particular, offers several advantages in mining large, diverse data sets resulting from high throughput screening. When used with binary molecular descriptors, the standard implementation of RP splits on single descriptors. We use simulated annealing (SA) to find combinations of molecular descriptors whose simultaneous presence best separates off the most active, chemically similar group of compounds. The search is incorporated into a recursive partitioning design to produce a regression tree for biological activity on the space of structural fingerprints. Each node is characterized by a specific combination of structural features, and the terminal nodes with high average activities correspond, roughly, to different classes of compounds. Using LeadScope structural features as descriptors to mine a database from the National Cancer Institute, the merging of RP and SA consistently identifies structurally homogeneous classes of highly potent anticancer agents.
C1 Leadscope Inc, Columbus, OH 43212 USA.
   Ohio State Univ, Dept Stat, Columbus, OH 43210 USA.
RP Blower, P (corresponding author), Leadscope Inc, 1245 Kinnear Rd, Columbus, OH 43212 USA.
CR BOYD MR, 1995, DRUG DEVELOP RES, V34, P91, DOI 10.1002/ddr.430340203
   Breiman L., 1984, CLASSIFICATION REGRE, P1
   Chen X, 1998, J CHEM INF COMP SCI, V38, P1054, DOI 10.1021/ci980089g
   Chen X, 1999, J CHEM INF COMP SCI, V39, P887, DOI 10.1021/ci990327n
   Cho SJ, 2000, J CHEM INF COMP SCI, V40, P668, DOI 10.1021/ci9908190
   Dorigo M., 1997, IEEE Transactions on Evolutionary Computation, V1, P53, DOI 10.1109/4235.585892
   FOYE WE, 1993, CANC CHEMOTHERAPEUTI
   GOBBI A, 1997, 1 INT EL C SYNTH ORG
   Hawkins D. M., 1982, TOPICS APPL MULTIVAR, P269
   Hawkins DM, 1997, QUANT STRUCT-ACT REL, V16, P296, DOI 10.1002/qsar.19970160404
   HOLLAND J, 1975, ADAPTATION NATURAL A
   Izrailev S, 2001, J CHEM INF COMP SCI, V41, P176, DOI 10.1021/ci000036s
   Jones-Hertzog DK, 1999, J PHARMACOL TOXICOL, V42, P207, DOI 10.1016/S1056-8719(00)00073-3
   Kearsley SK, 1996, J CHEM INF COMP SCI, V36, P118, DOI 10.1021/ci950274j
   KIRKPATRICK S, 1983, SCIENCE, V220, P67
   LU MC, 1993, CANC CHEMOTHERAPEUTI, P345
   Miller DW, 2001, J CHEM INF COMP SCI, V41, P168, DOI [10.1021/ci0003348, 10.1021/ci0000348]
   Roberts G, 2000, J CHEM INF COMP SCI, V40, P1302, DOI 10.1021/ci0000631
   Rusinko A, 1999, J CHEM INF COMP SCI, V39, P1017, DOI 10.1021/ci9903049
   Zheng WF, 1999, J CHEM INF COMP SCI, V39, P738, DOI 10.1021/ci980103p
NR 20
TC 51
Z9 52
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0095-2338
J9 J CHEM INF COMP SCI
JI J. Chem. Inf. Comput. Sci.
PD MAR-APR
PY 2002
VL 42
IS 2
BP 393
EP 404
AR PII 10.1021/ci0101049
DI 10.1021/ci0101049
PG 12
WC Chemistry, Multidisciplinary; Computer Science, Information Systems;
   Computer Science, Interdisciplinary Applications
SC Chemistry; Computer Science
GA 537AF
UT WOS:000174733500030
PM 11911709
DA 2021-08-04
ER

PT J
AU Alcaro, S
   Ortuso, F
   Coleman, RS
AF Alcaro, S
   Ortuso, F
   Coleman, RS
TI DNA cross-linking by azinomycin B: Monte Carlo simulations in the
   evaluation of sequence selectivity
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID ANTITUMOR AGENTS; STEREOCONTROLLED SYNTHESIS; RING-SYSTEM; ANTIBIOTICS;
   CARZINOPHILIN; BINDING; CORE
AB A new set of charges specifically developed for biologically relevant N7-alkylated purine adducts have been implemented in the AMBER* force field of the MacroModel package and applied to the conformational search of azinomycin B-DNA interactions. To perform a sequence dependent reactivity relationship study, four DNA triplets known to interact differently with the drug, 5'-GCT-3', 5'-GCC-3', 5'-GTC-3', and 5'-GTT-3', have been modeled in B-form and intercalative conformations. Monte Carlo simulations of all possible monoadducts and intercalative complexes have been carried out and analyzed using a filtering criterion that estimates the probability of covalent bond formation and covalent cross-linking. We observed a good correlation between existing experimental data and our computational estimations that validate the approach. The comparison of the conformational properties of the drug-DNA monoadducts and complexes confirms the most probable mechanism of action involving an initial aziridine and subsequent epoxide alkylation. The different hydrogen bond network in the monoadducts and in the intercalative complexes between the drug and the three base-pair receptor is the primary reason for the different cross-linking reactivity. In addition, steric hindrance of the major groove exposed methyl group of central thymine-based triplets plays an important role in the lack of the reactivity of these sequences. Synthetic work on the azinomycins and the information coming from this computational study will be important for the design of more potent or DNA sequence-selective agents based on the azinomycin skeleton.
C1 Univ Catanzaro Magna Graecia, Dipartimento Sci Farmacobiol, I-88021 Catanzaro, Italy.
   Ohio State Univ, Dept Chem, Columbus, OH 43210 USA.
RP Alcaro, S (corresponding author), Univ Catanzaro Magna Graecia, Dipartimento Sci Farmacobiol, Roccelletta Borgia, I-88021 Catanzaro, Italy.
OI ORTUSO, Francesco/0000-0001-6235-8161; ALCARO,
   Stefano/0000-0002-0437-358X
FU NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [CA
   65875] Funding Source: Medline; NATIONAL CANCER INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [R01CA065875] Funding Source:
   NIH RePORTER
CR Alcaro S, 1998, J ORG CHEM, V63, P4620, DOI 10.1021/jo972274j
   Alcaro S, 2000, J MED CHEM, V43, P2783, DOI 10.1021/jm990362l
   ARMSTRONG RW, 1992, J AM CHEM SOC, V114, P3144, DOI 10.1021/ja00034a074
   Coleman RS, 1998, J AM CHEM SOC, V120, P3538, DOI 10.1021/ja9801386
   Coleman RS, 1998, SYNLETT, P1031
   Coleman RS, 2001, ANGEW CHEM INT EDIT, V40, P1736, DOI 10.1002/1521-3773(20010504)40:9<1736::AID-ANIE17360>3.3.CO;2-R
   Coleman RS, 1998, J ORG CHEM, V63, P5738, DOI 10.1021/jo981006y
   COLEMAN RS, 1992, J ORG CHEM, V57, P5813, DOI 10.1021/jo00048a006
   Coleman RS, 1999, J AM CHEM SOC, V121, P9088, DOI 10.1021/ja992274w
   Fujiwara T, 1999, TETRAHEDRON LETT, V40, P315, DOI 10.1016/S0040-4039(98)02339-9
   ISHIZEKI S, 1987, J ANTIBIOT, V40, P60, DOI 10.7164/antibiotics.40.60
   JENKINS TC, 1994, J MED CHEM, V37, P4529, DOI 10.1021/jm00052a012
   MCDONALD DQ, 1992, TETRAHEDRON LETT, V33, P7743, DOI 10.1016/0040-4039(93)88034-G
   MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405
   NAGAOKA K, 1986, J ANTIBIOT, V39, P1527, DOI 10.7164/antibiotics.39.1527
   Rajski SR, 1998, CHEM REV, V98, P2723, DOI 10.1021/cr9800199
   Sugiyama H, 1996, J AM CHEM SOC, V118, P7063, DOI 10.1021/ja9609821
   Todd AK, 1999, J MED CHEM, V42, P536, DOI 10.1021/jm980479u
   *WAV INC, SPART SIL GRAPH VERS
   YOKOI K, 1986, CHEM PHARM BULL, V34, P4554
   Zang H, 2000, BIOCHEMISTRY-US, V39, P14968, DOI 10.1021/bi001998d
NR 21
TC 36
Z9 36
U1 0
U2 13
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD FEB 14
PY 2002
VL 45
IS 4
BP 861
EP 870
DI 10.1021/jm011040w
PG 10
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 523YN
UT WOS:000173985300011
PM 11831897
DA 2021-08-04
ER

PT J
AU Truskinovsky, L
   Zanzotto, G
AF Truskinovsky, L
   Zanzotto, G
TI Elastic crystals with a triple point
SO JOURNAL OF THE MECHANICS AND PHYSICS OF SOLIDS
LA English
DT Article
DE phase transformations; triple point; crystalline material; zirconia
   (ZrO2); energy methods; phase diagrams
ID PARTIALLY-STABILIZED ZIRCONIA; STRUCTURAL PHASE-TRANSITIONS;
   SHAPE-MEMORY MATERIALS; ORTHORHOMBIC ZIRCONIA; MARTENSITIC
   TRANSFORMATIONS; UNDOPED ZIRCONIA; HIGH-PRESSURE; MICROSTRUCTURE;
   DIAGRAM
AB The peculiar behavior of active crystals is due to the presence of evolving phase mixtures the variety of which depends on the number of coexisting phases and the multiplicity of symmetry-related variants. According to Gibbs' phase rule, the number of phases in a single-component crystal is maximal at a triple point in the p-T phase diagram. In the vicinity of this special point the number of metastable twinned microstructures will also be the highest-a desired effect for improving performance of smart materials. To illustrate the complexity of the energy landscape in the neighborhood of a triple point, and to produce a workable example for numerical simulations, in this paper we construct a generic Landau strain-energy function for a crystal with the coexisting tetragonal (t), orthorhombic (o), and monoelinic (m) phases. As a guideline, we utilize the experimental observations and crystallographic data on the t-o-m transformations of zirconia (ZrO2), a major toughening agent for ceramics. After studying the kinematics of the t-o-m phase transformations, we re-evaluate the available experimental data on zirconia polymorphs, and propose a new mechanism for the technologically important t-m transition. In particular, our proposal entails the softening of a different tetragonal modulus from the one previously considered in the literature. We derive the simplest expression for the energy function for a t-o-m crystal with a triple point as the lowest-order polynomial in the relevant strain components, exhibiting the complete set of wells associated with the t-o-m phases and their symmetry-related variants. By adding the potential of a hydrostatic loading, we study the p-T phase diagram and the energy landscape of our crystal in the vicinity of the t-o-m triple point. We show that the simplest assumptions concerning the order-parameter coupling and the temperature dependence of the Landau coefficients produce a phase diagram that is in good qualitative agreement with he experimental diagram of ZrO2. (C) 2002 Elsevier Science Ltd. All rights reserved.
C1 Univ Minnesota, Dept Aerosp Engn & Mech, Minneapolis, MN 55455 USA.
   Univ Padua, Dipartimento Metodi & Modelli Matemat Sci Appl, I-35131 Padua, Italy.
RP Truskinovsky, L (corresponding author), Univ Minnesota, Dept Aerosp Engn & Mech, 110 Union St SE, Minneapolis, MN 55455 USA.
CR BALL JM, 1992, PHILOS T R SOC A, V338, P389, DOI 10.1098/rsta.1992.0013
   BALL JM, 1987, ARCH RATION MECH AN, V100, P13, DOI 10.1007/BF00281246
   BALL JM, 2001, UNPUB MATH MICROSTRU
   BHATTACHARYA K, 1994, P ROY SOC EDINB A, V124, P843, DOI 10.1017/S0308210500022381
   Bhattacharya K, 1999, ARCH RATION MECH AN, V149, P123, DOI 10.1007/s002050050170
   BLOCK S, 1985, J AM CERAM SOC, V68, P497, DOI 10.1111/j.1151-2916.1985.tb15817.x
   Born M., 1954, DYNAMICAL THEORY CRY
   Born M., 1915, DYNAMIK KRYSTALLGITT
   BOYSEN H, 1991, ACTA CRYSTALLOGR B, V47, P881, DOI 10.1107/S010876819100856X
   BUDIANSKY B, 1993, J MECH PHYS SOLIDS, V41, P1445, DOI 10.1016/0022-5096(93)90034-D
   BUDIANSKY B, 1983, INT J SOLIDS STRUCT, V19, P337, DOI 10.1016/0020-7683(83)90031-8
   CHAN SK, 1988, PHYSICA B & C, V150, P212, DOI 10.1016/0378-4363(88)90124-6
   CHIPOT M, 1988, ARCH RATION MECH AN, V103, P237
   Christian J.W., 1975, THEORY TRANSFORMATIO
   Dewhurst JK, 1998, PHYS REV B, V57, P741, DOI 10.1103/PhysRevB.57.741
   DUNN JE, 1980, ARCH RATION MECH AN, V74, P1
   Ericksen J. L., 1970, International Journal of Solids and Structures, V6, P951, DOI 10.1016/0020-7683(70)90006-5
   ERICKSEN JL, 1989, ARCH RATION MECH AN, V107, P23
   Ericksen JL, 1999, J ELASTICITY, V55, P201, DOI 10.1023/A:1007621720603
   ERICKSEN JL, 1980, ARCH RATION MECH AN, V73, P99, DOI 10.1007/BF00258233
   ERICKSEN JL, 1993, LECT NOTES PHYSICS, V344
   Fabris S, 2000, PHYS REV B, V61, P6617, DOI 10.1103/PhysRevB.61.6617
   FREY F, 1990, ACTA CRYSTALLOGR B, V46, P724, DOI 10.1107/S0108768190007509
   Green D.J., 1989, TRANSFORMATION TOUGH
   HOWARD CJ, 1990, J AM CERAM SOC, V73, P2828, DOI 10.1111/j.1151-2916.1990.tb06682.x
   Hugo G. R., 1990, MATER SCI FORUM, V56-58, P357
   ISHIBASHI Y, 1989, J PHYS SOC JPN, V58, P4211, DOI 10.1143/JPSJ.58.4211
   James RD, 2000, ACTA MATER, V48, P197, DOI 10.1016/S1359-6454(99)00295-5
   Khachaturyan A., 1983, THEORY STRUCTURAL TR
   KISI EH, 1989, J AM CERAM SOC, V72, P1757, DOI 10.1111/j.1151-2916.1989.tb06322.x
   Kisi EH., 1998, ZIRCONIA ENG CERAMIC
   KUDOH Y, 1989, PREMONITORY TWINNING
   Landau L., 1986, THEORY ELASTICITY, V3
   LANDAU LD, 1937, COLLECTED PAPERS L D
   LEGER JM, 1993, PHYS REV B, V47, P14075, DOI 10.1103/PhysRevB.47.14075
   Love AEH., 1927, TREATISE MATH THEORY
   Luskin M., 1996, Acta Numerica, V5, P191, DOI 10.1017/S0962492900002658
   MULLER S, 1998, LECT NOTES M PLANCK, V2
   OHTAKA O, 1991, J AM CERAM SOC, V74, P505, DOI 10.1111/j.1151-2916.1991.tb04051.x
   Ondik H.M., 1998, PHASE DIAGRAMS ZIRCO
   PITTERI M, 1984, J ELASTICITY, V14, P175, DOI 10.1007/BF00041664
   PITTERI M, 2001, IN PRESS CONTINUUM M
   ROYTBURD AL, 1978, SOLID STATE PHYS, V33, P317
   SALJE EKH, 1986, PHASE T, V6, P248
   SIMHA N, 1996, CONT RES MECH MATH M
   Simha NK, 1997, J MECH PHYS SOLIDS, V45, P261, DOI 10.1016/S0022-5096(96)00074-9
   Smith G F, 1958, T AM MATH SOC, V88, P175
   STAKGOLD I, 1950, Q APPL MATH, V8, P169, DOI 10.1090/qam/36650
   SUBBARAO EC, 1974, PHYS STATUS SOLIDI A, V21, P9, DOI 10.1002/pssa.2210210102
   Syromyatnikov V.N., 1990, PHASE TRANSITIONS CR
   Toledano P., 1996, RECONSTRUCTIVE PHASE
   WECHSLER MS, 1953, T AM I MIN MET ENG, V197, P1503
   WEYMAN CM, 1964, INTRO THEORY MARTENS
   Wu XC, 1998, J INTEL MAT SYST STR, V9, P335, DOI 10.1177/1045389X9800900503
   Zanzotto G, 1996, ACTA CRYSTALLOGR A, V52, P839, DOI 10.1107/S0108767396006654
   ZANZOTTO G, 1996, WEAK SYMMETRY BREAKI
NR 56
TC 12
Z9 12
U1 0
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-5096
J9 J MECH PHYS SOLIDS
JI J. Mech. Phys. Solids
PD FEB
PY 2002
VL 50
IS 2
BP 189
EP 215
AR PII S0022-5096(01)00058-8
DI 10.1016/S0022-5096(01)00058-8
PG 27
WC Materials Science, Multidisciplinary; Mechanics; Physics, Condensed
   Matter
SC Materials Science; Mechanics; Physics
GA 536RF
UT WOS:000174715100002
DA 2021-08-04
ER

PT J
AU Gomez, C
   Saldivar-Gonzalez, JA
   Rodriguez, R
AF Gomez, C
   Saldivar-Gonzalez, JA
   Rodriguez, R
TI Animal models for studying anxiety: a critical approach.
SO SALUD MENTAL
LA Spanish
DT Article
DE anxiety; defense reactions; animal models
ID ELEVATED PLUS-MAZE; ANXIOLYTIC AGENTS; PANIC DISORDER; BEHAVIOR; BRAIN;
   FLUMAZENIL; EXPERIENCE; RECEPTOR; DRUGS; MICE
AB Recent evidence suggests that function and brain structure arc evolutionary related in several species. This historical relationship between different mammal species allows the study of higher human mental functions in animals under normal and pathological conditions. This idea constitutes theoretical support For the application of the experimental method in Psychiatry. The modeling of psychiatric illness in animals represents today an important chapter of medical and biological research conceptually supported by the above-described ideas. The introduction into the clinic of the chlorpromazine, an aliphatic phenotiazine, at the beginning of the 50's, resulted in a turning point in the development of experimental psychiatry. This fact was essential for the introduction of the experimental approach. Artificial or natural development of psychosis in humans could be observed under different medical conditions such as neurosyphilis, endocrinopathies; hypo and/or hyperthyroidism, head trauma, alcoholism and heavy metal intoxication and At the end of the 40's Hoffman synthesized a compound able tu strong disorganize a human or animal behavior, the lysergic diethialamide acid "LSD" even at very low doses. Nevertheless, the possibility of pharmacological correction of psychotic symptoms represented the real core for a radical change in the understanding of the neurological basis of higher mental function disturbances. This paradigmatic change could nut occur in the absence of a pharmacological treatment of psychotic symptoms. Based on this line of thinking, researchers started to model mental illnesses (other than psychosis disturbances'), using laboratory animals. The simulation of psychiatric illnesses was mainly oriented toward their pharmacological correction. This approach ignored the aethiopathological factors, focusing the efforts in the reduction of clinical symptoms. In addition, the lack of a conceptual body on the neurobiological basis of mental illness and the lack of adequate instruments fur its research delayed the development of the scientific basis fur clinical psychiatry. Nowadays, the chapter of anxiety disorders besides clinical classification includes animal research in most psychiatric areas. Preclinical approaches for the study of anxiety include more than 30 different animal models. These paradigms study behaviors that in a particular way are modified by anxiolytic or anxiogenic compounds; among them are the conditioning animal models based on punishment or conflict procedures. These experimental designs are founded on the assumption that laboratory animals modify their pattern of response when conditioned aversive and unconditioned stimuli are temporarily associated, eliciting operant or classical responses, Most of these designs inhibit animal response when aversive and unconditioned stimuli are paired. The classical dogma of such an approach assumes that well-known anxiolytic compounds (barbiturate, benzodiazepines), frequently used as gold standard compounds, decrease behavioral inhibition in trained individuals. Generally the aversive stimuli used is a low electrical shock, Thus, an animal trained to perform a particular response modifies it after treatment with a known (gold standard) or unknown (the testing molecule) compound. An interesting point of these models is their similarity with generalized anxiety i.e., the real aversive stimulus is absent when the experiment is carried out, a fact that resembles one of the conditions of anxiety in the clinic. This feature makes these models different from those based on fear-elicited responses, paradigms that model sim
   Conditioning experimental models allow the control of basal behavioral levels, however the animals require training previously to the experimental session. In addition, detailed analyses are necessary discriminate non-specific effects of drugs on learning, memory, motor, perception food and water consumption. Several authors consider these features as diminishing the construct validity of the conditioning models, arguing the involvement of artificial elements, unrelated with emotional stress in animals in wild conditions and different of clinical anxiety. Other important tests used for the study of anxiety evaluate unconditioned responses. These models are supported on the species memory, i.e., analyze the innate behaviors of naive animals. These groups of behaviors are observed each and every time the subjects encounter the same stressful situation, not necessarily associated with painful or electrical stimuli. Many researchers believe that these models offer higher level of neurological validity. However, a strong level of intraspecific variability compared with those based on conditioned responses his been found. Unconditioned models are less dependent on the memory or motivational processes. There is an important discrepancy between DSM IV anxiety inventory and the animal models used, This discrepancy is related to the lack of phylogenetic relationships between the illness and the models. This concept suggests that some human behaviors considered as disrupting responses represent the cultural expression of archaical pre-human behavior, such as hipervigilance, defensive avoidance and escape responses, adaptive in natural conditions, but disadaptive in some cases in human groups. The validity of the animal models for the study of anxiety depends on the consensus that normal and/or pathological anxiety has anatomic and neurochemical substrates that interact in the neural systems involved in the defensive species reactions. The participation of different brain areas regulating, unlike in nature forms of anxiety has been recently proposed. Before this notion, the unified theory of limbic system regulation of the emotional activity was generally accepted. In summary, based on the above-described ideas it seems that there is not one single animal model for the study of anxiety. Different tests reflect at least one specific feature of the anxiety disorder and it must be carefully chosen.
C1 Univ Nacl Autonoma Mexico, Dept Farmacol, Fac Med, Mexico City 04510, DF, Mexico.
RP Saldivar-Gonzalez, JA (corresponding author), Univ Nacl Autonoma Mexico, Dept Farmacol, Fac Med, Edif DP Piso, Mexico City 04510, DF, Mexico.
CR ADAMS DB, 1969, AM J PHYSIOL, V216, P1226
   ALMY TP, 1951, AM J MED, V10, P60, DOI 10.1016/0002-9343(51)90219-7
   *AS AM PSIQ, 1994, MAN DIAGN EST ENF ME
   Bard P, 1929, ARCH NEURO PSYCHIATR, V22, P230, DOI 10.1001/archneurpsyc.1929.02220020046002
   BELZUNG C, 1994, PHYSIOL BEHAV, V56, P623, DOI 10.1016/0031-9384(94)90311-5
   BERNARD C, 1957, LECONS EFFETS SUBSTA
   BLANCHARD DC, 1993, BEHAV BRAIN RES, V58, P113, DOI 10.1016/0166-4328(93)90096-9
   Blanchard RJ, 1997, NEUROSCI BIOBEHAV R, V21, P783, DOI 10.1016/S0149-7634(96)00062-0
   Cannon W.B., 1915, BODILY CHANGES PAIN
   Cannon WB, 1927, AM J PSYCHOL, V39, P106, DOI 10.2307/1415404
   Chiel HJ, 1997, TRENDS NEUROSCI, V20, P553, DOI 10.1016/S0166-2236(97)01149-1
   Coplan JD, 1998, BIOL PSYCHIAT, V44, P1264, DOI 10.1016/S0006-3223(98)00300-X
   CRAWLEY J, 1980, PHARMACOL BIOCHEM BE, V13, P167, DOI 10.1016/0091-3057(80)90067-2
   Crow TJ, 1997, SCHIZOPHR RES, V28, P127, DOI 10.1016/S0920-9964(97)00110-2
   Dalvi A, 1999, PHARMACOL BIOCHEM BE, V62, P727, DOI 10.1016/S0091-3057(98)00220-2
   DANIELSSEVERS A, 1973, PHARMACOLOGY, V9, P348, DOI 10.1159/000136408
   Darwin C., 1972, EXPRESSION EMOTIONS, V1st
   DAVIS M, 1993, BEHAV BRAIN RES, V58, P175, DOI 10.1016/0166-4328(93)90102-V
   DAWSON GR, 1995, TRENDS PHARMACOL SCI, V16, P33, DOI 10.1016/S0165-6147(00)88973-7
   DE MOLINA A. FERNANDEZ, 1959, JOUR PHYSIOL, V145, P251
   DELAY J, 1952, COMPTE RENDU C
   DETOURS JM, 1945, HASCHICH ALIENATION
   DEVRY J, 1995, PSYCHOPHARMACOLOGY, V121, P1
   File S E, 1992, Clin Neuropharmacol, V15 Suppl 1 Pt A, p525A
   FILE SE, 1985, NEUROPSYCHOBIOLOGY, V13, P55, DOI 10.1159/000118163
   FILE SE, 1990, NEUROSCI BIOBEHAV R, V14, P135, DOI 10.1016/S0149-7634(05)80214-3
   Fyer AJ, 1998, BIOL PSYCHIAT, V44, P1295, DOI 10.1016/S0006-3223(98)00274-1
   GELLER I, 1960, PSYCHOPHARMACOLOGIA, V1, P482, DOI 10.1007/BF00429273
   Gonzalez LE, 1997, J NEUROSCI, V17, P1505
   GRAY TS, 1991, STRESS NEUROBIOLOGY
   Griebel G, 1999, PSYCHOPHARMACOLOGY, V144, P121, DOI 10.1007/s002130050984
   Griebel G, 1996, PHYSIOL BEHAV, V60, P1255, DOI 10.1016/S0031-9384(96)00230-2
   GRIEBEL G, 1995, PHARMACOL THERAPEUT, V65, P319, DOI 10.1016/0163-7258(95)98597-J
   Hall CS, 1934, J COMP PSYCHOL, V18, P385, DOI 10.1037/h0071444
   HANDLEY SL, 1993, BEHAV BRAIN RES, V58, P203, DOI 10.1016/0166-4328(93)90104-X
   HARVEY W, 1994, INTRO HIST CRIT SOBR
   Hogg S, 1996, PHARMACOL BIOCHEM BE, V54, P21, DOI 10.1016/0091-3057(95)02126-4
   Holmes A, 1998, PHARMACOL BIOCHEM BE, V60, P473, DOI 10.1016/S0091-3057(98)00008-2
   Holmes A, 1999, NEUROSCI BIOBEHAV R, V23, P971, DOI 10.1016/S0149-7634(99)00030-5
   HUGHLINGSJACKSO.J, 1931, SELECTED WRITINGS J
   James W., 1884, MIND, V9, P188, DOI 10.1093/mind/os-IX.34.188
   JENCK F, 1995, PSYCHIAT RES, V57, P181, DOI 10.1016/0165-1781(95)02673-K
   KALIN NH, 1993, SCI AM, V5, P54
   KAPLIN HI, 1991, SYNOPSIS PSYCHIAT
   KIDMAN A, 1989, PROG NEUROBIOL, V32, P391, DOI 10.1016/0301-0082(89)90029-4
   LEDOUX JE, 1995, ANNU REV PSYCHOL, V46, P209, DOI 10.1146/annurev.ps.46.020195.001233
   LISTER RG, 1990, PHARMACOL THERAPEUT, V46, P321, DOI 10.1016/0163-7258(90)90021-S
   Lorenz K., 1965, EVOLUTION MODIFICATI
   Martin P, 1998, ACTA PSYCHIAT SCAND, V98, P74, DOI 10.1111/j.1600-0447.1998.tb05970.x
   MAYR E, 1993, LONG ARGUEMENT C DAR
   NUTT NJ, 1990, PHARMACOL THERAPEUT, V147, P233
   Parmigiani S, 1999, NEUROSCI BIOBEHAV R, V23, P957, DOI 10.1016/S0149-7634(99)00029-9
   Pavlov I. P., 1941, CONDITIONED REFLEXES
   PELLOW S, 1986, PHARMACOL BIOCHEM BE, V24, P525, DOI 10.1016/0091-3057(86)90552-6
   PINEL JP, 1978, J COMP PSYCHOL, V72, P708
   PRATT JA, 1992, PHARMACOL THERAPEUT, V55, P149, DOI 10.1016/0163-7258(92)90014-Q
   Ramos EA, 1997, COMP GEOM-THEOR APPL, V8, P57, DOI 10.1016/S0925-7721(96)00010-7
   Rodgers RJ, 1997, BEHAV PHARMACOL, V8, P477, DOI 10.1097/00008877-199711000-00003
   RODGERS RJ, 1995, PHARMACOL BIOCHEM BE, V52, P297, DOI 10.1016/0091-3057(95)00138-M
   Rodgers RJ, 1999, PHYSIOL BEHAV, V68, P47, DOI 10.1016/S0031-9384(99)00140-7
   Saldivar-Gonzalez A, 2000, PHARMACOL BIOCHEM BE, V66, P265, DOI 10.1016/S0091-3057(00)00177-5
   SaldivarGonzalez A, 1996, BEHAV PROCESS, V37, P75, DOI 10.1016/0376-6357(95)00080-1
   SaldivarGonzalez A, 1997, PHARMACOL BIOCHEM BE, V56, P211, DOI 10.1016/S0091-3057(96)00213-4
   Selye H, 1950, PHYSL PATHOLOGY EXPO
   SHEEHAN DV, 1990, J CLIN PSYCHOPHARM, V10, P3, DOI 10.1097/00004714-199002000-00002
   SKINNER BF, 1966, SCIENCE, V153, P1205, DOI 10.1126/science.153.3741.1205
   TALLMAN JF, 1980, SCIENCE, V207, P274, DOI 10.1126/science.6101294
   TREIT D, 1985, NEUROSCI BIOBEHAV R, V9, P203, DOI 10.1016/0149-7634(85)90046-6
   TREIT D, 1981, PHARMACOL BIOCHEM BE, V15, P619, DOI 10.1016/0091-3057(81)90219-7
   TREIT D, 1993, BEHAV BRAIN RES, V54, P23, DOI 10.1016/0166-4328(93)90045-R
   VOGEL JR, 1971, PSYCHOPHARMACOLOGIA, V21, P1, DOI 10.1007/BF00403989
   WALSH RN, 1976, PSYCHOL BULL, V83, P482, DOI 10.1037/0033-2909.83.3.482
   Willner P, 1991, BEHAV MODELS PSYCHOP, P3
NR 73
TC 6
Z9 9
U1 0
U2 25
PU INST MEX PSIQUIATRIA
PI MEXICO CITY
PA CALZ MEXICO-XOCHIMILCO #101, MEXICO CITY 22 DF, MEXICO
SN 0185-3325
J9 SALUD MENT
JI Salud Ment.
PD FEB
PY 2002
VL 25
IS 1
BP 14
EP 24
PG 11
WC Psychiatry
SC Psychiatry
GA 542XW
UT WOS:000175071800004
DA 2021-08-04
ER

PT J
AU Olson, DW
   Fujimoto, Y
   Madsen, KL
   Stewart, BG
   Carle, M
   Zeng, J
   Jewell, L
   Sheasgreen, JL
   Chong, FT
   Kneteman, NM
   Bigam, DL
   Churchill, TA
AF Olson, DW
   Fujimoto, Y
   Madsen, KL
   Stewart, BG
   Carle, M
   Zeng, J
   Jewell, L
   Sheasgreen, JL
   Chong, FT
   Kneteman, NM
   Bigam, DL
   Churchill, TA
TI Potentiating the benefit of vascular-supplied glutamine during small
   bowel storage - Importance of buffering agent
SO TRANSPLANTATION
LA English
DT Article
ID DIFFERENT PROTECTING SOLUTIONS; SMALL-INTESTINE; PRESERVATION SOLUTIONS;
   HYPOTHERMIC STORAGE; ORGAN PRESERVATION; EPITHELIAL-CELLS; TIGHT
   JUNCTIONS; COLD-STORAGE; UW SOLUTION; METABOLISM
AB Background. Glutamine (gln)-supplemented University of Wisconsin (UW) solution improves overall small bowel (SB) preservation. Sustained gln metabolism in a system devoid of hepatic detoxification will necessarily result in the accumulation of pH active end products leading to nonphysiologic pH shifts. We hypothesized that simultaneous addition of N,N-bis[2-hydroxyethyl]-2-aminoethane sulfonic, acid (BES), a known buffering agent, would potentiate the beneficial effect of gln supplementation by addressing the fundamental metabolic principle of pH homeostasis.
   Methods. Sprague-Dawley SB rats were administered a vascular flush with one of four solutions: UW; UW+90 mM BES (UWB); UW+2% gln (UWG); or UW+2% gln+90 mM BES (UVBG). Indices of energetics, barrier function, gln catabolism, and histology (light and electron microscopy) were assessed over a 10-hr cold storage time course.
   Results. Superior gln utilization in the UWBG group was indicated by elevated levels of key catabolites (glutamate, aspartate, glycine, ammonia). The addition of BES and gln resulted in significantly higher levels of all energetic parameters (ATP, total adenylates) at 10 hr compared with UW, UWB, and/or UWG. Barrier function was markedly improved after 10 hr storage in the UWBG group; mannitol permeability was 169 nmol/cm(2)/hr versus 572 and 445 nmol/cm(2)/hr (for UW and UWG, respectively). Histologic injury at 10 hr was 5.5,7.5, and 8 (Park's grade) for UWBG, UWG, and UW. Ultrastructural damage was markedly reduced with UWBG, as assessed by grade of mitochondria damage.
   Conclusion. This study strongly supports that the beneficial effects of gln-enriched UW solution can be amplified when combined with an effective buffering agent such as BES.
C1 Univ Alberta, Surg Med Res Inst, Edmonton, AB T6G 2N8, Canada.
   Univ Alberta, Dept Med, Div Gastroenterol, Edmonton, AB T6G 2N8, Canada.
   Univ Alberta Hosp, Dept Surg, Div Transplantat, Edmonton, AB T6G 2B7, Canada.
   Univ Alberta Hosp, Dept Pathol & Lab Med, Div Anat Pathol, Edmonton, AB T6G 2B7, Canada.
RP Churchill, TA (corresponding author), Univ Alberta, Surg Med Res Inst, 1074 Dent Pharm Bldg, Edmonton, AB T6G 2N8, Canada.
RI Madsen, Karen L/H-5898-2011
CR BEAULIEU JF, 1985, DIFFERENTIATION, V29, P50, DOI 10.1111/j.1432-0436.1985.tb00291.x
   BELZER FO, 1988, TRANSPLANTATION, V45, P673, DOI 10.1097/00007890-198804000-00001
   BRETSCHNEIDER HJ, 1975, J CARDIOVASC SURG, V16, P241
   BURGMANN H, 1992, EUR SURG RES, V24, P84, DOI 10.1159/000129192
   BUSZA AL, 1992, TRANSPLANTATION, V54, P562, DOI 10.1097/00007890-199209000-00037
   Churchill TA, 1998, TRANSPLANTATION, V65, P551, DOI 10.1097/00007890-199802270-00017
   CLARKSON TW, 1964, AM J PHYSIOL, V206, P658
   DOROVINIZIS K, 1984, BRAIN RES, V302, P383, DOI 10.1016/0006-8993(84)90254-3
   DUFFEY ME, 1981, NATURE, V294, P451, DOI 10.1038/294451a0
   FEDORAK RN, 1987, J CLIN INVEST, V79, P1571, DOI 10.1172/JCI112991
   GONZALEZMARISCAL L, 1984, J MEMBRANE BIOL, V79, P175, DOI 10.1007/BF01872121
   GOOD NE, 1966, BIOCHEMISTRY-US, V5, P467, DOI 10.1021/bi00866a011
   GRIEPP EB, 1983, J CELL BIOL, V96, P693, DOI 10.1083/jcb.96.3.693
   HIGASHI H, 1989, EUR SURG RES, V21, P76, DOI 10.1159/000129006
   Hochachka P.W, 1984, BIOCH ADAPTATION
   IMONDI AR, 1969, EXP CELL RES, V58, P323, DOI 10.1016/0014-4827(69)90512-6
   KOKUDO Y, 1994, TRANSPLANT P, V26, P1492
   Kuwabara Y, 2000, J SURG RES, V89, P38, DOI 10.1006/jsre.1999.5798
   LANIR A, 1988, HEPATOLOGY, V8, P471, DOI 10.1002/hep.1840080306
   LAREAU S, 1991, CAN J PHYSIOL PHARM, V69, P1726, DOI 10.1139/y91-256
   LEHNINGER AL, 1982, PRINCIPLES BIOCH, P79
   LEHNINGER AL, 1982, PRINCIPLES BIOCH, P627
   Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1
   Lew JI, 1996, TRANSPLANT P, V28, P2605
   NORDSTROM C, 1967, J HISTOCHEM CYTOCHEM, V15, P713, DOI 10.1177/15.12.713
   PARK PO, 1990, SURGERY, V107, P574
   PARKS DA, 1982, GASTROENTEROLOGY, V82, P9
   PASSONNEAU JV, 1993, ENZYMATIC ANAL PRACT, P111
   PINKUS LM, 1977, ARCH BIOCHEM BIOPHYS, V182, P506, DOI 10.1016/0003-9861(77)90531-8
   Pulis RP, 2000, AM J PHYSIOL-HEART C, V279, pH2151
   RECKENDORFER H, 1992, EUR SURG RES, V24, P339, DOI 10.1159/000129226
   REEVES RB, 1972, RESP PHYSIOL, V14, P219, DOI 10.1016/0034-5687(72)90030-8
   Sasaki K, 1996, TRANSPL P, V28, P2620
   Sasaki K, 1997, J SURG RES, V73, P90, DOI 10.1006/jsre.1997.5186
   SCHWEIZER E, 1992, TRANSPLANT P, V24, P1087
   SOUBA WW, 1985, JPEN-PARENTER ENTER, V9, P608, DOI 10.1177/0148607185009005608
   SOUBA WW, 1985, JPEN-PARENTER ENTER, V9, P18, DOI 10.1177/014860718500900118
   STERN BK, 1966, CAN J BIOCHEM, V44, P687
   TAGUCHI T, 1992, TRANSPLANTATION, V53, P1202, DOI 10.1097/00007890-199206000-00006
   Tsukamoto T, 1997, J BIOL CHEM, V272, P16133, DOI 10.1074/jbc.272.26.16133
   WINDMUELLER HG, 1980, J BIOL CHEM, V255, P107
   WINDMUELLER HG, 1974, J BIOL CHEM, V249, P5070
   WINDMUELLER HG, 1982, ADV ENZYMOL, V53, P202
   Wu GY, 1998, J NUTR, V128, P1249
   ZHANG W, 1993, TRANSPLANTATION, V56, P512, DOI 10.1097/00007890-199309000-00005
   ZHANG W, 1995, J SURG RES, V58, P159, DOI 10.1006/jsre.1995.1025
NR 46
TC 7
Z9 7
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD JAN 27
PY 2002
VL 73
IS 2
BP 178
EP 185
DI 10.1097/00007890-200201270-00005
PG 8
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 519TD
UT WOS:000173740800005
PM 11821727
DA 2021-08-04
ER

PT B
AU Fierro, R
   Edwan, E
AF Fierro, R
   Edwan, E
GP IEEE
   IEEE
TI The OSU multi-vehicle coordination testbed
SO 2002 45TH MIDWEST SYMPOSIUM ON CIRCUITS AND SYSTEMS, VOL III, CONFERENCE
   PROCEEDINGS
LA English
DT Proceedings Paper
CT 45th Midwest Symposium on Circuits and Systems (MWSCAS 2002)
CY AUG 04-07, 2002
CL TULSA, OK
SP IEEE, Circuits & Syst Soc, Oklahoma State Univ, Sch Elect & Comp Engn
AB In this paper we present the OSU Multi-Vehicle Coordination Testbed, a group of nonholonomic robots for testing and implementing hybrid control approaches for formation control, multi-agent coordination, multi-robot learning, and real-time wireless networked control system design, The vehicles are equipped with a suite of sensors, a vision system and wireless Ethernet for communications. The testbed will allow us to carry out experimental research to verify theoretical results that have been validated using only simulation. In addition, we describe a framework for adaptive leader-following formation control. The novel aspect of this research is that, we explicitly consider the dynamics of the vehicles and develop a modular adaptive formation control scheme.
C1 Oklahoma State Univ, Sch Elect & Comp Engn, MARHES Lab, Stillwater, OK 74078 USA.
RP Fierro, R (corresponding author), Oklahoma State Univ, Sch Elect & Comp Engn, MARHES Lab, Stillwater, OK 74078 USA.
EM rfieffo@okstate.edu; ezzalde@okstate.edu
RI Edwan, Ezzaldeen/H-4435-2019
OI Edwan, Ezzaldeen/0000-0002-0585-8941
CR Alur R, 2001, LECT NOTES CONTR INF, V271, P303
   BURGARD W, 2000, P IEEE INT C ROB AUT, V1, P476, DOI DOI 10.1109/ROBOT.2000.844100
   DAS AK, 2002, IN PRESS MULTI ROBOT
   Desai JP, 1998, IEEE INT CONF ROBOT, P2864, DOI 10.1109/ROBOT.1998.680621
   FEDDEMA J, 2001, P SPIE, V4364
   Fenwick JW, 2002, 2002 IEEE INTERNATIONAL CONFERENCE ON ROBOTICS AND AUTOMATION, VOLS I-IV, PROCEEDINGS, P1810, DOI 10.1109/ROBOT.2002.1014804
   Fierro R, 2002, APPL OPTIM, V66, P73
   Fierro R, 2001, IEEE INT CONF ROBOT, P157, DOI 10.1109/ROBOT.2001.932546
   Fierro R, 1997, J ROBOTIC SYST, V14, P149
   Fukao T, 2000, IEEE T ROBOTIC AUTOM, V16, P609, DOI 10.1109/70.880812
   Isidori A, 1995, NONLINEAR CONTROL SYSTEMS DESIGN 1995, VOLS 1 AND 2, P87
   Jennings JS, 1997, 8TH INTERNATIONAL CONFERENCE ON ADVANCED ROBOTICS, 1997 PROCEEDINGS - ICAR'97, P193, DOI 10.1109/ICAR.1997.620182
   Spletzer J, 2001, IROS 2001: PROCEEDINGS OF THE 2001 IEEE/RJS INTERNATIONAL CONFERENCE ON INTELLIGENT ROBOTS AND SYSTEMS, VOLS 1-4, P631, DOI 10.1109/IROS.2001.976240
   van der Schaft A. J., 2000, LECT NOTES CONTROL I, V251
NR 14
TC 1
Z9 1
U1 0
U2 0
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
PY 2002
BP 41
EP 44
PG 4
WC Computer Science, Artificial Intelligence; Computer Science, Theory &
   Methods; Engineering, Electrical & Electronic; Imaging Science &
   Photographic Technology
SC Computer Science; Engineering; Imaging Science & Photographic Technology
GA BW27H
UT WOS:000181396200011
DA 2021-08-04
ER

PT B
AU Ikenoue, S
   Asada, M
   Hosoda, K
AF Ikenoue, S
   Asada, M
   Hosoda, K
GP IEEE
   IEEE
TI Cooperative behavior acquistion by asynchronous policy renewal that
   enables simultaneous learning in multiagent enviroment
SO 2002 IEEE/RSJ INTERNATIONAL CONFERENCE ON INTELLIGENT ROBOTS AND
   SYSTEMS, VOLS 1-3, PROCEEDINGS
LA English
DT Proceedings Paper
CT IEEE/RSJ International Conference on Intelligent Robots and Systems
   (IROS 2002)
CY SEP 30-OCT 04, 2002
CL LAUSANNE, SWITZERLAND
SP IEEE Robot & Automat Soc, IEEE Ind Electr Soc, Robot Soc Japan, Soc Instruments & Control Engineers, INRIA Rhone Alpes Grenoble, EPFL Lausanne
ID VISION; ACQUISITION
AB This paper presents a method for simultaneous learning in multiagent environment to emerge the cooperative behaviors. Each agent has one policy and one action value function: the former is for action execution based on the action value function updated in the previous stage, and the latter is for learning based on the episodes experienced by the current policy. This makes all agents behave based on the fixed policies, by which the non-Markovian problem can be avoided except for the update periods that depends on the learning progress of each agent. In order to avoid Me local maxima due to such asynchronous renewal of action value functions, optimistic action values are given as initial ones, that helps the exploration process not to be trapped in the local maxima. The experimental results applied to one of the cooperative task in dynamic, multiagent environment, RoboCup, is shown and a discussion is given.
C1 Osaka Univ, Dept Apapt Machine Syst, Osaka, Japan.
RP Ikenoue, S (corresponding author), Osaka Univ, Dept Apapt Machine Syst, Osaka, Japan.
EM ikenoue@er.ams.eng.osaka-u.ac.jp; asada@er.ams.eng.osaka-u.ac.jp;
   hosoda@er.ams.eng.osaka-u.ac.jp
CR ANDOU T, 1998, ROBOCUP 97 ROBOT SOC, V1
   ASADA M, 1995, IEEE INT CONF ROBOT, P146, DOI 10.1109/ROBOT.1995.525277
   Asada M, 1999, ARTIF INTELL, V110, P193, DOI 10.1016/S0004-3702(99)00024-7
   Asada M, 1999, ARTIF INTELL, V110, P275, DOI 10.1016/S0004-3702(99)00026-0
   LITTMAN ML, 1994, P 11 INT C MACH LEAR, P157
   Nagayuki Y, 2000, FOURTH INTERNATIONAL CONFERENCE ON MULTIAGENT SYSTEMS, PROCEEDINGS, P215, DOI 10.1109/ICMAS.2000.858456
   OHTA M, 1988, ROBOCUP 97 ROBOT SOC, V1
   STONE P, 2000, 11 EUR C MACH LEARN
   STONE P, 2001, 18 INT C MACH LEARN
   Sutton R, 1998, INTRO REINFORCEMENT, V1st
   TAN M, P 10 INT C MACH LEAR, P330
   WATKINS CJCH, 1992, MACH LEARN, V8, P279, DOI 10.1007/bf00992698
   YAMAZAWA K, 1995, IEEE INT CONF ROBOT, P1062, DOI 10.1109/ROBOT.1995.525422
NR 13
TC 11
Z9 11
U1 0
U2 0
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
BN 0-7803-7398-7
PY 2002
BP 2728
EP 2734
PG 7
WC Automation & Control Systems; Computer Science, Artificial Intelligence;
   Robotics
SC Automation & Control Systems; Computer Science; Robotics
GA BV53N
UT WOS:000179289100444
DA 2021-08-04
ER

PT S
AU Park, TS
   Byun, IS
   Kim, HJ
   Yeom, HY
AF Park, TS
   Byun, IS
   Kim, HJ
   Yeom, HY
GP IEEE COMPUTER SOCIETY
   IEEE COMPUTER SOCIETY
TI The performance of checkpointing and replication schemes for fault
   tolerant mobile agent systems
SO 21ST IEEE SYMPOSIUM ON RELIABLE DISTRIBUTED SYSTEMS, PROCEEDINGS
SE Symposium on Reliable Distributed Systems Proceedings
LA English
DT Proceedings Paper
CT 21st IEEE Symposium on Reliable Distributed Systems
CY OCT 13-16, 2002
CL OSAKA UNIV, OSAKA, JAPAN
SP IEEE Comp Soc, Tech Comm Distributed Processing, IEEE Comp Soc, Tech Comm Fault Tolerant Comp, IFIP WG 10 4, IEICE Dependable Comp Tech Grp, Osaka Univ, Grad Sch Informat Sci & Technol
HO OSAKA UNIV
AB This paper evaluates the performance of checkpointing and replication schemes for the fault tolerant mobile agent system. For the quantitative comparison, we have implemented an experimental system on top of the Mole mobile agent system and also built a simulation system to include various failure cases. Our experiment aims to have the insight into the behavior of agents under two schemes and provide a guideline for the fault tolerant system design. The experimental results show that the checkpointing scheme shows a very stable performance; and for the replication scheme, some controllable system parameter values should be chosen carefully to achieve the desirable performance.
C1 Sejong Univ, Dept Comp Engn, Seoul 143747, South Korea.
RP Park, TS (corresponding author), Sejong Univ, Dept Comp Engn, Seoul 143747, South Korea.
EM tspark@sejong.ac.kr; widepis@sejong.ac.kr; hjkim@arirang.snu.ac.kr;
   yeom@arirang.snu.ac.kr
CR BAUMANN J, 1998, WORLD WIDE WEB J, V1, P12
   Gendelman E., 2000, P 20 INT C DISTR COM
   JOHANSEN D, 1999, P 10 INT C DISTR COM
   PHAM V, 1998, IEEE COMMUNICATIONS, V26, P38
   Pleisch S, 2001, INTERNATIONAL CONFERENCE ON DEPENDABLE SYSTEMS AND NETWORKS, PROCEEDINGS, P215, DOI 10.1109/DSN.2001.941407
   Pleisch S, 2000, SYM REL DIST SYST, P11, DOI 10.1109/RELDI.2000.885388
   SCHLICHTING RD, 1983, ACM T COMPUT SYST, V1, P222, DOI 10.1145/357369.357371
   Silva L. G., 2000, P INT C DEP SYST NET
   Strasser M, 1998, INT J COOP INF SYST, V7, P355, DOI 10.1142/S0218843098000179
   STRASSER M, 2000, P 20 INT C DISTR COM
   Vogler H, 1997, 1997 INTERNATIONAL CONFERENCE ON PARALLEL AND DISTRIBUTED SYSTEMS, PROCEEDINGS, P268, DOI 10.1109/ICPADS.1997.652560
NR 11
TC 9
Z9 11
U1 0
U2 0
PU IEEE COMPUTER SOC
PI LOS ALAMITOS
PA 10662 LOS VAQUEROS CIRCLE, PO BOX 3014, LOS ALAMITOS, CA 90720-1264 USA
SN 1060-9857
BN 0-7695-1659-9
J9 SYM REL DIST SYST
PY 2002
BP 256
EP 261
PG 6
WC Computer Science, Information Systems; Computer Science, Theory &
   Methods
SC Computer Science
GA BV46E
UT WOS:000179049500027
DA 2021-08-04
ER

PT S
AU Kurahashi, S
   Terano, T
AF Kurahashi, S
   Terano, T
BE Namatame, A
   Terano, T
   Kurumatani, K
TI Emergence, maintenance, and collapse of norms on information communal
   sharing: Analysis via agent-based simulation
SO AGENT-BASED APPROACHES IN ECONOMIC AND SOCIAL COMPLEX SYSTEMS
SE Frontiers in Artificial Intelligence and Applications
LA English
DT Proceedings Paper
CT 1st International Workshop on Agent Based Approaches in Economic and
   Social Complex Systems (AESCS)
CY MAY 21-22, 2001
CL MATSUE CITY, JAPAN
SP Koichi Kurumatani, Electrotech Lab, Hiroshi Sato Natl Defense Acad, Kiyoshi Izumi, Electrotech Lab
AB Analysis of norms in an information society is an interesting topic for social psychology research. This paper describes an agent-based simulation study on the emergence, maintenance, and collapse of norms on information communal sharing. To carry out the study, we utilize our simulator TRURL, which (1) contains software agents with decision making and communication functions, and (2) has the functionality to evolve artificial societies with specific characteristics defined by a given objective function to be optimized by genetic algorithms. Unlike the literature in social psychology research, which mainly applies evolutionary game theory to homogeneous agents for the simulation, TRURL focuses on the decision making behaviors of heterogeneous agents. Our experimental results have suggested that, contrary to the results of social psychology study so far, for information oriented properties, free riders in the society will not collapse the norm of communal sharing of the properties.
C1 Univ Tsukuba, Grad Sch Business Sci, Bunyo Ku, Tokyo 1120012, Japan.
RP Kurahashi, S (corresponding author), Univ Tsukuba, Grad Sch Business Sci, Bunyo Ku, 3-29-1 Otsuka, Tokyo 1120012, Japan.
CR AOKI M, 1988, INFORMATION INCENTIV
   AOKI M, 1996, COMP I ANAL NEW APPR
   AXELROD R, 1997, EVOLUTION STRATEGIES
   CARLEY K, 1998, MULTIAGENT SYSTEMS M, P299
   CARLEY KM, 1992, ARTIFICIAL INTELLIGE
   COSMIDES L, 1955, COGNITION, V73, P1
   Epstein J.M., 1996, GROWING ARTIFICIAL S
   FOA UG, 1971, SCIENCE, V171, P345, DOI 10.1126/science.171.3969.345
   GRANOVETTER MS, 1973, AM J SOCIOL, V78, P1360, DOI 10.1086/225469
   ISSAC G, 1997, SCI AM, V236, P90
   KANDORI M, 1993, ECONOMETRICA, V61, P29, DOI 10.2307/2951777
   KURAHASHI S, 1999, T SOC INSTRUMENT CON, V36, P1454
   LEVITT RE, 1994, COMPUTATIONAL ORG TH
   MITCHELL M, 1996, INTRO GENETIC ALGORI
   MOSCOVICI S, 1969, SOCIOMETRY, V32, P365, DOI 10.2307/2786541
   REGAN DT, 1971, J EXP SOC PSYCHOL, V7, P627, DOI 10.1016/0022-1031(71)90025-4
   TAKEZAWA M, 1999, COGNITIVE STUDIES, V6, P191
   Terano T, 1998, FROM ANIM ANIMAT, P326
   YOUNG H, 1997, ECONOMETRICA, V61, P57
NR 19
TC 0
Z9 0
U1 0
U2 0
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 0922-6389
EI 1879-8314
BN 1-58603-225-9
J9 FRONT ARTIF INTEL AP
PY 2002
VL 72
BP 25
EP 34
PG 10
WC Computer Science, Artificial Intelligence
SC Computer Science
GA BU46J
UT WOS:000176062200003
DA 2021-08-04
ER

PT S
AU Okada, I
   Ohta, T
AF Okada, I
   Ohta, T
BE Namatame, A
   Terano, T
   Kurumatani, K
TI Psychological personality and organizational performance with MAS
   simulation
SO AGENT-BASED APPROACHES IN ECONOMIC AND SOCIAL COMPLEX SYSTEMS
SE FRONTIERS IN ARTIFICIAL INTELLIGENCE AND APPLICATIONS
LA English
DT Proceedings Paper
CT 1st International Workshop on Agent Based Approaches in Economic and
   Social Complex Systems (AESCS)
CY MAY 21-22, 2001
CL MATSUE CITY, JAPAN
SP Koichi Kurumatani, Electrotech Lab, Hiroshi Sato Natl Defense Acad, Kiyoshi Izumi, Electrotech Lab
AB We use computer simulations to study an interesting relationship that emerges between human personality and organizational behaviors, in particular, organizational performance. We develop a multiagent system model, because using the positivistic approach in this field is difficult. Personality, as used in this study, has three parameters: task stickiness, emotional interpersonal attraction, and conservatism. Organizational performance, which is usually used in management science, is formulated here as processing cost, search cost, and coordination cost. Using computer simulations, we observe that organizational performance mechanisms emerge from personalities. The simulation reveals two insight. First, in the system that emerges, reciprocal actions between personalities as local entities give rise to organizational behaviors as global entities, and the organizational behaviors influence the personalities. Second, this model provides many theoretical hypotheses. For example one hypothesis is that a clique emerges among agents from their interpersonal attraction, from a chain between specialization and structurization among agents, from their tasks' relationship, and from agents' task stickiness. The model we propose is not for forecasting any kinds of instances immediately, but rather for describing would-be instances, that is, it is a theory-development model.
C1 Univ Electrocommun, Soka Univ, Chofu, Tokyo 182, Japan.
RP Okada, I (corresponding author), Univ Electrocommun, Soka Univ, Chofu, Tokyo 182, Japan.
CR BROCKNER J, 1984, ORGAN BEHAV HUM PERF, V33, P77, DOI 10.1016/0030-5073(84)90012-6
   BRYAN WL, PSYCHOL REV, V6, P345, DOI DOI 10.1037/H0073117
   BYRNE D, 1965, J PERS SOC PSYCHOL, V1, P659, DOI 10.1037/h0022073
   CROWSTON K, 1994, EVOLVING NOVEL ORG F, P19
   ENDO K, 1996, CAN WORLD BE THEORY, V1, P25
   FURUKAWA M, 1990, BREAKAGE STRUCTURE P
   ISHIDA K, 1996, J JAPAN SOC MANAGEME, V5, P19
   March J.G., 1958, ORGANIZATIONS
   OHTA T, 1996, THEORY SOCIAL INFORM, P1
   OKADA I, 1998, JAPAN ASS SOCIAL INF, V10, P98
   OYAMA T, 1990, PSYCHOLOGY
   Pervin L. A., 1993, PERSONALITY THEORY R
   Schmidt W.H., 1974, MANAGE REV, V63, P4
   Simon H., 1982, SCI ARTIFICIAL
   TERANO T, 1996, INFORMTION PROCESSIN, V96, P69
NR 15
TC 3
Z9 3
U1 0
U2 0
PU I O S PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 0922-6389
BN 1-58603-225-9
J9 FR ART INT
PY 2002
VL 72
BP 35
EP 44
PG 10
WC Computer Science, Artificial Intelligence
SC Computer Science
GA BU46J
UT WOS:000176062200004
DA 2021-08-04
ER

PT S
AU Mizuta, H
   Yamagata, Y
AF Mizuta, H
   Yamagata, Y
BE Namatame, A
   Terano, T
   Kurumatani, K
TI Agent-based simulation and gaming system for international emissions
   trading
SO AGENT-BASED APPROACHES IN ECONOMIC AND SOCIAL COMPLEX SYSTEMS
SE FRONTIERS IN ARTIFICIAL INTELLIGENCE AND APPLICATIONS
LA English
DT Proceedings Paper
CT 1st International Workshop on Agent Based Approaches in Economic and
   Social Complex Systems (AESCS)
CY MAY 21-22, 2001
CL MATSUE CITY, JAPAN
SP Koichi Kurumatani, Electrotech Lab, Hiroshi Sato Natl Defense Acad, Kiyoshi Izumi, Electrotech Lab
AB The need for new theoretical and experimental approaches to understand dynamic and heterogeneous behavior in complex economic and social systems is increasing. Computational and gaming simulations are expected to be able to reproduce complex phenomena in economics, and helps us to experiment with various controlling methods, to evaluate systematic designs, and to extract the fundamental elements which produce the interesting phenomena in depth analysis. We have developed a simple agent-based simulation framework "ASIA' and its applications for economic and environmental studies including the international greenhouse gas (GHG) emissions trading. We also constructed a Web application for the gaming simulation of the emissions trading with human players to investigate and improve the behavior model for agents.
C1 IBM Tokyo Res Lab, Kanagawa 2428502, Japan.
RP Mizuta, H (corresponding author), IBM Tokyo Res Lab, 1623-14 Shimotsuruma, Kanagawa 2428502, Japan.
RI Yamagata, Yoshiki/T-6489-2019
CR Grutter JM, 2000, WORLD MARKET GHG EMI
   IBA T, 2000, 1 INT WORKSH COMP IN
   LEVY M, 1994, ECON LETT, V45, P103, DOI 10.1016/0165-1765(94)90065-5
   MIZUTA H, 1999, 4 WORKSH EC HET INT
   MIZUTA H, 2000, P 2000 WINT SIM C
   Moss de Oliveira S, 1999, EVOLUTION MONEY WAR
   Steiglitz K., 1998, Computational Economics, V12, P35, DOI 10.1023/A:1008625731231
   STEIGLITZ K, 1996, MARKET BASED CONTROL, pCH1
NR 8
TC 5
Z9 5
U1 0
U2 2
PU I O S PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 0922-6389
BN 1-58603-225-9
J9 FR ART INT
PY 2002
VL 72
BP 69
EP 78
PG 10
WC Computer Science, Artificial Intelligence
SC Computer Science
GA BU46J
UT WOS:000176062200007
DA 2021-08-04
ER

PT S
AU Sato, H
   Matsui, H
   Ono, I
   Kita, H
   Terano, T
   Deguchi, H
   Shiozawa, Y
AF Sato, H
   Matsui, H
   Ono, I
   Kita, H
   Terano, T
   Deguchi, H
   Shiozawa, Y
BE Namatame, A
   Terano, T
   Kurumatani, K
TI Case report on U-Mart experimental system: Competition of software
   agents and gaming simulation with human agents
SO AGENT-BASED APPROACHES IN ECONOMIC AND SOCIAL COMPLEX SYSTEMS
SE FRONTIERS IN ARTIFICIAL INTELLIGENCE AND APPLICATIONS
LA English
DT Proceedings Paper
CT 1st International Workshop on Agent Based Approaches in Economic and
   Social Complex Systems (AESCS)
CY MAY 21-22, 2001
CL MATSUE CITY, JAPAN
SP Koichi Kurumatani, Electrotech Lab, Hiroshi Sato Natl Defense Acad, Kiyoshi Izumi, Electrotech Lab
AB U-Mart is an interdisciplinary research program of agent-based artificial market. U-Mart proposes an open-type test bed to study trading strategies of agents, behavior of the market and their relationship. Two experiments open to public (Pre U-Mart 2000 and U-Mart 200 1) using the proposed system are held in August 2000 and in August 2001 respectively, In both cases, More than 40 software agents (computer programs for trading) participated in this experiment. This paper reports the outline of these experiments, the trading strategies of the participated agents and the results of the experiment. While Pre U-Mart 2000 and U-Mart 2001 treated only software agents, the U-Mart system is designed considering participation of the human players as well as the software agents. A gaming simulation by human using the U-Mart system held in Kyoto University is also introduced briefly.
C1 Natl Def Acad, Dept Comp Sci, Yokosuka, Kanagawa, Japan.
RP Sato, H (corresponding author), Natl Def Acad, Dept Comp Sci, Hashirimizu 1-10-20, Yokosuka, Kanagawa, Japan.
CR KURUMATANI K, 2000, P 5 JOINT C INF SCI, V2, P957
   Murphy JJ., 1999, TECHNICAL ANAL FINAN
   Sato H, 2001, EVOLUTIONARY CONTROV, P179
   SATO H, IN PRESS U MART PROJ
   2000, J JAPANESE SOC ARTIF, V15
NR 5
TC 3
Z9 3
U1 0
U2 0
PU I O S PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 0922-6389
BN 1-58603-225-9
J9 FR ART INT
PY 2002
VL 72
BP 167
EP 178
PG 12
WC Computer Science, Artificial Intelligence
SC Computer Science
GA BU46J
UT WOS:000176062200016
DA 2021-08-04
ER

PT B
AU Riley, P
   Veloso, M
   Kaminka, G
AF Riley, P
   Veloso, M
   Kaminka, G
BE Asama, H
   Arai, T
   Fukuda, T
   Hasegawa, T
TI An empirical study of coaching
SO DISTRIBUTED AUTONOMOUS ROBOTIC SYSTEMS 5
LA English
DT Proceedings Paper
CT 6th International Symposium on Distributed Autonomous Robotic Systems
   (DARS 6)
CY JUN 25-27, 2002
CL FUKUOKA, JAPAN
SP IEEE, Robot & Automat Soc, Robot Soc Japan, Japan Soc Mech Engineers, Soc Instrument & Control Engineers Japan, Inst Phys & Chem Res, FANUC FA, Robot Fdn, Tateisi Sci & Technol Fdn
AB In simple terms, one can say that team coaching in adversarial domains consists of providing advice to distributed players to help the team to respond effectively to an adversary. We have been researching this problem to find that creating an autonomous coach is indeed a very challenging and fascinating endeavor. This paper reports on our extensive empirical study of coaching in simulated robotic soccer. We can view our coach as a special agent in our team. However, our coach is also capable of coaching other teams other than our own, as we use a recently developed universal coach language for simulated robotic soccer with a set of predefined primitives. We present three methods that extract models from past games and respond to an ongoing game: (i) formation learning, in which the coach captures a team's formation by analyzing logs of past play; (ii) set-play planning, in which the coach uses a model of the adversary to direct the players to execute a specific plan; (iii) passing rule learning, in which the coach learns clusters in space and conditions that define passing behaviors. We discuss these techniques within the context of experimental results with different teams. We show that the techniques can impact the performance of teams and our results further illustrate the complexity of the coaching problem.
C1 Carnegie Mellon Univ, Pittsburgh, PA 15213 USA.
RP Riley, P (corresponding author), Carnegie Mellon Univ, 5000 Forbes Ave, Pittsburgh, PA 15213 USA.
CR BAKKER P, 1996, AISB96 WORKSH LEARN, P3
   BALCH T, 2001, ROBOCUP 2000 ROBOT S
   CHEESEMAN P, 1988, ICML 88, P54
   CLOUSE J, 1995, ICML 95 WORKSH AG LE
   CORADESCHI ABS, 2002, ROBOCUP 2001 ROBOT S
   Dautenhahn K, 1995, ROBOT AUTON SYST, V16, P333, DOI 10.1016/0921-8890(95)00054-2
   DECHTER R, 1991, ARTIF INTELL, V49, P61, DOI 10.1016/0004-3702(91)90006-6
   Maclin R, 1996, MACH LEARN, V22, P251, DOI 10.1007/BF00114730
   Miller MS, 2000, LECT NOTES COMPUT SC, V1839, P63
   Noda I, 1998, APPL ARTIF INTELL, V12, P233, DOI 10.1080/088395198117848
   Paolucci M., 1996, Intelligent Tutoring Systems. Third International Conference, ITS '96. Proceedings, P372
   Quinlan J. R., 1993, C4 5 PROGRAMS MACHIN
   RAINES T, 2000, AGENTS 2000
   RILEY P, 2002, IN PRESS AIPS 2002
   RILEY P, 2002, IN PRESS AAMAS 02
   *ROB FED, 2001, SOCC SERV MAN
   SAMMUT C, 1992, ICML 92
   Stone P, 1999, ARTIF INTELL, V110, P241, DOI 10.1016/S0004-3702(99)00025-9
   Stone P, 2000, LECT NOTES ARTIF INT, V1856, P35
   Sue D, 1997, INT JOINT CONF ARTIF, P914
NR 20
TC 11
Z9 11
U1 0
U2 1
PU SPRINGER-VERLAG TOKYO
PI TOKYO
PA 37-3, HONGO 3-CHOME BONKYO-KU, TOKYO, 113, JAPAN
BN 4-431-70339-X
PY 2002
BP 215
EP 224
PG 10
WC Automation & Control Systems; Robotics
SC Automation & Control Systems; Robotics
GA BU87J
UT WOS:000177256400022
DA 2021-08-04
ER

PT J
AU Gourinchas, PO
   Parker, JA
AF Gourinchas, PO
   Parker, JA
TI Consumption over the life cycle
SO ECONOMETRICA
LA English
DT Article
DE consumption; precautionary saving; retirement; life cycle; simulated
   method of moments
ID CONSUMER EXPENDITURE SURVEY; INCOME FLUCTUATION PROBLEM;
   PERMANENT-INCOME; FUTURE INCOME; PANEL-DATA; EARNINGS; OPTIMIZATION;
   HYPOTHESIS; WEALTH
AB This paper estimates a structural model of optimal life-cycle consumption expenditures in the presence of realistic labor income uncertainty. We employ synthetic cohort techniques and Consumer Expenditure Survey data to construct average age-profiles of consumption and income over the working lives of typical households across different education and occupation groups. The model fits the profiles quite well. In addition to providing reasonable estimates of the discount rate and risk aversion, we find that consumer behavior changes strikingly over the life cycle. Young consumers behave as buffer-stock agents. Around age 40, the typical household starts accumulating liquid assets for retirement and its behavior mimics more closely that of a certainty equivalent consumer. Our methodology provides a natural decomposition of saving and wealth into its precautionary and life-cycle components.
C1 Princeton Univ, Dept Econ, Princeton, NJ 08544 USA.
   Princeton Univ, Woodrow Wilson Sch, Princeton, NJ 08544 USA.
RP Gourinchas, PO (corresponding author), Princeton Univ, Dept Econ, Fisher Hall, Princeton, NJ 08544 USA.
OI Gourinchas, Pierre-Olivier/0000-0003-4493-5628
CR ABOWD JM, 1989, ECONOMETRICA, V57, P411, DOI 10.2307/1912561
   Attanasio OP, 1999, J BUS ECON STAT, V17, P22, DOI 10.2307/1392236
   ATTANASIO OP, 1995, J POLIT ECON, V103, P1121, DOI 10.1086/601443
   Attanasio OP, 1995, AM ECON REV, V85, P1118
   AYAGARI R, 1994, Q J ECON, V109, P659
   BOUND J, 1991, J LABOR ECON, V9, P1, DOI 10.1086/298256
   BOUND J, 1994, J LABOR ECON, V12, P345, DOI 10.1086/298348
   BRANCH ER, 1994, MON LABOR REV, V117, P47
   BROWNING M, 1985, ECONOMETRICA, V53, P503, DOI 10.2307/1911653
   Browning M, 1996, J ECON LIT, V34, P1797
   *BUR LAB STAT, 1993, CONS EXP SURV 1993 I
   CABALLERO RJ, 1991, AM ECON REV, V81, P859
   CAGETTI M, 1998, UNPUB ESTIMATING PRE
   CAMPBELL JY, 1989, NBER MACROECON ANN, P185
   Carroll C. D., 1997, Q J ECON, V107, P1
   Carroll CD, 1997, J MONETARY ECON, V40, P41, DOI 10.1016/S0304-3932(97)00036-6
   CARROLL CD, 1994, Q J ECON, V109, P111, DOI 10.2307/2118430
   CARROLL CD, 1991, NATL SAVINGS EC PERF
   CARROLL CD, 1999, UNPUB BUFFER STOCK S
   CARROLL CD, 1992, BROOKINGS PAPERS EC, V2, P61
   CLARIDA RH, 1991, Q J ECON, V106, P851, DOI 10.2307/2937930
   *COUNC EC ADV, 1995, EC REP PRES
   DEATON A, 1985, J ECONOMETRICS, V30, P109, DOI 10.1016/0304-4076(85)90134-4
   Deaton A., 1992, UNDERSTANDING CONSUM
   DEATON A, 1991, ECONOMETRICA, V59, P1121
   DUFFIE D, 1993, ECONOMETRICA, V61, P929, DOI 10.2307/2951768
   FLAVIN MA, 1981, J POLIT ECON, V89, P974, DOI 10.1086/261016
   FRENCH E, 1998, EFFECTS HLTH WELATH
   FRIEDMAN M., 1957, THEORY CONSUMPTION F
   GAKIDIS HE, 1998, STOCKS OLD EARNINGS
   GHEZ GR, 1974, ALLOCATION TIME GOOD
   Gourinchas PO, 2001, AM ECON REV, V91, P406, DOI 10.1257/aer.91.2.406
   GOURINCHAS PO, 1997, 9722 SOC SCI RES I
   HUBBARD JA, 1994, MERRILL PALMER QUART, V40, P1
   HURD MD, 1989, ECONOMETRICA, V57, P779, DOI 10.2307/1913772
   Jappelli T, 1998, REV ECON STAT, V80, P251, DOI 10.1162/003465398557492
   Judd K., 1998, NUMERICAL METHODS EC
   KOTLIKOFF LJ, 1981, J POLIT ECON, V89, P706, DOI 10.1086/260999
   Ludvigson S, 2001, REV ECON STAT, V83, P242, DOI 10.1162/00346530151143789
   Lusardi A, 1996, J BUS ECON STAT, V14, P81, DOI 10.2307/1392101
   Meghir C, 1996, ECONOMETRICA, V64, P1151, DOI 10.2307/2171960
   MERTON RC, 1973, J ECON THEORY, V6, P213
   Newey W. K., 1994, HDB ECONOMETRICS, V4, P2111, DOI DOI 10.1016/S1573-4412(05)80005-4
   PAKES A, 1989, ECONOMETRICA, V57, P1027, DOI 10.2307/1913622
   Palumbo MG, 1999, REV ECON STUD, V66, P395, DOI 10.1111/1467-937X.00092
   Parker JA, 1999, AM ECON REV, V89, P959, DOI 10.1257/aer.89.4.959
   PISCHKE JS, 1995, ECONOMETRICA, V63, P805, DOI 10.2307/2171801
   SCHECHTMAN J, 1977, J ECON THEORY, V16, P151, DOI 10.1016/0022-0531(77)90003-5
   SCHECHTMAN J, 1976, J ECON THEORY, V12, P218, DOI 10.1016/0022-0531(76)90075-2
   SHEA J, 1995, AM ECON REV, V85, P186
   WEST KD, 1998, 9901 U WISC SOC SCI
   ZELDES SP, 1989, Q J ECON, V104, P275, DOI 10.2307/2937848
NR 52
TC 523
Z9 528
U1 7
U2 81
PU BLACKWELL PUBL LTD
PI OXFORD
PA 108 COWLEY RD, OXFORD OX4 1JF, OXON, ENGLAND
SN 0012-9682
J9 ECONOMETRICA
JI Econometrica
PD JAN
PY 2002
VL 70
IS 1
BP 47
EP 89
DI 10.1111/1468-0262.00269
PG 43
WC Economics; Mathematics, Interdisciplinary Applications; Social Sciences,
   Mathematical Methods; Statistics & Probability
SC Business & Economics; Mathematics; Mathematical Methods In Social
   Sciences
GA 515ZM
UT WOS:000173526700002
OA Green Published
DA 2021-08-04
ER

PT B
AU Popkov, VV
   Berg, DB
AF Popkov, VV
   Berg, DB
BE Takayasu, H
TI Empirical identification of competitive strategies: Russian bank system
SO EMPIRICAL SCIENCE OF FINANCIAL FLUCTUATIONS: THE ADVENT OF ECONOPHYSICS
LA English
DT Proceedings Paper
CT International Workshop on Empirical Science of Financial Fluctuations
CY NOV 15-17, 2000
CL TOKYO, JAPAN
SP Nihon Keizai Shimbun Inc, Osaka Securities Exchange, Canon Inc, Sony Corp, Informat Serv Int Dentsu Ltd, Dresdner Kleinwort Benson Ltd, Mitsui & Co Lt
DE strategies identification; competition simulation; bank system
AB Original technique of economic agents competitive strategies identification based on empirical data is proposed, Instead of traditional qualitative verbal description of strategies and comparison of firms with different kinds of animals (foxes, lions, etc.) the quantitative triangle diagram is used that looks like the three-component phase diagram. Agents' positions inside this triangle are determined by two dynamic empirical parameters. Corresponding points discover the superposition of three main competitive strategies (ruderals, stress-tolerants, competitors) in agent's behavior.
   The technique proposed is used for identification of competitive strategies of banks at the Russian financial market. Analysis is carried out for 32 credit institutions, Computer simulation and pattern recognition techniques were used in order to obtain some features of proposed empirical strategies identification.
C1 Int A Bogdanov Inst, Ekaterinburg 6200062, Russia.
CR BERG DB, 2000, EVOLUTIONARY EC MAIN, P163
   BERG DB, 2001, IN PRESS QUANTITATIV
   EVSEEV SY, 1997, REGIONAL BANKS ORIEN, P15
   GIBLONS R, 1992, GAME THEORY APPL EC
   GRIME JP, 1979, PLANT STRATEGIES VEG, P73
   Mayevsky V, 1998, J EVOL ECON, V8, P407, DOI 10.1007/s001910050070
   MINTZBERG H, 1998, STRATEGY SAFARI, P10
   PARISHEV KS, 1999, TAXES RUSSIA, V1, P14
   Theodoridis S., 1998, PATTERN RECOGNITION
   TOFFOLI T, 1990, CELLULAR AUTOMATA MA, P22
   WITTEN TA, 1983, PHYS REV B, V27, P5686, DOI 10.1103/PhysRevB.27.5686
   Yudanov A., 1990, WORLD EC INT AFFAIRS, V10, P51
NR 12
TC 2
Z9 3
U1 0
U2 1
PU SPRINGER-VERLAG TOKYO
PI TOKYO
PA 37-3, HONGO 3-CHOME BONKYO-KU, TOKYO, 113, JAPAN
BN 4-431-70316-0
PY 2002
BP 331
EP 340
PG 10
WC Economics; Statistics & Probability
SC Business & Economics; Mathematics
GA BT95E
UT WOS:000174575600036
DA 2021-08-04
ER

PT J
AU Decety, J
AF Decety, J
TI Empathy naturalized
SO ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE
LA French
DT Article
DE empathy; evolutionary psychology; intersubjectivity; neurophysiology;
   psychopathology; simulation theory; social cognition; theory of mind
ID BRAIN ACTIVITY; PERCEPTION; IMITATION; PET; RECOGNITION; GENERATION;
   MECHANISMS; SIMULATION; BEHAVIOR; ILLUSION
AB Empathy is the ability to share emotions with others. It is acknowledged to be a powerful means of tacit communication, a key ingredient in any therapeutic relationship as well as in psychotherapy. Empathy is the cornerstone in the humanist perspective (Ego-psychology) in clinical psychology. This approach is often considered as poorly grounded on scientific and objective evidence. It is however acknowledged that empathetic therapists are more effective than less empathetic therapists. I shall argue that this paradox, i.e. it is the least scientific and the less validated psychotherapeutic approach that is the most efficient, can be eliminated if one considers the nature of empathy, its biological foundation, its evolutionary origin and its cognitive architecture. In this paper I will suggest that empathy is based on specific information processing modules which have been designed by natural selection to cope with social regularities in expressing and reading emotional states. This has provided adaptive benefits to individuals living in large groups bestowing them with mechanisms for cooperativity, altruism and more generally various aspects of prosocial behaviour. The capacity to express emotions, and to read and understand emotions of others also ensures implicit communication with others and may be at the root of intersubjectivity. This perspective on empathy is then articulated with two concurrent hypotheses regarding theory of mind (the simulation and the theory-theory) which aim to explain the human capacity to understand that the behaviors of other intelligent agents are caused by intentions, desires and beliefs. In this context, empathy can be considered as a simulation (or analogical) process that is necessary to understand but not sufficient to interpret other people. This last issue is relevant to clinical practice.
C1 INSERM, U280, F-69424 Lyon 03, France.
CR Adolphs R, 2000, J NEUROSCI, V20, P2683
   Adolphs R, 1999, TRENDS COGN SCI, V3, P469, DOI 10.1016/S1364-6613(99)01399-6
   Baron-Cohen S., 1998, CECITE MENTALE ESSAI
   Barresi J, 1996, BEHAV BRAIN SCI, V19, P107, DOI 10.1017/S0140525X00041790
   Bartsch K., 1995, CHILDREN TALK MIND
   BLAKEMORE SJ, 2001, IN PRESS PSYCHOL MED
   BLAKEMORE SJ, 2001, IN PRESS IMITATION I
   Brothers L, 1996, J PSYCHOPHARMACOL, V10, P2, DOI 10.1177/026988119601000102
   Brunet E, 2000, NEUROIMAGE, V11, P157, DOI 10.1006/nimg.1999.0525
   BYRNE RW, 1998, THINKING APE EVOLUTI
   CHARMAN T, 1994, DEV PSYCHOPATHOL, V6, P403, DOI 10.1017/S0954579400006015
   CORCORAN R, 2000, UNDERSTANDING OTHER, P422
   DAMASIO A, 1995, ERREUR DESCARTES
   DAMASIO AR, 1990, BEHAV BRAIN RES, V41, P81, DOI 10.1016/0166-4328(90)90144-4
   Darwin C., 1998, EXPRESSION EMOTIONS
   Dawes R. M., 1994, HOUSE CARDS PSYCHOL
   Decety J, 1997, BRAIN, V120, P1763, DOI 10.1093/brain/120.10.1763
   Decety J, 2000, ENCEPHALE, V27, P12
   Decety J, 1999, TRENDS COGN SCI, V3, P172, DOI 10.1016/S1364-6613(99)01312-1
   DECETY J, IN PRESS NEUROIMAGE
   DEWALLS FBM, 1982, CHIMPANZEE POLITICS
   Dimberg U, 2000, PSYCHOL SCI, V11, P86, DOI 10.1111/1467-9280.00221
   EKMAN P, 1992, PSYCHOL SCI, V3, P34, DOI 10.1111/j.1467-9280.1992.tb00253.x
   Emanuel EJ, 2000, ANN INTERN MED, V132, P451, DOI 10.7326/0003-4819-132-6-200003210-00005
   FREUD SIGMUND, 1921, OEUVRES COMPLETES, VXVI
   Frith C. D., 1992, COGNITIVE NEUROPSYCH
   Gallagher HL, 2000, NEUROPSYCHOLOGIA, V38, P11, DOI 10.1016/S0028-3932(99)00053-6
   Gelder M, 1989, OXFORD TXB PSYCHIAT
   GEORGE MS, 1995, AM J PSYCHIAT, V152, P341
   Gibson JJ., 1979, ECOLOGICAL APPROACH
   Goldman A.I, 1992, MIND LANG, V7, P104, DOI [DOI 10.1111/J.1468-0017.1992.TB00200.X, 10.1111/j.1468-0017.1992.tb00200.x]
   GOPNIK A, 1993, BEHAV BRAIN SCI, V16, P1, DOI 10.1017/S0140525X00028636
   GORDON RM, 1992, MIND LANG, V1, P158, DOI DOI 10.1111/J.1468-0017.1986.TB00324.X
   Grezes J, 1998, COGN NEUROPSYCHOL, V15, P553, DOI 10.1080/026432998381023
   Grezes J, 2001, HUM BRAIN MAPP, V12, P1, DOI 10.1002/1097-0193(200101)12:1<1::AID-HBM10>3.0.CO;2-V
   HARRIS PL, 1992, MIND LANG, V7, P120, DOI DOI 10.1111/J.1468-0017.1992.TB00201.X
   HOBSON RP, 1989, DEV PSYCHOPATHOL, V1, P197
   Hutchison WD, 1999, NAT NEUROSCI, V2, P403, DOI 10.1038/8065
   IZARD CE, 1994, PSYCHOL BULL, V115, P288, DOI 10.1037/0033-2909.115.2.288
   Jerison H.J., 1973, EVOLUTION BRAIN INTE
   JOUVENT R, 1986, COMMUNICATION REPRES, P97
   Kugiumutzakis G, 1999, IMITATION INFANCY, P36
   Lane RD, 1997, NEUROPSYCHOLOGIA, V35, P1437, DOI 10.1016/S0028-3932(97)00070-5
   LEAKEY R, 1994, ORIGIN HUMANKIN
   LEBOVICI S, 1987, NOUVEAU TRAITE PSYCH, V1, P549
   Leslie A. M, 1994, MAPPING MIND DOMAIN, P119, DOI DOI 10.1017/CBO9780511752902.006
   LESLIE AM, 1987, PSYCHOL REV, V94, P412, DOI 10.1037/0033-295X.94.4.412
   LHERMITTE F, 1986, ANN NEUROL, V19, P326, DOI 10.1002/ana.410190404
   MARTZ E, 1987, HUM IMMUNOL, V18, P3, DOI 10.1016/0198-8859(87)90110-8
   MEALEY L, 1995, BEHAV BRAIN SCI, V18, P523, DOI 10.1017/S0140525X00039595
   Meltzoff A. N., 1998, WORDS THOUGHTS THEOR
   Meltzoff A. N., 1990, JD CT MACARTHUR FDN, P139
   MELTZOFF AN, 1977, SCIENCE, V198, P75, DOI 10.1126/science.198.4312.75
   MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402
   MESULAM MM, 1981, ARCH NEUROL-CHICAGO, V38, P176, DOI 10.1001/archneur.1981.00510030070010
   NADEL J, 1987, NOUVEAU TRAITE PSYCH, V1, P240
   NADEL J, 1992, IMITATION IDENTIFICA, P79
   Oatley Keith, 1992, BEST LAID SCHEMES PS
   OPPENHEIMER A, 1996, KOHUT PSYCHOL SELF
   Pinker Steven, 1997, COMMENT FONCTIONNE E
   Proust J., 2001, PSYCHOL FR, V45, P295
   Reiman EM, 1997, AM J PSYCHIAT, V154, P918
   Rochat P, 1999, EARLY SOCIAL COGNITION, P3
   Rochat P, 1998, EXP BRAIN RES, V123, P102, DOI 10.1007/s002210050550
   ROGERS C, 1985, COMPREHENSIVE TXB PS
   Rogers Carol., 1980, WAY BEING
   Rogers S. J., 1999, IMITATION INFANCY, P254
   Ruby P, 2001, NAT NEUROSCI, V4, P546
   RUSSELL J, 1998, SUBJECTIVITE CONSCIE, P139
   Spence SA, 1997, BRAIN, V120, P1997, DOI 10.1093/brain/120.11.1997
   Sperber D., 1997, COGNITION SCI SOCIAL, P123
   SPERRY RW, 1950, J COMP PHYSIOL PSYCH, V43, P482, DOI 10.1037/h0055479
   Stevens JA, 2000, NEUROREPORT, V11, P109, DOI 10.1097/00001756-200001170-00022
   Tattersall I., 1998, BECOMING HUMAN
   Teasdale JD, 1999, AM J PSYCHIAT, V156, P209
   Tomasello M., 2000, CULTURAL ORIGINS HUM
   Trevarthen C., 1999, IMITATION INFANCY, P127
   WALLBOTT HG, 1991, BRIT J SOC PSYCHOL, V30, P207, DOI 10.1111/j.2044-8309.1991.tb00939.x
   WOLPERT DM, 1995, SCIENCE, V269, P1880, DOI 10.1126/science.7569931
NR 79
TC 33
Z9 34
U1 0
U2 19
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0013-7006
J9 ENCEPHALE
JI Enceph.-Rev. Psychiatr. Clin. Biol. Ther.
PD JAN-FEB
PY 2002
VL 28
IS 1
BP 9
EP 20
PG 12
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 539ZV
UT WOS:000174904200002
PM 11963348
DA 2021-08-04
ER

PT B
AU Cao, JN
   Wang, XB
   Das, SK
AF Cao, JN
   Wang, XB
   Das, SK
BE Zhou, W
   Chi, XB
   Goscinski, A
   Li, GJ
TI A framework of using cooperating mobile agents to achieve load sharing
   in distributed web server groups
SO FIFTH INTERNATIONAL CONFERENCE ON ALGORITHMS AND ARCHITECTURES FOR
   PARALLEL PROCESSING, PROCEEDINGS
LA English
DT Proceedings Paper
CT 5th International Conference on Algorithms and Architectures for
   Parallel Processing
CY OCT 23-25, 2002
CL BEIJING, PEOPLES R CHINA
SP IEEE Beijing Sect, Chinese Acad Sci, China Nat Sci Fdn, Special Funds Major State Basic Res Project China, Deakin Univ
AB This paper studies the issues of using mobile agents to achieve load sharing for network services in a wide-area network environment such as the Internet. Traditionally, load sharing algorithms are based on the message-passing paradigm. In this paper, we propose the use of mobile agents as an aid to design filly distributed and dynamic load-sharing mechanisms for wide-area network services, which provide several advantages over the pure message passing-based approach. A framework (called MALS - mobile agent-enabled load sharing) for structuring and designing load sharing in wide-area network services is presented In particular, we describe the design of a mobile agent-enabled distributed dynamic load sharing scheme within the MALS framework. A simulation environment of the load sharing protocol is being implemented using Aglet(TM), a Java-compliant mobile agent platform from IBM. Preliminary experimental results demonstrated that the proposed framework is effective.
C1 Hong Kong Polytech Univ, Internet Comp & E Commerce Lab, Dept Comp, Kowloon, Hong Kong, Peoples R China.
RP Cao, JN (corresponding author), Hong Kong Polytech Univ, Internet Comp & E Commerce Lab, Dept Comp, Kowloon, Hong Kong, Peoples R China.
OI Das, Sajal/0000-0002-9471-0868; Cao, Jiannong/0000-0002-2725-2529
CR BUI M, IN PRESS INT J FDN C
   CAO J, 2001, P IPPC 2001 WORKSH W
   CAO J, 2001, P IPDPS2001 IEEE 200
   Cao JN, 2000, J SYST SOFTWARE, V54, P227, DOI 10.1016/S0164-1212(00)00040-6
   Cardellini V, 2000, 8TH INTERNATIONAL SYMPOSIUM ON MODELING, ANALYSIS AND SIMULATION OF COMPUTER AND TELECOMMUNICATION SYSTEMS, PROCEEDINGS, P20, DOI 10.1109/MASCOT.2000.876425
   CASAVANT TL, 1988, IEEE T SOFTWARE ENG, V14, P141, DOI 10.1109/32.4634
   Danny BL, 1998, PROGRAMMING DEPLOYIN
   EAGER DL, 1986, PERFORM EVALUATION, V6, P53, DOI 10.1016/0166-5316(86)90008-8
   Fuenfrocken S, 1998, P ANN HICSS, P34, DOI 10.1109/HICSS.1998.649164
   HE J, P 2000 IEEE INT C CO, V2, P1169
   Krueger P., 1988, 8th International Conference on Distributed Computing Systems (Cat. No.88CH2541-1), P123, DOI 10.1109/DCS.1988.12509
   Lange DB, 1999, COMMUN ACM, V42, P88, DOI 10.1145/295685.298136
   MINAR N, 1999, SOFTWARE AGENTS FUTU
   MIRCHANDANEY R, 1989, 9TH INTERNATIONAL CONFERENCE ON DISTRIBUTED COMPUTING SYSTEMS, P298, DOI 10.1109/ICDCS.1989.37959
   Moizumi K, 2001, MATH CONTROL SIGNAL, V14, P213, DOI 10.1007/PL00009883
   Pham VA, 1998, IEEE COMMUN MAG, V36, P26, DOI 10.1109/35.689628
   SHIVARATRI NG, 1992, COMPUTER, V25, P33, DOI 10.1109/2.179115
   WANG YT, 1985, IEEE T COMPUT, V34, P204
NR 18
TC 1
Z9 1
U1 0
U2 0
PU IEEE COMPUTER SOC
PI LOS ALAMITOS
PA 10662 LOS VAQUEROS CIRCLE, PO BOX 3014, LOS ALAMITOS, CA 90720-1264 USA
BN 0-7695-1512-6
PY 2002
BP 118
EP 125
PG 8
WC Computer Science, Hardware & Architecture; Computer Science, Software
   Engineering; Computer Science, Theory & Methods
SC Computer Science
GA BV53V
UT WOS:000179289800018
DA 2021-08-04
ER

PT B
AU Murakami, Y
   Minami, K
   Kawasoe, T
   Ishida, T
AF Murakami, Y
   Minami, K
   Kawasoe, T
   Ishida, T
GP IEEE COMPUTER SOCIETY
   IEEE COMPUTER SOCIETY
TI Multi-agent simulation for crisis management
SO IEEE WORKSHOP ON KNOWLEDGE MEDIA NETWORKING, PROCEEDINGS
LA English
DT Proceedings Paper
CT IEEE Workshop on Knowledge Media Networking
CY JUL 10-12, 2002
CL KYOTO, JAPAN
SP IEEE Comp Soc, Learning Technol Task Force
DE multi-agent simulator; evacuation simulation; social interaction
AB Traditional crowd simulators are based on a simple numerical analysis of inputs such as the positions of people and structures; they do not consider leadership. Since leaders (in terms of evacuations) are present in many real-world situations, the validity of evacuation simulations can be increased through their introduction. We assess the results of a real-world evacuation experiment to develop more realistic scenarios for simulation. The simulations produced by the improved scenarios are found to closely mimic the experimental results. This work shows that scenario based agent systems such as Flat Walk and Free Walk offer excellent promise in simulating evacuations more realistically.
C1 Kyoto Univ, Dept Social Informat, JST CREST Digital City Project, Kyoto, Japan.
RP Murakami, Y (corresponding author), Kyoto Univ, Dept Social Informat, JST CREST Digital City Project, Kyoto, Japan.
EM yohei@kuis.kyoto-u.ac.jp; minami@kuis.kyoto-u.ac.jp;
   kawasoe@kuis.kyoto-u.ac.jp; ishida@i.kyoto-u.ac.jp
RI Ishida, Toru/AAI-2102-2020; Ishida, Toru/H-5553-2017
OI Ishida, Toru/0000-0002-0479-4990; Ishida, Toru/0000-0002-0479-4990
CR HAREESH PV, 2000, INT C VIRT SYST MULT, P283
   ISHIDA T, 2002, IEEE COMPUTER, V35
   ISHIDA T, 2002, COMMUNICATIONS ACM, V45
   MILGRAM S, 1969, J PERS SOC PSYCHOL, V13, P79, DOI 10.1037/h0028070
   Nakanishi H, 1999, IEEE MULTIMEDIA, V6, P20, DOI 10.1109/93.771370
   OKAZAKI S, 1993, ENGINEERING FOR CROWD SAFETY, P271
   SUGIMAN T, 1988, J APPL PSYCHOL, V73, P3, DOI 10.1037/0021-9010.73.1.3
   Ulicny B, 2001, SPRING EUROGRAP, P163
NR 8
TC 32
Z9 36
U1 1
U2 5
PU IEEE COMPUTER SOC
PI LOS ALAMITOS
PA 10662 LOS VAQUEROS CIRCLE, PO BOX 3014, LOS ALAMITOS, CA 90720-1264 USA
BN 0-7695-1778-1
PY 2002
BP 135
EP 139
DI 10.1109/KMN.2002.1115175
PG 5
WC Computer Science, Information Systems; Telecommunications
SC Computer Science; Telecommunications
GA BV75A
UT WOS:000179944800021
DA 2021-08-04
ER

PT S
AU Gao, ZQ
   Kawasoe, T
   Yamamoto, A
   Ishida, T
AF Gao, ZQ
   Kawasoe, T
   Yamamoto, A
   Ishida, T
BE Kuwabara, K
   Lee, J
TI Meta-level architecture for executing multi-agent scenarios
SO INTELLIGENT AGENTS AND MULTI-AGENT SYSTEMS, PROCEEDINGS
SE Lecture Notes in Artificial Intelligence
LA English
DT Article; Proceedings Paper
CT 5th Pacific Rim International Workshop on Multi-Agent Systems
CY AUG 18-19, 2002
CL TOKYO, JAPAN
SP Inst Elect, Informat & Commun Engineers, Int Fdn Multiagent Syst Microsoft Res Asia
AB Scenarios, which constrain the behavior of agents, can be the interface between computer experts (agent system developers) and application designers (scenario writers), as well as the interface between scenario writers and agents. It raises a number of challenging issues to execute multi-agent scenarios: 1) How can scenario writers generate customized scenarios easily? 2) How can scenario writers monitor and control scenario execution so as to debug errors in scenarios? 3) How can agents negotiate for scenarios to achieve robust behavior against scenario errors? So, in this paper, we provide a web style CUI (Graphical User Interface) for scenario writers to customize scenarios. We propose a meta-level architecture for scenario writers to trace and control the execution of scenarios by observing scenarios, and for agents to negotiate with others as well as scenario writers for scenarios. The meta-level architecture is illustrated by an experimental multi-agent system of evacuation simulation.
C1 Kyoto Univ, Dept Social Informat, Kyoto, Japan.
   Math Syst Inc, Tokyo, Japan.
RP Gao, ZQ (corresponding author), Kyoto Univ, Dept Social Informat, Kyoto, Japan.
EM gaoz@lab7.kuis.kyoto-u.ac.jp; kawasoe@lab7.kuis.kyoto-u.ac.jp;
   yamamoto@msi.co.jp; ishida@i.kyoto-u.ac.jp
RI Ishida, Toru/AAI-2102-2020; Ishida, Toru/H-5553-2017
OI Ishida, Toru/0000-0002-0479-4990; Ishida, Toru/0000-0002-0479-4990
CR Bojinov H, 2000, FOURTH INTERNATIONAL CONFERENCE ON MULTIAGENT SYSTEMS, PROCEEDINGS, P143, DOI 10.1109/ICMAS.2000.858446
   Cassell J., 1999, EMBODIMENT CONVERSAT, P520
   FININ T, 1994, INT C INF KNOWL MAN
   HUBER MJ, 1995, P 1 INT C MULT SYST, P163
   Isbister K., 2000, CHI 2000 Conference Proceedings. Conference on Human Factors in Computing Systems. CHI 2000. The Future is Here, P57
   ISHIDA T, 2002, T JSAI, V17, P166
   ISHIDA T, 2000, LECT NOTES COMPUTER, V1765
   Jonker C.M., 2001, INT JOINT C ART INT, V17, P1195
   Kitamura Y, 2001, LECT NOTES ARTIF INT, V2182, P1
   Kuwabara K, 1995, PROC INT C TOOLS ART, P460, DOI 10.1109/TAI.1995.479841
   Nakanishi H, 1999, IEEE MULTIMEDIA, V6, P20, DOI 10.1109/93.771370
   ORIATT S, 1999, CHI 99, P576
   Pitt J, 1999, IJCAI-99: PROCEEDINGS OF THE SIXTEENTH INTERNATIONAL JOINT CONFERENCE ON ARTIFICIAL INTELLIGENCE, VOLS 1 & 2, P486
   Reeves B., 1996, MEDIA EQUATION PEOPL
   SUGIMAN T, 1988, J APPL PSYCHOL, V73, P3, DOI 10.1037/0021-9010.73.1.3
NR 15
TC 4
Z9 5
U1 0
U2 0
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 0302-9743
EI 1611-3349
BN 3-540-44026-7
J9 LECT NOTES ARTIF INT
PY 2002
VL 2413
BP 163
EP 177
PG 15
WC Computer Science, Artificial Intelligence
SC Computer Science
GA BX94L
UT WOS:000186904100012
DA 2021-08-04
ER

PT B
AU Mostafa, H
   Bahgat, R
   Holmgren, F
AF Mostafa, H
   Bahgat, R
   Holmgren, F
BE Elmaghraby, AS
   Dees, R
TI A multi-agent system for behavioral studies
SO INTELLIGENT SYSTEMS
LA English
DT Proceedings Paper
CT 11th International Conference on Intelligent Systems - Emerging
   Technologies
CY JUL 18-20, 2002
CL BOSTON, MA
SP Int Soc Comp & Their Applicat, Hewlett Packard Inc
AB In this paper, we propose a multi-agent system (MAS) to simulate a community of beings that move, eat, reproduce, and auction, among other activities. We demonstrate how beings using primitive rules result in emerging, non-primitive behavior. Heterogeneity of real world entities is captured by allowing the user to give the beings different biological characteristics (e.g. level of intelligence and risk taking) using a control panel. Our paper focuses on our modifications and additions to the work inspired from the sugarscape problem [2]. Interesting statistics are obtained from test-runs. The MAS and the GUI that allows the user to control and observe the model were developed using our Agent Base Environment built on top of the Mozart Programming System; a general-purpose development platform that supports concurrency, distribution, resource-aware and symbolic computation.
C1 Cairo Univ, Fac Comp & Informat, Dept Comp Sci, Cairo, Egypt.
RP Mostafa, H (corresponding author), Cairo Univ, Fac Comp & Informat, Dept Comp Sci, Cairo, Egypt.
CR CAHNNON AD, 1998, P 6 INT C ART LIF
   EPSTEIN JM, GROWING ARTIFICIAL
   Haridi S, 1998, NEW GENERAT COMPUT, V16, P223, DOI 10.1007/BF03037481
   HOLMGREN F, 2000, AGENT BASE ENV
   ROBERTO A, ACM CROSSROADS
   SANDHOLM TW, 1999, MULTIAGENT SYSTEMS M
   WOOLDRIDGE M, 1999, MULTIAGENT SYSTEMS M
NR 7
TC 0
Z9 0
U1 0
U2 0
PU INTERNATIONAL SOCIETY COMPUTER S & THEIR APPLICATIONS (ISCA)
PI RALEIGH
PA 8820 SIX FORKS ROAD, RALEIGH, NC 27615 USA
BN 1-880843-43-9
PY 2002
BP 120
EP 127
PG 8
WC Computer Science, Artificial Intelligence; Computer Science, Information
   Systems; Computer Science, Software Engineering
SC Computer Science
GA BV68T
UT WOS:000179771300022
DA 2021-08-04
ER

PT J
AU Kim, WU
   Chung, SM
   Han, TW
   Sah, WJ
   Kim, MH
AF Kim, WU
   Chung, SM
   Han, TW
   Sah, WJ
   Kim, MH
TI Elevated soluble Fas in aqueous humor of patients with Behcet's uveitis:
   Correlation with uveitis severity
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Behcet's uveitis; disease severity; soluble Fas
ID EXPERIMENTAL AUTOIMMUNE UVEORETINITIS; LIGAND-INDUCED APOPTOSIS;
   CELL-DEATH; MEDIATED APOPTOSIS; EXPRESSION; FAS/APO-1; FLUID
AB Purpose: To examine the role of soluble Fas (sFas) in patients with Behcet's uveitis.
   Methods: We measured the sFas levels in both sera and aqueous humor (AH) of patients (n = 40) with uveitis and of non-uveitis controls (n = 27) using an enzyme-linked immunosorbent assay. The patients with uveitis comprised 24 with Behcet's disease, 6 pan-uveitis, 5 anterior uveitis, 2 lens-induced uveitis, I Vogt-Koyanagi-Harada disease, I sarcoidosis, and I retinal vasculitis. The severity of uveitis was determined by the Hogan grading method (0-4 grade) at the time of sampling.
   Results: The concentration of aqueous sFas in uveitis patients was significantly higher than that in non-uveitis controls, while there was no difference in the serum concentration of sFas between the two groups. In the paired samples of serum and AH, obtained simultaneously, the aqueous sFas levels were higher than serum Fas levels in patients with uveitis, whereas the non-uveitis controls displayed significantly lower sFas levels in AH than in the serum. The sFas levels in AH or serum were not different between Behcet's uveitis patients and non-Behcet's uveitis patients. However, in patients with Behcet's uveitis, circulating sFas strongly correlated with aqueous sFas, which was not so in those with non-Behcet's uveitis, Patients (n = 29) with more active (grade greater than or equal to 2) uveitis had significantly higher levels of aqueous sFas than those (n = 11) with less active (grade < 2) uveitis. After treatment with Steroids and/or immunosuppressive agents, aqueous sFas levels decreased in parallel with a reduction in the number of inflammatory cells.
   Conclusions: The levels of sFas were elevated in patients with Behcet's uveitis and correlated well with the uveitis severity in these patients. Jpn J Ophthalmol 2002;46:18-23 (C) 2002 Japanese Ophthalmological Society.
C1 Apgujung St Marys Eye Ctr, Kangnam Ku, Seoul 135849, South Korea.
   Kangnam St Marys Hosp, Dept Internal Med, Seoul, South Korea.
RP Kim, MH (corresponding author), Apgujung St Marys Eye Ctr, Kangnam Ku, 621-3 Shinsa Dong, Seoul 135849, South Korea.
RI Kim, Wan-Uk/AAO-8502-2020
OI Kim, Wan-Uk/0000-0001-8224-8496
CR CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905
   Ciusani E, 1998, J NEUROIMMUNOL, V82, P5, DOI 10.1016/S0165-5728(97)00177-X
   Dick AD, 1999, INVEST OPHTH VIS SCI, V40, P2258
   Eischen CM, 1996, J IMMUNOL, V156, P2693
   GERY I, 1994, CURR OPIN IMMUNOL, V6, P938, DOI 10.1016/0952-7915(94)90017-5
   GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189
   Griffith TS, 1996, IMMUNITY, V5, P7, DOI 10.1016/S1074-7613(00)80305-2
   Hamzaoui K, 1998, MEDIAT INFLAMM, V7, P111, DOI 10.1080/09629359891261
   Hasunuma T, 1997, ARTHRITIS RHEUM, V40, P80, DOI 10.1002/art.1780400112
   HOGAN MH, 1959, AM J OPHTHALMOL, V47, P162
   ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5
   Lau HT, 1996, SCIENCE, V273, P109, DOI 10.1126/science.273.5271.109
   Li QA, 1999, AUTOIMMUNITY, V30, P171, DOI 10.3109/08916939908993851
   NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326
   Papoff G, 1996, J IMMUNOL, V156, P4622
   RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0
   Sotozono C, 2000, CURR EYE RES, V20, P54, DOI 10.1076/0271-3683(200001)20:1;1-H;FT054
   SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L
   Sueda J, 2000, INVEST OPHTH VIS SCI, V41, P799
   Sugita S, 2000, BRIT J OPHTHALMOL, V84, P1130, DOI 10.1136/bjo.84.10.1130
   Suss G, 1996, J EXP MED, V183, P1789, DOI 10.1084/jem.183.4.1789
   van Lopik T, 1999, J RHEUMATOL, V26, P60
   Yuan JY, 1996, J CELL BIOCHEM, V60, P4, DOI 10.1002/(SICI)1097-4644(19960101)60:1<4::AID-JCB2>3.0.CO;2-1
NR 23
TC 5
Z9 5
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0021-5155
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JAN-FEB
PY 2002
VL 46
IS 1
BP 18
EP 23
AR PII S0021-5155(01)00469-5
DI 10.1016/S0021-5155(01)00469-5
PG 6
WC Ophthalmology
SC Ophthalmology
GA 523PN
UT WOS:000173964400003
PM 11853709
DA 2021-08-04
ER

PT J
AU Ridwelski, K
   Meyer, F
   Hribaschek, A
   Kasper, U
   Lippert, H
AF Ridwelski, K
   Meyer, F
   Hribaschek, A
   Kasper, U
   Lippert, H
TI Intraoperative and early postoperative chemotherapy into the abdominal
   cavity using gemcitabine may prevent postoperative occurence of
   peritoneal carcinomatosis
SO JOURNAL OF SURGICAL ONCOLOGY
LA English
DT Article
DE tumor cell transfer; antineoplastic drug; intraperitoneal cytostatic
   lavage; greater omentum; small bowel; tumor nodes
ID PHASE-II TRIAL; INTRAPERITONEAL CHEMOTHERAPY; CURATIVE RESECTION;
   ADJUVANT THERAPY; CYTOREDUCTIVE SURGERY; PANCREATIC-CARCINOMA;
   RANDOMIZED TRIAL; GASTRIC-CANCER; COLON-CANCER; FAILURE
AB Background and Objectives: Malignant tumors of various abdominal organs are blamed to be the cause of death in approximately 40% of cases per year in Western Europe. At the time of death, about half of them show peritoneal carcinomatosis which is considered an unfavorable prognostic factor. In case of peritoneal carcinomatosis, there is no curative treatment available for any of the tumors in the abdominal cavity. The aim of this experimental study was to evaluate the preventive potential of intraoperative or early postoperative local adminstration of gemcitabine into the abdominal cavity against peritoneal carcinomatosis.
   Methods: Peritoneal carcinomatosis was induced in male WAG rats (n = 18) by transfer of 5 x 10(6) cells of the adenocarcinoma cell line CC-531 via minilaparotomy carried out in all rats under general anesthesia. Thirty days after cell transfer, rats were sacrificed and peritoneal carcinomatosis was confirmed using histologic investigation in specimens obtained from the peritoneal site. Extension of this carcinomatosis was quantified by (i) counting tumor nodes per square centimeter (mean of several counts) and (ii) determining tumor weight (weight of the greater omentum plus the resected mesentery). Rats were subdivided into three groups (n = 6 per group): group 1 (controls); group 2, simultaneously with tumor cell transfer 24 mg/kg of gemictabine were administered into the abdominal cavity; group 3, postoperative intraperitoneal irrigation with 24 mg/kg of gemictabine was achieved via a previously implanted port-a-cath on days(d) 15, 21, and 27.
   Results: On the 30th postoperative day, all six animals of the control group showed extensive tumor growth at the peritoneum and greater omentum, indicating carcinomatosis. In contrast, none of the rats of group 2 revealed any traces of intraperitoneal tumor growth. While all rats of group 3 demonstrated intraperitoneal tumor growth, but early postoperative treatment with gemcitabine, however, resulted in a significant reduction of the number of tumor nodes and tumor weight in comparison with group 1 (controls).
   Conclusions: Immediate, i.e., simultaneous intraoperative application of a cytostatic agent such as gemcitabine into the abdominal cavity may completely prevent the generation of peritoneal carcinomatosis from occuring tumor cells, whereas early postoperative locoregional chemotherapy into the abdominal cavity can only reduce the severity of the peritoneal carcinomatosis. J. Surg. Oncol. 2002; 79:10-16. (C) 2002 Wiley-Liss, Inc.
C1 Otto Von Guericke Univ, Univ Hosp, Dept Surg, Div Oncosurg Oncol, D-39120 Magdeburg, Germany.
RP Ridwelski, K (corresponding author), Otto Von Guericke Univ, Univ Hosp, Dept Surg, Div Oncosurg Oncol, D-39120 Magdeburg, Germany.
EM karsten.ridwelski@medizin.uni-magdeburg.de
CR Aparicio T, 1999, CARCINOGENESIS, V20, P1445, DOI 10.1093/carcin/20.8.1445
   Benoit L, 2000, GASTROEN CLIN BIOL, V24, P26
   Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403
   Carmichael J, 1996, BRIT J CANCER, V73, P101, DOI 10.1038/bjc.1996.18
   CASCINU S, 1998, P AN M AM SOC CLIN, V17, P264
   CASPER ES, 1994, INVEST NEW DRUG, V12, P29, DOI 10.1007/BF00873232
   Chung YC, 1996, J FORMOS MED ASSOC, V95, P138
   Fishman DA, 1997, GYNECOL ONCOL, V67, P193, DOI 10.1006/gyno.1997.4850
   Fujimura T, 2000, ONCOL REP, V7, P809
   Ghadimi BM, 1998, CHIRURG, V69, P1315, DOI 10.1007/s001040050576
   Green MR, 1996, SEMIN ONCOL, V23, P32
   GRIFFIN JF, 1990, CANCER, V66, P56, DOI 10.1002/1097-0142(19900701)66:1<56::AID-CNCR2820660112>3.0.CO;2-6
   HEINEMANN V, 1998, P ASCO, V18, P246
   HERMANS J, 1993, J CLIN ONCOL, V11, P1441, DOI 10.1200/JCO.1993.11.8.1441
   Jacquet N, 1998, Bull Mem Acad R Med Belg, V153, P414
   Jacquet P, 1998, ONCOLOGY-BASEL, V55, P130, DOI 10.1159/000011847
   JACQUET P, 1994, ACTA CHIR BELG, P191
   Jahne J, 1998, Langenbecks Arch Chir Suppl Kongressbd, V115, P1435
   JAKESZ R, 1990, WIEN MED WOCHENSCHR, V140, P199
   LANDRY J, 1990, INT J RADIAT ONCOL, V19, P1357, DOI 10.1016/0360-3016(90)90344-J
   LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C
   Loggie BW, 2000, AM SURGEON, V66, P561
   LOS G, 1990, CANCER LETT, V51, P109, DOI 10.1016/0304-3835(90)90045-Y
   MARTIN MS, 1973, DIGESTION, V8, P22, DOI 10.1159/000197298
   Moore M, 1996, CANCER, V78, P633
   MOORE M, 1995, P AN M AM SOC CLIN, V14, P199
   OETTLE H, 1998, P AN M AM SOC CLIN, V17, pA264
   Pasqualini R, 1996, NAT MED, V2, P1197, DOI 10.1038/nm1196-1197
   POPLIN EA, 1992, INVEST NEW DRUG, V10, P165, DOI 10.1007/BF00877241
   Rothenberg ML, 1996, ANN ONCOL, V7, P347
   Scheithauer W, 1998, BRIT J CANCER, V77, P1349, DOI 10.1038/bjc.1998.225
   SCHMOLL S, 1986, KOMPENDIUM INTERNIST, P2460
   Schwarz RE, 1999, SURGERY, V126, P562, DOI 10.1067/msy.2099.100267
   SUGARBAKER PH, 1990, CANCER RES, V50, P5790
   SUGARBAKER PH, 1995, ANN SURG, V221, P124, DOI 10.1097/00000658-199502000-00002
   Sugarbaker PH, 1997, PROGRESS IN GASTRIC CANCER RESEARCH 1997, P1399
   SUGARBAKER PH, 1996, PERITONEAL CARCINOMA, V13, P149
   TEPPER J, 1976, CANCER, V37, P1519, DOI 10.1002/1097-0142(197603)37:3<1519::AID-CNCR2820370340>3.0.CO;2-O
   Vaillant JC, 2000, ANN SURG, V231, P449, DOI 10.1097/00000658-200004000-00001
   Watson SA, 1996, BRIT J CANCER, V74, P1354, DOI 10.1038/bjc.1996.549
   Yoshikawa T, 2000, HEPATO-GASTROENTEROL, V47, P298
   Yu W, 1998, ANN SURG, V228, P347, DOI 10.1097/00000658-199809000-00007
NR 42
TC 17
Z9 17
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-4790
EI 1096-9098
J9 J SURG ONCOL
JI J. Surg. Oncol.
PD JAN
PY 2002
VL 79
IS 1
BP 10
EP 16
DI 10.1002/jso.10000
PG 7
WC Oncology; Surgery
SC Oncology; Surgery
GA 508PW
UT WOS:000173098500004
PM 11754372
DA 2021-08-04
ER

PT S
AU McManus, BM
   Yanagawa, B
   Rezai, N
   Luo, HL
   Taylor, L
   Zhang, M
   Yuan, J
   Buckley, J
   Triche, T
   Schreiner, G
   Yang, DC
AF McManus, BM
   Yanagawa, B
   Rezai, N
   Luo, HL
   Taylor, L
   Zhang, M
   Yuan, J
   Buckley, J
   Triche, T
   Schreiner, G
   Yang, DC
BE Aujame, L
   Burdin, N
   Dodet, B
   Vicari, M
TI Genetic determinants of coxsackievirus B3 pathogenesis
SO MICROARRAYS, IMMUNE RESPONSES AND VACCINES
SE Annals of the New York Academy of Sciences
LA English
DT Article; Proceedings Paper
CT Conference on Microarrays, Immune Responses and Vaccines
CY MAY 26-29, 2002
CL VEYRIER DU LAC, FRANCE
SP Fdn Merieux
DE genomic analysis; coxsackievirus B3; genetics; infectomics
ID INTERNAL RIBOSOME ENTRY; INFECTIOUS-DISEASE SUSCEPTIBILITY;
   MESSENGER-RNA; IN-VITRO; FUNCTIONAL-CHARACTERIZATION; POLY(A)-BINDING
   PROTEIN; VIRAL MYOCARDITIS; STRESS RESPONSES; HOST-RESISTANCE; DNA
   MICROARRAY
AB The development of high throughput genomic and bioinformatic analysis tools, coupled with established molecular techniques, has allowed new insights into the pathogenesis of infectious diseases. In humans, coxasackievirus B3 (CVB3) is the primary etiological agent of viral myocarditis, an inflammatory disease process involving the heart muscle. Early host cellular survival and apoptotic mechanisms during viral infections, as well as immune events, affect myocarditis progression and outcome. Therefore, our laboratory has been keenly interested in infectomics, defined here as the transcriptional events of both virus and host. We first elucidated up- or downregulated transcriptional activities in CVB3-infected hearts by mRNA differential display. Further characterization of these regulated genes including Nip21, IP10, and IGTPase, and study of their role in CVB3-infection are underway. In further dissection of the stages of myocarditis-peak viremia, inflammatory infiltration and tissue repair-we used cDNA microarrays to probe differential gene expression in the myocardium following virus infection. Following virus infection, there are global decreases in metabolic and mitochondrial genes, increases in signaling genes and distinctive patterns in other functional groups. To,establish early gene expression profiles in infected cells by themselves, we also used oligonucleotide arrays in an in vitro model of CVB3 infection. Notably, we have found increased expression of transcription factors c-fos and c-jun downstream of extracellular signal-related kinase, a pathway which is crucial for virus replication and pathogenesis. Our investigations based on gene profiling following CVB3 infection have thus far been fruitful in providing new experimental leads. High throughput genetic analysis has allowed us to simultaneously try on greater, than 12,000 potential genetic "glass slippers." Our in vitro experimental plan has enabled us to chart prominent patterns of gene expression, analyzed by novel bioinformatic approaches, and to separate varied and potentially significant gene expression events.
C1 UBC, St Pauls Hosp Prov Hlth Care, Dept Pathol & Lab Med, McDonald Res Lab,iCAPTRE Ctr, Vancouver, BC V6Z 146, Canada.
   Childrens Hosp, Los Angeles, CA 90027 USA.
   Scios Inc, Sunnyvale, CA USA.
RP McManus, BM (corresponding author), UBC, St Pauls Hosp Prov Hlth Care, Dept Pathol & Lab Med, McDonald Res Lab,iCAPTRE Ctr, Rm 292,1081 Burrold St, Vancouver, BC V6Z 146, Canada.
EM bmcmanus@mrl.ubc.ca
CR Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019
   Alcorn MJ, 2001, J VIROL, V75, P6450, DOI 10.1128/JVI.75.14.6450-6459.2001
   Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676
   BECK MA, 1995, NAT MED, V1, P433, DOI 10.1038/nm0595-433
   Beck MA, 2000, P NUTR SOC, V59, P581, DOI 10.1017/S0029665100000823
   Bergelson JM, 1997, J INFECT DIS, V175, P697, DOI 10.1093/infdis/175.3.697
   Bigger CB, 2001, J VIROL, V75, P7059, DOI 10.1128/JVI.75.15.7059-7066.2001
   Blackwell JM, 2001, TRENDS MOL MED, V7, P521, DOI 10.1016/S1471-4914(01)02169-4
   Brown AJP, 2001, EMBO J, V20, P3177, DOI 10.1093/emboj/20.12.3177
   Carthy CM, 1998, J VIROL, V72, P7669, DOI 10.1128/JVI.72.9.7669-7675.1998
   Coldwell MJ, 2000, ONCOGENE, V19, P899, DOI 10.1038/sj.onc.1203407
   Dempsey AA, 2001, J MOL CELL CARDIOL, V33, P1879, DOI 10.1006/jmcc.2001.1447
   Feuer R, 2002, J VIROL, V76, P4430, DOI 10.1128/JVI.76.9.4430-4440.2002
   Gan WN, 1998, J BIOL CHEM, V273, P5006, DOI 10.1074/jbc.273.9.5006
   Geiss GK, 2000, VIROLOGY, V266, P8, DOI 10.1006/viro.1999.0044
   Haase D, 2002, EUR J HEART FAIL, V4, P23, DOI 10.1016/S1388-9842(01)00226-4
   Hai T, 1999, GENE EXPRESSION, V7, P321
   HALDANE JBS, 1949, NATURE, V321, P744
   Henis-Korenblit S, 2000, MOL CELL BIOL, V20, P496, DOI 10.1128/MCB.20.2.496-506.2000
   Hill AVS, 1999, BRIT MED BULL, V55, P401, DOI 10.1258/0007142991902457
   Hogenesch JB, 2001, CELL, V106, P413, DOI 10.1016/S0092-8674(01)00467-6
   Holcik M, 2000, MOL CELL BIOL, V20, P4648, DOI 10.1128/MCB.20.13.4648-4657.2000
   HUANG SH, 2002, GENOMICS, V1, P331
   Huttunen P, 1998, VIROLOGY, V250, P85, DOI 10.1006/viro.1998.9343
   Kanda T, 1999, INT J CARDIOL, V68, P13, DOI 10.1016/S0167-5273(98)00250-2
   KANDOLF R, 1985, P NATL ACAD SCI USA, V82, P4818, DOI 10.1073/pnas.82.14.4818
   KELLAM P, 2000, GENOME BIOL, V1, P1009
   Kerekatte V, 1999, J VIROL, V73, P709, DOI 10.1128/JVI.73.1.709-717.1999
   Kuyumcu-Martinez NM, 2002, J VIROL, V76, P2062, DOI 10.1128/JVI.76.5.2062-2074.2002
   LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Lee MLT, 2000, P NATL ACAD SCI USA, V97, P9834, DOI 10.1073/pnas.97.18.9834
   Liang GS, 1996, J BIOL CHEM, V271, P1695, DOI 10.1074/jbc.271.3.1695
   Liu ZW, 1999, VIROLOGY, V265, P206, DOI 10.1006/viro.1999.0048
   Luo HL, 2002, J VIROL, V76, P3365, DOI 10.1128/JVI.76.7.3365-3373.2002
   Manger ID, 2000, CURR OPIN IMMUNOL, V12, P215, DOI 10.1016/S0952-7915(99)00077-1
   Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061
   Opavsky MA, 2002, J CLIN INVEST, V109, P1561, DOI 10.1172/JCI200213971
   Peng TQ, 2000, J CLIN MICROBIOL, V38, P3538, DOI 10.1128/JCM.38.10.3538-3543.2000
   Qureshi ST, 1999, EMERG INFECT DIS, V5, P36, DOI 10.3201/eid0501.990105
   Stingley SW, 2000, J VIROL, V74, P9916, DOI 10.1128/JVI.74.21.9916-9927.2000
   Takahashi M, 2001, CARDIOVASC RES, V52, P438, DOI 10.1016/S0008-6363(01)00408-4
   Taylor LA, 2000, CIRC RES, V87, P328, DOI 10.1161/01.RES.87.4.328
   Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040
   Willett WC, 2002, SCIENCE, V296, P695, DOI 10.1126/science.1071055
   Wolfgang CD, 2000, J BIOL CHEM, V275, P16865, DOI 10.1074/jbc.M909637199
   Wright FA, 2001, GENOME BIOL, V2
   Yang DC, 1997, VIROLOGY, V228, P63, DOI 10.1006/viro.1996.8366
   Yang DC, 1999, CIRC RES, V84, P704, DOI 10.1161/01.RES.84.6.704
   Zhang HM, 2002, CIRC RES, V90, P1251, DOI 10.1161/01.RES.0000024690.69379.5C
   Zhang JS, 1998, MOL BIOTECHNOL, V10, P155, DOI 10.1007/BF02760862
   Zhu H, 1998, P NATL ACAD SCI USA, V95, P14470, DOI 10.1073/pnas.95.24.14470
NR 52
TC 16
Z9 19
U1 0
U2 2
PU NEW YORK ACAD SCIENCES
PI NEW YORK
PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA
SN 0077-8923
BN 1-57331-447-1
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2002
VL 975
BP 169
EP 179
DI 10.1111/j.1749-6632.2002.tb05950.x
PG 11
WC Immunology; Multidisciplinary Sciences
SC Immunology; Science & Technology - Other Topics
GA BW05G
UT WOS:000180751500014
PM 12538163
DA 2021-08-04
ER

PT J
AU Kuntscher, MV
   Kastell, T
   Altmann, J
   Menke, H
   Gebhard, MM
   Germann, G
AF Kuntscher, MV
   Kastell, T
   Altmann, J
   Menke, H
   Gebhard, MM
   Germann, G
TI Acute remote ischemic preconditioning II: The role of nitric oxide
SO MICROSURGERY
LA English
DT Article
ID CONTROLLED BIOLOGICAL RELEASE; SKELETAL-MUSCLE; REPERFUSION;
   NUCLEOPHILES; COMPLEXES; INJURY; AGENTS; FLAP; NO
AB The purpose of this study was to determine whether nitric oxide (NO) plays a role in the mechanism of acute "classic" as well as acute remote ischemic preconditioning (IP). Thirtytwo male Wistar rats were divided into five experimental groups. The rat cremaster flap in vivo microscopy model was used for assessment of ischemia/reperfusion injury. In the control group (CG, n = 8), a 2-hr flap ischemia was induced after preparation of the cremaster muscle. The animals of group NO (n = 6) received 500 nmol/kg of the NO-donor spermine/nitric oxide complex (Sper/NO) intravenously 30 min prior to ischemia. The group LN + P (L-NAME + preclamping, n = 6) received 10 mg/kg N(i)-nitro-L-arginine methyl ester (L-NAME) intravenously before preclamping of the flap pedicle (10-min cycle length, 30-min reperfusion). L-NAME (10 mg/kg) was administered in group LN + T (L-NAME + tourniquet, n = 6) before ischemia of the right hindlimb was induced, using a tourniquet for 10 min after flap elevation. The limb was then reperfused for 30 min. Thereafter, flap ischemia was induced in each group as in group CG. In vivo microscopy was performed after 1 hr of flap reperfusion in each animal. Group NO demonstrated a significantly higher red blood cell velocity (RBV) in the first-order arterioles and capillaries, a higher capillary flow, and a decreased number of leukocytes adhering to the endothelium (stickers) of the postcapillary venules by comparison to all other groups (P < 0.05). The average capillary RBV and capillary flow were still higher in the CG than in the groups receiving L-NAME (P < 0.05). The data show that NO plays an important role in the mechanism of both acute "classic" as well as acute remote IP, since the administration of a NO-donor previous to ischemia simulates the effect of IP, whereas the nonspecific blocking of NO synthesis by L-NAME abolishes the protective effect of flap preconditioning.
C1 Univ Heidelberg, Dept Plast & Hand Surg, Burn Ctr, BG Trauma Ctr, D-67071 Ludwigshafen, Germany.
   Univ Heidelberg, Dept Expt Surg, D-6900 Heidelberg, Germany.
RP Kuntscher, MV (corresponding author), Univ Heidelberg, Dept Plast & Hand Surg, Burn Ctr, BG Trauma Ctr, Ludwig Guttmann Str 13, D-67071 Ludwigshafen, Germany.
CR Chen JX, 2001, J CELL PHYSIOL, V186, P116, DOI 10.1002/1097-4652(200101)186:1<116::AID-JCP1005>3.0.CO;2-X
   Cordeiro PG, 1998, PLAST RECONSTR SURG, V102, P2040, DOI 10.1097/00006534-199811000-00035
   DIODATI JG, 1993, J CARDIOVASC PHARM, V22, P287, DOI 10.1097/00005344-199308000-00018
   Ghaleh Bijan, 2000, Journal de la Societe de Biologie, V194, P137
   Jones WK, 1999, J MOL CELL CARDIOL, V31, P1469, DOI 10.1006/jmcc.1999.0983
   Knox LK, 1996, MICROSURG, V17, P425, DOI 10.1002/(SICI)1098-2752(1996)17:8<425::AID-MICR1>3.0.CO;2-D
   Kuntscher MV, 2002, MICROSURG, V22, P221, DOI 10.1002/micr.10041
   Kuntscher MV, 2002, PLAST RECONSTR SURG, V109, P2398
   Lowenstein CJ, 1999, P NATL ACAD SCI USA, V96, P10953, DOI 10.1073/pnas.96.20.10953
   MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013
   Nandagopal K, 2001, J PHARMACOL EXP THER, V297, P474
   Oshima H, 1996, MICROSURG, V17, P191, DOI 10.1002/(SICI)1098-2752(1996)17:4<191::AID-MICR5>3.0.CO;2-O
   Peralta C, 1997, HEPATOLOGY, V25, P934, DOI 10.1002/hep.510250424
   PERALTA C, 1996, BIOCHEM BIOPH RES CO, V229, P271
   Rakhit RD, 1999, CARDIOVASC RES, V43, P621, DOI 10.1016/S0008-6363(99)00081-4
   Wang WZ, 2000, J RECONSTR MICROSURG, V16, P621, DOI 10.1055/s-2000-9380
   Wang WZ, 1998, J TRAUMA, V45, P953, DOI 10.1097/00005373-199811000-00018
   Wang WZ, 1996, MICROSURG, V17, P324, DOI 10.1002/(SICI)1098-2752(1996)17:6<324::AID-MICR7>3.0.CO;2-H
NR 18
TC 40
Z9 45
U1 0
U2 1
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0738-1085
J9 MICROSURG
JI Microsurgery
PY 2002
VL 22
IS 6
BP 227
EP 231
DI 10.1002/micr.10042
PG 5
WC Surgery
SC Surgery
GA 598GE
UT WOS:000178266900003
PM 12375287
DA 2021-08-04
ER

PT B
AU Iourinski, D
   Starks, SA
   Kreinovich, V
AF Iourinski, D
   Starks, SA
   Kreinovich, V
BE Jamshidi, M
   Hata, Y
   Fathi, M
   Homaifar, A
   Jamshidi, JS
TI Swarm intelligence: Theoretical proof that empirical techniques are
   optimal
SO MULTIMEDIA, IMAGE PROCESSING AND SOFT COMPUTING: TRENDS, PRINCIPLES AND
   APPLICATIONS
SE TSI PRESS SERIES
LA English
DT Proceedings Paper
CT 5th Biannual World Automation Congress
CY JUN 09-13, 2002
CL ORLANDO, FL
SP Univ Cent Florida, Florida Atlantic Univ
DE swarm intelligence; autonomous agents; optimality proof
AB A natural way to distribute tasks between autonomous agents is to use swarm intelligence techniques, which simulate the way social insects (such as wasps) distribute tasks between themselves. In this paper, we theoretically prove that the corresponding successful biologically inspired formulas are indeed statistically optimal (in some reasonable sense).
C1 Univ Texas, NASA, Panamer Ctr Earth & Environm Studies, El Paso, TX 79968 USA.
RP Iourinski, D (corresponding author), Univ Texas, NASA, Panamer Ctr Earth & Environm Studies, El Paso, TX 79968 USA.
CR Aczel J., 1966, LECT FUNCTIONAL EQUA
   Bonabeau E., 1999, SWARM INTELLIGENCE N
   Cicirello V., 2001, P 5 INT C AUT AG
   Cicirello V. A., 2001, P 5 INT S AUT DEC SY
   CICIRELLO VA, 2001, P IJCAI 01 WORKSH AI
   Eberhart RC., 2001, SWARM INTELL-US
   Garey M., 1979, COMPUTERS INTRACTABI
   Nguyen H.T., 1997, APPL CONTINUOUS MATH
   WADSWORTH HM, 1990, HDB STAT METHODS ENG
NR 9
TC 3
Z9 3
U1 0
U2 1
PU TSI PRESS
PI ALBUQUERQUE
PA PO BOX 14126, ALBUQUERQUE, NM 87191-4126 USA
BN 1-889335-18-5
J9 TSI PRESS S
PY 2002
VL 13
BP 107
EP 112
PG 6
WC Automation & Control Systems; Computer Science, Artificial Intelligence;
   Computer Science, Information Systems; Engineering, Electrical &
   Electronic; Telecommunications
SC Automation & Control Systems; Computer Science; Engineering;
   Telecommunications
GA BV86P
UT WOS:000180264900017
OA Green Submitted
DA 2021-08-04
ER

PT B
AU Willis, A
   Kukla, R
   Kerridge, J
   Hine, J
AF Willis, A
   Kukla, R
   Kerridge, J
   Hine, J
BE Schreckenberg, M
   Sharma, SD
TI Laying the foundations: The use of video footage to explore pedestrian
   dynamics in PEDFLOW
SO PEDESTRIAN AND EVACUATION DYNAMICS
LA English
DT Proceedings Paper
CT International Conference on Pedestrian and Evacuation Dynamics
CY APR 04-06, 2001
CL GERHARD MERCATOR UNIV, DUISBURG, GERMANY
SP Duisburger Univ Gesell, Flensburger Schiffbau Gesell, Intraplan Consult, W Deutsch Landesbank, Stadt Duisburg, Duisburger Verkehrs Gesell, Inst Schiffstech, Inst Phys
HO GERHARD MERCATOR UNIV
AB This paper is concerned with how video footage of pedestrian activity in various urban environments can be used to inform the development of PEDFLOW - a microscopic, agent-based model of pedestrian flow that can be used to simulate the effects of an environmental change (e.g., widening a pavement) on how pedestrians negotiate urban space. The process can be summarized as follows: (1) video footage of pedestrians is digitized and calibrated according to real-world measurements of the filming area; (2) an interesting scenario is identified (e.g. two pedestrians approaching each other on a collision course) and all cases of this scenario are selected from the video for analysis; (3) for each case, qualitative information (e.g. pedestrian group size, or final action) and quantitative data (e.g. walking speed, gap size) are recorded For the latter, the frame-by-frame position of selected pedestrians is plotted using commercially-available image analysis software and related to key features of the environment (such as kerbs and obstacles); (4) statistical analyses are performed to extract patterns of behaviour which can be translated into algorithms that form the basis of the PEDFLOW model. In this way, the model can be developed according to realistic approximations of how pedestrians negotiate urban space.
C1 Napier Univ, Transport Res Inst, Edinburgh EH10 5BR, Midlothian, Scotland.
RP Willis, A (corresponding author), Napier Univ, Transport Res Inst, Redwood House,66 Spylaw Rd, Edinburgh EH10 5BR, Midlothian, Scotland.
CR BECHTEL R, 1970, ENV PSYCHOL
   Franklin S, 1996, P 3 INT WORKSH AG TH
   HELBING D, 1991, BEHAV SCI, V36, P298, DOI 10.1002/bs.3830360405
   KUKLA R, 2001, 8 ANN M TRANSP RES B
   Pushkarev B., 1975, URBAN SPACE PEDESTRI
NR 5
TC 10
Z9 10
U1 0
U2 1
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
BN 3-540-42690-6
PY 2002
BP 181
EP 186
PG 6
WC Mathematics, Applied
SC Mathematics
GA BV52V
UT WOS:000179254900012
DA 2021-08-04
ER

PT J
AU Rogel, E
   Contreras, E
   Leon, O
AF Rogel, E
   Contreras, E
   Leon, O
TI An experimental theoretical approach to the activity of amphiphiles as
   asphaltene stabilizers
SO PETROLEUM SCIENCE AND TECHNOLOGY
LA English
DT Article
DE molecular simulation; asphaltene stabilizer; adsorption
ID MOLECULAR RECOGNITION; ADSORPTION; POLYMERS; AGGREGATION; SURFACTANTS;
   MODEL
AB The addition of amphiphiles is one of the most frequent approaches used to prevent asphaltene precipitation in reservoir rocks and wellbore tubing. These substances can solubilize the asphaltenes otherwise insoluble under production conditions. The activity of the amphiphiles as asphaltene stabilizers is directly related to the adsorption behavior of the amphiphile on the asphaltene surface. In this study, a semiquantitative description of the adsorption behavior of different amphiphiles is carried out using molecular modeling to characterize the mutual interactions between the amphiphile, asphaltene and solvent. At the same time, flocculation onset measurements using n-heptane as a precipitating agent were carried out to evaluate the experimental activity of the different amphiphiles as asphaltene stabilizers. Two different indexes calculated using the mutual interaction energies amphiphile-asphaltene-n-heptane were used to correlate them with the experimental activity shown by the amphiphiles. The results obtained indicate that the activity of the amphiphiles as asphaltene stabilizers increases, as their adsorption on the asphaltene is more favorable. In fact, the net adsorption energies of amphiphiles on asphaltenes from n-heptane can be used as a good criterion for the selection of asphaltene precipitation inhibitors.
C1 Intevep SA, PDVSA, Caracas 1070A, Venezuela.
RP Leon, O (corresponding author), Intevep SA, PDVSA, Apdo 76343, Caracas 1070A, Venezuela.
EM leono@pdvsa.com
CR Allen M. P., 1993, COMPUTER SIMULATION
   Beerbower A., 1972, AM COSMETICS PERFUME, V87, P85
   BRINCK T, 1993, J CHEM PHYS, V98, P4305, DOI 10.1063/1.465038
   CHANG CL, 1994, LANGMUIR, V10, P1749, DOI 10.1021/la00018a022
   DEBOER RB, 1995, SPE PROD FACIL, P55
   GALOPPINI M, 1994, SPE EUR PROD OP C EX
   GONZALEZ G, 1991, COLLOID SURFACE, V52, P207, DOI 10.1016/0166-6622(91)80015-G
   GROFFE P, 1995, 030128 SPE
   Laux H, 2000, FUEL PROCESS TECHNOL, V67, P79, DOI 10.1016/S0378-3820(00)00087-4
   Leon O, 1999, LANGMUIR, V15, P7653, DOI 10.1021/la9812370
   LEONTARIRIS KJ, 1998, OIL GAS J       0901, P122
   LYKLEMA J, 1994, COLLOID SURFACE A, V91, P25, DOI 10.1016/0927-7757(94)02718-8
   MARCH J, 1992, ADV ORGANIC CHEM REA, P528
   MARQUES LCC, 1997, WORLD OIL        SEP, P125
   Murgich J, 1996, ENERG FUEL, V10, P68, DOI 10.1021/ef950112p
   Murgich J, 1999, ENERG FUEL, V13, P278, DOI 10.1021/ef980228w
   Pan HQ, 2000, AICHE J, V46, P416, DOI 10.1002/aic.690460219
   ROGEL E, 1995, COLLOID SURFACE A, V104, P85, DOI 10.1016/0927-7757(95)03234-5
   Rogel E, 2000, ENERG FUEL, V14, P566, DOI 10.1021/ef990166p
   ROGEL E, 1999, SPE LAT AM CAR PETR
   SAMII AA, 1990, PROG COLL POL SCI S, V82, P280
   Somasundaran P, 1998, COLLOID SURFACE A, V133, P125, DOI 10.1016/S0927-7757(97)00128-3
   Somasundaran P, 1997, COLLOID SURFACE A, V123, P491, DOI 10.1016/S0927-7757(96)03829-0
   Tamon H, 1995, J CHEM ENG JPN, V28, P823, DOI 10.1252/jcej.28.823
   TAYLOR SE, 1992, FUEL, V71, P1338, DOI 10.1016/0016-2361(92)90064-U
   Thomas D C, 1995, SPE PROD FACIL, P119
   Winsor P. A, 1974, SOLVENT PROPERTIES A
   ZHU BY, 1991, ADV COLLOID INTERFAC, V37, P1, DOI 10.1016/0001-8686(91)80037-K
NR 28
TC 11
Z9 12
U1 0
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1091-6466
EI 1532-2459
J9 PETROL SCI TECHNOL
JI Pet. Sci. Technol.
PY 2002
VL 20
IS 7-8
BP 725
EP 739
DI 10.1081/LFT-120003707
PG 15
WC Energy & Fuels; Engineering, Chemical; Engineering, Petroleum
SC Energy & Fuels; Engineering
GA 581WT
UT WOS:000177317900004
DA 2021-08-04
ER

PT J
AU White, SR
   Mather, PT
   Smith, MJ
AF White, SR
   Mather, PT
   Smith, MJ
TI Characterization of the cure-state of DGEBA-DDS epoxy using ultrasonic,
   dynamic mechanical, and thermal probes
SO POLYMER ENGINEERING AND SCIENCE
LA English
DT Article
ID NETWORK ARCHITECTURE; CROSS-LINKING; MIXED AMINE; RESINS; STOICHIOMETRY;
   BEHAVIOR; SPECTROSCOPY; RELAXATION; KINETICS; WAVES
AB Three experimental techniques were used to characterize the cure state of an epoxy resin system of DGEBA epoxide and DDS diamine curing agent. Samples were prepared from non-stoichiometric monomer mixtures designed so as to simulate various stages of cure of a stoichiometrically prepared epoxy. Such an approach allows for variable temperature characterization of specimens without concern for ongoing chemical reactions that would cloud interpretation of results. Additional experiments were performed on stoichiometric samples that were isothermally cured. Differential scanning calorimetry (DSC) was used to measure the heat of reaction and glass transition temperature. Dynamic mechanical analysis (DMA) was used to measure complex modulus, while ultrasonic cure monitoring (UCM) was used to measure longitudinal velocity throughout cure. DSC analysis was found to be insensitive to changes occurring at the latter stage of polymer network development, especially after vitrification. DMA characterization, however, was found to be quite sensitive to the rubbery modulus (and as such, the cure state), but is limited to cure states above gelation. Only the UCM technique was robust enough to accommodate all cure states while providing highly sensitive measurements of mechanical property development.
C1 Univ Illinois, Dept Aeronaut & Astronaut Engn, Urbana, IL 61801 USA.
   Univ Connecticut, Inst Mat Sci, Storrs, CT 06269 USA.
   Univ Connecticut, Dept Chem Engn, Storrs, CT 06269 USA.
   TRW Space & Elect Grp, Redondo Beach, CA 90278 USA.
RP White, SR (corresponding author), Univ Illinois, Dept Aeronaut & Astronaut Engn, Urbana, IL 61801 USA.
RI White, Scott/G-9667-2013
OI White, Scott/0000-0002-0831-9097
CR ALIG I, 1992, J POLYM SCI POL PHYS, V30, P791, DOI 10.1002/polb.1992.090300801
   ARRIDGE RGC, 1972, POLYMER, V13, P443, DOI 10.1016/0032-3861(72)90111-5
   CHARTOFF RP, 1994, AM SOC TEST MATER, V1249, P88, DOI 10.1520/STP15367S
   Crawford E, 1998, J POLYM SCI POL PHYS, V36, P1371, DOI 10.1002/(SICI)1099-0488(199806)36:8<1371::AID-POLB11>3.0.CO;2-4
   DIETZ AGH, 1956, IND ENG CHEM, V48, P75, DOI 10.1021/ie50553a025
   Frigione M, 2000, POLYM ENG SCI, V40, P656, DOI 10.1002/pen.11196
   GRACIET C, 1994, P IEEE ULTR S, V2, P1219
   Guerrero P, 1996, POLYMER, V37, P2195, DOI 10.1016/0032-3861(96)85865-4
   HAHN HT, 1984, NONDESTRUCTIVE METHO, P315
   HSIAO CP, 1984, P IEEE ULTR S, V1, P443
   Kim YK, 1996, POLYM ENG SCI, V36, P2852, DOI 10.1002/pen.10686
   KRAUTRAMER J, 1990, ULTRASONIC TESTING M
   Lesser AJ, 1997, J APPL POLYM SCI, V66, P387, DOI 10.1002/(SICI)1097-4628(19971010)66:2<387::AID-APP19>3.0.CO;2-V
   LINDROSE AM, 1978, EXP MECH, V18, P227, DOI 10.1007/BF02328418
   MASSINES F, 1987, NONDESTRUCTIVE CHARA, P49
   MATHER PT, 1990, P SPE REG TECHN C AD, P303
   McCrum N.G., 1967, ANELASTIC DIELECTRIC
   PARKER FR, 1986, REV PROGR QNDE, V5, P1063
   PEREPECHKO I, 1980, LOW TEMP PROPERTIES
   PICHE L, 1987, P IEEE ULTRASONICS S, V2, P1125
   ROKHLIN SI, 1986, J ACOUST SOC AM, V79, P1786, DOI 10.1121/1.393240
   ROKHLIN SI, 1987, NONDESTRUCTIVE CHARA, P19
   ROKHLIN SI, 1987, NONDESTRUCTIVE CHARA, P105
   SAUNDERS KJ, 1988, ORGANIC POLYM CHEM, pCH18
   SPEAKE JH, 1974, J PHYS D APPL PHYS, V7, P412, DOI 10.1088/0022-3727/7/3/307
   Turi E. A., 1981, THERMAL CHARACTERIZA
   White S. R., 1992, COMPOSITE POLYM, V4, P403
   WINFREE W, 1983, P IEEE ULTR S, V2, P866
   WINFREE WP, 1986, REV PROGR QNDE B, V5, P1055
   WINFREE WP, 1984, P IEEE ULTR S, V1, P447
   WINGARD CD, 1990, J APPL POLYM SCI, V40, P1981, DOI 10.1002/app.1990.070401114
   WINGARD CD, 1990, J APPL POLYM SCI, V41, P2539, DOI 10.1002/app.1990.070411101
NR 32
TC 72
Z9 73
U1 1
U2 39
PU SOC PLASTICS ENG INC
PI BROOKFIELD
PA 14 FAIRFIELD DR, BROOKFIELD, CT 06804-0403 USA
SN 0032-3888
J9 POLYM ENG SCI
JI Polym. Eng. Sci.
PD JAN
PY 2002
VL 42
IS 1
BP 51
EP 67
DI 10.1002/pen.10927
PG 17
WC Engineering, Chemical; Polymer Science
SC Engineering; Polymer Science
GA 519QM
UT WOS:000173737000005
DA 2021-08-04
ER

PT J
AU Vivaldo-Lima, E
   de Mendoza-Fuentes, A
AF Vivaldo-Lima, E
   de Mendoza-Fuentes, A
TI Development of a kinetic model for iniferter controlled/"living''
   free-radical polymerization considering diffusion-controlled effects
SO POLYMER REACTION ENGINEERING
LA English
DT Article; Proceedings Paper
CT 7th Pacific Polymer Conference
CY DEC 03-07, 2001
CL OAXACA, MEXICO
DE iniferter polymerization; living free-radical polymerization;
   diffusion-controlled reactions
ID EVALUATED RATE COEFFICIENTS; MONTE-CARLO-SIMULATION; TERMINATION
   KINETICS; HIGH-CONVERSION; STYRENE
AB A kinetic model incorporating the effects of diffusion-controlled reactions on INIFERTER (initiator-transfer agent-terminator) thermal free-radical polymerization has been developed. Molecular weight development is done using the method of moments. Diffusion-controlled effects are modeled using free-volume theory. The reactions considered to be diffusion-controlled are: monomer propagation, bimolecular radical termination, dormant termination, chain transfer to monomer, and chain transfer to iniferter. Radical, generation by thermal self-initiation is also included in the model. Model predictions indicate that diffusion-controlled propagation reduces the "living" behavior of the system, whereas a diffusion-controlled termination enhances its livingness. The livingness of the system is also enhanced by diffusion-controlled dormant termination. When diffusion-controlled termination is important, our simulations show that the overall effect of the diffusion controlled phenomena in iniferter polymerization is to enhance the livingness of the system. Experimental data from the literature for styrene, and methyl methacrylate homopolymerizations have been used to validate the kinetic model. The agreement is reasonably good.
C1 Univ Nacl Autonoma Mexico, Fac Quim, Dept Ingn Quim, Mexico City 04510, DF, Mexico.
RP Vivaldo-Lima, E (corresponding author), Univ Nacl Autonoma Mexico, Fac Quim, Dept Ingn Quim, Conjunto E,Ciudad Univ, Mexico City 04510, DF, Mexico.
EM vivaldo@servidor.unam.mx
RI Vivaldo-Lima, Eduardo/D-1518-2009
OI Vivaldo-Lima, Eduardo/0000-0001-8937-214X
CR ANDREWS RJ, 1998, POLYM HDB, V6
   Barner-Kowollik C, 2001, J POLYM SCI POL CHEM, V39, P1353, DOI 10.1002/pola.1112
   Beuermann S, 1997, MACROMOL CHEM PHYSIC, V198, P1545, DOI 10.1002/macp.1997.021980518
   Buback M, 2000, MACROMOL CHEM PHYSIC, V201, P464, DOI 10.1002/(SICI)1521-3935(20000201)201:4<464::AID-MACP464>3.0.CO;2-4
   BUBACK M, 1995, MACROMOL CHEM PHYS, V196, P3267, DOI 10.1002/macp.1995.021961016
   Buback M, 1998, MACROMOLECULES, V31, P3211, DOI 10.1021/ma971748d
   Butte A, 2002, MACROMOL THEOR SIMUL, V11, P37, DOI 10.1002/1521-3919(20020101)11:1<37::AID-MATS37>3.0.CO;2-3
   Butte A, 1999, CHEM ENG SCI, V54, P3225, DOI 10.1016/S0009-2509(98)00369-8
   DELGADILLOVELAZ.O, 2002, IN PRESS AICHE J
   Dube MA, 1997, IND ENG CHEM RES, V36, P966, DOI 10.1021/ie960481o
   Faliks A, 2001, POLYMER, V42, P2061, DOI 10.1016/S0032-3861(00)00469-9
   FLORESTLACUAHUA.A, 2002, IN PRESS ADV CHEM EN
   FUJITA H, 1993, CHEM ENG SCI, V48, P3037, DOI 10.1016/0009-2509(93)80169-Q
   Fukuda T, 2000, MACROMOL RAPID COMM, V21, P151, DOI 10.1002/(SICI)1521-3927(200003)21:4<151::AID-MARC151>3.3.CO;2-V
   Gao J, 1996, J MACROMOL SCI R M C, VC36, P199
   Greszta D, 1996, MACROMOLECULES, V29, P7661, DOI 10.1021/ma9608840
   He JP, 2000, MACROMOL THEOR SIMUL, V9, P463
   HUTCHINSON RA, 1993, POLYM REACT ENG, V1, P521
   Kothe T, 2001, J POLYM SCI POL CHEM, V39, P4009, DOI 10.1002/pola.10052
   Krajnc M, 2001, POLYMER, V42, P4153, DOI 10.1016/S0032-3861(00)00689-3
   Li L, 2000, CHEM J CHINESE U, V21, P1146
   MARTEN FL, 1982, J APPL POLYM SCI, V27, P489, DOI 10.1002/app.1982.070270213
   Matyjaszewski K., 2000, ACS S SERIES, V768, P2
   MITA I, 1987, J MACROMOL SCI R M C, VC27, P91
   Otsu T, 2000, J POLYM SCI POL CHEM, V38, P2121, DOI 10.1002/(SICI)1099-0518(20000615)38:12<2121::AID-POLA10>3.0.CO;2-X
   OTSU T, 1982, MAKROMOL CHEM-RAPID, V3, P127
   Qin SH, 2000, J POLYM SCI POL CHEM, V38, P2115, DOI 10.1002/(SICI)1099-0518(20000601)38:11<2115::AID-POLA210>3.0.CO;2-I
   Roussel J, 2001, POLYM INT, V50, P1029, DOI 10.1002/pi.741
   SCHRADER D, 1998, POLYM HDB, V91
   Shi AC, 1999, POLYM REACT ENG, V7, P283, DOI 10.1080/10543414.1999.10744511
   Shipp DA, 2000, MACROMOLECULES, V33, P1553, DOI 10.1021/ma991651m
   Shipp DA, 1999, MACROMOLECULES, V32, P2948, DOI 10.1021/ma9819135
   Tefera N, 1997, J APPL POLYM SCI, V63, P1649
   VIVALDOLIMA E, 1994, POLYM REACT ENG, V2, P17, DOI 10.1080/10543414.1994.10744448
   Ward JH, 2000, MACROMOLECULES, V33, P5137, DOI 10.1021/ma000001b
   Yu Q, 2001, MACROMOLECULES, V34, P1612, DOI 10.1021/ma001665o
   Zhang M, 2001, IND ENG CHEM RES, V40, P4336, DOI 10.1021/ie0009482
   ZHU S, 1989, MACROMOLECULES, V22, P3093, DOI 10.1021/ma00197a033
   Zhu SP, 1999, MACROMOL THEOR SIMUL, V8, P29, DOI 10.1002/(SICI)1521-3919(19990101)8:1<29::AID-MATS29>3.3.CO;2-Z
   Zhu SP, 1999, J POLYM SCI POL PHYS, V37, P2692, DOI 10.1002/(SICI)1099-0488(19990915)37:18<2692::AID-POLB13>3.0.CO;2-I
NR 40
TC 21
Z9 21
U1 1
U2 13
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016 USA
SN 1054-3414
J9 POLYM REACT ENG
JI Polym. React. Eng.
PY 2002
VL 10
IS 4
BP 193
EP 226
DI 10.1081/PRE-120016295
PG 34
WC Engineering, Chemical; Polymer Science
SC Engineering; Polymer Science
GA 624TY
UT WOS:000179778700002
DA 2021-08-04
ER

PT B
AU Mzuta, H
   Yamagata, Y
AF Mzuta, H
   Yamagata, Y
BE Yucesan, E
   Chen, CH
   Snowdon, JL
   Charnes, JM
TI Transaction cycle of agents and web-based gaming simulation for
   international emissions trading
SO PROCEEDINGS OF THE 2002 WINTER SIMULATION CONFERENCE, VOLS 1 AND 2
LA English
DT Proceedings Paper
CT 35th Winter Simulation Conference
CY DEC 08-11, 2002
CL SAN DIEGO, CA
SP Amer Stat Assoc, ACM SIGSIM, IEEE Comp Soc, IEEE Syst, Man & Cybernet Soc, Inst Ind Engineers, Inst Operat Res & Management Sci, Coll Simulat, Natl Inst Stand & Technol, Sci Modeling & Simulat Int
AB The need for new theoretical and experimental approaches to understand dynamic and heterogeneous behavior in complex economic and social systems is increasing. Computational and gaming simulations are expected to be able to reproduce complex phenomena in economics, and helps us to experiment with various controlling methods, to evaluate systematic designs, and to extract the fundamental elements which produce the interesting phenomena in depth analysis. We developed a simple agent-based simulation framework "ASIA" and its applications for economic and environmental studies including the international greenhouse gas (GHG) emissions trading. We also constructed a Web application for the gaming simulation of the emissions trading with human players to investigate and improve the behavior model for agents. In this paper, we introduce a transaction procedure with state transitions in the hierarchical cycle whose design is well suited to this type of social experiment. We also utilize this management system in the web-based gaming system.
C1 IBM Japan Ltd, Tokyo Res Lab, Yamato, Kanagawa 2428502, Japan.
RP Mzuta, H (corresponding author), IBM Japan Ltd, Tokyo Res Lab, Shimotsuruma 1623-14, Yamato, Kanagawa 2428502, Japan.
EM e28193@jp.ibm.com; yamagata@nies.go.jp
RI Yamagata, Yoshiki/H-7224-2018; Yamagata, Yoshiki/T-6489-2019
CR LEVY M, 1994, ECON LETT, V45, P103, DOI 10.1016/0165-1765(94)90065-5
   Mizuta H, 2001, WSC'01: PROCEEDINGS OF THE 2001 WINTER SIMULATION CONFERENCE, VOLS 1 AND 2, P535, DOI 10.1109/WSC.2001.977335
   MIZUTA H, 1999, 4 WORKSH EC HET INT
   Moss de Oliveira S, 1999, EVOLUTION MONEY WAR
NR 4
TC 6
Z9 6
U1 2
U2 4
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
BN 0-7803-7614-5
PY 2002
BP 801
EP 806
PG 6
WC Computer Science, Interdisciplinary Applications; Computer Science,
   Software Engineering; Engineering, Industrial; Engineering, Electrical &
   Electronic
SC Computer Science; Engineering
GA BV90S
UT WOS:000180358500102
DA 2021-08-04
ER

PT S
AU Martins, MR
   Nishimoto, K
   Ferreira, MD
AF Martins, MR
   Nishimoto, K
   Ferreira, MD
BE Chung, JS
   Matsui, T
   Chen, J
   Kyozuka, Y
TI Dynamic tension in risers and mooring lines: A comparison between an
   algebraic expression and finite element method
SO PROCEEDINGS OF THE TWELFTH (2002) INTERNATIONAL OFFSHORE AND POLAR
   ENGINEERING CONFERENCE, VOL 2
SE International Offshore and Polar Engineering Conference Proceedings
LA English
DT Proceedings Paper
CT 12th International Offshore and Polar Engineering Conference
   (ISOPE-2002)
CY MAY 26-31, 2002
CL KYUSHU, JAPAN
SP Int Soc Offshore & Polar Engineers
DE dynamic tension; mooring line; risers
ID APPROXIMATION
AB The forces and damping originated due to environmental agents and total mass (mass plus added mass) beyond the mooring lines system response are required to determine the dynamic behavior of the floating unit.
   Oceanic catenary lines play a crucial role in the "deep water oil exploration". Viscous damping in transversal motion is known to be very important and the resulting problem is intrinsically nonlinear. A riser or mooring line, when excited dynamically at its upper end, resists the imposed displacement by increasing its tension.
   Numerical Offshore Tanking (NOT) is a dynamic simulating system to preview the behavior of the production systems and was developed by Department of Naval Architecture and Ocean Engineering at USP. In this NOT an algebraic expression and a finite element method to estimate the dynamic tension in the time domain were implemented. In this paper, the results obtained with an algebraic expression for dynamic tension are compared with nonlinear time domain method, using a finite element method.
C1 Univ Sao Paulo, Dept Naval Architecture & Ocean Engn, Sao Paulo, Brazil.
RP Martins, MR (corresponding author), Univ Sao Paulo, Dept Naval Architecture & Ocean Engn, Sao Paulo, Brazil.
RI Martins, Marcelo Ramos/H-3641-2012; Nishimoto, Kazuo/F-5861-2016
OI Martins, Marcelo Ramos/0000-0002-4466-4437; 
CR Aranha JAP, 2001, APPL OCEAN RES, V23, P93, DOI 10.1016/S0141-1187(01)00010-4
   Aranha JAP, 2001, APPL OCEAN RES, V23, P83, DOI 10.1016/S0141-1187(01)00009-8
   Aranha JAP, 2001, APPL OCEAN RES, V23, P63, DOI 10.1016/S0141-1187(01)00008-6
   ARANHA JAP, 1993, POL ENG ISOPE 93 SIN
   MASETTI IQ, 1997, P 18 C IB LAT AM MET, V4, P1901
   SIVLEIRA ES, 2000, P 16 C IB LAT AM MET
NR 6
TC 0
Z9 0
U1 0
U2 1
PU INTERNATIONAL SOCIETY OFFSHORE& POLAR ENGINEERS
PI CUPERTINO
PA PO BOX 189, CUPERTINO, CA 95015-0189 USA
SN 1098-6189
BN 1-880653-58-3
J9 INT OFFSHORE POLAR E
PY 2002
BP 221
EP 228
PG 8
WC Engineering, Ocean; Engineering, Geological
SC Engineering
GA BAO32
UT WOS:000223062100032
DA 2021-08-04
ER

PT B
AU Vazquez-Semadeni, E
AF Vazquez-Semadeni, E
BE Taylor, AR
   Landecker, TL
   Willis, AG
TI Numerical models of the ISM
SO SEEING THROUGH THE DUST: THE DETECTION OF HI AND THE EXPLORATION OF THE
   ISM IN GALAXIES, PROCEEDINGS
SE Astronomical Society of the Pacific Conference Series
LA English
DT Proceedings Paper
CT Conference on Seeing Through the Dust
CY OCT 20-25, 2001
CL HERZBERG INST ASTROPHYS, PENTICTON, CANADA
SP Canadian Inst Theoret Astrophys
HO HERZBERG INST ASTROPHYS
ID MOLECULAR CLOUD COMPLEXES; THERMALLY BISTABLE FLOW; HIGH GALACTIC
   LATITUDES; SPIRAL DENSITY WAVE; INTERSTELLAR-MEDIUM; STAR-FORMATION;
   H-I; PARKER INSTABILITY; TURBULENT MODEL; MAGNETIC-FIELD
AB I review recent results from numerical simulations on the structure and dynamics of the ISM, and attempt to put together a coherent dynamical scenario. In particular, I discuss results on 1) the spatial distribution of the gas components, showing that reasonable agreement between simulations and observations exists, but noting that in most models the components axe simply defined as temperature intervals, because distinct thermodynamic "phases" do not arise; 2) some statistical issues of the physical fields, such as the dependence of the one-point statistics of the density field on the effective equation of state of the gas, the poor correlation of magnetic strength with density, the energy spectrum in weakly and highly compressible cases, and the one-point statistics of the velocity field; 3) the effects of spectroscopic observation on distorting the physical structures and results from synthetic observations of the simulations, and 4) several dynamical and thermodynamical issues, such as the role of the thermal instability in forming and confining clouds, the continuous, rather than abrupt, transition between "phases", which in turn may be consequences of the dynamics rather than the agents controlling it, the possibility of short time scales (similar to a few Myr) for molecular cloud formation, and the star-gas connection, mentioning that the models generally exhibit self-propagating star and cluster formation, while the stars may drive the medium- and small-scale gas motions, and that a "star formation instability" may induce chaotic behavior of the star-formation rate locally. I conclude with a summary, and a discussion of the work needed ahead.
C1 Univ Nacl Autonoma Mexico, Inst Astron, Morelia 58089, Michoacan, Mexico.
RP Vazquez-Semadeni, E (corresponding author), Univ Nacl Autonoma Mexico, Inst Astron, Campus Morelia,Apdo Postal 3-72, Morelia 58089, Michoacan, Mexico.
CR ADLER DS, 1992, ASTROPHYS J, V384, P95, DOI 10.1086/170854
   Avila-Reese V, 2001, ASTROPHYS J, V553, P645, DOI 10.1086/320944
   Ballesteros-Paredes J, 1999, ASTROPHYS J, V527, P285, DOI 10.1086/308076
   Ballesteros-Paredes J, 1999, ASTROPHYS J, V515, P286, DOI 10.1086/307007
   BALLESTEROSPARE.J, 2001, ASTROPH0108136
   BallesterosParedes J, 1997, AIP CONF PROC, P81
   BANIA TM, 1980, ASTROPHYS J, V239, P173, DOI 10.1086/158099
   BLITZ L, 1980, ASTROPHYS J, V238, P148, DOI 10.1086/157968
   Blitz L., 1993, PROTOSTARS PLANETS, P125
   BOULARES A, 1990, ASTROPHYS J, V365, P544, DOI 10.1086/169509
   BURKERT A, 2001, ASTROPH0109447
   BURTON WB, 1971, ASTRON ASTROPHYS, V10, P76
   Chappell D, 2001, MON NOT R ASTRON SOC, V325, P1, DOI 10.1046/j.1365-8711.2001.04196.x
   CHIANG WH, 1988, ASTROPHYS J, V328, P427, DOI 10.1086/166303
   CHIANG WH, 1985, ASTROPHYS J, V297, P507, DOI 10.1086/163546
   CHO J, 2001, ASTROPH0105235
   COX DP, 1974, ASTROPHYS J, V189, pL105, DOI 10.1086/181476
   CRUTCHER R, 2002, IN PRESS SIMULATIONS
   de Avillez MA, 2001, ASTROPHYS J, V551, pL57, DOI 10.1086/319842
   Deshpande AA, 2000, ASTROPHYS J, V543, P227, DOI 10.1086/317104
   Deshpande AA, 2000, MON NOT R ASTRON SOC, V317, P199, DOI 10.1046/j.1365-8711.2000.03631.x
   DICKEY JM, 1990, ANNU REV ASTRON ASTR, V28, P215, DOI 10.1146/annurev.aa.28.090190.001243
   DICKEY JM, 1977, ASTROPHYS J, V211, pL77, DOI 10.1086/182345
   Dickey JM, 2001, ASTROPHYS J, V561, P264, DOI 10.1086/323409
   ELMEGREEN BG, 1991, ASTROPHYS J, V378, P139, DOI 10.1086/170414
   Elmegreen BG, 2000, ASTROPHYS J, V530, P277, DOI 10.1086/308361
   ELMEGREEN BG, 1994, ASTROPHYS J, V433, P39, DOI 10.1086/174623
   ELMEGREEN BG, 1993, ASTROPHYS J, V419, pL29, DOI 10.1086/187129
   FALGARONE E, 1990, ASTROPHYS J, V359, P344, DOI 10.1086/169068
   FIELD GB, 1969, ASTROPHYS J, V155, pL149, DOI 10.1086/180324
   FIELD GB, 1965, ASTROPHYS J, V142, P531, DOI 10.1086/148317
   FRANCO J, 2001, ASTROPH0111406
   Gammie CF, 1996, ASTROPHYS J, V466, P814, DOI 10.1086/177556
   Gazol A, 2001, ASTROPHYS J, V557, pL121, DOI 10.1086/322873
   Gazol-Patino A, 1999, ASTROPHYS J, V518, P748, DOI 10.1086/307306
   GEROLA H, 1974, ASTROPHYS J, V189, P55, DOI 10.1086/152768
   Gerritsen JPE, 1997, ASTRON ASTROPHYS, V325, P972
   GOLDREICH P, 1995, ASTROPHYS J, V438, P763, DOI 10.1086/175121
   HARTMANN L, 2001, ASTROPH0108023
   Heiles C, 2001, ASTROPHYS J, V551, pL105, DOI 10.1086/319844
   Hennebelle P, 1999, ASTRON ASTROPHYS, V351, P309
   Hennebelle P, 2000, ASTRON ASTROPHYS, V359, P1124
   HENNEY WJ, 2002, UNPUB
   Jenkins EB, 2001, ASTROPHYS J SUPPL S, V137, P297, DOI 10.1086/323326
   Kadomtsev B. B., 1973, Soviet Physics - Doklady, V18, P115
   KEGEL WH, 1983, ASTRON ASTROPHYS, V119, P101
   Kim J, 2001, ASTROPHYS J, V561, pL135, DOI 10.1086/324422
   Kim J, 2001, ASTROPHYS J, V557, P464, DOI 10.1086/321634
   Kim WT, 2001, ASTROPHYS J, V559, P70, DOI 10.1086/322330
   KIM WT, 2001, ASTROPH0111398
   Klessen RS, 2000, ASTROPHYS J, V535, P869, DOI 10.1086/308854
   Korpi MJ, 1999, ASTROPHYS J, V514, pL99, DOI 10.1086/311954
   Koyama H, 2000, ASTROPHYS J, V532, P980, DOI 10.1086/308594
   KOYAMA H, 2001, ASTROPH0112420
   KRITSUK A, 2001, ASTROPH0112437
   Lazarian A, 2001, ASTROPHYS J, V555, P130, DOI 10.1086/321478
   Lazarian A, 2000, ASTROPHYS J, V537, P720, DOI 10.1086/309040
   LIOURE A, 1990, ASTRON ASTROPHYS, V235, P379
   MACLOW MM, 2001, ASTROPH0106509
   MACLOW MM, 2002, UNPUB ARAA
   Martos M, 1999, ASTROPHYS J, V526, pL89, DOI 10.1086/312381
   Martos MA, 1998, ASTROPHYS J, V509, P703, DOI 10.1086/306514
   MCKEE CF, 1977, ASTROPHYS J, V218, P148, DOI 10.1086/155667
   Minter AH, 1996, ASTROPHYS J, V458, P194, DOI 10.1086/176803
   Nordlund A. K., 1999, INTERSTELLAR TURBULE, P218, DOI DOI 10.1017/CB09780511564666.034)
   Norman CA, 1996, ASTROPHYS J, V467, P280, DOI 10.1086/177603
   Oort J. H., 1954, B ASTRON I NETHERLAN, V12, P177
   Ostriker EC, 2001, ASTROPHYS J, V546, P980, DOI 10.1086/318290
   Padoan P, 1999, ASTROPHYS J, V526, P279, DOI 10.1086/307956
   PADOAN P, 2000, ASTROPH0011465
   PARKER EN, 1966, ASTROPHYS J, V145, P811, DOI 10.1086/148828
   Passot T, 1998, PHYS REV E, V58, P4501, DOI 10.1103/PhysRevE.58.4501
   PASSOT T, 1995, ASTROPHYS J, V455, P536, DOI 10.1086/176603
   PASSOT T, 2002, UNPUB
   Pichardo B, 2000, ASTROPHYS J, V532, P353, DOI 10.1086/308546
   PORTER DH, 1992, PHYS REV LETT, V68, P3156, DOI 10.1103/PhysRevLett.68.3156
   Pringle JE, 2001, MON NOT R ASTRON SOC, V327, P663, DOI 10.1046/j.1365-8711.2001.04777.x
   ROSEN A, 1995, ASTROPHYS J, V440, P634, DOI 10.1086/175303
   Rosen A, 1996, ASTROPHYS J, V470, P839, DOI 10.1086/177915
   Saffman P.G., 1968, TOPICS NONLINEAR PHY, P485
   SANCHEZSALCEDO FJ, 2002, UNPUB APJ
   Santillan A, 2000, ASTROPHYS J, V545, P353, DOI 10.1086/317782
   Scalo J, 1999, ASTROPHYS J, V510, P258, DOI 10.1086/306567
   Scalo J, 1998, ASTROPHYS J, V504, P835, DOI 10.1086/306099
   SCALO JM, 1987, INTERSTELLAR PROCESS, P349
   Sellwood JA, 1999, ASTROPHYS J, V511, P660, DOI 10.1086/306728
   Shore S. N., 1995, Fundamentals of Cosmic Physics, V16, P1
   Stanimirovic S, 2001, ASTROPHYS J, V551, pL53, DOI 10.1086/319837
   TOHLINE JE, 1988, APJ, V322, P787
   Vazquez-Semadeni E, 2000, ASTROPHYS J, V540, P271, DOI 10.1086/309318
   Vazquez-Semadeni E., 1999, MILLIMETER WAVE ASTR, P161
   VAZQUEZSEMADENI E, 1995, ASTROPHYS J, V441, P702, DOI 10.1086/175393
   VazquezSemadeni E, 1996, ASTROPHYS J, V473, P881, DOI 10.1086/178200
   VAZQUEZSEMADENI E, 1994, ASTROPHYS J, V423, P681, DOI 10.1086/173847
   VAZQUEZSEMADENI E, 2000, PROTOSTARS PLANETS, V4, P3
   VAZQUEZSEMADENI E, 1999, INTERSTELLAR TURBULE, P223
   Wada K, 2000, ASTROPHYS J, V540, P797, DOI 10.1086/309347
   Wada K, 2001, ASTROPHYS J, V547, P172, DOI 10.1086/318344
   Wada K, 2001, ASTROPHYS J, V559, pL41, DOI 10.1086/323668
   Wada K, 1999, ASTROPHYS J, V516, pL13, DOI 10.1086/311987
   WADA K, 2001, ASTROPH0110228
NR 101
TC 8
Z9 8
U1 0
U2 0
PU ASTRONOMICAL SOC PACIFIC
PI SAN FRANCISCO
PA 390 ASHTON AVE, SAN FRANCISCO, CA 94112 USA
BN 1-58381-118-4
J9 ASTR SOC P
PY 2002
VL 276
BP 155
EP 169
PG 15
WC Astronomy & Astrophysics
SC Astronomy & Astrophysics
GA BW08B
UT WOS:000180802300024
DA 2021-08-04
ER

PT J
AU Morton, D
   Alden, CL
   Roth, AJ
   Usui, T
AF Morton, D
   Alden, CL
   Roth, AJ
   Usui, T
TI The Tg rasH2 mouse in cancer hazard identification
SO TOXICOLOGIC PATHOLOGY
LA English
DT Article
DE bioassay; carcinogenicity; CB6F1-TgN (RasH2); risk assessment; rodent;
   TgHras2; transgenic
ID TRANSGENIC MICE; GENE; TUMORS
AB The Tg rasH2 transgenic mouse has been developed as an alternative to the lifetime mouse bioassay to predict the carcinogenic potential of chemicals. Unlike the p53/mouse, the Tg rasH2 mouse is sensitive to both genotoxic and nongenotoxic carcinogens. The Tg rasH2 mouse, officially designated CB6F1-TgN (RasH2), contains multiple copies of the human c-Ha-ras oncogene and promoter within its genome. These mice develop spontaneous and chemically induced neoplasms earlier in life and in greater numbers than wild-type mice, reflecting their enhanced sensitivity to neoplasia. The most common spontaneous neoplasms in control Tg rasH2 mice 8 to 9 months of age are lung adenomas and carcinomas (7.4% incidence), splenic hemangiomas and hemangiosarcomas (5.4%), forestomach squamous cell papillomas and carcinomas (2.4%), and skin neoplasms (1.2%). Simulations have demonstrated that 20 to 25 mice/sex/treatment group are required to provide the assay with adequate statistical power. Four of 6 known or suspected human carcinogens tested in Tg rasH2 mice were positive in this assay. For 19 nonmutagenic agents testing positive in conventional rodent bioassays, 7 chemicals were positive, 10 chemicals were negative, and 2 were equivocal. None of the 10 nonmutagenic rodent carcinogens that were negative in the Tg rasH2 mouse model are considered to be human carcinogens. All nonmutagenic chemicals that were negative in the conventional rodent bioassays were also negative in the Tg rasH2 model. Results for 15 of 18 mutagenic chemicals tested in Tg rasH2 mice agreed with the results of conventional rodent bioassays, and 3 results were equivocal. The Tg rasH2 mouse model appears to predict known or suspected human carcinogens as well as the traditional mouse bioassay, but with fewer positive results for nongenotoxic compounds that are not considered human carcinogens. The Tg rasH2 mouse model is the most thoroughly tested in vivo alternative to the lifetime mouse bioassay for nongenotoxic compounds administered by oral or parenteral routes. The U. S. FDA Carcinogenicity Assessment Committee has determined that the Tg rasH2 model has been adequately evaluated for consideration for carcinogenicity testing of pharmaceutical candidates and its use could contribute to the weight of evidence for carcinogenicity assessment. The FDA will consider proposals to replace lifetime mouse carcinogenicity studies with 6-month Tg rasH2 mouse studies to support pharmaceutical registration on a case-by-case basis.
C1 Pharmacia Corp, Skokie, IL 60077 USA.
   Millennium Pharmaceut Inc, Boston, MA USA.
   Cent Inst Expt Anim, Kawasaki, Kanagawa, Japan.
RP Morton, D (corresponding author), Pharmacia Corp, 4901 Searle Pkwy,H-153A, Skokie, IL 60077 USA.
EM Dan.g.morton@pharmacia.com
CR AOKI T, 2000, WORKSH EV ALT METH C
   Contrera JF, 1998, ENVIRON HEALTH PERSP, V106, P71, DOI 10.2307/3433913
   De Jonghe S., 2000, WORKSH EV ALT METH C
   International Conference on Harmonisation, 1998, FED REGISTER, V63, P8983
   Maronpot RR, 2000, TOXICOLOGY, V146, P149, DOI 10.1016/S0300-483X(00)00168-2
   Mitsumori K, 1998, TOXICOL PATHOL, V26, P520, DOI 10.1177/019262339802600408
   MORTON D, 2000, WORKSH EV ALT METH C
   MUTAI M, 2000, WORKSH EV ALT METH C
   NESFIELD SR, 2000, WORKSH EV ALT METH C
   ROSENZWEIG BA, 2000, WORKSH EV ALT METH C
   SAITOH A, 1990, ONCOGENE, V5, P1195
   Suemizu H., 2000, WORKSH EV ALT METH C
   TANAKAMARU ZY, 2000, WORKSH EV ALT METH C
   Tennant RW, 1999, IARC SCI PUBL, P123
   TORII M, 2000, WORKSH EV ALT METH C
   TOYOSAWA K, 2000, WORKSH EV ALT METH C
   Tsuchiya T., 2001, P SOC TOX PATH ANN M
   UEDA M, 2000, WORKSH EV ALT METH C
   URANO K, 2000, WORKSH EV ALT METH C
   Yamagata N, 1997, CLASSICAL REV, V47, P2, DOI 10.1093/cr/47.1.2
   Yamamoto S, 1996, CARCINOGENESIS, V17, P2455, DOI 10.1093/carcin/17.11.2455
   Yamamoto S, 1998, ENVIRON HEALTH PERSP, V106, P57, DOI 10.2307/3433912
NR 22
TC 64
Z9 64
U1 0
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0192-6233
EI 1533-1601
J9 TOXICOL PATHOL
JI Toxicol. Pathol.
PD JAN 1
PY 2002
VL 30
IS 1
BP 139
EP 146
DI 10.1080/01926230252824851
PG 8
WC Pathology; Toxicology
SC Pathology; Toxicology
GA 558ED
UT WOS:000175952600023
PM 11890467
DA 2021-08-04
ER

PT B
AU Rebelo, E
AF Rebelo, E
BE Ural, O
   Abrantes, V
   Tadeu, A
TI How social housing can benerit from the competitive market
SO XXX IAHS WORLD CONGRESS ON HOUSING, HOUSING CONSTRUCTION: AN
   INTERDISCIPLINARY TASK, VOLS 1-3
LA English
DT Proceedings Paper
CT 30th IAHS World Congress on Housing
CY SEP 09-13, 2002
CL UNIV COIMBRA, COIMBRA, PORTUGAL
SP Int Assoc Housing Sci
HO UNIV COIMBRA
DE decision making; hedonic price model; geographic information systems;
   credit; free market
ID PROPERTY
AB This paper presents an analysis of statistical data, and develops a model of dwelling hedonic price level determination for the Oporto city (Portugal). This model is aimed to be a support to Municipal Planning decision processes, considering the complex inter-related system among the public powers and the free market functioning, involving different agents and their strategies, the administrative framework, the urban planning process and the municipal engineering. A cartographic interface was developed using geographic information systems, aimed to simulate alternative courses of municipal action, and to evaluate the expected results over housing price levels.
   A strategic proposal is made in order to transfer the responsibilities of the construction and management of the "social housing" sector to the private agents hands, suggesting that instead of the current system of dwelling support, a grant be allocated to the most needy families, so that they can choose their dwellings in the free market, thus contributing to their better social integration.
C1 Univ Porto, Fac Engn, Dept Civil Engn, Territorial & Environm Planning Sect, P-4200465 Oporto, Portugal.
RP Rebelo, E (corresponding author), Univ Porto, Fac Engn, Dept Civil Engn, Territorial & Environm Planning Sect, Rua Dr Roberto Frias SN, P-4200465 Oporto, Portugal.
RI Rebelo, Emilia Maria Delgado Domingos Antunes Malcata/X-4251-2019
OI Rebelo, Emilia Maria Delgado Domingos Antunes
   Malcata/0000-0003-4257-9017
CR ANDERSEN GE, 1995, STATO MERCATO, V45, P347
   Aydalot, 1985, EC REGIONALE URBAINE
   BALL M, 1985, ENVIRON PLANN A, V17, P503, DOI 10.1068/a170503
   BARLOW J, 1992, PROGR PLANNING, V38
   COAKLEY J, 1994, ENVIRON PLANN A, V26, P697, DOI 10.1068/a260697
   CONCEIACAO P, 2002, 5 MEIO DIA SECC PLAN
   Dehesh A, 2000, URBAN STUD, V37, P2581, DOI 10.1080/00420980020080701
   Doling J, 1999, HOUS THEORY SOC, V16, P156, DOI 10.1080/14036099950149884
   FINE B, 1995, LAND RENT HOUSING UR
   Giddens A., 1994, LEFT RIGHT FUTURE RA
   GUERRA I, 1994, SOC TERRITORIO, V20
   HAILA A, 1991, INT J URBAN REGIONAL, V15
   Haila A., 1988, ANTIPODE, V20, P79
   Harvey D., 1985, STUDIES HIST THEORY
   KEMENY, 1995, HOUSING FAMILY WEALT, P289
   KEMENY JM, 1998, P ENHR C HOUS FUT RE
   MACLENNAN D, 2000, HOUSING STUDIES, V12, P531
   MCNULTY JE, 1995, J REAL ESTATE FINANC, V11, P37, DOI 10.1007/BF01097935
   MENDES M, 1997, C POL HAB CES LISB
   NEVES V, CADERNOS REGIONAIS, V8
   PIMENTA M, 2001, ESTUDO SOCIOECONOMIC
   Scott AJ, 1980, URBAN LAND NEXUS STA
NR 22
TC 0
Z9 0
U1 0
U2 3
PU WIDE DREAMS PROJECTOS MULTIMEDIA LDA
PI COIMBRA
PA AV DR ELISIO DE MOURA, 417-1 G, COIMBRA 3030-183, PORTUGAL
BN 972-9027-31-5
PY 2002
BP 443
EP 450
PG 8
WC Architecture; Construction & Building Technology; Engineering, Civil;
   Environmental Studies; Urban Studies
SC Architecture; Construction & Building Technology; Engineering;
   Environmental Sciences & Ecology; Urban Studies
GA BV58K
UT WOS:000179444800057
DA 2021-08-04
ER

PT J
AU Joseph-McCarthy, D
   Tsang, SK
   Filman, DJ
   Hogle, JM
   Karplus, M
AF Joseph-McCarthy, D
   Tsang, SK
   Filman, DJ
   Hogle, JM
   Karplus, M
TI Use of MCSS to design small targeted libraries: Application to
   picornavirus ligands
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID COPY SIMULTANEOUS SEARCH; DRUG DESIGN; 3-DIMENSIONAL STRUCTURE;
   FUNCTIONALITY MAPS; ANTIVIRAL AGENTS; BINDING-SITES; POLIOVIRUS;
   INHIBITORS; CHEMISTRY; DYNAMICS
AB Computational methods were used to design structure-based combinatorial libraries of antipicornaviral capsid-binding ligands. The multiple copy simultaneous search (MCSS) program was employed to calculate functionality maps for many diverse functional groups for both the poliovirus and rhinovirus capsid structures in the region of the known drug binding pocket. Based on the results of the MCSS calculations, small combinatorial libraries consisting of 10s or 100s of three-monomer compounds were designed and synthesized. Ligand binding was demonstrated by a noncell-based mass spectrometric assay, a functional immunoprecipitation assay, and crystallographic analysis of the complexes of the virus with two of the candidate ligands. The P1/Mahoney poliovirus strain was used in the experimental studies. A comparison showed that the MCSS calculations had correctly identified the observed binding site for all three monomer units in one ligand and for two out of three in the other ligand. The correct central monomer position in the second ligand was reproduced in calculations in which the several key residues lining the pocket were allowed to move. This study validates the computational methodology. It also illustrates that subtle changes in protein structure can lead to differences in docking results and points to the importance of including target flexibility, as well as ligand flexibility, in the design process.
C1 Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
   Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA.
   Wyeth Ayerst Res, Dept Biol Chem, Cambridge, MA 02140 USA.
   Harvard Univ, Comm Higher Degrees Biophys, Cambridge, MA 02138 USA.
RP Joseph-McCarthy, D (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.
OI Hogle, James/0000-0002-3655-1504; filman, david/0000-0002-8714-1644
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI032480] Funding Source: NIH RePORTER
CR BADGER J, 1988, P NATL ACAD SCI USA, V85, P3304, DOI 10.1073/pnas.85.10.3304
   BADGER J, 1989, PROTEINS, V6, P1, DOI 10.1002/prot.340060102
   Bohacek RS, 1997, CURR OPIN CHEM BIOL, V1, P157, DOI 10.1016/S1367-5931(97)80004-X
   BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211
   BRUNGER AT, 1997, X PLOR MANUAL VERSIO
   Caflisch A, 1996, J COMPUT AID MOL DES, V10, P372, DOI 10.1007/BF00124471
   Caflisch A, 1995, PERSPECT DRUG DISCOV, V3, P51, DOI 10.1007/BF02174467
   CAFLISCH A, 1993, J MED CHEM, V36, P2142, DOI 10.1021/jm00067a013
   EVENSEN E, 1997, MCSSV2
   FILMAN DJ, 1989, EMBO J, V8, P1567, DOI 10.1002/j.1460-2075.1989.tb03541.x
   GRANT RA, 1994, CURR BIOL, V4, P784, DOI 10.1016/S0960-9822(00)00176-7
   Halgren TA, 1996, J COMPUT CHEM, V17, P490, DOI 10.1002/(SICI)1096-987X(199604)17:5/6<490::AID-JCC1>3.0.CO;2-P
   HOGLE JM, 1985, SCIENCE, V229, P1358, DOI 10.1126/science.2994218
   Jacobson DH, 1996, ACTA CRYSTALLOGR D, V52, P693, DOI 10.1107/S0907444996001060
   Joseph-McCarthy D, 1999, PHARMACOL THERAPEUT, V84, P179, DOI 10.1016/S0163-7258(99)00031-5
   JosephMcCarthy D, 1997, PROTEINS, V29, P32, DOI 10.1002/(SICI)1097-0134(199709)29:1<32::AID-PROT3>3.0.CO;2-H
   Klebe G, 2000, J MOL MED, V78, P269, DOI 10.1007/s001090000084
   KUNTZ ID, 1994, ACCOUNTS CHEM RES, V27, P117, DOI 10.1021/ar00041a001
   MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f
   MIRANKER A, 1991, PROTEINS, V11, P29, DOI 10.1002/prot.340110104
   Murcko MA, 1999, ANNU REP MED CHEM, V34, P297
   Neria E, 1996, J CHEM PHYS, V105, P1902, DOI 10.1063/1.472061
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Stultz CM, 1999, PROTEINS, V37, P512, DOI 10.1002/(SICI)1097-0134(19991201)37:4<512::AID-PROT3>3.3.CO;2-F
   Tsang SK, 2000, J MOL BIOL, V296, P335, DOI 10.1006/jmbi.1999.3483
   Tsang SK, 2001, CHEM BIOL, V8, P33, DOI 10.1016/S1074-5521(00)00053-3
   Wlodawer A, 1998, ANNU REV BIOPH BIOM, V27, P249, DOI 10.1146/annurev.biophys.27.1.249
   YEATES TO, 1991, EMBO J, V10, P2331, DOI 10.1002/j.1460-2075.1991.tb07772.x
   ZHANG A, 1992, VIROLOGY, V3, P453
NR 29
TC 31
Z9 32
U1 0
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD DEC 26
PY 2001
VL 123
IS 51
BP 12758
EP 12769
DI 10.1021/ja003972f
PG 12
WC Chemistry, Multidisciplinary
SC Chemistry
GA 505WZ
UT WOS:000172939700002
PM 11749532
DA 2021-08-04
ER

PT J
AU Smythe, RT
   Bickis, MG
   Krewski, D
   Fung, KY
AF Smythe, RT
   Bickis, MG
   Krewski, D
   Fung, KY
TI Efficiency of experimental designs for comparing two treatments with
   correlated binary responses
SO JOURNAL OF STATISTICAL PLANNING AND INFERENCE
LA English
DT Article
DE correlated binary data; randomization schemes; Pitman efficiency
AB In this article, we consider the efficiency of three experimental designs for comparing two treatments with correlated binary outcomes. This work is motivated in large part by the use of toxicological bioassays with laboratory animals used to identify agents capable of causing adverse health effects in humans, but has much broader research design implications. From the toxicological perspective, the completely randomized (CR), litter-matched (LM) and nested (NE) designs correspond to the random assignment of individual animals, littermates, or entire litters to either a control or test group. The randomization schemes underlying these three designs provide a framework for the construction of exact randomization tests for comparing the two treatment groups, and for the development of the asymptotic properties of these tests. The computed Pitman asymptotic relative efficiencies demonstrate that the LM design is the most powerful in the presence of positive intra-litter correlation, followed by the CR and NE designs, respectively. The relevance of these asymptotic results for the finite sample case is confirmed by computer simulation, The more detailed results presented in this paper will be of value in informing the design of experiments with two treatment groups involving correlated binary outcomes. (C) 2001 Elsevier Science B.V. All rights reserved.
C1 Oregon State Univ, Dept Stat, Corvallis, OR 97331 USA.
   Univ Saskatchewan, Saskatoon, SK S7N 0W0, Canada.
   Univ Ottawa, Ottawa, ON K1N 6N5, Canada.
   Carleton Univ, Ottawa, ON K1S 5B6, Canada.
   Univ Windsor, Windsor, ON N9B 3P4, Canada.
CR Bickis M, 1996, CAN J STAT, V24, P1, DOI 10.2307/3315686
   BICKIS M, 1988, THESIS CARLETON U OT
   BOLTHAUSEN E, 1984, Z WAHRSCHEINLICHKEIT, V66, P379, DOI 10.1007/BF00533704
   EINRICH LJ, 1991, AM STAT, V45, P302
   Feller W., 1968, INTRO PROBABILITY TH, V2
   Gart J.J., 1986, STAT METHODS CANC RE, V3
   Gaylor DW, 1999, TOXICOL SCI, V49, P318, DOI 10.1093/toxsci/49.2.318
   GODDARD M, 1990, DRUG INF J, V24, P381
   Krewski D, 1999, INHAL TOXICOL, V11, P579
   KREWSKI D, 1991, STAT TOXICOLOGY, P11
   KUPPER LL, 1986, BIOMETRICS, V42, P85, DOI 10.2307/2531245
   LEHMANN EL, 1975, NONPARAMETRICS STAT
   MANTEL N, 1979, CANCER RES, V39, P4308
   PAUL SR, 1982, BIOMETRICS, V38, P361, DOI 10.2307/2530450
   RYAN L, 1993, BIOMETRICS, V49, P1126, DOI 10.2307/2532254
   Serfling RJ, 1980, APPROXIMATION THEORE
NR 16
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-3758
J9 J STAT PLAN INFER
JI J. Stat. Plan. Infer.
PD DEC 2
PY 2001
VL 99
IS 2
BP 151
EP 173
DI 10.1016/S0378-3758(01)00083-0
PG 23
WC Statistics & Probability
SC Mathematics
GA 484BL
UT WOS:000171670300003
DA 2021-08-04
ER

PT J
AU Silin, DS
   Lyubomska, OV
   Weng, CN
AF Silin, DS
   Lyubomska, OV
   Weng, CN
TI Mycoplasma hyopneumoniae vaccination influence on porcine reproductive
   and respiratory syndrome virus and mycoplasma hyopneumoniae coinfection
SO ACTA VETERINARIA BRNO
LA English
DT Article
DE porcine reproductive and respiratory syndrome virus (PRRSV); Mycoplasma
   hyopneumoniae; vaccination; co-infection; pathogenesis
ID LELYSTAD VIRUS; PRRSV; POTENTIATION; PNEUMONIA; STRAIN
AB Simultaneous vaccination against porcine reproductive and respiratory syndrome virus and Mycoplasma hyopneumoniae can decrease the efficacy of the separate vaccination. The aim of present research was to clarify whether immunization against M. hyopneumoniae only protects against porcine reproductive and respiratory syndrome development. The challenge test with both porcine reproductive and respiratory syndrome virus and M. hyopneumoniae was performed in experimental conditions on Swine groups, with different immune protection against M. hyopneumoniae. The experiment was conducted Oil twenty specific pathogen free three-month-old piglets that previously acquired varying levels of protection against M. I Subcutaneous vaccination. The results suggest that M. hyopneumoniae initiates the pathogenic chain of M. hyopneumoniae - porcine reproductive and respiratory syndrome virus co-infection. Simultaneously vaccinated via oral and parenteral routes animals demonstrated maximal scoring of M. hyopneumoniae lesions (5.0 against 2.0 in control group), therefore such strategy seems unreasonable.
   The immunization against M. hyopneumoniae undoubtedly influences the development of porcine reproductive and respiratory syndrome virus - M. hyopneumoniae co-infection. however, the interactions between infections agents and immune defense depend oil the qualitative and quantitative parameters of immunity. These interactions are multi-factorial and too complicated for an absolutely correct prognosis. The protection against M. hyopneumoniae disease development can prevent or, at least, delay porcine reproductive and respiratory syndrome in piglets and vice versa: the lung lesions and immune suppression caused by M. hyopneumoniae can open the gate to porcine reproductive and respiratory syndrome virus, which additionally complicates pathogenesis and leads to unfavorable consequences.
C1 Pig Res Inst, Miaoli 35099, Taiwan.
   Odessa State Agr Inst, Odense, Denmark.
RP Weng, CN (corresponding author), Pig Res Inst, POB 23,1 Taiwan Sugar, Miaoli 35099, Taiwan.
CR CONZELMANN KK, 1993, VIROLOGY, V193, P329, DOI 10.1006/viro.1993.1129
   Gilbert SA, 1997, J CLIN MICROBIOL, V35, P264, DOI 10.1128/JCM.35.1.264-267.1997
   KATZ JB, 1995, VET MICROBIOL, V44, P65, DOI 10.1016/0378-1135(94)00113-B
   KULVANICH P, 1996, P 23 INT S CONTR REL, P143
   MARDASSI H, 1995, ARCH VIROL, V140, P1405, DOI 10.1007/BF01322667
   MARDASSI H, 1994, J GEN VIROL, V75, P681, DOI 10.1099/0022-1317-75-3-681
   MENG XJ, 1995, ARCH VIROL, V140, P745, DOI 10.1007/BF01309962
   MENG XJ, 1994, J GEN VIROL, V75, P1795, DOI 10.1099/0022-1317-75-7-1795
   MEULENBERG JJM, 1993, VIROLOGY, V192, P62, DOI 10.1006/viro.1993.1008
   NELSON EA, 1993, J CLIN MICROBIOL, V31, P3184, DOI 10.1128/JCM.31.12.3184-3189.1993
   Pol JMA, 1997, VET MICROBIOL, V55, P259, DOI 10.1016/S0378-1135(96)01323-5
   ROOF MB, 2000, P 16 C IPVS MELB AUS, P658
   SILIN DS, 2000, P 16 C IPVS MELB AUS, P186
   Solano GI, 1997, VET MICROBIOL, V55, P247, DOI 10.1016/S0378-1135(96)01325-9
   Thacker EL, 2000, VACCINE, V18, P1244, DOI 10.1016/S0264-410X(99)00395-3
   Thacker EL, 1999, J CLIN MICROBIOL, V37, P620, DOI 10.1128/JCM.37.3.620-627.1999
   VANSICKLE J, 1998, NATL HOG FARMER, V43, P132
   WENG CN, 1992, RES VET SCI, V53, P42, DOI 10.1016/0034-5288(92)90082-D
   WENSVOORT G, 1991, VET QUART, V13, P121, DOI 10.1080/01652176.1991.9694296
NR 19
TC 3
Z9 3
U1 0
U2 4
PU VYSOKA SKOLA VETERINARNI FARMACEUTICKA
PI BRNO 12
PA PALACKEHO 1-3, BRNO 12 612-42, CZECH REPUBLIC
SN 0001-7213
J9 ACTA VET BRNO
JI Acta Vet. BRNO
PD DEC
PY 2001
VL 70
IS 4
BP 413
EP +
DI 10.2754/avb200170040413
PG 9
WC Veterinary Sciences
SC Veterinary Sciences
GA 506GP
UT WOS:000172961800007
OA hybrid, Green Submitted
DA 2021-08-04
ER

PT J
AU Vandenabeele-Trambouze, O
   Garrelly, L
   Mion, L
   Boiteau, L
   Commeyras, A
AF Vandenabeele-Trambouze, O
   Garrelly, L
   Mion, L
   Boiteau, L
   Commeyras, A
TI Key parameters for carbamate stability in dilute aqueous-organic
   solution
SO ADVANCES IN ENVIRONMENTAL RESEARCH
LA English
DT Article
DE carbamates; stability; aqueous-organic medium; pesticides determination;
   carbamoyloximes; thiocarbamates; ureas
ID PERFORMANCE LIQUID-CHROMATOGRAPHY; CHIRAL STATIONARY PHASES;
   AMINO-ACIDS; 6-AMINOQUINOLYL-N-HYDROXYSUCCINIMIDYL CARBAMATE;
   INSECTICIDES; FLUORESCENT; RESOLUTION; REAGENT
AB Within the framework of the determination of pesticides of the carbamate family, the isocyanates prove to be excellent derivatizing agents of the hydrolysis products of pesticide residues. The optimum conditions for derivatization require the use of an aqueous organic solution (water-acetonitrile) with the presence of triethylamine. Under these conditions, the derivatives formed (ureas or carbamates) must be stable to enable a reliable and representative determination. Our objective, therefore, was to study the parameters, such as solvent, structure of the derivatizing agent, pH, nature of the catalyst, and the optimum conditions needed for stability. The kinetic and statistical analysis of 24 compounds (an analysis of variance based on 142 measurements) demonstrate that neither the effects of pH, nor of the group introduced by the derivatizing agent make it possible to simultaneously stabilize all of the formed derivatives. To ensure reliable and repeatable determination of the carbamate (obtained after derivatization), it is necessary to expulse the carbamate, in the organic phase, by adding NaCl to the aqueous-organic medium. (C) 2001 Elsevier Science Ltd. All rights reserved.
C1 Bouisson Bertrand Labs, F-34196 Montpellier, France.
   Lab Org Mol Evolut & Mat Fluores, UMR 5073, F-34095 Montpellier, France.
RP Vandenabeele-Trambouze, O (corresponding author), Bouisson Bertrand Labs, Parc Euromed,778 Rue Croix Verte, F-34196 Montpellier, France.
RI Boiteau, Laurent/F-2392-2018; Boiteau, Laurent/AAG-1814-2021
OI Boiteau, Laurent/0000-0002-4853-8032; Boiteau,
   Laurent/0000-0002-4853-8032
CR ADAMS P, 1965, CHEM REV, V65, P567, DOI 10.1021/cr60237a002
   ALI MS, 1993, J AOAC INT, V76, P1309
   BANK S, 1984, J AGR FOOD CHEM, V32, P1223, DOI 10.1021/jf00126a005
   CHANKVETADZE B, 1994, J CHROMATOGR A, V670, P39, DOI 10.1016/0021-9673(94)80278-5
   CHRISTENSON I, 1964, ACTA CHEM SCAND, V18, P904, DOI 10.3891/acta.chem.scand.18-0904
   COHEN SA, 1993, ANAL BIOCHEM, V211, P279, DOI 10.1006/abio.1993.1270
   DIXIT DS, 1994, B ENVIRON CONTAM TOX, V52, P772
   Duggan M. E., 1988, SYNTHESIS-STUTTGART, V2, P131
   FROST LN, 1973, J CHEM SOC CHEM COMM, P82, DOI 10.1039/c39730000082
   HANSEN KT, 1991, J PHARM SCI-US, V80, P793, DOI 10.1002/jps.2600800819
   HEGARTY AF, 1974, J ORG CHEM, V39, P1089, DOI 10.1021/jo00922a016
   HEGARTY AF, 1973, J CHEM SOC PERK T 2, P1719, DOI 10.1039/p29730001719
   JENSEN A, 1952, ACTA CHEM SCAND, V6, P395, DOI 10.3891/acta.chem.scand.06-0395
   JENSEN A, 1952, ACTA CHEM SCAND, V6, P385, DOI 10.3891/acta.chem.scand.06-0385
   KRAUSE RT, 1980, J ASSOC OFF ANA CHEM, V63, P1114
   KRAUSE RT, 1979, J CHROMATOGR, V185, P615, DOI 10.1016/S0021-9673(00)85635-6
   OKAMOTO Y, 1994, J CHROMATOGR A, V666, P403, DOI 10.1016/0021-9673(94)80400-1
   OLSEN J, 1952, ACTA CGEN SCABD, V12, P398
   PAWLOWSKA M, 1993, J CHROMATOGR, V641, P257, DOI 10.1016/0021-9673(93)80142-U
   THOMSEN KF, 1993, INT J PHARM, V91, P39, DOI 10.1016/0378-5173(93)90419-G
   Vandenabeele O, 1998, J CHROMATOGR A, V795, P239, DOI 10.1016/S0021-9673(97)00992-8
   VANDENABEELETRA.O, IN PRESS ADV ENV RES
   WILLIAMS A, 1972, J CHEM SOC PERK T 2, P808, DOI 10.1039/p29720000808
   WILLIAMS A, 1973, J CHEM SOC PERK T 2, P1244, DOI 10.1039/p29730001244
   YU JH, 1994, J CHROMATOGR B, V658, P249, DOI 10.1016/0378-4347(94)00242-8
NR 25
TC 8
Z9 8
U1 0
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1093-0191
J9 ADV ENVIRON RES
JI Adv. Environ. Res.
PD DEC
PY 2001
VL 6
IS 1
BP 67
EP 80
DI 10.1016/S1093-0191(00)00071-X
PG 14
WC Engineering, Environmental; Engineering, Chemical
SC Engineering
GA 486KW
UT WOS:000171817800007
DA 2021-08-04
ER

PT J
AU Franklin, S
AF Franklin, S
TI Models as implementations of a theory, rather than simulations: Dancing
   to a different drummer
SO BEHAVIORAL AND BRAIN SCIENCES
LA English
DT Editorial Material
AB Robots, as well as software agents, can be of use in biology as implementations of a theory rather than as simulations of specific real world target systems. Such implementations generate hypotheses rather than representing them. Their behavior is not predicted, but rather observed, and is not expected to duplicate that of a target system. Scientific knowledge is gained through the testing of generated hypotheses.
C1 Univ Memphis, Inst Intelligent Syst, Memphis, TN 38152 USA.
RP Franklin, S (corresponding author), Univ Memphis, Inst Intelligent Syst, Memphis, TN 38152 USA.
RI Franklin, Stan/AAI-5506-2020
CR Baars B., 1988, COGNITIVE THEORY CON, VSecond
   Baars B, 1997, THEATER CONSCIOUSNES
   Barsalou LW, 1999, BEHAV BRAIN SCI, V22, P577, DOI 10.1017/S0140525X99532147
   Franklin S, 1997, CYBERNET SYST, V28, P499, DOI 10.1080/019697297126029
   Franklin S, 1998, IEEE SYS MAN CYBERN, P2646, DOI 10.1109/ICSMC.1998.725059
   Franklin S., 2000, Neural Network World, V10, P505
   FRANKLIN S, 2001, PRACTICAL APPL INTEL
   Franklin S., 2000, P INT C COGN MOD MAR, P100
   Franklin Stan, 2001, P 23 ANN C COGN SCI, P301
   Glenberg AM, 1997, BEHAV BRAIN SCI, V20, P1, DOI 10.1017/S0140525X97470012
   James W., 1890, PRINCIPLES PSYCHOL, V2
   Kintsch W., 1998, COMPREHENSION
   Kondadadi R., 2001, P 6 INT S ART LIF RO, P280
   LIBET B, 1983, BRAIN, V106, P623, DOI 10.1093/brain/106.3.623
   LIBET B, 1999, J CONSCIOUSNESS STUD, V6
   SLOMAN A, 1999, FDN RATIONAL AGENCY
NR 16
TC 0
Z9 0
U1 0
U2 2
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 40 WEST 20TH ST, NEW YORK, NY 10011-4221 USA
SN 0140-525X
J9 BEHAV BRAIN SCI
JI Behav. Brain Sci.
PD DEC
PY 2001
VL 24
IS 6
BP 1059
EP +
DI 10.1017/S0140525X01310129
PG 9
WC Psychology, Biological; Behavioral Sciences; Neurosciences
SC Psychology; Behavioral Sciences; Neurosciences & Neurology
GA 609ZK
UT WOS:000178936100011
PM 18241370
DA 2021-08-04
ER

PT J
AU Goldenstein, S
   Karavelas, M
   Metaxas, D
   Guibas, L
   Aaron, E
   Goswami, A
AF Goldenstein, S
   Karavelas, M
   Metaxas, D
   Guibas, L
   Aaron, E
   Goswami, A
TI Scalable nonlinear dynamical systems for agent steering and crowd
   simulation
SO COMPUTERS & GRAPHICS-UK
LA English
DT Article
ID DELAUNAY
AB We present a new methodology for agent modeling that is scalable and efficient. It is based on the integration of nonlinear dynamical systems and kinetic data structures. The method consists of three layers, which together model 3D agent steering, crowds and flocks among moving and static obstacles. The first layer, the local layer employs nonlinear dynamical systems theory to models low-level behaviors. It is fast and efficient, and it does not depend on the total number of agents in the environment. This dynamical systems-based approach also allows us to establish continuous numerical parameters for modifying each agent's behavior. The second layer, a global environment layer consists of a specifically designed kinetic data structure to track efficiently the immediate environment of each agent and know which obstacles/agents are near or visible to the given agent. This layer reduces the complexity in the local layer. In the third layer, a global planning layer, the problem of target tracking is generalized in a way that allows navigation in maze-like terrains, avoidance of local minima and cooperation between agents. We implement this layer based on two approaches that are suitable for different applications: One approach is to track the closest single moving or static target; the second is to use a pre-specified vector field, which may be generated automatically (with harmonic functions, for example) or based on user input to achieve the desired output. We also discuss how hybrid systems concepts for global planning can capitalize on both our layered approach and the continuous, reactive nature of our agent steering.
   We demonstrate the power of the approach through a series of experiments simulating single/multiple agents and crowds moving towards moving/static targets in complex environments. (C) 2001 Published by Elsevier Science Ltd.
C1 Univ Penn, Dept Comp & Informat Sci, Philadelphia, PA 19104 USA.
   Stanford Univ, Dept Comp Sci, Stanford, CA 94305 USA.
RP Goldenstein, S (corresponding author), Univ Penn, Dept Comp & Informat Sci, Philadelphia, PA 19104 USA.
RI Goldenstein, Siome/A-4468-2013
CR AARON E, 2001, P 3 INT WORKSH INT V
   Alur R, 2000, P IEEE, V88, P971, DOI 10.1109/5.871304
   ALUR R, 2000, LECT NOTES COMPUTER, V1790
   ALUR R, 1996, LECT NOTES COMPUTER, V1066
   Arkin R. C., 1990, Robotics and Autonomous Systems, V6, P105, DOI 10.1016/S0921-8890(05)80031-4
   Atkinson K. E., 1978, INTRO NUMERICAL ANAL
   Basch J, 1999, J ALGORITHM, V31, P1, DOI 10.1006/jagm.1998.0988
   BEARDON C, 1995, COMPUTER GRAPHICS DE, P217
   BLUMBERG B, 1997, A3 C AUT AG
   Brogan DC, 1998, IEEE COMPUT GRAPH, V18, P58, DOI 10.1109/38.708561
   Cavazza M, 1998, IEEE COMPUT GRAPH, V18, P24, DOI 10.1109/38.708558
   Cheong Otfried, 1997, COMPUTATIONAL GEOMET
   CHEW LP, 1989, ALGORITHMICA, V4, P97
   CONNOLLY CI, 1992, INT S INT CONTR
   Costa M, 1996, COMPUT GRAPH, V20, P377, DOI 10.1016/0097-8493(96)00006-4
   Dang T, 1998, LECT NOTES COMPUT SC, V1386, P96
   FACELLO MA, 1995, COMPUT AIDED GEOM D, V12, P349, DOI 10.1016/0167-8396(94)00018-N
   Foster N, 1996, PROC GRAPH INTERF, P204
   FOSTER N, 1997, P SIGGRAPH 97
   FOX RW, 1989, INTRO FLUID MECH
   Funge J, 1999, COMP GRAPH, P29
   Goldenstein S, 1999, VISUAL COMPUT, V15, P349, DOI 10.1007/s003710050184
   GOLDENSTEIN S, 1998, P COMP AN 98 JUN
   GRZESZCZUK R, 1995, P 22 ANN C COMP GRAP, P63
   Guibas L. J., 1988, Proceedings of the Fourth Annual Symposium on Computational Geometry, P289, DOI 10.1145/73393.73423
   Guibas LJ, 1998, ROBOTICS: THE ALGORITHMIC PERSPECTIVE, P191
   GUIBAS LJ, 1992, LECT NOTES COMPUT SC, V570, P113
   Haumann D. R., 1988, Visual Computer, V4, P332, DOI 10.1007/BF01908878
   Haykin S., 1998, NEURAL NETWORKS COMP
   Henzinger TA, 1995, LECT NOTES COMPUT SC, V999, P252
   HODGINS JK, 1997, ANN C SERIES, P153
   KHATIB O, 1986, INT J ROBOT RES, V5, P90, DOI 10.1177/027836498600500106
   KURLANDER D, 1995, P CHI 95 C, P472
   LARGE E, 1998, INT J ROBOTICS RES
   Large EW, 1999, INT J ROBOT RES, V18, P37, DOI 10.1177/027836499901800103
   LETHBRIDGE TC, 1989, COMPUT GRAPH, V13, P297, DOI 10.1016/0097-8493(89)90077-0
   LYNCH NA, 2000, LECT NOTES COMPUTER, V1790
   Musse SR, 2001, IEEE T VIS COMPUT GR, V7, P152, DOI 10.1109/2945.928167
   NOSER H, 1995, COMPUTER GRAPHICS
   OPPENHEIM AV, 1983, SIGNAL SYSTEMS
   Pappas G. J., 1997, LECT NOTES COMPUTER, V1273, P329
   Perko L., 1991, TEXTS APPL MATH
   PERLIN K, 1996, SIGGRAPH 96, P205
   POTTINGER D, 1999, GAME DEV         JAN
   Press W. H., 1992, NUMERICAL RECIPES C, V2nd
   REINOLDS C, 1999, P GAM DEV C
   Renault O., 1990, Journal of Visualization and Computer Animation, V1, P18
   Reynolds CW., 1987, SIGGRAPH COMPUT GRAP, V21, P25, DOI [DOI 10.1145/37402.37406, 10.1145/37402.37406]
   Ridsdale G., 1990, Journal of Visualization and Computer Animation, V1, P66
   Sato K., 1993, Advanced Robotics, V7, P449
   Schoner G, 1995, ROBOT AUTON SYST, V16, P213, DOI 10.1016/0921-8890(95)00049-6
   STEINHAGE A, 1997, P IEEE INT S IND EL
   STOUT BW, 1996, GAME DEV         OCT
   THALMANN NM, 1995, P IEEE, V83, P1022, DOI 10.1109/5.390120
   Tu X., 2000, P 28 ACM ANN C COMP, P43, DOI [DOI 10.1145/192161.192170, 10.1145/192161.192170]
   VINCKLE S, 1997, GAME DEV         JUN
   WILFONG G, 1988, P 4 ACM S COMP GEOM, P179
   2000, P IEEE, V88
NR 58
TC 33
Z9 34
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0097-8493
EI 1873-7684
J9 COMPUT GRAPH-UK
JI Comput. Graph.-UK
PD DEC
PY 2001
VL 25
IS 6
BP 983
EP 998
DI 10.1016/S0097-8493(01)00153-4
PG 16
WC Computer Science, Software Engineering
SC Computer Science
GA 507YK
UT WOS:000173058700005
OA Green Submitted
DA 2021-08-04
ER

PT J
AU Precht, D
   Voigt, J
   Hagemeister, H
   Kanitz, W
AF Precht, D
   Voigt, J
   Hagemeister, H
   Kanitz, W
TI The influence of dietary rumen-protected linoleic acid on milk fat
   composition, spreadability of butter and energy balance in dairy cows
SO EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY
LA English
DT Article
DE milk fat quality; linoleic acid; trans fatty acids; CLA; butter
   spreadability
ID ANTICARCINOGENIC AGENTS; LIPID-METABOLISM; EARLY LACTATION;
   ADIPOSE-TISSUE; POSTPARTUM; ISOMERS; CATTLE; FERTILITY; HEALTH
AB The aim of this study was to determine the effects of a diet supplemented with rumen-protected linoleic acids (C18:2) on the composition of milk fat and the energy balance of dairy cattle during the first 15 wk of lactation. The 32 Holstein-Friesian cows were allotted in two treatment groups; in the experimental group one-third of the starch (relative to the control group) was substituted with protected fat on an energy basis. Milk samples from all cows were collected weekly from week 2 to 15 postpartum (p.p.). To analyze the milk fat composition milk samples from 16 cows in each group were collected from week 6 and 7 as well as from week 13 and 14 p.p. and were mixed together, respectively. Triglyceride analysis demonstrated an extensive use of depot fat in both cow groups at the beginning of the lactation period. However, calculated energy balance, triglyceride composition and back fat thickness showed that the usual deficit of energy intake in early lactation was significantly shortened in the experimental group by three weeks. In comparison with the control group the content of the saturated fatty acids (FAs) C12, C14 and C16 in the experimental group decreased by 17.3% at 6 to 7 wk and by 19.2% at 13 to 14 wk. The stearic acid content of milk fat was increased by 25.9% at 6 to 7 wk and by 27.7% at 13 to 14 wk in the experimental group. The content of cis Delta9 oleic acid was increased by 21.6% at 6 to 7 and by 30.3% at 13 to 14 wk, while the C18:2 FA content was doubled as compared with the control group. Thus besides the increase of the trans-C-18:1 FA (TFA) content the nutritional value of fats could be improved using the experimental fat supplement. The TFA content still remained within the range of variation of natural milk fats. Additionally the experimental fat intake led to a number of desired effects; an increase in the content of conjugated linoleic acids (cis Delta9,trans Delta11) by 55.9% (6 to 7 wk) and by 97.1% (13 to 14 wk p.p.), respectively, and a decrease in the cholesterol level. Further, the butyric acid content increased relatively by more than 20%. The addition of this fat resulted simultaneously in a changed triglyceride composition with increased C50, C52 and C54 contents. Thus a markedly improved spreadability of the resulting butter might be expected.
C1 Bundesanstalt Milchforsch, Inst Chem & Technol Milch, D-24103 Kiel, Germany.
   Forschungsinst Biol Landwirtschaftlicher Nutztier, Dummerstorf, Germany.
RP Precht, D (corresponding author), Bundesanstalt Milchforsch, Inst Chem & Technol Milch, Hermann Weigmann Str 1, D-24103 Kiel, Germany.
CR Adlof RO, 2000, LIPIDS, V35, P131, DOI 10.1007/BF02664761
   Chouinard PY, 1998, J DAIRY SCI, V81, P471, DOI 10.3168/jds.S0022-0302(98)75599-7
   Chouinard PY, 2001, J DAIRY SCI, V84, P680, DOI 10.3168/jds.S0022-0302(01)74522-5
   Collard BL, 2000, J DAIRY SCI, V83, P2683, DOI 10.3168/jds.S0022-0302(00)75162-9
   de Vries MJ, 1999, J DAIRY SCI, V82, P1927, DOI 10.3168/jds.S0022-0302(99)75428-7
   DLG Futterwerttabellen: Wiederkauer, 1997, DLG FUTTERWERTTABELL
   *EXP PAN T FATT AC, 1995, AM J CLIN NUTR, V62, pS655
   FREDE E, 1990, KIELER MILCHW FORSCH, V42, P225
   Fritsche J, 1998, FETT-LIPID, V100, P190, DOI 10.1002/(SICI)1521-4133(199806)100:6<190::AID-LIPI190>3.3.CO;2-X
   HART IC, 1978, J ENDOCRINOL, V77, P333, DOI 10.1677/joe.0.0770333
   Heuer C, 1999, J DAIRY SCI, V82, P295, DOI 10.3168/jds.S0022-0302(99)75236-7
   Klawuhn D, 1998, DEUT TIERARZTL WOCH, V105, P54
   McNamara JP, 1995, J DAIRY SCI, V78, P2782, DOI 10.3168/jds.S0022-0302(95)76909-0
   MCNAMARA JP, 1994, J NUTR, V124, pS1383
   PALMQUIST DL, 1993, J DAIRY SCI, V76, P1753, DOI 10.3168/jds.S0022-0302(93)77508-6
   Parodi PW, 1999, J DAIRY SCI, V82, P1339, DOI 10.3168/jds.S0022-0302(99)75358-0
   Parodi PW, 1997, J NUTR, V127, P1055
   Precht D, 1996, INT DAIRY J, V6, P791, DOI 10.1016/0958-6946(96)00004-0
   Precht D, 1997, NAHRUNG, V41, P330, DOI 10.1002/food.19970410603
   Precht D, 1995, NAHRUNG, V39, P343, DOI 10.1002/food.19950390503
   PRECHT D, 1992, Z LEBENSM UNTERS FOR, V194, P107, DOI 10.1007/BF01190178
   Precht D, 1998, FETT-LIPID, V100, P546, DOI 10.1002/(SICI)1521-4133(199812)100:12<546::AID-LIPI546>3.3.CO;2-I
   Precht D, 2001, NAHRUNG, V45, P2, DOI [10.1002/1521-3803(20010101)45:1<2::AID-FOOD2>3.0.CO;2-5, 10.1002/1521-3803(20010101)45:1&lt;2::AID-FOOD2&gt;3.0.CO;2-5]
   PRECHT D, 1985, FETT WISS TECHNOL, V87, P117, DOI 10.1002/lipi.19850870309
   PRECHT D, 1998, SCHRIFTENREIHE BUN A, pS33
   Rastani RR, 2001, J DAIRY SCI, V84, P1201, DOI 10.3168/jds.S0022-0302(01)74581-X
   SCHULTE E, 1989, FETT WISS TECHNOL, V91, P181, DOI 10.1002/lipi.19890910504
   Senatore EM, 1996, ANIM SCI, V62, P17, DOI 10.1017/S1357729800014260
   WU Z, 1991, J DAIRY SCI, V74, P3025, DOI 10.3168/jds.S0022-0302(91)78488-9
   ZOLLNER N, 1992, CLIN INVESTIGATOR, V70, P968
   2001, GESELLSCHAFT ERNAHRU
   1985, VERBAND DTSCH LANDWI, V6
NR 32
TC 8
Z9 8
U1 0
U2 7
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 1438-7697
J9 EUR J LIPID SCI TECH
JI Eur. J. Lipid Sci. Technol.
PD DEC
PY 2001
VL 103
IS 12
BP 783
EP 792
PG 10
WC Food Science & Technology; Nutrition & Dietetics
SC Food Science & Technology; Nutrition & Dietetics
GA 508JG
UT WOS:000173084500003
DA 2021-08-04
ER

PT J
AU Jaeger, BR
   Seidel, D
AF Jaeger, BR
   Seidel, D
TI Hyperlipoproteinemia and apheresis. Clinical experience with the
   HELP-system
SO HERZ
LA German
DT Article
DE hyperlipoproteinemia; coronary heart disease; therapy of lipid
   metabolism; LDL-apheresis; clinical experience with LDL-apheresis
ID CORONARY-ARTERY-DISEASE; LOW-DENSITY-LIPOPROTEIN; ANGIOGRAPHICALLY
   ASSESSED TRIAL; C-REACTIVE PROTEIN; HEART-DISEASE; LDL-APHERESIS;
   MYOCARDIAL-INFARCTION; PLASMA-FIBRINOGEN; RISK-FACTORS;
   CARDIOVASCULAR-DISEASE
AB No question, one of the leading causal factors for early atherosclerosis and coronary heart disease (CHD) is the abundance of LDL-cholesterol in the blood, exceeding limits of loo mg/dl. Thus, recommendations for therapy focus on LDL-levels less than loo mg/dl. With the introduction of the statins - a very potent family of lipid lowering agents - such target levels can be achieved in most of the patients, resulting in a drastic decrease of LDL, CHID incidences, as well as in a reduction of cardiac and total mortality.
   There is, however, a remaining small group of patients, who is more or less resistant to an adequate combination of dietary and drug therapy. For these patients, various techniques of apheresis are available for over 15 years. Some of them have been approved by the FDA in the US and comparable regulatory offices in Europe. The most extensive experimental and clinical experience was gathered with the H.E.L.P. system of B. Braun Melsungen, which differs from other apheresis techniques by its efficiency to eliminate LDL, Lp(a), Fibrinogen and CRP simultaneously. The clinical results obtained up to day with the apheresis clearly demonstrate a significant reduction of risk factors and clinical events, as well as an excellent long-term tolerance.
C1 Univ Munich, Klinikum Grosshadern, Inst Klin Chem, D-81377 Munich, Germany.
RP Seidel, D (corresponding author), Univ Munich, Klinikum Grosshadern, Inst Klin Chem, Marchioninistr 15, D-81377 Munich, Germany.
EM Dietrich.Seidel@klch.med.uni-muenchen.de
CR *AWMF, 019001 AWMF
   BANERJEE AK, 1992, THROMB HAEMOSTASIS, V68, P261
   BHAKDI S, 1995, J EXP MED, V182, P1959, DOI 10.1084/jem.182.6.1959
   Bosch T, 2000, ARTIF ORGANS, V24, P81, DOI 10.1046/j.1525-1594.2000.06476.x
   Bostom AG, 1996, JAMA-J AM MED ASSOC, V276, P544, DOI 10.1001/jama.276.7.544
   BOSTOM AG, 1994, CIRCULATION, V90, P1688, DOI 10.1161/01.CIR.90.4.1688
   *BUB, 2001, BUB RICHTL BUND RECH
   Cremer P, 1997, ATHEROSCLEROSIS, V129, P221, DOI 10.1016/S0021-9150(96)06030-3
   CREMER P, 1994, EUR J CLIN INVEST, V24, P444, DOI 10.1111/j.1365-2362.1994.tb02373.x
   DAVIES MJ, 1990, CIRCULATION, V82, P38
   DEGENNES JL, 1976, SOC MED HOSP PARIS, V118, P1377
   *DGFF, EMPF DTSCH GES BEK F
   EISENHAUER T, 1986, T AM SOC ART INT ORG, V32, P104
   ERNST E, 1990, J INTERN MED, V227, P365, DOI 10.1111/j.1365-2796.1990.tb00174.x
   FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406
   FUSTER V, 1992, NEW ENGL J MED, V326, P310
   GOTTO AM, 1995, CIRCULATION, V92, P646, DOI 10.1161/01.CIR.92.3.646
   GUYTON JR, 1989, AM J PATHOL, V134, P705
   HEINRICH J, 1995, THROMB HAEMOSTASIS, V73, P374
   Jaeger BR, 1999, ACT NEUR S, V73, P81
   Jaeger BR, 1997, CIRCULATION, V96, P154
   Jaeger BR, 2001, THER APHER, V5, P207, DOI 10.1046/j.1526-0968.2001.00289.x
   JAEGER BR, UNPUB DRASTIC CHOLES
   JAEGER BR, IN PRESS J PEDIAT
   JAEGER BR, IN PRESS THER APHER
   JAEGER BR, 1997, TRANSPLANTATIONSMEDI, V9, P192
   JAEGER BR, 2000, Z KARDIOL S5, V89, pA1114
   Labarrere CA, 1999, CURR OPIN CARDIOL, V14, P133, DOI 10.1097/00001573-199903000-00010
   LIUZZO G, 1994, NEW ENGL J MED, V331, P417, DOI 10.1056/NEJM199408183310701
   LUPIEN PJ, 1976, LANCET, V1, P1261
   MEADE TW, 1993, LANCET, V342, P1076, DOI 10.1016/0140-6736(93)92062-X
   Mellwig KP, 2000, EUR HEART J, V21, P495
   Mellwig KP, 2001, J AM COLL CARDIOL, V37, p443A
   MELLWIG KP, IN PRESS J PEDIAT
   Park JW, 1996, J HEART LUNG TRANSPL, V15, P572
   PEDERSEN TR, 1994, LANCET, V344, P1383
   Pfefferkorn TK, 1999, STROKE, V30, P1802, DOI 10.1161/01.STR.30.9.1802
   REICHART B, 1995, KIDNEY INT, V48, pS52
   Ridker PM, 2001, NEW ENGL J MED, V344, P1959, DOI 10.1056/NEJM200106283442601
   Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401
   Riegger G, 1999, ATHEROSCLEROSIS, V144, P263, DOI 10.1016/S0021-9150(99)00062-3
   RIESEN WF, 1986, SCHWEIZ MED WSCHR, V116, P8
   SCHUFFWERNER P, 1989, EUR J CLIN INVEST, V19, P30, DOI 10.1111/j.1365-2362.1989.tb00303.x
   SCHUFFWERNER P, 1994, EUR J CLIN INVEST, V24, P724, DOI 10.1111/j.1365-2362.1994.tb01068.x
   SCHUFFWERNER P, 2001, HDB FETTSTOFFWECHSEL, P538
   SEIDEL D, 1991, EUR J CLIN INVEST, V21, P375, DOI 10.1111/j.1365-2362.1991.tb01384.x
   Seidel D, 1988, J Clin Apher, V4, P78, DOI 10.1002/jca.2920040207
   Seidel D, 1996, ARTIF ORGANS, V20, P303, DOI 10.1111/j.1525-1594.1996.tb04449.x
   SEIDEL D, 1994, HELP REPORT 1994 10
   SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001
   STARY HC, 1990, EUR HEART J, V11, P3, DOI 10.1093/eurheartj/11.suppl_E.3
   Steinberg D, 1999, JAMA-J AM MED ASSOC, V282, P2043, DOI 10.1001/jama.282.21.2043
   STOFFEL W, 1981, P NATL ACAD SCI-BIOL, V78, P611, DOI 10.1073/pnas.78.1.611
   Suckfull M, 2000, EUR ARCH OTO-RHINO-L, V257, P59, DOI 10.1007/PL00007510
   Thiery J, 1998, CURR OPIN LIPIDOL, V9, P521, DOI 10.1097/00041433-199812000-00002
   THIERY J, 1990, EUR J PEDIATR, V149, P716, DOI 10.1007/BF01959530
   THOMPSON SG, 1995, NEW ENGL J MED, V332, P635, DOI 10.1056/NEJM199503093321003
   WILSON PW, 1980, AM J CARDIOL, V46, P649, DOI 10.1016/0002-9149(80)90516-0
   Windaus A, 1910, H-S Z PHYSIOL CHEM, V67, P174, DOI 10.1515/bchm2.1910.67.2.174
   Yano K, 2001, ARTERIOSCL THROM VAS, V21, P1065, DOI 10.1161/01.ATV.21.6.1065
   YOKOYAMA S, 1985, ARTERIOSCLEROSIS, V5, P613, DOI 10.1161/01.ATV.5.6.613
   ZEIHER AM, 1991, CIRCULATION, V83, P391, DOI 10.1161/01.CIR.83.2.391
   PERSONLICHE MITTEILU
NR 63
TC 4
Z9 4
U1 0
U2 2
PU URBAN & VOGEL
PI MUNICH
PA NEUMARKTER STRASSE 43, D-81673 MUNICH, GERMANY
SN 0340-9937
EI 1615-6692
J9 HERZ
JI Herz
PD DEC
PY 2001
VL 26
IS 8
BP 531
EP 544
DI 10.1007/PL00002058
PG 14
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 511AA
UT WOS:000173239300005
PM 11820156
DA 2021-08-04
ER

PT J
AU Basso, N
   Terragno, NA
AF Basso, N
   Terragno, NA
TI History about the discovery of the renin-angiotensin system
SO HYPERTENSION
LA English
DT Article
DE renin; angiotonin; angiotensin; renin substrate; renin activator
AB The history of the discovery of the renin-angiotensin system began in 1898 with the studies made by Tigerstedt and Bergman, who reported the pressor effect of renal extracts; they named the renal substance renin based on its origin. In 1934, Harry Goldblatt induced experimental hypertension in dogs by clamping a renal artery. About 1936, simultaneously in the Medical School of the University of Buenos Aires, Argentina, and in the Eli-Lilly Laboratories in Indianapolis, 2 independent groups of researchers, using the Goldblatt technique to produce experimental hypertension, demonstrated renal secretion of a pressor agent similar to renin. In the following years, both teams described the presence of a new compound in the renal vein blood of ischemic kidneys. This agent was extracted from blood with 70% acetone and had a short pressor effect. The final conclusion was that renin acted enzymatically on a plasma protein to produce the new substance. In Buenos Aires, it was called hypertensin; in the United States, angiotonin. In 1958, Eduardo Braun Menendez from Argentina and Irving H. Page from the United States agreed to name it angiotensin.
C1 Univ Buenos Aires, Fac Med, Inst Invest Cardiol, Buenos Aires, DF, Argentina.
RP Basso, N (corresponding author), Univ Buenos Aires, Fac Med, Inst Invest Cardiol, Marcelo T de Alvear 2270,C1122AAJ, Buenos Aires, DF, Argentina.
EM nidiabasso@yahoo.com
CR AQUINI AC, 1938, REV SOC ARG BIOL, V14, P422
   BOUCKAERT JJ, 1939, J PHYSL, V96, P44
   BRAUN MENENDEZ E., 1939, REV SOC ARGENTINA BIOL, V15, P420
   BRAUN MENENDEZ E., 1939, REV SOC ARGENTINA BIOL, V15, P161
   BRAUN MENENDEZ E., 1939, REV SOC ARGENTINA BIOL, V15, P401
   BRAUNMENENDEZ E, 1958, SCIENCE, V127, P242, DOI 10.1126/science.127.3292.242-a
   BRAUNMENENDEZ E, 1958, CIRCULATION, V17, P668, DOI 10.1161/01.CIR.17.4.668
   BRAUNMENENDEZ E, 1943, HIPERTENSION ARTERIA
   BRIGHT R, 1836, GUYS HOSP REP, V1, P380
   Fasciolo J C, 1940, Science, V92, P554, DOI 10.1126/science.92.2398.554
   Fasciolo JC, 1938, J PHYSIOL-LONDON, V94, P281, DOI 10.1113/jphysiol.1938.sp003680
   FASCIOLO JC, 1939, THESIS HNOS
   FREEMAN NE, 1937, AM HEART J, V14, P405
   Goldblatt H, 1934, J EXP MED, V59, P347, DOI 10.1084/jem.59.3.347
   Goldblatt H, 1937, ANN INTERN MED, V11, P69, DOI 10.7326/0003-4819-11-1-69
   GRIMSON KS, 1939, J PHYSL, V95, pP45
   Harrison TR, 1936, P SOC EXP BIOL MED, V35, P38
   Harrison TR, 1937, ARCH INTERN MED, V60, P1058, DOI 10.1001/archinte.1937.00180060111011
   Heymans C, 1938, P SOC EXP BIOL MED, V39, P94
   HOUSSAY B. A., 1938, REV SOC ARGENTINA BIOL, V14, P5
   Houssay B.A., 1937, REV SOC ARGENT BIOL, V13, P284
   Houssay BA, 1937, B ACAD NAC MED, V18, P342
   JOHNSON G, 1868, T R MED CHIR SOC, V51, P57
   Kohlstaedt KG, 1938, P SOC EXP BIOL MED, V39, P214
   Korotkoff NS., 1905, B IMP MIL MED ACAD, V11, P365, DOI [10.1093/ndt/gfg602, DOI 10.1093/NDT/GFG602]
   Leloir L. F., 1942, REV ARGENTINA CARDIOL, V9, P269
   LELOIR L. F., 1940, REV SOC ARGENTINA BIOL, V16, P75
   Mahomed F. A., 1872, MED TIMES GAZ, V1, P62
   Mahomed F. A., 1877, T PATH SOC, V28, P394
   Mahomed F. A., 1881, GUYS HOSP REP, V15, P295
   Page I. H., 1943, SCIENCE, V98, P153, DOI 10.1126/science.98.2537.153-a
   Page IH, 1940, J EXP MED, V71, P29, DOI 10.1084/jem.71.1.29
   Page IH, 1941, AM J PHYSIOL, V135, P0214
   Page IH, 1939, J EXP MED, V70, P521, DOI 10.1084/jem.70.5.521
   Page IH, 1936, P SOC EXP BIOL MED, V35, P112
   PAGE IH, 1968, RENAL HYPERTENSION
   Page IH, 1939, P CENTRAL SOC CLIN I, V12, P17
   Prinzmetal M, 1936, P SOC EXP BIOL MED, V35, P122
   Prinzmetal M, 1938, P SOC EXP BIOL MED, V38, P493
   RITTEL W, 1957, HELV CHIM ACTA, V40, P614, DOI 10.1002/hlca.19570400317
   RIVAROCCI S, 1896, GAZZ MED TORINO, V47, P981
   SCHWARTZ H, 1957, J AM CHEM SOC, P5697
   SCHWYZER R, 1957, CHIMIA, V11, P335
   Solandt DY, 1940, LANCET, V1, P873
   TAQUINI AC, 1958, CIRCULATION, V17, P672, DOI 10.1161/01.CIR.17.4.672
   TAQUINI AC, 1961, AM HEART J, V62, P558, DOI 10.1016/0002-8703(61)90265-4
   TAQUINI ALBERTO C., 1938, REV SOC ARGENTINA BIOL, V14, P456
   Tigerstedt R, 1898, SKAND ARCH PHYSL, V8, P223, DOI [10.1111/j.1748-1716.1898.tb00272.x., DOI 10.1111/J.1748-1716.1898.TB00272.X, 10.1111/j.1748-1716.1898.tb00272.x]
   Verney EB, 1938, Q J EXP PHYSIOL CMS, V28, P253, DOI 10.1113/expphysiol.1938.sp000779
   VOLHARD F, 1931, HDB INNEREN MED, P1
NR 50
TC 120
Z9 127
U1 0
U2 17
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0194-911X
EI 1524-4563
J9 HYPERTENSION
JI Hypertension
PD DEC
PY 2001
VL 38
IS 6
BP 1246
EP 1249
DI 10.1161/hy1201.101214
PG 4
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 509HT
UT WOS:000173141500004
PM 11751697
OA Bronze
DA 2021-08-04
ER

PT J
AU Panduric, V
   Knezevic, A
   Tarle, Z
   Sutalo, J
AF Panduric, V
   Knezevic, A
   Tarle, Z
   Sutalo, J
TI The efficiency of dentine adhesives in treating non-caries cervical
   lesions
SO JOURNAL OF ORAL REHABILITATION
LA English
DT Article
DE dentine adhesives; non-caries cervical lesions
ID HUMAN TEETH; ENAMEL; CLASSIFICATION; EROSION; AGENTS; RESIN
AB The aim of this study was to prove the hypothesis that dentine adhesives can be used as therapeutic material in treating dentine hypersensitivity, regardless of aetiology. The research was conducted on 492 students of Zagreb University School of Dental Medicine (154 male, 338 female), 20-25-years-old. The defects of the tooth neck were found in 38 patients, on 133 teeth (38 of male patients, 95 of female) and dentine hypersensitivity was recorded according to the subjective sensations of patients. Therapeutic characteristics of three adhesive materials were examined simultaneously: All Bond 2, fourth generation adhesive, Syntac Single Component and One Step, fifth generation adhesives. Teeth treated with dentine lacquer Cervitec were used as a control group. Tooth necks were treated with selected materials according to instructions of a manufacturer. A completed statistical survey of the results has clearly shown that dentine adhesives can be used in symptomatic therapy of dentine hypersensitivity of the non-caries cervical lesions (NCCL). The survey has also shown that dentine adhesives of the fifth generation (Syntac Single Component and One Step) have much higher efficiency rate than dentine adhesives of the fourth generation (All Bond 2) and dentine lacquer (Cervitec). According to data complied through this study the conclusion can be brought forward that dentine adhesives are not a final solution to the problem of dentine hypersensitivity, because their efficiency decreases with time.
C1 Univ Dent Med, Dept Dent Pathol, Gunduliceva 5, HR-10000 Zagreb, Croatia.
RP Panduric, V (corresponding author), Univ Dent Med, Dept Dent Pathol, Gunduliceva 5, HR-10000 Zagreb, Croatia.
EM vpanduric@usa.net
OI Tarle, Zrinka/0000-0001-7096-4575
CR Finger WJ, 1997, EUR J ORAL SCI, V105, P183, DOI 10.1111/j.1600-0722.1997.tb00198.x
   Finger WJ, 1996, DENT MATER, V12, P256, DOI 10.1016/S0109-5641(96)80032-7
   GASPERSIC D, 1995, ARCH ORAL BIOL, V40, P453, DOI 10.1016/0003-9969(94)00180-J
   Gillam DG, 1997, ENDOD DENT TRAUMATOL, V13, P36
   GOEL VK, 1991, J PROSTHET DENT, V66, P451, DOI 10.1016/0022-3913(91)90504-P
   GWINETT AJ, 1996, ARCH ORAL BIOL, V11, P1109
   HALLER B, 1996, IN VITRO EVALUATION
   Imfeld T, 1996, EUR J ORAL SCI, V104, P151, DOI 10.1111/j.1600-0722.1996.tb00063.x
   JUKIC S, 1999, ACTA STOMATOL CROAT, V33, P87
   Kleinberg I, 1986, Compend Contin Educ Dent, V7, P282
   LUNDY T, 1969, ORAL SURG ORAL MED O, V27, P187, DOI 10.1016/0030-4220(69)90172-8
   LYNCH E, 1995, J DENT RES, V74, P535
   Lyttle HA, 1998, J PROSTHET DENT, V79, P342, DOI 10.1016/S0022-3913(98)70248-3
   MANNERBURG FRITZ, 1962, ACTA ODONTOL SCAND, V20, P153, DOI 10.3109/00016356209026103
   Nunn JH, 1996, EUR J ORAL SCI, V104, P156, DOI 10.1111/j.1600-0722.1996.tb00064.x
   Opdam NJM, 1997, J DENT, V25, P391, DOI 10.1016/S0300-5712(96)00048-6
   Pashley DH, 1997, J DENT, V25, P355, DOI 10.1016/S0300-5712(96)00057-7
   PASHLEY DH, 1981, J PROSTHET DENT, V46, P351
   PEARCE NX, 1994, J PERIODONTOL, V65, P113, DOI 10.1902/jop.1994.65.2.113
   Perdigao J, 1996, DENT MATER, V12, P262, DOI 10.1016/S0109-5641(96)80033-9
   RADLANSKI RJ, 1997, ACTA MED DENT HELV, V2, P86
   SWIFT EJ, 1994, J AM DENT ASSOC, V125, P571, DOI 10.14219/jada.archive.1994.0080
   TAVARES M, 1994, J AM DENT ASSOC, V125, P1337, DOI 10.14219/jada.archive.1994.0168
   THEUNS HM, 1983, ARCH ORAL BIOL, V28, P797, DOI 10.1016/0003-9969(83)90035-3
   Uno S, 1996, J DENT, V24, P211, DOI 10.1016/0300-5712(95)00056-9
   VANMEEREBEEK B, 1994, DTSCH ZAHNARZTLICHE, V12, P977
   Xu J, 1997, J DENT RES, V76, P596, DOI 10.1177/00220345970760011101
NR 27
TC 17
Z9 19
U1 2
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0305-182X
EI 1365-2842
J9 J ORAL REHABIL
JI J. Oral Rehabil.
PD DEC
PY 2001
VL 28
IS 12
BP 1168
EP 1174
DI 10.1046/j.1365-2842.2001.00779.x
PG 7
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 507TU
UT WOS:000173046100015
PM 11874519
DA 2021-08-04
ER

PT J
AU Kiselev, VG
AF Kiselev, VG
TI On the theoretical basis of perfusion measurements by dynamic
   susceptibility contrast MRI
SO MAGNETIC RESONANCE IN MEDICINE
LA English
DT Article
DE perfusion imaging; dynamic MRI; bolus tracking; T-2 contrast;
   susceptibility contrast
ID CEREBRAL-BLOOD-FLOW; POSITRON-EMISSION-TOMOGRAPHY; HIGH-RESOLUTION
   MEASUREMENT; IMAGING BOLUS TRACKING; MAGNETIC-SUSCEPTIBILITY; SIGNAL
   BEHAVIOR; RELAXATION; PASSAGES; NETWORK; BRAIN
AB A quantitative analysis was undertaken to calibrate the perfusion quantification technique based on tracking the first pass of a bolus of a blood pool contrast agent. A complete simulation of the bolus passage, of the associated changes in the T-2 and T-2(*) signals, and of the data processing was performed using the tracer dilution theory, an analytical theory of the MR signal from living tissues and numerical simulations. The noise was excluded in the simulation in order to analyze the ultimate accuracy of the method. It is demonstrated that the relationship between the contrast agent concentration and the associated changes in the transverse relaxation rate shows essentially different forms in studied tissue and in the reference artery. This effect results in systematic deviations of the measured blood flow, blood volume, and the residue function obtained with conventional processing from their true values. The error depends on the microvascular composition, the properties of the contrast agent, and the weights of the various compartments in the total signal. The results show that dynamic susceptibility contrast MRI can reach the goal of absolute perfusion quantification only with additional input from measurements of the microvascular architecture. Alternatively, the method can be used to provide such information if the perfusion is quantified by another modality. (C) 2001 Wiley-Liss, Inc.
C1 Univ Hosp Freiburg, Sect Med Phys, Dept Diagnost Radiol, D-79106 Freiburg, Germany.
RP Kiselev, VG (corresponding author), Univ Hosp Freiburg, Sect Med Phys, Dept Diagnost Radiol, Hugstetterstr 55, D-79106 Freiburg, Germany.
EM kiselev@ukl.uni-freiburg.de
RI Kiselev, Valerij G./E-5535-2014
OI Kiselev, Valerij G./0000-0002-5349-5399
CR Akbudak E, 1998, P 6 ANN M ISMRM SYDN, P1197
   ALBERT MS, 1993, MAGNET RESON MED, V29, P700, DOI 10.1002/mrm.1910290520
   BOXERMAN JL, 1995, MAGNET RESON MED, V34, P555, DOI 10.1002/mrm.1910340412
   BROOKS RA, 1995, JMRI-J MAGN RESON IM, V5, P446, DOI 10.1002/jmri.1880050414
   BULL U, 1996, NUKLEARMEDIZIN
   Dennie J, 1998, MAGN RESON MED, V40, P793, DOI 10.1002/mrm.1910400602
   FRIBERG L, 1991, STIMULATED CEREBRAL, P141
   GOLDMAN M, 1988, QUANTUM DESCRIPTION, P226
   Hoogenraad FGC, 2001, MAGNET RESON MED, V45, P233, DOI 10.1002/1522-2594(200102)45:2<233::AID-MRM1032>3.0.CO;2-W
   Kiselev VG, 1998, PHYS REV LETT, V81, P5696, DOI 10.1103/PhysRevLett.81.5696
   Kiselev VG, 1999, MAGN RESON MED, V41, P499
   Landis CS, 2000, MAGNET RESON MED, V44, P563, DOI 10.1002/1522-2594(200010)44:4<563::AID-MRM10>3.0.CO;2-#
   LASSER NA, 1979, TRACER KINETIC METHO
   Le Bihan Denis, 1995, P134
   MEIBOOM S, 1958, REV SCI INSTRUM, V29, P688, DOI 10.1063/1.1716296
   Ostergaard L, 1998, J CEREBR BLOOD F MET, V18, P425, DOI 10.1097/00004647-199804000-00011
   Ostergaard L, 1998, J CEREBR BLOOD F MET, V18, P935
   Ostergaard L, 1996, MAGNET RESON MED, V36, P726, DOI 10.1002/mrm.1910360511
   Ostergaard L, 1996, MAGN RESON MED, V36, P715, DOI 10.1002/mrm.1910360510
   PAWLIK G, 1981, BRAIN RES, V208, P35, DOI 10.1016/0006-8993(81)90619-3
   SCHLENSKA G, 1969, Z ANAT ENTWICKLUNGS, V128, P47, DOI 10.1007/BF00522494
   Simonsen CZ, 2000, J MAGN RESON IMAGING, V12, P411, DOI 10.1002/1522-2586(200009)12:3<411::AID-JMRI6>3.0.CO;2-5
   Spees WM, 2001, MAGN RESON MED, V45, P533, DOI 10.1002/mrm.1072
   THULBORN KR, 1982, BIOCHIM BIOPHYS ACTA, V714, P265, DOI 10.1016/0304-4165(82)90333-6
   Tropres I, 2001, MAGN RESON MED, V45, P397, DOI 10.1002/1522-2594(200103)45:3<397::AID-MRM1052>3.0.CO;2-3
   TURNER R, 2001, P 9 ANN M ISMRM GLAS, P288
   VANOSCH MPJ, 2000, P 8 ANN M ISMRM DENV, P742
   Wirestam R, 2000, MAGNET RESON MED, V43, P691, DOI 10.1002/(SICI)1522-2594(200005)43:5<691::AID-MRM11>3.0.CO;2-B
   YABLONSKIY DA, 1994, MAGNET RESON MED, V32, P749, DOI 10.1002/mrm.1910320610
NR 29
TC 131
Z9 133
U1 0
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0740-3194
J9 MAGN RESON MED
JI Magn. Reson. Med.
PD DEC
PY 2001
VL 46
IS 6
BP 1113
EP 1122
DI 10.1002/mrm.1307
PG 10
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 497BM
UT WOS:000172432900011
PM 11746577
OA Bronze
DA 2021-08-04
ER

PT J
AU Graeff, FG
   Silva, M
   Del Ben, CM
   Zuardi, AW
   Hetem, LAB
   Guimaraes, FS
AF Graeff, FG
   Silva, M
   Del Ben, CM
   Zuardi, AW
   Hetem, LAB
   Guimaraes, FS
TI Comparison between two models of experimental anxiety in healthy
   volunteers and panic disorder patients
SO NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
LA English
DT Article; Proceedings Paper
CT 10th Annual Meeting of the International-Behavioral-Neuroscience-Society
   (IBNS)
CY APR 25-29, 2001
CL CANCUN, MEXICO
SP Int Behav Neurosci Soc
DE 5-HT; experimental anxiety; conditioning of skin conductance response;
   simulated public speaking; healthy volunteers; panic patients
ID SIMULATED PUBLIC-SPEAKING; D-FENFLURAMINE; PERIAQUEDUCTAL GRAY;
   SEROTONIN ANTAGONIST; SOCIAL PHOBIA; DUAL ROLE; 5-HT; RITANSERIN;
   AMYGDALA; PLACEBO
AB To further investigate the role of serotonin (5-HT) in anxiety, two tests were used in human subjects. The first was the conditioning of skin conductance response (CSCR) that associates a tone to a loud noise. The second was simulated public speaking (SPS), which is believed to represent unconditioned fear. In healthy volunteers the 5-HT2A receptor blocker and 5-HT reuptake inhibitor nefazodone reduced subjective anxiety and the number of spontaneous fluctuations of skin conductance during CSCR, but enhanced anxiety induced by SPS. Opposite effects had been reported with the 5-HT releasing and uptake-inhibiting agent D-fenfluramine. Panic patients behaved like controls in the CSCR. However, they had a higher level of baseline anxiety and were insensitive to SPS. This profile resembles the reported effect of the non-selective 5-HT receptor blocker metergoline in healthy volunteers. Therefore, panic patients seem to process unconditioned fear abnormally, which may be due to lack of 5-HT inhibition in brain structures commanding flight from proximal danger stimuli. (C) 2002 Elsevier Science Ltd. All rights reserved.
C1 Univ Sao Paulo, Fac Med Ribeirao Preto, Programa Saude Mental, Dept Neurol Psychiat & Med Psychol, BR-14025000 Ribeirao Preto, SP, Brazil.
   Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pharmacol, BR-14049900 Ribeirao Preto, SP, Brazil.
RP Graeff, FG (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, Programa Saude Mental, Dept Neurol Psychiat & Med Psychol, Av Nove Julho 980, BR-14025000 Ribeirao Preto, SP, Brazil.
EM fgraeff@keynet.com.br
RI Del-Ben, Cristina M/F-1817-2012; Guimaraes, Francisco S/C-1059-2012;
   Zuardi, Antonio W/B-6078-2016
OI Del-Ben, Cristina M/0000-0003-0145-9975; Guimaraes, Francisco
   S/0000-0003-4092-7778; Graeff, Frederico/0000-0002-0746-3118
CR ADLER CM, 1987, INTEGRATIVE PSYCHIAT, V5, P94
   BEL N, 1992, EUR J PHARMACOL, V229, P101, DOI 10.1016/0014-2999(92)90292-C
   Ben-Zion IZ, 1999, AM J PSYCHIAT, V156, P1635, DOI 10.1176/ajp.156.10.1635
   BLIER P, 1987, J CLIN PSYCHOPHARM, V7, pS24
   CEULEMANS DLS, 1985, PHARMACOPSYCHIATRY, V18, P303, DOI 10.1055/s-2007-1017385
   DEAKIN J F W, 1991, Journal of Psychopharmacology, V5, P305, DOI 10.1177/026988119100500414
   Deakin JFW, 1994, STRATEGIES STUDYING, V1, P211
   DEAKIN JFW, 1990, P WORLD FED SOC BIOL, P16
   DELBEN CM, 2001, IN PRESS PSYCHIAT RE
   DENBOER JA, 1990, PSYCHOPHARMACOLOGY, V102, P85, DOI 10.1007/BF02245749
   Furmark T, 1999, SOC PSYCH PSYCH EPID, V34, P416, DOI 10.1007/s001270050163
   GENTIL V, 1988, ANIMAL MODELS PSYCHI, V1, P142
   GRAEFF FG, 1991, P FABRE MON, V4, P288
   GRAEFF FG, 1985, PSYCHOPHARMACOLOGY, V86, P334, DOI 10.1007/BF00432224
   Graeff FG, 1996, PHARMACOL BIOCHEM BE, V54, P129, DOI 10.1016/0091-3057(95)02135-3
   Graeff FG, 1997, NEUROSCI BIOBEHAV R, V21, P791, DOI 10.1016/S0149-7634(96)00059-0
   GRAEFF FG, 1993, BEHAV BRAIN RES, V58, P123, DOI 10.1016/0166-4328(93)90097-A
   Graeff FG, 1990, HDB ANXIETY, V3, P307
   GRAEFF FG, 1988, ANIMAL MODELS PSYCHI, V1, P115
   Gray J. A., 2000, NEUROPSYCHOLOGY ANXI, V2nd
   Guimaraes F S, 1987, J Psychopharmacol, V1, P184, DOI 10.1177/026988118700100305
   Guimaraes FS, 1997, J PSYCHOPHARMACOL, V11, P225, DOI 10.1177/026988119701100305
   GUIMARAES FS, 1991, PSYCHOPHARMACOLOGY, V104, P231, DOI 10.1007/BF02244184
   HENSMAN R, 1991, PSYCHOPHARMACOLOGY, V104, P220, DOI 10.1007/BF02244182
   Hetem LAB, 1996, PSYCHOPHARMACOLOGY, V127, P276
   Hetem LAB, 1996, J CLIN PSYCHOPHARM, V16, P77, DOI 10.1097/00004714-199602000-00014
   HODGES H, 1987, PSYCHOPHARMACOLOGY, V92, P491
   JOHNSON MR, 1995, DRUGS, V49, P328, DOI 10.2165/00003495-199549030-00002
   Klein D. F., 1989, PSYCHOPHARMACOLOGY A, P135
   KLEIN DF, 1987, ACTA PSYCHIAT SCAND, V76, P87, DOI 10.1111/j.1600-0447.1987.tb07753.x
   Lovick TA, 2000, NEUROSCIENTIST, V6, P48, DOI 10.1177/107385840000600113
   MCNAIR DM, 1982, PSYCHOPHARMACOLOGY, V77, P7, DOI 10.1007/BF00436092
   Mortimore C, 2000, PSYCHOPHARMACOLOGY, V149, P251, DOI 10.1007/s002139900342
   NORRIS H, 1971, NEUROPHARMACOLOGY, V10, P181, DOI 10.1016/0028-3908(71)90039-6
   PALMA SM, 1994, BRAZ J MED BIOL RES, V27, P2895
   Phillips GC, 1997, J ANXIETY DISORD, V11, P215, DOI 10.1016/S0887-6185(97)00007-8
   SCHUTZ MTB, 1985, PSYCHOPHARMACOLOGY, V85, P340, DOI 10.1007/BF00428199
   SERIES HG, 1994, PSYCHOPHARMACOLOGY, V116, P508, DOI 10.1007/BF02247485
   Silva M, 2001, PSYCHOPHARMACOLOGY, V156, P454, DOI 10.1007/s002130100752
   SOLYOM L, 1994, AM J PSYCHIAT, V151, P621
   Spielberger C.D., 1970, MANUAL STATE TRAIT A
   STEIN MB, 1994, AM J PSYCHIAT, V151, P408
   TARGUM SD, 1989, PSYCHIAT RES, V28, P295, DOI 10.1016/0165-1781(89)90210-2
   TAYLOR DP, 1995, J CLIN PSYCHIAT, V56, P3
   Viana MB, 1997, PHARMACOL BIOCHEM BE, V58, P167, DOI 10.1016/S0091-3057(96)00451-0
   Viana MB, 1996, BRAZ J MED BIOL RES, V29, P639
   VILA J, 1977, BRIT J SOC CLIN PSYC, V16, P69, DOI 10.1111/j.2044-8260.1977.tb01004.x
   WANG M, 1986, ACTA PSYCHIAT SCAND, V73, P146, DOI 10.1111/j.1600-0447.1986.tb10552.x
   Zuardi AW, 1981, J BRAS PSIQUIAT, V30, P403
NR 49
TC 10
Z9 10
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0149-7634
EI 1873-7528
J9 NEUROSCI BIOBEHAV R
JI Neurosci. Biobehav. Rev.
PD DEC
PY 2001
VL 25
IS 7-8
BP 753
EP 759
AR PII S0149-7634(01)00055-0
DI 10.1016/S0149-7634(01)00055-0
PG 7
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA 521VB
UT WOS:000173861100018
PM 11801299
DA 2021-08-04
ER

PT J
AU Anderson, HV
   McNatt, J
   Clubb, FJ
   Herman, M
   Maffrand, JP
   DeClerck, F
   Ahn, C
   Buja, LM
   Willerson, JT
AF Anderson, HV
   McNatt, J
   Clubb, FJ
   Herman, M
   Maffrand, JP
   DeClerck, F
   Ahn, C
   Buja, LM
   Willerson, JT
TI Platelet inhibition reduces cyclic flow variations and neointimal
   proliferation in normal and hypercholesterolemic-atherosclerotic canine
   coronary arteries
SO CIRCULATION
LA English
DT Article
DE platelets; blood flow; hypercholesterolemia; atherosclerosis; arteries
ID MUSCLE CELL-PROLIFERATION; SERIAL INTRAVASCULAR ULTRASOUND; LOW-DENSITY
   LIPOPROTEINS; SMOOTH-MUSCLE; INTIMAL HYPERPLASIA; THROMBOXANE A(2);
   VASCULAR INJURY; CAROTID-ARTERY; RECEPTOR; RESTENOSIS
AB Background-Platelet-derived growth factors help stimulate the neointimal proliferation of restenosis after coronary interventions. Reducing platelet accumulation at treated sites may attenuate restenosis. We tested this hypothesis by inducing repetitive platelet aggregation at coronary angioplasty sites in dogs and measuring subsequent neointima formation.
   Methods and Results-Cholesterol-sensitive dogs (n=74) received either 4% cholesterol-enriched diets for >8 months (n=29), creating visible atheromas, or normal canine diets (n=45). A coronary balloon angioplasty cyclic flow variation (CFV) model was used. One group of control dogs (group 1, n =8)had angioplasty with no arterial constriction applied and no drug treatment. Three other groups had arterial constrictors applied to provoke CFVs: group 2 (n=28) received no drug therapy, group 3 (n=18) received oral aspirin alone, and group 4 (n=20) received 3 oral antiplatelet agents: ridogrel, ketanserin, and clopidogrel (R+K+C) to simultaneously inhibit the thromboxane A(2), serotonin, and ADP treated group pathways of platelet aggregation respectively. Bleeding times were moderately prolonged in the aspirin (124 +/-9 seconds after 3 weeks versus 76 +/-6 seconds at baseline, P <0.01) and greatly prolonged on R+K+C (> 600 versus 104 +/-5 seconds, P <0.001). The frequency and severity of CFVs were inversely related to the degree of platelet inhibition and prolongation of bleeding times, as was sudden death due to acute thrombotic coronary occlusion. Quantitative histology at 8 weeks revealed increased intima-to-media ratio with CFVs: 0.89 +/-0.14 in the untreated group 2 versus 0.11 +/-0.04 in the control group (P <0.001). Intima-to-media ratio was significantly reduced with antiplatelet treatment (0.27 +/-0.05 with aspirin treatment and 0.20 +/-0.05 with R+K+C treatment, respectively, P <0.001). Cholesterol feeding did not appear to influence results.
   Conclusions-Repetitive platelet accumulation at coronary angioplasty sites caused enhanced neointimal proliferation by 8 weeks. Oral inhibitors of platelet aggregation attenuated platelet function, prolonged bleeding times, reduced or prevented cyclic flows and abrupt thrombotic occlusions, and thereby inhibited neointimal proliferation. Platelet inhibition should continue to receive attention in efforts to reduce restenosis after coronary interventions.
C1 Univ Texas, Hlth Sci Ctr, Div Cardiol, Houston, TX 77225 USA.
   Texas Heart Inst, Houston, TX 77025 USA.
   Sanofi Rech, Paris, France.
   Janssen Pharmaceut, Beerse, Belgium.
RP Anderson, HV (corresponding author), Univ Texas, Hlth Sci Ctr, Div Cardiol, POB 20708, Houston, TX 77225 USA.
OI Buja, Louis Maximilian/0000-0001-8386-7029
FU NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [R01HL054839] Funding
   Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Heart Lung & Blood Institute (NHLBI) [R0-1-HL-54839] Funding Source:
   Medline
CR Abe J, 1997, CIRCULATION, V96, P1906, DOI 10.1161/01.CIR.96.6.1906
   AGUIRRE FV, 1995, CIRCULATION, V91, P2882, DOI 10.1161/01.CIR.91.12.2882
   Aikawa M, 2001, CIRCULATION, V103, P276
   ANDERSON HV, 1990, CORONARY ARTERY DIS, V1, P717, DOI 10.1097/00019501-199011000-00012
   ANDERSON WK, 1994, COMPUT FLUIDS, V23, P1, DOI 10.1016/0045-7930(94)90023-X
   ASHTON JH, 1987, CIRCULATION, V76, P952, DOI 10.1161/01.CIR.76.4.952
   ASHTON JH, 1989, J AM COLL CARDIOL, V13, P755, DOI 10.1016/0735-1097(89)90622-0
   BAURIEDEL G, 1992, CIRCULATION, V85, P554, DOI 10.1161/01.CIR.85.2.554
   Bustos C, 1998, J AM COLL CARDIOL, V32, P2057, DOI 10.1016/S0735-1097(98)00487-2
   CASSCELLS W, 1992, CIRCULATION, V86, P723, DOI 10.1161/01.CIR.86.3.723
   Chen LY, 1996, CIRCULATION, V93, P1740, DOI 10.1161/01.CIR.93.9.1740
   CHIEO TJA, 2001, CIRCULATION, V103, P1135
   CROWLEY ST, 1994, CIRCULATION, V90, P1908, DOI 10.1161/01.CIR.90.4.1908
   deLezo JS, 1997, AM HEART J, V133, P210, DOI 10.1016/S0002-8703(97)70211-4
   EICHHORN EJ, 1991, J AM COLL CARDIOL, V17, P43, DOI 10.1016/0735-1097(91)90702-B
   EIDT JF, 1989, AM J PHYSIOL, V257, pH873
   FINGERLE J, 1989, P NATL ACAD SCI USA, V86, P8412, DOI 10.1073/pnas.86.21.8412
   FOLTS JD, 1976, CIRCULATION, V54, P365, DOI 10.1161/01.CIR.54.3.365
   Fukumoto Y, 2001, CIRCULATION, V103, P993
   GLAGOV S, 1994, CIRCULATION, V89, P2888, DOI 10.1161/01.CIR.89.6.2888
   Hart CE, 1999, CIRCULATION, V99, P564, DOI 10.1161/01.CIR.99.4.564
   IKEDA H, 1993, J AM COLL CARDIOL, V21, P1008, DOI 10.1016/0735-1097(93)90361-4
   Koba S, 1999, J AM COLL CARDIOL, V34, P1644, DOI 10.1016/S0735-1097(99)00349-6
   Kornowski R, 1997, CIRCULATION, V95, P1366
   LeBreton H, 1996, J AM COLL CARDIOL, V28, P1643, DOI 10.1016/S0735-1097(96)00417-2
   Lincoff AM, 1997, AM J CARDIOL, V79, P286, DOI 10.1016/S0002-9149(96)00749-7
   Matsuno H, 1997, CIRCULATION, V96, P1299, DOI 10.1161/01.CIR.96.4.1299
   MATSUNO H, 1994, CIRCULATION, V90, P2203, DOI 10.1161/01.CIR.90.5.2203
   Mintz GS, 1996, CIRCULATION, V94, P35, DOI 10.1161/01.CIR.94.1.35
   Mudra H, 1997, CIRCULATION, V95, P363
   NEMECEK GM, 1986, P NATL ACAD SCI USA, V83, P674, DOI 10.1073/pnas.83.3.674
   Nofer JR, 1997, CIRCULATION, V95, P1370
   Pakala R, 1997, CIRCULATION, V96, P2280
   Pasterkamp G, 1996, CIRCULATION, V93, P1818, DOI 10.1161/01.CIR.93.10.1818
   SACHINIDIS A, 1995, HYPERTENSION, V26, P771, DOI 10.1161/01.HYP.26.5.771
   WILLERSON JT, 1991, P NATL ACAD SCI USA, V88, P10024
   YAO SK, 1992, CIRC RES, V70, P39, DOI 10.1161/01.RES.70.1.39
   ZAHGER D, 1995, CIRCULATION, V92, P1269, DOI 10.1161/01.CIR.92.5.1269
NR 38
TC 35
Z9 37
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 6
PY 2001
VL 104
IS 19
BP 2331
EP 2337
DI 10.1161/hc4401.098434
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 492NB
UT WOS:000172173500017
PM 11696474
OA Bronze
DA 2021-08-04
ER

PT J
AU Li, HZ
   Frank, X
   Funfschilling, D
   Mouline, Y
AF Li, HZ
   Frank, X
   Funfschilling, D
   Mouline, Y
TI Towards the understanding of bubble interactions and coalescence in
   non-Newtonian fluids: a cognitive approach
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article; Proceedings Paper
CT 5th International Conference on Gas-Liquid and Gas-Liquid-Solid Reactor
   Engineering
CY SEP 23-27, 2001
CL MELBOURNE, AUSTRALIA
SP Australian Res Council Special Res Ctr Multiphase Processes, Univ Newcastle
DE bubbles; interactions; coalescence; non-newtonian fluids; cognitive
   approach; adaptive agent
ID GAS-BUBBLES; FREE RISE
AB The present work provides new insights into the behavior of air bubbles in non-Newtonian fluids. The interactions and coalescence between bubbles rising in non-Newtonian fluids were simultaneously investigated by means of birefringence measurements and particle image velocimetry for a chain of bubbles formed from a submerged orifice. Two aspects are identified for the first time as central to interactions and coalescence: (i) the stress creation by the passage of bubbles, and (ii) their relaxation due to the fluid's memory. This competition displays complex nonlinear dynamics, from periodic phenomena to deterministic chaos. From these fundamental mechanisms, a cognitive model based on behavioral rules has been developed to describe collective behaviors of a group of bubbles. By simulating bubbles as adaptive agents with their fluid via residual stresses, model predictions for consecutive coalescence between a great number of bubbles compare very satisfactorily with the experimental investigation. (C) 2001 Elsevier Science Ltd. All rights reserved.
C1 INPL, Ctr Genie Chim Milieux Complexes, CNRS, ENSIC, F-54001 Nancy, France.
RP Li, HZ (corresponding author), INPL, Ctr Genie Chim Milieux Complexes, CNRS, ENSIC, 1 Rue Grandville,BP 451, F-54001 Nancy, France.
RI Frank, Xavier/B-4798-2012; Li, Huai/S-2162-2019
OI Li, Huai/0000-0001-7129-6660; FRANK, Xavier/0000-0003-3528-7892
CR ACHARYA A, 1978, AICHE J, V24, P348, DOI 10.1002/aic.690240227
   ASTARITA G, 1965, AICHE J, V11, P815, DOI 10.1002/aic.690110514
   CALDERBANK PH, 1970, CHEM ENG SCI, V25, P235, DOI 10.1016/0009-2509(70)80018-5
   Carreau P. J., 1974, Rheologica Acta, V13, P477, DOI 10.1007/BF01521744
   Chhabra R.P., 1992, BUBBLES DROPS PARTIC
   Clift R., 2005, BUBBLES DROPS PARTIC
   DEKEE D, 1990, J NON-NEWTON FLUID, V37, P1, DOI 10.1016/0377-0257(90)80001-G
   Funfschilling D, 2001, CHEM ENG SCI, V56, P1137, DOI 10.1016/S0009-2509(00)00332-8
   FUNFSCHILLING D, 1999, THESIS I NATL POLYTE
   GELLMANN M, 1994, QUARK JAGUAR ADVENTU
   HOLLAND JH, 1992, ADAPTATION NATURAL A
   Li HAZ, 1999, CHEM ENG SCI, V54, P2247, DOI 10.1016/S0009-2509(98)00294-2
   Li HZ, 1997, CR ACAD SCI II B, V324, P491, DOI 10.1016/S1251-8069(97)80187-X
   Li HZ, 1998, CHEM ENG SCI, V53, P2219, DOI 10.1016/S0009-2509(98)00048-7
   Li HZ, 1997, INT J MULTIPHAS FLOW, V23, P713, DOI 10.1016/S0301-9322(97)00004-9
   Li HZ, 1997, AICHE J, V43, P265, DOI 10.1002/aic.690430130
   Milne-Thomson L.M., 1960, THEORETICAL HYDRODYN
   Rodrigue D, 1996, J NON-NEWTON FLUID, V66, P213, DOI 10.1016/S0377-0257(96)01486-3
   Sadhal S.S., 1997, TRANSPORT PHENOMENA
   SCHUSTER HG, 1988, DETERMINISTIC CHAOS
   ZANA E, 1978, INT J MULTIPHAS FLOW, V4, P237, DOI 10.1016/0301-9322(78)90001-0
NR 21
TC 50
Z9 50
U1 0
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV
PY 2001
VL 56
IS 21-22
BP 6419
EP 6425
DI 10.1016/S0009-2509(01)00269-X
PG 7
WC Engineering, Chemical
SC Engineering
GA 503AP
UT WOS:000172775200062
DA 2021-08-04
ER

PT J
AU Gignoux, J
   House, JI
   Hall, D
   Masse, D
   Nacro, HB
   Abbadie, L
AF Gignoux, J
   House, JI
   Hall, D
   Masse, D
   Nacro, HB
   Abbadie, L
TI Design and test of a generic cohort model of soil organic matter
   decomposition: the SOMKO model
SO GLOBAL ECOLOGY AND BIOGEOGRAPHY
LA English
DT Article
DE carbon accumulation; C : N stoichiometry; demography; microbial biomass;
   nitrogen immobilization; nitrogen mineralization; simulation
ID NITROGEN TURNOVER; MICROBIAL BIOMASS; DYNAMICS; CARBON; SIMULATION;
   STATE; LAMTO
AB 1 SOMKO is a new simulation model of soil organic matter (SOM) dynamics aimed at predicting long-term and short-term SOM dynamics based on a mechanistic approach focusing on microbes as the key agents of decomposition.
   2 SOM is partitioned into cohorts and chemical quality pools (classified by age and chemical composition), the microbial community processes are explicitly represented, and the C : N stoichiometric constraints are accounted for through a new mechanism of offer and demand.
   3 The analysis of model equations shows that: (1) SOM C : N cannot decrease below microbial C : N; and (2) the nitrogen limitation of decomposition depends on SOM C : N, microbial biomass and soil mineral nitrogen. First tests of the: model show good qualitative behaviour for simulating the dynamics of short-term litter-bag type decomposition, longterm SOM increase, pulsed mineral nitrogen production, the priming effect due to easily decomposable carbon addition, and the effects of vegetation clearance and climate change on SOM. Simulations are in good agreement with long-term experimental data.
   4 SOMKO is an integrated component of the coupled soil-vegetation models within the ETEMA (European Terrestrial Ecosystem Modelling Activity) framework. Future extensions of this work include: (1) estimating microbial parameters from specific experiments; (2) spatial distribution of SOMKO in multistrata models; and (3) implementing nitrification/denitrification processes, phosphorus limitation and microfaunal activity.
C1 Ecole Normale Super, CNRS, Ecol Lab, UMR 7625, 46 Rue Ulm, F-75230 Paris 05, France.
   Ecole Normale Super, CNRS, Ecol Lab, UMR 7625, F-75230 Paris 05, France.
   Kings Coll London, Div Life Sci, London SE1 8WA, England.
   Inst Rech Dev, Dakar, Senegal.
EM gignoux@biologie.ens.fr; jo.house@bgc-jena.mpg.de;
   dominique.masse@ird.sn; nacro@esi.univ-ouaga.bf; abbadie@biologie.ens.fr
RI Masse, Dominique/A-7603-2011; House, Joanna I/B-6477-2016
OI Masse, Dominique/0000-0002-3165-1469; House, Joanna
   I/0000-0003-4576-3960
CR ABBADIE L, 1983, TRAVAUX CHERCHEURS L
   AGREN GI, 1991, ECOL APPL, V1, P118, DOI 10.2307/1941806
   AGREN GI, 1996, GLOBAL CHANGE EFFECT, P207
   ANDERSON DW, 1984, SOIL SCI SOC AM J, V48, P298, DOI 10.2136/sssaj1984.03615995004800020014x
   ANDERSON TH, 1985, SOIL BIOL BIOCHEM, V17, P197, DOI 10.1016/0038-0717(85)90115-4
   ARAH JRM, 1996, EVALUATION SOIL ORGA, P225
   Blagodatsky SA, 1998, SOIL BIOL BIOCHEM, V30, P1743, DOI 10.1016/S0038-0717(98)00028-5
   BOSATTA E, 1991, AM NAT, V138, P227, DOI 10.1086/285213
   BOSATTA E, 1982, OIKOS, V39, P143, DOI 10.2307/3544478
   BOSATTA E, 1994, SOIL BIOL BIOCHEM, V26, P143, DOI 10.1016/0038-0717(94)90206-2
   CHERTOV OG, 1996, EVALUATION SOIL ORGA, P231
   Christensen B. T., 1996, EVALUATION SOIL ORGA, P143
   DEWILLIGEN P, 1991, FERT RES, V27, P141, DOI 10.1007/BF01051122
   Dommergues Y., 1970, ECOLOGIE MICROBIENNE
   Gignoux J., 1998, Dynamics of tropical communities : the 37th symposium of the British Ecological Society, Cambridge University, 1996., P361
   GRANT RF, 1993, SOIL BIOL BIOCHEM, V25, P1317, DOI 10.1016/0038-0717(93)90046-E
   HANSEN S, 1991, IAHS PUBLICATIONS, V203, P185
   KATTERER T, 1998, EARTHS CHANGING LAND, P141
   Kirchmann H, 1994, ULTUNA LONG TERM SOI
   LEROUX X, 2000, IN PRESS LAMTO STRUC
   MCGILL WB, 1996, NATO ASI SERIES I, V38, P111, DOI DOI 10.1007/978-3-642-61094-3_9
   MELILLO JM, 1996, GLOBAL CHANGE TERRES, P431
   MENAUT JC, 1979, ECOLOGY, V60, P1197, DOI 10.2307/1936967
   MINDERMA.G, 1968, J ECOL, V56, P355, DOI 10.2307/2258238
   MOLINA JAE, 1996, EVALUATION SOIL ORGA, P269
   MUELLER T, 1996, EVALUATION SOIL ORGA, P275
   Nacro HB, 1996, SOIL BIOL BIOCHEM, V28, P1687, DOI 10.1016/S0038-0717(96)00246-5
   NACRO HB, 1997, THESIS U PARIS 6
   NEEL C, 1998, THESIS U PARIS 6
   NISBET RM, 1991, THEOR POPUL BIOL, V40, P125, DOI 10.1016/0040-5809(91)90050-P
   PARNAS H, 1975, SOIL BIOL BIOCHEM, V7, P161, DOI 10.1016/0038-0717(75)90014-0
   PARTON WJ, 1988, BIOGEOCHEMISTRY, V5, P109, DOI 10.1007/BF02180320
   PASTOR J, 1986, BIOGEOCHEMISTRY, V2, P3, DOI 10.1007/BF02186962
   PASTOR J, 1985, DEV LINKED FOREST PR
   Powlson D. S., 1996, EVALUATION SOIL ORGA, VI, P38
   SAS Institute Inc, 1989, SAS IML SOFTW US REF
   Schulten HR, 1996, GEODERMA, V69, P105, DOI 10.1016/0016-7061(95)00054-2
   Smith J.U., 1996, EVALUATION SOIL ORGA, V38, P181, DOI DOI 10.1007/978-3-642-61094-3_13
   Smith P, 1997, GEODERMA, V81, P153, DOI 10.1016/S0016-7061(97)00087-6
   Sterner RW, 1997, FRESHWATER BIOL, V38, P473, DOI 10.1046/j.1365-2427.1997.00234.x
   Stolp, 1988, MICROBIAL ECOLOGY OR
   Strong DT, 1999, AUST J SOIL RES, V37, P329, DOI 10.1071/S98043
   Sykes MT, 2001, GLOBAL ECOL BIOGEOGR, V10, P581, DOI 10.1046/j.1466-822x.2001.00263.x
   Trinsoutrot I, 2000, SOIL BIOL BIOCHEM, V32, P1717, DOI 10.1016/S0038-0717(00)00090-0
   VANDEWERF H, 1987, SOIL BIOL BIOCHEM, V19, P267, DOI 10.1016/0038-0717(87)90008-3
NR 45
TC 42
Z9 44
U1 0
U2 25
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1466-822X
EI 1466-8238
J9 GLOBAL ECOL BIOGEOGR
JI Glob. Ecol. Biogeogr.
PD NOV
PY 2001
VL 10
IS 6
BP 639
EP 660
DI 10.1046/j.1466-822X.2001.00250.x
PG 22
WC Ecology; Geography, Physical
SC Environmental Sciences & Ecology; Physical Geography
GA 496NV
UT WOS:000172403600005
DA 2021-08-04
ER

PT J
AU Sim, KM
   Wong, E
AF Sim, KM
   Wong, E
TI Toward market-driven agents for electronic auction
SO IEEE TRANSACTIONS ON SYSTEMS MAN AND CYBERNETICS PART A-SYSTEMS AND
   HUMANS
LA English
DT Article
DE agent-mediated; e-commerce; auction agent; automated negotiation
AB While there are several existing agent-based systems addressing the crucial and difficult issues of automated negotiation and auction, this research has designed and engineered a society of trading agents with two distinguishing features: 1) a market-driven negotiation strategy and 2) a deal optimizing auction protocol. Unlike some of the existing systems where users manually select predefined trading strategies, in the market-driven approach, trading agents automatically select the appropriate strategies by examining the changing market situations. Results from a series of experiments suggest that the market-driven approach generally achieved more favorable outcomes as compared to the fixed strategy approach. Furthermore, it provides a more intuitive simulation of trading because trading agents are able to respond to different market situations with appropriate strategies. By augmenting the auction protocol with a deal optimization stage, trading agents can be programmed to optimize transaction deals by delaying the finalization of deals in search of better deals. Experimental results showed that by having a deal optimization stage, the auction protocol produced generally optimistic outcomes.
C1 Chinese Univ Hong Kong, Dept Informat Engn, Shatin, Hong Kong, Peoples R China.
   Hong Kong Hosp Author, Chaiwan, Hong Kong, Peoples R China.
RP Sim, KM (corresponding author), Chinese Univ Hong Kong, Dept Informat Engn, Shatin, Hong Kong, Peoples R China.
EM kmsim@ie.cuhk.edu.hk; wyeric@netvigator.com
CR CHAVEZ A, 1996, P 1 INT C PRACT APPL
   CHAVEZ A, 1997, P 2 INT C PRACT APPL
   Guttman RH, 1998, KNOWL ENG REV, V13, P147, DOI 10.1017/S0269888998002082
   GUTTMAN RH, 1998, P 2 INT WORKSH COOP
   GUTTMANN RH, 1998, P WORKSH AG MED EL T
   Krovi R, 1999, IEEE T SYST MAN CY C, V29, P15, DOI 10.1109/5326.740666
   Rodriguez-Aguilar JA, 1998, AI COMMUN, V11, P5
   Rosenschein J. S., 1994, RULES ENCOUNTER DESI
   SIM KM, 2000, P PAC AS C INF SYST, P1128
   Wai Yat Wong, 2000, Knowledge-Based Electronic Markets. Papers from the AAAI Workshop (Technical Report WS-00-04), P85
   WURMAN P, 1998, P 2 INT C AUT AG MIN
   ZHANG DM, 1999, P WORKSH AG E COMM H, P79
NR 12
TC 35
Z9 35
U1 0
U2 1
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 1083-4427
EI 1558-2426
J9 IEEE T SYST MAN CY A
JI IEEE Trans. Syst. Man Cybern. Paart A-Syst. Hum.
PD NOV
PY 2001
VL 31
IS 6
BP 474
EP 484
PG 11
WC Computer Science, Cybernetics; Computer Science, Theory & Methods
SC Computer Science
GA 521MF
UT WOS:000173843200001
DA 2021-08-04
ER

PT J
AU Tardieu, A
   Finet, S
   Bonnete, F
AF Tardieu, A
   Finet, S
   Bonnete, F
TI Structure of the macromolecular solutions that generate crystals
SO JOURNAL OF CRYSTAL GROWTH
LA English
DT Article; Proceedings Paper
CT 8th International Conference on Crystallization of Biological
   Macromolecules
CY MAY 14-19, 2000
CL SANDESTIN, FL
DE biocrystallization; Hofmeister effect; phase diagrams; small angle X-ray
   scattering; proteins
ID LIQUID-PHASE-SEPARATION; X-RAY-SCATTERING; SUPERSATURATED LYSOZYME
   SOLUTIONS; 2ND VIRIAL-COEFFICIENT; PROTEIN INTERACTIONS; RELATIVE
   EFFECTIVENESS; CRYSTALLIZATION; SOLUBILITY; MOLECULES; COLLOIDS
AB Biomolecular interactions in solution include a variety of effects: hard sphere, electrostatic, van der Waals, hydrophobic, etc. The corresponding interaction potentials govern the macromolecular distribution in solution, the shapes of the phase diagrams and the crystallization process. Different techniques: small angle X-ray scattering (SAXS), light scattering, osmotic pressure, can be used to characterize these potentials. Here, SAXS was the tool of choice to follow the changes induced by the crystallizing agents in different physicochemical conditions. Moreover, the coupling of SAXS (experimental structure factors) and numerical simulations derived from statistical mechanics (calculated structure factors) allowed us to determine the best fit parameters of the relevant potentials. Several protein model systems have now been investigated, with different isoelectric points, sizes and compactness, After the studies performed on lysozyme, and on aspartate transcarbamylase (ATCase), we proceeded with lens gamma- and alpha-crystallins and with urate oxidase. We can now draw the following picture of the relevant potentials. With low molecular weight proteins, a coulombic, pH dependent, repulsive potential and a short range (a few Angstrom), possibly van der Waals, attraction are sufficient to account for the behavior observed at low ionic strength. At higher ionic strength, the salt specific effects that follow the (direct or reverse) order of the Hofmeister series, correspond to an additional short range salt specific attraction. With increasing protein size, the van der Waals contribution becomes negligible. The addition of polymers like polyethylene glycol (PEG) induces a depletion mechanism, which is equivalent to a protein-protein attraction. Crystallization definitively appears to be under control of sufficiently strong and short range (a few Angstrom) attractions, which means that, despite the diversity of protein sequences, it is possible to define a range of physicochemical conditions that may generate crystals. Yet, if salt addition appears to be sufficient to provide such conditions with small compact proteins, additives like PEG seem to be required at higher molecular weights. The success, of course, will also rely upon the protein purity and stability. (C) 2001 Elsevier Science B.V. All rights reserved.
C1 Univ Paris 06, CNRS, Lab Mineral Cristallog, F-75252 Paris 05, France.
   Univ Paris 07, CNRS, Lab Mineral Cristallog, F-75252 Paris 05, France.
RP Tardieu, A (corresponding author), Univ Paris 06, CNRS, Lab Mineral Cristallog, Case 115,4 Pl Jussieu, F-75252 Paris 05, France.
EM Annette.Tardieu@lmcp.jussieu.fr
RI Bonnete, Francoise/AAL-6725-2020; bonnete, francoise/Q-2143-2015
OI bonnete, francoise/0000-0002-1690-1757
CR ASAKURA S, 1958, J POLYM SCI, V33, P183, DOI 10.1002/pol.1958.1203312618
   ATHA DH, 1981, J BIOL CHEM, V256, P2108
   BELLONI L, 1985, CHEM PHYS, V99, P43, DOI 10.1016/0301-0104(85)80108-7
   BELLONI L, 1988, J CHEM PHYS, V88, P5143, DOI 10.1063/1.454668
   BERLAND CR, 1992, P NATL ACAD SCI USA, V89, P1214, DOI 10.1073/pnas.89.4.1214
   Bonnete F, 2001, J CRYST GROWTH, V232, P330, DOI 10.1016/S0022-0248(01)01054-5
   Bonnete F, 1997, ACTA CRYSTALLOGR D, V53, P438, DOI 10.1107/S090744499700200X
   Bonnete F, 1999, J CRYST GROWTH, V196, P403, DOI 10.1016/S0022-0248(98)00826-4
   Boyer M, 1999, J CRYST GROWTH, V196, P185, DOI 10.1016/S0022-0248(98)00838-0
   BROIDE ML, 1991, P NATL ACAD SCI USA, V88, P5660, DOI 10.1073/pnas.88.13.5660
   Budayova M, 1999, J CRYST GROWTH, V196, P297, DOI 10.1016/S0022-0248(98)00873-2
   Budayova M, 1999, J CRYST GROWTH, V196, P210, DOI 10.1016/S0022-0248(98)00844-6
   CARBONNAUX C, 1995, PROTEIN SCI, V4, P2123, DOI 10.1002/pro.5560041018
   Chernov AA, 1997, PHYS REP, V288, P61, DOI 10.1016/S0370-1573(97)00021-5
   COLLINS KD, 1985, Q REV BIOPHYS, V18, P323, DOI 10.1017/S0033583500005369
   Derjaguin B, 1940, T FARADAY SOC, V35, P0203, DOI 10.1039/tf9403500203
   Ducruix A, 1996, J CRYST GROWTH, V168, P28, DOI 10.1016/0022-0248(96)00359-4
   DUCRUIX A, 1992, CRYSTALLIZATION NUCL
   Ebel C, 1999, J CRYST GROWTH, V196, P395, DOI 10.1016/S0022-0248(98)00822-7
   Finet S, 2001, J CRYST GROWTH, V232, P40, DOI 10.1016/S0022-0248(01)01160-5
   FINET S, 1999, THESIS PARIS 6
   GEORGE A, 1994, ACTA CRYSTALLOGR D, V50, P361, DOI 10.1107/S0907444994001216
   Gripon C, 1997, J CRYST GROWTH, V177, P238, DOI 10.1016/S0022-0248(96)01077-9
   Gripon C, 1998, J CRYST GROWTH, V183, P258, DOI 10.1016/S0022-0248(97)00416-8
   GUILLOTEAU JP, 1991, THESIS STRASBOURG
   Guo B, 1999, J CRYST GROWTH, V196, P424, DOI 10.1016/S0022-0248(98)00842-2
   Haas C, 1999, J CRYST GROWTH, V196, P388, DOI 10.1016/S0022-0248(98)00831-8
   HAAS C, 1995, J CRYST GROWTH, V154, P126, DOI 10.1016/0022-0248(95)00135-2
   Hansen J. P, 1986, THEORY SIMPLE LIQUID
   Hofmeister F., 1888, ARCH EXP PATHOL PHAR, V24, P247, DOI DOI 10.1007/BF01918191
   Israelachvili JN, 1994, INTERMOLECULAR SURFA
   Lafont S, 1997, J CRYST GROWTH, V173, P132, DOI 10.1016/S0022-0248(96)00834-2
   Lekkerkerker HNW, 1997, PHYSICA A, V244, P227, DOI 10.1016/S0378-4371(97)00302-6
   Lomakin A, 1999, P NATL ACAD SCI USA, V96, P9465, DOI 10.1073/pnas.96.17.9465
   Lomakin A, 1996, J CHEM PHYS, V104, P1646, DOI 10.1063/1.470751
   Malfois M, 1996, J CHEM PHYS, V105, P3290, DOI 10.1063/1.471843
   MCPHERSON A, 1999, CRYSTALLIZATION MACR
   Muschol M, 1997, J CHEM PHYS, V107, P1953, DOI 10.1063/1.474547
   Muschol M, 1995, J CHEM PHYS, V103, P10424, DOI 10.1063/1.469891
   Neal BL, 1999, J CRYST GROWTH, V196, P377, DOI 10.1016/S0022-0248(98)00855-0
   Ninham BW, 1997, LANGMUIR, V13, P2097, DOI 10.1021/la960974y
   PETSEV D, IN PRESS PHYS REV LE
   Piazza R, 1999, J CRYST GROWTH, V196, P415, DOI 10.1016/S0022-0248(98)00867-7
   Poon W, 1996, PHYS WORLD, V9, P27, DOI 10.1088/2058-7058/9/4/23
   Retailleau P, 1999, EUROPHYS LETT, V46, P154, DOI 10.1209/epl/i1999-00238-x
   RIESKAUTT MM, 1989, J BIOL CHEM, V264, P745
   TARATUTA VG, 1990, J PHYS CHEM-US, V94, P2140, DOI 10.1021/j100368a074
   Tardieu A, 1999, J CRYST GROWTH, V196, P193, DOI 10.1016/S0022-0248(98)00828-8
   Tardieu A., 1994, NEUTRONS SYNCHROTRON, VIII, P145
   Tuinier R, 2000, LANGMUIR, V16, P1497, DOI 10.1021/la990202c
   Veesler S, 1996, J CRYST GROWTH, V168, P124, DOI 10.1016/0022-0248(96)00373-9
   Verwey E. J. W., 1948, THEORY STABILITY LYO
NR 52
TC 41
Z9 41
U1 2
U2 18
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-0248
EI 1873-5002
J9 J CRYST GROWTH
JI J. Cryst. Growth
PD NOV
PY 2001
VL 232
IS 1-4
BP 1
EP 9
DI 10.1016/S0022-0248(01)01053-3
PG 9
WC Crystallography; Materials Science, Multidisciplinary; Physics, Applied
SC Crystallography; Materials Science; Physics
GA 473KL
UT WOS:000171042700002
DA 2021-08-04
ER

PT J
AU Casson, AM
   Jones, JCG
   Youngson, CC
   Wood, DJ
AF Casson, AM
   Jones, JCG
   Youngson, CC
   Wood, DJ
TI The effect of luting media on the fracture resistance of a flame sprayed
   all-ceramic crown
SO JOURNAL OF DENTISTRY
LA English
DT Article
DE fracture resistance; luting agent; all-ceramic crown; failure
ID TO-METAL CROWNS; CEMENTATION; STRENGTHS; INVITRO; DENTIN; SYSTEM
AB Objectives: This in vitro study investigated the effect of selected luting media on the fracture resistance of a flame-sprayed all-ceramic crown.
   Methods: Three groups of 10 human upper premolar teeth were prepared for crowning using a standardised technique. Flame sprayed crowns were fabricated and cemented onto the preparations using zinc phosphate (ZPC), glass polyalkenoate (GPC) or composite luting cement (CLC). During crown seating, a pressure perfusion system simulated pulpal fluid outflow equivalent to 300 mm. of H2O. Compressive fracture resistance was determined for each group using a Universal Testing Machine with a crosshead speed of 1 mna min A group of unrestored teeth acted as a control.
   Results: The fracture resistance of the groups ranked as follows: ZPC > CLC much greater than GPC = unrestored teeth. The difference between the fracture resistance of ZPC and CLC groups and the control group was statistically significant. The mode of fracture between the luted crowns and natural crowns was markedly different.
   Conclusions: When tested in compression, a new, flame-sprayed all-ceramic crown, when luted in place using ZPC, GPC or CLC, could produce strengths comparable to or greater than natural unrestored teeth. The luting agent used significantly affected the recorded fracture loads. (C) 2001 Elsevier Science Ltd. All rights reserved.
C1 Leeds Dent Inst, Div Restorat Dent, Leeds LS2 9LU, W Yorkshire, England.
RP Wood, DJ (corresponding author), Leeds Dent Inst, Div Restorat Dent, Leeds LS2 9LU, W Yorkshire, England.
CR Bebermeyer R D, 1994, Quintessence Int, V25, P209
   Brecker S. C., 1956, J PROS DENT, V6, P801
   *BRIT SOC REST DEN, 1999, EUR J PROSTHODONT RE, V7, P3
   BRUKL CE, 1987, J PROSTHET DENT, V57, P404, DOI 10.1016/0022-3913(87)90003-5
   Burke F J, 1995, Quintessence Int, V26, P293
   Burke F J, 1994, Quintessence Int, V25, P335
   Burke FJT, 1998, QUINTESSENCE INT, V29, P21
   BURKE FJT, 1992, J DENT, V20, P131, DOI 10.1016/0300-5712(92)90124-U
   CHRISTENSEN GJ, 1994, J AM DENT ASSOC, V125, P311, DOI 10.14219/jada.archive.1994.0027
   Dwan A, 1996, J DENT RES, V75, P2136
   GREY NJA, 1993, J DENT, V21, P47, DOI 10.1016/0300-5712(93)90051-Q
   Harvey C K, 1996, J Prosthodont, V5, P95, DOI 10.1111/j.1532-849X.1996.tb00281.x
   JOSEPHSON BA, 1985, J PROSTHET DENT, V53, P301, DOI 10.1016/0022-3913(85)90496-2
   Kelly JR, 1999, J PROSTHET DENT, V81, P652, DOI 10.1016/S0022-3913(99)70103-4
   Li ZC, 1999, J PROSTHET DENT, V81, P597, DOI 10.1016/S0022-3913(99)70216-7
   Mak M, 1997, Quintessence Int, V28, P197
   McCormick J T, 1993, Quintessence Int, V24, P405
   McLean J W, 1965, Br Dent J, V119, P251
   PAMEIJER CH, 1994, SWED DENT J, V18, P59
   Passi P, 1992, Quintessence Int, V23, P845
   Probster L, 1992, Int J Prosthodont, V5, P409
   QUALTROUGH AJE, 1996, DENT PRACTICE, V34, P8
   Sallustio F W, 1992, Int J Prosthodont, V5, P463
   Scherrer S S, 1992, Int J Prosthodont, V5, P550
   SHORTALL AC, 1989, J PROSTHET DENT, V61, P24
   TAO L, 1988, DENT MATER, V4, P208, DOI 10.1016/S0109-5641(88)80066-6
   THOMPSON JY, 1994, J DENT RES, V73, P1824, DOI 10.1177/00220345940730120601
   VRIJHOEF MMA, 1988, DENT MATER, V4, P15, DOI 10.1016/S0109-5641(88)80082-4
   WHITE SN, 1992, J PROSTHET DENT, V68, P49, DOI 10.1016/0022-3913(92)90283-G
   WILSON PR, 1992, J DENT, V20, P156, DOI 10.1016/0300-5712(92)90128-Y
   Wood DJ, 1997, J PROSTHET DENT, V78, P275, DOI 10.1016/S0022-3913(97)70026-X
   WYLIE SG, 1994, J DENT RES, V73, P1684, DOI 10.1177/00220345940730110301
NR 32
TC 21
Z9 22
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0300-5712
J9 J DENT
JI J. Dent.
PD NOV
PY 2001
VL 29
IS 8
BP 539
EP 544
DI 10.1016/S0300-5712(01)00040-9
PG 6
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 497AD
UT WOS:000172429800005
PM 11700203
DA 2021-08-04
ER

PT J
AU Chen, SH
   Lux, T
   Marchesi, M
AF Chen, SH
   Lux, T
   Marchesi, M
TI Testing for non-linear structure in an artificial financial market
SO JOURNAL OF ECONOMIC BEHAVIOR & ORGANIZATION
LA English
DT Article
DE artificial financial markets; chaos; non-linearity; GARCH models
ID STOCK RETURNS; CHAOS; DYNAMICS; MODEL; NONLINEARITY; VOLATILITY
AB We present a stochastic simulation model of a prototype financial market. Our market is populated by both noise traders and fundamentalist speculators. The dynamics covers switches in the prevailing mood among noise traders (optimistic or pessimistic) as well as switches of agents between the noise trader and fundamentalist group in response to observed differences in profits. The particular behavioral variant adopted by an agent also determines his decision to enter on the long or short side of the market. Short-run imbalances between demand and supply lead to price adjustments by a market maker or auctioneer in the usual Walrasian manner. Our interest in this paper is in exploring the behavior of the model when testing for the presence of chaos or non-linearity in the simulated data. As it turns out, attempts to determine the fractal dimension of the underlying process give unsatisfactory results in that we experience a lack of convergence of the estimate. Explicit tests for non-linearity and dependence (the BDS and Kaplan tests) also give very unstable results in that both acceptance and strong rejection of IIDness can be found in different realizations of our model. All in all, this behavior is very similar to experience collected with empirical data and our results may point towards an explanation of why robustness of inference in this area is low. However, when testing for dependence in second moments and estimating GARCH models, the results appear much more robust and the chosen GARCH specification closely resembles the typical outcome of empirical studies. (C) 2001 Elsevier Science B.V. All rights reserved.
C1 Univ Kiel, Dept Econ, D-24118 Kiel, Germany.
   Natl Chengchi Univ, Dept Econ, Taipei 11623, Taiwan.
   Univ Cagliari, Dept Elect & Elect Engn, I-09123 Cagliari, Italy.
RP Lux, T (corresponding author), Univ Kiel, Dept Econ, Olshaussenstr 40, D-24118 Kiel, Germany.
RI Marchesi, Michele/U-7048-2019
OI Chen, Shu-Heng/0000-0003-4584-7646; Marchesi,
   Michele/0000-0003-1540-8773
CR Barnett WA, 1998, J ECONOMETRICS, V82, P157, DOI 10.1016/s0304-4076(97)00081-x
   Brock WA, 1996, REV ECON STAT, V78, P94, DOI 10.2307/2109850
   Broock W.A., 1996, ECONOMETRIC REV, V15, P197, DOI 10.1080/07474939608800353
   Chen S.-H., 1999, J MANAGEMENT EC, V3
   DAY RH, 1990, J ECON BEHAV ORGAN, V14, P299, DOI 10.1016/0167-2681(90)90061-H
   de Lima PJF, 1998, J BUS ECON STAT, V16, P227, DOI 10.2307/1392578
   De Vries CG, 1994, HDB INT MACROECONOMI, P348
   Durlauf Steven N., 1997, EC EVOLVING COMPLEX
   FRANK M, 1989, REV ECON STUD, V56, P553, DOI 10.2307/2297500
   GILMORE CG, 1993, J ECON BEHAV ORGAN, V22, P209, DOI 10.1016/0167-2681(93)90064-V
   HEAGY JF, 1994, PHYS REV E, V49, P1140, DOI 10.1103/PhysRevE.49.1140
   KAPLAN DT, 1994, PHYSICA D, V73, P38, DOI 10.1016/0167-2789(94)90224-0
   KIRMAN A, 1996, MONEY FINANCIAL MARK, pCH17
   Lux T, 1998, J ECON BEHAV ORGAN, V33, P143, DOI 10.1016/S0167-2681(97)00088-7
   LUX T, 1995, ECON J, V105, P881, DOI 10.2307/2235156
   Lux T, 1999, NATURE, V397, P498, DOI 10.1038/17290
   Lux T, 1997, J ECON DYN CONTROL, V22, P1, DOI 10.1016/S0165-1889(97)00061-4
   Lux T., 2000, INT J THEOR APPL FIN, V3, P675, DOI DOI 10.1142/S0219024900000826
   MEDIO A, 1992, CHAOTIC DYNAMICS THE
   Pagan A., 1996, J EMPIR FINANC, V3, P15, DOI [10.1016/0927-5398(95)00020-8, DOI 10.1016/0927-5398(95)00020-8]
   RUELLE D, 1990, P ROY SOC LOND A MAT, V427, P241, DOI 10.1098/rspa.1990.0010
   SCHEINKMAN JA, 1989, J BUS, V62, P311, DOI 10.1086/296465
   THEILER J, 1992, PHYSICA D, V58, P77, DOI 10.1016/0167-2789(92)90102-S
   Youssefmir M, 1997, J ECON BEHAV ORGAN, V32, P101, DOI 10.1016/S0167-2681(96)00021-2
NR 24
TC 49
Z9 55
U1 0
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-2681
J9 J ECON BEHAV ORGAN
JI J. Econ. Behav. Organ.
PD NOV
PY 2001
VL 46
IS 3
BP 327
EP 342
DI 10.1016/S0167-2681(01)00181-0
PG 16
WC Economics
SC Business & Economics
GA 485GA
UT WOS:000171744100005
DA 2021-08-04
ER

PT J
AU Barner-Kowollik, C
   Quinn, JF
   Nguyen, TLU
   Heuts, JPA
   Davis, TP
AF Barner-Kowollik, C
   Quinn, JF
   Nguyen, TLU
   Heuts, JPA
   Davis, TP
TI Kinetic investigations of reversible addition fragmentation chain
   transfer polymerizations: Cumyl phenyldithioacetate mediated
   homopolymerizations of styrene and methyl methacrylate
SO MACROMOLECULES
LA English
DT Article
ID FREE-RADICAL POLYMERIZATIONS; MOLECULAR-WEIGHT DISTRIBUTIONS;
   PROPAGATION RATE COEFFICIENTS; TRANSFER CONSTANTS; TRANSFER RAFT; LENGTH
AB A previously published simulation and data fitting procedure for the reversible addition fragmentation chain transfer (RAFT) process using the PREDICI simulation program has been extended to cumyl phenyldithioacetate mediated styrene and methyl methacrylate (MMA) bulk homopolymerizations. The experimentally obtained molecular weight distributions (MWDs) for the styrene system are narrow and unimodal and shift linearly with monomer conversion to higher molecular weights. The MMA system displays a hybrid of conventional chain transfer and living behavior, leading to bimodal MWDs. The styrene system has been subjected to a combined experimental and modeling study at 60 degreesC, yielding a rate coefficient for the addition reaction of free macroradicals to polymeric RAFT agent, k(beta), of approximately 5.6 x 10(-5) L mol(-1) s(-1) and a decomposition rate coefficient for macroradical RAFT species, k-(beta), of about 2.7 x 10(-1) s(-1). The transfer rate coefficient to cumyl phenyldithioacetate is found to be close to 2.2 x 10(5) L mol(-1) s(-1). The MMA system has been studied over the temperature range 25-60 degreesC. The hybrid behavior observed in the MMA polymerizations has been exploited (at low monomer conversions) to perform a Mayo analysis allowing the determination of the temperature dependence of the transfer to cumyl phenyldithioacetate reaction. The activation energy of this process is close to 26 kJ mol(-1). In contrast to the styrene system, the PREDICI simulation procedure cannot be successfully applied to cumyl phenyldithioacetate mediated MMA polymerizations for the deduction of k(beta) and k-(beta). This inability is due to the hybrid nature of the cumyl phenyldithioacetate-MMA system, leading to a significantly reduced sensitivity toward k(beta) and k(-beta).
C1 Univ New S Wales, Sch Chem Engn & Ind Chem, Ctr Adv Macromol Design, Sydney, NSW 2052, Australia.
RP Davis, TP (corresponding author), Univ New S Wales, Sch Chem Engn & Ind Chem, Ctr Adv Macromol Design, Sydney, NSW 2052, Australia.
RI Barner-Kowollik, Christopher/B-6287-2008; Heuts, Hans/D-9141-2011;
   Davis, Thomas P/B-6395-2008; Nguyen, Thi/C-3148-2008
OI Barner-Kowollik, Christopher/0000-0002-6745-0570; Heuts,
   Hans/0000-0002-9505-8242; Davis, Thomas P/0000-0003-2581-4986; Quinn,
   John/0000-0002-4593-1170
CR Barner-Kowollik C, 2001, J POLYM SCI POL CHEM, V39, P1353, DOI 10.1002/pola.1112
   Beuermann S, 1997, MACROMOL CHEM PHYSIC, V198, P1545, DOI 10.1002/macp.1997.021980518
   BUBACK M, 1994, MACROMOL CHEM PHYSIC, V195, P2117, DOI 10.1002/macp.1994.021950620
   Chong YK, 1999, MACROMOLECULES, V32, P2071, DOI 10.1021/ma981472p
   CLAY PA, 1995, MACROMOLECULES, V28, P552, DOI 10.1021/ma00106a021
   GOTO A, IN PRESS MACROMOLECU
   Hawthorne DG, 1999, MACROMOLECULES, V32, P5457, DOI 10.1021/ma990316v
   Heuts JPA, 1995, MACROMOLECULES, V28, P8771, DOI 10.1021/ma00130a009
   Heuts JPA, 1999, MACROMOLECULES, V32, P3907, DOI 10.1021/ma9901341
   Heuts JPA, 1999, MACROMOLECULES, V32, P6019, DOI 10.1021/ma990076j
   Heuts JPA, 1998, MACROMOLECULES, V31, P2894, DOI 10.1021/ma971541k
   MATYJASZEWSKI K, 2000, ACS S SERIES, V768
   Mayadunne RTA, 1999, MACROMOLECULES, V32, P6977, DOI 10.1021/ma9906837
   Moad G, 1996, MACROMOLECULES, V29, P7727, DOI 10.1021/ma960851k
   MOAD G, 1984, MAKROMOL CHEM-RAPID, V5, P793
   Moad G, 2000, POLYM INT, V49, P993, DOI 10.1002/1097-0126(200009)49:9<993::AID-PI506>3.0.CO;2-6
   MOAD G, 1998, ACS S SERIES, V685
   Monteiro MJ, 2001, MACROMOLECULES, V34, P349, DOI 10.1021/ma001484m
   Olaj OF, 2000, MACROMOL RAPID COMM, V21, P913
   Quinn JF, 2001, CHEM COMMUN, P1044, DOI 10.1039/b101794m
   SHIPP DA, 1999, POLYM PREPR AM CHEM, V40, P450
   Souaille M, 2000, MACROMOLECULES, V33, P7378, DOI 10.1021/ma000689s
   Wulkow M, 1996, MACROMOL THEOR SIMUL, V5, P393, DOI 10.1002/mats.1996.040050303
NR 23
TC 308
Z9 315
U1 3
U2 80
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0024-9297
J9 MACROMOLECULES
JI Macromolecules
PD OCT 23
PY 2001
VL 34
IS 22
BP 7849
EP 7857
DI 10.1021/ma010349m
PG 9
WC Polymer Science
SC Polymer Science
GA 484TP
UT WOS:000171705900046
DA 2021-08-04
ER

PT J
AU Rast, S
   Fries, PH
   Belorizky, E
   Borel, A
   Helm, L
   Merbach, AE
AF Rast, S
   Fries, PH
   Belorizky, E
   Borel, A
   Helm, L
   Merbach, AE
TI A general approach to the electronic spin relaxation of Gd(III)
   complexes in solutions. Monte Carlo simulations beyond the Redfield
   limit
SO JOURNAL OF CHEMICAL PHYSICS
LA English
DT Article
ID MRI CONTRAST AGENTS; AQUEOUS-SOLUTIONS; RESONANCE-SPECTRA; NMR
   RELAXATION; GD3+ COMPLEXES; TIME-DOMAIN; DYNAMICS; NUCLEAR; WATER; EPR
AB The time correlation functions of the electronic spin components of a metal ion without orbital degeneracy in solution are computed. The approach is based on the numerical solution of the time-dependent Schrodinger equation for a stochastic perturbing Hamiltonian which is simulated by a Monte Carlo algorithm using discrete time steps. The perturbing Hamiltonian is quite general, including the superposition of both the static mean crystal field contribution in the molecular frame and the usual transient ligand field term. The Hamiltonian of the static crystal field can involve the terms of all orders, which are invariant under the local group of the average geometry of the complex. In the laboratory frame, the random rotation of the complex is the only source of modulation of this Hamiltonian, whereas an additional Ornstein-Uhlenbeck process is needed to describe the time fluctuations of the Hamiltonian of the transient crystal field. A numerical procedure for computing the electronic paramagnetic resonance (EPR) spectra is proposed and discussed. For the [Gd(H2O)(8)](3+) octa-aqua ion and the [Gd(DOTA)(H2O)](-) complex [DOTA=1,4,7,10-tetrakis(carboxymethyl)-1,4,7,10-tetraazacyclo dodecane] in water, the predictions of the Redfield relaxation theory are compared with those of the Monte Carlo approach. The Redfield approximation is shown to be accurate for all temperatures and for electronic resonance frequencies at and above X-band, justifying the previous interpretations of EPR spectra. At lower frequencies the transverse and longitudinal relaxation functions derived from the Redfield approximation display significantly faster decays than the corresponding simulated functions. The practical interest of this simulation approach is underlined. (C) 2001 American Institute of Physics.
C1 CEA Grenoble, Dept Rech Fondamentale Mat Condensee, Lab Reconnaissance Ion, Serv Chim Inorgan & Biol,UMR 5046, F-38054 Grenoble 9, France.
   Univ Lausanne, Inst Chim Minerale & Analyt, CH-1015 Lausanne, Switzerland.
   Univ Grenoble 1, Spectrometrie Phys Lab, CNRS, UMR 5588, F-38402 St Martin Dheres, France.
RP Fries, PH (corresponding author), CEA Grenoble, Dept Rech Fondamentale Mat Condensee, Lab Reconnaissance Ion, Serv Chim Inorgan & Biol,UMR 5046, F-38054 Grenoble 9, France.
RI Borel, Alain/D-3451-2012
OI Borel, Alain/0000-0003-3268-3195
CR Abernathy SM, 1997, J CHEM PHYS, V106, P9032, DOI 10.1063/1.474035
   ABRAGAM A, 1961, PRINCIPLES NUCLEAR M, pCH8
   Aime S, 1999, ACCOUNTS CHEM RES, V32, P941, DOI 10.1021/ar970300u
   AYANT Y, 1975, J PHYS-PARIS, V36, P991, DOI 10.1051/jphys:019750036010099100
   AYANT Y, 1977, J PHYS-PARIS, V38, P325, DOI 10.1051/jphys:01977003803032500
   Banci L., 1991, NUCL ELECT RELAXATIO
   BAUER H, 1991, WAHRSCHEINLICHKEITST, P259
   BERTINI I, 1995, J MAGN RESON SER A, V113, P151, DOI 10.1006/jmra.1995.1074
   BIEDENHARN LC, 1981, ANGULAR MOMENTUM QUA, P39
   BLOEMBERGEN N, 1961, J CHEM PHYS, V34, P842, DOI 10.1063/1.1731684
   Botta M, 2000, EUR J INORG CHEM, P399
   BUCKMASTER HA, 1972, PHYS STATUS SOLIDI A, V13, P9, DOI 10.1002/pssa.2210130102
   Caravan P, 1999, CHEM REV, V99, P2293, DOI 10.1021/cr980440x
   Clarkson RB, 1998, MOL PHYS, V95, P1325, DOI 10.1080/002689798166323
   Dinesen TRJ, 1999, CHEM PHYS LETT, V303, P187, DOI 10.1016/S0009-2614(99)00208-0
   *EPAPS, EJCPSA6115522134 EPA
   EVIATAR H, 1994, CHEM PHYS, V181, P369, DOI 10.1016/0301-0104(94)00008-5
   Favier A, 2000, CHEM PHYS LETT, V320, P49, DOI 10.1016/S0009-2614(00)00205-0
   FRIES P, 1978, J PHYS-PARIS, V39, P1263, DOI 10.1051/jphys:0197800390120126300
   FRIES PH, 1983, J CHEM PHYS, V79, P1166, DOI 10.1063/1.445919
   FRIES PH, 1995, THEOCHEM-J MOL STRUC, V330, P335
   HOLZ M, 1986, PROG NUCL MAG RES SP, V18, P327, DOI 10.1016/0079-6565(86)80003-6
   HWANG LP, 1975, J CHEM PHYS, V63, P4017, DOI 10.1063/1.431841
   ITZKOWITZ MS, 1967, J CHEM PHYS, V46, P3048, DOI 10.1063/1.1841176
   JEANNIN M, 1994, THESIS GRENOBLE U
   KANNAN D, 1979, INTRO STOCHASTIC PRO
   KOWALEWSKI J, 1985, PROG NUCL MAG RES SP, V17, P141, DOI 10.1016/0079-6565(85)80007-8
   LAUFFER RB, 1987, CHEM REV, V87, P901, DOI 10.1021/cr00081a003
   Merbach A. E., 2001, CHEM CONTRAST AGENTS
   Miller JC, 2000, J PHYS CHEM A, V104, P4889, DOI 10.1021/jp000418j
   Odelius M, 1996, J CHEM PHYS, V104, P3181, DOI 10.1063/1.471083
   PEDERSEN JB, 1972, J CHEM PHYS, V57, P2680, DOI 10.1063/1.1678650
   POWELL DH, 1993, HELV CHIM ACTA, V76, P2129, DOI 10.1002/hlca.19930760524
   Powell DH, 1996, J AM CHEM SOC, V118, P9333, DOI 10.1021/ja961743g
   Press WH, 1989, NUMERICAL RECIPES AR
   Rast S, 2000, J CHEM PHYS, V113, P8724, DOI 10.1063/1.1289882
   Rast S, 1999, J CHIM PHYS PCB, V96, P1543, DOI 10.1051/jcp:1999231
   Rast S, 2001, J AM CHEM SOC, V123, P2637, DOI 10.1021/ja003707u
   Rast S, 2001, J PHYS CHEM B, V105, P1978, DOI 10.1021/jp003686q
   Red fi eld A. G., 1965, ADV MAGN RESON, V1, P1, DOI [DOI 10.1016/B978-1-4832-3114-3.50007-6, 10.1016/B978-1-4832-3114-3.50007-6]
   ROBINSON BH, 1992, J CHEM PHYS, V96, P2609, DOI 10.1063/1.462869
   Svoboda J, 1996, J MAGN RESON SER A, V121, P108, DOI 10.1006/jmra.1996.0149
   USOVA N, 1995, J CHEM PHYS, V103, P96, DOI 10.1063/1.469627
   Vigouroux C, 1998, CHEM PHYS LETT, V286, P93, DOI 10.1016/S0009-2614(98)00037-2
NR 44
TC 63
Z9 63
U1 0
U2 12
PU AMER INST PHYSICS
PI MELVILLE
PA CIRCULATION & FULFILLMENT DIV, 2 HUNTINGTON QUADRANGLE, STE 1 N O 1,
   MELVILLE, NY 11747-4501 USA
SN 0021-9606
J9 J CHEM PHYS
JI J. Chem. Phys.
PD OCT 22
PY 2001
VL 115
IS 16
BP 7554
EP 7563
DI 10.1063/1.1392364
PG 10
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA 484YT
UT WOS:000171719200026
DA 2021-08-04
ER

PT J
AU Hamel, S
   Krumm, W
AF Hamel, S
   Krumm, W
TI Mathematical modelling and simulation of bubbling fluidised bed
   gasifiers
SO POWDER TECHNOLOGY
LA English
DT Article; Proceedings Paper
CT 3rd European Conference on Fluidisation (EUROFLUIDISATION III)
CY MAY 28-31, 2000
CL TOULOUSE, FRANCE
DE gasification; pressurised fluidised bed; biomass; coal
ID GAS; FREEBOARD; FLOW; BEHAVIOR; COAL; COMBUSTION; VELOCITY; TARS
AB A mathematical model for simulation of gasification processes of solid fuels in atmospheric or pressurised bubbling fluidised beds incorporating bed and freeboard hydrodynamics, fuel drying and de volatilization, and chemical reaction kinetics is presented. The model has been used to simulate four bubbling fluidised bed gasifiers, described in literature, of different scales from atmospheric laboratory scale up to pressurised commercial scale, processing brown coal, peat and sawdust. The gasifiers have been operated within a wide range of parameters using air, air/steam or oxygen/steam as gasification agent, operating with or without recirculation of fines at operating pressures up to 2.5 MPa. The simulation results for overall carbon conversion, temperature and concentrations of gaseous species agree sufficiently well with published experimental data. (C) 2001 Elsevier Science B.V. All rights reserved.
C1 Univ Siegen, Inst Energietech, Lehrstuhl Energie & Unweltverfahrenstech, D-57068 Siegen, Germany.
RP Hamel, S (corresponding author), Univ Siegen, Inst Energietech, Lehrstuhl Energie & Unweltverfahrenstech, Paul Bonatz Str 9-11, D-57068 Siegen, Germany.
CR ADLHOCK W, 1992, VGB KRAFTWERKSTECH, V72
   AGARWAL PK, 1986, CHEM ENG SCI, V41
   ANTHONY DB, 1976, AICHE J, V22, P625, DOI 10.1002/aic.690220403
   ARPIAINEN V, 1989, J ANAL APPL PYROL, P355
   BARON T, 1990, POWDER TECHNOL, V63, P149, DOI 10.1016/0032-5910(90)80037-Y
   BERKELMANN KG, 1991, POWDER TECHNOL, V68, P271, DOI 10.1016/0032-5910(91)80052-K
   BRIENS CL, 1988, POWDER TECHNOL, V54, P183, DOI 10.1016/0032-5910(88)80077-9
   BURKLE KJ, 1991, THESIS U SIEGEN
   CHEN WJ, 1987, FUEL PROCESS TECHNOL, V16, P279, DOI 10.1016/0378-3820(87)90025-7
   CORELLA J, 1991, IND ENG CHEM RES, V30
   DERSCH J, 1994, THESIS U SIEGEN
   Field M, 1967, COMBUSTION PULVERIZE
   FUNG AS, 1993, POWDER TECHNOL, V74, P121, DOI 10.1016/0032-5910(93)87004-8
   HAIDER A, 1989, POWDER TECHNOL, V58, P63, DOI 10.1016/0032-5910(89)80008-7
   HAMDULLAHPUR F, 1986, AICHE J, V32, P2047, DOI 10.1002/aic.690321215
   HAMEL S, 1999, P 4 INT S COAL COMB
   HAMEL S, 1999, FINAL REPORT MWF
   HAYHURST AN, 1990, COMBUST FLAME, V79, P175, DOI 10.1016/0010-2180(90)90042-P
   HEGERMANN R, 1990, THESIS U KARLSRUHE G
   HEINBOCKEL I, 1995, THESIS U SIEGEN GERM
   HILLIGARDT K, 1986, THESIS TU HAMBURG HA
   HOFFMANN AC, 1986, CHEM ENG COMMUN, V41, P133, DOI 10.1080/00986448608911716
   HOTTEL HC, 1965, P 10 INT S COMB COMB, P111
   JENSEN A, 1995, FUEL, V74, P1555, DOI 10.1016/0016-2361(95)00155-X
   KURKELA E, 1992, FUEL PROCESS TECHNOL, V31
   LEPPALAHTI J, 1991, FUEL, V70, P491, DOI 10.1016/0016-2361(91)90026-7
   LEVY EK, 1983, AICHE J, V29, P383, DOI 10.1002/aic.690290306
   OLOWSON PA, 1990, CHEM ENG SCI, V45, P1733, DOI 10.1016/0009-2509(90)87051-S
   PEMBERTON ST, 1984, CHEM ENG SCI, V39, P829, DOI 10.1016/0009-2509(84)85052-6
   ROWE PN, 1984, XRAY OBSERVATOIN GAS, P53
   SCHIFFER HP, 1998, VDI BER, V1387
   SCIAZKO M, 1988, CHEM ENG PROCESS, V24, P49
   SERIO MA, 1987, IND ENG CHEM RES, V26, P1831, DOI 10.1021/ie00069a019
   SMOOT LD, 1985, COAL COMB GASIFICATI
   WEEDA M, 1995, THESIS U AMSTERDAM N
   WEIN JW, 1992, THESIS TU HAMBURG HA
   WIRSUM M, 1998, THESIS U SIEGEN
   WISCHNEWSKI R, 1998, DGMK TAGNGSBER, V9802, P143
NR 38
TC 45
Z9 51
U1 1
U2 17
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0032-5910
J9 POWDER TECHNOL
JI Powder Technol.
PD OCT 8
PY 2001
VL 120
IS 1-2
SI SI
BP 105
EP 112
DI 10.1016/S0032-5910(01)00356-4
PG 8
WC Engineering, Chemical
SC Engineering
GA 483FP
UT WOS:000171623200015
DA 2021-08-04
ER

PT J
AU Pioch, T
   Staehle, HJ
   Schneider, H
   Duschner, H
   Dorfer, CE
AF Pioch, T
   Staehle, HJ
   Schneider, H
   Duschner, H
   Dorfer, CE
TI Effect of intrapulpal pressure simulation in vitro on shear bond
   strengths and hybrid layer formation
SO AMERICAN JOURNAL OF DENTISTRY
LA English
DT Article
ID IN-VITRO; DENTIN; ULTRASTRUCTURE; PERMEABILITY; ADHESIVES; SYSTEMS;
   TEETH; VIVO
AB Purpose: To test the hypothesis that simulation of an intrapulpal pressure during the application of dentin bonding systems influences hybrid layer formation in vitro. Materials and Methods: 180 teeth and three different bonding agents were used for shear bond strength measurements and for confocal laser scanning microscopy studies on the dentin-composite interface. The bonding agents (30 teeth each material) were applied without (90 teeth, Group A) and with intrapulpal pressure simulation of 34 cm H2O with water (90 teeth, Group B). 45 specimens from each group were sheared in a testing machine, and 45 teeth from each group were used for CLSM studies after labeling the primer components of the bonding agents with a fluorescent dye. Results: After simulation of pulpal pressure the bond strengths decreased significantly in all groups (Syntac [without/with]: 16.0 +/- 4.5/8.0 +/- 3.7, P = 0.001; Gluma: 13.3 +/- 4.6/8.4 +/- 4.4, P = 0.008; Prime & Bond NT: 14.8 +/- 5.8/8.7 +/- 5.7, P = 0.007; n = 15 each; U-tests). There were no significant differences between the hybrid layer thickness without/with simulation of pulpal pressure (Syntac: 3.6 +/- 0.6/4.1 +/- 1.2, P = 0.35; Gluma: 3.5 +/- 0.6/3.7 +/- 0.9, P = 0.49; Prime & Bond NT: 3.5 +/- 0.9/3.8 +/- 0.8, P = 0.44; n = 15 each; U-tests). In the case of simulation of an intrapulpal pressure, CLSM examination revealed a distinctly shallower penetration of the adhesives into dentin compared to the samples treated without intrapulpal pressure.
C1 Heidelberg Univ, Dept Conservat Dent & Periodontol, Sch Dent, D-6900 Heidelberg, Germany.
   Univ Leipzig, Dept Restorat Dent, D-7010 Leipzig, Germany.
   Johannes Gutenberg Univ Mainz, Fac Med, Dept Appl Struct & Microanal, D-6500 Mainz, Germany.
RP Pioch, T (corresponding author), Heidelberg Univ, Dept Restorat Dent, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.
EM thomas_pioch@med.uni-heidelberg.de
RI Doerfer, Christof E/E-4041-2010
OI Doerfer, Christof E/0000-0002-2508-8075
CR Andrews S A, 1972, J Hosp Dent Pract, V6, P49
   CIUCCHI B, 1995, J ENDODONT, V21, P191, DOI 10.1016/S0099-2399(06)80564-9
   Coli P, 1999, EUR J ORAL SCI, V107, P400, DOI 10.1046/j.0909-8836.1999.eos107512.x
   DAVIDSON CL, 1993, J ORAL REHABIL, V20, P291, DOI 10.1111/j.1365-2842.1993.tb01611.x
   DSOUZA PD, 1999, ACTA MED DENT HELV, V4, P20
   GOODIS HE, 1991, ARCH ORAL BIOL, V36, P561, DOI 10.1016/0003-9969(91)90105-4
   Gwinnett A J, 1994, Am J Dent, V7, P144
   Gwinnett A J, 1994, Am J Dent, V7, P243
   GWINNETT AJ, 1993, AM J DENT, V5, P73
   HALLER B, 1999, DTSCH ZAHNARZTL Z, V54, P225
   Inai N, 1998, AM J DENT, V11, P123
   Kanca J 3rd, 1992, Quintessence Int, V23, P39
   Kanca J 3rd, 1992, Am J Dent, V5, P213
   KREJCI I, 1993, J DENT RES, V72, P490, DOI 10.1177/00220345930720020401
   MATTHEWS B, 1994, ARCH ORAL BIOL, V39, pS87, DOI 10.1016/0003-9969(94)90193-7
   NAKABAYASHI N, 1982, J BIOMED MATER RES, V16, P265, DOI 10.1002/jbm.820160307
   Nakabayashi N, 1992, Quintessence Int, V23, P135
   Nikaido T, 1995, Quintessence Int, V26, P221
   Pashley DH, 2000, DENT MATER, V16, P7, DOI 10.1016/S0109-5641(99)00077-9
   Paul S J, 1993, Schweiz Monatsschr Zahnmed, V103, P709
   Pioch T, 2001, AM J DENT, V14, P252
   Pioch T, 1999, J Adhes Dent, V1, P135
   Pioch T, 1997, Adv Dent Res, V11, P453
   Pioch T, 1998, AM J DENT, V11, P202
   PRATI C, 1991, DENT MATER, V7, P54, DOI 10.1016/0109-5641(91)90028-W
   Prati C, 1992, Am J Dent, V5, P33
   SANO H, 1995, OPER DENT, V20, P18
   SASAZAKI H, 1996, P INT C DENT PULP CO, P200
   Schneier H, 2000, J BIOMED MATER RES, V53, P86, DOI 10.1002/(SICI)1097-4636(2000)53:1<86::AID-JBM12>3.0.CO;2-Z
   Schupbach P, 1997, EUR J ORAL SCI, V105, P344, DOI 10.1111/j.1600-0722.1997.tb00251.x
   TAO L, 1989, DENT MATER, V5, P181, DOI 10.1016/0109-5641(89)90010-9
   Tao L, 1991, Am J Dent, V4, P73
   Tay FR, 1996, AM J DENT, V9, P161
   Tay FR, 1996, DENT MATER, V12, P236, DOI 10.1016/S0109-5641(96)80029-7
   TAY FR, 1995, QUINTESSENCE INT, V26, P63
   VANHASSEL HJ, 1971, ORAL SURG ORAL MED O, V32, P126, DOI 10.1016/0030-4220(71)90258-1
   VANMEERBEEK B, 1993, J DENT RES, V72, P495, DOI 10.1177/00220345930720020501
   Vargas MA, 1997, OPER DENT, V22, P159
   VONGSAVAN N, 1992, ARCH ORAL BIOL, V37, P175, DOI 10.1016/0003-9969(92)90087-O
   Watson T F, 1997, Adv Dent Res, V11, P433
   WATSON TF, 1987, CLIN MATER, V2, P33
NR 41
TC 32
Z9 34
U1 0
U2 1
PU MOSHER & LINDER, INC
PI WESTON
PA 318 INDIAN TRACE SUITE 500, WESTON, FL 33326 USA
SN 0894-8275
J9 AM J DENT
JI Am. J. Dent.
PD OCT
PY 2001
VL 14
IS 5
BP 319
EP 323
PG 5
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 497JN
UT WOS:000172451900013
PM 11803998
DA 2021-08-04
ER

PT J
AU Costopoulos, A
AF Costopoulos, A
TI Evaluating the impact of increasing memory on agent behaviour: Adaptive
   patterns in as agent based simulation of subsistence
SO JASSS-THE JOURNAL OF ARTIFICIAL SOCIETIES AND SOCIAL SIMULATION
LA English
DT Article
DE multi-agent simulation; subsistence; agent cognitive systems
AB This is an interim report on a set of ongoing agent-based simulation experiments. The main goal of the experiments is to evaluate the impact of varying memory capacities on the ability of agents to adapt to given subsistence environments and resource landscapes. The results so far suggest that-increasing the number of events which an agent can use in decision making does not directly lead to an increase in the agent's ability to adapt to an environment. Variable memory capacity, however, does lead to diversification of agent behaviour patterns in a given environment. The results also suggest that more permissive environments allow agents with greater memory to show a greater diversity of behaviour than similar agents in more restrictive environments. These early results are providing the starting hypotheses which are at the core of a larger set of experiments presently being carried out. The simulation engine and source code are available from the author.
C1 McGill Univ, Dept Anthropol, Montreal, PQ, Canada.
RP Costopoulos, A (corresponding author), McGill Univ, Dept Anthropol, Montreal, PQ, Canada.
CR Aldenderfer M., 1991, ARCHAEOLOGICAL METHO, V3, P195
   BRUES AM, 1954, AM J PHYSICAL AN DEC, P559
   COSTOPOULOS A, 1999, THESIS OULU U FINLAN
   DYKE B, 1981, ANNU REV ANTHROPOL, V10, P193, DOI 10.1146/annurev.an.10.100181.001205
   KUNSTADTER P, 1964, AM J PHYS ANTHROPOL, V21, P511
   Phillips J. D., 1999, EARTH SURFACE SYSTEM
   READ DW, 1998, J ARTIFICIAL SOC SOC, V1
   WOBST HM, 1974, AM ANTIQUITY, V39, P147, DOI 10.2307/279579
NR 8
TC 6
Z9 6
U1 1
U2 1
PU J A S S S
PI GUILDFORD
PA UNIV SURREY, DEPT SOCIOLOGY, GUILDFORD GU2 7XH, SURREY, ENGLAND
SN 1460-7425
J9 JASSS
JI JASSS
PD OCT
PY 2001
VL 4
IS 4
BP U153
EP U169
PG 17
WC Social Sciences, Interdisciplinary
SC Social Sciences - Other Topics
GA 498VX
UT WOS:000172533700007
DA 2021-08-04
ER

PT J
AU Raberto, M
   Cincotti, S
   Focardi, SM
   Marchesi, M
AF Raberto, M
   Cincotti, S
   Focardi, SM
   Marchesi, M
TI Agent-based simulation of a financial market
SO PHYSICA A
LA English
DT Article; Proceedings Paper
CT NATO Advanced Research Workshop on Application of Physics in Economic
   Modelling
CY FEB 08-10, 2001
CL PRAGUE, CZECH REPUBLIC
DE artificial financial markets; heterogeneous agents; financial time
   series; econophysics
ID STOCK-MARKET; MODEL; PRICE; FLUCTUATIONS; BEHAVIOR
AB This paper introduces an agent-based artificial financial market in which heterogeneous agents trade one single asset through a realistic trading mechanism for price formation. Agents are initially endowed with a finite amount of cash and a given finite portfolio of assets. There is no money-creation process; the total available cash is conserved in time. In each period, agents make random buy and sell decisions that are constrained by available resources, subject to clustering, and dependent on the volatility of previous periods. The model proposed herein is able to reproduce the leptokurtic shape of the probability density of log price returns and the clustering of volatility. Implemented using extreme programming and object-oriented technology, the simulator is a flexible computational experimental facility that can find applications in both academic and industrial research projects. (C) 2001 Elsevier Science B.V. All rights reserved.
C1 Univ Genoa, Dipartimento Ingn Biofis & Elettr, I-16145 Genoa, Italy.
   Intertek Grp, F-75015 Paris, France.
   Univ Cagliari, Dept Ingn Elettr & Elettr, I-09123 Cagliari, Italy.
RP Raberto, M (corresponding author), Univ Genoa, Dipartimento Ingn Biofis & Elettr, Via Opera Pia 11A, I-16145 Genoa, Italy.
RI Raberto, Marco/F-7990-2012; Marchesi, Michele/U-7048-2019; Cincotti,
   Silvano/A-4680-2016
OI Cincotti, Silvano/0000-0001-6778-0185; Marchesi,
   Michele/0000-0003-1540-8773
CR Bak P, 1997, PHYSICA A, V246, P430, DOI 10.1016/S0378-4371(97)00401-9
   Beck K., 1999, EXTREME PROGRAMMING
   Bouchand J.-P., 2001, Quantitative Finance, V1, P105, DOI 10.1088/1469-7688/1/1/307
   Bouchaud J.-P., 2000, THEORY FINANCIAL RIS
   Caldarelli G, 1997, EUROPHYS LETT, V40, P479, DOI 10.1209/epl/i1997-00491-5
   Chowdhury D, 1999, EUR PHYS J B, V8, P477, DOI 10.1007/s100510050714
   Cont R, 2000, MACROECON DYN, V4, P170
   Friedman M., 1953, ESSAYS POSITIVE EC
   Iori G, 1999, INT J MOD PHYS C, V10, P1149, DOI 10.1142/S0129183199000930
   LeBaron B, 1999, J ECON DYN CONTROL, V23, P1487, DOI 10.1016/S0165-1889(98)00081-5
   LeBaron B, 2000, J ECON DYN CONTROL, V24, P679, DOI 10.1016/S0165-1889(99)00022-6
   Liu YH, 1999, PHYS REV E, V60, P1390, DOI 10.1103/PhysRevE.60.1390
   Lux T, 1999, NATURE, V397, P498, DOI 10.1038/17290
   Mantegna RN, 2000, INTRO ECONOPHYSICS C
   PALMER RG, 1994, PHYSICA D, V75, P264, DOI 10.1016/0167-2789(94)90287-9
   Raberto M, 1999, PHYSICA A, V269, P148, DOI 10.1016/S0378-4371(99)00089-8
   Sato AH, 1998, PHYSICA A, V250, P231, DOI 10.1016/S0378-4371(97)00569-4
   Schwartz ES, 1997, J FINANC, V52, P923, DOI 10.2307/2329512
   Solomon, 2000, MICROSCOPIC SIMULATI
NR 19
TC 135
Z9 145
U1 0
U2 24
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-4371
J9 PHYSICA A
JI Physica A
PD OCT 1
PY 2001
VL 299
IS 1-2
BP 319
EP 327
DI 10.1016/S0378-4371(01)00312-0
PG 9
WC Physics, Multidisciplinary
SC Physics
GA 484DQ
UT WOS:000171675300037
OA Green Submitted
DA 2021-08-04
ER

PT J
AU Ramis, X
   Cadenato, A
   Morancho, JM
   Salla, JM
AF Ramis, X
   Cadenato, A
   Morancho, JM
   Salla, JM
TI Polyurethane-unsaturated polyester interpenetrating polymer networks:
   thermal and dynamic mechanical thermal behaviour
SO POLYMER
LA English
DT Article
DE interpenetrating polymer networks; polyurethane; unsaturated polyester
   resin
ID INJECTION-MOLDING PROCESS; CROSS-LINKING AGENT; REACTION-KINETICS;
   VISCOELASTIC PROPERTIES; TEMPERATURE; RESINS; MORPHOLOGY; CURE;
   COMPOSITES; DIAGRAM
AB A series of simultaneous interpenetrating polymer networks, IPNs, based on a polyurethane and an unsaturated polyester resin is studied. The curing process was followed using differential scanning calorimetry (DSC) and Fourier-transform infrared spectroscopy (FTIR). The IPNs were seen to crosslink completely and the kinetics of the curing process were modified greatly, accelerating with respect to the pure homopolymers. The process of styrene-polyester copolymerization varies from an azeotropic copolymerization in the pure polyester state to alternating copolymerization in the IPNs. Miscibility, phase continuity and phase separation are studied by dynamic mechanical thermal analysis (DMTA). In general, the IPNs obtained have a high degree of interpenetration and are semi-miscibles. Intermediate compositions are slightly less miscible than the outer ranges with a transition for the second component being apparent. The empirical loss modulus-composition curves are compared with those predicted by various theoretical models. In general, the IPNs follow the Budiansky model, which predicts a phase inversion at intermediate compositions. Compositions which are rich in a specific component show a continuous phase with the disperse minority component and the intermediate compositions show two co-continuous phases. It is also seen that these curves depend strongly on the temperature at which they are formed. The loss factor reveals strong synergism and the maximum of properties are found in a composition close to 40% in polyester. Comparison of simultaneous IPNs with sequential IPNs showed that the latter show a lesser tendency to phase separation in the systems studied. (C) 2001 Elsevier Science Ltd. All rights reserved.
C1 Univ Politecn Catalunya, ETSEIB, Lab Termodinamica, Barcelona 08028, Spain.
RP Salla, JM (corresponding author), Univ Politecn Catalunya, ETSEIB, Lab Termodinamica, Diagonal 647, Barcelona 08028, Spain.
RI Ramis, Xavier/J-9838-2014
OI Ramis, Xavier/0000-0003-2550-7185; Salla Tarrago, Josep
   M/0000-0002-5409-8416
CR AKAY M, 1993, POLYMER, V34, P1865, DOI 10.1016/0032-3861(93)90428-D
   BERMARK P, 1987, POLYMER, V28, P1662
   BUDIANSK.B, 1965, J MECH PHYS SOLIDS, V13, P223, DOI 10.1016/0022-5096(65)90011-6
   Cadenato A, 1997, J THERM ANAL, V49, P269, DOI 10.1007/BF01987448
   CHOU YC, 1995, POLYM ENG SCI, V35, P976, DOI 10.1002/pen.760351204
   DAVIES WEA, 1971, J PHYS D APPL PHYS, V4, P318, DOI 10.1088/0022-3727/4/2/318
   delaCaba K, 1996, POLYMER, V37, P275, DOI 10.1016/0032-3861(96)81099-8
   DICKIE RA, 1973, J APPL POLYM SCI, V17, P45, DOI 10.1002/app.1973.070170104
   DICKIE RA, 1988, POLYM BLENDS, V2, pCH8
   Fan LH, 1997, POLYMER, V38, P3609, DOI 10.1016/S0032-3861(96)00919-6
   Flory P.J, 1953, PRINCIPLES POLYM CHE
   Fox T.G., 1956, B AM PHYS SOC, V1, P123
   FRISCH KC, 1974, J POLYM SCI POL CHEM, V12, P885, DOI 10.1002/pol.1974.170120418
   FUNKE W, 1961, MAKROMOLEKUL CHEM, V49, P52
   Hourston DJ, 1996, POLYMER, V37, P3521, DOI 10.1016/0032-3861(96)00164-4
   Hourston DJ, 1998, THERMOCHIM ACTA, V324, P109, DOI 10.1016/S0040-6031(98)00528-0
   HSU TJ, 1985, POLYM ENG SCI, V25, P951, DOI 10.1002/pen.760251507
   Hua FJ, 1999, EUR POLYM J, V35, P103, DOI 10.1016/S0014-3057(98)00048-2
   HUANG YJ, 1992, J APPL POLYM SCI, V46, P1573, DOI 10.1002/app.1992.070460907
   Jo WH, 2000, J POLYM SCI POL PHYS, V38, P1005, DOI 10.1002/(SICI)1099-0488(20000415)38:8<1005::AID-POLB1>3.0.CO;2-A
   Johnson AF, 1979, ENG DESIGN PROPERTIE
   KAPLAN DS, 1976, J APPL POLYM SCI, V20, P2615, DOI 10.1002/app.1976.070201001
   KERNER EH, 1956, P PHYS SOC LOND B, V69, P808, DOI 10.1088/0370-1301/69/8/305
   KIM JH, 1987, POLYM ENG SCI, V27, P1252, DOI 10.1002/pen.760271608
   KIM SC, 1977, MACROMOLECULES, V10, P1187, DOI 10.1021/ma60060a004
   KIM SC, 1976, MACROMOLECULES, V9, P258, DOI 10.1021/ma60050a016
   KLEMPNER D, 1988, ENCY POLYM SCI ENG, V8
   LEWIS FM, 1948, J AM CHEM SOC, V70, P1519, DOI 10.1021/ja01184a066
   LUCAS JC, 1993, POLYMER, V34, P3216, DOI 10.1016/0032-3861(93)90393-O
   MANSON JA, 1976, POLYM BLENDS COMPOSI, pCH8
   MOONEY M, 1951, J COLL SCI IMP U TOK, V6, P162, DOI 10.1016/0095-8522(51)90036-0
   NIELSEN LE, 1969, J MACROMOL SCI-REV M, VC  3, P69, DOI 10.1080/15583726908545897
   Olabisi O, 1979, POLYM POLYM MISCIBIL
   Ramis X, 1999, J POLYM SCI POL PHYS, V37, P751, DOI 10.1002/(SICI)1099-0488(19990415)37:8<751::AID-POLB2>3.0.CO;2-V
   Ramis X, 1997, J POLYM SCI POL PHYS, V35, P371, DOI 10.1002/(SICI)1099-0488(19970130)35:2<371::AID-POLB13>3.3.CO;2-6
   RAMIS X, 1992, J APPL POLYM SCI, V45, P227, DOI 10.1002/app.1992.070450203
   Sperling L. H., 1981, INTERPENETRATING POL
   SPERLING LH, 1985, POLYM ENG SCI, V25, P517, DOI 10.1002/pen.760250902
   TOBOLSKY AV, 1961, J POLYM SCI, V54, P175, DOI 10.1002/pol.1961.1205415913
   TOMAS DA, 1988, POLYM BLENDS, V2, pCH11
   URBAN MW, 1991, POLYM COMMUN, V32, P171
   VRATSANOS MS, 1989, POLYM ENG SCI, V29, P806, DOI 10.1002/pen.760291209
   WILKINSON TC, 1983, POLYM PREPR AM CHEM, V49, P496
   XUE SC, 1989, POLYMER, V30, P1269, DOI 10.1016/0032-3861(89)90047-5
   YANG YS, 1988, POLYMER, V29, P1793, DOI 10.1016/0032-3861(88)90393-X
   YANG YS, 1987, MACROMOLECULES, V20, P1490, DOI 10.1021/ma00173a008
   ZHOU PG, 1994, MACROMOLECULES, V27, P1788, DOI 10.1021/ma00085a018
NR 47
TC 68
Z9 78
U1 0
U2 22
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0032-3861
J9 POLYMER
JI Polymer
PD OCT
PY 2001
VL 42
IS 23
BP 9469
EP 9479
DI 10.1016/S0032-3861(01)00492-X
PG 11
WC Polymer Science
SC Polymer Science
GA 465PC
UT WOS:000170598300020
DA 2021-08-04
ER

PT J
AU Li, DM
   Wang, XS
   Lai, YG
AF Li, DM
   Wang, XS
   Lai, YG
TI Study of water intakes for oncomelania control based on information of
   oncomelania behavior and CFD results
SO SCIENCE IN CHINA SERIES E-TECHNOLOGICAL SCIENCES
LA English
DT Article
DE oncomelania control; ecologic hydraulics; CFD; oncomelania-free intake
AB Schistosomiasis is a parasitic disease. They propagate in the Yangtze River valley of China. The spread of the disease is solely through a middle-agent named oncomelania, so the spread of schistosomiasis by oncomelania can be controlled by properly designing water intakes which prevent oncomelania from entering the farming land or residential areas. In this paper, a successful design process is reported and a new oncomelania-free intake device is demonstrated in the laboratory. The design of the new intake is based on a sound research program in which an extensive experimental studies have been carded out to gain knowledge of oncomelania eco-hydraulic behaviors and a detailed flow field information is obtained through CFD simulation.
C1 Wuhan Univ, Dept River Engn, Wuhan 430072, Peoples R China.
   Univ Iowa, Iowa Inst Hydraul, Iowa City, IA 52242 USA.
RP Li, DM (corresponding author), Wuhan Univ, Dept River Engn, Wuhan 430072, Peoples R China.
CR LAI YG, 2000, P 4 INT C HYDR INF I
   LI CB, 1986, J YANGTZE ACAD SCI, P163
   LI DM, 1991, RESOURCES ENV YANGTZ, V8, P112
   LI DM, 1991, J HYDRODYNAMICS SE B, V11, P33
   XU ZF, 1986, HYDRAULICS, V1, P13
   YANG X, 1992, CHINESE J SCHISTOSOM, V6, P137
   YANG XX, 1996, RES REPORT SCHISTOSO
   YING CM, 1992, RES REPORT SCHISTOSO
NR 8
TC 4
Z9 6
U1 0
U2 2
PU SCIENCE PRESS
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA
SN 1006-9321
J9 SCI CHINA SER E
JI Sci. China Ser. E-Technol. Sci.
PD OCT
PY 2001
VL 44
IS 5
BP 522
EP 530
DI 10.1007/BF02916738
PG 9
WC Engineering, Multidisciplinary; Materials Science, Multidisciplinary
SC Engineering; Materials Science
GA 488ZH
UT WOS:000171966800008
DA 2021-08-04
ER

PT J
AU Berger, T
AF Berger, T
TI Agent-based spatial models applied to agriculture: a simulation tool for
   technology diffusion, resource use changes and policy analysis
SO AGRICULTURAL ECONOMICS
LA English
DT Article; Proceedings Paper
CT 14th Triennial Congress of the
   International-Association-of-Agricultural-Economists
CY AUG 13-18, 2000
CL BERLIN, GERMANY
SP Int Assoc Agr Economists
DE diffusion of innovations; inter-household linkages; policy analysis;
   multi-agent systems; cellular automata
AB This paper presents a spatial multi-agent programming model, which has been developed for assessing policy options in the diffusion of innovations and resource use changes. Unlike conventional simulation tools used in agricultural economics, the model class described here applies a multi-agent/cellular automata (CA) approach by using heterogeneous farm-household models and capturing their social and spatial interactions explicitly. The individual choice of the farm-household among available production, consumption, investment and marketing alternatives is represented in recursive linear programming models. Adoption constraints are introduced in form of network-threshold values that reflect the cumulative effects of experience and observation of peers' experiences. The model's economic and hydrologic components are tightly connected into a spatial framework. The integration of economic and hydrologic processes facilitates the, consideration of feedback effects in the use of water for irrigation. The simulation runs of the model are carried out with an empirical data set, which has been derived from various data sources on an agricultural region in Chile. Simulation results show that agent-based spatial modelling constitutes a powerful approach to better understanding processes of innovation and resource use change. (C) 2001 Elsevier Science BN. All rights reserved.
C1 Univ Bonn, Ctr Dev Res, ZEF Bonn, D-53113 Bonn, Germany.
RP Berger, T (corresponding author), Univ Bonn, Ctr Dev Res, ZEF Bonn, Walter Flex St 3, D-53113 Bonn, Germany.
EM t.berger@uni-bonn.de
RI RASTOIN, Jean-Louis/F-3853-2011
OI Berger, Thomas/0000-0003-3316-9614
CR Balmann A, 1997, EUR REV AGRIC ECON, V24, P85, DOI 10.1093/erae/24.1.85
   BERGER T, 1997, EC AGRARIA, V1, P15
   BERGER T, 2000, AGRARWIRTSCHAFT
   Cochrane W., 1979, DEV AM AGR
   Cowan R, 1996, ECON J, V106, P521, DOI 10.2307/2235561
   DAY RH, 1978, MODELLING EC CHANGE, pCH1
   Dosi G., 1988, TECHNICAL CHANGE EC
   DOWNS GW, 1976, ADMIN SCI QUART, V21, P700, DOI 10.2307/2391725
   GILBERT G, 1999, SIMULATION SOCIAL SC
   GRILICHES Z, 1957, ECONOMETRICA, V25, P501, DOI 10.2307/1905380
   HANF CH, 1989, ANAL SECTOR ANAL LIN
   MCCARL BA, 1986, SO J AGR EC, V12, P155
   METCALFE JS, 1988, TECHNICAL CHANGE EC, P560
   MUCHNIK E, 1996, 253 U CAT CHIL
   Rogers EM, 2010, DIFFUSION INNOVATION
   SAUER U, 1995, THESIS TU MUNCHEN FR
   Schelling T. C., 1978, MICROMOTIVES MACROBE
   STALLMEISTER P, 1995, THESIS TU MUNCHEN FR
   Valente T.W., 1995, NETWORK MODELS DIFFU
   VOGELGESANG F, 1996, CEPAL REV, V58, P95
   VOSTI SA, 1997, SUSTAINABILITY GROWT, P1
NR 21
TC 343
Z9 362
U1 3
U2 243
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0169-5150
EI 1574-0862
J9 AGR ECON-BLACKWELL
JI Agric. Econ.
PD SEP
PY 2001
VL 25
IS 2-3
BP 245
EP 260
DI 10.1111/j.1574-0862.2001.tb00205.x
PG 16
WC Agricultural Economics & Policy; Economics
SC Agriculture; Business & Economics
GA 494DV
UT WOS:000172267200012
OA Green Published
DA 2021-08-04
ER

PT J
AU Mano, N
   Uchida, M
   Okuyama, H
   Sasaki, I
   Ikegawa, S
   Goto, J
AF Mano, N
   Uchida, M
   Okuyama, H
   Sasaki, I
   Ikegawa, S
   Goto, J
TI Simultaneous detection of cholyl adenylate and coenzyme A thioester
   utilizing liquid chromatography/electrospray ionization mass
   spectrometry
SO ANALYTICAL SCIENCES
LA English
DT Article
ID TAURINE-N-ACYLTRANSFERASE; RAT-LIVER MICROSOMES; BILE ACID-COA; A
   LIGASE; ACYL-ADENYLATE; PURIFICATION; ACTIVATION
AB It has been proposed that acyl adenylate is first formed during activation of the carboxy group into the acyl CoA thioester, an intermediate in the formation of amino acid conjugates. Acyl CoA synthetases may be responsible for this acyl adenylate formation. Recently, we hypothesized the preferential formation of cholic acid adenylate, a major bile acid, preceding production of the corresponding CoA thioester in incubations with rat liver microsomal fractions. To verify this biosynthetic mechanism, monitoring of the incubation mixture of acyl adenylate together with both substrate and acyl CoA thioester is needed. We have developed a detection method for the simultaneous detection of these cholic acid derivatives utilizing liquid chromatography/electrospray ionization mass spectrometry. The CoA thioester of cholic acid forms a chelation complex with the divalent cations remaining on the silica gel packed into the analytical column. Both the addition of a chelating agent, such as EDTA, to the mobile phase and an adjustment of the mobile phase pH to a weak alkaline effectively removed such chelate formation, producing a sharp CoA thioester peak. For a simultaneous mass spectrometric analysis of cholic acid, the corresponding adenylate and CoA thioester, the combined use of a 300 Angstrom particle diameter ODS column and 20 mM ammonium acetate buffer (pH 9.0)/2-propanol/acetonitrile as the mobile phase have been proved to be preferable. To avoid any degradation of the chemically unstable adenylate produced in the incubation, we employed a direct injection of the sample onto a preconcentration column. The obtained results indicated a high sensitivity of this method.
C1 Tohoku Univ, Grad Sch Pharmaceut Sci, Aoba Ku, Sendai, Miyagi 9808578, Japan.
   Kinki Univ, Fac Pharmaceut Sci, Higashiosaka, Osaka 5778502, Japan.
RP Goto, J (corresponding author), Tohoku Univ, Grad Sch Pharmaceut Sci, Aoba Ku, Sendai, Miyagi 9808578, Japan.
EM jun-goto@mail.pharm.tohoku.ac.jp
RI Mano, Nariyasu/AAS-9994-2020
CR ABBOTT DA, 1985, ANAL BIOCHEM, V146, P437, DOI 10.1016/0003-2697(85)90566-4
   BARTANA J, 1964, BIOCHEM J, V93, P533, DOI 10.1042/bj0930533
   BERG P, 1956, J BIOL CHEM, V222, P991
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Chang KH, 1997, BIOCHEMISTRY-US, V36, P15650, DOI 10.1021/bi971262p
   Cleland WW, 1970, ENZYMES, V2, P1
   CZUBA B, 1982, J BIOL CHEM, V257, P8761
   CZUBA B, 1980, J BIOL CHEM, V255, P5296
   Ikegawa S, 1999, ANAL BIOCHEM, V266, P125, DOI 10.1006/abio.1998.2944
   JENCKS WP, 1957, J BIOL CHEM, V225, P207
   KELLERMAN GM, 1958, J BIOL CHEM, V231, P427
   KELLEY M, 1994, BIOCHEM J, V304, P945, DOI 10.1042/bj3040945
   Kunau WH, 1995, PROG LIPID RES, V34, P267, DOI 10.1016/0163-7827(95)00011-9
   LYGRE T, 1986, J CHROMATOGR, V381, P95, DOI 10.1016/S0378-4347(00)83568-9
   MALLONEE DH, 1992, J BACTERIOL, V174, P2065, DOI 10.1128/JB.174.7.2065-2071.1992
   MAO LF, 1992, J BIOL CHEM, V267, P3143
   MILDVAN AS, 1970, ENZYMES, P456
   MOLDAVE K, 1957, J BIOL CHEM, V229, P463
   Nambara T, 1988, BILE ACIDS, V4, P43
   SIMION FA, 1983, BIOCHEMISTRY-US, V22, P5029, DOI 10.1021/bi00290a023
   VESSEY DA, 1987, J BIOL CHEM, V262, P5360
   VESSEY DA, 1977, BIOCHEM J, V163, P357, DOI 10.1042/bj1630357
   Watkins PA, 1997, PROG LIPID RES, V36, P55, DOI 10.1016/S0163-7827(97)00004-0
   WEBSTER LT, 1963, J BIOL CHEM, V238, P4010
   WEBSTER LT, 1962, J BIOL CHEM, V237, P1050
   Wheeler JB, 1997, ARCH BIOCHEM BIOPHYS, V348, P15, DOI 10.1006/abbi.1997.0391
NR 26
TC 15
Z9 15
U1 0
U2 3
PU JAPAN SOC ANALYTICAL CHEMISTRY
PI TOKYO
PA 26-2 NISHIGOTANDA 1 CHOME SHINAGAWA-KU, TOKYO, 141, JAPAN
SN 0910-6340
EI 1348-2246
J9 ANAL SCI
JI Anal. Sci.
PD SEP
PY 2001
VL 17
IS 9
BP 1037
EP 1042
DI 10.2116/analsci.17.1037
PG 6
WC Chemistry, Analytical
SC Chemistry
GA 474GG
UT WOS:000171097500003
PM 11708055
OA Bronze
DA 2021-08-04
ER

PT J
AU Gmytrasiewicz, PJ
   Durfee, EH
AF Gmytrasiewicz, PJ
   Durfee, EH
TI Rational communication in multi-agent environments
SO AUTONOMOUS AGENTS AND MULTI-AGENT SYSTEMS
LA English
DT Article
DE decision theory; rationality; multi-agent systems; communication;
   pragmatics
AB We address the issue of rational communicative behavior among autonomous self-interested agents that have to make decisions as to what to communicate, to whom, and how. Following decision theory, we postulate that a rational speaker should design a speech act so as to optimize the benefit it obtains as the result of the interaction. We quantify the gain in the quality of interaction in terms of the expected utility, and we present a framework that allows an agent to compute the expected utilities of various communicative actions. Our framework uses the Recursive Modeling Method as the specialized representation used for decision-making in a multi-agent environment. This representation includes information about the agent's state of knowledge, including the agent's preferences, abilities and beliefs about the world, as well as the beliefs the agent has about the other agents, the beliefs it has about the other agents' beliefs, and so on. Decision-theoretic pragmatics of a communicative act can be then defined as the transformation the act induces on the agent's state of knowledge about its decision-making situation. This transformation leads to a change in the quality of interaction, expressed in terms of the expected utilities of the agent's best actions before and after the communicative act. We analyze decision-theoretic pragmatics of a number of important kinds of communicative acts and investigate their expected utilities using examples. Finally, we report on the agreement between our method of message selection and messages that human subjects choose in various circumstances, and show an implementation and experimental validation of our framework in a simulated multi-agent environment.
C1 Univ Texas, Arlington, TX 76013 USA.
   Univ Michigan, Dept Elect Engn & Comp Sci, Ann Arbor, MI 48109 USA.
RP Gmytrasiewicz, PJ (corresponding author), Univ Illinois, Dept Comp Sci, Chicago, IL 60680 USA.
EM piotr@cse.uta.edu; durfee@umich.edu
RI Durfee, Edmund/AAG-8185-2019
CR AUMANN RJ, 1981, UNPUB REPETITION PAR
   Austin John Langshaw, 1962, DO THINGS WORDS
   Axelrod R., 2006, EVOLUTION COOPERATIO
   BALLIM A, 1991, ARTIFICIAL BELIEVERS
   Burghardt G. M., 1977, ANIMALS COMMUNICATE, P71
   Clark H.H., 1992, ARENAS LANGUAGE USE
   Cohen P. R., 1990, INTENTIONS COMMUNICA
   CRAWFORD VP, 1982, ECONOMETRICA, V50, P1431, DOI 10.2307/1913390
   Dennett D., 1986, BRAINSTORMS
   Dunbar RIM., 1998, APPROACHES EVOLUTION, P92, DOI DOI 10.1016/J.SOCNET.2013.01.003
   FISCHER G, 1991, MENTAL MODELS HUMAN
   Fudenberg D., 1991, GAME THEORY
   GMYTRASIEWICZ P, 1991, THESIS U MICHIGAN
   Gmytrasiewicz PJ, 2000, AUTON AGENT MULTI-AG, V3, P319, DOI 10.1023/A:1010028119149
   GMYTRASIEWICZ PJ, 1993, GROUP DECIS NEGOT, V2, P237
   GMYTRASIEWICZ PJ, 1995, P 1 INT C MULT SYST, P125
   GRICE HP, 1957, PHILOS REV, V66, P377, DOI 10.2307/2182440
   Grice HP., 1968, FOUND LANG, V4, P225
   GROSZ BJ, 1990, INTENTIONS COMMUNICA
   HALPERN JY, 1990, 74007 IBM CORP ALM R
   HARSANYI JC, 1978, AM ECON REV, V68, P223
   HECKERMAN D, 1996, MSRTR12 MICR CORP MI
   HOWARD RA, 1966, IEEE T SYST SCI CYB, VSSC2, P22, DOI 10.1109/TSSC.1966.300074
   JAMESON A, P 14 INT JOINT C ART, P1886
   JAMESON A, 1989, USER MODELS DIALOG S
   Konolige K., 1986, DEDUCTION MODEL BELI
   KRAUS S, 1991, P 12 INT JOINT C ART
   LABROU Y, 1994, P 3 INT CONF INF KNO
   MACLENNAN B, 1992, ARTIF LIFE, V2, P631
   Myerson R. B., 1988, Proceedings of the Second Conference on Theoretical Aspects of Reasoning about Knowledge, P179
   Myerson R. B., 1991, GAME THEORY ANAL CON
   PARIKH P, 1992, P C THEOR ASP REAS K, P85
   Pearl Judea, 1988, PROBABILISTIC REASON
   PERRAULT CR, 1990, INTENTIONS COMMUNICA
   POH KL, 1996, P 12 C UNC ART INT U, P427
   POLLACK ME, 1990, INTENTIONS COMMUNICA
   Russell S. J., 2010, ARTIFICIAL INTELLIGE
   Schiffer, 1972, MEANING
   SINGH M, 1991, P 12 INT JOINT C ART
   Smith IA, 1996, PROCEEDINGS OF THE THIRTEENTH NATIONAL CONFERENCE ON ARTIFICIAL INTELLIGENCE AND THE EIGHTH INNOVATIVE APPLICATIONS OF ARTIFICIAL INTELLIGENCE CONFERENCE, VOLS 1 AND 2, P24
   Tambe M., 1997, P NAT C ART INT, P22
   TAUBER MJ, 1991, MENTAL MODELS HUMAN, V2
   VANDERMEYDEN R, 1994, MOR KAUF R, P595
   WELLMAN MP, 1991, PROCEEDINGS : NINTH NATIONAL CONFERENCE ON ARTIFICIAL INTELLIGENCE, VOLS 1 AND 2, P698
   Winograd T, 1986, UNDERSTANDING COMPUT
   Worden Robert, 1998, APPROACHES EVOLUTION, P148
   ZLOTKIN G, 1990, PROCEEDINGS : EIGHTH NATIONAL CONFERENCE ON ARTIFICIAL INTELLIGENCE, VOLS 1 AND 2, P100
   ZLOTKIN G, 1989, P 11 INT JOINT C ART, P912
NR 48
TC 33
Z9 34
U1 0
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1387-2532
EI 1573-7454
J9 AUTON AGENT MULTI-AG
JI Auton. Agents Multi-Agent Syst.
PD SEP
PY 2001
VL 4
IS 3
BP 233
EP 272
DI 10.1023/A:1011495811107
PG 40
WC Automation & Control Systems; Computer Science, Artificial Intelligence
SC Automation & Control Systems; Computer Science
GA 462GF
UT WOS:000170411800003
DA 2021-08-04
ER

PT J
AU Roy, N
   Dudek, G
AF Roy, N
   Dudek, G
TI Collaborative robot exploration and rendezvous: Algorithms, performance
   bounds and observations
SO AUTONOMOUS ROBOTS
LA English
DT Article
DE multirobot; exploration; rendezvous
ID SEARCH; NAVIGATION; PLAYERS; LINE
AB We consider the problem of how two heterogeneous robots can arrange to meet in an unknown environment from unknown starting locations: that is, the problem of arranging a robot rendezvous. We are interested, in particular, in allowing two robots to rendezvous so that they can collaboratively explore an unknown environment. Specifically, we address the problem of how a pair of exploring agents that cannot communicate with one another over long distances can meet if they start exploring at different unknown locations in an unknown environment.
   We propose several alternative algorithms that robots could use in attempting to rendezvous quickly while continuing to explore. These algorithms exemplify different classes of strategy whose relative suitability depends on characteristics of the problem definition. We consider the performance of our proposed algorithms analytically with respect to both expected- and worst-case behavior. We then examine their behavior under a wider set of conditions using both numerical analysis and also a simulation of multi-agent exploration and rendezvous. We examine the exploration speed, and show that a multi-robot system can explore an unknown environment faster than a single-agent system, even with the constraint of performing rendezvous to allow communication.
   We conclude with a demonstration of rendezvous implemented on a pair of actual robots.
C1 Carnegie Mellon Univ, Inst Robot, Pittsburgh, PA 15213 USA.
   McGill Univ, Ctr Intelligent Machines, Montreal, PQ, Canada.
RP Roy, N (corresponding author), Carnegie Mellon Univ, Inst Robot, Pittsburgh, PA 15213 USA.
EM nicholas.roy@ri.cmu.edu
RI Dudek, Gregory L/H-3567-2012
CR ALPERN S, 1995, SIAM J CONTROL OPTIM, V33, P673, DOI 10.1137/S0363012993249195
   ALPERN S, 1995, SIAM J CONTROL OPTIM, V33, P1270, DOI 10.1137/S0363012993260288
   ANDERSON EJ, 1995, SIAM J CONTROL OPTIM, V33, P1637, DOI 10.1137/S0363012993260707
   Balch T., 1998, IEEE T ROBOTICS AUTO
   Balch T., 1994, AUTON ROBOT, V1, P1, DOI DOI 10.1007/BF00735341
   Beni G, 1996, IEEE T ROBOTIC AUTOM, V12, P485, DOI 10.1109/70.499830
   Borenstein J, 1997, J ROBOTIC SYST, V14, P231
   Brumitt BL, 1996, IEEE INT CONF ROBOT, P2396, DOI 10.1109/ROBOT.1996.506522
   CHATILA R, 1985, P IEEE INT C ROB AUT, P138
   Cohen WW, 1996, ROBOT AUTON SYST, V18, P411, DOI 10.1016/0921-8890(96)00012-7
   DONALD BR, 1995, ARTIF INTELL, V72, P217, DOI 10.1016/0004-3702(94)00024-U
   Dudek G, 1996, AUTON ROBOT, V3, P375
   DUDEK G, 1991, IEEE T ROBOTIC AUTOM, V7, P859, DOI 10.1109/70.105395
   Fox Dieter, 2000, AUTONOMOUS ROBOTS, V8
   HARA F, 1992, P INT S DISTR AUT RO, P3
   ISHIOKA K, 1993, P WORKSH DYN INT ROB, P58
   KLEEMAN L, 1994, IEEE INT CONF ROBOT, P3130, DOI 10.1109/ROBOT.1994.351089
   Kuipers B., 1991, Robotics and Autonomous Systems, V8, P47, DOI 10.1016/0921-8890(91)90014-C
   LACROIX S, 1997, P IEEE RSJ INT C INT
   MATARIC MJ, 1992, 1992 IEEE INTERNATIONAL CONF ON ROBOTICS AND AUTOMATION : PROCEEDINGS, VOLS 1-3, P830, DOI 10.1109/ROBOT.1992.220192
   Moravec H.P., 1985, P IEEE INT C ROB AUT, P116, DOI DOI 10.1109/ROBOT.1985.1087316
   PARKER LE, 1994, THESIS MIT
   RAO N, 1996, P IEEE INT C ROB AUT, V2, P1427
   REKLEITIS IM, 1997, P 15 INT JOINT C ART
   SHATKAY H, 1997, P INT JOINT C ART IN
   SIM R, 1998, P IEEE RSJ INT C INT
   Thrun S, 1998, ARTIF INTELL, V99, P21, DOI 10.1016/S0004-3702(97)00078-7
   THRUN S, 1996, P 13 NAT C ART INT P
   WILKES D, 1991, P VISION INTERFACE 1
NR 29
TC 71
Z9 72
U1 1
U2 12
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0929-5593
EI 1573-7527
J9 AUTON ROBOT
JI Auton. Robot.
PD SEP
PY 2001
VL 11
IS 2
BP 117
EP 136
DI 10.1023/A:1011219024159
PG 20
WC Computer Science, Artificial Intelligence; Robotics
SC Computer Science; Robotics
GA 465NH
UT WOS:000170596000002
DA 2021-08-04
ER

PT J
AU Wei, MX
   Kuukasjarvi, P
   Laurikka, J
   Honkonen, EL
   Kaukinen, S
   Laine, S
   Tarkka, M
AF Wei, MX
   Kuukasjarvi, P
   Laurikka, J
   Honkonen, EL
   Kaukinen, S
   Laine, S
   Tarkka, M
TI Cardioprotective effect of adenosine pretreatment in coronary artery
   bypass grafting
SO CHEST
LA English
DT Article
DE adenosine; coronary artery bypass grafting; cytokine responses;
   myocardial injury
ID HUMAN MYOCARDIUM; REPERFUSION; CYTOKINES; ISCHEMIA; GENERATION;
   ADHESION; RELEASE; INJURY; TRIAL
AB Objective: There are several reports of the use of adenosine as a cardioprotective agent during cardiac surgery. Adenosine treatment might affect neutrophils and inflammatory mediators. The present prospective randomized study was designed to investigate the effect of adenosine pretreatment on myocardial recovery and inflammatory response in patients undergoing elective coronary artery bypass surgery.
   Design: A prospective, randomized, controlled study.
   Setting: Operative unit and ICU in a university, hospital in Finland.
   Patients: Thirty male patients undergoing primary, elective coronary revascularization.
   Interventions: Patients in the adenosine group received a 7-min infusion of adenosine (total, 650 mug/kg) before the initiation of cardiopulmonary bypass.
   Measurements: Postoperative creatine kinase (CK)-MB release and hemodynamics were recorded. Perioperative leukocyte and cytokine release were measured.
   Results: Adenosine pretreatment resulted in less CK-MB release and an improved postbypass cardiac index. Similar leukocyte counts and cytokine responses were seen in both groups perioperatively. Neutrophil counts were similar between the groups before and after myocardial ischemia when measured simultaneously in arterial and coronary sinus blood.
   Conclusions: The present results support the hypothesis that adenosine pretreatment is cardioprotective in humans, but the present dose failed to regulate the inflammatory responses after coronary artery bypass grafting.
C1 Tampere Univ Hosp, Div Cardiovasc Surg, FIN-33521 Tampere, Finland.
   Tampere Univ Hosp, Dept Anesthesia & Intens Care, FIN-33521 Tampere, Finland.
   Tampere Univ Hosp, Dept Clin Microbiol, FIN-33521 Tampere, Finland.
RP Tarkka, M (corresponding author), Tampere Univ Hosp, Div Cardiovasc Surg, POB 2000, FIN-33521 Tampere, Finland.
EM matti.tarkka@tays.fi
RI Laurikka, Jari/F-2010-2014
OI Laurikka, Jari/0000-0001-7253-6048
CR BELARDINELLI L, 1995, FASEB J, V9, P359
   Bouma MG, 1996, AM J PHYSIOL-CELL PH, V270, pC522
   Bullough DA, 1996, CARDIOVASC RES, V32, P328, DOI 10.1016/0008-6363(96)00052-1
   Cain BS, 1998, J SURG RES, V76, P117, DOI 10.1006/jsre.1998.5304
   CERQUEIRA MD, 1994, J AM COLL CARDIOL, V23, P384, DOI 10.1016/0735-1097(94)90424-3
   Cohen G, 1998, CIRCULATION, V98, pII225
   CRONSTEIN BN, 1983, J EXP MED, V158, P1160, DOI 10.1084/jem.158.4.1160
   FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560
   Fremes SE, 1996, CIRCULATION, V94, P370
   Garratt KN, 1998, AM HEART J, V136, P196, DOI 10.1053/hj.1998.v136.89910
   HESS ML, 1994, J CARDIAC SURG, V9, P382
   JANSEN NJG, 1992, ANN THORAC SURG, V54, P744, DOI 10.1016/0003-4975(92)91021-Z
   Jordan JE, 1997, J PHARMACOL EXP THER, V280, P301
   Jordan JE, 1999, CARDIOVASC RES, V43, P860, DOI 10.1016/S0008-6363(99)00187-X
   KLONER RA, 1994, J CARDIAC SURG, V9, P397
   Lasley RD, 1998, BASIC RES CARDIOL, V93, P303, DOI 10.1007/s003950050099
   LEE HT, 1995, J CARDIAC SURG, V10, P665, DOI 10.1111/j.1540-8191.1995.tb00657.x
   Leesar MA, 1997, CIRCULATION, V95, P2500, DOI 10.1161/01.CIR.95.11.2500
   LeMoine O, 1996, J IMMUNOL, V156, P4408
   MANTOVANI A, 1989, IMMUNOL TODAY, V10, P370, DOI 10.1016/0167-5699(89)90270-3
   Mentzer RM, 1999, ANN SURG, V229, P643, DOI 10.1097/00000658-199905000-00006
   MENTZER RM, 1993, CARDIOVASC RES, V27, P28, DOI 10.1093/cvr/27.1.28
   Mentzer RM, 1997, AM J CARDIOL, V79, P38, DOI 10.1016/S0002-9149(97)00262-2
   Sommerschild HT, 2000, ACTA ANAESTH SCAND, V44, P1038, DOI 10.1034/j.1399-6576.2000.440903.x
   TOOMBS CF, 1992, CIRCULATION, V86, P986, DOI 10.1161/01.CIR.86.3.986
   Vinten-Johansen J, 1999, ANN THORAC SURG, V68, P1942, DOI 10.1016/S0003-4975(99)01018-8
   Wan S, 1996, J THORAC CARDIOV SUR, V112, P806, DOI 10.1016/S0022-5223(96)70068-5
   Wei Minxin, 2001, Int J Angiol, V10, P27, DOI 10.1007/s005470000123
NR 28
TC 21
Z9 24
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0012-3692
EI 1931-3543
J9 CHEST
JI Chest
PD SEP
PY 2001
VL 120
IS 3
BP 860
EP 865
DI 10.1378/chest.120.3.860
PG 6
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 472EN
UT WOS:000170970700031
PM 11555521
DA 2021-08-04
ER

PT J
AU McCartney, D
   Chen, HT
AF McCartney, D
   Chen, HT
TI Using a biocell to measure effect of compressive settlement on free air
   space and microbial activity in windrow composting
SO COMPOST SCIENCE & UTILIZATION
LA English
DT Article
AB This paper describes the first equipment developed to include compressive loads in a physical model of the composting environment. This new type of composting reactor was named a biological load cell, or biocell for short. Our hypothesis was that the exclusion of compressive settlement in existing physical models may lead to errors if the data is used to design full-scale windrow composting facilities. Municipal biosolids were mixed with three organic amendments (wood chips, straw, and leaves) to yield mixture moisture contents of 55%. Compressive settlement analyses were completed by subjecting the mixtures to loads of 0, 4.3, 8.6, arid 12.9 kPa using biocells. The effect of compressive settlement on microbial activity was investigated using the biosolids:leaf mixture under loaded (12.9 kPa) and unloaded conditions. The settlement behavior of all three mixtures was found to fit established soil compaction equations and new equations were developed to represent the vertical free air space (FAS) and bulk density profiles in composting systems. The FAS profiles indicated that existing physical models do not simulate the FAS conditions within a composting matrix and significant differences in microbial activity were observed between loaded and unloaded biocells. The microbial activity differences were attributed to the reduced FAS within the loaded biocells, which, in consequence, lead to lower pore space oxygen concentrations. It proved difficult, however, to simulate the air flow regime within a windrow composting matrix. To further develop the biocells, there is a need to investigate the in-situ stress conditions and natural draft ventilation rates of full-scale windrow systems. While further work is required to perfect the biocells as a physical model of the windrow composting environment, it has demonstrated its potential use for FAS analysis and as a standard bulk density apparatus. Using biocells, it is recommended that FAS curves be developed for a wide range of feedstock recipes. The biocell apparatus could also be developed as a standard bulk density test apparatus. Other important conclusions drawn from the work include: leaves should not be used as a bulking agent; wood chips showed superior bulking properties and are recommended for use in very high (3.7 m) windrows; straw showed intermediate bulking properties and should not be used for high windrows without further investigation; for all materials, compaction occurred rapidly after each incremental load, suggesting that windrow turning will do little to alleviate a low FAS problem associated with an incorrect composting recipe.
C1 Univ Manitoba, Dept Civil Engn, Winnipeg, MB R3T 2N2, Canada.
RP McCartney, D (corresponding author), Univ Manitoba, Dept Civil Engn, Winnipeg, MB R3T 2N2, Canada.
OI McCartney, Daryl/0000-0002-3330-6634
CR APHA, 1995, STAND METH EX WAT WA, V19th
   BRAUNACK MV, 1978, THESIS RUTGERS U NEW
   Carter M.R., 1993, SOIL SAMPLING METHOD
   CHEN H, 1998, THESIS U MANITOBA WI
   Das K, 1997, J ENVIRON ENG-ASCE, V123, P275, DOI 10.1061/(ASCE)0733-9372(1997)123:3(275)
   DEBERTOLDI M, 1988, WASTE MANAGE RES, V6, P239, DOI 10.1177/0734242X8800600141
   Haug R.T., 1980, COMPOST ENG PRINCIPL
   Haug R. T., 1993, PRACTICAL HDB COMPOS
   HOGAN JA, 1989, APPL ENVIRON MICROB, V55, P1082, DOI 10.1128/AEM.55.5.1082-1092.1989
   Klute A., 1986, METHODS SOIL ANAL, V2nd ed.
   MAGALHAES AMT, 1993, WASTE MANAGE RES, V11, P143, DOI 10.1006/wmre.1993.1015
   Michel FC, 1996, COMPOST SCI UTIL, V4, P26
   Reinhart Debra S., 1995, Compost Science and Utilization, V3, P38
   SCHAUB SM, 1997, P 7 ANN C COMP COUNC
   SHELL BJ, 1955, THESIS MICHIGAN STAT
   Titko S, 1996, BIOCYCLE, V37, P66
   *US EPA, 1985, EPA625485014
   VALLINI G, 1989, WASTE MANAGE RES, V7, P277
   WALL DK, 1995, J ENVIRON ENG, V121, P214, DOI 10.1061/(ASCE)0733-9372(1995)121:3(214)
   *WEF, 1995, BIOS COMP
NR 20
TC 32
Z9 36
U1 0
U2 5
PU JG PRESS, INC
PI EMMAUS
PA 419 STATE AVE, EMMAUS, PA 18049 USA
SN 1065-657X
J9 COMPOST SCI UTIL
JI Compost Sci. Util.
PD FAL
PY 2001
VL 9
IS 4
BP 285
EP 302
PG 18
WC Ecology; Soil Science
SC Environmental Sciences & Ecology; Agriculture
GA 501RR
UT WOS:000172700300002
DA 2021-08-04
ER

PT J
AU Mason, CF
   Phillips, OR
AF Mason, CF
   Phillips, OR
TI Dynamic learning in a two-person experimental game
SO JOURNAL OF ECONOMIC DYNAMICS & CONTROL
LA English
DT Article
DE learning; experiments; Kalman filtering
ID NORMAL-FORM GAMES; COORDINATION GAMES; EQUILIBRIUM; EXPECTATIONS;
   INFORMATION; MARKETS
AB We analyze learning in a two-person simultaneous choice repeated game. Agents form beliefs about their rival's strategies, which they revise as the game progresses. We test this model using data from a series of experiments. We obtain data on subjects' expectations by asking them to predict their rival's choice in each period of the game; subjects are paid for each correct prediction. We analyze the data using the Kalman filtering technique, and find that learning is broadly consistent with Bayesian updating. The predicted equilibrium based on this learning process is indistinguishable from observed behavior for most subjects in later periods. (C) 2001 Elsevier Science B.V, All rights reserved.
C1 Univ Wyoming, Dept Econ & Finance, Laramie, WY 82071 USA.
RP Mason, CF (corresponding author), Univ Wyoming, Dept Econ & Finance, Laramie, WY 82071 USA.
RI Mason, Charles/H-9162-2019
OI Mason, Charles/0000-0002-9846-0173
CR ARROW KJ, 1982, ECON INQ, V20, P1, DOI 10.1111/j.1465-7295.1982.tb01138.x
   CAMERER C, 1988, ECONOMETRICA, V56, P1, DOI 10.2307/1911840
   CAMERER CF, 1987, AM ECON REV, V77, P981
   CASKEY J, 1985, AM ECON REV, V75, P768
   CONRAD W, 1979, J ECON DYN CONTROL, V2, P177
   CRAWFORD VP, 1990, ECONOMETRICA, V58, P571, DOI 10.2307/2938191
   CRAWFORD VP, 1995, ECONOMETRICA, V63, P103, DOI 10.2307/2951699
   Cyert R.M., 1987, BAYESIAN ANAL UNCERT
   CYERT RM, 1970, J POLIT ECON, V78, P1168, DOI 10.1086/259698
   DeGroot MH, 1970, OPTIMAL STAT DECISIO
   Evans GW, 1996, ECON LETT, V53, P197, DOI 10.1016/S0165-1765(96)00903-2
   FOMBY TB, 1988, ADV EC METHODS
   Friedman J.W., 1986, GAME THEORY APPL EC
   FUDENBERG D, 1993, ECONOMETRICA, V61, P523, DOI 10.2307/2951716
   GREEN EJ, 1984, ECONOMETRICA, V52, P87, DOI 10.2307/1911462
   Greene WH, 1990, ECONOMETRIC ANAL
   GRETHER D, 1980, Q J ECON, V95, P538
   Harvey A.C., 1982, GAMES EC DYNAMICS TI, P306
   Harvey AC, 1989, FORECASTING STRUCTUR
   HATANAKA M, 1974, J ECONOMETRICS, V2, P199
   HEY JD, 1994, J ECON BEHAV ORGAN, V25, P329, DOI 10.1016/0167-2681(94)90104-X
   HOLT D, 1993, EMPIRICAL MODELS STR
   JORDAN JS, 1991, GAME ECON BEHAV, V3, P60, DOI 10.1016/0899-8256(91)90005-Y
   KALAI E, 1993, ECONOMETRICA, V61, P1231, DOI 10.2307/2951500
   KALAI E, 1993, ECONOMETRICA, V61, P1019, DOI 10.2307/2951492
   Kreps D., 1990, GAME THEORY EC MODEL
   KREPS DM, 1982, J ECON THEORY, V27, P245, DOI 10.1016/0022-0531(82)90029-1
   MASON CF, 1985, RESOUR ENERG, V7, P243, DOI 10.1016/0165-0572(85)90020-9
   MCKELVEY RD, 1992, ECONOMETRICA, V60, P803, DOI 10.2307/2951567
   MILGROM P, 1991, GAME ECON BEHAV, V3, P82, DOI 10.1016/0899-8256(91)90006-Z
   PESARAN H, 1987, LIMITS RATIONAL EXPE
   PHILLIPS OR, 1992, RAND J ECON, V23, P395, DOI 10.2307/2555870
   RIORDAN MH, 1985, RAND J ECON, V16, P41, DOI 10.2307/2555587
   Sargent T., 1993, BOUNDED RATIONALITY
   SHAPIRO L, 1980, BELL J ECON, V11, P730, DOI 10.2307/3003392
   Shubik M, 1982, GAME THEORY SOCIAL S
   STAHL D, 1994, J ECON BEHAV ORGAN, V25, P305
   STAHL DO, 1995, GAME ECON BEHAV, V10, P218, DOI 10.1006/game.1995.1031
   TESFATSION L, 1982, THEOR DECIS, V14, P177, DOI 10.1007/BF00133976
   TESFATSION L, 1990, J ECON DYN CONTROL, V14, P151, DOI 10.1016/0165-1889(90)90010-E
   VISCUSI WK, 1984, AM ECON REV, V74, P942
   WHITE H, 1980, ECONOMETRICA, V48, P817, DOI 10.2307/1912934
NR 42
TC 4
Z9 4
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-1889
J9 J ECON DYN CONTROL
JI J. Econ. Dyn. Control
PD SEP
PY 2001
VL 25
IS 9
BP 1305
EP 1344
DI 10.1016/S0165-1889(00)00014-2
PG 40
WC Economics
SC Business & Economics
GA 446ZW
UT WOS:000169544900004
DA 2021-08-04
ER

PT J
AU Gernhardt, CR
   Kielbassa, AM
   Hahn, P
   Schaller, HG
AF Gernhardt, CR
   Kielbassa, AM
   Hahn, P
   Schaller, HG
TI Tensile bond strengths of four different dentin adhesives on irradiated
   and non-irradiated human dentin in vitro
SO JOURNAL OF ORAL REHABILITATION
LA English
DT Article
DE bond strength; dentin; dentin bonding; dentin adhesives; radiation;
   dentin perfusion
ID RADIATION
AB This study evaluated the influence of irradiation on dentin bond strength. Sixty irradiated and 60 non-irradiated human third molars were used. The irradiation dose of 60 Gy was fractionally applied over 6 weeks (2 Gy day(-1), 5 days week(-1)). All teeth were prepared in a special manner allowing the simulation of intra-pulpal pressure and dentin perfusion. Dentin specimens with a thickness of 2.0 mm. were obtained under standardized conditions. The specimens were randomly assigned to four experimental groups. Tensile bond strength of four different dentin bonding agents (Scotchbond(TM) 1, Solobond Plus(R), Prime&Bond(TM) 2.1 and Syntac(R)) was evaluated using an Instron Universal testing machine. Pairwise comparison did not show any significant differences between the irradiated and non-irradiated groups. The influence of the different dentin adhesives was significant (P = 0.0001; ANOVA). Compared with Solobond Plus' and Prime&Bond(TM) 2.1, the use of Scotchbond(TM) 1 resulted in a significantly higher tensile bond strength in non-irradiated specimen (P < 0.05; closed test procedure based on Kruskal-Wallis test). within the limitations of an in vitro study, it can be concluded that adhesive restoration procedures can be successfully used in patients irradiated for cancer of the head and neck.
C1 Univ Halle Wittenberg, Univ Sch Dent Med, Dept Operat Dent & Periodontol, D-06108 Halle Saale, Germany.
   Univ Freiburg, Univ Sch Dent Med, Dept Operat Dent & Periodontol, Freiburg, Germany.
RP Gernhardt, CR (corresponding author), Univ Halle Wittenberg, Univ Sch Dent Med, Dept Operat Dent & Periodontol, Grosse Steinstr 19, D-06108 Halle Saale, Germany.
RI Kielbassa, Andrej M./C-1062-2019
OI Kielbassa, Andrej M./0000-0001-7493-2175
CR BROWN LR, 1975, J DENT RES, V54, P740, DOI 10.1177/00220345750540040801
   Chappell R P, 1994, Quintessence Int, V25, P359
   DAVIS WB, 1975, J DENT RES, V54, P1078, DOI 10.1177/00220345750540051201
   Elhabashy A, 1993, Am J Dent, V6, P123
   FISHER BV, 1971, RADIAT RES, V46, P229, DOI 10.2307/3573016
   FRANK RM, 1965, J AM DENT ASSOC, V70, P868, DOI 10.14219/jada.archive.1965.0220
   FRANKENBERGER KJ, 1996, DTSCH ZAHNARZTLICHE, V51, P556
   GARBEROGLIO R, 1976, ARCH ORAL BIOL, V21, P355, DOI 10.1016/S0003-9969(76)80003-9
   Geursten W., 1991, JB PSYCHOL PSYCHOSOM, P207
   HALLER B, 1993, DENT MATER, V9, P198
   Hinoura K, 1991, Am J Dent, V4, P273
   JERVOE P, 1970, ACTA ODONTOL SCAND, V28, P623, DOI 10.3109/00016357009058587
   Jongebloed W L, 1988, Am J Dent, V1, P139
   Kielbassa AM, 1997, EUR J ORAL SCI, V105, P444, DOI 10.1111/j.1600-0722.1997.tb02142.x
   Kielbassa AM, 1997, J DENT CHILD, V64, P183
   KIELBASSA AM, 1997, DTSCH ZAHNARZTLICHE, V52, P252
   Kielbassa AM, 1998, ACTA MED DENT HELV, V3, P161
   Kielbassa AM, 1999, DTSCH ZAHNARZTL Z, V54, P31
   KIELBASSA AM, 1997, THESIS A LUGWIGS U F
   May KN, 1997, AM J DENT, V10, P195
   MIYAZAKI M, 1995, AM J DENT, V8, P245
   Odlum O, 1991, J Esthet Dent, V3, P227, DOI 10.1111/j.1708-8240.1991.tb00820.x
   OSTROWSKI K, 1973, CLIN ORTHOP RELAT R, P213
   Pashley D H, 1991, Am J Dent, V4, P5
   Pashley D H, 1993, Quintessence Int, V24, P618
   Paul S J, 1993, Schweiz Monatsschr Zahnmed, V103, P709
   PERDIGAO J, 1994, J DENT RES, V73, P5
   Pioch T, 1996, Quintessence Int, V27, P711
   PIOCH T, 1992, ENDOD DENT TRAUMATOL, V8, P241
   PIOCH T, 1998, THESIS R KARLS U HEI
   Prati C, 1992, Am J Dent, V5, P33
   PRATI C, 1990, DENT MATER, V6, P201
   PRATI C, 1991, DENT MATER, V7, P59
   PYYKONEN H, 1986, INT J ORAL MAX SURG, V15, P401, DOI 10.1016/S0300-9785(86)80028-X
   QVIST V, 1987, SCAND J DENT RES, V95, P87
   Retief D H, 1989, Am J Dent, V2, P269
   SCHALLER HG, 1998, DTSCH ZAHNARZTL Z, V53, P69
   SCHALLER HG, 1994, DTSCH ZAHNARZTLICHE, V49, P830
   Shabka A A, 1995, Egypt Dent J, V41, P1031
   TAGAMI J, 1991, DENT MATER, V7, P240
   TERKLA LG, 1987, J DENT RES, V66, P1775
   VANMEERBEEK B, 1992, J DENT RES, V71, P1530, DOI 10.1177/00220345920710081301
   WOSTMANN B, 1995, ZAHNARZTL WELT, V104, P627
NR 43
TC 30
Z9 33
U1 0
U2 2
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 0305-182X
J9 J ORAL REHABIL
JI J. Oral Rehabil.
PD SEP
PY 2001
VL 28
IS 9
BP 814
EP 820
DI 10.1046/j.1365-2842.2001.00758.x
PG 7
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 480QZ
UT WOS:000171474600003
PM 11580819
DA 2021-08-04
ER

PT J
AU Knoll, AC
AF Knoll, AC
TI Distributed contract networks of sensor agents with adaptive
   reconfiguration: modelling, simulation, implementation and experiments
SO JOURNAL OF THE FRANKLIN INSTITUTE-ENGINEERING AND APPLIED MATHEMATICS
LA English
DT Article
DE multi-agent contract network; sensor-fusion; fault tolerance; task
   adaptation; uncalibrated visual servoing; distributed vision systems
AB As both sensors and communication technologies are becoming more powerful at decreasing costs, sensor networks are constantly growing in complexity, i.e. in the information they generate and in the need for coordinating network resources. In this paper we comparatively explore the performance of multi-level hierarchical networks and flat networks, i.e, arrays of sensor agents with specific competences but without predefined communication or control structures. We develop a model of the performance of these types of networks for analysing the throughput of sensing tasks depending on a variety of network and sensor parameters. This analytical model serves as the basis for numerical simulation runs, which reveal the specific advantages of the different network structures. Motivated by these results, we develop an adaptive control scheme, which enables the network to organise itself at runtime so as to achieve the highest result precision in minimum time with minimum communication overhead, maximum parallelism and maximum fault tolerance. This control scheme is a computer-operational version of the contract network, originally proposed for problem solving in distributed artificial intelligence, with agents teaming up dynamically after a negotiation phase following a task specification. The metaphor of contracting also holds the potential to integrate agents that control actuators, e.g. cooperating robots, by assigning appropriate competences to them. Hence the design of sensorimotor systems, whose behaviour is adaptively controlled in a situation-dependent way by a team of different sensors, is a straightforward extension. Moreover, it is also easy to extend the network by adding agents that do not have a sensing component and can only perform sensor data processing tasks. We introduce a complete software framework for implementing these kinds of networks. It consists of a formal specification of the requirements that the sensory component of an agent has to meet and a comprehensive library of C ++ objects encapsulating all of the negotiation protocol and communications routines. In the experimental section of the paper we show how several uncalibrated cameras are used to estimate the trajectory of a manipulator in order to guide the manipulator towards a target in real time. We also illustrate how agent-teams may easily reconfigure during task execution in the case of unexpected events. We then go on to show how complex vision tasks can be broken down into tasks that identical agents may work on in parallel. Finally we show how fusion for vision at a symbolic, i.e. object description level, may contribute to solve the hard problem of recognising occluded objects from different view points. We conclude the paper by summarising our results and sketching future research, in particular the automatic mutual reprogramming of agents using a specifically developed ontology. (C) 2001 The Franklin Institute. Published by Elsevier Science Ltd. All rights reserved.
C1 Univ Bielefeld, Fac Technol, D-33501 Bielefeld, Germany.
RP Knoll, AC (corresponding author), Univ Bielefeld, Fac Technol, D-33501 Bielefeld, Germany.
EM knoll@techfak.uni-bielefeld.de
RI Knoll, Alois/AAN-8417-2021
OI Knoll, Alois/0000-0003-4840-076X
CR Bar-Shalom Y., 1993, ESTIMATION TRACKING
   BIANCHI R, 1996, IEEE WORKSH CYB VIS, P225
   BOISSIER O, 1994, P IEEE C MULT FUS IN, P731
   BOISSIER O, 1994, PREPR 6 EUR WORKSH M, P107
   Brooks R.R., 1997, MULTISENSOR FUSION F
   CANTONI V, 1997, HUMAN MACHINE PERCEP
   CARVER N, 1993, DISTRIBUTED SENSOR I
   DASARATHY B, 1999, P 2 INT C INF FUS IN
   DAVIS R, 1983, ARTIF INTELL, V20, P63, DOI 10.1016/0004-3702(83)90015-2
   Dekhil M, 1998, INT J ROBOT RES, V17, P402, DOI 10.1177/027836499801700406
   DEMAZEAU Y, 1994, P WORKSH SOLV COMPL
   ERDMANN D, 1995, INT J ROBOTICS RES, V14
   FROHLICH C, 1991, INT WORKSH INF PROC
   GIRAUD C, 1994, 1 IEEE C MULT FUS IN
   GOODMAN I, 1997, THEORY DECISION LI B, V37
   Graf T, 1998, 1998 IEEE INTERNATIONAL CONFERENCE ON FUZZY SYSTEMS AT THE IEEE WORLD CONGRESS ON COMPUTATIONAL INTELLIGENCE - PROCEEDINGS, VOL 1-2, P1566, DOI 10.1109/FUZZY.1998.686352
   HAGER G, 1991, INT J ROBOTICS RES, V10
   Hall D., 1992, MATH TECHNIQUES MULT
   HARRIS D, 1984, COMPUTER GRAPHICS AP
   HENDERSON TC, 1984, IEEE T SYST MAN CYB, V14, P784, DOI 10.1109/TSMC.1984.6313304
   IYENGAR S, 1992, IEEE T SIGNAL PROCES, V40
   KNOLL A, 1993, ERZEUGUNG ENTFERNUNG
   KNOLL A, 1997, P IEEE C ROB AUT ALB
   *LB JOHNS SPAC CTR, 1998, CLIPS REF GUID, V1
   Marchand E, 1998, INT J ROBOT RES, V17, P418, DOI 10.1177/027836499801700407
   Mutambara Arthur G. O., 1998, DECENTRALIZED ESTIMA
   RAO B, 1991, INT J ROBOTICS RES, V12
   SADJADI F, 1996, SPIE MILESTONE SERIE, V124
   SCHEERING C, 1998, P IEEE INT C ROB AUT
   SCHEERING C, 1998, P EUR OCT
   SHAPIRO M, 1986, 6 INT C DISTR COMP S
   SMITH R, 1981, IEEE T SYSTEMS MAN C, V11
   TOMLIN C, 1997, IEEE C DEC CONTR SAN
   Waltz E., 1990, MULTISENSOR DATA FUS
   WEISS LE, 1987, IEEE T ROBOTIC AUTOM, V3, P404, DOI 10.1109/JRA.1987.1087115
   WOOLDRIDGE M, 1995, KNOWL ENG REV, V10, P115, DOI 10.1017/S0269888900008122
   Wooldridge M., 1995, Intelligent Agents. ECAI-94 Workshop on Agent Theories, Architectures, and Languages Proceedings, P1
   Yanai K, 1998, INT C PATT RECOG, P278
NR 38
TC 11
Z9 11
U1 2
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0016-0032
EI 1879-2693
J9 J FRANKLIN I
JI J. Frankl. Inst.-Eng. Appl. Math.
PD SEP
PY 2001
VL 338
IS 6
BP 669
EP 705
DI 10.1016/S0016-0032(01)00019-9
PG 37
WC Automation & Control Systems; Engineering, Multidisciplinary;
   Engineering, Electrical & Electronic; Mathematics, Interdisciplinary
   Applications
SC Automation & Control Systems; Engineering; Mathematics
GA 468BE
UT WOS:000170737600003
DA 2021-08-04
ER

PT J
AU Henke, A
   Zell, R
   Ehrlich, G
   Stelzner, A
AF Henke, A
   Zell, R
   Ehrlich, G
   Stelzner, A
TI Expression of immunoregulatory cytokines by recombinant coxsackievirus
   B3 variants confers protection against virus-caused myocarditis
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID DILATED CARDIOMYOPATHY; INTERFERON-GAMMA; B3-INDUCED MYOCARDITIS;
   ENTEROVIRAL GENOMES; MURINE MYOCARDITIS; HEART-DISEASE; MICE;
   INTERLEUKIN-2; INFECTION; PHENOTYPE
AB Clinical and laboratory investigations have demonstrated the involvement of viruses and bacteria as potential causative agents in cardiovascular disease and have specifically found coxsackievirus B3 (CVB3) to be a leading cause. Experimental data indicate that cytokines are involved in controlling CVB3 replication. Therefore, recombinant CVB3 (CVB3rec) variants expressing the T-helper-1 (T(H)1)-specific gamma interferon (IFN-gamma) or the T(H)2-specific interleukin-10 (IL-10) as well as the control virus CVB3(muIL-10), which produce only biologically inactive IL-10, were established. Coding regions of murine cytokines were cloned into the 5' end of the CVB3 wild type (CVB3wt) open reading frame and were supplied with an artificial viral 3Cpro-specific Q-G cleavage site. Correct processing releases active cytokines, and the concentration of IFN-gamma and IL-10 was analyzed by enzyme-linked immunosorbent assay and bioassays. In mice, CVB3wt was detectable in pancreas and heart tissue, causing massive destruction of the exocrine pancreas as well as myocardial inflammation and heart cell lysis. Most of the CVB3wt-infected mice revealed virus-associated symptoms, and some died within 28 days postinfection. In contrast, CVB3rec variants were present only in the pancreas of infected mice, causing local inflammation with subsequent healing. Four weeks after the first infection, surviving mice were challenged with the lethal CVB3H3 variant, causing casualties in the CVB3wt- and CVB3(muIL-10)-infected groups, whereas almost none of the CVB3(IFN-gamma)- and CVB3(IL-10)-infected mice died and no pathological disorders were detectable. This study demonstrates that expression of immunoregulatory cytokines during CVB3 replication simultaneously protects mice against a lethal disease and prevents virus-caused tissue destruction.
C1 Univ Jena, Ctr Med, Inst Virol, D-07745 Jena, Germany.
RP Henke, A (corresponding author), Univ Jena, Ctr Med, Inst Virol, Winzerlaer Str 10, D-07745 Jena, Germany.
RI Zell, Roland/J-4676-2019
OI Zell, Roland/0000-0002-8317-2152
CR ANDINO R, 1994, SCIENCE, V265, P1448, DOI 10.1126/science.8073288
   Chapman NM, 2000, J VIROL, V74, P7952, DOI 10.1128/JVI.74.17.7952-7962.2000
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999
   FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081
   GAUNTT CJ, 1993, CLIN IMMUNOL IMMUNOP, V68, P129, DOI 10.1006/clin.1993.1108
   HASHIMOTO I, 1983, BRIT J EXP PATHOL, V64, P497
   Henke A, 1998, J VIROL, V72, P8327, DOI 10.1128/JVI.72.10.8327-8331.1998
   Henke A, 2000, J VIROL, V74, P4284, DOI 10.1128/JVI.74.9.4284-4290.2000
   HENKE A, 1995, J VIROL, V69, P6720, DOI 10.1128/JVI.69.11.6720-6728.1995
   Henke A, 2001, ANTIVIR RES, V49, P49, DOI 10.1016/S0166-3542(00)00132-7
   Hofling K, 2000, J VIROL, V74, P4570, DOI 10.1128/JVI.74.10.4570-4578.2000
   Horwitz MS, 1999, J VIROL, V73, P1756, DOI 10.1128/JVI.73.3.1756-1766.1999
   Horwitz MS, 2000, NAT MED, V6, P693
   Horwitz MS, 1997, NAT MED, V3, P1037, DOI 10.1038/nm0997-1037
   HUBER SA, 1994, J VIROL, V68, P5126, DOI 10.1128/JVI.68.8.5126-5132.1994
   HUBER SA, 1994, J VIROL, V68, P195, DOI 10.1128/JVI.68.1.195-206.1994
   Jenkins DE, 1998, J INFECT DIS, V178, P940, DOI 10.1086/515702
   KANDOLF R, 1987, P NATL ACAD SCI USA, V84, P6272, DOI 10.1073/pnas.84.17.6272
   KISHIMOTO C, 1994, CIRCULATION, V89, P2836, DOI 10.1161/01.CIR.89.6.2836
   Knowlton KU, 1996, J VIROL, V70, P7811, DOI 10.1128/JVI.70.11.7811-7818.1996
   Leipner C, 2000, HERZ, V25, P245, DOI 10.1007/s000590050014
   Leipner C, 1999, J HUMAN VIROL, V2, P102
   Li YW, 2000, CIRCULATION, V101, P231, DOI 10.1161/01.CIR.101.3.231
   LINDBERG AM, 1992, VIRUS RES, V24, P187, DOI 10.1016/0168-1702(92)90006-U
   MCMANUS BM, 1993, CLIN IMMUNOL IMMUNOP, V68, P159, DOI 10.1006/clin.1993.1113
   Merkle I, 1999, J HUMAN VIROL, V2, P369
   Nishio R, 1999, CIRCULATION, V100, P1102, DOI 10.1161/01.CIR.100.10.1102
   RAMSAY AJ, 1993, IMMUNOL TODAY, V14, P155, DOI 10.1016/0167-5699(93)90277-R
   REIMANN BY, 1991, J VIROL, V65, P3475, DOI 10.1128/JVI.65.7.3475-3480.1991
   SCHLAAK JF, 1994, J IMMUNOL METHODS, V168, P49, DOI 10.1016/0022-1759(94)90208-9
   SCHMITT E, 1990, EUR J IMMUNOL, V20, P1709, DOI 10.1002/eji.1830200813
   SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223
   Seko Y, 1997, J PATHOL, V183, P105
   SPITALNY GL, 1984, J EXP MED, V159, P1560, DOI 10.1084/jem.159.5.1560
   Tang SB, 1997, J VIROL, V71, P7841, DOI 10.1128/JVI.71.10.7841-7850.1997
   Wessely R, 1998, J CLIN INVEST, V102, P1444, DOI 10.1172/JCI1972
   WHY HJF, 1994, CIRCULATION, V89, P2582, DOI 10.1161/01.CIR.89.6.2582
NR 37
TC 39
Z9 42
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD SEP
PY 2001
VL 75
IS 17
BP 8187
EP 8194
DI 10.1128/JVI.75.17.8187-8194.2001
PG 8
WC Virology
SC Virology
GA 461AZ
UT WOS:000170343900043
PM 11483764
OA Green Published, Bronze
DA 2021-08-04
ER

PT J
AU Pedone, R
   Conte, R
AF Pedone, R
   Conte, R
TI Dynamics of status symbols and social complexity
SO SOCIAL SCIENCE COMPUTER REVIEW
LA English
DT Article
DE status symbols dynamics; social hierarchy; Simmel effect; multiagents
   computational model
AB In this article, a symbolic version of the Simmel effect has been explored via computer simulation. The Simmel effect refers to the dynamics of status symbols in hierarchically ordered societies. This phenomenon was highlighted by the sociologist Georg Simmel, when he attempted to explain the rapid diffusion and decline of fashion. Simmel hypothesized that the instability of fashion results from the combined action of imitation of higher status members and distinction from those belonging to lower statuses. To test Simmel's hypothesis, the authors implemented a simulation model: the symbolic Simmel model (SySM), wherein a set of artificial agents hierarchically ordered apply in different combination the rules of imitation and distinction in the common task of sharing symbols. The findings support the view that the Simmel condition allows for a variable or unstable fate of symbols: The success of status symbols starts to decline as soon as they become dominant.
C1 Natl Res Council, Inst Psychol, I-00137 Rome, Italy.
RP Pedone, R (corresponding author), Natl Res Council, Inst Psychol, V Marx 15, I-00137 Rome, Italy.
OI PEDONE, Roberto/0000-0003-3396-8344
CR Aunger R., 2000, DARWINIZING CULTURE
   Benvenuto S., 2000, DICERIE PETTEGOLEZZI
   Blackmore S., 1999, MEME MACHINE
   Dawkins, 1976, SELFISH GENE
   Dennett D. C., 1995, DARWINS DANGEROUS ID
   EDMONDS B, 2000, J MEMETICS EVOLUTION, V4
   Epstein J.M., 1996, GROWING ARTIFICIAL S
   LATANE B, 1981, AM PSYCHOL, V36, P343, DOI 10.1037/0003-066X.36.4.343
   PEDONE R, 2001, P MABS 2000 2 INT IM
   Peyton-Young H, 1998, INDIVIDUAL STRATEGY
   SCHELLING TC, 1969, AM ECON REV, V59, P488
   SIMMEL G, 1957, AM J SOCIOL, V62, P541, DOI 10.1086/222102
   WALKER A, 1995, P 1 INT C MULT SYST, P384
   Wooldridge M, 1999, MULTIAGENT SYSTEMS, P27
NR 14
TC 2
Z9 2
U1 2
U2 6
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0894-4393
J9 SOC SCI COMPUT REV
JI Soc. Sci. Comput. Rev.
PD FAL
PY 2001
VL 19
IS 3
BP 249
EP 262
DI 10.1177/089443930101900302
PG 14
WC Computer Science, Interdisciplinary Applications; Information Science &
   Library Science; Social Sciences, Interdisciplinary
SC Computer Science; Information Science & Library Science; Social Sciences
   - Other Topics
GA 455MV
UT WOS:000170031400002
DA 2021-08-04
ER

PT J
AU Fechner, JH
   Dong, YC
   Hong, XN
   Brunner, KG
   Tsuchida, M
   Neville, D
   Scharff, J
   Lee, F
   Oberley, TD
   Peters, D
   Schultz, JM
   Manthei, ER
   Hamawy, MM
   Knechtle, SJ
AF Fechner, JH
   Dong, YC
   Hong, XN
   Brunner, KG
   Tsuchida, M
   Neville, D
   Scharff, J
   Lee, F
   Oberley, TD
   Peters, D
   Schultz, JM
   Manthei, ER
   Hamawy, MM
   Knechtle, SJ
TI Graft survival in a rhesus renal transplant model after
   immunotoxin-mediated T-cell depletion is enhanced by mycophenolate and
   steroids
SO TRANSPLANTATION
LA English
DT Article; Proceedings Paper
CT 18th Annual Meeting of the American-Society-of-Transplantation
CY MAY 15-19, 1999
CL CHICAGO, ILLINOIS
SP Amer Soc Transplantat
ID MONOCLONAL-ANTIBODIES; IMMUNOSUPPRESSIVE ACTIVITY; WORKING
   CLASSIFICATION; ALLOGRAFT REJECTION; NONHUMAN-PRIMATES; TOLERANCE;
   LYMPHOCYTES; ANTI-CD3-IMMUNOTOXIN; MONKEYS; PERITRANSPLANT
AB Background. Anti-CD3 immunotoxin (IT), a T-cell-depleting agent, prolongs survival of renal allografts in a rhesus monkey model without the need for longterm immunosuppression. In this study we sought to further prolong allograft survival by giving short-term conventional immunosuppression. simultaneous with IT administration.
   Methods. MHC class II mismatched, juvenile rhesus monkeys were paired as donor and recipient for renal transplantation. Recipients received two to three daily doses of IT starting on the day of transplantation. Additional immunosuppression was given for no more than 60 days. Graft function was monitored by serum creatinine and renal biopsies. Flow cytometry was used to monitor T-cell recovery.
   Results. Graft survival time (GST) in animals receiving IT was prolonged compared with controls with 50% of IT-treated monkeys surviving > 100 days. Animals treated with IT plus mycophenolate mofetil (MMF) and steroids had significantly enhanced GST (mean GST, 305 days) compared with those treated with IT alone (mean GST, 94 days). In contrast, addition of cyclosporine or 40-O-[2-Hydroxyethyl]rapamycin did not significantly increase graft survival time. A comparison among animals from all treatment groups with short (< 100 days) and long (> 100 days) GST demonstrated that those with the shorter GST had a higher blood T-cell count 2 weeks after transplantation. Full recovery of CD4(+) T cells required longer than 6 months.
   Conclusions. A combination with MMF and steroids given for 4 days after renal allograft transplantation significantly increases GST in IT-treated monkeys. We hypothesize that MMF and steroids suppress the initial T-cell activation mediated by IT.
C1 Univ Wisconsin, Dept Surg, Madison, WI 53792 USA.
   Univ Wisconsin, Dept Radiol, Madison, WI 53792 USA.
   Univ Wisconsin, Dept Pathol, Madison, WI 53792 USA.
   NIMH, Mol Biol Lab, Bethesda, MD 20892 USA.
RP Knechtle, SJ (corresponding author), Room H4-784 CSC,600 Highland Ave, Madison, WI 53792 USA.
RI Fechner, John/C-5962-2016
OI Fechner, John/0000-0002-8220-7237; Knechtle, Stuart/0000-0002-1625-385X
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI040597] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL
   HEALTHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH) [Z01MH002747] Funding Source: NIH RePORTER; NIAID NIH HHSUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [R01 AI40597] Funding Source: Medline
CR Contreras JL, 1998, TRANSPLANTATION, V65, P1159, DOI 10.1097/00007890-199805150-00003
   EUGUI EM, 1993, ANN NY ACAD SCI, V685, P309, DOI 10.1111/j.1749-6632.1993.tb35881.x
   EUGUI EM, 1991, TRANSPLANT P, V23, P15
   Fechner JH, 1997, TRANSPLANTATION, V63, P1339, DOI 10.1097/00007890-199705150-00023
   Fuchimoto Y, 2000, J CLIN INVEST, V105, P1779, DOI 10.1172/JCI8721
   Hamawy MM, 1999, TRANSPLANTATION, V68, P693, DOI 10.1097/00007890-199909150-00016
   Hu HH, 1997, CELL IMMUNOL, V177, P26, DOI 10.1006/cimm.1997.1096
   Kirk AD, 1999, NAT MED, V5, P686, DOI 10.1038/9536
   Knechtle SJ, 1998, SURGERY, V124, P438, DOI 10.1016/S0039-6060(98)70151-5
   Knechtle SJ, 1997, TRANSPLANTATION, V63, P1, DOI 10.1097/00007890-199701150-00002
   Meng G, 1998, TRANSPL IMMUNOL, V6, P53, DOI 10.1016/S0966-3274(98)80035-X
   Neville DM, 1996, J IMMUNOTHER, V19, P85, DOI 10.1097/00002371-199603000-00001
   NOOIJ FJM, 1986, EUR J IMMUNOL, V16, P981, DOI 10.1002/eji.1830160818
   Racusen LC, 1999, KIDNEY INT, V55, P713, DOI 10.1046/j.1523-1755.1999.00299.x
   REIMANN KA, 1989, TRANSPLANTATION, V48, P906, DOI 10.1097/00007890-198912000-00003
   REIMANN KA, 1994, CYTOMETRY, V17, P102, DOI 10.1002/cyto.990170113
   SOLEZ K, 1993, KIDNEY INT, V44, P411, DOI 10.1038/ki.1993.259
   Thomas FT, 1999, TRANSPLANTATION, V67, P846, DOI 10.1097/00007890-199903270-00011
   Thomas JM, 1997, TRANSPLANTATION, V64, P124, DOI 10.1097/00007890-199707150-00022
   THOMPSON J, 1995, J BIOL CHEM, V270, P28037
   Wu A, 1999, TRANSPLANT P, V31, P957, DOI 10.1016/S0041-1345(98)01854-5
NR 21
TC 7
Z9 8
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD AUG 27
PY 2001
VL 72
IS 4
BP 581
EP 587
DI 10.1097/00007890-200108270-00005
PG 7
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 472DP
UT WOS:000170968400005
PM 11544415
DA 2021-08-04
ER

PT J
AU Shaheen, RM
   Ahmad, SA
   Liu, W
   Reinmuth, N
   Jung, YD
   Tseng, WW
   Drazan, KE
   Bucana, CD
   Hicklin, DJ
   Ellis, LM
AF Shaheen, RM
   Ahmad, SA
   Liu, W
   Reinmuth, N
   Jung, YD
   Tseng, WW
   Drazan, KE
   Bucana, CD
   Hicklin, DJ
   Ellis, LM
TI Inhibited growth of colon cancer carcinomatosis by antibodies to
   vascular endothelial and epidermal growth factor receptors
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE antiangiogenic therapy; VEGF; EGF; receptor; apoptosis; endothelial
   cell; DC101; C225
ID MONOCLONAL-ANTIBODIES; NUDE-MICE; TUMOR; CELLS; ANGIOGENESIS; APOPTOSIS;
   SURVIVAL; PERMEABILITY; METASTASIS; INDUCTION
AB Vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) regulate colon cancer growth and metastasis. Previous studies utilizing antibodies against the VEGF receptor (DC101) or EGF receptor (C225) have demonstrated independently that these agents can inhibit tumour growth and induce apoptosis in colon cancer in in vivo and in vitro systems. We hypothesized that simultaneous blockade of the VEGF and EGF receptors would enhance the therapy of colon cancer in a mouse model of peritoneal carcinomatosis. Nude mice were given intraperitoneal injection of KM12L4 human colon cancer cells to generate peritoneal metastases. Mice were then randomized into one of four treatment groups: control, anti-VEGFR (DC101), anti-EGFR (C225), or DC101 and C225. Relative to the control group, treatment with DC101 or with DC101+C225 decreased tumour vascularity, growth, proliferation, formation of ascites and increased apoptosis of both tumour cells and endothelial cells. Although C225 therapy did not change any of the above parameters, C225 combined with DC101 led to a significant decrease in tumour vascularity and increases in tumour cell and endothelial cell apoptosis (vs the DC101 group). These findings suggest that DC101 inhibits angiogenesis, endothelial cell survival, and VEGF-mediated ascites formation in a murine model of colon cancer carcinomatosis. The addition of C225 to DC101 appears to lead to a further decrease in angiogenesis and ascites formation. Combination anti-VEGF and anti-EGFR therapy may represent a novel therapeutic strategy for the management of colon peritoneal carcinomatosis. (C) 2001 Cancer Research Campaign http://www.bjcancer.com.
C1 Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA.
   Stanford Univ, Dept Surg, Palo Alto, CA 94304 USA.
   ImClone Syst Inc, New York, NY 10014 USA.
RP Ellis, LM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, 1515 Holcombe Blvd,444, Houston, TX 77030 USA.
FU NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [T32
   CA 09599, CA16672] Funding Source: Medline; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [T32CA009599, P30CA016672] Funding Source: NIH RePORTER
CR *AM CANC SOC, 2000, CANC FACTS FIG
   Aparicio T, 1999, CARCINOGENESIS, V20, P1445, DOI 10.1093/carcin/20.8.1445
   Bruns CJ, 2000, CANCER RES, V60, P2926
   Bruns CJ, 2000, CANCER, V89, P488, DOI 10.1002/1097-0142(20000801)89:3<488::AID-CNCR3>3.3.CO;2-O
   Ciardiello F, 1999, CLIN CANCER RES, V5, P909
   COPELAND EM, 1968, AM J SURG, V116, P875, DOI 10.1016/0002-9610(68)90458-3
   Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608
   Goldstein NI, 1995, CLIN CANCER RES, V1, P1311
   KE L, 1996, EUR J CANCER, V32, P2467
   Liu B, 2000, BRIT J CANCER, V82, P1991
   Marcus EA, 1999, CANCER INVEST, V17, P249, DOI 10.3109/07357909909040593
   MORIKAWA K, 1988, CANCER RES, V48, P1943
   Perrotte P, 1999, CLIN CANCER RES, V5, P257
   Prewett M, 1999, CANCER RES, V59, P5209
   RADINSKY R, 1995, CLIN CANCER RES, V1, P19
   SENGER DR, 1990, CANCER RES, V50, P1774
   Shaheen RM, 1999, CANCER RES, V59, P5412
   TAKAHASHI Y, 1995, CANCER RES, V55, P3964
   Witte L, 1998, CANCER METAST REV, V17, P155, DOI 10.1023/A:1006094117427
   Workman P, 1998, BRIT J CANCER, V77, P1
   Zebrowski BK, 1999, CLIN CANCER RES, V5, P3364
NR 21
TC 199
Z9 203
U1 0
U2 5
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0007-0920
J9 BRIT J CANCER
JI Br. J. Cancer
PD AUG 17
PY 2001
VL 85
IS 4
BP 584
EP 589
DI 10.1054/bjoc.2001.1936
PG 6
WC Oncology
SC Oncology
GA 466CN
UT WOS:000170626900019
PM 11506500
OA Green Published, hybrid
DA 2021-08-04
ER

PT J
AU Foster, AD
   Rosenzweig, MR
AF Foster, AD
   Rosenzweig, MR
TI Imperfect commitment, altruism, and the family: Evidence from transfer
   behavior in low-income rural areas
SO REVIEW OF ECONOMICS AND STATISTICS
LA English
DT Article
ID RISK; INSURANCE; INDIA; PERFORMANCE; CONSUMPTION; CONTRACTS; WEATHER
AB In this paper, we examine empirically whether risk pooling is more advantageous among altruistic compared to selfish agents in a framework where individuals cannot make binding commitments. In particular, we incorporate altuism into a model of risk sharing under imperfect commitment and use simulation methods to establish tests of the roles of both altruism and commitment problems in determining the extent of insurance and the intertemporal movements in interhousehold transfers. The tests are carried out using three panel data sets from two countries of rural South Asia that provide detailed information on transfers and enable the measurement of income shocks. The estimates provide strong support for the notion that imperfect commitment substantially constrains informal transfer arrangements, whether kin-based or not, but also provide evidence that altruism plays an important role in ameliorating commitment constraints and thus in increasing the gains from income pooling.
C1 Brown Univ, Providence, RI 02912 USA.
   Univ Penn, Philadelphia, PA 19104 USA.
RP Foster, AD (corresponding author), Brown Univ, Providence, RI 02912 USA.
CR Altonji JG, 1997, J POLIT ECON, V105, P1121, DOI 10.1086/516388
   ALTONJI JG, 1992, AM ECON REV, V82, P1177
   Becker G. S., 1991, TREATISE FAMILY ENLA
   BEHRMAN J, 1987, J BUSINESS EC STAT, V77, P187
   CIGNO A, 2000, SHARING WEALTH DEMOG, P235
   COATE S, 1993, J DEV ECON, V40, P1, DOI 10.1016/0304-3878(93)90102-S
   COATE S, 1995, AM ECON REV, V85, P46
   COX D, 1987, J POLIT ECON, V95, P508, DOI 10.1086/261470
   FOSTER AD, 1988, THESIS U CALIFORNIA
   FOSTER AD, 1993, POPULATION STUDIES, V48, P97
   Hoff K, 1998, J DEV ECON, V55, P485, DOI 10.1016/S0304-3878(98)00062-5
   HOFF K, 1997, INFORMAL INSURANCE P
   KIMBALL MS, 1988, AM ECON REV, V78, P224
   KLETZER K, UNPUB SOVEREIGN DEBT
   LIGON E, IN PRESS REV EC DYNA
   Morduch J, 1991, THESIS HARVARD U
   PAXSON CH, 1992, AM ECON REV, V82, P15
   RITTER JA, 1994, AM ECON REV, V84, P694
   ROGERSON WP, 1985, ECONOMETRICA, V53, P69, DOI 10.2307/1911724
   ROSE E, J DEV EC, V64, P371
   ROSENZWEIG MR, 1994, AM ECON REV, V84, P1195
   ROSENZWEIG MR, 1988, ECON J, V98, P1148, DOI 10.2307/2233724
   ROSENZWEIG MR, 1989, J POLIT ECON, V97, P905, DOI 10.1086/261633
   ROSENZWEIG MR, EC J, P56
   THOMAS J, 1988, REV ECON STUD, V55, P541, DOI 10.2307/2297404
   THOMAS JP, 1995, UNPUB INFORMAL INSUR
   TOWNSEND RM, 1994, ECONOMETRICA, V62, P539, DOI 10.2307/2951659
   Udry C, 1995, AM ECON REV, V85, P1287
   UDRY C, 1994, REV ECON STUD, V61, P495, DOI 10.2307/2297901
   WOLPIN KI, 1982, INT ECON REV, V23, P583, DOI 10.2307/2526376
NR 30
TC 117
Z9 118
U1 0
U2 16
PU M I T PRESS
PI CAMBRIDGE
PA FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA
SN 0034-6535
J9 REV ECON STAT
JI Rev. Econ. Stat.
PD AUG
PY 2001
VL 83
IS 3
BP 389
EP 407
DI 10.1162/00346530152480054
PG 19
WC Economics; Social Sciences, Mathematical Methods
SC Business & Economics; Mathematical Methods In Social Sciences
GA 456JR
UT WOS:000170079800001
OA Green Submitted
DA 2021-08-04
ER

PT J
AU Martin, MJ
   Jimenez, MD
   Motilva, V
AF Martin, MJ
   Jimenez, MD
   Motilva, V
TI New issues about nitric oxide and its effects on the gastrointestinal
   tract
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; GASTRIC-MUCOSAL INJURY;
   ISCHEMIA-REPERFUSION INJURY; INFLAMMATORY-BOWEL-DISEASE;
   PLATELET-ACTIVATING-FACTOR; N-ACETYL-PENICILLAMINE; VASCULAR
   SMOOTH-MUSCLE; CENTRAL-NERVOUS-SYSTEM; PROTEIN-KINASE-C; EXPERIMENTAL
   COLITIS
AB Over the last years the important role of nitric oxide (NO) as endogenous modulator of numerous physiological functions has been shown. NO is involved in the regulation of blood flow, maintenance of vascular tone, control of platelet aggregation, and modulation of the activity of the mastocytes. It also plays a key role as neurotransmitter in the central and peripheric nervous system (non adrenergic non colinergic, NANC, neurons), in the nervous control of the cerebral blood flow and in the neuroendocrine regulation or synaptic plasticity. However, NO shows a dual behavior: at physiological concentrations, released through the constitutive synthase (cNOS), it regulates house-keeping functions, whereas its overproduction by the inducible isoenzyme (iNOS) exhibits cytotoxic activity because interacting with reactive species producing peroxinitrites (ONOO.) and other compounds, which are highly damaging for the tissues.
   In the gastrointestinal tract (GIT) NO participates in the modulation of the smooth musculature tone, such as the regulation of intestinal peristaltism, gastric emptying and antral motor activity. It also regulates acid and gastric mucus secretion, alkaline production, and is involved in the maintenance of mucosal blood flow. In physiological conditions, NO acts as an endogenous mediator modulating both, the repairing and integrity of the tissues, and exhibits gastroprotective properties against different types of aggressive agents. However, high concentrations of NO are related to numerous pathological processes of GIT including peptic ulcer, chronic gastritis, gastrointestinal cancer, bacterial gastroenteritis, celiac or chronic inflammatory bowel diseases. Recently, this hypothesis that cNOS is always beneficial and iNOS is always deleterious, has been questioned, since that a series of data suggest that the increase of cNOS activity could be responsible for the derived pathological changes and, by contrast, NO liberated by the inducible isoenzyme might play a repairing effect in certain pathological disorders.
   The pharamceutical industry is really interested in proving the clinical benefits of the mediator. Numerous NO-donor drugs, nitrite derivatives, have been frequently used in the cardiovascular diseases due to their vasodilating properties, which allow an enhancement of coronary blood flow. More recently, the protective effect of NO against non-steroidal antiinflammatory drugs (NSAID)-gastroenteropathy has been shown, because its vasodilating and antioxidant properties render it a potentially useful agent. Different NSAID, including acetyl salicylic acid, diclofenac or naproxen, have been formulated by attaching a NO releasing-moiety. These NO-NSAID, antiinflammatories combined with precursors of the mediator, or with inhibitors of the inducible synthase, are currently being evaluated. However, although the pharmacotherapeutical possibilities of NO are considerable, it is necessary to elucidate the exact mechanisms derived from simulation/inhibition of the isoenzymes in order to determine the clinical utility of NO-donors.
C1 Univ Seville, Fac Pharm, Dept Pharmacol, E-41012 Seville, Spain.
RP Martin, MJ (corresponding author), Univ Seville, Fac Pharm, Dept Pharmacol, P Garcia Gonzalez S-N, E-41012 Seville, Spain.
EM calero@fafar.us.es
OI Motilva Sanchez, Virginia/0000-0001-5674-6969; JIMENEZ GORDILLO, MARIA
   DOLORES/0000-0002-5664-2139
CR AEBERHARD EE, 1995, BIOCHEM BIOPH RES CO, V208, P1053, DOI 10.1006/bbrc.1995.1441
   Akiba Y, 1998, J CLIN GASTROENTEROL, V27, pS64, DOI 10.1097/00004836-199800001-00011
   ALBINA JE, 1993, J IMMUNOL, V150, P5080
   ALICAN I, 1995, INFLAMM RES, V44, P164, DOI 10.1007/BF01782814
   Aly A, 1997, Nord Med, V112, P195
   ANDREWS FJ, 1994, DIGEST DIS SCI, V39, P366, DOI 10.1007/BF02090210
   ANGGARD E, 1994, LANCET, V343, P1199, DOI 10.1016/S0140-6736(94)92405-8
   Aoki C, 1997, BRAIN RES, V750, P25, DOI 10.1016/S0006-8993(96)01147-X
   Armstrong AM, 2000, SCAND J GASTROENTERO, V35, P832
   ASAKO H, 1992, GASTROENTEROLOGY, V103, P146, DOI 10.1016/0016-5085(92)91107-F
   Avila JR, 1996, INFLAMM RES, V45, P83, DOI 10.1007/BF02265120
   Baader SL, 1996, J NEUROSCI, V16, P1440
   BARRACHINA D, 1994, EUR J PHARMACOL, V262, P181, DOI 10.1016/0014-2999(94)90044-2
   BARTSCH H, 1988, MUTAT RES, V202, P307, DOI 10.1016/0027-5107(88)90194-7
   Bastaki SMA, 1999, CAN J GASTROENTEROL, V13, P123, DOI 10.1155/1999/738968
   Bauer J A, 1995, Adv Pharmacol, V34, P361
   Bayguinov O, 1999, BRIT J PHARMACOL, V126, P1543, DOI 10.1038/sj.bjp.0702450
   Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424
   Belmont HM, 1997, ARTHRITIS RHEUM, V40, P1810, DOI 10.1002/art.1780401013
   Benjamin N, 1997, LANCET, V349, P1776, DOI 10.1016/S0140-6736(05)63002-4
   BHAT GK, 1995, NEUROENDOCRINOLOGY, V62, P187, DOI 10.1159/000127004
   BILLIAR TR, 1995, ANN SURG, V221, P339, DOI 10.1097/00000658-199504000-00003
   Bogle RG, 1996, J PHYSIOL-LONDON, V490, P229, DOI 10.1113/jphysiol.1996.sp021138
   BOUGHTON S, 1992, AGENTS ACTIONS, V3
   BOUGHTONSMITH NK, 1990, EUR J PHARMACOL, V191, P485, DOI 10.1016/0014-2999(90)94185-Z
   BOUGHTONSMITH NK, 1993, BRIT J PHARMACOL, V110, P1189, DOI 10.1111/j.1476-5381.1993.tb13940.x
   BREDT DS, 1992, J BIOL CHEM, V267, P10976
   BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135
   BROWN JF, 1993, AM J PHYSIOL, V265, pG418
   BROWN JF, 1992, BIOCHEM BIOPH RES CO, V184, P680, DOI 10.1016/0006-291X(92)90643-Y
   BROWN JF, 1993, BIOCHEM BIOPH RES CO, V195, P1354, DOI 10.1006/bbrc.1993.2192
   Brzozowski T, 1997, J GASTROENTEROL, V32, P442, DOI 10.1007/BF02934081
   Bulut R, 1999, DIGEST DIS SCI, V44, P1417, DOI 10.1023/A:1026608020133
   BUSCONI L, 1993, J BIOL CHEM, V268, P8410
   CALATAYUD S, 1998, HEPATOLOGY, V21, P26
   CALATAYUD S, 2000, BRIT J PHARMACOL, V127, P1111
   CAPLAN MS, 1994, GASTROENTEROLOGY, V106, P346, DOI 10.1016/0016-5085(94)90591-6
   Carretero JE, 1996, REV ESP ENFERM DIG, V88, P423
   Ceccatelli S, 1996, NEUROENDOCRINOLOGY, V64, P357, DOI 10.1159/000127139
   Chang RH, 1997, IMMUNOLOGY, V90, P364, DOI 10.1111/j.1365-2567.1997.00364.x
   Chen K, 1999, SURGERY, V126, P553, DOI 10.1016/S0039-6060(99)70098-X
   Ciccocioppo R, 1999, ITAL J GASTROENTEROL, V31, P162
   Clancy RM, 1997, J CELL PHYSIOL, V172, P183, DOI 10.1002/(SICI)1097-4652(199708)172:2<183::AID-JCP5>3.0.CO;2-K
   Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554
   Cochran FR, 1996, MED RES REV, V16, P547, DOI 10.1002/(SICI)1098-1128(199611)16:6<547::AID-MED3>3.3.CO;2-W
   COHEN RA, 1995, PROG CARDIOVASC DIS, V38, P105, DOI 10.1016/S0033-0620(05)80002-7
   Davies NM, 1997, ALIMENT PHARM THER, V11, P69, DOI 10.1046/j.1365-2036.1997.115286000.x
   DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808
   Del Soldato P., 1996, Inflammopharmacology, V4, P181
   DEMBINSKAKIEC A, 1991, BRIT J PHARMACOL, V104, P811, DOI 10.1111/j.1476-5381.1991.tb12511.x
   DENNINGER JW, 1999, BIOCHIM BIOPHYS ACTA, P1411
   Dixit C, 1999, PHARMACOL RES, V39, P33, DOI 10.1006/phrs.1998.0406
   Doi C, 1999, CANCER LETT, V144, P161, DOI 10.1016/S0304-3835(99)00222-0
   Evans SM, 2000, EUR J PHARMACOL, V388, P281, DOI 10.1016/S0014-2999(99)00869-9
   Everts B, 1999, EUR J CLIN INVEST, V29, P692
   Farrell AJ, 1996, ANN RHEUM DIS, V55, P7, DOI 10.1136/ard.55.1.7
   Fischer H, 1999, BBA-MOL CELL RES, V1450, P414, DOI 10.1016/S0167-4889(99)00049-X
   Fischer H, 1999, ALIMENT PHARM THERAP, V13, P507
   Forte P, 1999, GUT, V45, P355, DOI 10.1136/gut.45.3.355
   Franco L, 1998, EUR J PHARMACOL, V348, P247, DOI 10.1016/S0014-2999(98)00161-7
   Fu SD, 1999, GASTROENTEROLOGY, V116, P1319, DOI 10.1016/S0016-5085(99)70496-8
   FURCHGOTT RF, 1984, ANNU REV PHARMACOL, V24, P175, DOI 10.1146/annurev.pa.24.040184.001135
   FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0
   FURCHGOTT RF, 1988, VASODILATATION, V4, P401
   Goto T, 1999, CLIN CANCER RES, V5, P1411
   GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X
   GREEN LC, 1981, SCIENCE, V212, P56, DOI 10.1126/science.6451927
   GREENBLATT MS, 1994, CANCER RES, V54, P4855
   Grossmann J, 1998, AM J PHYSIOL-GASTR L, V274, pG1117
   Gupta SK, 1998, AM J GASTROENTEROL, V93, P795
   HAHM KB, 1998, DIG DIS SCI S, V43, P72
   HASSALL CJS, 1992, NEUROSCI LETT, V143, P65, DOI 10.1016/0304-3940(92)90234-X
   Hatakeyama S, 1996, J CHEM NEUROANAT, V11, P243, DOI 10.1016/S0891-0618(96)00166-4
   HECKER M, 1993, J CELL PHYSIOL, V156, P571, DOI 10.1002/jcp.1041560317
   HECKER M, 1990, P NATL ACAD SCI USA, V87, P8612, DOI 10.1073/pnas.87.21.8612
   HERDEGEN T, 1993, J NEUROSCI, V13, P4130
   Herulf M, 1999, J INFECT DIS, V180, P542, DOI 10.1086/314908
   Herulf M, 1998, SCAND J GASTROENTERO, V33, P164
   HOGABOAM CM, 1995, AM J PHYSIOL-GASTR L, V268, pG673
   Hogg N, 1999, BBA-BIOENERGETICS, V1411, P378, DOI 10.1016/S0005-2728(99)00027-4
   Holstad M, 1997, GEN PHARMACOL-VASC S, V29, P697, DOI 10.1016/S0306-3623(97)00012-8
   Hortelano S, 1997, FEBS LETT, V410, P373, DOI 10.1016/S0014-5793(97)00623-6
   Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668
   IGNARRO LJ, 1988, J PHARMACOL EXP THER, V244, P181
   Iwata F, 1998, J GASTROEN HEPATOL, V13, P997, DOI 10.1111/j.1440-1746.1998.tb00560.x
   IWATA F, 1992, AM J PHYSIOL, V263, pG149
   Jimenez M. D., 1997, Methods and Findings in Experimental and Clinical Pharmacology, V19, P181
   JIMENEZ MD, 1999, METH FIND EXP CLI SA, V21, P173
   JIN JG, 1993, AM J PHYSIOL, V264, pG470
   Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997
   KANNER J, 1991, ARCH BIOCHEM BIOPHYS, V289, P130, DOI 10.1016/0003-9861(91)90452-O
   Katz JA, 1999, CURR OPIN GASTROEN, V15, P291, DOI 10.1097/00001574-199907000-00003
   Kawano S, 2000, J GASTROEN HEPATOL, V15, pD1
   Kelm M, 1999, BBA-BIOENERGETICS, V1411, P273, DOI 10.1016/S0005-2728(99)00020-1
   KELU M, 1999, BIOCHIM BIOPHYS ACTA, V1411, P273
   KENNETH KW, 1995, ADV PHARMACOL, V33, P179
   KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33
   KERWIN JF, 1995, J MED CHEM, V38, P4343, DOI 10.1021/jm00022a001
   KIECHLE FL, 1993, AM J CLIN PATHOL, V100, P567, DOI 10.1093/ajcp/100.5.567
   Kimura H, 1998, GUT, V42, P180, DOI 10.1136/gut.42.2.180
   KITAGAWA H, 1990, J PHARMACOL EXP THER, V253, P1133
   KITAGAWA T, 1992, PROG BIOPHYS MOL BIO, V58, P1, DOI 10.1016/0079-6107(92)90009-U
   Kitamura M, 1999, J PHARMACOL EXP THER, V291, P181
   Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132
   Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639
   KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159
   Konturek JW, 1999, ALIMENT PHARM THERAP, V13, P1683
   Konturek PC, 1997, J PHYSIOL PHARMACOL, V48, P3
   Konturek PC, 1998, SCAND J GASTROENTERO, V33, P691
   KONTUREK SJ, 1995, SCAND J GASTROENTERO, V30, P620, DOI 10.3109/00365529509096303
   KONTUREK SJ, 1995, SCAND J GASTROENTERO, V30, P22, DOI 10.3109/00365529509090264
   Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X
   KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651
   Kubes P, 2000, GUT, V47, P6, DOI 10.1136/gut.47.1.6
   KUBES P, 1992, AM J PHYSIOL, V262, pH611
   KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761
   Lamarque D, 1996, GASTROEN CLIN BIOL, V20, P1085
   LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348
   LAMBRECHT N, 1992, GASTROENTEROLOGY, V102, pA407
   Laszlo F, 1998, EUR J PHARMACOL, V344, P191, DOI 10.1016/S0014-2999(97)01599-9
   Laszlo F, 1999, EUR J PHARMACOL, V375, P211, DOI 10.1016/S0014-2999(99)00233-2
   LAUBACH VE, 1995, P NATL ACAD SCI USA, V92, P10688, DOI 10.1073/pnas.92.23.10688
   LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0
   Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1
   Levine JJ, 1998, J PEDIATR GASTR NUTR, V26, P34, DOI 10.1097/00005176-199801000-00006
   LICHTENSTEIN D, 2000, JAMA-J AM MED ASSOC, V284, P1025
   LIEW FY, 1995, ADV NEUROIMMUNOL, V5, P201, DOI 10.1016/0960-5428(95)00009-Q
   LOPEZBELMONTE J, 1993, BRIT J PHARMACOL, V108, P73, DOI 10.1111/j.1476-5381.1993.tb13442.x
   LUNDBERG JON, 1994, GUT, V35, P1543, DOI 10.1136/gut.35.11.1543
   Lyons CR, 1995, ADV IMMUNOL, V60, P323, DOI 10.1016/S0065-2776(08)60589-1
   Mahmud T, 1996, ARTHRITIS RHEUM, V39, P1998, DOI 10.1002/art.1780391208
   Marin J, 1997, PHARMACOL THERAPEUT, V75, P111, DOI 10.1016/S0163-7258(97)00051-X
   MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F
   Martin Calero MJ, 1997, PHARM SCI, V3, P609
   McCafferty DM, 1997, GASTROENTEROLOGY, V112, P1022, DOI 10.1053/gast.1997.v112.pm9041266
   McCaffery DM, 1999, GUT, V45, P864, DOI 10.1136/gut.45.6.864
   Mei JM, 2000, FASEB J, V14, P1188
   Mendez A, 1997, AM J PHYSIOL-GASTR L, V272, pG894
   MERRYMAN PF, 1993, ARTHRITIS RHEUM, V36, P1414, DOI 10.1002/art.1780361014
   MILLER MJS, 1994, DIGEST DIS SCI, V39, P1185, DOI 10.1007/BF02093782
   MILLER MJS, 1995, GASTROENTEROLOGY, V109, P1475, DOI 10.1016/0016-5085(95)90633-9
   MILLS CD, 1991, J IMMUNOL, V146, P2719
   MITJAVILA MT, 1997, MUNDO CIENTLFICO, V177, P275
   MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2
   Molero M, 1998, ACTA PHYSIOL SCAND, V164, P229
   MONCADA S, 1991, PHARMACOL REV, V43, P109
   MONCADA S, 1995, FASEB J, V9, P1319
   Moncada S, 1997, PHARMACOL REV, V49, P137
   Moncada S, 1991, INVESTIGACION CIENCI, V176, P60
   Motilva V, 1996, GASTROENTEROLOGY, V110, pA202
   Naito Y, 1998, DIGEST DIS SCI, V43, p30S
   Nakamura H, 1999, SCAND J GASTROENTERO, V34, P1117, DOI 10.1080/003655299750024922
   NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6
   Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782
   NATHAN C, 1994, J BIOL CHEM, V269, P13725
   Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998
   Nishida K, 1999, J LAB CLIN MED, V133, P440, DOI 10.1016/S0022-2143(99)90021-5
   Nishida K, 1998, PHARMACOL RES, V38, P393, DOI 10.1006/phrs.1998.0379
   NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092
   NUSSLER AK, 1993, J LEUKOCYTE BIOL, V54, P171
   Orihata M, 1996, DIGEST DIS SCI, V41, P1303, DOI 10.1007/BF02088551
   Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977
   Packer MA, 1997, BIOCHEM SOC T, V25, P909, DOI 10.1042/bst0250909
   PALMER RMJ, 1989, BIOCHEM BIOPH RES CO, V158, P348, DOI 10.1016/S0006-291X(89)80219-0
   PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0
   PARK JH, 1999, GUT, V45, pA248
   Parkinson JF, 1997, J MOL MED, V75, P174, DOI 10.1007/s001090050102
   PFEIFFER CJ, 1995, J PHARM PHARMACOL, V47, P827, DOI 10.1111/j.2042-7158.1995.tb05749.x
   Pignatelli B, 1998, EUR J CANCER PREV, V7, P439, DOI 10.1097/00008469-199812000-00003
   PIQUE JM, 1992, GASTROENTEROLOGY, V102, P168, DOI 10.1016/0016-5085(92)91797-8
   PIQUE JM, 1989, EUR J PHARMACOL, V174, P293, DOI 10.1016/0014-2999(89)90324-5
   PRICE KJ, 1994, EUR J PHARMACOL, V263, P199, DOI 10.1016/0014-2999(94)90542-8
   PUIGPARELADA P, 2000, METHOD FIND EXP CLIN, V22, P43
   RACHMILEWITZ D, 1995, GUT, V36, P718, DOI 10.1136/gut.36.5.718
   RACHMILEWITZ D, 1995, GUT, V37, P247, DOI 10.1136/gut.37.2.247
   RENGASAMY A, 1993, MOL PHARMACOL, V44, P124
   Reutov VP, 1998, BIOCHEMISTRY-MOSCOW+, V63, P874
   ROBINSON LJ, 1995, BIOL NITRIC OXIDE, P33
   Rogler G, 1997, GASTROENTEROLOGY, V112, pA1077
   Sacco S, 1998, J NEUROCHEM, V71, P2063
   Saha SK, 1997, JPN J PHYSIOL, V47, P477, DOI 10.2170/jjphysiol.47.477
   Sakaguchi AA, 1999, FREE RADICAL BIO MED, V27, P781, DOI 10.1016/S0891-5849(99)00124-0
   SALA DP, 1998, NITRIC OXIDE DISCOVE, P30
   SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240
   SANCHEZ S, 2000, IN PRESS DIG DIS SCI
   SANTUCCI L, 1994, GUT, V56, P417
   SARTOR RB, 1994, GASTROENTEROLOGY, V106, P533, DOI 10.1016/0016-5085(94)90614-9
   SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4
   Singh Gurkirpal, 1998, American Journal of Medicine, V105, p31S, DOI 10.1016/S0002-9343(98)00072-2
   Slomiany BL, 1998, BIOCHEM MOL BIOL INT, V46, P1063
   Somasundaram S, 1997, GUT, V41, P344, DOI 10.1136/gut.41.3.344
   STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0
   SUEMATSU M, 1994, AM J PHYSIOL, V266, pH2410
   Szabo C, 1996, SHOCK, V6, P79, DOI 10.1097/00024382-199608000-00001
   TACHE Y, 1994, J GASTROEN HEPATOL, V9, pS29, DOI 10.1111/j.1440-1746.1994.tb01298.x
   Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395
   Takakura K, 1999, JPN J PHARMACOL, V80, P155, DOI 10.1254/jjp.80.155
   Takakura K, 1997, ANESTHESIOLOGY, V87, P652, DOI 10.1097/00000542-199709000-00027
   Takeuchi K, 1999, J PHYSIOLOGY-PARIS, V93, P423, DOI 10.1016/S0928-4257(99)00125-4
   Takeuchi K, 2000, J GASTROEN HEPATOL, V15, pD37, DOI 10.1046/j.1440-1746.2000.02143.x
   TAKEUCHI K, 1994, GASTROENTEROLOGY, V106, P367, DOI 10.1016/0016-5085(94)90594-0
   TAKEUCHI K, 1993, JPN J PHARMACOL, V61, P13, DOI 10.1254/jjp.61.13
   TAMIR S, 1996, BIOCHIM BIOPHYS ACTA, V188, pF31
   TANNENBAUM SR, 1974, JNCI-J NATL CANCER I, V53, P79
   TEPPERMAN BL, 1993, BRIT J PHARMACOL, V110, P229, DOI 10.1111/j.1476-5381.1993.tb13797.x
   TORRES G, 1994, BRAIN RES, V647, P1, DOI 10.1016/0006-8993(94)91391-9
   Tsuji S, 1997, J CLIN GASTROENTEROL, V25, pS186, DOI 10.1097/00004836-199700001-00030
   Tsujimoto Y, 1998, GEN PHARMACOL, V31, P405, DOI 10.1016/S0306-3623(98)00044-5
   VANE JR, 1994, P NATL ACAD SCI USA, V91, P2046, DOI 10.1073/pnas.91.6.2046
   WAGNER DA, 1983, P NATL ACAD SCI-BIOL, V80, P4518, DOI 10.1073/pnas.80.14.4518
   Wallace JL, 1999, TRENDS PHARMACOL SCI, V20, P4, DOI 10.1016/S0165-6147(98)01283-8
   WALLACE JL, 1994, GASTROENTEROLOGY, V107, P173, DOI 10.1016/0016-5085(94)90074-4
   WALLACE JL, 1992, TIPS, V13, P1298
   WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0
   Weitzberg E, 1998, NITRIC OXIDE-BIOL CH, V2, P1, DOI 10.1006/niox.1997.0162
   WELCH G, 1994, J CARDIAC SURG, V9, P361, DOI 10.1111/j.1540-8191.1994.tb00857.x
   Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413
   WHITTLE BJR, 1990, BRIT J PHARMACOL, V99, P607, DOI 10.1111/j.1476-5381.1990.tb12977.x
   Whittle Brendan J. R., 1994, P267
   Wink DA, 1998, FREE RADICAL BIO MED, V25, P434, DOI 10.1016/S0891-5849(98)00092-6
   Wink DA, 1997, J BIOL CHEM, V272, P11147
   Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017
   WITTHOFT T, 1998, DIGESTION, V5
   WU WT, 1994, NEUROSCI LETT, V179, P157, DOI 10.1016/0304-3940(94)90958-X
   Xu DL, 1996, AM J PHYSIOL-REG I, V271, pR1739
   YAMAMOTO H, 1998, DIG DIS WEEK, P16
   YANAKA A, 1995, AM J PHYSIOL-GASTR L, V268, pG933
   Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129
   YOSHIDA K, 1980, INT ARCH OCC ENV HEA, V46, P71, DOI 10.1007/BF00377461
   YOSHIKAWA T, 1994, ANN NY ACAD SCI, V723, P208, DOI 10.1111/j.1749-6632.1994.tb36727.x
   Zingarelli B, 1999, GUT, V45, P199, DOI 10.1136/gut.45.2.199
NR 231
TC 100
Z9 107
U1 0
U2 14
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD JUL
PY 2001
VL 7
IS 10
BP 881
EP 908
DI 10.2174/1381612013397645
PG 28
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 448WJ
UT WOS:000169652700002
PM 11472246
DA 2021-08-04
ER

PT J
AU West, AC
   Mayer, S
   Reid, J
AF West, AC
   Mayer, S
   Reid, J
TI A superfilling model that predicts bump formation
SO ELECTROCHEMICAL AND SOLID STATE LETTERS
LA English
DT Article
ID SUPERCONFORMAL ELECTRODEPOSITION; BLOCKING INHIBITORS; TRANSPORT; COPPER
AB Numerical simulations of a superfilling model are shown to be consistent with experimental results obtained in the absence of an inhibiting, leveling agent that can be described by a diffusion-adsorption mechanism. The model, which assumes that superfilling is caused by accumulation of the adsorbed accelerator at the feature bottom as surface area available for deposition within a feature shrinks, also predicts the formation of bumps. Because the model parameters have not been independently measured, the details of the model may need further refinement, but the general approach appears feasible. (C) 2001 The Electrochemical Society.
C1 Columbia Univ, Dept Chem Engn, New York, NY 10027 USA.
   Novellus Syst, Wilsonville, OR 97070 USA.
RP West, AC (corresponding author), Columbia Univ, Dept Chem Engn, New York, NY 10027 USA.
EM acw17@columbia.edu
CR Andricacos PC, 1998, IBM J RES DEV, V42, P567, DOI 10.1147/rd.425.0567
   CAO Y, IN PRESS J ELECTROCH
   Cheng CC, 1998, J ELECTROCHEM SOC, V145, P560, DOI 10.1149/1.1838303
   Cheng CC, 1997, J ELECTROCHEM SOC, V144, P3050, DOI 10.1149/1.1837957
   Deligianni H, 1999, ELEC SOC S, V99, P52
   DUKOVIC JO, 1990, J ELECTROCHEM SOC, V137, P3748, DOI 10.1149/1.2086296
   JORDAN KG, 1991, J ELECTROCHEM SOC, V138, P1251, DOI 10.1149/1.2085768
   KRUGLIKOV SS, 1966, T I MET FINISH, V44, P152
   Madore C, 1996, J ELECTROCHEM SOC, V143, P3927, DOI 10.1149/1.1837318
   Madore C, 1996, J ELECTROCHEM SOC, V143, P3936, DOI 10.1149/1.1837319
   Moffat TP, 2001, ELECTROCHEM SOLID ST, V4, pC26, DOI 10.1149/1.1354496
   Moffat TP, 2000, J ELECTROCHEM SOC, V147, P4524, DOI 10.1149/1.1394096
   Reid J., 2000, Advanced Metallization Conference 1999 (AMC 1999). Proceedings of the Conference, P53
   RICHARD E, 2000, ADV MET C 1999, P59
   Ritzdorf T., 2000, Advanced Metallization Conference 1999 (AMC 1999). Proceedings of the Conference, P101
   ROHA D, 1990, J ELECTROCHEM SOC, V137, P824, DOI 10.1149/1.2086563
   TAEPHAISITPHONG.P, IN PRESS J ELECTROCH
   West AC, 2000, J ELECTROCHEM SOC, V147, P227, DOI 10.1149/1.1393179
NR 18
TC 212
Z9 214
U1 2
U2 44
PU ELECTROCHEMICAL SOC INC
PI PENNINGTON
PA 65 SOUTH MAIN STREET, PENNINGTON, NJ 08534 USA
SN 1099-0062
EI 1944-8775
J9 ELECTROCHEM SOLID ST
JI Electrochem. Solid State Lett.
PD JUL
PY 2001
VL 4
IS 7
BP C50
EP C53
DI 10.1149/1.1375856
PG 4
WC Electrochemistry; Materials Science, Multidisciplinary
SC Electrochemistry; Materials Science
GA 430XP
UT WOS:000168601000005
DA 2021-08-04
ER

PT J
AU Leiby, P
   Rubin, J
AF Leiby, P
   Rubin, J
TI Intertemporal permit trading for the control of greenhouse gas emissions
SO ENVIRONMENTAL & RESOURCE ECONOMICS
LA English
DT Article
DE emission trading; greenhouse gases; marketable permits; stock pollutant
ID MARKETS; BANKING
AB This paper integrates two themes in the intertemporal permit literature through the construction of an intertemporal banking system for a pollutant that creates both stock and flow damages. A permit banking system for the special case of a pollutant that only causes stock damages is also developed. This latter, simpler case corresponds roughly to the greenhouse gas emission reduction regime proposed by the U.S. Department of State as a means of fulfilling the U.S. commitment to the Framework Convention on Climate Change. This paper shows that environmental regulators can achieve the socially optimal level of emissions and output through time by setting the correct total sum of allowable emissions, and specifying the correct intertemporal trading ratio for banking and borrowing. For the case of greenhouse gases, we show that the optimal growth rate of permit prices, and therefore the optimal intertemporal trading rate, has the closed-form solution equal to the ratio of current marginal stock damages to the discounted future value of marginal stock damages less the decay rate of emissions in the atmosphere. Given a non-optimal negotiated emission path we then derive a permit banking system that has the potential to lower net social costs by adjusting the intertemporal trading ratio taking into account the behavior of private agents. We use a simple numerical simulation model to illustrate the potential gains from various possible banking systems.
C1 Oak Ridge Natl Lab, Div Energy, Oak Ridge, TN 37831 USA.
   Univ Maine, Dept Resource Econ & Policy, Margaret Chase Smith Ctr Publ Policy, Orono, ME 04469 USA.
RP Leiby, P (corresponding author), Oak Ridge Natl Lab, Div Energy, POB 2008,MS 6205, Oak Ridge, TN 37831 USA.
OI Rubin, Jonathan/0000-0002-4793-8499
CR Arrow KJ, 1996, CLIMATE CHANGE 1995
   Baumol W., 1988, THEORY ENV POLICY
   BIGLAISER G, 1995, J REGUL ECON, V8, P33, DOI 10.1007/BF01066598
   Burtraw Dallas, 1996, 9530REV
   Cronshaw MB, 1996, J REGUL ECON, V9, P179
   CROPPER ML, 1992, J EC LIT         JUN, P675
   *EN INF AG, 1995, DOEEIA057394
   FALK I, 1993, J ENVIRON ECON MANAG, V25, P76, DOI 10.1006/jeem.1993.1027
   HAHN RW, 1993, PAPER PREPARED GLOBA
   Houghton J.T., 1996, CLIMATE CHANGE 1995
   JACKSON T, 1995, ENERG POLICY, V23, P117, DOI 10.1016/0301-4215(95)91416-A
   Kamien M. I., 1991, DYNAMIC OPTIMIZATION
   KLING CL, 1997, IN PRESS J PUBLIC EC
   KOSOBUD RF, 1994, ENERGY J, V15, P213
   MCGARTLAND AM, 1985, J ENVIRON ECON MANAG, V12, P207, DOI 10.1016/0095-0696(85)90031-2
   MONTGOMERY WD, 1972, J ECON THEORY, V5, P395, DOI 10.1016/0022-0531(72)90049-X
   Nordhaus WD, 1996, AM ECON REV, V86, P741
   Nordhaus William D., 1996, MANAGING GLOBAL COMM
   Rubin JD, 1996, J ENVIRON ECON MANAG, V31, P269, DOI 10.1006/jeem.1996.0044
   SWART RJ, 1993, NAT RESOUR FORUM, V17, P43, DOI 10.1111/j.1477-8947.1993.tb00159.x
   TRENBERTH KE, 1992, CLIMATE SYSTEM MODEL
   United Nations, 1997, FRAM CONV CLIM CHANG
   *US DEP STAT, 1997, DRAFT PROT FRAM CONV
   *US GEN ACC OFF, 1994, AIR POLL ALL TRAD OF
NR 24
TC 61
Z9 64
U1 0
U2 14
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 0924-6460
J9 ENVIRON RESOUR ECON
JI Environ. Resour. Econ.
PD JUL
PY 2001
VL 19
IS 3
BP 229
EP 256
DI 10.1023/A:1011124215404
PG 28
WC Economics; Environmental Studies
SC Business & Economics; Environmental Sciences & Ecology
GA 448GJ
UT WOS:000169618800002
DA 2021-08-04
ER

PT J
AU Al-Ankari, AR
   Bradbury, JM
   Naylor, CJ
   Worthington, KJ
   Payne-Johnson, C
   Jones, RC
AF Al-Ankari, AR
   Bradbury, JM
   Naylor, CJ
   Worthington, KJ
   Payne-Johnson, C
   Jones, RC
TI Avian pneumovirus infection in broiler chicks inoculated with
   Escherichia coli at different time intervals
SO AVIAN PATHOLOGY
LA English
DT Article
ID SWOLLEN-HEAD-SYNDROME; TURKEY RHINOTRACHEITIS VIRUS; PATHOGEN-FREE
   CHICKENS; BRONCHITIS VIRUS; STRAINS; ANTIBODIES; MIXTURES
AB The effects of dual infection of 1-day-old broiler chicks with a chicken isolate of avian pneumovirus (APV) and a pool of pathogenic Escherichia coli strains were studied by supraconjunctival application of the bacteria simultaneously with the virus, or at 4, 7 or 11 days afterwards. When the agents were given together, the clinical disease was significantly more severe than that caused by the virus alone, but when the bacterium was given later the signs were less severe. None of the infections resulted in swollen head syndrome by 32 days. All mixed infections caused moderate to severe congestion in the turbinates, when birds were examined at 32 days of age, at which time no such lesions were present in birds having been infected with APV alone. E. coli was isolated from almost 100% of birds with mixed infections, while rates of those given only E. coli isolation varied between 56 and 67%. Furthermore, E. coli colony counts were consistently higher from mixed infection groups. Virus persistence in the choanal cleft was slightly prolonged in birds with the simultaneous mixed infection. Although the pool of E. coli included O2, O78 and O18 serotypes, only those of the O2 serotype and a small number of untypable strains were re-isolated from selected mixed and single E. coli-infected groups. Mixed APV and E. coli infection did not affect APV enzyme-linked immunosorbent assay antibody titres at 21 or 32 days. Thus, experimental infection of broiler chicks with APV and E. coli, simultaneously or at intervals afterwards, demonstrated a synergistic effect between the two agents, but none of the infection protocols caused swollen head syndrome.
C1 Univ Liverpool, Dept Vet Pathol, Neston CH64 7TE, England.
RP Bradbury, JM (corresponding author), Univ Liverpool, Dept Vet Pathol, Jordan Bldg, Neston CH64 7TE, England.
EM jmb41@liverpool.ac.uk
RI Naylor, Clive/B-3186-2010
CR ALEXANDER DJ, 1997, DIS POULTRY, P699
   AVELLANEDA GE, 1994, AVIAN DIS, V38, P589, DOI 10.2307/1592083
   BREE A, 1989, AVIAN DIS, V33, P134, DOI 10.2307/1591078
   British Veterinary Poultry Association, 1985, Veterinary Record, V117, P653
   BUMSTEAD N, 1989, BRIT POULTRY SCI, V30, P39, DOI 10.1080/00071668908417123
   BUYS SB, 1989, J S AFR VET ASSOC, V60, P221
   Catelli E, 1998, AVIAN PATHOL, V27, P632, DOI 10.1080/03079459808419395
   Cook J. K. A., 1996, Poultry diseases,, P243
   COOK JKA, 1991, AVIAN PATHOL, V20, P155, DOI 10.1080/03079459108418750
   COOK JKA, 1988, AVIAN PATHOL, V17, P403, DOI 10.1080/03079458808436458
   COOK JKA, 1986, J GEN VIROL, V67, P1427, DOI 10.1099/0022-1317-67-7-1427
   COOK JKA, 1993, AVIAN PATHOL, V22, P257, DOI 10.1080/03079459308418919
   CUBILLOS A, 1991, AVIAN PATHOL, V20, P85, DOI 10.1080/03079459108418744
   DROUAL R, 1994, AVIAN PATHOL, V23, P733, DOI 10.1080/03079459408419042
   Ganapathy K, 1998, AVIAN PATHOL, V27, P80, DOI 10.1080/03079459808419278
   GOUGH RE, 1988, VET REC, V123, P58, DOI 10.1136/vr.123.2.58
   GROSS WB, 1958, AM J VET RES, V19, P448
   HAFEZ HM, 1990, DEUT TIERARZTL WOCH, V97, P322
   JONES RC, 1992, RES VET SCI, V53, P38, DOI 10.1016/0034-5288(92)90081-C
   JONES RC, 1991, VET REC, V129, P509
   JONES RC, 1988, AVIAN PATHOL, V17, P841, DOI 10.1080/03079458808436506
   JONES RC, 1986, VET REC, V119, P599
   *MAFF, 1984, LAB TECHNIQUES, V1
   Majo N, 1997, VET MICROBIOL, V57, P29, DOI 10.1016/S0378-1135(97)00101-6
   NAKAMURA K, 1992, AVIAN DIS, V36, P881, DOI 10.2307/1591546
   Nakamura K, 1998, AVIAN PATHOL, V27, P21, DOI 10.1080/03079459808419270
   NAYLOR CJ, 1992, AVIAN PATHOL, V27, P21
   NAYLOR CJ, 1992, VET B, V63, P339
   OBRIEN JDP, 1985, VET REC, V117, P619, DOI 10.1136/vr.117.23.619
   PATTISON M, 1989, VET REC, V125, P229, DOI 10.1136/vr.125.9.229
   PERELMAN B, 1988, VET REC, V123, P444, DOI 10.1136/vr.123.17.444
   PICAULT JP, 1987, VET REC, V121, P135, DOI 10.1136/vr.121.6.135-a
   SMITH HW, 1985, J GEN VIROL, V66, P777, DOI 10.1099/0022-1317-66-4-777
   Stuart J. C., 1989, Recent advances in turkey science., P217
   WYETH PJ, 1987, VET REC, V120, P286, DOI 10.1136/vr.120.12.286
NR 35
TC 10
Z9 10
U1 0
U2 5
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0307-9457
EI 1465-3338
J9 AVIAN PATHOL
JI Avian Pathol.
PD JUN
PY 2001
VL 30
IS 3
BP 257
EP 267
DI 10.1080/03079450120054686
PG 11
WC Veterinary Sciences
SC Veterinary Sciences
GA 443WM
UT WOS:000169365400009
PM 19184908
DA 2021-08-04
ER

PT J
AU Davidson, MH
   Toth, P
   Weiss, S
   McKenney, J
   Hunninghake, D
   Isaacsohn, J
   Donovan, JM
   Burke, SK
AF Davidson, MH
   Toth, P
   Weiss, S
   McKenney, J
   Hunninghake, D
   Isaacsohn, J
   Donovan, JM
   Burke, SK
TI Low-dose combination therapy with colesevelam hydrochloride and
   lovastatin effectively decreases low-density lipoprotein cholesterol in
   patients with primary hypercholesterolemia
SO CLINICAL CARDIOLOGY
LA English
DT Article
DE hypercholesterolemia; lipid-lowering therapy; bile acid sequestrants;
   3-hydroxy-3-methylglutaryl coenzyme; A reductase inhibitors; combination
   lipid-lowering therapy
ID CORONARY-HEART-DISEASE; PRIMARY PREVENTION; BILE-ACID; ATHEROSCLEROSIS;
   PRAVASTATIN; MEN; PHARMACOKINETICS; CHOLESTYRAMINE; REGRESSION;
   MEVINOLIN
AB Background: Colesevelam hydrochloride is a novel, lipid-lowering agent that binds bile acids with high affinity. A multicenter, randomized, double-blind, placebo-controlled, parallel-design study was conducted to assess the efficacy and tolerability of combination low-dose colesevelam and lovastatin treatment in patients with primary hypercholesterolemia.
   Hypothesis: Combination therapy with low doses of colesevelam and lovastatin decreases low density (LDL) cholesterol with minimal adverse events.
   Methods: Following a 4- to 6-week dietary lead in, 135 patients were randomized into five groups for a 4-week treatment period: placebo, colesevelam 2.3 g at dinner, lovastatin 10 mg at dinner, the combination of colesevelam and lovastatin given at dinner (dosed together), and combination treatment with colesevelam given at dinner and lovastatin administered at bedtime (dosed apart).
   Results: Combination colesevelam and lovastatin treatment decreased LDL cholesterol by 34% (60 mg/dl, p < 0.0001) and 32% (53 mg/dl, p < 0.0001) when colesevelam and lovastatin were dosed together or dosed apart, respectively. Both combination therapies were superior to either agent alone (p < 0.05). Decreases in LDL cholesterol exceeded the combined decreases observed for colesevelam alone (13 mg/dl, 7%) and lovastatin alone (39 mg/dl, 22%). Both combination treatments reduced total cholesterol by 21% (p < 0.0001) and apolipoprotein B by 24% (p < 0.0001). Neither combination treatment significantly altered high-density lipoprotein cholesterol or triglycerides. Adverse side effects were not significantly different among randomized groups.
   Conclusions: Combination colesevelam and lovastatin was efficacious and well tolerated, resulting in additive decreases in LDL cholesterol levels whether or not both agents were administered simultaneously.
C1 GelTex Pharmaceut Inc, Waltham, MA 02451 USA.
   Metab & Atherosclerosis Res Ctr, Cincinnati, OH USA.
   Univ Minnesota, Heart Dis Prevent Clin, Minneapolis, MN USA.
   Natl Clin Res Inc, Richmond, VA USA.
   San Diego Endocrine & Med Clin, San Diego, CA USA.
   Midw Inst Clin Res Inc, Indianapolis, IN USA.
   Chicago Ctr Clin Res, Chicago, IL USA.
RP Donovan, JM (corresponding author), GelTex Pharmaceut Inc, 153 2nd Ave, Waltham, MA 02451 USA.
CR *AM HEART ASS, 2000, 2000 HEART STROKE ST
   ANDRADE SE, 1995, NEW ENGL J MED, V332, P1125, DOI 10.1056/NEJM199504273321703
   Avorn J, 1998, JAMA-J AM MED ASSOC, V279, P1458, DOI 10.1001/jama.279.18.1458
   BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233
   Braunlin W, 2000, POLYM PREPRINTS, V41, P708
   BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901
   Campeau L, 1999, CIRCULATION, V99, P3241, DOI 10.1161/01.CIR.99.25.3241
   Cooper AD, 1999, GASTROENTEROL CLIN N, V28, P211, DOI 10.1016/S0889-8553(05)70051-0
   Davidson M, 2000, J AM COLL CARDIOL, V35, p215A
   DAVIDSON M, 2000, ATHEROSCLEROSIS, V151, P130
   Davidson MH, 1999, ARCH INTERN MED, V159, P1893, DOI 10.1001/archinte.159.16.1893
   DENKE MA, 1995, ARCH INTERN MED, V155, P17, DOI 10.1001/archinte.155.1.17
   Donovan JM, 2000, CARDIOVASC DRUG THER, V14, P681, DOI 10.1023/A:1007831418308
   Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615
   EINARSSON K, 1991, EUR J CLIN PHARMACOL, V40, pS53, DOI 10.1007/BF01409410
   FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
   Grundy SM, 1999, CIRCULATION, V100, P988, DOI 10.1161/01.CIR.100.9.988
   Holmes-Farley SS, 2000, POLYM PREPRINTS, V4, P735
   KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007
   Knopp RH, 1999, NEW ENGL J MED, V341, P498, DOI 10.1056/NEJM199908123410707
   MA PTS, 1986, P NATL ACAD SCI USA, V83, P8370, DOI 10.1073/pnas.83.21.8370
   *MED EC COMP INC, 1999, PHYS DESK REF COL, P857
   *MED EC COMP INC, 1999, PHYS DESK REF COL, P2465
   MEVACOR L, 1999, PHYSICIANS DESK REFE, P1834
   Muck W, 1997, INT J CLIN PHARM TH, V35, P250
   MYERS GL, 1989, CLIN LAB MED, V9, P105, DOI 10.1016/S0272-2712(18)30645-0
   *NAT CHOL ED PROGR, 1994, CIRCULATION, V89, P1333
   PAN HY, 1990, CLIN PHARMACOL THER, V48, P201, DOI 10.1038/clpt.1990.136
   Pasternak RC, 1996, ANN INTERN MED, V125, P529, DOI 10.7326/0003-4819-125-7-199610010-00001
   PEDERSEN TR, 1994, LANCET, V344, P1383
   RIFAI N, 1994, LAB MEASUREMENT LIPI, P1
   RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351
   Roberts WC, 1997, AM J CARDIOL, V80, P106, DOI 10.1016/S0002-9149(97)00298-1
   Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401
   Schectman G, 1996, AM J MED, V100, P197, DOI 10.1016/S0002-9343(97)89459-4
   Schectman G, 1996, ANN INTERN MED, V125, P990, DOI 10.7326/0003-4819-125-12-199612150-00011
   SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001
   *SUMM 2 REP NAT CH, 1996, JAMA-J AM MED ASSOC, V269, P3015
   VEGA GL, 1987, JAMA-J AM MED ASSOC, V257, P33, DOI 10.1001/jama.257.1.33
NR 39
TC 70
Z9 70
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0160-9289
EI 1932-8737
J9 CLIN CARDIOL
JI Clin. Cardiol.
PD JUN
PY 2001
VL 24
IS 6
BP 467
EP 474
DI 10.1002/clc.4960240610
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 437RJ
UT WOS:000169007100008
PM 11403509
OA Green Published
DA 2021-08-04
ER

PT J
AU Rienmuller, R
   Brekke, O
   Kampenes, VB
   Reiter, U
AF Rienmuller, R
   Brekke, O
   Kampenes, VB
   Reiter, U
TI Dimeric versus monomeric nonionic contrast agents in visualization of
   coronary arteries
SO EUROPEAN JOURNAL OF RADIOLOGY
LA English
DT Article
DE iodixanol; iohexol; coronary artery imaging; electron beam computed
   tomography
ID ULTRAFAST COMPUTED-TOMOGRAPHY; MYOCARDIAL PERFUSION
AB A cubital intravenous iodine contrast agent enhancement is used to visualize coronary arteries using EBT. The quality of the coronary artery visualization however is limited by the nearly simultaneous approximation of CT values in coronary arteries and myocardial tissue. The objective of the study was to evaluate if "under real clinical circumstances" the lower iodine concentration and the dimeric based characteristic or iodixanol may effect the kinetic of the applied contrast agent and the visualization of coronary arteries studied noninvasively by EBT. A double-blind, randomized, parallel study was performed in 111 cardiac patients, using iodixanol 270 mg I/ml or iohexol 300 mg I/ml. The kinetics of contrast enhancement was studied in the flow mode measuring following parameters: mean arrival time and mean time to reach peak CT values in the pulmonary trunk, transit time from the pulmonary trunk to the aorta as well as mean and maximum CT values in the left ventricular chamber and in the myocardium with respect to the body mass index. The mean difference of CT values in the left ventricular chamber and the myocardium was calculated. The length of the visualized coronary arteries was assessed and the diagnostic quality of coronary artery visualization scored on a visual analogue scale. Although iodixanol was used with a Power iodine concentration than iohexol there was no significant statistical difference between both groups with respect to the diagnostic visualization and length assessment of the coronary arteries as well as in the mean difference of CT values in the left ventricular chamber and the myocardium. This means that the advantageous dimeric characteristics of iodixanol may be used to reduce the amount of applicated iodine in contrast agents without loss of diagnostic image quality and information. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
C1 Univ Klinikum Graz, Landeskrankenhaus, Div Gen Radiol, A-8036 Graz, Austria.
RP Rienmuller, R (corresponding author), Univ Klinikum Graz, Landeskrankenhaus, Div Gen Radiol, Auenbruggerpl 9-P, A-8036 Graz, Austria.
RI Reiter, Ursula/P-7259-2016; Rienmuller, Rainer/H-6315-2016
OI Rienmuller, Rainer/0000-0002-6068-5027
CR KOSLING S, 1995, ROFO FORTSCHR RONTG, V163, P111, DOI 10.1055/s-2007-1015956
   MANNINEN H, 1995, EUR RADIOL, V5, P364
   MUETZEL W, 1984, INVEST RADIOL, V19, pS140
   Rienmuller R, 1997, RADIOLOGE, V37, P410, DOI 10.1007/s001170050230
   Rienmuller R, 1997, HERZ, V22, P63, DOI 10.1007/BF03044305
   SAKO M, 1993, NIPPON ACTA RADIOL, V54, P32
   Schmermund A, 1997, HERZ, V22, P29, DOI 10.1007/BF03044568
   STANFORD W, 1991, SEMIN ULTRASOUND CT, V12, P45
   THOMPSON BH, 1994, RADIOL CLIN N AM, V32, P537
NR 9
TC 12
Z9 13
U1 0
U2 2
PU ELSEVIER SCI IRELAND LTD
PI CLARE
PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE,
   IRELAND
SN 0720-048X
J9 EUR J RADIOL
JI Eur. J. Radiol.
PD JUN
PY 2001
VL 38
IS 3
BP 173
EP 178
DI 10.1016/S0720-048X(01)00304-7
PG 6
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 442RA
UT WOS:000169297700002
PM 11399369
DA 2021-08-04
ER

PT J
AU Matilla, A
   Tercero, JM
   Valenzuela, C
   Moreno, C
   Sanjuan, MA
AF Matilla, A
   Tercero, JM
   Valenzuela, C
   Moreno, C
   Sanjuan, MA
TI Zinc(II), cadmium(II), mercury(II), and lead(II) complexes of
   N-carboxymethyl-D,L-threonine in aqueous solution
SO JOURNAL OF SOLUTION CHEMISTRY
LA English
DT Article
DE zinc(II), cadmium(II), mercury(II), lead(II) complexes;
   N-carboxymethyl-D,L-threonine complexes; stability constants; selective
   chelating agent for mercury(II); potentiometric methods;
   spectrophotometry
ID EQUILIBRIA; COPPER(II); THERAPY
AB The formation of complexes of Zn(II), Cd(II), HE(II), and Pb(II) and N-carboxymethyl-D,L-threonine (H2CMT, H2L) in aqueous solutions has been studied by spectrophotometric and potentiometric methods. The complexation model for each system has been established by the HYPERQUAD program from the potentiometric data. Three different behaviors are found: ML2H, MLH, ML, MLOH, and ML2 complexes are formed by Zn(II) and Cd(II) ions, ML2H. ML, MLOH, and ML2 are formed by HB(II) ion, and only 1/1 complexes MLH, ML, and MLOH are formed by the Pb(II) ion. The formation constants determined for all these complexes allow simulation of experimental titration curves with good agreement. The speciation of multimetal systems with H2CMT shows that this compound is a good and selective ligand at low pH for the Hg(II) ion.
C1 Univ Granada, Fac Farm, Dept Quim Inorgan, E-18071 Granada, Spain.
RP Matilla, A (corresponding author), Univ Granada, Fac Farm, Dept Quim Inorgan, E-18071 Granada, Spain.
RI Matilla, Antonio/I-5006-2015
OI Matilla, Antonio/0000-0001-5513-1815
CR ABRAMS MJ, 1993, SCIENCE, V261, P725, DOI 10.1126/science.8102010
   BULMAN RA, 1987, STRUCT BOND, V67, P91
   DOBBIN PS, 1990, CHEM BRIT, V26, P565
   Farrell N., 1989, TRANSITION METAL COM
   Gans P, 1996, TALANTA, V43, P1739, DOI 10.1016/0039-9140(96)01958-3
   GUENTHER WB, 1968, QUANTITATIVE CHEM ME, P431
   KARADAKOV BP, 1976, RUSS J INORG CHEM, V21, P56
   LEOPARTI E, 1988, J CHEM SOC DA, P421
   LEPORATI E, 1985, J CHEM SOC DALTON, P1605, DOI 10.1039/dt9850001605
   MATILLA A, SIMPOT PC PROGRAM SI
   MIYAZAWA T, 1980, B CHEM SOC JPN, V55, P2555
   PERRIN DD, 1967, TALANTA, V14, P833, DOI 10.1016/0039-9140(67)80105-X
   Powel K. J., 1997, IUPAC STABILITY CONS
   Sigel H., 1982, METAL IONS BIOL SYST, P14
   SNYDER RV, 1973, J INORG NUCL CHEM, V35, P527
   TERCERO J, 1994, ARS PHARM, V35, P75
   Tercero JM, 1995, J COORD CHEM, V34, P139, DOI 10.1080/00958979508055393
NR 17
TC 0
Z9 0
U1 0
U2 4
PU KLUWER ACADEMIC/PLENUM PUBL
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0095-9782
J9 J SOLUTION CHEM
JI J. Solut. Chem.
PD JUN
PY 2001
VL 30
IS 6
BP 549
EP 559
DI 10.1023/A:1010386802650
PG 11
WC Chemistry, Physical
SC Chemistry
GA 454MQ
UT WOS:000169976700004
DA 2021-08-04
ER

PT J
AU Elliott, JE
   Anseth, JW
   Bowman, CN
AF Elliott, JE
   Anseth, JW
   Bowman, CN
TI Kinetic modeling of the effect of solvent concentration on primary
   cyclization during polymerization of multifunctional monomers
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE polymer; gels; crosslinking; cyclization; solvent effects; simulation
ID ETHYLENE-GLYCOL DIMETHACRYLATE; CROSS-LINKING COPOLYMERIZATION; VINYL
   GROUP REACTIVITY; NETWORK FORMATION; COMPUTER-SIMULATION;
   METHYL-METHACRYLATE; POLY(ACRYLIC ACID); DELIVERY SYSTEMS; GELATION
   MODEL; GEL FORMATION
AB Controlling the swelling ratio, diffusion rate, and mechanical properties of a crosslinked polymer is important in hydrogel design for biomedical applications. Each of these factors depends strongly on the degree of crosslinking. Primary cyclization, where a propagating radical reacts intramolecularly with a pendant double bond on the same chain, decreases the crosslinking density and increases the molecular weight between crosslinks. Processing conditions, specifically the solvent concentration, strongly affect the extent of primary cyclization. In this work the effects of solvent concentration and comonomer composition on primary cyclization are investigated using a novel kinetic model and experimental measurement of mechanical properties. Two divinyl crosslinking agents were investigated, diethyleneglycol dimethacrylate (DEGDMA) and polyethyleneglycol 600 dimethacrylate (PEG(600)DMA), and each was copolymerized with hydroxyethyl methacrylate (HEMA) and octyl methacrylate (OcMA). The model is further used to predict the gel point conversion and swelling ratio of PAA hydrogels polymerized in the presence of varying amounts of water. Model results show how increasing the solvent concentration during the polymerization increases the molecular weight between crosslinks by nearly a factor of three and more than doubles the swelling ratio. Where possible, experimental results provide quantitative agreement with model predictions. (C) 2001 Elsevier Science Ltd. All rights reserved.
C1 Univ Colorado, Dept Chem Engn, Ctr Engn, Boulder, CO 80309 USA.
   Univ Colorado, Ctr Hlth Sci, Sch Dent, Denver, CO 80045 USA.
RP Bowman, CN (corresponding author), Univ Colorado, Dept Chem Engn, Ctr Engn, ECCH 111,Campus 424, Boulder, CO 80309 USA.
RI Bowman, Christopher N/B-1490-2008
OI Bowman, Christopher N/0000-0001-8458-7723
CR ANSETH KS, 1994, CHEM ENG SCI, V49, P2207, DOI 10.1016/0009-2509(94)E0055-U
   Anseth KS, 1996, BIOMATERIALS, V17, P1647, DOI 10.1016/0142-9612(96)87644-7
   BAE YH, 1993, ADV DRUG DELIVER REV, V11, P109, DOI 10.1016/0169-409X(93)90029-4
   BANSIL R, 1984, MACROMOLECULES, V17, P998, DOI 10.1021/ma00135a004
   BOOTS HMJ, 1984, POLYM BULL, V11, P415, DOI 10.1007/BF00265480
   BOOTS HMJ, 1985, BRIT POLYM J, V17, P219, DOI 10.1002/pi.4980170224
   BOWMAN CN, 1992, CHEM ENG SCI, V47, P1411, DOI 10.1016/0009-2509(92)80286-L
   CHIU YY, 1995, J POLYM SCI POL CHEM, V33, P269, DOI 10.1002/pola.1995.080330209
   Dusek K, 1996, MACROMOL SYMP, V106, P119, DOI 10.1002/masy.19961060113
   DUSEK K, 1980, POLYMER, V21, P750, DOI 10.1016/0032-3861(80)90290-6
   DUSEK K, 1975, J POLYM SCI S, V53, P57
   DUSEK K, 1982, DEV POLYM, V3
   DUSEK K, 1998, POLYM NETWORKS PRINC
   Elliott JE, 1999, MACROMOLECULES, V32, P8621, DOI 10.1021/ma990797i
   ELLIOTT JE, 1999, WILEY POLYM NETWORKS, V2, P27
   Ende MTA, 1996, J APPL POLYM SCI, V59, P673, DOI 10.1002/(SICI)1097-4628(19960124)59:4<673::AID-APP13>3.3.CO;2-6
   Flory P.J, 1953, PRINCIPLES POLYM CHE
   FLORY PJ, 1969, STATISTICAL MECHANIC, P11
   GALINA H, 1980, EUR POLYM J, V16, P1043, DOI 10.1016/0014-3057(80)90221-9
   Gonzales D, 1996, J POLYM SCI POL CHEM, V34, P2019, DOI 10.1002/(SICI)1099-0518(19960730)34:10<2019::AID-POLA19>3.0.CO;2-K
   Goodner MD, 1997, IND ENG CHEM RES, V36, P1247, DOI 10.1021/ie9605387
   GORDON M, 1962, PROC R SOC LON SER-A, V268, P240, DOI 10.1098/rspa.1962.0136
   GORDON M, 1966, PROC R SOC LON SER-A, V295, P29, DOI 10.1098/rspa.1966.0224
   HASA J, 1967, J POLYM SCI C, V16, P317
   Jen AC, 1996, BIOTECHNOL BIOENG, V50, P357, DOI 10.1002/(SICI)1097-0290(19960520)50:4<357::AID-BIT2>3.0.CO;2-K
   Kao FJ, 1997, J BIOMED MATER RES, V38, P191, DOI 10.1002/(SICI)1097-4636(199723)38:3<191::AID-JBM2>3.0.CO;2-K
   KLOOSTERBOER JG, 1988, ADV POLYM SCI, V84, P1
   LANDIN DT, 1988, MACROMOLECULES, V21, P846, DOI 10.1021/ma00181a048
   LEHR CM, 1992, EUR J PHARM BIOPHARM, V38, P55
   Luo YW, 1997, J APPL POLYM SCI, V64, P1691
   MACOSKO CW, 1976, MACROMOLECULES, V9, P199, DOI 10.1021/ma60050a003
   MANNEVILLE, 1981, NUMERICAL METHODS ST
   MILLER DR, 1976, MACROMOLECULES, V9, P206, DOI 10.1021/ma60050a004
   MILLER DR, 1988, J POLYM SCI PHYS ED, V26, P11
   MONTHEARD JP, 1992, J MACROMOL SCI R M C, VC32, P1, DOI 10.1080/15321799208018377
   MOUSSAID A, 1994, MACROMOLECULES, V27, P2102, DOI 10.1021/ma00086a019
   Naghash HJ, 1997, POLYMER, V38, P1187, DOI 10.1016/S0032-3861(96)00615-5
   NAGHASH HJ, 1995, J APPL POLYM SCI, V56, P477, DOI 10.1002/app.1995.070560409
   NG CO, 1976, BRIT POLYM J, V8, P118, DOI 10.1002/pi.4980080403
   Okay O, 1997, POLYM BULL, V39, P233, DOI 10.1007/s002890050143
   OKAY O, 1995, MACROMOLECULES, V28, P2728, DOI 10.1021/ma00112a019
   OKAY O, 1993, POLYMER, V35, P786
   Peppas N.A., 1987, HYDROGELS MED PHARM, V2
   PEPPAS NA, 1993, ADV DRUG DELIVER REV, V11, P1, DOI 10.1016/0169-409X(93)90025-Y
   Schroder UP, 1997, MACROMOL THEOR SIMUL, V6, P151, DOI 10.1002/mats.1997.040060110
   SIMON GP, 1989, MACROMOLECULES, V22, P3555, DOI 10.1021/ma00199a010
   Stockmayer WH, 1943, J CHEM PHYS, V11, P45, DOI 10.1063/1.1723803
   TOBITA H, 1988, MAKROMOL CHEM-M SYMP, V20-1, P501, DOI 10.1002/masy.19880200152
   TOBITA H, 1992, POLYMER, V33, P3647, DOI 10.1016/0032-3861(92)90651-C
   TOBITA H, 1989, MACROMOLECULES, V22, P3098, DOI 10.1021/ma00197a034
   WALLING BC, 1945, J AM CHEM SOC, V67, P441
   Wheeler JC, 1996, J LONG-TERM EFF MED, V6, P207
   WICHTERLE O, 1960, NATURE, V185, P117, DOI 10.1038/185117a0
NR 53
TC 67
Z9 68
U1 0
U2 33
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY
PY 2001
VL 56
IS 10
BP 3173
EP 3184
DI 10.1016/S0009-2509(00)00547-9
PG 12
WC Engineering, Chemical
SC Engineering
GA 443NV
UT WOS:000169348000013
DA 2021-08-04
ER

PT J
AU De Paepe, P
   Van Sassenbroeck, DK
   Belpaire, FM
   Buylaert, WA
AF De Paepe, P
   Van Sassenbroeck, DK
   Belpaire, FM
   Buylaert, WA
TI Influence of naloxone on the increased sensitivity to propofol during
   hypovolemia in the rat
SO CRITICAL CARE MEDICINE
LA English
DT Article
DE propofol; naloxone; anesthesia; endogenous opioids; shock; hemorrhage;
   hypovolemia; pharmacodynamics; effect-site; rat
ID DISEASE STATES; DRUG-ACTION; PHARMACOKINETICS; PHARMACODYNAMICS;
   INHIBITION; KINETICS; OPIOIDS
AB Objective: Hypovolemia has been shown to decrease the dose requirement for propofol, This increased effect has been explained partially by an increased end organ sensitivity to the anesthetic effect of propofol, We used the opioid blocking agent naloxone to test the hypothesis that endogenous opioids may be involved in this increased sensitivity,
   Subjects: Thirty-two chronically instrumented rats were assigned randomly to either the hypovolemia (n = 16) or the control (n = 16) group.
   Interventions: After pretreatment of each rat in the two groups with either intravenous saline (n = 8) or naloxone (3 mg/kg; n = 8), an intravenous infusion of propofol (150 mg.kg(-1).hr(-1)) was given until 5 secs of electrical suppression of the electroencephalographic signal was observed. Return of righting reflex was used to assess depth of anesthesia, and the propofol blood concentration was determined simultaneously with high-performance liquid chromatography,
   Measurements and Main Results: The mean propofol blood concentrations at the return of righting reflex were significantly lower in the hypovolemic animals compared with the controls within both naloxone-treated (2.1 +/- 0.2 mug/mL vs, 2.9 +/- 0.2 mug/mL; p <.01) and saline-treated (2.2 <plus/minus> 0.1 vs, 3.0 +/- 0.2 mug/mL; p <.01) rats, The mean concentrations were not different between the saline- and naloxone-treated rats either within the hypovolemic group or within the control group.
   Conclusions: The results of our study indicate that it is unlikely that the increased end organ sensitivity to propofol during hypovolemia is mediated by endogenous opioids, because it was not reversed by naloxone.
C1 State Univ Ghent, Heymans Inst Pharmacol, B-9000 Ghent, Belgium.
   State Univ Ghent Hosp, Dept Emergency Med, Ghent, Belgium.
RP De Paepe, P (corresponding author), State Univ Ghent, Heymans Inst Pharmacol, Pintelaan 185, B-9000 Ghent, Belgium.
CR Buggy DJ, 2000, ANESTHESIOLOGY, V92, P1067, DOI 10.1097/00000542-200004000-00025
   De Paepe P, 1999, J PHARMACOL EXP THER, V290, P1048
   De Paepe P, 2000, ANESTHESIOLOGY, V93, P1482, DOI 10.1097/00000542-200012000-00021
   JIANG ZG, 1992, J NEUROSCI, V12, P356
   KLOCKOWSKI PM, 1988, J PHARMACOL EXP THER, V245, P508
   KLOCKOWSKI PM, 1988, J PHARM SCI, V77, P365, DOI 10.1002/jps.2600770417
   MARTIN WR, 1983, PHARMACOL REV, V35, P283
   MISRA AL, 1976, J PHARMACOL EXP THER, V196, P257
   Molina PE, 1999, LIFE SCI, V66, P399
   NGAI SH, 1976, ANESTHESIOLOGY, V44, P398, DOI 10.1097/00000542-197605000-00008
   PLUMMER GF, 1987, J CHROMATOGR-BIOMED, V421, P171, DOI 10.1016/0378-4347(87)80394-8
   SATO S, 1989, J PHARM SCI, V78, P785, DOI 10.1002/jps.2600780919
   SCHADT JC, 1991, AM J PHYSIOL, V260, P305
   SEYDE WC, 1985, AM J PHYSIOL, V249, pH164
NR 14
TC 8
Z9 8
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0090-3493
J9 CRIT CARE MED
JI Crit. Care Med.
PD MAY
PY 2001
VL 29
IS 5
BP 997
EP 999
DI 10.1097/00003246-200105000-00023
PG 3
WC Critical Care Medicine
SC General & Internal Medicine
GA 431DB
UT WOS:000168615700015
PM 11378611
DA 2021-08-04
ER

PT J
AU Kurz, M
   Motolese, M
AF Kurz, M
   Motolese, M
TI Endogenous uncertainty and market volatility
SO ECONOMIC THEORY
LA English
DT Article
DE market volatility; diversity of beliefs; stable dynamical system;
   empirical distribution; stationary measure; rational Belief; Rational
   Belief Equilibrium; state of beliefs; regime variables; assessment
   regime variables; equity premium puzzle; market optimism and pessimism;
   garch; forward discount bias in foreign exchange markets
ID EQUITY PREMIUM PUZZLE; RATIONAL BELIEF EQUILIBRIA; RISK-FREE RATE;
   STOCK-PRICES; ASSET PRICES; ASYMMETRIC INFORMATION; ASYMPTOTIC-BEHAVIOR;
   INCOMPLETE MARKETS; MEAN REVERSION; TRADING VOLUME
AB We advance the theory that the distribution of beliefs in the market is the most important propagation mechanism of economic volatility. Our model is based on the theory of Rational Beliefs (RB) and Rational Belief Equilibrium (RBE) developed by Kurz (1994, 1997). We argue that the diverse market puzzles which are examined, such as the equity premium puzzle, are all driven by the structure of market expectations. In support of our view, we present an RBE model with which we study financial markets. The model is able to simulate the correct order of magnitude of: (i) the long term mean and standard deviation of the price\dividend ratio: (ii) the long term mean and standard deviation of the risky rate of return on equities; (iii) the long term mean and standard deviation of the riskless rate, (iv) the long term mean equity premium. In addition, the model predicts (v) the GARCH property of risky asset returns: (vi) the observed pattern of the predictability of long returns on assets, and (vii) the Forward Discount Bias in foreign exchange markets.
   The common economic explanation for these phenomena is the existence of heterogenous agents with diverse but correlated beliefs such that some agents are optimistic and some pessimistic about future capital gains. The model has a unique parameterization under which the model makes all the above predictions simultaneously. The parameterization requires the optimists to be in the majority but the rationality of belief conditions: of the RBE require the pessimists to have a higher intensity level. In simple terms, the large equity premium and the low equilibrium riskless rate are the result of the fact that at any moment of time there are agents who hold extreme pessimistic beliefs and they have a relatively stronger impact on the market. The paper also studies the effect of correlation of beliefs among investors. it shows that the main effect of such correlation is on the dynamic patterns of asset prices and returns and is hence important for studying such phenomena as stochastic volatility.
C1 Stanford Univ, Dept Econ, Stanford, CA 94305 USA.
   Catholic Univ Milan, Ist Polit Econ, I-20123 Milan, Italy.
RP Kurz, M (corresponding author), Stanford Univ, Dept Econ, Serra St & Galvez, Stanford, CA 94305 USA.
CR Abel AB, 1999, J MONETARY ECON, V43, P3, DOI 10.1016/S0304-3932(98)00039-7
   ANDERSON E, 1999, RISK ROBUSTNESS EQUI
   AZARIADIS C, 1986, REV ECON STUD, V53, P725, DOI 10.2307/2297716
   AZARIADIS C, 1981, J ECON THEORY, V25, P380, DOI 10.1016/0022-0531(81)90038-7
   BRENNAN MJ, 1997, STOCK PRICE VOLATILI
   Brock WA, 1996, REV ECON STAT, V78, P94, DOI 10.2307/2109850
   Campbell JY, 1999, J POLIT ECON, V107, P205, DOI 10.1086/250059
   CAMPBELL JY, 1988, J FINANC, V43, P661, DOI 10.2307/2328190
   CASS D, 1983, J POLIT ECON, V91, P193, DOI 10.1086/261139
   CECCHETTI SG, 1990, AM ECON REV, V80, P398
   CECCHETTI SG, 1993, J MONETARY ECON, V31, P21, DOI 10.1016/0304-3932(93)90015-8
   CHEROZHUKOV V, 1999, ECONOMETRIC MODELING
   CONSTANTINIDES GM, 1990, J POLIT ECON, V98, P519, DOI 10.1086/261693
   DIACONIS P, 1986, ANN STAT, V14, P1, DOI 10.1214/aos/1176349830
   DUFFIE D, 1994, ECONOMETRICA, V62, P745, DOI 10.2307/2951731
   Engel C., 1996, J EMPIR FINANC, V3, P123, DOI [10.1016/0927-5398(95)00016-X, DOI 10.1016/0927-5398(95)00016-X]
   EPSTEIN LG, 1990, J MONETARY ECON, V26, P387, DOI 10.1016/0304-3932(90)90004-N
   FAMA EF, 1988, J POLIT ECON, V96, P246, DOI 10.1086/261535
   Farmer R., 1993, MACROECONOMICS SELF
   Feldman M., 1991, ECON THEOR, V1, P301
   Frankel J.A., 1995, HDB INT EC, VIII, P1689, DOI DOI 10.1016/S1573-4404(05)80013-9
   Frankel J. A, 1990, PRIVATE BEHAV GOVT P, P73
   FREEDMAN DA, 1965, ANN MATH STAT, V36, P454, DOI 10.1214/aoms/1177700155
   FREEDMAN DA, 1963, ANN MATH STAT, V34, P1386, DOI 10.1214/aoms/1177703871
   FROOT KA, 1990, 3247 NAT BUR RES
   GARMAISE MJ, 1998, THESIS STANFORD U
   GROSSMAN SJ, 1980, AM ECON REV, V70, P393
   GROSSMAN SJ, 1981, REV ECON STUD, V48, P541, DOI 10.2307/2297195
   HAMILTON JD, 1989, ECONOMETRICA, V57, P357, DOI 10.2307/1912559
   HANSEN L. P, 1999, ROBUST PERMANENT INC
   Heaton J, 1996, J POLIT ECON, V104, P443, DOI 10.1086/262030
   JACKSON M, 1991, J ECON THEORY, V55, P274, DOI 10.1016/0022-0531(91)90041-2
   KANDEL E, 1995, J POLIT ECON, V103, P831, DOI 10.1086/262005
   Kocherlakota NR, 1996, J ECON LIT, V34, P42
   Kurz M, 1996, ECON THEORY, V8, P383, DOI 10.1007/s001990050098
   Kurz M, 1996, ECON THEORY, V8, P489, DOI 10.1007/s001990050102
   KURZ M, 1997, STUDIES EC THEORY, V6
   Kurz M., 1994, EC THEORY COMMUN, V4, P877, DOI DOI 10.1007/BF01213817
   KURZ M, 1974, ESSAYS EC BEHAV UNCE, P389
   KURZ M, 1997, STUDIES THEORY RATIO, P317
   KURZ M, 1998, FUNCTIONAL ANAL EC T, P171
   KURZ M, 1997, STUDIES THEORY RATIO, P283
   KURZ M, 1997, STUDIES THEORY RATIO, P211
   KYLE AS, 1985, ECONOMETRICA, V53, P1315, DOI 10.2307/1913210
   Lindhal Erik, 1939, STUDIES THEORY MONEY
   LUCAS RE, 1978, ECONOMETRICA, V46, P1429, DOI 10.2307/1913837
   LUCAS RE, 1973, AM ECON REV, V63, P236
   Magill M, 1996, J MATH ECON, V26, P133, DOI 10.1016/0304-4068(95)00746-6
   Mankiw G.N., 1986, J MONETARY ECON, V15, P145
   MEHRA R, 1985, J MONETARY ECON, V15, P145, DOI 10.1016/0304-3932(85)90061-3
   MILGROM P, 1982, J ECON THEORY, V26, P17, DOI 10.1016/0022-0531(82)90046-1
   MOTOLESE M, 1998, THESIS U BOLOGNA
   Myrdal Gunnar., 1939, MONETARY EQUILIBRIUM
   Nielsen CK, 1996, ECON THEORY, V8, P399, DOI 10.1007/BF01213503
   NIELSEN CK, 1997, FLOATING EXCHANGE RA
   Phelps Edmund S., 1970, MICROECONOMIC FDN EM
   Pigou A.C., 1941, EMPLOYMENT EQUILIBRI
   POTERBA JM, 1988, J FINANC ECON, V22, P27, DOI 10.1016/0304-405X(88)90021-9
   RADNER R, 1979, ECONOMETRICA, V47, P655, DOI 10.2307/1910413
   RADNER R, 1972, ECONOMETRICA, V40, P289, DOI 10.2307/1909407
   REITZ TA, 1988, J MONETARY ECON, V22, P117
   Sargent T., 1993, BOUNDED RATIONALITY
   Savage L.J., 1954, FDN STAT
   SHILLER RJ, 1981, AM ECON REV, V71, P421
   Siegel J.J., 1994, STOCKS LONG RUN GUID
   TAKAGI S, 1991, INT MONET FUND S PAP, V38, P156
   Thornton H., 1802, INQUIRY NATURE EFFEC
   WANG J, 1994, J POLIT ECON, V102, P127, DOI 10.1086/261924
   WANG J, 1993, REV ECON STUD, V60, P249, DOI 10.2307/2298057
   WEIL P, 1989, J MONETARY ECON, V24, P401, DOI 10.1016/0304-3932(89)90028-7
   WOODFORD M, 1986, J ECON THEORY, V40, P128, DOI 10.1016/0022-0531(86)90011-6
   WU HM, 1998, ASSET PRICING SPECUL
NR 72
TC 40
Z9 41
U1 0
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0938-2259
J9 ECON THEOR
JI Econ. Theory
PD MAY
PY 2001
VL 17
IS 3
BP 497
EP 544
PG 48
WC Economics
SC Business & Economics
GA 428VY
UT WOS:000168483400001
DA 2021-08-04
ER

PT J
AU Lahmandi-Ayed, R
AF Lahmandi-Ayed, R
TI Oligopoly equilibria in exchange economies: a limit theorem
SO ECONOMIC THEORY
LA English
DT Article
DE strategic behaviour; oligopoly equilibrium; replication; convergence;
   competitive equilibrium
ID COURNOT; COMPETITION
AB In a pure exchange economy, agents have the possibility of behaving strategically by putting only a part of their initial endowments on the market. An oligopoly equilibrium is defined to be a Nash equilibrium of the game in which agents choose simultaneously quantities to be put on the market. It is proved that under standard hypotheses, the oligopoly equilibrium leads to the competitive equilibrium when the economy is replicated an infinite number of times.
C1 Ecole Polytech Tunisie, La Marsa 2078, Tunisia.
RP Lahmandi-Ayed, R (corresponding author), Ecole Polytech Tunisie, BP 743, La Marsa 2078, Tunisia.
RI Lahmandi-Ayed, Rim/J-7482-2019
OI Lahmandi-Ayed, Rim/0000-0002-6427-4778
CR AUMANN RJ, 1964, ECONOMETRICA, V32, P39, DOI 10.2307/1913732
   CODOGNATO G, 1991, REV ECON, V42, P1013, DOI 10.2307/3502021
   DEBREU G, 1984, THEORIE VALEUR
   Florenzano M., 1981, EQUILIBRE EC GEN TRA
   GABSZEWICZ JJ, 1972, J ECON THEORY, V4, P381
   Gabszewicz JJ, 1997, TRADE TECHNOLOGY EC, P217
   GUESNERIE R, 1985, INT ECON REV, V26, P525, DOI 10.2307/2526701
   HILDENBRAND W, 1976, INTRO EQUILIBRIUM AN
   Jackson MO, 1997, J ECON THEORY, V77, P354, DOI 10.1006/jeth.1997.2327
   OTANI Y, 1990, J ECON THEORY, V51, P295, DOI 10.1016/0022-0531(90)90020-K
   POSTLEWAITE A, 1976, ECONOMETRICA, V44, P115
   ROBERTS K, 1980, J ECON THEORY, V22, P256, DOI 10.1016/0022-0531(80)90043-5
   SAFRA FZ, 1985, J ECON THEORY, V37, P366
NR 13
TC 11
Z9 11
U1 0
U2 4
PU SPRINGER-VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010 USA
SN 0938-2259
J9 ECON THEOR
JI Econ. Theory
PD MAY
PY 2001
VL 17
IS 3
BP 665
EP 674
DI 10.1007/PL00004122
PG 10
WC Economics
SC Business & Economics
GA 428VY
UT WOS:000168483400007
DA 2021-08-04
ER

PT J
AU Zhang, XH
   Lowe, D
   Giles, P
   Fell, S
   Connock, MJ
   Maslin, DJ
AF Zhang, XH
   Lowe, D
   Giles, P
   Fell, S
   Connock, MJ
   Maslin, DJ
TI Gender may affect the action of garlic oil on plasma cholesterol and
   glucose levels of normal subjects
SO JOURNAL OF NUTRITION
LA English
DT Article
DE plasma lipids; antioxidants; gender; garlic; normal men and women
ID CORONARY HEART-DISEASE; CONTROLLED TRIAL; BLOOD-LIPIDS; RISK-FACTORS;
   HYPERCHOLESTEROLEMIC MEN; ANTIOXIDANT CAPACITY; RAT HEPATOCYTES;
   CLINICAL-TRIALS; METAANALYSIS; SUPPLEMENTATION
AB Early trials of garlic preparations on blood lipids mainly supported a lipid-lowering effect, whereas later well-designed garlic tablet trials were mainly entirely null. However, enteric simulation tests suggest that this discordance may result from ineffective delivery of bioactive agents from the brands of garlic powder (GP) and cyclodextrin-bound garlic oil (GO) tablets tested in some recent negative trials. In contrast, enteric simulation tests show that the preformed bioactive agents present in "traditional" gelatin capsules of GO are efficiently released, although such capsules have rarely been investigated in lipid-lowering trials. It was hypothesized that gelatin capsules of GO given to normal subjects would improve specified coronary heart disease risk factors. Effects of a GP preparation were also investigated. Subjects (n = 51;men and women, mean age 27 y) were randomly assigned to receive either 8.2 mg/d of GO (allyl sulfides) or placebo for 11 wk. Another 27 subjects received garlic powder (GP) of similar biopotential (7.8 mg allicin/d). Outcome measures were 95% confidence intervals (CI) between GO and placebo groups for differences between baseline and subsequent sample times. Men and women combined showed no significant differences save for an improved total antioxidant capacity at 6 wk (P = 0.01). Hence, no benefit from GO after 11 wk is one plausible conclusion. However, there were significant differences in effect of GO between men and women for HDL cholesterol (HDL-C) (P = 0.004) and total cholesterol (TC)/HDL-C (P = 0.003), Women showed favorable effects in terms of CHD risk factors (i.e., increases in HDL-C and reductions in TC/HDL-C), whereas men had small adverse effects. There was a significant difference in the GO effect for glucose (P = 0.006), with a reduction seen for men and an increase for women. The gender effects were unexpected and such analyses were not planned in advance. Confirmation of these findings with larger numbers of subjects would have importance for the use of garlic against CHD and for the design of future garlic studies.
C1 Wolverhampton Univ, Sch Hlth Sci, Div Biomed Sci & Human Biol, Wolverhampton WV1 1DJ, England.
   Wolverhampton Univ, Sch Appl Sci, Wolverhampton WV1 1SB, England.
   Manor Hosp, Walsall NHS Trust, Dept Biochem, Walsall WS2 9PS, W Midlands, England.
   Astraglobe Ltd, Mossley, Cheshire, England.
RP Maslin, DJ (corresponding author), Wolverhampton Univ, Sch Hlth Sci, Div Biomed Sci & Human Biol, Wolverhampton WV1 1DJ, England.
EM D.Maslin@wlv.ac.uk
CR Adler AJ, 1997, AM J CLIN NUTR, V65, P445
   ALBEKAIRI AM, 1990, J ETHNOPHARMACOL, V29, P117, DOI 10.1016/0378-8741(90)90049-Y
   Augusti K. T., 1996, Indian Journal of Experimental Biology, V34, P634
   AUSTIN MA, 1990, CIRCULATION, V82, P495, DOI 10.1161/01.CIR.82.2.495
   BARRIE SA, 1987, J ORTHOMOL MED, V2, P15
   Beaglehole R, 1996, LANCET, V348, P1186, DOI 10.1016/S0140-6736(05)65477-3
   Berthold HK, 1998, JAMA-J AM MED ASSOC, V279, P1900, DOI 10.1001/jama.279.23.1900
   BIMMERMANN A, 1988, THERAPIEWOCHE, V38, P3885
   Bjornholt JV, 1999, DIABETES CARE, V22, P45, DOI 10.2337/diacare.22.1.45
   BORDIA A, 1981, AM J CLIN NUTR, V34, P2100
   BREWITT B, 1991, PATIENTEN KASSENARZT, V5, P47
   BRINDLE NPJ, 1988, BIOCHEM J, V250, P363, DOI 10.1042/bj2500363
   *BUND GERM HLTH DE, 1988, K E MON BGA BERL GER
   Byrne DJ, 1999, CLIN CHIM ACTA, V285, P21, DOI 10.1016/S0009-8981(99)00063-7
   Castelli WP, 1996, ATHEROSCLEROSIS, V124, pS1, DOI 10.1016/0021-9150(96)05851-0
   CHANG MLW, 1980, J NUTR, V110, P931
   CLIFTON PM, 1994, ATHEROSCLEROSIS, V110, P25, DOI 10.1016/0021-9150(94)90064-7
   Devaki T., 1992, Medical Science Research, V20, P725
   FALKNER B, 1994, AM J HYPERTENS, V7, P948, DOI 10.1093/ajh/7.11.948
   Gardner CD, 2001, ATHEROSCLEROSIS, V154, P213, DOI 10.1016/S0021-9150(00)00466-4
   GEBHARDT R, 1993, LIPIDS, V28, P613, DOI 10.1007/BF02536055
   Gebhardt R, 1995, PHYTOMEDICINE, V2, P29, DOI 10.1016/S0944-7113(11)80045-0
   GEBHARDT R, 2000, AHPA INT GARL S 2000
   GLASER ERHARD, 1939, ARCH EXP PATH U PHARMAKOL, V193, P1
   HAGVE TA, 1988, SCAND J CLIN LAB INV, V48, P33
   Hokanson J E, 1996, J Cardiovasc Risk, V3, P213, DOI 10.1097/00043798-199604000-00014
   Isaacsohn JL, 1998, ARCH INTERN MED, V158, P1189, DOI 10.1001/archinte.158.11.1189
   Johnston CS, 1998, J AM COLL HEALTH, V46, P209, DOI 10.1080/07448489809600224
   KANNAR D, 2001, IN PRESS J AM COLL N
   Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1
   KIESEWETTER H, 1991, INT J CLIN PHARM TH, V29, P151
   KLEIJNEN J, 1989, BRIT J CLIN PHARMACO, V28, P535, DOI 10.1111/j.1365-2125.1989.tb03539.x
   Lash JP, 1998, TRANSPLANT P, V30, P189, DOI 10.1016/S0041-1345(97)01227-X
   LAU BHS, 1987, NUTR RES, V7, P139, DOI 10.1016/S0271-5317(87)80026-X
   Lawson L, 1996, GARLIC SCI THERAPEUT, P37
   LAWSON LD, 1991, PLANTA MED, V57, P363, DOI 10.1055/s-2006-960119
   Lawson LD, 2001, PLANTA MED, V67, P13, DOI 10.1055/s-2001-10624
   LAWSON LD, 1998, Q REV NAT MED    FAL, P187
   LAWSON LD, 1998, Q REV NAT MED    FAL, P185
   LAWSON LD, 1998, PHYTOMEDICINES EUROP, P176
   LEITERSDORF E, 1994, DRUGS, V47, P54, DOI 10.2165/00003495-199400472-00010
   Lonnqvist F, 1997, ARTERIOSCL THROM VAS, V17, P1472, DOI 10.1161/01.ATV.17.7.1472
   LULEY C, 1986, ARZNEIMITTEL-FORSCH, V36-1, P766
   Luxon BA, 1998, AM J PHYSIOL-GASTR L, V274, pG52
   MACKNESS MI, 1992, LIPOPROTEIN ANAL PRA, P1
   MAHLER P, 1924, MED KLIN, V11, P335
   McCrindle BW, 1998, ARCH PEDIAT ADOL MED, V152, P1089
   Neil HAW, 1996, J ROY COLL PHYS LOND, V30, P329
   NITIYANANT W, 1987, Journal of the Medical Association of Thailand, V70, P646
   OI Y, 1995, J NUTR BIOCHEM, V6, P250, DOI 10.1016/0955-2863(95)00025-U
   PEDERSEN TR, 1994, LANCET, V344, P1383
   PENTZ R, 1996, GARLIC SCI THERAPEUT, P109
   PHELPS S, 1993, LIPIDS, V28, P475, DOI 10.1007/BF02535949
   PLENGVIDHYA C, 1988, Journal of the Medical Association of Thailand, V71, P248
   Pocock SJ., 1983, CLIN TRIALS PRACTICA
   PUSHPENDRAN CK, 1982, INDIAN J EXP BIOL, V20, P428
   Rabinkov A, 1998, BBA-GEN SUBJECTS, V1379, P233, DOI 10.1016/S0304-4165(97)00104-9
   Reuter HD, 1996, GARLIC SCI THERAPEUT, P135
   Rosengren A, 1998, BMJ-BRIT MED J, V317, P425
   Saradeth T, 1994, Phytomedicine, V1, P183, DOI 10.1016/S0944-7113(11)80062-0
   Schiewe FP, 1995, Z PHYTOTHER, V16, P343
   SHEELA C G, 1992, Indian Journal of Experimental Biology, V30, P523
   SILAGY CA, 1994, J ROY COLL PHYS LOND, V28, P39
   SIMONS LA, 1995, ATHEROSCLEROSIS, V113, P219, DOI 10.1016/0021-9150(94)05449-S
   STARK B, 1987, EXPERIENTIA, V43, P1104, DOI 10.1007/BF01956049
   STEINBERG D, 1995, LANCET, V346, P36, DOI 10.1016/S0140-6736(95)92657-7
   Steiner M, 1996, AM J CLIN NUTR, V64, P866
   Stevinson C, 2000, ANN INTERN MED, V133, P420, DOI 10.7326/0003-4819-133-6-200009190-00009
   Superko HR, 2000, J AM COLL CARDIOL, V35, P321, DOI 10.1016/S0735-1097(99)90541-7
   Taucher J, 1996, J AGR FOOD CHEM, V44, P3778, DOI 10.1021/jf960640e
   Venmadhi S., 1992, Medical Science Research, V20, P729
   WAHRENBERG H, 1991, EUR J CLIN INVEST, V21, P534, DOI 10.1111/j.1365-2362.1991.tb01406.x
   WARSHAFSKY S, 1993, ANN INTERN MED, V119, P599, DOI 10.7326/0003-4819-119-7_Part_1-199310010-00009
   WHITEHEAD TP, 1992, ANAL CHIM ACTA, V266, P265, DOI 10.1016/0003-2670(92)85052-8
   Woodford FP, 1998, ANN CLIN BIOCHEM, V35, P48, DOI 10.1177/000456329803500105
   Zhang XH, 2001, BLOOD COAGUL FIBRIN, V12, P67, DOI 10.1097/00001721-200101000-00010
NR 76
TC 55
Z9 58
U1 0
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0022-3166
EI 1541-6100
J9 J NUTR
JI J. Nutr.
PD MAY
PY 2001
VL 131
IS 5
BP 1471
EP 1478
PG 8
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 432BH
UT WOS:000168666400014
PM 11340102
DA 2021-08-04
ER

PT J
AU Russell, RJ
   Axel, AC
   Shields, KL
   Pishko, MV
AF Russell, RJ
   Axel, AC
   Shields, KL
   Pishko, MV
TI Mass transfer in rapidly photopolymerized poly(ethylene glycol)
   hydrogels used for chemical sensing
SO POLYMER
LA English
DT Article
DE poly(ethylene glycol); microspheres; penetrant diffusion
ID CROSS-LINKED COPOLYMERS; DIFFUSION-COEFFICIENTS; POLYMER HYDROGELS;
   NETWORK STRUCTURE; MOLECULAR-WEIGHT; DRUG-RELEASE; DIMETHACRYLATE; GELS;
   BIOCOMPATIBILITY; PERMEABILITY
AB Mass transfer in rapidly photopoIymerized hydrogel networks of poly(ethylene glycol) (PEG) was investigated to characterize these materials for potential biosensor applications. The rapid polymerization from a concentrated polymer precursor solution results in a tightly cross-linked hydrogel network that potentially contains microgels, all conditions that can hinder analyte mass transfer. We examined the mass transfer characteristics of microspheres fabricated from diacrylated PEG (MW 575), dimethacrylated PEG (MW 1000), or tetra-acrylated PEG (MW 18,500) mixed with trimethylolpropane triacrylate, a triacrylated cross-linking agent, whose concentration ranged up to 20% (v/v). Swelling behavior was dynamically characterized starting from a dehydrated state using a CCD-camera integrated with an inverted microscope. Hydrogel swelling was extremely rapid with gel front diffusivities on the order of 10(-6) cm(2)/s. Estimated hydrogel mesh sizes ranged from 8.6 to 13.7 (A) over dot for spheres fabricated using PEG with molecular weights between 575 and 1000, to 103 (A) over dot for spheres fabricated using PEG with a molecular weight of 18,500. Dynamic uptake of tetramethylrhodamine was followed using a fluorescence microscope to estimate small analyte diffusivities into the hydrogel networks. Tetramethylrhodamine diffusivities were on the order of 10(-7)10(-9) cm(2)/s. Experimental diffusivities were used to simulate mass transfer into the gel and thus the potential response time of biosensors based on these systems. (C) 2001 EIsevier Science Ltd. All rights reserved.
C1 Texas A&M Univ, Dept Chem Engn, College Stn, TX 77843 USA.
RP Pishko, MV (corresponding author), Texas A&M Univ, Dept Chem Engn, College Stn, TX 77843 USA.
CR Amsden B, 1999, MACROMOLECULES, V32, P874, DOI 10.1021/ma980922a
   Barnes MD, 1999, CYTOMETRY, V36, P169, DOI 10.1002/(SICI)1097-0320(19990701)36:3<169::AID-CYTO4>3.0.CO;2-I
   BRINKLEY M, 1992, BIOCONJUGATE CHEM, V3, P2, DOI 10.1021/bc00013a001
   Crank J., 1975, MATH DIFFUSION
   Cruise GM, 1998, BIOMATERIALS, V19, P1287, DOI 10.1016/S0142-9612(98)00025-8
   DELGADO C, 1992, CRIT REV THER DRUG, V9, P249
   DESAI NP, 1991, J BIOMED MATER RES, V25, P829, DOI 10.1002/jbm.820250704
   DRUMHELLER PD, 1995, J BIOMED MATER RES, V29, P207, DOI 10.1002/jbm.820290211
   Elliott JE, 1999, MACROMOLECULES, V32, P8621, DOI 10.1021/ma990797i
   Flory P.J, 1953, PRINCIPLES POLYM CHE
   Gayet JC, 1996, J CONTROL RELEASE, V38, P177, DOI 10.1016/0168-3659(95)00118-2
   Ghosh P, 1999, ANGEW CHEM INT EDIT, V38, P1592, DOI 10.1002/(SICI)1521-3773(19990601)38:11<1592::AID-ANIE1592>3.0.CO;2-I
   Goodner MD, 1999, MACROMOLECULES, V32, P6552, DOI 10.1021/ma9901947
   Hamalainen KM, 1997, J CONTROL RELEASE, V49, P97
   Hansen RL, 1998, ANAL CHEM, V70, P1281, DOI 10.1021/ac9709918
   Hassan CM, 1997, MACROMOLECULES, V30, P6166, DOI 10.1021/ma970117g
   HILLWEST JL, 1994, P NATL ACAD SCI USA, V91, P5967, DOI 10.1073/pnas.91.13.5967
   Hong SS, 1998, J CONTROL RELEASE, V51, P185, DOI 10.1016/S0168-3659(97)00167-3
   Jeong B, 2000, J CONTROL RELEASE, V63, P155, DOI 10.1016/S0168-3659(99)00194-7
   Kannurpatti AR, 1998, MACROMOLECULES, V31, P3311, DOI 10.1021/ma970721r
   Kato E, 1998, POLYM GELS NETW, V6, P179, DOI 10.1016/S0966-7822(98)00010-0
   Keys KB, 1998, MACROMOLECULES, V31, P8149, DOI 10.1021/ma980999z
   Kofinas P, 1996, BIOMATERIALS, V17, P1547, DOI 10.1016/0142-9612(96)89781-X
   Kumar A, 1998, FUNDAMENTALS POLYM
   LANDIN DT, 1988, MACROMOLECULES, V21, P846, DOI 10.1021/ma00181a048
   LONGSWORTH LG, 1952, J AM CHEM SOC, V74, P4155, DOI 10.1021/ja01136a059
   MCDANIELS B, 1999, THESIS TEXAS A M U
   MELLOTT MB, 2001, IN PRESS BIOMATERIAL
   NGUYEN AL, 1986, BIOTECHNOL BIOENG, V28, P1261, DOI 10.1002/bit.260280819
   PATHAK CP, 1992, J AM CHEM SOC, V114, P8311, DOI 10.1021/ja00047a065
   QUINN CP, 1995, BIOMATERIALS, V16, P389, DOI 10.1016/0142-9612(95)98856-9
   REINHART CT, 1984, J MEMBRANE SCI, V18, P227, DOI 10.1016/S0376-7388(00)85036-X
   REVZIN A, 2000, T 6 WORD BIOM C, V1, P232
   RITGER PL, 1987, FUEL, V66, P815, DOI 10.1016/0016-2361(87)90130-X
   Russell RJ, 1999, ANAL CHEM, V71, P4909, DOI 10.1021/ac990901u
   Russell RJ, 1999, ANAL CHEM, V71, P3126, DOI 10.1021/ac990060r
   SAWHNEY AS, 1993, BIOMATERIALS, V14, P1008, DOI 10.1016/0142-9612(93)90194-7
   SAWHNEY AS, 1994, J BIOMED MATER RES, V28, P831, DOI 10.1002/jbm.820280710
   Scott RA, 1999, BIOMATERIALS, V20, P1371, DOI 10.1016/S0142-9612(99)00040-X
   Scott RA, 1999, MACROMOLECULES, V32, P6139, DOI 10.1021/ma980612s
   Sirkar K, 1998, ANAL CHEM, V70, P2888, DOI 10.1021/ac971236x
   Stringer JL, 1996, J CONTROL RELEASE, V42, P195, DOI 10.1016/0168-3659(96)01457-5
   TOBITA H, 1989, MACROMOLECULES, V22, P3098, DOI 10.1021/ma00197a034
   WEST JL, 1995, REACT POLYM, V25, P139, DOI 10.1016/0923-1137(94)00096-N
   WESTRIN BA, 1994, J CONTROL RELEASE, V30, P189, DOI 10.1016/0168-3659(94)90025-6
NR 45
TC 87
Z9 89
U1 0
U2 34
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0032-3861
J9 POLYMER
JI Polymer
PD MAY
PY 2001
VL 42
IS 11
BP 4893
EP 4901
DI 10.1016/S0032-3861(00)00851-X
PG 9
WC Polymer Science
SC Polymer Science
GA 409KD
UT WOS:000167382100014
DA 2021-08-04
ER

PT J
AU Morris, KF
   Shannon, R
   Lindsey, BG
AF Morris, KF
   Shannon, R
   Lindsey, BG
TI Changes in cat medullary neurone firing rates and synchrony following
   induction of respiratory long-term facilitation
SO JOURNAL OF PHYSIOLOGY-LONDON
LA English
DT Article
ID PHRENIC MOTOR OUTPUT; SYNAPTIC CONNECTIONS; INSPIRATORY NEURONS;
   MEMBRANE-PROPERTIES; CROSS-CORRELATION; RAPHE NEURONS; SEROTONIN;
   MODULATION; HYPOXIA; MOTONEURONS
AB 1. Long-term facilitation is a respiratory memory expressed as an increase in motor output lasting more than an hour. This change is induced by repeated hypoxia, stimulation of carotid chemoreceptors, or electrical stimulation of the carotid sinus nerve or brainstem mid-line. The present work addressed the hypothesis that persistent changes in medullary respiratory neural networks contribute to long-term facilitation.
   2. Carotid chemoreceptors were stimulated by close arterial injection of CO2-saturated saline solution. Phrenic nerve efferent activity and up to 30 single medullary neurones were recorded simultaneously in nucleus tractus solitarii (NTS) including the dorsal respiratory group (DRG), Botzinger-ventral respiratory group (Bot-VRG), and nucleus raphe obscurus of nine adult cats, anaesthetized, injected with a neuromuscular blocking agent, vagotomized and artificially ventilated.
   3. The firing rates of 87 of 105 neurones (83%) changed following induction of long-term facilitation. Nine of eleven DRG and Bot-VRG putative premotor inspiratory neurones had increased firing rates with long-term facilitation. Fourteen of twenty-one raphe obscurus neurones with control firing rates less than 4 Hz had significant long-term increases in activity.
   4. Cross-correlogram analysis suggested that there were changes in effective connectivity of neuron pairs with long-term facilitation. Joint peristimulus time histograms and pattern detection methods used with 'gravity' analysis also detected changes in short time scale correlations associated with long-term facilitation.
   5. The results suggest that changes in firing rates and synchrony of VRG and DRG premotor neurones and altered effective connectivity among other functionally antecedent elements of the medullary respiratory network contribute to the expression of long-term facilitation.
C1 Univ S Florida, Ctr Hlth Sci, Dept Physiol & Biophys, Tampa, FL 33612 USA.
   Univ S Florida, Ctr Hlth Sci, Program Neurosci, Tampa, FL 33612 USA.
RP Morris, KF (corresponding author), Univ S Florida, Ctr Hlth Sci, Dept Physiol & Biophys, Tampa, FL 33612 USA.
EM kmorris@hsc.usf.edu
RI Morris, Kendall F/J-9859-2012
FU NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS)
   [R01NS019814, R37NS019814] Funding Source: NIH RePORTER; NINDS NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Neurological
   Disorders & Stroke (NINDS) [R01 NS019814, NS19814, R37 NS019814] Funding
   Source: Medline
CR AERTSEN AMHJ, 1985, BRAIN RES, V340, P341, DOI 10.1016/0006-8993(85)90931-X
   AERTSEN AMHJ, 1989, J NEUROPHYSIOL, V61, P900
   Bach KB, 1996, RESP PHYSIOL, V104, P251, DOI 10.1016/0034-5687(96)00017-5
   Baker TL, 2000, J PHYSIOL-LONDON, V529, P215, DOI 10.1111/j.1469-7793.2000.00215.x
   Beaumont V, 2000, NAT NEUROSCI, V3, P133, DOI 10.1038/72072
   BERGER AJ, 1992, NEUROSCI LETT, V143, P164, DOI 10.1016/0304-3940(92)90257-8
   BIANCHI AL, 1995, PHYSIOL REV, V75, P1, DOI 10.1152/physrev.1995.75.1.1
   COHEN MI, 1974, BRAIN RES, V81, P319, DOI 10.1016/0006-8993(74)90946-9
   CONNELLY CA, 1989, NEUROSCI LETT, V105, P34, DOI 10.1016/0304-3940(89)90007-4
   DAVIES JGM, 1985, J PHYSIOL-LONDON, V368, P63, DOI 10.1113/jphysiol.1985.sp015846
   Dwinell MR, 1997, RESP PHYSIOL, V108, P1, DOI 10.1016/S0034-5687(96)02522-4
   Fuller DD, 2000, RESP PHYSIOL, V121, P135, DOI 10.1016/S0034-5687(00)00124-9
   FULLER DD, 2000, SOC NEUR ABSTR, V26, P556
   GERSTEIN GL, 1985, J NEUROSCI, V5, P881
   GERSTEIN GL, 1985, J NEUROPHYSIOL, V54, P1513
   Gozal D, 1999, AM J PHYSIOL-REG I, V276, pR17
   Gozal D, 1999, NEUROSCI LETT, V262, P93, DOI 10.1016/S0304-3940(99)00065-8
   HAYASHI F, 1993, AM J PHYSIOL, V265, pR811
   HOLTMAN JR, 1986, J NEUROSCI, V6, P1185
   JACOBS BL, 1992, PHYSIOL REV, V72, P165
   KORTEN JB, 1989, COMPUT BIOL MED, V19, P207, DOI 10.1016/0010-4825(89)90009-7
   LINDSAY AD, 1993, J PHYSIOL-LONDON, V461, P213, DOI 10.1113/jphysiol.1993.sp019510
   Lindsey BG, 1998, J PHYSIOL-LONDON, V512, P863, DOI 10.1111/j.1469-7793.1998.863bd.x
   Lindsey BG, 1997, J NEUROPHYSIOL, V78, P1714
   LINDSEY BG, 1992, J NEUROPHYSIOL, V67, P905
   Lu YF, 1999, J NEUROSCI, V19, P10250
   Mason P, 1997, J NEUROPHYSIOL, V77, P1087
   Michael D, 1998, P NATL ACAD SCI USA, V95, P1864, DOI 10.1073/pnas.95.4.1864
   MILLHORN DE, 1980, RESP PHYSIOL, V42, P171, DOI 10.1016/0034-5687(80)90113-9
   MITCHELL GS, 1992, NEUROSCI LETT, V141, P75, DOI 10.1016/0304-3940(92)90338-8
   MONTEAU R, 1990, NEUROSCI LETT, V111, P127, DOI 10.1016/0304-3940(90)90356-E
   Morris KF, 1996, J PHYSIOL-LONDON, V491, P241, DOI 10.1113/jphysiol.1996.sp021212
   Morris KF, 1996, J PHYSIOL-LONDON, V490, P463, DOI 10.1113/jphysiol.1996.sp021158
   MORRIS KF, 1993, SOC NEUROSCIENCE ABS, V19
   MORRIS KF, 1996, PHYSIOLOGIST, V39, P186
   MORRISON SF, 1984, AM J PHYSIOL, V246, pR338
   OREM J, 1983, J NEUROPHYSIOL, V50, P1098
   PALKOVIT.M, 1974, BRAIN RES, V80, P237, DOI 10.1016/0006-8993(74)90688-X
   PERKEL DH, 1967, BIOPHYS J, V7, P419, DOI 10.1016/S0006-3495(67)86597-4
   Powell FL, 1998, RESP PHYSIOL, V112, P123, DOI 10.1016/S0034-5687(98)00026-7
   Rekling JC, 1998, ANNU REV PHYSIOL, V60, P385, DOI 10.1146/annurev.physiol.60.1.385
   Richter DW, 1999, J PHYSIOL-LONDON, V514, P567, DOI 10.1111/j.1469-7793.1999.567ae.x
   SEGERS LS, 1987, J NEUROPHYSIOL, V57, P1078
   SMITH JC, 1989, J COMP NEUROL, V281, P69, DOI 10.1002/cne.902810107
   Solomon IC, 2000, J NEUROPHYSIOL, V83, P2854
   Turner DL, 1997, J PHYSIOL-LONDON, V499, P543, DOI 10.1113/jphysiol.1997.sp021947
   VILLANI F, 1993, BRAIN RES, V606, P304, DOI 10.1016/0006-8993(93)90998-3
   WALLEN P, 1989, J NEUROPHYSIOL, V61, P759
   Woch G, 1996, J PHYSIOL-LONDON, V490, P745, DOI 10.1113/jphysiol.1996.sp021182
NR 49
TC 44
Z9 44
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3751
EI 1469-7793
J9 J PHYSIOL-LONDON
JI J. Physiol.-London
PD APR 15
PY 2001
VL 532
IS 2
BP 483
EP 497
DI 10.1111/j.1469-7793.2001.0483f.x
PG 15
WC Neurosciences; Physiology
SC Neurosciences & Neurology; Physiology
GA 425UK
UT WOS:000168309900020
PM 11306666
OA Green Published
DA 2021-08-04
ER

PT J
AU Le Bars, D
   Gozariu, M
   Cadden, SW
AF Le Bars, D
   Gozariu, M
   Cadden, SW
TI Evaluating acute pain in experimental animals. First part.
SO ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION
LA French
DT Review
DE acute pain; animal models; nociception; pain; phasic pain; tests; tonic
   pain
ID C-FIBER REFLEX; NOXIOUS VISCERAL STIMULUS; TOOTH-PULP STIMULATION;
   TAIL-IMMERSION TEST; HOT-PLATE TEST; FORMALIN TEST; COLORECTAL
   DISTENSION; BEHAVIORAL CHARACTERIZATION; SUBCUTANEOUS FORMALIN;
   NOCICEPTIVE RESPONSES
AB Objective: To describe tests of nociception which appear in the "pre-clinical" literature.
   Data sources: References obtained by computerized bibliographic research (Medline (R)) and the authors' personal data.
   Data synthesis: Ethical problems arising from the study of the pain in awake animals, problems arising from the choice of stimulus and stimulus parameters and the quantification of responses are presented. Pain in animals can be estimated only by examining their reactions, but at the same time, the existence of a reaction does not necessarily mean that there is a concomitant sensation. A description of the signs of pain in mammals is proposed. A noxious stimulus can be defined by its physical nature, its site of application and what has previously happened to the tissues at this site. Electrical stimulation short-circuits the process of transduction at free nerve endings and is not specific; however it has the advantage that it can be applied suddenly and briefly and thus results in synchronised signals in the relevant primary afferent fibres which can be differentiated into A delta and C fibres. Heat selectively stimulates thermoreceptors and nociceptors, but the low calorific power of conventional stimulators restricts their usefulness. Radiant sources have the disadvantage of emitting waves in the visible and the adjacent infrared spectra, for which the skin is a poor absorber and good reflector. Thermodes have the disadvantage of activating mechanoreceptors and thermoreceptors simultaneously; furthermore, their capacity for transferring heat depends on the quality of contact with skin and thus on the pressure with which they are applied. These problems can be overcome by using CO, lasers but even today, the cost of these is a major disadvantage. Chemical stimuli differ from those mentioned above by the progressive onset of their effectiveness, their duration of action and the fact that they are of an inescapable nature. Experimental models employing chemical stimuli are undoubtedly the most similar to acute clinical pain. A wide spectrum of reactions are observed in nociceptive tests, but in almost every case they involve motor responses. After defining the ideal characteristics of a nociceptive test, tests based on the use of short duration and longer duration stimuli are presented. In tests of phasic pain, reactions are evoked by thermal (tail-flick test, hot-plate test), mechanical or electrical (flinch-jump test, vocalisation test) stimuli. Tests of tonic pain employ injections of algogenic agents intradermally (formalin test) or intraperitoneally (writhing test) or even the dilation of hollow organs. All these tests will be critically appraised in a subsequent paper [1].
   Conclusion: The tail-flick and hot-plate tests are the most used, but there is an increasing recourse to the formalin test and tests involving foot withdrawal after mechanical stimulation. (C) 2001 Editions scientifiques et medicales Elsevier SAS.
C1 INSERM, U161, F-75014 Paris, France.
RP Le Bars, D (corresponding author), INSERM, U161, 2 Rue Alesia, F-75014 Paris, France.
EM lebars@broca.inserm.fr
CR ANKIER SI, 1974, EUR J PHARMACOL, V27, P1, DOI 10.1016/0014-2999(74)90195-2
   ARCHER S, 1965, PROGR DRUG RES, V8, P261
   ARDID D, 1993, NEUROREPORT, V5, P105, DOI 10.1097/00001756-199311180-00002
   BARDO MT, 1979, PHARMACOL BIOCHEM BE, V10, P481, DOI 10.1016/0091-3057(79)90221-1
   BATESON P, 1991, ANIM BEHAV, V42, P827, DOI 10.1016/S0003-3472(05)80127-7
   BAUMANS V, 1994, LAB ANIM-UK, V28, P97, DOI 10.1258/002367794780745308
   BEECHER HK, 1957, PHARMACOL REV, V9, P59
   BENBASSAT J, 1959, ARCH INT PHARMACOD T, V122, P434
   BISHOP MA, 1981, AM J ANAT, V160, P213, DOI 10.1002/aja.1001600207
   BORSZCZ GS, 1995, BEHAV NEUROSCI, V109, P648, DOI 10.1037/0735-7044.109.4.648
   BORSZCZ GS, 1995, BEHAV NEUROSCI, V109, P502, DOI 10.1037/0735-7044.109.3.502
   BOUHASSIRA D, 1995, PAIN, V62, P195, DOI 10.1016/0304-3959(94)00270-O
   BRAGARD D, 1998, 28 ANN M SOC NEUR, P831
   BRASCH H, 1982, N-S ARCH PHARMACOL, V319, P161, DOI 10.1007/BF00503931
   Brennan TJ, 1996, PAIN, V64, P493, DOI 10.1016/0304-3959(95)01441-1
   BUETTNER K, 1951, J APPL PHYSIOL, V3, P703
   BURTON MB, 1995, BRAIN RES, V672, P77, DOI 10.1016/0006-8993(94)01382-R
   CADDEN SW, 1985, BRAIN RES, V336, P33, DOI 10.1016/0006-8993(85)90413-5
   CARMON A, 1981, LIFE SCI, V29, P11, DOI 10.1016/0024-3205(81)90109-0
   CARROLL MN, 1960, ARCH INT PHARMACOD T, V125, P383
   CARSTENS E, 1993, J NEUROPHYSIOL, V70, P630
   CARTER GM, 1989, ELECTROMYOGRAPHY JAW, P205
   CASEY KL, 1989, ISSUES PAIN MEASUREM, V12, P159
   CERVERO F, 1994, PHYSIOL REV, V74, P95
   Charpentier J., 1968, PAIN, P171
   CHERNOV HI, 1967, ARCH INT PHARMACOD T, V167, P171
   CLARK SJ, 1985, N-S ARCH PHARMACOL, V330, P179, DOI 10.1007/BF00572431
   CLARKE RW, 1987, BRIT J PHARMACOL, V91, P579, DOI 10.1111/j.1476-5381.1987.tb11251.x
   CLAVELOU P, 1995, PAIN, V62, P295, DOI 10.1016/0304-3959(94)00273-H
   CLAVELOU P, 1989, NEUROSCI LETT, V103, P349, DOI 10.1016/0304-3940(89)90125-0
   CODERRE TJ, 1993, PAIN, V54, P43, DOI 10.1016/0304-3959(93)90098-A
   COLBURN RW, 1989, PHYSIOL BEHAV, V45, P191, DOI 10.1016/0031-9384(89)90184-4
   Conte B, 1996, J PHARMACOL EXP THER, V276, P212
   COOPER BY, 1986, PAIN, V26, P393, DOI 10.1016/0304-3959(86)90065-5
   Coutinho SV, 1996, BRAIN RES, V736, P7, DOI 10.1016/0006-8993(96)00661-0
   Covino B.G., 1980, PAIN, V9, P141, DOI [10.1016/0304-3959(80)90002-0, DOI 10.1016/0304-3959(80)90002-0]
   CRAFT RM, 1993, PAIN, V55, P205, DOI 10.1016/0304-3959(93)90149-J
   D'amour FE, 1941, J PHARMACOL EXP THER, V72, P74
   DALLEL R, 1995, PAIN, V61, P11, DOI 10.1016/0304-3959(94)00212-W
   DANNEMAN PJ, 1994, PAIN, V58, P39, DOI 10.1016/0304-3959(94)90183-X
   Dennis S.G., 1983, P151
   Dirig DM, 1997, J NEUROSCI METH, V76, P183, DOI 10.1016/S0165-0270(97)00097-6
   DUBUISSON D, 1977, PAIN, V4, P161, DOI 10.1016/0304-3959(77)90130-0
   DUYSENS J, 1988, J NEUROSCI METH, V24, P73, DOI 10.1016/0165-0270(88)90035-0
   ESCHALIER A, 1988, J PHARMACOL METHOD, V19, P175, DOI 10.1016/0160-5402(88)90038-1
   ESPEJO EF, 1993, BEHAV BRAIN RES, V56, P171, DOI 10.1016/0166-4328(93)90035-O
   EVANS WO, 1961, PSYCHOPHARMACOLOGIA, V2, P318, DOI 10.1007/BF00404119
   FALINOWER S, 1994, J NEUROPHYSIOL, V72, P194
   FAN RJ, 1995, PHYSIOL BEHAV, V57, P1131, DOI 10.1016/0031-9384(94)00372-C
   GALBRAITH JA, 1993, J NEUROSCI METH, V49, P63, DOI 10.1016/0165-0270(93)90109-5
   GAMBLE GD, 1989, NEUROSCI LETT, V96, P312, DOI 10.1016/0304-3940(89)90397-2
   GIAMBERARDINO MA, 1990, PAIN, V43, P227, DOI 10.1016/0304-3959(90)91076-U
   GIAMBERARDINO MA, 1995, PAIN, V61, P459, DOI 10.1016/0304-3959(94)00208-V
   Gozariu M, 1997, J NEUROPHYSIOL, V78, P3165
   GREEN AF, 1951, BRIT J PHARM CHEMOTH, V6, P572, DOI 10.1111/j.1476-5381.1951.tb00668.x
   Grumbach L., 1966, PAIN, P163, DOI 10.1016/S0304-3959(00)00348-1
   GUIRIMAND F, 1994, J PHARMACOL EXP THER, V269, P1007
   HA H, 1978, EXP NEUROL, V61, P260, DOI 10.1016/0014-4886(78)90245-5
   HAMMOND DL, 1989, ADV PAIN RES THER, V12, P69
   HANDWERKER HO, 1993, PHYSIOL REV, V73, P639
   HANNAM AG, 1969, ARCH ORAL BIOL, V14, P415, DOI 10.1016/0003-9969(69)90096-X
   HANWERKER HO, 1987, DEUTSCHSPRACHIGE KLA, P288
   HARADA Y, 1995, ANESTHESIOLOGY, V83, P336, DOI 10.1097/00000542-199508000-00014
   Hardy J. D., 1952, PAIN SENSATION REACT
   HARDY JD, 1953, J APPL PHYSIOL, V5, P725
   HARDY JD, 1957, AM J PHYSIOL, V189, P1
   HARDY JD, 1965, J APPL PHYSIOL, V20, P1014
   HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7
   HOUGHTON KJ, 1991, P SOC EXP BIOL MED, V197, P290
   HUNSKAAR S, 1986, BEHAV BRAIN RES, V21, P101, DOI 10.1016/0166-4328(86)90088-4
   HUNSKAAR S, 1987, PAIN, V30, P103, DOI 10.1016/0304-3959(87)90088-1
   IRWIN S, 1951, J PHARMACOL EXP THER, V101, P132
   JENSEN FM, 1992, ACTA ANAESTH SCAND, V36, P837, DOI 10.1111/j.1399-6576.1992.tb03574.x
   Jett MF, 1996, PAIN, V64, P19, DOI 10.1016/0304-3959(95)00098-4
   JIFFRY MTM, 1981, EXP NEUROL, V73, P209, DOI 10.1016/0014-4886(81)90056-X
   Jourdan D, 1997, PAIN, V71, P265, DOI 10.1016/S0304-3959(97)03366-6
   JOURDAN D, 1995, PAIN, V63, P237, DOI 10.1016/0304-3959(95)00049-X
   KAYSER V, 1987, PAIN, V28, P99, DOI 10.1016/0304-3959(87)91064-5
   Kelemen K., 1955, ACTA PHYSL HUNG, V8, P327
   LAI YY, 1982, PHYSIOL BEHAV, V28, P1111, DOI 10.1016/0031-9384(82)90184-6
   LANGLOIS A, 1994, EUR J PHARMACOL, V271, P245, DOI 10.1016/0014-2999(94)90780-3
   LEBARS D, 2001, IN PRESS ANN FR ANES, V20
   LEMBECK F, 1982, N-S ARCH PHARMACOL, V321, P116, DOI 10.1007/BF00518478
   LEVINE JD, 1980, BRAIN RES, V201, P129, DOI 10.1016/0006-8993(80)90780-5
   LINEBERRY CG, 1981, METHODS ANIMAL EXPT, V6, P237
   LOUX JJ, 1978, ARZNEIMITTEL-FORSCH, V28-2, P1644
   LUTTINGER D, 1985, J PHARMACOL METHOD, V13, P351, DOI 10.1016/0160-5402(85)90017-8
   MALMBERG AB, 1992, J PHARMACOL EXP THER, V263, P136
   MARTIN WR, 1964, J PHARMACOL EXP THER, V144, P8
   McCall WD, 1996, NEUROSCI LETT, V208, P45, DOI 10.1016/0304-3940(96)12552-0
   McCLANE T. K., 1967, INT J NEURO PHARMACOL, V6, P89
   MCMAHON SB, 1995, BRIT J ANAESTH, V75, P132, DOI 10.1093/bja/75.2.132
   MCMAHON SB, 1987, PAIN, V28, P109, DOI 10.1016/0304-3959(87)91065-7
   MERSKEY H, 1979, PAIN, V7, P271, DOI 10.1016/0304-3959(79)90084-8
   MIAMPAMBA M, 1994, PAIN, V57, P327, DOI 10.1016/0304-3959(94)90008-6
   MICHAELTITUS A, 1988, ACTUAL CHIM THER, V15, P311
   MILLER LC, 1948, ANN NY ACAD SCI, V51, P34, DOI 10.1111/j.1749-6632.1948.tb27249.x
   MITCHELL CL, 1964, J PHARMACOL EXP THER, V146, P1
   MORTEAU O, 1994, FUND CLIN PHARMACOL, V8, P553, DOI 10.1111/j.1472-8206.1994.tb00837.x
   MORTON DB, 1985, VET REC, V116, P431, DOI 10.1136/vr.116.16.431
   MOSS HE, 1990, BRIT J PHARMACOL, V100, P497, DOI 10.1111/j.1476-5381.1990.tb15836.x
   NATHAN PW, 1986, BRAIN, V109, P1003, DOI 10.1093/brain/109.5.1003
   NESS TJ, 1988, BRAIN RES, V450, P153, DOI 10.1016/0006-8993(88)91555-7
   NESS TJ, 1991, NEUROSCI LETT, V131, P113, DOI 10.1016/0304-3940(91)90349-X
   PAALZOW G, 1975, PSYCHOPHARMACOLOGIA, V45, P9, DOI 10.1007/BF00426204
   PARSONS CG, 1989, BRIT J PHARMACOL, V98, P533, DOI 10.1111/j.1476-5381.1989.tb12627.x
   PERKINS MN, 1993, PAIN, V53, P191, DOI 10.1016/0304-3959(93)90080-9
   PIERCEY MF, 1980, ARCH INT PHARMACOD T, V248, P294
   PLAGHKI L, 1994, PAIN, V57, P181, DOI 10.1016/0304-3959(94)90222-4
   Plone MA, 1996, PAIN, V66, P265, DOI 10.1016/0304-3959(96)03048-5
   Puig S, 1996, PAIN, V64, P345, DOI 10.1016/0304-3959(95)00121-2
   RAJAONA J, 1986, EXP NEUROL, V93, P291, DOI 10.1016/0014-4886(86)90190-1
   RANDALL LO, 1957, ARCH INT PHARMACOD T, V111, P409
   ROBBINS A, 1991, J AUTONOM NERV SYST, V33, P55, DOI 10.1016/0165-1838(91)90018-X
   ROBERTS VJ, 1989, ISSUES PAIN MEASUREM, V12, P169
   ROSLAND JH, 1990, PAIN, V42, P235, DOI 10.1016/0304-3959(90)91167-H
   Rouzade ML, 1998, NEUROGASTROENT MOTIL, V10, P157
   ROZA C, 1995, NEUROSCI LETT, V198, P9, DOI 10.1016/0304-3940(95)11947-U
   Sandkuhler J, 1996, NEUROSCIENCE, V73, P657, DOI 10.1016/0306-4522(96)00073-5
   SCHOUENBORG J, 1992, EXP BRAIN RES, V90, P469
   SEWELL RDE, 1976, NEUROPHARMACOLOGY, V15, P683, DOI 10.1016/0028-3908(76)90037-X
   Sherrington CS, 1906, INTEGRATIVE ACTION N
   SHIBATA M, 1989, PAIN, V38, P347, DOI 10.1016/0304-3959(89)90222-4
   STERNBACH RA, 1976, PAIN, V2, P35, DOI 10.1016/0304-3959(76)90044-0
   STOLWIJK JA, 1965, J APPL PHYSIOL, V20, P1006
   STRIMBUGOZARIU M, 1993, EUR J PHARMACOL, V237, P197, DOI 10.1016/0014-2999(93)90269-N
   Svensson P, 1997, SOMATOSENS MOT RES, V14, P113, DOI 10.1080/08990229771114
   SWEDBERG MDB, 1994, J PHARMACOL EXP THER, V269, P1021
   TABER RI, 1974, NARCOTIC ANTAGONISTS, V8, P191
   TAYLOR BK, 1995, J NEUROSCI, V15, P7575
   Taylor BK, 1997, J PHARMACOL EXP THER, V280, P876
   TJOLSEN A, 1992, PAIN, V51, P5, DOI 10.1016/0304-3959(92)90003-T
   TJOLSEN A, 1997, PHARM PAIN, P1
   VIERCK CJ, 1976, J AM VET MED ASSOC, V168, P510
   Vyklicky L., 1979, ADV PAIN RES THER, V3, P727
   WALL PD, 1976, PAIN, V2, P1
   WALTERS ET, 1994, INT REV NEUROBIOL, V36, P325, DOI 10.1016/S0074-7742(08)60307-4
   Wesselmann U, 1998, NEUROSCI LETT, V246, P73, DOI 10.1016/S0304-3940(98)00234-1
   WHEELERACETO H, 1991, PSYCHOPHARMACOLOGY, V104, P35, DOI 10.1007/BF02244551
   WINTER CA, 1965, J PHARMACOL EXP THER, V150, P165
   WOOLF C, 1986, NEUROSCI LETT, V66, P226, DOI 10.1016/0304-3940(86)90195-3
   Woolfe G, 1944, J PHARMACOL EXP THER, V80, P300
   YARNITSKY D, 1990, PAIN, V40, P85, DOI 10.1016/0304-3959(90)91055-N
   Yashpal K, 1998, EUR J PAIN-LONDON, V2, P63, DOI 10.1016/S1090-3801(98)90047-7
   Yeomans DC, 1996, PAIN, V68, P133, DOI 10.1016/S0304-3959(96)03176-4
   YEOMANS DC, 1994, PAIN, V59, P85, DOI 10.1016/0304-3959(94)90051-5
   YOBURN BC, 1984, LIFE SCI, V34, P1755, DOI 10.1016/0024-3205(84)90575-7
   Zahn PK, 1997, ANESTHESIOLOGY, V86, P1066, DOI 10.1097/00000542-199705000-00010
   Zimmerman M, 1986, ASSESSING PAIN FARM, P16
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4
NR 150
TC 25
Z9 27
U1 1
U2 8
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0750-7658
EI 1769-6623
J9 ANN FR ANESTH
JI Ann. Fr. Anest. Reanim.
PD APR
PY 2001
VL 20
IS 4
BP 347
EP 365
PG 19
WC Anesthesiology
SC Anesthesiology
GA 433BB
UT WOS:000168734500005
PM 11392245
DA 2021-08-04
ER

PT J
AU Greenwald, A
   Friedman, EJ
   Shenker, S
AF Greenwald, A
   Friedman, EJ
   Shenker, S
TI Learning in network contexts: Experimental results from simulations
SO GAMES AND ECONOMIC BEHAVIOR
LA English
DT Article
ID RATIONALIZABLE STRATEGIC BEHAVIOR; FORM GAMES; EQUILIBRIUM; REPUTATION
AB This paper describes the results of simulation experiments performed on a suits of learning algorithms. We focus on games in network contexts. These are contexts in which (1) agents have very limited information about the game and (2) play can be extremely asynchronous. There are many proposed learning algorithms in the literature. We choose a small sampling of such algorithms and use numerical simulation to explore the nature of asymptotic play. In particular, we explore the extent to which the asymptotic play depends on three factors: limited information, asynchronous play, and the degree of responsiveness of the learning algorithm. (C) 2001 Academic Press.
C1 Brown Univ, Dept Comp Sci, Providence, RI 02912 USA.
   Rutgers State Univ, Dept Econ, New Brunswick, NJ 08903 USA.
   Xero Palo Alto Res Ctr, Palo Alto, CA 94304 USA.
RP Greenwald, A (corresponding author), Brown Univ, Dept Comp Sci, Box 1910, Providence, RI 02912 USA.
EM amygreen@cs.brown.edu; friedman@econ.rutgers.edu; shenker@parc.xerox.com
CR Auer P, 1995, AN S FDN CO, P322, DOI 10.1109/SFCS.1995.492488
   BANOS A, 1968, ANN MATH STAT, V39, P1932, DOI 10.1214/aoms/1177698023
   BERNHEIM BD, 1984, ECONOMETRICA, V52, P1007, DOI 10.2307/1911196
   Blackwell D., 1956, PAC J MATH, V6, P1, DOI [10.2140/pjm.1956.6.1, DOI 10.2140/PJM.1956.6.1]
   BORGERS T, 1995, UNPUB LEARNING REINF
   BORODIN A, 1998, ONLINE COMPUTATON CO
   CHEN Y, 1997, UNPUB ASYNCHRONICITY
   Cover T.M., 1991, MATH FINANC, V1, P1, DOI DOI 10.1111/J.1467-9965.1991.TB00002.X
   EREV I, 1996, UNPUB NEED LOW RATIO
   FOSTER D, 1995, CALIBRATED LEARNING
   Foster DP, 1997, GAME ECON BEHAV, V21, P40, DOI 10.1006/game.1997.0595
   FOSTER DP, 1993, OPER RES, V41, P704, DOI 10.1287/opre.41.4.704
   Freund Y., 1996, Proceedings of the Ninth Annual Conference on Computational Learning Theory, P325, DOI 10.1145/238061.238163
   FRIEDMAN E, 1997, UNPUB LEARNING IMPLE
   FRIEDMAN E, 1998, UNPUB LEARNABILITY C
   Friedman EJ, 1996, GAME ECON BEHAV, V16, P65, DOI 10.1006/game.1996.0074
   FRIEDMAN EJ, 1996, UNPUB SYNCHRONOUS AS
   FUDENBERG D, 1989, ECONOMETRICA, V57, P759, DOI 10.2307/1913771
   FUDENBERG D, 1995, J ECON DYN CONTROL, V19, P1065, DOI 10.1016/0165-1889(94)00819-4
   Fudenberg D., 1998, THEORY LEARNING GAME
   FUDENBERG D, 1995, UNPUB CONDITIONAL UN
   GITTENS J, 1989, MULTIARMED BANDIT AL
   GREENWALD A, 2000, LECT NOTES ARTIFICIA
   GREENWALD A, 1999, THESIS NEW YORK U NE
   HANNAN JF, 1957, CONTRIBUTIONS THEORY, V3, P97
   HART S, 1997, SIMPLE ADAPTIVE PROC
   HUBERMAN BA, 1993, P NATL ACAD SCI USA, V90, P7716, DOI 10.1073/pnas.90.16.7716
   Kaelbling LP, 1996, J ARTIF INTELL RES, V4, P237, DOI 10.1613/jair.301
   KALAI E, 1993, ECONOMETRICA, V61, P1019, DOI 10.2307/2951492
   LITTMAN ML, 1994, P 11 INT C MACH LEAR, P157
   LUKOSE R, 1997, 3 INT C COMP EC
   MEGIDDO N, 1986, INT J GAME THEORY, V9, P157
   MILGROM P, 1991, GAME ECON BEHAV, V3, P82, DOI 10.1016/0899-8256(91)90006-Z
   Mookherjee D, 1997, GAME ECON BEHAV, V19, P97, DOI 10.1006/game.1997.0540
   NARENDRA KS, 1974, IEEE T SYST MAN CYB, VSMC4, P323, DOI 10.1109/TSMC.1974.5408453
   PEARCE DG, 1984, ECONOMETRICA, V52, P1029, DOI 10.2307/1911197
   ROSENTHAL RW, 1991, GAME ECON BEHAV, V3, P237, DOI 10.1016/0899-8256(91)90024-9
   ROTH AE, 1995, GAME ECON BEHAV, V8, P164, DOI 10.1016/S0899-8256(05)80020-X
   Sandholm TW, 1996, BIOSYSTEMS, V37, P147, DOI 10.1016/0303-2647(95)01551-5
   Shapley Lloyd., 1953, CONTRIBUTIONS THEORY, P307, DOI DOI 10.1515/9781400881970-018
   Shenker SJ, 1995, IEEE ACM T NETWORK, V3, P819, DOI 10.1109/90.477727
   SHOHAM Y, 1993, COLEARNING EVOLUTION
   STONE P, 1997, 193 CARN MELL U
   Sutton R, 1998, INTRO REINFORCEMENT, V1st
   VANHUYCK J, 1996, UNPUB SELECTION DYNA
   Watkins C. J. C. H., 1989, THESIS CAMBRIDGE U C
   WATSON J, 1993, ECONOMETRICA, V61, P199, DOI 10.2307/2951784
   Wellman MP, 1998, MACH LEARN, V33, P179, DOI 10.1023/A:1007514623589
NR 48
TC 10
Z9 10
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0899-8256
EI 1090-2473
J9 GAME ECON BEHAV
JI Games Econ. Behav.
PD APR-MAY
PY 2001
VL 35
IS 1-2
BP 80
EP 123
DI 10.1006/game.2000.0835
PG 44
WC Economics
SC Business & Economics
GA 421NN
UT WOS:000168070600005
DA 2021-08-04
ER

PT J
AU Gimblett, HR
   Richards, MT
   Itami, RM
AF Gimblett, HR
   Richards, MT
   Itami, RM
TI RBSim - Geographic simulation of wilderness recreation behavior
SO JOURNAL OF FORESTRY
LA English
DT Article
DE computer simulation; multiple use; recreation
AB Simulation techniques are used to explore the complex spatial interactions between recreationists and their environment as a way to improve wildland recreation management. The Recreation Behavior Simulator (RBSim) uses rule-driven autonomous agents as surrogates for human visitors coupled with geographic information systems to represent the environment for dynamically simulating recreation behavior. Behavioral rules are derived from visitor surveys conducted in Broken Arrow Canyon, Sedona, Arizona. Model runs allow both statistical and spatial analysis to quantify and explore recreationists' movement patterns, encounters, and the influence of management actions on visitor use levels.
C1 Univ Arizona, Sch Renewable Nat Resources, Tucson, AZ 85721 USA.
   No Arizona Univ, Sch Forestry, Coll Ecosyst Sci & Management, Flagstaff, AZ 86011 USA.
RP Gimblett, HR (corresponding author), Univ Arizona, Sch Renewable Nat Resources, Tucson, AZ 85721 USA.
CR BORKAN RE, 1989, ENVIRON MANAGE, V13, P347, DOI 10.1007/BF01874914
   Gimblett H. R., 2000, INTEGRATING GIS AGEN
   GIMBLETT HR, 2000, P WILD SCI TIM CHANG
   GIMBLETT HR, 1997, MODSIM 97 INT C MODE
   ITAMI RM, 2000, INTEGRATING GIS AGEN
   LOUVIERE JJ, 1986, P ASS CONS RES ANN M
   MCCOOL SF, 1977, 28NC FOR SERV
   RICHARDS MT, 1991, MULTIRESOURCE MANAGE
   SHECTER M, 1975, SIMULATION MODEL WIL
   SHECTER M, 1978, SIMULATION RECREATIO
   Shelby B., 1986, CARRYING CAPACITY RE
   Smith V. K., 1976, STRUCTURE PROPERTIES
   Wang B, 1999, ENVIRON MANAGE, V23, P193, DOI 10.1007/s002679900179
   Wing M, 1999, J FOREST, V97, P12
NR 14
TC 20
Z9 21
U1 1
U2 5
PU SOC AMER FORESTERS
PI BETHESDA
PA 5400 GROSVENOR LANE, BETHESDA, MD 20814 USA
SN 0022-1201
J9 J FOREST
JI J. For.
PD APR
PY 2001
VL 99
IS 4
BP 36
EP 42
PG 7
WC Forestry
SC Forestry
GA 418PJ
UT WOS:000167900300007
DA 2021-08-04
ER

PT J
AU Gill, WN
   Duquette, DJ
   Varadarajan, D
AF Gill, WN
   Duquette, DJ
   Varadarajan, D
TI Mass transfer models for the electrodeposition of copper with a
   buffering agent
SO JOURNAL OF THE ELECTROCHEMICAL SOCIETY
LA English
DT Article
AB A model based on physical phenomena has been developed to improve the filling by pulse plating of copper into high aspect ratio features by using a copper complex which dissolves in solution and acts as a buffering agent. Mass transfer pulse-plating models are formulated to account for this effect and solved numerically to show the competition between step coverage and deposition rate. An important parameter, the Damkohler number, applied to filling nanoscale features for the first time, has been identified from the model and its effect on step coverage and deposition rate has been systematically studied. An analytical model is also developed that assumes linear deposition kinetics and neglects boundary movement due to deposition. It describes the initial part of the fill and is used to obtain important trends to guide the numerical simulations. A new criterion, based on the pulse-plating parameters, to obtain the optimal plating conditions has also been developed. I-D and 2-D profile simulations are performed to demonstrate the significant improvement in gap filling in the presence of a buffering agent. Copper has been deposited into submicrometer features using an alkaline ammoniacal bath. Model results have been compared to experimental observations with good correlation between them. (C) 2001 The Electrochemical Society. All rights reserved.
C1 Rensselaer Polytech Inst, Ctr Integrated Elect & Elect Mfg, Ctr Adv Interconnect Sci & Technol, Troy, NY 12180 USA.
   Rensselaer Polytech Inst, Howard P Isermann Dept Chem Engn, Troy, NY 12180 USA.
   Rensselaer Polytech Inst, Dept Mat Sci & Engn, Troy, NY 12180 USA.
RP Gill, WN (corresponding author), Rensselaer Polytech Inst, Ctr Integrated Elect & Elect Mfg, Ctr Adv Interconnect Sci & Technol, Troy, NY 12180 USA.
EM gillw@rpi.edu
CR Andricacos PC, 1999, ELEC SOC S, V98, P48
   Andricacos PC, 1998, IBM J RES DEV, V42, P567, DOI 10.1147/rd.425.0567
   BANK RE, 1981, NUMER MATH, V37, P279, DOI 10.1007/BF01398257
   BANK RE, 1992, NUMER MATH, V61, P7, DOI 10.1007/BF01385495
   BANK RE, 1982, MATH COMPUT, V39, P453, DOI 10.2307/2007324
   BANK RE, 1994, PLTMG SOFTWARE PACKA
   BANKS RE, 1988, NUMER MATH, V52, P487
   DUKOVIC JO, 1990, J ELECTROCHEM SOC, V137, P3748, DOI 10.1149/1.2086296
   GANGULI S, 1995, IND ENG CHEM RES, V34, P3380, DOI 10.1021/ie00037a025
   HAZLEBECK DA, 1990, AICHE J, V36, P1145, DOI 10.1002/aic.690360804
   KREYZIG E, 1983, ADV ENG MATH, P122
   Kruglikov S.S., 1965, ELECTROCHIM ACTA, V10, P253, DOI 10.1016/0013-4686(65)87023-2
   Price D. T., 1999, Advanced Metallization Conference in 1998 (AMC 1998). Proceedings of the Conference, P653
   Price DT, 1997, THIN SOLID FILMS, V308, P523, DOI 10.1016/S0040-6090(97)00479-3
   PRICE DT, 1999, THESIS RENSSELAER PO
   Takahashi KM, 1999, J ELECTROCHEM SOC, V146, P4499, DOI 10.1149/1.1392664
   UHLIG HH, 1971, CORROSION CORROSION
   Varadarajan D, 2000, J ELECTROCHEM SOC, V147, P3382, DOI 10.1149/1.1393910
   WAN HH, 1988, J ELECTROCHEM SOC, V135, P658, DOI 10.1149/1.2095695
   WEST AC, 1998, J ELECTROCHEM SOC, V135, P658
NR 20
TC 10
Z9 10
U1 0
U2 3
PU ELECTROCHEMICAL SOC INC
PI PENNINGTON
PA 65 SOUTH MAIN STREET, PENNINGTON, NJ 08534 USA
SN 0013-4651
EI 1945-7111
J9 J ELECTROCHEM SOC
JI J. Electrochem. Soc.
PD APR
PY 2001
VL 148
IS 4
BP C289
EP C296
DI 10.1149/1.1354618
PG 8
WC Electrochemistry; Materials Science, Coatings & Films
SC Electrochemistry; Materials Science
GA 420MF
UT WOS:000168008200030
DA 2021-08-04
ER

PT J
AU d'Angelo, J
   Mouscadet, JF
   Desmaele, D
   Zouhiri, F
   Leh, H
AF d'Angelo, J
   Mouscadet, JF
   Desmaele, D
   Zouhiri, F
   Leh, H
TI HIV-1 integrase: the next target for AIDS therapy?
SO PATHOLOGIE BIOLOGIE
LA English
DT Review
DE AIDS; antiviral agents; enzyme inhibitors; HIV; virus integration
ID IMMUNODEFICIENCY-VIRUS TYPE-1; CATALYTIC DOMAIN; POTENT INHIBITORS;
   STYRYLQUINOLINE DERIVATIVES; RETROVIRAL INTEGRASES; STRUCTURAL BASIS;
   ACTIVE-SITE; IN-VITRO; REPLICATION; PROTEIN
AB HIV-1 is the aetiological agent of AIDS. Present treatment of AIDS uses a combination therapy with reverse transcriptase and protease inhibitors. Recently, the integrase (IN), the third enzyme of HIV-1 which is necessary for the integration process of proviral DNA into the host genome, has reached as a legitimate new drug target. Several families of inhibitors of the catalytic core domain of HIV-1 IN exhibiting submicromolar activities have now been identified. Our contribution in this field was related to the development of new polyhydroxylated styrylquinolines. The latter compounds have proved to be potent HIV-1 IN inhibitors, that block the replication of HIV-1 in cell culture, and are devoid of cytotoxicity. The crystal structure of the catalytically active core domain of a HIV-1 IN mutant has been determined. The active site region is identified by the position of two of the conserved carboxylate residues essential for catalysis, Asp(64) and Asp(116), which coordinate a Mg2+ ion, whereas the third catalytic residue, Glu(152) does not participate in metal binding. However, a recent molecular dynamics simulation of the HIV-1 IN catalytic domain provides support to the hypothesis that a second metal ion is likely to be carried into the HIV-1 IN active site by the DNA substrate. The structure of a complex of the HIV-1 IN core domain with the inhibitor 5-CITEP has been recently reported. The inhibitor binds centrally in the active site of the IN and makes a number of close contacts with the protein, particularly with Lys(156), Lys(159) and Gln(148), amino acids which were identified to be near the active site of the enzyme, through site-directed mutagenis and photo-crosslinking experiments. The exact mechanism by which HIV-1 IN inhibitors block the catalytic activity of the protein remains unknown. However, several putative pharmacophore components have been characterized. All these groups lie in a possible coordination to a divalent ion, supporting thus the hypothesis that the interaction causing the inhibition is mediated by one or two cations. Finally, among the HIV-1 IN inhibitors, three classes have proved to exhibit significant antiviral activities. Thus, it seems likely that the efficient use of HIV-1 IN as a target for rational design will become possible in the next future, possibly through the use of combination regimens including IN inhibitors. (C) 2001 Editions scientifiques et medicales Elsevier SAS.
C1 Fac Pharm, CNRS, Unite Associe, F-92296 Chatenay Malabry, France.
   Inst Gustave Roussy, CNRS, Unite Associe, F-94805 Villejuif, France.
   BioAlliance Pharma SA, F-75013 Paris, France.
RP d'Angelo, J (corresponding author), Fac Pharm, CNRS, Unite Associe, 5 Rue Jean Baptiste Clement, F-92296 Chatenay Malabry, France.
RI Desmaele, Didier/X-9435-2019
CR BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x
   Bouziane M, 1996, J BIOL CHEM, V271, P10359, DOI 10.1074/jbc.271.17.10359
   Brown P. O., 1997, P161
   BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525
   Bujacz G, 1996, FEBS LETT, V398, P175, DOI 10.1016/S0014-5793(96)01236-7
   CARTEAU S, 1993, ARCH BIOCHEM BIOPHYS, V305, P606, DOI 10.1006/abbi.1993.1468
   CARTEAU S, 1993, BIOCHEM BIOPH RES CO, V192, P1409, DOI 10.1006/bbrc.1993.1573
   Cherepanov P, 1997, MOL PHARMACOL, V52, P771, DOI 10.1124/mol.52.5.771
   CUSHMAN M, 1992, BIOCHEM BIOPH RES CO, V185, P85, DOI 10.1016/S0006-291X(05)80958-1
   CUSHMAN M, 1995, J MED CHEM, V38, P443, DOI 10.1021/jm00003a007
   DEPREZ E, 2000, IN PRESS BIOCHEMISTR, V39
   Drake RR, 1998, P NATL ACAD SCI USA, V95, P4170, DOI 10.1073/pnas.95.8.4170
   DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124
   Eich E, 1996, J MED CHEM, V39, P86, DOI 10.1021/jm950387u
   FESEN MR, 1994, BIOCHEM PHARMACOL, V48, P595, DOI 10.1016/0006-2952(94)90291-7
   Finzi D, 1999, NAT MED, V5, P512
   FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2
   Goldgur Y, 1999, P NATL ACAD SCI USA, V96, P13040, DOI 10.1073/pnas.96.23.13040
   Goldgur Y, 1998, P NATL ACAD SCI USA, V95, P9150, DOI 10.1073/pnas.95.16.9150
   Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646
   King PJ, 1999, J MED CHEM, V42, P497, DOI 10.1021/jm9804735
   King PJ, 1998, J VIROL, V72, P8420, DOI 10.1128/JVI.72.10.8420-8424.1998
   LAFEMINA RL, 1995, ANTIMICROB AGENTS CH, V39, P320, DOI 10.1128/AAC.39.2.320
   LEH H, 2000, IN PRESS BIOCHEMISTR, V39
   Lins RD, 2000, BIOPOLYMERS, V53, P308, DOI 10.1002/(SICI)1097-0282(20000405)53:4<308::AID-BIP3>3.0.CO;2-H
   Lubkowski J, 1998, P NATL ACAD SCI USA, V95, P4831, DOI 10.1073/pnas.95.9.4831
   MAZUMDER A, 1995, BIOCHEM PHARMACOL, V49, P1165, DOI 10.1016/0006-2952(95)98514-A
   MAZUMDER A, 1995, BIOCHEMISTRY-US, V34, P15111, DOI 10.1021/bi00046a018
   Mekouar K, 1998, J MED CHEM, V41, P2846, DOI 10.1021/jm980043e
   Neamati N, 1997, J MED CHEM, V40, P942, DOI 10.1021/jm960759e
   Neamati N, 1997, MOL PHARMACOL, V52, P1041
   Neamati N, 1997, ANTIMICROB AGENTS CH, V41, P385, DOI 10.1128/AAC.41.2.385
   Ouali M, 2000, J MED CHEM, V43, P1949, DOI 10.1021/jm9911581
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12762, DOI 10.1021/bi9529566
   Pommier Y, 1999, ADV VIRUS RES, V52, P427, DOI 10.1016/S0065-3527(08)60310-3
   Ramratnam B, 2000, NAT MED, V6, P82, DOI 10.1038/71577
   Rice P, 1996, CURR OPIN STRUC BIOL, V6, P76, DOI 10.1016/S0959-440X(96)80098-4
   VENCLOVAS C, 1994, PROTEINS, V20, P279, DOI 10.1002/prot.340200308
   Zhao H, 1997, J MED CHEM, V40, P937, DOI 10.1021/jm960755+
   Zhao H, 1997, J MED CHEM, V40, P242, DOI 10.1021/jm960450v
   Zouhiri F, 2000, J MED CHEM, V43, P1533, DOI 10.1021/jm990467o
NR 42
TC 49
Z9 49
U1 0
U2 5
PU EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS CEDEX 15
PA 23 RUE LINOIS, 75724 PARIS CEDEX 15, FRANCE
SN 0369-8114
J9 PATHOL BIOL
JI Pathol. Biol.
PD APR
PY 2001
VL 49
IS 3
BP 237
EP 246
DI 10.1016/S0369-8114(01)00135-3
PG 10
WC Pathology
SC Pathology
GA 431PR
UT WOS:000168640200009
PM 11367559
DA 2021-08-04
ER

PT J
AU Tadic, B
AF Tadic, B
TI Dynamics of directed graphs: the World-Wide Web
SO PHYSICA A
LA English
DT Article
ID RANDOM NETWORKS; INTERNET; SANDPILES
AB We introduce and simulate a growth model of the world-wide Web based on the dynamics of outgoing links that is motivated by the conduct of the agents in the real Web to update outgoing links (re)directing them towards constantly changing selected nodes. Emergent statistical correlation between the distributions of outgoing and incoming links is a key feature of the dynamics of the Web. The growth phase is characterized by temporal fractal structures which are manifested in the hierarchical organization of links. We obtain quantitative agreement with the recent empirical data in the real Web for the distributions of in- and out-links and for the size of the connected component. In a fully grown network of N nodes, we study the structure of connected clusters of nodes that are accessible along outgoing links from a randomly selected node. The distributions of size and depth of the connected clusters with a giant component exhibit supercritical behavior. By decreasing the control parameter - average fraction beta of updated and added links per time step - towards beta (c)(N) < 10% the Web can resume a critical structure with no giant component in it. We find a different universality class when the updates of links are not allowed, i.e., for <beta> equivalent to 0, corresponding to the network of science citations. (C) 2001 Elsevier Science B.V. All rights reserved.
C1 Jozef Stefan Inst, Ljubljana 1001, Slovenia.
RP Tadic, B (corresponding author), Jozef Stefan Inst, POB 3000, Ljubljana 1001, Slovenia.
RI Tadic, Bosiljka/X-3144-2019
CR ALBERT R, CONDMAT0008064
   AMARAL LAN, CONDMAT0001458
   Barabasi AL, 1999, PHYSICA A, V272, P173, DOI 10.1016/S0378-4371(99)00291-5
   Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509
   BRODER A, GRAPH STRUCTURE WEB
   CALAWAY DS, CONDMAT0007300
   Caldarelli G, 2000, EUROPHYS LETT, V52, P386, DOI 10.1209/epl/i2000-00450-8
   Dhar D, 1999, PHYSICA A, V263, P4, DOI 10.1016/S0378-4371(98)00493-2
   Dorogovtsev SN, 2000, PHYS REV LETT, V85, P4633, DOI 10.1103/PhysRevLett.85.4633
   DOROGOVTSEV SN, CONDMAT0009090
   DOROGOVTSEV SN, CONDMAT0009065
   Faloutsos M, 1999, COMP COMM R, V29, P251
   GLEISS PM, CONDMAT0009124
   Grimmett G., 1999, PERCOLATION
   Huberman BA, 1998, SCIENCE, V280, P95, DOI 10.1126/science.280.5360.95
   Huberman BA, 1999, NATURE, V401, P131
   Krapivsky PL, 2000, PHYS REV LETT, V85, P4629, DOI 10.1103/PhysRevLett.85.4629
   Lawrence S, 1999, NATURE, V400, P107, DOI 10.1038/21987
   MORELLI R, 2000, JAVA JAVA JAVA OBJEC
   NEWMAN MEJ, CONDMAT0007235
   NEWMAN MEJ, CONDMAT0007214
   Peitgen H-O, 1992, CHAOS FRACTALS NEW F
   Redner S, 1998, EUR PHYS J B, V4, P131, DOI 10.1007/s100510050359
   Tadic B, 1999, PHYS REV E, V59, P1452, DOI 10.1103/PhysRevE.59.1452
   Tadic B, 1997, PHYS REV LETT, V79, P1519, DOI 10.1103/PhysRevLett.79.1519
   VAZQUEZ A, CONDMAT0006132, P26118
   Wasserman S., 1994, SOCIAL NETWORK ANAL
NR 27
TC 97
Z9 101
U1 0
U2 13
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-4371
J9 PHYSICA A
JI Physica A
PD APR 1
PY 2001
VL 293
IS 1-2
BP 273
EP 284
DI 10.1016/S0378-4371(01)00014-0
PG 12
WC Physics, Multidisciplinary
SC Physics
GA 413TP
UT WOS:000167628300021
OA Green Submitted
DA 2021-08-04
ER

PT J
AU Bousquet, F
   Le Page, C
   Bakam, I
   Takforyan, A
AF Bousquet, F
   Le Page, C
   Bakam, I
   Takforyan, A
TI Multiagent simulations of hunting wild meat in a village in eastern
   Cameroon
SO ECOLOGICAL MODELLING
LA English
DT Article; Proceedings Paper
CT 2nd European Ecological Modelling Conference
CY SEP 20-24, 1999
CL PULA, CROATIA
DE duiker (Cephalophus munticola); hunting; multiagent system; population
   dynamics; spatially explicit individual-based model; wild fauna
   management
ID CEPHALOPHUS-MONTICOLA THUNBERG; EVOLUTIVE SITUATION; DORSALIS GRAY;
   BEHAVIOR; VIABILITY
AB This paper is based on a study of blue duiker hunting in Djemiong, a forest village in eastern Cameroon. The aim of the study is to understand how the organization of the hunting activity between villagers constitutes a management system. The main species hunted is a small antelope, the blue duiker (Cephalophus monticola, Thunberg). Surveys were conducted to understand the inhabitants' hunting behaviour. Hunting takes place 6 months/year and is subject to a spatial shifting rule. Every year, each hunter changes the location of his traps. This behaviour is presented as a management rule that is implemented by the hunters. A spatially explicit individual-based model is used to compare different rules for trap locations in space and time. We propose a model based on the use of multiagent systems. Creating a multiagent system involves reproducing an artificial world that resembles the observed world - i.e. it is made up of different actors - for experimental purposes. Each agent is represented as an independent computerized entity capable of acting locally in response to stimuli or to communication with other agents. CORMAS (Common-pool resources and multiagent systems), a generic simulation environment based on SMALLTALK, makes it possible to build flexible spatially explicit individual-based models. Using this multiagent simulation software, a model was built based on the life history of the blue-duiker and on the inhabitants' hunting behaviour. The model incorporates data from a geographical information system (GIS) to create an artificial landscape that resembles the village landscape. The results highlight the importance of coordination between hunters, particularly the fact that trap networks are appropriated by family groups. The spatial location of traps seems to have a much more crucial influence on the model than global hunting pressure and the duration of the close season. (C) 2001 Elsevier Science B.V. All rights reserved.
C1 CIRAD, TERA, ERE, F-34938 Montpellier 5, France.
   Yaounde I Univ, Yaounde, Cameroon.
RP Le Page, C (corresponding author), CIRAD, TERA, ERE, TA60-15,73 Av JF Breton, F-34938 Montpellier 5, France.
EM lepage@cirad.fr
RI Bousquet, Francois/G-3605-2010; Le Page, Christophe/E-6856-2010;
   Bousquet, Francois/Y-7904-2019
OI Le Page, Christophe/0000-0002-1920-0091; Bousquet,
   Francois/0000-0002-4552-3724
CR Allen TFH, 1992, UNIFIED ECOLOGY, P384
   Barreteau O, 2000, ANN OPER RES, V94, P139, DOI 10.1023/A:1018908931155
   Beissinger SR, 1998, J WILDLIFE MANAGE, V62, P821, DOI 10.2307/3802534
   Bissonette J. A., 1995, P 1 INT WILDL MAN C
   Bousquet F, 1999, PEOPLE AND RANGELANDS BUILDING THE FUTURE, VOLS 1 AND 2, P831
   BOUSQUET F, 1998, LECT NOTES ARTIF INT, V1416, P826, DOI DOI 10.1007/3-540-64574-8
   BOUSQUET F, 1999, ADV ENV ECOLOGICAL M, P113
   CHARDONNET P, 1995, INTEGRATING PEOPLE W, P304
   Chardonnet P., 1995, FAUNE SAUVAGE AFRICA
   Congleton WR, 1997, ECOL MODEL, V103, P1, DOI 10.1016/S0304-3800(97)00069-0
   DUBOST G, 1980, Z TIERPSYCHOL, V54, P205
   DUBOST G, 1983, MAMMALIA, V47, P141, DOI 10.1515/mamm.1983.47.2.141
   DUBOST G, 1983, MAMMALIA, V47, P281
   Ferber J., 1999, MULTIAGENT SYSTEMS I, P509
   HOLLING CS, 1987, EUR J OPER RES, V30, P139, DOI 10.1016/0377-2217(87)90091-9
   Inamdar A., 1999, NATURAL RESOURCE PER, V44
   Lorek H, 1999, ECOL MODEL, V115, P199, DOI 10.1016/S0304-3800(98)00193-8
   Minar N., 1996, 9606042 SANT FE I
   NGANDJUI G, 1997, THESIS P VALERY U MO
   Robinson JG, 1999, J WILDLIFE MANAGE, V63, P1, DOI 10.2307/3802482
   Robinson John G., 1994, Oryx, V28, P249, DOI 10.1017/S0030605300028647
   VILLA F, 1992, TRENDS ECOL EVOL, V7, P179, DOI 10.1016/0169-5347(92)90069-N
   WEISS G, 1999, MULTIAGENT SYSTEMS M, P643
NR 23
TC 46
Z9 50
U1 2
U2 21
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-3800
EI 1872-7026
J9 ECOL MODEL
JI Ecol. Model.
PD MAR 15
PY 2001
VL 138
IS 1-3
BP 331
EP 346
DI 10.1016/S0304-3800(00)00412-9
PG 16
WC Ecology
SC Environmental Sciences & Ecology
GA 437MT
UT WOS:000168996000025
DA 2021-08-04
ER

PT J
AU Fenouillot, F
   Terrisse, J
   Rimlinger, T
AF Fenouillot, F
   Terrisse, J
   Rimlinger, T
TI Experimental study and simulation of the polymerization of methyl
   methacrylate at high temperature in a continuous reactor
SO JOURNAL OF APPLIED POLYMER SCIENCE
LA English
DT Article
DE methyl methacrylate; high temperature; continuous reactor; simulation
ID FREE-RADICAL POLYMERIZATION
AB The bulk polymerization of MMA at high temperature (120-180 degreesC) in a continuous pilot-plant reactor has been studied. The polymerization is initiated by diterbutyle peroxide and the chain transfer agent is 1-butanethiol. A simulation program has been developed to predict the steady state behavior of the reactor. The particular features of the kinetic at above-T-g temperature are included in the model, especially the thermal initiation of the reation and the attenuation of the autoacceleration effect. For the flow and mixing model, the actual vessel cannot be approximated to a single ideal reactor because of its design and of the moderate agitation imposed by the high viscosity of the reacting fluid. A tanks in series model with a recycle stream between tanks is proposed to evaluate the backmixing caused by the special design of the agitator. The parameters of the model are determined with the help of the experimental residence time distribution measured on the reactor. The data collected on the actual reactor, i.e., operation, conversion, molecular weight, temperature, are compared to the calculated one. The agreement is satisfactory but the tendencies are slightly underestimated. The program is a tool to evaluate the effect of modifications of the design of the reactor or changes on the operation parameters like input rate, temperature, and agitation on its behavior. (C) 2001 John Wiley & Sons, Inc.
C1 ECPM, Lab Proc & Mat Polymeres, F-67087 Strasbourg 2, France.
RP Fenouillot, F (corresponding author), Inst Natl Sci Appl, Mat Macromol Lab, Batiment 403,20 Ave Albert Einstein, F-69621 Villeurbanne, France.
EM Francoise.Fenouillot@insa-lyon.fr
CR BAILLAGOU PE, 1985, POLYM ENG SCI, V25, P212, DOI 10.1002/pen.760250405
   BAILLAGOU PE, 1985, POLYM ENG SCI, V25, P232, DOI 10.1002/pen.760250406
   Brandup J., 1975, POLYM HDB
   CHIU WY, 1983, MACROMOLECULES, V16, P348, DOI 10.1021/ma00237a002
   CLOUET G, 1993, J POLYM SCI POL CHEM, V31, P2815, DOI 10.1002/pola.1993.080311119
   CORPART P, 1990, THESIS U L PASTEUR S
   DEY SK, 1987, ANTEC, P133
   Fenouillot F, 1998, INT POLYM PROC, V13, P154, DOI 10.3139/217.980154
   Fenouillot F, 1999, J APPL POLYM SCI, V72, P1589, DOI 10.1002/(SICI)1097-4628(19990620)72:12<1589::AID-APP12>3.0.CO;2-S
   FLEURY PA, 1992, CHEM ENG SCI, V47, P2597, DOI 10.1016/0009-2509(92)87099-C
   FLEURY PA, 1993, THESIS U LAUSANNE EP
   GANZEVELD KJ, 1992, THESIS U GRONINGEN
   KIM KJ, POLYM ENG SCI, P494
   LEONTIEV A, 1985, THEORIE ECHANGES CHA
   Rase H.F., 1977, CHEM REACTOR DESIGN, V1
   STICKLER M, 1983, MAKROMOL CHEM, V184, P2563
   STUBER NP, 1986, THESIS U MINNESOTA
   STUBER NP, 1985, POLYM PROCESS ENG, V3, P71
   TEYMOUR F, 1989, CHEM ENG SCI, V44, P1967, DOI 10.1016/0009-2509(89)85135-8
NR 19
TC 3
Z9 3
U1 1
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-8995
EI 1097-4628
J9 J APPL POLYM SCI
JI J. Appl. Polym. Sci.
PD MAR 14
PY 2001
VL 79
IS 11
BP 2038
EP 2051
DI 10.1002/1097-4628(20010314)79:11<2038::AID-APP1013>3.0.CO;2-L
PG 14
WC Polymer Science
SC Polymer Science
GA 396QY
UT WOS:000166649100014
DA 2021-08-04
ER

PT J
AU Jaffe, K
AF Jaffe, K
TI On the relative importance of haplo-diploidy, assortative mating and
   social synergy on the evolutionary emergence of social behavior
SO ACTA BIOTHEORETICA
LA English
DT Article
DE evolution; haplo-diploidy; sex; strategy; polyploidy; assortative
   mating; sociality; economy
ID MATE SELECTION; SYMPATRIC SPECIATION; ENERGY-CONSUMPTION;
   SEX-DIFFERENCES; EUSOCIALITY; HAPLODIPLOIDY; HYMENOPTERA; ORGANISMS;
   DYNAMICS; COLONIES
AB Advances in multiagent simulation techniques make it possible to study more realistic dynamics of complex systems and allow evolutionary theories to be tested. Here I use simulations to assess the relative importance of reproductive systems (haplodiploidy vs. diploidy), mate selection (assortative mating vs. random mating) and social economics (pay-off matrices of evolutionary games) in the evolutionary dynamics leading to the emergence of social cooperation in the provision of parental care. The simulations confirm that haplo-diploid organisms and organisms mating assortatively have a higher probability for fixing alleles and require less favorable conditions for their fixation, than diploids or organisms mating randomly. The simulations showed that social behavior was most likely to emerge a) when the cost for parental investment was much lower than the benefits to the offspring, b) when cooperation improved synergistically the fitness of offspring compared to the corresponding egoistic behavior and c) when alleles coding for altruistic or social behavior could be rapidly fixed in the population, thanks to mechanisms such as haplo-diploidy and/or assortative mating. Cooperative social behavior always appeared if sociality conferred much higher fitness gains compared to non cooperative alternatives suggesting that the most important factors for the emergence and maintenance of social behavior are those based on energetic or efficiency considerations. The simulations, in congruence with the scant experimental evidence available, suggest that economic considerations rather than genetic ones are critical in explaining the emergence and maintenance of sociality.
C1 Univ Simon Bolivar, Dept Biol Organismos, Caracas 1080A, Venezuela.
RP Jaffe, K (corresponding author), Univ Simon Bolivar, Dept Biol Organismos, Apartado 89000, Caracas 1080A, Venezuela.
EM kjaffe@usb.ve
CR Alexander R.D., 1974, Annual Rev Ecol Syst, V5, P325, DOI 10.1146/annurev.es.05.110174.001545
   Bull JJ., 1983, EVOLUTION SEX DETERM
   BUSS DM, 1989, BEHAV BRAIN SCI, V12, P1, DOI 10.1017/S0140525X00023992
   Cabrera S, 1998, INTERCIENCIA, V23, P350
   CAPRIO MA, 1995, J ECON ENTOMOL, V88, P205, DOI 10.1093/jee/88.2.205
   CASWELL H, 1986, AM NAT, V128, P707, DOI 10.1086/284598
   Crespi B. J., 1997, EVOLUTION SOCIAL BEH
   CRESSMAN R, 1988, J THEOR BIOL, V130, P167, DOI 10.1016/S0022-5193(88)80091-2
   Davis Craig H., 1995, Evolutionary Theory, V11, P51
   Dieckmann U, 1999, NATURE, V400, P354, DOI 10.1038/22521
   Fonck C, 1996, PHYSIOL BEHAV, V59, P713, DOI 10.1016/0031-9384(95)02028-4
   GADAGKAR R, 1991, J GENET, V70, P1, DOI 10.1007/BF02923575
   GADAGKAR R, 1990, PHILOS T ROY SOC B, V329, P17, DOI 10.1098/rstb.1990.0146
   Goldberg D., 1989, GENETIC ALGORITHMS S
   Goldringer I, 1996, CROP SCI, V36, P1171, DOI 10.2135/cropsci1996.0011183X003600050018x
   HAMILTON WD, 1964, J THEOR BIOL, V7, P17, DOI 10.1016/0022-5193(64)90039-6
   HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI 10.1016/0022-5193(64)90039-6
   JAFFE K, 1995, HUM BIOL, V67, P111
   JAFFE K, 1994, NUOVO CIMENTO D, V16, P543, DOI 10.1007/BF02451653
   Jaffe K, 1996, INTERCIENCIA, V21, P259
   Jaffe K, 1997, J THEOR BIOL, V188, P289, DOI 10.1006/jtbi.1997.0472
   Jaffe K, 1999, ACTA BIOTHEOR, V47, P29, DOI 10.1023/A:1002022126388
   Jaffe K, 2000, ACTA BIOTHEOR, V48, P137, DOI 10.1023/A:1002765101959
   JAFFE K, 1995, BIODYNAMICA SIMULATI
   JAFFE K, 1998, LECT NOTES COMPUTER, V1447, P483
   JIMENEZ AW, 1998, J COMP BIOL, V3, P1
   Kondrashov AS, 1999, NATURE, V400, P351
   LeClerc JE, 1996, SCIENCE, V274, P1208, DOI 10.1126/science.274.5290.1208
   Levin SA, 1997, SCIENCE, V275, P334, DOI 10.1126/science.275.5298.334
   Mable BK, 1998, BIOESSAYS, V20, P453, DOI 10.1002/(SICI)1521-1878(199806)20:6<453::AID-BIES3>3.0.CO;2-N
   Michener C.D., 1974, SOCIAL BEHAV BEES
   MILLER GF, 1994, P 3 INT C SIM AD BEH, P21
   Muradian R, 1999, PHYSIOL BEHAV, V66, P731, DOI 10.1016/S0031-9384(99)00011-6
   Ochoa G, 1999, J THEOR BIOL, V199, P1, DOI 10.1006/jtbi.1999.0931
   Osborn F, 1997, J RES LEPIDOPTERA, V34, P69
   QUELLER DC, 1994, P ROY SOC B-BIOL SCI, V256, P105, DOI 10.1098/rspb.1994.0056
   QUELLER DC, 1988, SCIENCE, V242, P1155, DOI 10.1126/science.242.4882.1155
   REEVE HK, 1993, PHILOS T R SOC B, V342, P335, DOI 10.1098/rstb.1993.0163
   Roff Derek A., 1992
   RUELLE D, 1991, CHANCE CHAOS
   SIMON HA, 1990, SCIENCE, V250, P1665, DOI 10.1126/science.2270480
   SMITH JM, 1976, AM SCI, V64, P41
   West Eberhard M.J., 1975, Quarterly Review of Biology, V50, P1
   WILSON EO, 1976, SOCIOBIOLOGY NEW SYN
NR 44
TC 14
Z9 15
U1 1
U2 8
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0001-5342
EI 1572-8358
J9 ACTA BIOTHEOR
JI Acta Biotheor.
PD MAR
PY 2001
VL 49
IS 1
BP 29
EP 42
DI 10.1023/A:1010229506863
PG 14
WC Mathematical & Computational Biology
SC Mathematical & Computational Biology
GA 423RU
UT WOS:000168191700003
PM 11368476
DA 2021-08-04
ER

PT J
AU Fernandez-Pol, JA
   Hamilton, PD
   Klos, DJ
AF Fernandez-Pol, JA
   Hamilton, PD
   Klos, DJ
TI Essential viral and cellular zinc and iron containing metalloproteins as
   targets for novel antiviral and anticancer agents: Implications for
   prevention and therapy of viral diseases and cancer
SO ANTICANCER RESEARCH
LA English
DT Review
DE chelating agents; picolinic acids; herpes virus; AIDS virus;
   metalloproteins
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HERPES-SIMPLEX VIRUS; MURINE
   LEUKEMIA-VIRUS; NUCLEIC-ACID BINDING; TYPE-1 NUCLEOCAPSID PROTEIN;
   MESSENGER-RNA EXPRESSION; HEAT-SHOCK PROTEINS; PICOLINIC-ACID;
   RIBONUCLEOTIDE REDUCTASE; IN-VITRO
AB In this review the authors summarize the experimental data on the role of a selected group of metalloproteins, particularly viral (v) and cellular (c) zinc finger proteins (ZFP) and iron containing proteins which are involved in cell proliferation, neovascularization, apoptosis, and viral infection. Furthermore, this review summarizes the data embracing the hypothesis that disruption of certain metalloproteins by novel pharmacological agents is a key factor in controlling viral and proliferative diseases. The primary goal of this review is to show the potential therapeutic applications of ZFP disrupting agents, zinc chelators and iron chelators in the control of viral diseases and cancer. It is known that zinc or iron deficiency, resulting from exposure of culture cells to membrane-permeable Zn2+ or Fe2+-chelators, can induced apoptosis in virally transformed Fe cells while normal cells remain unaffected under these conditions. Apoptosis is possibly due to simultaneous inactivation of vZFP, cZFP, and/or iron containing proteins, which are essential for maintenance of cellular and viral structure and which are activated in virally transformed cells. New insights concerning apoptosis, viral metalloproteins, and novel antiviral agents will also be reviewed. From the evidence reviewed one can infer that development of a variety of drugs that control or neutralize vZFP may lean to a new therapeutic approach directed at controlling and preventing a wide spectrum of viral diseases and cancer. Furthermore, the results suggest that these agents may be useful to prevent transmission of viral diseases. Finally, this review not only points out the limits of our understanding of this system, but also directs scientists to opportunities for future research.
C1 DVA Med Ctr, Mol Oncol Lab, St Louis, MO 63106 USA.
RP Fernandez-Pol, JA (corresponding author), 437 Hunters Hill Dr, Chesterfield, MO 63017 USA.
EM fernandez-pol@earthlink.net
CR ALANI RM, 1998, SCI MED, V5, P28
   ALANI RM, 1998, SCI MED, V270, P28
   Babe LM, 1997, CELL, V91, P427, DOI 10.1016/S0092-8674(00)80426-2
   Bais C, 1998, NATURE, V391, P86
   BATTLETT JG, 1998, SCI AM           JUL, P84
   BENINGER RJ, 1994, NEUROSCIENCE, V61, P603, DOI 10.1016/0306-4522(94)90438-3
   BERG JM, 1990, J BIOL CHEM, V265, P6513
   BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409
   BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405
   BERKOWITZ BA, 1988, J PHARMACOL EXP THER, V245, P850
   BESS JW, 1992, J VIROL, V66, P840, DOI 10.1128/JVI.66.2.840-847.1992
   BIANCHI V, 1994, P NATL ACAD SCI USA, V91, P8403, DOI 10.1073/pnas.91.18.8403
   BLASI E, 1994, J NEUROIMMUNOL, V52, P205, DOI 10.1016/0165-5728(94)90114-7
   BLASI E, 1993, ANTIMICROB AGENTS CH, V37, P2422, DOI 10.1128/AAC.37.11.2422
   BLASI E, 1988, J IMMUNOL, V141, P2153
   BOEGMAN RJ, 1990, ANN NY ACAD SCI, V585, P261, DOI 10.1111/j.1749-6632.1990.tb28059.x
   BOEHME RE, 1994, ANNU REP MED CHEM, V29, P145
   BOMFORD A, 1986, BIOCHEM J, V236, P243, DOI 10.1042/bj2360243
   Bosco MC, 2000, J IMMUNOL, V164, P3283, DOI 10.4049/jimmunol.164.6.3283
   Brandt CR, 1996, ANTIMICROB AGENTS CH, V40, P1078, DOI 10.1128/AAC.40.5.1078
   Brem S., 1999, CANCER CONTROL, V6, P1, DOI [DOI 10.1177/107327489900600502, 10.1177/107327489900600502]
   Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9
   BUKI KG, 1991, FEBS LETT, V290, P181, DOI 10.1016/0014-5793(91)81255-7
   BUNGE M, 1978, APPL MATH MODEL, V2, P201, DOI 10.1016/0307-904X(78)90008-2
   CAMERON JM, 1988, J GEN VIROL, V69, P2607, DOI 10.1099/0022-1317-69-10-2607
   CARSON DA, 1993, LANCET, V341, P1251, DOI 10.1016/0140-6736(93)91154-E
   Chan YL, 1996, BIOCHEM BIOPH RES CO, V228, P141, DOI 10.1006/bbrc.1996.1629
   Chan YL, 1996, BIOCHEM BIOPH RES CO, V225, P952, DOI 10.1006/bbrc.1996.1277
   Chinami M, 1996, J VIROL METHODS, V59, P173, DOI 10.1016/0166-0934(96)02040-X
   Coates TJ, 1998, SCI AM, V279, P96, DOI 10.1038/scientificamerican0798-96
   COCKHILL J, 1992, BRAIN RES, V599, P57, DOI 10.1016/0006-8993(92)90852-Z
   COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6
   COHEN SM, 1993, SURG ONCOL, V2, P35, DOI 10.1016/0960-7404(93)90057-6
   COLE GA, 1991, BIOCHEM BIOPH RES CO, V180, P504, DOI 10.1016/S0006-291X(05)81093-9
   Collin JP, 1998, EUR J INORG CHEM, P1
   COLLINS JJ, 1979, J BACTERIOL, V138, P923, DOI 10.1128/JB.138.3.923-932.1979
   CONDRA JH, 1997, SCI MED, V4, P14
   CONSTANTINI MG, 1981, EXP CELL RES, V132, P443
   Conte D, 1996, J BIOL CHEM, V271, P5125
   Cory J. G., 1989, INHIBITORS RIBONUCLE, P1
   COTTER TG, 1990, ANTICANCER RES, V10, P1153
   COX GW, 1991, J IMMUNOL, V147, P3809
   Cullen Bryan R., 1993, P1
   Duke RC, 1996, SCI AM, V275, P80, DOI 10.1038/scientificamerican1296-80
   EASTMAN A, 1993, TOXICOL APPL PHARM, V121, P160, DOI 10.1006/taap.1993.1141
   EIGEN M, 1993, SCI AM, V269, P42, DOI 10.1038/scientificamerican0793-42
   ESTES MK, 1996, FIELDS VIROLOGY, P1625
   EVANS GW, 1980, PEDIATR RES, V14, P876, DOI 10.1203/00006450-198014070-00007
   Fernandez-Pol J. Albert, 1991, Critical Reviews in Oncogenesis, V2, P173
   Fernandez-Pol JA, 1998, ANN ONCOL, V9, P33
   Fernandez-Pol JA, 2000, HEMATOL ONCOL CLIN N, V14, P25, DOI 10.1016/S0889-8588(05)70276-8
   Fernandez-Pol JA, 1997, COMPREHENSIVE GERIAT, P179
   FERNANDEZPOL J, 1980, BIOCHEMISTRY-US, V19, P3904, DOI 10.1021/bi00558a003
   FernandezPol JA, 1997, ANTICANCER RES, V17, P1519
   FERNANDEZPOL JA, 1993, J BIOL CHEM, V268, P21198
   FERNANDEZPOL JA, 1994, CELL GROWTH DIFFER, V5, P811
   FERNANDEZPOL JA, 1978, EXP MOL PATHOL, V29, P348, DOI 10.1016/0014-4800(78)90077-1
   FERNANDEZPOL JA, 1977, P NATL ACAD SCI USA, V74, P2889, DOI 10.1073/pnas.74.7.2889
   FERNANDEZPOL JA, 1993, ANTICANCER RES, V13, P57
   FERNANDEZPOL JA, 1978, CELL, V14, P489, DOI 10.1016/0092-8674(78)90235-0
   FERNANDEZPOL JA, 1977, CANCER RES, V37, P4276
   FERNANDEZPOL JA, 1981, INT J NUCL MED BIOL, V8, P231, DOI 10.1016/0047-0740(81)90027-9
   FERNANDEZPOL JA, 1977, BIOCHEM BIOPH RES CO, V76, P413, DOI 10.1016/0006-291X(77)90740-9
   FERNANDEZPOL JA, 1977, BIOCHEM BIOPH RES CO, V78, P136, DOI 10.1016/0006-291X(77)91231-1
   FERNANDEZPOL JA, 1982, CANCER RES, V42, P609
   FERNANDEZPOL JA, 1994, 2 INT C GER ONC, P43
   FERNANDEZPOL JA, 1999, 3 NAT AIDS MAL C BET
   FERNANDEZPOL JA, 1992, GERIATRIC ONCOLOGY, P60
   FERNANDEZPOL JA, 1978, BY PICOLINIC ACID CE, V2, P433
   FIELDS BN, 1996, FIELDS VIROLOGY, V1, P1
   Fraker PJ, 1997, P SOC EXP BIOL MED, V215, P229, DOI 10.3181/00379727-215-44132
   GABAI VL, 1995, FEBS LETT, V375, P21, DOI 10.1016/0014-5793(95)01152-5
   Ganem D, 1997, CELL, V91, P157, DOI 10.1016/S0092-8674(00)80398-0
   GARGAS ML, 1994, DRUG METAB DISPOS, V22, P522
   GAUDREAU P, 1990, J MED CHEM, V33, P723, DOI 10.1021/jm00164a040
   Giacca M, 1996, AIDS RES HUM RETROV, V12, P677, DOI 10.1089/aid.1996.12.677
   Gorelick RJ, 1996, J VIROL, V70, P2593, DOI 10.1128/JVI.70.4.2593-2597.1996
   GORELICK RJ, 1993, J VIROL, V67, P4027, DOI 10.1128/JVI.67.7.4027-4036.1993
   GORELICK RJ, 1988, P NATL ACAD SCI USA, V85, P8420, DOI 10.1073/pnas.85.22.8420
   GORELICK RJ, 1990, J VIROL, V64, P3207, DOI 10.1128/JVI.64.7.3207-3211.1990
   GREEN MR, 1989, NATURE, V338, P200, DOI 10.1038/338200a0
   GURNEY LR, 1980, CELL TISSUE KINET, V14, P269
   HAINAUT P, 1993, CANCER RES, V53, P1739
   HANN HWL, 1988, CANCER RES, V48, P4168
   HARDING MM, 1993, J MED CHEM, V36, P3056, DOI 10.1021/jm00073a003
   Hathout Y, 1996, DRUG METAB DISPOS, V24, P1395
   Hetts SW, 1998, JAMA-J AM MED ASSOC, V279, P300, DOI 10.1001/jama.279.4.300
   HOCKENBERY D, 1995, AM J PATHOL, V146, P16
   HOUGHTON M, 1996, FIELDS VIROLOGY, P1035
   Howley P M, 1987, Important Adv Oncol, P55
   HOWLEY PM, 1996, FIELDS VIROLOGY, P2045
   IDOWU AD, 1992, ANTIVIR RES, V17, P145, DOI 10.1016/0166-3542(92)90048-A
   JACOBSON JG, 1989, VIROLOGY, V173, P276, DOI 10.1016/0042-6822(89)90244-4
   JOHNSON GS, 1977, FEBS LETT, V74, P201, DOI 10.1016/0014-5793(77)80846-6
   KALISCH BE, 1994, BRAIN RES, V668, P1, DOI 10.1016/0006-8993(94)90504-5
   KANE AB, 1995, AM J PATHOL, V146, P1
   KIMURA N, 1983, J BIOL CHEM, V258, P2609
   Kiss E, 2000, J INORG BIOCHEM, V78, P97, DOI 10.1016/S0162-0134(99)00215-9
   KIYONO T, 1992, VIROLOGY, V186, P628, DOI 10.1016/0042-6822(92)90029-O
   KOFF RS, 1998, SCI MED, V5, P16
   Komatsu H, 1996, BIOCHEM MOL BIOL INT, V38, P1143
   KRIEGER I, 1982, PEDIATRICS, V69, P773
   LAMMERS M, 1983, STRUCT BOND, V54, P27
   LEUTHAUSER SWC, 1982, J NATL CANCER I, V68, P123
   Lien E J, 1987, Prog Drug Res, V31, P101
   LlinasBrunet M, 1996, BIOORG MED CHEM LETT, V6, P2881, DOI 10.1016/S0960-894X(96)00532-X
   Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7
   MAJEWSKI S, 1992, AM J MED SCI, V304, P174, DOI 10.1097/00000441-199209000-00006
   MAJNO G, 1995, AM J PATHOL, V146, P3
   Maul GG, 1998, CELL GROWTH DIFFER, V9, P743
   MEHLER AH, 1956, J BIOL CHEM, V223, P449
   MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683
   MELILLO G, 1993, J IMMUNOL, V150, P4031
   Melillo G, 1996, ADV EXP MED BIOL, V398, P135
   MELILLO G, 1994, J BIOL CHEM, V269, P8128
   MERIC C, 1989, J VIROL, V63, P1558
   MIHICH E, 1994, APOPTOSIS, V5, P1
   MIKOGAMI T, 1995, BIOCHEM J, V308, P391, DOI 10.1042/bj3080391
   Mizuno A, 1996, AIDS RES HUM RETROV, V12, P793, DOI 10.1089/aid.1996.12.793
   Monini P, 1999, J VIROL, V73, P4029, DOI 10.1128/JVI.73.5.4029-4041.1999
   MORIMOTO RI, 1991, CANCER CELL-MON REV, V3, P295
   MOSS N, 1993, J MED CHEM, V36, P3005, DOI 10.1021/jm00072a021
   Muriaux D, 1996, J BIOL CHEM, V271, P33686, DOI 10.1074/jbc.271.52.33686
   NG TB, 1992, GEN PHARMACOL-VASC S, V23, P575, DOI 10.1016/0306-3623(92)90131-3
   Ogata S, 1998, BIOSCI BIOTECH BIOCH, V62, P2351, DOI 10.1271/bbb.62.2351
   OTSUKA M, 1994, J MED CHEM, V37, P4267, DOI 10.1021/jm00051a002
   Pais TF, 2000, J IMMUNOL, V164, P389, DOI 10.4049/jimmunol.164.1.389
   Pfister H, 1992, Semin Cancer Biol, V3, P263
   Pieroni L, 1997, J VIROL, V71, P6373, DOI 10.1128/JVI.71.9.6373-6380.1997
   Poltorakov AP, 1996, IZV AKAD NAUK BIOL+, P645
   PRIEL E, 1995, FEBS LETT, V362, P59, DOI 10.1016/0014-5793(95)00208-Q
   REIN A, 1994, J VIROL, V68, P6124, DOI 10.1128/JVI.68.9.6124-6129.1994
   Rein A, 1996, J VIROL, V70, P4966, DOI 10.1128/JVI.70.8.4966-4972.1996
   RICE WG, 1995, SCIENCE, V270, P1194, DOI 10.1126/science.270.5239.1194
   RICE WG, 1993, NATURE, V361, P473, DOI 10.1038/361473a0
   RICE WG, 1992, P NATL ACAD SCI USA, V89, P7703, DOI 10.1073/pnas.89.16.7703
   Richardson K, 1998, POETRY REV, V88, P89
   ROBBINS E, 1970, P NATL ACAD SCI USA, V66, P1244, DOI 10.1073/pnas.66.4.1244
   RODRIGUES RR, 1995, J INORG BIOCHEM, V60, P277, DOI 10.1016/0162-0134(95)00027-5
   ROIZMAN B, 1996, LIPPINCOTT, P2221
   RUFFMANN R, 1984, J IMMUNOPHARMACOL, V6, P291, DOI 10.3109/08923978409028605
   RUFFMANN R, 1987, DRUG EXP CLIN RES, V13, P607
   Samali A, 1996, EXP CELL RES, V223, P163, DOI 10.1006/excr.1996.0070
   SantaCruz DJ, 1997, J CUTAN PATHOL, V24, P533, DOI 10.1111/j.1600-0560.1997.tb01457.x
   SHAH KV, 1996, FIELDS VIROLOGY, P2077
   SHENK T, 1991, ADV CANCER RES, V57, P47
   Shoji Y, 1996, J CLIN PATHOL, V49, P134, DOI 10.1136/jcp.49.2.134
   SOUTH TL, 1989, J AM CHEM SOC, V111, P395, DOI 10.1021/ja00183a074
   SOUTH TL, 1990, BIOCHEM PHARMACOL, V40, P123, DOI 10.1016/0006-2952(90)90187-P
   SPECTOR T, 1991, BIOCHEM PHARMACOL, V42, P91, DOI 10.1016/0006-2952(91)90685-X
   Stack BC, 1999, ANTICANCER RES, V19, P5503
   STACK BC, 2000, OTORINOLARYNGOLOGY H, V125, P128
   STIRPE F, 1986, BIOCHEM J, V240, P659, DOI 10.1042/bj2400659
   SUNDERMAN FW, 1995, ANN CLIN LAB SCI, V25, P134
   SUTOW WW, 1975, CANCER CHEMOTH REP 1, V59, P341
   Taguchi H., 1999, J CLIN MED, V57, P2319
   TAKE Y, 1989, J ANTIBIOT, V42, P107, DOI 10.7164/antibiotics.42.107
   TapiaRamirez J, 1997, P NATL ACAD SCI USA, V94, P1177, DOI 10.1073/pnas.94.4.1177
   TESTA U, 1985, BRIT J HAEMATOL, V60, P491, DOI 10.1111/j.1365-2141.1985.tb07446.x
   THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464
   TOMEI LD, 1994, CC CELL MOL, V8, P1
   Tummino PJ, 1996, P NATL ACAD SCI USA, V93, P969, DOI 10.1073/pnas.93.3.969
   Turpin JA, 1996, J VIROL, V70, P6180, DOI 10.1128/JVI.70.9.6180-6189.1996
   Vaarala MH, 1998, INT J CANCER, V78, P27, DOI 10.1002/(SICI)1097-0215(19980925)78:1<27::AID-IJC6>3.3.CO;2-A
   VARADINOVA TL, 1993, J CHEMOTHERAPY, V5, P3
   Varesio L, 1992, Curr Top Microbiol Immunol, V181, P209
   VARESIO L, 1990, J IMMUNOL, V145, P4265
   vonWeizsacker F, 1997, HEPATOLOGY, V26, P251, DOI 10.1002/hep.510260237
   VROOMAN L, 1993, BRAIN RES, V627, P193, DOI 10.1016/0006-8993(93)90320-M
   WHITE E, 1994, CC CELL MOL, V8, P111
   Wool IG, 1996, TRENDS BIOCHEM SCI, V21, P164, DOI 10.1016/0968-0004(96)20011-8
   Wool IG, 1995, BIOCHEM CELL BIOL, V73, P933, DOI 10.1139/o95-101
   WOOL IG, 1997, RIBOSOMAL RNA GROUP, P153
   WUNDERLICH V, 1982, ARCH VIROL, V73, P171, DOI 10.1007/BF01314725
   XYNOS FP, 1994, ANTICANCER RES, V14, P773
   zurHausen H, 1996, BBA-REV CANCER, V1288, pF55
NR 176
TC 32
Z9 35
U1 1
U2 3
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD MAR-APR
PY 2001
VL 21
IS 2A
BP 931
EP 957
PG 27
WC Oncology
SC Oncology
GA 437UQ
UT WOS:000169012300017
PM 11396187
DA 2021-08-04
ER

PT J
AU Brazier, FMT
   van Eck, PAT
   Treur, J
AF Brazier, FMT
   van Eck, PAT
   Treur, J
TI Modelling a society of simple agents: From conceptual specification to
   experimentation
SO APPLIED INTELLIGENCE
LA English
DT Article
DE multi-agent systems; social simulation; modelling
ID DESIRE
AB Much research concerning the design of multi-agent systems (at a conceptual level) addresses complex agents that exhibit complex interaction patterns. Due to this complexity, it is difficult to perform rigorous experimentation. On the other hand, systematic experimental work regarding behaviour of societies of more simple agents, while reporting valuable results, often lacks conceptual specification of the system under consideration. In this paper, the compositional multi-agent modelling framework DESIRE is not only successfully used to develop a conceptual specification of the simple agents discussed by A. Cesta, M. Miceli and P. Rizzo (Lecture Notes in Artificial Intelligence, vol. 1038, Springer-Verlag: Berlin, pp. 128-138, 1996), but also to simulate the behaviour in a dynamical environment. In the DESIRE framework, a conceptual specification, which provides a high-level view of an agent, has enough detail for automatic prototype generation. The prototype implementation of the conceptual specification of the simple agents has been used to replicate, and extend, one of the experiments reported by Cesta et al.
C1 Vrije Univ Amsterdam, Dept Artificial Intelligence, NL-1081 HV Amsterdam, Netherlands.
RP Brazier, FMT (corresponding author), Vrije Univ Amsterdam, Dept Artificial Intelligence, De Beolelaan 1081A, NL-1081 HV Amsterdam, Netherlands.
CR Axelrod R., 1997, COMPLEXITY COOPERATI
   Brazier F, 1999, LECT NOTES ARTIF INT, V1760, P36
   Brazier F. M. T., 1998, Proceedings. Artificial Intelligence and Manufacturing Workshop. State of the Art and State of the Practice, P30
   Brazier FMT, 1999, DATA KNOWL ENG, V29, P17, DOI 10.1016/S0169-023X(98)00029-9
   Brazier FMT, 2000, ARTIFICIAL INTELLIGENCE IN DESIGN '00, P633
   Brazier FMT, 1997, INT J COOP INF SYST, V6, P67, DOI 10.1142/S0218843097000069
   BRAZIER FMT, 1997, LECT NOTES EC MATH S, V456, P103
   BRAZIER FMT, 1997, LECT NOTES ARTIF INT, V1193, P141
   CASTELFRANCHI C, 1999, LECT NOTES AI
   CESTA A, 1996, LECT NOTES ARTIF INT, V1038, P128
   CESTA A, 1996, P 2 INT C MULT SYST
   FISHER M, 1995, LECT NOTES ARTIFICIA, V890
   GAYLFORD RJ, 1998, SIMULATING SOC MATH
   HANKS S, 1993, AI MAG, V14, P17
   JONKER CM, 1998, AGENT BASED SIMULATI, P33
   MONTGOMERY TA, 1990, P IEEE C TOOLS ART I
   Moss S., 1998, Computational & Mathematical Organization Theory, V4, P43, DOI 10.1023/A:1009600530279
   Mulder M, 1998, LECT NOTES ARTIF INT, V1365, P193
   Nwana HS, 1996, KNOWL ENG REV, V11, P205, DOI 10.1017/S026988890000789X
   VANDEVELDE W, 1996, LECT NOTES ARTIFICIA, V1038
   WOOLDRIDGE M, 1995, KNOWL ENG REV, V10, P115, DOI 10.1017/S0269888900008122
NR 21
TC 4
Z9 4
U1 0
U2 1
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 0924-669X
J9 APPL INTELL
JI Appl. Intell.
PD MAR-APR
PY 2001
VL 14
IS 2
BP 161
EP 178
DI 10.1023/A:1008366009807
PG 18
WC Computer Science, Artificial Intelligence
SC Computer Science
GA 417GW
UT WOS:000167827900003
OA Green Published, Green Submitted
DA 2021-08-04
ER

PT J
AU Khullar, SC
   Badler, NI
AF Khullar, SC
   Badler, NI
TI Where to look? Automating attending behaviors of virtual human
   characters
SO AUTONOMOUS AGENTS AND MULTI-AGENT SYSTEMS
LA English
DT Article; Proceedings Paper
CT 3rd International Conference on Autonomous Agents (Agents 99)
CY MAY 01-05, 1999
CL SEATTLE, WA
DE cognitive modeling; virtual humans; visual attention; synthetic agents
ID VISUAL-ATTENTION; EYE-MOVEMENTS; COORDINATION; CAPTURE; TASKS
AB This research proposes a computational framework for generating visual attending behavior in an embodied simulated human agent. Such behaviors directly control eye and head motions, and guide other actions such as locomotion and reach. The implementation of these concepts, referred to as the AVA, draws on empirical and qualitative observations known from psychology, human factors and computer vision. Deliberate behaviors, the analogs of scanpaths in visual psychology, compete with involuntary attention capture and lapses into idling or free viewing. Insights provided by implementing this framework are: a defined set of parameters that impact the observable effects of attention, a defined vocabulary of looking behaviors for certain motor and cognitive activity, a defined hierarchy of three levels of eye behavior (endogenous, exogenous and idling) and a proposed method of how these types interact.
C1 Univ Penn, Dept Comp & Informat Sci, Philadelphia, PA 19104 USA.
RP Khullar, SC (corresponding author), Univ Penn, Dept Comp & Informat Sci, Philadelphia, PA 19104 USA.
EM schopra@graphics.cis.upenn.edu; badler@central.cis.upenn.edu
CR ABRAMS RA, 1990, J EXP PSYCHOL HUMAN, V16, P248, DOI 10.1037/0096-1523.16.2.248
   ALLPORT A, 1994, ATTENTION PERFORM, V15, P421
   ALLPORT A, 1993, ATTENTION PERFORM, V14, P183
   BALLARD D, 1992, INVEST OPHTH VIS SCI, V33, P1355
   BROOKS R, 1999, AAAI98
   CASSELL J, 1994, ANN C SERIES, P413
   CHOPRAKHULLAR S, 1999, 3 P ACM AUT AG, P16
   FISCHER B, 1986, PSYCHOL RES-PSYCH FO, V48, P251, DOI 10.1007/BF00309089
   HACISALIHZADE SS, 1992, IEEE T SYST MAN CYB, V22, P474, DOI 10.1109/21.155948
   HILLSTROM AP, 1994, PERCEPT PSYCHOPHYS, V55, P399, DOI 10.3758/BF03205298
   Hirst W., 1986, MIND BRAIN DIALOGUES, P105
   JOHNSON MH, 1994, ATTENTION PERFORM, V15, P291
   Jonides J., 1981, ATTENTION PERFORM, VIX, P187, DOI DOI 10.1037/0096-1523.29.5.835
   KAHNEMAN D, 1973, ATTENTION EFFORTS
   KOCH C, 1985, HUM NEUROBIOL, V4, P219
   Ladavas E, 1997, J COGNITIVE NEUROSCI, V9, P67, DOI 10.1162/jocn.1997.9.1.67
   MARJANOVIC M, 1996, 4 INT C SIM AD BEH C
   Moray N., 1993, ATTENTION SELECTION, P53
   RAO R, 1996, ADV NEURAL INFORMATI
   RICKEL J, 1997, P AUT AG 1997
   SCASSELLATI B, 1996, AAAI FALL S ENB CONG
   STARK L, 1996, ADV PSYCHOL VISUAL A, pCH1
   SWAIN MJ, 1993, INT J COMPUT VISION, V11, P109, DOI 10.1007/BF01469224
   Terzopoulos Demetri, 1994, Artificial Life, V1, P327, DOI 10.1162/artl.1994.1.4.327
   Trias TS, 1996, P IEEE VIRT REAL ANN, P156, DOI 10.1109/VRAIS.1996.490523
   TSOTSOS JK, 1995, ARTIF INTELL, V78, P507, DOI 10.1016/0004-3702(95)00025-9
   YANTIS S, 1990, J EXP PSYCHOL HUMAN, V16, P121, DOI 10.1037/0096-1523.16.1.121
   YANTIS S, 1993, J EXP PSYCHOL HUMAN, V19, P676, DOI 10.1037/0096-1523.19.3.676
   Yarbus AL., 1967, EYE MOVEMENTS VISION
NR 29
TC 34
Z9 34
U1 0
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1387-2532
EI 1573-7454
J9 AUTON AGENT MULTI-AG
JI Auton. Agents Multi-Agent Syst.
PD MAR-JUN
PY 2001
VL 4
IS 1-2
BP 9
EP 23
DI 10.1023/A:1010010528443
PG 15
WC Automation & Control Systems; Computer Science, Artificial Intelligence
SC Automation & Control Systems; Computer Science
GA 412FF
UT WOS:000167543800002
PM 12143881
DA 2021-08-04
ER

PT J
AU Moss, S
AF Moss, S
TI Game theory: Limitations and an alternative
SO JASSS-THE JOURNAL OF ARTIFICIAL SOCIETIES AND SOCIAL SIMULATION
LA English
DT Article
DE game theory; agent; multi agent system; simulation; market;
   intermediation
ID IMPLEMENTATION; AGENTS
AB The purpose of this paper is to describe current practice in the game theory literature, to identify particular characteristics that ensure the literature is remote from anything we observe and to demonstrate an alternative drawn from agent based social simulation. The key issue is the process of social interaction among agents. A survey of game theoretic models found no models representing interaction among more than three agents, though sometimes more agents were involved in a round robin tournament. An ABSS model is reported in which there is a dense pattern of interaction among agents and outputs from the model are shown to have the same statistical signature as high-frequency data from competitive retail and financial markets. Moreover, the density of agent interaction is seen to be necessary both to obtain the validating statistical signature and for simulated market efficiency. As far as competitive markets are concerned, game theoretic models evidently assume away the source of the properties observed in real high frequency data and also the properties required for market efficiency.
C1 Manchester Metropolitan Univ, Ctr Policy Modelling, Manchester M1 3GH, Lancs, England.
RP Moss, S (corresponding author), Manchester Metropolitan Univ, Ctr Policy Modelling, Aytoun Bldg, Manchester M1 3GH, Lancs, England.
CR Alos-Ferrer C, 1999, J ECON THEORY, V86, P245, DOI 10.1006/jeth.1999.2522
   Anderson J. R., 1993, RULES MIND
   Bak P., 1997, NATURE WORKS SCI SEL
   Battigalli P, 1999, J ECON THEORY, V88, P188, DOI 10.1006/jeth.1999.2555
   Bergin J, 1999, J ECON THEORY, V86, P50, DOI 10.1006/jeth.1998.2505
   BINMORE K, 1997, SIMULATING SOCIAL PH, P113
   Brusco S, 1999, J ECON THEORY, V87, P356, DOI 10.1006/jeth.1999.2546
   Chakrabarti SK, 1999, J ECON THEORY, V85, P294, DOI 10.1006/jeth.1998.2493
   Chakravorti B, 1999, J ECON THEORY, V84, P216, DOI 10.1006/jeth.1998.2466
   Cohen P. R., 1985, HEURISTIC REASONING
   Cozzi G, 1999, J ECON THEORY, V86, P17, DOI 10.1006/jeth.1998.2502
   Dekel E, 1999, J ECON THEORY, V87, P125, DOI 10.1006/jeth.1999.2537
   Gale D, 1999, J ECON THEORY, V84, P1, DOI 10.1006/jeth.1998.2477
   Jackson MO, 1999, J ECON THEORY, V88, P40, DOI 10.1006/jeth.1999.2538
   Jensen H.J., 1998, SELF ORGANIZED CRITI
   LAIRD JE, 1987, ARTIF INTELL, V33, P1, DOI 10.1016/0004-3702(87)90050-6
   Moss S., 2000, Computational & Mathematical Organization Theory, V6, P249, DOI 10.1023/A:1009629602618
   MOSS S, 2000, P 4 INT C MULT AG SY
   MOSS S, 1998, J ARTIFICIAL SOC SOC, V1
   MOSS S, 1996, COMPUTATIONAL MATH O, V4, P43
   NAGEL K, 1995, PHYS REV E, V51, P2909, DOI 10.1103/PhysRevE.51.2909
   NEILSEN, 1992, RETAIL POCKET BOOK 1
   Pareto V, 1896, COURS EC POLITIQUE
   Saez-Marti M, 1999, J ECON THEORY, V86, P268, DOI 10.1006/jeth.1999.2528
   Saijo T, 1999, J ECON THEORY, V84, P227, DOI 10.1006/jeth.1998.2476
   Stamland T, 1999, J ECON THEORY, V89, P148, DOI 10.1006/jeth.1999.2563
   Von Neumann J., 1947, THEORY GAMES EC BEHA
   Wallner K, 1999, J ECON THEORY, V84, P251, DOI 10.1006/jeth.1998.2484
NR 28
TC 4
Z9 4
U1 0
U2 10
PU J A S S S
PI GUILDFORD
PA UNIV SURREY, DEPT SOCIOLOGY, GUILDFORD GU2 7XH, SURREY, ENGLAND
SN 1460-7425
J9 JASSS
JI JASSS
PD MAR
PY 2001
VL 4
IS 2
BP U21
EP U39
PG 19
WC Social Sciences, Interdisciplinary
SC Social Sciences - Other Topics
GA 417FC
UT WOS:000167823900003
DA 2021-08-04
ER

PT J
AU Medvedovic, M
   Succop, P
   Shukla, R
   Dixon, K
AF Medvedovic, M
   Succop, P
   Shukla, R
   Dixon, K
TI Clustering mutational spectra via classification likelihood and Markov
   chain Monte Carlo algorithms
SO JOURNAL OF AGRICULTURAL BIOLOGICAL AND ENVIRONMENTAL STATISTICS
LA English
DT Article
DE classification expectation maximization algorithm; cluster analysis;
   Gibbs sampling; multinomial distribution; stochastic expectation
   maximization algorithm
ID SHUTTLE VECTOR PLASMID; HUMAN-CELLS; XERODERMA-PIGMENTOSUM; MUTAGENIC
   SPECIFICITY; POINT MUTATIONS; 11,12-DIHYDRODIOL 13,14-EPOXIDE;
   1,2-DIHYDRODIOL 3,4-EPOXIDE; SEQUENCE SPECIFICITY; MAMMALIAN-CELLS;
   MONKEY CELLS
AB We have analyzed a set of 39 mutational spectra of the supF gene that were generated by different mutagenic agents and under different experimental conditions. The cluster analyses was performed using a newly developed clustering procedure. The clustering criterion used in the procedure was developed by applying the classification likelihood approach to multinomial observations. We also developed a Gibbs sampling-based optimization procedure that outperformed previously developed methods in a comparative simulation study. The results of the cluster analysis showed that our clustering procedure was able to recreate natural grouping of the mutational spectra with respect to the characteristics of mutagenic agents used to generate them and with respect to experimental conditions applied in the process of generating spectra. These results are an important confirmation of the relevance of mutational spectra in characterizing mutagenic mechanisms of different carcinogens.
C1 Univ Cincinnati, Med Ctr, Dept Environm Hlth, Cincinnati, OH 45267 USA.
RP Medvedovic, M (corresponding author), Univ Cincinnati, Med Ctr, Dept Environm Hlth, 3223 Eden Ave, Cincinnati, OH 45267 USA.
CR ADAMS WT, 1987, J MOL BIOL, V194, P391, DOI 10.1016/0022-2836(87)90669-3
   AITKIN M, 1981, J ROY STAT SOC A STA, V144, P419, DOI 10.2307/2981826
   BIGGER CAH, 1991, MOL CARCINOGEN, V4, P176, DOI 10.1002/mc.2940040303
   BIGGER CAH, 1990, CARCINOGENESIS, V11, P2263, DOI 10.1093/carcin/11.12.2263
   BIGGER CAH, 1989, P NATL ACAD SCI USA, V86, P2291, DOI 10.1073/pnas.86.7.2291
   BIGGER CAH, 1992, P NATL ACAD SCI USA, V89, P368, DOI 10.1073/pnas.89.1.368
   BOLDT J, 1991, CARCINOGENESIS, V12, P119, DOI 10.1093/carcin/12.1.119
   BREDBERG A, 1986, P NATL ACAD SCI USA, V83, P8273, DOI 10.1073/pnas.83.21.8273
   BRYANT PG, 1991, J CLASSIF, V8, P31, DOI 10.1007/BF02616246
   CARTY MP, 1995, ENVIRON MOL MUTAGEN, V26, P139, DOI 10.1002/em.2850260207
   CELLEUX G, 1991, J CLASSIF, V8, P157
   CELLEUX G, 1985, COMPUTATIONAL STAT Q, V2, P73
   CELLEUX G, 1992, COMPUTATOINAL STAT D, V14, P315
   Cohen J., 1969, STAT POWER ANAL BEHA
   COURTEMANCHE C, 1994, MUTAT RES, V306, P143, DOI 10.1016/0027-5107(94)90025-6
   DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x
   ENDO H, 1994, CANCER RES, V54, P3745
   EVERITT BS, 1993, CLUSTER ANAL
   Feng ZD, 1996, J ROY STAT SOC B MET, V58, P609
   GELFAND AE, 1990, J AM STAT ASSOC, V85, P398, DOI 10.2307/2289776
   Gilks WR., 1996, MARKOV CHAIN MONTE C
   HAUSER J, 1986, MOL CELL BIOL, V6, P277, DOI 10.1128/MCB.6.1.277
   Jennison C., 1993, J ROYAL STAT SOC B, V55, P54
   KEYSE SM, 1988, MOL CELL BIOL, V8, P5425, DOI 10.1128/MCB.8.12.5425
   LEVY DD, 1992, CANCER RES, V52, P5668
   Maccubbin AE, 1997, ENVIRON MOL MUTAGEN, V29, P143
   MAH MCM, 1989, CARCINOGENESIS, V10, P2321, DOI 10.1093/carcin/10.12.2321
   MCLACHLN JG, 1987, MIXTURE MODELS INFER
   Page JE, 1996, CANCER LETT, V110, P249, DOI 10.1016/S0304-3835(96)04506-5
   PAGE JE, 1995, CHEM RES TOXICOL, V8, P143, DOI 10.1021/tx00043a019
   Page JE, 1996, CARCINOGENESIS, V17, P283, DOI 10.1093/carcin/17.2.283
   PARRIS CN, 1994, J MOL BIOL, V236, P491, DOI 10.1006/jmbi.1994.1160
   ROILIDES E, 1988, MUTAT RES, V198, P199, DOI 10.1016/0027-5107(88)90055-3
   SEETHARAM S, 1987, J CLIN INVEST, V80, P1613, DOI 10.1172/JCI113248
   SEIDMAN MM, 1985, GENE, V38, P233, DOI 10.1016/0378-1119(85)90222-7
   SYMONS MJ, 1981, BIOMETRICS, V37, P35, DOI 10.2307/2530520
   SZELIGA J, 1994, CHEM RES TOXICOL, V7, P420, DOI 10.1021/tx00039a021
   SZELIGA J, 1995, CHEM RES TOXICOL, V8, P1014, DOI 10.1021/tx00050a004
   Van Laarhoven P.J., 1987, SIMULATED ANNEALING
   YAGI T, 1994, MUTAGENESIS, V9, P73, DOI 10.1093/mutage/9.1.73
   YAGI T, 1991, CANCER RES, V51, P3177
   YANG JL, 1987, P NATL ACAD SCI USA, V84, P3787, DOI 10.1073/pnas.84.11.3787
   YANG JL, 1988, MOL CELL BIOL, V8, P3364, DOI 10.1128/MCB.8.8.3364
NR 43
TC 4
Z9 4
U1 0
U2 1
PU AMER STATISTICAL ASSOC & INTERNATIONAL BIOMETRIC SOC
PI WASHINGTON
PA 1444 I ST NW, STE 700, WASHINGTON, DC 20005 USA
SN 1085-7117
J9 J AGRIC BIOL ENVIR S
JI J. Agric. Biol. Environ. Stat.
PD MAR
PY 2001
VL 6
IS 1
BP 19
EP 37
DI 10.1198/108571101300325111
PG 19
WC Biology; Mathematical & Computational Biology; Statistics & Probability
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology; Mathematics
GA 404UA
UT WOS:000167119000003
DA 2021-08-04
ER

PT J
AU Tang, P
   Zubryzcki, I
   Xu, Y
AF Tang, P
   Zubryzcki, I
   Xu, Y
TI Ab initio calculation of structures and properties of halogenated
   general anesthetics: Halothane and sevoflurane
SO JOURNAL OF COMPUTATIONAL CHEMISTRY
LA English
DT Article
DE ab initio calculation; B3LYP; electrostatic potential; general
   anesthetics; halothane; partial atomic charge; sevoflurane
ID DENSITY-FUNCTIONAL THERMOCHEMISTRY; VIBRATIONAL CIRCULAR-DICHROISM;
   PREDOMINANT CONFORMATIONS; ELECTROSTATIC POTENTIALS;
   ABSOLUTE-CONFIGURATION; NUMERICAL-INTEGRATION; VOLATILE ANESTHETICS;
   MOLECULAR-DYNAMICS; ATOMIC PROPERTIES; GRAMICIDIN-A
AB To correctly analyze the effects of general anesthetics on their potential targets by large-scale molecular simulation, the structural parameters and partial atomic charges of the anesthetics are of determinant importance. Geometric optimizations using the Hartree-Fock and the B3LYP density functional theory methods with the large 6-311+G(2d,p) basis set were performed to determine the structures and charge distributions of two halogenated anesthetics, 2-bromo-2-chloro-1,1,1-trifluoroethane (halothane) and fluoromethyl-2,2,2,-trifluoro-1-(trifluoromethyl) ethyl ether (sevoflurane). The calculated bond lengths and angles are within 3% of the corresponding experimental values reported for the similar molecular groups. Charges are assigned using the Mulliken population analysis and the electrostatic potential (ESP) based on the Merz-Kollman-Singh scheme. The atoms-in-molecules (AIM) theory is also used to assign the charges in halothane. The dipole moments calculated with the Mulliken population analysis and ESP for the structures optimized by B3LYP/6-311+(2d,p) were respectively 1.355 and 1.430 D for halothane and 2.255 and 2.315 D for sevoflurane. These are in excellent agreement with the experimental values of 1.41 and 2.33 D for halothane and. sevoflurane, respectively. The calculated structures and partial charge distributions can be readily parameterized for molecular mechanics and molecular dynamics simulations involving these halogenated agents. (C) 2001 John Wiley & Sons, Inc.
C1 Univ Pittsburgh, Sch Med, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15261 USA.
   Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA.
RP Xu, Y (corresponding author), Univ Pittsburgh, Sch Med, Dept Anesthesiol & Crit Care Med, W1358 Biomed Sci Tower, Pittsburgh, PA 15261 USA.
EM xuy@anes.upmc.edu
OI Xu, Yan/0000-0003-2773-8024
CR Bader R. F. W., 1990, ATOMS MOL QUANTUM TH
   BECKE AD, 1992, J CHEM PHYS, V96, P2155, DOI 10.1063/1.462066
   BECKE AD, 1992, J CHEM PHYS, V97, P9173, DOI 10.1063/1.463343
   BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913
   BESLER BH, 1990, J COMPUT CHEM, V11, P431, DOI 10.1002/jcc.540110404
   BRENEMAN CM, 1990, J COMPUT CHEM, V11, P361, DOI 10.1002/jcc.540110311
   CAR R, 1985, PHYS REV LETT, V55, P2471, DOI 10.1103/PhysRevLett.55.2471
   CHIRLIAN LE, 1987, J COMPUT CHEM, V8, P894, DOI 10.1002/jcc.540080616
   CIOSLOWSKI J, 1994, CHEM PHYS LETT, V219, P151, DOI 10.1016/S0009-2614(94)87001-2
   CIOSLOWSKI J, 1995, MOL PHYS, V84, P707, DOI 10.1080/00268979500100481
   CIOSLOWSKI J, 1992, CHEM PHYS LETT, V194, P73, DOI 10.1016/0009-2614(92)85745-V
   CIOSLOWSKI J, 1993, CHEM PHYS LETT, V203, P137, DOI 10.1016/0009-2614(93)85377-Z
   CIOSLOWSKI J, 1992, J MOL STRUC-THEOCHEM, V87, P9
   CIOSLOWSKI J, 1993, J AM CHEM SOC, V115, P11213, DOI 10.1021/ja00077a020
   Eckenhoff RG, 1997, PHARMACOL REV, V49, P343
   FENCLOVA D, 1990, J CHEM THERMODYN, V22, P219, DOI 10.1016/0021-9614(90)90086-6
   Forrest LR, 2000, BIOPHYS J, V78, P55, DOI 10.1016/S0006-3495(00)76572-6
   Frisch MJ., 1998, GAUSSIAN 98 REVISION
   Johansson JS, 2000, BIOPHYS J, V78, P982, DOI 10.1016/S0006-3495(00)76656-2
   KRISHNAN R, 1980, J CHEM PHYS, V72, P650, DOI 10.1063/1.438955
   Leach AR, 1996, MOL MODELLING PRINCI
   LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785
   LIDE DR, 1994, CRC HDB CHEM PHYSICS
   MCLEAN AD, 1980, J CHEM PHYS, V72, P5639, DOI 10.1063/1.438980
   MULLIKEN RS, 1955, J CHEM PHYS, V23, P1833, DOI 10.1063/1.1740588
   Polavarapu PL, 1999, TETRAHEDRON-ASYMMETR, V10, P1099, DOI 10.1016/S0957-4166(99)00089-0
   Polavarapu PL, 1999, J PHYS CHEM B, V103, P6127, DOI 10.1021/jp990550n
   Scharf D, 1996, CHEM PHYS LETT, V258, P276, DOI 10.1016/0009-2614(96)00652-5
   STEFANOV BB, 1995, J COMPUT CHEM, V16, P1394, DOI 10.1002/jcc.540161108
   STEWART JJP, 1990, J COMPUT AID MOL DES, V4, P1, DOI 10.1007/BF00128336
   Tang P, 2000, BIOPHYS J, V78, P1804, DOI 10.1016/S0006-3495(00)76730-0
   Tang P, 1999, BIOPHYS J, V77, P739, DOI 10.1016/S0006-3495(99)76928-6
   Tang P, 1999, BIOPHYS J, V76, P2346, DOI 10.1016/S0006-3495(99)77391-1
   Trudell JR, 1998, TOXICOL LETT, V101, P413, DOI 10.1016/S0378-4274(98)00215-X
   VANDERBILT D, 1990, PHYS REV B, V41, P7892, DOI 10.1103/PhysRevB.41.7892
   Woska AB, 1998, TOXICOL LETT, V101, P377, DOI 10.1016/S0378-4274(98)00210-0
   Xu Y, 2000, BIOPHYS J, V78, P746, DOI 10.1016/S0006-3495(00)76632-X
   Xu Y, 1998, TOXICOL LETT, V101, P347
   Zubrzycki IZ, 2000, J CHEM PHYS, V112, P3437, DOI 10.1063/1.480924
NR 39
TC 32
Z9 32
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0192-8651
EI 1096-987X
J9 J COMPUT CHEM
JI J. Comput. Chem.
PD MAR
PY 2001
VL 22
IS 4
BP 436
EP 444
DI 10.1002/1096-987X(200103)22:4<436::AID-JCC1014>3.0.CO;2-U
PG 9
WC Chemistry, Multidisciplinary
SC Chemistry
GA 406CW
UT WOS:000167198200006
DA 2021-08-04
ER

PT J
AU Duffy, J
AF Duffy, J
TI Learning to speculate: Experiments with artificial and real agents
SO JOURNAL OF ECONOMIC DYNAMICS & CONTROL
LA English
DT Article
DE learning; search; money; agent-based computational economics;
   experimental design
ID MONEY; EXCHANGE
AB This paper employs an artificial agent-based computational approach to understanding and designing laboratory environments in which to lest Kiyotaki and Wright's search model of money. The behavioral rules of the artificial agents are modeled on the basis of prior evidence from human subject experiments. Simulations of the artificial agent-based model are conducted in two new versions of the Kiyotaki-Wright environment and yield some testable predictions. These predictions are examined using data from new, human subject experiments. The results are encouraging and suggest that artificial agent-based modeling may be a useful device for both understanding and designing human subject experiments. (C) 2001 Elsevier Science B.V. Ail rights reserved. JEL classification: D83; C73; C90; E40.
C1 Univ Pittsburgh, Dept Econ, Pittsburgh, PA 15260 USA.
RP Duffy, J (corresponding author), Univ Pittsburgh, Dept Econ, 4S01 Posvar Hall, Pittsburgh, PA 15260 USA.
RI Duffy, John/F-6968-2015
OI Duffy, John/0000-0002-7660-2281
CR Basci E, 1999, J ECON DYN CONTROL, V23, P1569, DOI 10.1016/S0165-1889(98)00084-0
   Brown PM, 1996, J ECON DYN CONTROL, V20, P583, DOI 10.1016/0165-1889(95)00865-9
   Duffy J, 1999, AM ECON REV, V89, P847, DOI 10.1257/aer.89.4.847
   DUFFY J, 1999, FIAT MONEY MEDIUM EX
   DURLAUF SN, 1997, EC EVOLVING COMPLEX, V2
   Fudenberg D., 1998, THEORY LEARNING GAME
   Hicks JR, 1935, ECONOMICA-NEW SER, V2, P1, DOI 10.2307/2549103
   Holland J.H., 1986, MACHINE LEARNING ART, VVolume 2
   KIYOTAKI N, 1989, J POLITICAL EC, V97, P924
   MARIMOM R, 1990, J ECON DYN CONTROL, V14, P329, DOI 10.1016/0165-1889(90)90025-C
   ROTH AE, 1995, GAME ECON BEHAV, V8, P164, DOI 10.1016/S0899-8256(05)80020-X
   STAUDINGER S, 1998, MONEY MEDIUM EXCHANG
   WALLACE N, 1998, FEDERAL RESERVE BANK, V22, P20
   WRIGHT R, 1995, J ECON DYN CONTROL, V19, P181, DOI 10.1016/0165-1889(93)00770-5
   Young H., 1998, INDIVIDUAL STRATEGY
NR 15
TC 59
Z9 62
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-1889
J9 J ECON DYN CONTROL
JI J. Econ. Dyn. Control
PD MAR
PY 2001
VL 25
IS 3-4
BP 295
EP 319
DI 10.1016/S0165-1889(00)00028-2
PG 25
WC Economics
SC Business & Economics
GA 380TG
UT WOS:000165719100002
DA 2021-08-04
ER

PT J
AU Chen, SH
   Yeh, CH
AF Chen, SH
   Yeh, CH
TI Evolving traders and the business school with genetic programming: A new
   architecture of the agent-based artificial stock market
SO JOURNAL OF ECONOMIC DYNAMICS & CONTROL
LA English
DT Article
DE agent-based computational economics; social learning; genetic
   programming; business school; artificial stock markets
ID ADAPTIVE AGENTS; MODEL; ALGORITHM; ECONOMIES; BEHAVIOR; DYNAMICS
AB In this paper, we propose a new architecture to study artificial stock markets. This architecture rests on a mechanism called 'school' which is a procedure to map the phenotype to the genotype or, in plain English, to uncover the secret of success. We propose an agent-based model of 'school', and consider school as an evolving population driven by single-population GP (SGP). The architecture also takes into consideration traders' search behavior. By simulated annealing, traders' search density can be connected to psychological factors, such as peer pressure or economic factors such as the standard of living. This market architecture was then implemented in a standard artificial stock market. Our econometric study of the resultant artificial time series evidences that the return series is independently and identically distributed (iid), and hence supports the efficient market hypothesis (EMH). What is interesting though is that this lid series was generated by traders, who do not believe in the EMH at all. In fact, our study indicates that many of our traders were able to find useful signals quite often from business school, even though these signals were short-lived. (C) 2001 Elsevier Science B.V. All rights reserved. JEL classification: G12; G14; D83.
C1 Natl Chengchi Univ, Dept Econ, AI ECON Res Grp, Taipei 11623, Taiwan.
   I Shou Univ, Dept Finance, AI ECON Res Grp, Kaohsiung 84008, Taiwan.
RP Chen, SH (corresponding author), Natl Chengchi Univ, Dept Econ, AI ECON Res Grp, 64 Chihnan Rd,Sec 2 Wenshan, Taipei 11623, Taiwan.
OI Chen, Shu-Heng/0000-0003-4584-7646
CR ANDREWS M, 1994, ADV GENETIC PROGRAMM, V1, P355
   ARIFOVIC J, 1995, J MONETARY ECON, V36, P219, DOI 10.1016/0304-3932(95)01203-7
   ARIFOVIC J, 1994, J ECON DYN CONTROL, V18, P3, DOI 10.1016/0165-1889(94)90067-1
   Arifovic J, 1996, J POLIT ECON, V104, P510, DOI 10.1086/262032
   Arifovic J., 1997, J ECON GROWTH, V2, P185, DOI [10.1023/A:1009733218546, DOI 10.1023/A:1009733218546]
   Arthur W. Brian, 1997, EC EVOLVING COMPLEX, VII, P15
   Bullard J., 1999, Computational Economics, V13, P41, DOI 10.1023/A:1008610307810
   Bullard J, 1998, MACROECON DYN, V2, P22, DOI 10.1017/S1365100598006026
   Bullard J, 1998, J ECON DYN CONTROL, V22, P179, DOI 10.1016/S0165-1889(97)00072-9
   Chen KH, 1999, ELEC SOC S, V99, P13
   Chen S.-H., 1997, LECT NOTES COMPUTER, V1213, P137
   CHEN SH, 2000, 20001 AIECON RES GRO
   CHEN SH, 2000, IN PRESS EVOLUTIONAR
   CHEN SH, 1996, EVOLUTIONARY PROGRAM, V5, P277
   Chen SH, 1996, ADV GENETIC PROGRAMM, V2, P443
   CHEN SH, 1998, LECT NOTES COMPUTER, V1447, P829
   CHEN SH, 2000, IN PRESS J EC BEHAV
   DICKEY DA, 1981, ECONOMETRICA, V49, P1057, DOI 10.2307/1912517
   GROSSMAN SJ, 1980, AM ECON REV, V70, P393
   HARRALD P, 1998, 7 INT C EV PROGR MAR
   HERREINER D, 1998, 4 INT C SOC COMP EC
   HEYMANN D, 1998, J MANAGEMENT EC, V2
   HOLLAND JH, 1991, AM ECON REV, V81, P365
   Koza JR, 1992, GENETIC PROGRAMMING, V1
   LeBaron B, 2000, J ECON DYN CONTROL, V24, P679, DOI 10.1016/S0165-1889(99)00022-6
   Lux T, 1998, J ECON BEHAV ORGAN, V33, P143, DOI 10.1016/S0167-2681(97)00088-7
   LUX T, 1995, ECON J, V105, P881, DOI 10.2307/2235156
   Lux T, 1999, NATURE, V397, P498, DOI 10.1038/17290
   Miller JH, 1996, J ECON BEHAV ORGAN, V29, P87, DOI 10.1016/0167-2681(95)00052-6
   Minsky ML., 1986, SOC MIND
   Pagan A., 1996, J EMPIR FINANC, V3, P15, DOI [10.1016/0927-5398(95)00020-8, DOI 10.1016/0927-5398(95)00020-8]
   PALMER RG, 1994, PHYSICA D, V75, P264, DOI 10.1016/0167-2789(94)90287-9
   Peterson DL, 1997, GLOBAL ECOL BIOGEOGR, V6, P7, DOI 10.2307/2997523
   Sargent T., 1993, BOUNDED RATIONALITY
   STAUDINGER S, 1998, P C COMP EC FIN ENG
   TAYLER P, 1995, INTELLIGENT SYSTEMS, P271
   VILA X, 1997, LECT NOTES EC MATH S, P437
   VRIEND N, 1998, ILLUSTRATION ESSENTI
NR 38
TC 132
Z9 154
U1 2
U2 29
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-1889
J9 J ECON DYN CONTROL
JI J. Econ. Dyn. Control
PD MAR
PY 2001
VL 25
IS 3-4
BP 363
EP 393
DI 10.1016/S0165-1889(00)00030-0
PG 31
WC Economics
SC Business & Economics
GA 380TG
UT WOS:000165719100004
DA 2021-08-04
ER

PT J
AU Muraki, S
   Morris, CD
   Budde, JM
   Velez, DA
   Zhao, ZQ
   Guyton, RA
   Vinten-Johansen, J
AF Muraki, S
   Morris, CD
   Budde, JM
   Velez, DA
   Zhao, ZQ
   Guyton, RA
   Vinten-Johansen, J
TI Experimental off-pump coronary artery revascularization with
   adenosine-enhanced reperfusion
SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
LA English
DT Article
ID REDUCES INFARCT SIZE; BEATING HEART; INTRACORONARY ADENOSINE; MYOCARDIAL
   PROTECTION; BYPASS-SURGERY; CANINE MODEL; INJURY; RECEPTOR; ISCHEMIA;
   BLOOD
AB Objective: Although beating heart coronary artery bypass grafting has recently gained popularity, it eliminates the protective strategies tie, cardioplegia) developed for use in conventional cardiac operations. We recently introduced the technique of perfusion-assisted direct coronary artery bypass to perfuse the grafted vessels during multivessel off-pump coronary artery bypass grafting. In the present study we tested the hypothesis that intracoronary reperfusion with the cardioprotective agent adenosine during simulated perfusion-assisted direct coronary artery bypass attenuates reperfusion injury.
   Methods: In anesthetized dogs the heart was exposed, and the left anterior descending coronary artery was ligated for 75 minutes. Reperfusion was achieved through a catheter in the left anterior descending coronary artery by means of a computer-controlled pump. Intracoronary left anterior descending coronary artery perfusion pressure was continuously matched to mean arterial blood pressure. In one group (adenosine group) 10 mu mol/L adenosine was added to the blood during the first 30 minutes of reperfusion, whereas another group (vehicle group) received a comparable volume of saline solution.
   Results: During the first 30 minutes of reperfusion, blood flow through the left anterior descending coronary artery was significantly greater (P < .05) in the adenosine group than in the vehicle group (150.6 <plus/minus> 21.9 vs 50.2 +/- 11.3 mL/min at 15 minutes of reperfusion). Although there were no group differences in postischemic wall motion, infarct size was significantly smaller in the adenosine group than in the vehicle group (11.1% +/- 3.0% vs 28.0% +/- 4.0% of area at risk, P < .05). Myeloperoxidase activity in the necrotic tissue, an index of neutrophil accumulation, tended to be lower in the adenosine group than in the vehicle group (58.6 <plus/minus> 14.2 vs 91.0 +/- 21.6 Delta AbsUnits . min(-1) . g(-1) tissue). In isolated postischemic left anterior descending coronary artery rings, the maximal relaxation response to the endothelium-dependent vasodilator acetylcholine was significantly greater in the adenosine group than in the vehicle group (97.9% +/- 5.6% vs 64.7% +/- 6.5%, P < .05).
   Conclusion: This novel reperfusion strategy for off-pump coronary artery bypass grafting can be used not only in cases requiring multiple grafting but also to attenuate necrosis and endothelial dysfunction in acute evolving infarction.
C1 Emory Univ, Sch Med, Carlyle Fraser Heart Ctr, Div Cardiothorac Surg, Atlanta, GA USA.
RP Vinten-Johansen, J (corresponding author), Cardiothorac Res Lab, 550 Peachtree St NE, Atlanta, GA 30365 USA.
CR Ambrosio G, 1999, AM HEART J, V138, pS69, DOI 10.1016/S0002-8703(99)70323-6
   ANGELLO DA, 1991, AM J PHYSIOL, V260, pH193
   Arom KV, 2000, ANN THORAC SURG, V69, P704, DOI 10.1016/S0003-4975(99)01510-6
   BABBITT DG, 1989, CIRCULATION, V80, P1388, DOI 10.1161/01.CIR.80.5.1388
   Bonatti J, 1998, ANN THORAC SURG, V66, P1093, DOI 10.1016/S0003-4975(98)00733-4
   Boyle EM, 1997, ANN THORAC SURG, V64, pS24, DOI 10.1016/S0003-4975(97)00958-2
   Brown PM, 1999, CIRCULATION, V100, P125
   Cargnoni A, 1999, J CARDIOVASC PHARM, V33, P883, DOI 10.1097/00005344-199906000-00008
   CRONSTEIN BN, 1986, J CLIN INVEST, V78, P760, DOI 10.1172/JCI112638
   Dapunt OE, 1999, EUR J CARDIO-THORAC, V15, P173, DOI 10.1016/S1010-7940(98)00290-5
   DAWICKI DD, 1988, BIOCHEM PHARMACOL, V37, P621, DOI 10.1016/0006-2952(88)90134-7
   Flameng WJ, 1997, ANN THORAC SURG, V63, pS18, DOI 10.1016/S0003-4975(97)00356-1
   Guyton RA, 2000, ANN THORAC SURG, V69, P171, DOI 10.1016/S0003-4975(99)01386-7
   HOMEISTER JW, 1990, CIRCULATION, V82, P595, DOI 10.1161/01.CIR.82.2.595
   JOHNSON RE, 1982, J THORAC CARDIOV SUR, V83, P813
   Jordan JE, 1997, J PHARMACOL EXP THER, V280, P301
   Jordan JE, 1999, AM J PHYSIOL-HEART C, V277, pH1895
   JUNEAU CF, 1993, CARDIOVASC RES, V27, P720, DOI 10.1093/cvr/27.5.720
   KOWALLIK P, 1991, CIRCULATION, V83, P974, DOI 10.1161/01.CIR.83.3.974
   LASLEY RD, 1990, J MOL CELL CARDIOL, V22, P39, DOI 10.1016/0022-2828(90)90970-D
   Lockowandt U, 2000, ANN THORAC SURG, V70, P206, DOI 10.1016/S0003-4975(00)01410-7
   Mentzer RM, 1999, ANN SURG, V229, P643, DOI 10.1097/00000658-199905000-00006
   Mentzer RM, 1997, AM J CARDIOL, V79, P38, DOI 10.1016/S0002-9149(97)00262-2
   NAKANISHI K, 1992, AM J PHYSIOL, V263, pH1650
   NICHOLS WW, 1994, AM HEART J, V127, P1201, DOI 10.1016/0002-8703(94)90037-X
   Sydzyik R T, 1997, J Extra Corpor Technol, V29, P145
   Tasdemir O, 1998, J THORAC CARDIOV SUR, V116, P68, DOI 10.1016/S0022-5223(98)70244-2
   Todd J, 1996, ANN THORAC SURG, V62, P1364, DOI 10.1016/0003-4975(96)00495-X
   Tracey WR, 1997, CARDIOVASC RES, V33, P410, DOI 10.1016/S0008-6363(96)00240-4
   van Aarnhem EEHL, 1999, EUR J CARDIO-THORAC, V16, pS2, DOI 10.1016/S1010-7940(99)00260-2
   VELASCO CE, 1991, AM HEART J, V122, P1561, DOI 10.1016/0002-8703(91)90272-J
   Vinten-Johansen J, 1999, ANN THORAC SURG, V68, P1942, DOI 10.1016/S0003-4975(99)01018-8
   Zhao ZQ, 1996, AM J PHYSIOL-HEART C, V271, pH1456
   Zhao ZQ, 1997, AM J PHYSIOL-HEART C, V273, pH1677
   Zhao ZQ, 1999, CORONARY ARTERY DIS, V10, P617, DOI 10.1097/00019501-199912000-00011
NR 35
TC 14
Z9 14
U1 0
U2 0
PU MOSBY, INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA
SN 0022-5223
J9 J THORAC CARDIOV SUR
JI J. Thorac. Cardiovasc. Surg.
PD MAR
PY 2001
VL 121
IS 3
BP 570
EP 579
DI 10.1067/mtc.2001.112342
PG 10
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 415KT
UT WOS:000167721100023
PM 11241093
OA Bronze
DA 2021-08-04
ER

PT J
AU Ohki, T
   Parodi, J
   Veith, FJ
   Bates, M
   Bade, M
   Chang, D
   Mehta, M
   Rabin, J
   Goldstein, K
   Harvey, J
   Lipsitz, E
AF Ohki, T
   Parodi, J
   Veith, FJ
   Bates, M
   Bade, M
   Chang, D
   Mehta, M
   Rabin, J
   Goldstein, K
   Harvey, J
   Lipsitz, E
TI Efficacy of a proximal occlusion catheter with reversal of flow in the
   prevention of embolic events during carotid artery stenting: An
   experimental analysis
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Article; Proceedings Paper
CT 14th Annual Meeting of the Eastern-Vascular-Society
CY MAY 05-07, 2000
CL BALTIMORE, MD
SP Eastern Vasc Soc
ID TRANSCRANIAL DOPPLER ULTRASONOGRAPHY; BALLOON ANGIOPLASTY;
   CEREBRAL-ISCHEMIA; DISTAL EMBOLIZATION; ENDARTERECTOMY; PROTECTION;
   STATEMENT; STROKE; SAFETY; RISK
AB Objective: The role of percutaneous angioplasty and stenting of carotid bifurcation lesions has been limited by its potential for producing embolic debris. We evaluated the efficacy of a proximal occlusion catheter (POC) in the prevention Of embolic events during carotid artery stenting. In addition, pressure measurements relevant to the clinical application Of this device were obtained from 10 patients undergoing carotid endarterectomy.
   Methods: The POC is a guiding catheter with an occlusion balloon attached on the outside of the catheter at its distal end. Occlusion of the common carotid artery (CCA) was achieved by inflating the balloon while access to carotid bifurcation lesions was obtained through the inner lumen. The POC was inserted in the CCA of 10 dogs via the femoral artery. The side port of the POC was connected to a sheath placed in the femoral vein, thereby creating an external arteriovenous shunt. Ten artificial radiopaque particles simulating embolic particles and contrast agent were introduced in the CCA and monitored fluoroscopically. As a control, the same procedure was performed with a standard guiding catheter without an occlusion balloon. In 10 patients undergoing carotid endarterectomy, the internal carotid artery (ICA) and external carotid artery stump pressures and the pressure in the internal jugular vein were measured.
   Results. Without the external arteriovenous shunt, in all animals there was prograde flow in the distal CCA despite CCA occlusion. This flow was derived from the thyroid artery. However, once the arteriovenous shunt was activated, reversal of now in the distal CCA was achieved in each animal, and all the artificial particles were recovered from the side port of the POC. In the control group, each particle embolized to the brain (100%, P < .01). In the patients, the mean stump pressures in the ICA and external carotid artery and the jugular vein pressure mere 51.8 +/- 14.2, 62.2 +/- 15.1, and 6.5 +/- 3.5 mm Hg, respectively. In each case, the jugular vein pressure was the lowest among the three.
   Conclusions: Obtaining proximal CCA control by inflating the POC does not sufficiently prevent embolization. However, reversal of flow in the ICA can always be created with the external shunt, which effectively prevents embolization. Thus, POC may markedly lower procedural stroke rates during carotid artery stenting. The ability of POC to prevent embolization before crossing the lesion with a guidewire may be an important advantage over other distal protection devices.
C1 Montefiore Med Ctr, Albert Einstein Coll Med, Dept Surg, Div Vasc Surg, Bronx, NY 10467 USA.
   Inst Cardiovasc Buenos Aires, Buenos Aires, DF, Argentina.
   Charleston Area Med Ctr, Charleston, WV USA.
RP Ohki, T (corresponding author), Montefiore Med Ctr, Albert Einstein Coll Med, Dept Surg, Div Vasc Surg, 111 E 210th St, Bronx, NY 10467 USA.
EM takohki@msn.com
FU NHLBI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [HL 02990-05] Funding Source: Medline; NATIONAL HEART,
   LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [K07HL002990] Funding Source: NIH RePORTER
CR ACKERSTAFF RGA, 1995, J VASC SURG, V21, P963, DOI 10.1016/S0741-5214(95)70224-5
   ARCHIE JP, 1991, J VASC SURG, V13, P319, DOI 10.1016/0741-5214(91)90225-J
   Beebe HG, 1996, STROKE, V27, P197, DOI 10.1161/01.STR.27.2.197
   Bergeron P, 1996, J CARDIOVASC SURG, V37, P73
   Bettmann MA, 1998, STROKE, V29, P336, DOI 10.1161/01.STR.29.1.336
   Callahan TJ, 1996, STROKE, V27, P2144
   Carlino M, 1999, CIRCULATION, V99, P3221, DOI 10.1161/01.CIR.99.25.3221
   Coggia M, 2000, J VASC SURG, V31, P550
   Crawley F, 1997, STROKE, V28, P2460, DOI 10.1161/01.STR.28.12.2460
   Criado FJ, 1997, AM J SURG, V174, P111, DOI 10.1016/S0002-9610(97)90065-9
   DEMONTE F, 1989, J NEUROSURG, V70, P138, DOI 10.3171/jns.1989.70.1.0138
   Diethrich EB, 1996, J ENDOVASC SURG, V3, P132, DOI 10.1583/1074-6218(1996)003<0132:IFCASA>2.0.CO;2
   Dorros G, 1998, CIRCULATION, V98, P927, DOI 10.1161/01.CIR.98.9.927
   GAUNT ME, 1994, BRIT J SURG, V81, P1435, DOI 10.1002/bjs.1800811009
   HARRISON MJG, 1977, BRIT J SURG, V64, P511, DOI 10.1002/bjs.1800640717
   Henry M, 1998, J ENDOVASC SURG, V5, P293, DOI 10.1583/1074-6218(1998)005<0293:AASOTE>2.0.CO;2
   HOBSON RW, 1993, NEW ENGL J MED, V328, P221, DOI 10.1056/NEJM199301283280401
   HUSSAIN T, 1999, BRIT J SURG, V86, P690
   Jordan WD, 1999, CARDIOVASC SURG, V7, P33, DOI 10.1016/S0967-2109(98)00097-0
   Kachel R, 1996, J ENDOVASC SURG, V3, P22, DOI 10.1583/1074-6218(1996)003<0022:ROBAIT>2.0.CO;2
   Lawrence PF, 1998, J VASC SURG, V27, P329, DOI 10.1016/S0741-5214(98)70363-5
   Mathur A, 1998, CIRCULATION, V97, P1239, DOI 10.1161/01.CIR.97.13.1239
   McCleary AJ, 1998, BRIT J SURG, V85, P771
   McGuinness CL, 1996, BRIT J SURG, V83, P1171, DOI 10.1046/j.1365-2168.1996.02495.x
   Milei J, 1998, AM HEART J, V136, P1096, DOI 10.1016/S0002-8703(98)70169-3
   MIYAKE K, 1992, J PHARMACOL EXP THER, V260, P1058
   MOORE WS, 1995, STROKE, V26, P188, DOI 10.1161/01.STR.26.1.188
   MOREAU P, 1993, ANN CHIR, V47, P742
   Muller M, 2000, AM J NEURORADIOL, V21, P47
   Naylor AR, 1998, J VASC SURG, V28, P326, DOI 10.1016/S0741-5214(98)70182-X
   O'Hara PJ, 1999, J VASC SURG, V29, P236
   Ohki T, 1998, J VASC SURG, V27, P463, DOI 10.1016/S0741-5214(98)70321-0
   Ohki T, 1999, J VASC SURG, V30, P1034, DOI 10.1016/S0741-5214(99)70041-8
   PARODI JC, 2000, IN PRESS J VASC SURG
   Roubin GS, 1996, AM J CARDIOL, V78, P8, DOI 10.1016/S0002-9149(96)00487-0
   Samson RH, 1998, CARDIOVASC SURG, V6, P475, DOI 10.1016/S0967-2109(98)00018-0
   SCHWARTZ RB, 1992, AM J ROENTGENOL, V159, P1057, DOI 10.2214/ajr.159.5.1414775
   TAYLOR DW, 1991, NEW ENGL J MED, V325, P445
   THERON J, 1990, AM J NEURORADIOL, V11, P869
   Theron J, 1996, J ENDOVASC SURG, V3, P484, DOI 10.1583/1074-6218(1996)003<0484:>2.0.CO;2
   Wain RA, 1999, J AM COLL SURGEONS, V189, P93, DOI 10.1016/S1072-7515(99)00070-8
   WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035
   WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P
   Wholey MH, 1997, J ENDOVASC SURG, V4, P326, DOI 10.1583/1074-6218(1997)004<0326:ESFCAO>2.0.CO;2
   Wholey MH, 1998, CATHETER CARDIO DIAG, V44, P1
   Zarins CK, 1996, J ENDOVASC SURG, V3, P10, DOI 10.1583/1074-6218(1996)003<0010:CETGS>2.0.CO;2
NR 46
TC 87
Z9 90
U1 0
U2 6
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD MAR
PY 2001
VL 33
IS 3
BP 504
EP 509
DI 10.1067/mva.2001.112278
PG 6
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 410JT
UT WOS:000167437400009
PM 11241119
OA Bronze
DA 2021-08-04
ER

PT J
AU Liu, YX
   Beveridge, DL
AF Liu, YX
   Beveridge, DL
TI A refined prediction method for gel retardation of DNA oligonucleotides
   from dinucleotide step parameters: Reconciliation of DNA bending models
   with crystal structure data
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article
ID DOUBLE-HELICAL DNA; SEQUENCE-DIRECTED CURVATURE; NUCLEIC-ACID DATABASE;
   B-DNA; CURVED DNA; MOLECULAR-DYNAMICS; ADENINE TRACT; A-TRACTS; AGENT
   2-METHYL-2,4-PENTANEDIOL; CONFORMATIONAL MAPS
AB The development and assessment or a prediction method for gel retardation and sequence dependent curvature of DNA based on dinucleotide step parameters are described. The method is formulated using the Babcock-Olson equations for base pair step geometry ii) and employs Monte Carte simulated annealing for parameter optimization against experimental data. The refined base pair step parameters define a structural construct which, when the width of observed parameter distributions is taken into account, is consistent with the results of DNA oligonucleotide crystal structures. The predictive power of the method is demonstrated and rested via comparisons with DNA bending data on sets of sequences not included in the training set, including A-tracts with and without periodic helix phasing, phased A(4)T(4) and T(4)A(4) motifs, a sequence with a phased GGGCCC motif, some "unconventional" helix phasing sequences, and three short fragments of kinetoplast DNA from Crithidia fasiculata that exhibit significantly different behavior on non-denaturing polyacrylamide gels. The nature of the structural construct produced by the methodology is discussed with respect to static and dynamic models of structure and representations of bending and bendability. An independent theoretical account of sequence dependent chemical footprinting results is provided. Detailed analysis of sequences with A-tract induced axis bending forms the basis for a critical discussion of the applicability of wedge models, junction models and non A-tract, general sequence models for understanding the origin of DNA curvature at the molecular level.
C1 Wesleyan Univ, Dept Chem, Middletown, CT 06459 USA.
   Wesleyan Univ, Mol Biophys Program, Middletown, CT 06459 USA.
RP Beveridge, DL (corresponding author), Wesleyan Univ, Dept Chem, Middletown, CT 06459 USA.
FU NIGMS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [GM37909] Funding Source: Medline; NATIONAL
   INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of General Medical Sciences (NIGMS) [R37GM037909, R01GM037909]
   Funding Source: NIH RePORTER
CR AKAIKE H, 1978, ANN I STAT MATH, V30, P9, DOI 10.1007/BF02480194
   BABCOCK MS, 1994, J MOL BIOL, V237, P125, DOI 10.1006/jmbi.1994.1213
   Berman HM, 1996, PROG BIOPHYS MOL BIO, V66, P255, DOI 10.1016/S0079-6107(97)00019-9
   BERMAN HM, 1992, BIOPHYS J, V63, P751, DOI 10.1016/S0006-3495(92)81649-1
   Beveridge DL, 2000, CURR OPIN STRUC BIOL, V10, P182, DOI 10.1016/S0959-440X(00)00076-2
   BEVERIDGE DL, 1998, ENCY COMPUTATIONAL C
   BOLSHOY A, 1991, P NATL ACAD SCI USA, V88, P2312, DOI 10.1073/pnas.88.6.2312
   Bonvin AMJJ, 2000, EUR BIOPHYS J BIOPHY, V29, P57, DOI 10.1007/s002490050251
   BRESLAUER KJ, 1992, METHOD ENZYMOL, V211, P533
   BRUKNER I, 1995, EMBO J, V14, P1812, DOI 10.1002/j.1460-2075.1995.tb07169.x
   BRUKNER I, 1991, NUCLEIC ACIDS RES, V19, P3549, DOI 10.1093/nar/19.13.3549
   BRUKNER I, 1993, NUCL ACIDS RES, V21
   BUC H, 1986, BIOCHEM SOC T, V14, P196, DOI 10.1042/bst0140196
   BURKHOFF AM, 1988, NATURE, V331, P455, DOI 10.1038/331455a0
   CACCHIONE S, 1989, BIOCHEMISTRY-US, V28, P8706, DOI 10.1021/bi00448a006
   Calladine C. R., 1997, UNDERSTANDING DNA MO
   CALLADINE CR, 1988, J MOL BIOL, V201, P127, DOI 10.1016/0022-2836(88)90444-5
   Chan SS, 1997, BIOPHYS J, V72, P1512, DOI 10.1016/S0006-3495(97)78799-X
   DESANTIS P, 1990, BIOCHEMISTRY-US, V29, P9269, DOI 10.1021/bi00491a023
   Dickerson RE, 1996, J MOL BIOL, V256, P108, DOI 10.1006/jmbi.1996.0071
   Dickerson RE, 1997, BIOPOLYMERS, V44, P321, DOI 10.1002/(SICI)1097-0282(1997)44:4<321::AID-BIP1>3.0.CO;2-9
   DICKERSON RE, 1997, P 10 CONV STAT U NEW, P17
   Dickerson RE, 1989, EMBO J, V8, P1
   Dlakic M, 1996, J BIOL CHEM, V271, P17911, DOI 10.1074/jbc.271.30.17911
   Dlakic M, 1998, NUCLEIC ACIDS RES, V26, P4274, DOI 10.1093/nar/26.18.4274
   ELCOCK AH, 1995, J AM CHEM SOC, V117, P10161, DOI 10.1021/ja00145a047
   ElHassan MA, 1996, J MOL BIOL, V259, P95, DOI 10.1006/jmbi.1996.0304
   ELHASSAN MA, 1995, J MOL BIOL, V251, P648, DOI 10.1006/jmbi.1995.0462
   FRIEDMAN RA, 1995, BIOPHYS J, V69, P1528, DOI 10.1016/S0006-3495(95)80023-8
   Ganunis RM, 1996, BIOCHEMISTRY-US, V35, P13729, DOI 10.1021/bi961880q
   GOODSELL DS, 1994, NUCLEIC ACIDS RES, V22, P5497, DOI 10.1093/nar/22.24.5497
   GOODSELL DS, 1993, P NATL ACAD SCI USA, V90, P2930, DOI 10.1073/pnas.90.7.2930
   GORIN AA, 1995, J MOL BIOL, V247, P34, DOI 10.1006/jmbi.1994.0120
   GRIFFITH JD, 1988, STRUCTURE EXPRESSION
   HAGERMAN PJ, 1986, NATURE, V321, P449, DOI 10.1038/321449a0
   HAGERMAN PJ, 1985, BIOCHEMISTRY-US, V24, P7033, DOI 10.1021/bi00346a001
   HAGERMAN PJ, 1990, ANNU REV BIOCHEM, V59, P755, DOI 10.1146/annurev.bi.59.070190.003543
   HARVEY SC, 1995, J BIOMOL STRUCT DYN, V13, P301, DOI 10.1080/07391102.1995.10508841
   HUNTER CA, 1993, J MOL BIOL, V230, P1025, DOI 10.1006/jmbi.1993.1217
   IOSHIKHES I, 1992, J BIOMOL STRUCT DYN, V9, P1111, DOI 10.1080/07391102.1992.10507982
   KABSCH W, 1982, NUCLEIC ACIDS RES, V10, P1097, DOI 10.1093/nar/10.3.1097
   KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0
   KOO HS, 1990, BIOCHEMISTRY-US, V29, P4227, DOI 10.1021/bi00469a027
   KOO HS, 1988, P NATL ACAD SCI USA, V85, P1763, DOI 10.1073/pnas.85.6.1763
   LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728
   LAVERY R, 1996, I BIOL PHYSICO CHIMI
   LIU Y, 2000, UNPUB
   LIU Y, 2000, DISTRIBUTION HELICOI
   MARINI JC, 1982, P NATL ACAD SCI-BIOL, V79, P7664, DOI 10.1073/pnas.79.24.7664
   MAROUN RC, 1988, BIOPOLYMERS, V27, P561, DOI 10.1002/bip.360270403
   MAROUN RC, 1988, BIOPOLYMERS, V27, P585, DOI 10.1002/bip.360270404
   MCCONNELL KJ, 2000, UNPUB
   MCCONNELL KJ, 2000, IN PRESS J MOL BIOL
   METROPOLIS N, 1953, J CHEM PHYS, V21, P1087, DOI 10.1063/1.1699114
   Munteanu MG, 1998, TRENDS BIOCHEM SCI, V23, P341, DOI 10.1016/S0968-0004(98)01265-1
   Olson WK, 1996, BIOLOGICAL STRUCTURE AND DYNAMICS, VOL 2, P341
   OLSON WK, 1988, STRUCTURE EXPRESSION, P225
   OLSON WK, 1985, BIOMOLECULAR STEREOD, V4, P75
   Packer MJ, 2000, J MOL BIOL, V295, P71, DOI 10.1006/jmbi.1999.3236
   Packer MJ, 2000, J MOL BIOL, V295, P85, DOI 10.1006/jmbi.1999.3237
   Pedersen AG, 1998, J MOL BIOL, V281, P663, DOI 10.1006/jmbi.1998.1972
   PILCH DS, 1995, CURR OPIN STRUC BIOL, V5, P334, DOI 10.1016/0959-440X(95)80095-6
   PRICE MA, 1993, BIOCHEMISTRY-US, V32, P127, DOI 10.1021/bi00052a018
   Rouzina I, 1998, BIOPHYS J, V74, P3152, DOI 10.1016/S0006-3495(98)78021-X
   SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3
   Shakked Z., 1999, OXFORD HDB NUCL ACID, P455
   SHRADER TE, 1990, J MOL BIOL, V216, P69, DOI 10.1016/S0022-2836(05)80061-0
   Sinden R. R., 1994, DNA STRUCTURE FUNCTI
   Sprous D, 1999, J MOL BIOL, V285, P1623, DOI 10.1006/jmbi.1998.2241
   SPROUS D, 1995, NUCLEIC ACIDS RES, V23, P1816, DOI 10.1093/nar/23.10.1816
   SRINIVASAN AR, 1987, J BIOMOL STRUCT DYN, V5, P459, DOI 10.1080/07391102.1987.10506409
   SUNDARALINGAM M, 1988, STRUCTURE EXPRESSION, V3, P9
   Suzuki M, 1997, J MOL BIOL, V274, P421, DOI 10.1006/jmbi.1997.1406
   TRIFONOV EN, 1985, CRC CR REV BIOCH MOL, V19, P89, DOI 10.3109/10409238509082540
   TULLIUS TD, 1988, STRUCTURE EXPRESSION, V3, P77
   ULYANOV NB, 1984, J BIOMOL STRUCT DYN, V2, P361, DOI 10.1080/07391102.1984.10507573
   Ulyanov NB, 1995, METHOD ENZYMOL, V261, P90
   WANG W, 2000, UNPUB
   YANAGI K, 1991, J MOL BIOL, V217, P201, DOI 10.1016/0022-2836(91)90620-L
   Young MA, 1995, METHOD ENZYMOL, V261, P121
   Young MA, 1998, J MOL BIOL, V281, P675, DOI 10.1006/jmbi.1998.1962
   Young MA, 1997, J AM CHEM SOC, V119, P59, DOI 10.1021/ja960459m
   1992, CAMBRIDGE U PRESS, P444
NR 83
TC 24
Z9 25
U1 0
U2 1
PU ADENINE PRESS INC
PI GUILDERLAND
PA PO BOX 355/340, GUILDERLAND, NY 12084 USA
SN 0739-1102
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
PD FEB
PY 2001
VL 18
IS 4
BP 505
EP 526
DI 10.1080/07391102.2001.10506684
PG 22
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 426NZ
UT WOS:000168356400002
PM 11245247
DA 2021-08-04
ER

PT J
AU Shibanai, Y
   Yasuno, S
   Ishiguro, I
AF Shibanai, Y
   Yasuno, S
   Ishiguro, I
TI Effects of global information feedback on diversity - Extensions to
   Axelrod's adaptive culture model
SO JOURNAL OF CONFLICT RESOLUTION
LA English
DT Article
ID POLARIZATION
AB Based on Axelrod's adaptive culture model, the effects of the distribution of global information feedback are examined in two simulations. The first model is the generalized other model, where the most preferred features are hypothesized to represent the mental model of the most ordinary person and have the same influential power as real neighbors. The second model is the filter model, where neighbors are influential only when their traits are concordant with the most common trait among whole agents. In both simulations, the global distribution of information facilitated an earlier convergence and maintenance of cultural diversity. These counterintuitive results suggest that information about a global society, for example mass media coverage, would provide support for a local minority.
C1 Doshisha Univ, Dept Social Sci, Kyoto, Japan.
   Kagawa Univ, Dept Reg & Social Syst, Takamatsu, Kagawa 760, Japan.
   Univ Tokyo, Dept Social Psychol, Tokyo, Japan.
RP Shibanai, Y (corresponding author), Doshisha Univ, Dept Social Sci, Kyoto, Japan.
RI SHIBANAI, Yasufumi/H-6400-2018
OI SHIBANAI, Yasufumi/0000-0001-9395-0512
CR Axelrod R, 1997, J CONFLICT RESOLUT, V41, P203, DOI 10.1177/0022002797041002001
   DAVISON WP, 1983, PUBLIC OPIN QUART, V47, P1, DOI 10.1086/268763
   FIELDS JM, 1976, PUBLIC OPINION Q, V0040
   Huckfeldt R., 1995, CITIZENS POLITICS SO
   ISHIGURO IS, 2000, JAPANESE J SOCIAL PS, V16, P114
   IYENGAR S, 1987, NEWS THAT MATTERS AG
   Iyengar Shanto., 1991, IS ANYONE RESPONSIBL
   Katz E., 1955, PERSONAL INFLUENCE
   Kennedy J, 1998, J CONFLICT RESOLUT, V42, P56, DOI 10.1177/0022002798042001003
   LATANE B, 1994, BEHAV SCI, V39, P1, DOI 10.1002/bs.3830390102
   Latane B, 1996, J PERS SOC PSYCHOL, V70, P1218
   Lazarsfeld P., 1948, PEOPLES CHOICE
   MARKS G, 1987, PSYCHOL BULL, V102, P72, DOI 10.1037/0033-2909.102.1.72
   MCCOMBS ME, 1972, PUBLIC OPIN QUART, V36, P176, DOI 10.1086/267990
   MEAD GH, 1934, MIND SELF SOCIETY ST
   Mutz D. C., 1998, IMPERSONAL INFLUENCE
   MUTZ DC, 1994, RES MICROPOLITICS, V4, P143, DOI DOI 10.2307/3088437
   Noelle-Neumann E, 1993, SPIRAL SILENCE PUBLI
   OLIEN CN, 1995, PUBLIC OPINION COMMU, P314
   Oshagan H, 1996, INT J PUBLIC OPIN R, V8, P335
   Rogers E. M., 1982, DIFFUSION INNOVATION
   ROSS L, 1977, J EXP SOC PSYCHOL, V13, P279, DOI 10.1016/0022-1031(77)90049-X
   Schelling T. C., 1978, MICROMOTIVES MACROBE
NR 23
TC 71
Z9 72
U1 0
U2 11
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022-0027
J9 J CONFLICT RESOLUT
JI J. Confl. Resolut.
PD FEB
PY 2001
VL 45
IS 1
BP 80
EP 96
DI 10.1177/0022002701045001004
PG 17
WC International Relations; Political Science
SC International Relations; Government & Law
GA 418XB
UT WOS:000167918700004
DA 2021-08-04
ER

PT J
AU Dolnik, M
   Zhabotinsky, AM
   Epstein, IR
AF Dolnik, M
   Zhabotinsky, AM
   Epstein, IR
TI Resonant suppression of Turing patterns by periodic illumination
SO PHYSICAL REVIEW E
LA English
DT Article
ID CHLORINE DIOXIDE; LIGHT; IODINE; INSTABILITY; OSCILLATION; DYNAMICS;
   STATE
AB We study the resonant behavior of Turing. pattern suppression in a model of the chlorine dioxide-iodine-malonic acid reaction with periodic illumination. The results of simulations based on integration of partial differential equations display resonance at the frequency of autonomous oscillations in the corresponding well stirred system. The resonance in Turing pattern suppression is sharper at lower complexing agent concentration and is affected by the waveform of the periodic driving force. Square wave ton-off) periodic forcing is more effective in suppressing Turing patterns than sinusoidal forcing. We compare the dynamics of periodically forced Turing patterns with the dynamics of periodically forced nonhomogeneous states in a system of two identical coupled cells. Bifurcation analysis based on numerical continuation of the latter system gives good predictions for the boundaries of the major resonance regions of the periodically forced patterns.
C1 Brandeis Univ, Dept Chem, Waltham, MA 02454 USA.
   Brandeis Univ, Volen Ctr Complex Syst, Waltham, MA 02454 USA.
RP Dolnik, M (corresponding author), Brandeis Univ, Dept Chem, Waltham, MA 02454 USA.
CR CASTETS V, 1990, PHYS REV LETT, V64, P2953, DOI 10.1103/PhysRevLett.64.2953
   DOEDEL E, 1986, AUTO SOFTWARE CONTIN
   DOLNIK M, 1989, J PHYS CHEM-US, V93, P2764, DOI 10.1021/j100344a015
   Fecher F, 1999, CHEM PHYS LETT, V313, P205, DOI 10.1016/S0009-2614(99)01033-7
   GLASS L, 1982, PHYS REV LETT, V48, P1772, DOI 10.1103/PhysRevLett.48.1772
   Horvath AK, 2000, J PHYS CHEM A, V104, P5766, DOI 10.1021/jp000352s
   Horvath AK, 1999, PHYS REV LETT, V83, P2950, DOI 10.1103/PhysRevLett.83.2950
   JENSEN O, 1993, PHYS LETT A, V179, P91, DOI 10.1016/0375-9601(93)90655-J
   Kadar S, 1997, J PHYS CHEM A, V101, P8200, DOI 10.1021/jp971937y
   KEVREKIDIS IG, 1986, CHEM ENG SCI, V41, P1549, DOI 10.1016/0009-2509(86)85237-X
   KUHNERT L, 1989, NATURE, V337, P244, DOI 10.1038/337244a0
   LENGYEL I, 1991, SCIENCE, V251, P650, DOI 10.1126/science.251.4994.650
   LENGYEL I, 1993, ACCOUNTS CHEM RES, V26, P235, DOI 10.1021/ar00029a002
   Lengyel I, 1991, CHAOS, V1, P69, DOI 10.1063/1.165819
   Lin AL, 2000, PHYS REV LETT, V84, P4240, DOI 10.1103/PhysRevLett.84.4240
   LUBICEK M, 1983, COMPUTATIONAL METHOD
   Marek M., 1991, CHAOTIC BEHAV DETERM
   Munuzuri AP, 1999, J AM CHEM SOC, V121, P8065, DOI 10.1021/ja9910457
   OUYANG Q, 1991, NATURE, V352, P610, DOI 10.1038/352610a0
   Petrov V, 1997, NATURE, V388, P655, DOI 10.1038/41732
   Petrov V, 1996, J PHYS CHEM-US, V100, P18992, DOI 10.1021/jp961392s
   PRIGOGIN.I, 1968, J CHEM PHYS, V48, P1695, DOI 10.1063/1.1668896
   Rudovics B, 1999, J PHYS CHEM A, V103, P1790, DOI 10.1021/jp983210v
   SCHREIBER I, 1986, J STAT PHYS, V43, P489, DOI 10.1007/BF01020650
   STEINBOCK O, 1993, NATURE, V366, P322, DOI 10.1038/366322a0
   TOMITA K, 1982, PHYS REP, V86, P113, DOI 10.1016/0370-1573(82)90148-X
   TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012
   TYSON J, 1975, J MATH BIOL, V1, P289, DOI 10.1007/BF00279848
   Vanag VK, 2000, NATURE, V406, P389, DOI 10.1038/35019038
   Watzl M, 1998, J PHYS CHEM A, V102, P2540, DOI 10.1021/jp9727411
   ZHABOTINSKY AM, 1995, J CHEM PHYS, V103, P10306, DOI 10.1063/1.469932
NR 31
TC 55
Z9 55
U1 3
U2 9
PU AMER PHYSICAL SOC
PI COLLEGE PK
PA ONE PHYSICS ELLIPSE, COLLEGE PK, MD 20740-3844 USA
SN 1539-3755
EI 1550-2376
J9 PHYS REV E
JI Phys. Rev. E
PD FEB
PY 2001
VL 63
IS 2
AR 026101
DI 10.1103/PhysRevE.63.026101
PN 2
PG 10
WC Physics, Fluids & Plasmas; Physics, Mathematical
SC Physics
GA 403BK
UT WOS:000167022500010
PM 11308536
DA 2021-08-04
ER

PT J
AU Frigerio, F
   Carluccio, L
   Parker, WO
   Millini, R
AF Frigerio, F
   Carluccio, L
   Parker, WO
   Millini, R
TI Dynamic behaviour of azonia-spiro-alkanes within the MOR and MTW zeolite
   pore structures
SO JOURNAL OF MOLECULAR CATALYSIS A-CHEMICAL
LA English
DT Article; Proceedings Paper
CT Symposium on Material Simulation for the 21st Century
CY AUG   03, 1999
CL CATHOLIC UNIV, ARENBERG CASTLE, LEUVEN, BELGIUM
HO CATHOLIC UNIV, ARENBERG CASTLE
DE molecular dynamics; Monte Carlo; zeolite; template; mobility
ID CRYSTAL-STRUCTURE
AB The molecular packing stability and the dynamic behaviour of three azonia-spiro-alkanes involved as structure determining agents in the zeolite synthesis has been examined in the frameworks of MOR and MTW. A detailed molecular model has been set up by computer graphics methods and used to perform Monte Carlo packing and molecular dynamics simulations. The energetic stabilisation and molecular mobility have been calculated and compared to previous experimental characterisation data. The results are found useful to discuss the packing preferences of this class of molecules in the zeolite pores under investigation, with the aim of rationalising their templating ability and selectivity. (C) 2001 Elsevier Science B.V. All rights reserved.
C1 EniTecnol SpA, I-20097 San Donato Milanese, MI, Italy.
RP Frigerio, F (corresponding author), EniTecnol SpA, Via F Maritano 26, I-20097 San Donato Milanese, MI, Italy.
OI Parker, Wallace/0000-0002-2944-8533
CR ALBERTI A, 1986, Z KRISTALLOGR, V175, P249, DOI 10.1524/zkri.1986.175.3-4.249
   CARLUCCIO L, 1997, Patent No. 0796821
   FYFE CA, 1990, J PHYS CHEM-US, V94, P3718, DOI 10.1021/j100372a066
   GIES H, 1992, ZEOLITES, V12, P42, DOI 10.1016/0144-2449(92)90008-D
   HILL JR, 1994, J PHYS CHEM-US, V98, P1238, DOI 10.1021/j100055a032
   LEWIS DW, 1995, J PHYS CHEM-US, V99, P11194, DOI 10.1021/j100028a022
   Millini R, 1998, MICROPOR MESOPOR MAT, V24, P199, DOI 10.1016/S1387-1811(98)00165-6
   *MOL SIM INC, 1996, INS 2 CAT 4 0 0 DISC
   Szostak R., 1989, MOL SIEVES PRINCIPLE
NR 9
TC 5
Z9 5
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1381-1169
J9 J MOL CATAL A-CHEM
JI J. Mol. Catal. A-Chem.
PD JAN 22
PY 2001
VL 166
IS 1
BP 167
EP 174
DI 10.1016/S1381-1169(00)00461-1
PG 8
WC Chemistry, Physical
SC Chemistry
GA 397WR
UT WOS:000166721300016
DA 2021-08-04
ER

PT J
AU Lopez-Rodriguez, ML
   Morcillo, MJ
   Fernandez, E
   Rosado, ML
   Pardo, L
   Schaper, KJ
AF Lopez-Rodriguez, ML
   Morcillo, MJ
   Fernandez, E
   Rosado, ML
   Pardo, L
   Schaper, KJ
TI Synthesis and structure-activity relationships of a new model of
   arylpiperazines. 6. Study of the 5-HT1A/alpha(1)-adrenergic receptor
   affinity by classical Hansch analysis, artificial neural networks, and
   computational simulation of ligand recognition
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID 5-HT1A RECEPTOR; BINDING; ANTAGONISTS; INHIBITORS; PROTEINS; AGONIST;
   AGENTS; ACIDS
AB A classical quantitative structure-activity relationship (Hansch) study and artificial neural networks (ANNs) have been applied to a training set of 32 substituted phenylpiperazines with affinity for 5-HT1A and alpha (1)-adrenergic receptors, to evaluate the structural requirements that are responsible for 5-HT1A/alpha (1) selectivity. The resulting models provide a significant correlation of electronic, steric, and hydrophobic parameters with the biological affinities. Although the derived linear Hansch correlations give good statistics and acceptable predictions, the introduction of nonlinear relationships in the analysis gives more solid models and more accurate predictions. In the ANN models on the basis of the obtained 3D plots, the 5-HT1A affinity has a nonlinear dependence on F, V-o, V-m, and pi (o), although the nonlinear relationship is not far from a planar one. The alpha (1)-adrenergic receptor affinity has a clear nonlinear dependence on F, V-o, V-m, pi (o), and pi (m). A comparison of both analyses gives an additional understanding for 5-HT1A/alpha (1) selectivity: (a) high F values increase the binding affinity for 5-HT1A receptors and decrease the affinity for alpha (1) sites; (b) the hydrophobicity at the meta-position has only influence for the alpha (1)-adrenergic receptor; (c) the meta-position seems to be implicated in the 5-HT1A/alpha (1) selectivity. While the 5-HT1A receptor is able to accommodate bulky substituents in the region of its active site, the steric requirements of the alpha (1)-adrenergic receptor at this position are more restricted. This information was used for the design of the new ligand EF-7412 (33) (5-HT1A: K-i (exptl) = 27 nM, alpha (1): K-i (exptl) > 1000 nM; 5-HT1A: K-i (pred) (ANN) = 36 nM, alpha (1): K-i (pred) (ANN) = 2745 nM) which was characterized as an antagonist in vivo in pre- and postsynaptic 5-HT1AR sites. Computational simulations of the complex between EF-7412 (33) and a 3D model of the transmembrane domain of the 5-HT1A receptor allowed us to define the molecular details of the ligand-receptor interaction that includes: (i) the ionic interaction between the protonated amine of the ligand and Asp 3.32; (ii) the hydrogen bonds between the m-NHSO2Et group of the ligand and Asn 7.39; and the hydrogen bonds between the hydantoin moiety of the ligand and (iii) Thr 3.37, (iv) Ser 5.42, and (v) Thr 5.43. These QSAR and ANN results in combination with computational simulations of ligand recognition will be useful for the design of potent selective 5-HT1A ligands.
C1 Univ Complutense, Fac Ciencias Quim, Dept Quim Organ 1, E-28040 Madrid, Spain.
   Univ Nacl Educ Distancia, Fac Ciencias, E-28040 Madrid, Spain.
   Univ Autonoma Barcelona, Fac Med, Unitat Bioestadist, Lab Med Computac, Bellaterra 08193, Spain.
   Res Ctr Borstel, D-23845 Borstel, Germany.
RP Lopez-Rodriguez, ML (corresponding author), Univ Complutense, Fac Ciencias Quim, Dept Quim Organ 1, E-28040 Madrid, Spain.
EM mluzlr@eucmax.sim.ucm.es
RI Lopez-Rodriguez, Maria L/S-6342-2016
OI Lopez-Rodriguez, Maria L/0000-0001-8607-1085; Pardo,
   Leonardo/0000-0003-1778-7420
CR AMBROSIO E, 1984, NEUROSCI LETT, V49, P193, DOI 10.1016/0304-3940(84)90159-9
   ANDREA TA, 1991, J MED CHEM, V34, P2824, DOI 10.1021/jm00113a022
   AOYAMA T, 1991, CHEM PHARM BULL, V39, P1222
   BALLANTYNE CK, 1995, HOLOCENE, V5, P25, DOI 10.1177/095968369500500104
   BENNET CA, 1963, STAT ANAL CHEM CHEM
   Bourne HR, 2000, SCIENCE, V289, P733, DOI 10.1126/science.289.5480.733
   CASE DA, 1997, AMBER 5
   Cavalli A, 1996, FEBS LETT, V399, P9, DOI 10.1016/S0014-5793(96)01286-0
   CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
   CIEPLAK P, 1995, J COMPUT CHEM, V16, P1357, DOI 10.1002/jcc.540161106
   CLARK RD, 1990, J MED CHEM, V33, P633, DOI 10.1021/jm00164a026
   CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002
   Devillers J., 1996, PRINCIPLES QSAR DRUG
   FLETCHER A, 1993, TRENDS PHARMACOL SCI, V14, P441, DOI 10.1016/0165-6147(93)90185-M
   FRISCH MJ, GAUSSIAN 98
   Glennon RA, 1996, MOL PHARMACOL, V49, P198
   GUAN XM, 1992, MOL PHARMACOL, V41, P695
   HANSCH C, 1964, J AM CHEM SOC, V86, P1616, DOI 10.1021/ja01062a035
   Hansch C., 1995, EXPLORING QSAR HYDRO
   HANSCH C, 1973, STRUCTURE ACTIVITY R, V1, P50
   HO BY, 1992, FEBS LETT, V312, P259, DOI 10.1016/0014-5793(92)80948-G
   KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399
   LopezRodriguez ML, 1996, J MED CHEM, V39, P4439, DOI 10.1021/jm960416g
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   LYON RA, 1986, J MED CHEM, V29, P630, DOI 10.1021/jm00155a008
   MARTIN GE, 1989, J MED CHEM, V32, P1052, DOI 10.1021/jm00125a020
   Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739
   Pardo Leonardo, 1996, Journal of Biomedical Science, V3, P98, DOI 10.1007/BF02255537
   RHEE AMV, 1996, DRUG DEVELOP RES, V37, P1
   RUMELHART DE, 1986, NATURE, V323, P533, DOI 10.1038/323533a0
   Schaper KJ, 1999, QUANT STRUCT-ACT REL, V18, P354, DOI 10.1002/(SICI)1521-3838(199910)18:4<354::AID-QSAR354>3.0.CO;2-2
   SCHAPER KJ, 1995, QSAR MOL MODELLING C, P73
   SO SS, 1992, J MED CHEM, V35, P3201, DOI 10.1021/jm00095a016
   SURYANARAYANA S, 1993, MOL PHARMACOL, V44, P111
   *TRIP ASS, SYBYL MOL MOD SYST V
   WILLIAMS SG, 1976, J AM CHEM SOC, V98, P508, DOI 10.1021/ja00418a030
   ZUPAN J, 1993, NEURAL NETWORKS CHEM
NR 37
TC 66
Z9 67
U1 0
U2 9
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD JAN 18
PY 2001
VL 44
IS 2
BP 198
EP 207
DI 10.1021/jm000930t
PG 10
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 394BV
UT WOS:000166504900008
PM 11170629
DA 2021-08-04
ER

PT S
AU Lucidarme, P
   Rongier, P
   Liegeois, A
AF Lucidarme, P
   Rongier, P
   Liegeois, A
GP IEEE
   IEEE
TI Implementation and evaluation of a reactive multi-robot system
SO 2001 IEEE/ASME INTERNATIONAL CONFERENCE ON ADVANCED INTELLIGENT
   MECHATRONICS PROCEEDINGS, VOLS I AND II
SE IEEE ASME International Conference on Advanced Intelligent Mechatronics
LA English
DT Proceedings Paper
CT IEEE/ASME International Conference on Advanced Intelligent Mechatronics
   (AIM 01)
CY JUL 08-12, 2001
CL COMO, ITALY
SP IEEE Ind Electr Soc, Amer Soc Mech Engineers, Dynam Syst & Control Div, IEEE Robot & Automat Soc, IEE Japan, ISCIE, IFAC, JSME, JSPE, Robot Soc Japan, SICE
DE multi-robots; autonomous mobile robots; distributed intelligence;
   reactive agents; modular hardware
ID ARCHITECTURE; COOPERATION
AB This paper presents the implementation of an experimental setup to study the behavior of a group of purely reactive mobile robots subject to serious unrecoverable failures: some of them have lost mobility, others have lost infrared vision. To survive, each robot must reach a supply center. The eventually degraded mission uses complementary capabilities of the two types of robots by letting a blind robot meeting by chance an invalid one, carry it The latter is able to "see" a supply center within a wide range. The hardware and software of the experimental devices are described, using very simple and low-cost components. Experiments are run with the robots in different initial positions. The results are compared to those obtained by many computer simulations and by a Markovian process model, both are also described.
C1 Univ Montpellier 2, LIRMM, F-34392 Montpellier, France.
RP Lucidarme, P (corresponding author), Univ Montpellier 2, LIRMM, 161 Rue Ada, F-34392 Montpellier, France.
EM lucidarm@lirmm.fr; rongier@lirmm.fr; liegeois@lirmm.fr
CR ARKIN RC, 1992, J ROBOTIC SYST, V9, P351, DOI 10.1002/rob.4620090304
   Botelho SC, 1999, ICRA '99: IEEE INTERNATIONAL CONFERENCE ON ROBOTICS AND AUTOMATION, VOLS 1-4, PROCEEDINGS, P1234, DOI 10.1109/ROBOT.1999.772530
   BROOKS RA, 1986, IEEE T ROBOTIC AUTOM, V2, P14, DOI 10.1109/JRA.1986.1087032
   MALMSTROM K, 1998, P 3 IFAC S INT AUT V, P37
   Martinoli A, 1999, ROBOT AUTON SYST, V29, P51, DOI 10.1016/S0921-8890(99)00038-X
   MORI A, 1998, DISTRIBUTED AUTONOMO, V3, P225
   NOREILS FR, 1993, INT J ROBOT RES, V12, P79, DOI 10.1177/027836499301200106
   Parker LE, 1998, IEEE T ROBOTIC AUTOM, V14, P220, DOI 10.1109/70.681242
   PINCHARD O, 1995, INTELLIGENT AUTONOMOUS SYSTEMS - IAS-4, P413
   Reynolds CW., 1987, SIGGRAPH COMPUT GRAP, V21, P25, DOI [DOI 10.1145/37402.37406, 10.1145/37402.37406]
   Rongier P, 2000, IEEE SYS MAN CYBERN, P3033, DOI 10.1109/ICSMC.2000.884463
   RONGIER P, 1999, P IEEE INT C SMC, P143
   Simonin O, 2000, DISTRIBUTED AUTONOMOUS ROBOTIC SYSTEMS, P35
   Simonin O., 2000, 6 INT C SIM AD BEH S, V6, P314
NR 14
TC 1
Z9 1
U1 0
U2 0
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
SN 2159-6255
BN 0-7803-6736-7
J9 IEEE ASME INT C ADV
PY 2001
BP 165
EP 170
PG 4
WC Automation & Control Systems; Computer Science, Artificial Intelligence;
   Engineering, Electrical & Electronic; Robotics
SC Automation & Control Systems; Computer Science; Engineering; Robotics
GA BS94R
UT WOS:000171467700032
DA 2021-08-04
ER

PT S
AU Goldenstein, S
   Karavelas, M
   Metaxas, D
   Guibas, L
   Goswami, A
AF Goldenstein, S
   Karavelas, M
   Metaxas, D
   Guibas, L
   Goswami, A
GP IEEE
   IEEE
   IEEE
TI Scalable dynamical systems for multi-agent steering and simulation
SO 2001 IEEE INTERNATIONAL CONFERENCE ON ROBOTICS AND AUTOMATION, VOLS
   I-IV, PROCEEDINGS
SE IEEE International Conference on Robotics and Automation ICRA
LA English
DT Proceedings Paper
CT IEEE International Conference on Robotics and Automation
CY MAY 21-26, 2001
CL SEOUL, SOUTH KOREA
SP IEEE Robot & Automat Soc, IEEE
ID DELAUNAY
AB We present a new methodology for agent modeling that is scalable and efficient. It is based on the integration of nonlinear dynamical systems and kinetic data structures. The method consists of three-layers that model steering, nocking, and crowding agent behaviors among moving and static obstacles in 2 and 3D. The first layer, the local layer is based on the the use of nonlinear dynamical systems theory and models low level behaviors, it is fast and efficient, and does not depend on the total number of agents in the environment. The use of dynamical systems allows the use of continuous numerical parameters with which we can modify the interaction of each agent with the environment. This creates controllable distinctive behaviors, The second layer, a global environment layer consists of a specifically designed kinetic data structure to track efficiently the immediate environment of each agent and know which obstacle/agents are near or visible to the given agent. This layer reduces the complexity in the local layer. In the third layer, a global planning layer, the problem of target tracking is generalized in a way that allows navigation in maze-like terrains, avoidance of local minima and cooperation between agents. We implement this layer based on two approaches that are suitable for different applications. One is to track the closest single moving or static target. The second is to use a pre-specified vector field. This vector can be generated automatically (with harmonic functions, for example) or based on user input to achieve tht desired output.
   We demonstrate the power of the approach through a series of experiments simulating single/multiple agents and crowds moving towards moving/static targets in complex environments.
C1 Univ Penn, Philadelphia, PA 19104 USA.
RP Goldenstein, S (corresponding author), Univ Penn, Philadelphia, PA 19104 USA.
EM siome@graphics.cis.upenn; menelaos@graphics.stanford.edu;
   dnm@graphics.cis.upenn; guibas@graphics.stanford.edu;
   ambarish.goswami@autodesk.com
RI Goldenstein, Siome/A-4468-2013
CR ARKAN R, 1990, J ROBOTICS AUTONOMOU, V6, P105
   Atkinson K. E., 1978, INTRO NUMERICAL ANAL
   Basch J, 1999, J ALGORITHM, V31, P1, DOI 10.1006/jagm.1998.0988
   BEARDON C, 1995, COMPUTER GRAPHICS DE, P217
   BLUMBERG B, 1997, AIII C AUT AG
   Cavazza M, 1998, IEEE COMPUT GRAPH, V18, P24, DOI 10.1109/38.708558
   Cheong Otfried, 1997, COMPUTATIONAL GEOMET
   CHEW LP, 1989, ALGORITHMICA, V4, P97
   CONNOLLY CI, 1992, INT S INT CONTR
   FACELLO MA, 1995, COMPUT AIDED GEOM D, V12, P349, DOI 10.1016/0167-8396(94)00018-N
   Funge J, 1999, COMP GRAPH, P29
   Goldenstein S, 1999, VISUAL COMPUT, V15, P349, DOI 10.1007/s003710050184
   GOLDENSTEIN S, 1998, P COMP AUT 98 JUN
   Guibas L. J., 1988, Proceedings of the Fourth Annual Symposium on Computational Geometry, P289, DOI 10.1145/73393.73423
   Guibas LJ, 1998, ROBOTICS: THE ALGORITHMIC PERSPECTIVE, P191
   GUIBAS LJ, 1992, LECT NOTES COMPUT SC, V570, P113
   Haykin S., 1998, NEURAL NETWORKS COMP
   HODGINS JK, 1997, ANN C SERIES, P153
   KHATIB O, 1986, INT J ROBOT RES, V5, P90, DOI 10.1177/027836498600500106
   KURLANDER D, 1995, P CHI 95 C, P472
   Large EW, 1999, INT J ROBOT RES, V18, P37, DOI 10.1177/027836499901800103
   NOSER H, 1995, COMPUTER GRAPHICS
   OPPENHEIM AV, 1983, SIGNAL SYSTEMS
   PERKO I, 1991, TEXTS APPL MATH
   PERLIN K, 1996, SIGGRAPH 96, P205
   Press W. H., 1992, NUMERICAL RECIPES C, V2nd
   REYNOLDS C, 1999, P GAM DEV C
   Reynolds CW., 1987, SIGGRAPH COMPUT GRAP, V21, P25, DOI [DOI 10.1145/37402.37406, 10.1145/37402.37406]
   Ridsdale G., 1990, Journal of Visualization and Computer Animation, V1, P66
   Sato K., 1993, Advanced Robotics, V7, P449
   Schoner G, 1995, ROBOT AUTON SYST, V16, P213, DOI 10.1016/0921-8890(95)00049-6
   STEINHAGE A, 1997, P IEEE INT S IND EL
   THALMANN NM, 1995, P IEEE, V83, P1022, DOI 10.1109/5.390120
   Tu X., 2000, P 28 ACM ANN C COMP, P43, DOI [DOI 10.1145/192161.192170, 10.1145/192161.192170]
   VINCKLE S, 1997, GAME DEV         JUN
   WILFONG G, 1988, P 4 ACM S COMP GEOM, P179
NR 36
TC 1
Z9 1
U1 0
U2 0
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
SN 1050-4729
EI 2577-087X
BN 0-7803-6576-3
J9 IEEE INT CONF ROBOT
PY 2001
BP 3973
EP 3980
PG 8
WC Automation & Control Systems; Engineering, Electrical & Electronic;
   Robotics
SC Automation & Control Systems; Engineering; Robotics
GA BT31J
UT WOS:000172615800633
OA Green Submitted
DA 2021-08-04
ER

PT J
AU Balicka-Ramisz, A
AF Balicka-Ramisz, A
TI Studies on the influence of coccidiostats and selenium on the course of
   coccidiosis in lambs
SO ACTA PARASITOLOGICA
LA English
DT Article
DE lambs; infection rate; coccidiostats; selenium
ID SHEEP
AB The studies were carried out on 120 lambs in the weight range 21-22.5 kg, divided into the following groups control (A); treated with salinomycin 0.6 mg/kg body weight, (B); treated with selenium (Se) - 2 mi of 0.1% solution monthly (C); treated with salinomycin and Se as above (D); treated with toltrazuril 20 mg/kg body weight, twice at the age of 110 and 117 of days (E); and treated with selenium and toltrazuril (F) as above. The selenium level was determined with the Watkinson method. The extensity and intensity of coccidia infection were examined using the Willis-Schlaaf and McMaster methods. The body weight was recorded monthly. The coccidiostats salinomycin and toltrazuril were highly efficient against Eimeria and are suited for coccidiosis prophylaxis in lambs. In particular toltrazuril is active against all intracellular stages, and can be used for controlling and treatment coccidiosis. The use of coccidiostats simultaneously with selenium had increased the body weight gains in lambs. The best results were obtained in experimental groups in which both agents were used. The results of the studies show, that selenium enhances the activity of coccidiostats. It seems to be useful to administer selenium simultaneously with coccidiostats as an agent aiding their efficiency when controlling the coccidiosis.
C1 Univ Agr, Dept Anim Hyg & Prophylaxis, PL-71466 Szczecin, Poland.
RP Balicka-Ramisz, A (corresponding author), Univ Agr, Dept Anim Hyg & Prophylaxis, Dr Judyma 6, PL-71466 Szczecin, Poland.
RI Balicka-Ramisz, Aleksandra/W-6891-2018
OI Balicka-Ramisz, Aleksandra/0000-0002-3111-8648
CR ANDERSON PH, 1983, VET REC, V113, P498, DOI 10.1136/vr.113.21.498
   Andrews E D, 1976, N Z Vet J, V24, P111, DOI 10.1080/00480169.1976.34296
   BALICKALAURANS A, 1992, MAT 9 K PTNW 17 19 S, P20
   BIRD M, 1974, NEW ZEAL J AGR, V129, P19
   CIURUS J, 1988, ROCZ NAUK ZOOT MONOG, V26, P159
   COLNAGO GL, 1984, POULTRY SCI, V63, P1136, DOI 10.3382/ps.0631136
   Coudert, 1995, BIOTECHNOLOGY GUIDEL
   FAGASINSKI A, 1973, MED WETER, V29, P388
   GRACE ND, 1990, NEW ZEAL J AGR RES, V33, P635, DOI 10.1080/00288233.1990.10428468
   GRZEBULA S, 1977, Polskie Archiwum Weterynaryjne, V20, P125
   PELLERDY L, 1974, COCCIDIA COCCIDIOSIS
   Pinkiewicz E, 1986, NOW WET, V16, P13
   RAMISZ A, 1989, COLLOQ INRA, V49, P431
   Thienpont D., 1986, DIAGNOSING HELMINTHI, V2nd
NR 14
TC 1
Z9 2
U1 0
U2 2
PU VERSITA
PI WARSAW
PA SOLIPSKA 14A-1, 02-482 WARSAW, POLAND
SN 1230-2821
J9 ACTA PARASITOL
JI Acta Parasitolog.
PD JAN
PY 2001
VL 46
IS 1
BP 35
EP 38
PG 4
WC Parasitology; Veterinary Sciences; Zoology
SC Parasitology; Veterinary Sciences; Zoology
GA 404AR
UT WOS:000167075700007
DA 2021-08-04
ER

PT J
AU Gadanho, SC
   Hallam, J
AF Gadanho, SC
   Hallam, J
TI Robot learning driven by emotions
SO ADAPTIVE BEHAVIOR
LA English
DT Article
DE robotics; emotions; reinforcement learning
AB The adaptive value of emotions in nature indicates that they might also be useful in artificial creatures. Experiments were carried out to investigate this hypothesis in a simulated learning robot. For this purpose, a non-symbolic emotion model was developed that takes the form of a recurrent artificial neural network where emotions both depend on and influence the perception of the state of the world. This emotion model was integrated in a reinforcement-learning architecture with three different roles: influencing perception, providing reinforcement value, and determining when to reevaluate decisions. Experiments to test and compare this emotion-dependent architecture with a more conventional architecture were done in the context of a solitary learning robot performing a survival task. This research led to the conclusion that artificial emotions are a useful construct to have in the domain of behavior-based autonomous agents with multiple goals and faced with an unstructured environment, because they provide a unifying way to tackle different issues of control, analogous to natural systems' emotions.
C1 Univ Edinburgh, Dept Artificial Intelligence, Edinburgh EH8 9YL, Midlothian, Scotland.
RP Gadanho, SC (corresponding author), Inst Super Tecn, Inst Sistemas & Robot, Torne Norte 6-10,Av Rovisco Pais 1, P-1049001 Lisbon, Portugal.
EM sandra@isr.ist.utl.pt
CR Albus James S., 1990, P 5 IEEE INT S INT C
   ARAUJO AFR, 1994, THESIS SUSSEZ U
   ASADA M, 1996, P 1996 IROS WORKSH R, P19
   AUBE M, 1998, AAAI FALL S EM INT T, P13
   BATES J, 1992, ARTIFICIAL SOCIAL SY
   BATES J, 1994, CMUCS94136 CARN U SC
   BATES J, 1992, CMUCS92142 CARN U SC
   BEAUDOIN LP, 1993, FR ART INT, P229
   Bechara A, 1997, SCIENCE, V275, P1293, DOI 10.1126/science.275.5304.1293
   BECK RC, 1983, MOTIVATION THEORIES
   BLANEY PH, 1986, PSYCHOL BULL, V99, P229, DOI 10.1037/0033-2909.99.2.229
   Blumberg Bruce, 1996, THESIS MIT
   BOWER GH, 1981, AM PSYCHOL, V36, P129, DOI 10.1037/0003-066X.36.2.129
   BOWER GH, 1982, AFFECT COGNITION, P291
   Bozinovski S., 1982, CYBERNET SYST, P397
   BREAZEAL C, 1998, AAAI FALL S EM INT T, P31
   CANAMERO D, 1997, P 1 INT S AUT AG AA9
   CANAMERO D, 1998, AAAI FALL S EM INT T, P49
   CHARLAND LC, 1995, PHILOS PSYCHOL, V8, P59, DOI 10.1080/09515089508573145
   Cytowic RE, 1993, MAN WHO TASTED SHAPE
   Damasio AR., 1994, DESCARTES ERROR EMOT
   Darwin C., 1965, EXPRESSION EMOTIONS
   De Sousa R., 1987, RATIONALITY EMOTION
   Derryberry D., 1994, HEARTS EYE EMOTIONAL, P167, DOI DOI 10.1016/B978-0-12-410560-7.50014-4
   Dreyfus H.L., 1992, WHAT COMPUTERS STILL
   DYER MG, 1987, COGNITION EMOTION, V1, P323
   EKMAN P, 1992, COGNITION EMOTION, V6, P169, DOI 10.1080/02699939208411068
   ELNASR MS, 1998, AAAI FALL S EM INT T, P150
   FOLIOT G, 1998, WORKSH W5 GROUND EM, P25
   Frijda N. H., 1987, COGNITION EMOTION, V1, P235
   Gadanho SC, 1998, FROM ANIM ANIMAT, P354
   GADANHO SC, 2001, GROUNDING EMOTIONS A, V32, P531
   GADANHO SD, 1999, THESIS U EDINBURGH
   Goleman D., 1995, EMOTIONAL INTELLIGEN
   GROSSBERG S, 1987, PSYCHOL REV, V94, P300, DOI 10.1037/0033-295X.94.3.300
   HERTZ J, 1991, INTRO THEORY NEUTRAL
   IZARD CE, 1993, PSYCHOL REV, V100, P68
   Kaelbling LP, 1996, J ARTIF INTELL RES, V4, P237, DOI 10.1613/jair.301
   Kaiser S, 1996, P 9 C INT SOC RES EM, P276
   KITANO H, 1995, IJCAI95 P 14 INT JOI, V1, P532
   KLEIN JT, 1996, THESIS MIT
   LAZARUS RS, 1982, AM PSYCHOL, V37, P1019, DOI 10.1037/0003-066X.37.9.1019
   LeDoux J., 1998, EMOTIONAL BRAIN
   LIN LJ, 1992, MACH LEARN, V8, P293, DOI 10.1023/A:1022628806385
   LIN LJ, 1993, THESIS CARNEGIEMELLO
   MAHADEVAN S, 1992, ARTIF INTELL, V55, P311, DOI 10.1016/0004-3702(92)90058-6
   Mataric MJ, 1994, MACH LEARN, P181, DOI 10.1016/B978-1-55860-335-6.50030-1
   MCCAULEY L, 1998, AAAI FALL S EM INT T, P122
   MICHAUD F, 1996, ANIMALS ANIMALS, V4, P245
   MICHEL O, 1996, KHEPERA SIMULATOR PA
   Minsky ML., 1986, SOC MIND
   MORIGNOT P, 1995, AAAI SPR S REPR MENT, P97
   Mowrer O.H., 1960, LEARNING THEORY BEHA
   Niedenthal P. M., 1994, HEARTS EYE EMOTIONAL, P87, DOI 10.1016/b978-0-12-410560-7.50011-9
   Ortony A., 1988, COGNITIVE STRUCTURE
   PANKSEPP J, 1995, ADV BIOL PSYCH, V1, P263
   PFEIFER R, 1985, PROGR ARTIFICIAL INT, P184
   PFEIFER R, 1982, 436 CIP CARN U DEP P
   Picard R. W., 1997, AFFECTIVE COMPUTING
   POWER M, 1997, COGNITION EMOTION OR
   RODRIGUEZ M, 1995, LECT NOTES ARTIFICIA, V929
   SHAVER P, 1987, J PERS SOC PSYCHOL, V52, P1061, DOI 10.1037/0022-3514.52.6.1061
   Shibata T, 1996, IEEE INT CONF ROBOT, P2426, DOI 10.1109/ROBOT.1996.506527
   SIMON HA, 1967, PSYCHOL REV, V74, P29, DOI 10.1037/h0024127
   SLOMAN A, 1981, IJCAI 81, P2369
   Sloman A., 1994, P C INT SOC RES EM, P344
   Sutton R, 1998, INTRO REINFORCEMENT, V1st
   TODA M, 1994, 94102 SCCS CHUYK U
   TODAY M, 1993, 93101 SCCS CHUYK U
   TOMKINS SS, 1984, APPROACHES EMOTION
   VELASQUEZ JD, 1998, WORKSH W5 GROUND EM, P62
   VENTURA R, 1998, AAAI FALL S EM INT T, P170
   Watkins C. J. C. H., 1989, LEARNING DELAYED REW
   WEHRLE T, 1998, WORKSH W5 GROUND EM, P71
   WILSON SW, 1991, FROM ANIMALS TO ANIMATS, P15
   WRIGHT I, 1996, ANIMALS ANIMATS, V4, P273
   Zajonc RB, 1984, APPROACHES EMOTION
NR 77
TC 35
Z9 35
U1 0
U2 9
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1059-7123
EI 1741-2633
J9 ADAPT BEHAV
JI Adapt. Behav.
PY 2001
VL 9
IS 1
BP 42
EP 64
DI 10.1177/105971230200900102
PG 23
WC Computer Science, Artificial Intelligence; Psychology, Experimental;
   Social Sciences, Interdisciplinary
SC Computer Science; Psychology; Social Sciences - Other Topics
GA 561DC
UT WOS:000176121500004
DA 2021-08-04
ER

PT J
AU Toro, H
   Gonzalez, O
   Escobar, C
   Cerda, L
   Morales, MA
   Gonzalez, C
AF Toro, H
   Gonzalez, O
   Escobar, C
   Cerda, L
   Morales, MA
   Gonzalez, C
TI Vertical induction of the inclusion body hepatitis/hydropericardium
   syndrome with fowl adenovirus and chicken anemia virus
SO AVIAN DISEASES
LA English
DT Article
DE fowl; adenovirus; hepatitis; anemia; Chile
ID HEPATITIS HYDROPERICARDIUM SYNDROME; PATHOGENICITY; VALUES; CHILE; AGENT
AB The hypothesis that fowl adenovirus (FAV) and chicken anemia virus (CAV), transmitted vertically and simultaneously induce the inclusion body hepatitis (IBH)/hydropericardium (HP) syndrome in progeny chickens was tested. Thus, 35-wk-old light brown layer breeders, showing absence of antibodies against FAV and variable titers against CAV, were intramuscularly singly infected with the FAV serotype 4 isolate 341 or dually infected with CAV (isolate 10343) and FAV. All hens (groups A [FAV alone], B [FAV + CAV], and C [noninfected]) were clinically healthy throughout the experimental period. Both infectious viruses FAV and CAV were isolated from progenies obtained as early as 5 days after infection of their breeders. Hematocrit, serum proteins, and aspartate-aminotransferase values showed a few statistical differences between the progeny groups. Most of these differences were detected in the progeny chickens of group B. However, almost all values met reference values for the species. The pathologic findings showed that progeny chickens obtained from both singly and dually infected breeders developed macroscopic and histopathologic changes of IBH/HP. The pathologic findings shown by progeny chickens of group A (FAV) were not expected because neither synergism nor prior immunodepression by CAV was concurrent. Chickens of group B (CAV + FAV) also developed IBM/HP! Although not many differences in the evaluated parameters between groups A and B were statistically significant, most pathologic findings of group B indicated a more severe manifestation of the disease. However, because FAV alone did reproduce the syndrome, the results shown by group B would not allow a definitive confirmation of the hypothesis that the association of FAV and CAV is necessary for the successful induction of the IBH/HP syndrome in chickens when transmitted vertically.
C1 Univ Chile, Fac Vet Sci, Santiago, Chile.
   Minist Agr, Vet Sci Div, Santiago, Chile.
RP Toro, H (corresponding author), Univ Chile, Fac Vet Sci, Casilla 2,Correo 15, Santiago, Chile.
OI Gonzalez, Carlos/0000-0002-7639-0434
CR Bulow v.V., 1986, J VET MED B, V33, P717
   CEROLINI S, 1987, 22 S INT ZOOT MIL IT, P239
   COWEN B, 1982, J AM VET MED ASSOC, V181, P283
   COWEN B, 1978, AVIAN DIS, V22, P459, DOI 10.2307/1589301
   COWEN B, 1996, P INT S AD REOV INF, P79
   COWEN BS, 1992, WORLD POULTRY SCI J, V48, P247, DOI 10.1079/WPS19920019
   CUBILLOS A, 1986, ARCH MED VET, V18, P115
   DAWSON GJ, 1981, AM J VET RES, V42, P1833
   FADLY AM, 1976, AVIAN DIS, V20, P467, DOI 10.2307/1589379
   HEMBOLDT CF, 1963, AVIAN DIS, V7, P446
   Hodges R. D., 1977, Comparative clinical haematology,, P483
   Mazaheri A, 1998, AVIAN PATHOL, V27, P269, DOI 10.1080/03079459808419335
   MCFERRAN JB, 1991, DISEASES POULTRY, P552
   MCFERRAN JB, 1989, LAB MANUAL ISOLATION, P77
   MCNULTY MS, 1991, AVIAN PATHOL, V20, P187, DOI 10.1080/03079459108418756
   MCNULTY MS, 1989, LAB MANUAL ISOLATION, P108
   MELUZZI A, 1992, POULTRY SCI, V71, P337, DOI 10.3382/ps.0710337
   ROSS JG, 1978, VET REC, V102, P29, DOI 10.1136/vr.102.2.29
   SCHAT KA, 1989, LAB MANUAL ISOLATION, P167
   Toro H, 1997, AVIAN PATHOL, V26, P485, DOI 10.1080/03079459708419229
   Toro H, 2000, AVIAN DIS, V44, P51, DOI 10.2307/1592507
   Toro H, 1999, AVIAN DIS, V43, P262, DOI 10.2307/1592616
   VILLEGAS P, 1989, LAB MANUAL ISOLATION, P186
   WEICHSELBAUM T E, 1946, Am J Clin Pathol, V10, P40
   YUASA N, 1983, NATL I ANIM HEALTH Q, V23, P99
NR 25
TC 35
Z9 36
U1 0
U2 4
PU AMER ASSOC AVIAN PATHOLOGISTS
PI KENNETT SQ
PA UNIV PENN, NEW BOLTON CENTER, KENNETT SQ, PA 19348-1692 USA
SN 0005-2086
J9 AVIAN DIS
JI Avian Dis.
PD JAN-MAR
PY 2001
VL 45
IS 1
BP 215
EP 222
DI 10.2307/1593031
PG 8
WC Veterinary Sciences
SC Veterinary Sciences
GA 416LU
UT WOS:000167783000027
PM 11336070
DA 2021-08-04
ER

PT B
AU Seeley, TD
AF Seeley, TD
BE Gigerenzer, G
   Selten, R
TI Decision making in superorganisms - How collective wisdom arises from
   the poorly informed masses
SO BOUNDED RATIONALITY: THE ADAPTIVE TOOL
SE DAHLEM WORKSHOP REPORTS : ENVIRONMENTAL SCIENCES RESEARCH REPORT
LA English
DT Proceedings Paper
CT 84th Dahlem Workshop on Bounded Rationality
CY MAR 14-19, 1999
CL BERLIN, GERMANY
AB This chapter considers the mechanisms of decision making in groups that possess a high level of functional integration (superorganisms). Such groups, which include colonies of social insects, often possess impressive powers of decision making, especially with respect to simultaneous-option decisions. Since no one member of a social insect colony can possess a synoptic knowledge of its colony's options, or can perform the complex information processing needed to estimate the utility of each option and then choose among them, the concepts of bounded rationality and heuristics are highly relevant to solving the mystery of how colonies of social insects make decisions. To give substance to these ideas, one specific example of group decision making is examined: how honeybee swarms choose a home site. Experimental studies of this subject indicate that even though the swarm as a whole is a sophisticated and skilled decision-making agent, the cognitive skills required of the individual bees involved appear to be surprisingly simple.
C1 Cornell Univ, Neurobiol & Behav Sect, Ithaca, NY 14853 USA.
RI Gigerenzer, Gerd/A-6250-2012
OI Gigerenzer, Gerd/0000-0002-6163-5419
CR Dawkins R., 1982, EXTENDED PHENOTYPE
   DENEUBOURG JL, 1989, ETHOL ECOL EVOL, V1, P295, DOI 10.1080/08927014.1989.9525500
   FRANKS NR, 1987, BIOL J LINN SOC, V30, P229, DOI 10.1111/j.1095-8312.1987.tb00298.x
   Gigerenzer G., 1999, SIMPLE HEURISTICS MA, P3, DOI DOI 10.1177/1354067X0171006
   Griffin Donald R., 1992, ANIMAL MINDS
   LANDAUER M, 1961, COMMUNICATION SOCIAL
   LINDAUER M, 1955, Z VERGL PHYSIOL, V37, P263, DOI 10.1007/BF00303153
   MARKL H, 1985, EXPT BEHAV ECOLOGY S, P163
   Maynard Smith J., 1997, MAJOR TRANSITIONS EV
   Oster G.F., 1978, Monographs in Population Biology, pi
   Pamilo, 1996, EVOLUTION SOCIAL INS
   Pratt SC, 1998, ANIM BEHAV, V56, P603, DOI 10.1006/anbe.1998.0811
   SEELEY T, 1977, BEHAV ECOL SOCIOBIOL, V2, P201, DOI 10.1007/BF00361902
   Seeley T.D., 1995, WISDOM HIVE
   Seeley TD, 1999, BEHAV ECOL SOCIOBIOL, V45, P19, DOI 10.1007/s002650050536
   Simon H., 1981, SCI ARTIFICIAL
   Todd P. M., 1999, SIMPLE HEURISTICS MA, P287, DOI DOI 10.1111/.1745-9125.2010.00223.X
   Visscher PK, 1999, NATURE, V397, P400, DOI 10.1038/17047
   Von Frisch K., 1967, DANCE LANGUAGE ORIEN
   Wilson EO., 1971, INSECT SOC
   Winston M.L, 1987, BIOL HONEYBEE
   WINSTON ML, 1992, AM SCI, V80, P374
NR 22
TC 12
Z9 12
U1 0
U2 5
PU MIT PRESS
PI CAMBRIDGE
PA ONE ROGERS ST, CAMBRIDGE, MA 02142 USA
BN 0-262-07214-9
J9 DAHL WS ENV
PY 2001
BP 249
EP 261
PG 13
WC Social Sciences, Mathematical Methods; Psychology, Social
SC Mathematical Methods In Social Sciences; Psychology
GA BU36H
UT WOS:000175774300014
DA 2021-08-04
ER

PT B
AU McCabe, KA
   Smith, VL
AF McCabe, KA
   Smith, VL
BE Gigerenzer, G
   Selten, R
TI Goodwill accounting and the process of exchange
SO BOUNDED RATIONALITY: THE ADAPTIVE TOOL
SE DAHLEM WORKSHOP REPORTS : ENVIRONMENTAL SCIENCES RESEARCH REPORT
LA English
DT Proceedings Paper
CT 84th Dahlem Workshop on Bounded Rationality
CY MAR 14-19, 1999
CL BERLIN, GERMANY
AB Since the brain of any organism is a scarce resource, we expect to see specialization of cortical fields to solve content-dependent problems that occurred frequently over evolutionary time. We expect these solutions to exhibit bounded rationality in so far as the amount of information processing engaged on any problem is limited by the opportunity cost of cortical fields devoted to this problem. In this chapter we hypothesize that personal exchange is one of these problems. We begin by proposing a strategy called Goodwill Accounting for implementing reciprocal behavior that has been observed in both "Trust" and "Punishment" games. We hypothesize that this strategy represents a fast and frugal heuristic for tracking individual reputations without conscious awareness. We provide evidence for mental modules, studied by evolutionary psychologists, which together support this heuristic. These modules include friend-or-foe detection, cheater detection, and shared attention. We then examine the results from an agent-based simulation of this strategy in an ecology of prisoner's dilemma games. These simulations demonstrate the basic robustness of the strategy and suggest desirable parameter settings. We conclude with a discussion of the role of institutions as extensions of the mind's capacity for exchange.
C1 Univ Arizona, Econ Sci Lab, Tucson, AZ 85721 USA.
RI Gigerenzer, Gerd/A-6250-2012
OI Gigerenzer, Gerd/0000-0002-6163-5419
CR AMEDEN H, 1999, FREE RIDERS COOPERAT
   Axelrod R., 1997, COMPLEXITY COOPERATI
   Axelrod R., 2006, EVOLUTION COOPERATIO
   Baron-Cohen S., 1995, MINDBLINDNESS ESSAY
   Coleman J., 1990, FDN SOCIAL CHOICE TH
   COSMIDES L, 1989, COGNITION, V31, P187, DOI 10.1016/0010-0277(89)90023-1
   Cosmides L., 1992, ADAPTED MIND EVOLUTI, P163, DOI DOI 10.1098/RSTB.2006.1991
   CROSON RTA, 1998, THEORETIES ALTRUISM
   Hoffman RS, 1998, J TOXICOL-CLIN TOXIC, V36, P3, DOI 10.3109/15563659809162576
   KUHN HW, 1953, CONTRIBUTIONS THEORY
   MCCABE KA, 1989, J ECON BEHAV ORGAN, V12, P215, DOI 10.1016/0167-2681(89)90056-5
   MCCABE KA, 1999, STRATEGIC ANAL PLAYE
   North D.C., 1990, I I CHANGE EC PERFOR
   ORBELL JM, 1993, AM SOCIOL REV, V58, P787, DOI 10.2307/2095951
   Premack David, 1995, P205
   SCHELLING T, 1960, STRATEGIES CONFLICT
   1998, NY TIMES        1112
NR 17
TC 26
Z9 26
U1 0
U2 2
PU M I T PRESS
PI CAMBRIDGE
PA FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA
BN 0-262-07214-9
J9 DAHL WS ENV
PY 2001
BP 319
EP 340
PG 22
WC Social Sciences, Mathematical Methods; Psychology, Social
SC Mathematical Methods In Social Sciences; Psychology
GA BU36H
UT WOS:000175774300018
DA 2021-08-04
ER

PT J
AU Grotta, J
AF Grotta, J
CA Trial Investigators
TI Combination therapy stroke trial: Recombinant tissue-type plasminogen
   activator with/without lubeluzole
SO CEREBROVASCULAR DISEASES
LA English
DT Article
DE stroke; neuroprotection; thrombolysis; combination therapy
ID ACUTE ISCHEMIC STROKE; EXPERIMENTAL FOCAL ISCHEMIA; RANDOMIZED
   CONTROLLED TRIAL; THROMBOLYTIC THERAPY; NITRIC-OXIDE; DOUBLE-BLIND;
   ALTEPLASE; RATS; NEUROPROTECTION; REPERFUSION
AB Background. A neuroprotective drug may be safe and effective if given very early and in combination with recombinant tissue-type plasminogen activator (rt-PA) to acute stroke patients. No clinical trial has yet tested this hypothesis. Objective: To assess the feasibility, safety and efficacy of simultaneously combining the neuroprotective drug lubeluzole with rt-PA. Method. Patients who qualified for and received rt-PA within 3 h of symptom onset were randomly allocated 1:1 to lubeluzole (7.5 mg i.v. over 1 h, then continuous 5-day infusion of 10 mg/ day) or placebo. Infusion of the study medication was started before the end of the 1-hour rt-PA infusion. Inclusion criteria were the same as those of the FDA-approved guidelines for rt-PA, plus National Institutes of Health Stroke Scale (NIHSS) >5 and absence of serious ventricular arrhythmia, atrioventricular block or Q-T >450 ms. EKG was continuously monitored until 48 h after treatment. The primary outcomes were adverse events, especially hemorrhage and severe arrhythmia, and functionality as determined by the Barthel Index divided into >70,0-70 and dead. Results: 89 patients were randomized at 34 centers over 8 months. The study was terminated by the sponsor before the planned enrollment of 200 patients when a concurrent phase 3 trial of lubeluzole versus placebo given up to 8 h after stroke was negative. In our study, the mean NIHSS was 14.5, and the mean time from symptom onset to rt-PA was 2.5 h and to randomization to lubeluzole or placebo 3.2 h. Mortality was 26%, intracerebral hemorrhage occurred in 10% and serious adverse events in 51%. There were no differences between the two treatment groups in any of these variables, outcomes or in the Barthel Index or other measures of functionality. Conclusion: Combining neuroprotective drugs such as lubeluzole simultaneously with rt-PA is feasible and safe. The efficacy of this strategy, using a potentially more effective neuroprotective agent, should be evaluated in an adequately powered clinical trial. Copyright (C) 2001 S. Karger AG, Basel.
C1 Univ Texas, Sch Med, Stroke Program, Houston, TX 77030 USA.
RP Grotta, J (corresponding author), Univ Texas, Sch Med, Stroke Program, 6431 Fannin, Houston, TX 77030 USA.
CR Adams HP, 1996, STROKE, V27, P1711
   Albers GW, 2000, JAMA-J AM MED ASSOC, V283, P1145, DOI 10.1001/jama.283.9.1145
   Aronowski J, 1996, STROKE, V27, P1571, DOI 10.1161/01.STR.27.9.1571
   Aronowski J, 1996, NEUROPHARMACOLOGY, V35, P689, DOI 10.1016/0028-3908(96)84640-5
   BuchkremerRatzmann I, 1997, EUR J PHARMACOL, V320, P103, DOI 10.1016/S0014-2999(96)00891-6
   Chiu D, 1998, STROKE, V29, P18, DOI 10.1161/01.STR.29.1.18
   Christou I, 2000, STROKE, V31, P1812, DOI 10.1161/01.STR.31.8.1812
   Clark WM, 1999, JAMA-J AM MED ASSOC, V282, P2019, DOI 10.1001/jama.282.21.2019
   DeRyck M, 1996, J PHARMACOL EXP THER, V279, P748
   Diener HC, 1998, CEREBROVASC DIS, V8, P172, DOI 10.1159/000015847
   Diener HC, 1996, STROKE, V27, P76, DOI 10.1161/01.STR.27.1.76
   GROTTA J, 1995, J INTERN MED, V237, P89, DOI 10.1111/j.1365-2796.1995.tb01145.x
   Grotta J, 1997, STROKE, V28, P2338, DOI 10.1161/01.STR.28.12.2338
   Grotta JC, 1998, STROKE, V29, P429, DOI 10.1161/01.STR.29.2.429
   Grotta JC, 1999, STROKE, V30, P1722, DOI 10.1161/01.STR.30.8.1722
   Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9
   HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017
   Katzan IL, 2000, JAMA-J AM MED ASSOC, V283, P1151, DOI 10.1001/jama.283.9.1151
   Lesage AS, 1996, J PHARMACOL EXP THER, V279, P759
   Maiese K, 1997, J NEUROCHEM, V68, P710
   MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401
   Scheller DKA, 1997, EUR J PHARMACOL, V338, P243, DOI 10.1016/S0014-2999(97)81927-9
   Tilley BC, 1996, STROKE, V27, P2136, DOI 10.1161/01.STR.27.11.2136
   ZHANG RL, 1995, STROKE, V26, P1438, DOI 10.1161/01.STR.26.8.1438
   Zhang RL, 1999, NEUROLOGY, V52, P273, DOI 10.1212/WNL.52.2.273
   ZIVIN J A, 1989, Neurology, V39, P372
NR 26
TC 41
Z9 41
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-9770
J9 CEREBROVASC DIS
JI Cerebrovasc. Dis.
PY 2001
VL 12
IS 3
BP 258
EP 263
DI 10.1159/000047713
PG 6
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 487LE
UT WOS:000171875900017
PM 11641593
DA 2021-08-04
ER

PT J
AU Sanchez-Navarro, A
   Colino, CI
   Recio, MMS
AF Sanchez-Navarro, A
   Colino, CI
   Recio, MMS
TI A retrospective analysis of pharmacokinetic-pharmacodynamic parameters
   as indicators of the clinical efficacy of ceftizoxime
SO CLINICAL PHARMACOKINETICS
LA English
DT Review
ID DUAL INDIVIDUALIZATION PRINCIPLES; MATHEMATICAL EXAMINATION; ALEXANDER
   PROJECT; INHIBITORY CURVE; ESCHERICHIA-COLI; SUSCEPTIBILITY;
   CIPROFLOXACIN; ANTIBIOTICS; CEFMENOXIME; INFECTIONS
AB Objective: To analyse the relationship between a series of estimated pharmacokinetic-pharmacodynamic parameters and the reported efficacy of ceftizoxime.
   Design: Retrospective literature search and analysis using different correlation models.
   Methods: The following parameters were calculated for each group of patients included in the study from the simulated plasma concentration curves corresponding to the dosage regimen administered: (i) peak concentration at steady state divided by the minimum inhibitory concentration (Cmax (SS)/MIC); (ii) the time that the plasma drug concentration exceeded the MIC scaled to 24 hours at steady state [(t(ss))(24h) > MIC]; (iii) the total area under the concentration-time curve over 24 hours at steady state divided by the MIC [(AUC(SS))(24h)/MIC]; and (iv) the AUC at steady state for the period of time that the concentration is above the MIC over a period of 24 hours divided by the MIC [(AUIC(SS))24h] A univariate correlation analysis was performed considering efficacy [rate (%) of clinical cure or bacterial eradication] as the dependent variable and the pharmacokinetic-pharmacodynamic parameter as the independent variable, using linear and nonlinear models.
   Results: (tss)24h > MIC was the only parameter that was statistically correlated with efficacy, the linear model being the best choice among the 4 relationship approaches tested. A biased frequency distribution of reported efficacy data constricts the correlation analysis to a narrow range of efficacy and hinders interpretation of the results.
   Conclusions: The reporting of cases with low efficacy rates as well as those with high efficacy rates, including information on patient idiosyncrasies and the infecting organisms, would be of great help in performing retrospective analyses of the use of antimicrobial agents, leading to the optimisation of therapy with this type of drug in clinical practice.
C1 Univ Salamanca, Fac Farm, Dept Farm & Tecnol Farmaceut, E-37007 Salamanca, Spain.
RP Sanchez-Navarro, A (corresponding author), Univ Salamanca, Fac Farm, Dept Farm & Tecnol Farmaceut, Avda Campo Charro SN, E-37007 Salamanca, Spain.
CR Ament PW, 1999, FORMULARY, V34, P1033
   BARRY AL, 1982, J ANTIMICROB CHEMOTH, V10, P25, DOI 10.1093/jac/10.suppl_C.25
   BECHARD DL, 1982, J ANTIMICROB CHEMOTH, V10, P175, DOI 10.1093/jac/10.suppl_C.175
   BODEY GP, 1981, ANTIMICROB AGENTS CH, V20, P226, DOI 10.1128/AAC.20.2.226
   CLINI V, 1992, DRUG INVEST S1, V4, P38
   Craig WA, 1998, CLIN INFECT DIS, V26, P1, DOI 10.1086/516284
   CUTLER RE, 1982, J ANTIMICROB CHEMOTH, V10, P91, DOI 10.1093/jac/10.suppl_C.91
   DIVOIRE MIJ, 1996, CLIN DRUG INVEST, V11, P229
   DRULAK MW, 1981, ANTIMICROB AGENTS CH, V20, P683, DOI 10.1128/AAC.20.5.683
   DUDLEY MN, 1991, AM J MED, V91, pS45, DOI 10.1016/0002-9343(91)90311-K
   DUNNE AP, 1992, PCNONLIN 4 2 SCIE SO
   EBERT SC, 1995, HDB PHARMACOKINETIC, P35
   FAINSTEIN V, 1982, J ANTIMICROB CHEMOTH, V10, P167, DOI 10.1093/jac/10.suppl_C.167
   Felmingham D, 2000, J ANTIMICROB CHEMOTH, V45, P191, DOI 10.1093/jac/45.2.191
   Felmingham D, 1996, J ANTIMICROB CHEMOTH, V38, P1
   Forrest A, 1997, J ANTIMICROB CHEMOTH, V40, P45, DOI 10.1093/jac/40.suppl_1.45
   FU KP, 1980, ANTIMICROB AGENTS CH, V17, P583, DOI 10.1128/AAC.17.4.583
   FURLANUT M, 1983, DRUG EXP CLIN RES, V9, P657
   GOSS TF, 1994, ANN PHARMACOTHER, V28, P863, DOI 10.1177/106002809402800707
   GREENWOOD D, 1980, ANTIMICROB AGENTS CH, V17, P397, DOI 10.1128/AAC.17.3.397
   HYATT JM, 1995, CLIN PHARMACOKINET, V28, P143, DOI 10.2165/00003088-199528020-00005
   KOWALSKY SF, 1983, ANTIMICROB AGENTS CH, V24, P151, DOI 10.1128/AAC.24.2.151
   Li RC, 1999, CLIN PHARMACOKINET, V37, P1, DOI 10.2165/00003088-199937010-00001
   Livermore DM, 2000, J ANTIMICROB CHEMOTH, V45, P205, DOI 10.1093/jac/45.2.205
   LUZIER A, 1992, ANN PHARMACOTHER, V26, P1358, DOI 10.1177/106002809202601103
   MONTGOMERIE JZ, 1982, J ANTIMICROB CHEMOTH, V10, P247, DOI 10.1093/jac/10.suppl_C.247
   MUYTJENS HL, 1982, ANTIMICROB AGENTS CH, V21, P925, DOI 10.1128/AAC.21.6.925
   NAKASHIMA N, 1981, J CLIN PHARMACOL, V21, P388, DOI 10.1002/j.1552-4604.1981.tb01738.x
   NEU HC, 1984, PHARMACOTHERAPY, V4, P47
   NEU HC, 1981, ANTIMICROB AGENTS CH, V20, P366, DOI 10.1128/AAC.20.3.366
   OHKAWA M, 1982, ANTIMICROB AGENTS CH, V22, P308, DOI 10.1128/AAC.22.2.308
   PARKS D, 1982, J ANTIMICROB CHEMOTH, V10, P327, DOI 10.1093/jac/10.suppl_C.327
   PETERSON LR, 1982, ANTIMICROB AGENTS CH, V22, P878, DOI 10.1128/AAC.22.5.878
   QUINTILIANI R, 1982, J ANTIMICROB CHEMOTH, V10, P99, DOI 10.1093/jac/10.suppl_C.99
   RICHARDS DM, 1985, DRUGS, V29, P281, DOI 10.2165/00003495-198529040-00001
   RIMOLDI R, CEFTIZOXIME       32, P36
   SACHS L, 1982, APPL STAT, P382
   Sanchez-Navarro A, 1999, CLIN PHARMACOKINET, V37, P289
   Sanchez-Recio MM, 2000, J ANTIMICROB CHEMOTH, V45, P321, DOI 10.1093/jac/45.3.321
   SCHENTAG JJ, 1991, DICP ANN PHARMAC, V25, P1050, DOI 10.1177/106002809102501003
   SCHENTAG JJ, 1992, APPL PHARMACOKINETIC, V17, P1
   SHAH PM, 1976, DEUT MED WOCHENSCHR, V101, P325, DOI 10.1055/s-0028-1104083
   SHIMADA J, 1982, J ANTIMICROB CHEMOTH, V10, P311
   SHYU WC, CEFTIZOXIME       32, P29
   VALLEE F, 1991, ANTIMICROB AGENTS CH, V35, P2057, DOI 10.1128/AAC.35.10.2057
   YABUUCHI E, 1981, ANTIMICROB AGENTS CH, V20, P136, DOI 10.1128/AAC.20.1.136
   YAMAOKA K, 1978, J PHARMACOKINET BIOP, V6, P547, DOI 10.1007/BF01062109
NR 47
TC 5
Z9 6
U1 0
U2 2
PU ADIS INTERNATIONAL LTD
PI AUCKLAND
PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 10, NEW
   ZEALAND
SN 0312-5963
J9 CLIN PHARMACOKINET
JI Clin. Pharmacokinet.
PY 2001
VL 40
IS 2
BP 125
EP 134
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 414EL
UT WOS:000167652900004
PM 11286322
DA 2021-08-04
ER

PT S
AU Borders, M
   Bryan, D
AF Borders, M
   Bryan, D
BE Beynon, M
   Nehaniv, CL
   Dautenhahn, K
TI Experimental politics: Ways of virtual worldmaking
SO COGNITIVE TECHNOLOGY: INSTRUMENTS OF MIND, PROCEEDINGS
SE LECTURE NOTES IN ARTIFICIAL INTELLIGENCE
LA English
DT Article; Proceedings Paper
CT 4th International Conference on Cognitive Technology - Instruments of
   Mind
CY AUG 06-09, 2001
CL UNIV WARWICK, COVENTRY, ENGLAND
HO UNIV WARWICK
AB We think that Massively Multi-user Online Role-Playing Games (MMORPGs) will soon evolve into Online Societies of political and economic interest. Studying them will require a methodology that balances observation, theory, and application. This paper outlines such a methodology. First we examine the nature of theory itself (meta-theory), including holism (a meta-theory about systematic interconnections between beliefs) and reflective equilibrium (a meta-theory on the recursive nature of theory and information). Next we determine starting points for our studies. We appeal to the production of "spontaneous orders," orders that are not designed but rather emerge from the behavior of agents in a simulation, and which proceed from simple, normative, non-teleological rules. Lastly we examine the character of those rules. We look to where morality and rational choice converge (Gauthier's minimax relative concession) and derive guidelines for designing rules.
C1 Ctr Strateg Technol Res, Northbrook, IL 60062 USA.
RP Borders, M (corresponding author), Ctr Strateg Technol Res, 3773 Willow Rd, Northbrook, IL 60062 USA.
CR Black M., 1962, MODELS METAPHORS STU
   Epstein Richard A., 1995, SIMPLE RULES COMPLEX
   Gauthier D, 1986, MORALS AGREEMENT
   Gauthier D, 1991, CONTRACTARIANISM RAT
   Goodman, 1978, WAYS WORLDMAKING
   Hayek F.A., 1973, LAW LEGISLATION LIBE
   Nozick R, 1977, ANARCHY STATE UTOPIA
   Nozick Robert, 1981, PHILOS EXPLANATIONS
   Rawls J., 1971, THEORY JUSTICE
NR 9
TC 0
Z9 0
U1 0
U2 4
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 0302-9743
BN 3-540-42406-7
J9 LECT NOTES ARTIF INT
PY 2001
VL 2117
BP 432
EP 441
PG 10
WC Computer Science, Artificial Intelligence; Computer Science,
   Interdisciplinary Applications
SC Computer Science
GA BU09Z
UT WOS:000175011000038
DA 2021-08-04
ER

PT S
AU Brogan, DC
AF Brogan, DC
BE Spillman, WB
TI Control of complex, physically simulated robot groups
SO COMPLEX ADAPTIVE STRUCTURES
SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
   (SPIE)
LA English
DT Proceedings Paper
CT 1st International Conference on Complex Adaptive Structures
CY JUN 04-06, 2001
CL HUTCHINSON ISL, FL
SP SPIE
DE multiagent; dynamic simulation; group navigation; herds; swarms
AB Actuated systems such as robots take many forms and sizes but each requires solving the difficult task of utilizing available control inputs to accomplish desired system performance. Coordinated groups of robots provide the opportunity to accomplish more complex tasks, to adapt to changing environmental conditions, and to survive individual failures. Similarly, groups of simulated robots, represented as graphical characters, can test the design of experimental scenarios and provide autonomous interactive counterparts for video games. The complexity of writing control algorithms for these groups currently hinders their use. A combination of biologically inspired heuristics, search strategies, and optimization techniques serve to reduce the complexity of controlling these real and simulated characters and to provide computationally feasible solutions.
C1 Univ Virginia, Charlottesville, VA 22903 USA.
RP Brogan, DC (corresponding author), Univ Virginia, Charlottesville, VA 22903 USA.
CR ARKIN RC, 1992, J ROBOTIC SYST, V9, P351, DOI 10.1002/rob.4620090304
   Brogan DC, 1997, AUTON ROBOT, V4, P137, DOI 10.1023/A:1008867321648
   Brogan DC, 1998, IEEE COMPUT GRAPH, V18, P58, DOI 10.1109/38.708561
   CAVANAGH P, 1986, SCI CYCLING
   CULLEN JM, 1965, ANIM BEHAV, V13, P534, DOI 10.1016/0003-3472(65)90117-X
   DEMPSTER WT, 1967, AM J ANAT, V120, P33, DOI 10.1002/aja.1001200104
   HODGHINA JK, 1997, ANN C SERIES ACM SIG
   Hodgins J. K., 1995, Computer Graphics Proceedings. SIGGRAPH 95, P71
   LIEN SL, 1984, IEEE COMPUT GRAPH, V4, P35, DOI 10.1109/MCG.1984.6429334
   MATARIC M, 1992, P INT C SIM AD BEH A, V2, P432
   MATARIC MJ, 1993, PROCEEDINGS OF THE FIFTEENTH ANNUAL CONFERENCE OF THE COGNITIVE SCIENCE SOCIETY, P705
   Reynolds CW., 1987, SIGGRAPH COMPUT GRAP, V21, P25, DOI [DOI 10.1145/37402.37406, 10.1145/37402.37406]
   ROSENTHAL DE, 1986, J ASTRONAUT SCI, V34, P223
   Shaw E, 1970, DEV EVOLUTION BEHAVI, P452
   Sugihara K., 1990, Proceedings. 5th IEEE International Symposium on Intelligent Control 1990 (Cat. No.90TH0333-5), P138, DOI 10.1109/ISIC.1990.128452
   TAN KH, 1996, IROS 1996
   VEHERENCAMP S, 1987, HDB BEHAV NEUROBIOLO, V3
NR 17
TC 2
Z9 2
U1 0
U2 0
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 0-8194-4227-5
J9 P SOC PHOTO-OPT INS
PY 2001
VL 4512
BP 172
EP 184
DI 10.1117/12.446765
PG 13
WC Engineering, Biomedical; Optics
SC Engineering; Optics
GA BU57L
UT WOS:000176402900018
DA 2021-08-04
ER

PT B
AU Micelli, F
   Myers, JJ
   Murthy, S
AF Micelli, F
   Myers, JJ
   Murthy, S
BE Figueiras, J
   Juvanders, L
   Faria, R
TI Effect of environmental cycles on concrete cylinders confined with FRP
SO COMPOSITES IN CONSTRUCTION
LA English
DT Proceedings Paper
CT International Conference Composites in Construction (CCC2001)
CY OCT 10-12, 2001
CL OPORTO, PORTUGAL
SP Univ Porto
ID COMPOSITE JACKETED CONCRETE; UNIAXIAL COMPRESSION; COLUMNS
AB Structural strengthening and repairing of columns and bridge piers with fiber reinforced polymer (FRP) composites has been widely used to enhance the capacity and ductility for seismic and axial loads. Variations in the type of composite materials as well as the geometry and properties of the concrete column have been shown to influence the hoop action of the FRP. Although a large number of experimental studies, validated by analytical models, have demonstrated the effectiveness of concrete confinement with FRP in terms of load capacity and ductility for circular sections, concerns have arisen about the long-term performance of FRP. It was found that freeze thaw cycles and wet-dry cycling resulted in a reduction in the strength and ductility of the wrapped system due to changes in the mechanical properties of the materials. A significant decrease in ductility was observed especially for cylinders confined with Glass FRP (GFRP). In this study the mechanical behavior of concrete cylinders confined with FRP exposed to environmental cycles and immersion in saline solutions was investigated. Twenty-four concrete cylinders were strengthened with CFRP and GFRP sheets, using the wet lay-up wrapping technique. The cylinders were subjected to combined environmental agents including freeze-thaw cycles, extreme (high) temperature cycles, high moisture cycling, and indirect ultraviolet radiation exposure. This accelerated exposure regime was developed to simulate external environmental effects over time. In addition to the cycling regime wrapped cylinders for each FRP material were immersed in a saline solution (85% water, 15% NaCl) in order to observe the effects of the immersion in a deicing salt solution on GFRP and CFRP systems used for the confinement. FRP wrapped specimens were kept at a constant temperature of 22 C, to serve as the control series for the wrapped specimens. Finally unwrapped cylinders were tested to determine the unconfined properties of the concrete in order to evaluate the strengthening contribution of the FRP jackets in terms of capacity and enhanced ductility. All of the specimens were tested in uniaxial compression to observe the stress-strain changes due to the environmental effects. The modes of failure and the changes in strength properties and ductility due to the environmental exposure and saline solution immersion were investigated and are discussed herein.
C1 Univ Lecce, I-73100 Lecce, Italy.
RP Micelli, F (corresponding author), Univ Lecce, I-73100 Lecce, Italy.
CR Karbhari VM, 2000, J COMPOS CONSTR, V4, P191, DOI 10.1061/(ASCE)1090-0268(2000)4:4(191)
   Karbhari VM, 1997, J MATER CIVIL ENG, V9, P185, DOI 10.1061/(ASCE)0899-1561(1997)9:4(185)
   KARBHARI VM, 1994, J COLD REG ENG, V8, P73, DOI 10.1061/(ASCE)0887-381X(1994)8:3(73)
   Kshirsagar S, 2000, ACI MATER J, V97, P703
   LATEGOLA A, 1999, ACI INT, P217
   Mander J. B., 1988, J STRUCTURAL ENG ASC, V114, P1805
   NANNI A, 1995, CONSTR BUILD MATER, V9, P115, DOI 10.1016/0950-0618(95)00004-Y
   Picher F, 1996, P 1 INT C COMP INFR, P829
   SAADATMANESH H, 1994, ACI STRUCT J, V91, P434
   Samaan M, 1998, J STRUCT ENG-ASCE, V124, P1025, DOI 10.1061/(ASCE)0733-9445(1998)124:9(1025)
   SEIBLE FR, 1995, PROGR RES PRACT
   Spoelstra MR., 1999, J COMPOS CONSTR, V3, P143, DOI [10.1061/(ASCE)1090-0268(1999)3:3(143), DOI 10.1061/(ASCE)1090-0268(1999)3:3(143)]
   Toutanji HA, 1999, COMPOS STRUCT, V44, P155, DOI 10.1016/S0263-8223(98)00125-1
   Toutanji HA, 1999, ACI MATER J, V96, P397
   Xiao Y, 2000, J MATER CIVIL ENG, V12, P139, DOI 10.1061/(ASCE)0899-1561(2000)12:2(139)
NR 15
TC 20
Z9 21
U1 0
U2 9
PU A A BALKEMA PUBLISHERS
PI LEIDEN
PA SCHIPHOLWEG 107C, PO BOX 447, 2316 XC LEIDEN, NETHERLANDS
BN 90-5809-260-7
PY 2001
BP 317
EP 322
PG 6
WC Engineering, Civil; Materials Science, Composites
SC Engineering; Materials Science
GA BT59Q
UT WOS:000173445500056
DA 2021-08-04
ER

PT S
AU Ashida, K
   Lee, SJ
   Allbeck, JM
   Sun, H
   Badler, NI
AF Ashida, K
   Lee, SJ
   Allbeck, JM
   Sun, H
   Badler, NI
BE Ko, HS
TI Pedestrians: Creating agent behaviors through statistical analysis of
   observation data
SO COMPUTER ANIMATION 2001, PROCEEDINGS
SE COMPUTER ANIMATION CONFERENCE PROCEEDINGS
LA English
DT Proceedings Paper
CT 14th Conference on Computer Animation
CY NOV 07-08, 2001
CL SEOUL, SOUTH KOREA
SP Graph & Media Lab, Seoul Natl Univ, Coll Engn, Korea Comp Graph Soc, SNU Brain Korea 21 It Program, IEEE Comp Soc
AB Creating a complex virtual environment with human inhabitants that behave as we would expect real humans to behave is a difficult and time consuming task. Time must be spent to construct the environment, to create human figures, to create animations for the agents' actions, and to create controls for the agents' behaviors, such as scripts, plans, and decision-makers. Often work done for one virtual environment must be completely replicated for another. The creation of robust, procedural actions that can be ported from one simulation to another would ease the creation of new virtual environments. As walking is useful in many different virtual environments, the creation of natural looking walking is important. In this paper we present a system for producing more natural looking walking by incorporating actions for the upper body. We aim to provide a tool that authors of virtual environments can use to add realism to their characters without effort.
C1 Univ Penn, Ctr Human Modeling & Simulat, Philadelphia, PA 19104 USA.
RP Ashida, K (corresponding author), Univ Penn, Ctr Human Modeling & Simulat, Philadelphia, PA 19104 USA.
EM ashida@graphics.cis.upenn.edu
CR ALLBECK JM, 2001, IN PRESS WORKSH REPR
   ANDERSON F, 1999, INT SOC BIOM 17 C, P381
   BINDIGANAVALE R, 2000, AUTONOMOUS AGENTS
   Boulic R., 1990, Visual Computer, V6, P344, DOI 10.1007/BF01901021
   Bruderlin A., 1989, Computer Graphics, V23, P233
   Bruderlin A, 1996, PROC GRAPH INTERF, P213
   Chi D, 2000, COMP GRAPH, P173
   Funge J, 1999, COMP GRAPH, P29
   GALLAHER PE, 1992, J PERS SOC PSYCHOL, V63, P133, DOI 10.1037/0022-3514.63.1.133
   Girard M., 1985, Computer Graphics, V19, P263
   GLEICHER M, 1997, S INT 3D GRAPH, P139
   HODGINS JK, 1995, SIGGRAPH 95, P71
   Ko H, 1996, IEEE COMPUT GRAPH, V16, P50, DOI 10.1109/38.486680
   LASZLO J, 1996, SIGGRAPH 96 C P, P155
   Lee J, 1999, COMP GRAPH, P39
   MCKENNA M, 1990, SIGGRAPH 90, P29
   Musse SR, 2001, IEEE T VIS COMPUT GR, V7, P152, DOI 10.1109/2945.928167
   PERLIN K, 1996, SIGGRAPH 96, P205
   Popovic Z, 1999, COMP GRAPH, P11
   REYNOLDS C, 1987, P SIGGRAPH 87, V21
   Rose C, 1998, IEEE COMPUT GRAPH, V18, P32, DOI 10.1109/38.708559
   SUN H, 1999, INT SOC BIOM 17 C, P514
   Tolani D, 2000, GRAPH MODELS, V62, P353, DOI 10.1006/gmod.2000.0528
   USSE SR, 1997, P WORKSH COMP AN SIM
NR 24
TC 11
Z9 11
U1 0
U2 1
PU IEEE COMPUTER SOC
PI LOS ALAMITOS
PA 10662 LOS VAQUEROS CIRCLE, PO BOX 3014, LOS ALAMITOS, CA 90720-1264 USA
SN 1087-4844
BN 0-7803-7237-9
J9 COMP ANIM CONF PROC
PY 2001
BP 84
EP 92
DI 10.1109/CA.2001.982380
PG 9
WC Computer Science, Software Engineering; Computer Science, Theory &
   Methods
SC Computer Science
GA BU50D
UT WOS:000176153700009
OA Green Published
DA 2021-08-04
ER

PT J
AU Li, HG
   Rosser, JB
AF Li, HG
   Rosser, JB
TI Emergent volatility in asset markets with heterogeneous agents
SO DISCRETE DYNAMICS IN NATURE AND SOCIETY
LA English
DT Article
DE emergent volatility; heterogeneous agents; complex dynamics; moving
   average strategy
ID SPECULATION; PROFITABILITY
AB This paper examines the emergence of complex volatility in dynamic asset markets when there are heterogeneous agents. A discrete formulation is studied with two categories of market participants, fundamentalist traders who buy when the asset price is below the fundamental value and sell when it is above and noise traders who use moving average technical trading rules that can lead them to chase trends. Agents switch from one type of strategy to the other according to relative returns. A variety of outcomes are studied using numerical simulation, including variation of market price responsiveness to changes in excess demand, in switching behavior, and the introduction of noise. Bifurcation analysis of certain parameters is presented.
C1 Beijing Normal Univ, Sch Management, Beijing 100875, Peoples R China.
   James Madison Univ, Program Econ MSC 0204, Harrisonburg, VA 22807 USA.
RP Li, HG (corresponding author), Beijing Normal Univ, Sch Management, Beijing 100875, Peoples R China.
EM hg.li@263.net; rosserjb@jmu.edu
CR Arthur W., 1997, EC EVOLVING COMPLEX, P15
   BAUMOL WJ, 1957, REV ECON STAT, V39, P263, DOI 10.2307/1926042
   BLACK F, 1986, J FINANC, V41, P529, DOI 10.2307/2328481
   Brock WA, 1998, J ECON DYN CONTROL, V22, P1235, DOI 10.1016/S0165-1889(98)00011-6
   CHIARELLA C, 2000, UNPUB ASSET PRICE DY
   DAY RH, 1990, J ECON BEHAV ORGAN, V14, P299, DOI 10.1016/0167-2681(90)90061-H
   De Grauwe P., 1993, EXCHANGE RATE THEORY
   DELONG JB, 1991, J BUS, V64, P1
   DELONG JB, 1990, J FINANC, V45, P379, DOI 10.2307/2328662
   Friedman M., 1953, ESSAYS POSITIVE EC, P157
   GRASWINCKEL D, 1651, PLACAETBOOK OP HET S
   Keynes JM, 1936, GEN THEORY EMPLOYMEN
   Lux T, 1998, J ECON BEHAV ORGAN, V33, P143, DOI 10.1016/S0167-2681(97)00088-7
   Mill J. S., 1848, PRINCIPLES POLITICAL
   MUTH JF, 1961, ECONOMETRICA, V29, P315, DOI 10.2307/1909635
   Rosser JB, 2000, CATASTROPHE CHAOS GE
   Shiller R. J., 1989, MARKET VOLATILITY
   TELSER LG, 1959, REV ECON STAT, V41, P295, DOI 10.2307/1927455
   TIROLE J, 1982, ECONOMETRICA, V50, P1163, DOI 10.2307/1911868
   Zeeman E.C., 1974, J MATH ECON, V1, P39, DOI [DOI 10.1016/0304-4068(74)90034-2, 10.1016/0304-4068(74)90034-2]
NR 20
TC 5
Z9 6
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1026-0226
EI 1607-887X
J9 DISCRETE DYN NAT SOC
JI Discrete Dyn. Nat. Soc.
PY 2001
VL 6
IS 3
BP 171
EP 180
DI 10.1155/S1026022601000188
PG 10
WC Mathematics, Interdisciplinary Applications; Multidisciplinary Sciences
SC Mathematics; Science & Technology - Other Topics
GA 464ZJ
UT WOS:000170563000003
OA gold, Green Submitted
DA 2021-08-04
ER

PT J
AU Panzarasa, P
   Jennings, NR
   Norman, TJ
AF Panzarasa, P
   Jennings, NR
   Norman, TJ
TI Going public and the sale of shares with heterogeneous investors:
   Agent-based computational modelling and computer simulations
SO GROUP DECISION AND NEGOTIATION
LA English
DT Article
DE agent-based modelling and simulation; sale of shares; ownership
   structure; initial public offering
ID CORPORATE-CONTROL; OWNERSHIP STRUCTURE; EMPIRICAL-ANALYSIS;
   COORDINATION; SHAREHOLDERS; COMPANIES; OFFERINGS; DECISION
AB In this paper we use agent-based computational modelling and computer simulations to examine the interrelationship between different selling strategies for going public. A great deal of recent empirical evidence suggests that to maximise the revenue raised from the shares sold in the public offering, it is fundamental to choose the appropriate design for the sale which, in turn, reflects the final ownership structure. This literature establishes that the market for shares is segmented and, particularly, that firms manage the sale of shares with the purpose of discriminating between relatively small and passive investors and applicants for large potentially controlling blocks. One of the key questions in this area, then, is: How and to what extent should this heterogeneity among potential investors influence the firm's strategy for selling shares ? Here we attempt to address this question from the standpoint of using agent-based computational modelling and computer simulations. Results show that the design of the sale is an important determinant of the performance of the negotiation process through which the firm is sold. A sequential sale beginning with an initial public offering of dispersed shares, followed by a negotiated sale of a controlling block is, in general, more effective than other alternative selling strategies. Changing the negotiation protocol itself can act as an effective way of impacting upon the revenue raised and the length of the process. The interrelationship between the method of sale and the performance may also depend on the degree of cognitive accuracy that characterises the negotiating agents' mental representations of their physical and social environment.
C1 Univ Southampton, Dept Elect & Comp Sci, Southampton SO17 1BJ, Hants, England.
   Univ Aberdeen, Dept Comp Sci, Aberdeen AB24 3UE, Scotland.
RP Panzarasa, P (corresponding author), Univ Southampton, Dept Elect & Comp Sci, Southampton SO17 1BJ, Hants, England.
RI Jennings, Nick R/F-7358-2011
OI Jennings, Nick R/0000-0003-0166-248X; Norman,
   Timothy/0000-0002-6387-4034
CR Abelson R. P., 1968, HDB SOCIAL PSYCHOL, P274
   Baligh HelmyH., 1967, VERTICAL MARKET STRU
   BARBUCEANU M, 1997, P 14 NAT C ART INT, P16
   BARCLAY MJ, 1989, J FINANC ECON, V25, P371, DOI 10.1016/0304-405X(89)90088-3
   BARRY CB, 1990, J FINANC ECON, V27, P447, DOI 10.1016/0304-405X(90)90064-7
   BEBCHUK L, 1995, PRIVATE VERSUS SOCIA
   BEBCHUK LA, 1994, Q J ECON, V109, P957, DOI 10.2307/2118353
   BERLE AA, 1932, MODERN CORP PRIVATE
   Bond AH., 1988, READINGS DISTRIBUTED
   BRATMAN MICHAEL, 1987, INTENTION PLANS PRAC
   BRENNAN M, 1995, 1295 U CAL, P12
   Burtt BL, 1995, GESNERIANA, V1, P1
   CARLEY K, 1989, J MATH SOCIOL, V14, P171, DOI 10.1080/0022250X.1989.9990049
   Carley K, 1994, COMPUTATIONAL ORG TH
   CARLEY KM, 1995, COMPUTATIONAL MATH O, V1, P5
   Castelfranchi C, 1998, ARTIF INTELL, V103, P157, DOI 10.1016/S0004-3702(98)00056-3
   CASTELFRANCHI C, 1995, P 1 INT C MULT SYST, P41
   CHEMMANUR TJ, 1993, J FINANC, V48, P285, DOI 10.2307/2328890
   COHEN PR, 1990, ARTIF INTELL, V42, P213, DOI 10.1016/0004-3702(90)90055-5
   DAVIS R, 1980, KNOWLEDGEBASE SYSTEM
   DENNET D, 1987, INTENTIONAL STANCE
   DURFEE EH, 1991, IEEE T SYST MAN CYB, V21, P1167, DOI 10.1109/21.120067
   FISHER K, 1995, P 1 INT C MULT SYST, P109
   FRANKLIN S, 1997, INTELLIGENT AGENTS, V3, P21, DOI DOI 10.1007/BFB0013570
   GALLIERS JR, 1988, P 8 EUR C ART INT EC, P415
   GROSSMAN SJ, 1980, BELL J ECON, V11, P42, DOI 10.2307/3003400
   HANLEY KW, 1995, J FINANC ECON, V37, P239, DOI 10.1016/0304-405X(94)00797-5
   Hayes-Roth F., 1983, BUILDING EXPERT SYST
   HOLDERNESS CG, 1988, J FINANC ECON, V20, P317, DOI 10.1016/0304-405X(88)90049-9
   Jennings N.R., 1998, AUTON AGENT MULTI-AG, V1, P275
   Jennings NR, 2000, ARTIF INTELL, V117, P277, DOI 10.1016/S0004-3702(99)00107-1
   Jennings NR, 1996, INT J COOP INF SYST, V5, P105, DOI 10.1142/S0218843096000051
   KAHAN M, 1993, J LAW ECON ORGAN, V9, P368
   KINNY D, 1992, ARTIFICIAL SOCIAL SY, V830, P226
   Klein A., 1991, MANAGERIAL DECISION, V12, P449
   Kraus S, 1998, ARTIF INTELL, V104, P1, DOI 10.1016/S0004-3702(98)00078-2
   KRAUS S, 1995, COMPUT INTELL, V11, P132, DOI 10.1111/j.1467-8640.1995.tb00026.x
   LEE J, 1994, C INT ROB FIELD FACT, P842
   LEVESQUE J, 1990, P 8 NAT C ART INT AA, P94
   MALONE TW, 1987, MANAGE SCI, V33, P1317, DOI 10.1287/mnsc.33.10.1317
   Mello AS, 1998, J FINANC ECON, V49, P79, DOI 10.1016/S0304-405X(98)00018-X
   MIKKELSON WH, 1985, J FINANC ECON, V14, P523, DOI 10.1016/0304-405X(85)90025-X
   MIKKELSON WH, 1995, PERFORMANCE CO INITI
   MILGROM PR, 1982, ECONOMETRICA, V50, P1089, DOI 10.2307/1911865
   Pagano M, 1998, J FINANC, V53, P27, DOI 10.1111/0022-1082.25448
   PANZARASA P, 1999, INTELLIGENT AGENT TE, P202
   PANZARASA P, 2001, UNPUB J LOGIC COMPUT
   Parsons S, 1998, J LOGIC COMPUT, V8, P261, DOI 10.1093/logcom/8.3.261
   Pruitt D., 1981, NEGOTIATION BEHAV
   RAO S, 1991, P 2 INT C PRINC KNOW, P473
   ROCK K, 1986, J FINANC ECON, V15, P187, DOI 10.1016/0304-405X(86)90054-1
   Rosenschein J. S., 1994, RULES ENCOUNTER DESI
   RYDQVIST K, 1994, EUROPEAN FINANCIAL M, V1, P287
   SHIPPERK, 1986, J FINANCIAL EC, V15, P153
   SHLEIFER A, 1986, J POLIT ECON, V94, P461, DOI 10.1086/261385
   Shoham Y, 1992, P AAAI 92, P276
   SINGH MP, 1995, LECT NOTES COMPUTER, V799
   STASSER G, 1988, J EXP SOC PSYCHOL, V24, P393, DOI 10.1016/0022-1031(88)90028-5
   Stoughton NM, 1998, J FINANC ECON, V49, P45, DOI 10.1016/S0304-405X(98)00017-8
   SYCARA K, 1988, READINGS DISTRIBUTED
   SYCARA K, 1989, P 11 INT JOINT C ART, P517
   Waterman D. A., 1986, GUIDE EXPERT SYSTEMS
   WESTON F, 1990, MERGERS RESTRUCTUING
   Williamson O.E., 1975, MARKETS HIERARCHIES
   WILLIAMSON OE, 1981, AM J SOCIOL, V87, P548, DOI 10.1086/227496
   Wooldridge M., 1997, IEE Proceedings-Software Engineering, V144, P26, DOI 10.1049/ip-sen:19971026
   WOOLDRIDGE M, 2000, REASONING RATIONAL A
   YOST GR, 1993, SOAR PAPERS RES INTE, V2, P982
   ZINGALES L, 1995, REV ECON STUD, V62, P425, DOI 10.2307/2298036
NR 69
TC 5
Z9 5
U1 0
U2 9
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 0926-2644
J9 GROUP DECIS NEGOT
JI Group Decis. Negot.
PY 2001
VL 10
IS 5
BP 423
EP 470
DI 10.1023/A:1011871430501
PG 48
WC Management; Social Sciences, Interdisciplinary
SC Business & Economics; Social Sciences - Other Topics
GA 472MC
UT WOS:000170987100004
OA Green Submitted
DA 2021-08-04
ER

PT B
AU Lee, A
   Lyu, M
   King, I
AF Lee, A
   Lyu, M
   King, I
BE Graham, P
   Maheswaran, M
   Eskicioglu, R
TI An agent-based platform for online auctions
SO IC'2001: PROCEEDINGS OF THE INTERNATIONAL CONFERENCE ON INTERNET
   COMPUTING, VOLS I AND II
LA English
DT Proceedings Paper
CT 2nd International Conference on Internet Computing (IC 2001)
CY JUN 25-28, 2001
CL LAS VEGAS, NV
SP Comp Sci Res, Educ, & Applicat Press, Int Technol Inst, Korea Informat Processing Soc, World Acad Sci Informat Technol, PACT Corp
DE software agent; E-commerce; negotiation protocol; Markov chain
AB This paper proposes a web-based agent platform for E-commerce which allows humans and software agents to perform automatic auctions over the Internet. Internet-based auction is a profitable, exciting and dynamic part of E-commerce. However, the lack of standard on negotiation protocol between agents and an auctioneer makes full automation of E-commerce infeasible. Hence, we design a complete architecture and a set of negotiation protocols based on advanced agent technologies. Moreover, wr evaluated the negotiation protocol using a Markov chain model. Our experimental results show that (1) thc Markov chain can model independently simulated bidder's behaviour accurately, (2) a wider range of bidder's behaviour can be simulated with agents having partial knowledge of other bidders' willingness to bid and the closing time. In summary, our agent-based platform can incorporate realistic scenarios for simulation in online auction and other E-commerce applications.
C1 Chinese Univ Hong Kong, Dept CSE, Shatin, Hong Kong, Peoples R China.
RP Lee, A (corresponding author), Chinese Univ Hong Kong, Dept CSE, Shatin, Hong Kong, Peoples R China.
CR CARDOSO HL, 1999, EPIA 99 PORT C ART I
   CARRIE B, 1999, CMIT WORKING PAPER 9
   Lee JG, 1997, 1997 INTERNATIONAL CONFERENCE ON PARALLEL AND DISTRIBUTED SYSTEMS, PROCEEDINGS, P648, DOI 10.1109/ICPADS.1997.652611
   Lucking-Reiley D, 2000, J IND ECON, V48, P227
   Oliver J. R., 1996, Journal of Management Information Systems, V13, P83
   SANDHOLM T, 1995, 1 INT C MULT SYST IC, P328
   SIERRA C, 1997, P 8 EUR WORKSH MOD A, P17
   WURMAN P, 1999, 1 IAC WORKSH INT BAS
NR 8
TC 0
Z9 0
U1 0
U2 0
PU C S R E A PRESS
PI ATHENS
PA 115 AVALON DR, ATHENS, GA 30606 USA
BN 1-892512-84-X
PY 2001
BP 743
EP 749
PG 7
WC Computer Science, Artificial Intelligence; Computer Science, Information
   Systems; Engineering, Electrical & Electronic; Telecommunications
SC Computer Science; Engineering; Telecommunications
GA BT34W
UT WOS:000172696600114
DA 2021-08-04
ER

PT B
AU El Hadouaj, S
   Espie, S
   Drogoul, A
AF El Hadouaj, S
   Espie, S
   Drogoul, A
BE Arabnia, HR
TI A road traffic simulation model based on an economic approach
SO IC-AI'2001: PROCEEDINGS OF THE INTERNATIONAL CONFERENCE ON ARTIFICIAL
   INTELLIGENCE, VOLS I-III
LA English
DT Proceedings Paper
CT International Conference on Artificial Intelligence
CY JUN 25-28, 2001
CL LAS VEGAS, NV
SP Comp Sci Res, Educ & Appl Press, Int Technol Inst Korea Informat Processing Soc, World Acad Sci Informat Technol, PACT Corp
DE traffic simulation; multi-agent architecture; economic approach
AB In this article we present a road traffic simulation model based on an economic approach. This work, is part of INRETS ARCHISIM project whose aim is to produce a global realistic road traffic evolution by means of a reproduction of a realistic driver behavior. After having demonstrated the decentralized nature of the traffic simulation problem, we show that the fundamental problem of a road traffic simulation comes down to a resource allocation problem, then we detail the driver behavior and we show that it is based on a rationality abstraction. The simulation of the driver behavior is based upon the works of driving psychology carried out under the patronage of INRETS. To show that the economic approach fits well the case of road traffic simulation, we have demonstrated an experimental validation in comparison with real driver.
C1 INRETS, F-94114 Arcueil, France.
RP El Hadouaj, S (corresponding author), INRETS, 2,Ave Malleret Joinville, F-94114 Arcueil, France.
CR COHEN S, 1990, INGENIERIE TRAFIC RO
   DOYLE J, 1992, COMPUTATIONAL INTELL, V8
   ESPIE S, 1955, 2 WORLD C INT TRANSP
   HADOUAJ SEL, 2000, THESIS U PARIS 6
   PREIST C, 1998, HPL9877
   SAAD F, MODELE CONCEPTUEL CO
   TORRIERI V, 1995, DENSITA LIVELLI SERV
   VIDAL JM, 1998, J EXPT THEORETICAL A
   Wellman MP, 1993, J ARTIF INTELL RES, V1, P1
   WELLMAN P, 1995, ACM COMP SURV S ART
   WELLMAN P, 1996, MARKET BASED CONTROL
NR 11
TC 0
Z9 0
U1 0
U2 0
PU C S R E A PRESS
PI ATHENS
PA 115 AVALON DR, ATHENS, GA 30606 USA
BN 1-892512-81-5
PY 2001
BP 110
EP 115
PG 6
WC Computer Science, Artificial Intelligence
SC Computer Science
GA BT75P
UT WOS:000173960400018
DA 2021-08-04
ER

PT S
AU Le Bars, M
   Attonaty, JM
AF Le Bars, M
   Attonaty, JM
GP IEEE COMPUTER SOCIETY
   IEEE COMPUTER SOCIETY
TI A multi-agent system to the common management of a renewable resource:
   Application to water sharing
SO ICTAI 2001: 13TH IEEE INTERNATIONAL CONFERENCE ON TOOLS WITH ARTIFICIAL
   INTELLIGENCE, PROCEEDINGS
SE Proceedings - International Conference on Tools With Artificial
   Intelligence
LA English
DT Proceedings Paper
CT 13th IEEE International Conference on Tools with Artificial Intelligence
   (ICTAI 2001)
CY NOV 07-09, 2001
CL DALLAS, TX
SP IEEE Comp Soc, IEEE CS Virtual Intelligence Task Force, Informat Technol Res Inst, Wright State Univ, AIIS Inc
DE distributed artificial intelligence; multi-agent systems; simulation;
   negotiation; irrigation
AB Water sharing has become an important problem in France. A lot of negotiations are taking place at a local level between farmers, water suppliers, public services and environmentalists to allocate water resources between users. The problem is to share water with respect of different criteria like economic (global output) ethical (disparities between actors) environmental (water savings). Different approaches have been already taken using linear programming or game theory, but they are always based on the hypothesis that decision-makers are completely rational, take into account few players and are often monoperiodic. We suggest that art Agent-Based Modelling (ABM) built with a Multi-Agent approach could help negotiations between different players by showing the consequences of water allocation rules and taking in consideration the players respective attitudes and their ability to change their behaviour. In this paper we will first present the model structure with the different types of agents modelled, how the model rims over a number of years and the first results of simulations.
C1 Univ Paris 09, LAMSADE Lab, F-75775 Paris 16, France.
RP Le Bars, M (corresponding author), Univ Paris 09, LAMSADE Lab, F-75775 Paris 16, France.
EM lebarsm@aol.com; attonaty@grigon.inra.fr
RI Le Bars, Marjorie/J-7371-2016
OI Le Bars, Marjorie/0000-0002-8553-5930
CR AXELROD R, 1997, LECT NOTES EC MATH S
   BARRETEAU O, 1998, THESIS ECOLE NATL GE
   Bousquet F., 1996, MODELISATION ACCOMPA
   BUCHANAN M, 2000, NEW SCI, V167
   Conte R, 2000, APPLICATIONS OF SIMULATION TO SOCIAL SCIENCES, P19, DOI 10.1142/S0219525900000030
   Cyert R.M., 1963, BEHAV THEORY FIRM
   DONNELY JR, 1997, 18 INT GRASAS C
   DORAN J, 2001, ACAI 2001 AGENT LINK
   ERCEAU J, 1991, RECHERCHE, V233
   Ferber J., 1995, SYSTEMES MULTIAGENTS
   MARTIN S, 2000, GESTION VOLUMETRIQUE
   Misra J, 1986, COMPUTING SURVEYS, V18
   MORARDET S, 2000, RAPPORT FINAL AGENCE
   MOSS S, 2001, J ARTIFICIAL SOC SOC, V4
   POIX C, 1998, MODELES SYSTEMES MUL, P187
   QUEROU N, 2000, MODELLING AGENTS INT
   RAO A, 1999, FDN RATIONAL AGENCY, V14, P1
   RIEU T, 1994, ACT COMM INRA 12, P187
   Russell S, 1999, APPL LOG SER, V14, P11
   Rykiel EJ, 1996, ECOL MODEL, V90, P229, DOI 10.1016/0304-3800(95)00152-2
   SIAN SS, 1991, ADAPTATION BASED COO, P257
   Simon H. A., 1969, SCI ARTIFICIAL
   Simon Herbert., 1997, ADM BEHAV, V4th
   THOYER S, 2000, MODELLING AGENTS INT
   WOOLDRIDGE M, 1995, KNOWL ENG REV, V10, P62
   WOOLDRIDGE M, 1999, MULTIAGENT SYSTEMS
NR 26
TC 2
Z9 2
U1 0
U2 7
PU IEEE COMPUTER SOC
PI LOS ALAMITOS
PA 10662 LOS VAQUEROS CIRCLE, PO BOX 3014, LOS ALAMITOS, CA 90720-1264 USA
SN 1082-3409
BN 0-7695-1417-0
J9 PROC INT C TOOLS ART
PY 2001
BP 42
EP 49
DI 10.1109/ICTAI.2001.974447
PG 8
WC Computer Science, Artificial Intelligence
SC Computer Science
GA BU48K
UT WOS:000176125600006
DA 2021-08-04
ER

PT B
AU Takahashi, K
   Ueda, H
   Miyahara, T
AF Takahashi, K
   Ueda, H
   Miyahara, T
BE Tien, D
   Liang, YC
TI A learning simulator for testing CAI systems
SO IEEE REGION 10 INTERNATIONAL CONFERENCE ON ELECTRICAL AND ELECTRONIC
   TECHNOLOGY, VOLS 1 AND 2
LA English
DT Proceedings Paper
CT IEEE Region 10 International Conference on Electrical and Electronic
   Technology
CY AUG 19-22, 2001
CL SINGAPORE, SINGAPORE
SP IEEE Singapore Sect, IEEE Reg 10
DE inductive logic programming; Prolog; FOIL; CAI
AB In this paper, we present a learning simulator consisting of an interface, an inference engine and an inductive logic programming(ILP) system. Possible usage of the simulator includes to check the behavior of CAI systems, to be adopted as a novice agent in CAI systems, and for a teacher to check contents for study by observing the response of the simulator. The learning simulator learns interactively. First, a teacher ( or a CAI system) gives background knowledge as basic rules and examples. Next, a teacher asks the simulator some question. Using the background knowledge, rules generated by ILP and examples stored in the memory, the simulator answers the question. Then, the simulator stores the examples and updates rules for the next question, after the teacher tells the correct answer. We implement the simulator, using a Prolog interpreter and ILP system FOIL. We show learning results obtained through computer simulations.
C1 Hiroshima City Univ, Intelligent Syst Dept, Hiroshima 7313194, Japan.
RP Takahashi, K (corresponding author), Hiroshima City Univ, Intelligent Syst Dept, Hiroshima 7313194, Japan.
CR MUGGLETON S, 1997, INDUCTIVE LOGIC PROG
   Muggleton S. H, 1992, INDUCTIVE LOGIC PROG
   OHTSUKI S, 2000, T IEICE JAPAN D1, V83, P515
   PAZZANI MJ, 1992, INDUCTIVE LOGIC PROG
   Quinlan J. R., 1986, Machine Learning, V1, P81, DOI 10.1007/BF00116251
   SHOHAM Y, 1994, ARTIFICIAL INTELLIGE
   Wenger E., 1987, ARTIFICIAL INTELLIGE
NR 7
TC 0
Z9 0
U1 0
U2 0
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
BN 0-7803-7101-1
PY 2001
BP 415
EP 419
PG 5
WC Computer Science, Information Systems; Engineering, Electrical &
   Electronic; Telecommunications
SC Computer Science; Engineering; Telecommunications
GA BT37E
UT WOS:000172789300089
DA 2021-08-04
ER

PT J
AU Paternina-Arboleda, CD
   Das, TK
AF Paternina-Arboleda, CD
   Das, TK
TI Intelligent dynamic control policies for serial production lines
SO IIE TRANSACTIONS
LA English
DT Article
ID PRODUCTION INVENTORY SYSTEM; KANBAN CONTROL MECHANISMS
AB Heuristic production control policies such as CONWIP, kanban, and other hybrid policies have been in use for years as better alternatives to MRP-based push control policies. It is a fact that these policies, although efficient, are far from optimal. Our goal is to develop a methodology that, for a given system, finds a dynamic control policy via intelligent agents. Such a policy while achieving the productivity (i.e., demand service rate) goal of the system will optimize a cost/reward function based on the WIP inventory. To achieve this goal we applied a simulation-based optimization technique called Reinforcement Learning (RL) on a four-station serial line. The control policy attained by the application of a RL algorithm was compared with the other existing policies on the basis of total average WIP and average cost of WIP. We also develop a heuristic control policy in light of our experience gained from a close examination of the policies obtained by the RL algorithm. This heuristic policy named Behavior-Based Control (BBC), although placed second to the RL policy, proved to be a more efficient and leaner control policy than most of the existing policies in the literature. The performance of the BBC policy was found to be comparable to the Extended Kanban Control System (EKCS), which as per our experimentation, turned out to be the best of the existing policies. The numerical results used for comparison purposes were obtained from a four-station serial line with two different (constant and Poisson) demand arrival processes.
C1 Univ Norte, Dept Ingn Ind, Barranquilla, Colombia.
   Univ S Florida, Dept Ind & Management Syst Engn, Tampa, FL 33620 USA.
RP Paternina-Arboleda, CD (corresponding author), Univ Norte, Dept Ingn Ind, Barranquilla, Colombia.
CR ABOUNADI J, 1998, THESIS MIT CAMBRIDGE
   Arkin R., 1998, BEHAV BASED ROBOTICS
   Askin R. G., 1993, MODELING ANAL MANUFA
   Berkeley B. J., 1992, Production and Operations Management, V1, P393
   Bertsekas DP, 1996, NEURODYNAMIC PROGRAM
   Bonvik AM, 1997, INT J PROD RES, V35, P789, DOI 10.1080/002075497195713
   Buzacott J. A., 1992, PRODUCTION OPERATION, V1, P34
   Dallery Y, 2000, IIE TRANS, V32, P369, DOI 10.1080/07408170008963914
   Das TK, 1999, MANAGE SCI, V45, P560, DOI 10.1287/mnsc.45.4.560
   Das TK, 1999, IIE TRANS, V31, P537, DOI 10.1080/07408179908969857
   FREIN Y, 2000, IN PRESS INT J OPERA
   Gershwin S. B, 1994, MANUFACTURING SYSTEM
   GOSAVI A, 1999, THESIS U S FLORIDA T
   Kaelbling LP, 1996, J ARTIF INTELL RES, V4, P237, DOI 10.1613/jair.301
   Law AM., 1991, SIMULATION MODELING, V2
   Lutz CM, 1998, EUR J OPER RES, V106, P301, DOI 10.1016/S0377-2217(97)00276-2
   MAHADEVAN S, 1998, P 11 INT FLAIRS C ME, P372
   MUCKSTADT JA, 1995, IIE TRANS, V27, P151, DOI 10.1080/07408179508936727
   MUCKSTADT JA, 1995, IIE TRANS, V27, P140, DOI 10.1080/07408179508936726
   Putterman ML, 1994, MARKOV DECISION PROC
   Sethi S. P., 1994, HIERARCHICAL DECISIO
   Sethi SP, 1997, J MATH ANAL APPL, V214, P151, DOI 10.1006/jmaa.1997.5602
   SO KC, 1988, INT J PROD RES, V26, P1959, DOI 10.1080/00207548808948008
   SPEARMAN ML, 1990, INT J PROD RES, V28, P879, DOI 10.1080/00207549008942761
   SUGIMORI Y, 1977, INT J PROD RES, V15, P553, DOI 10.1080/00207547708943149
   Sutton R, 1998, INTRO REINFORCEMENT, V1st
   Sutton R. S., 1988, Machine Learning, V3, P9, DOI 10.1023/A:1022633531479
   TABE T, 1980, INT J PROD RES, V18, P245, DOI 10.1080/00207548008919664
   VANRYZIN G, 1993, IIE TRANS, V25, P5, DOI 10.1080/07408179308964312
   VEATCH MH, 1994, OPER RES, V42, P337, DOI 10.1287/opre.42.2.337
   Watkins C.J.C.H., 1989, THESIS KINGS COLLEGE
NR 31
TC 31
Z9 33
U1 1
U2 13
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 0740-817X
J9 IIE TRANS
JI IIE Trans.
PD JAN
PY 2001
VL 33
IS 1
BP 65
EP 77
DI 10.1023/A:1007641824604
PG 13
WC Engineering, Industrial; Operations Research & Management Science
SC Engineering; Operations Research & Management Science
GA 360FH
UT WOS:000089655400006
DA 2021-08-04
ER

PT S
AU Nagi, K
AF Nagi, K
BE Wagner, T
   Rana, O
TI Scalability of a transactional infrastructure for Multi-Agent Systems
SO INFRASTRUCTURE FOR AGENTS, MULTI-AGENT SYSTEMS, AND SCALABLE MULTI-AGENT
   SYSTEMS
SE LECTURE NOTES IN ARTIFICIAL INTELLIGENCE
LA English
DT Article; Proceedings Paper
CT International Workshop on Infrastructure for Scalable Multi-Agent
   Systems
CY JUN 03-07, 2000
CL BARCELONA, SPAIN
AB One of the reasons for attending to agent technology is the ever-growing complexity of information systems and the increasing difficulty to foresee and plan for all potentially arising situations. Unfortunately, some pressing issues in practical applications still remain outside the focus of agent research. Chief among them is robustness in environments that are prone to disturbances, failures or uncontrolled interactions. In our research effort, we provide a middleware, based on database transactions, that formally guarantees robustness of execution of agent actions and automates many standard actions carried out in case of disturbances. We built a simulator to test the scalability of the proposed middleware. The simulator also gives us a better understanding of the behavior of the various planning strategies reflected by the transaction trees executed by the middleware and is a valuable tool for evaluating the performance of any multi-agent system before its actual deployment. In this paper, the agent transaction model executed by the middleware is outlined. The simulator is described and the experimental results of simulating a growing number of antagonist agents with collective conflicts over a common database are presented.
C1 Univ Karlsruhe, Inst Program Struct & Data Org, D-76131 Karlsruhe, Germany.
RP Nagi, K (corresponding author), Univ Karlsruhe, Inst Program Struct & Data Org, Fasanengarten 5, D-76131 Karlsruhe, Germany.
CR ALLEN JF, 1990, READINGS PLANNING
   Bernstein P. A., 1987, CONCURRENCY CONTROL
   CAREY M, 1991, P ACM SIGMOD INT C M, P357
   Chauhan D., 1998, Proceedings of the Second International Conference on Autonomous Agents, P100, DOI 10.1145/280765.280782
   FERBER J, 1999, MULTI AGENT SYSTEMS
   Gray J., 1981, Proceedings of the Seventh International Conference on Very Large Data Bases, P144
   KLUSCH M, 1999, INTELLIGENT INFORMAT
   LANGE D, 1998, PROGAMMING DEPLOYING
   NAGI K, 1999, 23 GERM C AI SEPT
   NAGI K, 1999, P 1 WORKSH AG OR INF
   SHEN W, 1999, INT J KNOWLEDGE INFO
   TRAIGER IL, 1983, TRENDS SYSTEMS ASPEC
   WEISS G, 1999, MULTI AGENT SYSTEMS
NR 13
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 0302-9743
BN 3-540-42315-X
J9 LECT NOTES ARTIF INT
PY 2001
VL 1887
BP 266
EP 278
PG 13
WC Computer Science, Artificial Intelligence; Computer Science, Software
   Engineering
SC Computer Science
GA BU08N
UT WOS:000174950300027
DA 2021-08-04
ER

PT S
AU Letia, A
   Craciun, F
   Kope, Z
AF Letia, A
   Craciun, F
   Kope, Z
BE Wagner, T
   Rana, O
TI Towards validation of specifications by simulation
SO INFRASTRUCTURE FOR AGENTS, MULTI-AGENT SYSTEMS, AND SCALABLE MULTI-AGENT
   SYSTEMS
SE LECTURE NOTES IN ARTIFICIAL INTELLIGENCE
LA English
DT Article; Proceedings Paper
CT International Workshop on Infrastructure for Scalable Multi-Agent
   Systems
CY JUN 03-07, 2000
CL BARCELONA, SPAIN
AB The aim is to study the behaviour (in terms of utility) of a large number of autonomous agents under various environmental situations. Our experimental framework is an extension of the Swarm simulator with an array of intelligent agents developed in C++ and Prolog.
C1 Tech Univ Cluj Napoca, Dept Comp Sci, RO-3400 Cluj Napoca, Romania.
RP Letia, A (corresponding author), Tech Univ Cluj Napoca, Dept Comp Sci, Baritiu 28, RO-3400 Cluj Napoca, Romania.
RI Craciun, Florin/G-4689-2016; Craciun, Florin/AAM-2152-2020
OI Craciun, Florin/0000-0003-0335-8369; Craciun, Florin/0000-0003-0335-8369
CR BELL J, 1998, P EON 98, P127
   JENNINGS NR, 1998, AUTON AGENT MULTI-AG, V1, P7, DOI DOI 10.1023/A:1010090405266
   Letia I. A., 1999, Proceedings of the Third International Conference on Autonomous Agents, P410, DOI 10.1145/301136.301276
   Minar M., 1996, SWARM SIMULATION SYS
   VICTOR R, 1998, AUTON AGENT MULTI-AG, V1, P89
   VINCENT R, 1998, INT C WEB BAS MOD SI, P114
NR 6
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 0302-9743
BN 3-540-42315-X
J9 LECT NOTES ARTIF INT
PY 2001
VL 1887
BP 293
EP 295
PG 3
WC Computer Science, Artificial Intelligence; Computer Science, Software
   Engineering
SC Computer Science
GA BU08N
UT WOS:000174950300029
DA 2021-08-04
ER

PT B
AU Chekalin, AN
   Konyukhov, VM
   Kosterin, AV
AF Chekalin, AN
   Konyukhov, VM
   Kosterin, AV
BE Maron, DM
TI Simulation of two-phase multi-component filtration in layered reservoir
SO INTERNATIONAL SYMPOSIUM ON MULTI-PHASE FLOW AND TRANSPORT PHENOMENA
LA English
DT Proceedings Paper
CT 2nd International Symposium on Multi-Phase Flow and Transport Phenomena
CY NOV 05-10, 2000
CL ANTALYA, TURKEY
SP Int Ctr Heat & Mass Transfer
AB The oil displacement in a layered reservoir with the use of thickening agents of various types is considered. The primary attention is given to the filtration process of a chemically reacting mixture. During this process a movable field of the thickening agent (e.g., hydrogel) can be formed and evolved in the reservoir consisting of hydraulically interconnected layers. The mathematical simulation of this process in the vertical cross-section of the reservoir is done on the basis of well-known model of two-phase five-component filtration within the framework of the macro-scale description, The governing system includes hydrodynamic and physical-chemical groups of equations. To solve this system, the special numerical methods and algorithms are developed. The results of computations are presented. In particular, it is shown that in comparison with polymer flooding the use of the movable hydrogel field leads to much higher efficiency of the reservoir development.
C1 Kazan VI Lenin State Univ, Kazan 420008, Russia.
RP Chekalin, AN (corresponding author), Kazan VI Lenin State Univ, Kazan 420008, Russia.
RI Kosterin, Alexander/P-7574-2018
CR VOLKOV YA, 1997, P ICHMT S ANT NOV 3, P435
NR 1
TC 0
Z9 0
U1 0
U2 2
PU BEGELL HOUSE, INC
PI NEW YORK
PA 145 MADISON AVE, NEW YORK, NY 10016 USA
BN 1-56700-162-9
PY 2001
BP 209
EP 216
PG 8
WC Thermodynamics; Engineering, Chemical; Mechanics; Physics, Fluids &
   Plasmas
SC Thermodynamics; Engineering; Mechanics; Physics
GA BT06T
UT WOS:000171845500021
DA 2021-08-04
ER

PT B
AU Zhou, CJ
AF Zhou, CJ
GP IEEE
   IEEE
TI Robot learning assisted by perception-based information: A computing
   with words approach
SO IROS 2001: PROCEEDINGS OF THE 2001 IEEE/RJS INTERNATIONAL CONFERENCE ON
   INTELLIGENT ROBOTS AND SYSTEMS, VOLS 1-4: EXPANDING THE SOCIETAL ROLE OF
   ROBOTICS IN THE NEXT MILLENNIUM
LA English
DT Proceedings Paper
CT IEEE Conference on Intelligent Robots and Systems (IROS 2001)
CY OCT 29-NOV 03, 2001
CL MAUI, HI
SP IEEE Ind Electr Soc, IEEE Robot & Automat Soc, Robot Soc Japan, Soc Instrument & Control Engineers
AB Sensor-based operation of autonomous robots in unstructured environments has been proved to be an extremely challenging problem. However, humans seem to cope very well with uncertain and unpredictable environments, often relying on their perceptions. Furthermore, humans can also utilize the perceptions to guide their learning on those parts of the perception-action space that are actually relevant for the task. To make use of perceptions to assist robot learning and control, by using computational theory of perceptions (CTP), a linguistic version of Lyapunov synthesis working with fuzzy arithmetic operations in the domain of computing with words (CW) is proposed to derive a set of stable fuzzy control rules from the perception based information. Then the fuzzy rules are incorporated in a fuzzy reinforcement learning (FRL) agent to accelerate its learning. The experimental and simulation results show that it is possible for a robot to start with the perception-based information and then refine its behavior through further learning.
C1 Sch Elect & Elect Engn, Singapore 139651, Singapore.
RP Zhou, CJ (corresponding author), Sch Elect & Elect Engn, 500 Dover Rd, Singapore 139651, Singapore.
EM zhoucj@sp.edu.sg
CR BERENJI HR, 1992, IEEE T NEURAL NETWOR, V3, P724, DOI 10.1109/72.159061
   KLIR GL, 1999, UNCERTAINTY ANAL ENG, P1
   Margaliot M, 1999, FUZZY SET SYST, V106, P49, DOI 10.1016/S0165-0114(98)00356-X
   Schaal S, 1999, TRENDS COGN SCI, V3, P233, DOI 10.1016/S1364-6613(99)01327-3
   Sutton R, 1998, INTRO REINFORCEMENT, V1st
   VOKOBRATOVIC M, 1990, BIPED LOCOMOTION DYN
   Zadeh LA, 1996, IEEE T FUZZY SYST, V4, P103, DOI 10.1109/91.493904
   Zadeh LA, 1999, IEEE T CIRCUITS-I, V46, P105, DOI 10.1109/81.739259
   ZADEH LA, 2001, AI MAGAZINE      SPR, P73
   Zhou C., 2000, Soft Computing, V4, P238, DOI 10.1007/s005000000053
   ZHOU C, IN PRESS FUZZY SETS
   ZHOU C, IN PRESS INT J INFOR
NR 12
TC 0
Z9 0
U1 0
U2 0
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
BN 0-7803-6612-3
PY 2001
BP 272
EP 277
PG 6
WC Automation & Control Systems; Computer Science, Artificial Intelligence;
   Robotics
SC Automation & Control Systems; Computer Science; Robotics
GA BU64S
UT WOS:000176593900044
DA 2021-08-04
ER

PT B
AU Ishihara, H
   Fukuda, T
AF Ishihara, H
   Fukuda, T
GP IEEE
   IEEE
TI Individuality of agent with emotional algorithm
SO IROS 2001: PROCEEDINGS OF THE 2001 IEEE/RJS INTERNATIONAL CONFERENCE ON
   INTELLIGENT ROBOTS AND SYSTEMS, VOLS 1-4: EXPANDING THE SOCIETAL ROLE OF
   ROBOTICS IN THE NEXT MILLENNIUM
LA English
DT Proceedings Paper
CT IEEE Conference on Intelligent Robots and Systems (IROS 2001)
CY OCT 29-NOV 03, 2001
CL MAUI, HI
SP IEEE Ind Electr Soc, IEEE Robot & Automat Soc, Robot Soc Japan, Soc Instrument & Control Engineers
AB This paper discuss with the individuality of the agent consisting the group. We have been studying the emotional algorithm evaluating and deciding the statement with artificial emotional model. This paper shows the efficiency of the different characteristics of the agent with emotional algorithm, so-called Individuality, and proposes the new traffic signal system, which optimizes the traffic flow by estimation of the driver's mind. The proposed traffic signal system applies the emotional algorithm to determine its motion. The emotional algorithm estimates the emotional value based on the emotional functions, which are defined on the emotional space. The emotional space consists of four factors, "HAPPY," "RELIEF," "AFRAID" and "ANGRY," and provides the emotional states of the system by the value on it. The emotional function imitates the state of driver's mind, and aims at the system not to inflict the psychological stress onto the driver. Moreover, the emotional function achieves the different characteristics of performances, individuality. The individuality of traffic signals can optimize the arrangements of signals. This report proposes the principal architecture of the emotional algorithm with above individual and the traffic signal system simulator using it. The numerical simulations clear the effectiveness of the new emotional algorithm with individuality and show the optimized arrangements of traffic signals. The DEA simulator, of which parameters dynamically change by evaluating the congestion of a road, improves the architecture of traffic signals networks.
C1 Kagawa Univ, Dept Intelligent Mech Syst Engn, Takamatsu, Kagawa 7610301, Japan.
RP Ishihara, H (corresponding author), Kagawa Univ, Dept Intelligent Mech Syst Engn, 2170-20,Shin Machi, Takamatsu, Kagawa 7610301, Japan.
EM ishihara@eng.kagawa-u.ac.jp; fukuda@mein.nagoya-u.ac.jp
CR Franklin S., 1995, ARTIFICIAL MINDS
   Hayashi K., 1999, Proceedings 199 IEEE/IEEJ/JSAI International Conference on Intelligent Transportation Systems (Cat. No.99TH8383), P988, DOI 10.1109/ITSC.1999.821198
   Hollnagel E., 1993, HUMAN RELIABILITY AN
   Ishihara H, 2000, 2000 IEEE/RSJ INTERNATIONAL CONFERENCE ON INTELLIGENT ROBOTS AND SYSTEMS (IROS 2000), VOLS 1-3, PROCEEDINGS, P2274, DOI 10.1109/IROS.2000.895307
   Ishihara H., 1997, Proceedings of the 1997 IEEE/RSJ International Conference on Intelligent Robot and Systems. Innovative Robotics for Real-World Applications. IROS '97 (Cat. No.97CH36108), P1445, DOI 10.1109/IROS.1997.656549
   ISHIHARA H, 2000, P IEEE INT TRANSP SY
   Miki I., 1999, Proceedings 199 IEEE/IEEJ/JSAI International Conference on Intelligent Transportation Systems (Cat. No.99TH8383), P148, DOI 10.1109/ITSC.1999.821044
   Morimoto S., 1999, Proceedings 199 IEEE/IEEJ/JSAI International Conference on Intelligent Transportation Systems (Cat. No.99TH8383), P839, DOI 10.1109/ITSC.1999.821171
   SAITO I, 1987, HDB EXPT SOCIAL PSYC, V1
   Shimizu H., 1999, Proceedings 199 IEEE/IEEJ/JSAI International Conference on Intelligent Transportation Systems (Cat. No.99TH8383), P164, DOI 10.1109/ITSC.1999.821047
NR 10
TC 10
Z9 10
U1 0
U2 0
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
BN 0-7803-6612-3
PY 2001
BP 1195
EP 1200
PG 6
WC Automation & Control Systems; Computer Science, Artificial Intelligence;
   Robotics
SC Automation & Control Systems; Computer Science; Robotics
GA BU64S
UT WOS:000176593900191
DA 2021-08-04
ER

PT J
AU Auer, K
   Norris, T
AF Auer, K
   Norris, T
TI "ArrierosAlife" a multi-agent approach simulating the evolution of a
   social system: Modeling the emergence of social networks with "'Ascape"
SO JASSS-THE JOURNAL OF ARTIFICIAL SOCIETIES AND SOCIAL SIMULATION
LA English
DT Article
DE cellular automata; multi-agent model; evolution; social networks; object
   oriented programming language; artificial landscape
AB The behavior of cellular automata is a very close representation of the evolution of complex social systems. We developed the simulation model "ArrierosAlife" to explore the behavior of changes in social networks over time. The model is based on empirical data, a result out of a longitudinal field work. The focus of this research is a comparison of network changes over time in the "real world" compared with the emergence of social networks in an artificial society. "Ascape" was used as a modeling frame work to facilitate the development and analysis of the simulation model. We will give a brief overview of the developed model and describe the experiences using "Ascape" as a framework.
C1 Univ Cologne, Dept Anthropol, Cologne, Germany.
   Univ Calif Berkeley, Dept Geog, Berkeley, CA 94720 USA.
RP Auer, K (corresponding author), Univ Cologne, Dept Anthropol, Cologne, Germany.
CR ADAMI C, 1998, INTRO ARTIFICIAL LIF
   AUER K, 2000, 3 IM
   Axelrod R., 1997, COMPLEXITY COOPERATI
   Bicchieri C., 1997, DYNAMICS NORMS, P17
   BORGATTI SP, 1990, UCINET 4 COLUMBIA AN
   Doreian P., 1997, EVOLUTION SOCIAL NET
   EPSTEIN J, 2000, IN PRESS COMPUTATION
   Epstein J.M., 1996, GROWING ARTIFICIAL S
   Freeman LC, 1998, SOC NETWORKS, V20, P109, DOI 10.1016/S0378-8733(97)00016-6
   FREEMAN LC, 2000, J SOCIAL STRUCTURE, V1
   Gilbert N., 1999, SIMULATION SOCIAL SC
   Gilbert N, 1995, SIMULATION EMERGENT
   GIMBLETT R, 1997, THESIS U MELBOURNE A
   GIMBLETT R, 1996, 3 AUSTR COMPL SYST C
   GIMBLETT R, 1996, ISSUES DESIGNING CAL
   HEGSELMANN R, 1998, J ARTIFICIAL SOC SOC, V1
   Hegselmann R., 1998, COMPUTER MODELING SO, P37
   Kauffman S., 1993, ORIGINS ORDER
   Kauffman S. A., 1995, HOME UNIVERSE SEARCH
   Lorenz E., 1993, ESSENCE CHAOS
   Nicolis G, 1989, EXPLORING COMPLEXITY
   PARKER M, 1998, ASCAPE ABSTRACTING C
   Schweizer T., 1996, MUSTER SOZIALER ORDN
   Wasserman S., 1994, SOCIAL NETWORK ANAL
NR 24
TC 2
Z9 2
U1 0
U2 1
PU J A S S S
PI GUILDFORD
PA UNIV SURREY, DEPT SOCIOLOGY, GUILDFORD GU2 7XH, SURREY, ENGLAND
SN 1460-7425
J9 JASSS
JI JASSS
PD JAN
PY 2001
VL 4
IS 1
BP U123
EP U143
PG 21
WC Social Sciences, Interdisciplinary
SC Social Sciences - Other Topics
GA 397KB
UT WOS:000166693900007
DA 2021-08-04
ER

PT S
AU Noguez, J
   Espinosa, ED
   Ramos, F
AF Noguez, J
   Espinosa, ED
   Ramos, F
BE Baba, N
   Jain, LC
   Howlett, RJ
TI Use of conversational agents and dynamic Bayesian nets for message
   recognition
SO KNOWLEDGE-BASED INTELLIGENT INFORMATION ENGINEERING SYSTEMS & ALLIED
   TECHNOLOGIES, PTS 1 AND 2
SE Frontiers in Artificial Intelligence and Applications
LA English
DT Proceedings Paper
CT 5th International Conference on Knowledge-Based Intelligent Information
   Engineering Systems and Allied Technologies (KES 2001)
CY SEP 06-08, 2001
CL OSAKA KYOIKU UNIV, OSAKA, JAPAN
SP FOST, Koei Ltd, Matsushita Elect Works Ltd
HO OSAKA KYOIKU UNIV
AB This work establishes a hypothesis: the use of conversational agents with human shape as tools to improve the interaction in distant collaborative learning will help people who live in rural areas, and lack a computer science culture, to incorporate the use of technology into their business activities. This will them the benefits provided by the e-business global process. Hereby, it is important to explore new motivating and familiar but technologically-devised ways of communication that allow people to come close to the other people, in ways that closely resemble our own behavior: socially, personally and emotionally. As a first stage of the project, we present a simulator of the interpretation of combinations of words, gesture, looks, movement of arm and head using Bayesian Nets. In order to differentiate them from other expressions and to emphasize the importance of key words inside a message.
C1 Inst Tecnol Estudios Super Monterrey, Cuernavaca, Morelos, Mexico.
RP Noguez, J (corresponding author), Inst Tecnol Estudios Super Monterrey, Campus Ciudad Mexico,Campus Cuernavaca, Cuernavaca, Morelos, Mexico.
EM jnoguez@campus.ccm.itesm.mx; eespinos@campus.ccm.itesm.mx;
   framos@campus.mor.itesm.mx
RI Noguez, Julieta/AAD-9865-2020
CR ARBYLE M, 1976, GAZE MUTUAL GAZE
   BADLER N, 2000, PARAMETERIZED ACTION, P256
   Cassell J, 2000, EMBODIED CONVERSATIONAL AGENTS, P1
   CASSELL J, IN PRESS AI MAGAZINE
   CASSELL J, IN PRESS MIT MEDIA L
   CASSELL J, ANIMATED CONVERSATIO
   Dean T., 1989, Computational Intelligence, V5, P142, DOI 10.1111/j.1467-8640.1989.tb00324.x
   MASSARO DW, 2000, DEV EVALUATING CONVE, P287
   PETRAZZINI B, 1999, COMMUNICACION ACM, V42
   POGGI I, 2000, PERFORMATIVE FACIAL, P155
   TURBAN E, 1999, INFORMATION TECHNOLO
   ZWEIG G, 1998, AAAI
NR 12
TC 0
Z9 0
U1 0
U2 1
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 0922-6389
EI 1879-8314
BN 1-58603-192-9
J9 FRONT ARTIF INTEL AP
PY 2001
VL 69
BP 733
EP 737
PG 5
WC Automation & Control Systems; Computer Science, Artificial Intelligence
SC Automation & Control Systems; Computer Science
GA BS99P
UT WOS:000171608300141
DA 2021-08-04
ER

PT S
AU Moss, S
AF Moss, S
BE Moss, S
   Davidsson, P
TI Editorial introduction: Messy systems - The target for multi agent based
   simulation
SO MULTI-AGENT-BASED SIMULATION
SE Lecture Notes in Artificial Intelligence
LA English
DT Article; Proceedings Paper
CT 2nd International Workshop on Multi-Agent-Based Simulation (MABS 2000)
CY JUL, 2000
CL BOSTON, MA
AB Messy systems have no clear boundaries; they are composed of so many natural and/or artificial entities with patterns of interaction so dense that they cannot be understood by inspection and system behaviour cannot be predicted by statistical or qualitative analysis. Obvious examples are real social systems and the Internet. Analysing and designing software to exploit such systems requires a different approach to software engineering and mechanism design. The issue addressed in the MABS-2000 workshop and in this volume is the development of a methodology and technology to identify which techniques hold promise and which cannot possibly lead to useful applications for messy software or social systems.
C1 Manchester Metropolitan Univ, Ctr Policy Modelling, Manchester M1 3GH, Lancs, England.
RP Moss, S (corresponding author), Manchester Metropolitan Univ, Ctr Policy Modelling, Manchester M1 3GH, Lancs, England.
EM s.moss@mmu.ac.uk
CR AXTELL R., 1996, COMPUTATIONAL MATH O, V1, P123, DOI DOI 10.1007/BF01299065
   Brainov S, 2000, FOURTH INTERNATIONAL CONFERENCE ON MULTIAGENT SYSTEMS, PROCEEDINGS, P71, DOI 10.1109/ICMAS.2000.858433
   Bussmann S, 2000, FOURTH INTERNATIONAL CONFERENCE ON MULTIAGENT SYSTEMS, PROCEEDINGS, P87, DOI 10.1109/ICMAS.2000.858435
   CASTELFRANCHI C, 1998, P 3 INT C MULT AG SY
   Chandler A., 1961, STRATEGY STRUCTURE
   Cohen P. R., 1985, HEURISTIC REASONING
   CONTE R, 1996, SOCIAL SCI MICROSIMU
   EDMONDS B, 1998, 9846 CTR POL MOD
   Fisher M, 1997, J LOGIC COMPUT, V7, P429, DOI 10.1093/logcom/7.4.429
   Giddens A., 1984, CONSTITUTION SOC CONSTITUTION SOC
   GRANOVETTER M, 1985, AM J SOCIOL, V91, P481, DOI 10.1086/228311
   Moss S, 2000, FOURTH INTERNATIONAL CONFERENCE ON MULTIAGENT SYSTEMS, PROCEEDINGS, P199, DOI 10.1109/ICMAS.2000.858454
   MOSS S, 1999, 9956 CTR POL MOD
   Nwana HS, 1999, KNOWL ENG REV, V14, P125, DOI 10.1017/S0269888999142012
   Parunak HV, 1998, LECT NOTES ARTIF INT, V1534, P10
   Penrose E., 1959, THEORY GROWTH FIRM
   Rosenberg N., 1983, INSIDE BLACK BOX
   Sullivan DG, 2000, FOURTH INTERNATIONAL CONFERENCE ON MULTIAGENT SYSTEMS, PROCEEDINGS, P293, DOI 10.1109/ICMAS.2000.858466
   WOOLDRIDGE M, 1998, AG 98 P 2 INT C AUT
NR 19
TC 6
Z9 6
U1 0
U2 0
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 0302-9743
BN 3-540-41522-X
J9 LECT NOTES ARTIF INT
PY 2001
VL 1979
BP 1
EP 14
PG 14
WC Computer Science, Artificial Intelligence
SC Computer Science
GA BY35K
UT WOS:000189006500001
DA 2021-08-04
ER

PT S
AU Edmonds, B
AF Edmonds, B
BE Moss, S
   Davidsson, P
TI The use of models - Making MABS more informative
SO MULTI-AGENT-BASED SIMULATION
SE Lecture Notes in Artificial Intelligence
LA English
DT Article; Proceedings Paper
CT 2nd International Workshop on Multi-Agent-Based Simulation (MABS 2000)
CY JUL, 2000
CL BOSTON, MA
ID REPRESENTATION
AB The use of MABS (Multi-Agent Based Simulations) is analysed as the modelling of distributed (usually social) systems using MAS (Multi-Agent Systems) as the model structure. It is argued that rarely is direct modelling of target systems attempted but rather an abstraction of the target systems is modelled and insights gained about the abstraction then applied back to the target systems. The MABS modelling process is divided into six steps: abstraction, design, inference, analysis, interpretation and application. Some types of MABS papers are characterised in terms of the steps they focus on and some criteria for good MABS formulated in terms of the soundness with which the steps are established. Finally some practical proposals that might improve the informativeness of the field are suggested.
C1 Manchester Metropolitan Univ, Ctr Policy Modelling, Manchester M1 3GH, Lancs, England.
RP Edmonds, B (corresponding author), Manchester Metropolitan Univ, Ctr Policy Modelling, Aytoun Bldg,Autoun St, Manchester M1 3GH, Lancs, England.
EM b.edmonds@mmu.ac.uk
RI Edmonds, Bruce/A-6030-2012
OI Edmonds, Bruce/0000-0002-3903-2507
CR Axelrod R., 2006, EVOLUTION COOPERATIO
   AXTELL R., 1996, COMPUTATIONAL MATH O, V1, P123, DOI DOI 10.1007/BF01299065
   BARRO RJ, 1984, Q J ECON, V99, P817, DOI 10.2307/1883127
   Cartwright N., 1983, LAWS PHYS LIE
   CHATTOE E, 1998, J ARTIFICIAL SOC SOC
   Cooper R, 1996, ARTIF INTELL, V85, P3, DOI 10.1016/0004-3702(95)00112-3
   DORAN J, 1997, LECT NOTES EC MATH S, V456, P457
   DOWNING T, 2000, INTEGRATED ASSESSMEN
   EDMONDS B, 2000, 0075 CPM MMU
   EDMONDS B, 2000, USE MODELS
   EDMONDS B, IN PRESS COMPUTATION
   EDMONDS B, IN PRESS FDN SCI
   Fisher M, 2000, FOURTH INTERNATIONAL CONFERENCE ON MULTIAGENT SYSTEMS, PROCEEDINGS, P127, DOI 10.1109/ICMAS.2000.858444
   HEMELRIJK CK, 2000, SEXUAL ATTRACTION IN
   Hesse M. B., 1963, MODELS ANALOGIES SCI
   Hughes RIG, 1997, PHILOS SCI, V64, pS325, DOI 10.1086/392611
   Kuhn T. S., 1962, STRUCTURE SCI REVOLU
   LAKATOS I, 1983, METHODOLOGY SCI RES
   MCGEARY F, 2000, MODELLING VIRTUAL FO
   MOSS S, 1994, J FORECASTING, V13, P299, DOI 10.1002/for.3980130305
   Moss S., 2000, Computational & Mathematical Organization Theory, V6, P249, DOI 10.1023/A:1009629602618
   MOSS S, 1997, 9725 CPM
   MOSS SJ, 1998, CYBERNET SYST, V29, P5
   Rosen R., 1985, ANTICIPATORY SYSTEMS
   SAWYER RK, 2000, SIMULATING EMERGENCE
   SIMON H. A., 1986, CHALLENGE, V29, P18
   TERAN O, MAPPING ENVELOPE SOC
   Wheeler M, 1999, BRIT J PHILOS SCI, V50, P103, DOI 10.1093/bjps/50.1.103
   Wooldridge M, 2000, FOURTH INTERNATIONAL CONFERENCE ON MULTIAGENT SYSTEMS, PROCEEDINGS, P341, DOI 10.1109/ICMAS.2000.858472
   Wooldridge M, 2000, FOURTH INTERNATIONAL CONFERENCE ON MULTIAGENT SYSTEMS, PROCEEDINGS, P13, DOI 10.1109/ICMAS.2000.858426
   2000, EFFECTS INTERACTION
NR 31
TC 44
Z9 45
U1 0
U2 2
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 0302-9743
BN 3-540-41522-X
J9 LECT NOTES ARTIF INT
PY 2001
VL 1979
BP 15
EP 32
PG 18
WC Computer Science, Artificial Intelligence
SC Computer Science
GA BY35K
UT WOS:000189006500002
DA 2021-08-04
ER

PT S
AU Norling, E
   Sonenberg, L
   Ronnquist, R
AF Norling, E
   Sonenberg, L
   Ronnquist, R
BE Moss, S
   Davidsson, P
TI Enhancing multi-agent based simulation with human-like decision making
   strategies
SO MULTI-AGENT-BASED SIMULATION
SE Lecture Notes in Artificial Intelligence
LA English
DT Article; Proceedings Paper
CT 2nd International Workshop on Multi-Agent-Based Simulation (MABS 2000)
CY JUL, 2000
CL BOSTON, MA
AB We are exploring the enhancement of models of agent behaviour with more "human-like" decision making strategies than are presently available. Our motivation is to build multi-agent based simulations of human societies that would exhibit more realistic simulation behaviours. This in turn will allow researchers to study more complex issues regarding individual and organisational performance than is possible with present systems. Drawing on studies into naturalistic decision making, which looks at people's decision making in their natural environments, we propose ways of integrating a recognition-primed decision making approach with the popular BDI agent architecture, and report on preliminary empirical studies.
C1 Univ Melbourne, Dept Informat Syst, Parkville, Vic 3052, Australia.
RP Norling, E (corresponding author), Univ Melbourne, Dept Informat Syst, Parkville, Vic 3052, Australia.
CR Anderson J. R., 1998, ATOMIC COMPONENTS TH
   Bratman M. E., 1988, Computational Intelligence, V4, P349, DOI 10.1111/j.1467-8640.1988.tb00284.x
   BRATMAN MICHAEL, 1987, INTENTION PLANS PRAC
   *CHI SYST INC, COGNET COGN NETW TAS
   d'Inverno M, 1998, LECT NOTES ARTIF INT, V1365, P155
   Dreyfus HL, 1997, EXP RES APPL, P17
   EDMONDS B, 1999, SPRINGER LECT NOTES, V1688, P119
   Flin R, 1996, HUM FACTORS, V38, P262, DOI 10.1518/001872096779048110
   HEINZE G, 1998, P 8 AUSTR JOINT C AR
   Jones RM, 1999, AI MAG, V20, P27
   KLEIN G, 1998, SOURCES POWER
   KOLODNER J., 1993, CASE BASED REASONING
   LAIRD JE, 1987, ARTIF INTELL, V33, P1, DOI 10.1016/0004-3702(87)90050-6
   LAIRD JE, 2000, SS0002 AAAI
   LIPSHITZ R, 1993, DECISION MAKING ACTI, P103
   Mellers BA, 1998, ANNU REV PSYCHOL, V49, P447, DOI 10.1146/annurev.psych.49.1.447
   Orasanu J., 1993, DECISION MAKING ACTI, P3
   Rao A.S., 1991, P INT C PRINC KNOWL
   Sutton R, 1998, INTRO REINFORCEMENT, V1st
   Tidhar G, 1998, APPL INTELL, V8, P195, DOI 10.1023/A:1008271016283
   Zsambok CE, 1997, EXP RES APPL, P3
NR 21
TC 7
Z9 7
U1 0
U2 2
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 0302-9743
BN 3-540-41522-X
J9 LECT NOTES ARTIF INT
PY 2001
VL 1979
BP 214
EP 228
PG 15
WC Computer Science, Artificial Intelligence
SC Computer Science
GA BY35K
UT WOS:000189006500016
DA 2021-08-04
ER

PT S
AU David, N
   Sichman, JS
   Coelho, H
AF David, N
   Sichman, JS
   Coelho, H
BE Moss, S
   Davidsson, P
TI Agent-based social simulation with coalitions in social reasoning
SO MULTI-AGENT-BASED SIMULATION
SE Lecture Notes in Artificial Intelligence
LA English
DT Article; Proceedings Paper
CT 2nd International Workshop on Multi-Agent-Based Simulation (MABS 2000)
CY JUL, 2000
CL BOSTON, MA
AB There is a growing belief that the agents' cognitive structures play a central role on the enhancement of predicative capacities of decision-making strategies. This paper analyses and simulates the construction of cognitive social structures in the process of decision making with multiple actors. In this process it is argued that the agent's rational choices may be assessed by its motivations, according to different patterns of social interactions. We first construct an abstract model of social dependence between agents, and define a set of social structures that are easily identifiable according to potential interactions. We then carry out a set of experiments at micro-social levels of analysis, where the agents' cognitive structures are explicitly represented. These experiments indicate that different social dependence structures imply distinct structural patterns of negotiation proposals, which appear to have diverse patterns of complexity in the search space. It is subsequently shown that this observation emerges as an issue of ambiguity in the regulation of different decision-making criteria, relative to motivation-oriented and utility-oriented choices. In the scope of this ambiguity, we finally make some conjectures relative to further analytical and empirical analysis around the relation between patterns of complexity of social structures and decision-making.
C1 DCTI, ISCTE, Dept Informat Sci & Technol, Lisbon, Portugal.
   Univ Sao Paulo, Intelligent Tech Lab, Sao Paulo, Brazil.
   Univ Lisbon, Dept Informat, P-1699 Lisbon, Portugal.
RP David, N (corresponding author), DCTI, ISCTE, Dept Informat Sci & Technol, Lisbon, Portugal.
EM Nuno.David@iscte.pt; jaime@pcs.usp.br; hcoelho@di.fc.ul.pt
RI David, Nuno/B-4662-2012; Sichman, Jaime S./A-5711-2011; Sichman,
   Jaime/AAK-9332-2020
OI David, Nuno/0000-0001-8141-5053; Sichman, Jaime S./0000-0001-8924-9643;
   Sichman, Jaime/0000-0001-8924-9643
CR Alonso E, 1998, INTERNATIONAL CONFERENCE ON MULTI-AGENT SYSTEMS, PROCEEDINGS, P18, DOI 10.1109/ICMAS.1998.699027
   ANTUNES L, INTELLIGENTS AGENTS, V7
   CASTELFRANCHI C, 1999, ROBOTICS AUTONOMOUS, V24
   CASTELFRANCHI C, 1992, P MAAMAW92, P215
   Coleman J. S., 1992, RATIONAL CHOICE THEO
   Conte R, 1998, LECT NOTES ARTIF INT, V1534, P156
   CONTE R, 1996, LECT NOTES EC, P394
   DAVID N, 1999, LECT NOTES ARTIF INT, V1647, P175
   DAVID N, 1999, P 3 EUR C COGN SCI E, P57
   DINVERNO M, 1997, P 15 INT JOINT C ART, P600
   Epstein J.M., 1996, GROWING ARTIFICIAL S
   *FIPA, 1998, SPECIFICATION 2
   FISCHER K, 1996, LNAI, V1038
   GILBERT N, 1998, LNAI, V1534
   Hales D, 1998, LECT NOTES ARTIF INT, V1534, P140
   JENNINGS NR, 1999, LECT NOTES ARTIF INT, V1647, P1
   JENNINGS NR, 1997, IEEE P SOFTWARE ENG, V144, P11
   Marini M. M., 1992, KEY ISSUES SOCIOLOGI, P21
   NEWELL A, 1982, ARTIF INTELL, V18, P87, DOI 10.1016/0004-3702(82)90012-1
   PRUDKOV P, 1999, SYNTHESIS PURPOSEFUL
   RAO AS, 1991, P 2 INT C PRINC KNOW
   Russell S., 1995, Advances in Electronic Packaging 1995. Proceedings of the International Electronic Packaging Conference - INTERpack '95, P473
   SICHMAN JS, 1994, P 11 EUR C ART INT, P188
   SICHMAN JS, 1996, P 2 INT C MULT AG SY
   SICHMAN JS, 1995, P 1 INT C MULT SYST, P352
   SICHMAN JS, 1998, J ARTIFICIAL SOC SOC, V1
   SIMON H, 1957, Q J ECON, P99
   TERNA P, 1998, J ARTIFICIAL SOC SOC
   ZLOTKIN G, 1994, PROCEEDINGS OF THE TWELFTH NATIONAL CONFERENCE ON ARTIFICIAL INTELLIGENCE, VOLS 1 AND 2, P432
NR 29
TC 6
Z9 6
U1 0
U2 2
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 0302-9743
EI 1611-3349
BN 3-540-41522-X
J9 LECT NOTES ARTIF INT
PY 2001
VL 1979
BP 244
EP 265
PG 22
WC Computer Science, Artificial Intelligence
SC Computer Science
GA BY35K
UT WOS:000189006500018
OA Green Submitted, Green Accepted
DA 2021-08-04
ER

PT S
AU Koopman, JS
   Jacquez, G
   Chick, SE
AF Koopman, JS
   Jacquez, G
   Chick, SE
BE Weinstein, M
   Hermalin, AI
   Stoto, MA
TI New data and tools for integrating discrete and continuous population
   modeling strategies
SO POPULATION HEALTH AND AGING: STRENGTHENING THE DIALOGUE BETWEEN
   EPIDEMIOLOGY AND DEMOGRAPHY
SE Annals of the New York Academy of Sciences
LA English
DT Article; Proceedings Paper
CT Conference on Demography and Epidemiology: Frontiers in Population
   Health and Aging
CY FEB 08-10, 2001
CL GEORGETOWN UNIV, WASHINGTON, D.C.
SP Natl Inst Aging, Behav & Social Res Program, Univ Michigan, Inst Social Res, Michigan Ctr Demog Aging, Populat Stud Ctr
HO GEORGETOWN UNIV
DE new data; new tools; discrete models; continuous models; population
   modeling
ID SEXUALLY-TRANSMITTED-DISEASE; INFECTION TRANSMISSION; SOCIAL NETWORK;
   PAIR FORMATION; EPIDEMIOLOGY; INFERENCE; SPREAD; SIMULATION; DYNAMICS;
   FUTURE
AB Realistic population models have interactions between individuals. Such interactions cause populations to behave as systems with nonlinear dynamics. Much population data analysis is done using linear models assuming no interactions between individuals. Such analyses miss strong influences on population behavior and can lead to serious errors-especially for infectious diseases. To promote more effective population system analyses, we present a flexible and intuitive modeling framework for infection transmission systems. This framework will help population scientists gain insight into population dynamics, develop theory about population processes, better analyze and interpret population data, design more powerful and informative studies, and better inform policy decisions. Our framework uses a hierarchy of infection transmission system models. Four levels are presented here: deterministic compartmental models using ordinary differential equations (DE); stochastic compartmental (SC) models that relax assumptions about population size and include stochastic effects; individual event history models (IEH) that relax the SC compartmental structure assumptions by allowing each individual to be unique. IEH models also track each individual's history, and thus, allow the simulation of field studies. Finally, dynamic network (DNW) models relax the assumption of the previous models that contacts between individuals are instantaneous events that do not affect subsequent contacts. Eventually it should be possible to transit between these model forms at the click of a mouse. An example is presented dealing with Cryptosporidium. It illustrates how transiting model forms helps assess water contamination effects, evaluate control options, and design studies of infection transmission systems using nucleotide sequences of infectious agents.
C1 Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA.
   Univ Michigan, Ctr Study Complex Syst, Ann Arbor, MI 48109 USA.
   Biomedware Inc, Ann Arbor, MI USA.
   Univ Michigan, Dept Ind & Operat Engn, Ann Arbor, MI 48109 USA.
   Univ Michigan, Ctr Study Complex Syst, Ann Arbor, MI USA.
RP Koopman, JS (corresponding author), Univ Michigan, Dept Epidemiol, SPH-1,109 Observ St, Ann Arbor, MI 48109 USA.
EM jkoopman@umich.edu
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R44 AI049007-02, R44 AI049007-03, R44
   AI049007] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R44AI049007] Funding Source:
   NIH RePORTER
CR ANDERSON R M, 1991
   Andersson H, 2000, STOCHASTIC EPIDEMIC
   Aral SO, 2000, SEX TRANSM DIS, V27, P556, DOI 10.1097/00007435-200011000-00003
   BECKER NG, 1993, MATH BIOSCI, V117, P239, DOI 10.1016/0025-5564(93)90026-7
   Benaim M., 1999, FIELDS I COMMUN, V21, P31
   Britton T, 1998, J ROY STAT SOC B, V60, P663, DOI 10.1111/1467-9868.00147
   Chick SE, 2000, MATH BIOSCI, V166, P45, DOI 10.1016/S0025-5564(00)00028-6
   Chick SE, 2001, SCI TOTAL ENVIRON, V274, P197, DOI 10.1016/S0048-9697(01)00749-5
   DIEKMANN O, 1990, J MATH BIOL, V28, P365
   DIETZ K, 1988, J MATH BIOL, V26, P1, DOI 10.1007/BF00280169
   FROST F, 1999, 2 CITY CRYPTOSPORIDI
   Garnett GP, 1996, J INFECT DIS, V174, pS150, DOI 10.1093/infdis/174.Supplement_2.S150
   Koopman JS, 2000, SEX TRANSM DIS, V27, P617, DOI 10.1097/00007435-200011000-00010
   Koopman JS, 1996, AM J PUBLIC HEALTH, V86, P630, DOI 10.2105/AJPH.86.5.630
   Koopman JS, 1997, J ACQ IMMUN DEF SYND, V14, P249, DOI 10.1097/00042560-199703010-00009
   KOOPMAN JS, 1994, AM J PUBLIC HEALTH, V84, P836, DOI 10.2105/AJPH.84.5.836
   KOOPMAN JS, 2001, UNPUB MATH BIOSCI
   KRETZSCHMAR M, 1994, MATH BIOSCI, V124, P181, DOI 10.1016/0025-5564(94)90042-6
   Kretzschmar M, 1998, MATH BIOSCI, V148, P83, DOI 10.1016/S0025-5564(97)10008-6
   Kretzschmar M, 1996, MATH BIOSCI, V133, P165, DOI 10.1016/0025-5564(95)00093-3
   MORRIS M, 1995, SOC NETWORKS, V17, P299, DOI 10.1016/0378-8733(95)00268-S
   NEE S, 1994, PHILOS T ROY SOC B, V344, P305, DOI 10.1098/rstb.1994.0068
   Ong CSL, 1999, AM J TROP MED HYG, V61, P63, DOI 10.4269/ajtmh.1999.61.63
   Poole D, 2000, J AM STAT ASSOC, V95, P1244, DOI 10.2307/2669764
   Pybus OG, 2000, GENETICS, V155, P1429
   Rothenberg R, 1996, SEX TRANSM DIS, V23, P24, DOI 10.1097/00007435-199601000-00007
   Rothenberg RB, 1998, SEX TRANSM DIS, V25, P154, DOI 10.1097/00007435-199803000-00009
   SCHRIBER TJ, 1991, INTRO SIMULATION USI
   Schwartz S, 1999, ANNU REV PUBL HEALTH, V20, P15, DOI 10.1146/annurev.publhealth.20.1.15
   Susser M, 1996, AM J PUBLIC HEALTH, V86, P674, DOI 10.2105/AJPH.86.5.674
   Susser M, 1998, J EPIDEMIOL COMMUN H, V52, P608, DOI 10.1136/jech.52.10.608
   Vlad MO, 1996, J PHYS A-MATH GEN, V29, P4895, DOI 10.1088/0305-4470/29/16/015
   Widmer G, 1998, ADV PARASIT, V40, P223, DOI 10.1016/S0065-308X(08)60122-0
NR 33
TC 27
Z9 29
U1 0
U2 9
PU NEW YORK ACAD SCIENCES
PI NEW YORK
PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA
SN 0077-8923
BN 1-57331-372-6
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2001
VL 954
BP 268
EP 294
PG 27
WC Public, Environmental & Occupational Health; Multidisciplinary Sciences
SC Public, Environmental & Occupational Health; Science & Technology -
   Other Topics
GA BT75V
UT WOS:000173961000015
PM 11797861
DA 2021-08-04
ER

PT S
AU Stengel, RF
   Ghigliazza, R
   Kulkarni, N
   Laplace, O
AF Stengel, RF
   Ghigliazza, R
   Kulkarni, N
   Laplace, O
GP AACC
   AACC
   AACC
TI Optimal control of a viral disease
SO PROCEEDINGS OF THE 2001 AMERICAN CONTROL CONFERENCE, VOLS 1-6
SE PROCEEDINGS OF THE AMERICAN CONTROL CONFERENCE
LA English
DT Proceedings Paper
CT American Control Conference (ACC)
CY JUN 25-27, 2001
CL ARLINGTON, VA
SP Amer Automat Control Council, IFAC
ID IMMUNE NETWORK BEHAVIOR; STATIONARY STATES; OSCILLATIONS
AB Treatment of a viral disease process is interpreted as the optimal control of a dynamic system. Evolution of the disease is characterized by a nonlinear, fourth-order ordinary differential equation that describes concentrations of pathogenic antigens (or pathogens), plasma cells, and antibodies, as well as a numerical indication of patient health. Without control, the dynamic model evidences sub-clinical or clinical decay, chronic stabilization, or unrestrained lethal growth of the pathogen, depending on the initial conditions for a simulated viral attack. The dynamic equations are controlled by therapeutic agents that affect the rate of change of system variables. Control histories that minimize a quadratic cost function are generated by numerical optimization over a fixed time interval, given otherwise lethal initial conditions. Tradeoffs between cost function weighting of pathogens, organ health, and use of therapeutics are evaluated. Optimal control solutions that defeat the virus and preserve organ health are demonstrated for individual and combined therapies. It is shown that control theory can point the way toward new protocols for treatment and cure of human diseases.
C1 Princeton Univ, Dept Mech & Aerosp Engn, Princeton, NJ 08544 USA.
RP Stengel, RF (corresponding author), Princeton Univ, Dept Mech & Aerosp Engn, Princeton, NJ 08544 USA.
CR ASACHENKOV A, 1992, WP9256 INT I APPL SY
   Asachenkov A, 1994, DIS DYNAMICS
   Bellman R., 1983, MATH METHODS MED
   CARSON ER, 1985, COMPUTERS CONTROL CL, P1
   CHIZECK HJ, 1985, COMPUTERS CONTROL CL, P95
   DEBOER RJ, 1993, B MATH BIOL, V55, P781, DOI 10.1016/S0092-8240(05)80189-2
   DEBOER RJ, 1993, B MATH BIOL, V55, P745, DOI 10.1016/S0092-8240(05)80188-0
   Hethcote HW, 2000, SIAM REV, V42, P599, DOI 10.1137/S0036144500371907
   NEUMANN AU, 1992, B MATH BIOL, V54, P21, DOI 10.1007/BF02458618
   NOVAK A, 1993, INT J SYST SCI, V24, P1253, DOI 10.1080/00207729308949557
   PERELSON AS, 1992, B MATH BIOL, V54, P649, DOI 10.1007/BF02459638
   Perelson AS, 1997, REV MOD PHYS, V69, P1219, DOI 10.1103/RevModPhys.69.1219
   RUNDELL A, 1995, PROCEEDINGS OF THE 1995 AMERICAN CONTROL CONFERENCE, VOLS 1-6, P255
   SCHUKTZ FW, 1986, MODELLING BIOMED SYS, P41
   SPOUGE JL, 1989, B MATH BIOL, V51, P715, DOI 10.1007/BF02459657
   Stengel R.F., 1994, OPTIMAL CONTROL ESTI
   SWAN GW, 1981, OPTIM CONTR APPL MET, V2, P311
   VANROSSUM JM, 1986, MODELLING BIOMEDICAL, P121
   WHITING B, 1985, COMPUTERS CONTROL ME, P59
   Wiener N, 1948, CYBERNETICS CONTROL
   WITTEN M, 1986, MODELLING BIOMEDICAL, P65
NR 21
TC 6
Z9 6
U1 0
U2 1
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
SN 0743-1619
BN 0-7803-6495-3
J9 P AMER CONTR CONF
PY 2001
BP 3795
EP 3800
PG 6
WC Automation & Control Systems; Engineering, Electrical & Electronic;
   Robotics
SC Automation & Control Systems; Engineering; Robotics
GA BT65Z
UT WOS:000173663300677
DA 2021-08-04
ER

PT B
AU Li, S
   Chen, J
   Ye, Z
   Sun, ZQ
AF Li, S
   Chen, J
   Ye, Z
   Sun, ZQ
GP IEEE
   IEEE
TI Learning competition in robot soccer game based on an adapted
   neuro-fuzzy inference system
SO PROCEEDINGS OF THE 2001 IEEE INTERNATIONAL SYMPOSIUM ON INTELLIGENT
   CONTROL (ISIC'01)
LA English
DT Proceedings Paper
CT IEEE International Symposium on Intelligent Control (ISIC 01)
CY SEP 05-07, 2001
CL MEXICO CITY, MEXICO
SP IEEE Control Syst Soc, Amer Soc Mech Engineers, European Union Control Assoc, Soc Instrument & Control Engineers
DE RoboCup; MAS; ANFIS; machine learning
AB RoboCup (Robot World Cup Tournament) is a worldwide popular research domain in recent years. The main dealing of it includes complex system behavior of multiple autonomous agents. Because of the complexity of system, how to describe cooperation and competition between agents becomes a great challenge in RoboCup Simulation Game. On one hand, the rich experience of human soccer player is of great service to the robot players. On the other hand, the difference between simulation game and real game make it a must to fit the transcendental knowledge into the new environment.
   Commonly used reinforcement learning is weak in utilizing transcendental knowledge, thus is limited in complex Multi-agent System (MAS) learning problems. This thesis puts forward a supervised learning method on the basis of Adapted Neuro-Fuzzy Inference System (ANFIS) to mapping the competition among the robots. This method can build an ANFIS according to experts' knowledge, and with data obtained in the simulation environment; it is able to adjust parameters of the system's antecedents and consequents in a self-adapt way. So it can establish a correct map to describe the competition among the robots.
   We use this method to describe the antagonization between the shooter and goalie, and successfully apply it in the RoboCup Simulation Game to build the champion team in RoboCup 2000 of China.
C1 Tsinghua Univ, Dept Comp Sci, State Key Lab Intelligent Technol Syst, Beijing 100084, Peoples R China.
RP Li, S (corresponding author), Tsinghua Univ, Dept Comp Sci, State Key Lab Intelligent Technol Syst, Beijing 100084, Peoples R China.
EM lishi@s100e.cs.tsinghua.edu.cn; yz@s100e.cs.tsinghua.edu.cn;
   szq-dcs@mail.tsinghua.edu.cn
CR BURKHARD HD, 1998, AT HUMBOLDT DEV PRAC, P1
   Kitano H., 1998, RoboCup-97: Robot Soccer. World Cup I, P1
   KITANO H, 1998, ROBOCUP 98 ROBOT SOC
   Kostiadis K., 1999, Proceedings 1999 IEEE/RSJ International Conference on Intelligent Robots and Systems. Human and Environment Friendly Robots with High Intelligence and Emotional Quotients (Cat. No.99CH36289), P990, DOI 10.1109/IROS.1999.812809
   LIN CT, FUZZY SETS SYSTEMS, V111, P285
   Muller J, 1996, DESIGN INTELLIGENT A
   NODA I, SOCCER SERVER MANUAL
   Oliveira E, 1999, ROBOT AUTON SYST, V27, P91, DOI 10.1016/S0921-8890(98)00085-2
   RIEKKI J, 1998, THESIS OULU
   STONE P, 1998, THESIS CARNEGIE MELL
   WEISS G, 1997, DISTRIBUTED ARTIFICI
   Weiss G., 1999, MULTIAGENT SYSTEMS M
   Yan XW, 2000, NINTH IEEE INTERNATIONAL CONFERENCE ON FUZZY SYSTEMS (FUZZ-IEEE 2000), VOLS 1 AND 2, P865, DOI 10.1109/FUZZY.2000.839145
NR 13
TC 7
Z9 7
U1 0
U2 1
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
BN 0-7803-6722-7
PY 2001
BP 195
EP 199
DI 10.1109/ISIC.2001.971507
PG 5
WC Computer Science, Artificial Intelligence; Engineering, Electrical &
   Electronic
SC Computer Science; Engineering
GA BT40H
UT WOS:000172901600033
DA 2021-08-04
ER

PT S
AU Nouri-Baranger, T
   Piquer, E
   Canet, E
AF Nouri-Baranger, T
   Piquer, E
   Canet, E
GP IEEE
   IEEE
   IEEE
TI A new coronary model for MRI perfusion studies
SO PROCEEDINGS OF THE 23RD ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE
   ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY, VOLS 1-4: BUILDING NEW
   BRIDGES AT THE FRONTIERS OF ENGINEERING AND MEDICINE
SE PROCEEDINGS OF ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING
   IN MEDICINE AND BIOLOGY SOCIETY
LA English
DT Proceedings Paper
CT 23rd Annual International Conference of the
   IEEE-Engineering-in-Medicine-and-Biology-Society
CY OCT 25-28, 2001
CL ISTANBUL, TURKEY
SP Natl Sci Fdn, TUBITAK, Sci & Tech Res Ctr Turkey, ISIK Univ, COMNET, EREL Techno Grp, GUZEL SANATLAR Printinghouse, JOHNSON&JOHNSON Med, PFIZER, SIEMENS Med, TURKCELL Iletism Hizmetler A S, ALSTOM Elect Ltd Co, GANTEK Technol & SUN Microsyst, TURCOM Co Grp
DE Windkessel; coronary circulation; capillaries; resistances; compliances;
   non-beating heart; MRI data
ID CMD-A2-GD-DOTA; HEART
AB This paper proposes a modified Windkessel model applied to the coronary circulation and first pass imaging techniques. A compartmental description of the blood flow is used. The compartments taken into account are the arteries, capillaries, lymphatic and venous systems, extravascular/extracellular and cellular domains. In addition the model includes mass transport by blood flow between compartments.
   The predictions of the model are presented in the simple case of first pass output concentration curves obtained with MR contrast agent in a non-beating blood perfused pig heart. The first results are obtained for low and high input flows in a normal heart. The last one is a simulation of an ischemic heart behavior.
   The results are in a good agreement with the experimental data from the normal heart and with the characteristic behavior of the microcirculation in the ischemic heart. In conclusion this method which integrates both pressure-flow-volume and mass transport models would be well adapted for the modelisation of perfusion imaging studies.
C1 Univ Lyon 1, Mecal INSERM U556, Lyon, France.
RP Nouri-Baranger, T (corresponding author), Univ Lyon 1, Mecal INSERM U556, Lyon, France.
RI BARANGER, Thouraya NOURI/A-4123-2013
OI BARANGER, Thouraya NOURI/0000-0003-3693-094X
CR BASSINGTHWAIGHT.JB, NATL SIMULATION RESO
   Canet EP, 2000, MAGN RESON MED, V43, P403, DOI 10.1002/(SICI)1522-2594(200003)43:3<403::AID-MRM12>3.0.CO;2-6
   Canet EP, 1999, JMRI-J MAGN RESON IM, V10, P423, DOI 10.1002/(SICI)1522-2586(199909)10:3<423::AID-JMRI26>3.3.CO;2-E
   Casali C, 1998, ACAD RADIOL, V5, pS214, DOI 10.1016/S1076-6332(98)80109-8
   CLARK JW, 1980, IEEE T BIO-MED ENG, V27, P20, DOI 10.1109/TBME.1980.326687
   COHEN SD, 1994, UCRLMA118618 NUM MAT
   Corot C, 1997, ACTA RADIOL, V38, P91
   NEYRAN B, UNPUB MAPPING MYOCAR
   Rideout V.C., 1991, BIOPHYSICS BIOENGINE
   SNYDER MF, 1969, IEEE T BIO-MED ENG, VBM16, P325, DOI 10.1109/TBME.1969.4502663
NR 10
TC 2
Z9 2
U1 0
U2 2
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
SN 1094-687X
BN 0-7803-7211-5
J9 P ANN INT IEEE EMBS
PY 2001
VL 23
BP 109
EP 112
PN 1-4
PG 4
WC Cardiac & Cardiovascular Systems; Computer Science, Interdisciplinary
   Applications; Engineering, Biomedical; Neurosciences
SC Cardiovascular System & Cardiology; Computer Science; Engineering;
   Neurosciences & Neurology
GA BV41G
UT WOS:000178871900033
DA 2021-08-04
ER

PT J
AU Gjerdrum, J
   Shah, N
   Papageorgiou, LG
AF Gjerdrum, J
   Shah, N
   Papageorgiou, LG
TI A combined optimization and agent-based approach to supply chain
   modelling and performance assessment
SO PRODUCTION PLANNING & CONTROL
LA English
DT Article
DE supply chain modelling; multi-agent system; optimal scheduling;
   inventory policy; service level
ID COORDINATION; ENTERPRISE; NETWORKS; SYSTEMS
AB The main objective of this paper is to give an example of how expert systems techniques for distributed decision-making can be combined with contemporary numerical optimization techniques for the purposes of supply chain optimization and to describe the resulting software implementation. In this paper, multi-agent modelling techniques are applied to simulate and control a simple demand-driven supply chain network system, with the manufacturing component being optimized through mathematical programming. The system measures supply chain performance and the effect of different parameters in the replenishment control system, and can be used to simulate the behaviour of a system that uses optimization for part of its decision-making. The objective of this supply chain network system is to reduce operating cost, while maintaining a high level of customer order fulfilment.
C1 Univ London Imperial Coll Sci Technol & Med, Ctr Proc Syst Engn, Dept Chem Engn & Chem Technol, London SW7 2BY, England.
   UCL, Dept Chem Engn, London WC1E 7JE, England.
RP Gjerdrum, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Ctr Proc Syst Engn, Dept Chem Engn & Chem Technol, London SW7 2BY, England.
EM n.shah@ic.ac.uk
RI Shah, Nilay/E-4925-2015; Papageorgiou, Lazaros/L-2122-2013
OI Shah, Nilay/0000-0002-8906-6844; Papageorgiou,
   Lazaros/0000-0003-4652-6086
CR Balasubramanian S, 1996, INT J COOP INF SYST, V5, P153, DOI 10.1142/S0218843096000075
   Barbuceanu M, 1999, APPL ARTIF INTELL, V13, P11, DOI 10.1080/088395199117478
   BARBUCEANU M, 1995, P I JCAI 95
   Ekenberg L, 1996, INT J COOP INF SYST, V5, P315, DOI 10.1142/S0218843096000129
   Fox MS, 1996, COMPUT IND, V29, P123, DOI 10.1016/0166-3615(95)00079-8
   Fulkerson B, 1997, ANN OPER RES, V75, P325, DOI 10.1023/A:1018971832353
   GJERDRUM J, 1998, THESIS IMPERIAL COLL
   Gu P, 1997, COMPUT IND ENG, V32, P477, DOI 10.1016/S0360-8352(96)00056-3
   Lin FR, 1998, INT J FLEX MANUF SYS, V10, P197, DOI 10.1023/A:1008069816606
   MARQUARDT W, 1992, COMPUT CHEM ENG, V16, pS329, DOI 10.1016/S0098-1354(09)80039-2
   NAGEL RN, 1991, AGILITY FORUM
   Parunak HV, 1997, ANN OPER RES, V75, P69
   SILCORA R, 1998, MANAGE SCI, V44, pS65
   Stephanopoulos G, 1996, COMPUT CHEM ENG, V20, P743, DOI 10.1016/0098-1354(95)00194-8
   STRADER TJ, 1998, J ARTIFICIAL SOC SOC, V1
   Tuma A, 1998, INT J PROD ECON, V56-7, P641, DOI 10.1016/S0925-5273(97)00146-1
NR 16
TC 107
Z9 107
U1 2
U2 49
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0953-7287
J9 PROD PLAN CONTROL
JI Prod. Plan. Control
PD JAN
PY 2001
VL 12
IS 1
BP 81
EP 88
DI 10.1080/09537280150204013
PG 8
WC Engineering, Industrial; Engineering, Manufacturing; Operations Research
   & Management Science
SC Engineering; Operations Research & Management Science
GA 382UJ
UT WOS:000165843500011
DA 2021-08-04
ER

PT B
AU Pegoraro, R
   Costa, AHR
   Ribeiro, CHC
AF Pegoraro, R
   Costa, AHR
   Ribeiro, CHC
GP IEEE COMPUTER SOCIETY
   IEEE COMPUTER SOCIETY
TI Experience generalization for multi-agent reinforcement learning
SO SCCC 2001: XXI INTERNATIONAL CONFERENCE OF THE CHILEAN COMPUTER SCIENCE
   SOCIETY, PROCEEDINGS
LA English
DT Proceedings Paper
CT 21st International Conference of the Chilean-Computer-Science-Society
CY NOV 07-09, 2001
CL PUNTA ARENAS, CHILE
SP Informat Profess Assoc, Latin Amer Ctr Studies Informat, Iberoamer Cooperat Program Sci & Technol, IEEE Comp Soc, Univ Magallanes, Univ Chile, Soc Chilena Ciencias Computac
AB On-line learning methods have been applied successfully in multi-agent systems to achieve coordination among agents. Learning in multi-agent systems implies in a non-stationary scenario perceived by the agents, since the behavior of other agents may change as they simultaneously learn how to improve their actions. Non-stationary scenarios can be modeled as Markov Games, which can be solved using the Minimax-Q algorithm a combination of Q-learning (a Reinforcement Learning (RL) algorithm which directly learns an optimal control policy) and the Minimax algorithm. However, finding optimal control policies using any RL algorithm (Q-learning and Minimax-Q included) can be very time consuming. Trying to improve the learning time of Q-learning, we considered the QS-algorithm. in which a single experience can update more than a single action value by using a spreading function. In this paper, we contribute a Minimax-QS algorithm which combines the Minimax-Q algorithm and the QS-algorithm. We conduct a series of empirical evaluation of the algorithm in a simplified simulator of the soccer domain. We show that even using a very simple domain-dependent spreading function, the performance of the learning algorithm can be improved.
C1 Univ Estadual Paulista, Dept Computacao, BR-17033360 Bauru, SP, Brazil.
RP Pegoraro, R (corresponding author), Univ Estadual Paulista, Dept Computacao, Av Luiz Edmundo Carrijo Coube, BR-17033360 Bauru, SP, Brazil.
RI Costa, Anna Helena Reali/I-2469-2012; Ribeiro, Carlos/E-2641-2013
OI Costa, Anna Helena Reali/0000-0001-7309-4528; Ribeiro,
   Carlos/0000-0002-5760-8426; Pegoraro, Rene/0000-0003-0314-8660
CR BOUTILIER C, 1997, P 14 NAT C ART INT
   GOLDMAN CV, 1994, PROCEEDINGS OF THE TWELFTH NATIONAL CONFERENCE ON ARTIFICIAL INTELLIGENCE, VOLS 1 AND 2, P408
   JENNINGS N, 1996, FDN DISTRIBUTED ARTI
   Kaelbling LP, 1996, J ARTIF INTELL RES, V4, P237, DOI 10.1613/jair.301
   LITTMAN ML, 1994, MARKOV GAMES FRAMEWO, V11, P157
   Mataric MJ, 1998, J EXP THEOR ARTIF IN, V10, P357, DOI 10.1080/095281398146806
   Ribeiro C., 1996, P ISRF IEE INT C INT, P32
   Sen S, 1998, J EXP THEOR ARTIF IN, V10, P333, DOI 10.1080/095281398146798
   Tan M., 1993, P 10 INT C MACH LEAR, P330
   WATKIN CJC, 1989, THESIS U CAMBRIDGE
   WEISS G, 1998, READINGS AGENTS, P481
NR 11
TC 1
Z9 1
U1 0
U2 0
PU IEEE COMPUTER SOC
PI LOS ALAMITOS
PA 10662 LOS VAQUEROS CIRCLE, PO BOX 3014, LOS ALAMITOS, CA 90720-1264 USA
BN 0-7695-1396-4
PY 2001
BP 233
EP 239
DI 10.1109/SCCC.2001.972652
PG 7
WC Computer Science, Theory & Methods; Engineering, Electrical & Electronic
SC Computer Science; Engineering
GA BT33S
UT WOS:000172674500027
DA 2021-08-04
ER

PT B
AU Mannelli, A
   Mandola, ML
   Pedri, P
   Tripoli, M
   Nebbia, P
AF Mannelli, A
   Mandola, ML
   Pedri, P
   Tripoli, M
   Nebbia, P
BE Menzies, FD
   Reid, SWJ
TI Use of spatial statistics and GIS to study the distribution of
   seropositivity for Rickettsia conorii in dogs in Piemonte (Italy)
SO SOCIETY FOR VETERINARY EPIDEMIOLOGY AND PREVENTIVE MEDICINE, PROCEEDINGS
LA English
DT Proceedings Paper
CT Meeting of the
   Society-for-Veterinary-Epidemiology-and-Preventive-Medicine
CY MAR 28-30, 2001
CL LEEUWENHORST, NETHERLANDS
SP AUV, Univ Glasgow Vet Sch, Comparat Epidemiol & Prevent Med, Univ Strathclyde, Dept Statist & Model Sci, Elanco Anim Hlth, Univ Glasgow, Fac Vet Med, Horserace Betting Levy Board, Merial B V, Intervet Int B V
ID FEVER GROUP RICKETTSIAE; SPOTTED-FEVER; DISEASES; IXODIDAE; ACARI
AB A Geographic Information System and second order neighbourhood analysis were used to evaluate the spatial association of seropositivity for Rickettsia conorii, the causative agent of Mediterranean spotted fever (MSF), in dogs, and human cases of the infection in Piemonte, northwestern Italy. Eighteen out of 116 examined dogs were IFA+ (titre greater than or equal to 1:160). Residence sites of dogs were clustered within distances < 1 km from residences of human cases of MSF. Monte Carlo simulations demonstrated that there was a statistically significant departure from a random spatial distribution, and clustering of IFA+ dogs was significantly higher than that for all dogs, at distances of between 0.36 and 0.59 km.
C1 Univ Turin, Dipartimento Prod Anim Epidemiol & Ecol, I-10126 Turin, Italy.
RP Mannelli, A (corresponding author), Univ Turin, Dipartimento Prod Anim Epidemiol & Ecol, Via Nizza 52, I-10126 Turin, Italy.
RI Nebbia, Patrizia/AAF-4789-2019
OI Nebbia, Patrizia/0000-0002-9256-0413
CR Boots B., 1988, POINT PATTERN ANAL
   GETIS A, 1987, ECOLOGY, V68, P473, DOI 10.2307/1938452
   KEYSARY A, 1988, Israel Journal of Veterinary Medicine, V44, P103
   KITRON U, 1992, J MED ENTOMOL, V29, P259, DOI 10.1093/jmedent/29.2.259
   Kitron U, 1998, J MED ENTOMOL, V35, P435, DOI 10.1093/jmedent/35.4.435
   KITRON U, 1994, ECOLOGICAL DYNAMICS, V7, P198
   LaScola B, 1997, J CLIN MICROBIOL, V35, P2715, DOI 10.1128/JCM.35.11.2715-2727.1997
   Lederberg J, 1992, EMERGING INFECT MICR
   MANLY BFJ, RANDOMIZATION MONTE
   Maroli Michele, 1996, Annali dell'Istituto Superiore di Sanita, V32, P387
   MUMCUOGLU KY, 1993, J MED ENTOMOL, V30, P114, DOI 10.1093/jmedent/30.1.114
   OBRIEN DJ, 1964, PREV VET MED, V42, P1
   *SAS I INC, 1990, SAS LANG REF VERS 6
   *SAS I INC, 1989, SAS STAT US GUID VER, V2
   *SAS I INC, 1990, SAS GUID MACR PROC V
   Segura-Porta F, 1998, EUR J EPIDEMIOL, V14, P395, DOI 10.1023/A:1007479909654
NR 16
TC 0
Z9 0
U1 0
U2 4
PU SOC VETERINARY EPIDEMIOLOGY & PREVENTIVE MEDICINE
PI EDINBURGH
PA DEPT VETERINARY CLINIC STUDIES ROYAL DICK SCH VETERINARY STUDIES,
   VETERINARY FIELD STN, EDINBURGH EH25 9RG, MIDLOTHIAN, SCOTLAND
BN 0-948073-49-7
PY 2001
BP 92
EP 99
PG 8
WC Agriculture, Dairy & Animal Science; Veterinary Sciences
SC Agriculture; Veterinary Sciences
GA BR94Y
UT WOS:000168150400013
DA 2021-08-04
ER

PT S
AU Raupach, M
   Brockmann, J
AF Raupach, M
   Brockmann, J
BE Brebbia, CA
TI Effectiveness of polymer-based impregnation agents on natural stones -
   long-term studies
SO STRUCTURAL STUDIES, REPAIRS, AND MAINTENANCE OF HISTORICAL BUILDINGS VII
SE ADVANCES IN ARCHITECTURE SERIES
LA English
DT Proceedings Paper
CT 7th International Conference on Structural Studies, Repairs and
   Maintenance of Historical Buildings
CY MAY 28-30, 2001
CL BOLOGNA, ITALY
SP Wessex Inst Technol
AB In recent decades, polymer-based impregnation agents have been developed with the aim of reducing the deterioration of natural stone buildings and monuments. Prior to using these products on historic buildings, various tests on effectiveness and durability had to be carried out.
   The problem of accelerated ageing methods is that they can induce material damage which is not comparable with processes occurring in nature, but longterm outdoor exposure is time-consuming and costly. At the Institute for Building Materials Research an experimental apparatus called "VENUS" (German anagram denoting 'test plant for the development of realistic environmental simulation concepts') is used for accelerated, reproducible, complex weathering. The weathering cycle of the VENUS plant that is described in this paper has been selected specifically to investigate the long-term behaviour of polymer-based impregnation agents applied to natural stones. To estimate the quality of natural simulation and the rate of acceleration in the VENUS concept, additional outdoor weathering has been carried out. Specimens with polymer-based impregnation agents were being exposed to weathering in four different European climates (Duisburg, Eifel (rural), Corsica, Wank (Alps)). The characteristic material parameters, such as elastic modulus, flexural strength, water absorption and water repellence, have been determined on the stone specimens exposed to outside weathering for a period of approximately 10 years and on the specimens subjected to weathering in the VENUS plant. The VENUS plant represents changes in characteristic material parameters with a good degree of correspondence to natural weathering. The experiments have shown that an acceleration of the ageing process compared to natural ageing in the field by a factor of two has been attained via use of the VENUS plant on natural stone specimens.
C1 Univ Technol, Inst Bldg Mat Res, Ibac, Aachen, Germany.
RP Raupach, M (corresponding author), Univ Technol, Inst Bldg Mat Res, Ibac, Aachen, Germany.
RI Raupach, Michael/ABD-4654-2020
OI Raupach, Michael/0000-0003-0688-3839
CR HONSINGER D, 1990, THESIS TH AACHEN
   RIECKEN B, 1993, WERKSTOFFWISSENSCH 2, P890
   SASSE HR, 1993, P INT RILEM UNESCO C, V2, P801
NR 3
TC 1
Z9 1
U1 0
U2 1
PU WIT PRESS
PI SOUTHAMPTON
PA ASHURST LODGE, SOUTHAMPTON SO40 7AA, ASHURST, ENGLAND
SN 1368-1435
BN 1-85312-869-4
J9 ADV ARC SER
PY 2001
VL 13
BP 161
EP 170
PG 4
WC Construction & Building Technology; Engineering, Civil
SC Construction & Building Technology; Engineering
GA BS87N
UT WOS:000171310600017
DA 2021-08-04
ER

PT S
AU Arentze, T
   Timmermans, H
AF Arentze, T
   Timmermans, H
GP TRB
   TRB
TI Inductive learning approach to evolutionary decision processes in
   activity-scheduling behavior - Theory and numerical experiments
SO TRAVEL PATTERNS AND BEHAVIOR; EFFECTS OF COMMUNICATIONS TECHNOLOGY:
   PLANNING AND ADMINISTRATION
SE TRANSPORTATION RESEARCH RECORD-SERIES
LA English
DT Article; Proceedings Paper
CT 80th Annual Meeting of the Transportation-Research-Board
CY JAN, 2001
CL WASHINGTON, D.C.
SP Transportat Res Board
AB The development of an inductive learning agent for simulating evolutionary processes (Ilse), which is meant to be linked to the ALBATROSS model, is discussed. The agent was developed to simulate learning and adaptation in travel behavior. It is assumed that at the start of the process, characterized by a high degree of uncertainty, individuals will display information-seeking behavior and choose the alternative that maximizes the entropy of outcomes. As learning proceeds, individuals will switch to goal-seeking behavior and select the alternative that maximizes the expected size of the outcome value. A series of computer experiments using simulated data were conducted to illustrate the system. Simulations showed that the system is able to learn even under conditions of noisy feedback, irrelevant attribute information, and fairly complicated interactions between relevant attributes. A combined information- and goal-seeking strategy increases learning speed.
C1 Eindhoven Univ Technol, Urban Planning Grp, NL-5600 MB Eindhoven, Netherlands.
RP Arentze, T (corresponding author), Eindhoven Univ Technol, Urban Planning Grp, POB 513, NL-5600 MB Eindhoven, Netherlands.
CR ARENTZE TA, IN PRESS GEOGRAPHICA
   Breiman L., 1984, CLASSIFICATION REGRE, P1
   Kass G.V., 1980, APPL STAT, V29, P119, DOI [10.2307/2986296, DOI 10.2307/2986296]
   MARCA JE, 2000, 79 ANN M TRANSP RES
   Nakayama S, 2000, TRANSPORT RES REC, P63, DOI 10.3141/1725-09
   Quinlan J. R., 1993, C4 5 PROGRAMS MACHIN
   Timmermans H, 2000, TRANSPORT RES REC, P27
NR 7
TC 1
Z9 1
U1 0
U2 0
PU TRANSPORTATION RESEARCH BOARD NATL RESEARCH COUNCIL
PI WASHINGTON
PA 500 FIFTH ST, NW, WASHINGTON, DC 20001 USA
SN 0361-1981
BN 0-309-07213-1
J9 TRANSPORT RES REC
PY 2001
IS 1752
BP 1
EP 7
PG 7
WC Engineering, Civil; Transportation Science & Technology
SC Engineering; Transportation
GA BU63D
UT WOS:000176559300001
DA 2021-08-04
ER

PT B
AU Mizuta, H
   Yamagata, Y
AF Mizuta, H
   Yamagata, Y
BE Peters, BA
   Smith, JS
   Medeiros, DJ
   Rohrer, MW
TI Agent-based simulation and greenhouse gas emissions trading
SO WSC'01: PROCEEDINGS OF THE 2001 WINTER SIMULATION CONFERENCE, VOLS 1 AND
   2
LA English
DT Proceedings Paper
CT Winter Simulation Conference (WSC 01)
CY 2001
CL ARLINGTON, VA
SP Amer Stat Assoc, ACM SIGSIM, IEEE Comp Soc, IEEE Syst, Man & Cybernet Soc, Inst Ind Engineers, INFORMS Coll Simulat, Natl Inst Stand & Technol, Soc Comp Simulat Int
AB The need for now theoretical and experimental approaches to understand dynamic and heterogeneous behavior in complex economic and social systems is increasing recently. An approach using the agent-based simulation and the artificial market on the computer system is considered to be an effective approach. The computational simulation with dynamically interacting heterogeneous agents is expected to re-produce complex phenomena in economics, and helps us to experiment various controlling methods, to evaluate systematic designs, and to extract the fundamental elements which produce the interesting phenomena for future analytical works. In the previous works, we investigated the stability of a virtual commodities market and the aggregated behavior of the dynamic online auctions with heterogeneous agents. In this paper, we will introduce a simple framework to develop agent-based simulations systematically and consider an application of the agent-based simulation for a dynamical model of the international greenhouse gas emissions trading.
C1 IBM Japan Ltd, Tokyo Res Lab, Kanagawa 2428502, Japan.
RP Mizuta, H (corresponding author), IBM Japan Ltd, Tokyo Res Lab, Shimotsuruma 1623-14, Kanagawa 2428502, Japan.
RI Yamagata, Yoshiki/H-7224-2018; Yamagata, Yoshiki/T-6489-2019
CR Grutter JM, 2000, WORLD MARKET GHG EMI
   IBA T, 2000, 1 INT WORKSH COMP IN
   LEVY M, 1994, ECON LETT, V45, P103, DOI 10.1016/0165-1765(94)90065-5
   Mizuta H, 2000, PROCEEDINGS OF THE 2000 WINTER SIMULATION CONFERENCE, VOLS 1 AND 2, P1772, DOI 10.1109/WSC.2000.899168
   MIZUTA H, 1999, 4 WORKSH EC HET INT
   Moss de Oliveira S, 1999, EVOLUTION MONEY WAR
   Steiglitz K., 1998, Computational Economics, V12, P35, DOI 10.1023/A:1008625731231
   STEIGLITZ K, 1996, MARKET BASED CONTROL
NR 8
TC 11
Z9 12
U1 0
U2 0
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
BN 0-7803-7307-3
PY 2001
BP 535
EP 540
DI 10.1109/WSC.2001.977335
PG 6
WC Computer Science, Interdisciplinary Applications; Computer Science,
   Software Engineering
SC Computer Science
GA BV20W
UT WOS:000178162700069
DA 2021-08-04
ER

PT J
AU Di Paolo, EA
AF Di Paolo, EA
TI Behavioral coordination, structural congruence and entrainment in a
   simulation of acoustically coupled agents.
SO ADAPTIVE BEHAVIOR
LA English
DT Article
DE social behavior; embodied autonomous agents; acoustic interaction;
   coordination; entrainment; structural congruence
ID EVOLUTIONARY ROBOTICS; PAIR BOND; HYPOTHESIS
AB Social coordination is studied in a simulated model of autonomous embodied agents that interact acoustically. Theoretical concepts concerning social behavior are presented from a systemic perspective and their usefulness is evaluated in interpreting the results obtained. Two agents moving in an unstructured arena must locate each other, and remain within a short distance of one another for as long as possible using noisy continuous acoustic interaction. Evolved dynamical recurrent neural networks are used as the control architecture. Acoustic coupling poses nontrivial problems lit discriminating 'self' from 'non-self' and structuring production of signals in time so as to minimize interference. Detailed observation of the most frequently evolved behavioral strategy shows that interacting agents perform rhythmic signals leading to the coordination of movement. During coordination, signals become entrained in an anti-phase mode that resembles turn-taking. Perturbation techniques show that signalling behavior not only performs an external function, but it is also integrated into the movement of the producing agent, thus showing the difficulty of separating behavior into social and non-social classes. Structural congruence between agents is shown by exploring internal dynamics as well as the response of single agents in the presence of signalling beacons that reproduce the signal patterns of the interacting agents. Lack of entrainment with the signals produced by the beacons shows the importance of transient periods of mutual dynamic perturbation wherein agents achieve congruence.
C1 Univ Sussex, Brighton BN1 9QH, E Sussex, England.
RP Di Paolo, EA (corresponding author), Univ Sussex, Brighton BN1 9QH, E Sussex, England.
RI Di+Paolo, Ezequiel/AAF-2339-2020
OI Di+Paolo, Ezequiel/0000-0002-3296-5021
CR Beer R. D., 1996, From Animals to Animats 4. Proceedings of the Fourth International Conference on Simulation of Adaptive Behavior, P421
   Beer R. D., 1995, MIND MOTION EXPLORAT, P121
   Beer Randall D., 1992, Adaptive Behavior, V1, P91, DOI 10.1177/105971239200100105
   BILLARD A, 1997, TECHNICAL REPORT SER
   Byrne RW., 1988, MACHIAVELLIAN INTELL
   Condon W. S., 1979, SPEECH BEGINNING INT, P131
   CONDON WS, 1974, SCIENCE, V183, P99, DOI 10.1126/science.183.4120.99
   Dautenhahn K, 1995, ROBOT AUTON SYST, V16, P333, DOI 10.1016/0921-8890(95)00054-2
   Di Paolo EA, 1997, ADAPT BEHAV, V6, P285, DOI 10.1177/105971239700600204
   FAITH J, 1997, P 4 EUR C ART LIF CA
   FARABAUGH SM, 1982, ACOUSTIC COMMUNICATI, V2
   FEDDERSEN UE, 1957, J ACOUST SOC AM, V29, P988
   Grey Walter William, 1950, SCI AM, V182, P42, DOI DOI 10.1038/SCIENTIFICAMERICAN0550-42
   HAIMOFF EH, 1986, J HUM EVOL, V15, P51, DOI 10.1016/S0047-2484(86)80065-3
   Harvey I, 1997, ROBOT AUTON SYST, V20, P205, DOI 10.1016/S0921-8890(96)00067-X
   HOLLAND O, 1996, P AL 5 C NAR JAP, P16
   HOOKER T, 1969, BIRD VOCALIZATIONS T
   Humphrey N, 1976, GROWING POINTS ETHOL
   Jakobi N, 1997, ADAPT BEHAV, V6, P325, DOI 10.1177/105971239700600205
   Kandel E. R., 1991, PRINCIPLES NEURAL SC
   Kelso JAS., 1995, DYNAMIC PATTERNS SEL
   KING AJ, 1995, COGNITIVE NEUROSCIEN
   Kuramoto Y., 2003, CHEM OSCILLATIONS WA
   LUND HH, 1997, P 4 EUR C ART LIF CA
   MACLENNAN BJ, 1994, ADAPT BEHAV, V2, P151
   Mataric MJ, 1995, ADAPT BEHAV, V4, P51, DOI 10.1177/105971239500400104
   Maturana H., 1980, AUTOPOIESIS COGNITIO
   Port R. F., 1998, NONLINEAR ANAL DEV P
   Press W. H., 1992, NUMERICAL RECIPES C, V2nd
   ROZENWEIG MR, 1961, SCI AM, V205
   ROZENWEIG MR, 1954, J COMP PHYSIOL PSYCH, V47, P269
   SAUNDERS GM, 1996, ANIMALS ANIMATS, V4, P580
   Thorpe W. H., 1972, DUETTING ANTIPHONAL
   Varela F.J., 1979, PRINCIPLES BIOL AUTO
   Walter W. G., 1953, LIVING BRAIN
   WERNER GM, 1991, SFI STUDIES SCI COMP, V10
   WHITTEN A, 1997, MACHIAVELLIAN INTELL, V2
   WICKLER W, 1980, Z TIERPSYCHOL, V52, P217
   WICKLER W, 1979, Z TIERPSYCHOL, V51, P153
   WICKLER W, 1980, Z TIERPSYCHOL, V52, P201
   Winfree A.T., 1980, GEOMETRY BIOL TIME
NR 41
TC 61
Z9 61
U1 0
U2 6
PU INT SOC ADAPTIVE BEHAVIOR
PI HONOLULU
PA 2430 CAMPUS RD, HONOLULU, HI 96822 USA
SN 1059-7123
J9 ADAPT BEHAV
JI Adapt. Behav.
PD WIN
PY 2000
VL 8
IS 1
BP 27
EP 48
DI 10.1177/105971230000800103
PG 22
WC Computer Science, Artificial Intelligence; Psychology, Experimental;
   Social Sciences, Interdisciplinary
SC Computer Science; Psychology; Social Sciences - Other Topics
GA 397LE
UT WOS:000166696500003
DA 2021-08-04
ER

PT J
AU Lokich, J
AF Lokich, J
TI Phase I clinical trial of weekly combined paclitaxel plus docetaxel in
   patients with solid tumors
SO CANCER
LA English
DT Article
DE paclitaxel; docetaxel; solid tumors; phase I clinical trial; maximum
   tolerated dose; dose-limiting toxicity
ID COMBINATION CHEMOTHERAPY; DOSE SCHEDULE; CISPLATIN; ETOPOSIDE; INFUSION
AB BACKGROUND. A Phase I and feasibility study of combined docetaxel (D) plus paclitaxel (P) was undertaken to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) for each analogue delivered concomitantly on a weekly schedule.
   METHODS. Patients were accrued in 3-6 patient cohorts to P administered over a course of 45-60 minutes followed by D infused over a course of 30 minutes for 4 consecutive weeks with the cycles repeated at 6 weeks. The MTD was defined as the dose of each agent administered with at least Grade 3 (according to National Cancer Institute standard criteria) hematologic toxicity in 50% of the patients but without Grade 4 toxicity.
   RESULTS. Twenty patients received D plus P weekly for 4 weeks at 4 dose levels. At the highest P dose (80 mg/m(2); total dose per cycle, 320 mg/m(2)) 2 of 6 patients received treatment for 4 consecutive weeks but 5 of 6 patients developed hematologic and/or nonhematologic (skin) DLTs. The recommended treatment doses for this combined taxane regimen is D, 35 mg/m(2)/week, plus P, 65 mg/m(2)/week, for 4 weeks. An unusual cutaneous syndrome was observed in four patients that was manifested as erythema and blistering on the dorsum of the hands.
   CONCLUSIONS. The lack of complete cross-resistance for D and P in experimental systems and the clinical observation that tumor resistance to one taxane does not necessarily convey resistance to the alternative taxane was the basis for exploring the use of both analogues administered simultaneously. This Phase I trial establishes the optimal weekly dose for each taxane when administered in combination. Cancer 2000;89:2309-14. (C) 2000 American Cancer Society.
C1 Canc Ctr Boston, Dept Neoplast Dis, Boston, MA 02120 USA.
RP Lokich, J (corresponding author), Canc Ctr Boston, Dept Neoplast Dis, 125 Parker Hill Ave, Boston, MA 02120 USA.
EM jlokich@cancercenter-of-boston.com
CR Akerley W, 1998, J CLIN ONCOL, V16, P153, DOI 10.1200/JCO.1998.16.1.153
   ALLEN LM, 1982, CANCER CHEMOTH PHARM, V7, P151
   Androulakis N, 1998, ANN ONCOL, V9, P1127, DOI 10.1023/A:1008497322508
   ARBUCK SG, 1993, SEMIN ONCOL, V20, P31
   ASBURY R, 1998, P AM SOC CLIN ONCOL
   BREIER S, 1998, P AM SOC CLIN ONCOL
   Fennelly D, 1997, J CLIN ONCOL, V15, P187, DOI 10.1200/JCO.1997.15.1.187
   Hainsworth JD, 1998, J CLIN ONCOL, V16, P2164, DOI 10.1200/JCO.1998.16.6.2164
   LOEFFLER TM, 1998, P AN M AM SOC CLIN, V17, pA113
   Lokich J, 1999, CANCER INVEST, V17, P547, DOI 10.3109/07357909909032865
   Lokich J, 1998, EUR J CANCER, V34, P659, DOI 10.1016/S0959-8049(97)10104-6
   Lokich JJ, 1999, CANCER, V85, P499, DOI 10.1002/(SICI)1097-0142(19990115)85:2<499::AID-CNCR31>3.0.CO;2-V
   LUCK HJ, 1997, EJC SUPPL, V33, pS158
   PICCART MJ, 1990, J NATL CANCER I, V82, P703, DOI 10.1093/jnci/82.8.703
   SEIDMAN A, 1997, P AN M AM SOC CLIN, V16, P148
   SIKOV W, 1998, P AM SOC CLIN ONCOL
   Soulie P, 1997, EUR J CANCER, V33, P1400, DOI 10.1016/S0959-8049(97)00122-6
   STEWART DJ, 1987, AM J CLIN ONCOL-CANC, V10, P335, DOI 10.1097/00000421-198708000-00016
   TOMIAK E, 1994, J CLIN ONCOL, V12, P1458, DOI 10.1200/JCO.1994.12.7.1458
   Valero V, 1998, J CLIN ONCOL, V16, P3362, DOI 10.1200/JCO.1998.16.10.3362
   VERWEIJ J, 1994, ANN ONCOL, V5, P495, DOI 10.1093/oxfordjournals.annonc.a058903
   WINER E, 1998, P AM SOC CLIN ONCOL
NR 22
TC 6
Z9 7
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD DEC 1
PY 2000
VL 89
IS 11
BP 2309
EP 2314
DI 10.1002/1097-0142(20001201)89:11<2309::AID-CNCR20>3.0.CO;2-8
PG 6
WC Oncology
SC Oncology
GA 378XB
UT WOS:000165609700020
PM 11147602
DA 2021-08-04
ER

PT J
AU Hsu, C
AF Hsu, C
TI Volume-volatility dynamics in an intertemporal asset pricing model
SO MACROECONOMIC DYNAMICS
LA English
DT Article
ID TRADING VOLUME; VARIANCE; HETEROSKEDASTICITY; RETURNS; PRICES
AB This paper embeds time-varying volatility into a dynamic equilibrium model of returns and trading. The model allows us to ask how time-varying volatility might affect the relation among return autocorrelation, volatility, and trading volume, as opposed to the pairwise relations that have been studied previously. It is shown analytically that, with time-varying volatility, the relationship between volume and stock return autocorrelation is ambiguous even if agents have symmetric information, which may explain the contradictory findings in the empirical literature, In the numerical exercise, the model is simulated in a way that mimics the persistent volatility of high-frequency stock data documented in numerous empirical studies, Specially, the time-varying volatility of stock returns is approximated with a highly persistent chaotic tent map, which is known to have the same autocorrelation coefficients as an AR(1) process. The simulated data can approximate GARCH-type behavior very well. Whereas in the simulated data, no significant relation between volume and return autocorrelation can be found, there is a significantly positive relation between volume and one-step-ahead stock return volatility. The ambiguous volume-persistence and positive volume-volatility relations are confirmed empirically by using four heavily traded individual stocks. Therefore, the data simulated from the highly stylized asset pricing model with deterministic time-varying volatility can mimic well the volume-return dynamics revealed in the observed data in these two respects.
RP Hsu, C (corresponding author), 1 Cabot Sq, London E14 4QJ, England.
CR ANTONIEWICZ R, 1992, THESIS U WISCONSIN M
   BOLLERSLEV T, 1986, J ECONOMETRICS, V31, P307, DOI 10.1016/0304-4076(86)90063-1
   BOLLERSLEV T, 1992, J ECONOMETRICS, V52, P5, DOI 10.1016/0304-4076(92)90064-X
   Brock WA, 1996, REV ECON STAT, V78, P94, DOI 10.2307/2109850
   CAMPBELL JY, 1993, Q J ECON, V108, P905, DOI 10.2307/2118454
   CLARK PK, 1973, ECONOMETRICA, V41, P135, DOI 10.2307/1913889
   CONRAD JS, 1994, J FINANC, V49, P1305, DOI 10.2307/2329187
   DROST FC, 1993, ECONOMETRICA, V61, P909, DOI 10.2307/2951767
   ENGLE RF, 1982, ECONOMETRICA, V50, P987, DOI 10.2307/1912773
   GALLANT AR, 1992, REV FINANC STUD, V5, P199, DOI 10.1093/rfs/5.2.199
   Gallant AR, 1997, J ECONOMETRICS, V81, P159, DOI 10.1016/S0304-4076(97)00039-0
   KARPOFF JM, 1987, J FINANC QUANT ANAL, V22, P109, DOI 10.2307/2330874
   LAMOUREUX CG, 1990, J FINANC, V45, P221, DOI 10.2307/2328817
   LeBaron B., 1992, PERSISTENCE DOW JONE
   LINTNER JW, 1956, AM EC REV P, V66, P97
   LO AW, 1990, J ECONOMETRICS, V45, P181, DOI 10.1016/0304-4076(90)90098-E
   Merchant K. A., 1989, REWARDING RESULTS MO
   MILGROM P, 1982, J ECON THEORY, V26, P17, DOI 10.1016/0022-0531(82)90046-1
   MORSE D, 1978, J FINANCIAL QUANTITA, V6, P461
   NELSON DB, 1992, J ECONOMETRICS, V52, P61, DOI 10.1016/0304-4076(92)90065-Y
   PHILLIPS PCB, 1988, BIOMETRIKA, V75, P335, DOI 10.2307/2336182
   SAKAI H, 1980, IEEE T ACOUST SPEECH, V28, P588, DOI 10.1109/TASSP.1980.1163449
   Tauchen G, 1996, J ECONOMETRICS, V74, P177, DOI 10.1016/0304-4076(95)01755-0
   TAUCHEN GE, 1983, ECONOMETRICA, V51, P485, DOI 10.2307/1912002
   VARIAN HR, 1989, FINANCIAL RISK : THEORY, EVIDENCE AND IMPLICATIONS, P3
   WANG J, 1994, J POLIT ECON, V102, P127, DOI 10.1086/261924
NR 26
TC 2
Z9 2
U1 0
U2 1
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 40 WEST 20TH STREET, NEW YORK, NY 10011-4211 USA
SN 1365-1005
J9 MACROECON DYN
JI Macroecon. Dyn.
PD DEC
PY 2000
VL 4
IS 4
BP 506
EP 533
DI 10.1017/S1365100500017053
PG 28
WC Economics
SC Business & Economics
GA 391XF
UT WOS:000166381000005
DA 2021-08-04
ER

PT J
AU Lepperhoff, N
AF Lepperhoff, N
TI Dreamscape: Simulation of the emergence of norms out of the state of
   nature using a computer-based rational choice model
SO ZEITSCHRIFT FUR SOZIOLOGIE
LA German
DT Article
ID ESSER,HARTMUT; DEFINITION; SITUATION
AB This paper illustrates the use of computer simulation for the formalization of theories. The multi-agent model Dreamscape is an operationalization of Esser's Rational Choice Theory with a multi-agent system. The author examines the dynamics of the Rational Choice Theory by analyzing the emergence of social order our of the "state of nature" (Hobbes). The computer-based rational choice model Dreamscape models the "state of nature" as described by Hobbes with relative exactness. The computer-based analysis shows that conjunct norms emerge if deadly violence is not allowed. Oil the other hand, if individuals use deadly violence no social order emerges. A further result is the demand for an extension of the rules that regulate the creation of bridge hypotheses, which guide the operationalization of Esser's rational choice theory.
C1 Forschungszentrum Julich, Programmgrp Syst Forsch & Technol Entwicklung, STE, D-52425 Julich, Germany.
RP Lepperhoff, N (corresponding author), Forschungszentrum Julich, Programmgrp Syst Forsch & Technol Entwicklung, STE, Postfach 1913, D-52425 Julich, Germany.
CR *AMN INT, 1997, JAHR 1997
   AXELROD R, 1997, EVOLUTION KOOPERATIO
   AXELROD R, 1997, SIMULATING SOCIAL PH, P15
   Axelrod R., 1997, COMPLEXITY COOPERATI
   Bahrdt H. P., 1994, SCHLUSSELBEGRIFFE SO
   BRASSEL KH, 1997, SIMULATING SOCIAL PH, P55
   Bratley P., 1987, GUIDE SIMULATION
   CASTELFRANCHI CV, 1998, J ARTIFICIAL SOC SOC
   Coleman J. S., 1986, PARADOXICAL EFFECTS, P55, DOI DOI 10.1007/978-3-642-95874-8_6
   COLEMAN JS, 1991, GRUNDLAGEN SOZIALTHE, V1
   COLL JCM, 1986, SOC SCI INFORM, V25, P493, DOI 10.1177/053901886025002010
   DELAHAYE JP, 1998, SPEKTRUM WISSENSCHAF, P82
   DEVOS H, 1991, MODELLIERUNG SOZIALE, P397
   Donninger C, 1986, PARADOXICAL EFFECTS, P123
   DORAN J, 1998, J ARTIFICIAL SOC SOC
   Egger M, 1997, KOLNER Z SOZIOL SOZ, V49, P306
   Epstein J.M., 1996, GROWING ARTIFICIAL S
   Esser H, 1996, KOLNER Z SOZIOL SOZ, V48, P1
   Esser H., 1991, ALLTAGSHANDELN VERST
   ESSER H, 1991, MODELLIERUNG SOZIALE, P13
   Gilbert N., 1999, SIMULATION SOCIAL SC
   Hall Edward T., 1973, SILENT LANGUAGE
   Hobbes T., 1998, LEVIATHAN
   HOLLER MJ, 1986, PARADOXICAL EFFECTS, P223
   KELLE U, 1995, KOLNER Z SOZIOL SOZ, V47, P249
   KIRK J, 1967, FORMALISIERTE MODELL, P169
   KUNZ V, 1997, THEORIE RATIONALEN H
   LEPPERHOFF N, 1999, SYS599 U DORTM FACHB
   Lindenberg S, 1989, RATION SOC, V1, P51
   Lindenberg S., 1990, SOZIALSTRUKTUR KULTU, P249
   LINDENBERG S, 1992, DYNAMICS COHORT GENE, P283
   Ludemann C, 1996, Z SOZIOL, V25, P278
   MACY WM, 1998, J ARTIFICIAL SOC SOC, V1
   MAINDOK H, 1998, EINFUHRUNG SOZIOLOGI
   MAJESKI S, 1997, SIMULATING SOCIAL PH, P161
   MILLER M, 1994, SOZ WELT, V45, P5
   OPP KD, 1991, MODELLIERUNG SOZIALE, P373
   Parisi D, 1997, SIMULATING SOCIAL PH, P133
   Saam N. J., 1999, J ARTIFICIAL SOC SOC, V2
   SCHNELL R, 1991, MODELLIERUNG SOZIALE, P139
   SCHUSSLER RA, 1986, PARADOXICAL EFFECTS, P105
   SCHUSSLER RA, 1991, MODELLIERUNG SOZIALE, P457
   SCRUBAR I, 1992, Z SOZIOL, V21, P157
   Taylor M., 1987, POSSIBILITY COOPERAT
   TROITZSCH KG, 2000, SOZIOLOGIE, V2, P33
   Voss T, 1985, RATIONALE AKTEURE SO
NR 46
TC 6
Z9 6
U1 0
U2 1
PU LUCIUS LUCIUS VERLAG MBH
PI STUTTGART
PA GEROKSTR 51, D-70184 STUTTGART, GERMANY
SN 0340-1804
J9 Z SOZIOL
JI Z. Soziol.
PD DEC
PY 2000
VL 29
IS 6
BP 463
EP +
PG 23
WC Sociology
SC Sociology
GA 386GX
UT WOS:000166053500003
DA 2021-08-04
ER

PT J
AU Bailly, C
   Goossens, JF
   Laine, W
   Anizon, F
   Prudhomme, M
   Ren, JS
   Chaires, JB
AF Bailly, C
   Goossens, JF
   Laine, W
   Anizon, F
   Prudhomme, M
   Ren, JS
   Chaires, JB
TI Formaldehyde-induced alkylation of a 2 '-aminoglucose rebeccamycin
   derivative to both A center dot T and G center dot C base pairs in DNA
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID TOPOISOMERASE-I INHIBITION; CIRCULAR-DICHROISM SPECTRA; ACID BUTYLAMINE
   COMPLEXES; CHEMICAL CROSS-LINKING; DEOXYRIBONUCLEIC-ACID; CONFORMATIONAL
   CHARACTERISTICS; DAUNORUBICIN; BINDING; RECOGNITION; DIFFRACTION
AB Rebeccamycin derivatives represent a promising class of antitumor agents. In this series, two glycosylated indolocarbazoles, NB-506 and NSC-655649, are currently undergoing clinical trials. Their anticancer activities are associated with their capacities to interact with DNA and to inhibit DNA topoisomerases. Previous studies revealed that the planar indolocarbazole chromophore can intercalate into DNA, locating the appended carbohydrate residue in one of the two helical grooves, probably the minor groove as is the case with the anthracyclines and other DNA-binding antibiotics. The sugar residue contributes significantly to the DNP; binding free energy of NB-506. However, the exact positioning of the glycosyl residue of rebeccamycin derivatives in the drug-DNA complex remains poorly understood. To better understand how glycosylated indolocarbazoles interact with DNA, we investigated the interaction of a rebeccamycin derivative (85) bearing a 2'-amino group on the sugar residue. We show that the presence of the 2'-amino function permits the formation of covalent drug-DNA complexes in the presence of formaldehyde. Complementary biochemical and spectroscopic measurements attest that 85 reacts covalently with the 2-amino group of guanines exposed in the minor groove of the double helix, as is the case with daunomycin. In contrast to daunomycin, 85 also forms cross-links with an oligonucleotide containing only A.T base pairs. The covalent binding to A.T base pairs was detected using a gel mobility shift assay and was independently confirmed by thermal denaturation studies and by fluorescence measurements using a series of synthetic polynucleotides. The HCHO-mediated alkylation reaction of the drug with A.T base pairs apparently involves the 6-amino group of adenines exposed in the major groove whereas the covalent attachment to G.C base pairs implicates the 2-amino group of guanines situated in the opposite minor groove. Therefore, the results suggest that either the drug is able to switch grooves in response to sequence or it can simultaneously bind to both the minor and major grooves of the double helix. This study will help to guide the rational design of new DNA-binding antitumor indolocarbazole drugs and also provides a general experimental approach for probing minor versus major groove interactions between small molecules and DNA.
C1 INSERM, U524, F-59045 Lille, France.
   Ctr Oscar Lambret, Lab Pharmacol Antitumorale, F-59045 Lille, France.
   Fac Pharm, Chim Analyt Lab, F-59006 Lille, France.
   Univ Blaise Pascal, UMR 6504 CNRS, SEESIB, F-63177 Clermont Ferrand, France.
   Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA.
RP Bailly, C (corresponding author), INSERM, U524, F-59045 Lille, France.
RI ANIZON, Fabrice/M-7940-2016; BAILLY, Christian/AAK-2799-2021
OI ANIZON, Fabrice/0000-0001-7869-9622; BAILLY,
   Christian/0000-0002-2973-9357; Chaires, Jonathan/0000-0001-5477-945X
FU NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [R01CA035635] Funding Source: NIH RePORTER; NCI NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [CA35635] Funding Source: Medline
CR Bailly C, 1998, MOL PHARMACOL, V53, P77
   Bailly C, 1999, MOL PHARMACOL, V55, P377
   Bailly C, 1997, BIOCHEMISTRY-US, V36, P3917, DOI 10.1021/bi9624898
   Bailly C, 2000, CURR MED CHEM, V7, P39, DOI 10.2174/0929867003375489
   Bailly C, 1999, CHEM BIOL, V6, P277, DOI 10.1016/S1074-5521(99)80073-8
   Chaires J. B., 1996, ADV DNA SEQUENCE SPE, V2, P141
   Chaires JB, 1997, BIOPOLYMERS, V44, P201, DOI 10.1002/(SICI)1097-0282(1997)44:3<201::AID-BIP2>3.0.CO;2-Z
   CHAIRES JB, 1993, J AM CHEM SOC, V115, P5360, DOI 10.1021/ja00066a002
   CHAW YFM, 1980, BIOCHEMISTRY-US, V19, P5525, DOI 10.1021/bi00565a010
   CHEN C, 1981, BIOCHEMISTRY-US, V20, P4987, DOI 10.1021/bi00520a027
   CHEN C, 1987, BIOCHEMISTRY-US, V26, P8213, DOI 10.1021/bi00399a029
   CHEN CY, 1983, BIOCHEMISTRY-US, V22, P4746, DOI 10.1021/bi00289a020
   CHEN HF, 1995, J AM CHEM SOC, V117, P5901, DOI 10.1021/ja00127a001
   DOWLATI A, 1999, P AN M AM SOC CLIN, V18, pA181
   Dutta R, 1998, NUCLEIC ACIDS RES, V26, P3001, DOI 10.1093/nar/26.12.3001
   FISH SR, 1983, BIOCHEMISTRY-US, V22, P4751, DOI 10.1021/bi00289a021
   GAO YG, 1991, P NATL ACAD SCI USA, V88, P4845, DOI 10.1073/pnas.88.11.4845
   Gao YG, 1997, J AM CHEM SOC, V119, P1496, DOI 10.1021/ja963793r
   Gao YG, 1996, EUR J BIOCHEM, V240, P331, DOI 10.1111/j.1432-1033.1996.0331h.x
   KILKUSKIE R, 1988, BIOCHEMISTRY-US, V27, P4377, DOI 10.1021/bi00412a026
   Leng FF, 1996, J AM CHEM SOC, V118, P4731, DOI 10.1021/ja9542606
   Leng FF, 1998, BBA-GENE STRUCT EXPR, V1442, P71, DOI 10.1016/S0167-4781(98)00122-5
   Long BH, 2000, EXPERT OPIN THER PAT, V10, P635, DOI 10.1517/13543776.10.5.635
   MAIBENCO D, 1989, BIOPOLYMERS, V28, P549, DOI 10.1002/bip.360280203
   OHE Y, 1997, P ACSO, V16, pA199
   Parker BS, 1999, NUCLEIC ACIDS RES, V27, P2918, DOI 10.1093/nar/27.14.2918
   Prudhomme M, 1997, CURR PHARM DESIGN, V3, P265
   WANG AHJ, 1991, BIOCHEMISTRY-US, V30, P3812, DOI 10.1021/bi00230a002
   WELLS R D, 1970, Journal of Molecular Biology, V54, P465, DOI 10.1016/0022-2836(70)90121-X
   ZHANG H, 1993, J BIOL CHEM, V268, P10095
NR 30
TC 14
Z9 16
U1 0
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD NOV 30
PY 2000
VL 43
IS 24
BP 4711
EP 4720
DI 10.1021/jm0003438
PG 10
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 378ZK
UT WOS:000165616200015
PM 11101362
DA 2021-08-04
ER

PT J
AU Mosca, PJ
   Hobeika, AC
   Clay, TM
   Nair, SK
   Thomas, EK
   Morse, MA
   Lyerly, HK
AF Mosca, PJ
   Hobeika, AC
   Clay, TM
   Nair, SK
   Thomas, EK
   Morse, MA
   Lyerly, HK
TI A subset of human monocyte-derived dendritic cells expresses high levels
   of interleukin-12 in response to combined CD40 Ligand and
   interferon-gamma treatment
SO BLOOD
LA English
DT Article
ID BLOOD MONONUCLEAR-CELLS; NECROSIS-FACTOR-ALPHA; T-CELLS;
   CANCER-IMMUNOTHERAPY; MURINE MACROPHAGES; IL-12 PRODUCTION; IFN-GAMMA;
   IN-VITRO; LIPOPOLYSACCHARIDE; CD14
AB Dendritic cells (DCs) may arise from multiple lineages and progress through a series of intermediate stages until fully mature, at which time they are capable of optimal antigen presentation and T-cell activation. High cell surface expression of CD83 is presumed to correlate with full maturation of DCs, and a number of agents have been shown to increase CD83 expression on DCs, We hypothesized that interleukin 12 (IL-12) expression would be a more accurate marker of functionally mature DCs capable of activating antigen-specific T cells. We used combinations of signaling through CD40, using CD40 ligand trimer (CD40L), and interferon gamma to demonstrate that CD83 expression is necessary but not sufficient for optimal production of IL-12 by DCs, Phenotypically mature DCs could be induced to produce high levels of IL-12 p70 only when provided 2 simultaneous stimulatory signals. By intracellular cytokine detection, we determined that only a subset of cells that express high levels of CD80 and CD83 generate large amounts of IL-12, DCs matured with both signals are superior to DCs stimulated with the individual agents in activating antigen-specific T cell in vitro. These findings have important implications regarding the identification, characterization, and clinical application of functionally mature DCs, (C) 2000 by The American Society of Hematology.
C1 Duke Univ, Med Ctr, Ctr Genet & Cellular Therapies, Dept Gen & Thorac Surg, Durham, NC 27710 USA.
   Duke Univ, Med Ctr, Ctr Genet & Cellular Therapies, Dept Pathol, Durham, NC 27710 USA.
   Duke Univ, Med Ctr, Ctr Genet & Cellular Therapies, Dept Immunol, Durham, NC 27710 USA.
   Duke Univ, Med Ctr, Ctr Genet & Cellular Therapies, Dept Internal Med, Durham, NC 27710 USA.
   Immunex Inc, Seattle, WA USA.
RP Lyerly, HK (corresponding author), Duke Univ, Med Ctr, Ctr Genet & Cellular Therapies, Dept Gen & Thorac Surg, Durham, NC 27710 USA.
EM k.lyerly@cgct.duke.edu
RI Lyerly, Herbert Kim/AAX-4925-2020; Lyerly, Herbert K/B-6528-2014; Nair
   Jain, Smita/M-2765-2018
OI Lyerly, Herbert Kim/0000-0002-0063-4770; Lyerly, Herbert
   K/0000-0002-0063-4770; Nair Jain, Smita/0000-0002-1542-9913
FU NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [CA77894-02, P01 CA 78673 01A1] Funding Source: Medline; NCRR NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [MO1RR00030] Funding Source: Medline; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [F32CA077894, P01CA078673] Funding Source: NIH RePORTER; NATIONAL CENTER
   FOR RESEARCH RESOURCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Research Resources (NCRR) [M01RR000030] Funding Source: NIH RePORTER
CR Ahuja SS, 1998, J IMMUNOL, V161, P868
   BETTE M, 1994, EUR J IMMUNOL, V24, P2435, DOI 10.1002/eji.1830241026
   Buelens C, 1997, EUR J IMMUNOL, V27, P1848, DOI 10.1002/eji.1830270805
   CAUX C, 1994, J EXP MED, V180, P1263, DOI 10.1084/jem.180.4.1263
   Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747
   COHEN L, 1995, J IMMUNOL, V155, P5337
   CORRALES I, 1993, IMMUNOLOGY, V80, P84
   DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387
   DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183
   DENTENER MA, 1993, J IMMUNOL, V150, P2885
   Fernandez-Lago L, 1999, J MED MICROBIOL, V48, P1065, DOI 10.1099/00222615-48-12-1065
   Haziot A, 1998, J IMMUNOL, V160, P2570
   Kuniyoshi JS, 1999, CELL IMMUNOL, V193, P48, DOI 10.1006/cimm.1999.1469
   MACATONIA SE, 1995, J IMMUNOL, V154, P5071
   Morse MA, 1997, ANN SURG, V226, P6, DOI 10.1097/00000658-199707000-00002
   Morse MA, 1998, CYTOKINES CELL MOL T, V4, P35
   Mountford AP, 1999, IMMUNOLOGY, V97, P588
   Okamoto Y, 1998, IMMUNOPHARMACOLOGY, V39, P107, DOI 10.1016/S0162-3109(98)00007-1
   Perera PY, 1997, J IMMUNOL, V158, P4422
   Romani N, 1996, J IMMUNOL METHODS, V196, P137, DOI 10.1016/0022-1759(96)00078-6
   SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376
   Schmidt CS, 1999, J IMMUNOL, V163, P2561
   Snijders A, 1996, J IMMUNOL, V156, P1207
   Snijders A, 1998, INT IMMUNOL, V10, P1593, DOI 10.1093/intimm/10.11.1593
   Suri RM, 1998, J IMMUNOL METHODS, V214, P149, DOI 10.1016/S0022-1759(98)00048-9
   Szabolcs P, 1996, BLOOD, V87, P4520, DOI 10.1182/blood.V87.11.4520.bloodjournal87114520
   Timmerman JM, 1999, ANNU REV MED, V50, P507
   TSANG KY, 1995, J NATL CANCER I, V87, P982, DOI 10.1093/jnci/87.13.982
   Tuting T, 1998, J IMMUNOL, V160, P1139
   Vanderheyde N, 1999, TRANSPLANTATION, V67, P1342, DOI 10.1097/00007890-199905270-00009
   Vieira PL, 2000, J IMMUNOL, V164, P4507, DOI 10.4049/jimmunol.164.9.4507
   WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311
   Yang RC, 1999, J IMMUNOL, V163, P1037
NR 33
TC 122
Z9 124
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD NOV 15
PY 2000
VL 96
IS 10
BP 3499
EP 3504
PG 6
WC Hematology
SC Hematology
GA 372HA
UT WOS:000165227200028
PM 11071647
DA 2021-08-04
ER

PT J
AU Robinson, DA
   Williams, RBG
AF Robinson, DA
   Williams, RBG
TI Experimental weathering of sandstone by combinations of salts
SO EARTH SURFACE PROCESSES AND LANDFORMS
LA English
DT Article; Proceedings Paper
CT Annual Conference of the RGS-IBG
CY JAN, 2000
CL UNIV SUSSEX, SUSSEX, ENGLAND
SP RGS-IBG
HO UNIV SUSSEX
DE experimental weathering; salt weathering; sandstone weathering
ID LABORATORY SIMULATION; FROST; ROCK
AB Laboratory experiments are described that examined the effectiveness of certain naturally occurring combinations of salts as weathering agents. Cubes of a highly quartzose sandstone were repeatedly soaked in one of a series of salt solutions and then oven-dried to simulate natural weathering. The weathering effect of both potassium alum and ammonium alum is enhanced by the presence of alunogen or gypsum whereas sodium chloride depresses the effect of the alums. Sodium chloride combined with gypsum is confirmed as appreciably more destructive than either of the salts alone. The results indicate that it is difficult to predict the weathering behaviour of combinations of salts from the weathering behaviour of the salts individually. Possible causes of enhanced weathering by some combined salt solutions are discussed. Copyright (C) 2000 John Wiley & Sons, Ltd.
C1 Univ Sussex, Sch Chem Phys & Environm Sci, Environm Res Ctr, Brighton BN1 9QJ, E Sussex, England.
RP Robinson, DA (corresponding author), Univ Sussex, Sch Chem Phys & Environm Sci, Environm Res Ctr, Brighton BN1 9QJ, E Sussex, England.
CR Beyer O, 1911, Z DTSCH GEOL GES, V63, P429
   Brimblecombe P., 1994, PREVENTIVE CONSERVAT, V39, P90, DOI DOI 10.1179/SIC.1994.39.SUPPLEMENT-2.90
   Evans I.S., 1970, REV GEOMORPHOLOGIE D, V19, P153
   GILL ED, 1981, EARTH SURF PROC LAND, V6, P81, DOI 10.1002/esp.3290060109
   Goudie A., 1974, Z GEOMORPHOLOGIE   S, V21, P1
   Goudie A, 1997, SALT WEATHERING HAZA
   GOUDIE AS, 1986, EARTH SURF PROCESSES, V11, P275, DOI 10.1002/esp.3290110305
   Goudie AS, 1997, J ARID ENVIRON, V37, P581, DOI 10.1006/jare.1997.0297
   GOUDIE AS, 1984, GEOFORUM, V15, P563, DOI 10.1016/0016-7185(84)90025-3
   GOUDIE AS, 1970, AREA, V4, P42, DOI DOI 10.2139/SSRN.2149615
   GOUDIE AS, 1985, SALT WEATHERING
   KWAAD FJM, 1970, U AMSTERDAM FYSISCH, V16, P203
   LENTSCHIGSOMMER S, 1961, VORKOMMEN ALUNOGEN K, P109
   LENTSCHIGSOMMER S, 1960, JB STAATLICHES MUSEU, P111
   LITVAN GG, 1975, J AM CERAM SOC, V58, P26, DOI 10.1111/j.1151-2916.1975.tb18975.x
   MCGREEVY JP, 1982, EARTH SURF PROC LAND, V7, P475, DOI 10.1002/esp.3290070508
   Mellor J.W., 1956, COMPREHENSIVE TREATI
   MOTTERSHEAD DN, 1994, EARTH SURF PROCESSES, V19, P543, DOI 10.1002/esp.3290190607
   Partington J. R., 1966, GEN INORGANIC CHEM
   PEDRO G, 1957, CR HEBD ACAD SCI, V245, P333
   PRICK A, 1996, THESIS U LIEGE
   Rast H., 1959, GEOLOGISCHER FUHRER
   READ HH, 1962, RUTLEYS ELEMENTS MIN
   Remy H, 1956, TREATISE INORGANIC C
   ROBINSON DA, 1982, AREA, V14, P293
   Robinson DA, 1974, P GEOLOGISTS ASS, V87, P93, DOI 10.1016/S0016-7878(76)80038-7
   SPERLING CHB, 1985, EARTH SURF PROC LAND, V10, P541, DOI 10.1002/esp.3290100603
   Williams RBG, 1998, Q J ENG GEOL HYDROGE, V31, P369, DOI 10.1144/GSL.QJEG.1998.031.P4.10
   WILLIAMS RBG, 1981, EARTH SURF PROC LAND, V6, P1, DOI 10.1002/esp.3290060102
   WINKLER EM, 1975, STONE PROPERTIES DUR
NR 30
TC 24
Z9 26
U1 0
U2 15
PU JOHN WILEY & SONS LTD
PI W SUSSEX
PA BAFFINS LANE CHICHESTER, W SUSSEX PO19 1UD, ENGLAND
SN 0197-9337
J9 EARTH SURF PROC LAND
JI Earth Surf. Process. Landf.
PD NOV
PY 2000
VL 25
IS 12
BP 1309
EP 1315
DI 10.1002/1096-9837(200011)25:12<1309::AID-ESP139>3.0.CO;2-5
PG 7
WC Geography, Physical; Geosciences, Multidisciplinary
SC Physical Geography; Geology
GA 375AP
UT WOS:000165377600004
DA 2021-08-04
ER

PT J
AU Kawakami, T
   Sato, S
   Suzuki, K
AF Kawakami, T
   Sato, S
   Suzuki, K
TI Beneficial effect of Cyclosporin A on acute hepatic injury induced by
   galactosamine and lipopolysaccharide in rats
SO HEPATOLOGY RESEARCH
LA English
DT Article
DE acute hepatic failure; cyclosporin A; interleukin 8; neutrophil; tumor
   necrosis factor-alpha
ID TUMOR-NECROSIS-FACTOR; ISCHEMIA-REPERFUSION; ENDOTHELIAL-CELLS;
   LIVER-INJURY; ACTIVATION; ADHESION; MODEL; MICE
AB Cyclosporin A (CsA). a potent immunosuppressive agent, is used clinically to prevent allograft rejection after organ transplantation. Although recent experimental studies show that CsA prevents severe hepatic injury associated with tumor necrosis factor-alpha (TNF-alpha), the efficacy of CsA has not been confirmed. In the present study, we evaluated whether CsA protects against the severe hepatic injury induced by simultaneous administration of D-galactosamine (GaIN, 200 mg/kg) and lipopolysaccharide (LPS, 10 mu g/kg) into the portal vein. The method of CsA (10 mg/kg) was divided into four groups: i.e. preinjection (24 and 2 h before administration of GaIN and LPS), concomitant single-injection, multiple-interval injection (0, 3, 6, 9 and 15 h after administration of GaIN and LPS) and no treatment. In the group receiving multiple-interval injections of CsA, liver function parameters (total bilirubin, asparate aminotransferase and alanine aminotransferase levels in sera) were significantly improved and the development of massive hepatic necrosis was significantly prevented, but no improvement of liver function parameters or histological changes was shown either the pre- or concomitant single-injection groups. The serum levels of TNF-alpha. and interferon-gamma showed no differences between the no treatment and multiple-interval injection groups. However, the serum level of interleukin 8 and neutrophil infiltration into the liver tissue after 24 h GaIN and LPS administration were significantly lower than those of the control group. The apoptotic index of liver tissue using the TUNEL method was not significantly different. Our data suggest that CsA protects against acute hepatic injury, if it is administered at the appropriate time during the course of hepatic injury. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.
C1 Iwate Med Univ, Sch Med, Dept Internal Med 1, Morioka, Iwate 0208505, Japan.
RP Kawakami, T (corresponding author), Iwate Med Univ, Sch Med, Dept Internal Med 1, Uchimaru 19-1, Morioka, Iwate 0208505, Japan.
CR ALMEIDA JD, 1969, LANCET, V2, P983
   ANDO K, 1993, J EXP MED, V178, P1541, DOI 10.1084/jem.178.5.1541
   DUDLEY FJ, 1972, LANCET, V1, P723
   ELLIOTT JF, 1984, SCIENCE, V226, P1439, DOI 10.1126/science.6334364
   IWATSUKI S, 1988, TRANSPLANT P, V20, P498
   JAESCHKE H, 1991, AM J PHYSIOL, V260, P355
   KOMATSU Y, 1994, HEPATOLOGY, V20, P1548, DOI 10.1002/hep.1840200626
   LIU P, 1990, Gastroenterologia Japonica, V25, P339
   MOCHIDA S, 1995, J GASTROEN HEPATOL, V10, pS38, DOI 10.1111/j.1440-1746.1995.tb01795.x
   Morikawa A, 1996, INFECT IMMUN, V64, P734, DOI 10.1128/IAI.64.3.734-738.1996
   MUTO Y, 1988, LANCET, V2, P72
   OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0
   OHIRA H, 1995, SCAND J GASTROENTERO, V30, P1027, DOI 10.3109/00365529509096349
   Sakr MF, 1996, INT SURG, V81, P180
   SAKR MF, 1993, J HEPATOL, V17, P301, DOI 10.1016/S0168-8278(05)80209-0
   SAKR MF, 1991, HEPATOLOGY, V13, P947, DOI 10.1002/hep.1840130524
   SATO A, 1999, ACTA HEPATOL JPN, V40, P217
   Serizawa A, 1996, HEPATOLOGY, V23, P1656
   Tojimbara T, 1996, TRANSPLANT P, V28, P1381
   Toshima Keiko, 1998, Journal of Saitama Medical School, V25, P123
   TYGSTRUP N, 1979, GUT, V20, P620
   Wasaki S, 1997, LIVER, V17, P107
   YOSHIBA M, 1995, J GASTROENTEROL, V30, P67, DOI 10.1007/BF01211377
NR 23
TC 7
Z9 8
U1 0
U2 0
PU ELSEVIER SCI IRELAND LTD
PI CLARE
PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE,
   IRELAND
SN 1386-6346
J9 HEPATOL RES
JI Hepatol. Res.
PD NOV
PY 2000
VL 18
IS 3
BP 284
EP 297
DI 10.1016/S1386-6346(00)00088-7
PG 14
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 365CE
UT WOS:000089930200011
PM 11058832
DA 2021-08-04
ER

PT J
AU Ickx, BE
   Rigolet, M
   Van der Linden, PJ
AF Ickx, BE
   Rigolet, M
   Van der Linden, PJ
TI Cardiovascular and metabolic response to acute normovolemic anemia -
   Effects of anesthesia
SO ANESTHESIOLOGY
LA English
DT Article; Proceedings Paper
CT Annual Meeting of the American-Society-of-Anesthesiologists
CY OCT 07-22, 1999
CL Dallas, TX
SP Amer Soc Anesthesiologists
DE anesthetic agents; cardiovascular system; oxygen consumption; oxygen
   transport
ID ANESTHETIZED DOGS; ISOVOLEMIC ANEMIA; HEMODILUTION; ISOFLURANE;
   CONTRACTILITY; PHYSIOLOGY; HALOTHANE; ENFLURANE; TOLERANCE; SURGERY
AB Background: The maintenance of adequate tissue oxygenation during acute anemia depends on an increase in both cardiac output and tissue oxygen extraction. This study tested the hypothesis that anesthesia blunts the cardiac output response associated with acute normovolemic hemodilution.
   Methods: Forty patients undergoing major abdominal surgery were prospectively randomized to undergo acute normovolemic hemodilution (ANH) either awake (awake group, n = 20) or with fentanyl-nitrous oxide-isoflurane anesthesia (anesthetized group, n = 20). Radial and pulmonary artery catheters were placed in all patients. After hemodynamic measurements were taken, patients In the two groups underwent hemodilution to decrease their hemoglobin concentration from 13 to 8 g/dl. A total of 1,875 +/- 222 ml (mean +/- SD) of blood was collected and simultaneously replaced by the same volume of medium molecular weight hydroxyethylstarch in both groups.
   Results: In the awake group, ANH resulted in a significant increase in cardiac index (from 3.1 +/- 0.5 to 4.8 +/- 1.01 . min(-1) . m(-2)) related to both an increase in heart rate and stroke index. Oxygen delivery remained unchanged, but oxygen consumption increased significantly, resulting in an increase in oxygen extraction ratio. In the anesthetized group, ANH. resulted in a significantly smaller increase in cardiac index (from 2.3 +/- 0.5 to 3.1 +/- 0.71 . min(-1) . m(-2)) related solely to an increase in stroke index. Oxygen delivery decreased but oxygen consumption was maintained as oxygen extraction increased.
   Conclusions: Anesthesia significantly reduces the cardiac output response associated with ANH. This could be related to the effects of the anesthetic drugs on the autonomic and the cardiovascular systems.
C1 Erasme Univ Hosp, Dept Anesthesiol, B-1070 Brussels, Belgium.
RP Van der Linden, PJ (corresponding author), CHU Charleroi, Dept Anesthesiol, Site Jumet,73 Route Gosselies, B-6040 Jumet, Belgium.
EM pvanderlinden@skynet.be
CR ARCHIE JP, 1981, ANN SURG, V193, P296, DOI 10.1097/00000658-198103000-00008
   Biboulet P, 1996, BRIT J ANAESTH, V76, P81
   CAIN SM, 1977, J APPL PHYSIOL, V42, P228
   CANE RD, 1987, ANESTHESIOL CLIN N A, V5, P717
   DAPER A, 1989, ACUTE CARE, V12, P113
   ECKSTEIN JW, 1961, ANESTHESIOLOGY, V22, P525, DOI 10.1097/00000542-196107000-00002
   FOWLER NO, 1975, J APPL PHYSIOL, V39, P453
   GLICK G, 1964, J CLIN INVEST, V43, P2112, DOI 10.1172/JCI105085
   Habler OP, 1996, ANESTH ANALG, V83, P451, DOI 10.1097/00000539-199609000-00002
   HATCHER JD, 1978, J APPL PHYSIOL, V44, P696
   HEIKKILA H, 1984, ACTA ANAESTH SCAND, V28, P683, DOI 10.1111/j.1399-6576.1984.tb02145.x
   HOUSMANS PR, 1988, ANESTHESIOLOGY, V69, P451, DOI 10.1097/00000542-198810000-00003
   Kreimeier U, 1996, WORLD J SURG, V20, P1208
   Lieberman JA, 2000, ANESTHESIOLOGY, V92, P407, DOI 10.1097/00000542-200002000-00022
   MESSMER K, 1991, TISSUE OXYGEN UTILIZ, P103
   MURRAY JF, 1969, AM J PHYSIOL, V216, P638
   NATHAN HJ, 1988, ANESTHESIOLOGY, V68, P407, DOI 10.1097/00000542-198803000-00015
   REITAN JA, 1978, ANESTH ANALG, V57, P31
   REVES JG, 1999, CARDIAC ANESTHESIA, P611
   RICHARDSON TQ, 1959, AM J PHYSIOL, V197, P1167
   RODRIGUEZ JA, 1974, J APPL PHYSIOL, V36, P28
   ROIZEN MF, 1981, ANESTHESIOLOGY, V54, P390, DOI 10.1097/00000542-198105000-00008
   Schou H, 1997, ACTA ANAESTH SCAND, V41, P218, DOI 10.1111/j.1399-6576.1997.tb04669.x
   Spahn DR, 1997, BRIT J ANAESTH, V78, P381
   SPAHN DR, 1994, ANESTH ANALG, V78, P1000
   Spahn DR, 1996, ANESTH ANALG, V82, P681, DOI 10.1097/00000539-199604000-00002
   Trouwborst A, 1998, BRIT J ANAESTH, V81, P73
   TUMAN KJ, 1990, ANESTHESIOL CLIN N A, V8, P451
   VANDERLINDEN P, 1994, ACTA ANAESTH SCAND, V38, P490, DOI 10.1111/j.1399-6576.1994.tb03935.x
   VANDERLINDEN P, 1998, UPD INT CAR, V33, P116
   VIITANEN A, 1990, ANESTHESIOLOGY, V73, P393, DOI 10.1097/00000542-199009000-00005
   Weiskopf RB, 1998, JAMA-J AM MED ASSOC, V279, P217, DOI 10.1001/jama.279.3.217
NR 32
TC 98
Z9 110
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-3022
EI 1528-1175
J9 ANESTHESIOLOGY
JI Anesthesiology
PD OCT
PY 2000
VL 93
IS 4
BP 1011
EP 1016
DI 10.1097/00000542-200010000-00024
PG 6
WC Anesthesiology
SC Anesthesiology
GA 360MN
UT WOS:000089671900019
PM 11020756
DA 2021-08-04
ER

PT J
AU Stefanovic, MM
   Stakic, MB
AF Stefanovic, MM
   Stakic, MB
TI Simulation of a computer-controlled dehydrator
SO COMPUTERS AND ELECTRONICS IN AGRICULTURE
LA English
DT Article; Proceedings Paper
CT 3rd IFAC/CIGR Workshop on Artificial Intelligence in Agriculture
CY APR 24-26, 1998
CL MAKUHARI, JAPAN
SP Int Federat Automat Control, Int Commiss Agr Engn, Japanese Soc High Technol Agr, Japanese Soc Environm Control Biol, Japan Assoc Int Commiss Agr Engn
DE simulation; process control; PID control; time constants; control system
   analysis; disturbance variables
AB Experimental data that can be obtained during investigation of a real system in operation, under different working conditions and different input parameters (combined with different control parameters), are usually not sufficient. Unsuitable working conditions can cause losses during production (which cannot be afforded), while some of the input parameters (like moisture content of the input material) are not under the control of the investigator. A suitable way to avoid this problem is to use a simulation program in order to explore different regimes and to obtain the optimal one. Investigations can be carried out using simulation programs in order to ascertain the influence of different control parameters on the behavior of the entire system, and to obtain control parameters that give the smallest deviations of a certain variable from the nominal value. It is also possible to obtain the values of control parameters causing nonstability of the system. The developed simulation program for the control system of a dehydrator includes a model of the drying process, a model describing the behavior of different functional blocks of the dehydrator (including the inertia of the system), simulation of the control of drying agent temperature at the dryer exit as a function of the fuel flow rate, and simulation of the fuel consumption as well as the dried material production. (C) 2000 Elsevier Science B.V. All rights reserved.
C1 Inst Nucl Sci Vinca, Lab Thermal Engn & Energy, YU-11001 Belgrade, Yugoslavia.
RP Stefanovic, MM (corresponding author), Inst Nucl Sci Vinca, Lab Thermal Engn & Energy, POB 522, YU-11001 Belgrade, Yugoslavia.
CR DAZZO JJ, 1966, FEEDBACK CONTROL SYS, pCH19
   STEFANOVIC MM, 1996, P 3 MINSK INT HEAT M, P145
   STEFANOVIC MS, 1992, NIVITE7 VINC I NUCL
   STOJIC MR, 1986, INT J CONTROL, V43, P1229, DOI 10.1080/00207178608933534
   Ziegler J.G., 1942, Transactions of the ASME, V64, P759
NR 5
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0168-1699
J9 COMPUT ELECTRON AGR
JI Comput. Electron. Agric.
PD OCT
PY 2000
VL 29
IS 1-2
BP 161
EP 178
DI 10.1016/S0168-1699(00)00143-5
PG 18
WC Agriculture, Multidisciplinary; Computer Science, Interdisciplinary
   Applications
SC Agriculture; Computer Science
GA 356JC
UT WOS:000089439300012
DA 2021-08-04
ER

PT J
AU Cavalieri, S
   Garetti, M
   Macchi, M
   Taisch, M
AF Cavalieri, S
   Garetti, M
   Macchi, M
   Taisch, M
TI An experimental benchmarking of two multi-agent architectures for
   production scheduling and control
SO COMPUTERS IN INDUSTRY
LA English
DT Article; Proceedings Paper
CT Workshop of the Intelligent-Manufacturing-Systems-Working-Group
CY APR 15-17, 1998
CL LAUSANNE, SWITZERLAND
DE multi-agent systems; manufacturing; scheduling
ID MANUFACTURING SYSTEMS
AB The paper provides a first experimental contribution to the validation and comparison of multi-agent heterarchical architectures in order to point out their limits, their main peculiarities and real applicability. For this purpose, the behaviours of two particular control solutions, characterised by a different degree of decision-making delegation assigned to physical and information units in the production system, have been simulated. The experimental campaign is divided into three trials, in order to measure the performances of the two architectures not only under stable and predictable conditions, but also in case of unexpected events, such as the release of urgent manufacturing orders and the occurrence of failures in production resources. (C) 2000 Elsevier Science B.V. All rights reserved.
C1 Politecn Milan, Dipartimento Econ & Prod, I-20133 Milan, Italy.
RP Cavalieri, S (corresponding author), Politecn Milan, Dipartimento Econ & Prod, Piazza Leonardo da Vinci 32, I-20133 Milan, Italy.
RI cavalieri, sergio/A-1273-2009; cavalieri, sergio/O-1605-2019
OI cavalieri, sergio/0000-0002-7598-0379; cavalieri,
   sergio/0000-0002-7598-0379; MACCHI, MARCO/0000-0003-3078-6051
CR DILTS DM, 1991, J MANUF SYST, V10, P79, DOI 10.1016/0278-6125(91)90049-8
   Dorigo M, 1996, IEEE T SYST MAN CY B, V26, P29, DOI 10.1109/3477.484436
   Maturana FP, 1996, J INTELL MANUF, V7, P257, DOI 10.1007/BF00124828
   Rabelo R. J., 1996, Studies in Informatics and Control, V5, P89
   RABELO RJ, 1994, ROBOT CIM-INT MANUF, V11, P303, DOI 10.1016/0736-5845(95)00007-0
   SHAW MJ, 1988, J MANUF SYST, V7, P83, DOI 10.1016/0278-6125(88)90016-7
   SOLBERG JJ, 1992, IIE T, V24, P57
   SOLBERG JJ, 1994, COMPUTER CONTROL FLE, P169
   Van Brussel H, 1998, COMPUT IND, V37, P255, DOI 10.1016/S0166-3615(98)00102-X
   ZWEGERS AJR, 1996, P ADV PROD MAN SYST, P293
NR 10
TC 41
Z9 41
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-3615
J9 COMPUT IND
JI Comput. Ind.
PD OCT
PY 2000
VL 43
IS 2
SI SI
BP 139
EP 152
DI 10.1016/S0166-3615(00)00063-4
PG 14
WC Computer Science, Interdisciplinary Applications
SC Computer Science
GA 366MH
UT WOS:000090008800004
DA 2021-08-04
ER

PT J
AU DeCanio, SJ
   Dibble, C
   Amir-Atefi, K
AF DeCanio, SJ
   Dibble, C
   Amir-Atefi, K
TI The importance of organizational structure for the adoption of
   innovations
SO MANAGEMENT SCIENCE
LA English
DT Article
DE organizational theory; innovation; inequality; structural change;
   algorithmic computation
AB Organizational structure affects both the overall behavior of firms and the situations of individuals and subunits within firms. The effect of exogenous changes in the environment (market prices, costs, or regulations) on organizations can be partitioned into the immediate direct effect of the change and the full effect after organizational structure has had time to adjust. This paper develops a computational model of the diffusion of a profitable innovation through a firm, and uses numerical simulations to calculate the relative importance of the direct and structural adjustment components of changes in profitability. One finding is that a failure to recognize the importance of organizational structure on the performance of firms will lead to serious bias in estimation of the costs or benefits of a change in external circumstances. The type of network model developed also has implications for the individuals and divisions that make up the firm. We examine some of the structural characteristics of well-adapted organizations, and show that asymmetries and economic inequalities emerge even when the individual agents' personal characteristics are identical.
C1 Univ Calif Santa Barbara, Dept Econ, Santa Barbara, CA 93106 USA.
   Univ Calif Santa Barbara, Dept Geog, Santa Barbara, CA 93106 USA.
RP DeCanio, SJ (corresponding author), Univ Calif Santa Barbara, Dept Econ, Santa Barbara, CA 93106 USA.
CR Brynjolfsson E, 1996, MANAGE SCI, V42, P541, DOI 10.1287/mnsc.42.4.541
   Burton RM, 1995, STRATEGIC ORG DIAGNO
   CARLEY K, 1991, AM SOCIOL REV, V56, P331, DOI 10.2307/2096108
   Carley K, 1994, COMPUTATIONAL ORG TH
   CARLEY K, 1998, ADV STRATEGIC MANAGE, V15
   DeCanio SJ, 1998, J ECON BEHAV ORGAN, V36, P275, DOI 10.1016/S0167-2681(98)00096-1
   DECANIO SJ, 2000, ADV EC ENV RESOURCES, V3
   GERSBACH H, 1998, REV ECON DES, V3, P149, DOI DOI 10.1007/S100580050010
   Goldberg D., 1989, GENETIC ALGORITHMS S
   Graicunas V. A., 1933, B INT MANAGEMENT I, V7, P39
   GRANDORI A, 1991, J ECON BEHAV ORGAN, V16, P319, DOI 10.1016/0167-2681(91)90017-R
   HARARY F., 1973, GRAPHICAL ENUMERATIO
   HOLLAND JH, 1992, ADAPTATION NATURAL A
   HUBER J, 1995, PARTY POLIT, V1, P73, DOI 10.1177/1354068895001001004
   KENNEDY PW, 1994, J ECONOM BEHAV ORG, V353, P37
   Kollman K, 1997, AM ECON REV, V87, P977
   Krackhardt D., 1994, COMPUTATIONAL ORG TH, V89, P123, DOI DOI 10.5555/185382.185391
   LANT TK, 1994, COMPUTATIONAL ORG TH, P195
   LEVINE D, 1996, ANL PUBLICATION
   Levinthal DA, 1997, MANAGE SCI, V43, P934, DOI 10.1287/mnsc.43.7.934
   Levitt R.E., 1994, COMPUTATIONAL ORG TH, P1
   LIN Z, 1994, 1994 AAAI SPRING S
   Marschak T, 1998, J ECON THEORY, V79, P106, DOI 10.1006/jeth.1997.2375
   MEAGHER K, 1997, UNPUB MANGERIAL COST
   MIHAVICS K, 1996, COMPUTATIONAL MATH O, V1, P143
   MILLER JH, 1996, UNPUB EVOLVING INFOR
   OBERSCHELP W, 1967, MATH ANN, V174, P53, DOI 10.1007/BF01363123
   Page SE, 1998, ADV STRAT M, V15, P299
   Page SE, 1996, ECON THEORY, V8, P321, DOI 10.1007/BF01211821
   RADNER R, 1992, J ECON LIT, V30, P1382
   RADNER R, 1993, ECONOMETRICA, V61, P1109, DOI 10.2307/2951495
   REICHMAN N, 1999, EARTH TECHN FOR WASH
   *T SAW SOFTW, 1999, GRAPH LAYOUT TOOLK
   Valente T.W., 1995, NETWORK MODELS DIFFU
   VANZANDT T, 1996, CONT EC DEV REVIEWED, V4
   VANZANDT T, 1996, IN PRESS ORG INCOMPL
   VANZANDT T, 1997, REV ECON DES, V3, P15
   VANZANDT T, 1998, REV ECON DES, V3, P93
   VANZANDT T, 1996, UNPUB REAL TIME DECE
   Wasserman S., 1994, SOCIAL NETWORK ANAL
   Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918
   WEINBERG DH, 1996, P60191 US CENS BUR
   Wilson R.J., 1985, INTRO GRAPH THEORY
NR 43
TC 56
Z9 61
U1 2
U2 78
PU INST OPERATIONS RESEARCH  MANAGEMENT SCIENCES
PI LINTHICUM HTS
PA 901 ELKRIDGE LANDING RD, STE 400, LINTHICUM HTS, MD 21090-2909 USA
SN 0025-1909
J9 MANAGE SCI
JI Manage. Sci.
PD OCT
PY 2000
VL 46
IS 10
BP 1285
EP 1299
DI 10.1287/mnsc.46.10.1285.12270
PG 15
WC Management; Operations Research & Management Science
SC Business & Economics; Operations Research & Management Science
GA 373ZR
UT WOS:000165320400002
DA 2021-08-04
ER

PT J
AU Chin, CT
   Burns, PN
AF Chin, CT
   Burns, PN
TI Predicting the acoustic response of a microbubble population for
   contrast imaging in medical ultrasound
SO ULTRASOUND IN MEDICINE AND BIOLOGY
LA English
DT Article
DE microbubble contrast agents; acoustic modeling; nonlinear scattering;
   ultrasound contrast
ID GAS-BUBBLES; MICROSPHERES; DISTORTION; AMPLITUDE
AB Although the behavior of a bubble in an acoustic field has been studied extensively, few theoretical treatments to date have been applied to simulate the acoustic response of a real population of variably sized microbubbles in a finite-width sound beam. In this paper, we present a modified Trilling equation for single bubble dynamics that has been solved numerically for different conditions. Radiated waveforms from a large number of such bubbles are combined, reflecting their size distribution and location and the shape of a real acoustic beam. The resulting time-domain pressure waveforms can be compared with those obtained experimentally. The dependence of second-harmonic radiation on incident focal amplitude at different frequencies is presented. This model is particularly suited to the study of interaction between a medical ultrasound beam and microbubble contrast agents in aqueous media. (C) 2000 World Federation for Ultrasound in Medicine & Biology.
C1 Univ Toronto, Dept Med Biophys, Toronto, ON, Canada.
RP Burns, PN (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, Room S-660,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.
CR AKULICHE.VA, 1968, SOV PHYS ACOUST+, V13, P281
   Averkiou MA, 1997, J ACOUST SOC AM, V102, P2539, DOI 10.1121/1.420308
   BURNS PN, 1996, ANGIOLOGY, V47, P63
   Christopher T, 1997, IEEE T ULTRASON FERR, V44, P125, DOI 10.1109/58.585208
   CHURCH CC, 1989, J ACOUST SOC AM, V86, P215, DOI 10.1121/1.398328
   DEJONG N, 1993, ULTRASONICS, V31, P175, DOI 10.1016/0041-624X(93)90004-J
   DEJONG N, 1994, ULTRASONICS, V32, P447, DOI 10.1016/0041-624X(94)90064-7
   DEVIN C, 1959, J ACOUST SOC AM, V31, P1654, DOI 10.1121/1.1907675
   EATOCK BC, 1985, J ACOUST SOC AM, V77, P1692, DOI 10.1121/1.391916
   ELLER AI, 1970, J ACOUST SOC AM, V47, P1469, DOI 10.1121/1.1912063
   Gilmore F.R., 1952, GROWTH COLLAPSE SPHE
   Herring C., 1941, 236 OFF SCI RES DEV
   HICKLING R, 1964, PHYS FLUIDS, V7, P7, DOI 10.1063/1.1711058
   KELLER JB, 1980, J ACOUST SOC AM, V68, P628, DOI 10.1121/1.384720
   Leighton TG, 1997, ACOUSTIC BUBBLE
   MILLER DL, 1981, ULTRASONICS, V19, P217, DOI 10.1016/0041-624X(81)90006-8
   PLESSET MS, 1949, J APPL MECH-T ASME, V16, P277
   PORITSKY H, 1951, P 1 US NAT C APPL PH, V1, P813
   PROSPERETTI A, 1991, J FLUID MECH, V222, P587, DOI 10.1017/S0022112091001234
   Rayleigh J.W., 1917, PHILOS MAG, V34, P94
   Simpson DH, 1999, IEEE T ULTRASON FERR, V46, P372, DOI 10.1109/58.753026
   Skyba DM, 1996, J AM COLL CARDIOL, V28, P1292, DOI 10.1016/S0735-1097(96)00328-2
   TRILLING L, 1952, J APPL PHYS, V23, P14, DOI 10.1063/1.1701962
   UHLENDORF V, 1994, P IEEE ULTR S, P1559
   Umemura S, 1996, IEEE T ULTRASON FERR, V43, P1054, DOI 10.1109/58.542456
   VOKURKA K, 1986, ACUSTICA, V59, P214
NR 26
TC 26
Z9 29
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA
SN 0301-5629
J9 ULTRASOUND MED BIOL
JI Ultrasound Med. Biol.
PD OCT
PY 2000
VL 26
IS 8
BP 1293
EP 1300
DI 10.1016/S0301-5629(00)00299-4
PG 8
WC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
SC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
GA 385CA
UT WOS:000165983000010
PM 11120367
DA 2021-08-04
ER

PT J
AU Zhang, RL
   Zhang, L
   Jiang, Q
   Zhang, ZG
   Goussev, A
   Chopp, M
AF Zhang, RL
   Zhang, L
   Jiang, Q
   Zhang, ZG
   Goussev, A
   Chopp, M
TI Postischemic intracarotid treatment with TNK-tPA reduces infarct volume
   and improves neurological deficits in embolic stroke in the
   unanesthetized rat
SO BRAIN RESEARCH
LA English
DT Article
DE embolic ischemia; TNK-tPA; intracarotid treatment; unanesthetized rat
ID TISSUE-PLASMINOGEN-ACTIVATOR; MIDDLE CEREBRAL-ARTERY; LOCAL
   INTRAARTERIAL FIBRINOLYSIS; CAROTID TERRITORY; ISCHEMIC STROKE;
   THROMBOLYSIS; UROKINASE; PERFUSION; THERAPY; AGENTS
AB Background and purpose: To simulate human stroke, we developed a model of focal cerebral embolic ischemia in the unanesthetized rat. Using this model, we tested the hypothesis that intra-arterial administration of TNK-tPA, a fibrin specific second generation thrombolytic agent, is effective in reducing ischemic volume without increasing intra-cerebral hemorrhage. Methods: Under anesthesia, a catheter was inserted to the origin of the MCA of male Wistar rats. Forty-five minutes after recovery from anesthesia, the MCA was occluded in the awake rat by a single fibrin rich clot placed via the catheter. TNK-tPA (1.5 mg/kg) was administered intraarterially via the catheter at either 2 h or 4 h after stroke. All rats were sacrificed at 48 h after ischemia. Neurological deficits, gross hemorrhage and ischemic lesion volume were measured. Results: A clot was detected at the origin of the MCA 4 h after MCA occlusion in the awake rats (n = 4). Rats (n = 12) subjected to MCA occlusion showed immediate neurological deficits which persisted for 48 h of ischemia. Ischemic rats had a lesion volume of 38.2+/-3.8% and 25% of rats exhibited gross hemorrhage. Ischemic rats (n=10) treated with TNK-tPA at 2 h showed a significant (P<0.05) reduction of neurological deficits, body weight loss and infarct volume (22.8+/-2.1%) without an increase in gross hemorrhage (10%) compared with the non treated ischemic rats (25%). Although treatment with TNK-tPA of ischemic rats (n=12) at 4 h did not significantly (P=0.06) reduce infarct volume (28.6+/-3.0%), it also did not increase gross hemorrhage (25%) compared with the control group (25%). Conclusions: This study demonstrates that intraarterial administration of TNK-tPA at 2 h of ischemia in the unanesthesthetized rat is effective in reducing neurological deficits and ischemic lesion volume without increasing hemorrhagic transformation and that administration of TNK-tPA at 4 h of ischemia does not increase the incidence of hemorrhagic transformation. (C) 2000 Elsevier Science B.V. All rights reserved.
C1 Henry Ford Hosp, Hlth Sci Ctr, Dept Neurol, Detroit, MI 48202 USA.
   Oakland Univ, Dept Phys, Rochester, MI USA.
RP Chopp, M (corresponding author), Henry Ford Hosp, Hlth Sci Ctr, Dept Neurol, 2799 W Grand Blvd, Detroit, MI 48202 USA.
EM chopp@neuro.hfh.edu
FU NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS)
   [R01NS035504, P01NS023393] Funding Source: NIH RePORTER; NINDS NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Neurological
   Disorders & Stroke (NINDS) [P01 NS23393, R01 NS35504] Funding Source:
   Medline
CR ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723
   Bendszus M, 1998, NEURORADIOLOGY, V40, P54, DOI 10.1007/s002340050540
   BENEDICT CR, 1995, CIRCULATION, V92, P3032, DOI 10.1161/01.CIR.92.10.3032
   BENES V, 1990, STROKE, V21, P1594, DOI 10.1161/01.STR.21.11.1594
   Burnette WC, 1999, NEUROIMAG CLIN N AM, V9, P491
   del Zoppo GJ, 1998, NEUROLOGY, V51, pS59, DOI 10.1212/WNL.51.3_Suppl_3.S59
   del Zoppo GJ, 1998, STROKE, V29, P4, DOI 10.1161/01.STR.29.1.4
   DELZOPPO GJ, 1992, ANN NEUROL, V32, P78, DOI 10.1002/ana.410320113
   DELZOPPO GJ, 1990, STROKE, V21, P155
   DELZOPPO GJ, 1988, STROKE, V19, P307, DOI 10.1161/01.STR.19.3.307
   DELZOPPO GJ, 1986, STROKE, V17, P1254, DOI 10.1161/01.STR.17.6.1254
   delZoppo GJ, 1997, THROMB HAEMOSTASIS, V78, P183
   DELZOPPO GJ, 1986, STROKE, V17, P638, DOI 10.1161/01.STR.17.4.638
   DRUMMOND JC, 1993, ANESTHESIOLOGY, V79, P877
   FIESCHI C, 1989, J NEUROL SCI, V91, P311, DOI 10.1016/0022-510X(89)90060-9
   Furlan AJ, 1999, STROKE, V30, P234
   GINSBERG MD, 1989, STROKE, V20, P1627, DOI 10.1161/01.STR.20.12.1627
   Gonner F, 1998, STROKE, V29, P1894, DOI 10.1161/01.STR.29.9.1894
   HAMILTON MG, 1994, STROKE, V25, P651, DOI 10.1161/01.STR.25.3.651
   Jiang Q, 1998, J CEREBR BLOOD F MET, V18, P758, DOI 10.1097/00004647-199807000-00007
   Jiang Q, 2000, J CEREBR BLOOD F MET, V20, P21, DOI 10.1097/00004647-200001000-00005
   JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773
   Katzan IL, 1999, NEUROLOGY, V52, P1081, DOI 10.1212/WNL.52.5.1081
   KEYT BA, 1994, P NATL ACAD SCI USA, V91, P3670, DOI 10.1073/pnas.91.9.3670
   LEBIHAN D, 1986, RADIOLOGY, V161, P401, DOI 10.1148/radiology.161.2.3763909
   MORI E, 1988, STROKE, V19, P802, DOI 10.1161/01.STR.19.7.802
   OGATA J, 1976, STROKE, V7, P54, DOI 10.1161/01.STR.7.1.54
   Shuaib A, 1998, EXP NEUROL, V154, P330, DOI 10.1006/exnr.1998.6925
   THERON J, 1989, AM J NEURORADIOL, V10, P753
   THOMAS GR, 1994, STROKE, V25, P2072, DOI 10.1161/01.STR.25.10.2072
   WARNER DS, 1993, ANESTHESIOLOGY, V79, P985, DOI 10.1097/00000542-199311000-00017
   WEINSTEIN PR, 1986, STROKE, V17, P318, DOI 10.1161/01.STR.17.2.318
   WILLIAMS DS, 1992, P NATL ACAD SCI USA, V89, P212, DOI 10.1073/pnas.89.1.212
   Zea Longa E. L., 1989, STROKE, V20, P84
   ZEUMER H, 1993, NEURORADIOLOGY, V35, P159, DOI 10.1007/BF00593977
   ZEUMER H, 1983, AM J NEURORADIOL, V4, P401
   ZEUMER H, 1992, INTERV NEURORADIOL, P141
   Zhang RL, 1997, BRAIN RES, V766, P83, DOI 10.1016/S0006-8993(97)00580-5
   Zhang RL, 1999, NEUROLOGY, V52, P273, DOI 10.1212/WNL.52.2.273
   Zhang RL, 1998, J NEUROL SCI, V160, P1, DOI 10.1016/S0022-510X(98)00155-5
   Zivin JA, 1998, NEUROLOGY, V50, P599, DOI 10.1212/WNL.50.3.599
NR 41
TC 18
Z9 21
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
J9 BRAIN RES
JI Brain Res.
PD SEP 29
PY 2000
VL 878
IS 1-2
BP 64
EP 71
DI 10.1016/S0006-8993(00)02693-7
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA 358FN
UT WOS:000089547900006
PM 10996136
DA 2021-08-04
ER

PT J
AU El-Nasr, MS
   Yen, J
   Ioerger, TR
AF El-Nasr, MS
   Yen, J
   Ioerger, TR
TI FLAME - Fuzzy logic adaptive model of emotions
SO AUTONOMOUS AGENTS AND MULTI-AGENT SYSTEMS
LA English
DT Article
DE emotions; emotional agents; social agents; believable agents; life-like
   agents
ID AGENTS
AB Emotions are an important aspect of human intelligence and have been shown to play a significant role in the human decision-making process. Researchers in areas such as cognitive science, philosophy, and artificial intelligence have proposed a variety of models of emotions. Most of the previous models focus on an agent's reactive behavior, for which they often generate emotions according to static rules or pre-determined domain knowledge. However, throughout the history of research on emotions, memory and experience have been emphasized to have a major influence on the emotional process. In this paper, we propose a new computational model of emotions that can be incorporated into intelligent agents and other complex, interactive programs. The model uses a fuzzy-logic representation to map events and observations to emotional states. The model also includes several inductive learning algorithms for learning patterns of events, associations among objects, and expectations. We demonstrate empirically through a computer simulation of a pet that the adaptive components of the model are crucial to users' assessments of the believability of the agent's interactions.
C1 Northwestern Univ, Inst Learning Sci, Evanston, IL 60201 USA.
   Texas A&M Univ, Dept Comp Sci, College Stn, TX 77844 USA.
RP El-Nasr, MS (corresponding author), Northwestern Univ, Inst Learning Sci, 1890 Maple Ave, Evanston, IL 60201 USA.
EM magy@cs.nwu.edu; yen@cs.tamu.edu; ioerger@cs.tamu.edu
CR ARMONY JL, 1995, BEHAV NEUROSCI, V109, P246, DOI 10.1037/0735-7044.109.2.246
   Baecker R.M., 1995, READINGS HUMAN COMPU, V2
   BATES J, 1994, COMMUN ACM, V37, P122, DOI 10.1145/176789.176803
   BATES J, 1992, CMUCS92142 SCH COMP
   BATES J, 1992, CMUCS92144 SCH COMP
   BENYON DR, 1993, KNOWLEDGE BASED SYST, V6
   BLUMBERG B, 1996, THESIS MIT CAMBRIDGE
   BLUMBERG BM, 1996, ANIMALS ANIMATES
   BOLLES RC, 1980, BEHAV BRAIN SCI, V3, P291, DOI 10.1017/S0140525X0000491X
   BOWER GH, 1982, AFFECT COGNITION, P291
   BREAZEAL C, IN PRESS SPECIAL ISS
   BROOKS R, IN PRESS SPRINGER VE
   Damasio AR., 1994, DESCARTES ERROR EMOT
   Dautenhahn K, 1998, APPL ARTIF INTELL, V12, P573, DOI 10.1080/088395198117550
   Descartes R., 1989, PASSIONS SOUL
   DOMJAN M, 1998, PRINCIPLES LEARNING
   EKMAN P, 1992, COGNITION EMOTION, V6, P169, DOI 10.1080/02699939208411068
   El-Nasr M. S., 1999, P COMP AN C 1999 GEN
   Elliott C, 1998, AI MAG, V19, P13
   Elliott C., 1997, 15 INT JOINT C ART I, P113
   ELLIOTT C, 1994, AAAI 94
   ELLIOTT CD, 1992, THESIS NW U EVANSTON
   ELNASR M, 1999, P 3 INT C AUT AG SEA
   ELNASR MS, 1998, THESIS TEXAS A M U
   FISKE AP, 1992, PSYCHOL REV, V99, P689, DOI 10.1037/0033-295X.99.4.689
   FORGAS JP, 1994, J PERS SOC PSYCHOL, V66, P56, DOI 10.1037/0022-3514.66.1.56
   FORGAS JP, 1995, PSYCHOL BULL, V117, P39, DOI 10.1037/0033-2909.117.1.39
   Gardner H, 1983, FRAMES MIND
   Goleman D., 1995, EMOTIONAL INTELLIGEN
   HUHNS MN, 1998, READING AGENTS
   Inoue K, 1996, RO-MAN '96 - 5TH IEEE INTERNATIONAL WORKSHOP ON ROBOT AND HUMAN COMMUNICATION, PROCEEDINGS, P461, DOI 10.1109/ROMAN.1996.568880
   Izard CE, 1977, HUMAN EMOTIONS
   James W., 1884, MIND, V9, P188, DOI 10.1093/mind/os-IX.34.188
   JENNINGS NR, 1998, AUTON AGENT MULTI-AG, V1, P7, DOI DOI 10.1023/A:1010090405266
   Kaelbling LP, 1996, J ARTIF INTELL RES, V4, P237, DOI 10.1613/jair.301
   KIM J, 1998, INTERACTING COMPUT I, V10
   Koda T, 1996, RO-MAN '96 - 5TH IEEE INTERNATIONAL WORKSHOP ON ROBOT AND HUMAN COMMUNICATION, PROCEEDINGS, P189, DOI 10.1109/ROMAN.1996.568812
   KONEV AD, 1987, ZH VYSSH NERV DEYAT+, V37, P875
   KOSKO B, 1997, FUZZY ENG
   LeDoux J.E., 1996, EMOTIONAL BRAIN
   Lester J., 1997, P CHI 97 C ATL GA
   LOYALL AB, 1997, P 1 AUT AG C MAR DEL
   MAES P, 1995, COMMUN ACM, V38, P108, DOI 10.1145/219717.219808
   MAES P, 1994, COMMUN ACM, V37, P31
   MAMDANI EH, 1975, INT J MAN MACH STUD, V7, P1, DOI 10.1016/S0020-7373(75)80002-2
   MARK MA, 1991, THESIS U SASKATCHEWA
   MASUYAMA E, 1994, IEEE INT WORKSH ROB, P156
   MILLER GA, PHSYL REV, V63, P81
   Minsky ML., 1986, SOC MIND
   Mitchell T., 1996, MACHINE LEARNING
   Mizoguchi H, 1997, IEEE INT CONF ROBOT, P581, DOI 10.1109/ROBOT.1997.620099
   Nwana HS, 1996, KNOWL ENG REV, V11, P205, DOI 10.1017/S026988890000789X
   NYE JL, 1996, WHATS SOCIAL ABOUT S
   OHMAN A, 1994, PSYCHOPHYSIOLOGY EMO
   Ortony A., 1988, COGNITIVE STRUCTURE
   Pfeifer R., 1988, COGNITIVE PERSPECTIV, V44, P287
   Picard R. W., 1997, AFFECTIVE COMPUTING
   Picard RW, 1997, FIRST INTERNATIONAL SYMPOSIUM ON WEARABLE COMPUTERS - DIGEST OF PAPERS, P90, DOI 10.1109/ISWC.1997.629924
   PICARD RW, 221 MIT MED LAB
   PRICE DD, 1985, MOTIVAT EMOTION, V9
   REILLY WS, 1997, 1 AUT AG C MAR DELR
   REILLY WS, 1992, CMUCS92143
   REILLY WSN, 1996, THESIS CARNEGIE MELL
   RESCORLA RA, 1988, AM PSYCHOL, V43, P151, DOI 10.1037/0003-066X.43.3.151
   RESCORLA RA, 1991, Q J EXP PSYCHOL-B, V43, P1
   REVELLE W, 1995, ANNU REV PSYCHOL, V46, P295, DOI 10.1146/annurev.ps.46.020195.001455
   Revelle W., 1993, ATTENTION SELECTION, P346
   RICKEL J, IN PRESS J APPL ARTI
   Riso D., 1996, PERSONALITY TYPES
   ROSEMAN IJ, 1990, J PERS SOC PSYCHOL, V59, P899, DOI 10.1037/0022-3514.59.5.899
   ROUSSEAU D, 1996, AAAI 96 WORKSH AI AL
   ROUSSEAU D, 1997, KSL9706
   RUSSELL S, 1995, ARTIFICAIL INTELLIGE
   SCHERER KR, 1993, COGNITION EMOTION, V7, P325, DOI 10.1080/02699939308409192
   SCHUMACHER R, 1984, PERCEPT MOTOR SKILL, V58, P339, DOI 10.2466/pms.1984.58.2.339
   Shibata T, 1996, RO-MAN '96 - 5TH IEEE INTERNATIONAL WORKSHOP ON ROBOT AND HUMAN COMMUNICATION, PROCEEDINGS, P466, DOI 10.1109/ROMAN.1996.568881
   Shibata T, 1996, IEEE INT CONF ROBOT, P2426, DOI 10.1109/ROBOT.1996.506527
   SHIIDA T, 1989, EMOTION BEHAV SYST A, V2, P275
   Simon H., 1996, SCI ARTIFICAL
   SIMON HA, 1967, PSYCHOL REV, V74, P29, DOI 10.1037/h0024127
   SUCHMAN L, 1981, PLANS SITUATED ACTIO
   Sugano S, 1996, IEEE INT CONF ROBOT, P1191, DOI 10.1109/ROBOT.1996.506869
   TAKAGI H, 1985, IEEE T SYST MAN CYBE, V15
   TAYRER S, 1992, PSYCHOL PSYCHIAT CHR
   THOMAS F, 1981, ILLUSION LIFE
   VELASQUEZ JD, 1997, P AAAI 97, P10
   Yen J, 1999, IEEE T KNOWL DATA EN, V11, P153, DOI 10.1109/69.755624
   Yen John, 1999, FUZZY LOGIC INTELLIG
   ZADEH LA, 1965, INF CONT, V8
NR 89
TC 228
Z9 231
U1 0
U2 43
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1387-2532
EI 1573-7454
J9 AUTON AGENT MULTI-AG
JI Auton. Agents Multi-Agent Syst.
PD SEP
PY 2000
VL 3
IS 3
BP 219
EP 257
DI 10.1023/A:1010030809960
PG 39
WC Automation & Control Systems; Computer Science, Artificial Intelligence
SC Automation & Control Systems; Computer Science
GA 412FD
UT WOS:000167543600001
DA 2021-08-04
ER

PT J
AU Blank, VC
   Pena, C
   Roguin, LP
AF Blank, VC
   Pena, C
   Roguin, LP
TI Suitable experimental conditions are required to characterize
   interferon-alpha 2b synthetic peptides
SO EUROPEAN JOURNAL OF BIOCHEMISTRY
LA English
DT Article
DE antiproliferative activity; binding properties; interferon-alpha 2b;
   interferon-receptor interaction; synthetic peptides
ID LIGAND-BINDING; RECEPTOR; ALPHA; CLONING; RESOLUTION; FRAGMENTS; CELLS;
   BETA
AB The binding and antiproliferative activities of synthetic peptides 29-35 and 122-139 of interferon-alpha 2b, both of which contain a cysteine residue in their sequences, were studied in the presence or absence of a dissociation medium containing mainly urea, dithiothreitol and 2-mercaptoethanol. Although interferon-alpha 2b peptides either did not modify or slightly increased I-125-labelled interferon-alpha 2b specific binding to WISH cell-membrane receptors in the absence of dissociation medium, significant binding inhibition was obtained when both peptides were assayed in dissociation medium. Furthermore, also in the presence of dissociating agents, the two fragments inhibited cell growth in a concentration-dependent manner, the 122-139 sequence being more effective than the 29-35 sequence. No additive effect on interferon binding and cell proliferation was observed when both peptides were added simultaneously. Results obtained after submitting peptide 122-139 to gel filtration or PAGE under different experimental conditions showed the presence of dimers and/or noncovalent aggregates arising from intermolecular disulfide bridges or hydrophobic interactions. Thus, our results indicated that peptide effects on I-125-labelled interferon-alpha 2b binding and WISH cell proliferation were dearly manifested when the amount of monomeric species increased, showing that suitable experimental conditions should be used to study peptide behavior. The ability of both peptides to effectively trigger an interferon-specific biological action, such as cell growth inhibition, strongly suggested that 29-35 and 122-139 interferon-alpha 2b fragments constitute the conformational epitope or mimotope that interacts with the cytokine-specific receptor.
C1 Univ Buenos Aires, Fac Farm & Bioquim, Inst Quim & Fisioquim Biol, RA-1113 Buenos Aires, DF, Argentina.
RP Roguin, LP (corresponding author), Univ Buenos Aires, Fac Farm & Bioquim, Inst Quim & Fisioquim Biol, Junin 956, RA-1113 Buenos Aires, DF, Argentina.
OI Blank, Viviana/0000-0002-1103-3778; Roguin, Leonor/0000-0002-0293-0477
CR Blank VC, 1999, EUR J BIOCHEM, V265, P11, DOI 10.1046/j.1432-1327.1999.00554.x
   Chuntharapai A, 1999, J IMMUNOL, V163, P766
   Cutrone EC, 1997, FEBS LETT, V404, P197, DOI 10.1016/S0014-5793(97)00129-4
   Daniels RE, 1995, SPILL SCI TECHNOL B, V2, P161, DOI 10.1016/1353-2561(95)00026-7
   Danilkovitch A, 1997, HYBRIDOMA, V16, P69, DOI 10.1089/hyb.1997.16.69
   Domanski Paul, 1996, Cytokine and Growth Factor Reviews, V7, P143, DOI 10.1016/1359-6101(96)00017-2
   FISH EN, 1995, FEBS LETT, V365, P87, DOI 10.1016/0014-5793(95)00422-6
   FISH EN, 1992, J INTERFERON RES, V12, P257, DOI 10.1089/jir.1992.12.257
   Klaus W, 1997, J MOL BIOL, V274, P661, DOI 10.1006/jmbi.1997.1396
   LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0
   LANGER JA, 1988, IMMUNOL TODAY, V9, P393, DOI 10.1016/0167-5699(88)91241-8
   LEACH SJ, 1983, BIOPOLYMERS, V22, P425, DOI 10.1002/bip.360220156
   LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x
   NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6
   Owczarek CM, 1997, J BIOL CHEM, V272, P23865, DOI 10.1074/jbc.272.38.23865
   PENA C, 1981, INT J PEPT PROT RES, V18, P289
   PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.bi.56.070187.003455
   Roth J, 1975, Methods Enzymol, V37, P223
   SALACINSKI PRP, 1981, ANAL BIOCHEM, V117, P136, DOI 10.1016/0003-2697(81)90703-X
   SCHIGGER H, 1987, ANAL BIOCHEM, V166, P368
   SEN GC, 1992, J BIOL CHEM, V267, P5017
   SENDA T, 1995, J MOL BIOL, V253, P187, DOI 10.1006/jmbi.1995.0544
   UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z
   Viscomi GC, 1997, BIOTHERAPY, V10, P59, DOI 10.1007/BF02678218
   VISCOMI GC, 1995, MED RES REV, V15, P445, DOI 10.1002/med.2610150504
NR 25
TC 7
Z9 7
U1 0
U2 0
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 0014-2956
J9 EUR J BIOCHEM
JI Eur. J. Biochem.
PD SEP
PY 2000
VL 267
IS 18
BP 5711
EP 5716
DI 10.1046/j.1432-1327.2000.01618.x
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 361GJ
UT WOS:000089715100007
PM 10971581
OA Bronze
DA 2021-08-04
ER

PT J
AU Zarkesh-Esfahani, SH
   Kolstad, O
   Metcalfe, RA
   Watson, PF
   Von Laue, S
   Walters, S
   Revhaug, A
   Weetman, AP
   Ross, RJM
AF Zarkesh-Esfahani, SH
   Kolstad, O
   Metcalfe, RA
   Watson, PF
   Von Laue, S
   Walters, S
   Revhaug, A
   Weetman, AP
   Ross, RJM
TI High-dose growth hormone does not affect proinflammatory cytokine (tumor
   necrosis factor-alpha, interleukin-6, and interferon-gamma) release from
   activated peripheral blood mononuclear cells or after minimal to
   moderate surgical stress
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID FACTOR-I; TRANSGENIC MICE; BINDING-PROTEIN; IMMUNE FUNCTION; RESPONSES;
   RECEPTOR; GH; CHOLECYSTECTOMY; PROLACTIN; ENDOTOXIN
AB High-dose GH therapy, with GH doses 10-20 times the normal replacement dose for GH-deficient adults, has been used as an anti-catabolic agent in a number of different patient groups. A recent study, however, has shown an increase in mortality in critically ill patients treated with high-dose GH. The increased mortality was associated with multiorgan failure, septic shock, and uncontrolled infection, suggesting that GH may have altered the immune response. The GH receptor and GH are both expressed in peripheral blood mononuclear cells (PBMCs); thus, GH could act as either an endocrine or an autocrine modulator of the immune response. We have examined the hypothesis that high-dose GH therapy may induce proinflammatory cytokines, which are implicated in septic shock. To do this we measured cytokine production by PBMCs incubated in conditions that simulated high-dose GH therapy, and we measured cytokine levels in patients undergoing laparoscopic cholecystectomy who were randomized to receive either high-dose GH therapy (13 IU/m(2) day) or placebo.
   To confirm the biological activity of GH in our cell culture system we used a Stat5 functional assay. In this assay GH induced a bell-shaped curve, with a maximal response at GH levels between 100-1000 ng/mL. PBMCs from healthy volunteers were incubated with GH in doses from 1-1000 ng/mL for 6-72 h under resting conditions and after activation with endotoxin and the mixed lymphocyte reaction. Studies were repeated with PBMCs from six individuals using a GH dose of 100 ng/mL (the level of GH found after high-dose GH therapy) and an endotoxin dose that gave a submaximal response (0.01 ng/mL). GH had no effect on cell proliferation or the production of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), or interferon-gamma (IFN gamma). In patients undergoing laparoscopic cholecystectomy there was a time-related effect of surgery on cytokine levels. There was a rise in IL-6 and a fall in TNF alpha at 24 h after surgery; however, high-dose GH therapy had no effect on the cytokine response. We considered the possibility that endogenous GH production by PBMCs could influence the cytokine response in activated PBMCs; however, incubation of PBMCs in the presence of the GH receptor antagonist, B2036, had no effect on TNF alpha, IL-6, or IFN gamma production by PBMCs in either the mixed lymphocyte reaction or when activated by endotoxin.
   These results suggest that high-dose GH therapy does not alter the proinflammatory cytokine response to surgery or endotorrin. The results do not exclude an effect of GH on the immune response, but they suggest that the mortality seen in critically ill patients may be due to factors other than immune modulation.
C1 Univ Sheffield, Div Clin Sci, Sheffield S5 7AU, S Yorkshire, England.
   Univ Sheffield, SCHARR, Sheffield S5 7AU, S Yorkshire, England.
   Univ Tromso, Tromso, Norway.
RP Ross, RJM (corresponding author), No Gen Hosp, Sheffield S5 7AU, S Yorkshire, England.
EM r.j.ross@sheffield.ac.uk
RI Ross, Richard/B-2672-2012
OI Ross, Richard/0000-0001-9222-9678; von Laue,
   Sigward/0000-0002-5229-4712; Revhaug, Arthur/0000-0002-7949-3770;
   Walters, Stephen/0000-0001-9000-8126
CR Balteskard L, 1998, EUR SURG RES, V30, P79, DOI 10.1159/000008562
   Bellon JM, 1998, INT SURG, V83, P24
   Bellon JM, 1997, EUR SURG RES, V29, P27, DOI 10.1159/000129504
   Bozzola M, 1998, EUR J ENDOCRINOL, V138, P640, DOI 10.1530/eje.0.1380640
   Bresson JL, 1999, ENDOCRINOLOGY, V140, P3203, DOI 10.1210/en.140.7.3203
   CHEN WY, 1991, MOL ENDOCRINOL, V5, P1845, DOI 10.1210/mend-5-12-1845
   CHEN WY, 1990, P NATL ACAD SCI USA, V87, P5061, DOI 10.1073/pnas.87.13.5061
   CHEN WY, 1991, ENDOCRINOLOGY, V129, P1402, DOI 10.1210/endo-129-3-1402
   CHEN Z, 1994, ALGEBRA C, V1, P1
   Clark R, 1997, ENDOCR REV, V18, P157, DOI 10.1210/er.18.2.157
   EDWARDS CK, 1991, ENDOCRINOLOGY, V128, P989, DOI 10.1210/endo-128-2-989
   ELSASSER TH, 1994, ENDOCRINOLOGY, V134, P1082, DOI 10.1210/en.134.3.1082
   FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677
   Galdiero M, 1997, EUR CYTOKINE NETW, V8, P83
   GOTTARDIS M, 1991, J TRAUMA, V31, P81, DOI 10.1097/00005373-199101000-00015
   HERNDON DN, 1990, ANN SURG, V212, P424, DOI 10.1097/00000658-199010000-00005
   HORSEMAN ND, 1994, ENDOCR REV, V15, P627, DOI 10.1210/er.15.5.627
   INOUE L, 1995, ARCH SURG-CHICAGO, V130, P1115
   Jenkins RC, 1996, QJM-MON J ASSOC PHYS, V89, P813, DOI 10.1093/qjmed/89.11.813
   KAPPEL M, 1994, HORM METAB RES, V26, P612, DOI 10.1055/s-2007-1001771
   Liao W, 1996, EUR J CLIN INVEST, V26, P254, DOI 10.1046/j.1365-2362.1996.140268.x
   Maamra M, 1999, J BIOL CHEM, V274, P14791, DOI 10.1074/jbc.274.21.14791
   MALE D, 1993, CYTOKINES CYTOKINE R
   Mealy K, 1998, INTENS CARE MED, V24, P128, DOI 10.1007/s001340050533
   Nguyen BY, 1998, AIDS, V12, P895, DOI 10.1097/00002030-199808000-00012
   Reber PU, 1998, DIGEST SURG, V15, P92, DOI 10.1159/000018600
   Ross RJM, 1997, MOL ENDOCRINOL, V11, P265, DOI 10.1210/me.11.3.265
   Serri O, 1999, J CLIN ENDOCR METAB, V84, P58, DOI 10.1210/jc.84.1.58
   Sommese L, 1996, J MED MICROBIOL, V45, P40, DOI 10.1099/00222615-45-1-40
   Takagi K, 1998, ANN SURG, V228, P106, DOI 10.1097/00000658-199807000-00016
   Takala J, 1999, NEW ENGL J MED, V341, P785, DOI 10.1056/NEJM199909093411102
   VARATHORBECK R, 1993, WORLD J SURG, V17, P530, DOI 10.1007/BF01655116
   WARWICKDAVIES J, 1995, J IMMUNOL, V154, P1909
   WEIGENT DA, 1988, FASEB J, V2, P2812
   WILMORE DW, 1991, NEW ENGL J MED, V325, P695, DOI 10.1056/NEJM199109053251005
NR 35
TC 23
Z9 24
U1 0
U2 1
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD SEP
PY 2000
VL 85
IS 9
BP 3383
EP 3390
DI 10.1210/jc.85.9.3383
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 351NZ
UT WOS:000089166200064
PM 10999838
DA 2021-08-04
ER

PT J
AU Oyabu, T
   Misawa, T
   Kimura, H
   Nanto, H
AF Oyabu, T
   Misawa, T
   Kimura, H
   Nanto, H
TI Proposition of sensor agent for estimation of air-pollution direction
   and its experimental simulation
SO MATERIALS SCIENCE & ENGINEERING C-BIOMIMETIC AND SUPRAMOLECULAR SYSTEMS
LA English
DT Article; Proceedings Paper
CT Biomolecular Mechanism and Design Workshop 99: an Approach to
   Environmental Sensing
CY JUN 11-12, 1999
CL NATL INST ADV INTERDISCIPLINARY RES, TSUKUBA, JAPAN
HO NATL INST ADV INTERDISCIPLINARY RES
DE multiagent system; sensor system; odor sensor; air-pollution direction;
   environmental problem
AB Air pollutants appear at various areas on the earth due to economic growth, and harm the health of the residents of those regions. Various countries around those areas are also polluted. Many kinds of air-polluting factors must be grasped, for example, the place of origin, kind of pollutant, its direction and speed. These factors are also grasped quickly over a wide area. Various kinds of chemical sensors have been investigated and developed to detect air pollutants. In this study, metal oxide odor sensors are installed at 12 points in an experimental residence and experimental simulations are carried out. Each sensor with a microprocessor has the ability of an agent, which can autonomously make many advanced decisions and estimations. This sensor system is named sensor agent. The sensor agents can derive pollution direction by cooperation and collaboration with other sensor agents. Derived directions are compared with daily resident behaviors and reliability is examined. Results show that polluting direction is estimated with good reliability and a clue to practical use is achieved. (C) 2000 Published by Elsevier Science S.A.
C1 Kanazawa Univ Econ, Kanazawa, Ishikawa 9208620, Japan.
   Kanazawa Univ, Fac Engn, Kanazawa, Ishikawa 9208667, Japan.
   Kanazawa Inst Technol, Kanazawa, Ishikawa 9240838, Japan.
RP Oyabu, T (corresponding author), Kanazawa Univ Econ, Ushi 10,Gosho Machi, Kanazawa, Ishikawa 9208620, Japan.
CR Bradshaw J. M., 1994, SOFTWARE AGENTS
   Oyabu T, 1997, SENSOR MATER, V9, P177
   Oyabu T, 1996, SENSOR ACTUAT B-CHEM, V36, P308, DOI 10.1016/S0925-4005(97)80087-1
   Oyabu T., 1998, Transactions of the Institute of Electrical Engineers of Japan, Part E, V118-E, P572
   OYABU T, 1999, 3 INT C ENG DES AUT, P321
   OYABU T, 1999, E AS C CHEM SENS NOV
   OYABU T, 1999, BIOM MECH DES WORKSH
   Russell S. J., 2010, ARTIFICIAL INTELLIGE
   WEISS G, 1999, MULTIAGENT SYSTEM
NR 9
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0928-4931
J9 MAT SCI ENG C-BIO S
JI Mater. Sci. Eng. C-Biomimetic Supramol. Syst.
PD AUG 18
PY 2000
VL 12
IS 1-2
SI SI
BP 89
EP 95
DI 10.1016/S0928-4931(00)00164-8
PG 7
WC Materials Science, Multidisciplinary
SC Materials Science
GA 350HQ
UT WOS:000089095500017
DA 2021-08-04
ER

PT J
AU Garcia-Nieto, R
   Manzanares, I
   Cuevas, C
   Gago, F
AF Garcia-Nieto, R
   Manzanares, I
   Cuevas, C
   Gago, F
TI Bending of DNA upon binding of ecteinascidin 743 and phthalascidin 650
   studied by unrestrained molecular dynamics simulations
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID B-DNA; MINOR-GROOVE; CRYSTAL-STRUCTURES; ATOMIC CHARGES; NUCLEIC-ACIDS;
   FORCE-FIELD; GUANINE N2; A-DNA; NF-Y; TURBINATA
AB Recognition of DNA sequence information by the natural antitumor agent ecteinascidin 743 (ET743) has been proposed to operate through a direct readout mechanism involving specific hydrogen bonding interactions between the drug and the DNA minor groove prior to covalent alkylation of a guanine base. 5'-AGC and 5'-CGG are examples of high-reactivity target triplets whereas 5'-CGA is a low-reactivity sequence. Molecular dynamics computer simulations were first used to explore the stability and behavior of the pre-covalent complex between ET743 and a DNA nonamer containing the 5'-AGC binding site in the central region. The pre-covalent complex was stable, and some unreported distinctive features were observed that may not be amenable to direct experimental verification. A similar simulation with ET743 bound to another nonamer containing a central 5'-CGA triplet did not result in a stable association supporting the proposed role of a hydrogen bonding network in the stabilization of these complexes. The covalent complexes between ET743 and the nonamers containing the 5'-AGC and 5'-CGG target sites were then simulated. In each case the drug displayed the predicted binding mode and gave rise to a widening of the minor groove. In addition, we show that as a consequence of ET743 binding to the target sequences, positive roll is introduced that results in smooth bending of the helix toward the major groove, in agreement with results from gel electrophoresis experiments. Similar results were obtained with the synthetic compound phthalascidin, which presents a biological profile almost indistinguishable from that of ET743. The local bending elements in AGC and CGG were found to be different, and the distinct behavior of these sequences in the absence of bound drugs was in consonance with their intrinsic bending propensities.
C1 Univ Alcala de Henares, Dept Farmacol, E-28871 Alcala De Henares, Madrid, Spain.
   Pharma Mar SA, Madrid 28760, Spain.
RP Gago, F (corresponding author), Univ Alcala de Henares, Dept Farmacol, E-28871 Alcala De Henares, Madrid, Spain.
RI Gago, Federico/AAS-3992-2020; Gago, Federico/H-1004-2015
OI Gago, Federico/0000-0002-3071-4878; Gago, Federico/0000-0002-3071-4878
CR AQVIST J, 1990, J PHYS CHEM-US, V94, P8021
   ARNOTT S, 1972, BIOCHEM BIOPH RES CO, V47, P1504, DOI 10.1016/0006-291X(72)90243-4
   BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004
   Bertrand HO, 1998, NUCLEIC ACIDS RES, V26, P1261, DOI 10.1093/nar/26.5.1261
   BESLER BH, 1990, J COMPUT CHEM, V11, P431, DOI 10.1002/jcc.540110404
   BEVERIDGE DL, 1994, CURR OPIN STRUC BIOL, V4, P246, DOI 10.1016/S0959-440X(94)90316-6
   Bonfanti M, 1999, ANTI-CANCER DRUG DES, V14, P179
   Cheatham TE, 1999, J BIOMOL STRUCT DYN, V16, P845, DOI 10.1080/07391102.1999.10508297
   Cheatham TE, 1996, J MOL BIOL, V259, P434
   Cheatham TE, 1997, J AM CHEM SOC, V119, P4805, DOI 10.1021/ja963641w
   Cheatham TE, 1998, J BIOMOL STRUCT DYN, V16, P265, DOI 10.1080/07391102.1998.10508245
   CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Denisov VP, 2000, P NATL ACAD SCI USA, V97, P629, DOI 10.1073/pnas.97.2.629
   ELCOCK AH, 1997, COMP SIM BIOMOL SYST, V3, P244
   Frisch MJ, 1995, GAUSSIAN 94 REVISION
   GAGO F, 1989, MOL PHARMACOL, V35, P232
   GALLEGO J, 1993, J MED CHEM, V36, P1548, DOI 10.1021/jm00063a005
   GORIN AA, 1995, J MOL BIOL, V247, P34, DOI 10.1006/jmbi.1994.0120
   GUAN Y, 1993, J BIOMOL STRUCT DYN, V10, P793
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483
   LAVERY R, 1985, J BIOMOL STRUCT DYN, V2, P1021, DOI 10.1080/07391102.1985.10507618
   Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6
   Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135
   Martinez EJ, 1999, P NATL ACAD SCI USA, V96, P3496, DOI 10.1073/pnas.96.7.3496
   MCCONNELL KJ, 1994, J AM CHEM SOC, V116, P4461, DOI 10.1021/ja00089a039
   MENGER FM, ADV CHEM SER, V215, P209
   Miller JL, 1997, J MOL BIOL, V270, P436, DOI 10.1006/jmbi.1997.1113
   *MOL SIM INC, 1998, INS 2 VERS 98 0
   Moore BM, 1997, J AM CHEM SOC, V119, P5475, DOI 10.1021/ja9704500
   Moore BM, 1998, J AM CHEM SOC, V120, P2490, DOI 10.1021/ja974109r
   Moore BM, 1998, J AM CHEM SOC, V120, P9975
   NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405
   Ohndorf UM, 1999, NATURE, V399, P708, DOI 10.1038/21460
   ORTIZ AR, 1993, J MED CHEM, V36, P1866, DOI 10.1021/jm00065a010
   Pastor N, 1997, BIOPHYS J, V73, P640, DOI 10.1016/S0006-3495(97)78099-8
   PEARLMAN DA, 1995, AMBER4 1
   Pommier Y, 1996, BIOCHEMISTRY-US, V35, P13303, DOI 10.1021/bi960306b
   Rinehart KL, 2000, MED RES REV, V20, P1
   RINEHART KL, 1990, J ORG CHEM, V55, P4512, DOI 10.1021/jo00302a007
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5
   Schuerman GS, 2000, J AM CHEM SOC, V122, P232, DOI 10.1021/ja992180m
   Seaman FC, 1998, J AM CHEM SOC, V120, P13028, DOI 10.1021/ja983091x
   Sherer EC, 1999, J AM CHEM SOC, V121, P5981, DOI 10.1021/ja983715z
   Sprous D, 1999, J MOL BIOL, V285, P1623, DOI 10.1006/jmbi.1998.2241
   STEWART JJP, 1993, MOPAC 93
   TRAVERS AA, 1995, NAT STRUCT BIOL, V2, P615, DOI 10.1038/nsb0895-615
   van Aalten DMF, 1999, P NATL ACAD SCI USA, V96, P11809, DOI 10.1073/pnas.96.21.11809
   Werner MH, 1996, SCIENCE, V271, P778, DOI 10.1126/science.271.5250.778
   WOLFE SA, 1995, CHEM BIOL, V2, P213, DOI 10.1016/1074-5521(95)90271-6
   WRIGHT AE, 1990, J ORG CHEM, V55, P4508, DOI 10.1021/jo00302a006
   Young MA, 1998, J MOL BIOL, V281, P675, DOI 10.1006/jmbi.1998.1962
   YOUNG MA, 1995, BIOPHYS J, V68, P2454, DOI 10.1016/S0006-3495(95)80427-3
   Zewail-Foote M, 1999, ANTI-CANCER DRUG DES, V14, P1
   Zewail-Foote M, 1999, J MED CHEM, V42, P2493, DOI 10.1021/jm990241l
NR 56
TC 35
Z9 35
U1 0
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD AUG 2
PY 2000
VL 122
IS 30
BP 7172
EP 7182
DI 10.1021/ja000964q
PG 11
WC Chemistry, Multidisciplinary
SC Chemistry
GA 342RF
UT WOS:000088658400003
DA 2021-08-04
ER

PT J
AU Waki, K
   Zhao, JC
   Horikoshi, S
   Watanabe, N
   Hidaka, H
AF Waki, K
   Zhao, JC
   Horikoshi, S
   Watanabe, N
   Hidaka, H
TI Photooxidation mechanism of nitrogen-containing compounds at TiO2/H2O
   interfaces: an experimental and theoretical examination of hydrazine
   derivatives
SO CHEMOSPHERE
LA English
DT Article
DE photooxidation; photodegradation; hydrazine; photocatalysis; titanium
   dioxide; gas-generating agent
ID PHOTOCATALYTIC DEGRADATION; ORGANIC-COMPOUNDS; TITANIUM-DIOXIDE; WATER
   INTERFACE; NO3 IONS; OXIDATION; MINERALIZATION; AMMONIUM; NITRATE; NH4+
AB The photocatalytic oxidation of oxalyldihydrazide, N, N'-bis(hydrazocarbonyl)hydrazide, N, N'-bis(ethoxycarbonyl)hydrazide, malonyldihydrazide, N-malonyl-bis[(N'-ethoxycarbonyl)hydrazide] was examined in aqueous TiO2 dispersions under UV illumination. The photomineralization of nitrogen and carbon atoms in the substrates into N-2 gas, NH4+ (and/or NO3-) ions, and CO2 gas was determined by HPLC and GC analysis. The formation of carboxylic acid intermediates also occurred in the photooxidation process. The photocatalytic mechanism is discussed on the basis of the experimental results, and with molecular orbital (MO) simulation of frontier electron density and point charge. Substrate carbonyl groups readily adsorb on the TiO2 surface, and the bonds between carbonyl group carbon atoms and adjacent hydrate group nitrogen atoms are cleaved predominantly in the initial photooxidation process. The hydrate groups were photoconverted mainly into N-2 gas (in mineralization yields above 70%) and partially to NH4+ ions (below 10%). The formation of NO3- ions was scarcely recognized. (C) 2000 Elsevier Science Ltd. All rights reserved.
C1 Iwaki Meisei Univ, Frontier Res Ctr Global Environm Protect, Hino, Tokyo 1918506, Japan.
   Chinese Acad Sci, Inst Photog Chem, Beijing 100101, Peoples R China.
   Toyo Univ, Dept Appl Chem, Fac Engn, Kawagoe, Saitama 3500815, Japan.
RP Hidaka, H (corresponding author), Iwaki Meisei Univ, Frontier Res Ctr Global Environm Protect, Hino, Tokyo 1918506, Japan.
CR HIDAKA H, 1994, NEW J CHEM, V18, P541
   HIDAKA H, 1996, J ADV OXID TECHNOL, V1, P27
   LOW GKC, 1989, CHEMOSPHERE, V19, P1611, DOI 10.1016/0045-6535(89)90504-3
   LOW GKC, 1991, ENVIRON SCI TECHNOL, V25, P460, DOI 10.1021/es00015a013
   Nohara K, 1996, CATAL LETT, V36, P115, DOI 10.1007/BF00807215
   Nohara K, 1997, J PHOTOCH PHOTOBIO A, V102, P265, DOI 10.1016/S1010-6030(96)04478-4
   PELIZZETTI E, 1992, CHEMOSPHERE, V24, P891, DOI 10.1016/0045-6535(92)90008-F
   PELIZZETTI E, 1993, COORDIN CHEM REV, V125, P183, DOI 10.1016/0010-8545(93)85017-X
   PELLIZZETI E, 1989, CHEMOSPHERE, V18, P1437
   WAKI K, 1995, J MOL CATAL A-CHEM, V95, P53, DOI 10.1016/1381-1169(94)00135-9
NR 10
TC 31
Z9 31
U1 0
U2 26
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0045-6535
J9 CHEMOSPHERE
JI Chemosphere
PD AUG
PY 2000
VL 41
IS 3
BP 337
EP 343
DI 10.1016/S0045-6535(99)00500-7
PG 7
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA 309UB
UT WOS:000086786700006
PM 11057595
DA 2021-08-04
ER

PT J
AU de Vries, P
   Singer, JW
AF de Vries, P
   Singer, JW
TI Lisofylline suppresses ex vivo release by murine spleen cells of
   hematopoietic inhibitors induced by cancer chemotherapeutic agents
SO EXPERIMENTAL HEMATOLOGY
LA English
DT Article
DE hematopoietic inhibitors; lisofylline; cancer chemotherapeutic agents;
   spleen cell conditioned media
ID TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR-BETA; COLONY-STIMULATING FACTOR;
   BONE-MARROW TRANSPLANTATION; ACTIVATED PROTEIN-KINASE; SERUM
   ERYTHROPOIETIN LEVELS; MYELOID PROGENITOR CELLS; HIGH-DOSE CHEMOTHERAPY;
   DNA-DAMAGING AGENTS; LINOLEIC-ACID
AB Objective. Many cytotoxic cancer therapeutic drugs activate stress response signaling pathways that transcriptionally activate a variety of genes. We decided to determine if cytotoxic therapies induce inflammatory cytokines with inhibitory effects on hematopoiesis and if lisofylline (LSF), a novel antiinflammatory compound, suppresses this induction.
   Materials and Methods. Mice were treated with cytosine beta-d-arabinofuranoside (AraC), cisplatinum(II)diammine-dichloride (CisP), etoposide (VF-16), or melphalan at clinically relevant doses, with or without LSF,
   Results. Spleen cell conditioned media (CM) derived from mice treated with cytotoxic agents, but not from control or LSF treated mice, reduced colony formation by murine hone marrow progenitors belonging to the myeloid, erythroid, megakaryocytic, and beta-lymphoid lineages, LSF (100 mg/kg), administered either simultaneously with or up to 48 hours before the cytotoxic agents, suppressed the release of this inhibitory activity. Treatment of inhibitory Chi with neutralizing antibodies against known growth inhibitory cytokines, including tumor necrosis factor alpha, transforming growth factor beta, and macrophage inflammatory protein-1 alpha, resulted in enhanced colony growth.
   Conclusion. We conclude that treatment of mice with chemotherapeutic drugs induces the ex vivo production of multilineage hematopoietic inhibitors and that induction of these Inhibitors could be abrogated by treatment with LSF. These findings suggest a mechanism whereby I,SF can accelerate recovery of hematopoiesis following cytotoxic therapies, (C) 2000 International Society for Experimental Hematology. Published by Elsevier Science.
C1 Cell Therapeut Inc, Seattle, WA 98119 USA.
RP de Vries, P (corresponding author), Cell Therapeut Inc, 201 Elliott Ave W, Seattle, WA 98119 USA.
OI Singer, Jack/0000-0003-4001-4549
CR ABRAHAM E, 1995, J EXP MED, V181, P569, DOI 10.1084/jem.181.2.569
   BACKX B, 1991, LEUKEMIA, V5, P66
   BEKSAC M, 1994, EXP HEMATOL, V22, P480
   BENSINGER W, 1993, BLOOD, V81, P3158
   BODINE DM, 1991, BLOOD, V78, P914
   Bright JJ, 1998, J IMMUNOL, V161, P7015
   BROXMEYER HE, 1990, BLOOD, V76, P1110
   BROXMEYER HE, 1991, J IMMUNOL, V147, P2586
   BROXMEYER HE, 1986, J IMMUNOL, V136, P4487
   BROXMEYER HE, 1993, J IMMUNOL, V150, P3448
   BUCHANAN MR, 1985, THROMB HAEMOSTASIS, V53, P306
   CARIO MS, 1992, BLOOD, V79, P1869
   Clarke E, 1996, CANCER RES, V56, P105
   Clarke E., 1995, Blood, V86, p690A
   Coon ME, 1999, J IMMUNOL, V163, P6567
   DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5
   DUNLOP DJ, 1992, BLOOD, V79, P221
   FOLCIK VA, 1994, J LIPID RES, V35, P1570
   GEWIRTZ AM, 1995, BLOOD, V86, P2559, DOI 10.1182/blood.V86.7.2559.bloodjournal8672559
   GRACE RJ, 1991, EUR J HAEMATOL, V47, P81
   GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0
   GROOPMAN JE, 1989, NEW ENGL J MED, V321, P1449, DOI 10.1056/NEJM198911233212106
   GUIDOT DM, 1997, AM J PHYSIOL, V17, P957
   HAAS R, 1993, EXP HEMATOL, V21, P109
   HAN ZC, 1992, BRIT J HAEMATOL, V81, P1, DOI 10.1111/j.1365-2141.1992.tb08161.x
   HO AD, 1994, BLOOD, V84, P3550
   Hybertson BM, 1997, J APPL PHYSIOL, V82, P226
   IWAMOTO KS, 1994, RADIAT RES, V139, P103, DOI 10.2307/3578739
   JACOBSEN SEW, 1994, EXP HEMATOL, V22, P985
   JACOBSEN SEW, 1992, J EXP MED, V175, P1759, DOI 10.1084/jem.175.6.1759
   Kadar E, 1997, ACTA HAEMATOL-BASEL, V98, P119
   KADUCE TL, 1989, J BIOL CHEM, V264, P6823
   KAWANO Y, 1993, BLOOD, V81, P856
   KELLER JR, 1988, J EXP MED, V168, P737, DOI 10.1084/jem.168.2.737
   KELLER JR, 1992, INT J CELL CLONING, V10, P2, DOI 10.1002/stem.5530100103
   KELLER JR, 1989, J CELL BIOCHEM, V39, P175, DOI 10.1002/jcb.240390209
   KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0
   KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0
   KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0
   LEITMEAN DC, 1991, J BIOL CHEM, V226, P9343
   Maini A, 1997, ANTICANCER RES, V17, P3803
   MAYANI H, 1995, EXP HEMATOL, V23, P422
   METCALF D, 1984, HEMATOPOIETIC COLONY
   MILLERGRAZIANO CL, 1991, J CLIN IMMUNOL, V11, P95, DOI 10.1007/BF00917745
   MOORE MAS, 1991, BLOOD, V78, P1
   MURPHY M, 1988, EXP HEMATOL, V16, P131
   NEMUNAITIS J, 1991, NEW ENGL J MED, V324, P1773, DOI 10.1056/NEJM199106203242504
   NEWELL CL, 1994, J LEUKOCYTE BIOL, V56, P27
   OTTMANN OG, 1988, J IMMUNOL, V140, P2661
   PEETRE C, 1986, J CLIN INVEST, V78, P1694, DOI 10.1172/JCI112764
   RABINOWITZ J, 1993, BLOOD, V81, P2452
   REINAUD O, 1989, BIOCHEM BIOPH RES CO, V161, P883, DOI 10.1016/0006-291X(89)92682-X
   RHOADES KL, 1992, J BIOL CHEM, V267, P22102
   RICE GC, 1994, SHOCK, V1, P254, DOI 10.1097/00024382-199404000-00003
   SALEEM A, 1995, CELL GROWTH DIFFER, V6, P1651
   SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4
   SCHAPIRA L, 1990, BLOOD, V76, P2354
   Schiffer CA, 1996, BLOOD, V88, P3675, DOI 10.1182/blood.V88.10.3675.bloodjournal88103675
   SING GK, 1988, BLOOD, V72, P1504
   SINGER JW, 1998, MODIFICATION REGIMEN
   SNOECK HW, 1994, J EXP MED, V180, P1177, DOI 10.1084/jem.180.3.1177
   SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0
   STONE K, 2000, AM SOC CLIN ONCOL
   Teicher BA, 1997, INT J ONCOL, V11, P265
   Waxman K, 1996, CRIT CARE MED, V24, P1724, DOI 10.1097/00003246-199610000-00021
   WodnarFilipowicz A, 1996, BLOOD, V88, P4493, DOI 10.1182/blood.V88.12.4493.bloodjournal88124493
   WOLPE SD, 1989, FASEB J, V3, P2565
   Wong JS, 1996, ONCOL RES, V8, P513
   Woodgett JR, 1996, CANCER SURV, V27, P127
NR 69
TC 16
Z9 17
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA
SN 0301-472X
J9 EXP HEMATOL
JI Exp. Hematol.
PD AUG
PY 2000
VL 28
IS 8
BP 916
EP 923
DI 10.1016/S0301-472X(00)00493-8
PG 8
WC Hematology; Medicine, Research & Experimental
SC Hematology; Research & Experimental Medicine
GA 353LR
UT WOS:000089276100005
PM 10989192
DA 2021-08-04
ER

PT J
AU Cini, R
   Chindamo, D
   Catenaccio, M
   Lorenzini, S
   Marcolongo, R
AF Cini, R
   Chindamo, D
   Catenaccio, M
   Lorenzini, S
   Marcolongo, R
TI Density functional geometry optimization and energy calculations of
   calcium(II)-triphosphate complexes. Polyphosphates as possible
   dissolving agents for calcium pyrophosphate dihydrate crystals in
   chondrocalcinosis disease
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article
ID ADENOSINE
AB Geometry optimizations and energy calculations have been carried out via molecular orbital methods at the density functional B3LYP/LANL2DZ level on the molecules PO3-, OPO33-, HOPO32-, CH3OPO32-, H(CH3OPO3)(-), O(PO3)(2)(4-), HO(PO3)(2)(3-), CH2(PO3)(2)(4-), (CH3OPO2)O(PO3)(3-) O(PO3)(3)(5-), HO(PO3)(3)(4-), (PO3)(3)(3-), (CH3OPO2)O(PO3)(2)(4-) [Mg{O(PO3)(2)} ](2-), [Ca{O(PO3)(2)}](2-), [Ca{CH2(PO3)(2)}](2-), [Ca{CH3OPO2}O(PO3)}](-), [Ca(PO3)(3)](-), [Ca{O(PO3)(3)}](3-), and [Ca{CH3OPO2)O(PO3)(2)}](2-) with the aim to find reliable and easily accessible computational methods to simulate some phosphate-containing molecules of importance for the living cells and to study the energetics for protonation and metal-complex formation reactions. The analysis is part of a general investigation on phosphate-containing molecules as potential dissolving agents for calcium pyrophosphate dihydrate (CPPD) crystals which deposit in certain articular diseases. The basis set was expanded to 6-31G** for the P atoms for all the molecules investigated and to 6-31G* for the O atoms for OPO33-. Calculations at the semi-empirical MNDO/d level were also carried out for comparison purposes on the free ligand molecules and on [Mg{O(PO3)(2)}](2-). The density functional analysis reproduced well the geometry found at the solid state via X-ray diffraction. The analyses of the geometrical parameters and the total electronic energy of the molecules shows that O(PO3)(2)(4-) and other di- and tri-phosphates are versatile ligands for divalent metal ions like Ca2+. The computed P-O-P bond angle for free O(PO3)(2)(4-) is 180 degrees and the conformation of the two PO3- groupings is staggered along the P P vector. The linear arrangement for P-O-P is assisted by P-O pi interactions. The bending of the P-O-P angle when accompanied by a slight P-O(b) elongation requires a very small amount of energy; 4.65 kcal/mol to pass from 180 to 140 degrees, as calculated at the DFT level.
   The computed Ca-O and Mg-O bond distances for [M{O(PO3)(2)}](2-) are 2.378 and 2.079 Angstrom, when the metal ions link two oxygen atoms from each PO3 group. The computed Ca-O bond lengths for [Ca{CH3OPO2)O(PO3)}](-) are 2.482 (PalphaO2) and 2.358 Angstrom (PbetaO2), showing a significant lengthening for Ca-OPalpha, when compared to the pyrophosphate derivative. The Ca-O bond lengths for [Ca{O(PO3)(3)}](3-) and [Ca{CH3OPO2(PO3)(2)}](2-) are 2.251 Angstrom and 2.525 (PalphaO2), 2.407 and 2.338 (PbetaO2), and 2.251 and 2.228 Angstrom (PgammaO2), showing a shortening for the Ca-OP gamma bond upon methylation. The (P-beta)O-P-gamma bond length increases significantly (0,09 Angstrom) upon Ca.(II) coordination to (CH3OPO2)O(PO3)(2)(4-) via all the three PO3 groups. This latter result suggests that metal complexes of linear organic-triphosphates have a larger tendency to release the P gamma O-3, group when compared to the free ligand molecules. The electronic contribution to the energy of the complex formation reaction for [Ca{CH2(PO3)(2)}](2-) is only slightly higher (some 1.8 kcal) than that for [Ca{O(PO3)(2)}](2-); but is much higher (some 63 kcal) than that relevant to the formation of [Ca{CH3OPO2)O(PO3)(2)}](2-). Therefore the linear methyltriphosphates (and reasonably nucleoside triphosphates) are predicted to form metal complexes which are less stable than diphosphonate or inorganic diphosphate ligands, at least in the case the organic moiety does not have any appreciable coordination ability toward the metal. The energy of complex formation for [Ca{O(PO3)(3)}](3-) is much higher than that for [Ca{O(PO3)(2)}](2-) and [Ca(PO3)(3)}](-) (some 116 and 345 kcal, respectively). This is in part a rationale for the high dissolving ability (DA) toward CPPD crystals, shown by solutions of pentasodium tripolyphosphate. DA values of 65.4+/-3.0 mu g Ca/mL were detected, via atomic absorption spectroscopy, in solutions of Na-5{O(PO3)(3)} 0.06 M after digestion (1.00 h, 37 degrees C, pH 7.4) in the presence of CPPD crystals. Efficient non-toxic dissolving agents for CPPD crystals are needed to cure chondrocalcinosis desease. The semi-empirical computations gave correct overall optimized structures and conformations for, at least, the free not-substituted ligands and the relevant Mg(II)-complexes. The optimized structure for [Mg(O(PO3)(2)}](2-) has computed P-O(t) and P-O(d) bond distances of 1.503 and 1.598 Angstrom, in perfect agreement with the results from DFT calculations.
C1 Univ Siena, Dept Chem & Biosyst Sci & Technol, I-53100 Siena, Italy.
   Univ Siena, Inst Rheumatol, I-53100 Siena, Italy.
RP Cini, R (corresponding author), Univ Siena, Dept Chem & Biosyst Sci & Technol, Via E Bastianini 12, I-53100 Siena, Italy.
EM cini@unisi.it
CR Becke A. D., 1993, PHYS REV A, V98, P5648, DOI DOI 10.1103/PHYS.REV.B.37-785
   BELMONT HM, 1999, MOL CELLULAR BASIS I, pCH15
   BRUZIK K, 1987, BIOPHOSPHATES THEIR
   CALVO C, 1965, CAN J CHEMISTRY, V43, P1139, DOI 10.1139/v65-151
   CATENACCIO M, 1999, C SOC IT REUM SIR CA
   Cheetham GMT, 1999, SCIENCE, V286, P2305, DOI 10.1126/science.286.5448.2305
   CINI R, 1984, J CHEM SOC DALTON, P2467, DOI 10.1039/dt9840002467
   Cini R, 1999, J CHEM SOC DALTON, P699, DOI 10.1039/a807793b
   Cini R, 1999, J BIOMOL STRUCT DYN, V16, P1225, DOI 10.1080/07391102.1999.10508330
   CINI R, UNPUB
   CLEMENTS PJ, 1996, SYSTEMIC SCLEROSIS, pCH7
   CRONSTEIN BN, 1999, MOL CELLULAR BASIS I, pCH12
   FRISCH MJ, 1995, GAUSSAIN 94
   HAY PJ, 1985, J CHEM PHYS, V82, P229
   *HYP INC, 1997, HYP CHEM REL 5 1 PRO
   JOHNSON CK, 1998, ORTEP 3 WINDOWS ORNL
   Lippert B, 1999, CISPLATIN
   MANDEL NS, 1975, ACTA CRYSTALLOGR B, V31, P1730, DOI 10.1107/S0567740875005997
   McCarthy WJ, 1998, J AM CHEM SOC, V120, P6113, DOI 10.1021/ja972715g
   ORIOLI P, 1980, NATURE, V283, P691, DOI 10.1038/283691a0
   ROBERTSON BE, 1970, J SOLID STATE CHEM, V1, P120
   SCHEINER S, 1997, HYDROGEN BONDING
   SIGEL A, 1996, METAL IONS BIOLS SYS, V32
   SIGEL A, 1996, METAL IONS BIOL SYST, V33
   WEBB NC, 1966, ACTA CRYSTALLOGR, V21, P942, DOI 10.1107/S0365110X66004225
   ZSOLNAI L, 1998, XPMA ZORTEP 98 INTER
NR 26
TC 2
Z9 2
U1 0
U2 4
PU ADENINE PRESS INC
PI GUILDERLAND
PA PO BOX 355/340, GUILDERLAND, NY 12084 USA
SN 0739-1102
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
PD AUG
PY 2000
VL 18
IS 1
BP 155
EP 168
DI 10.1080/07391102.2000.10506655
PG 14
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 358VE
UT WOS:000089577200014
PM 11021660
DA 2021-08-04
ER

PT J
AU Blanusa, M
   Prester, L
   Varnai, VM
   Pavlovic, D
   Kostial, K
   Jones, MM
   Singh, PK
AF Blanusa, M
   Prester, L
   Varnai, VM
   Pavlovic, D
   Kostial, K
   Jones, MM
   Singh, PK
TI Chelation of aluminium by combining DFO and L1 in rats
SO TOXICOLOGY
LA English
DT Article
DE chelation; 1,2 dimethyl-3-hydroxypyrid-4-one; desferrioxamine;
   aluminium; iron; urine; serum
ID MESO-2,3-DIMERCAPTOSUCCINIC ACID; MOBILIZING ACTIONS; IRON;
   DEFEROXAMINE; TOXICITY; CADMIUM; THERAPY; AGENTS; MICE; LEAD
AB The hypothesis that two known chelators 1,2-dimethyl-3-hydroxypyrid-4-one (L1) and desferrioxamine (DFO) might be more efficient as combined treatment than as monotherapies in removing aluminium from the body was tested in a new acute rat model. Five-week old female rats received chelators: L1 (p.o.), DFO (i.p.) or L1 + DFO as 100 or 200 mg/kg dose half an hour after a single i.p. administration of 6 mg Al/kg body weight in the form of chloride. Serum aluminium concentration and urinary aluminium and iron excretions were determined by electrothermal or flame atomic absorption spectrometry. Both chelators were effective only at the higher dose level. While DFO was more effective than L1 in enhancing urinary aluminium excretion, L1 was more effective than DFO in enhancing urinary iron excretion. In the combined treatment group L1 did not increase the DFO effect on aluminium and DFO did not increase the effect of L1 on iron elimination. However, in this group a simultaneous increase in both aluminium and iron elimination was observed. Our results support the usefulness of this animal model for preliminary in vivo testing of aluminium chelators. Urinary values were more useful because of the high variability of serum results. Result of combined chelators treatment should be confirmed in a different experimental model before extrapolation to other systems. This testing procedure of course does not provide all the relevant answers for evaluating the efficiency of chelating agents in aluminium toxicity. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.
C1 Inst Med Res & Occupat Hlth, Zagreb 10001, Croatia.
   Clin Hosp Sv Duh, Zagreb, Croatia.
   Vanderbilt Univ, Dept Chem, Nashville, TN 37235 USA.
   TN Dept Agr, Food Residue & Toxicol Lab, Nashville, TN 37220 USA.
RP Blanusa, M (corresponding author), Inst Med Res & Occupat Hlth, 2 Ksaverska St, Zagreb 10001, Croatia.
RI Pavlovic, Drasko/AAD-4566-2019
OI Pavlovic, Drasko/0000-0002-2380-869X
CR BERDOUKAS V, 1993, LANCET, V341, P1088, DOI 10.1016/0140-6736(93)92443-W
   Blanusa Maja, 1997, Arhiv za Higijenu Rada i Toksikologiju, V48, P197
   BOSQUE MA, 1995, ARCH TOXICOL, V69, P467, DOI 10.1007/s002040050200
   CHERIAN MG, 1980, NATURE, V287, P871, DOI 10.1038/287871a0
   CLARKE ET, 1992, INORG CHIM ACTA, V191, P57, DOI 10.1016/S0020-1693(00)80327-8
   Elorriaga R., 1992, Drugs of Today, V28, P177
   FLORA SJS, 1995, FUND APPL TOXICOL, V25, P233, DOI 10.1006/faat.1995.1059
   GALE GR, 1991, RES COMMUN CHEM PATH, V73, P299
   Gomez M, 1998, PHARMACOL TOXICOL, V82, P295, DOI 10.1111/j.1600-0773.1998.tb01576.x
   Gomez M, 1998, TOXICOLOGY, V130, P175, DOI 10.1016/S0300-483X(98)00109-7
   GOMEZ M, 1994, METAL IONS BIOL MED, P97
   GRAFF L, 1995, RES COMMUN MOL PATH, V88, P271
   JONES MM, 1991, CRIT REV TOXICOL, V21, P209, DOI 10.3109/10408449109089880
   KONTOGHIORGHES GJ, 1995, ANALYST, V120, P845, DOI 10.1039/an9952000845
   KONTOGHIORGHES GJ, 1987, INORG CHIM A-BIOINOR, V136, pL11, DOI 10.1016/S0020-1693(00)85549-8
   Kostial K, 1997, PHARMACOL TOXICOL, V81, P242, DOI 10.1111/j.1600-0773.1997.tb00054.x
   Kostial K, 1996, J APPL TOXICOL, V16, P157, DOI 10.1002/(SICI)1099-1263(199603)16:2<157::AID-JAT322>3.0.CO;2-Q
   Kostial K, 1999, J APPL TOXICOL, V19, P143
   WINSHIP KA, 1993, ADVERSE DRUG REACT T, V12, P177
   YOKEL RA, 1987, TOXICOL APPL PHARM, V91, P281, DOI 10.1016/0041-008X(87)90109-8
NR 20
TC 24
Z9 25
U1 0
U2 3
PU ELSEVIER SCI IRELAND LTD
PI CLARE
PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE,
   IRELAND
SN 0300-483X
J9 TOXICOLOGY
JI Toxicology
PD JUL 5
PY 2000
VL 147
IS 3
BP 151
EP 156
DI 10.1016/S0300-483X(00)00214-6
PG 6
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA 337UR
UT WOS:000088380500001
PM 10924797
DA 2021-08-04
ER

PT J
AU Sanyal, U
   Nanda, R
   Samanta, S
   Pain, A
   Dutta, S
   Verma, AS
   Rider, BJ
   Agrawal, KC
AF Sanyal, U
   Nanda, R
   Samanta, S
   Pain, A
   Dutta, S
   Verma, AS
   Rider, BJ
   Agrawal, KC
TI Evaluation of dimethylaminosulfonates of alkane diols as a novel group
   of anticancer agents
SO CANCER LETTERS
LA English
DT Article; Proceedings Paper
CT 17th UICC International Cancer Congress
CY AUG 23-28, 1998
CL RIO JANEIRO, BRAZIL
SP UICC
DE new anticancer agents; human tumor cell lines; cytotoxicity assay; mice;
   toxicological assay
ID ESTRONE SULFATASE; HEPSULFAM; TOXICITY; MECHANISM; SITE
AB A series of title compounds has been synthesized and evaluated by the cytotoxicity assays conducted in vitro in seven human tumor cell lines, initially in MT-4 and H-9, followed by U-937, PM-I, MCF-7, Hep-3B, and K-562. These compounds were simultaneously compared with the existing clinical drug, busulfan and also with an experimental drug, hepsulfam. IC50 values of these agents in T-cell lymphoma and leukemic cell lines indicate that two of these agents hexsulfamyl and octsulfamyl (compounds 3 and 4) were significantly more potent than busulfan and were comparable in antileukemic activity with hepsulfam. In order to determine the effect of these agents on normal proliferating cells, the toxicity of 3 and 4 was also determined in vitro against human peripheral blood mononuclear cells (PBMC) and against murine bone marrow progenitor cells. PBMC assay data indicate that these agents were generally less toxic than hepsulfam. The results of the colony forming unit-erythroid (CFU-E) and granulocyte-macrophage colony forming unit (CFU-GM) assays, however, indicate that these agents were more toxic than hepsulfam to erythroid progenitor cells than to granulocyte-macrophage progenitors. The toxicity of octsulfamyl was further assessed in vivo in normal Swiss mice by measuring drug-induced changes in hematological parameters, femoral bone marrow cellularity and splenic cellularity as well as hepatotoxicity and nephrotoxicity on day 7 and 14 following drug treatment at the dose of 1.0 mg/kg body weight from days 1 to 5. The results indicate that the compound did not adversely affect hematopoiesis. Marginal bone marrow suppression was observed on day 7, which gradually tends to reach normalcy on day 14. The other parameters were within normal limit. (C) 2000 Published by Elsevier Science Ireland Ltd. All rights reserved.
C1 Chittaranjan Natl Canc Inst, Dept Anticanc Drug Dev & Chemotherapy, Calcutta 700026, W Bengal, India.
   Tulane Univ, Med Ctr, Dept Pharmacol, New Orleans, LA 70112 USA.
RP Sanyal, U (corresponding author), Chittaranjan Natl Canc Inst, Dept Anticanc Drug Dev & Chemotherapy, Calcutta 700026, W Bengal, India.
CR ATWELL GJ, 1972, J MED CHEM, V15, P611, DOI 10.1021/jm00276a011
   Ghosh M, 1999, NEOPLASMA, V46, P242
   Ghosh M, 1999, CANCER LETT, V138, P107, DOI 10.1016/S0304-3835(98)00384-X
   GOGU SR, 1991, EXP HEMATOL, V19, P649
   HINCKS JR, 1990, CANCER RES, V50, P7559
   HOWARTH NM, 1994, J MED CHEM, V37, P219, DOI 10.1021/jm00028a002
   Mauck JC, 1980, GRADWOHLS CLIN LAB M, P305
   PACHECO DY, 1989, CANCER RES, V49, P5108
   PACHECO DY, 1990, CANCER RES, V50, P7555
   RAVDIN PM, 1991, CANCER RES, V51, P6268
   SANYAL U, 1993, NEOPLASMA, V40, P219
   STREEPER RT, 1995, CANCER RES, V55, P1491
   Woo LWL, 1996, J MED CHEM, V39, P1349, DOI 10.1021/jm950931z
NR 13
TC 6
Z9 6
U1 0
U2 0
PU ELSEVIER SCI IRELAND LTD
PI CLARE
PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE,
   IRELAND
SN 0304-3835
J9 CANCER LETT
JI Cancer Lett.
PD JUL 3
PY 2000
VL 155
IS 1
BP 89
EP 97
DI 10.1016/S0304-3835(00)00409-2
PG 9
WC Oncology
SC Oncology
GA 396WZ
UT WOS:000166662100012
PM 10814884
DA 2021-08-04
ER

PT J
AU Maillet, A
   Zaouali-Ajina, M
   Vorobiev, D
   Blanc, S
   Pastouchkova, L
   Reushkina, G
   Morukov, B
   Grigoriev, AI
   Gharib, C
   Gauquelin-Koch, G
AF Maillet, A
   Zaouali-Ajina, M
   Vorobiev, D
   Blanc, S
   Pastouchkova, L
   Reushkina, G
   Morukov, B
   Grigoriev, AI
   Gharib, C
   Gauquelin-Koch, G
TI Orthostatic tolerance and hormonal changes in women during 120 days of
   head-down bed rest
SO AVIATION SPACE AND ENVIRONMENTAL MEDICINE
LA English
DT Article
DE bed rest; women; volume regulating hormones; microgravity simulation;
   orthostatic tolerance; countermeasures
ID BODY NEGATIVE-PRESSURE; SPACE-FLIGHTS; HUMANS; TILT; COUNTERMEASURE;
   WEIGHTLESSNESS; INTOLERANCE; SPACEFLIGHT; ELECTROLYTE; CONFINEMENT
AB Background: Women will be included as mission specialists in the upcoming international Space Station program. This paper describes the changes in volume-regulating hormones and determines the degree of degradation in orthostatic tolerance in a group of women after 120 d of bed rest. The aim of this study was to test a countermeasure program to be used by women during long-duration spaceflights. Methods: For 120 d of -6 degrees head-down bed rest (HDBR), eight healthy women were assigned either to a no-countermeasure (No-CM, n = 4), or to a countermeasure (CM, n = 4) group. In the countermeasure group, exercise began after 2 wk, pharmacological agents were given during the ist and 3rd mo, and the "Centaur" suit was worn on the last day of bed rest and during the day time for several days after bed rest. Diet supplements were taken during the 1st and 4th mo of HDBR. Tilt tests were run before and after HDBR. Results: After the HDBR, none of the CM subjects, had pre-syncopal or syncopal symptoms during tilt tests: BP was well maintained in the CM group, while heart rate and BP changed in the No-CM group. In plasma, atrial natriuretic peptide (ANP) increased in both groups and remained high throughout HDBR, while aldosterone increased and remained elevated in the No-CM group. Natriuresis was decreased during HDBR. Conclusion: The CM protocols used during this study were efficient and prevented orthostatic intolerance for the four CM subjects. It would be necessary to obtain more data regarding this set of CM protocols on female subjects to lead to statistical and formal conclusions.
C1 Fac Med Lyon Grange Blanche, Lab Physiol Environm, EA645, F-69373 Lyon 08, France.
   CHU Rangueil, Clin Spatiale MEDES, F-31054 Toulouse, France.
   Minist Publ Hlth, Inst Biomed Problems, Moscow, Russia.
   Ctr Natl Etud Spatiales, Paris, France.
RP Maillet, A (corresponding author), Fac Med Lyon Grange Blanche, Lab Physiol Environm, EA645, 8 Ave Rockefeller, F-69373 Lyon 08, France.
CR Agureev A N, 1997, Aviakosm Ekolog Med, V31, P47
   ALLEN MJ, 1989, J PHYSIOL-LONDON, V410, P341, DOI 10.1113/jphysiol.1989.sp017536
   CHARLES JB, 1994, J CLIN PHARMACOL, V34, P571, DOI 10.1002/j.1552-4604.1994.tb02009.x
   Convertino V., 1996, HDB PHYSL 4, V3, P815, DOI DOI 10.1002/CPHY.CP040236
   Convertino VA, 1998, AM J PHYSIOL-REG I, V275, pR1909
   Convertino VA, 1998, AVIAT SPACE ENVIR MD, V69, P875
   DALLMAN MF, 1984, STRESS ROLE CATECHOL, V2, P1057
   FORTNEY SM, 1991, AVIAT SPACE ENVIR MD, V62, P97
   FORTNEY SM, 1991, J CLIN PHARMACOL, V31, P888, DOI 10.1002/j.1552-4604.1991.tb03644.x
   FORTNEY SM, 1996, HDB PHYSL 4, V2, P889, DOI DOI 10.1002/CPHY.CP040239
   FRITSCHYELLE JM, 1994, J APPL PHYSIOL, V77, P1776
   Gharib C, 1992, Adv Space Biol Med, V2, P113, DOI 10.1016/S1569-2574(08)60019-2
   GHARIB C, 1992, AVIAT SPACE ENVIR MD, V63, P3
   GREENLEAF JE, 1992, J APPL PHYSIOL, V72, P1887
   GREENLEAF JE, 1977, J APPL PHYSIOL, V42, P67
   GRIGORIEV AI, 1992, J BONE MINER RES, V7, pS449, DOI 10.1002/jbmr.5650071416
   GRIGORIEV AI, 1994, CLIN INVESTIGATOR, V72, P169
   GRIGORIEV AI, 1983, AVIAT SPACE ENVIR MD, V54, P318
   GUELL A, 1991, AVIAT SPACE ENVIR MD, V62, P331
   HORDINSKY JR, 1981, AVIAT SPACE ENVIR MD, V52, P16
   HUGHSON RL, 1994, J APPL PHYSIOL, V77, P69
   Johansen LB, 1997, CLIN PHYSIOL, V17, P203, DOI 10.1046/j.1365-2281.1997.02626.x
   JOHNSON PC, 1979, ACTA ASTRONAUT, V6, P1335, DOI 10.1016/0094-5765(79)90125-5
   JONES RF, 1974, J APPL PHYSIOL, V36, P323
   Koryak Y, 1998, EUR J APPL PHYSIOL O, V78, P128, DOI 10.1007/s004210050397
   Kotovskaia A R, 1998, Aviakosm Ekolog Med, V32, P30
   Kozlovsaya IB, 1995, ACTA ASTRONAUT, V36, P661, DOI 10.1016/0094-5765(95)00156-5
   LEACH CS, 1981, ACTA ASTRONAUT, V8, P977, DOI 10.1016/0094-5765(81)90068-0
   LOUISY F, 1990, EUR J APPL PHYSIOL O, V61, P349, DOI 10.1007/BF00236052
   MAILLET A, 1994, EUR J APPL PHYSIOL O, V68, P497, DOI 10.1007/BF00599519
   Maillet A, 1996, J Gravit Physiol, V3, P37
   Maillet A, 1998, AVIAT SPACE ENVIR MD, V69, P1045
   MAILLET A, 1993, AVIAT SPACE ENVIR MD, V64, P287
   Maillet A, 1998, J Gravit Physiol, V5, P55
   MENNINGER RP, 1969, AEROSPACE MED, V40, P1323
   NICOGOSSIAN AE, 1994, SPACE PHYSL MED, P447
   POLESE A, 1992, AVIAT SPACE ENVIR MD, V63, P467
   SANDLER H, 1978, NASA, P430
   Sigaudo D, 1996, EUR J APPL PHYSIOL O, V73, P28, DOI 10.1007/BF00262806
   Sigaudo D, 1998, AM J PHYSIOL-HEART C, V274, pH1875
   USHAKOV AS, 1978, AVIAT SPACE ENVIR MD, V49, P1184
   VERNIKOS J, 1991, J CLIN PHARMACOL, V31, P974, DOI 10.1002/j.1552-4604.1991.tb03659.x
   White DD, 1996, J APPL PHYSIOL, V80, P1138
NR 43
TC 16
Z9 18
U1 0
U2 1
PU AEROSPACE MEDICAL ASSOC
PI ALEXANDRIA
PA 320 S HENRY ST, ALEXANDRIA, VA 22314-3579 USA
SN 0095-6562
J9 AVIAT SPACE ENVIR MD
JI Aviat. Space Environ. Med.
PD JUL
PY 2000
VL 71
IS 7
BP 706
EP 714
PG 9
WC Public, Environmental & Occupational Health; Medicine, General &
   Internal; Sport Sciences
SC Public, Environmental & Occupational Health; General & Internal
   Medicine; Sport Sciences
GA 329RE
UT WOS:000087921000007
PM 10902934
DA 2021-08-04
ER

PT J
AU Lee, SY
   Chiang, HC
   Lin, CT
   Huang, HM
   Dong, DR
AF Lee, SY
   Chiang, HC
   Lin, CT
   Huang, HM
   Dong, DR
TI Finite element analysis of thermo-debonding mechanism in dental
   composites
SO BIOMATERIALS
LA English
DT Article
DE dental composite; thermal stress; debonding; finite element analysis
ID ACOUSTIC-EMISSION; BOND STRENGTH; STRESS-ANALYSIS; MATRIX;
   MICROFRACTURE; CARBON
AB Finite element method (FEM) has been extensively used for evaluating interfacial status inside biomaterials. This study using FEM was designed to evaluate the thermal stress behavior of a filler-matrix interface. The results were then compared to those of a previous study obtained by a laser thermoacoustic technique (LTAT). The experimental systems (75/25 Bis-GMA/TEGDMA resin reinforced with 0, 25, 50, and 75 wt% 8-mu m silanized/unsilanized BaSiO6) as used in the previous study were modeled in this study. The established finite element models were based on coefficient of thermal expansion (CTE) Mismatch Phenomenon. The mechanical properties of the silane coupling agent, such as elastic modulus and thermal expansion coefficient used in the silanized model, were assumed to have optimal heat flux transfer. A third (imaginary) material was proposed to block the transfer of thermal stress between the filler and matrix in the unsilanized model. The thermal load simulation was based on steady-state thermal analysis. The results showed that: (1) The strain energy and interfacial shearing stress calculated from FEM validate the results from the previous LTAT study. (2) Comparing the stress distribution of silanized and unsilanized FEM models, the acoustic signals in LTAT study are mainly derived from debonding of the filler-matrix interface of silanized specimens, and from the matrix area of unsilanized specimens. Based on results to date. we conclude that the finite element method may be a powerful tool for exploring thermoacoustic mechanisms of dental composites. (C) 2000 Elsevier Science Ltd. All rights reserved.
C1 Taipei Med Coll, Grant Inst Oral Rehabil Sci, Taipei, Taiwan.
   Wan Fang Hosp, Dept Dent, Taipei, Taiwan.
   Taipei Med Coll, Sch Med Technol, Taipei, Taiwan.
   Natl Def Med Ctr, Sch Dent, Taipei, Taiwan.
RP Lee, SY (corresponding author), Taipei Med Coll, Grant Inst Oral Rehabil Sci, 250 Wu Hsing St, Taipei, Taiwan.
CR BOLL DJ, 1990, J COMPOS MATER, V24, P208, DOI 10.1177/002199839002400205
   BROUTMAN LJ, 1968, STP ASTM, V452, P27
   Duray SJ, 1996, DENT MATER, V12, P13, DOI 10.1016/S0109-5641(96)80058-3
   FOWLER CS, 1992, DENT MATER, V8, P265, DOI 10.1016/0109-5641(92)90097-V
   HAMSTAD MA, 1985, EXP MECH, V26, P7
   KATONA TR, 1994, J DENT RES, V73, P1470, DOI 10.1177/00220345940730081201
   KIM KH, 1994, J DENT RES, V73, P499, DOI 10.1177/00220345940730020301
   KIM KH, 1991, J BIOMED MAT ENG, V1, P49
   Kondo S, 1985, Dent Mater J, V4, P81
   LEE SY, 2000, IN PRESS J ORAL REHA
   LIN CT, 2000, IN PRESS J DENT RES
   MCMAHON PE, 1973, STP ASTM, V521, P367
   MILES W, 1992, STRAIN MEASUREMENT B, P169
   MOHSEN NM, 1995, J ORAL REHABIL, V22, P183, DOI 10.1111/j.1365-2842.1995.tb01562.x
   NARISAWA I, 1984, J MATER SCI, V19, P1777, DOI 10.1007/BF00550247
   NARKIS M, 1988, POLYM COMPOSITE, V9, P245, DOI 10.1002/pc.750090402
   PETERS PWM, 1987, J COMPOS MATER, V21, P157, DOI 10.1177/002199838702100206
   PLUEDDEMANN EP, 1982, SILANE COUPLING AGEN, P139
   POLVANI RS, 1988, J TEST EVAL, V16, P12
   REDDY JN, 1984, INTRO FINITE ELEMENT, pCH1
   ROY C, 1988, POLYM COMPOSITE, V9, P345, DOI 10.1002/pc.750090507
   SACHSE W, 1987, ULTRASONICS, V25, P195, DOI 10.1016/0041-624X(87)90033-3
   SODERHOLM KJM, 1984, J DENT RES, V63, P1321, DOI 10.1177/00220345840630111401
   SODERHOLM KJM, 1985, FILLER SYSTEMS RESIN, P139
   TUMMALA RR, 1970, J APPL PHYS, V41, P5104, DOI 10.1063/1.1658618
   VANNOORT R, 1988, J DENT, V16, P286, DOI 10.1016/0300-5712(88)90129-7
   VANNOORT R, 1991, J DENT RES, V70, P889, DOI 10.1177/00220345910700050501
   VANNOORT R, 1989, J DENT, V17, P61, DOI 10.1016/0300-5712(89)90131-0
   WILLIAMS JH, 1978, J COMPOS MATER, V12, P348, DOI 10.1177/002199837801200402
   Winkler MM, 1996, J DENT RES, V75, P1477, DOI 10.1177/00220345960750070701
   WU WL, 1990, SAMPE J, V26, P11
   YUYAMA S, 1988, J ACOUST SOC AM, V83, P976, DOI 10.1121/1.395975
   ZAHAVI E, 1992, FINITE ELEMENT METHO, pCH1
NR 33
TC 16
Z9 18
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD JUL
PY 2000
VL 21
IS 13
BP 1315
EP 1326
DI 10.1016/S0142-9612(99)00217-3
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 315BF
UT WOS:000087092200002
PM 10850925
DA 2021-08-04
ER

PT J
AU Casadevall, G
   Turull, A
   Piera, C
   Queralt, J
AF Casadevall, G
   Turull, A
   Piera, C
   Queralt, J
TI Simultaneous technetium-99 MAG(3), iodine-131-orthoiodohippurate and
   iodine-125 iothalamate clearance and biodistribution after bolus
   injection in rats
SO BIOPHARMACEUTICS & DRUG DISPOSITION
LA English
DT Article
DE technetium-99m MAG(3) clearance); iodine-131-orthoiodohippurate
   clearance; iodine-125 iothalamate clearance; glomerular filtration rate;
   renal blood flow; biodistribution; rat
ID GLOMERULAR-FILTRATION-RATE; RENAL PLASMA-FLOW; SINGLE-INJECTION; I-125
   IOTHALAMATE; I-131 OIH; HIPPURAN; MAG3; KINETICS; PROGRAM
AB A bolus injection multiple blood sampling method was developed for the simultaneous measurement of blood and plasma clearance of three radiopharmaceuticals in rats. Technetium-99m mercaptoacetyltriglycine ([Tc-99m]MAG(3)) and iodine-131-orthoiodohippurate ([I-131]OIH) were used as makers of effective renal blood now (ERBF), and iodine-125 iothalamate ([I-125]IOT) was used as a marker of glomerular filtration rate (GFR). These methods can be easily performed in rats without arterial catheterization. Tissue biodistribution was studied in four groups of rats subjected to the following: group A, renal pedicle isolation (sham-operated); group B, ligature of one kidney pedicle; group C, ligature of both renal pedicles; and group D, ligature of both kidney pedicles and the bile duct. Renal clearance of [Tc-99m]MAG(3) was greater than [I-131]OIH and both agents were cleared faster than ([I-125]- IOT). Either of the two markers of ERBF may be used in experimental studies, but it should be borne in mind that these are relative measurements of kidney performance. [99(m)Tc]MAG(3) and [I-125]-IOT showed bile excretion in healthy rats, so they cannot completely fulfill the requirements for use as markers of ERBF. When renal function was impaired experimentally, [Tc-99m]MAG(3) and [I-125]-IOT were excreted in bile and [I-131]OIH was secreted in the intestine. Thus, while the markers of ERBF and GFR may be reliable under normal physiological conditions, they may give progressively more erroneous values as renal function deteriorates. Copyright (C) 2000 John Wiley & Sons, I,td.
C1 Univ Barcelona, Fac Farm, Dept Fisiol, Div 4, E-08028 Barcelona, Spain.
   Hosp Clin & Prov, Unitat Med Nucl, Barcelona, Spain.
RP Queralt, J (corresponding author), Univ Barcelona, Fac Farm, Dept Fisiol, Div 4, Avda Joan XXIII S-N, E-08028 Barcelona, Spain.
CR AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705
   BLAUFOX MD, 1970, AM J PHYSIOL, V218, P542
   BRYAN CW, 1972, J LAB CLIN MED, V80, P845
   CASADEVALL G, 1995, MECH AGEING DEV, V82, P51, DOI 10.1016/0047-6374(95)01598-T
   COVENEY IR, 1988, EUR J NUCL MED, V14, P256
   DUNNE A, 1985, COMPUT METH PROG BIO, V20, P269, DOI 10.1016/0169-2607(85)90085-9
   ESHIMA D, 1987, J NUCL MED, V28, P1180
   FRITZBERG AR, 1986, J NUCL MED, V27, P111
   GAGNON JA, 1971, J APPL PHYSIOL, V30, P774
   GRIFFIN KA, 1993, AM J PHYSIOL, V264, pR1254
   GUTTMAN J, 1982, LINEAR MODELS INTRO
   HARVEY JN, 1988, DIABETES RES CLIN EX, V9, P67
   ITKIN RJ, 1994, AM J VET RES, V55, P1652
   JACKSON EK, 1993, HYPERTENSION, V22, P687
   LEVINSKY R, 1973, HDB PHYSL RENAL PHYS, P103
   MULLERSUUR R, 1986, EUR J NUCL MED, V12, P438, DOI 10.1007/BF00254747
   Palmer BF, 1995, J INVEST MED, V43, P516
   PAVIA J, 1991, NUCL MED COMMUN, V12, P529, DOI 10.1097/00006231-199106000-00007
   REHILING M, 1995, EUR J NUCL MED, V22, P1379
   REHLING M, 1995, CLIN PHYSIOL, V15, P57
   SAPIRSTEIN LA, 1955, AM J PHYSIOL, V181, P330
   SHATTUCK LA, 1994, J NUCL MED, V35, P349
   TAYLOR A, 1994, HYPERTENSION, V23, P96, DOI 10.1161/01.HYP.23.1.96
   TAYLOR A, 1988, J NUCL MED, V29, P616
   TAYLOR A, 1988, J NUCL MED, V29, P669
   TAYLOR A, 1985, J NUCL MED, V26, P77
   YAMAOKA K, 1981, J PHARMACOBIO-DYNAM, V4, P879, DOI 10.1248/bpb1978.4.879
NR 27
TC 1
Z9 1
U1 0
U2 1
PU JOHN WILEY & SONS LTD
PI W SUSSEX
PA BAFFINS LANE CHICHESTER, W SUSSEX PO19 1UD, ENGLAND
SN 0142-2782
J9 BIOPHARM DRUG DISPOS
JI Biopharm. Drug Dispos.
PD JUL
PY 2000
VL 21
IS 5
BP 181
EP 192
DI 10.1002/1099-081X(200007)21:5<181::AID-BDD227>3.0.CO;2-J
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 395ZD
UT WOS:000166611100003
PM 11180197
DA 2021-08-04
ER

PT J
AU Tixier, J
   Pimienta, V
   Buhse, T
   Lavabre, D
   Nagarajan, R
   Micheau, JC
AF Tixier, J
   Pimienta, V
   Buhse, T
   Lavabre, D
   Nagarajan, R
   Micheau, JC
TI Ester containing aggregates in the autocatalytic biphasic hydrolysis of
   ethyl alkanoate
SO COLLOIDS AND SURFACES A-PHYSICOCHEMICAL AND ENGINEERING ASPECTS
LA English
DT Article; Proceedings Paper
CT 72nd ACS Colloid and Surface Science Symposium
CY JUN, 1998
CL PENN ST UNIV, UNIVERSITY PK, PENNSYLVANIA
SP Amer Chem Soc Div Colloid & Surface Chem
HO PENN ST UNIV
DE autocatalytic biphasic hydrolysis; ethyl alkanoates; kinetic model
ID WATER OIL INTERFACE; MICELLES; SOLUBILIZATION; SIMULATIONS; DYNAMICS
AB Autocatalytic kinetics are observed during the biphasic alkaline hydrolysis of C-4, C-6 and C-8 (butanoate, hexanoate and octanaoate) ethyl esters. Ethanol and alkanoate anions are the products of the reaction. A kinetic model including spontaneous dissolution of the organic phase into the aqueous phase, aqueous hydrolysis of the ester, formation of ester containing aggregates and micellisation has been proposed. For C-4, taking into account salting-in and solvent effects is sufficient to reproduce the autocatalytic behaviour. For C-8, the major autocatalytic process is an ester containing aggregates (ECA) mediated phase transfer. For C-6, it appears that the role of ECA is double. Small sized ECA which are formed at the beginning of the reaction do not perform rapid phase transfer and trap surfactant molecules. Larger ECA which appear at the end of the reaction are the main phase transfer agent. Using an empirical formula to describe the size of the interface, the model is able to reproduce the effect of a variation of the volumic ratio of the two phases as well as the effect of stirring rate and non-emulsified experiments. (C) 2000 Elsevier Science B.V. All rights reserved.
C1 Univ Toulouse 3, CNRS, UMR 5623, Lab IMRCP, F-31062 Toulouse, France.
   Penn State Univ, Dept Chem Engn, University Pk, PA 16802 USA.
RP Micheau, JC (corresponding author), Univ Toulouse 3, CNRS, UMR 5623, Lab IMRCP, 118 Route Narbonne, F-31062 Toulouse, France.
RI TIXIER, jerome/M-7831-2016; Buhse, Thomas/H-9156-2019
OI Nagarajan, Ramanathan/0000-0003-4758-2231; Tixier,
   Jerome/0000-0001-8513-5104; Buhse, Thomas/0000-0001-5082-0873
CR ABRAHAM MH, 1984, J CHEM SOC FARAD T 1, V80, P153, DOI 10.1039/f19848000153
   BACHMANN PA, 1992, NATURE, V357, P57, DOI 10.1038/357057a0
   BENJAMIN L, 1964, J PHYS CHEM-US, V68, P3575, DOI 10.1021/j100794a023
   Buhse T, 1998, J PHYS CHEM A, V102, P10552, DOI 10.1021/jp982765n
   Buhse T, 1997, J PHYS CHEM A, V101, P3910, DOI 10.1021/jp9705838
   Davies G, 1940, J CHEM SOC, P339, DOI 10.1039/jr9400000339
   Evans DP, 1938, J CHEM SOC, P1439, DOI 10.1039/jr9380001439
   GROS AT, 1952, J AM OIL CHEM SO AUG, P313
   KARABORNI S, 1993, LANGMUIR, V9, P1175, DOI 10.1021/la00029a004
   SMIT B, 1990, NATURE, V348, P624, DOI 10.1038/348624a0
   SMIT B, 1991, J PHYS CHEM-US, V95, P6361, DOI 10.1021/j100169a052
   WANG SQ, 1990, J PHYS CHEM-US, V94, P8381, DOI 10.1021/j100385a001
   Wattis JAD, 1997, J CHEM PHYS, V106, P9122, DOI 10.1063/1.474018
   Weiss J, 1996, J PHYS CHEM-US, V100, P1066, DOI 10.1021/jp9524892
NR 14
TC 6
Z9 6
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-7757
J9 COLLOID SURFACE A
JI Colloid Surf. A-Physicochem. Eng. Asp.
PD JUN 30
PY 2000
VL 167
IS 1-2
BP 131
EP 142
DI 10.1016/S0927-7757(99)00470-7
PG 12
WC Chemistry, Physical
SC Chemistry
GA 298CT
UT WOS:000086122300013
DA 2021-08-04
ER

PT J
AU Shohet, RV
   Chen, SY
   Zhou, YT
   Wang, ZW
   Meidell, RS
   Unger, TH
   Grayburn, PA
AF Shohet, RV
   Chen, SY
   Zhou, YT
   Wang, ZW
   Meidell, RS
   Unger, TH
   Grayburn, PA
TI Echocardiographic destruction of albumin microbubbles directs gene
   delivery to the myocardium
SO CIRCULATION
LA English
DT Article
DE echocardiography; gene therapy; microbubbles
ID IN-VIVO; DIRECT-INJECTION; THERAPY; ADENOVIRUS; ULTRASOUND;
   ANGIOGENESIS; EXPRESSION; VECTORS; DISEASE; TISSUE
AB Background-The noninvasive, tissue-specific delivery of therapeutic agents to the heart would be a valuable clinical tool. This study addressed the hypothesis that albumin-coated microbubbles could be used to effectively deliver an adenoviral transgene to rat myocardium by ultrasound-mediated microbubble destruction,
   Methods and Results-Recombinant adenovirus containing beta-galactosidase and driven by a constitutive promoter was attached to the surface of albumin-coated, perfluoropropane-filled microbubbles, These bubbles were infused into the jugular vein of rats with or without simultaneous echocardiography. Additional controls included ultrasound of microbubbles that did not contain virus, virus alone, and virus plus ultrasound. One group underwent ultrasound-mediated destruction of microbubbles followed by adenovirus infusion. Rats were killed after 4 days and examined for beta-galactosidase expression. The hearts of all rats that underwent ultrasound-mediated destruction of microbubbles containing virus showed nuclear staining with 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside substrate, indicating expression of the transgene. None of the control animals showed myocardial expression of the beta-galactosidase transgene. By quantitative analysis, beta-galactosidase activity was 10-fold higher in the treated group than in controls (P<0.0001).
   Conclusions-Ultrasound-mediated destruction of albumin-coated microbubbles is a promising method for the delivery of bioactive agents to the heart.
C1 VA Med Ctr, Div Cardiol 111A, Dallas, TX 75216 USA.
   Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX USA.
RP Grayburn, PA (corresponding author), VA Med Ctr, Div Cardiol 111A, 4500 S Lancaster Rd, Dallas, TX 75216 USA.
RI Shohet, ralph V/A-1731-2011
FU NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [K24HL003980] Funding
   Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Heart Lung & Blood Institute (NHLBI) [1 K24 HL03980-01] Funding Source:
   Medline
CR Anderson WF, 1998, NATURE, V392, P25
   BARR E, 1994, GENE THER, V1, P51
   BLAESE RM, 1995, SCIENCE, V270, P475, DOI 10.1126/science.270.5235.475
   Chen GX, 1996, P NATL ACAD SCI USA, V93, P14795, DOI 10.1073/pnas.93.25.14795
   FRENCH BA, 1994, CIRCULATION, V90, P2414, DOI 10.1161/01.CIR.90.5.2414
   GERARD RD, 1995, DNA CLONING PRACTICA
   GUZMAN RJ, 1993, CIRC RES, V73, P1202, DOI 10.1161/01.RES.73.6.1202
   KASSEISLER A, 1993, P NATL ACAD SCI USA, V90, P11498, DOI 10.1073/pnas.90.24.11498
   Kay MA, 1997, P NATL ACAD SCI USA, V94, P12744, DOI 10.1073/pnas.94.24.12744
   Lee JS, 1998, NAT MED, V4, P739, DOI 10.1038/nm0698-739
   LIN H, 1990, CIRCULATION, V82, P2217, DOI 10.1161/01.CIR.82.6.2217
   Main ML, 1999, AM HEART J, V137, P144, DOI 10.1016/S0002-8703(99)70470-9
   NABEL EG, 1995, CIRCULATION, V91, P541, DOI 10.1161/01.CIR.91.2.541
   Porter TR, 1996, J ULTRAS MED, V15, P577
   Porter TR, 1997, J AM COLL CARDIOL, V29, P791, DOI 10.1016/S0735-1097(96)00575-X
   Price RJ, 1998, CIRCULATION, V98, P1264, DOI 10.1161/01.CIR.98.13.1264
   Rosengart TK, 1999, CIRCULATION, V100, P468, DOI 10.1161/01.CIR.100.5.468
   Skyba DM, 1998, CIRCULATION, V98, P290, DOI 10.1161/01.CIR.98.4.290
   Unger EC, 1997, INVEST RADIOL, V32, P723, DOI 10.1097/00004424-199712000-00001
   Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410
   Wei K, 1997, J AM COLL CARDIOL, V29, P1081, DOI 10.1016/S0735-1097(97)00029-6
NR 21
TC 361
Z9 434
U1 1
U2 26
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD JUN 6
PY 2000
VL 101
IS 22
BP 2554
EP 2556
DI 10.1161/01.CIR.101.22.2554
PG 3
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 320ZU
UT WOS:000087431100003
PM 10840004
OA Bronze, Green Published
DA 2021-08-04
ER

PT J
AU Jim, KC
   Giles, CL
AF Jim, KC
   Giles, CL
TI Talking helps: Evolving communicating agents for the predator-prey
   pursuit problem
SO ARTIFICIAL LIFE
LA English
DT Article
DE multi-agent communication; agent communication languages; multi-agent
   simulation; evolution of agents
AB We analyze a general model of multi-agent communication in which all agents communicate simultaneously to a message board. A genetic algorithm is used to evolve multi-agent languages for the predator agents in a version of the predator-prey pursuit problem. We show that the resulting behavior of the communicating multi-agent system is equivalent to that of a Mealy finite state machine whose states are determined by the agents' usage of the evolved language. Simulations show that the evolution of a communication language improves the performance of the predators. Increasing the language size (and thus increasing the number of possible states in the Mealy machine) improves the performance even further. Furthermore, the evolved communicating predators perform significantly better than all previous work on similar prey. We introduce a method for incrementally increasing the language size, which results in an effective coarse-to-fine search that significantly reduces the evolution time required to find a solution. We present some observations on the effects of language size, experimental setup, and prey difficulty on the evolved Mealy machines. In particular, we observe that the start state is often revisited, and incrementally increasing the language size results in smaller Mealy machines. Finally, a simple rule is derived that provides a pessimistic estimate on the minimum language size that should be used for any multi-agent problem.
C1 NEC Res Inst, Princeton, NJ 08540 USA.
   Physiome Sci Inc, Princeton, NJ 08540 USA.
   Penn State Univ, Sch Informat Sci & Technol & Comp Sci & Engn, University Pk, PA 16801 USA.
RP Jim, KC (corresponding author), NEC Res Inst, 4 Independence Way, Princeton, NJ 08540 USA.
EM kamjim@research.nj.nec.com; giles@ist.psu.edu
OI Giles, C Lee/0000-0002-1931-585X
CR ACKLEY D, 1994, ARTIF LIFE, V4, P40
   Balch T., 1994, AUTON ROBOT, V1, P1, DOI DOI 10.1007/BF00735341
   BENDA M, 1985, OPTIMAL COOPERATION
   BROOKS RA, 1991, FROM ANIMALS TO ANIMATS, P434
   De Jong K. A., 1992, Annals of Mathematics and Artificial Intelligence, V5, P1
   Deb D. G. K., 1991, FDN GENETIC ALGORITH, P69, DOI DOI 10.1016/B978-0-08-050684-5.50008-2
   GMYTRASIEWICZ PJ, 1995, P 1 INT C MULT SYST, P125
   GMYTRASIEWICZ PJ, 1995, AAAI FALL S EMB LANG, P35
   HASIDA K, 1995, P 1 INT C MULT SYST, P140
   Haynes T., 1996, Adaption and Learning in Multi-Agent Systems. IJCAI '95 Workshop. Proceedings, P113
   KORF RE, 1992, 11 INT WORKSH DISTR, P183
   LABROU Y, 1994, P 3 INT C INF KNOWL, P447
   MacLennan Bruce J., 1993, Adaptive Behavior, V2, P161, DOI 10.1177/105971239300200203
   Nishimura Shin I., 1997, Artificial Life, V3, P243, DOI 10.1162/artl.1997.3.4.243
   NOLFI S, 1998, ARTIF LIFE, V4, P337
   SAUNDERS GM, 1996, ANIMALS ANIMATS, V4, P580
   Savill Nicholas J., 1997, Artificial Life, V3, P81, DOI 10.1162/artl.1997.3.2.81
   Searle John R., 1969, SPEECH ACTS ESSAY PH, V626
   STEELS L, 1996, P AL, V5
   STEPHENS LM, 1990, P 10 INT WORKSH DAI
   Tan M., 1993, P 10 INT C MACH LEAR, P330
   WALKER A, 1995, P 1 INT C MULT SYST, P384
NR 22
TC 41
Z9 43
U1 0
U2 4
PU MIT PRESS
PI CAMBRIDGE
PA ONE ROGERS ST, CAMBRIDGE, MA 02142-1209 USA
SN 1064-5462
EI 1530-9185
J9 ARTIF LIFE
JI Artif. Life
PD SUM
PY 2000
VL 6
IS 3
BP 237
EP 254
DI 10.1162/106454600568861
PG 18
WC Computer Science, Artificial Intelligence; Computer Science, Theory &
   Methods
SC Computer Science
GA 404GL
UT WOS:000167089000004
PM 11224918
OA Green Accepted
DA 2021-08-04
ER

PT J
AU Grossman, M
   Kalmanson, J
   Bernhardt, N
   Morris, J
   Stern, MB
   Hurtig, HI
AF Grossman, M
   Kalmanson, J
   Bernhardt, N
   Morris, J
   Stern, MB
   Hurtig, HI
TI Cognitive resource limitations during sentence comprehension in
   Parkinson's disease
SO BRAIN AND LANGUAGE
LA English
DT Article
ID ADULT AGE-DIFFERENCES; WORKING MEMORY; INDIVIDUAL-DIFFERENCES; SYNTAX
   COMPREHENSION; ALZHEIMERS-DISEASE; DEFICITS; CAPACITY; ATTENTION;
   STRATEGIES; CLAUSES
AB Patients with idiopathic Parkinson's disease (PD) were asked to identify the agent of the action in orally presented sentences with subject-relative or object-relative center-embedded clauses while simultaneously performing a secondary task that was less resource-demanding (finger tapping) or more resource-demanding (recognition span). We found that a subgroup of PD patients with impaired sentence comprehension at baseline (no secondary task) did not differ from random in their accuracy understanding all types of sentences during the more demanding (recognition span) condition and also had difficulty understanding the most complex sentences during the less demanding (finger tapping) condition. Control subjects and PD patients without baseline sentence comprehension difficulty were random only in their comprehension of the most complex sentences under the more demanding (recognition span) secondary task condition. Examination of response latencies for accurately understood sentences revealed only an effect for the type of sentence, and this was equally evident across all groups of subjects and regardless of the condition under which the sentences were administered. The sensitivity of PD patients' sentence comprehension accuracy to secondary task resource demands is most consistent with the hypothesis that limited cognitive resources contribute to sentence comprehension difficulty in PD. (C) 2000 Academic Press.
C1 Univ Penn, Med Ctr, Dept Neurol, Philadelphia, PA 19104 USA.
RP Grossman, M (corresponding author), Hosp Univ Penn, Dept Neurol, Cognit Neurol Sect, 3 Gates,3400 Spruce St, Philadelphia, PA 19104 USA.
FU NIA NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)
   [AG15116] Funding Source: Medline; NINDS NIH HHSUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Neurological Disorders & Stroke (NINDS) [NS35867]
   Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS
   AND STROKEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Neurological
   Disorders & Stroke (NINDS) [R01NS035867] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Aging (NIA) [R01AG015116] Funding Source: NIH RePORTER
CR BLACKWELL A, 1995, J COGNITIVE NEUROSCI, V7, P228, DOI 10.1162/jocn.1995.7.2.228
   BROWN RG, 1991, BRAIN, V114, P215
   BROWN RG, 1988, BRAIN, V111, P325
   CAPLAN D, 1985, COGNITION, V21, P117, DOI 10.1016/0010-0277(85)90048-4
   Caplan D, 1988, DISORDERS SYNTACTIC
   Chomsky N., 1981, LECT GOVT BINDING
   CLEMENTS GN, 1983, LINGUIST INQ, V14, P1
   Craik F. I. M., 1990, NEUROPSYCHOLOGICAL I, P247
   DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6
   DANEMAN M, 1983, J EXP PSYCHOL LEARN, V9, P561, DOI 10.1037/0278-7393.9.4.561
   DANEMAN M, 1987, ATTENTION PERFORM, V12, P491
   ENGLE RW, 1992, J EXP PSYCHOL LEARN, V18, P972, DOI 10.1037/0278-7393.18.5.972
   Fodor J. A., 1983, MODULARITY MIND ESSA
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   FORD M, 1983, J VERB LEARN VERB BE, V22, P203, DOI 10.1016/S0022-5371(83)90156-1
   GEYER HL, 1994, J NEUROLINGUIST, V8, P191, DOI 10.1016/0911-6044(94)90026-4
   GROSSMAN M, 1992, BRAIN LANG, V42, P347, DOI 10.1016/0093-934X(92)90074-O
   GROSSMAN M, 1991, NEUROLOGY, V41, P1620
   GROSSMAN M, 1994, BRAIN LANG, V44, P351
   HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427
   JUST MA, 1992, PSYCHOL REV, V99, P122, DOI 10.1037/0033-295X.99.1.122
   KEMMERER DL, UNPUB INVESTIGATION
   Lang A.E.T., 1989, QUANTIFICATION NEURO, P285
   LIEBERMAN P, 1992, BRAIN LANG, V43, P169, DOI 10.1016/0093-934X(92)90127-Z
   LIEBERMAN P, 1990, J NERV MENT DIS, V178, P360, DOI 10.1097/00005053-199006000-00003
   Maddox WT, 1996, NEUROPSYCHOLOGY, V10, P197, DOI 10.1037/0894-4105.10.2.197
   MCELREE B, 1989, J PSYCHOLINGUIST RES, V18, P21, DOI 10.1007/BF01069044
   MCNAMARA P, 1992, BRAIN LANG, V42, P38, DOI 10.1016/0093-934X(92)90055-J
   Miller G.A., 1978, LINGUISTIC THEORY PS, P119
   MIYAKE A, 1994, COGNITIVE NEUROPSYCH, V11, P671, DOI 10.1080/02643299408251989
   NATSOPOULOS D, 1993, NEUROPSYCHOLOGIA, V31, P951, DOI 10.1016/0028-3932(93)90150-X
   NATSOPOULOS D, 1991, CORTEX, V27, P255, DOI 10.1016/S0010-9452(13)80130-X
   NICOL J, 1989, J PSYCHOLINGUIST RES, V18, P5, DOI 10.1007/BF01069043
   SALTHOUSE TA, 1991, PSYCHOL SCI, V2, P179, DOI 10.1111/j.1467-9280.1991.tb00127.x
   Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403
   SHARPE MH, 1992, NEUROPSYCHOLOGIA, V30, P101, DOI 10.1016/0028-3932(92)90019-I
   TAYLOR AE, 1986, BRAIN, V109, P845, DOI 10.1093/brain/109.5.845
   TURNER ML, 1989, J MEM LANG, V28, P127, DOI 10.1016/0749-596X(89)90040-5
   Ullman MT, 1997, J COGNITIVE NEUROSCI, V9, P266, DOI 10.1162/jocn.1997.9.2.266
   WATERS GS, 1995, COGN NEUROPSYCHOL, V12, P1, DOI 10.1080/02643299508251990
NR 40
TC 59
Z9 60
U1 0
U2 9
PU ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0093-934X
J9 BRAIN LANG
JI Brain Lang.
PD JUN 1
PY 2000
VL 73
IS 1
BP 1
EP 16
DI 10.1006/brln.2000.2290
PG 16
WC Audiology & Speech-Language Pathology; Linguistics; Neurosciences;
   Psychology, Experimental
SC Audiology & Speech-Language Pathology; Linguistics; Neurosciences &
   Neurology; Psychology
GA 319EU
UT WOS:000087329200001
PM 10872635
DA 2021-08-04
ER

PT J
AU Ahmad, S
   Yang, LH
   Ahsan, A
   Fu, K
   Iqbal, O
   Hoppensteadt, DA
   Lewis, BE
   Walenga, JM
   Fareed, J
AF Ahmad, S
   Yang, LH
   Ahsan, A
   Fu, K
   Iqbal, O
   Hoppensteadt, DA
   Lewis, BE
   Walenga, JM
   Fareed, J
TI Pharmacokinetics of argatroban in primates: Evidence on endogenous
   uptake
SO INTERNATIONAL ANGIOLOGY
LA English
DT Article
DE antithrombins; pipecolic acids, pharmacokinetics
ID HEPARIN-INDUCED THROMBOCYTOPENIA; THROMBOSIS SYNDROME;
   PLASMINOGEN-ACTIVATOR; PLATELET-AGGREGATION; ARTERIAL THROMBOSIS;
   ANTICOAGULATION; INHIBITOR; NOVASTAN(R); BINDING; TIME
AB Background. Antithrombin agent, argatroban, is currently undergoing several clinical trials for cardiovascular indications. Because of its solubility, this drug is usually administered ria an intravenous bolus followed by infusion. The purpose of this study was to determine the pharmacokinetics of argatroban after intravenous bolus injection in primates.
   Methods. Parallel in vitro studies in primate whole blood were carried out to simulate a one-compartment system. Argatroban (range 1.0-7.5 mg/kg) was administered to four groups of primates and blood samples were drawn at various time periods. Argatroban measurements were made in plasma using functional (aPTT, Heptest, TT) and HPLC methods.
   Results. In vitro, argatroban primarily distributed in the plasma in proportionate amounts. Relative uptake of argatroban to the blood cells (leukocytes and erythrocytes) was minimum. However, in vitro, argatroban followed a complex pharmacokinetics, Within 5 min after the bolus administration, only <20% of argatroban was recovered. The recovered amount tvas proportionate to the dosage and followed the expected kinetics with a half-life of <20 min. Simultaneous quantitation of M1-metabolite of argatroban revealed only a fraction of recovered argatroban (similar to 25%) converted into M1 in these experimental settings. Results obtained from the functional and absolute methods correlated well. HPLC profile did not reveal the presence of any other metabolite(s),
   Conclusions. These observations suggest that argatroban mag be endogenously taken up by the vascular or other sites and may exhibit a complex kinetics. In acute settings, the metabolic transformation of argatroban to M1 is relatively low. To further clarify the pharmacokinetics/pharmacodynamics of this drug, additional studies are warranted.
C1 Loyola Univ, Stritch Sch Med, Dept Pathol Pharmacol & Thorac Cardiovasc Surg, Maywood, IL 60153 USA.
RP Fareed, J (corresponding author), Loyola Univ, Stritch Sch Med, Dept Pathol Pharmacol & Thorac Cardiovasc Surg, 2160 S 1st Ave, Maywood, IL 60153 USA.
RI Ahsan, Amimul/S-5068-2019
OI Ahsan, Amimul/0000-0002-0015-6123
CR Ahmad S, 1998, CLIN APPL THROMB-HEM, V4, P243, DOI 10.1177/107602969800400405
   Ahmad S, 1999, INT ANGIOL, V18, P198
   AHMAD S, IBC LIB SERIES, V1924, P233
   BANNER DW, 1991, J BIOL CHEM, V266, P20085
   Berry CN, 1998, THROMB HAEMOSTASIS, V79, P228
   BERRY CN, 1994, BRIT J PHARMACOL, V113, P1209, DOI 10.1111/j.1476-5381.1994.tb17126.x
   BODE W, 1990, EUR J BIOCHEM, V193, P175, DOI 10.1111/j.1432-1033.1990.tb19320.x
   CLARKE RJ, 1991, CIRCULATION, V83, P1510, DOI 10.1161/01.CIR.83.5.1510
   EIDT JF, 1989, J CLIN INVEST, V84, P18, DOI 10.1172/JCI114138
   Fitzgerald D, 1996, CORONARY ARTERY DIS, V7, P455, DOI 10.1097/00019501-199606000-00008
   FITZGERALD DJ, 1989, P NATL ACAD SCI USA, V86, P7585, DOI 10.1073/pnas.86.19.7585
   Jang IK, 1998, J THROMB THROMBOLYS, V5, P49, DOI 10.1023/A:1008872031770
   JANG IK, 1990, CIRCULATION, V81, P219, DOI 10.1161/01.CIR.81.1.219
   KAWAI H, 1994, THROMB RES, V74, P185, DOI 10.1016/0049-3848(94)90107-4
   KUMADA T, 1981, THROMB RES, V24, P285, DOI 10.1016/0049-3848(81)90002-5
   Lewis BE, 1996, J INVASIVE CARDIOL, V8, P410
   Lewis BE, 1998, ANGIOLOGY, V49, P61
   Lewis BE, 1997, SEMIN THROMB HEMOST, V23, P197, DOI 10.1055/s-2007-996091
   Walenga JM, 1999, SEMIN HEMATOL, V36, P22
NR 19
TC 2
Z9 2
U1 0
U2 1
PU EDIZIONI MINERVA MEDICA
PI TURIN
PA CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY
SN 0392-9590
EI 1827-1839
J9 INT ANGIOL
JI Int. Angiol.
PD JUN
PY 2000
VL 19
IS 2
BP 126
EP 134
PG 9
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 323XL
UT WOS:000087590200003
PM 10905795
DA 2021-08-04
ER

PT J
AU Ushiwata, O
   de Moraes, JV
   Bottino, MA
   da Silva, EG
AF Ushiwata, O
   de Moraes, JV
   Bottino, MA
   da Silva, EG
TI Marginal fit of nickel-chromium copings before and after internal
   adjustments with duplicated stone dies and disclosing agent
SO JOURNAL OF PROSTHETIC DENTISTRY
LA English
DT Article
ID CAST RESTORATIONS; IMPROVE; CROWNS
AB Statement of problem. Despite careful procedures, master stone dies may be damaged during laboratory procedures. The dentist routinely adjusts castings because the marginal fit of casting is not as accurate as on the dies.
   Purpose. This study evaluated the technique of internal adjustment of castings with use of duplicated stone dies and a disclosing agent to improve marginal fit discrepancy.
   Material and methods. Thirty-two nickel-chromium copings were fabricated and simulated standard clinical and laboratory procedures with 2 variables: tooth preparation convergence angles of 6 and 18 degrees, with or without internal relief. Master stone dies and their duplicates were selected for coping construction and internal adjustment, respectively. A specimen positioning device was coupled with a Toolmakers microscope to allow reproducibility of measurements. Each coping was evaluated at 8 locations of its marginal perimeter, before and after internal adjustment.
   Results. Marginal fit discrepancy of copings were significantly reduced with an internal adjustment technique (mean > 52%) for all experimental groups. Tooth preparations with greater convergence and internally relieved castings recorded a better marginal fit.
   Conclusion. The casting internal adjustment technique with use of duplicated stone dies and a disclosing agent substantially reduced marginal fit discrepancy.
C1 Univ State Sao Paulo, Sao Jose Campos Sch Dent, Dent Mat & Prosthodont Dept, Sao Paulo, Brazil.
RP Ushiwata, O (corresponding author), R Carlos Sampaio,304 Cj 81, BR-01311000 Sao Paulo, Brazil.
RI da Silva, Eduardo Galera/ABD-7346-2020
OI da Silva, Eduardo Galera/0000-0002-5536-0535; Bottino, Marco
   Antonio/0000-0003-0077-3161
CR CAMPAGNI WV, 1986, J PROSTHET DENT, V55, P324, DOI 10.1016/0022-3913(86)90112-5
   Davis R D, 1991, Quintessence Int, V22, P631
   DAVIS SH, 1989, J PROSTHET DENT, V62, P288, DOI 10.1016/0022-3913(89)90334-X
   EAMES WB, 1981, J PROSTHET DENT, V45, P283, DOI 10.1016/0022-3913(81)90390-5
   EAMES WB, 1978, J AM DENT ASSOC, V96, P432, DOI 10.14219/jada.archive.1978.0090
   GARDNER FM, 1982, J PROSTHET DENT, V48, P396, DOI 10.1016/0022-3913(82)90072-5
   GRAJOWER R, 1985, J ORAL REHABIL, V12, P235, DOI 10.1111/j.1365-2842.1985.tb00640.x
   KASHANI HG, 1981, J AM DENT ASSOC, V103, P882, DOI 10.14219/jada.archive.1981.0431
   MARKER VA, 1987, J PROSTHET DENT, V57, P425, DOI 10.1016/0022-3913(87)90007-2
   MARTIGNONI M, 1990, PRECISION FIXED PROS, P231
   MILLER LL, 1977, DENT CLIN N AM, V21, P699
   Rosenstiel S.F., 1988, CONTEMPORARY FIXED P, P475
   SCHWARTZ IS, 1986, J PROSTHET DENT, V56, P279, DOI 10.1016/0022-3913(86)90003-X
   Ushiwata O, 2000, J PROSTHET DENT, V83, P362, DOI 10.1016/S0022-3913(00)70141-7
   WHEELER RC, 1969, ATLAS TOOTH FORM, P23
   White S N, 1991, Int J Prosthodont, V4, P323
   White S N, 1993, Int J Prosthodont, V6, P248
NR 17
TC 8
Z9 11
U1 0
U2 1
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA
SN 0022-3913
J9 J PROSTHET DENT
JI J. Prosthet. Dent.
PD JUN
PY 2000
VL 83
IS 6
BP 634
EP 643
DI 10.1067/mpr.2000.106551
PG 10
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 325RF
UT WOS:000087689600008
PM 10842130
DA 2021-08-04
ER

PT J
AU Balducelli, C
   D'Esposito, C
AF Balducelli, C
   D'Esposito, C
TI Genetic agents in an EDSS system to optimize resources management and
   risk object evacuation
SO SAFETY SCIENCE
LA English
DT Article; Proceedings Paper
CT 6th Conference of the International-Emergency-Management-Society (TIEMS
   99)
CY 1999
CL DELFT, NETHERLANDS
SP Int Emergency Management Soc
DE multi-agents systems; case-based reasoning; genetic algorithms and
   operators; adaptation and learning; resources management; evacuation
   planning; emergency management
AB Emerging efficient and intelligent behaviors from co-operative activities of many autonomous agents comprise unexpected events that often take place inside animal social organizations. This type of evidence induced artificial intelligence researchers to re-design the artificial computing system architectures, from monolithic and hierarchical structures toward networked and component distributed environments. In this work the co-operative capacity of three different software agents is experimented to front the management problem, emerging during fires emergencies, relative to fire-proof resources optimization and dangerous products evacuation inside large oil storage and production plants. The three software components include, respectively, a repository or memory of past solutions (managed by case-based reasoning methods), the capacity to discovery new solutions (using evolutionary algorithms), and the capacity to verify solutions (using numerical simulation models). The main result of the work was that, from the co-operative activities of these three software components, together with the human agent, the capacity to learn and adapt solutions for the current problem arises as a proper and additional feature of such hybrid system. The general problem of anti-fire resources optimization and evacuation of risk products, during fire emergencies, inside a petrol-chemical plant, is firstly described. Then, the models and the software algorithms, implemented in the three mentioned components, are illustrated in the central part of the work. Finally, a set of test cases are reported, for different scenarios in the physical domain, experimented and analyzed. (C) 2000 Elsevier Science Ltd. All rights reserved.
C1 ENEA Casaccia, I-00060 Rome, Italy.
RP Balducelli, C (corresponding author), ENEA Casaccia, Via Anguillarese 301, I-00060 Rome, Italy.
EM balducelli_c@casaccia.enea.i
CR AAMODT A, 1994, AI COMMUN, V7, P39
   BALDUCELLI C, 1993, P 1 INT ROUND TABL A
   BALDUCELLI C, 1996, P 8 EUR SIM S SIM IN, V2, P298
   CHEN X, 1997, IEEE P SOFTWARE ENG, V144
   Davis L., 1991, HDB GENETIC ALGORITH
   GEYERSCHULZ A, 1996, STUDIES FUZZINESS SO
   Goldberg D., 1989, GENETIC ALGORITHMS S
   Goldberg DE, 1999, GECCO-99: PROCEEDINGS OF THE GENETIC AND EVOLUTIONARY COMPUTATION CONFERENCE, P220
   KOLODNER J., 1993, CASE BASED REASONING
   RICCI F, 1995, LEARNING ASYMMETRIC
   Rich C, 1998, USER MODEL USER-ADAP, V8, P315, DOI 10.1023/A:1008204020038
   WOOLDRIDGE M, 1985, KNOWL ENG REV, P115
NR 12
TC 10
Z9 10
U1 0
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0925-7535
EI 1879-1042
J9 SAFETY SCI
JI Saf. Sci.
PD JUN-AUG
PY 2000
VL 35
IS 1-3
BP 59
EP 73
DI 10.1016/S0925-7535(00)00022-9
PG 15
WC Engineering, Industrial; Operations Research & Management Science
SC Engineering; Operations Research & Management Science
GA 335MT
UT WOS:000088247800005
DA 2021-08-04
ER

PT J
AU Song, YG
   Kwon, HM
   Kim, JM
   Hong, BK
   Kim, DS
   Huh, AJ
   Chang, KH
   Kim, HY
   Kang, TS
   Lee, BK
   Choi, DH
   Jang, YS
   Kim, HS
AF Song, YG
   Kwon, HM
   Kim, JM
   Hong, BK
   Kim, DS
   Huh, AJ
   Chang, KH
   Kim, HY
   Kang, TS
   Lee, BK
   Choi, DH
   Jang, YS
   Kim, HS
TI Serologic and histopathologic study of Chlamydia pneumoniae infection in
   atherosclerosis: A possible pathogenetic mechanism of atherosclerosis
   induced Chlamydia pneumoniae
SO YONSEI MEDICAL JOURNAL
LA English
DT Article
DE Chlamydia pneumoniae; atherosclerosis; cyclooxygenase-2 (COX-2); matrix
   metalloproteinases (MMPs)
ID CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; ARTERY DISEASE; RISK
   FACTOR; TWAR; INFLAMMATION; ATHEROMA; CYTOMEGALOVIRUS; ASSOCIATION;
   PLAQUES
AB Chronic infection and inflammation have recently been implicated as important etiologic agents for atherosclerosis in general and, in particular, ischemic heart disease. Several agents have been suggested as possible candidates for the chronic inflammation including cytomegalovirus, Helicobacter pylori and Chlamydia pneumoniae. We hypothesized that a vascular infection with C. pneumoniae may induce a chronic inflammatory reaction in the host vascular tissue and activated inflammatory cells may express inflammatory mediators such as cyclooxygenase-2 (COX-2) and matrix metalloproteinases (MMPs). At first, we evaluated the relationship between C. pneumoniae infection and atherosclerosis indirectly by serologic study, and then, to confirm our hypothesis, we performed an immunohistochemical study of atherosclerotic plaques. The seropositive rate of anti-Chlamydia pneumoniae IgG was higher in the disease group (Group I, 59.8%, n = 254) than in the negative control group (Group III, 47.4%, n = 97) (p = 0.041), but the anci-Chlamydia pneumoniae IgA was not different in seropositivity between the two groups (Group I, 64.6%; Group III, 57.7%). The simultaneous seropositive rates of both IgG and IgA were 56.7% in Group I and 43.3% in Group III (p = 0.033). Tn subgroups without the conventional risk factors of atherosclerosis, these findings were more prominent. Furthermore, we performed immunohistochemical staining on the atherosclerotic aortic tissues obtained from patients that were seropositive to C. pneumoniae (n = 5), by using antibodies to C. pneumoniae, COX-2, and MMP-9. The immunoreactivity for COX-2 and MMP-9 increased in the atherosclerotic plaques itself, predominantly in the surrounding area of immunoreactive C. pneumoniae. These findings support our hypothesis and C. pneumoniae may participate in a pathogenetic mechanism for atherogenesis or progression of atherosclerosis. The present study may open a promising perspective concerning future therapeutic trials of chronic inflammation related atherogenesis under pathophysiological conditions.
C1 Yonsei Univ, Coll Med, Cardiovasc Res Inst, Dept Internal Med, Seoul 135270, South Korea.
RP Kwon, HM (corresponding author), Yonsei Univ, Coll Med, Yongdong Severance Hosp, Dept Internal Med, POB 1217, Seoul 135270, South Korea.
OI Song, Young Goo/0000-0002-0733-4156; Kwon, Hyuck
   Moon/0000-0001-9901-5015
CR Aikawa M, 1998, CIRCULATION, V97, P2433, DOI 10.1161/01.CIR.97.24.2433
   ALEXANDER RW, 1994, NEW ENGL J MED, V331, P468, DOI 10.1056/NEJM199408183310709
   Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506
   CAMPBELL LA, 1995, J INFECT DIS, V172, P585, DOI 10.1093/infdis/172.2.585
   Cheng JM, 1998, ANN PHARMACOTHER, V32, P1310, DOI 10.1345/aph.18057
   Chiu B, 1997, CIRCULATION, V96, P2144
   Gibbs RGJ, 1998, BRIT J SURG, V85, P1191, DOI 10.1046/j.1365-2168.1998.00861.x
   HE H, 1999, J CLIN INVEST, V103, P747
   JONASSON L, 1986, ARTERIOSCLEROSIS, V6, P131, DOI 10.1161/01.ATV.6.2.131
   Kol A, 1998, CIRCULATION, V98, P300, DOI 10.1161/01.CIR.98.4.300
   KUO CC, 1993, J INFECT DIS, V167, P841, DOI 10.1093/infdis/167.4.841
   KUO CC, 1995, P NATL ACAD SCI USA, V92, P6911, DOI 10.1073/pnas.92.15.6911
   KUO CC, 1995, CLIN MICROBIOL REV, V8, P451, DOI 10.1128/CMR.8.4.451
   LINNANMAKI E, 1993, CIRCULATION, V87, P1130, DOI 10.1161/01.CIR.87.4.1130
   LIUZZO G, 1994, NEW ENGL J MED, V331, P417, DOI 10.1056/NEJM199408183310701
   Mattila KJ, 1998, CLIN INFECT DIS, V26, P719, DOI 10.1086/514570
   MERTZ PM, 1994, J BIOL CHEM, V269, P21322
   Numazaki K, 1996, FEMS IMMUNOL MED MIC, V14, P179, DOI 10.1016/0928-8244(96)00029-6
   Ridker PM, 1998, CIRCULATION, V97, P1671, DOI 10.1161/01.CIR.97.17.1671
   Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401
   ROBINSON DT, 1998, ATHEROSCLEROSIS SUPP, V140, pS21
   ROBINSON DT, 1998, J CLIN PATHOL, V51, P793
   ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0
   SAIKKU P, 1992, ANN INTERN MED, V116, P273, DOI 10.7326/0003-4819-116-4-273
   SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6
   SHOR A, 1992, S AFR MED J, V82, P158
   Shor A, 1998, J CLIN PATHOL, V51, P812, DOI 10.1136/jcp.51.11.812
   THOM DH, 1992, JAMA-J AM MED ASSOC, V268, P68, DOI 10.1001/jama.268.1.68
   VANDERWAL AC, 1994, CIRCULATION, V89, P36, DOI 10.1161/01.CIR.89.1.36
   WAHL LM, 1977, P NATL ACAD SCI USA, V74, P4955, DOI 10.1073/pnas.74.11.4955
   WON SCY, 1998, CIRCULATION, V98, P100
   Wong YK, 1999, HEART, V81, P232, DOI 10.1136/hrt.81.3.232
NR 32
TC 14
Z9 22
U1 0
U2 1
PU YONSEI UNIV COLLEGE MEDICINE
PI SEOUL
PA C/O KYUN0-IL IM, M.D., PH.D, SHINCHON DONG 134, SEODAEMOON KU, SEOUL
   120-752, SOUTH KOREA
SN 0513-5796
J9 YONSEI MED J
JI Yonsei Med. J.
PD JUN
PY 2000
VL 41
IS 3
BP 319
EP 327
DI 10.3349/ymj.2000.41.3.319
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 331LT
UT WOS:000088021100004
PM 10957885
OA Green Submitted, gold
DA 2021-08-04
ER

PT J
AU DiResta, GR
   Lee, J
   Healey, JH
   Levchenko, A
   Larson, SM
   Arbit, E
AF DiResta, GR
   Lee, J
   Healey, JH
   Levchenko, A
   Larson, SM
   Arbit, E
TI "Artificial lymphatic system": A new approach to reduce interstitial
   hypertension and increase blood flow, pH and pO(2) in solid tumors
SO ANNALS OF BIOMEDICAL ENGINEERING
LA English
DT Article
DE interstitial fluid pressure; artificial lymphatic system; Walker 256
   mammary carcinoma; monoclonal antibody; 3F8; NMB-7 neuroblastoma; tumor
   blood flow; pH and pO(2)
ID FLUID PRESSURE; MONOCLONAL-ANTIBODY; THERAPEUTIC AGENTS; MAMMARY-TUMORS;
   NEURO-BLASTOMA; TRANSPORT; MACROMOLECULES; DELIVERY; OXYGENATION;
   PERFUSION
AB A mechanical drainage system, the "artificial lymphatic system" (ALS), consisting of a vacuum source and drain, is evaluated for its ability to aspirate the interstitial fluids responsible for the elevated interstitial fluid pressure (IFP) observed in solid tumors. IFP, pH, and pO(2) radial profiles were measured before and after aspiration using wick-in-needle (WIN) probes, needle pH and oxygen electrodes, respectively. Laser Doppler flowmetry measured temporal changes in blood flow rate (BFR) at the tumor surface during aspiration. The WIN probe and IFP profile data were analyzed using numerical simulation and distributed mathematical models, respectively. The model parameter, p(E), reflecting central tumor IFP, was reduced from 15.3 to 5.7 mm Hg in neuroblastoma and from 13.3 to 12.1 mm Hg in Walker 256, respectively, following aspiration. The simulation demonstrated that spatial averaging inherent in WIN measurements reduced the calculated magnitude of the model parameter changes. IFP was significantly lower (p<0.05), especially in regions surrounding the drain, and BFR was significantly higher (p<0.05) following 25 and 45 min of aspiration, respectively; pH and pO(2) profiles increased following aspiration. The experimental and mathematical findings suggest that ALS aspiration may be a viable way of reducing IFP and increasing BFR, pO(2) and pH and should enhance solid tumor chemo and radiation therapy. (C) 2000 Biomedical Engineering Society. [S0090-6964(00)00605-6].
C1 Mem Sloan Kettering Canc Ctr, Dept Surg, Orthopaed Serv, New York, NY 10021 USA.
   Mem Sloan Kettering Canc Ctr, Nucl Med Res Lab, New York, NY 10021 USA.
   Staten Isl Univ, Med Ctr, Dept Surg, New York, NY USA.
RP DiResta, GR (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg, Orthopaed Serv, 1275 York Ave, New York, NY 10021 USA.
RI Arbit, Ehud/N-9033-2019
OI Healey, John/0000-0002-0802-1186
FU NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [1R01-CA78494-01A1] Funding Source: Medline; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [R01CA078494] Funding Source: NIH RePORTER
CR ACKER JC, 1990, INT J HYPERTHER, V6, P287, DOI 10.3109/02656739009141139
   BAXTER LT, 1989, MICROVASC RES, V37, P77, DOI 10.1016/0026-2862(89)90074-5
   BAXTER LT, 1990, MICROVASC RES, V40, P246, DOI 10.1016/0026-2862(90)90023-K
   BIRD RB, 1960, TRANSPORT PHENOMENA, P739
   BOUCHER Y, 1990, CANCER RES, V50, P4478
   BOUCHER Y, 1992, CANCER RES, V52, P5110
   BUTLER TP, 1975, CANCER RES, V35, P3084
   CHEUNG NKV, 1986, J NATL CANCER I, V77, P739, DOI 10.1093/jnci/77.3.739
   CHEUNG NKV, 1987, J NUCL MED, V28, P1577
   Dillehay LE, 1997, ANTICANCER RES, V17, P461
   DIRESTA GR, 1987, AM J PHYSIOL, V253, pG573
   DIRESTA GR, 1993, MICROVASC RES, V46, P158, DOI 10.1006/mvre.1993.1044
   FADNES HO, 1977, MICROVASC RES, V14, P27, DOI 10.1016/0026-2862(77)90138-8
   FUNG YC, 1990, FLUID MOVEMENT INTER, P320
   GUTMANN R, 1992, CANCER RES, V52, P1993
   Huang YQ, 1997, AM J PHYSIOL-HEART C, V272, pH2023
   JAIN RK, 1990, CANCER METAST REV, V9, P253, DOI 10.1007/BF00046364
   JAIN RK, 1994, SCI AM, V271, P58, DOI 10.1038/scientificamerican0794-58
   JAIN RK, 1988, CANCER RES, V48, P7022
   JAIN RK, 1989, JNCI-J NATL CANCER I, V81, P570, DOI 10.1093/jnci/81.8.570
   JAIN RK, 1987, CANCER RES, V47, P3039
   JAIN RK, 1987, RADIAT RES, V2, P813
   KIEFER J, 1990, BIOL RAD EFFECTS, P157
   KOZEN SV, 1996, INT J HYPERTHER, V12, P139
   LAIFOOK SJ, 1991, J APPL PHYSIOL, V70, P1928
   LAVIE E, 1991, CANCER IMMUNOL IMMUN, V33, P223, DOI 10.1007/BF01744941
   LEUNIG M, 1992, CANCER RES, V52, P487
   Netti PA, 1997, AICHE J, V43, P818, DOI 10.1002/aic.690430327
   NETTI PA, 1995, CANCER RES, V55, P5451
   OSHIMA T, 1993, NIPPON ACTA RADIOL, V53, P960
   ROH HD, 1991, CANCER RES, V51, P6695
   SHEPHERD AP, 1987, AM J PHYSIOL, V252, pG832
   WIIG H, 1982, SCAND J CLIN LAB INV, V42, P159
   Znati CA, 1996, CANCER RES, V56, P964
NR 34
TC 24
Z9 25
U1 2
U2 9
PU AMER INST PHYSICS
PI MELVILLE
PA 2 HUNTINGTON QUADRANGLE, STE 1NO1, MELVILLE, NY 11747-4501 USA
SN 0090-6964
J9 ANN BIOMED ENG
JI Ann. Biomed. Eng.
PD MAY
PY 2000
VL 28
IS 5
BP 543
EP 555
DI 10.1114/1.295
PG 13
WC Engineering, Biomedical
SC Engineering
GA 336VB
UT WOS:000088322700007
PM 10925952
DA 2021-08-04
ER

PT J
AU Majewski, S
   Kutner, A
   Jablonska, S
AF Majewski, S
   Kutner, A
   Jablonska, S
TI Vitamin D analogs in cutaneous malignancies
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
ID BREAST-CANCER CELLS; INDEPENDENT PROGNOSTIC INDICATOR;
   1,25-DIHYDROXYVITAMIN D-3; D-RECEPTOR; TUMOR ANGIOGENESIS;
   GROWTH-FACTOR; INHIBITS ANGIOGENESIS; INTERFERON-ALPHA; D DERIVATIVES;
   SKIN-LESIONS
AB In this article are reviewed available experimental and clinical studies on vitamin D analogs, and molecular and cellular mechanisms of their antineoplastic activity. In more detail are discussed the antiproliferative and pro-differentiative effects, inhibition of tumor-induced angiogenesis and induction of apoptosis. The use of vitamin D analogs is however hampered by their toxicity. In various experimental systems it was shown that the activities of vitamin D analogs can be enhanced by combined application with retinoids or other biological active compounds, such as cytokines and growth factors. Retinoids and vitamin D analogs were found to have synergistic inhibitory effects on tumor cell proliferation and angiogenic capability, and both agents applied simultaneously are efficacious in small doses. Thus combined therapy could find application in clinical practice. There are up to now only very limited data on the treatment of cutaneous malignancies with vitamin D analogs, and it appears that a combined therapy, preferably with retinoids, could be more beneficial. The new synthetic, more potent and less calcemic analogs might find wide application in chemotherapy of premalignant and early malignant cutaneous tumors, and could be especially useful for chemoprevention in the high-risk groups, eg, xeroderma pigmentosum, organ transplant recipients, arsenical keratoses and others.
C1 Warsaw Acad Med & Hosp, Dept Dermatol & Venerol, PL-02008 Warsaw, Poland.
   Pharmaceut Res Inst, Dept Chem, Warsaw, Poland.
RP Majewski, S (corresponding author), Warsaw Acad Med & Hosp, Dept Dermatol & Venerol, Koszykowa 82A, PL-02008 Warsaw, Poland.
RI KUTNER, ANDRZEJ/P-8823-2015; Kutner, Andrzej/AAB-6213-2020
OI Kutner, Andrzej/0000-0002-9518-4142
CR ABUAMER Y, 1994, J CELL BIOCHEM, V55, P435, DOI 10.1002/jcb.240550404
   Agadir A, 1999, CARCINOGENESIS, V20, P577, DOI 10.1093/carcin/20.4.577
   Barker JNWN, 1999, BRIT J DERMATOL, V141, P274
   Barroga EF, 1999, RES VET SCI, V66, P231, DOI 10.1053/rvsc.1998.0265
   BENASSI L, 1997, J INVEST DERMATOL, V109, P76
   BIKLE DD, 1991, J INVEST DERMATOL, V97, P435, DOI 10.1111/1523-1747.ep12481267
   BINDERUP L, 1995, ONCOGENE, V11, P1853
   Blutt SE, 1997, ENDOCRINOLOGY, V138, P1491, DOI 10.1210/en.138.4.1491
   Boehm MF, 1999, CHEM BIOL, V6, P265, DOI 10.1016/S1074-5521(99)80072-6
   Bollag W., 1994, Retinoids: from basic science to clinical applications., P267
   BOLLAG W, 1994, LEUKEMIA, V8, P1453
   BOUCK N, 1990, CANCER CELL-MON REV, V2, P179
   BROWN LF, 1995, HUM PATHOL, V26, P86, DOI 10.1016/0046-8177(95)90119-1
   BRUNDA MJ, 1994, CLIN IMMUNOL IMMUNOP, V71, P253, DOI 10.1006/clin.1994.1081
   BURAS RR, 1994, BREAST CANCER RES TR, V31, P191, DOI 10.1007/BF00666153
   CAMPBELL MJ, 1999, BRIT J CANCER, V79, P191
   CARRINGTON MN, 1988, J IMMUNOL, V140, P4013
   Castelijns FACM, 1999, ACTA DERM-VENEREOL, V79, P111
   CHEN TC, 1995, J INVEST DERMATOL, V104, P113, DOI 10.1111/1523-1747.ep12613601
   Dam TN, 1999, J INVEST DERMATOL, V113, P1082, DOI 10.1046/j.1523-1747.1999.00811.x
   Danielsson C, 1997, J CELL BIOCHEM, V66, P552, DOI 10.1002/(SICI)1097-4644(19970915)66:4<552::AID-JCB14>3.0.CO;2-D
   DEFACQUE H, 1994, J PHARMACOL EXP THER, V271, P193
   DENEKAMP J, 1993, BRIT J RADIOL, V66, P181, DOI 10.1259/0007-1285-66-783-181
   DORE BT, 1992, CANCER RES, V33, P2640
   ELSTNER E, 1995, CANCER RES, V55, P2822
   Evans SRT, 1998, CLIN CANCER RES, V4, P2869
   FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27
   FRENCH LE, 1994, LANCET, V344, P686, DOI 10.1016/S0140-6736(94)92122-9
   FUKUOKA M, 1997, NIPPON YAKURIGAKUJ Z, V1, P39
   GASPARINI G, 1993, INT J CANCER, V55, P739, DOI 10.1002/ijc.2910550507
   Hedlund TE, 1997, CLIN CANCER RES, V3, P1331
   HORAK ER, 1992, LANCET, V340, P1120, DOI 10.1016/0140-6736(92)93150-L
   JAMES SY, 1995, J MOL ENDOCRINOL, V14, P391, DOI 10.1677/jme.0.0140391
   James SY, 1996, J STEROID BIOCHEM, V58, P395, DOI 10.1016/0960-0760(96)00048-9
   James SY, 1999, GEN PHARMACOL, V32, P143, DOI 10.1016/S0306-3623(98)00098-6
   KARP JE, 1995, NAT MED, V1, P309, DOI 10.1038/nm0495-309
   KERKHOF PCM, 1996, J DERMATOL TREAT, V7, P195
   KESLEY SM, 1990, LEUKEMIA RES, V14, P1027
   Kleuser B, 1998, CANCER RES, V58, P1817
   Kornfehl J, 1996, EUR ARCH OTO-RHINO-L, V253, P341
   KREFT B, 1995, EXP NEPHROL, V3, P288
   KUTNER A, 1998, Patent No. 324274
   Lazzaro G., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P446
   LEMIRE JM, 1995, J NUTR, V125, pS1704, DOI 10.1093/jn/125.suppl_6.1704S
   LEMIRE JM, 1995, J STEROID BIOCHEM, V53, P599, DOI 10.1016/0960-0760(95)00106-A
   LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C
   MACCHIARINI P, 1992, LANCET, V340, P145, DOI 10.1016/0140-6736(92)93217-B
   MAIONE TE, 1990, TRENDS PHARMACOL SCI, V11, P457, DOI 10.1016/0165-6147(90)90127-T
   MAJEWSKI S, 1993, CANCER LETT, V75, P35, DOI 10.1016/0304-3835(93)90204-M
   Majewski S, 1996, J INVEST DERMATOL, V106, P1114, DOI 10.1111/1523-1747.ep12340161
   MAJEWSKI S, 1994, LANCET, V344, P1510, DOI 10.1016/S0140-6736(94)90330-1
   MAJEWSKI S, 1995, CANCER LETT, V89, P117, DOI 10.1016/0304-3835(95)90166-3
   MAJEWSKI S, 1994, INT J CANCER, V57, P81, DOI 10.1002/ijc.2910570115
   Majewski S, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 1, APRIL 1996, V1, P97
   Mehta RG, 1997, JNCI-J NATL CANCER I, V89, P212, DOI 10.1093/jnci/89.3.212
   Miller GJ, 1995, CLIN CANCER RES, V1, P997
   Mommers JM, 1998, BRIT J DERMATOL, V139, P468
   Nowicka D, 1998, ARCH DERMATOL RES, V290, P696, DOI 10.1007/s004030050375
   Odrzywolska M, 1999, CHIRALITY, V11, P701, DOI 10.1002/(SICI)1520-636X(1999)11:9<701::AID-CHIR6>3.3.CO;2-C
   OIKAWA T, 1990, EUR J PHARMACOL, V178, P247, DOI 10.1016/0014-2999(90)90483-M
   PARK K, 1994, CANCER RES, V54, P6087
   Polly P, 1996, J CELL BIOCHEM, V60, P322, DOI 10.1002/(SICI)1097-4644(19960301)60:3<322::AID-JCB4>3.0.CO;2-Y
   Ratnam AV, 1996, J INVEST DERMATOL, V106, P522, DOI 10.1111/1523-1747.ep12343898
   Reichrath J, 1998, HISTOCHEM J, V30, P561, DOI 10.1023/A:1003283117492
   Reichrath J, 1997, J AM ACAD DERMATOL, V36, P19, DOI 10.1016/S0190-9622(97)70320-7
   REICHRATH J, 1993, CELL TISSUE CULTURE, P43
   Rozen F, 1997, J NATL CANCER I, V89, P652, DOI 10.1093/jnci/89.9.652
   Schwartz GG, 1997, CANCER EPIDEM BIOMAR, V6, P727
   Shabahang M., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P456
   SHOKRAVI MT, 1995, INVEST OPHTH VIS SCI, V36, P83
   SIDKY YA, 1987, CANCER RES, V47, P5155
   Skopinska M, 1997, J DERMATOL TREAT, V8, P5, DOI 10.3109/09546639709160501
   SRIVASTAVA A, 1988, AM J PATHOL, V133, P419
   TAMAKI K, 1990, BRIT J DERMATOL, V123, P333, DOI 10.1111/j.1365-2133.1990.tb06293.x
   TESTA U, 1993, J IMMUNOL, V150, P2418
   Texereau M, 1992, EUR J DERMATOL, V2, P258
   TOI M, 1993, INT J CANCER, V55, P371, DOI 10.1002/ijc.2910550305
   Tone Takeshi, 1993, Journal of Dermatology (Tokyo), V20, P581
   TRINCHIERI G, 1987, CANCER RES, V47, P2236
   TSOUKAS CD, 1984, SCIENCE, V224, P1438, DOI 10.1126/science.6427926
   VOEST EE, 1995, J NATL CANCER I, V87, P581, DOI 10.1093/jnci/87.8.581
   WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875
   Xie SP, 1997, J ENDOCRINOL, V154, P495, DOI 10.1677/joe.0.1540495
   YU JA, 1995, ANTI-CANCER DRUG, V6, P101, DOI 10.1097/00001813-199502000-00012
   YU XP, 1991, P NATL ACAD SCI USA, V88, P8347, DOI 10.1073/pnas.88.19.8347
   Yudoh K, 1997, TUMOR BIOL, V18, P69, DOI 10.1159/000218016
   ZHANG TK, 1997, CANCER RES, V38, P578
   ZUCKERMAN SH, 1988, BLOOD, V71, P619
NR 88
TC 13
Z9 13
U1 0
U2 0
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD MAY
PY 2000
VL 6
IS 7
BP 829
EP 838
DI 10.2174/138161200780574593
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 323UE
UT WOS:000087582700010
PM 10928819
DA 2021-08-04
ER

PT J
AU Marchioro, M
   Tanksley, M
   Prosperetti, A
AF Marchioro, M
   Tanksley, M
   Prosperetti, A
TI Flow of spatially son-uniform suspensions. Part I: Phenomenology
SO INTERNATIONAL JOURNAL OF MULTIPHASE FLOW
LA English
DT Article
DE suspensions; spatial non-uniformity; direct numerical simulation
ID DISPERSE 2-PHASE FLOW; TURBULENT BOUNDARY-LAYER; SPHERICAL-PARTICLES;
   CONCENTRATED SUSPENSIONS; EFFECTIVE CONDUCTIVITY; STOKES-FLOW;
   NONCOLLOIDAL PARTICLES; EFFECTIVE VISCOSITY; AVERAGED EQUATIONS; DIRECT
   SIMULATION
AB The response of a spatially non-uniform suspension of spheres to several forcing agents - forces and torques applied to the spheres, and an imposed simple shear - is studied numerically for Stokes flow conditions. While the standard results are recovered in the uniform case, it is found that the nonuniformity of the particle probability distribution gives rise to qualitatively new features. For example, the rheological behavior of the system cannot be described solely in terms of an effective viscosity; a relative velocity between particles and fluid can arise; the particles can either lead or lag the local angular velocity of the fluid elements. It is shown that a mixture effective viscosity can be calculated for all three cases with mutually consistent results. In a subsequent paper the present results will be used to derive in a systematic way closure relations for an averaged-equations description of the suspension. (C) 2000 Elsevier Science Ltd. All rights reserved.
C1 Johns Hopkins Univ, Dept Mech Engn, Baltimore, MD 21218 USA.
   Univ Twente, Fac Appl Phys, NL-7500 AE Enschede, Netherlands.
   Univ Twente, Twente Inst Mech, NL-7500 AE Enschede, Netherlands.
RP Prosperetti, A (corresponding author), Johns Hopkins Univ, Dept Mech Engn, Baltimore, MD 21218 USA.
EM prosperetti@jhu.edu
RI Prosperetti, Andrea/A-6263-2008
OI Prosperetti, Andrea/0000-0003-4129-7130
CR ACRIVOS A, 1995, J RHEOL, V39, P813, DOI 10.1122/1.550619
   ACRIVOS A, 1980, J FLUID MECH, V101, P403, DOI 10.1017/S0022112080001723
   Allen M. P., 1987, COMPUTER SIMULATION
   Balucani U., 1994, DYNAMICS LIQUID STAT
   BARNES HA, 1990, INTRO RHEOLOGY
   BATCHELOR GK, 1972, J FLUID MECH, V56, P401, DOI 10.1017/S0022112072002435
   BATCHELOR GK, 1970, J FLUID MECH, V41, P545, DOI 10.1017/S0022112070000745
   BATCHELOR GK, 1972, J FLUID MECH, V52, P245, DOI 10.1017/S0022112072001399
   BIESHEUVEL A, 1989, INT J MULTIPHAS FLOW, V15, P911, DOI 10.1016/0301-9322(89)90020-7
   BONNECAZE RT, 1991, P ROY SOC LOND A MAT, V432, P445, DOI 10.1098/rspa.1991.0025
   Brady JF, 1997, J FLUID MECH, V348, P103, DOI 10.1017/S0022112097006320
   BRADY JF, 1988, ANNU REV FLUID MECH, V20, P111, DOI 10.1146/annurev.fl.20.010188.000551
   BRENNER H, 1984, INT J ENG SCI, V22, P645, DOI 10.1016/0020-7225(84)90042-9
   BRENNER H, 1972, CHEM ENG SCI, V27, P1069, DOI 10.1016/0009-2509(72)80021-6
   BRENNER H, 1970, J COLLOID INTERF SCI, V32, P141, DOI 10.1016/0021-9797(70)90110-4
   BUYEVICH YA, 1995, CHEM ENG SCI, V50, P641, DOI 10.1016/0009-2509(94)00436-U
   BUYEVICH YA, 1995, INT J HEAT MASS TRAN, V38, P381, DOI 10.1016/0017-9310(95)90035-7
   Cercignani C., 1988, BOLTZMANN EQUATION I
   CHANG CY, 1994, PHYS FLUIDS, V6, P1628, DOI 10.1063/1.868226
   CHANG CY, 1994, J FLUID MECH, V281, P51, DOI 10.1017/S0022112094003034
   CICHOCKI B, 1994, J CHEM PHYS, V100, P3780, DOI 10.1063/1.466366
   Cowling TG., 1952, MATH THEORY NONUNIFO
   DAVIS RH, 1985, ANNU REV FLUID MECH, V17, P91, DOI 10.1146/annurev.fl.17.010185.000515
   DREW DA, 1983, ANNU REV FLUID MECH, V15, P261, DOI 10.1146/annurev.fl.15.010183.001401
   Esmaeeli A, 1996, J FLUID MECH, V314, P315, DOI 10.1017/S002211209600033X
   FENG J, 1994, J FLUID MECH, V261, P95, DOI 10.1017/S0022112094000285
   FEUILLEBOIS F, 1984, J FLUID MECH, V139, P145, DOI 10.1017/S0022112084000306
   Hansen J.-P., 1990, THEORY SIMPLE LIQUID
   HASIMOTO H, 1959, J FLUID MECH, V5, P317, DOI 10.1017/S0022112059000222
   Hetsroni G, 1982, HDB MULTIPHASE SYSTE
   HINCH EJ, 1977, J FLUID MECH, V83, P695, DOI 10.1017/S0022112077001414
   Hu HH, 1996, INT J MULTIPHAS FLOW, V22, P335, DOI 10.1016/0301-9322(95)00068-2
   Ishii M., 1975, THERMOFLUID DYNAMIC
   JEFFREY DJ, 1973, PROC R SOC LON SER-A, V335, P355, DOI 10.1098/rspa.1973.0130
   Johnson AA, 1997, COMPUT METHOD APPL M, V145, P301, DOI 10.1016/S0045-7825(96)01223-6
   Johnson AA, 1996, COMPUT METHOD APPL M, V134, P351, DOI 10.1016/0045-7825(95)00988-4
   JONES AV, 1985, INT J MULTIPHAS FLOW, V11, P133, DOI 10.1016/0301-9322(85)90041-2
   KAFTORI D, 1995, PHYS FLUIDS, V7, P1107, DOI 10.1063/1.868552
   KAFTORI D, 1995, PHYS FLUIDS, V7, P1095, DOI 10.1063/1.868551
   Ladd AJC, 1997, PHYS FLUIDS, V9, P491, DOI 10.1063/1.869212
   LADD AJC, 1988, J CHEM PHYS, V88, P5051, DOI 10.1063/1.454658
   LADD AJC, 1993, PHYS FLUIDS A-FLUID, V5, P299, DOI 10.1063/1.858695
   LADD AJC, 1990, J CHEM PHYS, V93, P3484, DOI 10.1063/1.458830
   Lamb H., 1932, HYDRODYNAMICS, V6th edn
   LANDAU LD, 1969, STAT PHYSICS
   LEIGHTON D, 1987, J FLUID MECH, V181, P415, DOI 10.1017/S0022112087002155
   LHUILLIER D, 1992, EUR J MECH B-FLUID, V11, P649
   LHUILLIER D, 1992, PHYSICA A, V181, P427, DOI 10.1016/0378-4371(92)90099-C
   Marchioro M, 1999, P ROY SOC A-MATH PHY, V455, P1483, DOI 10.1098/rspa.1999.0369
   Marchioro M, 1999, INT J MULTIPHAS FLOW, V25, P1395, DOI 10.1016/S0301-9322(99)00061-0
   MARCHIORO M, 2000, UNPUB INT J MULTIPHA
   MARTYS N, 1994, PHYS FLUIDS, V6, P1434, DOI 10.1063/1.868258
   MITTAL S, 1994, COMPUT METHOD APPL M, V112, P253, DOI 10.1016/0045-7825(94)90029-9
   MO GB, 1994, PHYS FLUIDS, V6, P1637, DOI 10.1063/1.868227
   NOTT PR, 1994, J FLUID MECH, V275, P157, DOI 10.1017/S0022112094002326
   NUNAN KC, 1984, J FLUID MECH, V142, P269, DOI 10.1017/S0022112084001105
   Pan Y, 1996, PHYS FLUIDS, V8, P2733, DOI 10.1063/1.869059
   PHILLIPS RJ, 1992, PHYS FLUIDS A-FLUID, V4, P30, DOI 10.1063/1.858498
   PROSPERETTI A, 1984, INT J MULTIPHAS FLOW, V10, P425, DOI 10.1016/0301-9322(84)90054-5
   PROSPERETTI A, 1998, PARTICULATE FLOWS PR, P99
   RUSSELL WB, 1989, COLLOIDAL DISPERSION
   Salacuse JJ, 1996, PHYS REV E, V53, P2382, DOI 10.1103/PhysRevE.53.2382
   SANGANI AS, 1982, INT J MULTIPHAS FLOW, V8, P343, DOI 10.1016/0301-9322(82)90047-7
   SANGANI AS, 1983, P ROY SOC LOND A MAT, V386, P263, DOI 10.1098/rspa.1983.0036
   Sangani AS, 1996, PHYS FLUIDS, V8, P1990, DOI 10.1063/1.869003
   Sangani AS, 1996, J FLUID MECH, V313, P309, DOI 10.1017/S0022112096002224
   SANGANI AS, 1988, J APPL PHYS, V63, P1334, DOI 10.1063/1.339960
   STEWART HB, 1984, J COMPUT PHYS, V56, P363
   Studart N, 1996, PHYS REV E, V53, P2350, DOI 10.1103/PhysRevE.53.2350
   TANKSLEY M, 1999, UNPUB J ENG MATH
   THROOP GJ, 1965, J CHEM PHYS, V42, P2408, DOI 10.1063/1.1696308
   TORQUATO S, 1990, PHYSICA A, V167, P361, DOI 10.1016/0378-4371(90)90121-8
   Torquato S., 1987, REV CHEM ENG, V4, P151
   UNVERDI SO, 1992, PHYSICA D, V60, P70
   WEINBAUM S, 1990, ANNU REV FLUID MECH, V22, P275
   ZHANG DZ, 1994, J FLUID MECH, V267, P185, DOI 10.1017/S0022112094001151
   ZHANG DZ, 1994, PHYS FLUIDS, V6, P2956, DOI 10.1063/1.868122
   Zhang DZ, 1997, INT J MULTIPHAS FLOW, V23, P425, DOI 10.1016/S0301-9322(96)00080-8
   ZUZOVSKY M, 1983, PHYS FLUIDS, V26, P1714, DOI 10.1063/1.864370
NR 79
TC 25
Z9 25
U1 1
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0301-9322
J9 INT J MULTIPHAS FLOW
JI Int. J. Multiph. Flow
PD MAY
PY 2000
VL 26
IS 5
BP 783
EP 831
DI 10.1016/S0301-9322(99)00068-3
PG 49
WC Mechanics
SC Mechanics
GA 308JA
UT WOS:000086705800005
DA 2021-08-04
ER

PT J
AU Oesch, F
   Herrero, ME
   Hengstler, JG
   Lohmann, M
   Arand, M
AF Oesch, F
   Herrero, ME
   Hengstler, JG
   Lohmann, M
   Arand, M
TI Metabolic detoxification: Implications for thresholds
SO TOXICOLOGIC PATHOLOGY
LA English
DT Article
DE epoxide hydrolase; alpha/beta hydrolase fold; ester intermediate; epoxy
   compounds metabolism; V79 Chinese hamster lung fibroblasts; DNA damage;
   genotoxicity
ID MICROSOMAL EPOXIDE HYDROLASE; CHINESE-HAMSTER CELLS; CATALYTIC
   MECHANISM; ENZYME INTERMEDIATE; HALF-REACTION; HYDROLYSIS; EXPRESSION;
   TRIAD; V79
AB The fact that chemical carcinogenesis involves single, isolated, essentially irreversible molecular events as discrete steps. several of which must occur in a row to finally culminate in the development of a malignancy. rather suggests that an absolute threshold for chemical carcinogens may not exist. However, practical thresholds may exist due to saturable pathways involved in the metabolic processing, especially in the metabolic inactivation, of such compounds. An important example for such a pathway is the enzymatic hydrolysis of epoxides via epoxide hydrolases, a group of enzymes for which the catalytic mechanism has recently been established. These enzymes convert their substrates via the intermediate formation of a covalent enzyme-substrate complex. Interestingly, the formation of the intermediate proceeds faster by orders of magnitude than the subsequent hydrolysis, ie, the formation of the terminal product. Under normal circumstances, this does not pose a problem, since the microsomal epoxide hydrolase (mEH). the epoxide hydrolases with the best documented importance in the metabolism of carcinogens, is highly abundant in the liver, the organ with the highest capacity to metabolically generate epoxides. Computer simulation provides evidence that the high amount of mEH enzyme is favorable for the control of the steady-state level of a substrate epoxide and can keep it extremely low. However, once the mEH is titrated out under conditions of extraordinarily high epoxide concentration, the epoxide steady-state level steeply rises, leading to a sudden burst of the genotoxic effect of the noxious agent. This prediction of the computer simulation is nicely supported by experimental work. V79 Chinese hamster cells that we have generically engineered to express human mEH at about the same level as that observed in human liver are completely protected from any measurable genotoxic effect of the model compound styrene oxide (STO) up to a dose of 100 mu M in the cell culture medium (toxicokinetic threshold). In V79 cells that do not express mEH, STO leads to the formation of DNA strand breaks in a dose-dependent manner with no toxicokinetic threshold observable. Above 100 mu-M. the genotoxic effect of STO in the mEH-expressing cell line parallels the one in the parental cell line. Thus, the saturable protection from STO-induced strand breaks by mEH represents a typical example of a practical threshold. However, it must be: pointed out that even in the presence of protective amounts of mEH. a minute but definite level of STO is present that does not contribute sufficiently to the strand break formation to overcome the background noise of the detection procedure. As pointed out above, absolute thresholds probably do not exist in chemical carcinogenesis.
C1 Univ Mainz, Inst Toxicol, D-55131 Mainz, Germany.
RP Oesch, F (corresponding author), Univ Mainz, Inst Toxicol, Obere Zahlbacher Str 67, D-55131 Mainz, Germany.
RI Oesch, Franz/AAA-8746-2020; Arand, Michael/J-3926-2014; Hengstler, Jan
   G./O-1415-2013
OI Arand, Michael/0000-0003-2413-3177; Hengstler, Jan/0000-0002-1427-5246
CR Arand M, 1999, BIOCHEM J, V337, P37, DOI 10.1042/0264-6021:3370037
   ARAND M, 1994, FEBS LETT, V338, P251, DOI 10.1016/0014-5793(94)80278-5
   Arand M, 1996, J BIOL CHEM, V271, P4223
   DENENGELSE L, 1994, REGUL TOXICOL PHARM, V19, P14, DOI 10.1006/rtph.1994.1002
   DOEHMER J, 1988, P NATL ACAD SCI USA, V85, P5769, DOI 10.1073/pnas.85.16.5769
   HAMMOCK BD, 1994, BIOCHEM BIOPH RES CO, V198, P850, DOI 10.1006/bbrc.1994.1121
   Herrero ME, 1997, ENVIRON MOL MUTAGEN, V30, P429, DOI 10.1002/(SICI)1098-2280(1997)30:4<429::AID-EM8>3.0.CO;2-D
   LACOURCIERE GM, 1993, J AM CHEM SOC, V115, P10466, DOI 10.1021/ja00075a115
   LACOURCIERE GM, 1994, CHEM RES TOXICOL, V7, P121, DOI 10.1021/tx00038a001
   Laughlin LT, 1998, BIOCHEMISTRY-US, V37, P2897, DOI 10.1021/bi972737f
   Muller F, 1997, EUR J BIOCHEM, V245, P490, DOI 10.1111/j.1432-1033.1997.00490.x
   OESCH F, 1973, XENOBIOTICA, V3, P305, DOI 10.3109/00498257309151525
   OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197
   Purchase IFH, 1995, REGUL TOXICOL PHARM, V22, P199, DOI 10.1006/rtph.1995.0001
   THOMAS H, 1990, FRONTIERS BIOTRANSFO, V2, P278
   Tzeng HF, 1998, BIOCHEMISTRY-US, V37, P2905, DOI 10.1021/bi9727388
   Tzeng HF, 1996, J AM CHEM SOC, V118, P9436, DOI 10.1021/ja961826x
   1991, REP HLTH SOC SUBJ LO, V42, P1
NR 18
TC 45
Z9 46
U1 0
U2 3
PU SOC TOXICOLOGIC PATHOLOGISTS
PI MT ROYAL
PA 19 MANTUA RD, MT ROYAL, NJ 08061 USA
SN 0192-6233
J9 TOXICOL PATHOL
JI Toxicol. Pathol.
PD MAY-JUN
PY 2000
VL 28
IS 3
BP 382
EP 387
DI 10.1177/019262330002800305
PG 6
WC Pathology; Toxicology
SC Pathology; Toxicology
GA 321KT
UT WOS:000087455200004
PM 10862554
OA Bronze
DA 2021-08-04
ER

PT J
AU Jauchem, JR
   Ryan, KL
   Frei, MR
AF Jauchem, JR
   Ryan, KL
   Frei, MR
TI Cardiovascular and thermal effects of microwave irradiation at 1 and/or
   10 GHz in anesthetized rats
SO BIOELECTROMAGNETICS
LA English
DT Article
DE radio-frequency electromagnetic radiation; heart rate; blood pressure;
   respiratory rate
ID LETHAL HEAT-STRESS; RADIOFREQUENCY RADIATION; THERMOREGULATORY
   RESPONSES; H-ORIENTATION; KETAMINE; EXPOSURE; AGENTS
AB Relatively large thermal gradients may exist during exposure of an animal to microwaves (MWs), particularly at high frequencies. Differences in thermal gradients within the body may lead to noticeable differences in the magnitude of cardiovascular changes resulting from MW exposure. This study compares the thermal distribution and cardiovascular effects of exposure to a single MW frequency with effects of simultaneous exposure to two frequencies. Ketamine-anesthetized male Sprague-Dawley rats (n = 58) were exposed individually to one of three conditions: 1-GHz, 10-GHz, or combined 1- and 10-GHz MWs at an equivalent whole-body specific absorption rate of 12 W/kg. The continuous-wave irradiation was conducted under far-field conditions with animals in E orientation (left lateral exposure, long axis parallel to the electric field) or in H orientation (left lateral exposure, long axis perpendicular to the electric field). Irradiation was started when colonic temperature was 37.5 degrees C and was continued until lethal temperatures were attained. Colonic, tympanic, left and right subcutaneous, and tail temperatures, and arterial blood pressure, heart rate, and respiratory rate were continuously recorded. In both E and Il orientations, survival time (i.e., time from colonic temperature of 37.5 degrees C until death) was lowest in animals exposed at 1-GHz, intermediate in those exposed at 1- and 10-GHz combined, and greatest in the 10-GHz group (most differences statistically significant). At all sites (with the exception of right subcutaneous), temperature values in the 1- and 10-GHz combined group were between those of the single-frequency exposure groups in both E and H orientations. During irradiation, arterial blood pressure initially increased and then decreased until death. Heart rate increased throughout the exposure period. The general, overall patterns of these changes were similar in all groups. The results indicate that no unusual physiological responses occur during multi-frequency MW exposure, when compared with results of single-frequency exposure. Published 2000 Wiley-Liss, Inc.(dagger)
C1 AFRL, HEDR,Human Effectiveness Directorate, Directed Energy Bioeffects Div, Radio Frequency Radiat Branch, Brooks AFB, TX 78235 USA.
   Trinity Univ, Dept Biol, San Antonio, TX 78212 USA.
RP Jauchem, JR (corresponding author), AFRL, HEDR,Human Effectiveness Directorate, Directed Energy Bioeffects Div, Radio Frequency Radiat Branch, 8315 Hawks Rd, Brooks AFB, TX 78235 USA.
EM james.jauchem@afrlars.brooks.af.mil
CR ALLEN SJ, 1979, RADIO SCI, V14, P1, DOI 10.1029/RS014i06Sp00001
   BYNUM G, 1977, J APPL PHYSIOL, V43, P292
   CHOU CK, 1985, BIOELECTROMAGNETICS, V6, P73, DOI 10.1002/bem.2250060108
   DURNEY CH, 1978, USAFSAMTR7822 BROOKS
   FREI M, 1988, J MICROWAVE POWER EE, V23, P85
   FREI MR, 1995, NATO ADV SCI INST SE, V274, P295
   FREI MR, 1992, PHYSIOL CHEM PHYS ME, V24, P1
   FREI MR, 1989, RADIAT ENVIRON BIOPH, V28, P67, DOI 10.1007/BF01209724
   FREI MR, 1989, PHYSIOL CHEM PHYS ME, V21, P65
   GORDON CJ, 1983, AM J PHYSIOL, V244, pR778
   Jauchem JR, 1996, P SOC EXP BIOL MED, V211, P236
   JAUCHEM JR, 1990, P SOC EXP BIOL MED, V194, P358
   JAUCHEM JR, 1988, PHYSIOL CHEM PHYS M, V20, P135
   JAUCHEM JR, 1991, LAB ANIM SCI, V41, P70
   JAUCHEM JR, 1992, COMP BIOCHEM PHYS A, V101, P1, DOI 10.1016/0300-9629(92)90619-2
   JAUCHEM JR, 1994, J APPL PHYSIOL, V77, P434
   Jauchem JR, 1997, BIOELECTROMAGNETICS, V18, P335, DOI 10.1002/(SICI)1521-186X(1997)18:4<335::AID-BEM6>3.0.CO;2-3
   JAUCHEM JR, 1984, AVIAT SPACE ENVIR MD, V55, P1036
   Jauchem JR, 1997, J AUTON PHARMACOL, V17, P165, DOI 10.1046/j.1365-2680.1997.00453.x
   JAUCHEM JR, 1984, P SOC EXP BIOL MED, V177, P383
   JAUCHEM JR, 1995, METHOD FIND EXP CLIN, V17, P241
   JAUCHEM JR, 1983, 54TH ANN M AER MED A, P241
   KREGEL KC, 1990, J APPL PHYSIOL, V68, P1220
   LIN MT, 1978, CAN J PHYSIOL PHARM, V56, P963, DOI 10.1139/y78-153
   Menhaj A, 1998, MEAS SCI TECHNOL, V9, P283, DOI 10.1088/0957-0233/9/2/017
   MIKOLAJCZYK H, 1991, J THERM BIOL, V16, P115, DOI 10.1016/0306-4565(91)90008-P
   NAGASAKA T, 1980, JPN J PHYSIOL, V30, P799
   PADILLA JM, 1986, USAFSAMTP863 BROOKS
   POLSON P, 1974, MORTALITY RATS EXPOS
   REFINETTI R, 1989, J PHYSIOL-PARIS, V83, P300
   Ryan KL, 1996, SHOCK, V6, P71, DOI 10.1097/00024382-199607000-00015
   SCHAEFER CF, 1984, CIRC SHOCK, V12, P125
   Stuchly MA, 1998, CRIT REV BIOMED ENG, V26, P117, DOI 10.1615/CritRevBiomedEng.v26.i1-2.20
   1998, COMMERCE BUSINE 0727
NR 34
TC 38
Z9 42
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0197-8462
EI 1521-186X
J9 BIOELECTROMAGNETICS
JI Bioelectromagnetics
PD APR
PY 2000
VL 21
IS 3
BP 159
EP 166
DI 10.1002/(SICI)1521-186X(200004)21:3<159::AID-BEM2>3.0.CO;2-#
PG 8
WC Biology; Biophysics
SC Life Sciences & Biomedicine - Other Topics; Biophysics
GA 298GG
UT WOS:000086130500002
PM 10723015
DA 2021-08-04
ER

PT J
AU Hillner, BE
   Agarwala, S
   Middleton, MR
AF Hillner, BE
   Agarwala, S
   Middleton, MR
TI Post hoc economic analysis of temozolomide versus dacarbazine in the
   treatment of advanced metastatic melanoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID COST-EFFECTIVENESS ANALYSIS; CHEMOTHERAPY; HEALTH; TRIAL
AB Purpose: To determine the potential economic implications resulting from oral temozolomide (TEM) compared with intravenous (IV) dacarbazine (DTIC) for metastatic melanoma,
   Patients and Methods: We performed a cost-effectiveness (CE) analysis using hazard ratios (HRs) from the phase III (Schering 195-018) trial comparing TEM 200 mg/m(2)/d orally for 5 days every 28 days with DTIC 250 mg/m2/d IV for 5 days every 21 days. Sensitivity analyses assessed a range of TEM's efficacy and costs, direct nonmedical costs, and the DTIC schedule,
   Results: The trial found an overall survival trend favoring TEM; median survival times of patients heated with DTIC and TEM were 6.4 and 7.7 months, respectively (HR = 1.18; 95% confidence interval [Cl], 0.92 to 1.52; intention to heat, P = .20), The mean increase in survival of TEM over DTIC was 1.1 months. The projected average cash per patient were greater with TEM than DTIC ($6,902 v $3,697, respectively). The incremental CE ratio using TEM was $36,990 per life-year or $101 per day of life gained. The CE ratio's 95% CT ranged from -$65,180 (DTIC is more effective) to $18,670 per year of life gained. The CE ratios decreased 50% if direct nonmedical casts were included and increased 50% if DTIC's efficacy was unchanged if given as a single daily dosage, Sixty percent of simulations found TEM with a CE threshold of less than $50,000 per life-year gained.
   Conclusion: Although the base-case efficacy of TEM compared with DTIC was not statistically significant, its associated incremental CE would be comparable with many interventions. TEM for metastatic melanoma illustrates the tension confronting providers choosing between similar agents that markedly differ in convenience and costs. (C) 2000 by American Society of Clinical Oncology.
C1 Virginia Commonwealth Univ, Med Coll Virginia, Dept Internal Med, Richmond, VA 23298 USA.
   Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Richmond, VA 23298 USA.
   Univ Pittsburgh, Pittsburgh Canc Inst, Pittsburgh, PA USA.
   Christie Hosp NHS Trust, Dept Med Oncol, Manchester M20 4BX, Lancs, England.
RP Hillner, BE (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Internal Med, Box 980170, Richmond, VA 23298 USA.
RI Hillner, Bruce/A-6852-2009
CR Atkins Michael B., 1997, Current Opinion in Oncology, V9, P205
   Balch Charles M., 1997, P1947
   Buxton MJ, 1997, HEALTH ECON, V6, P217, DOI 10.1002/(SICI)1099-1050(199705)6:3<217::AID-HEC267>3.0.CO;2-W
   DeMario MD, 1998, J CLIN ONCOL, V16, P2557, DOI 10.1200/JCO.1998.16.7.2557
   DETSKY AS, 1990, ANN INTERN MED, V113, P147, DOI 10.7326/0003-4819-113-2-147
   Drummond MF, 1997, JAMA-J AM MED ASSOC, V277, P1552, DOI 10.1001/jama.277.19.1552
   Falkson CI, 1998, J CLIN ONCOL, V16, P1743, DOI 10.1200/JCO.1998.16.5.1743
   Hayman J, 1996, INT J RADIAT ONCOL, V35, P827, DOI 10.1016/0360-3016(96)00172-1
   Hillner BE, 1997, J CLIN ONCOL, V15, P2351, DOI 10.1200/JCO.1997.15.6.2351
   LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473
   Liu G, 1997, J CLIN ONCOL, V15, P110, DOI 10.1200/JCO.1997.15.1.110
   Middleton MR, 2000, J CLIN ONCOL, V18, P158, DOI 10.1200/JCO.2000.18.1.158
   Perez EA, 1998, J CLIN ONCOL, V16, P754, DOI 10.1200/JCO.1998.16.2.754
   Russell LB, 1996, JAMA-J AM MED ASSOC, V276, P1172, DOI 10.1001/jama.276.14.1172
   SMITH TJ, 1995, J CLIN ONCOL, V13, P2166, DOI 10.1200/JCO.1995.13.9.2166
   Trippoli S, 1998, JAMA-J AM MED ASSOC, V280, P1992, DOI 10.1001/jama.280.23.1992-a
NR 16
TC 21
Z9 21
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD APR
PY 2000
VL 18
IS 7
BP 1474
EP 1480
DI 10.1200/JCO.2000.18.7.1474
PG 7
WC Oncology
SC Oncology
GA 300RG
UT WOS:000086265500009
PM 10735895
DA 2021-08-04
ER

PT J
AU Levin, ML
   Fish, D
AF Levin, ML
   Fish, D
TI Immunity reduces reservoir host competence of Peromyscus leucopus for
   Ehrlichia phagocytophila
SO INFECTION AND IMMUNITY
LA English
DT Article
ID HUMAN GRANULOCYTIC EHRLICHIOSIS; WHITE-FOOTED MICE; LYME-DISEASE;
   BORRELIA-BURGDORFERI; IXODES-SCAPULARIS; IMMUNOGLOBULIN-G;
   EXPERIMENTAL-INFECTION; SERUM COMPONENTS; DIGESTIVE-TRACT; TICKS ACARI
AB Infection with Ehrlichia phagocytophila in white-footed mice is transient and followed by a strong immune response. We investigated whether the presence of acquired immunity against E. phagocytophila precludes whitefooted mice from further maintenance of this agent in nature. Mice were infected with E. phagocytophila via tick bite and challenged either 12 or 16 weeks later by Ixodes scapularis nymphs infected with the same agent. Xenodiagnostic larvae fed upon each mouse simultaneously with challenging nymphs and 1 week thereafter. Ticks were tested for the agent by PCR, and the prevalence of infection was compared to that in ticks that fed upon nonimmune control mice. Only 30% of immunized mice sustained cofeeding transmission of E. phagocytophila between simultaneously feeding infected and uninfected ticks, compared to 100% of control mice. An average of 6.3% of xenodiagnostic ticks acquired Ehrlichia from previously immunized mice when fed 1 week after the challenge, compared to 82.5% infection in the control group. Although an immune response to a single infection with E. phagocytophila in white-footed mice provided only partial protection against reinfection with the same agent, the majority of mice were rendered reservoir incompetent for at least 12 to 16 weeks. Immunity acquired by mice during I. scapularis nymphal activity in early summer may exclude a large proportion of the mouse population from maintaining E. phagocytophila during the period of larval activity Later in the season.
C1 Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA.
RP Fish, D (corresponding author), Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, 60 Coll St,POB 208034, New Haven, CT 06520 USA.
CR ACKERMAN S, 1981, J PARASITOL, V67, P737, DOI 10.2307/3280459
   BARLOUGH JE, 1995, J CLIN MICROBIOL, V33, P3333, DOI 10.1128/JCM.33.12.3333-3334.1995
   Belongia EA, 1997, J CLIN MICROBIOL, V35, P1465, DOI 10.1128/JCM.35.6.1465-1468.1997
   BENYAKIR D, 1989, J MED ENTOMOL, V26, P243, DOI 10.1093/jmedent/26.4.243
   BROSSARD M, 1984, EXPERIENTIA, V40, P561, DOI 10.1007/BF01982330
   Brun-Hansen H, 1998, J VET MED B, V45, P193, DOI 10.1111/j.1439-0450.1998.tb00783.x
   Bunnell JE, 1998, J WILDLIFE DIS, V34, P179, DOI 10.7589/0090-3558-34.1.179
   Chang YF, 1998, VET PARASITOL, V78, P137, DOI 10.1016/S0304-4017(98)00133-2
   CHEN SM, 1994, J CLIN MICROBIOL, V32, P589, DOI 10.1128/JCM.32.3.589-595.1994
   CHINZEI Y, 1987, MED VET ENTOMOL, V1, P409, DOI 10.1111/j.1365-2915.1987.tb00371.x
   Daniels TJ, 1997, EMERG INFECT DIS, V3, P353, DOI 10.3201/eid0303.970312
   Das S, 1998, INFECT IMMUN, V66, P1803, DOI 10.1128/IAI.66.4.1803-1805.1998
   Des Vignes F, 1999, J MED ENTOMOL, V36, P182, DOI 10.1093/jmedent/36.2.182
   deSilva AM, 1996, J EXP MED, V183, P271, DOI 10.1084/jem.183.1.271
   DesVignes F, 1997, J MED ENTOMOL, V34, P379, DOI 10.1093/jmedent/34.4.379
   DONAHUE JG, 1987, AM J TROP MED HYG, V36, P92, DOI 10.4269/ajtmh.1987.36.92
   DUMLER JS, 1995, J CLIN MICROBIOL, V33, P1098, DOI 10.1128/JCM.33.5.1098-1103.1995
   FIKRIG E, 1992, P NATL ACAD SCI USA, V89, P5418, DOI 10.1073/pnas.89.12.5418
   FISH D, 1995, AM J MED, V98, pS2, DOI 10.1016/S0002-9343(99)80038-2
   FOGGIE A, 1951, J PATHOL BACTERIOL, V63, P1, DOI 10.1002/path.1700630103
   FUJISAKI K, 1984, ANN TROP MED PARASIT, V78, P449, DOI 10.1080/00034983.1984.11811847
   Greig B, 1996, J CLIN MICROBIOL, V34, P44, DOI 10.1128/JCM.34.1.44-48.1996
   Hodzic E, 1998, J INFECT DIS, V177, P737, DOI 10.1086/514236
   Hodzic E, 1998, J CLIN MICROBIOL, V36, P3574, DOI 10.1128/JCM.36.12.3574-3578.1998
   Horowitz HW, 1998, ANN INTERN MED, V129, P461, DOI 10.7326/0003-4819-129-6-199809150-00007
   HUDSON J. R., 1950, British Veterinary Journal, V106, P3
   Kocan KM, 1996, EXP APPL ACAROL, V20, P297, DOI 10.1007/BF00052960
   LARSEN HJS, 1994, RES VET SCI, V56, P216, DOI 10.1016/0034-5288(94)90107-4
   Levin M, 1997, J MED ENTOMOL, V34, P569, DOI 10.1093/jmedent/34.5.569
   Levin ML, 1999, EMERG INFECT DIS, V5, P204, DOI 10.3201/eid0502.990203
   LEVINE JF, 1985, AM J TROP MED HYG, V34, P355, DOI 10.4269/ajtmh.1985.34.355
   Madigan JE, 1996, J CLIN MICROBIOL, V34, P434, DOI 10.1128/JCM.34.2.434-435.1996
   Magnarelli LA, 1997, J WILDLIFE DIS, V33, P466, DOI 10.7589/0090-3558-33.3.466
   MBOGO SK, 1992, INSECT SCI APPL, V13, P481, DOI 10.1017/S1742758400016052
   Nicholson WL, 1998, J CLIN MICROBIOL, V36, P695, DOI 10.1128/JCM.36.3.695-700.1998
   NYINDO MBA, 1978, AM J VET RES, V39, P15
   PANCHOLI P, 1995, J INFECT DIS, V172, P1007, DOI 10.1093/infdis/172.4.1007
   Pusterla N, 1998, J CLIN MICROBIOL, V36, P2035, DOI 10.1128/JCM.36.7.2035-2037.1998
   Schwartz I, 1997, NEW ENGL J MED, V337, P49, DOI 10.1056/NEJM199707033370111
   STAMP J T, 1950, Vet Rec, V62, P465
   Sumner JW, 1997, J CLIN MICROBIOL, V35, P2087, DOI 10.1128/JCM.35.8.2087-2092.1997
   Sun W, 1997, J CLIN INVEST, V100, P3014, DOI 10.1172/JCI119855
   Telford SR, 1996, P NATL ACAD SCI USA, V93, P6209, DOI 10.1073/pnas.93.12.6209
   TUOMI J, 1967, ACTA PATHOL MIC SC, V70, P429
   TYZZER ERNEST E., 1938, PARASITOLOGY, V30, P242
   Van Andel AE, 1998, J AM VET MED ASSOC, V212, P1910
   Walls JJ, 1997, J CLIN MICROBIOL, V35, P853, DOI 10.1128/JCM.35.4.853-855.1997
   WOLDEHIWET Z, 1982, J COMP PATHOL, V92, P457, DOI 10.1016/0021-9975(82)90032-9
   WOLDEHIWET Z, 1983, VET RES COMMUN, V6, P163, DOI 10.1007/BF02214910
NR 49
TC 42
Z9 42
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD MAR
PY 2000
VL 68
IS 3
BP 1514
EP 1518
DI 10.1128/IAI.68.3.1514-1518.2000
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 285UW
UT WOS:000085407400069
PM 10678968
OA Green Published, Bronze
DA 2021-08-04
ER

PT J
AU Jain, P
   Reinhardt, JW
   Krell, KV
AF Jain, P
   Reinhardt, JW
   Krell, KV
TI Effect of dentin desensitizers and dentin bonding agents on dentin
   permeability
SO AMERICAN JOURNAL OF DENTISTRY
LA English
DT Article
ID EVAPORATIVE WATER-LOSS; IN-VITRO; THICKNESS; INVITRO; TIME
AB Purpose: To determine the effect of dentin desensitizing agents (oxalates and glutaraldehyde) and dentin bonding agents, with and without resin-based composite (RBC) on dentin permeability and morphology of the dentin surface. The influence of saliva and toothbrushing on these agents was also evaluated. Materials and Methods: Radicular dentin discs +/-1 mm thick were obtained from extracted human teeth. The thickness of the discs was standardized by grinding them with 600 grit silicon carbide powder. Both pulpal and periodontal surfaces of the discs were treated with 6% citric acid for 2 min prior to the baseline measurement of dentin permeability. Permeability was measured for the discs, using a split-chamber apparatus, at four different time points: at baseline, after treatment with each desensitizing modality, after 24 hrs of saliva immersion and after simulated toothbrushing equivalent to 3 weeks of normal brushing. The treatment modalities were: Sensodyne Dentin Desensitizer, Gluma Dentin Desensitizer, All-Bond DS (primers without etching), Etch+Primers (All-Bond 2 system), Etch+Primers+Adhesive and Etch+Primers+ Adhesive+RBC (Elite Flo). Radicular dentin discs were prepared separately for scanning electron microscopy (SEM). One group was left untreated as the control group. Discs in the other groups were treated with the modalities listed above. One disc from each group was viewed under the SEM after treatment with the desensitizing modality. The second disc in each group was viewed after 24 hrs of saliva immersion following desensitizing treatment and the third disc after 3 weeks of simulated toothbrushing following desensitizing treatment and saliva immersion. Results: The greatest reduction in permeability was caused by All-Bond DS followed by Sensodyne Dentin Desensitizer and Etch+Primers+Adhesive+RBC. Gluma Dentin Desensitizer, Etch+Primers, and Etch+Primers+Adhesive did not reduce permeability by a significant amount. Saliva immersion increased permeability significantly only for the Gluma and Etch+ Primers+Adhesive groups. There was a trend towards increase in permeability after toothbrushing; however, this increase was not statistically significant for any group (P> 0.05). Thus, placement of primers without etching (All-Bond DS) reduced permeability more than any other treatment modality. These data indicate that etching a sensitive dentin area may be appropriate only if RBC is to be placed in the area. Exposure to saliva and toothbrushing countered the decrease in permeability caused by dedicated desensitizers and dentin bonding agents. The SEM micrographs revealed that in most cases, form corroborated function and the morphology of the dentin surface corresponded to the dentin permeability values.
C1 SIU, Sch Dent Med, Dept Restorat Dent, Alton, IL 62002 USA.
   Univ Iowa, Dept Operat Dent, Iowa City, IA USA.
   Univ Iowa, Dept Endodont, Iowa City, IA USA.
RP Jain, P (corresponding author), SIU, Sch Dent Med, Dept Restorat Dent, Bldg 284,2800 Coll Ave, Alton, IL 62002 USA.
CR BOWES J. H., 1966, J ROY MICROSCOP SOC, V85, P193
   CAMPS J, 1994, DENT MATER, V10, P210, DOI 10.1016/0109-5641(94)90034-5
   CIUCCHI B, 1995, J ENDODONT, V21, P191, DOI 10.1016/S0099-2399(06)80564-9
   DIJKMAN GEHM, 1994, SCAND J DENT RES, V102, P144
   FOGEL HM, 1988, J DENT RES, V67, P1381, DOI 10.1177/00220345880670110401
   Goodis H. E., 1994, Archives of Oral Biology, V39, p128S, DOI 10.1016/0003-9969(94)90202-X
   GOODIS H E, 1992, Journal of Dental Research, V71, P162
   GOODIS HE, 1990, ARCH ORAL BIOL, V35, P523, DOI 10.1016/0003-9969(90)90082-L
   Hansen S E, 1992, J Esthet Dent, V4, P169, DOI 10.1111/j.1708-8240.1992.tb00689.x
   MATTHEWS WG, 1993, ARCH ORAL BIOL, V38, P517, DOI 10.1016/0003-9969(93)90188-R
   OUTHWAITE WC, 1974, J DENT RES, V53, P1503, DOI 10.1177/00220345740530064101
   OUTHWAITE WC, 1976, ARCH ORAL BIOL, V21, P599, DOI 10.1016/0003-9969(76)90029-7
   Pashley D H, 1991, Am J Dent, V4, P123
   PASHLEY DH, 1981, J DENT RES, V60, P763, DOI 10.1177/00220345810600031801
   PASHLEY DH, 1988, DENT MATER, V4, P60, DOI 10.1016/S0109-5641(88)80091-5
   's-Gravenmade E J, 1975, J Endod, V1, P233
   Tagami Junji, 1994, Archives of Oral Biology, V39, p146S, DOI 10.1016/0003-9969(94)90220-8
   THOMAS HF, 1983, ARCH ORAL BIOL, V28, P465, DOI 10.1016/0003-9969(83)90145-0
   Zhang Y, 1998, J CLIN PERIODONTOL, V25, P884, DOI 10.1111/j.1600-051X.1998.tb02386.x
NR 19
TC 25
Z9 30
U1 1
U2 4
PU MOSHER & LINDER, INC
PI SAN ANTONIO
PA 9859 IH-10 WEST, SUITE 107/489, SAN ANTONIO, TX 78230-2236 USA
SN 0894-8275
J9 AM J DENT
JI Am. J. Dent.
PD FEB
PY 2000
VL 13
IS 1
BP 21
EP 27
PG 7
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 293PE
UT WOS:000085860700005
PM 11763898
DA 2021-08-04
ER

PT J
AU Howarth, RB
AF Howarth, RB
TI Climate change and the representative agent
SO ENVIRONMENTAL & RESOURCE ECONOMICS
LA English
DT Article
DE climate change; overlapping generations models
ID OVERLAPPING GENERATIONS MODEL; INTERGENERATIONAL EQUITY; DEBATE
AB The artifice of an infinitely-lived representative agent is commonly invoked to balance the present costs and future benefits of climate stabilization policies. Since actual economies are populated by overlapping generations of finite-lived persons, this approach begs important questions of welfare aggregation. This paper compares the results of representative agent and overlapping generations models that are numerically calibrated based on standard assumptions regarding climate-economy interactions. Under two social choice rules - Pareto efficiency and classical utilitarianism - the models generate closely similar simulation results. In the absence of policies to redistribute income between present and future generations, efficient rates of carbon dioxide emissions abatement rise from 15 to 20% between the years 2000 and 2105. Under classical utilitarianism, in contrast, optimal control rates rise from 48 to 79% this same period.
C1 Dartmouth Coll, Environm Studies Program, Hanover, NH 03755 USA.
RP Howarth, RB (corresponding author), Dartmouth Coll, Environm Studies Program, Hanover, NH 03755 USA.
OI Howarth, Richard/0000-0003-3182-7345
FU EPAUnited States Environmental Protection Agency Funding Source: Federal
   RePORTER
CR Auerbach A., 1987, DYNAMIC FISCAL POLIC
   Blanchard Olivier Jean, 1989, LECT MACROECONOMICS
   Broome J, 1992, COUNTING COST GLOBAL
   BURTON PS, 1993, J ENVIRON ECON MANAG, V24, P119, DOI 10.1006/jeem.1993.1008
   CHAPMAN D, 1995, CONTEMP ECON POLICY, V13, P1
   Cline W.R., 1992, EC GLOBAL WARMING
   COASE RH, 1960, J LAW ECON, V3, P1, DOI 10.1086/466560
   GEANAKOPLOS J, 1987, NEW PALGRAVE GEN EQU
   GOLOMBEK R, 1995, RESOUR ENERGY ECON, V17, P25, DOI 10.1016/0928-7655(94)00022-C
   HOWARTH R, 1995, HDB ENV EC
   Howarth RB, 1996, GLOBAL PLANET CHANGE, V11, P187, DOI 10.1016/0921-8181(95)00052-6
   Howarth RB, 1998, SCAND J ECON, V100, P575, DOI 10.1111/1467-9442.00123
   Howarth RB, 1996, CONTEMP ECON POLICY, V14, P100, DOI 10.1111/j.1465-7287.1996.tb00637.x
   KIRMAN AP, 1992, J ECON PERSPECT, V6, P117, DOI 10.1257/jep.6.2.117
   MANNE AS, 1995, ENERG POLICY, V23, P391, DOI 10.1016/0301-4215(95)90163-2
   MANNE AS, 1996, INTERGENERATIONAL AL
   MARINI G, 1995, J ENVIRON ECON MANAG, V29, P64, DOI 10.1006/jeem.1995.1031
   MOURMOURAS A, 1993, J PUBLIC ECON, V51, P249, DOI 10.1016/0047-2727(93)90088-B
   Nordhaus W. D., 1994, MANAGING GLOBAL COMM
   Ramsey FP, 1928, ECON J, V38, P543, DOI 10.2307/2224098
   ROSE A, 1993, RESOUR ENERGY ECON, V15, P117, DOI 10.1016/0928-7655(93)90021-L
   SCHMIDT AA, 1995, HDB ENV EC
   Stephan Gunter., 1997, ENVIRON RESOUR ECON, V10, P27, DOI [10.1023/A:1026479106896, DOI 10.1023/A:1026479106896]
NR 23
TC 1
Z9 1
U1 0
U2 3
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 0924-6460
J9 ENVIRON RESOUR ECON
JI Environ. Resour. Econ.
PD FEB
PY 2000
VL 15
IS 2
BP 135
EP 148
DI 10.1023/A:1008361812597
PG 14
WC Economics; Environmental Studies
SC Business & Economics; Environmental Sciences & Ecology
GA 280UQ
UT WOS:000085122500003
DA 2021-08-04
ER

PT J
AU Kumar, A
   Hovland, AR
   La Rosa, FG
   Cole, WC
   Prasad, JE
   Prasad, KN
AF Kumar, A
   Hovland, AR
   La Rosa, FG
   Cole, WC
   Prasad, JE
   Prasad, KN
TI Relative sensitivity of undifferentiated and cyclic adenosine 3 ',5
   '-monophosphate-induced differentiated neuroblastoma cells to
   cyclosporin A: Potential role of beta-amyloid and ubiquitin in
   neurotoxicity
SO IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL
LA English
DT Article
DE cyclosporine A; differentiated neuroblastoma cells; undifferentiated
   neuroblastoma cells; cAMP; beta-amyloid; ubiquitin; degeneration
ID ALZHEIMERS-DISEASE; NEUROFIBRILLARY TANGLES; BRAIN UBIQUITIN; PROTEIN;
   EXPRESSION; TAU; IMMUNOPHILINS; ACCUMULATION; PATHOGENESIS; PATHOLOGY
AB Cyclosporin A is routinely used in transplant therapy following allogeneic or xenogeneic tissue transplantation to prevent rejection. This immunosuppressive drug is also neurotoxic; however, its mechanisms of action for neurotoxicity are poorly understood. Undifferentiated and cyclic adenosine 3',5'-monophosphate (cAMP)-induced differentiated neuroblastoma (NB) cells were used as an experimental model to study the toxicity of cyclosporin A. Results showed that cyclosporin A promoted the outgrowth of neurites and inhibited the growth of undifferentiated NB cells. When cyclosporin A was added simultaneously with R020-1724, an inhibitor of cyclic nucleotide phosphodiesterase, or with prostaglandin E-1, a stimulator of adenylate cyclase, it markedly enhanced the growth inhibitory and differentiation effects of these cAMP-stimulating agents. In addition, cyclosporin A added to cAMP-induced differentiated NB cells caused dose-dependent degeneration of these cells as evidenced by the vacuolization of cytoplasm and the fragmentation of nuclear and cytoplasmic materials; however, neurites remained intact. Cyclosporin A alone did not alter the intensity of cell immunostaining for ubiquitin or beta-amyloid peptide (amino acids 1-14) (A beta(1-14)); however, it enhanced the intensity of staining for both ubiquitin and A beta in cells that were treated with cAMP-stimulating agents. The intensity of staining of amyloid precursor protein (amino acids 44-63) (APP(44-63)) did not change in any treated group, suggesting that the increase in A beta staining is due to increased processing of APP to A beta. We propose that one of the mechanisms of cyclosporin A-induced neurotoxicity involves increased levels of A beta and ubiquitin.
C1 Univ Colorado, Hlth Sci Ctr, Coll Med, Ctr Vitamins & Canc Res, Denver, CO 80262 USA.
   Univ Colorado, Hlth Sci Ctr, Coll Med, Dept Radiol, Denver, CO 80262 USA.
   Univ Colorado, Hlth Sci Ctr, Webb Waring Inst, Denver, CO 80262 USA.
RP Prasad, KN (corresponding author), Univ Colorado, Hlth Sci Ctr, Coll Med, Ctr Vitamins & Canc Res, 4200 E 9th Ave,Campus Box C 278, Denver, CO 80262 USA.
EM Kedar.Prasad@uchac.edu
RI La Rosa, Francisco G./AAE-9174-2020
FU NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS)
   [R01NS029982, R01NS035348] Funding Source: NIH RePORTER; NINDS NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Neurological
   Disorders & Stroke (NINDS) [R01 NS35348, R01 NS29982] Funding Source:
   Medline
CR CUMMINGS BJ, 1993, NEUROBIOL AGING, V14, P547, DOI 10.1016/0197-4580(93)90038-D
   Dewji NN, 1996, SCIENCE, V271, P159, DOI 10.1126/science.271.5246.159
   Edwards L. L., 1996, Acta Neurologica Scandinavica, V94, P358
   EDWARDS LL, 1995, ACTA NEUROL SCAND, V92, P423
   Gregori L, 1997, J BIOL CHEM, V272, P58
   GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913
   GRUNDKEIQBAL I, 1989, P NATL ACAD SCI USA, V86, P2853, DOI 10.1073/pnas.86.8.2853
   HARDY J, 1991, TRENDS PHARMACOL SCI, V12, P383, DOI 10.1016/0165-6147(91)90609-V
   Hauben M, 1996, PHARMACOTHERAPY, V16, P576
   JENNISSEN HP, 1995, EUR J BIOCHEM, V231, P1
   JOACHIM CL, 1992, ALZ DIS ASSOC DIS, V6, P7, DOI 10.1097/00002093-199205000-00003
   KIM H, 1995, NEUROLOGY, V45, P1768, DOI 10.1212/WNL.45.9.1768
   KUDO T, 1994, BRAIN RES, V639, P1, DOI 10.1016/0006-8993(94)91757-4
   LaFerla FM, 1997, J CLIN INVEST, V100, P310, DOI 10.1172/JCI119536
   LaRosa FG, 1996, J NEUROCHEM, V66, P1845
   LOWE J, 1988, J PATHOL, V155, P9, DOI 10.1002/path.1711550105
   Marks AR, 1996, PHYSIOL REV, V76, P631
   MARTIN LJ, 1994, AM J PATHOL, V145, P1358
   Martinsson P, 1997, EUR J CLIN PHARMACOL, V52, P199, DOI 10.1007/s002280050274
   MARUYAMA K, 1990, NATURE, V347, P566, DOI 10.1038/347566a0
   McDonald JW, 1996, ANN NEUROL, V40, P750, DOI 10.1002/ana.410400511
   MORISHIMAKAWASHIMA M, 1993, NEURON, V10, P1151, DOI 10.1016/0896-6273(93)90063-W
   NAIR APK, 1994, NATURE, V369, P239, DOI 10.1038/369239a0
   PERRY G, 1992, AM J PATHOL, V140, P283
   PRASAD KN, 1973, NATURE-NEW BIOL, V241, P117
   PRASAD KN, 1994, J AM COLL NUTR, V13, P298, DOI 10.1080/07315724.1994.10718412
   PRASAD KN, 1991, BIOL REV, V66, P431, DOI 10.1111/j.1469-185X.1991.tb01148.x
   Prasad KN, 1998, IN VITRO CELL DEV-AN, V34, P265, DOI 10.1007/s11626-998-0133-7
   RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245
   SARAIVA AA, 1985, J SUBMICR CYTOL PATH, V17, P459
   Sasahara Y, 1996, J BIOL CHEM, V271, P25950, DOI 10.1074/jbc.271.42.25950
   SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cellbio.10.1.373
   Shea TB, 1997, J NEUROSCI RES, V49, P759, DOI 10.1002/(SICI)1097-4547(19970915)49:6<759::AID-JNR10>3.0.CO;2-N
   SNYDER SH, 1995, NAT MED, V1, P32, DOI 10.1038/nm0195-32
   Soldatenkov VA, 1997, CANCER RES, V57, P3881
   Steiner JP, 1997, NAT MED, V3, P421, DOI 10.1038/nm0497-421
   TWENTYMAN PR, 1992, BRIT J CANCER, V65, P335, DOI 10.1038/bjc.1992.68
   WANG GP, 1991, BRAIN RES, V566, P146, DOI 10.1016/0006-8993(91)91692-T
   YANKNER BA, 1991, NEW ENGL J MED, V325, P1849
NR 39
TC 2
Z9 2
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1071-2690
EI 1543-706X
J9 IN VITRO CELL DEV-AN
JI In Vitro Cell. Dev. Biol.-Anim.
PD FEB
PY 2000
VL 36
IS 2
BP 81
EP 87
PG 7
WC Cell Biology; Developmental Biology
SC Cell Biology; Developmental Biology
GA 296UY
UT WOS:000086046200004
PM 10718363
DA 2021-08-04
ER

PT J
AU Moll, K
   Haller, B
AF Moll, K
   Haller, B
TI Effect of intrinsic and extrinsic moisture on bond strength to dentine
SO JOURNAL OF ORAL REHABILITATION
LA English
DT Article
ID 4-META/MMA-TBB RESIN; INTERDIFFUSION ZONE; SURFACE MOISTURE; ADHESIVE
   SYSTEMS; WATER-FREE; IN-VIVO; PRESSURE; PRIMER; AGENTS; ULTRASTRUCTURE
AB Objectives: The aim of this in vitro study was to investigate the effects of simulated pulpal pressure (PP) and moist bonding (MB) on the shear bond strength of three different dentine bonding systems (DBSs). Methods: Dentine surfaces were exposed on 120 extracted human molars and bonded with one out of three restorative systems (A.R.T. Bond/Brilliant, OptiBond FL/Herculite XRV, Scotchbond 1/Z100). In one-half of the specimens, the DBSs were applied under hydrostatic pulpal pressure of 30 cm H2O (PP). Forty specimens were prepared for each DBS according to the following experimental groups (each n=10): no PP/no MB; with PP/no MB; no PP/with MB; with PP/with MB. Shear bond stengths after 24 h were measured in a universal testing machine (Zwicki 1120) and statistically analysed by 2-way ANOVA. Fractured surfaces were investigated for the type of failure under an optical stereomicroscope and by SEM. Results: Ln all DBSs, pulpal pressure resulted in a decrease of dentinal bond strength. This effect was significant in A.R.T. Bond and OptiBond FL (P < 0.001), but not in Scotchbond 1 (P=0.060). Moist bonding significantly increased the bond strength of Scotchbond 1 (P < 0.001), significantly decreased the bond strength of A.R.T. Bond (P=0.032), but had no effect in the case of OptiBond FL (P=0.691). In A.R.T. Bond, the combination of hydrostatic pulpal pressure and moist bonding resulted in complete failure of most of the specimens prior to the debonding tests. The fracture patterns as detected by SEM fracture analyses were typical for each DBS and specific bonding condition and consistent with the results of the bond strength measurements. Significance: The results indicate that continuous intrinsic moisture in the form of hydrostatic pulpal pressure adversely affects the efficacy of DBSs, while limited extrinsic moisture by moist bonding is acceptable or even essential. The effect of moist bonding on the efficacy of DBSs seems to depend not only on the monomers used and the solvents per se, but also on the water content of the dentine primer and the self-priming adhesive, respectively.
C1 Univ Ulm, Dept Conservat Dent Periodontol & Pedodont, D-89070 Ulm, Germany.
RP Moll, K (corresponding author), Univ Ulm, Dept Conservat Dent Periodontol & Pedodont, Albert Einstein Allee 11, D-89070 Ulm, Germany.
EM karl-heinz.moll@medizin.uni-ulm.de
CR BERGENHOLTZ G, 1993, J DENT, V21, P220, DOI 10.1016/0300-5712(93)90133-B
   CHARLTON DG, 1994, OPER DENT, V19, P154
   CIUCCHI B, 1995, J ENDODONT, V21, P191, DOI 10.1016/S0099-2399(06)80564-9
   Cox C F, 1994, Am J Dent, V7, P293
   Elhabashy A, 1993, Am J Dent, V6, P123
   ERICKSON RL, 1992, OPER DENT, P81
   Finger WJ, 1996, AM J DENT, V9, P27
   FRIEDL KH, 1995, DTSCH ZAHNAERZTLICHE, V50, P577
   FUSAYAMA T, 1979, J DENT RES, V58, P1364, DOI 10.1177/00220345790580041101
   GARBEROGLIO R, 1976, ARCH ORAL BIOL, V21, P355, DOI 10.1016/S0003-9969(76)80003-9
   Gwinnett A J, 1994, Am J Dent, V7, P144
   Gwinnett A J, 1992, Am J Dent, V5, P127
   HALLER B, 1995, DTSCH ZAHNARZTL Z, V50, P824
   HALLER B, 1992, DTSCH ZAHNARZTL Z, V47, P171
   HOFMANN N, 1991, 1 INT S COMP REST QU, P151
   JACOBSEN T, 1995, DENT MATER, V11, P132, DOI 10.1016/0109-5641(95)80048-4
   Kanca J 3rd, 1992, Quintessence Int, V23, P39
   Kanca J 3rd, 1992, Am J Dent, V5, P213
   MIEARS JR, 1995, AM J DENT, V8, P80
   MITCHEM JC, 1988, DENT MATER, V4, P351, DOI 10.1016/S0109-5641(88)80048-4
   MITCHEM JC, 1991, J PROSTHET DENT, V66, P619, DOI 10.1016/0022-3913(91)90441-X
   NAKABAYASHI N, 1992, DENT MATER, V8, P259, DOI 10.1016/0109-5641(92)90096-U
   NAKABAYASHI N, 1995, AM J DENT, V8, P37
   Nakabayashi N, 1991, J Esthet Dent, V3, P133, DOI 10.1111/j.1708-8240.1991.tb00985.x
   NAKABAYASHI N, 1982, J BIOMED MATER RES, V16, P265, DOI 10.1002/jbm.820160307
   NAKABAYASHI N, 1985, INT DENT J, V35, P145
   Nakabayashi N, 1992, Quintessence Int, V23, P135
   Nikaido T, 1995, Quintessence Int, V26, P221
   ODOR TM, 1994, ENDOD DENT TRAUMATOL, V10, P144
   Pashley D H, 1993, Quintessence Int, V24, P618
   Pashley D H, 1991, Am J Dent, V4, P237
   PASHLEY DH, 1995, DENT MATER, V11, P117, DOI 10.1016/0109-5641(95)80046-8
   Pashley DH, 1994, DTSCH ZAHNARZTL Z, V49, P760
   PASHLEY EL, 1991, ENDOD DENT TRAUMATOL, V7, P207
   PASHLEY EL, 1993, DENT MATER, V9, P19, DOI 10.1016/0109-5641(93)90099-C
   PASHLEY RM, 1981, J COLLOID INTERF SCI, V83, P531, DOI 10.1016/0021-9797(81)90348-9
   Paul S J, 1993, J Esthet Dent, V5, P179
   Perdigao J, 1993, Am J Dent, V6, P61
   PRATI C, 1991, DENT MATER, V7, P54, DOI 10.1016/0109-5641(91)90028-W
   Prati C, 1992, Am J Dent, V5, P33
   SCHALLER HG, 1994, DTSCH ZAHNARZTLICHE, V49, P830
   Swift E J Jr, 1995, Quintessence Int, V26, P95
   TAO L, 1989, DENT MATER, V5, P181, DOI 10.1016/0109-5641(89)90010-9
   Tao L, 1991, Am J Dent, V4, P73
   Tay FR, 1998, J DENT, V26, P147, DOI 10.1016/S0300-5712(96)00090-5
   Tay FR, 1996, AM J DENT, V9, P161
   Tay FR, 1996, J DENT RES, V75, P1034, DOI 10.1177/00220345960750040601
   Tay FR, 1996, DENT MATER, V12, P236, DOI 10.1016/S0109-5641(96)80029-7
   TONDER KJH, 1983, J ENDODONT, V9, P105, DOI 10.1016/S0099-2399(83)80106-X
   Van Meerbeek B, 1992, Curr Opin Dent, V2, P117
   Van Meerbeek B, 1998, J DENT RES, V77, P50, DOI 10.1177/00220345980770010501
   VANHASSEL HJ, 1971, ORAL SURG ORAL MED O, V32, P126, DOI 10.1016/0030-4220(71)90258-1
   VANMEERBEEK B, 1992, J DENT RES, V71, P1530, DOI 10.1177/00220345920710081301
   VANMEERBEEK B, 1993, J DENT RES, V72, P495, DOI 10.1177/00220345930720020501
   Vongsavan N, 1992, Proc Finn Dent Soc, V88 Suppl 1, P491
   Walshaw P R, 1996, Quintessence Int, V27, P619
NR 56
TC 25
Z9 28
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0305-182X
EI 1365-2842
J9 J ORAL REHABIL
JI J. Oral Rehabil.
PD FEB
PY 2000
VL 27
IS 2
BP 149
EP 164
DI 10.1046/j.1365-2842.2000.00495.x
PG 16
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 286TM
UT WOS:000085461800009
PM 10672152
DA 2021-08-04
ER

PT B
AU Terada, K
   Nakamura, T
   Takeda, H
   Ogasawara, T
AF Terada, K
   Nakamura, T
   Takeda, H
   Ogasawara, T
GP IEEE
   IEEE
TI Towards cognitive agents: Embodiment based object recognition for
   vision-based mobile agents
SO 2000 IEEE/RSJ INTERNATIONAL CONFERENCE ON INTELLIGENT ROBOTS AND SYSTEMS
   (IROS 2000), VOLS 1-3, PROCEEDINGS
LA English
DT Proceedings Paper
CT IEEE/Robotics-Society-of-Japan International Conference on Intelligent
   Robots and Systems (IROS 2000)
CY OCT 31-NOV 05, 2000
CL KAGAWA UNIV, TAKAMATSU, JAPAN
SP IEEE, Ind Electr Soc, IEEE, Robot & Automat Soc, Robot Soc Japan, Soc Instrument & Control Engineers, New Technol Fdn, Kagawa Univ
HO KAGAWA UNIV
AB In this paper, we propose a new architecture for recognizing objects based on a concept "embodiment" as one of primitive functions for a cognitive robot. We define the term "embodiment" as the size and shape of the agent's body, locomotive ability and its sensor. According to embodiment, an object is represented by reaching action paths, which correspond to a set of sequences of movements taken by the agent for reaching the object. Such behavior is acquired by the trial-and-error method based on the visual and tactile information. Visual information is used to obtain sensorimotor mapping which represents the relationship between the change of object's appearance and the movement of the agent. On the other hands, tactile information is utilized to evaluate the change of physical condition of the object caused by such movement. By means of this method, the agent can recognize an object without depending on its position and orientation in the environment. To show the validity of our method, we show an experimental result of computer simulation.
C1 Nara Inst Sci & Technol, Dept Informat Syst, Nara 6300101, Japan.
RP Terada, K (corresponding author), Nara Inst Sci & Technol, Dept Informat Syst, 8916-5 Takayama, Nara 6300101, Japan.
RI Takeda, Hideaki/C-4956-2008
OI Takeda, Hideaki/0000-0002-2909-7163; Terada,
   Kazunori/0000-0002-8728-0943; Ogasawara, Tsukasa/0000-0001-9767-6039
CR FUKUDA H, 15 INT C NEUR INF PR, P467
   Gibson JJ., 1979, ECOLOGICAL APPROACH
   NEHMZOW U, 1991, PRACTICE AUTONOMOUS, P96
   SMART WD, 1994, P 3 INT C SIM AD BEH, P174
   Zingaretti P, 1998, IEEE T PATTERN ANAL, V20, P407, DOI 10.1109/34.677272
NR 5
TC 0
Z9 0
U1 0
U2 0
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
BN 0-7803-6349-3
PY 2000
BP 2067
EP 2072
PG 6
WC Engineering, Industrial; Engineering, Electrical & Electronic;
   Instruments & Instrumentation; Robotics
SC Engineering; Instruments & Instrumentation; Robotics
GA BR61C
UT WOS:000166948600332
DA 2021-08-04
ER

PT J
AU Rezvani, AH
   Overstreet, DH
   Mason, GA
   Janowsky, DS
   Hamedi, M
   Clark, E
   Yang, Y
AF Rezvani, AH
   Overstreet, DH
   Mason, GA
   Janowsky, DS
   Hamedi, M
   Clark, E
   Yang, Y
TI Combination pharmacotherapy: A mixture of small doses of naltrexone,
   fluoxetine, and a thyrotropin-releasing hormone analogue reduces alcohol
   intake in three strains of alcohol-preferring rats
SO ALCOHOL AND ALCOHOLISM
LA English
DT Article
ID FREELY MOVING RATS; FAWN-HOODED RATS; TRH ANALOG; DRUG-DEPENDENCE;
   PREFERENCE; ETHANOL; TA-0910; DRINKING; DOPAMINE; HYPERTENSION
AB It is common to treat some diseases with more than one medication simultaneously Since more than one neurotransmitter system is involved in alcohol-seeking behaviour, then a therapeutic approach that targets more than one system should be more effective in reducing alcohol intake than one addressing a single system. To test this hypothesis, we compared the efficacy of low doses of individual drugs reported to reduce voluntary alcohol drinking to the efficacy of a mixture of these agents at the same low doses in reducing alcohol intake in three strains of alcohol-preferring rats (P, HAD, and Fawn-Hooded). After establishment of a stable baseline for alcohol intake in a continuous access paradigm. each rat received separate single i.p. injections of relatively low doses of either naltrexone (2.0 mg/kg), fluoxetine (1.0 mg/kg), the thyrotropin-releasing hormone analogue TA-0910 (0.2 mg). a mixture of all three drugs, or the vehicle at 09:30. Each rat received all treatments, with an inter-injection washout period of at least 3 days. Alcohol and water intakes were measured at 6 and 24 h, and food intake was measured at 24 h, after the injection. Our results show that individual drugs did not significantly affect food, water, or alcohol intake. However, the mixture significantly reduced alcohol intake in all three strains, but had no effect on food intake. Similar results were obtained when the HAD rats received an oral dose of the individual drugs or the mixture. When P rats were given an i.p. injection of the mixture for 10 consecutive days, there was a continued suppressing effect. These findings show that a combination treatment designed to target simultaneously serotonergic, dopaminergic, and opioidergic systems can reduce alcohol intake, even though the doses of the individual drugs in the mixture are relatively low and ineffective when given singly.
C1 Duke Univ, Med Ctr, Dept Psychiat, Durham, NC 27710 USA.
   Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA.
RP Rezvani, AH (corresponding author), Duke Univ, Med Ctr, Dept Psychiat, Box 3412, Durham, NC 27710 USA.
FU NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)
   [R01AA007809] Funding Source: NIH RePORTER; NIAAA NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)
   [AA07809] Funding Source: Medline
CR Anton RF, 1996, ARCH GEN PSYCHIAT, V53, P225
   BAKRIS GL, 1995, J HYPERTENS, V13, pS95, DOI 10.1097/00004872-199508001-00016
   BENJAMIN D, 1993, BRAIN RES, V621, P137, DOI 10.1016/0006-8993(93)90309-B
   BIRKENHAGER TK, 1995, INT CLIN PSYCHOPHARM, V10, P181, DOI 10.1097/00004850-199510030-00008
   CHALMERS J, 1993, CLIN EXP HYPERTENS, V15, P1299, DOI 10.3109/10641969309037113
   Cowen MS, 1999, ALCOHOL CLIN EXP RES, V23, P1008, DOI 10.1097/00000374-199906000-00007
   DEVINE DP, 1993, EUR J PHARMACOL, V243, P55, DOI 10.1016/0014-2999(93)90167-G
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   FARRNE CK, 1997, ALCOHOLISM CLIN EXPT, V21, P64
   Froehlich J C, 1993, Recent Dev Alcohol, V11, P187
   FROEHLICH JC, 1990, PHARMACOL BIOCHEM BE, V35, P385, DOI 10.1016/0091-3057(90)90174-G
   Gardell LR, 1997, ALCOHOL CLIN EXP RES, V21, P1435
   GRANT KA, 1995, DRUG ALCOHOL DEPEN, V38, P155, DOI 10.1016/0376-8716(95)01120-N
   HODGE CW, 1993, ALCOHOL, V10, P191, DOI 10.1016/0741-8329(93)90034-L
   HODGE CW, 1993, ALCOHOL CLIN EXP RES, V17, P370, DOI 10.1111/j.1530-0277.1993.tb00778.x
   KOOB GF, 1994, EXS, V71, P103
   Lankford MF, 1996, ALCOHOL, V13, P53, DOI 10.1016/0741-8329(95)02011-X
   LE AD, 1994, ALCOHOL ALCOHOLIS S2, V29, P545
   LEVINE JH, 1995, AM J HYPERTENS, V8, P494, DOI 10.1016/0895-7061(95)00053-R
   LI TK, 1995, CLIN NEUROSCI, V3, P182
   MASON GA, 1994, ALCOHOL CLIN EXP RES, V18, P1196, DOI 10.1111/j.1530-0277.1994.tb00104.x
   Mason GA, 1996, ALCOHOL CLIN EXP RES, V20, P1000, DOI 10.1111/j.1530-0277.1996.tb01937.x
   Mason GA, 1997, ALCOHOL CLIN EXP RES, V21, P1623, DOI 10.1111/j.1530-0277.1997.tb04499.x
   MCBRIDE WJ, 1990, ALCOHOL, V7, P199, DOI 10.1016/0741-8329(90)90005-W
   Menard J, 1993, Blood Press Suppl, V1, P5
   MURPHY JM, 1988, ALCOHOL, V5, P283, DOI 10.1016/0741-8329(88)90066-3
   NAKAGAWA H, 1996, JAPANESE J CANC CHEM, V23, P783
   OMALLEY SS, 1992, ARCH GEN PSYCHIAT, V49, P881
   Overstreet DH, 1996, ALCOHOL CLIN EXP RES, V20, P221, DOI 10.1111/j.1530-0277.1996.tb01633.x
   OVERSTREET DH, 1995, SOC NEUR ABSTR
   PRISANT LM, 1995, AM HEART J, V130, P359, DOI 10.1016/0002-8703(95)90454-9
   PUCILOWSKI O, 1992, PSYCHOPHARMACOLOGY, V107, P447, DOI 10.1007/BF02245174
   REID LD, 1991, ALCOHOL, V8, P247, DOI 10.1016/0741-8329(91)90305-G
   REZVANI AH, 1991, ALCOHOL ALCOHOLISM, V26, P161, DOI 10.1093/oxfordjournals.alcalc.a045097
   REZVANI AH, 1990, PROG NEURO-PSYCHOPH, V14, P623, DOI 10.1016/0278-5846(90)90013-7
   REZVANI AH, 1994, PHARMACOL BIOCHEM BE, V48, P105, DOI 10.1016/0091-3057(94)90505-3
   REZVANI AH, 1995, PHARMACOL BIOCHEM BE, V52, P615, DOI 10.1016/0091-3057(95)00152-M
   REZVANI AH, 1990, ALCOHOL ALCOHOLISM, V25, P573
   REZVANI AH, 1986, ALCOHOL, V3, P273, DOI 10.1016/0741-8329(86)90037-6
   REZVANI AH, 1992, ALCOHOL CLIN EXP RES, V16, P326, DOI 10.1111/j.1530-0277.1992.tb01385.x
   REZVANI AH, 1991, ALCOHOL ALCOHOLISM, P433
   REZVANI AH, 1996, SOC NEUR ABSTR
   Rezvani Amir H., 1993, Alcoholism Clinical and Experimental Research, V17, P515
   ROSE JE, 1992, PHARMACOL BIOCHEM BE, V41, P219, DOI 10.1016/0091-3057(92)90086-U
   ROSENTHAL TC, 1992, AM FAM PHYSICIAN, V46, P1721
   Salloum IM, 1998, PSYCHOPHARMACOL BULL, V34, P111
   Schumm-Draeger P M, 1993, Z Gesamte Inn Med, V48, P592
   TANDA G, 1995, PSYCHOPHARMACOLOGY, V119, P15, DOI 10.1007/BF02246048
   TILLER JWG, 1992, AUST NZ J PSYCHIAT, V26, P327, DOI 10.3109/00048679209072051
   VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876
   WILLIAMS LD, 1997, ALCOHOLISM CLIN EXPT, V21, P33
   YAMAMURA M, 1991, JPN J PHARMACOL, V55, P57, DOI 10.1254/jjp.55.57
   ZINK RW, 1997, ALCOHOLISM CLIN EX S, V21, P105
NR 53
TC 49
Z9 50
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0735-0414
EI 1464-3502
J9 ALCOHOL ALCOHOLISM
JI Alcohol Alcohol.
PD JAN-FEB
PY 2000
VL 35
IS 1
BP 76
EP 83
DI 10.1093/alcalc/35.1.76
PG 8
WC Substance Abuse
SC Substance Abuse
GA 286MC
UT WOS:000085448900016
PM 10684782
OA Bronze
DA 2021-08-04
ER

PT J
AU Kersten, JR
   Montgomery, MW
   Pagel, PS
   Warltier, DC
AF Kersten, JR
   Montgomery, MW
   Pagel, PS
   Warltier, DC
TI Levosimendan, a new positive inotropic drug, decreases myocardial
   infarct size via activation of K-ATP channels
SO ANESTHESIA AND ANALGESIA
LA English
DT Article
ID POTASSIUM CHANNELS; CALCIUM SENSITIZER; TROPONIN-C; BLOOD-FLOW; DOGS;
   HEART; RELAXATION; MILRINONE; BLOCKADE; AGENT
AB We tested the hypothesis that levosimendan, a new positive inotropic drug that activates adenosine triphosphate-regulated potassium (K-ATP) channels in vitro, decreases myocardial infarct size in vivo. Myocardial infarct size was measured after a 60-min left anterior descending coronary artery occlusion and 3 h of reperfusion in dogs receiving either IV vehicle (0.9% saline) or levosimendan (24 mu g/kg bolus followed by an infusion of 0.4 mu g . kg(-1) . min(-1)) in the presence or absence of glyburide (a K-ATP channel antagonist) pretreatment (100 mu g/kg). Levosimendan increased (P < 0.05) the maximal rate of increase of left ventricular pressure and decreased myocardial infarct size from 24% +/- 2% (control experiments) to 11% +/- 2% of the left ventricular area at risk for infarction. Glyburide did not alter the hemodynamic effects of levosimendan but blocked levosimendan-induced reductions of infarct size. Subendocardial collateral blood flow was similar among groups. However, levosimendan increased subepicardial and midmyocardial collateral perfusion in the absence, but not in the presence, of glyburide. Levosimendan exerts cardioprotective effects via activation of K-ATP channels at a dose that simultaneously enhances myocardial contractility. Implications: Levosimendan may be advantageous in patients requiring inotropic support who are also at risk of myocardial ischemia. Activation of adenosine triphosphate-regulated potassium channels during infusion of levosimendan may produce cardioprotective effects while simultaneously enhancing ventricular contractile function.
C1 Med Coll Wisconsin, Dept Anesthesiol, Milwaukee, WI 53226 USA.
   Med Coll Wisconsin, Dept Pharmacol, Milwaukee, WI 53226 USA.
   Med Coll Wisconsin, Dept Med, Div Cardiovasc Dis, Milwaukee, WI 53226 USA.
   Zablocki Vet Affairs Med Ctr, Milwaukee, WI USA.
RP Kersten, JR (corresponding author), Med Coll Wisconsin, Dept Anesthesiol, MEB Room 462C,8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.
FU NHLBI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [HL 54280, HL 03690] Funding Source: Medline; NIGMS
   NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [GM 08377] Funding Source: Medline; NATIONAL
   HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Heart Lung & Blood Institute (NHLBI) [K08HL003690] Funding Source: NIH
   RePORTER
CR AUCHAMPACH JA, 1992, CIRCULATION, V86, P311, DOI 10.1161/01.CIR.86.1.311
   AUCHAMPACH JA, 1993, AM J PHYSIOL, V264, pH1327
   Bowman P, 1999, J PHARMACOL EXP THER, V288, P316
   EDES I, 1995, CIRC RES, V77, P107, DOI 10.1161/01.RES.77.1.107
   GROSS GJ, 1992, CIRC RES, V70, P223, DOI 10.1161/01.RES.70.2.223
   HAIKALA H, 1995, J CARDIOVASC PHARM, V25, P794, DOI 10.1097/00005344-199505000-00016
   Haikala H, 1997, CARDIOVASC RES, V34, P536, DOI 10.1016/S0008-6363(97)00057-6
   HARKIN CP, 1995, J CARDIOVASC PHARM, V26, P179, DOI 10.1097/00005344-199508000-00002
   Jamali IN, 1997, ANESTH ANALG, V85, P23, DOI 10.1097/00000539-199707000-00005
   Kersten JR, 1999, ANESTHESIOLOGY, V90, P246, DOI 10.1097/00000542-199901000-00031
   Kersten JR, 1997, ANESTHESIOLOGY, V87, P361, DOI 10.1097/00000542-199708000-00024
   Kersten JR, 1998, ANESTHESIOLOGY, V88, P495, DOI 10.1097/00000542-199802000-00029
   Kitakaze M, 1997, CIRCULATION, V95, P2108, DOI 10.1161/01.CIR.95.8.2108
   LAMPING KA, 1984, J PHARMACOL EXP THER, V229, P359
   Lamping KG, 1998, BASIC RES CARDIOL, V93, P136, DOI 10.1007/s003950050074
   Lilleberg J, 1995, J CARDIOVASC PHARM, V26, pS63
   LILLEBERG J, 1994, EUR J CLIN PHARMACOL, V47, P267, DOI 10.1007/BF02570507
   MINKES RK, 1991, AM J PHYSIOL, V260, pH957
   Nijhawan N, 1999, J CARDIOVASC PHARM, V34, P219, DOI 10.1097/00005344-199908000-00007
   PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103
   PAGEL PS, 1994, ANESTHESIOLOGY, V81, P974, DOI 10.1097/00000542-199410000-00025
   RUMP AFE, 1994, BRIT J PHARMACOL, V112, P757, DOI 10.1111/j.1476-5381.1994.tb13143.x
   SARGENT CA, 1991, J PHARMACOL EXP THER, V259, P97
   YAO ZH, 1994, CIRCULATION, V89, P1769, DOI 10.1161/01.CIR.89.4.1769
   Yokoshiki H, 1997, J PHARMACOL EXP THER, V283, P375
   Yokoshiki H, 1997, EUR J PHARMACOL, V333, P249, DOI 10.1016/S0014-2999(97)01108-4
NR 26
TC 191
Z9 206
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD JAN
PY 2000
VL 90
IS 1
BP 5
EP 11
DI 10.1097/00000539-200001000-00003
PG 7
WC Anesthesiology
SC Anesthesiology
GA 270WF
UT WOS:000084559600003
PM 10624967
DA 2021-08-04
ER

PT J
AU Chen, SH
   Yeh, CH
AF Chen, SH
   Yeh, CH
TI Simulating economic transition processes by genetic programming
SO ANNALS OF OPERATIONS RESEARCH
LA English
DT Article
DE Kolmogorov complexity; minimum description length principle; genetic
   programming; bounded rationality; short selling
ID AUTOREGRESSIVE CONDITIONAL HETEROSKEDASTICITY
AB Recently, genetic programming has been proposed to model agents' adaptive behavior in a complex transition process where uncertainty cannot be formalized within the usual probabilistic framework. However, this approach has not been widely accepted by economists. One of the main reasons is the lack of the theoretical foundation of using genetic programming to model transition dynamics. Therefore, the purpose of this paper is two-fold. First, motivated by the recent applications of algorithmic information theory in economics, we would like to show the relevance of genetic programming to transition dynamics given this background. Second, we would like to supply two concrete applications to transition dynamics. The first application, which is designed for the pedagogic purpose, shows that genetic programming can simulate the Iron-smooth transition, which is;difficult to be captured by conventional tool kits, such as differential equations and difference equations. In the second application, genetic;programming is:applied to simulate the adaptive behavior of speculators. This simulation shows that genetic programming can generate artificial time series with the statistical properties frequently observed in real financial time series.
C1 Natl Chengchi Univ, Dept Econ, AI ECON Res Grp, Taipei 11623, Taiwan.
RP Chen, SH (corresponding author), Natl Chengchi Univ, Dept Econ, AI ECON Res Grp, 64 Chihnan Rd,Sec 2 Wenshan, Taipei 11623, Taiwan.
OI Chen, Shu-Heng/0000-0003-4584-7646
CR ARTHUR B, 1992, 9207038 SANT FE I EC
   Arthur B.W., 1996, SANTA FE I WORKING P
   BLACK F, 1986, J FINANC, V41, P529, DOI 10.2307/2328481
   BOLLERSLEV T, 1986, J ECONOMETRICS, V31, P307, DOI 10.1016/0304-4076(86)90063-1
   BOLLERSLEV T, 1992, J ECONOMETRICS, V52, P5, DOI 10.1016/0304-4076(92)90064-X
   BROWN RL, 1975, J ROY STAT SOC B MET, V37, P149
   CHEN S, 1996, ISIS INFORMATION STA, P200
   Chen S.-H., 1997, LECT NOTES COMPUTER, V1213, P137
   CHEN SH, 1996, MANAGING INT BUSINES, V1, P159
   CHEN SH, 1996, P 5 ANN C EV PROGR E, P277
   Chen SH, 1996, ADV GENETIC PROGRAMM, V2, P443
   CHEN SH, 1996, 1996 CHIN SOC STAT A
   DAVIDSON P, 1991, J ECON PERSPECT, V5, P129, DOI 10.1257/jep.5.1.129
   DELIMA PJF, 1997, NONLINEARITIES NONST
   DOWE DL, 1996, ISIS INFORMATION STA, P200
   Ezekiel M, 1938, Q J ECON, V52, P255, DOI 10.2307/1881734
   HAAVELMO T, 1944, ECONOMETRICA S, V12, P1
   HAMILTON JD, 1994, J ECONOMETRICS, V64, P307, DOI 10.1016/0304-4076(94)90067-1
   KALMAN RE, 1994, MODEL IDENT CONTROL, V15, P141, DOI 10.4173/mic.1994.3.3
   Koza JR, 1992, GENETIC PROGRAMMING, V1
   KUAN CM, 1995, J APPL ECONOMET, V10, P347, DOI 10.1002/jae.3950100403
   LEIJONHUFVUD A, 1993, SOUTHERN ECON J, V60, P1, DOI 10.2307/1059926
   LENSBERG T, 1997, GENETIC PROGRAMMING
   MARCET A, 1989, J ECON THEORY, V48, P337, DOI 10.1016/0022-0531(89)90032-X
   MUTH JF, 1961, ECONOMETRICA, V29, P315, DOI 10.2307/1909635
   NEIL JR, 1996, ISIS INFORMATION STA, P78
   Rissanen J., 1989, STOCHASTIC COMPLEXIT
   Sargent T., 1993, BOUNDED RATIONALITY
   SOLOMONOFF R, 1996, C INF STAT IND SCI M
   Velupillai K., 1995, TAIWAN J POLITICAL E, V1, p53 
   Vintanyi P, 1993, INTRO KOLMOGOROV COM
NR 31
TC 8
Z9 8
U1 0
U2 1
PU BALTZER SCI PUBL BV
PI BUSSUM
PA PO BOX 221, 1400 AE BUSSUM, NETHERLANDS
SN 0254-5330
J9 ANN OPER RES
JI Ann. Oper. Res.
PY 2000
VL 97
BP 265
EP 286
DI 10.1023/A:1018972006990
PG 22
WC Operations Research & Management Science
SC Operations Research & Management Science
GA 396NR
UT WOS:000166643900018
DA 2021-08-04
ER

PT B
AU Bonnefoy, JL
   Le Page, C
   Rouchier, J
   Bousquet, F
AF Bonnefoy, JL
   Le Page, C
   Rouchier, J
   Bousquet, F
BE Ballot, G
   Weisbuch, G
TI Modelling spatial practices and social representations of space using
   multi-agent systems
SO APPLICATIONS OF SIMULATION TO SOCIAL SCIENCES
LA English
DT Proceedings Paper
CT 2nd International Conference on Computer Simulations and the Social
   Sciences
CY SEP 18-20, 2000
CL PARIS, FRANCE
SP Univ Paris 2 Pantheon Assas, CNRS
DE modelling; multi-agent systems; geographical space; social
   representations; sustainable development
ID HABITAT
AB This paper demonstrates that multi-agent systems have the capacity to model a region in all its complexity. An example is developed to show that these tools are not only capable of spatializing and distributing the behaviour of individuals, but above all, that they allow individuals to integrate different perceptions of space as well as the constraints imposed on them by a community. A dialectic is established between individuals, spaces and society, which is used to simulate a region using clearly defined social representations and spatial practices, which are suitable for testing our geographical theories and hypotheses.
C1 Univ Aix Marseille 1, UFR Geog, F-13628 Aix En Provence, France.
RI Bousquet, Francois/G-3605-2010; Le Page, Christophe/E-6856-2010;
   Bousquet, Francois/Y-7904-2019
OI Le Page, Christophe/0000-0002-1920-0091; Bousquet,
   Francois/0000-0002-4552-3724
CR BONNEFOY JL, 1998, CIRCULARITE ENTRE MO
   BOUSQUET F, 1999, ADV ENV ECOLOGICAL M, P113
   BOUSQUET F, 1999, REV EUROPEENNE GEOGR
   BOUSQUET F, 1996, TRAGEDY COMMONS GAME
   BURA S, 1993, MULTIAGENT SYSTEMS D
   Drogoul A., 1993, SIMULATION MULTIAGEN
   Epstein J.M., 1996, GROWING ARTIFICIAL S
   Ferber J., 1995, SYSTEMES MULTIAGENTS
   FOLSE LJ, 1989, ECOL MODEL, V46, P57, DOI 10.1016/0304-3800(89)90069-0
   Gilbert N, 1995, ARTIFICIAL SOCIETIES, P144
   HARDIN G, 1968, SCIENCE, V162, P1243, DOI 10.1126/science.162.3859.1243
   Kohler T. A., 1996, ARCH APPL GIS UISPP
   Krebs F, 1997, ECOL MODEL, V96, P143, DOI 10.1016/S0304-3800(96)00050-6
   LANSING JS, 1994, ARTIFICIAL LIFE, V3
   PEPPER JW, 1999, DYNAMICS HUMAN PRIMA
   ROESE JH, 1991, ECOL MODEL, V57, P133, DOI 10.1016/0304-3800(91)90058-9
   Schmitz OJ, 1997, EVOL ECOL, V11, P379, DOI 10.1023/A:1018476606256
NR 17
TC 6
Z9 6
U1 0
U2 2
PU HERMES SCIENCE PUBLICATIONS
PI PARIS
PA 8 QUAI DU MARCHE-NEUF, 75004 PARIS, FRANCE
BN 1-903398-04-5
PY 2000
BP 155
EP 168
PG 4
WC Computer Science, Interdisciplinary Applications; Social Sciences,
   Mathematical Methods
SC Computer Science; Mathematical Methods In Social Sciences
GA BS80E
UT WOS:000171155300011
DA 2021-08-04
ER

PT B
AU Ewasiuk, RJ
   Hong, S
   Desai, V
   Maze, J
   Storey, C
   Easter, W
AF Ewasiuk, RJ
   Hong, S
   Desai, V
   Maze, J
   Storey, C
   Easter, W
BE Opila, RL
   Ali, I
   Arimoto, YA
   Homma, Y
   ReidsmaSimpson, C
   Sundaram, KV
TI Filtration effects on chemical mechanical polishing slurries
SO CHEMICAL MECHANICAL PLANARIZATION IN IC DEVICE MANUFACTURING III,
   PROCEEDINGS
SE ELECTROCHEMICAL SOCIETY SERIES
LA English
DT Proceedings Paper
CT 3rd International Symposium on Chemical Mechanical Planarization in
   Integrated Circuit Device Manufacturing
CY OCT 20-22, 1999
CL HONOLULU, HI
SP Electrochem Soc, Electr Div, Electrochem Soc, Dielect Sci & Technol Div
AB The filtration of a silica based slurry was evaluated under oxide CMP processing conditions at Lucent Technologies' Orlando, Florida facility. Initially, the particle size and particle size distribution of the slurry was characterized with a dynamic light scatterer and a single optical particle sizer. The particle size distribution analysis was confirmed with a SEM. The change in particle size was then measured during pH titration of the slurry from 10.6 (stock pH) to 2 pH. Only minimal aggregation in the slurry was apparent even at the lowest pH, though severe aggregation is expected near the isoelectric point, between 2 and 4. This behavior is probably due to the proprietary stabilizing agents (surfactants) in the slurry.
   The oxide polishing line at Lucent Technologies currently supports a global filtration system that incorporates two Millipore CMP polypropylene graded density microfilters in series. To evaluate POU filtration, a toot filter was placed just before the polishing station on the first table of an Ebara polisher, while the second table was left unfiltered. The two tables polished blanket oxide wafers simultaneously and defect data was analyzed before and after a post clean bath on a KLA-Tencor Surfscan AIT.
   Preliminary results show that there is no statistical difference in defect data between POU filtered and unfiltered silica based slurry at Lucent when recirculating filters are being used. This is true for both doped (PSG) and un-doped (USG) oxide wafers, with and without post cleaning of the wafers. This defect data includes not only macroscratches and large particles, but also small particles and microscratches. A study is now underway to determine if a difference in the POU filtered and unfiltered slurry polishing data may lie in the microscratch number only.
C1 Univ Cent Florida, Adv Mat Proc & Anal Ctr, Orlando, FL 32826 USA.
RP Ewasiuk, RJ (corresponding author), Univ Cent Florida, Adv Mat Proc & Anal Ctr, Orlando, FL 32826 USA.
CR ALI S, 1994, SOLID STATE TECHNOL, V10, P63
   CAPITANIO D, 1999, J ADV APPL CONTAMINA, V2, P25
   Elimelech M., 1995, PARTICLE DEPOSITION
   LIN Z, 1998, MILLIPORE MICROELECT
   MYERS T, 1995, SOLID STATE TECHNOL, V10, P59
   NICOLI DF, 1995, AM LAB, V4, P42
NR 6
TC 0
Z9 0
U1 0
U2 0
PU ELECTROCHEMICAL SOCIETY INC
PI PENNINGTON
PA 65 S MAIN ST, PENNINGTON, NJ 08534-2839 USA
BN 1-56677-260-5
J9 ELEC SOC S
PY 2000
VL 99
IS 37
BP 408
EP 419
PG 2
WC Computer Science, Hardware & Architecture; Electrochemistry;
   Engineering, Electrical & Electronic
SC Computer Science; Electrochemistry; Engineering
GA BP98L
UT WOS:000086805700044
DA 2021-08-04
ER

PT S
AU Lux, T
   Marchesi, M
AF Lux, T
   Marchesi, M
BE Holly, S
TI Volatility clustering in financial markets: A micro-simulation of
   interacting agents
SO COMPUTATION IN ECONOMICS, FINANCE AND ENGINEERING: ECONOMIC SYSTEMS
SE IFAC SYMPOSIA SERIES
LA English
DT Proceedings Paper
CT IFAC Symposium on Computation in Economics, Finance and Engineering:
   Economic Systems
CY JUN 29-JUL 01, 1998
CL CAMBRIDGE, ENGLAND
SP Int Federat Automat Control, Soc Computat Econ
DE volatility clustering; interacting agents; on-off intermittency
ID INTERMITTENCY; DYNAMICS; CHAOS
AB The finding of clustered volatility and ARCH effects is ubiquitous in financial data. This paper presents a possible explanation of this phenomenon within a multi-agent framework of speculative activity. In the model, both chartist and fundamentalist strategies are considered with agents switching between both behavioural variants according to observed differences in pay-offs. Price changes are brought about by a market maker reacting on imbalances between demand and supply. Most of the time, a stable and efficient market results. However, its usual tranquil performance is interspersed by sudden transient phases of destabilisation. Outbreak of volatility occurs if the fraction of agents using chartist techniques surpasses a certain threshold value, but such phases are quickly brought to an end by stabilising tendencies. Formally, this pattern can be understood as an example of a new type of dynamic behaviour denoted on-off intermittency in physics literature. Statistical analysis of simulated time series shows that the main stylised facts (unit roots in levels together with heteroscedasticity and leptokurtosis of returns) can be found in this "artificial" market. Copyright (C) 1998 IFAC.
C1 Univ Bonn, Dept Econ, D-5300 Bonn, Germany.
RP Lux, T (corresponding author), Univ Bonn, Dept Econ, D-5300 Bonn, Germany.
RI Marchesi, Michele/U-7048-2019
CR DAY RH, 1990, J ECON BEHAV ORGAN, V14, P299, DOI 10.1016/0167-2681(90)90061-H
   De Vries CG, 1994, HDB INT MACROECONOMI, P348
   FUJISAKA H, 1986, PROG THEOR PHYS, V75, P1087, DOI 10.1143/PTP.75.1087
   HEAGY JF, 1994, PHYS REV E, V49, P1140, DOI 10.1103/PhysRevE.49.1140
   KIRMAN A, 1993, Q J ECON, V108, P137, DOI 10.2307/2118498
   Lux T, 1998, J ECON BEHAV ORGAN, V33, P143, DOI 10.1016/S0167-2681(97)00088-7
   LUX T, 1995, ECON J, V105, P881, DOI 10.2307/2235156
   Lux T, 1997, J ECON DYN CONTROL, V22, P1, DOI 10.1016/S0165-1889(97)00061-4
   Pagan A., 1996, J EMPIR FINANC, V3, P15, DOI [10.1016/0927-5398(95)00020-8, DOI 10.1016/0927-5398(95)00020-8]
   Youssefmir M, 1997, J ECON BEHAV ORGAN, V32, P101, DOI 10.1016/S0167-2681(96)00021-2
NR 10
TC 1
Z9 1
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI KIDLINGTON
PA THE BOULEVARD, LANGFORD LANE,, KIDLINGTON OX5 1GB, OXFORD, ENGLAND
SN 0962-9505
BN 0-08-043048-1
J9 IFAC SYMP SERIES
PY 2000
BP 7
EP 10
PG 4
WC History & Philosophy Of Science; Mathematics
SC History & Philosophy of Science; Mathematics
GA BT50H
UT WOS:000173158300002
DA 2021-08-04
ER

PT B
AU Rekleitis, IM
   Dudek, G
   Milios, EE
AF Rekleitis, IM
   Dudek, G
   Milios, EE
BE Parker, LE
   Bekey, G
TI Graph-based. exploration using multiple robots
SO DISTRIBUTED AUTONOMOUS ROBOTIC SYSTEMS
LA English
DT Proceedings Paper
CT 5th International Symposium on Distributed Autonomous Robotic Systems
   (DARS 2000)
CY OCT 04-06, 2000
CL OAK RIDGE NATL LAB, KNOXVILLE, TN
SP Oak Ridge Natl Lab, USDOE, Engn Res Program, Off Basic Energy Sci, IEEE, Robot & Automat Soc, IEEE, Ind Electr Soc, Robot Soc Japan, Japan Soc Mech Engn, Soc Instrument & Control Engn Japan
HO OAK RIDGE NATL LAB
DE multi-robot; exploration; mapping; cooperation; sensor fusion
ID NAVIGATION
AB We present an approach to multi-robot exploration of large environments. Our method is designed to be robust in the face of arbitrarily large odometry errors or objects with poor reflectance characteristics. The algorithm achieves its robustness by using a team of cooperating agents. The critical aspect of our method is the use of a vision system that sweeps areas of free space and generates a graph-based description of the environment. This graph is used to guide the exploration process and can also be used for subsequent tasks such as place recognition or path planning. As a result of the guidance provided by the dual graph of the triangulated environment, our system can guarantee complete exploration without any overlaps.
   We present an algorithmic solution, simulation results, as well as a cost analysis and experimental data. In this approach a pair of robots observe one another's behavior, thus greatly reducing odometry errors. We assume the robots can both directly sense nearby obstacles and see one another (if their view is not obstructed). We have implemented both these capabilities with actual robots in our lab.
C1 McGill Univ, Ctr Intelligent Mach, Montreal, PQ H3A 2A7, Canada.
RP Rekleitis, IM (corresponding author), McGill Univ, Ctr Intelligent Mach, 3480 Univ St, Montreal, PQ H3A 2A7, Canada.
RI Dudek, Gregory L/H-3567-2012
OI Rekleitis, Ioannis/0000-0002-0655-224X
CR Bachelder IA, 1995, ROBOT AUTON SYST, V16, P267, DOI 10.1016/0921-8890(95)00051-8
   Balch T., 1994, Autonomous Robots, V1, P27, DOI 10.1007/BF00735341
   Borenstein J, 1997, J ROBOTIC SYST, V14, P231
   DUDEK G, 1995, IROS '95 - 1995 IEEE/RSJ INTERNATIONAL CONFERENCE ON INTELLIGENT ROBOTS AND SYSTEMS: HUMAN ROBOT INTERACTION AND COOPERATIVE ROBOTS, PROCEEDINGS, VOL 2, P268, DOI 10.1109/IROS.1995.526171
   Lin CC, 1997, J ROBOTIC SYST, V14, P93
   Lu F, 1997, AUTON ROBOT, V4, P333, DOI 10.1023/A:1008854305733
   LUMELSKY VJ, 1990, IEEE T ROBOTIC AUTOM, V6, P462, DOI 10.1109/70.59357
   MACKENZIE P, 1994, P INT C ROB AUT
   Rekleitis IM, 1997, INT JOINT CONF ARTIF, P1340
   SIM R, 1999, P INT C ROB AUT ICRA
   Thrun S, 1998, MACH LEARN, V31, P29, DOI 10.1023/A:1007436523611
   Thrun S, 1998, AUTON ROBOT, V5, P253, DOI 10.1023/A:1008806205438
NR 12
TC 17
Z9 17
U1 0
U2 0
PU SPRINGER-VERLAG TOKYO
PI TOKYO
PA 37-3, HONGO 3-CHOME BONKYO-KU, TOKYO, 113, JAPAN
BN 4-431-70295-4
PY 2000
BP 241
EP 250
PG 10
WC Automation & Control Systems
SC Automation & Control Systems
GA BR08T
UT WOS:000165613900023
DA 2021-08-04
ER

PT B
AU Riley, P
   Veloso, M
AF Riley, P
   Veloso, M
BE Parker, LE
   Bekey, G
TI On behavior classification in adversarial environments
SO DISTRIBUTED AUTONOMOUS ROBOTIC SYSTEMS
LA English
DT Proceedings Paper
CT 5th International Symposium on Distributed Autonomous Robotic Systems
   (DARS 2000)
CY OCT 04-06, 2000
CL OAK RIDGE NATL LAB, KNOXVILLE, TN
SP Oak Ridge Natl Lab, USDOE, Engn Res Program, Off Basic Energy Sci, IEEE, Robot & Automat Soc, IEEE, Ind Electr Soc, Robot Soc Japan, Japan Soc Mech Engn, Soc Instrument & Control Engn Japan
HO OAK RIDGE NATL LAB
AB In order for robotic systems to be successful in domains with other agents possibly interfering with the accomplishing of goals, the agents must be able to adapt to the opponents' behavior. The more quickly the agents can respond to a new situation, the better they will perform. We present an approach to doing adaptation which relies on classification of the current adversary into predefined adversary classes. For feature extraction, we present a windowing technique to abstract useful but not overly complicated features. The feature extraction and classification steps are fully implemented in the domain of simulated robotic soccer, and experimental results are presented.
C1 Carnegie Mellon Univ, Dept Comp Sci, Pittsburgh, PA 15213 USA.
RP Riley, P (corresponding author), Carnegie Mellon Univ, Dept Comp Sci, Pittsburgh, PA 15213 USA.
EM pfr@cs.cmu.edu; veloso@cs.cmu.edu
CR CARMEL D, 1995, LECT NOTES ARTIF INT, P40
   HAN K, 1999, P IJCAI 99 WORKSH TE
   MATATIC MJ, 1995, LECT NOTES ARTIF INT, P206
   Noda I, 1998, APPL ARTIF INTELL, V12, P233, DOI 10.1080/088395198117848
   Quinlan J. R., 1993, C4 5 PROGRAMS MACHIN
   RAMONI M, 1999, KMITR78 OP U KNOWL M
   RILEY P, 1999, CMUCS99175
   SEN S, 1995, LECT NOTES ARTIF INT, P206
   Stone P, 1999, LECT NOTES ARTIF INT, V1604, P61
   THOM B, 1999, INT C COMP MUS CHIN
NR 10
TC 30
Z9 30
U1 0
U2 0
PU SPRINGER-VERLAG TOKYO
PI TOKYO
PA 37-3, HONGO 3-CHOME BONKYO-KU, TOKYO, 113, JAPAN
BN 4-431-70295-4
PY 2000
BP 371
EP 380
PG 10
WC Automation & Control Systems
SC Automation & Control Systems
GA BR08T
UT WOS:000165613900035
DA 2021-08-04
ER

PT J
AU Gieschke, R
   Steimer, JL
AF Gieschke, R
   Steimer, JL
TI Pharmacometrics: modelling and simulation tools to improve decision
   making in clinical drug development
SO EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
LA English
DT Article; Proceedings Paper
CT FIP Bio-International 99 Conference
CY SEP 29-OCT 01, 1999
CL LONDON, ENGLAND
SP Int Pharmacetu Federat, Acad Pharmaceut Sci & Technol, Agcy Evaluat Med Prod, Human Med Evaluat Unit, Bundesinstitut Arzneimmittel & Med Prod, European Federat Pharmaceut Sci, Japan Pharmaceut Assoc, Japan Pharmacuet MFG Assoc, Royal Pharmaceut Soc Great Britain, US Pharmacopoe Convent Inc, Therapeutic Prod Programme, Hlth Canada, US FAO
DE pharmacometrics; clinical drug development; mathematical model;
   pharmacokinetics; pharmacodynamics; computer simulation; clinical trial
ID POPULATION PHARMACOKINETICS
AB There is broad recognition within the pharmaceutical industry that the drug development process, especially the clinical part of it, needs considerable improvement to cope with rapid changes in research and health care environments. Modelling and simulation are mathematically founded techniques that have been used extensively and for a long time in other areas than the pharmaceutical industry (e.g. automobile, aerospace) to design and develop products more efficiently. Both modelling and simulation rely on the use of (mathematical and statistical) models which are essentially simplified descriptions of complex systems under investigation. It has been proposed to integrate pharmacokinetic (PK) and pharmacodynamic (PD) principles into drug development to make it more rational and efficient. There is evidence from a survey on 18 development projects that a PK/PD guided approach can contribute to streamline the drug development process. This approach extensively relies on PK/PD models describing the relationships among dose, concentration land more generally exposure), and responses such as surrogate markers, efficacy measures, adverse events. Well documented empirical and physiologically based PK/PD models are becoming available more and more, and there are ongoing efforts to integrate models for disease progression and patient behavior (e.g. compliance) as well.
   Other types of models which are becoming increasingly important are population PK/PD models which, in addition to the characterization of PK and PD, involve relationships between covariates (i.e. patient characteristics such as age, body weight) and PK/PD parameters. Population models allow to assess and to quantify potential sources of variability in exposure and response in the target population, even under sparse sampling conditions. As will be shown for an anticancer agent, implications of significant covariate effects can be evaluated by computer simulations using the population PK/PD model.
   Stochastic simulation is widely used as a tool for evaluation of statistical methodology including for example the evaluation of performance of measures for bioequivalence assessment. Recently, it was suggested to expand the use of simulations in support of clinical drug development for predicting outcomes of planned trials. The methodological basis for this approach is provided by (population) PK/PD models together with random sampling techniques. Models for disease progression and behavioral features like compliance, drop-out rates, adverse event dependent dose reductions, etc. have to be added to population PK/PD models in order to mimic the real situation. It will be shown that computer simulation helps to evaluate consequences of design features on safety and efficacy assessment of the drug, enabling identification of statistically valid and practically realisable study designs. For both modelling and simulation a guidance on 'best practices' is currently worked out by a panel of experts comprising representatives from academia, regulatory bodies and industry, thereby providing a necessary condition that model-based analysis and simulation will further contribute to streamlining pharmaceutical drug development processes.
C1 F Hoffmann La Roche, Pharma Dev, Basel, Switzerland.
RP Gieschke, R (corresponding author), F Hoffmann La Roche, Dept Biometr Biostat, CH-4070 Basel, Switzerland.
CR Amstein R., 1996, PHARM RES, V13, pS452
   DAYNEKA NL, 1993, J PHARMACOKINET BIOP, V21, P457, DOI 10.1007/BF01061691
   Food Drug Administration: U.S. Department of Health and Human Services, 1999, GUID IND POP PHARM C
   Gieschke R, 1997, INT J CLIN PHARM TH, V35, P469
   Gieschke R, 1999, CLIN PHARMACOKINET, V37, P75, DOI 10.2165/00003088-199937010-00005
   GIESCHKE R, 1999, ANN M AM SOC CLIN ON
   Hale MD, 1996, APPL CLIN TRIALS, V5, P35
   Holford N. H. G., 1999, SIMULATION DRUG DEV
   HOLFORD NHG, 1981, CLIN PHARMACOKINET, V6, P429, DOI 10.2165/00003088-198106060-00002
   INGRAM D, 1986, MATH METHODS MED, P1
   NOWAK MA, 1991, MATH BIOSCI, V106, P1, DOI 10.1016/0025-5564(91)90037-J
   PECKHAM M, 1995, OXFORD TXB ONCOLOGY, P3
   *PRIC, 1999, PHARM 2005 SIL RALL
   Reigner BG, 1997, CLIN PHARMACOKINET, V33, P142, DOI 10.2165/00003088-199733020-00005
   Samara E, 1997, CLIN PHARMACOKINET, V32, P294, DOI 10.2165/00003088-199732040-00003
   SHEINER LB, 1979, CLIN PHARMACOL THER, V25, P358
   STEIMER JL, 1994, HANDB EXP PHARMACOL, V110, P405
   STEIMER JL, 1998, MEASUREMENT KINETICS, P79
   Vozeh S, 1996, CLIN PHARMACOKINET, V30, P81, DOI 10.2165/00003088-199630020-00001
   WEINSTEIN GD, 1985, PSORIASIS, P233
NR 20
TC 48
Z9 49
U1 0
U2 11
PU MEDECINE ET HYGIENE
PI GENEVA 4
PA 78 AVE ROSERALE, 1211 GENEVA 4, SWITZERLAND
SN 0378-7966
J9 EUR J DRUG METAB PH
JI Eur. J. Drug Metabol. Pharmacokinet.
PD JAN-MAR
PY 2000
VL 25
IS 1
BP 49
EP 58
DI 10.1007/BF03190058
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 358PN
UT WOS:000089566600012
PM 11032091
DA 2021-08-04
ER

PT B
AU Sullivan, DG
   Grosz, BJ
   Kraus, S
AF Sullivan, DG
   Grosz, BJ
   Kraus, S
GP IEEE
   IEEE
TI Intention reconciliation by collaborative agents
SO FOURTH INTERNATIONAL CONFERENCE ON MULTIAGENT SYSTEMS, PROCEEDINGS
LA English
DT Proceedings Paper
CT 4th International Conference on MultiAgent Systems
CY JUL 10-12, 2000
CL BOSTON, MA
SP IFMAS, Charles River Analyt, Nokia, DARPA, NSF, AAAI
AB Research on resource-bounded agents has established that rational agents need to be able to revise their commitments in the light of new opportunities. In the context of collaborative activities rational agents must be able to reconcile their intentions to do team-related actions with other conflicting intentions. The SPIRE experimental system allows the process of intention reconciliation in team contexts to be simulated and studied. Prior work with SPIRE examined the effect of team norms, environmental factors, and agent utility functions on individual and group outcomes for homogeneous groups of agents. This paper extends these results to situations involving heterogeneous groups in which agents use different utility functions. The paper provides new illustrations of the ways in which SPIRE can reveal unpredicted interactions among the variables involved, and it suggests preliminary principles for designers of collaborative agents.
C1 Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA.
RP Sullivan, DG (corresponding author), Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA.
CR BRATMAN MICHAEL, 1987, INTENTION PLANS PRAC
   Castelfranchi C, 1998, ARTIF INTELL, V103, P157, DOI 10.1016/S0004-3702(98)00056-3
   Decker K, 1998, INTERNATIONAL CONFERENCE ON MULTI-AGENT SYSTEMS, PROCEEDINGS, P104, DOI 10.1109/ICMAS.1998.699038
   DOYLE J, 1991, PRINCIPLES OF KNOWLEDGE REPRESENTATION AND REASONING, P163
   GLASS A, 1999, IN PRESS P 4 INT C A
   Grosz BJ, 1999, APPL LOG SER, V14, P227
   Grosz BJ, 1996, ARTIF INTELL, V86, P269, DOI 10.1016/0004-3702(95)00103-4
   Grosz BJ, 1999, AI MAG, V20, P23
   HOLLANDER H, 1990, AM ECON REV, V80, P1157
   HORTY J, 1998, P 7 C THEOR ASP RAT, P249
   IANNACCONE LR, 1992, J POLIT ECON, V100, P271, DOI 10.1086/261818
   KALENKA S, 1999, P 5 INT C COGN SCI, P153
   Kinny D., 1994, Artificial Social Systems. 4th European Workshop on Modelling Autonomous Agents in a Multi-Agent World, MAAMAW '92. Selected Papers, P227
   Kraus S, 1996, ARTIF INTELL, V83, P297, DOI 10.1016/0004-3702(95)00059-3
   LEVESQUE HJ, 1990, PROCEEDINGS : EIGHTH NATIONAL CONFERENCE ON ARTIFICIAL INTELLIGENCE, VOLS 1 AND 2, P94
   Rosenschein J. S., 1994, RULES ENCOUNTER DESI
   Sandholm T, 1999, IJCAI-99: PROCEEDINGS OF THE SIXTEENTH INTERNATIONAL JOINT CONFERENCE ON ARTIFICIAL INTELLIGENCE, VOLS 1 & 2, P535
   Sen S, 1997, INT J HUM-COMPUT ST, V47, P407, DOI 10.1006/ijhc.1997.0139
   SEN S, 1996, P 2 INT C MULT SYST, P322
   Sullivan DG, 1999, LECT NOTES ARTIF INT, V1652, P149
   Sycara K, 1996, INT J COOP INF SYST, V5, P181, DOI 10.1142/S0218843096000087
   Tambe M, 1997, J ARTIF INTELL RES, V7, P83, DOI 10.1613/jair.433
   XUAN P, 1999, P ATAL 99, P221
NR 23
TC 11
Z9 11
U1 0
U2 1
PU IEEE COMPUTER SOC
PI LOS ALAMITOS
PA 10662 LOS VAQUEROS CIRCLE, PO BOX 3014, LOS ALAMITOS, CA 90720-1264 USA
BN 0-7695-0625-9
PY 2000
BP 293
EP 300
DI 10.1109/ICMAS.2000.858466
PG 8
WC Computer Science, Artificial Intelligence
SC Computer Science
GA BR48W
UT WOS:000166609100038
OA Green Published
DA 2021-08-04
ER

PT B
AU Witkowski, M
   Pitt, J
AF Witkowski, M
   Pitt, J
GP IEEE
   IEEE
TI Objective trust-based agents: Trust and trustworthiness in a multiagent
   trading society
SO FOURTH INTERNATIONAL CONFERENCE ON MULTIAGENT SYSTEMS, PROCEEDINGS
LA English
DT Proceedings Paper
CT 4th International Conference on MultiAgent Systems
CY JUL 10-12, 2000
CL BOSTON, MA
SP IFMAS, Charles River Analyt, Nokia, DARPA, NSF, AAAI
AB In this paper we develop a notion of "objective trust" for Software Agents, that is trust of or between, Agents based on actual experiences between those Agents. Experiential objective trust allows Agents to make decisions about how to select other Agents when a choice has to be made. We introduce a mechanism for such an "objective Trust-Based Agent" (oTB-Agent). The trust one Agent places in another is dynamic, updated on the basis of each experience. We summarise experimental results obtained from a simulated trading environment.
C1 Univ London Imperial Coll Sci Technol & Med, Intelligent & Interact Syst Grp, Dept Elect & Elect Engn, London SW7 2BT, England.
RP Witkowski, M (corresponding author), Univ London Imperial Coll Sci Technol & Med, Intelligent & Interact Syst Grp, Dept Elect & Elect Engn, Exhibit Rd, London SW7 2BT, England.
CR Castelfranchi C, 1998, INTERNATIONAL CONFERENCE ON MULTI-AGENT SYSTEMS, PROCEEDINGS, P72, DOI 10.1109/ICMAS.1998.699034
   Gambetta Diego., 1988, TRUST MAKING BREAKIN
   JONKER CM, 1999, P 9 EUR WORKSH MOD A, P221
   WITKOWSKI M, 2000, P WORKSH TRUST FRAUD
NR 4
TC 2
Z9 2
U1 0
U2 0
PU IEEE COMPUTER SOC
PI LOS ALAMITOS
PA 10662 LOS VAQUEROS CIRCLE, PO BOX 3014, LOS ALAMITOS, CA 90720-1264 USA
BN 0-7695-0625-9
PY 2000
BP 463
EP 464
DI 10.1109/ICMAS.2000.858526
PG 2
WC Computer Science, Artificial Intelligence
SC Computer Science
GA BR48W
UT WOS:000166609100098
OA Green Submitted
DA 2021-08-04
ER

PT B
AU Hait, FB
AF Hait, FB
BE Arabnia, HR
TI A multi-agent system integrating a learning process applied to Financial
   market
SO IC-AI'2000: PROCEEDINGS OF THE INTERNATIONAL CONFERENCE ON ARTIFICIAL
   INTELLIGENCE, VOL 1-III
LA English
DT Proceedings Paper
CT International Conference on Artificial Intelligence (IC-AI'2000)
CY JUN 26-29, 2000
CL LAS VEGAS, NV
SP Comp Sci, Res, Educ, & Applicat Press, Int Technol Inst, Korea Informat Processing Soc, PDPTA, World Sci & Engn Soc
DE objets; agents; learning; financial market; Ada '95
AB This paper presents a Multi-agent System (MAS) applied model to design a financial market system. The key impact of an agent approach is that the behavior of the whole system can be understood by fragmenting it into many small autonomous and interacting units and by specifying the behavior of each unit. The agents actions in their environment are inductive. It means the market agents are allowed to adapt and learn from their environment by recording the success and the failure of their past actions. It is shown in the paper how agents make or loose money according to their ability for learning from their environment. An interesting result concerns agent oriented simulation in social systems where various issues can be investigated to study the emergent dynamic of the system and understand more about the relationship between micro-levels specification of individual entities and the macro level emergent behavior of the whole system. Our experimental results show clearly emergent features like the mass effect and the correlation appearing between the number of agents and their enrichment's speed and performance in the market.
C1 Univ Paris 12, Dept Math Informat, F-94010 Creteil, France.
RP Hait, FB (corresponding author), Univ Paris 12, Dept Math Informat, 61 Ave GAL de Gaulle, F-94010 Creteil, France.
CR ARTHUR WB, 1991, LEARNING ADAPTIV MAY, P353
   BENACHOUR F, UNPUB METHODE APPREN
   BIAIS B, 1997, MICROSTRUCTURE MARCH
   BURNS A, 1998, CONCURRENCY ADA
   COELMAN D, 1996, FUSION METHODE ORIEN
   Ferber J., 1995, SYSTEMES MULTIAGENTS
   GROSSMAN SJ, 1981, REV ECON STUD, V48, P541, DOI 10.2307/2297195
   HAIT FB, 1999, TR19
   *INT STAND ORG, 1995, 8652 ISOIEC
   JENNINGS NR, 1998, AGENTS TECHNOLOGY FD
   KINNY D, LNAI, P56
   KUHNEL R, 1997, P SEARCH INT C ART I
   LIN LJ, 1992, MACH LEARN, V8, P293, DOI 10.1023/A:1022628806385
   LITTLEFIELD AI, ACM ADA LETT, V18
   LOEPER H, 1997, ADA LETT, V17
   NAIDITCH DJ, 1995, RENDEZVOUS ADA 95
   PALMER RG, 1994, PHYSICA D, V75, P264, DOI 10.1016/0167-2789(94)90287-9
   Rumbaugh J, 1991, OBJECT ORIENTED MODE
   SMITH MA, 1996, OBJECT ORIENTED SOFT
   TAN GSH, 1998, SIM S
   TAYLER P., 1995, INTELLIGENT SYSTEMS
   Uhrmacher AM, 1997, T SOC COMPUT SIMUL I, V14, P59
   WATKINS CJCH, 1992, MACH LEARN, V8, P279, DOI 10.1007/bf00992698
   WEISS G, 1996, LECT NOTES ARTIF INT, V1042, P1
NR 24
TC 0
Z9 0
U1 0
U2 0
PU C S R E A PRESS
PI ATHENS
PA 115 AVALON DR, ATHENS, GA 30606 USA
BN 1-892512-59-9
PY 2000
BP 681
EP 690
PG 10
WC Computer Science, Artificial Intelligence; Computer Science, Information
   Systems
SC Computer Science
GA BS04Y
UT WOS:000168455000092
DA 2021-08-04
ER

PT S
AU Baldini, A
   Benso, A
   Chiusano, S
   Prinetto, P
AF Baldini, A
   Benso, A
   Chiusano, S
   Prinetto, P
GP IEEE COMPUTER SOCIETY
   IEEE COMPUTER SOCIETY
TI "BOND": An interposition agents based fault injector for Windows NT
SO IEEE INTERNATIONAL SYMPOSIUM ON DEFECT AND FAULT TOLERANCE IN VLSI
   SYSTEMS, PROCEEDINGS
SE IEEE International Symposium on Defect and Fault Tolerance in VLSI
   Systems
LA English
DT Proceedings Paper
CT IEEE International Symposium on Defect and Fault Tolerance in VLSI
   Systems
CY OCT 25-27, 2000
CL YAMANASHI, JAPAN
SP IEEE Comp Soc, IEEE Comp Soc Tech Comm Fault Tolerant Comp, IEEE Comp Soc Test Technol Techn Comm, Techn Grp Fault Tolerant Syst,IEICE
AB The goal of this paper is To present BOND, a Software Fault Injection tool able to simulate abnormal behavior of a computer system running Windows NT4.0 Operating System. The Fault injector is based on interposition techniques, which guarantees a low impact on the execution of the target program, and allows the injection of Commercial off-the-Shelf software programs.
   BOND allows performing both statistical and deterministic Fault Injection experiments, tracking-off between overhead and precision of the obtained results. Moreover; the tool is capable of injecting faults into different locations, at any level of the application context (code and data sections, stack, heap, processor's registers, system calls,...). A complete set of experimental results on different application programs demonstrates the effectiveness and the flexibility of the tool.
C1 Politecn Torino, Dipartimento Automat & Informat, I-10129 Turin, Italy.
RP Baldini, A (corresponding author), Politecn Torino, Dipartimento Automat & Informat, Corso Abruzzi 24, I-10129 Turin, Italy.
EM baldini@polito.it; benso@polito.it; chiusano@polito.it;
   prinetto@polito.it
RI Benso, Alfredo/ABC-5311-2020
OI Benso, Alfredo/0000-0003-3433-7739; CHIUSANO, SILVIA
   ANNA/0000-0002-5740-5004
CR ARLAT J, 1990, IEEE T SOFTWARE ENG, V16, P166, DOI 10.1109/32.44380
   BINDERBERGER M, 1998, RISKS DIGEST, V19
   CHOI GS, 1992, IEEE T COMPUT, V41, P1515, DOI 10.1109/12.214660
   CLARK JA, 1993, P A REL MAI, P428, DOI 10.1109/RAMS.1993.296819
   CLARK JA, 1995, IEEE COMPUTER    JUN, P47
   CZECK E, 1993, INT WORK FAULT ERR I
   FUCHS E, 1998, P 6 DEP COMP CRIT AP, P225
   GHORMLEY DP, 1997, INTERPOSITION OPERAT
   GHOSH AK, WRAPPING WINDOWS NT
   GOSWAMI KK, 1991, P 5 INT C FAULT TOL, P300
   JONES MB, 1993, ACM SIGOPS OPERATING, V27, P80
   Kanawati G.A., 1992, P 22 INT S FAULT TOL, P336, DOI DOI 10.1109/FTCS.1992.243567
   KANAWATI GA, 1993, COMP AER C SAN DIEG, P1297
   NARASIMHAN P, 1999, IEEE COMPUTER, V32
   RIMEN M, 1994, 24 INT S FAULT TOL C, P76
   SEGALL Z, 1988, P 18 INT S FAULT TOL, P102
NR 16
TC 11
Z9 11
U1 0
U2 0
PU IEEE COMPUTER SOC
PI LOS ALAMITOS
PA 10662 LOS VAQUEROS CIRCLE, PO BOX 3014, LOS ALAMITOS, CA 90720-1264 USA
SN 1550-5774
BN 0-7695-0719-0; 0-7695-0720-4
J9 INT SYM DEFEC FAU TO
PY 2000
BP 387
EP 395
PG 9
WC Computer Science, Hardware & Architecture; Engineering, Electrical &
   Electronic
SC Computer Science; Engineering
GA BR64Q
UT WOS:000167065500042
DA 2021-08-04
ER

PT J
AU Stewart, LS
AF Stewart, LS
TI Differential effects of a physiologically patterned low-intensity agent
   on tie formation of an olfactory memory trace
SO INTERNATIONAL JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE electromagnetic fields; hippocampus; learning; olfactory recognition;
   rat
ID LONG-TERM POTENTIATION; SYNAPTIC PLASTICITY; HIPPOCAMPUS; RATS
AB Male rats were exposed to a low-intensity (300 500 nT) electromagnetic (EM) field designed to simulate primed burst potentiation (PB) for 30 min preceding a one-trial olfactory learning task involving two brief encounters a with a juvenile rat during a baseline (reference) and an experimental (EM) trial. The amount of time spent engaged in behaviors defining social investigation (i.e., sniffing, grooming) during the second encounter of the experimental trial was significantly elevated in adult rats receiving continuous EM stimulation prior to the initial encounter. These results support the hypothesis that LTP-like stimulation disrupts the acquisition of a learning task if the stimulus is delivered before training.
C1 Laurentian Univ, Dept Biol, Behav Neurosci Lab, Sudbury, ON P3E 2C6, Canada.
RP Stewart, LS (corresponding author), Laurentian Univ, Dept Biol, Behav Neurosci Lab, Sudbury, ON P3E 2C6, Canada.
CR Abraham WC, 1996, TRENDS NEUROSCI, V19, P126, DOI 10.1016/S0166-2236(96)80018-X
   BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0
   BRENNAN PA, 1994, NEUROSCIENCE, V60, P701, DOI 10.1016/0306-4522(94)90498-7
   Brennan PA, 1997, PROG NEUROBIOL, V51, P457, DOI 10.1016/S0301-0082(96)00069-X
   Chaillan FA, 1996, J PHYSIOLOGY-PARIS, V90, P343, DOI 10.1016/S0928-4257(97)87916-8
   Griesbach GS, 1998, BEHAV BRAIN RES, V97, P29, DOI 10.1016/S0166-4328(98)00015-1
   Maaswinkel H, 1996, PHYSIOL BEHAV, V60, P55, DOI 10.1016/0031-9384(95)02233-3
   MAREN S, 1994, BEHAV NEUROSCI, V108, P44, DOI 10.1037/0735-7044.108.1.44
   MORRIS RGM, 1994, NMDA RECEPTOR, P340
   Rose G., 1988, SYNAPTIC PLASTICITY, P96
   STEWART LS, 1999, IN PRESS INT J NEURO
NR 11
TC 3
Z9 3
U1 1
U2 1
PU GORDON BREACH SCI PUBL LTD
PI READING
PA C/O STBS LTD, PO BOX 90, READING RG1 8JL, BERKS, ENGLAND
SN 0020-7454
J9 INT J NEUROSCI
JI Int. J. Neurosci.
PY 2000
VL 103
IS 1-4
BP 19
EP 23
DI 10.3109/00207450009003248
PG 5
WC Neurosciences
SC Neurosciences & Neurology
GA 346BG
UT WOS:000088849900002
PM 10938559
DA 2021-08-04
ER

PT J
AU Puura, AIE
   Rorarius, MGF
   Laippala, P
   Baer, GA
AF Puura, AIE
   Rorarius, MGF
   Laippala, P
   Baer, GA
TI Does monitoring of post-tetanic count prevent alarms of airway pressure
   or visible muscle activity during intratracheal jet ventilation? A
   prospective study with five different neuromuscular blocking agents
SO JOURNAL OF CLINICAL MONITORING AND COMPUTING
LA English
DT Article
DE monitoring, airway pressure; neuromuscular block; Ventilation,
   intratracheal jet ventilation
ID POSTTETANIC COUNT; SUCCINYLCHOLINE; STIMULATION; BLOCKADE; PTC
AB Objective. Profound neuromuscular block (NMB) quantified by post-tetanic count (PTC) may prevent all muscle activity during anesthesia. We studied whether monitoring of PTC prevents airway pressure alarms or visible movements of the vocal cords and the abdomen during endo-laryngeal procedures (ELPs). Methods. In this prospective, double blind, study 50 healthy (ASA 1-3) patients scheduled for ELPs were randomized into five groups: atracurium, mivacurium, rocuronium, vecuronium and succinylcholine. During alfentanil-propofol anaesthesia, profound NMB was controlled by monitoring the PTC (target level PTC 0-2, 50 Hz tetanic stimulation) of the adductor pollicis muscle. The muscle relaxants were administered using bolus dosing in all groups but in the succinylcholine group. The early signs of recovery of NMB to be observed were: 1) airway pressure alarms, 2) movements of vocal cords on the laryngeal video monitor and 3) movements of the abdomen. The inference was based on 90% confidence interval tests. Results. During 50 ELP:s following signs of early recovery of NMB were recognized: 2 alarms of airway pressure, 16 laryngeal movements and 11 movements of the abdomen. The proportion of airway pressure alarms was significantly lower than proportion of all detectable movements (95% confidence interval analysis). Twelve of the movements were recorded at PTC zero level. The signs of early recovery of NMB were detected in all groups. Conclusions. PTC-monitoring following 50 Hz stimulation does not ensure total inactivity of muscles during alfentanil-propofol anesthesia, regardless which relaxant has been chosen. During ELPs, simultaneous observation of the vocal cords and the abdomen is more sensitive in detecting early recovery of NMB compared to our method of airway pressure monitoring.
C1 Tampere Univ, Sch Med, FIN-33101 Tampere, Finland.
   Tampere Univ Hosp, Dept Anaesthesia, Tampere, Finland.
   Tampere Univ, Sch Publ Hlth, FIN-33101 Tampere, Finland.
RP Puura, AIE (corresponding author), Katajatie 19 B, FIN-36200 Kangasala, Finland.
CR BAER GA, 1995, J CLIN MONITOR, V11, P373, DOI 10.1007/BF01616743
   BAER GA, 1985, THESIS ACTA U TAMPER
   Dhonneur G, 1999, ANESTHESIOLOGY, V90, P951, DOI 10.1097/00000542-199904000-00004
   ERIKSSON LI, 1990, BRIT J ANAESTH, V65, P487, DOI 10.1093/bja/65.4.487
   Fernandes LA, 1997, J CLIN ANESTH, V9, P48, DOI 10.1016/S0952-8180(96)00210-3
   FERNANDO PUE, 1987, ACTA ANAESTH SCAND, V31, P593, DOI 10.1111/j.1399-6576.1987.tb02627.x
   HOWARDYHANSEN P, 1984, ANESTHESIOLOGY, V60, P372, DOI 10.1097/00000542-198404000-00019
   LEE C, 1980, BRIT J ANAESTH, V52, P173, DOI 10.1093/bja/52.2.173
   MEISTELMAN C, 1991, ANESTH ANALG, V73, P278
   MERLE JC, 1995, BRIT J ANAESTH, V74, P333, DOI 10.1093/bja/74.3.333
   Puura AIE, 1999, ANESTH ANALG, V88, P1335
   Roberts F L, 1988, Anaesthesia, V43 Suppl, P14, DOI 10.1111/j.1365-2044.1988.tb09061.x
   SADDLER JM, 1992, BRIT J ANAESTH, V69, P26, DOI 10.1093/bja/69.1.26
   SILVERMAN DG, 1993, ANESTH ANALG, V76, P1284, DOI 10.1213/00000539-199376060-00017
   SMITH CE, 1988, ANESTH ANALG, V67, P625
   VIBYMOGENSEN J, 1981, ANESTHESIOLOGY, V55, P458, DOI 10.1097/00000542-198110000-00024
   VIBYMOGENSEN J, 1984, NEW DEV NEUROMUSCULA, P71
NR 17
TC 2
Z9 2
U1 0
U2 0
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 1387-1307
J9 J CLIN MONITOR COMP
JI J. Clin. Monitor. Comp.
PY 2000
VL 16
IS 7
BP 523
EP 528
DI 10.1023/A:1011431723515
PG 6
WC Anesthesiology
SC Anesthesiology
GA 450KH
UT WOS:000169741400008
PM 12580211
DA 2021-08-04
ER

PT J
AU Blasizza, E
   Fermeglia, M
   Pricl, S
AF Blasizza, E
   Fermeglia, M
   Pricl, S
TI Dendrimers as functional materials. A molecular simulation study of
   poly(propylene) imine starburst molecules
SO MOLECULAR SIMULATION
LA English
DT Article; Proceedings Paper
CT Virtual Conference on Applications and Methodology of Molecular
   Simulation in the Physical and Biological Sciences
CY APR 19-MAY 04, 1999
CL ELECTR NETWORK
SP Molec Simulat
DE dendrimers; functional materials; poly(propylene)imine
ID DYNAMICS SIMULATIONS
AB Dendritic macromolecules are hyperbranched polymers that emanate from a central core, have a defined number of generations and functional end groups, and are synthesized in a stepwise process by a repetitive reaction sequence. This hyperbranched topology results in a unique series of physical and chemical properties exhibited by these molecules which, in turn, could be exploited in a number of diverse possible applications, such as nanoscale catalysis, micelle mimics, immune-diagnostic and NMR imaging agents, chemical sensors, molecular antennae, just to name a few.
   Nonetheless, if on one hand the synthesis procedure allows for control over parameters such as size, shape and reactivity (and hence, on final properties), on the other hand it really hampers the production of large quantities of these materials. Accordingly, their cost is still quite high and, therefore, the materials available for characterization is still rather limited.
   Since, however, their full application potentials (particularly in material science and engineering) will not be realized before the understanding of their physical properties is considerably more advanced, in this work we report the results obtained on structural details and related properties of several amine- and nitrile-terminated poly(propylene)imine dendrimer generations by computer simulation studies and discuss them in the light of(scarce) available experimental data.
C1 Univ Trieste, DICAMP, Dept Chem Environm & Raw Mat Engn, Comp Aided Syst Lab, I-34127 Trieste, Italy.
RP Pricl, S (corresponding author), Univ Trieste, DICAMP, Dept Chem Environm & Raw Mat Engn, Comp Aided Syst Lab, Piazzale Europa 1, I-34127 Trieste, Italy.
RI Pricl, Sabrina/M-7493-2015; Fermeglia, Maurizio/O-3973-2018
OI Pricl, Sabrina/0000-0001-8380-4474; Fermeglia,
   Maurizio/0000-0001-8810-5082
CR AMIT AG, 1986, SCIENCE, V233, P7047
   ANDERSEN HC, 1980, J CHEM PHYS, V72, P2384, DOI 10.1063/1.439486
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   BONDI A, 1968, PHYSICAL PROPERTIES
   CONNOLLY ML, 1985, J AM CHEM SOC, V107, P1118, DOI 10.1021/ja00291a006
   CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985
   CRAM DJ, 1988, ANGEW CHEM INT EDIT, V27, P109
   de Gennes P. G., 1983, J PHYS LETT, V44, P351, DOI DOI 10.1051/IPHYSLET:01983004409035100
   deBrabander EMM, 1996, MACROMOL SYMP, V102, P9, DOI 10.1002/masy.19961020104
   DEBRABANDERVANDENBERG EMM, 1993, ANGEW CHEM INT EDIT, V32, P1308, DOI 10.1002/anie.199313081
   HANSEN CM, 1969, IND ENG CHEM PROD RD, V8, P2, DOI 10.1021/i360029a002
   Lehn JM, 1988, ANGEW CHEM, V100, P91, DOI DOI 10.1002/ANGE.19881000110
   LEWIS M, 1985, SCIENCE, V230, P1163, DOI 10.1126/science.4071040
   MAYO SL, 1990, J PHYS CHEM-US, V94, P8897, DOI 10.1021/j100389a010
   RAPPE AK, 1991, J PHYS CHEM-US, V95, P3358, DOI 10.1021/j100161a070
   Scott, 1950, SOLUBILITY NONELECTR
   TOMALIA DA, 1990, ANGEW CHEM INT EDIT, V29, P138, DOI 10.1002/anie.199001381
   Van Krevelen D.W., 1990, PROPERTIES POLYM, V3rd ed.
   WALDMAN M, 1993, J COMPUT CHEM, V14, P1077, DOI 10.1002/jcc.540140909
NR 19
TC 9
Z9 9
U1 0
U2 6
PU GORDON BREACH SCI PUBL LTD
PI READING
PA C/O STBS LTD, PO BOX 90, READING RG1 8JL, BERKS, ENGLAND
SN 0892-7022
J9 MOL SIMULAT
JI Mol. Simul.
PY 2000
VL 24
IS 1-3
BP 167
EP +
DI 10.1080/08927020008024194
PG 25
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA 355VK
UT WOS:000089409100012
DA 2021-08-04
ER

PT B
AU Eccles, JS
   Dickerson, JA
   Shao, JQ
AF Eccles, JS
   Dickerson, JA
   Shao, JQ
GP IEEE
   IEEE
TI Evolving a virtual ecosystem with genetic algorithms
SO PROCEEDINGS OF THE 2000 CONGRESS ON EVOLUTIONARY COMPUTATION, VOLS 1 AND
   2
SE IEEE Congress on Evolutionary Computation
LA English
DT Proceedings Paper
CT 2000 Congress on Evolutionary Computation (CEC2000)
CY JUL 16-19, 2000
CL LA JOLLA, CA
SP IEEE Neural Network Council, Evolutionary Programming Soc, Inst Elect Engineers, Parallel Problem Solving Nat, EvoNet, Evolut Artificielle, ANTS, SEAL
AB A virtual ecosystem was developed using genetic algorithms, artificial neural networks, and fuzzy systems. The ecosystem simulated and regulated the motions and interactions of computer animated agents in a virtual environment, Within the ecosystem, each agent has its own neural networks that govern its motion strategy so that the creature could learn to perform different behaviors, such as searching for food and evading predators. The inputs of the neural networks were connected with creatures' eye-like sensors and the outputs of the networks were attached to creatures' legs to drive the creatures. The neural networks were evolved using genetic algorithms, including single tournament selection, two-point crossover, and one point mutation. Augmented fuzzy cognitive maps regulated the overall operation of the environment and allowed each creature to switch between different neural networks for finding food and avoiding predators, The experimental results demonstrated that animated agents can evolve and learn how to survive in a complex and dynamic virtual environment.
C1 German Natl Res Ctr Informat Technol, Inst Media Commun, St Augustin, Germany.
RP Eccles, JS (corresponding author), German Natl Res Ctr Informat Technol, Inst Media Commun, St Augustin, Germany.
EM julied@iastate.edu; junqing@iastate.edu
CR Anderson DB, 1997, IEEE SPECTRUM, V34, P46, DOI 10.1109/6.576008
   Ashlock D, 1996, IEEE INTERNATIONAL JOINT SYMPOSIA ON INTELLIGENCE AND SYSTEMS, PROCEEDINGS, P170, DOI 10.1109/IJSIS.1996.565066
   ASHLOCK D, 1998, UNPUB OPTIMIZATION M
   Braitenberg, 1984, VEHICLES EXPT SYNTHE
   Dickerson J.A., 1994, PRESENCE, V3, P173, DOI DOI 10.1162/PRES.1994.3.2.173
   ECCLES J, 1998, THESIS IOWA STATE U
   ECCLES J, 1998, RES CUEVADEFUEGO
   Pausch R., 1996, Computer Graphics Proceedings. SIGGRAPH '96, P193
   TU X, 1994, ANN C SERIES, P43
   WALKER J, 1995, THESIS IOWA STATE U
NR 10
TC 5
Z9 6
U1 0
U2 1
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
BN 0-7803-6375-2
J9 IEEE C EVOL COMPUTAT
PY 2000
BP 753
EP 760
PG 8
WC Computer Science, Theory & Methods; Engineering, Electrical & Electronic
SC Computer Science; Engineering
GA BQ87A
UT WOS:000089884700106
DA 2021-08-04
ER

PT B
AU Hait, FB
AF Hait, FB
BE Arabnia, HR
TI Implementing a multi-agent system with Ada'95: A case study of a stock
   market
SO PROCEEDINGS OF THE INTERNATIONAL CONFERENCE ON PARALLEL AND DISTRIBUTED
   PROCESSING TECHNIQUES AND APPLICATIONS, VOLS I-V
LA English
DT Proceedings Paper
CT International Conference on Parallel and Distributed Processing
   Techniques and Applications (PDPTA 2000)
CY JUN 26-29, 2000
CL LAS VEGAS, NV
SP Comp Sci Res, Educ & Applicat Press, Informat Processing Soc Japan, SIGMPS, Int Technol Inst, Java High Performance Comp Res Grp, Korea Informat Processing Soc, World Sci & Engn Soc
DE object-oriented programming Ada'95; agents; simulation
AB In this paper we will prove the suitability of the programming language Ada'95 for multi-agent system (MAS) simulation and agent oriented programming. Agent oriented programming relies on the assumption, that a complex distributed software system can be programmed as a set of communicating, interacting, knowledge based entities called (software) agents. If one defines roughly an agent as an object combination of mental state to perceive its environment, achieve some goals, a knowledge base to hold its memory and an interfacing communication with other entities then ada'95 fits well for all the above properties, through it's features programming like concurrency, parallelism and active objects. For the case study, we tested our MAS design to model a financial market behavior. The results obtained in the experimental part lead to some validation keys, like the agent's performance in increasing their own wealth and their adapted behavior throughout the evolving market.
C1 Univ Paris 12, Dept Math Informat, F-94010 Creteil, France.
RP Hait, FB (corresponding author), Univ Paris 12, Dept Math Informat, 61 Ave GAL de Gaulle, F-94010 Creteil, France.
CR BURNS A, 1998, CONCURRECY ADA
   Ferber J., 1995, SYSTEMES MULTIAGENTS
   HAIT FB, UNPUB MULTIAGENT SYS
   *INT STAND ORG, 1995, 8652 ISO IEC AD INT
   LOEPER H, 1997, ADA LETT, V17
   NAIDITCH DJ, 1995, RENDEZVOUS ADA 95
   PALMER RG, 1994, PHYSICA D, V75, P264, DOI 10.1016/0167-2789(94)90287-9
   SHOAM Y, 1993, ARTIF INTELL, V60, P139
   TAN GSH, 1998, SIM S
NR 9
TC 0
Z9 0
U1 0
U2 0
PU C S R E A PRESS
PI ATHENS
PA 115 AVALON DR, ATHENS, GA 30606 USA
BN 1-892512-52-1
PY 2000
BP 2739
EP 2744
PG 6
WC Computer Science, Hardware & Architecture; Computer Science, Information
   Systems; Computer Science, Software Engineering; Computer Science,
   Theory & Methods
SC Computer Science
GA BR82C
UT WOS:000167676300375
DA 2021-08-04
ER

PT S
AU Stone, P
   Veloso, M
AF Stone, P
   Veloso, M
BE Veloso, M
   Pagello, E
   Kitano, H
TI Layered learning and flexible teamwork in RoboCup simulation agents
SO ROBOCUP-99: ROBOT SOCCER WORLD CUP III
SE LECTURE NOTES IN ARTIFICIAL INTELLIGENCE
LA English
DT Article; Proceedings Paper
CT 3rd Robot World Cup Soccer Games and Conference
CY JUL 27-AUG 06, 1999
CL STOCKHOLM, SWEDEN
SP Sony Corp
ID SOCCER SERVER
AB RoboCup was introduced as a challenge area at IJCAI-97. We have been actively pursuing research in this area and have participated in the RoboCup competitions, winning the RoboCup-98 and RoboCup-99 simulator competitions. In this paper, we report on the main technical issues that we encountered and addressed in direct response to the learning and teamwork challenges stated in the IJCAI-97 challenge paper. We describe "layered learning" in which off-line and online, individual and collaborative, learned robotic soccer behaviors are combined hierarchically. We achieve effective teamwork through a team member agent architecture that encompasses a "flexible teamwork structure." Agents are capable of decomposing the task space into flexible roles and can switch roles while acting. We report detailed empirical results verifying the effectiveness of the learned behaviors and the components of the team member agent architecture.
C1 AT&T Labs Res, Res, Florham Pk, NJ 07932 USA.
   Carnegie Mellon Univ, Dept Comp Sci, Pittsburgh, PA 15213 USA.
RP Stone, P (corresponding author), AT&T Labs Res, Res, 180 Pk Ave,Room A273, Florham Pk, NJ 07932 USA.
CR Asada M, 1996, MACH LEARN, V23, P279, DOI 10.1023/A:1018237008823
   ASADA M, 1999, LECT NOTES ARTIFICIA, V1604
   KITANO H, 1998, ROBOCUP 97 ROBOT SOC
   KITANO H, 1997, P 15 INT JOINT C ART, P24
   Noda I, 1998, APPL ARTIF INTELL, V12, P233, DOI 10.1080/088395198117848
   Quinlan J. R., 1993, C4 5 PROGRAMS MACHIN
   Stone P, 1999, ARTIF INTELL, V110, P241, DOI 10.1016/S0004-3702(99)00025-9
   Stone P, 1998, APPL ARTIF INTELL, V12, P165, DOI 10.1080/088395198117811
   Stone P., 1999, Proceedings of the Third International Conference on Autonomous Agents, P206, DOI 10.1145/301136.301195
   STONE P, 1998, THESIS CARNEGIE MELL
   Tambe M., 1998, RoboCup-97: Robot Soccer. World Cup I, P123
   Watkins C. J. C. H., 1989, LEARNING DELAYED REW
NR 12
TC 4
Z9 4
U1 0
U2 0
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 0302-9743
BN 3-540-41043-0
J9 LECT NOTES ARTIF INT
PY 2000
VL 1856
BP 495
EP 508
PG 14
WC Computer Science, Artificial Intelligence; Robotics
SC Computer Science; Robotics
GA BS61U
UT WOS:000170571300042
DA 2021-08-04
ER

PT B
AU Han, K
   Veloso, M
AF Han, K
   Veloso, M
BE Hollerbach, JM
   Koditschek, DE
TI Automated robot behavior recognition
SO ROBOTICS RESEARCH
LA English
DT Proceedings Paper
CT 9th International Symposium of Robotics Research (ISRR 99)
CY OCT 09-12, 1999
CL SNOWBIRD, UT
ID HIDDEN
AB Automated recognition of the behavior of robots is increasingly needed in a variety of tasks, as we develop more autonomous robots and general information processing agents. For example, in environments with multiple autonomous robots, a robot may need to make decisions based on the behavior of the other robots. As another interesting example, an intelligent narrator agent observing a robot will need to automatically identify the robot's behaviors. In this paper, we introduce a novel framework for using Hidden Markov Models (HMMs) to represent and recognize strategic behaviors of robotic agents. We first introduce and characterize the perceived signal in terms of behavioral-relevant state features. We then show how several HMMs capture different defined robot behaviors. Finally we present the HMM-based recognition algorithm which orchestrates and selects the appropriate HMMs in real time. We use the multi-robot robotic soccer domain as the substrate of our empirical validation, both in simulation and using real robots. Robots will then adapt their behaviors as a function of the autonomously recognized behavior of the other agents, either teammates or opponents.
C1 Carnegie Mellon Univ, Dept Comp Sci, Pittsburgh, PA 15213 USA.
RP Han, K (corresponding author), Carnegie Mellon Univ, Dept Comp Sci, Pittsburgh, PA 15213 USA.
CR BALCH T, 1995, AUTONOMOUS ROBOTS, V1
   BINSTED K, 1999, ROBOCUP 98 ROBOT SOC, pR2
   BOWLING M, 1996, WORK NOTES IROS 96 W
   BROOKS RA, 1986, IEEE T ROBOTIC AUTOM, V2, P14, DOI 10.1109/JRA.1986.1087032
   HAN K, 1998, P INT C ROB AUT BELG
   KITANO H, 1997, P 15 INT JOINT C ART, P24
   Lee C, 1996, IEEE INT CONF ROBOT, P2982, DOI 10.1109/ROBOT.1996.509165
   MATARIC MJ, 1994, AITR1495 MIT EECS AI
   RABINER LR, 1989, P IEEE, V77, P257, DOI 10.1109/5.18626
   TAMBE M, 1997, P AAAI97 MENL PARK C
   Veloso M, 1998, AI MAG, V19, P61
   YANG J, 1994, IEEE T ROBOTIC AUTOM, V10, P621, DOI 10.1109/70.326567
NR 12
TC 6
Z9 6
U1 0
U2 0
PU SPRINGER-VERLAG LONDON LTD
PI GODALMING
PA SWEETAPPLE HOUSE CATTESHALL RD FARNCOMBE, GODALMING GU7 1NH, SURREY,
   ENGLAND
BN 1-85233-292-1
PY 2000
BP 249
EP 256
PG 8
WC Automation & Control Systems
SC Automation & Control Systems
GA BQ19G
UT WOS:000087440500030
DA 2021-08-04
ER

PT B
AU Gnyloskurenko, SV
   Nakamura, T
   Waseda, Y
AF Gnyloskurenko, SV
   Nakamura, T
   Waseda, Y
BE Mishra, B
   Yamauchi, C
TI A review of processes for metallic foams and a basic study of bubble
   formation in liquids.
SO SECOND INTERNATIONAL CONFERENCE ON PROCESSING MATERIALS FOR PROPERTIES
LA English
DT Proceedings Paper
CT 2nd International Conference on Processing Materials for Properties
CY NOV 05-08, 2000
CL SAN FRANCISCO, CA
SP Minerals, Met & Mat Soc, Min & Mat Proc Inst Japan
AB Present paper reviews the various processes for making of metallic foams. These methods are classified in accordance with the state of initial metals - liquid, powdered and ionized. Liquid metal can be foamed by direct inputting of gas into melt, using gas releasing foaming agents or producing supersaturated metal-gas solutions. This group also includes methods creating voids in the melt. Powder route is based on using powdered matrix metal with foamable precursor materials. Finally Deposition techniques allows making highly porous metallic structures using ionized metal.
   Experimental study presented shows importance of wettability in bubble formation at gas blowing into melt simulation liquid (water) through holes. Good wettability of injection holes by water ensures formation of bubbles with smaller sizes that effect to the final foam structure.
C1 Tohoku Univ, Inst Adv Mat, Aoba Ku, Sendai, Miyagi 9808577, Japan.
RP Gnyloskurenko, SV (corresponding author), Tohoku Univ, Inst Adv Mat, Aoba Ku, Sendai, Miyagi 9808577, Japan.
RI Gnyloskurenko, Svyatoslav/AAE-4279-2019
OI Gnyloskurenko, Svyatoslav/0000-0003-0201-7191
CR AKIYAMA S, 1987, Patent No. 4713277
   Baumeister J., 1992, U.S. Patent, Patent No. [5151246 A, 5151246]
   Benjamin S., 1948, U.S. Patent, Patent No. [2,434,775, 2434775]
   BJORKSTEN J, 1972, Patent No. 3707367
   BJORKSTEN J, 1976, Patent No. 3941182
   Dunand DC, 1998, MATER RES SOC SYMP P, V521, P231, DOI 10.1557/PROC-521-231
   Elliott J.C., 1956, US Patent, Patent No. [2,751,289, 2751289]
   FIEDLER WS, 1965, Patent No. 3214265
   HIUDRO N, 1995, Patent No. 2046151
   JIN I, 1992, Patent No. 5112697
   NADLER JH, 1999, METF 99 S BREM GERM, pA16
   NIEBYLSKI LM, 1974, Patent No. 3743353
   NIEBYSKI LM, 1974, Patent No. 3816952
   Shapovalov V.I., 1993, Patent, Patent No. [5,181,549, 5181549]
   Simancik F, 1997, KOVOVE MATER, V35, P265
   SPEED SE, 1976, Patent No. 3981720
   YOSHIDA Y, 1990, P C CAST SCI TECHN S, P103
NR 17
TC 3
Z9 3
U1 0
U2 3
PU MINERALS, METALS & MATERIALS SOC
PI WARRENDALE
PA 184 THORN HILL RD, WARRENDALE, PA 15086-7514 USA
BN 0-87339-495-X
PY 2000
BP 49
EP 52
PG 4
WC Materials Science, Multidisciplinary; Metallurgy & Metallurgical
   Engineering; Mining & Mineral Processing
SC Materials Science; Metallurgy & Metallurgical Engineering; Mining &
   Mineral Processing
GA BR45F
UT WOS:000166445900008
DA 2021-08-04
ER

PT S
AU Metta, G
   Panerai, F
   Sandini, G
AF Metta, G
   Panerai, F
   Sandini, G
BE McKEE, GT
   Schenker, PS
TI Babybot: a biologically inspired developing robotic agent
SO SENSOR FUSION AND DECENTRALIZED CONTROL IN ROBOTIC SYSTEMS III
SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
   (SPIE)
LA English
DT Proceedings Paper
CT Conference on Sensor Fusion and Decentralized Control in Robotic Systems
   III
CY NOV 06-08, 2000
CL BOSTON, MA
SP SPIE
DE biomimetic robotics; learning; development; sensori-motor coordination
ID VESTIBULOOCULAR REFLEX; HEAD MOVEMENTS; MOTOR; STABILIZATION;
   COORDINATION; SYSTEMS
AB The study of development either artificial or biological, can highlight the mechanisms underlying learning and adaptive behavior. We shall argue whether developmental studies might provide a different and potentially interesting perspective either on how to build an artificial adaptive agent, or on understanding how the brain solves sensory, motor, and cognitive tasks. It is our opinion that the acquisition of the proper behavior might indeed be facilitated because within an ecological context, the agent, its adaptive structure and the environment dynamically interact thus constraining the otherwise difficult "learning problem".
   In very general terms we shall describe the proposed approach and supporting biological related facts. In order to further analyze these aspects from the modeling point of view, we shall demonstrate how a twelve degrees of freedom "baby" humanoid robot acquires orienting and reaching behaviors, and what advantages the proposed framework might offer.
   In particular, the experimental setup consists of a five degrees-of-freedom (dof) robot head, and an off-the-shelf six dof robot manipulator, both mounted on a rotating base: i.e. the torso. From the sensory point of view, the robot is equipped with two space-variant cameras, an inertial sensor simulating the vestibular system, and proprioceptive information through motor encoders.
   The biological parallel is exploited at many implementation levels. It is worth mentioning, for example, the space-variant eyes, exploiting foveal and peripheral vision in a single arrangement, the inertial sensor providing efficient image stabilization (vestibulo-ocular reflex).
C1 Univ Genoa, DIST, LIRA Lab, Genoa, Italy.
RP Metta, G (corresponding author), Univ Genoa, DIST, LIRA Lab, Genoa, Italy.
CR Aloimonos J., 1988, INT J COMPUT VISION, V1, P333, DOI DOI 10.1007/BF00133571
   Atkinson J., 1998, DEV SENSORY MOTOR CO, P3
   BAJCSY R, 1985, 3 IEEE WORKSH COMP V
   Beer RD, 1998, CURR OPIN NEUROBIOL, V8, P777, DOI 10.1016/S0959-4388(98)80121-9
   BERTHOUZE L, 1996, IEEE RSJ IROS 1996
   BERTHOUZE L, 1998, MACH LEARN, P187
   BIZZI E, 1974, SCI AM, V231, P100
   BROOKS R, 1996, IEEE RSJ IROS 96
   Carpenter R. H. S., 1999, J CONSCIOUSNESS STUD, V6, P13
   Carpenter RHS, 1988, MOVEMENTS EYES, V2nd
   FINOCCHIO DV, 1991, VISION RES, V31, P1717, DOI 10.1016/0042-6989(91)90022-W
   Gilmore R. O., 1998, DEV SENSORY MOTOR CO, P25
   Goodale M.A., 1995, VISUAL BRAIN ACTION, V27
   GOODALE MA, 1989, COMPUTATIONAL PROCES, P262
   HIRAI K, 1998, IEEE INT C ROB AUT L
   KPANERAI F, 2000, 8 EUR S ART NEUR NET
   KUNIYOSHI Y, 1999, COMMUNICATION
   Lisberger SG, 1998, OTOLARYNG HEAD NECK, V119, P43, DOI 10.1016/S0194-5998(98)70172-X
   LISBERGER SG, 1988, TRENDS NEUROSCI, V11, P147, DOI 10.1016/0166-2236(88)90140-3
   McCrea RA, 1999, J NEUROPHYSIOL, V82, P416
   METTA G, 2000, INT JOINT C NEUR NET
   MILES FA, 1974, BRAIN RES, V80, P512, DOI 10.1016/0006-8993(74)91035-X
   Panerai F, 1998, NEURAL NETWORKS, V11, P1191, DOI 10.1016/S0893-6080(98)00026-4
   Panerai F, 2000, ROBOT AUTON SYST, V30, P195, DOI 10.1016/S0921-8890(99)00072-X
   Pfeifer R, 1997, ROBOT AUTON SYST, V20, P157, DOI 10.1016/S0921-8890(97)80707-5
   Quartz SR, 1997, BEHAV BRAIN SCI, V20, P537
   RUCCI M, 1997, IEEE INT C ROB AUT A
   Sandini G, 1997, P OTT MARTH FISCHB S
   SANDINI G, 1997, HUMAN SENSORI MOTOR
   SANDINI G, 1981, 4 EUR C VIS PERC GOU
   SHUPERT C, 1988, DEV CONJUGATE HUMAN, P585
   TURKEWITZ G, 1982, DEV PSYCHOBIOL, V15, P357, DOI 10.1002/dev.420150408
   VAIDYANATHAN R, 1997, 11 VPI SU S STRUCT D
   VANHOPSTAL AJ, 1993, 2 DIMENSIONAL ENSEMB, P19
   VonHofsten C, 1997, VISION RES, V37, P1799
NR 35
TC 2
Z9 2
U1 0
U2 2
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 0-8194-3861-8
J9 P SOC PHOTO-OPT INS
PY 2000
VL 4196
BP 42
EP 53
DI 10.1117/12.403742
PG 12
WC Robotics; Imaging Science & Photographic Technology
SC Robotics; Imaging Science & Photographic Technology
GA BR66K
UT WOS:000167105100004
DA 2021-08-04
ER

PT S
AU Schenker, PS
   Huntsberger, TL
   Pirjanian, P
   Trebi-Ollennu, A
   Das, H
   Joshi, S
   Aghazarian, H
   Ganino, AJ
   Kennedy, BA
   Garrett, MS
AF Schenker, PS
   Huntsberger, TL
   Pirjanian, P
   Trebi-Ollennu, A
   Das, H
   Joshi, S
   Aghazarian, H
   Ganino, AJ
   Kennedy, BA
   Garrett, MS
BE McKEE, GT
   Schenker, PS
TI Robot work crews for planetary outposts: close cooperation and
   coordination of multiple mobile robots
SO SENSOR FUSION AND DECENTRALIZED CONTROL IN ROBOTIC SYSTEMS III
SE Proceedings of SPIE
LA English
DT Proceedings Paper
CT Conference on Sensor Fusion and Decentralized Control in Robotic Systems
   III
CY NOV 06-08, 2000
CL BOSTON, MA
SP SPIE
DE mobile robots; cooperating robots; robot control architecture; sensor
   fusion; intelligent control; Mars exploration; Mars rovers; robot
   outposts; field robotics; mobile manipulation; robotic navigation; SRR
   (Sample Return Rover)
AB We report on the development of cooperating multiple robots. This work builds from our earlier research on autonomous planetary revers and robot arms. Here, we seek to closely coordinate the mobility and manipulation of multiple robots to perform site construction operations-as an example, the autonomous deployment of a planetary power station-a task viewed as essential to a sustained robotic presence and human habitation on Mars. There are numerous technical challenges; these include the mobile handling of extended objects, as well as cooperative transport/navigation of such objects over natural, unpredictable terrain. We describe an extensible system concept, related simulations, a hardware implementation, and preliminary experimental results. In support of this work we have developed an enabling hybrid control architecture wherein multi-robot mobility and sensor-based controls are derived as group compositions and coordination of more basic behaviors under a task-level multi-agent planner. We summarize this Control Architecture for Multi-robot Planetary Outposts (CAMPOUT), and its application to physical experiments where two revers carry an extended payload over natural terrain.
C1 CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA.
RP Schenker, PS (corresponding author), CALTECH, Jet Prop Lab, 4800 Oak Grove Dr,MS 125-224, Pasadena, CA 91109 USA.
EM paul.s.schenker@jpl.nasa.gov
RI Trebi-Ollennu, Ashitey/AAB-2382-2020
OI Trebi-Ollennu, Ashitey/0000-0001-8429-1578
CR Arkin R., 1998, BEHAV BASED ROBOTICS
   ARKIN RC, 1997, ROBOT COLONIES, V4
   COLOZZA A, 1991, CR187119 NASA LEW RE
   HARA M, IROS 99
   HISASHI M, 1998 IEEE INT C ROB
   HOSHINO H, 1998 IEEE INT C ROB
   Huntsberger T, 2000, ROBOTICS CHALLENGES
   Huntsberger TL, 1999, PROC SPIE, V3839, P2, DOI 10.1117/12.360327
   HUNTSBERGER TL, 1999, P SPIE, V3839
   HUNTSBERGER TL, 2000, IEEE AER 2000 BIG SK
   JOSHI S, 2000, CONTR NAV C DENV CO
   KHATIB O, 1996, 5 IEEE INT WORKSH RO
   Pirjanian P, 2000, ROBOT AUTON SYST, V31, P53, DOI 10.1016/S0921-8890(99)00081-0
   Pirjanian P., 1999, IRIS99375 U SO CAL S
   SCHENKER PS, 1997, P SPIE, V3208
   SCHENKER PS, 1998, P SPIE, V3522
   VINEY T, 1998, 3 BIENN ENG MATH APP
   WEISBIN CR, 2000, 5 INT S ART INT ROB
NR 18
TC 6
Z9 6
U1 0
U2 0
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
EI 1996-756X
BN 0-8194-3861-8
J9 PROC SPIE
PY 2000
VL 4196
BP 210
EP 220
DI 10.1117/12.403720
PG 11
WC Robotics; Imaging Science & Photographic Technology
SC Robotics; Imaging Science & Photographic Technology
GA BR66K
UT WOS:000167105100020
DA 2021-08-04
ER

PT B
AU Stone, P
   Riley, P
   Veloso, M
AF Stone, P
   Riley, P
   Veloso, M
GP AAAI
   AAAI
TI Defining and using ideal teammate and opponent agent models
SO SEVENTEENTH NATIONAL CONFERENCE ON ARTIFICIAL INTELLIGENCE (AAAI-2001) /
   TWELFTH INNOVATIVE APPLICATIONS OF ARTIFICIAL INTELLIGENCE CONFERENCE
   (IAAI-2000)
LA English
DT Proceedings Paper
CT 17th National Conference on Artificial Intelligence (AAAI-2000)/12th
   Conference on Innovative Applications of Artificial Intelligence
   (IAAI-2000)
CY JUL 30-AUG 03, 2000
CL AUSTIN, TX
SP Amer Assoc Artificial Intelligence
AB A common challenge for agents in multiagent systems is trying to predict what other agents are going to do in the future. Such knowledge can help an agent determine which of its current action options is most likely to achieve its goals. There is a long history in adversarial game playing of using a model of an opponent which assumes that it always acts optimally. Our research extends this strategy to adversarial domains in which the agents have incomplete information, noisy sensors and actuators, and a continuous action space. We introduce "ideal-model-based behavior outcome prediction" (IMBBOP) which models the results of other agents' future actions in relation to their optimal actions based on an ideal world model. Our technique also includes a method for relaxing this optimality assumption. IMBBOP was a key component of our successful CMUNITED-99 simulated robotic soccer application. We define IMBBOP and illustrate its use within the simulated robotic soccer domain. We include empirical results demonstrating the effectiveness of IMBBOP.
C1 AT&T Labs Res, Florham Pk, NJ 07932 USA.
RP Stone, P (corresponding author), AT&T Labs Res, 180 Pk Ave,Room A273, Florham Pk, NJ 07932 USA.
CR CORTEN E, 1999, ROBOCUP1999001
   Durfee E. H., 1995, P 1 INT C MULT SYST, P406
   GMYTRASIEWICZ PJ, 1991, P 12 INT JOINT C ART, P62
   HUBER MJ, 1995, P 1 INT C MULT SYST, P163
   KITANO H, 1997, P 15 INT JOINT C ART, P24
   Noda I, 1998, APPL ARTIF INTELL, V12, P233, DOI 10.1080/088395198117848
   STONE P, 2000, LAYERED LEARNING MUL
   STONE P, 2000, ROBOCUP 99 ROBOT SOC
   Stone Peter, 1999, ROBOCUP 98 ROBOT SOC
   TAMBE M, 1995, P 1 INT C MULT SYST, P368
   VIDAL JM, 1995, P 1 INT C MULT SYST, P376
   WANG X, 1996, P 3 INT C AI PLANN S
NR 12
TC 18
Z9 18
U1 0
U2 0
PU M I T PRESS
PI CAMBRIDGE
PA FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA
BN 0-262-51112-6
PY 2000
BP 1040
EP 1045
PG 6
WC Computer Science, Artificial Intelligence; Engineering, Electrical &
   Electronic; Robotics
SC Computer Science; Engineering; Robotics
GA BT26B
UT WOS:000172441000159
DA 2021-08-04
ER

PT S
AU Tanaka-Yamawaki, M
AF Tanaka-Yamawaki, M
BE Tokuyama, M
   Stanley, HE
TI A study of chaotic and non-chaotic phase structure in the positive
   feedback model of trading agents
SO STATISTICAL PHYSICS
SE AIP CONFERENCE PROCEEDINGS
LA English
DT Proceedings Paper
CT 3rd Tohwa University International Conference on Statistical Physics
CY NOV 09-12, 1999
CL TOHWA UNIV, FUKUDA MINERVA HALL, FUKUOKA, JAPAN
SP Tohwa Inst Sci
HO TOHWA UNIV, FUKUDA MINERVA HALL
ID DIMENSION
AB We consider a dynamical model of trading agents in which the flows of cash and goods among a large number of agents are treated as explicit variables. Each agent's assets and individual price setting, as well as their averages over the entire trading system are traced as outputs for a long time period. We have observed that die time series of the average price exhibit two different types of oscillatory patterns, depending on the regions in the parameter space. The first type (C-type) stays chaotic throughout the period of the simulation and the second type (P-type) shifts the pattern from chaotic to periodic in the course of trading activity. The latter case accompanies the gradual toss of active agents and eventually fall into periodic motions of a small number of naturally-formed groups in which a number of agents move identically, as if the entire system tunes itself to a synchronized motion. Also the statistical property of the latter case (P-type) can be regarded as Levy's stable distribution, while the former case (C-type) is more like Gaussian.
C1 Miyazaki Univ, Fac Engn, Dept Comp Sci & Syst Engn, Miyazaki 8892192, Japan.
RP Tanaka-Yamawaki, M (corresponding author), Miyazaki Univ, Fac Engn, Dept Comp Sci & Syst Engn, 1-1 Gakuen Kibanadai Nishi, Miyazaki 8892192, Japan.
CR DING MZ, 1993, PHYS REV LETT, V70, P3872, DOI 10.1103/PhysRevLett.70.3872
   Fogel DB, 1999, IEEE T EVOLUT COMPUT, V3, P142, DOI 10.1109/4235.771167
   GRASSBERGER P, 1983, PHYS REV LETT, V50, P346, DOI 10.1103/PhysRevLett.50.346
   LAROUX L, 1999, PHYS REV LETT, V83, P1467
   MANTEGNA RN, 1995, NATURE, V376, P46, DOI 10.1038/376046a0
   Plerou V, 1999, PHYS REV LETT, V83, P1471, DOI 10.1103/PhysRevLett.83.1471
   SATO S, 1987, PROG THEOR PHYS, V77, P1, DOI 10.1143/PTP.77.1
   Tanaka-Yamawaki M., 1998, Proceedings of the 5th International Conference on Soft Computing and Information/Intelligent Systems. Methodologies for the Conception, Design and Application of Soft Computing, P884
   TANAKAYAMAWAKI M, 1997, P 1997 INT S NONL TH
   TANAKAYAMAWAKI M, 1995, P ETD2000, P571
   TANAKAYAMAWAKI M, 1999, P 3 INT WORKSH ROB A, P548
   TANAKAYAMAWAKI M, 1998, NLP984 IEICE, P23
   YANAGAWA K, 1998, THESIS NIHON U
NR 13
TC 2
Z9 2
U1 0
U2 0
PU AMER INST PHYSICS
PI MELVILLE
PA 2 HUNTINGTON QUADRANGLE, STE 1NO1, MELVILLE, NY 11747-4501 USA
SN 0094-243X
BN 1-56396-940-8
J9 AIP CONF PROC
PY 2000
VL 519
BP 692
EP 698
PG 7
WC Biophysics; Physics, Condensed Matter; Physics, Mathematical
SC Biophysics; Physics
GA BQ56X
UT WOS:000088786100129
DA 2021-08-04
ER

PT B
AU Griss, ML
AF Griss, ML
BE Li, QY
   Firesmith, D
   Riehle, R
   Pour, G
   Meyer, B
TI Agent-mediated E-commerce - Agents, components, services, workflow, UML,
   java, XML and games ...
SO TECHNOLOGY OF OBJECT-ORIENTED LANGUAGES AND SYSTEMS - TOOLS 34,
   PROCEEDINGS
LA English
DT Proceedings Paper
CT 34th International Conference on Technology of Object-Oriented Languages
   and Systems (TOOLS 34)
CY JUL 30-AUG 04, 2000
CL SANTA BARBARA, CA
SP Microsoft, CMP, Borders Bookstores, Software Council So Calif, PCAI Magazine, Interact Software Engn
DE agents; E-commerce; java; components; workflow; XML; UML; games;
   simulation; CBSE; features; product lines; aspects
AB Effective large-scale E-commerce will require significantly many more applications, and more flexible systems to address the ever growing Heeds of customers and business. Reusable component and framework techniques must be augmented with a variety of flexible systems based on autonomous agent components and dynamically composed services. We are building an experimental multi-player e-commerce game, in which agents represent buyers, sellers, brokers and services of various kinds. This is a controlled vehicle for experimenting with alternative individual and group economic strategies, and different agent and component technologies. Software agents are a specialized kind of distributed component, offering greater flexibility than traditional components. We are integrating several technologies, including components, agents, workflow, software busses, UML, XML, Java, aspects and HP E-Speak.
C1 Hewlett Packard Co, Software Technol Lab, Palo Alto, CA 94304 USA.
RP Griss, ML (corresponding author), Hewlett Packard Co, Software Technol Lab, 1501 Page Mill Rd, Palo Alto, CA 94304 USA.
CR ARANGO G, SOFTWARE REUSABILITY
   CHAVEZ A, 1996, P 1 INT C PRACT APPL
   CHAVEZ A, 1997, P 2 INT C PRACT APPL
   CHEN Q, P AUT AG 2000 JUN BA
   DURANTE A, 2000, HPL200017
   GLUSHKO RJ, 1999, COMMUNICATIONS ACM, V42
   Griss M. L., P 5 INT C SOFTW REUS, P76
   GRISS ML, 2000, WORKSH P AUT AG 2000
   GRISS ML, 2000, IN PRESS P 1 SOFTW P
   GRISS ML, TRHPL1999159
   GSCHWIND T, P ASA MA 99 OCT PALM, P13
   GUTTMAN RH, 1998, P 2 INT WORKSH COOP
   HUHNS MN, READINGS AGENTS
   JACOBSON I, SOFTWARE REUSE ARCHI
   Kindberg T, 2000, HPL200016
   LONGSON J, 2000, THESIS U UTAH
   Maes P, 1999, COMMUN ACM, V42, P81, DOI 10.1145/295685.295716
   MUELLERPLANITZ C, 2000, THESIS U UTAH
   Nwana HS, 1999, APPL ARTIF INTELL, V13, P129, DOI 10.1080/088395199117513
   PREIST CW, 1999, SOFTWARE AGENTS FUTU
   SHARMA T, SOFTWARE DEV, V7
NR 21
TC 0
Z9 0
U1 0
U2 0
PU IEEE COMPUTER SOC
PI LOS ALAMITOS
PA 10662 LOS VAQUEROS CIRCLE, PO BOX 3014, LOS ALAMITOS, CA 90720-1264 USA
BN 0-7695-0775-1
PY 2000
BP 3
EP 9
PG 7
WC Computer Science, Software Engineering; Computer Science, Theory &
   Methods
SC Computer Science
GA BQ83F
UT WOS:000089736600001
DA 2021-08-04
ER

PT B
AU Kacperski, K
   Holyst, JA
AF Kacperski, K
   Holyst, JA
BE Helbing, D
   Herrmann, HJ
   Schreckenberg, M
   Wolf, DE
TI Formation of opinions under the influence of competing agents - a mean
   field approach
SO TRAFFIC AND GRANULAR FLOW'99: SOCIAL, TRAFFIC, AND GRANULAR DYNAMICS
LA English
DT Proceedings Paper
CT Workshop on Traffic and Granular Flow: Social, Traffic, and Granular
   Dynamics
CY SEP 27-29, 1999
CL STUTTGART, GERMANY
ID DYNAMIC SOCIAL IMPACT; STATISTICAL-MECHANICS; MODEL; COMMUNICATION;
   BEHAVIOR
AB We study a model of opinion formation based on the theory of social impact and the concept of cellular automata. The case is considered when two strong agents influence the group: a strong leader and an external social impact acting uniformly on every individual. There are two basic stationary states of the system: cluster of the leader's adherents and unification of opinions. In the deterministic limit the variation of parameters like the leader's strength or external impact can change the size of the cluster or, when they reach some critical values, make the system jump to another phase. In the presence of noise (social temperature) the rapid changes can be regarded as the first order phase transitions. When both agents are in a kind of balance, a second order transition and critical behaviour can be observed. Analytical results obtained within a mean field approximation are well reproduced in computer simulations.
C1 Max Planck Inst Complex Syst, D-01187 Dresden, Germany.
RP Kacperski, K (corresponding author), Max Planck Inst Complex Syst, Nothnitzer Str 38, D-01187 Dresden, Germany.
RI Holyst, Janusz/B-6516-2013
CR Amit D. J., 1989, MODELING BRAIN FUNCT
   Bahr DB, 1998, J MATH SOCIOL, V23, P29, DOI 10.1080/0022250X.1998.9990211
   BAK P, 1993, PHYS REV LETT, V71, P4083, DOI 10.1103/PhysRevLett.71.4083
   Browne Antony, 1997, NEURAL NETWORK ANAL
   COWAN GA, 1994, COMPLEXITY METAPHORS
   Domany E, 1995, MODELS NEURAL NETWOR
   Fink EL, 1996, J COMMUN, V46, P4, DOI 10.1111/j.1460-2466.1996.tb01500.x
   Fort J, 1999, PHYS REV LETT, V82, P867, DOI 10.1103/PhysRevLett.82.867
   Galam S, 1997, PHYSICA A, V238, P66, DOI 10.1016/S0378-4371(96)00456-6
   Galam S, 1996, PHYSICA A, V230, P174, DOI 10.1016/0378-4371(96)00034-9
   GUTOWITZ H, 1991, CELLULAR AUTOMATA TH
   HAKEN H, 1983, ADV SYNERGETICS
   Haken H, 1983, SYNERGETICS INTRO
   HELBING D, 1995, PHYS REV E, V51, P4282, DOI 10.1103/PhysRevE.51.4282
   HELBING D, 1994, J MATH SOCIOL, V19, P189, DOI 10.1080/0022250X.1994.9990143
   HELBING D, 1993, PHYSICA A, V193, P241, DOI 10.1016/0378-4371(93)90028-3
   Helbing D., 1995, QUANTITATIVE SOCIODY
   JOHANSEN A, 1994, PHYSICA D, V78, P186, DOI 10.1016/0167-2789(94)90114-7
   Kacperski K, 1996, J STAT PHYS, V84, P169, DOI 10.1007/BF02179581
   Kacperski K, 1999, PHYSICA A, V269, P511, DOI 10.1016/S0378-4371(99)00174-0
   KACPERSKI K, 1997, SELF ORG COMPLEX STR, V2
   Kohring GA, 1996, J PHYS I, V6, P301, DOI 10.1051/jp1:1996150
   LATANE B, 1981, AM PSYCHOL, V36, P343, DOI 10.1037/0003-066X.36.4.343
   Latane B, 1996, J COMMUN, V46, P13, DOI 10.1111/j.1460-2466.1996.tb01501.x
   LEWENSTEIN M, 1992, PHYS REV A, V45, P763, DOI 10.1103/PhysRevA.45.763
   NOWAK A, 1990, PSYCHOL REV, V97, P362, DOI 10.1037/0033-295X.97.3.362
   Pekalski A, 1998, PHYSICA A, V252, P325, DOI 10.1016/S0378-4371(97)00639-0
   Plewczynski D, 1998, PHYSICA A, V261, P608, DOI 10.1016/S0378-4371(98)00349-5
   SORNETTE D, 1997, PHYSICA A, V245, P1
   Tuckwell HC, 1998, PHYS REV E, V57, P2163, DOI 10.1103/PhysRevE.57.2163
   Vallacher R. R., 1994, DYNAMICAL SYSTEMS SO
   Vandewalle N, 1998, EUR PHYS J B, V4, P139, DOI 10.1007/s100510050361
   WEIDLICH W, 1991, PHYS REP, V204, P1, DOI 10.1016/0370-1573(91)90024-G
   WEIDLICH W, 1994, J MATH SOCIOL, V18, P267, DOI 10.1080/0022250X.1994.9990129
   WEIDLICH W, 1983, CONCEPTS MODELS QUAN
   Wolfram S., 1986, THEORY APPL CELLULAR
NR 36
TC 1
Z9 2
U1 0
U2 1
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
BN 3-540-67091-2
PY 2000
BP 69
EP 80
PG 12
WC Mathematics, Applied; Physics, Mathematical
SC Mathematics; Physics
GA BQ71Z
UT WOS:000089259600006
DA 2021-08-04
ER

PT B
AU Louca, F
AF Louca, F
BE BarYam, Y
TI Ragnar Frisch at the edge of chaos
SO UNIFYING THEMES IN COMPLEX SYSTEMS
SE NEW ENGLAND COMPLEX SYSTEMS INSTITUTE SERIES ON COMPLEXITY
LA English
DT Proceedings Paper
CT 2nd International Conference on Complex Systems
CY OCT 25-30, 1998
CL NEW ENGLAND COMPLEX SYST INST, NASHUA, NH
SP Oxford Univ Press, Natl Sci Fdn, Coopers & Lybrand Consulting, McKinsey & Co, Addison Wesley Longman Publisher, John Benjamin Publisher, Santa Fe Inst, Soc Chaos Theory Psychol & Life Sci, Boston Univ, Coll Engn
HO NEW ENGLAND COMPLEX SYST INST
AB The paper investigates a simple nonlinear dynamic model set by Ragnar Frisch in 1935 and never published until now. The model describes a simple economy with two agents, each producing one commodity and consuming the other's one, and is designed to discuss whether capitalism is doomed to collapse or not. Although Frisch did neither solve nor simulate the behaviour of the system, he eventually understood that at least some very complicated dynamics emerged from it.
   Although this is not the only instance of Frisch's concern with the wild side of the street, all along his life he carefully avoided publishing any nonlinear model and argued that linear specifications were satisfactory. Yet, evidence shows that he looked around for something else. The current model is the proof that he found complexity, although he could not deepen the study of the problem.
   Section 1 presents the author and the problem, section 2 summarizes some of the findings about the numerical simulation, and finally section 3 indicates some conclusions.
C1 Univ Lisbon, UECE, ISEG, P-1699 Lisbon, Portugal.
RP Louca, F (corresponding author), Univ Lisbon, UECE, ISEG, P-1699 Lisbon, Portugal.
CR FRISCH R, 1934, ECONOMETRICA    0702, P258
   FRISCH R, 1935, NONCURATIVE POWER LI
   Frisch Ragnar, 1933, EC ESSAYS HONOUR G C, P171
   Louca F., 1997, TURBULENCE EC EVOLUT
NR 4
TC 0
Z9 0
U1 1
U2 1
PU PERSEUS PUBLISHING
PI CAMBRIDGE
PA 11 CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA
BN 0-7382-0049-2
J9 NEW ENGL COMPL SYST
PY 2000
BP 319
EP 324
PG 6
WC Mathematics, Applied
SC Mathematics
GA BP77W
UT WOS:000086160100029
DA 2021-08-04
ER

PT S
AU Schultz, AC
   Grefenstette, JJ
AF Schultz, AC
   Grefenstette, JJ
BE Gerhart, GR
   Gunderson, RW
   Shoemaker, CM
TI Continuous and embedded learning in autonomous vehicles: Adapting to
   sensor failures
SO UNMANNED GROUND VEHICLE TECHNOLOGY II
SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
   (SPIE)
LA English
DT Proceedings Paper
CT Conference on Unmanned Ground Vehicle Technology II
CY APR 24-25, 2000
CL ORLANDO, FL
SP SPIE
DE Robotics; Learning; Genetic Algorithms; adaptation; Evolutionary
   Algorithms
AB This project describes an approach to creating autonomous systems that can continue to learn throughout their lives, that is, to be adaptive to changes in the environment and in their own capabilities. Evolutionary learning methods have been found to be useful in several areas in the development of autonomous vehicles. In our research, evolutionary algorithms are used to explore alternative robot behaviors within a simulation model as a way of reducing the overall knowledge engineering effort. The learned behaviors are then tested in the actual robot and the results compared. Initial research demonstrated the ability to learn reasonable complex robot behaviors such as herding, and navigation and collision avoidance using this offline learning approach. In this work, the vehicle is always exploring different strategies via an internal simulation model; the simulation, in turn, is changing over time to better match the world.
   This model, which we call Continuous and Embedded Learning (also referred to as Anytime Learning), is a general approach to continuous learning in a changing environment. The agent's learning module continuously tests new strategies against a simulation model of the task environment, and dynamically updates the knowledge base used by the agent on the basis of the results. The execution module controls the agent's interaction with the environment, and includes a monitor that can dynamically modify the simulation model based on its observations of the environment. When the simulation model is modified, the learning process continues on the modified model. The learning system is assumed to operate indefinitely, and the execution system uses the results of learning as they become available. Early experimental studies demonstrate a robot that can learn to adapt to failures in its sonar sensors.
C1 USN, Res Lab, Intelligent Syst Sect, Washington, DC 20375 USA.
RP Schultz, AC (corresponding author), USN, Res Lab, Intelligent Syst Sect, Washington, DC 20375 USA.
CR BUGAJSKA MD, 2000, P WORKSH EV SENS GEC
   Floreano D, 1996, IEEE T SYST MAN CY B, V26, P396, DOI 10.1109/3477.499791
   Grefenstette J., 1992, P 9 INT C MACH LEARN, P189
   GREFENSTETTE JJ, 1990, MACH LEARN, V5, P355, DOI 10.1023/A:1022677607120
   GREFENSTETTE JJ, 1996, ROBOTICS MANUFACTURI, V6, P265
   HARVEY I, 1993, P 2 INT C SIM AD BEH
   HOLLAND J, 1975, ADAPTATION NATURAL A
   LEE WP, 1996, P IEEE 3 INT C EV CO
   LUND HH, 1998, P 1 EUR WORKSH EV RO
   Nolfi S., 1994, Artificial Life IV. Proceedings of the Fourth International Workshop on the Synthesis and Simulation of Living Systems, P190
   RAMSEY CL, 1994, CASE BASED REASONING
   Schultz A., 1996, ROBOTICS MANUFACTURI, V6, P763
   Schultz A C, 1991, P 7 INT S UNM UNT SU, P213
   SCHULTZ AC, 1994, INTELL AUTOM SOFT CO, P607
   Schultz Alan C., 1992, P AIAA GUID NAV CONT
   SIMS K, 1994, ARTIF LIFE, V4, P28
NR 16
TC 6
Z9 6
U1 0
U2 0
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 0-8194-3650-X
J9 P SOC PHOTO-OPT INS
PY 2000
VL 4024
BP 55
EP 62
DI 10.1117/12.391649
PG 8
WC Engineering, Aerospace
SC Engineering
GA BQ62J
UT WOS:000088995200007
DA 2021-08-04
ER

PT J
AU Alam, MN
   Szymusiak, R
   Gong, H
   King, J
   McGinty, D
AF Alam, MN
   Szymusiak, R
   Gong, H
   King, J
   McGinty, D
TI Adenosinergic modulation of rat basal forebrain neurons during sleep and
   waking: neuronal recording with microdialysis
SO JOURNAL OF PHYSIOLOGY-LONDON
LA English
DT Article
ID CENTRAL-NERVOUS-SYSTEM; NUCLEUS BASALIS; ACETYLCHOLINE-RELEASE;
   SUBSTANTIA INNOMINATA; POSSIBLE INVOLVEMENT; CHOLINERGIC NEURONS;
   CEREBRAL-CORTEX; DIAGONAL BAND; STIMULATION; WAKEFULNESS
AB 1. The cholinergic system of the basal forebrain (BF) is hypothesized to play an important role in behavioural and electrocortical arousal. Adenosine has been proposed as a sleep-promoting substance that induces sleep by inhibiting cholinergic neurons of the BF and brainstem. However, adenosinergic influences on the activity of BF neurons in naturally awake and sleeping animals have not been demonstrated.
   2. We recorded the sleep-make discharge profile of BF neurons and simultaneously assessed adenosinergic influences on wake- and sleep-related activity of these neurons by delivering adenosinergic agents adjacent to the recorded neurons with a microdialysis probe. Discharge rates of BF neurons were recorded through two to three sleep-wake episodes during baseline (artificial cerebrospinal fluid perfusion), and after delivering an adenosine transport inhibitor (s-(p-nitrobenzyl)-6-thioinosine; NBTI), or exogenous adenosine, or a selective adenosine A1. receptor antagonist (8-cyclopentyl-1,3-dimethylxanthine; CPDX).
   3. NBTI and adenosine decreased the discharge rate of BF neurons during both waking and non-rapid eye movement (NREM) sleep. In contrast, CPDX increased the discharge rate of BF neurons during both waking and NREM sleep. These results suggest that in naturally awake and sleeping animals, adenosine exerts tonic inhibitory influences on BF neurons, supporting the hypothesized role of adenosine in sleep regulation.
   4. However, in the presence of exogenous adenosine, NBTI or CPDX, BF neurons retained their wake- and sleep-related discharge patterns, i.e. still exhibited changes in discharge rate during transitions between waking and NREM sleep. This suggests that other neuro transmitters/neuromodulators also contribute to the sleep-wake discharge modulation of BF neurons.
C1 Vet Affairs Greater Los Angeles Hlth Care Syst, North Hills, CA 91343 USA.
   Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90033 USA.
   Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90033 USA.
RP McGinty, D (corresponding author), Vet Affairs Greater Los Angeles Hlth Care Syst, 16111 Plummer St, North Hills, CA 91343 USA.
EM dmcginty@ucla.edu
RI Lazarus, Michael/G-3130-2010
OI Lazarus, Michael/0000-0003-3863-4474
FU NHLBI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [HC 60296] Funding Source: Medline; NIMH NIH HHSUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01
   MH047480, MH 47480] Funding Source: Medline; NATIONAL INSTITUTE OF
   MENTAL HEALTHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH) [R01MH047480] Funding Source: NIH RePORTER
CR ALAM MN, 1995, AM J PHYSIOL-REG I, V269, pR1240
   ALAM MN, 1995, BRAIN RES, V696, P221, DOI 10.1016/0006-8993(95)00884-S
   Alam MN, 1997, BRAIN RES, V752, P81
   BASSANT MH, 1995, NEURODEGENERATION, V4, P61, DOI 10.1006/neur.1995.0007
   BENINGTON JH, 1995, BRAIN RES, V692, P79, DOI 10.1016/0006-8993(95)00590-M
   BENINGTON JH, 1995, PROG NEUROBIOL, V45, P347, DOI 10.1016/0301-0082(94)00057-O
   BUZSAKI G, 1988, J NEUROSCI, V8, P4007
   CASAMENTI F, 1986, BRAIN RES BULL, V16, P689, DOI 10.1016/0361-9230(86)90140-1
   CORRADETTI R, 1984, EUR J PHARMACOL, V104, P19, DOI 10.1016/0014-2999(84)90364-9
   DEKKER AJ, 1993, NEUROCHEM RES, V18, P277, DOI 10.1007/BF00969083
   DESANCHEZ VC, 1995, CAN J PHYSIOL PHARM, V73, P339, DOI 10.1139/y95-044
   DETARI L, 1984, ELECTROEN CLIN NEURO, V58, P362, DOI 10.1016/0013-4694(84)90062-2
   DUNWIDDIE TV, 1985, INT REV NEUROBIOL, V27, P63, DOI 10.1016/S0074-7742(08)60556-5
   FASTBOM J, 1985, ACTA PHYSIOL SCAND, V125, P121, DOI 10.1111/j.1748-1716.1985.tb07698.x
   Fredholm BB, 1999, PHARMACOL REV, V51, P83
   GREENE RW, 1991, PROG NEUROBIOL, V36, P329, DOI 10.1016/0301-0082(91)90005-L
   HARS B, 1993, NEUROSCIENCE, V56, P61, DOI 10.1016/0306-4522(93)90562-T
   Huston JP, 1996, NEUROSCIENCE, V73, P99, DOI 10.1016/0306-4522(96)00021-8
   JASPER HH, 1971, SCIENCE, V172, P601, DOI 10.1126/science.172.3983.601
   JONES BE, 1993, PROG BRAIN RES, V98, P61
   KOYAMA Y, 1994, NEUROSCI RES, V19, P31, DOI 10.1016/0168-0102(94)90005-1
   KUROSAWA M, 1989, NEUROSCI LETT, V98, P45, DOI 10.1016/0304-3940(89)90371-6
   LANDOLT HP, 1995, NEUROPSYCHOPHARMACOL, V12, P229, DOI 10.1038/sj.npp.1380255
   LUDVIG N, 1994, J NEUROSCI METH, V55, P31, DOI 10.1016/0165-0270(94)90037-X
   MAQUET P, 1995, BEHAV BRAIN RES, V69, P75, DOI 10.1016/0166-4328(95)00017-N
   MESULAM MM, 1983, J COMP NEUROL, V214, P170, DOI 10.1002/cne.902140206
   MORAIRTY S, 1998, SLEEP, V21, P17
   Paxinos G, 1997, RAT BRAIN STEREOTAXI
   PHILLIS J W, 1968, Brain Research, V7, P378, DOI 10.1016/0006-8993(68)90004-8
   PHILLIS JW, 1981, PROG NEUROBIOL, V16, P187, DOI 10.1016/0301-0082(81)90014-9
   Porkka-Heiskanen T, 1997, SCIENCE, V276, P1265, DOI 10.1126/science.276.5316.1265
   Portas CM, 1997, NEUROSCIENCE, V79, P225, DOI 10.1016/S0306-4522(96)00640-9
   PULL I, 1972, BIOCHEM J, V126, P965, DOI 10.1042/bj1260965
   RADULOVACKI M, 1984, J PHARMACOL EXP THER, V228, P268
   RAINNIE DG, 1994, SCIENCE, V263, P689, DOI 10.1126/science.8303279
   RASMUSSON DD, 1988, EXP BRAIN RES, V70, P276
   RASMUSSON DD, 1992, BRAIN RES, V594, P150, DOI 10.1016/0006-8993(92)91041-C
   RASMUSSON DD, 1994, NEUROSCIENCE, V60, P665, DOI 10.1016/0306-4522(94)90495-2
   Reddington M, 1991, ADENOSINE NERVOUS SY, P77
   RIEKKINEN P, 1990, BRAIN RES BULL, V24, P839, DOI 10.1016/0361-9230(90)90148-S
   RYE DB, 1984, NEUROSCIENCE, V13, P627, DOI 10.1016/0306-4522(84)90083-6
   SAPER CB, 1984, J COMP NEUROL, V222, P313, DOI 10.1002/cne.902220302
   Satoh S, 1996, P NATL ACAD SCI USA, V93, P5980, DOI 10.1073/pnas.93.12.5980
   Schwierin B, 1996, EUR J PHARMACOL, V300, P163, DOI 10.1016/0014-2999(96)00021-0
   SEMBA K, 1991, BASAL FOREBRAIN ANAT, P197
   STEWART DJ, 1984, BRAIN RES, V322, P219, DOI 10.1016/0006-8993(84)90112-4
   SZYMUSIAK R, 1995, SLEEP, V18, P478, DOI 10.1093/sleep/18.6.478
   SZYMUSIAK R, 1989, BRAIN RES BULL, V22, P423, DOI 10.1016/0361-9230(89)90069-5
   SZYMUSIAK R, 1986, BRAIN RES, V370, P82, DOI 10.1016/0006-8993(86)91107-8
   Thakkar MM, 1998, J NEUROSCI, V18, P5490
   TIMOIARIA C, 1970, PHYSIOL BEHAV, V5, P1057, DOI 10.1016/0031-9384(70)90162-9
   VIRUS RM, 1990, NEUROPSYCHOPHARMACOL, V3, P243
   WAINER BH, 1985, NEUROSCI LETT, V54, P45, DOI 10.1016/S0304-3940(85)80116-6
   WOOLF NJ, 1984, BRAIN RES BULL, V13, P751, DOI 10.1016/0361-9230(84)90236-3
NR 54
TC 123
Z9 130
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3751
EI 1469-7793
J9 J PHYSIOL-LONDON
JI J. Physiol.-London
PD DEC 15
PY 1999
VL 521
IS 3
BP 679
EP 690
DI 10.1111/j.1469-7793.1999.00679.x
PG 12
WC Neurosciences; Physiology
SC Neurosciences & Neurology; Physiology
GA 273DB
UT WOS:000084691200011
PM 10601498
OA Green Published
DA 2021-08-04
ER

PT J
AU Billard, A
   Hayes, G
AF Billard, A
   Hayes, G
TI DRAMA, a connectionist architecture for control and learning in
   autonomous robots
SO ADAPTIVE BEHAVIOR
LA English
DT Article
DE time-delay recurrent neural network; Hebbian learning; spatio-temporal
   associations; unsupervised dynamical learning; autonomous robots
ID ASSOCIATIVE MEMORY; TIME; BEHAVIOR
AB Adaptation to their environment is a fundamental capability for living agents, from which autonomous robots could also benefit. This work proposes a connectionist architecture, DRAMA, for dynamic control and learning of autonomous robots. DRAMA stands for dynamical recurrent associative memory architecture. It is a time-delay recurrent neural network, using Hebbian update rules. It allows learning of spatio-temporal regularities and time series in discrete sequences of inputs, in the face of an important amount of noise. The first part of this paper gives the mathematical description of the architecture and analyses theoretically and through numerical simulations its performance. The second part of this paper reports on the implementation of DRAMA in simulated and physical robotic experiments. Training and rehearsal of the DRAMA architecture is computationally fast and inexpensive, which makes the model particularly suitable for controlling 'computationally-challenged' robots. In the experiments, ave use a basic hardware system with very limited computational capability and show that our robot can carry out real time computation and on-line learning of relatively complex cognitive tasks. In these experiments, two autonomous robots wander randomly in a fixed environment, collecting information about its elements. By mutually associating information of their sensors and actuators, they learn about physical regularities underlying their experience of varying stimuli. The agents learn also from their mutual interactions. We use a teacher-learner scenario, based on mutual following of the two agents, to enable transmission of a vocabulary from one robot to the other.
C1 Univ Edinburgh, Edinburgh EH8 9YL, Midlothian, Scotland.
RP Billard, A (corresponding author), Swiss Fed Inst Technol, LAMI, IN F Ecublens, CH-1015 Lausanne, Switzerland.
EM billard@lamisun1.epfl.ch
CR ASADA M, 1997, P 1 INT WORKSH COOP, P127
   Billard A, 1998, LECT NOTES ARTIF INT, V1545, P79, DOI 10.1007/3-540-49240-2_6
   Billard A, 1998, ROBOT AUTON SYST, V24, P71, DOI 10.1016/S0921-8890(98)00023-2
   BILLARD A, 1998, THESIS U EDINBURGH
   BILLARD A, 1997, P 6 EUR WORKSH LEARN, P137
   BILLARD A, ADAPTIVE BEHAV SPEC
   BILLARD A, 1998, CPM9838 CTR POL MOD
   BILLARD A, 1996, 43 U ED
   BUCKINGHAM J, 1992, NETWORK-COMP NEURAL, V3, P407, DOI 10.1088/0954-898X/3/4/005
   CHAUVIN Y, 1995, BACK PROPAGATION THE
   Dautenhahn K, 1995, ROBOT AUTON SYST, V16, P333, DOI 10.1016/0921-8890(95)00054-2
   DAY SP, 1993, IEEE T NEURAL NETWOR, V4, P348, DOI 10.1109/72.207622
   ELMAN JL, 1990, COGNITIVE SCI, V14, P179, DOI 10.1207/s15516709cog1402_1
   Floreano D, 1996, IEEE T SYST MAN CY B, V26, P396, DOI 10.1109/3477.499791
   GAUSSIER P, 1998, APPL ARTIFICIAL INTE, V7
   GILES CG, 1994, IEEE T NEURAL NETWOR, V52, P153
   GRAHAM B, 1995, BIOL CYBERN, V72, P337, DOI 10.1007/BF00202789
   GRAHAM B, 1996, P INT C ART NEUR NET, P35
   GROSSBERG S, 1992, COGNITIVE BRAIN RES, V1, P3, DOI 10.1016/0926-6410(92)90003-A
   Hattori M, 1996, NEUROCOMPUTING, V12, P1, DOI 10.1016/0925-2312(95)00022-4
   Hinton G E, 1986, PARALLEL DISTRIBUTED, V1, P282, DOI DOI 10.1234/12345678
   Jordan M.I., 1986, P 8 ANN C COGN SCI S, P531
   Klingspor V, 1997, APPL ARTIF INTELL, V11, P719
   Kohonen T., 1989, SELF ORG ASS MEMORY
   KOLEN JF, 1991, P 13 ANN C COGN SCI, P7
   KUIPERS B, 1987, AAAI WORKSH SPAT REA, P774
   KURZ A, 1996, IEEE T SYSTEMS, V26, P40
   LIN DT, 1993, P WORLD C NEUR NETW, V1, P291
   Mataric MJ, 1997, AUTON ROBOT, V4, P73, DOI 10.1023/A:1008819414322
   MOZER MC, 1993, PREDICTING FUTURE UN
   Nolfi S, 1997, ADAPT BEHAV, V5, P343, DOI 10.1177/105971239700500306
   Nordin P, 1996, ADAPT BEHAV, V5, P107, DOI 10.1177/105971239700500201
   OWEN C, 1996, 1 EUR WORKSH ADV MOB
   PEARLMUTTER BA, 1995, IEEE T NEURAL NETWOR, V6, P1212, DOI 10.1109/72.410363
   PFEIFER R, 1998, ROBOTICS AUTONOMOUS, P2
   PINEDA FJ, 1987, PHYS REV LETT, V59, P2229, DOI 10.1103/PhysRevLett.59.2229
   RINKUS G, 1995, THESIS BOSTON U MASS
   Schwenker F, 1996, NEURAL NETWORKS, V9, P445, DOI 10.1016/0893-6080(95)00112-3
   STEELS L, 1997, P 4 EUR C ART LIF, P473
   TANI J, 1997, P 4 EUR C ART LIF, P309
   Thrun S., 1996, EXPLANATION BASED NE
   TORRANCE MC, 1992, WORK NOT AAAI FALL S
   WILLSHAW DJ, 1969, NATURE, V222, P960, DOI 10.1038/222960a0
   WYATT J, 1998, ROBOTICS AUTONOMOUS, V1, P41
   YANCO H, 1993, ANIMALS ANIMATS, V2, P478
   Zimmer UR, 1996, NEUROCOMPUTING, V13, P247, DOI 10.1016/0925-2312(95)00097-6
   ZREHEN S, 1995, THESIS SWISS FEDERAL
NR 47
TC 49
Z9 51
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1059-7123
J9 ADAPT BEHAV
JI Adapt. Behav.
PD WIN
PY 1999
VL 7
IS 1
BP 35
EP 63
DI 10.1177/105971239900700103
PG 29
WC Computer Science, Artificial Intelligence; Psychology, Experimental;
   Social Sciences, Interdisciplinary
SC Computer Science; Psychology; Social Sciences - Other Topics
GA 198FT
UT WOS:000080413000003
OA Green Published
DA 2021-08-04
ER

PT J
AU Lachenbruch, CA
   Diller, KR
AF Lachenbruch, CA
   Diller, KR
TI A network thermodynamic model of kidney perfusion with a cryoprotective
   agent
SO JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME
LA English
DT Article
ID MULTICELLULAR TISSUE; RABBIT KIDNEYS; BOND GRAPHS; TRANSPORT;
   CRYOPRESERVATION
AB A network thermodynamic model has been devised to describe the coupled movement of water and a permeable additive within a kidney during perfusion under the combined action of diffusive, hydrodynamic, and mechanical processes. The model has been validated by simulating perfusions with Me2SO, glycerol, and sucrose and comparing predicted weight and vascular resistance,vith experimental results obtained by Pegg (1993). The flows of CPA, water, colloid and cellular impermeants are governed by a combination of the individual osmotic potential and pressure differences between compartments of the kidney, the viscoelastic behavior of the tissue, and the momentum transferred between the flows. The model developed in this sturdy presents an analytical tool for understanding the dynamics of the perfused kidney system and for modifying perfusion protocols to minimize the changes in cell volume, internal pressure build-up, and increases in vascular resistance that currently present barriers to the successful perfusion of organs.
C1 Univ Texas, Dept Engn Mech, Biomed Engn Program, Austin, TX 78712 USA.
RP Lachenbruch, CA (corresponding author), Univ Texas, Dept Engn Mech, Biomed Engn Program, Austin, TX 78712 USA.
FU FOGARTY INTERNATIONAL CENTERUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Fogarty
   International Center (FIC) [F06TW001412] Funding Source: NIH RePORTER;
   FIC NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [1 FO6 TW01412-01] Funding Source: Medline
CR BASSINGTHWAITE JB, 1979, CIRCULN RES, V35, P483
   BEAMAN JJ, 1999, IN PRESS PHYSICAL SY
   Chapra SC, 1988, NUMERICAL METHODS EN
   De Freitas RC, 1998, ANN NY ACAD SCI, V858, P191
   DENBIGH K, 1971, PRINCIPLES CHEM EQUI
   DILLER KR, 1990, CRYO-LETT, V11, P151
   DILLER KR, 1988, J HEAT TRANS-T ASME, V110, P938, DOI 10.1115/1.3250596
   DILLER KR, 1988, LOW TEMPERATURE BIOT, P203
   FAHY GM, 1985, CRYOBIOLOGY, V22, P607
   Fox R.W., 1985, INTRO FLUID MECH
   Guyton A. C., 1981, TXB MED PHYSL
   JACOBSEN IA, 1984, CRYOBIOLOGY, V21, P377, DOI 10.1016/0011-2240(84)90076-2
   KEDEM O, 1958, BIOCHIM BIOPHYS ACTA, V27, P229, DOI 10.1016/0006-3002(58)90330-5
   KROGH A, 1919, J PHYSL, V52, P109
   LACHENBRUCH CA, 1998, ANN NY ACAD SCI, V858, P300
   LACHENBRUCH CA, 1999, UNPUB CRYOBIOLOGY
   LEVIN RL, 1981, ADV BIOENG, P131
   MCGRATH JJ, 1988, LOW TEMPERATURE BIOT, P273
   MICKULECKY DC, 1983, AM J PHYSIOL, V245, pR1
   OSTER GF, 1973, Q REV BIOPHYS, V6, P1, DOI 10.1017/S0033583500000081
   PAPANEK TH, 1976, THESIS MIT CAMBRIDGE
   PAYNTER M, 1961, ANAL DESIGN ENG SYST
   PEGG DE, 1987, CRYOBIOLOGY, V24, P420, DOI 10.1016/0011-2240(87)90045-9
   PEGG DE, 1986, SURG CLIN N AM, V66, P617
   PEGG DE, 1977, CRYOBIOLOGY, V14, P168, DOI 10.1016/0011-2240(77)90137-7
   PEGG DE, 1972, CRYOBIOLOGY, V9, P411, DOI 10.1016/0011-2240(72)90158-7
   PEGG DE, 1978, CRYOBIOLOGY, V15, P609, DOI 10.1016/0011-2240(78)90085-8
   PEGG DE, 1993, UNPUB TRANSPORT CRYO
   PERL W, 1968, CIRC RES, V22, P273, DOI 10.1161/01.RES.22.2.273
   Peusner L., 1986, STUDIES NETWORK THER
   POLLOCK GA, 1986, CRYOBIOLOGY, V23, P500, DOI 10.1016/0011-2240(86)90059-3
   ROSENBERG RC, 1983, INTRO PHYSICAL SYSTE
   ROSENBERG RC, 1994, ENPORT REFERENCE MAN
   RUBINSKY B, 1982, CRYOBIOLOGY, V19, P70, DOI 10.1016/0011-2240(82)90126-2
   SMITH MW, 1972, HIBERNATION HYPOTHER, P219
   THOMA J, 1985, J FRANKLIN I, V319, P217, DOI 10.1016/0016-0032(85)90075-4
   THOMAS SR, 1978, AM J PHYSIOL, V235, pP638
   TSONEV LI, 1994, CRYO-LETT, V15, P251
   WALSH JR, 1999, UNPUB ASME
   WEAST RC, 1974, HDB CHEM PHYSICS
NR 40
TC 4
Z9 4
U1 0
U2 3
PU ASME-AMER SOC MECHANICAL ENG
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
SN 0148-0731
J9 J BIOMECH ENG-T ASME
JI J. Biomech. Eng.-Trans. ASME
PD DEC
PY 1999
VL 121
IS 6
BP 574
EP 583
DI 10.1115/1.2800856
PG 10
WC Biophysics; Engineering, Biomedical
SC Biophysics; Engineering
GA 271KN
UT WOS:000084592900003
PM 10633256
DA 2021-08-04
ER

PT J
AU Baxter, DA
   Canavier, CC
   Clark, JW
   Byrne, JH
AF Baxter, DA
   Canavier, CC
   Clark, JW
   Byrne, JH
TI Computational model of the serotonergic modulation of sensory neurons in
   Aplysia
SO JOURNAL OF NEUROPHYSIOLOGY
LA English
DT Article
ID PROTEIN-KINASE-C; SENSITIVE POTASSIUM CHANNEL; LONG-TERM FACILITATION;
   IONIC CONDUCTANCE MECHANISMS; MEDIATING INKING BEHAVIOR; PRE-SYNAPTIC
   FACILITATION; ACTION-POTENTIAL DURATION; SIPHON WITHDRAWAL REFLEX;
   PRESYNAPTIC FACILITATION; TRANSMITTER RELEASE
AB Serotonergic modulation of the sensory neurons that mediate the gill-and tail-withdrawal reflexes of Aplysia is a useful model system for studies of neuronal plasticity that contributes to learning and memory. The effects of serotonin (5-HT) are mediated, in part, via two protein kinases (protein kinase A, PKA, and protein kinase C, PKC), which in turn, modulate at least four membrane currents, including a S ("serotonin-sensitive") K+ current (I-K,(S)), a steeply voltage-dependent K+ current (IK-V), a slow component of the Ca2+ activated K+ current (I-K,I-Ca-S), and a L-type Ca2+ current (ICa-L). The present study investigated how the modulation of these currents altered the spike duration and excitability of sensory neurons and examined the relative contributions of PKA- and PKC-mediated effects to the actions of 5-HT. A Hodgkin-Huxley type model was developed that described the ionic conductances in the somata of sensory neurons. The descriptions of these currents and their modulation were based largely on voltage-clamp data from sensory neurons. Simulations were preformed with the program SNNAP (Simulator for Neural Networks and Action Potentials). The model was sufficient to replicate empirical data that describes the membrane currents, action potential waveform and excitability as well as their modulation by application of 5-HT, increased levels of adenosine cyclic monophosphate or application of active phorbol esters. In the model, modulation of IK-V, by PKC played a dominate role in 5-HT-induced spike broadening, whereas the concurrent modulation of I-K,I-S and I-K,I-Ca-S by PKA primarily accounted for 5-HT-induced increases in excitability. Finally, simulations indicated that a PKC-induced increase in excitability resulted from decreases of I-K,I-S and I-K,I-Ca-S which was likely the indirect result of cross-talk between the PKC and PKA systems. The results provide several predictions that warrant additional experimental investigation and illustrate the importance of considering indirect as well as direct effects of modulatory agents on the modulation of membrane currents.
C1 Univ Texas, Sch Med, Dept Neurobiol & Anat,Labs Origin, WM Keck Ctr Neurobiol Learning & Memory, Houston, TX 77225 USA.
   Rice Univ, Dept Elect & Comp Engn, Houston, TX 77251 USA.
RP Baxter, DA (corresponding author), Univ Texas, Sch Med, Dept Neurobiol & Anat,Labs Origin, WM Keck Ctr Neurobiol Learning & Memory, POB 20708, Houston, TX 77225 USA.
FU NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Research Resources (NCRR) [R01RR011626] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Neurological Disorders &
   Stroke (NINDS) [P01NS038310] Funding Source: NIH RePORTER; NCRR NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [R01-RR-11626] Funding Source: Medline; NINDS NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Neurological
   Disorders & Stroke (NINDS) [P01-NS-38310] Funding Source: Medline
CR ABRAMS TW, 1984, P NATL ACAD SCI-BIOL, V81, P7956, DOI 10.1073/pnas.81.24.7956
   ADAMS DJ, 1979, J PHYSIOL-LONDON, V289, P115, DOI 10.1113/jphysiol.1979.sp012728
   ADAMS DJ, 1979, J PHYSIOL-LONDON, V289, P143, DOI 10.1113/jphysiol.1979.sp012729
   Almers W, 1978, Rev Physiol Biochem Pharmacol, V82, P96, DOI 10.1007/BFb0030498
   ANDRESEN MC, 1979, J PHYSIOL-LONDON, V287, P267, DOI 10.1113/jphysiol.1979.sp012658
   BACSKAI BJ, 1993, SCIENCE, V260, P222, DOI 10.1126/science.7682336
   BAXTER DA, 1990, J NEUROPHYSIOL, V64, P978
   BAXTER DA, 1990, J NEUROPHYSIOL, V64, P1474
   BAXTER DA, 1989, J NEUROPHYSIOL, V62, P665
   BAXTER DA, 1999, SOC NEUR ABSTR, V25, P246
   BELARDETTI F, 1986, J PHYSIOL-LONDON, V374, P289, DOI 10.1113/jphysiol.1986.sp016080
   BERNIER L, 1982, J NEUROSCI, V2, P1682
   BLUMENFELD H, 1992, BIOPHYS J, V63, P1146, DOI 10.1016/S0006-3495(92)81670-3
   BRAHA O, 1993, J NEUROSCI, V13, P1839
   BREZINA V, 1987, J PHYSIOL-LONDON, V382, P267, DOI 10.1113/jphysiol.1987.sp016367
   BYRNE JH, 1980, J NEUROPHYSIOL, V43, P651
   Byrne JH, 1996, J NEUROSCI, V16, P425
   BYRNE JH, 1980, J NEUROPHYSIOL, V43, P630
   CANAVIER CC, 1991, J NEUROPHYSIOL, V66, P2107
   CASTELLUCCI VF, 1982, J NEUROSCI, V2, P1673
   Cleary LJ, 1998, J NEUROSCI, V18, P5988
   CRITZ SD, 1992, J NEUROPHYSIOL, V68, P1079
   CRITZ SD, 1991, J NEUROPHYSIOL, V66, P1912
   DALE N, 1987, J NEUROSCI, V7, P2232
   ECKERT R, 1984, PROG BIOPHYS MOL BIO, V44, P215, DOI 10.1016/0079-6107(84)90009-9
   EDMONDS B, 1990, SCIENCE, V250, P1142, DOI 10.1126/science.2174573
   ELIOT LS, 1994, J NEUROSCI, V14, P368
   ELIOT LS, 1993, NATURE, V361, P634, DOI 10.1038/361634a0
   FARQUHARSON DA, 1984, CELL MOL NEUROBIOL, V4, P97, DOI 10.1007/BF00710998
   FIEBER LA, 1995, J EXP BIOL, V198, P2337
   GHIRARDI M, 1992, NEURON, V9, P479, DOI 10.1016/0896-6273(92)90185-G
   Gilly WF, 1997, J NEUROPHYSIOL, V77, P2373
   GINGRICH KJ, 1985, J NEUROPHYSIOL, V53, P652
   GINGRICH KJ, 1988, BRAIN RES BULL, V21, P513, DOI 10.1016/0361-9230(88)90167-0
   GOLDSMITH BA, 1992, P NATL ACAD SCI USA, V89, P11481, DOI 10.1073/pnas.89.23.11481
   GORMAN ALF, 1970, J PHYSIOL-LONDON, V210, P919, DOI 10.1113/jphysiol.1970.sp009249
   GORMAN ALF, 1972, J PHYSIOL-LONDON, V227, P35, DOI 10.1113/jphysiol.1972.sp010018
   HERMANN A, 1981, J GEN PHYSIOL, V78, P87, DOI 10.1085/jgp.78.1.87
   HILLE B, 1992, IONIC CHANNELS EXCIT
   HOCHNER B, 1986, P NATL ACAD SCI USA, V83, P8794, DOI 10.1073/pnas.83.22.8794
   HOCHNER B, 1986, P NATL ACAD SCI USA, V83, P8410, DOI 10.1073/pnas.83.21.8410
   HOCHNER B, 1992, P NATL ACAD SCI USA, V89, P11476, DOI 10.1073/pnas.89.23.11476
   JARRARD HE, 1993, BRAIN RES, V616, P188, DOI 10.1016/0006-8993(93)90209-6
   JOHNSTON D, 1980, J PHYSIOL-LONDON, V298, P145, DOI 10.1113/jphysiol.1980.sp013072
   JOYNER RW, 1981, FED PROC, V40, P2814
   KANDEL ER, 1982, SCIENCE, V218, P433, DOI 10.1126/science.6289442
   KLEIN M, 1978, P NATL ACAD SCI USA, V75, P3512, DOI 10.1073/pnas.75.7.3512
   KLEIN M, 1982, P NATL ACAD SCI-BIOL, V79, P5713, DOI 10.1073/pnas.79.18.5713
   KLEIN M, 1986, P NATL ACAD SCI USA, V83, P7994, DOI 10.1073/pnas.83.20.7994
   KLEIN M, 1980, J EXP BIOL, V89, P117
   KLEIN M, 1993, J NEUROSCI, V13, P3793
   Manseau F, 1998, J NEUROPHYSIOL, V79, P1210
   MERCER AR, 1991, SCIENCE, V254, P1811, DOI 10.1126/science.1662413
   Michael D, 1998, P NATL ACAD SCI USA, V95, P1864, DOI 10.1073/pnas.95.4.1864
   MIROLLI M, 1972, J PHYSIOL-LONDON, V227, P19, DOI 10.1113/jphysiol.1972.sp010017
   Nakanishi K, 1997, J NEUROPHYSIOL, V78, P409
   OCORR KA, 1985, NEUROSCI LETT, V55, P113, DOI 10.1016/0304-3940(85)90004-7
   PARTRIDGE LD, 1978, AM J PHYSIOL, V234, pC155
   PIERONI JP, 1992, J NEUROSCI, V12, P2633
   POLLOCK JD, 1987, BRAIN RES, V410, P367, DOI 10.1016/0006-8993(87)90340-4
   POLLOCK JD, 1985, J NEUROSCI, V5, P1862
   ROMEY G, 1980, BIOCHIM BIOPHYS ACTA, V602, P610, DOI 10.1016/0005-2736(80)90339-9
   SACKTOR TC, 1990, P NATL ACAD SCI USA, V87, P2036, DOI 10.1073/pnas.87.5.2036
   SAH P, 1988, J GEN PHYSIOL, V91, P373, DOI 10.1085/jgp.91.3.373
   SCHOLZ KP, 1987, SCIENCE, V235, P685, DOI 10.1126/science.2433766
   SHUSTER MJ, 1991, J PHYSIOL-LONDON, V440, P601, DOI 10.1113/jphysiol.1991.sp018727
   SHUSTER MJ, 1987, J GEN PHYSIOL, V90, P587, DOI 10.1085/jgp.90.4.587
   SHUSTER MJ, 1985, NATURE, V313, P392, DOI 10.1038/313392a0
   SIEGELBAUM SA, 1982, NATURE, V299, P413, DOI 10.1038/299413a0
   SIEGELBAUM SA, 1986, J EXP BIOL, V124, P287
   Sossin W S, 1994, Learn Mem, V1, P189
   SOSSIN WS, 1992, J NEUROSCI, V12, P1160
   Sossin WS, 1997, LEARN MEMORY, V3, P389, DOI 10.1101/lm.3.5.389
   Stark LL, 1996, J NEUROPHYSIOL, V75, P855
   Stark LL, 1999, J NEUROSCI, V19, P334
   SUGITA S, 1994, J NEUROPHYSIOL, V72, P1250
   SUGITA S, 1994, J NEUROPHYSIOL, V72, P1240
   Sugita S, 1997, J NEUROSCI, V17, P7237
   Sugita S, 1997, J NEUROPHYSIOL, V77, P177
   SUGITA S, 1992, J NEUROPHYSIOL, V68, P643
   THOMPSON S, 1986, J NEUROSCI, V6, P3169
   THOMPSON SM, 1985, J NEUROSCI, V5, P817
   TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4
   WALSH JP, 1989, J NEUROPHYSIOL, V61, P32
   WALTERS ET, 1983, J NEUROPHYSIOL, V50, P1543
   WHITE JA, 1994, BIOPHYS J, V66, P710, DOI 10.1016/S0006-3495(94)80845-8
   Wright WG, 1996, EVOLUTION, V50, P2248, DOI 10.1111/j.1558-5646.1996.tb03614.x
   WRIGHT WG, 1995, LEARN MEMORY, V2, P178, DOI 10.1101/lm.2.3-4.178
   YAMADA WM, 1998, METHODS NEURONAL MOD, P137
   ZIV I, 1994, J NEUROPHYSIOL, V71, P294
NR 90
TC 39
Z9 41
U1 0
U2 3
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-3077
EI 1522-1598
J9 J NEUROPHYSIOL
JI J. Neurophysiol.
PD DEC
PY 1999
VL 82
IS 6
BP 2914
EP 2935
PG 22
WC Neurosciences; Physiology
SC Neurosciences & Neurology; Physiology
GA 268NH
UT WOS:000084422100007
PM 10601429
DA 2021-08-04
ER

PT J
AU Kimura, K
   Adachi, M
   Kubo, K
AF Kimura, K
   Adachi, M
   Kubo, K
TI Histamine release during the induction of anesthesia with propofol in
   allergic patients: A comparison with the induction of anesthesia using
   midazolam-ketamine
SO INFLAMMATION RESEARCH
LA English
DT Article
DE propofol; midazolam-ketamine; allergic patients; histamine release
ID TOTAL INTRAVENOUS ANESTHESIA; CARDIAC SURGICAL PATIENTS; TRACHEAL
   INTUBATION; INVITRO PROVOCATION; CONTINUOUS INFUSION;
   GENERAL-ANESTHESIA; MAST-CELLS; ASTHMA; FENTANYL; DIPRIVAN
AB Objective: A prospective randomized controlled study was performed for patients with a history of allergy to evaluate the effect of the induction of anesthesia with propofol against histamine release, skin reactions, hemodynamic changes and other clinical symptoms, while also comparing these parameters during the induction of anesthesia with midazolam-ketamine for patients with a history of allergy.
   Subjects: We examined 40 patients undergoing oral surgery, who had a history of allergy and/or the percentage of eosinophils in the leukocytes was more than 3%.
   Methods: Forty patients were randomly allocated into two groups and thus received either midazolam-ketamine (M-K group, n = 20) or fentanyl-propofol (propofol group, n = 20) for the induction of anesthesia. Venous blood samples (4 mi each) were obtained before induction as a control and at 0.5, 1, 3, 5 minutes after the administration of each induction agent, and then furthermore at 0.5, 1, 3, 5 minutes after tracheal intubation in order to measure the plasma histamine level by using the HPLC post-label system. In addition, the blood pressure and heart rate were also simultaneously recorded. Skin reactions were also evaluated by two anesthesiologists.
   Results: The incidence of 50% histamine release during the induction of anesthesia with propofol occurred in 15% of the patients with a history of allergy. Sixteen patients out of 20 (80%) showed a decrease in the systolic blood pressure after the administration of propofol without any evidence of histamine release. The incidence of 50% histamine release, skin reactions and an increase in the heart rate between the two groups were not statistically significant after the administration of each anesthetic agent. Moreover, some patients also demonstrated histamine release after tracheal intubation. Hemodynamic changes after tracheal intubation showed a similar tendency in both groups. No significant difference was observed regarding the incidence of histamine release, skin reactions and hemodynamic changes between both groups after tracheal intubation.
   Conclusions: Propofol was found to show a similar incidence of histamine release during the induction of anesthesia using midazolam-ketamine, and thus was also found to be a useful induction agent against histamine release for patients with a history of allergy when hydroxizine was used as a premedication.
C1 Kyushu Univ, Fac Dent, Dept Dent Anesthesiol, Higashi Ku, Fukuoka 8128582, Japan.
RP Kimura, K (corresponding author), Kyushu Univ, Fac Dent, Dept Dent Anesthesiol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.
CR AITKEN HA, 1988, ANAESTHESIA, V43, P170
   BAILIE R, 1989, ANAESTHESIA, V44, P60, DOI 10.1111/j.1365-2044.1989.tb11102.x
   BARAKA A, 1973, ANESTH ANALG, V52, P198
   BETTS GK, 1971, ANESTH ANALG, V50, P420
   BILAINE J, 1985, POSTGRAD MED J, V61, P38
   BLACK TE, 1984, ANAESTHESIA, V39, P883, DOI 10.1111/j.1365-2044.1984.tb06575.x
   BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505
   CHAI M, 1989, ANAESTHESIA, V44, P364, DOI 10.1111/j.1365-2044.1989.tb11317.x
   CHARLES TJ, 1979, CLIN SCI, V57, P39, DOI 10.1042/cs0570039
   COATES DP, 1987, ANESTH ANALG, V66, P64
   DAHL JB, 1994, LANCET, V343, P929, DOI 10.1016/S0140-6736(94)90059-0
   DAHLGREN N, 1981, ANAESTHESIA, V36, P1022, DOI 10.1111/j.1365-2044.1981.tb08676.x
   DERBYSHIRE DR, 1983, BRIT J ANAESTH, V55, P855, DOI 10.1093/bja/55.9.855
   DESOUZA G, 1993, ANESTHESIOLOGY, V79, pA492
   DOENICKE A, 1985, POSTGRAD MED J, V61, P15
   DOENICKE A, 1995, CLIN PHARMACOL THER, V58, P81, DOI 10.1016/0009-9236(95)90075-6
   DUDA D, 1992, AGENTS ACTIONS, pC149
   DUDZIAK R, 1987, ANAESTHESIST, V36, P412
   DURHAM SR, 1989, J ALLERGY CLIN IMMUN, V84, P931, DOI 10.1016/0091-6749(89)90391-6
   FISHER MM, 1977, ANAESTHESIA, V32, P771, DOI 10.1111/j.1365-2044.1977.tb10079.x
   FLACKE JW, 1983, ANESTHESIOLOGY, V59, pA51
   FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6
   GATEAU O, 1989, BRIT J ANAESTH, V63, P692, DOI 10.1093/bja/63.6.692
   GULDAGER H, 1985, ACTA ANAESTH SCAND, V29, P352, DOI 10.1111/j.1399-6576.1985.tb02213.x
   Harris C E, 1988, Anaesthesia, V43 Suppl, P32, DOI 10.1111/j.1365-2044.1988.tb09065.x
   HERMENS JM, 1985, ANESTHESIOLOGY, V62, P124, DOI 10.1097/00000542-198502000-00005
   HORINOUCHI Y, 1993, AGENTS ACTIONS, V40, P28, DOI 10.1007/BF01976748
   INADA E, 1986, CLIN PHARMACOL THER, V40, P575, DOI 10.1038/clpt.1986.226
   KAY B, 1985, ANAESTHESIA, V40, P960, DOI 10.1111/j.1365-2044.1985.tb10550.x
   Kimura K, 1999, INFLAMM RES, V48, P128, DOI 10.1007/s000110050435
   Laxenaire M C, 1987, Ann Fr Anesth Reanim, V6, P230, DOI 10.1016/S0750-7658(87)80026-6
   LAXENAIRE MC, 1992, ANESTHESIOLOGY, V77, P275, DOI 10.1097/00000542-199208000-00009
   LAXENAIRE MC, 1991, ACTA ANAESTH SCAND, V35, P706, DOI 10.1111/j.1399-6576.1991.tb03376.x
   LEONCASASOLA OA, 1992, ANESTHESIOLOGY, V77, P384
   LORENZ W, 1994, LANCET, V343, P933, DOI 10.1016/S0140-6736(94)90063-9
   Lorenz W, 1990, J Clin Anesth, V2, P345, DOI 10.1016/0952-8180(90)90083-F
   LORENZ W, 1982, KLIN WOCHENSCHR, V60, P896, DOI 10.1007/BF01716946
   MCHALE SP, 1992, ANAESTHESIA, V47, P864, DOI 10.1111/j.1365-2044.1992.tb03150.x
   Mitsuhata H, 1993, J Anesth, V7, P206, DOI 10.1007/s0054030070206
   MITSUHATA R, 1993, J ANESTH, V7, P189
   PEDERSEN CM, 1993, EUR J PHARMACOL, V238, P75, DOI 10.1016/0014-2999(93)90507-E
   PIZOV R, 1995, ANESTHESIOLOGY, V82, P1111, DOI 10.1097/00000542-199505000-00004
   RESTALL J, 1988, ANAESTHESIA, V43, P46, DOI 10.1111/j.1365-2044.1988.tb05424.x
   ROSOW CE, 1982, ANESTHESIOLOGY, V56, P93, DOI 10.1097/00000542-198202000-00003
   RUSSELL WJ, 1981, BRIT J ANAESTH, V53, P837, DOI 10.1093/bja/53.8.837
   SCHATZ M, 1982, ARCH INTERN MED, V142, P1515, DOI 10.1001/archinte.142.8.1515
   SHEREF SE, 1985, ANAESTHESIA, V40, P701, DOI 10.1111/j.1365-2044.1985.tb10962.x
   SMITH H, 1992, CLIN EXP ALLERGY, V22, P187, DOI 10.1111/j.1365-2222.1992.tb03072.x
   STARK RD, 1985, POSTGRAD MED J, V61, P152
   STRUBE PJ, 1986, ANAESTHESIA, V41, P1017, DOI 10.1111/j.1365-2044.1986.tb12744.x
   Thomas V L, 1988, Anaesthesia, V43 Suppl, P73, DOI 10.1111/j.1365-2044.1988.tb09077.x
   THOMPSON MC, 1990, ANAESTHESIA, V45, P690, DOI 10.1111/j.1365-2044.1990.tb14414.x
   UEHARA M, 1990, CLIN EXP DERMATOL, V15, P264, DOI 10.1111/j.1365-2230.1990.tb02086.x
   WHITE PF, 1982, ANESTHESIOLOGY, V57, P279, DOI 10.1097/00000542-198210000-00005
   WILSON LE, 1993, BRIT J ANAESTH, V71, P544, DOI 10.1093/bja/71.4.544
   WITHINGTON DE, 1988, AGENTS ACTIONS, V23, P337, DOI 10.1007/BF02142581
   YAMATODANI A, 1985, J CHROMATOGR, V344, P115, DOI 10.1016/S0378-4347(00)82012-5
NR 57
TC 8
Z9 8
U1 0
U2 3
PU BIRKHAUSER VERLAG AG
PI BASEL
PA VIADUKSTRASSE 40-44, PO BOX 133, CH-4010 BASEL, SWITZERLAND
SN 1023-3830
J9 INFLAMM RES
JI Inflamm. Res.
PD NOV
PY 1999
VL 48
IS 11
BP 582
EP 587
DI 10.1007/s000110050507
PG 6
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA 261AQ
UT WOS:000083986000005
PM 10598014
DA 2021-08-04
ER

PT J
AU Perez, HL
   Cheong, HK
   Yang, JS
   Osterman-Golkar, S
AF Perez, HL
   Cheong, HK
   Yang, JS
   Osterman-Golkar, S
TI Simultaneous analysis of hemoglobin adducts of acrylamide and
   glycidamide by gas chromatography-mass spectrometry
SO ANALYTICAL BIOCHEMISTRY
LA English
DT Article
ID ALKYLATING-AGENTS; EXPOSURE; WORKERS; RAT
AB Acrylamide (AA) is a carcinogen in experimental animals. Glycidamide (GA), formed by metabolic epoxidation of AA, is believed to be responsible for the carcinogenicity of AA. Occupational exposure to AA has been assessed earlier by measurement of its adducts with N-terminal valine in hemoglobin. A background of AA adducts [N-(2-carbamoylethyl) valine (AAVal), about 30 pmol/g globin] was found in individuals without known exposure to the compound. The method previously available for adducts of GA only allowed analysis of samples from highly exposed individuals and showed similar levels of AAVal and adducts of GA [N-(2-hydroxy-2-carbamoylethyl)valine (GAVal)]. We have developed a sensitive method for simultaneous quantification of adducts of GA and AA, which is suitable down to low exposure levels. The method is based on the so-called modified Edman method, where globin is reacted with pentafluorophenyl isothiocyanate under neutral conditions, The valine adducts are then extracted in the form of pentafluorophenylthiohydantoin (PFPTH) derivatives, The analytical procedure included reaction of the PFPTH derivatives with acetic anhydride in order to protect the hydroxyl group of GAVal, The PFPTH derivatives of AAVal and GAVal were analyzed by gas chromatography/tandem mass spectrometry, (H-2(2))AAVal-PFPTH was used as the internal standard. The method was applied to samples from 11 workers at an AA production plant, 1 nonexposed nonsmoker, and a few participants of a smoking cessation program. AAVal levels were in the range 27-1854 pmol/g globin, Recorded levels of GAVal were 3-12% of those of AAVal, suggesting that previous measurements of GAVal overestimate GAVal at low levels Of exposure to AA. (C) 1999 Academic Press.
C1 Stockholm Univ, Dept Mol Genome Res, SE-10691 Stockholm, Sweden.
   Dongguk Univ, Coll Med, Dept Prevent Med, Kyongju 780714, South Korea.
   Korea Ind Safety Corp, Ind Hlth Res Inst, Inchon, South Korea.
RP Perez, HL (corresponding author), Stockholm Univ, Dept Mol Genome Res, SE-10691 Stockholm, Sweden.
EM hermes.licea_perez@molgen.su.se
OI Cheong, Hae-Kwan/0000-0003-2758-9399
CR Bergmark E, 1997, CHEM RES TOXICOL, V10, P78, DOI 10.1021/tx960113p
   BERGMARK E, 1993, TOXICOL APPL PHARM, V120, P45, DOI 10.1006/taap.1993.1085
   BERGMARK E, 1991, TOXICOL APPL PHARM, V111, P352, DOI 10.1016/0041-008X(91)90036-E
   CALLEMAN CJ, 1994, TOXICOL APPL PHARM, V126, P361, DOI 10.1006/taap.1994.1127
   DEARFIELD KL, 1995, MUTAT RES-FUND MOL M, V330, P71, DOI 10.1016/0027-5107(95)00037-J
   IARC, 1995, IARC MON, V60, P389
   Landin HH, 1996, ANAL BIOCHEM, V240, P1, DOI 10.1006/abio.1996.0322
   MEIENHOFER J, 1979, INT J PEPT PROT RES, V13, P35
   MOWRER J, 1986, TOXICOL ENVIRON CHEM, V11, P215, DOI 10.1080/02772248609357133
   OSTERMANGOLKAR S, 1976, MUTAT RES, V34, P1, DOI 10.1016/0027-5107(76)90256-6
   Perez HL, 1997, CHEM-BIOL INTERACT, V105, P181, DOI 10.1016/S0009-2797(97)00049-5
   SEGERBACK D, 1995, CARCINOGENESIS, V16, P1161, DOI 10.1093/carcin/16.5.1161
   Smith Eldon A., 1991, Reviews on Environmental Health, V9, P215
   TORNQVIST M, 1988, J APPL TOXICOL, V8, P159, DOI 10.1002/jat.2550080303
   TORNQVIST M, 1998, 798 PM SWED CHEM INS
NR 15
TC 50
Z9 50
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0003-2697
EI 1096-0309
J9 ANAL BIOCHEM
JI Anal. Biochem.
PD OCT 1
PY 1999
VL 274
IS 1
BP 59
EP 68
DI 10.1006/abio.1999.4267
PG 10
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 243XG
UT WOS:000083022300008
PM 10527497
DA 2021-08-04
ER

PT J
AU Ranta, E
   Kaitala, V
   Lindstrom, J
AF Ranta, E
   Kaitala, V
   Lindstrom, J
TI Spatially autocorrelated disturbances and patterns in population
   synchrony
SO PROCEEDINGS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
LA English
DT Article
DE Moran effect; population dynamics; spatial autocorrelation; dispersal;
   synchrony
ID METAPOPULATION DYNAMICS; LARGE-SCALE; FLUCTUATIONS; ASYNCHRONY;
   OUTBREAKS; ECOLOGY
AB Spatially synchronous population dynamics have been documented in many taxa. The prevailing view is that the most plausible candidates to explain this pattern are extrinsic disturbances (the Moran effect) and dispersal. In most cases disentangling these factors is difficult. Theoretical studies have shown that dispersal between subpopulations is more likely to produce a negative relationship between population synchrony and distance between the patches than perturbations. As analyses of empirical data frequently show this negative relationship between the level of synchrony and distance between populations, this has emphasized the: importance of dispersal as a synchronizing agent. However, several weather patterns show spatial autocorrelation, which could potentially produce patterns in population synchrony similar to those caused by dispersal. By using spatially extended versions of several population dynamic models, we show that this is indeed the case. Our results show that, especially when both factors (spatially autocorrelated perturbations and distance-dependent dispersal) act together, there may exist groups of local populations in synchrony together but fluctuating asynchronously with some other groups of local populations. We also show, by analysing 56 long-term population data sets, that patterns of population synchrony similar to those found in our simulations are found in natural populations as well. This finding highlights the subtlety in the interactions of dispersal and noise in organizing spatial patterns in population fluctuations.
C1 Univ Helsinki, Integrat Ecol Unit, Div Populat Biol, Dept Ecol & Systemat, FIN-00014 Helsinki, Finland.
   Univ Jyvaskyla, Dept Biol & Enviromn Sci, FIN-40351 Jyvaskyla, Finland.
   Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England.
RP Ranta, E (corresponding author), Univ Helsinki, Integrat Ecol Unit, Div Populat Biol, Dept Ecol & Systemat, POB 17,Arkadiankatu 7, FIN-00014 Helsinki, Finland.
EM esa.ranta@helsinki.fi
RI Lindstrom, Jan/A-8890-2008
OI Lindstrom, Jan/0000-0001-5630-6680
CR Arnfield AL, 1998, PROG PHYS GEOG, V22, P533
   BASCOMPTE J, 1995, TRENDS ECOL EVOL, V10, P361, DOI 10.1016/S0169-5347(00)89134-X
   Bascompte J., 1997, MODELING SPATIOTEMPO
   Bjornstad ON, 1999, ECOLOGY, V80, P622, DOI 10.2307/176640
   Earn DJD, 1998, P ROY SOC B-BIOL SCI, V265, P7, DOI 10.1098/rspb.1998.0256
   GOODRIDGE JD, 1991, P 7 ANN PAC CLIM WOR, P109
   Grenfell B, 1997, TRENDS ECOL EVOL, V12, P395, DOI 10.1016/S0169-5347(97)01174-9
   Grenfell BT, 1998, NATURE, V394, P674, DOI 10.1038/29291
   HANSKI I, 1993, J ANIM ECOL, V62, P656, DOI 10.2307/5386
   Hanski I., 1997, METAPOPULATION BIOL
   Haydon D, 1997, P ROY SOC B-BIOL SCI, V264, P1375, DOI 10.1098/rspb.1997.0191
   Heino M, 1997, P ROY SOC B-BIOL SCI, V264, P481, DOI 10.1098/rspb.1997.0069
   Heino R, 1994, FINNISH METEOROLOGIC, P12
   Higgins K, 1997, SCIENCE, V276, P1431, DOI 10.1126/science.276.5317.1431
   Holyoak M, 1996, J ANIM ECOL, V65, P640, DOI 10.2307/5743
   HURRELL JW, 1995, SCIENCE, V269, P676, DOI 10.1126/science.269.5224.676
   Kaitala V, 1998, ECOL LETT, V1, P186
   KEITH LB, 1963, WILDLIFES 10 YEAR CY
   Koenig WD, 1999, TRENDS ECOL EVOL, V14, P22, DOI 10.1016/S0169-5347(98)01533-X
   KRIPALANI RH, 1997, INT J CLIMATOL, V17, P155
   Lambin X, 1998, P ROY SOC B-BIOL SCI, V265, P1491, DOI 10.1098/rspb.1998.0462
   LESLIE P. H., 1959, PHYSIOL ZOOL, V32, P151
   Liebhold A, 1996, RES POPUL ECOL, V38, P87, DOI 10.1007/BF02514974
   LINDAUER D, 1988, WORLD BANK RES OBSER, V3, P1
   Lindstrom J, 1996, OIKOS, V76, P221, DOI 10.2307/3546193
   MORAN PAP, 1953, AUST J ZOOL, V1, P291, DOI 10.1071/ZO9530291
   Myers JH, 1998, ECOLOGY, V79, P1111, DOI 10.1890/0012-9658(1998)079[1111:SIOOFL]2.0.CO;2
   NORDO J, 1967, GEOPHYSICA NORWEGICA, V26, P1
   Paradis E, 1999, ECOL LETT, V2, P114, DOI 10.1046/j.1461-0248.1999.22060.x
   POLLARD E, 1991, OIKOS, V60, P7, DOI 10.2307/3544985
   RANTA E, 1995, P ROY SOC B-BIOL SCI, V262, P113, DOI 10.1098/rspb.1995.0184
   RANTA E, 1995, J ANIM ECOL, V64, P767, DOI 10.2307/5855
   Ranta E, 1997, SCIENCE, V278, P1621, DOI 10.1126/science.278.5343.1621
   Ranta E, 1997, AM NAT, V149, P765, DOI 10.1086/286019
   RANTA E, 1997, MODELING SPATIOTEMPO, P47
   ROYAMA T, 1992, ANAL POPULATION DYNA
   Schwerdtfeger F., 1941, Zeitschrift fuer Angewandte Entomologie, V28, P254
   Steen H, 1996, ECOLOGY, V77, P2365, DOI 10.2307/2265738
   Sutcliffe OL, 1996, J ANIM ECOL, V65, P85, DOI 10.2307/5702
   Tilman D, 1997, SPATIAL ECOLOGY ROLE
   TURCHIN P, 1990, NATURE, V344, P660, DOI 10.1038/344660a0
   Xu M, 1997, CLIMATE RES, V8, P209, DOI 10.3354/cr008209
NR 42
TC 121
Z9 123
U1 0
U2 27
PU ROYAL SOC
PI LONDON
PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 0962-8452
J9 P ROY SOC B-BIOL SCI
JI Proc. R. Soc. B-Biol. Sci.
PD SEP 22
PY 1999
VL 266
IS 1431
BP 1851
EP 1856
DI 10.1098/rspb.1999.0856
PG 6
WC Biology; Ecology; Evolutionary Biology
SC Life Sciences & Biomedicine - Other Topics; Environmental Sciences &
   Ecology; Evolutionary Biology
GA 243LJ
UT WOS:000082998500005
OA Green Published
DA 2021-08-04
ER

PT J
AU Li, YS
   Li, MS
   Chang, FC
AF Li, YS
   Li, MS
   Chang, FC
TI Kinetics and curing mechanism of epoxy and boron trifluoride monoethyl
   amine complex system
SO JOURNAL OF POLYMER SCIENCE PART A-POLYMER CHEMISTRY
LA English
DT Article
DE epoxy; cationic polymerization; kinetics; reaction mechanism
ID CURE KINETICS; POLYMERIZATION MECHANISM; RESIN CURE; DGEBA
AB The kinetics of cationic polymerization of epoxy resin has been studied. Due to multiple reaction exotherms and irregular baselines involved in this system, the ASTM E 698 method was chosen to determine the kinetic parameters of this epoxy/BF3-MEA system. The DER 332/BF3-MEA system follows the first order active chain end (ACE) reaction mechanism. The adding of the hydroxyl group into the system is prone to decrease the activation energy and shifts the curing into the activated monomer (AM) mechanism due to the stronger nucleophilicity of the hydroxyl group than the epoxide group. On the other hand, the DER 331/BF3-MEA system possesses lower activation energy because the DER 331 contains more hydroxyl groups-alpha-glycol and secondary alcohol. The former is the major contributor in lowering the activation energy. The hydroxyl group also can act as a chain transfer agent by retarding the propagation process, thus the reaction rate of the DER 332/BF3-MEA system is higher than the DER 331/BF3-MEA system. The DER 332/BF3-MEA system shows good correlation between the experimental data (FT-IR, DSC, and GPC) and the simulation curve based on ASTM E 698 before gelation, while a larger deviation is observed in the DER 331/BF3-MEA system. After gelation, the hydroxyl group also acts as an active site to react with residual epoxy monomers and obtain a more condense matrix. (C) 1999 John Wiley & Sons, Inc.
C1 Natl Chiao Tung Univ, Dept Appl Chem, Hsinchu 300, Taiwan.
RP Chang, FC (corresponding author), Natl Chiao Tung Univ, Dept Appl Chem, Hsinchu 300, Taiwan.
RI Chang, Feng-Chih/G-5195-2010
CR *ASTM, 69879 ASTM E
   BARTON JM, 1980, POLYMER, V21, P603, DOI 10.1016/0032-3861(80)90314-6
   BOUILLON N, 1990, MAKROMOL CHEM, V191, P1417
   CHANDRA R, 1993, POLYM INT, V31, P239, DOI 10.1002/pi.4990310305
   CHEN CS, 1989, J APPL POLYM SCI, V37, P1105, DOI 10.1002/app.1989.070370421
   CHIAO L, 1990, MACROMOLECULES, V23, P1286, DOI 10.1021/ma00207a010
   Ghaemy M, 1998, EUR POLYM J, V34, P1151, DOI 10.1016/S0014-3057(97)00247-4
   GRILLET AC, 1989, POLYMER, V30, P2094, DOI 10.1016/0032-3861(89)90300-5
   HAMMOND JM, 1971, J POLYM SCI A, V19, P265
   HEISE MS, 1990, J APPL POLYM SCI, V39, P721, DOI 10.1002/app.1990.070390321
   HSIEH TH, 1990, J APPL POLYM SCI, V41, P1271, DOI 10.1002/app.1990.070410535
   Li MS, 1997, POLYMER, V38, P4903, DOI 10.1016/S0032-3861(96)01089-0
   OZAWA T, 1976, J THERM ANAL, V9, P369, DOI 10.1007/BF01909401
   Ozawa T, 1970, J THERM ANAL CALORIM, V2, P301, DOI DOI 10.1007/BF01911411
   PATEL RD, 1987, BRIT POLYM J, V19, P37, DOI 10.1002/pi.4980190106
   PENCZEK S, 1986, MAKROMOL CHEM-M SYMP, V3, P203, DOI 10.1002/masy.19860030116
   SENEN PA, 1998, J POLYM SCI POL CHEM, V36, P1001
   SMITH RE, 1984, J APPL POLYM SCI, V29, P3697, DOI 10.1002/app.1984.070291206
   SMITH RE, 1986, J APPL POLYM SCI, V31, P929, DOI 10.1002/app.1986.070310316
   SPACEK V, 1987, EUR POLYM J, V23, P377, DOI 10.1016/0014-3057(87)90166-2
   TACKIE M, 1993, J APPL POLYM SCI, V48, P793, DOI 10.1002/app.1993.070480505
   WENDTLANDT WW, 1986, THERMAL ANAL, V1, pCH
   WOJTANIA M, 1986, MAKROMOL CHEM-M SYMP, V6, P201, DOI 10.1002/masy.19860060118
   WOO EM, 1990, J APPL POLYM SCI, V40, P1237, DOI 10.1002/app.1990.070400713
NR 24
TC 37
Z9 39
U1 0
U2 26
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0887-624X
J9 J POLYM SCI POL CHEM
JI J. Polym. Sci. Pol. Chem.
PD SEP 15
PY 1999
VL 37
IS 18
BP 3614
EP 3624
DI 10.1002/(SICI)1099-0518(19990915)37:18<3614::AID-POLA9>3.3.CO;2-Q
PG 11
WC Polymer Science
SC Polymer Science
GA 231XJ
UT WOS:000082336400009
DA 2021-08-04
ER

PT J
AU Horimoto, H
   Saltman, AE
   Gaudette, GR
   Krukenkamp, IB
AF Horimoto, H
   Saltman, AE
   Gaudette, GR
   Krukenkamp, IB
TI Nitric oxide-generating beta-adrenergic blocker nipradilol preserves
   postischemic cardiac function
SO ANNALS OF THORACIC SURGERY
LA English
DT Article; Proceedings Paper
CT 35th Annual Meeting of the Society-of-Thoracic-Surgeons
CY JAN 24-29, 1999
CL SAN ANTONIO, TX
SP Soc Thorac Surgeons
ID ISCHEMIC MYOCARDIUM; REPERFUSION; INVOLVEMENT; MECHANISMS; CHANNEL;
   PATHWAY; MUSCLE; INJURY; HEARTS
AB Background. Preconditioning protects the heart from ischemic injury, but some of its effects are reversed by beta-adrenergic blockade. We hypothesize that because nitric oxide is known to precondition the heart, the nitric oxide-generating beta-blocker nipradilol may simultaneously precondition and provide clinically relevant beta-blockade.
   Methods. Isolated, crystalloid-perfused rabbit hearts underwent 1 hour of left anterior descending coronary artery ischemia followed by 1 hour of reperfusion. Before ischemia, six hearts received nipradilol, six received the nitric oxide donor L-arginine, four hearts received the nitric oxide synthase inhibitor N-G-nitro-L-arginine methyl ester before L-arginine, nine underwent ischemic preconditioning, and six received beta-blockade by esmolol before ischemic preconditioning. Seven hearts received no pretreatment (control). Action potential duration and ventricular pressure were measured. Infarct size was determined at the end of reperfusion.
   Results. Both L-arginine and ischemic preconditioning prolonged action potential duration significantly at 60 minutes of reperfusion. Compared with control, infarct size was reduced by ischemic preconditioning (26% +/- 4% versus 49% +/- 3%, IPC versus control; p < 0.01), L-arginine (24% +/- 2%; p < 0.01 versus control), and nipradilol (24% +/- 2% p < 0.01 versus control). Only nipradilol preserved peak developed pressure during reperfusion.
   Conclusions. Despite its properties as a beta-adrenergic blocking agent, nipradilol was able to precondition the heart, probably as a result of its ability to produce nitric oxide. (Ann Thorac Surg 1999;68:844-9) (C) 1999 by The Society of Thoracic Surgeons.
C1 SUNY Stony Brook, Univ Hosp Stony Brook, Div Cardiothorac Surg, Hlth Sci Ctr T19 080, Stony Brook, NY 11794 USA.
RP Krukenkamp, IB (corresponding author), SUNY Stony Brook, Univ Hosp Stony Brook, Div Cardiothorac Surg, Hlth Sci Ctr T19 080, Stony Brook, NY 11794 USA.
EM ibkmd@hotmail.com
CR AMEZCUA JL, 1989, BRIT J PHARMACOL, V97, P1119, DOI 10.1111/j.1476-5381.1989.tb12569.x
   BALLIGAND JL, 1993, P NATL ACAD SCI USA, V90, P347, DOI 10.1073/pnas.90.1.347
   BANERJEE A, 1993, CIRC RES, V73, P656, DOI 10.1161/01.RES.73.4.656
   DOWNEY JM, 1992, TRENDS CARDIOVAS MED, V2, P170, DOI 10.1016/1050-1738(92)90045-T
   GALARIS D, 1989, ARCH BIOCHEM BIOPHYS, V273, P497, DOI 10.1016/0003-9861(89)90509-2
   HARRIS L, 1993, J MOL CELL CARDIOL, V25, P1075, DOI 10.1006/jmcc.1993.1120
   HORIMOTO H, 1998, SURG FORUM, V48, P202
   HU KL, 1995, CIRCULATION, V92, P2259, DOI 10.1161/01.CIR.92.8.2259
   KHANDOUDI N, 1994, BRIT J PHARMACOL, V112, P1007, DOI 10.1111/j.1476-5381.1994.tb13183.x
   LEVI RC, 1989, PFLUG ARCH EUR J PHY, V413, P685, DOI 10.1007/BF00581823
   Maulik N, 1996, CIRCULATION, V94, P398
   MONCADA S, 1993, NEW ENGL J MED, V329, P2002
   MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124
   PARRATT JR, 1994, CARDIOVASC RES, V28, P783, DOI 10.1093/cvr/28.6.783
   PATTERSON E, 1991, CLIN CARDIOL, V14, P505, DOI 10.1002/clc.4960140610
   VEGH A, 1992, BRIT J PHARMACOL, V107, P648, DOI 10.1111/j.1476-5381.1992.tb14501.x
   Xie YW, 1996, CIRC RES, V79, P381, DOI 10.1161/01.RES.79.3.381
   YAO ZH, 1993, CIRC RES, V73, P1193, DOI 10.1161/01.RES.73.6.1193
   YOKOTA R, 1995, AM J PHYSIOL-HEART C, V268, pH1149
NR 19
TC 21
Z9 22
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
EI 1552-6259
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD SEP
PY 1999
VL 68
IS 3
BP 844
EP 849
DI 10.1016/S0003-4975(99)00809-7
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 239BF
UT WOS:000082748400016
PM 10509972
DA 2021-08-04
ER

PT J
AU Morin, P
   Dreux, M
   Usse, S
   Viaud, MC
   Guillaumet, G
AF Morin, P
   Dreux, M
   Usse, S
   Viaud, MC
   Guillaumet, G
TI Comparison of sulfobutylether- and sulfated-beta-cyclodextrins as
   additives for the chiral separation of basic spirobenzopyrans by
   capillary electrophoresis
SO ELECTROPHORESIS
LA English
DT Article
DE enantiomer separation; capillary electrophoresis;
   sulfobutylether-beta-cyclodextrin; sulfated-beta-CD; spirobenzopyran
ID POTENTIAL ANXIOLYTIC AGENTS; 5-HT1A RECEPTOR LIGANDS; THEORETICAL
   ASPECTS; RESOLVING AGENTS; ELECTROKINETIC CHROMATOGRAPHY;
   ZONE-ELECTROPHORESIS; DERIVATIVES; ETHER; RESOLUTION; SELECTORS
AB Three charged substituted beta-cyclodextrins (beta-CDs), sulfobutylether-beta-(SBE-beta-CD), degree of substitution (DS) 4 and 7), and sulfated-beta-(S-beta-CD) cyclodextrins, were compared as chiral additives in capillary electrophoresis for the enantiomeric separation of basic spirobenzopyran derivatives (pK(a) 9.9) which differ from each other by an N-alkyl group. The number of sulfobutylether groups attached to the cyclodextrin moiety significantly influences the enantioseparation of the basic drugs. SBE-beta-CD (DS 7) which is more strongly bound to cationic analyte than SBE-beta-CD (DS 4.6), requires smaller concentrations to achieve the same resolution. Besides, better enantioresolutions were obtained with S-beta-CD rather than with SBE-beta-CDs though higher concentrations are required, which led to high current values. However, both pairs of enantiomers cannot be resolved using S-beta-CD while SBE-beta-CDs make it possible to resolve simultaneous enantioseparation of such solutes slightly differing in hydrophobicity. This supports the hypothesis that hydrophobic interactions (outside of the CD cavity) between the butyl group attached to SBE-beta-CD and the N-alkyl group of spirobenzopyran play a role in the enantioseparation. On the other hand, the sulfate group of S-beta-CD was directly attached to the CD moiety which means that the S-beta-CD-drug complexation mechanism arises through the combination of electrostatic and hydrophobic (inside the CD cavity) interactions. Finally, enantiomers of spirobenzopyran drugs were satisfactorily resolved by CE using a 20 mg/mL S-beta-CD concentration (resolution 4.0), 7 mg/mL SBE-beta-CD DS 4 (resolution 1.3), or 5 mg/mL SBE-beta-CD DS 7 (resolution 3.3) added to the phosphate buffer (pH 2.6, 50 mM ionic strength).
C1 Univ Orleans, CNRS, Inst Organ & Analyt Chem, UPRESA 6005, F-45067 Orleans 2, France.
RP Morin, P (corresponding author), Univ Orleans, CNRS, Inst Organ & Analyt Chem, UPRESA 6005, BP 6759, F-45067 Orleans 2, France.
CR BAUMY P, 1995, J CHROMATOGR A, V707, P311, DOI 10.1016/0021-9673(95)00325-H
   Cai H, 1998, ANAL CHEM, V70, P580, DOI 10.1021/ac970822n
   Comoy C, 1996, J MED CHEM, V39, P4285, DOI 10.1021/jm950861w
   DESIDERIO C, 1995, J CHROMATOGR A, V716, P183, DOI 10.1016/0021-9673(95)00550-7
   Fillet M, 1996, J PHARMACEUT BIOMED, V14, P1107, DOI 10.1016/S0731-7085(95)01756-9
   Fillet M., 1996, J HIGH RES CHROMATOG, V19, P669
   Francotte E, 1997, J CHROMATOGR A, V792, P379, DOI 10.1016/S0021-9673(97)00979-5
   Gahm KH, 1996, CHIRALITY, V8, P316
   Gahm KH, 1998, J CHROMATOGR A, V793, P135, DOI 10.1016/S0021-9673(97)00802-9
   Ishibuchi K, 1997, ELECTROPHORESIS, V18, P1007, DOI 10.1002/elps.1150180624
   Jung M, 1996, J CHROMATOGR A, V755, P81, DOI 10.1016/S0021-9673(96)00589-4
   Juvancz Z, 1997, ELECTROPHORESIS, V18, P1002, DOI 10.1002/elps.1150180623
   LURIE IS, 1994, ANAL CHEM, V66, P4019, DOI 10.1021/ac00094a026
   Morin P, 1997, ANALUSIS, V25, P340
   Morin P, 1998, J CHROMATOGR A, V796, P375, DOI 10.1016/S0021-9673(97)01021-2
   Okimoto K, 1996, PHARMACEUT RES, V13, P256, DOI 10.1023/A:1016047215907
   Parmerter S.M., 1969, United States Patent, Patent No. [US 3,426,011, 3426011]
   PODONA T, 1994, J MED CHEM, V37, P1779, DOI 10.1021/jm00038a007
   RIPOCHE I, 1995, TETRAHEDRON LETT, V36, P6675, DOI 10.1016/0040-4039(95)01352-I
   Ripoche I, 1996, TETRAHEDRON LETT, V37, P3991, DOI 10.1016/0040-4039(96)00621-1
   Rubiralta M., 1991, PIPERIDINE STRUCTURE
   Skanchy DJ, 1997, ELECTROPHORESIS, V18, P985, DOI 10.1002/elps.1150180621
   Stalcup AM, 1996, ANAL CHEM, V68, P1360, DOI 10.1021/ac950764a
   Stella V.J., 1994, Patent, Patent No. [5,376,645, 5376645, US5376645]
   Szeman J, 1996, J CHROMATOGR A, V728, P423, DOI 10.1016/0021-9673(95)01312-1
   TAIT RJ, 1994, ANAL CHEM, V66, P4013, DOI 10.1021/ac00094a025
   TERABE S, 1985, J CHROMATOGR, V332, P211, DOI 10.1016/S0021-9673(01)83299-4
   UMEZAWA S, 1970, J ANTIBIOT, V23, P28, DOI 10.7164/antibiotics.23.28
   Verleysen K, 1998, J CHROMATOGR A, V824, P91, DOI 10.1016/S0021-9673(98)00667-0
   Vincent JB, 1997, ANAL CHEM, V69, P4419, DOI 10.1021/ac970418o
   Vincent JB, 1997, ANAL CHEM, V69, P4226, DOI 10.1021/ac970252r
   Wang H, 1998, ANAL CHIM ACTA, V359, P39, DOI 10.1016/S0003-2670(97)00655-7
   WREN SAC, 1992, J CHROMATOGR, V603, P235, DOI 10.1016/0021-9673(92)85366-2
   WREN SAC, 1993, J CHROMATOGR, V635, P113, DOI 10.1016/0021-9673(93)83120-H
   WREN SAC, 1992, J CHROMATOGR, V609, P363, DOI 10.1016/0021-9673(92)80181-S
   WU WH, 1995, J LIQ CHROMATOGR, V18, P1289, DOI 10.1080/10826079508010414
NR 36
TC 16
Z9 17
U1 0
U2 6
PU WILEY-V C H VERLAG GMBH
PI BERLIN
PA MUHLENSTRASSE 33-34, D-13187 BERLIN, GERMANY
SN 0173-0835
J9 ELECTROPHORESIS
JI Electrophoresis
PD SEP
PY 1999
VL 20
IS 13
BP 2630
EP 2637
DI 10.1002/(SICI)1522-2683(19990901)20:13<2630::AID-ELPS2630>3.0.CO;2-9
PG 8
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 279KZ
UT WOS:000085044100007
PM 10532328
DA 2021-08-04
ER

PT J
AU Hirose, M
   Takahashi, S
   Ogawa, K
   Futakuchi, M
   Shirai, T
AF Hirose, M
   Takahashi, S
   Ogawa, K
   Futakuchi, M
   Shirai, T
TI Phenolics: Blocking agents for heterocyclic amine-induced carcinogenesis
SO FOOD AND CHEMICAL TOXICOLOGY
LA English
DT Article; Proceedings Paper
CT Symposium on Antioxidants and Health
CY MAR 18-20, 1998
CL BORDEAUX, FRANCE
DE phenolic antioxidant; heterocyclic amine; chemoprevention;
   carcinogenesis; rat
ID FOOD-BORNE CARCINOGEN; RAT HEPATOCARCINOGENESIS; METABOLIC-ACTIVATION;
   INDUCED MUTAGENESIS; ANTIOXIDANTS; DNA;
   2-AMINO-3,8-DIMETHYLIMIDAZO<4,5-F>QUINOXALINE; IDENTIFICATION;
   INDUCTION; 1-O-HEXYL-2,3,5-TRIMETHYLHYDROQUINONE
AB Chemopreventive effects of synthetic and naturally occurring antioxidants on heterocyclic amine (HCA)-induced rat carcinogenesis and mechanisms of inhibition were assessed. In a medium-term liver bioassay, combined treatment with 0.03% 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) and synthetic antioxidants such as 1-O-hexyl-2,3,5-trimethylhydroquinone (HTHQ), butylated hydroxyanisole (BHA), butylated hydroxutoluene (BHT), tert-butylhydroquinone (TBHQ) or propyl gallate, each at a dose of 0.25%, inhibited development of preneoplastic glutathione S-transferase placental form (GST-P) positive foci as compared with MeIQx alone, after initiation with diethylnitrosamine (DEN). Of these antioxidants, HTHQ showed the greatest activity. 8-Hydroxydeoxyguanosine (8-OHdG), a marker for DNA damage induced by active oxygen species, and malonedialdehyde and 4-hydroxynonenal levels were not largely influenced by the treatment with MeIQx or antioxidants, either alone or in combination. In the same medium-term liver bioassay, effects of some naturally occurring antioxidants, such as green tea catechins (GTC), hesperidin, chlorogenic acid, quercetin, rutin, curcumin, daidzin, ferulic acid and genistein were also examined. Of these antioxidants, only GTC tended to inhibit GST-P positive foci development, while quercetin, rutin, curcumin, daidzin, ferulic acid and genistein all exerted significant enhancing effects. Examination of HTHQ influence in a medium term liver bioassay with HCA Glu-P-1, in which the experimental period was extended for up to 26 weeks, also demonstrated a significant decrease in the incidence of liver tumours to 40% in the group treated with 0.5% HTHQ and 0.03% 2-amino-6-methyldipyrido[1,2-a:3',2'-d]imidazole (Glu-P-1) as compared with the Glu-P-1 alone value of 89%. Effects of HTHQ on colon carcinogenesis induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine (PhIP) were evaluated in a two-stage colon carcinogenesis model using 1,2-dimethylhydrazine (DMH) as an initiator. At week 36, the multiplicity of colon tumours induced by 0.02% PhIP after DMH initiation (9.1 +/- 6.2/rat) was dose-dependently decreased by the combined treatment with 0.5% HTHQ (3.6 +/- 1.8, P < 0.001) and 0.125% HTHQ (6.2 +/- 3.2, not significant). Similarly, the incidence of mammary carcinomas in female F344 rats induced by oral administration of 0.02% PhIP (40%) for 52 weeks was significantly decreased by simultaneous treatment with 0.5% HTHQ (5%). alpha-Tocopherol and chlorophyllin only reduced the multiplicity of carcinomas. Analysis of the influence of HTHQ on metabolic activation of Glu-P-1 or PhIP after incubation with rat S9 mixture and NADPH by HPLC, revealed that each major metabolite was strongly reduced by the addition of HTHQ. Immunohistochemically detected PhIP-DNA adduct positive nuclei in the colon induced by continuous oral treatment with 0.02% PhIP for 2 weeks decreased by the combined treatment with 0.5 or 0.125% HTHQ. These results indicate that synthetic antioxidant HTHQ is a very strong chemopreventor of heterocyclic amine (HCA)-induced carcinogenesis and that depressed metabolic activation rather than antioxidant activity is responsible for the observed effect. (C) 1999 Elsevier Science Ltd. All rights reserved.
C1 Nagoya City Univ, Sch Med, Dept Pathol 1, Mizuho Ku, Nagoya, Aichi 4678501, Japan.
RP Hirose, M (corresponding author), Natl Inst Hlth Sci, Biol Safety Res Ctr, Div Pathol, Setagaya Ku, 1-18-1 Kamiyoga, Tokyo 1588501, Japan.
RI Futakuchi, Mitsuru/S-2441-2019
OI Futakuchi, Mitsuru/0000-0001-8647-583X
CR ADAMSON RH, 1990, JPN J CANCER RES, V81, P10, DOI 10.1111/j.1349-7006.1990.tb02500.x
   DEVERDIER MG, 1991, INT J CANCER, V49, P520, DOI 10.1002/ijc.2910490408
   HASEGAWA R, 1995, CARCINOGENESIS, V16, P2243, DOI 10.1093/carcin/16.9.2243
   HAYATSU H, 1985, JPN J CANCER RES, V76, P445
   HIRAMOTO K, 1995, JPN J CANCER RES, V86, P155, DOI 10.1111/j.1349-7006.1995.tb03033.x
   HIRAMOTO K, 1988, CARCINOGENESIS, V9, P2003, DOI 10.1093/carcin/9.11.2003
   Hirose M, 1998, EUR J CANCER PREV, V7, P61
   HIROSE M, 1995, CARCINOGENESIS, V16, P217, DOI 10.1093/carcin/16.2.217
   Hirose M, 1995, CARCINOGENESIS, V16, P3049, DOI 10.1093/carcin/16.12.3049
   Hirose M, 1998, EUR J CANCER PREV, V7, P233, DOI 10.1097/00008469-199806000-00008
   HIROSE M, 1995, CARCINOGENESIS, V16, P2227, DOI 10.1093/carcin/16.9.2227
   HIROSE M, 1997, FOOD FACTORS CANC PR, P82
   KAHL R, 1984, TOXICOLOGY, V33, P185, DOI 10.1016/0300-483X(84)90038-6
   KATO R, 1987, JPN J CANCER RES, V78, P297
   KENET P, 1994, INT J CANCER, V59, P756
   LANG NP, 1994, CANCER EPIDEM BIOMAR, V3, P675
   LIN DX, 1992, CHEM RES TOXICOL, V5, P691, DOI 10.1021/tx00029a016
   LIN JK, 1992, MUTAT RES, V3, P524
   MATSUKAWA Y, 1997, FOOD FACTORS CANC PR, P623
   SAITO K, 1983, CARCINOGENESIS, V4, P1551, DOI 10.1093/carcin/4.12.1551
   SATO K, 1992, JPN J CANCER RES, V83, P1204, DOI 10.1111/j.1349-7006.1992.tb02746.x
   SCHIFFMAN MH, 1990, AM J EPIDEMIOL, V131, P376, DOI 10.1093/oxfordjournals.aje.a115508
   SNYDERWINE EG, 1988, CARCINOGENESIS, V9, P1061, DOI 10.1093/carcin/9.6.1061
   TADA A, 1994, CARCINOGENESIS, V15, P1275, DOI 10.1093/carcin/15.6.1275
   TOTUKA Y, 1996, CARCINOGENESIS, V17, P1029
   TURESKY RJ, 1992, CHEM RES TOXICOL, V5, P479, DOI 10.1021/tx00028a005
   TURESKY RJ, 1990, CHEM RES TOXICOL, V3, P524, DOI 10.1021/tx00018a006
   WAKABAYASHI K, 1993, ENVIRON HEALTH PERSP, V99, P129, DOI 10.2307/3431468
NR 28
TC 48
Z9 49
U1 0
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0278-6915
EI 1873-6351
J9 FOOD CHEM TOXICOL
JI Food Chem. Toxicol.
PD SEP-OCT
PY 1999
VL 37
IS 9-10
BP 985
EP 992
DI 10.1016/S0278-6915(99)00092-7
PG 8
WC Food Science & Technology; Toxicology
SC Food Science & Technology; Toxicology
GA 249PG
UT WOS:000083341000012
PM 10541455
DA 2021-08-04
ER

PT J
AU LeBaron, B
   Arthur, WB
   Palmer, R
AF LeBaron, B
   Arthur, WB
   Palmer, R
TI Time series properties of an artificial stock market
SO JOURNAL OF ECONOMIC DYNAMICS & CONTROL
LA English
DT Article
DE learning; asset pricing; evolution; financial time series
ID FOREIGN-EXCHANGE MARKET; TRADING VOLUME; AGENTS; VOLATILITY; DYNAMICS;
   MODEL; CHAOS
AB This paper presents results from an experimental computer simulated stock market. In this market artificial intelligence algorithms take on the role of traders. They make predictions about the future, and buy and sell stock as indicated by their expectations of future risk and return. Prices are set endogenously to clear the market. Time series from this market are analyzed from the standpoint of well-known empirical features in real markets. The simulated market is able to replicate several of these phenomenon, including fundamental and technical predictability, volatility persistence, and leptokurtosis. Moreover, agent behavior is shown to be consistent with these features, in that they condition on the variables that are found to be significant in the time series tests. Agents are also able to collectively learn a homogeneous rational expectations equilibrium for certain parameters giving both time series and individual forecast values consistent with the equilibrium parameter values. (C) 1999 Elsevier Science B.V. All rights reserved.
C1 Brandeis Univ, Grad Sch Int Econ & Finance, Waltham, MA 02453 USA.
   Santa Fe Inst, Santa Fe, NM 87501 USA.
   Duke Univ, Dept Phys, Durham, NC 27708 USA.
RP LeBaron, B (corresponding author), Brandeis Univ, Grad Sch Int Econ & Finance, 415 South St,Mailstop 021, Waltham, MA 02453 USA.
CR ADMATI AR, 1991, J MONETARY ECON, V28, P347, DOI 10.1016/0304-3932(91)90057-U
   Arthur W. Brian, 1997, EC EVOLVING COMPLEX, VII, P15
   BACK T, 1997, EVOLUTIONARY ALGORIT, V2, P15
   BENINK H, 1996, EXPLORATION NEOAUSTR
   BOLLERSLEV T, 1990, J ECONOMETRICS, V52, P5
   BRAY M, 1982, J ECON THEORY, V26, P318, DOI 10.1016/0022-0531(82)90007-2
   BROCK W, 1992, J FINANC, V47, P1731, DOI 10.2307/2328994
   Brock W.A., 1991, NONLINEAR DYNAMICS C
   Brock WA, 1998, J ECON DYN CONTROL, V22, P1235, DOI 10.1016/S0165-1889(98)00011-6
   Brock WA, 1996, REV ECON STAT, V78, P94, DOI 10.2307/2109850
   Broock W.A., 1996, ECONOMETRIC REV, V15, P197, DOI 10.1080/07474939608800353
   Campbell J. Y., 1996, ECONOMETRICS FINANCI
   Campbell J. Y., 1989, NBER MACROECONOMICS
   Campbell JY, 1988, REV FINANC STUD, V1, P195, DOI 10.1093/rfs/1.3.195
   CAMPBELL JY, 1988, J FINANC, V43, P661, DOI 10.2307/2328190
   Chiarella C., 1992, Annals of Operations Research, V37, P101, DOI 10.1007/BF02071051
   COCHRANE JH, 1989, AM ECON REV, V79, P319
   Conlisk J, 1996, J ECON LIT, V34, P669
   DAY RH, 1990, J ECON BEHAV ORGAN, V14, P299, DOI 10.1016/0167-2681(90)90061-H
   De Grauwe P., 1993, EXCHANGE RATE THEORY
   de la Maza M, 1995, EVOLUTIONARY ALGORIT, P290
   DELONG JB, 1990, J POLIT ECON, V98, P703, DOI 10.1086/261703
   ENGLE RF, 1982, ECONOMETRICA, V50, P987, DOI 10.2307/1912773
   EVANS GW, 1989, J MONETARY ECON, V23, P297, DOI 10.1016/0304-3932(89)90053-6
   FAMA EF, 1991, J FINANC, V46, P1575, DOI 10.2307/2328565
   Fogel DB., 1995, EVOLUTIONARY COMPUTA
   Frankel J. A., 1988, AGR MACROECONOMICS E
   GENNOTTE G, 1990, AM ECON REV, V80, P999
   Goldberg D., 1989, GENETIC ALGORITHMS S
   GROSSMAN SJ, 1989, INFORMATIONAL ROLE P
   Holland J., 1986, INDUCTION
   HOLLAND JH, 1992, ADAPTATION NATURAL A
   KARPOFF JM, 1987, J FINANC QUANT ANAL, V22, P109, DOI 10.2307/2330874
   Kocherlakota NR, 1996, J ECON LIT, V34, P42
   KURZ M, 1995, EQUITY PREMIUM IS NO
   Kurz M., 1994, EC THEORY, V4, P859
   LeBaron B., 1998, ADV TRADING RULES, P5
   LEBARON B, 1999, IN PRESS J EC DYNAMI
   Lettau M, 1997, J ECON DYN CONTROL, V21, P1117, DOI 10.1016/S0165-1889(97)00046-8
   Lettau M, 1999, AM ECON REV, V89, P148, DOI 10.1257/aer.89.1.148
   LEVICH RM, 1993, J INT MONEY FINANC, V12, P451, DOI 10.1016/0261-5606(93)90034-9
   Lux T, 1998, J ECON BEHAV ORGAN, V33, P143, DOI 10.1016/S0167-2681(97)00088-7
   MARENGO L, 1995, WP9517 INT I APPL SY
   Margarita S., 1993, New Trends in Neural Computation. International Workshop on Artificial Neural Networks. IWANN '93 Proceedings, P714
   MARIMOM R, 1990, J ECON DYN CONTROL, V14, P329, DOI 10.1016/0165-1889(90)90025-C
   MITCHELL M, 1996, INTRO GENETIC ALGORI
   Rieck C., 1994, MANY AGENT SIMULATIO
   ROUTLEDGE BR, 1994, ARTIFICIAL SELECTION
   SARGENT T, 1993, BOUNDED RATIOINALITY
   Simon H. A., 1969, SCI ARTIFICIAL
   Steiglitz K., 1996, MARKET BASED CONTROL, P1
   SWEENEY RJ, 1988, J FINANC QUANT ANAL, V23, P285, DOI 10.2307/2331068
   SWEENEY RJ, 1986, J FINANC, V41, P163, DOI 10.2307/2328350
   TAYLOR MP, 1992, J INT MONEY FINANC, V11, P304, DOI 10.1016/0261-5606(92)90048-3
   TAYLOR SJ, 1992, ECON REC, P105, DOI 10.1111/j.1475-4932.1992.tb02298.x
   THALER RH, 1991, QUASI RATIONAL EC
   THALER RH, 1992, WINNERS CURSE PARADO
   WOODFORD M, 1990, ECONOMETRICA, V58, P277, DOI 10.2307/2938205
   Youssefmir M, 1997, J ECON BEHAV ORGAN, V32, P101, DOI 10.1016/S0167-2681(96)00021-2
   Zeeman E.C., 1974, J MATH ECON, V1, P39, DOI [DOI 10.1016/0304-4068(74)90034-2, 10.1016/0304-4068(74)90034-2]
NR 60
TC 352
Z9 369
U1 8
U2 68
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-1889
J9 J ECON DYN CONTROL
JI J. Econ. Dyn. Control
PD SEP
PY 1999
VL 23
IS 9-10
BP 1487
EP 1516
DI 10.1016/S0165-1889(98)00081-5
PG 30
WC Economics
SC Business & Economics
GA 236PZ
UT WOS:000082608900010
OA Green Published
DA 2021-08-04
ER

PT J
AU Basci, E
AF Basci, E
TI Learning by imitation
SO JOURNAL OF ECONOMIC DYNAMICS & CONTROL
LA English
DT Article
DE learning; imitation; dynamic optimization; classifier systems;
   Kiyotaki-Wright model of money
ID EXCHANGE; MONEY
AB This paper introduces a learning algorithm that allows for imitation in recursive dynamic games. The Kiyotaki-Wright model of money is a well-known example of such decision environments. In this context, learning by experience has been studied before. Here, we introduce imitation as an additional channel for learning. In numerical simulations, we observe that the presence of imitation either speeds up social convergence to the theoretical Markov-Nash equilibrium or leads every agent of the same type to the same mode of suboptimal behavior. We observe an increase in the probability of convergence to equilibrium, as the incentives for optimal play become more pronounced. (C) 1999 Elsevier Science B.V. All rights reserved.
C1 Bilkent Univ, Dept Econ, TR-06533 Ankara, Turkey.
RP Basci, E (corresponding author), Bilkent Univ, Dept Econ, TR-06533 Ankara, Turkey.
CR ARTHUR WB, 1997, EC COMPLEX SYSTEMS, pR2
   ARTHUR WB, 1991, AM ECON REV, V81, P352
   BASCI E, 1998, 9818 BILK U
   BASCI E, 1998, UNPUB REINFORCEMENT
   Beltrametti L, 1997, J ECON DYN CONTROL, V21, P1543, DOI 10.1016/S0165-1889(97)00035-3
   BOOKER LB, 1989, ARTIF INTELL, V40, P253
   Brown PM, 1996, J ECON DYN CONTROL, V20, P583, DOI 10.1016/0165-1889(95)00865-9
   DUFFY J, 1996, IN PRESS AM EC REV
   ELLISON G, 1993, J POLIT ECON, V101, P612, DOI 10.1086/261890
   HOLLAND J, 1975, ADAPTATION NATURAL A
   KIYOTAKI N, 1989, J POLIT ECON, V97, P927, DOI 10.1086/261634
   LETTAU M, 1995, IN PRESS AM EC REV
   MARIMOM R, 1990, J ECON DYN CONTROL, V14, P329, DOI 10.1016/0165-1889(90)90025-C
   Offerman T, 1998, J ECON BEHAV ORGAN, V34, P559, DOI 10.1016/S0167-2681(97)00109-1
   Sargent T., 1993, BOUNDED RATIONALITY
   Schlag KH, 1998, J ECON THEORY, V78, P130, DOI 10.1006/jeth.1997.2347
   Selten R., 1975, International Journal of Game Theory, V4, P25, DOI 10.1007/BF01766400
   Vriend NJ, 1996, J ECON BEHAV ORGAN, V29, P263, DOI 10.1016/0167-2681(95)00063-1
NR 18
TC 17
Z9 17
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-1889
J9 J ECON DYN CONTROL
JI J. Econ. Dyn. Control
PD SEP
PY 1999
VL 23
IS 9-10
BP 1569
EP 1585
PG 17
WC Economics
SC Business & Economics
GA 236PZ
UT WOS:000082608900013
OA Green Published
DA 2021-08-04
ER

PT J
AU Park, MS
   Lee, FY
   Suh, GI
   Waniewski, J
   Werynski, A
   Lee, HB
AF Park, MS
   Lee, FY
   Suh, GI
   Waniewski, J
   Werynski, A
   Lee, HB
TI Peritoneal transport of glucose in rat
SO PERITONEAL DIALYSIS INTERNATIONAL
LA English
DT Article
DE glucose transport; high glucose; insulin; diffusive transport;
   nondiffusive transport
ID CONVECTIVE SOLUTE TRANSPORT; DISTRIBUTED MODEL; FLUID TRANSPORT;
   DIALYSIS; COEFFICIENTS; CAPD; SIMULATIONS; EXPRESSION
AB Objective:To evaluate the convective transport characteristics of glucose and the effect of high glucose and insulin during experimental peritoneal dialysis in rat.
   Methods: Male Sprague-Dawley rats weighing 300 - 400 g were used in this study. Mannitol (5%) was used as osmotic agent. Glucose was added to dialysis solution to yield a concentration of 100 mg/dL (group 1) or 300 mg/dL (group 2). Mannitol solution (5%) containing the same concentration of electrolytes and lactate but without glucose was used as control (group 3). In group 2, blood sugar was maintained at approximately 300 mg/dL by continuous intravenous infusion of 25% glucose solution and 0.9% NaCl solution. A 2-hour dwell study was performed with 30 mt of test solutions. Intraperitoneal volume was calculated by volume marker (18.5 kBq of I-131-human radioiodinated serum albumin, RISA) dilution with corrections made for the elimination of RISA from the peritoneal cavity (K-E) and sample volume. The diffusive mass transport coefficient (K-BD) and sieving coefficient (S-BRF) were calculated by using the Babb-Randerson-Farrell model. S was also calculated directly by using isocratic methods (S-I). The peritoneal fluid absorption rate (K-E) was taken into account for the calculation of S-I.
   Results: Intraperitoneal volume was significantly higher in group 2 compared with groups 1 and 3. Peritoneal fluid absorption rate, K-E, was similar in all three groups. S-BRF and S-I for glucose were significantly lower in group 2 compared with groups 1 and 3. S-BRF for glucose in group 2 was below zero and S-I near zero. K-BD for glucose was significantly higher in group 2 than in groups 1 and 3. Plasma and dialysate concentrations of insulin increased during the initial hour and then decreased to the baseline value in groups 1 and 3, while in group 2 it continuously increased.
   Conclusion: Significantly lower sieving coefficients for glucose in the high glucose and high insulin group suggest that transport mechanisms other than simple passive transport are involved in peritoneal glucose transport, and that high glucose per se and/or high insulin may be important factors that determine glucose transport characteristics.
C1 Soon Chun Hyang Univ, Hyonam Kidney Lab, Seoul 140743, South Korea.
   Soon Chun Hyang Univ, Dept Internal Med, Seoul 140743, South Korea.
   Polish Acad Sci, Inst Biocybernet & Biomed Engn, Warsaw, Poland.
RP Lee, HB (corresponding author), Soon Chun Hyang Univ, Hyonam Kidney Lab, 657 Hannam Dong, Seoul 140743, South Korea.
RI Waniewski, Jacek/A-6967-2008
OI Lee, Eun Young/0000-0002-4513-9888
CR FLESSNER MF, 1985, AM J PHYSIOL, V248, pF413
   FLESSNER MF, 1991, J AM SOC NEPHROL, V2, P122
   GOKAL R, 1990, CONTRIB NEPHROL, V85, P126
   HEIMBURGER O, 1992, KIDNEY INT, V41, P1320, DOI 10.1038/ki.1992.196
   KAHN BB, 1990, DIABETES CARE, V13, P548, DOI 10.2337/diacare.13.6.548
   Kruse M, 1996, Perit Dial Int, V16 Suppl 1, pS58
   LEYPOLDT JK, 1994, BLOOD PURIFICAT, V12, P327, DOI 10.1159/000170181
   Lindholm B, 1987, T AM SOC ART INT ORG, V33, P19
   LU CS, 1998, PERITON DIAL INT S2, V18, pS66
   MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x
   PARK MS, 1994, NEPHROL DIAL TRANSPL, V9, P404
   PARK MS, 1995, ARTIF ORGANS, V19, P307, DOI 10.1111/j.1525-1594.1995.tb02333.x
   Park MS, 1995, BLOOD PURIFICAT, V13, P289, DOI 10.1159/000170213
   Popovich R P, 1979, Contrib Nephrol, V17, P59
   Raderson DH, 1980, AM SOC ARTIF INTERNA, V3, P140
   RIPPE B, 1989, KIDNEY INT, V35, P1234, DOI 10.1038/ki.1989.115
   RIPPE B, 1991, KIDNEY INT, V40, P315, DOI 10.1038/ki.1991.216
   Schroppel B, 1998, KIDNEY INT, V53, P1278, DOI 10.1046/j.1523-1755.1998.00899.x
   SEAMES EL, 1990, AM J PHYSIOL, V258, pR958
   SEIFTER S, 1990, DIABETES MELLITUS TH, P1
   STELIN G, 1990, KIDNEY INT, V38, P465, DOI 10.1038/ki.1990.227
   TWARDOWSKI ZJ, 1987, PERITON DIALYSIS INT, V7, P138
   TWARDOWSKI ZJ, 1987, TORONTO PERITONEAL D, V3, P171
   WANIEWSKI J, 1993, BLOOD PURIFICAT, V11, P248, DOI 10.1159/000170121
   WANIEWSKI J, 1991, BLOOD PURIFICAT, V9, P129, DOI 10.1159/000170009
   WANIEWSKI J, 1992, NEPHROL DIAL TRANSPL, V7, P50
   WANIEWSKI J, 1995, ARTIF ORGANS, V19, P295, DOI 10.1111/j.1525-1594.1995.tb02332.x
   Waniewski J, 1992, ASAIO J, V38, P788
NR 28
TC 7
Z9 7
U1 0
U2 2
PU MULTIMED INC
PI TORONTO
PA 66 MARTIN ST, TORONTO, ON L9T 2R2, CANADA
SN 0896-8608
J9 PERITON DIALYSIS INT
JI Perit. Dial. Int.
PD SEP-OCT
PY 1999
VL 19
IS 5
BP 442
EP 450
PG 9
WC Urology & Nephrology
SC Urology & Nephrology
GA 251ZG
UT WOS:000083475800007
PM 11379857
DA 2021-08-04
ER

PT J
AU Johnson, PE
AF Johnson, PE
TI Simulation modeling in political science
SO AMERICAN BEHAVIORAL SCIENTIST
LA English
DT Article
ID REPEATED PRISONERS-DILEMMA; TIT-FOR-TAT; PERCEPTUAL ILLUSIONS; MILITARY
   REALITIES; ARMS-RACE; COOPERATION; STRATEGY; EVOLUTION; PARTIES; GAME
AB Simulation research has made some notable contributions in political science. This article describes a variety of simulation projects and points out the strengths and weaknesses of simulation in contrast with other methods of research. The strength of simulation research is that it is naturally suited to modeling projects that include a large number of autonomous, interacting agents. Statistical and formal methods of analysis have made contributions in these areas, but there is good reason to believe that simulation can go further. This point is explored in several contexts, including social choice theory, individual-level simulation models, international relations the prisoner's dilemma game, and more general agent-based models of multiperson interaction.
C1 Univ Kansas, Lawrence, KS 66045 USA.
RP Johnson, PE (corresponding author), Univ Kansas, Lawrence, KS 66045 USA.
CR AINSWORTH S, 1993, AM J POLIT SCI, V37, P834, DOI 10.2307/2111576
   Albers Wulf, 1994, SOCIAL DILEMMAS COOP
   Arrow K. J., 1951, SOCIAL CHOICE INDIVI
   Arthur W. Brian, 1997, EC EVOLVING COMPLEX, VII, P15
   AUSTENSMITH D, 1992, SOC CHOICE WELFARE, V9, P229
   AUSTENSMITH D, 1993, AM J POLIT SCI, V37, P799, DOI 10.2307/2111575
   AXELROD R, 1981, SCIENCE, V211, P1390, DOI 10.1126/science.7466396
   AXELROD R, 1981, AM POLIT SCI REV, V75, P306, DOI 10.2307/1961366
   Axelrod R., 1997, COMPLEXITY COOPERATI
   Axelrod R., 2006, EVOLUTION COOPERATIO
   Axelrod R., 1987, GENETIC ALGORITHMS S, P32
   BANKES S, 1993, OPER RES, V41, P435, DOI 10.1287/opre.41.3.435
   BARTOS OJ, 1995, ANN AM ACAD POLIT SS, V542, P48, DOI 10.1177/0002716295542001004
   BENDOR J, 1987, AM J POLIT SCI, V31, P531, DOI 10.2307/2111282
   BENSON O, 1961, INT POLITICS FOREIGN, P504
   BINMORE K, 1998, J ARTIFICIAL SOC SOC
   BLACK D, 1951, COMMITTEE DECISIONS
   Black D., 1958, THEORY COMMITTEES EL
   BOYD R, 1987, NATURE, V327, P58, DOI 10.1038/327058a0
   BREMER SA, 1977, PROBLEMS WORLD MODEL, P303
   BREMER SM, 1987, GLOBUS MODEL COMPUTE
   Bueno de Mesquita B., 1981, WAR TRAP
   BUNN G, 1988, ARMS CONTROL, V9, P207
   Burch TK, 1996, SOCIOL QUART, V37, P59, DOI 10.1111/j.1533-8525.1996.tb02331.x
   CALVERT RL, 1985, AM J POLIT SCI, V29, P69, DOI 10.2307/2111212
   Campbell Angus, 1960, AM VOTER
   CEDERMAN L. -E., 1997, EMERGENT ACTORS WORL
   CEDERMAN LE, 1998, COMP POL EC C U MICH
   Cherryholmes C., 1969, REPRESENTATIVES ROLL
   CUSACK TR, 1990, EXPLORING REALPOLITI
   DACEY R, 1989, INT INTERACT, V15, P45
   DEMEYER F, 1970, ECONOMETRICA, V38, P345, DOI 10.2307/1913015
   Downs A., 1957, EC THEORY DEMOCRACY
   DUFFY G, 1992, MATH COMPUT MODEL, V16, P241, DOI 10.1016/0895-7177(92)90099-7
   DUGATKIN LA, 1991, AM NAT, V138, P687, DOI 10.1086/285243
   Epstein J.M., 1996, GROWING ARTIFICIAL S
   Forrester JW., 1971, WORLD DYNAMICS
   GARMAN MB, 1968, BEHAV SCI, V13, P306, DOI 10.1002/bs.3830130405
   GEHRLEIN WV, 1976, J ECON THEORY, V13, P14, DOI 10.1016/0022-0531(76)90063-6
   GRIECO J, 1993, AM POLIT SCI REV, V87, P729, DOI 10.2307/2938747
   GUETZKOW H, 1981, SIMULATED INT PROCES
   Guetzkow H, 1963, SIMULATION INT RELAT
   GUETZKOW H, 1962, SIMULATION SOCIAL SC
   Hanneman R., 1988, COMPUTER ASSISTED TH
   HIRSHLEIFER D, 1989, J ECON BEHAV ORGAN, V12, P87, DOI 10.1016/0167-2681(89)90078-4
   HOLLAND J, 1975, ADAPTATION NATURAL A
   HOLLAND JH, 1991, AM ECON REV, V81, P365
   Johnson PE, 1996, J THEOR POLIT, V8, P299, DOI 10.1177/0951692896008003001
   JOHNSON PE, 1998, ANN M AM POL SCI ASS
   JOHNSON PE, 1998, SOCIAL CHOICE THEORY
   JONES CO, 1995, AM POLIT SCI REV, V89, P1, DOI 10.2307/2083070
   KINGDON JW, 1977, J POLIT, V39, P564
   KLAHR D, 1966, AM POLIT SCI REV, V60, P384, DOI 10.2307/1953365
   Kollman K, 1998, BRIT J POLIT SCI, V28, P139, DOI 10.1017/S0007123498000131
   KOLLMAN K, 1992, AM POLIT SCI REV, V86, P929, DOI 10.2307/1964345
   Kollman K, 1997, AM ECON REV, V87, P977
   Kollman K., 1997, EC EVOLVING COMPLEX, P461
   Lindgren K, 1991, ARTIFICIAL LIFE, Vvol 10, P295
   LINDGREN K, 1995, ARTIFICIAL LIFE OVER, P15
   Lomborg B, 1996, AM SOCIOL REV, V61, P278, DOI 10.2307/2096335
   LOMBORG B, 1997, SIMULATING SOCIAL PH, P335
   MAJESKI S, 1997, SIMULATING SOCIAL PH, P161
   Matthews Donald R., 1975, YEAS NAYS NORMAL DEC
   McPhee W. N., 1962, PUBLIC OPINION C ELE, P123
   MILLER JH, 1996, J ECON BEHAV ORGAN, V29, P8
   Mookherjee D., 1987, AM POLIT SCI REV, V81, P129
   NIEMI RG, 1968, BEHAV SCI, V13, P317, DOI 10.1002/bs.3830130406
   NIOU E, 1989, BALANCE POWER STABIL
   NIOU EMS, 1990, AM POLIT SCI REV, V84, P1208
   NOWAK M, 1993, NATURE, V364, P56, DOI 10.1038/364056a0
   NOWAK MA, 1992, NATURE, V355, P250, DOI 10.1038/355250a0
   Nowak MA, 1993, INT J BIFURCAT CHAOS, V3, P35, DOI 10.1142/S0218127493000040
   NYE JA, 1987, SUPERPOWER ARMS CONT, P165
   Ordeshook P.C., 1986, GAME THEORY POLITICA
   PALMER RG, 1994, PHYSICA D, V75, P264, DOI 10.1016/0167-2789(94)90287-9
   PLOUS S, 1987, J CONFLICT RESOLUT, V31, P5, DOI 10.1177/0022002787031001002
   PLOUS S, 1985, J CONFLICT RESOLUT, V29, P363, DOI 10.1177/0022002785029003001
   POOL ID, 1969, INT POLITICS FOREIGN, P664
   Powell Robert, 1990, NUCL DETERRENCE THEO
   Raiffa, 1957, GAMES DECISIONS INTR
   Raser J. R., 1969, SIMULATION SOC EXPLO
   REYNOLDS CW, 1993, ANIMALS ANIMATS, V2, P384
   Riker W.H., 1982, LIBERALISM POPULISM
   Schelling T. C., 1978, MICROMOTIVES MACROBE
   SCHELLING TC, 1971, J MATH SOCIOL, V1, P143, DOI 10.1080/0022250X.1971.9989794
   SCHRODT PA, 1981, BEHAV SCI, V26, P37, DOI 10.1002/bs.3830260104
   Simon H.A., 1957, MODELS MAN
   Singer J. David, 1972, WAGES WAR 1816 1965
   STONE WJ, 1995, AM J POLIT SCI, V39, P135, DOI 10.2307/2111761
   Taylor M., 1976, ANARCHY COOPERATION
   Taylor M., 1987, POSSIBILITY COOPERAT
   Timpone RJ, 1998, SOC SCI COMPUT REV, V16, P72, DOI 10.1177/089443939801600109
   Van Deemen A, 1999, SOC CHOICE WELFARE, V16, P171, DOI 10.1007/s003550050138
   Van Deemen AMA, 1998, PUBLIC CHOICE, V97, P475, DOI 10.1023/A:1005098111179
   WAGNER RH, 1986, WORLD POLIT, V38, P546, DOI 10.2307/2010166
   Ward M. D., 1985, THEORIES MODELS SIMU
   WEISBERG HF, 1978, AM J POLIT SCI, V22, P554, DOI 10.2307/2110461
   WEISBERG HF, 1971, PROBABILITY MODELS C, P204
NR 98
TC 39
Z9 39
U1 2
U2 33
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0002-7642
J9 AM BEHAV SCI
JI Am. Behav. Sci.
PD AUG
PY 1999
VL 42
IS 10
BP 1509
EP 1530
DI 10.1177/0002764299042010004
PG 22
WC Psychology, Clinical; Social Sciences, Interdisciplinary
SC Psychology; Social Sciences - Other Topics
GA 214WE
UT WOS:000081349900003
DA 2021-08-04
ER

PT J
AU Hassan, Z
   Fadeel, B
   Zhivotovsky, B
   Hellstrom-Lindberg, E
AF Hassan, Z
   Fadeel, B
   Zhivotovsky, B
   Hellstrom-Lindberg, E
TI Two pathways of apoptosis induced with all-trans retinoic acid and
   etoposide in the myeloid cell line P39
SO EXPERIMENTAL HEMATOLOGY
LA English
DT Article
DE P39 cell line; apoptosis; Bcl-2; actin; all-trans retinoic acid;
   etoposide
ID ACUTE PROMYELOCYTIC LEUKEMIA; COLONY-STIMULATING FACTOR; INTERLEUKIN
   1-BETA-CONVERTING ENZYME; DRUG-INDUCED APOPTOSIS; BONE-MARROW CELLS;
   MYELODYSPLASTIC SYNDROMES; MYELOMONOCYTIC LEUKEMIA; EXPRESSION; BCL-2;
   DIFFERENTIATION
AB P3B/Tsugane is a myelomonocytoid cell line derived from a patient with myelodysplastic syndrome (MDS), The cells readily undergo apoptosis in response to various agents, and the cell line has been suggested as a useful model to study apoptosis in MDS, The aims of the present study were to assess differentiation and apoptosis induced with all-trans retinoic acid (ATRA) and etoposide, to characterize the mode of apoptosis in these two model systems, and to assess the influence of granulocyte colony-stimulating factor (G-CSF), which in combination with erythropoietin has been shown to inhibit apoptosis in MDS, ATRA induced differentiation and apoptosis in a concentration- and time-dependent manner. Differentiated cells were partially rescued (by 50%) from apoptosis with G-CSF, Etoposide induced apoptosis in a concentration- and time-dependent manner, but no signs of preceding maturation or G-CSF rescue were detected. ATRA- and etoposide-induced apoptosis were both mediated through the caspase pathway and were partially blocked with the general caspase inhibitor zVAD-fmk, Simultaneous treatment with G-CSP and zVAD-fmk additively blocked ATRA-induced apoptosis, However, the two pathways differed in terms of substrate cleavage during apoptosis, ATRA-induced apoptosis caused actin cleavage, which was not affected by G-CSF, and Bcl-2 downregulation, Etoposide induced a caspase-dependent cleavage of Bcl-2, while actin remained intact. The Fas system did not seem to play a major role in any of these apoptotic pathways, Our results may provide new tools to study the mechanisms of apoptosis in MDS. (C) 1999 International Society for Experimental Hematology. Published by Elsevier Science Inc.
C1 Huddinge Univ Hosp, Dept Hematol, S-14186 Huddinge, Sweden.
   Karolinska Inst, Dept Med, Stockholm, Sweden.
   Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden.
   Karolinska Hosp, Astrid Lindgren Childrens Hosp, Childhood Canc Res Unit, S-10401 Stockholm, Sweden.
RP Hassan, Z (corresponding author), Huddinge Hosp, Novum, KFC, Hematol Lab, S-14186 Huddinge, Sweden.
EM Hassan@kfcmail.hs.sll.se
RI Zhivotovsky, Boris/A-4346-2014
OI Zhivotovsky, Boris/0000-0002-2238-3482
CR ANZAI N, 1994, LEUKEMIA, V8, P446
   BEGLEY CG, 1988, EXP HEMATOL, V16, P71
   BENDALL LJ, 1994, EXP HEMATOL, V22, P1252
   Bouscary D, 1997, LEUKEMIA, V11, P839, DOI 10.1038/sj.leu.2400654
   Calabresse C, 1995, LEUKEMIA, V9, P2049
   CARSON DA, 1993, LANCET, V341, P1251, DOI 10.1016/0140-6736(93)91154-E
   Chen ZH, 1996, CANCER RES, V56, P5224
   CHEN ZX, 1991, BLOOD, V78, P1413
   Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966
   CHOMIENNE C, 1986, LEUKEMIA RES, V10, P631, DOI 10.1016/0145-2126(86)90265-1
   Cock JGRBD, 1998, APOPTOSIS, V3, P17, DOI 10.1023/A:1009603001888
   DELIA D, 1992, BLOOD, V79, P1291, DOI 10.1182/blood.V79.5.1291.bloodjournal7951291
   Dirks W, 1997, BRIT J HAEMATOL, V96, P584, DOI 10.1046/j.1365-2141.1997.d01-2048.x
   Doll DC, 1998, LEUKEMIA RES, V22, P7, DOI 10.1016/S0145-2126(97)00149-5
   Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943
   Freude B, 1998, BASIC RES CARDIOL, V93, P85, DOI 10.1007/s003950050066
   Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574
   Fujita N, 1998, BIOCHEM BIOPH RES CO, V246, P484, DOI 10.1006/bbrc.1998.8587
   Fulda S, 1997, CANCER RES, V57, P3823
   GIANNI M, 1994, BLOOD, V83, P1909
   Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268
   HELLSTROM E, 1989, LEUKEMIA RES, V13, P1113, DOI 10.1016/0145-2126(89)90157-4
   Hellstrom-Lindberg E., 1996, Blood, V88, p96A
   HellstromLindberg E, 1997, LEUKEMIA RES, V21, P415, DOI 10.1016/S0145-2126(96)00110-5
   Hetts SW, 1998, JAMA-J AM MED ASSOC, V279, P300, DOI 10.1001/jama.279.4.300
   HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567
   Kayalar C, 1996, P NATL ACAD SCI USA, V93, P2234, DOI 10.1073/pnas.93.5.2234
   Ketley NJ, 1997, BLOOD, V90, P4578, DOI 10.1182/blood.V90.11.4578.4578_4578_4587
   Kitagawa M, 1998, LEUKEMIA, V12, P486, DOI 10.1038/sj.leu.2400980
   MAJNO G, 1995, AM J PATHOL, V146, P3
   Maravei DV, 1997, CELL DEATH DIFFER, V4, P707, DOI 10.1038/sj.cdd.4400311
   MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448
   Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894
   Mizuno Y, 1998, INTERNAL MED, V37, P192, DOI 10.2169/internalmedicine.37.192
   MOORE MAS, 1990, CANCER, V65, P836, DOI 10.1002/1097-0142(19900201)65:3+<836::AID-CNCR2820651331>3.0.CO;2-X
   NAGAI M, 1984, JPN J CANCER RES, V75, P1100
   Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2
   OHNO R, 1993, BLOOD, V81, P1152
   OYAIZU N, 1993, BLOOD, V82, P3392
   Rajapaksa R, 1996, BLOOD, V88, P4275
   RAZA A, 1995, BLOOD, V86, P268, DOI 10.1182/blood.V86.1.268.bloodjournal861268
   Song QZ, 1997, P NATL ACAD SCI USA, V94, P157, DOI 10.1073/pnas.94.1.157
   Watson RWG, 1997, FEBS LETT, V412, P603, DOI 10.1016/S0014-5793(97)00779-5
   Wattel E, 1996, BLOOD, V88, P2480, DOI 10.1182/blood.V88.7.2480.bloodjournal8872480
NR 44
TC 23
Z9 25
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0301-472X
EI 1873-2399
J9 EXP HEMATOL
JI Exp. Hematol.
PD AUG
PY 1999
VL 27
IS 8
BP 1322
EP 1329
DI 10.1016/S0301-472X(99)00066-1
PG 8
WC Hematology; Medicine, Research & Experimental
SC Hematology; Research & Experimental Medicine
GA 219NX
UT WOS:000081614300011
PM 10428509
DA 2021-08-04
ER

PT J
AU Cronin, KA
   Freedman, LS
   Lieberman, R
   Weiss, HL
   Beenken, SW
   Kelloff, GJ
AF Cronin, KA
   Freedman, LS
   Lieberman, R
   Weiss, HL
   Beenken, SW
   Kelloff, GJ
TI Bayesian monitoring of Phase II trials in cancer chemoprevention
SO JOURNAL OF CLINICAL EPIDEMIOLOGY
LA English
DT Article
DE clinical trial design; sequential analysis; group sequential designs;
   Bayesian inference; cancer chemoprevention; Phase II trials
ID MULTIPLE TESTING PROCEDURE; GROUP SEQUENTIAL-METHODS; CLINICAL-TRIALS;
   DESIGN; GUIDELINES
AB Early randomized Phase II cancer chemoprevention trials which assess short-term biological activity are critical to the decision process to advance to late Phase II/Phase III trials. We have adapted published Bayesian interim analysis methods (Spiegelhalter et al., J. R. Statist. Soc A, 1994; 157: 357-416) which give greater flexibility and simplicity of inference to the monitoring of randomized controlled Phase II trials using intermediate endpoints. The Bayesian stopping rule is designed to stop the trial more quickly when the evidence suggests ineffectiveness rather than when it suggests biological activity, thus allowing resources to be concentrated on those agents that show the most promise in this early stage of testing. We investigate frequentist performance characteristics of the proposed method through simulation of randomized placebo controlled trials with a growth factor intermediate end-point using mean and variance values derived from the literature. Simulation results show expected error rates and trial size similar to other commonly used group sequential methods for this setting. These results suggest that the Bayesian approach to interim analysis is well suited for monitoring small randomized controlled Phase II chemoprevention trials fur early detection of either inactive or promising agents. J CLIN EPIDEMIOL 52;8:705-711, 1999. (C) 1999 Elsevier Science Inc.
C1 NCI, Biometry Branch, Div Canc Prevent, Bethesda, MD 20892 USA.
   NCI, Chemoprevent Branch, Div Canc Prevent, Bethesda, MD 20892 USA.
   Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
RP Cronin, KA (corresponding author), NCI, Biometry Branch, Div Canc Prevent, EPN 313,6130 Execut Blvd, Bethesda, MD 20892 USA.
CR BEENKEN SW, 1994, J CELL BIOCHEM, P270
   Box G., 1992, BAYESIAN INFERENCE S
   FLEMING TR, 1982, BIOMETRICS, V38, P143, DOI 10.2307/2530297
   FREEDMAN LS, 1989, CONTROL CLIN TRIALS, V10, P357, DOI 10.1016/0197-2456(89)90001-9
   FREEDMAN LS, 1994, STAT MED, V13, P1371, DOI 10.1002/sim.4780131312
   GEHAN EA, 1961, J CHRON DIS, V13, P346, DOI 10.1016/0021-9681(61)90060-1
   GROSSMAN J, 1994, STAT MED, V13, P1815, DOI 10.1002/sim.4780131804
   Jennison C., 1990, STAT SCI, V5, P299, DOI DOI 10.1214/SS/1177012099
   Kelloff G J, 1996, Oncology (Williston Park), V10, P1471
   KELLOFF GJ, 1995, CANCER EPIDEM BIOMAR, V4, P1
   KELLOFF GJ, 1994, J CELL BIOCHEM, P1
   KIM K, 1987, BIOMETRIKA, V74, P149, DOI 10.2307/2336029
   LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502
   Mariani L, 1996, INT STAT REV, V64, P61, DOI 10.2307/1403424
   MEHTA CR, 1984, J CLIN ONCOL, V2, P676, DOI 10.1200/JCO.1984.2.6.676
   OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245
   POCOCK SJ, 1977, BIOMETRIKA, V64, P191, DOI 10.1093/biomet/64.2.191
   POCOCK SJ, 1989, CONTROL CLIN TRIALS, V10, pS209
   ROSNER GL, 1988, BIOMETRIKA, V75, P723
   SIMON R, 1989, CONTROL CLIN TRIALS, V10, P1, DOI 10.1016/0197-2456(89)90015-9
   SPIEGELHALTER DJ, 1994, J R STAT SOC A STAT, V157, P357, DOI 10.2307/2983527
   Thall PF, 1996, J CLIN ONCOL, V14, P296, DOI 10.1200/JCO.1996.14.1.296
   THALL PF, 1994, BIOMETRICS, V50, P337, DOI 10.2307/2533377
   THALL PF, 1994, CONTROL CLIN TRIALS, V15, P463, DOI 10.1016/0197-2456(94)90004-3
NR 24
TC 11
Z9 11
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0895-4356
EI 1878-5921
J9 J CLIN EPIDEMIOL
JI J. Clin. Epidemiol.
PD AUG
PY 1999
VL 52
IS 8
BP 705
EP 711
PG 7
WC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA 227DD
UT WOS:000082062300001
PM 10465313
DA 2021-08-04
ER

PT J
AU Kacperski, K
   Holyst, JA
AF Kacperski, K
   Holyst, JA
TI Opinion formation model with strong leader and external impact: a mean
   field approach
SO PHYSICA A
LA English
DT Article
DE social impact model; opinion formation; phase transition; critical
   phenomena; mean field approximation
ID DYNAMIC SOCIAL IMPACT; STATISTICAL-MECHANICS; COLLECTIVE BEHAVIOR;
   COMMUNICATION; SOCIOLOGY
AB We study a model of opinion formation based on the theory of social impact and the concept of cellular automata. The case is considered when two strong agents influence the group: a strong leader and an external social impact acting uniformly on every individual. There are two basic stationary states of the system: cluster of the leader's adherents and unification of opinions. In the deterministic limit the variation of parameters like the leader's strength or external impact can change the size of the cluster or, when they reach some critical values, make the system jump to another phase, For a certain range of parameters multistability and hysteresis phenomena are observed. In the presence of noise (social temperature) the rapid changes can be regarded as the first-order phase transitions. When both agents are in a kind of balance, a second-order transition and critical behaviour can be observed, Another kind of noise-induced transitions are the inverses (flips) of the unified group opinion due to random flips of the leader's opinion. Analytical results obtained within a mean field approximation are well reproduced in computer simulations. (C) 1999 Elsevier Science B.V. All rights reserved.
C1 Max Planck Inst Phys Complex Syst, D-01187 Dresden, Germany.
   Warsaw Univ Technol, Inst Phys, PL-00662 Warsaw, Poland.
   Univ Bialystok, Inst Phys, PL-15424 Bialystok, Poland.
RP Kacperski, K (corresponding author), Max Planck Inst Phys Complex Syst, Nothnitzer Str 38, D-01187 Dresden, Germany.
RI Holyst, Janusz/B-6516-2013
OI Holyst, Janusz/0000-0003-2645-0037; Kacperski,
   Krzysztof/0000-0002-5693-0050
CR Amit D. J., 1989, MODELING BRAIN FUNCT
   Bahr DB, 1998, J MATH SOCIOL, V23, P1
   Bahr DB, 1998, J MATH SOCIOL, V23, P29, DOI 10.1080/0022250X.1998.9990211
   BAK P, 1993, PHYS REV LETT, V71, P4083, DOI 10.1103/PhysRevLett.71.4083
   Browne Antony, 1997, NEURAL NETWORK ANAL
   COWAN GA, 1994, COMPLEXITY METAPHORS
   Domany E, 1995, MODELS NEURAL NETWOR
   Fink EL, 1996, J COMMUN, V46, P4, DOI 10.1111/j.1460-2466.1996.tb01500.x
   Fort J, 1999, PHYS REV LETT, V82, P867, DOI 10.1103/PhysRevLett.82.867
   Galam S, 1997, PHYSICA A, V238, P66, DOI 10.1016/S0378-4371(96)00456-6
   Galam S, 1996, PHYSICA A, V230, P174, DOI 10.1016/0378-4371(96)00034-9
   GUTOWITZ H, 1991, CELLULAR AUTOMATA TH
   HAKEN H, 1983, ADV SYNERGETICS
   Haken H, 1983, SYNERGETICS INTRO
   HELBING D, 1995, PHYSICA A, V219, P375, DOI 10.1016/0378-4371(95)00174-6
   HELBING D, 1995, PHYS REV E, V51, P4282, DOI 10.1103/PhysRevE.51.4282
   HELBING D, 1994, J MATH SOCIOL, V19, P189, DOI 10.1080/0022250X.1994.9990143
   Helbing D, 1997, PHYS REV E, V55, P3735, DOI 10.1103/PhysRevE.55.3735
   HELBING D, 1993, PHYSICA A, V193, P241, DOI 10.1016/0378-4371(93)90028-3
   Helbing D., 1995, QUANTITATIVE SOCIODY
   JOHANSEN A, 1994, PHYSICA D, V78, P186, DOI 10.1016/0167-2789(94)90114-7
   Kacperski K, 1996, J STAT PHYS, V84, P169, DOI 10.1007/BF02179581
   KACPERSKI K, 1997, SELF ORG COMPLEX STR, V2
   Kohring GA, 1996, J PHYS I, V6, P301, DOI 10.1051/jp1:1996150
   LATANE B, 1981, AM PSYCHOL, V36, P343, DOI 10.1037/0003-066X.36.4.343
   Latane B, 1996, J COMMUN, V46, P13, DOI 10.1111/j.1460-2466.1996.tb01501.x
   LEWENSTEIN M, 1992, PHYS REV A, V45, P763, DOI 10.1103/PhysRevA.45.763
   NOWAK A, 1990, PSYCHOL REV, V97, P362, DOI 10.1037/0033-295X.97.3.362
   Pekalski A, 1998, PHYSICA A, V252, P325, DOI 10.1016/S0378-4371(97)00639-0
   Plewczynski D, 1998, PHYSICA A, V261, P608, DOI 10.1016/S0378-4371(98)00349-5
   SORNETTE D, 1997, PHYSICA A, V245, P1
   Tuckwell HC, 1998, PHYS REV E, V57, P2163, DOI 10.1103/PhysRevE.57.2163
   Vallacher R. R., 1994, DYNAMICAL SYSTEMS SO
   Vandewalle N, 1998, EUR PHYS J B, V4, P139, DOI 10.1007/s100510050361
   WEIDLICH W, 1991, PHYS REP, V204, P1, DOI 10.1016/0370-1573(91)90024-G
   WEIDLICH W, 1994, J MATH SOCIOL, V18, P267, DOI 10.1080/0022250X.1994.9990129
   WEIDLICH W, 1983, CONCEPTS MODELS QUAN
   Wolfram S., 1986, THEORY APPL CELLULAR
NR 38
TC 69
Z9 73
U1 0
U2 15
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-4371
J9 PHYSICA A
JI Physica A
PD JUL 15
PY 1999
VL 269
IS 2-4
BP 511
EP 526
DI 10.1016/S0378-4371(99)00174-0
PG 16
WC Physics, Multidisciplinary
SC Physics
GA 225XL
UT WOS:000081991200029
DA 2021-08-04
ER

PT J
AU Maturana, F
   Shen, W
   Norrie, DH
AF Maturana, F
   Shen, W
   Norrie, DH
TI MetaMorph: an adaptive agent-based architecture for intelligent
   manufacturing
SO INTERNATIONAL JOURNAL OF PRODUCTION RESEARCH
LA English
DT Article
AB Global competition and rapidly changing customer requirements are forcing major changes in the production styles and configuration of manufacturing organizations. Traditional centralized manufacturing systems are not able to meet such requirements. This paper proposes an agent-based approach for dynamically creating and managing agent communities in such widely distributed and ever-changing manufacturing environments. After reviewing the research literature, an adaptive multi-agent manufacturing system architecture called MetaMorph is presented and its main features are described. Such architecture facilitates multi-agent coordination by minimizing communication and processing overheads. Adaptation is facilitated through organizational structural change and two learning mechanisms: learning from past experiences and learning future agent interactions by simulating future dynamic, emergent behaviours. The MetaMorph architecture also addresses other specific requirements for next generation manufacturing systems, including scalability, reliability, stability, maintainability, flexibility, real-time planning and scheduling, standardized communication, fault tolerance, and security. The proposed architecture is implemented as a multi-agent virtual manufacturing system, in simulation form, which incorporates heterogeneous manufacturing agents within different agent-based shop floors or factories. The experimental results have shown the potential of the agent-based approach for advanced manufacturing systems.
C1 Univ Calgary, Div Mfg Engn, Calgary, AB T2N 1N4, Canada.
RP Norrie, DH (corresponding author), Rockwell Automat, Cleveland, OH USA.
CR Balasubramanian S, 1996, INT J COOP INF SYST, V5, P153, DOI 10.1142/S0218843096000075
   BARBUCEANU M, 1997, P 1 INT C AUT AG MAR
   BRENNAN RW, 1997, P INT C INT SYST ADV
   BUSSMANN S, 1998, P 1 INT WORKSH INT M, P1
   Christensen J., 1994, P 1 EUR C HOL MAN SY
   Cutkosky MR, 1996, COMMUN ACM, V39, P78, DOI 10.1145/234215.234474
   DECKER KS, 1995, THESIS U MASSACHUSET
   FININ T, 1993, KQML LANGUAGE PROTOC
   FISCHER K, 1994, P 2 INT WORK C COOP, P83
   GAINES BR, 1995, P 1995 IEEE INT C SY, P964
   JENNINGS NR, 1995, P 1 INT C MULT SYST, P423
   MATURANA F, 1997, P INT SYST SEM 97 LE
   MATURANA F, 1997, THESIS U CALGARY
   MATURANA F, 1996, P 3 ISPE INT C CONC, P272
   Maturana FP, 1996, J INTELL MANUF, V7, P257, DOI 10.1007/BF00124828
   PAN JYC, 1991, IEEE T SYST MAN CYB, V21, P1391, DOI 10.1109/21.135684
   PARUNAK HVD, 1997, P 1 INT C AUT AG MAR
   ROBOAM M, 1992, ARTIF INTELL, P401
   SAAD A, 1995, P 1995 INT JOINT C A, P310
   VANLEEUWEN H, 1997, MANUFACTURING ENG, V76, P86
   WIEDERHOLD G, 1992, IEEE COMPUT, V25, P38
   WOOLDRIDGE M, 1995, KNOWL ENG REV, V10, P115, DOI 10.1017/S0269888900008122
NR 22
TC 133
Z9 138
U1 3
U2 38
PU TAYLOR & FRANCIS LTD
PI LONDON
PA ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND
SN 0020-7543
J9 INT J PROD RES
JI Int. J. Prod. Res.
PD JUL 10
PY 1999
VL 37
IS 10
BP 2159
EP 2173
DI 10.1080/002075499190699
PG 15
WC Engineering, Industrial; Engineering, Manufacturing; Operations Research
   & Management Science
SC Engineering; Operations Research & Management Science
GA 200MV
UT WOS:000080544800001
DA 2021-08-04
ER

PT J
AU Perdigao, J
   Van Meerbeek, B
   Lopes, MM
   Ambrose, WW
AF Perdigao, J
   Van Meerbeek, B
   Lopes, MM
   Ambrose, WW
TI The effect of a re-wetting agent on dentin bonding
SO DENTAL MATERIALS
LA English
DT Article
DE dental bonding; dental etching; composite resin; electron microscopy
ID X-RAY-DIFFRACTION; ADHESIVE SYSTEMS; BOVINE DENTIN; COLLAGEN
   INTERACTIONS; WATER-FREE; IN-VITRO; RESIN; HEMA; MATRIX; ACID
AB Objectives: Recently, a new generation of simplified one-bottle dentin bonding systems, sensitive to variations in the degree of substrate moisture, was introduced. This in vitro project compared the dentin bond strengths and interfacial ultra-morphology formed by three one-bottle bonding systems [OptiBond SOLO (ethanol-based), Prime&Bond 2.1 (acetone-based), and Single Bond (ethanol- and water-based)]. The null hypothesis tested was that re-wetting a dried dentin surface with a HEMA aqueous solution would not result in bond strengths, and resin impregnation into demineralized dentin, comparable to those obtained for moist dentin.
   Methods: Dentin specimens were assigned to the following three etched surface conditions: moist dentin-control group; dentin dried for 5 s; and dentin dried for 5 s and re-moistened with a commercial 35% HEMA aqueous solution. Mean shear bond strengths were calculated and analyzed with one- and two-way ANOVA. Dentin discs treated with the same combination of surface condition/adhesive were processed and observed under both transmission and scanning electron microscopes.
   Results: For moist dentin. the morphology of the resin-dentin interfaces showed penetration of the dentin adhesives to the depth of the transition between demineralized and unaffected dentin. Drying dentin for 5 s resulted in a significant decrease in mean bond strengths and an incompletely infiltrated collagen structure with areas of unveiled collagen fibers, regardless of the solvent. Re-wetting dentin with the aqueous HEMA solution re-established the level of bond strengths obtained to moist dentin and resulted in a raise of the fiber network with simultaneous increase in interfibrillar space dimensions.
   Significance: The results suggest that the use of an aqueous HEMA solution might compensate for the dryness induced on dentin surfaces by using air blasts from an air syringe, after rinsing off the etchant. As the behavior of the material that contained water was also affected by surface dryness, the percentage of water included in the composition of current ethanol- and water-based adhesives, such as Single Bond, may not be enough to compensate for the collapse of the collagen filigree upon drying. (C) 1999 Academy of Dental Materials. Published by Elsevier Science Ltd. All rights reserved.
C1 Univ N Carolina, Sch Dent, Dept Operat Dent, Chapel Hill, NC 27599 USA.
   Katholieke Univ Leuven, Dept Operat Dent & Dent Mat, BIOMAT, Louvain, Belgium.
   Univ N Carolina, Dent Res Ctr, Electron Microscopy Lab, Chapel Hill, NC 27599 USA.
RP Perdigao, J (corresponding author), Univ N Carolina, Sch Dent, Dept Operat Dent, CB 7450-302, Chapel Hill, NC 27599 USA.
EM jorge_perdigao@dentistry.unc.edu
RI Perdigao, Jorge/F-5028-2016; Lopes, Maria Manuela/AAO-9815-2020
OI Perdigao, Jorge/0000-0003-1841-6365; Lopes, Maria
   Manuela/0000-0003-1207-3525
CR ALSTER D, 1992, J DENT RES, V71, P1619, DOI 10.1177/00220345920710091401
   Barkmeier W W, 1994, Am J Dent, V7, P239
   Barkmeier WW, 1999, OPER DENT, V24, P51
   Boyde A, 1969, J MICROSC-OXFORD, V90, P221, DOI 10.1111/j.1365-2818.1969.tb00709.x
   Carvalho RM, 1996, ARCH ORAL BIOL, V41, P369, DOI 10.1016/0003-9969(95)00115-8
   CHAPPELL RP, 1994, J PROSTHET DENT, V72, P183, DOI 10.1016/0022-3913(94)90078-7
   CLARKSON BH, 1991, CARIES RES, V25, P166
   CURLEYJOSEPH J, 1979, J DENT RES, V58, P1625, DOI 10.1177/00220345790580061201
   DUNG SZ, 1994, ARCH ORAL BIOL, V39, P901, DOI 10.1016/0003-9969(94)90022-1
   EANES ED, 1970, CALC TISS RES, V6, P239, DOI 10.1007/BF02196204
   Eick JD, 1997, CRIT REV ORAL BIOL M, V8, P306, DOI 10.1177/10454411970080030501
   ELIADES GC, 1993, STATE ART DIRECT POS, P49
   FERRACANE JL, 1995, CRIT REV ORAL BIOL M, V6, P302, DOI 10.1177/10454411950060040301
   Finger WJ, 1996, DENT MATER, V12, P256, DOI 10.1016/S0109-5641(96)80032-7
   Francci C, 1998, J DENT RES, V77, P169
   FUSAYAMA T, 1979, J DENT RES, V58, P1364, DOI 10.1177/00220345790580041101
   Gwinnett A J, 1994, Am J Dent, V7, P144
   Gwinnett AJ, 1996, AM J DENT, V9, P140
   Halvorson R, 1997, J DENT RES, V76, P417
   Harashima I, 1990, Dent Mater J, V9, P36
   INABA D, 1995, CARIES RES, V29, P231, DOI 10.1159/000262074
   Jacobsen T, 1998, AM J DENT, V11, P225
   JACOBSEN T, 1995, DENT MATER, V11, P132, DOI 10.1016/0109-5641(95)80048-4
   JONES IL, 1974, ARCH ORAL BIOL, V19, P371, DOI 10.1016/0003-9969(74)90178-2
   Kanca J, 1996, AM J DENT, V9, P273
   Kanca J 3rd, 1992, Quintessence Int, V23, P39
   Kanca J 3rd, 1992, Am J Dent, V5, P213
   LEES S, 1986, INT J BIOL MACROMOL, V8, P66, DOI 10.1016/0141-8130(86)90001-2
   Maciel KT, 1996, J DENT RES, V75, P1851, DOI 10.1177/00220345960750110601
   MUNKSGAARD EC, 1984, J DENT RES, V63, P1087, DOI 10.1177/00220345840630081701
   NAKABAYASHI N, 1992, DENT MATER, V8, P259, DOI 10.1016/0109-5641(92)90096-U
   NAKABAYASHI N, 1982, J BIOMED MATER RES, V16, P265, DOI 10.1002/jbm.820160307
   NAKABAYASHI N, 1992, DENT MATER, V8, P125, DOI 10.1016/0109-5641(92)90067-M
   PASHLEY DH, 1988, ARCH ORAL BIOL, V33, P265, DOI 10.1016/0003-9969(88)90188-4
   Pashley EL, 1998, DENT MATER, V14, P6, DOI 10.1016/S0109-5641(98)00003-7
   Paul S, 1998, J DENT RES, V77, P914
   Paul S, 1998, J DENT RES, V77, P226
   PERDIGAO J, 1995, J BIOMED MATER RES, V29, P1111, DOI 10.1002/jbm.820290911
   Perdigao J, 1998, AM J DENT, V11, P207
   PERDIGAO J, 1995, THESIS KUL LEUVEN
   PINERI MH, 1978, BIOPOLYMERS, V17, P2799, DOI 10.1002/bip.1978.360171205
   Romney RL, 1997, J DENT RES, V76, P1948
   SANO H, 1994, J DENT RES, V73, P1205, DOI 10.1177/00220345940730061201
   SASAKI N, 1983, BIOPOLYMERS, V22, P2539, DOI 10.1002/bip.360221208
   Sasaki N, 1996, J BIOMECH, V29, P655, DOI 10.1016/0021-9290(95)00110-7
   SCHUMACHER GE, 1992, DENT MATER, V8, P278, DOI 10.1016/0109-5641(92)90100-Q
   SCOTT JE, 1990, J ANAT, V169, P23
   SNOWDEN JM, 1982, BIOCHIM BIOPHYS ACTA, V703, P21, DOI 10.1016/0167-4838(82)90005-X
   Sugizaki J, 1991, JPN J CONSERV DENT, V34, P228
   Swafford JR, 1998, J DENT RES, V77, P224
   Swift EJ, 1997, AM J DENT, V10, P184
   Tay FR, 1997, AM J DENT, V10, P77
   Tay FR, 1996, J DENT RES, V75, P1034, DOI 10.1177/00220345960750040601
   Tay FR, 1996, DENT MATER, V12, P236, DOI 10.1016/S0109-5641(96)80029-7
   Van Meerbeek B, 1998, J DENT, V26, P1, DOI 10.1016/S0300-5712(96)00070-X
   Van Meerbeek B, 1998, J DENT RES, V77, P50, DOI 10.1177/00220345980770010501
   VANDERGRAAF ER, 1993, ARCH ORAL BIOL, V38, P97, DOI 10.1016/0003-9969(93)90162-F
   VANMEERBEEK B, 1993, J DENT RES, V72, P1434, DOI 10.1177/00220345930720101401
   VANMEERBEEK B, 1992, J DENT RES, V71, P1530, DOI 10.1177/00220345920710081301
   VanMeerbeek B, 1996, J DENT RES, V75, P879, DOI 10.1177/00220345960750030401
   VANMEERBEEK B, 1996, FUNDAMENTALS OPERATI, P141
   Xu J, 1997, J DENT RES, V76, P596, DOI 10.1177/00220345970760011101
NR 62
TC 80
Z9 81
U1 1
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0109-5641
EI 1879-0097
J9 DENT MATER
JI Dent. Mater.
PD JUL
PY 1999
VL 15
IS 4
BP 282
EP 295
DI 10.1016/S0109-5641(99)00049-4
PG 14
WC Dentistry, Oral Surgery & Medicine; Materials Science, Biomaterials
SC Dentistry, Oral Surgery & Medicine; Materials Science
GA 228CT
UT WOS:000082119800010
PM 10551097
DA 2021-08-04
ER

PT J
AU Pea, F
   Damiani, D
   Michieli, M
   Ermacora, A
   Baraldo, M
   Russo, D
   Fanin, R
   Baccarani, M
   Furlanut, M
AF Pea, F
   Damiani, D
   Michieli, M
   Ermacora, A
   Baraldo, M
   Russo, D
   Fanin, R
   Baccarani, M
   Furlanut, M
TI Multidrug resistance modulation in vivo: The effect of cyclosporin A
   alone or with dexverapamil on idarubicin pharmacokinetics in acute
   leukemia
SO EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Article
DE acute myelogenous leukemia; idarubicin pharmacokinetics; P-gp modulation
ID ACUTE MYELOGENOUS LEUKEMIA; TRIAL COMPARING IDARUBICIN; ACUTE
   MYELOID-LEUKEMIA; PHASE-I TRIAL; P-GLYCOPROTEIN;
   MYELODYSPLASTIC-SYNDROME; CYTOSINE-ARABINOSIDE; REVERSING AGENTS;
   DRUG-RESISTANCE; ADULT PATIENTS
AB Objective. To determine the effect of the coadministration of the multidrug resistance (MDR) modulators cyclosporin A (CyA) alone or plus dexverapamil (D-Ver) on idarubicin (IDA) pharmacokinetics in patients with acute leukemia.
   Methods: Pharmacokinetic studies were performed in 27 patients with a diagnosis of acute myelogenous leukemia (AML), who were being treated with a combination chemotherapy regimen including idarubicin and cytarabine for the induction of a first remission (n = 14), or of a second remission (n = 7), or for remission consolidation (n = 6). Of these 27 patients, nine were coadministered CyA and seven were coadministered CyA plus D-Ver as MDR modulators. Blood was sampled at appropriate intervals after each of the three IDA daily administrations. IDA and idarubicinol (IDAOL) were assayed by HPLC. Pharmacokinetic evaluations were performed by means of a two-compartment open model with zero-order absorption and first-order elimination using the WinNonlin pharmacokinetic software package.
   Results: CyA markedly increased the area under the concentration time-curve (AUC) of both IDA [558.26 (197.25) mu g.h.l(-1) vs 315.44 (158.28) mu g.h.l(-1); P < 0.01] and IDAOL [2896.60 (736.383) mu g.h.l(-1) vs 1028.49 (603.95) mu g.h.l(-1); P < 0.001] when coadministered as a single modulator, due to a lower total body clearance (CL) [83.51 (52.44) l.h(-1).m(-2) vs 139.65 (69.45) l.h(-1).m(-2); NS]. When patients received two MDR modulators simultaneously (D-Ver plus CyA), IDA exposure was essentially the same as in those of the no inhibitor group [331.29 (95.49) mu g.h.l(-1) vs 315.44 (158.28) mu g.h.l(-1); NS], whereas the IDAOL total body exposure was greater than in the no inhibitor group [2030.32 (401.11) mu g.h.l(-1) vs 1028.49 (603.95) mu g.h.l(-1); P < 0.01], even if less than in patients receiving CyA as a single MDR modulator (IDA + CyA group) [AUC 2030.32 (401.11) mu g.h.l(-1) vs 2896.60 (736.38) mu g.h.l(-1); P < 0.05], suggesting an antagonistic effect against those of CyA on IDA and IDAOL elimination and/or an unpredictable redistribution. The main pharmacokinetic parameters of IDA, such as CL and volume of distribution at steady state (Vd(ss)), were remarkably affected by the coadministration of CyA or CyA plus D-Ver, but no statistically significant difference was noted because of IDA pharmacokinetic interpatient variation.
   Conclusion: The results show that CyA alone at a dose of 10 mg.kg(-1) daily significantly increased systemic body exposure to both IDA and IDAOL in acute leukemia, and suggest that these pharmacokinetic effects were at least partially decreased when D-Ver was coadministered with CyA. Our findings raise important questions concerning the need for a dosage adjustment of IDA when MDR modulators are coadministered.
C1 Univ Udine, Inst Clin Pharmacol & Toxicol, DPMSC, I-33100 Udine, Italy.
   Udine Univ Hosp, Dept Bone Marrow Transplantat, Div Hematol, Udine, Italy.
RP Furlanut, M (corresponding author), Univ Udine, Inst Clin Pharmacol & Toxicol, DPMSC, P SM Misericordia 3, I-33100 Udine, Italy.
EM mario.furlanut@dpmsc.uniud.it
RI Russo, Domenico/C-3947-2011; Pea, Federico/O-3636-2019; Michieli,
   Mariagrazia/AAC-3302-2020
OI Pea, Federico/0000-0002-6966-7167; Michieli,
   Mariagrazia/0000-0001-6302-0488; DAMIANI, Daniela/0000-0002-1663-4468
CR AKAIKE H, 1978, ANN I STAT MATH, V30, P9, DOI 10.1007/BF02480194
   AMES MM, 1992, LEUKEMIA, V6, P70
   Arboix M, 1997, J PHARMACOL EXP THER, V281, P1226
   Ayesh S, 1996, BBA-MOL BASIS DIS, V1316, P8, DOI 10.1016/0925-4439(96)00008-7
   BAGNIS C, 1994, NEPHROL DIAL TRANSPL, V9, P1143, DOI 10.1093/ndt/9.8.1143
   Bellamy WT, 1996, ANNU REV PHARMACOL, V36, P161, DOI 10.1146/annurev.pa.36.040196.001113
   BERMAN E, 1991, BLOOD, V77, P1666
   BERMAN E, 1992, BLOOD, V79, P3267
   CAMAGGI CM, 1992, CANCER CHEMOTH PHARM, V30, P303, DOI 10.1007/BF00686300
   COLOMBO T, 1994, J PHARMACOL EXP THER, V269, P22
   DALTON WS, 1995, CANCER, V75, P815, DOI 10.1002/1097-0142(19950201)75:3<815::AID-CNCR2820750311>3.0.CO;2-R
   DAMIANI D, 1995, LEUKEMIA, V9, P1792
   ESTEY EH, 1993, SEMIN ONCOL, V20, P1
   FAULDS D, 1993, DRUGS, V45, P953, DOI 10.2165/00003495-199345060-00007
   FORD JM, 1990, PHARMACOL REV, V42, P155
   GSUR A, 1993, LEUKEMIA LYMPHOMA, V12, P91, DOI 10.3109/10428199309059575
   HARRIS AL, 1992, ACTA ONCOL, V31, P205, DOI 10.3109/02841869209088904
   HOLLINGSHEAD LM, 1991, DRUGS, V42, P690, DOI 10.2165/00003495-199142040-00010
   HU XF, 1990, CANCER RES, V50, P2953
   ISHIDA Y, 1990, JPN J CANCER RES, V81, P834, DOI 10.1111/j.1349-7006.1990.tb02653.x
   KERR DJ, 1986, CANCER CHEMOTH PHARM, V18, P239
   KUWAZURU Y, 1990, CANCER, V66, P868, DOI 10.1002/1097-0142(19900901)66:5<868::AID-CNCR2820660510>3.0.CO;2-Z
   LAY CS, 1988, HEPATO-GASTROENTEROL, V35, P121
   Lehnert M, 1996, EUR J CANCER, V32A, P862, DOI 10.1016/0959-8049(96)00004-4
   LIST AF, 1993, J CLIN ONCOL, V11, P1652, DOI 10.1200/JCO.1993.11.9.1652
   LUM BL, 1993, CANCER, V72, P3502, DOI 10.1002/1097-0142(19931201)72:11+<3502::AID-CNCR2820721618>3.0.CO;2-N
   LUM BL, 1992, J CLIN ONCOL, V10, P1635, DOI 10.1200/JCO.1992.10.10.1635
   Lyubimov E, 1996, ANTI-CANCER DRUG, V7, P60, DOI 10.1097/00001813-199601000-00007
   MANDELLI F, 1991, EUR J CANCER, V27, P750, DOI 10.1016/0277-5379(91)90181-C
   MERKEL C, 1988, BRIT J CLIN PHARMACO, V26, P273, DOI 10.1111/j.1365-2125.1988.tb05277.x
   MICHIELI M, 1993, LEUKEMIA LYMPHOMA, V9, P255, DOI 10.3109/10428199309147379
   MICHIELI M, 1994, HAEMATOLOGICA, V79, P119
   MICHIELI M, 1994, HAEMATOLOGICA, V79, P500
   MICHIELI M, 1996, LEUKEMIA LYMPHOMA, V18, P179
   NOOTER K, 1994, LEUKEMIA RES, V18, P233, DOI 10.1016/0145-2126(94)90025-6
   NUSSLER V, 1994, ANN HEMATOL, V69, pS25, DOI 10.1007/BF01757351
   OSANN K, 1992, CANCER CHEMOTH PHARM, V30, P152, DOI 10.1007/BF00686409
   ROBERT J, 1994, ANTICANCER RES, V14, P2371
   ROBERT J, 1993, CLIN PHARMACOKINET, V24, P275, DOI 10.2165/00003088-199324040-00002
   ROOTH P, 1988, TRANSPLANTATION, V45, P433, DOI 10.1097/00007890-198802000-00038
   SHAIKH MG, 1993, INT J EXP PATHOL, V74, P389
   SIKIC BI, 1993, J CLIN ONCOL, V11, P1629, DOI 10.1200/JCO.1993.11.9.1629
   TIDEFELT U, 1994, EUR J HAEMATOL, V52, P276
   VOGLER WR, 1989, SEMIN ONCOL, V16, P21
   Weinlander G, 1997, J CANCER RES CLIN, V123, P452, DOI 10.1007/s004320050086
   WIERNIK PH, 1992, BLOOD, V79, P313
   WILSON WH, 1995, J CLIN ONCOL, V13, P1985, DOI 10.1200/JCO.1995.13.8.1985
   YAHANDA AM, 1992, J CLIN ONCOL, V10, P1624, DOI 10.1200/JCO.1992.10.10.1624
   YAMAOKA K, 1978, J PHARMACOKINET BIOP, V6, P165, DOI 10.1007/BF01117450
NR 49
TC 12
Z9 12
U1 0
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0031-6970
EI 1432-1041
J9 EUR J CLIN PHARMACOL
JI Eur. J. Clin. Pharmacol.
PD JUL
PY 1999
VL 55
IS 5
BP 361
EP 368
DI 10.1007/s002280050641
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 219XL
UT WOS:000081633700004
PM 10456485
DA 2021-08-04
ER

PT J
AU Fogel, DB
   Chellapilla, K
   Angeline, PJ
AF Fogel, DB
   Chellapilla, K
   Angeline, PJ
TI Inductive reasoning and bounded rationality reconsidered
SO IEEE TRANSACTIONS ON EVOLUTIONARY COMPUTATION
LA English
DT Article
DE bounded rationality; complex adaptive systems; EI Farol problem;
   inductive reasoning
AB Complex adaptive systems have historically been studied using simplifications that mandate deterministic interactions between agents or instead treat their interactions only with regard to their statistical expectation. This has led to an anticipation, even in the case of agents employing inductive reasoning in light of limited information, that such systems may have equilibria that can be predicted a priori, This hypothesis is tested here using a simulation of a simple market economy in which each agent's behavior is based on the result of an iterative evolutionary process of variation and selection applied to competing internal models of its environment. The results indicate no tendency for convergence to stability or a longterm equilibrium and highlight fundamental differences between deterministic and stochastic models of complex adaptive systems.
C1 Nat Select Inc, La Jolla, CA 92037 USA.
   Univ Calif San Diego, Dept Elect & Comp Engn, La Jolla, CA 92093 USA.
   Nat Select Inc, Vestal, NY 13850 USA.
RP Fogel, DB (corresponding author), Nat Select Inc, La Jolla, CA 92037 USA.
EM dfogel@nathural-selection.com; kchellap@ece.ucsd.edu;
   angeline@natural-selection.com
CR ARTHUR WB, 1994, AM ECON REV, V84, P406
   Carnahan J., 1997, ARTIF LIFE, VV, P387
   Casti, 1997, WOULD BE WORLDS
   Dawkins Richard, 1989, SELFISH GENE, V2nd
   Fogel DB, 1997, BIOSYSTEMS, V44, P135, DOI 10.1016/S0303-2647(97)00050-6
   Fogel L.J., 1966, ARTIFICIAL INTELLIGE
   HOFSTADTER D, 1995, FLUID CONCEPTS CREAT, P115
   NASH JF, 1950, P NATL ACAD SCI USA, V36, P48, DOI 10.1073/pnas.36.1.48
   RUDOLPH G, 1994, IEEE T NEURAL NETWOR, V5, P96, DOI 10.1109/72.265964
   Simon H., 1982, MODELS BOUNDED RATIO
   Smith J.M., 1982, pi
   TAYLOR C, 1995, ARTIFICIAL LIFE OVER, P1
   Tesfatsion L., 1996, Evolutionary Programming V. Proceedings of the Fifth Annual Conference on Evolutionary Programming, P45
   Vriend N. J., 1995, Computational Economics, V8, P205, DOI 10.1007/BF01298460
NR 14
TC 39
Z9 41
U1 0
U2 7
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 1089-778X
EI 1941-0026
J9 IEEE T EVOLUT COMPUT
JI IEEE Trans. Evol. Comput.
PD JUL
PY 1999
VL 3
IS 2
BP 142
EP 146
DI 10.1109/4235.771167
PG 5
WC Computer Science, Artificial Intelligence; Computer Science, Theory &
   Methods
SC Computer Science
GA 238MD
UT WOS:000082713300006
DA 2021-08-04
ER

PT J
AU Deadman, PJ
AF Deadman, PJ
TI Modelling individual behaviour and group performance in an intelligent
   agent-based simulation of the tragedy of the commons
SO JOURNAL OF ENVIRONMENTAL MANAGEMENT
LA English
DT Article
DE intelligent agents; common-pool resources; modelling; simulation;
   resource management; tragedy of the commons
ID NATURAL-RESOURCE MANAGEMENT; SYSTEMS
AB This work introduces and illustrates the potential of intelligent agent-based modelling and simulation as a tool for understanding individual action and group performance in common-pool resource dilemmas. A model was developed, based on previously documented common-pool resource experiments, and simulated using the Swarm multi-agent simulation environment. Agents in these models were designed to represent the actions of the individual appropriators in the experiments and the common-pool resource itself. The intelligent agents developed for these simulations possess adaptive capabilities. They select amongst alternative strategies the one that appears to yield the best performance under current conditions. Simulations of this model rendered observations of some potential relationships between individual action and group performance in common-pool resource experimental situations. In particular adaptive agents generated group level behaviour with similar performance characteristics to groups in actual experiments. Some potential future directions for this research, and possible applications iri natural resources management, are discussed. (C) 1999 Academic Press.
C1 Univ Waterloo, Dept Geog, Waterloo, ON N2L 3G1, Canada.
RP Deadman, PJ (corresponding author), Univ Waterloo, Dept Geog, Waterloo, ON N2L 3G1, Canada.
CR ANDERSON J, 1994, MATH COMPUT MODEL, V20, P109, DOI 10.1016/0895-7177(94)90235-6
   Arthur W. B., 1993, J EVOLUTIONARY EC, V3, P1
   ARTHUR WB, 1994, AM ECON REV, V84, P406
   AXELROD R, 1986, AM POLIT SCI REV, V80, P1095, DOI 10.2307/1960858
   COHEN PR, 1989, AI MAG, V10, P32
   Conte R, 1995, ARTIFICIAL SOCIETIES, P1
   DEADMAN P, 1994, MATH COMPUT MODEL, V20, P121, DOI 10.1016/0895-7177(94)90236-4
   DEANGELIS DL, 1992, INDIVIDUAL BASED MOD
   Drogoul A., 1995, SIMULATING SOC COMPU, P127
   FOLSE LJ, 1989, ECOL MODEL, V46, P57, DOI 10.1016/0304-3800(89)90069-0
   Gimblett H, 1996, COMPLEXITY INT J, V3
   GIMBLETT HR, 1997, MODSIM 97 INT C MOD
   HACKETT S, 1994, J ENVIRON ECON MANAG, V27, P99, DOI 10.1006/jeem.1994.1029
   HARDIN G, 1968, SCIENCE, V162, P1243, DOI 10.1126/science.162.3859.1243
   HIEBELER D, 1994, DECISION SUPPORT 200, V1, P474
   HOFFMAN E, 1986, ARTIF INTELL, P1
   HOLLAND JH, 1991, AM ECON REV, V81, P365
   HOLLAND JH, 1986, INDUCTION PROCESSES
   Kiser Larry L., 1982, STRATEGIES POLITICAL, P179
   KOHLER TA, 1996, 3 INT C INT GIS ENV
   LANSING JS, 1994, ARTIF LIFE, V3, P201
   LANSING JS, 1998, 9801014 SANT FE I
   Lansing JS, 1991, PRIESTS PROGRAMMERS
   Minar N., 1996, SWARM SIMULATION SYS SWARM SIMULATION SYS
   OPENSHAW S, 1995, ENVIRON PLANN A, V27, P159, DOI 10.1068/a270159
   OPENSHAW S, 1994, ENVIRON PLANN A, V26, P499
   Ostrom E., 1990, GOVERNING COMMONS EV, DOI 10.1017/CBO9780511807763
   Ostrom E., 1994, RULES GAMES COMMON P
   SAARENMAA H, 1995, AI APPLICATIONS, V9, P99
   ZEIGLER BP, 1976, THEORY MODELLING SIM
NR 30
TC 58
Z9 59
U1 1
U2 18
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0301-4797
EI 1095-8630
J9 J ENVIRON MANAGE
JI J. Environ. Manage.
PD JUL
PY 1999
VL 56
IS 3
BP 159
EP 172
DI 10.1006/jema.1999.0272
PG 14
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA 216KR
UT WOS:000081441700001
DA 2021-08-04
ER

PT J
AU Martin, A
   Scahill, L
   Klin, A
   Volkmar, FR
AF Martin, A
   Scahill, L
   Klin, A
   Volkmar, FR
TI Higher-functioning pervasive developmental disorders: Rates and patterns
   of psychotropic drug use
SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY
LA English
DT Article
DE Asperger's disorder; autism; pervasive developmental disorders;
   psychotropic drugs; drug patterns
ID AUTISTIC DISORDER; ASPERGER SYNDROME; DOUBLE-BLIND; CLOMIPRAMINE;
   ADULTS; DISABILITIES; FLUVOXAMINE; CHILDREN; PLACEBO
AB Objective: To explore the frequency, characteristics, and associated target symptoms of psychotropic drug use among subjects with higher-functioning pervasive developmental disorders (HFPDDs). Method: A total of 109 children, adolescents, and adults (mean age = 13.9 years, SD = 6.9) consecutively seeking enrollment into the Yale Child Study Center's Project on Social Learning Disabilities were included in the study. Individuals in whom Asperger's disorder, autism, or pervasive developmental disorder-not otherwise specified had been previously diagnosed and who had a documented Full Scale IQ greater than or equal to 70 completed surveys on demographic, clinical, and medication history information. To naturalistically evaluate medication use patterns in this population, each drug class was analyzed with respect to demographic and clinical variables. Results: In all, 55% of subjects were taking psychotropics, with 29.3% taking 2 or more medications simultaneously. Antidepressants were the most commonly used agents (32.1%), followed by stimulants (20.2%) and neuroleptics (16.5%). The clinical presentation of subjects taking psychotropic agents was heterogeneous, and most consistently included anxiety-related target symptoms (in 65% of medicated individuals). Conclusions: Psychotropic medication use appears to be common among subjects with HFPDDs, yet not generally based on the results of empirical research. Clinical heterogeneity among treated subjects suggests that psychiatric comorbidity may be overlooked in this population.
C1 Yale Univ, Ctr Child Study, Sch Med, Dev Disabil Clin, New Haven, CT 06520 USA.
RP Martin, A (corresponding author), Yale Univ, Ctr Child Study, Sch Med, Dev Disabil Clin, 230 S Frontage Rd,POB 207900, New Haven, CT 06520 USA.
EM andres.martin@yale.edu
OI Scahill, Lawrence/0000-0001-5073-1707
FU NCRR NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [M01RR06022] Funding Source: Medline; NIMH NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH) [MH97CR0001, T32MH1912609] Funding Source: Medline; NATIONAL
   CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Research Resources (NCRR) [M01RR006022] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Mental Health (NIMH) [T32MH019126] Funding Source: NIH
   RePORTER
CR AMAN MG, 1995, J AM ACAD CHILD PSY, V34, P1672, DOI 10.1097/00004583-199512000-00018
   American Psychiatric Association, 1994, DIAGN STAT MAN MENT, V4th ed.
   BAILEY A, 1995, PSYCHOL MED, V25, P63, DOI 10.1017/S0033291700028099
   BALTAXE CAM, 1992, HIGH FUNCTIONING IND, P201
   BIRMAHER B, 1988, J AM ACAD CHILD PSY, V27, P248, DOI 10.1097/00004583-198803000-00020
   Cook EH, 1997, MOL PSYCHIATR, V2, P247
   COOK EH, 1992, J AM ACAD CHILD PSY, V31, P739, DOI 10.1097/00004583-199207000-00024
   Eisenmajer R, 1996, J AM ACAD CHILD PSY, V35, P1523, DOI 10.1097/00004583-199611000-00022
   GORDON CT, 1993, ARCH GEN PSYCHIAT, V50, P441
   KLIN A, 1995, J CHILD PSYCHOL PSYC, V36, P1127, DOI 10.1111/j.1469-7610.1995.tb01361.x
   Klin A., 1997, HDB AUTISM PERVASIVE, P94
   KLIN A, 1997, 44 ANN M AM AC CHILD
   KRUG DA, 1980, J CHILD PSYCHOL PSYC, V21, P221, DOI 10.1111/j.1469-7610.1980.tb01797.x
   McDougle CJ, 1998, J CLIN PSYCHOPHARM, V18, P62, DOI 10.1097/00004714-199802000-00010
   MCDOUGLE CJ, 1992, J AM ACAD CHILD PSY, V31, P746, DOI 10.1097/00004583-199207000-00025
   MCDOUGLE CJ, 1995, J CLIN PSYCHIAT, V56, P526
   McDougle CJ, 1996, ARCH GEN PSYCHIAT, V53, P1001
   MCDOUGLE CJ, 1997, HDB AUTISM PERVASIVE, P707
   Nordin V, 1998, J AUTISM DEV DISORD, V28, P69, DOI 10.1023/A:1026067104198
   Olfson M, 1998, ARCH GEN PSYCHIAT, V55, P310, DOI 10.1001/archpsyc.55.4.310
   OZONOFF S, 1991, J CHILD PSYCHOL PSYC, V32, P1107, DOI 10.1111/j.1469-7610.1991.tb00352.x
   Potenza M, 1997, CNS SPECTRUMS, V2, P25
   ROURKE BP, 1989, J LEARN DISABIL-US, V22, P169, DOI 10.1177/002221948902200305
   Sanchez LE, 1996, J AM ACAD CHILD PSY, V35, P537, DOI 10.1097/00004583-199604000-00021
   Schopler E, 1996, J AUTISM DEV DISORD, V26, P109, DOI 10.1007/BF02276238
   Schopler E., 1998, ASPERGER SYNDROME HI, P293
   SCHOPLER E, 1992, HIGH FUNCTIONING IND
   Tanguay PE, 1998, J AM ACAD CHILD PSY, V37, P271, DOI 10.1097/00004583-199803000-00011
   Towbin K.E., 1997, HDB AUTISM PERVASIVE, P123
   Volkmar F. R, 1997, HDB AUTISM PERVASIVE, V2nd, P5
   VOLKMAR FR, 1989, J CHILD PSYCHOL PSYC, V30, P591, DOI 10.1111/j.1469-7610.1989.tb00270.x
   VOLKMAR FR, 1990, J AM ACAD CHILD PSY, V29, P127, DOI 10.1097/00004583-199001000-00020
   VOLKMAR FR, 1998, AUTISM, V2, P45, DOI DOI 10.1177/1362361398021005
   *WHO, 1993, INT CLASS DIS DIAGN
NR 34
TC 80
Z9 81
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0890-8567
EI 1527-5418
J9 J AM ACAD CHILD PSY
JI J. Am. Acad. Child Adolesc. Psychiatr.
PD JUL
PY 1999
VL 38
IS 7
BP 923
EP 931
DI 10.1097/00004583-199907000-00024
PG 9
WC Psychology, Developmental; Pediatrics; Psychiatry
SC Psychology; Pediatrics; Psychiatry
GA 212NQ
UT WOS:000081223400024
PM 10405512
DA 2021-08-04
ER

PT J
AU Tobita, H
   Mima, T
   Okada, A
   Mori, J
   Tanabe, T
AF Tobita, H
   Mima, T
   Okada, A
   Mori, J
   Tanabe, T
TI Molecular weight distribution formed during free-radical polymerization
   in the presence of polyfunctional chain transfer agents
SO JOURNAL OF POLYMER SCIENCE PART B-POLYMER PHYSICS
LA English
DT Article
DE molecular weight distribution; branched polymers; chain transfer; size
   exclusion chromatography; radius of gyration; Monte Carlo method
ID TERMINATION
AB Free-radical polymerization of styrene was carried out in the presence of chain transfer agents (CTAs) with functionality, f = 1-4. The size exclusion chromatography (SEC) with an ultraviolet absorption detector (UV) was used to measure the molecular weight distribution (MWD). A Monte Carlo simulation method proposed earlier was used to investigate the experimental results. In this simulation method, one can observe the structure of each polymer molecule directly, and very detailed information can be obtained in a straightforward manner, including the elution curve of SEC. It was found that up to the functionality f = 3, the equal reactivity model that assumes the reactivity of all functional groups in a CTA is equal agrees reasonably well with the experimental results. However, with f = 4, the reactivity of the fourth functional group seems to decrease and the substitution effects may need to be accounted for to fine control the formed branched structure. (C) 1999 John Wiley & Sons, Inc.
C1 Fukui Univ, Dept Mat Sci & Engn, Fukui 9108507, Japan.
RP Tobita, H (corresponding author), Fukui Univ, Dept Mat Sci & Engn, 3-9-1 Bunkyo, Fukui 9108507, Japan.
CR CLAY PA, 1995, MACROMOLECULES, V28, P552, DOI 10.1021/ma00106a021
   DOUGLAS JF, 1990, MACROMOLECULES, V23, P4168, DOI 10.1021/ma00220a022
   FLORY PJ, 1969, STAT MECH CHAIN MOL, P41
   HAMIELEC AE, 1992, ULLMANNS ENCY IND A, V21, P305
   Immergut, 1989, POLYM HDB
   JACKSON C, 1994, J CHROMATOGR A, V662, P1, DOI 10.1016/0021-9673(94)85290-1
   KURATA M, 1989, POLYM HDB
   MORI S, 1991, SIZE EXCLUSION CHROM
   OHTSU T, 1979, KOBUNSHI GOSEI NO KA
   OSHAUGHNESSY B, 1994, MACROMOLECULES, V27, P5079, DOI 10.1021/ma00096a033
   RUSSELL GT, 1992, MACROMOLECULES, V25, P2459, DOI 10.1021/ma00035a026
   Small P. A., 1975, MACROCONFORMATION PO, P1
   TOBITA H, 1995, MACROMOLECULES, V28, P5119, DOI 10.1021/ma00118a046
   Tobita H, 1996, J POLYM SCI POL PHYS, V34, P671, DOI 10.1002/(SICI)1099-0488(199603)34:4<671::AID-POLB7>3.0.CO;2-T
   Tobita H, 1996, MACROMOLECULES, V29, P693, DOI 10.1021/ma950693h
   ULLISCH B, 1977, MAKROMOL CHEM, V178, P1427
   ULLISCH B, 1977, MAKROMOL CHEM, V178, P1403
   YUAN CM, 1994, MACROMOL THEOR SIMUL, V3, P193, DOI 10.1002/mats.1994.040030116
   YUAN CM, 1994, MACROMOL THEOR SIMUL, V3, P203, DOI 10.1002/mats.1994.040030117
   YUAN CM, 1995, MACROMOL CHEM PHYSIC, V196, P2905, DOI 10.1002/macp.1995.021960915
   ZIMM BH, 1949, J CHEM PHYS, V17, P1301, DOI 10.1063/1.1747157
NR 21
TC 8
Z9 8
U1 1
U2 7
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0887-6266
J9 J POLYM SCI POL PHYS
JI J. Polym. Sci. Pt. B-Polym. Phys.
PD JUN 15
PY 1999
VL 37
IS 12
BP 1267
EP 1275
DI 10.1002/(SICI)1099-0488(19990615)37:12<1267::AID-POLB7>3.3.CO;2-U
PG 9
WC Polymer Science
SC Polymer Science
GA 197BR
UT WOS:000080345200007
DA 2021-08-04
ER

PT J
AU Barone, PMVB
   Dantas, SO
   Galvao, DS
AF Barone, PMVB
   Dantas, SO
   Galvao, DS
TI A semi-empirical study on the electronic structure of ellipticines
SO JOURNAL OF MOLECULAR STRUCTURE-THEOCHEM
LA English
DT Article
DE semi-empirical methods; ellipticines; PM3; ZINDO
ID ANTITUMOR AGENTS; MOLECULES; DNA; OPTIMIZATION; PARAMETERS; BINDING;
   SERIES; STATES; MODEL; BASE
AB Ellipticine and some of its derivatives are organic molecules with intense antitumor activity. In this work we report a semiempirical study on the electronic structure of ellipticine and some derivatives. Geometrical and spectroscopic aspects were investigated through the use of the well-known PM3 (Parametric Method 3) and ZINDO (Zerner's Intermediate Neglect of Differential Overlap) methods. Comparing PM3 and previously reported AM1 (Austin Method One) results, we found out that overall PM3 results are better. The ZINDO simulated absorption spectra compare well to the available experimental data. We have observed a very simple correlation between the dipole moment value (DM) and the antitumor activity. These results suggest a way to improve and design new antitumor ellipticine derivatives, as well as, to select promising molecules from untested groups. (C) 1999 Elsevier Science B.V. All rights reserved.
C1 Univ Estadual Campinas, Inst Fis Gleb Wataghin, BR-13081970 Campinas, SP, Brazil.
   Univ Fed de Juiz de Fora, Inst Ciencias Exatas, Dept Fis, BR-36036330 Juiz De Fora, MG, Brazil.
RP Galvao, DS (corresponding author), Univ Estadual Campinas, Inst Fis Gleb Wataghin, Caixa Postal 6165, BR-13081970 Campinas, SP, Brazil.
EM galvao@ifi.unicamp.br
RI Galvao, Douglas/J-6017-2013
OI Galvao, Douglas/0000-0003-0145-8358
CR ACTON EM, 1994, J MED CHEM, V37, P2185, DOI 10.1021/jm00040a010
   ADENIER A, 1992, J PHYS CHEM-US, V96, P8785, DOI 10.1021/j100201a020
   AGGARWAL A, 1983, ACTA CRYSTALLOGR C, V39, P631, DOI 10.1107/S0108270183005727
   ALLARD B, 1995, J CHEM RES-S, P218
   ANDERSON WK, 1994, J MED CHEM, V37, P1955, DOI 10.1021/jm00039a007
   AUCLAIR C, 1987, ARCH BIOCHEM BIOPHYS, V259, P1, DOI 10.1016/0003-9861(87)90463-2
   BRAGA SF, UNPUB
   COURSEILLE C, 1974, ACTA CRYSTALLOGR B, V30, P2628, DOI 10.1107/S0567740874007692
   DANTAS SO, 1992, J MOL STRUC-THEOCHEM, V257, P437, DOI 10.1016/0166-1280(92)85054-O
   DANTAS SO, 1992, J MOL STRUC-THEOCHEM, V253, P319
   DEWAR MJS, 1977, J AM CHEM SOC, V99, P5231, DOI 10.1021/ja00458a001
   DEWAR MJS, 1985, J AM CHEM SOC, V107, P3902, DOI 10.1021/ja00299a024
   DODIN G, 1988, EUR J BIOCHEM, V176, P371, DOI 10.1111/j.1432-1033.1988.tb14291.x
   DOSSANTOS MC, 1995, P SOC PHOTO-OPT INS, V2528, P135, DOI 10.1117/12.219552
   EDWARDS WD, 1987, THEOR CHIM ACTA, V72, P347, DOI 10.1007/BF01192227
   GALVAO DS, 1993, J CHEM PHYS, V98, P3016, DOI 10.1063/1.464128
   Gribble G.W., 1990, ALKALOIDS CHEM PHARM, P239
   MARINEZBOLIVAR LE, 1996, J PHYS CHEM-US, V106, P11029
   Mathe G, 1996, BIOMED PHARMACOTHER, V50, P510, DOI 10.1016/S0753-3322(97)89284-0
   RIDLEY JE, 1976, THEOR CHIM ACTA, V42, P223, DOI 10.1007/BF00574445
   SCANO P, 1991, J COMPUT CHEM, V12, P172, DOI 10.1002/jcc.540120205
   SIZUM P, 1988, BIOPOLYMERS, V27, P1906
   SOOS ZG, 1994, J PHYS CHEM-US, V98, P1029, DOI 10.1021/j100054a046
   STEWART JJP, 1989, J COMPUT CHEM, V10, P221, DOI 10.1002/jcc.540100209
   STEWART JJP, 1989, J COMPUT CHEM, V10, P209, DOI 10.1002/jcc.540100208
   STEWART JJP, MOPAC PROGRAM VERSIO
   TERCE F, 1982, EUR J BIOCHEM, V125, P203, DOI 10.1111/j.1432-1033.1982.tb06669.x
   *WAV INC, SPARTAN PROGR VERS 4
   ZERNER MC, 1991, REV COMPUTATIONAL CH, V2, P313, DOI DOI 10.1002/9780470125793
NR 29
TC 15
Z9 15
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-1280
J9 J MOL STRUC-THEOCHEM
JI Theochem-J. Mol. Struct.
PD JUN 8
PY 1999
VL 465
IS 2-3
BP 219
EP 229
DI 10.1016/S0166-1280(98)00375-3
PG 11
WC Chemistry, Physical
SC Chemistry
GA 200CR
UT WOS:000080522500012
DA 2021-08-04
ER

PT J
AU Vantesone, DL
   Luna, JD
   Muino, JC
   Juarez, CP
AF Vantesone, DL
   Luna, JD
   Muino, JC
   Juarez, CP
TI Effects of topical diclofenac and prednisolone eyedrops in laser in situ
   keratomileusis patients
SO JOURNAL OF CATARACT AND REFRACTIVE SURGERY
LA English
DT Article
ID PHOTOREFRACTIVE KERATECTOMY; EXCIMER-LASER; ANTIINFLAMMATORY DRUGS;
   RABBITS
AB Purpose: To compare the effects of a topical nonsteroidal anti-inflammatory agent, diclofenac, and prednisolone acetate on wound healing, postoperative inflammation, and other clinical parameters in laser in situ keratomileusis (LASIK) patients.
   Setting: Fundacion VER, Cordoba, Argentina.
   Methods: Laser in situ keratomileusis for myopia was performed simultaneously in both eyes of 16 patients by 1 surgeon. Patients were prospectively randomized to receive diclofenac eyedrops in the right eyes and prednisolone acetate eyedrops in the left, Postoperatively, the drops were administered topically every 2 hours the first day, every 6 hours the first week, every 8 hours the second week, and once a day the fourth week. Preoperatively and at each postoperative visit, evaluation of visual acuity, slitlamp biomicroscopy, corneal topography, and clinical scoring (0-III) of pain and photophobia were done; epithelial interface opacities were objectively evaluated. Follow-up was at 24, 48, and 72 hours, 1, 2, and 3 weeks, and 1, 2, 3, and 6 months. A paired t test was used for statistical analysis.
   Results: Mean age of the 16 patients was 29.4 years +/- 6.5 (SD). Preoperatively, mean spherical equivalent was -5.83 +/- 3.61 diopters (D) in the right eyes and -6.96 +/- 4.66 D in the left eyes. At 6 months postoperatively, it was -1.83 +/- 1.87 D and -1.88 +/- 2.13 D, respectively. In the first 24 hours, there were significant clinical symptoms in the diclofenac group.
   Conclusions: Wound healing was stable, with no regression, in the diclofenac and prednisolone groups. Both anti-inflammatory agents worked well in LASIK patients. J Cataract Refract Surg 1999; 25:836-841 (C) 1999 ASCRS and ESCRS.
C1 Fdn Ver, RA-500 Cordoba, Argentina.
RP Juarez, CP (corresponding author), Fdn Ver, POB 743, RA-500 Cordoba, Argentina.
CR Amm M, 1996, J REFRACT SURG, V12, P758
   ASHTON N, 1951, BRIT J OPHTHALMOL, V35, P708, DOI 10.1136/bjo.35.11.708
   BASU PK, 1981, BRIT J OPHTHALMOL, V65, P694, DOI 10.1136/bjo.65.10.694
   BEAMS R, 1968, AM J OPHTHALMOL, V66, P1131, DOI 10.1016/0002-9394(68)90822-2
   BERGMAN RH, 1994, OPHTHALMIC SURG LAS, V25, P170
   Clark R., 1996, Mezhdunarodnyi Sel'skokhozyaistvennyi Zhurnal, P3
   FERRARI M, 1994, J REFRACT CORNEAL S, V10, pS287
   GASSET AR, 1969, ARCH OPHTHALMOL-CHIC, V81, P589
   HERSH PS, 1990, ARCH OPHTHALMOL-CHIC, V108, P577, DOI 10.1001/archopht.1990.01070060125062
   LEIBOWTIZ H M, 1980, International Ophthalmology Clinics, V20, P117, DOI 10.1097/00004397-198002030-00012
   LEOPOLD IH, 1951, AMA ARCH OPHTHALMOL, V46, P159
   LOYA N, 1994, J REFRACT CORNEAL S, V10, P423
   MALMSTEN CL, 1986, AM J MED, V80, P11, DOI 10.1016/0002-9343(86)90073-2
   MCCAREY BE, 1995, CORNEA, V14, P290, DOI 10.1097/00003226-199505000-00010
   MCDONALD MB, 1993, INVEST OPHTH VIS SCI, V34, P803
   MCDONALD TO, 1970, INVEST OPHTH VISUAL, V9, P703
   MILLER D, 1981, ARCH OPHTHALMOL-CHIC, V99, P681, DOI 10.1001/archopht.1981.03930010681016
   PHILLIPS K, 1983, ARCH OPHTHALMOL-CHIC, V101, P640
   WALKENBACH RJ, 1982, EXP EYE RES, V34, P161, DOI 10.1016/0014-4835(82)90050-1
NR 19
TC 6
Z9 7
U1 0
U2 2
PU AMER SOC CATARACT REFRACTIVE SURGERY
PI FAIRFAX
PA 4000 LEGATO RD, SUITE 850, FAIRFAX, VA 22030 USA
SN 0886-3350
J9 J CATARACT REFR SURG
JI J. Cataract. Refract. Surg.
PD JUN
PY 1999
VL 25
IS 6
BP 836
EP 841
DI 10.1016/S0886-3350(99)00027-9
PG 6
WC Ophthalmology; Surgery
SC Ophthalmology; Surgery
GA 205KX
UT WOS:000080821200024
PM 10374166
DA 2021-08-04
ER

PT J
AU Kozlovsky, Y
   Cohen, I
   Golding, I
   Ben-Jacob, E
AF Kozlovsky, Y
   Cohen, I
   Golding, I
   Ben-Jacob, E
TI Lubricating bacteria model for branching growth of bacterial colonies
SO PHYSICAL REVIEW E
LA English
DT Article
ID ADAPTIVE SELF-ORGANIZATION; LUXR-LUXI FAMILY; BACILLUS-SUBTILIS;
   PATTERN-FORMATION; DICTYOSTELIUM-DISCOIDEUM; TRANSCRIPTIONAL REGULATORS;
   SALMONELLA-TYPHIMURIUM; COOPERATIVE FORMATION; COMPUTER-SIMULATION;
   SNOWFLAKE FORMATION
AB Various bacterial strains (e.g., strains belonging to the genera Bacillus, Paenibacillus, Serratia, and Salmonella) exhibit colonial branching patterns during growth on poor semisolid substrates. These patterns reflect the bacterial cooperative self-organization. A central part of the cooperation is the collective formation of a lubricant on top of the agar which enables the bacteria to swim. Hence it provides the colony means to advance towards the food. One method of modeling the colonial development is via coupled reaction-diffusion equations which describe the time evolution of the bacterial density and the concentrations of the relevant chemical fields. This idea has been pursued by a number of groups. Here we present an additional model which specifically includes an evolution equation for the lubricant excreted by the bacteria. We show that when the diffusion of the fluid is governed by a nonlinear diffusion coefficient, branching patterns evolve. We study the effect of the rates of emission and decomposition of the lubricant fluid on the observed patterns. The results are compared with experimental observations. We also include fields of chemotactic agents and food chemotaxis and conclude that these features are needed in order to explain the observations.
C1 Tel Aviv Univ, Sch Phys & Astron, IL-69978 Tel Aviv, Israel.
   Tel Aviv Univ, Raymond & Beverly Sackler Fac Exact Sci, IL-69978 Tel Aviv, Israel.
RP Kozlovsky, Y (corresponding author), Tel Aviv Univ, Sch Phys & Astron, IL-69978 Tel Aviv, Israel.
CR ADLER J, 1969, SCIENCE, V166, P1588, DOI 10.1126/science.166.3913.1588
   AZBEL MY, 1993, EUROPHYS LETT, V22, P311, DOI 10.1209/0295-5075/22/4/012
   Ben-Jacob E, 1998, ANNU REV MICROBIOL, V52, P779, DOI 10.1146/annurev.micro.52.1.779
   Ben-Jacob E, 1998, SCI AM, V279, P82, DOI 10.1038/scientificamerican1098-82
   Ben-Jacob E, 1994, FRACTALS, V2, P15, DOI 10.1142/S0218348X9400003X
   BenJacob E, 1997, PHYSICA A, V238, P181, DOI 10.1016/S0378-4371(96)00457-8
   BENJACOB E, 1993, CONTEMP PHYS, V34, P247, DOI 10.1080/00107519308222085
   BENJACOB E, 1995, PHYS REV LETT, V75, P2899, DOI 10.1103/PhysRevLett.75.2899
   BENJACOB E, 1995, NATURE, V373, P566, DOI 10.1038/373566a0
   BENJACOB E, 1994, PHYSICA A, V202, P1, DOI 10.1016/0378-4371(94)90165-1
   BENJACOB E, 1992, PHYSICA A, V187, P378, DOI 10.1016/0378-4371(92)90002-8
   BenJacob E, 1997, CONTEMP PHYS, V38, P205, DOI 10.1080/001075197182405
   BENJACOB E, 1990, NATURE, V343, P523, DOI 10.1038/343523a0
   BENJACOB E, 1994, NATURE, V368, P46, DOI 10.1038/368046a0
   BENJACOB E, 1997, BACTERIA MULTICELLUL
   BENJACOB E, 1997, LECT NOTE PHYS, P307
   BENJACOB E, IN PRESS ADV PHYS
   BERG HC, 1977, BIOPHYS J, V20, P193, DOI 10.1016/S0006-3495(77)85544-6
   BERGE HC, 1993, RANDOM WALKS BIOL
   BLAT Y, 1995, J BACTERIOL, V177, P1683, DOI 10.1128/jb.177.7.1683-1691.1995
   BUDRENE EO, 1995, NATURE, V376, P49, DOI 10.1038/376049a0
   BUDRENE EO, 1991, NATURE, V349, P630, DOI 10.1038/349630a0
   Cohen I, 1996, PHYSICA A, V233, P678, DOI 10.1016/S0378-4371(96)00247-6
   COHEN I, 1997, THESIS TEL AVIV U
   Desai JD, 1997, MICROBIOL MOL BIOL R, V61, P47, DOI 10.1128/.61.1.47-64.1997
   DEVREOTES P, 1989, SCIENCE, V245, P1054, DOI 10.1126/science.2672337
   DOUDORFF M, 1957, MICROBIAL WORLD
   Esipov SE, 1998, J MATH BIOL, V36, P249, DOI 10.1007/s002850050100
   FUJIKAWA H, 1989, J PHYS SOC JPN, V58, P3875, DOI 10.1143/JPSJ.58.3875
   Fuqua C, 1996, ANNU REV MICROBIOL, V50, P727, DOI 10.1146/annurev.micro.50.1.727
   FUQUA WC, 1994, J BACTERIOL, V176, P269, DOI 10.1128/JB.176.2.269-275.1994
   GALITSKI T, 1995, SCIENCE, V268, P421, DOI 10.1126/science.7716546
   Golding I, 1998, PHYSICA A, V260, P510, DOI 10.1016/S0378-4371(98)00345-8
   HARSHEY RM, 1994, MOL MICROBIOL, V13, P389, DOI 10.1111/j.1365-2958.1994.tb00433.x
   HENRICI TH, 1948, BIOL BACTERIAL BACIL
   HORGAN J, 1995, SCI AM, V272, P104, DOI 10.1038/scientificamerican0695-104
   Kawasaki K, 1997, J THEOR BIOL, V188, P177, DOI 10.1006/jtbi.1997.0462
   KESSLER DA, 1988, ADV PHYS, V37, P255, DOI 10.1080/00018738800101379
   KESSLER DA, 1993, PHYS REV E, V48, P4801, DOI 10.1103/PhysRevE.48.4801
   Kessler J .O., 1997, BACTERIA MULTICELLUL, P417
   KESSLER JO, 1985, CONTEMP PHYS, V26, P147, DOI 10.1080/00107518508210745
   Kitsunezaki S, 1997, J PHYS SOC JPN, V66, P1544, DOI 10.1143/JPSJ.66.1544
   LACKIIE JM, 1986, BIOL CHEMOTACTIC RES
   LANGER JS, 1989, SCIENCE, V243, P1150, DOI 10.1126/science.243.4895.1150
   LATIFI A, 1995, MOL MICROBIOL, V17, P333, DOI 10.1111/j.1365-2958.1995.mmi_17020333.x
   Levine H, 1997, PHYSICA D, V106, P375, DOI 10.1016/S0167-2789(97)00038-9
   MACKAY SA, 1978, J CELL SCI, V33, P1
   MARAHIEL MA, 1993, MOL MICROBIOL, V7, P631, DOI 10.1111/j.1365-2958.1993.tb01154.x
   Matsushita M, 1998, PHYSICA A, V249, P517, DOI 10.1016/S0378-4371(97)00511-6
   MATSUSHITA M, 1990, PHYSICA A, V168, P498, DOI 10.1016/0378-4371(90)90402-E
   MATSUYAMA T, 1992, J BACTERIOL, V174, P1769, DOI 10.1128/jb.174.6.1769-1776.1992
   MATSUYAMA T, 1993, CRIT REV MICROBIOL, V19, P117, DOI 10.3109/10408419309113526
   Matsuyama T, 1996, COLLOID SURFACE B, V7, P207, DOI 10.1016/0927-7765(96)01300-8
   MATSUYAMA T, 1995, FRACTAL GEOMETRY BIO, P127
   Matsuyama T, 1993, FRACTALS, V1, P302, DOI 10.1142/S0218348X93000320
   Mendelson NH, 1996, J BACTERIOL, V178, P1980, DOI 10.1128/jb.178.7.1980-1989.1996
   MENDELSON NH, 1978, P NATL ACAD SCI USA, V75, P2478, DOI 10.1073/pnas.75.5.2478
   Miller RV, 1998, SCI AM, V278, P66, DOI 10.1038/scientificamerican0198-66
   Murray JD., 1989, MATH BIOL, P109, DOI 10.1007/978-3-662-08539-4_5
   PARNAS H, 1978, J THEOR BIOL, V71, P185, DOI 10.1016/0022-5193(78)90266-7
   PEDLEY TJ, 1992, SCI PROG, V76, P105
   RAFOLS I, 1998, THESIS CHUO U JAPAN
   RASICELLA JP, 1995, SCIENCE, V268, P418
   SALHI B, 1993, J BACTERIOL, V175, P5000, DOI 10.1128/JB.175.16.5000-5008.1993
   Samid-Merzel N, 1998, PHYS REV E, V57, P2906, DOI 10.1103/PhysRevE.57.2906
   SANDER LM, 1986, NATURE, V322, P789, DOI 10.1038/322789a0
   SHAPIRO JA, 1988, SCI AM, V258, P82, DOI 10.1038/scientificamerican0688-82
   SHAPIRO JA, 1991, PHYSICA D, V49, P214, DOI 10.1016/0167-2789(91)90209-R
   SMITH RN, 1938, J BACTERIOL, V35, P59
   STAHL SJ, 1983, J BACTERIOL, V154, P930, DOI 10.1128/JB.154.2.930-937.1983
   Tcherpakov M, 1999, INT J SYST BACTERIOL, V49, P239, DOI 10.1099/00207713-49-1-239
   Vicsek T., 1989, FRACTAL GROWTH PHENO
   WITTEN TA, 1981, PHYS REV LETT, V47, P1400, DOI 10.1103/PhysRevLett.47.1400
   WOODWARD DE, 1995, BIOPHYS J, V68, P2181
NR 74
TC 108
Z9 109
U1 1
U2 22
PU AMER PHYSICAL SOC
PI COLLEGE PK
PA ONE PHYSICS ELLIPSE, COLLEGE PK, MD 20740-3844 USA
SN 1539-3755
EI 1550-2376
J9 PHYS REV E
JI Phys. Rev. E
PD JUN
PY 1999
VL 59
IS 6
BP 7025
EP 7035
DI 10.1103/PhysRevE.59.7025
PG 11
WC Physics, Fluids & Plasmas; Physics, Mathematical
SC Physics
GA 210YY
UT WOS:000081134200094
PM 11969691
OA Green Submitted
DA 2021-08-04
ER

PT J
AU Pillay, V
   Fassihi, R
AF Pillay, V
   Fassihi, R
TI In vitro release modulation from crosslinked pellets for site-specific
   drug delivery to the gastrointestinal tract - I. Comparison of
   pH-responsive drug release and associated kinetics
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE crosslinked pellets; calcium-alginate; calcium-pectinate; site-specific
   delivery; multiple unit dosage form; swelling; erosion; weight change
   dynamics; release modulation; diclofenac sodium
ID CALCIUM ALGINATE MICRODISCS; BINARY POLYMER SYSTEM; MECHANISM; GELATION;
   MATRIX
AB Multiple unit dosage forms for oral delivery of bioactive agents offer many advantages over single unit products (e.g., site-specific delivery, predictable gastrointestinal transit time and less localized adverse effects). In view of such benefits, this paper investigates the crosslinking of sodium alginate, low methoxylated pectin and their novel binary mixture with calcium ions through ionotropic gelation to pelletize the model drug, diclofenac sodium, using "environmentally benign" solvents and processing techniques. Crosslinked pellets of the above polymers in 2% (w/v) aqueous calcium chloride solution were prepared and evaluated for their structural and release behavior. The average size of the different pellets was 1.3 mm and drug entrapment capacity was optimized by reducing the calcium chloride solution pH to 1.6. Three types of pellet formulations were subjected to dissolution studies using the USP 23 Apparatus 2 and 3 over a pH range simulating the human gastrointestinal tract. Negligible drug release occurred in pH 1-4. However, rate of drug release in pH 6.6 ranged from rapid to slow (i.e., 100% drug release in 4 to 10 h, respectively) but always in a controlled manner. Weight change/erosion studies and swelling measurements were used to provide experimental correlation of kinetic model analysis for each of the three pellet systems. From model fitting studies and statistical treatment, the modified Hopfenberg equation {M-t/M-infinity = 1-[1-k(1)(t-t(L,) (min))](n)} best described the release kinetics for calcium-pectinate pellets. The model assumes heterogeneous erosion with kinetic constant k(1) = k(0)/C(0)r(0), in which k(0) is the erosion rate constant, C-0 is the uniform initial concentration of drug in the matrix, r(0) is the initial radius and t(L,) (min) is the lag time. The n values of 1, 2 and 3 apply to a slab, cylinder and sphere, respectively. In addition, the exponential models, namely the Power Law (M-t/M-infinity = k(1)t(n)) and its derivative containing the lag time [M-t/M-infinity = k(1)(t-t(L, min))(n)], employed in the statistical treatment of data provided n values of approximate to 0.8-1 in the case of the calcium-alginate and calcium-alginate-pectinate release kinetics. It is concluded that the proper selection of rate-controlling polymers and their interactive potential for crosslinking is important, and will determine the overall size and shape of pellets, the duration and pattern of dissolution profiles, pH sensitivity, drug loading capacity and mechanism of drug release. (C) 1999 Elsevier Science B.V. All rights reserved.
C1 Temple Univ, Sch Pharm, Dept Pharmaceut Sci, Philadelphia, PA 19140 USA.
RP Fassihi, R (corresponding author), Temple Univ, Sch Pharm, Dept Pharmaceut Sci, 3307 N Broad St, Philadelphia, PA 19140 USA.
RI Pillay, Viness/C-1569-2010
OI Pillay, Viness/0000-0002-8119-3347
CR BODMEIER R, 1989, PHARMACEUT RES, V6, P413, DOI 10.1023/A:1015987516796
   Chen HM, 1997, PHARMACEUT RES, V14, P537, DOI 10.1023/A:1012124205524
   CHOWDARY K P R, 1988, Indian Journal of Pharmaceutical Sciences, V50, P173
   COUPE AJ, 1991, PHARMACEUT RES, V8, P360, DOI 10.1023/A:1015849700421
   Desai MP, 1997, PHARMACEUT RES, V14, P1568, DOI 10.1023/A:1012126301290
   Garcia AM, 1996, J CONTROL RELEASE, V40, P179, DOI 10.1016/0168-3659(95)00179-4
   HAUG A, 1963, ACTA CHEM SCAND, V17, P1466, DOI 10.3891/acta.chem.scand.17-1466
   HEINAMAKI J, 1988, INT J PHARM, V42, P105, DOI 10.1016/0378-5173(88)90166-4
   Katzhendler I, 1997, J PHARM SCI, V86, P110, DOI 10.1021/js9600538
   Kim H, 1997, J PHARM SCI, V86, P323, DOI 10.1021/js960307p
   Kim H, 1997, J PHARM SCI-US, V86, P316, DOI 10.1021/js960302s
   LIN SY, 1993, J MICROENCAPSUL, V10, P319, DOI 10.3109/02652049309031521
   MARTIN A, 1993, PHYSICAL PHARM
   MONSHIPOURI M, 1995, J MICROENCAPSUL, V12, P117, DOI 10.3109/02652049509015282
   MURATA Y, 1993, J CONTROL RELEASE, V23, P21, DOI 10.1016/0168-3659(93)90067-F
   OSTBERG T, 1994, INT J PHARM, V112, P241, DOI 10.1016/0378-5173(94)90360-3
   Paul D. R., 1976, ACS SYM SER, V33, P26
   PEPPAS NA, 1989, INT J PHARM, V57, P169, DOI 10.1016/0378-5173(89)90306-2
   Pillay V, 1998, J MICROENCAPSUL, V15, P215, DOI 10.3109/02652049809006851
   Pillay V, 1998, DRUG DELIV, V5, P25, DOI 10.3109/10717549809052024
   Pillay V, 1998, DRUG DELIV, V5, P35, DOI 10.3109/10717549809052025
   RAJAONARIVONY M, 1993, J PHARM SCI, V82, P912, DOI 10.1002/jps.2600820909
   RITGER P L, 1987, Journal of Controlled Release, V5, P37, DOI 10.1016/0168-3659(87)90035-6
   RITSCHEL WA, 1991, METHOD FIND EXP CLIN, V13, P313
   *SCI SOFTW, 1995, WINN US GUID
   SINGH R, 1993, PHARMAZIE, V48, P728
   YAMAOKA K, 1978, J PHARMACOKINET BIOP, V6, P165, DOI 10.1007/BF01117450
   Yang LB, 1997, J CONTROL RELEASE, V44, P135, DOI 10.1016/S0168-3659(96)01512-X
   YOTSUYANAGI T, 1991, CHEM PHARM BULL, V39, P1072
NR 29
TC 138
Z9 151
U1 0
U2 36
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
J9 J CONTROL RELEASE
JI J. Control. Release
PD MAY 20
PY 1999
VL 59
IS 2
BP 229
EP 242
DI 10.1016/S0168-3659(98)00196-5
PG 14
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 199YU
UT WOS:000080512300010
PM 10332057
DA 2021-08-04
ER

PT J
AU Fontana, M
   Dunipace, AJ
   Stookey, GK
   Gregory, RL
AF Fontana, M
   Dunipace, AJ
   Stookey, GK
   Gregory, RL
TI Intranasal immunization against dental caries with a Streptococcus
   mutans-enriched fimbrial preparation
SO CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY
LA English
DT Article
ID TOXIN-B-SUBUNIT; SYSTEMIC ANTIBODY-RESPONSES; CHOLERA-TOXIN; PROTEIN
   ANTIGEN; IMMUNOGLOBULIN-A; PROTECTIVE IMMUNITY; GNOTOBIOTIC-RATS;
   SALIVARY; I/II; SANGUIS
AB Streptococcus mutans has been identified as the major etiological agent of human dental caries. The first step in the initiation of infection by this pathogenic bacterium is its attachment (i,e., through bacterial surface proteins such as glucosyltransferases, P1, glucan-binding proteins, and fimbriae) to a suitable receptor. It is hypothesized that a mucosal vaccine against a combination of S. mutans surface proteins would protect against dental caries by inducing specific salivary immunoglobulin A (IgA) antibodies which may reduce bacterial pathogenesis and adhesion to the tooth surface by affecting several adhesins simultaneously. Conventional Sprauge-Dawley rats, infected,vith S, mutans at 18 to 20 days of age, were intranasally immunized with a mixture of S, mutans surface proteins, enriched for fimbriae and conjugated with cholera toxin B subunit (CTB) plus free cholera toxin (CT) at 13, 15, 22, 29, and 36 days of age (group A). Control rats were either not immunized (group B) or immunized with adjuvant alone (CTB and CT [group C]), At the termination of the study (when rats were 46 days of age), immunized animals (group A) had significantly (P < 0.05) higher salivary IgA and serum IgG antibody responses to the mixture of surface proteins and to whole bacterial cells than did the other two groups (B and C), No significant differences were found in the average numbers of recovered S, mutans cells among groups. However, statistically fewer smooth-surface enamel lesions (buccal and lingual) were detected in the immunized group than in the two other groups, Therefore, a mixture of S, mutans surface proteins, enriched with fimbria components, appears to be a promising immunogen candidate for a mucosal vaccine against dental caries.
C1 Oral Hlth Res Inst, Indianapolis, IN 46202 USA.
   Indiana Univ, Sch Dent, Dept Oral Biol, Indianapolis, IN 46202 USA.
   Indiana Univ, Sch Dent, Dept Pathol, Indianapolis, IN 46202 USA.
   Indiana Univ, Sch Dent, Dept Lab Med, Indianapolis, IN 46202 USA.
   Indiana Univ, Sch Med, Dept Oral Biol, Indianapolis, IN 46202 USA.
   Indiana Univ, Sch Med, Dept Pathol, Indianapolis, IN 46202 USA.
   Indiana Univ, Sch Med, Dept Lab Med, Indianapolis, IN 46202 USA.
RP Fontana, M (corresponding author), Oral Hlth Res Inst, 415 Lansing St, Indianapolis, IN 46202 USA.
OI Fontana, Margherita/0000-0003-2357-7534
CR BAKALETZ LO, 1988, INFECT IMMUN, V56, P331, DOI 10.1128/IAI.56.2.331-335.1988
   BERGQUIST C, 1995, INFECT IMMUN, V63, P2021, DOI 10.1128/IAI.63.5.2021-2025.1995
   CZERKINSKY C, 1989, INFECT IMMUN, V57, P1072, DOI 10.1128/IAI.57.4.1072-1077.1989
   FACHONKALWEIT S, 1985, INFECT IMMUN, V48, P617, DOI 10.1128/IAI.48.3.617-624.1985
   Fontana M, 1996, CARIES RES, V30, P112, DOI 10.1159/000262146
   FONTANA M, 1995, CLIN DIAGN LAB IMMUN, V2, P719, DOI 10.1128/CDLI.2.6.719-725.1995
   FONTANA M, 1998, UNPUB
   GREGORY RL, 1983, MICROBIOL IMMUNOL, V27, P787, DOI 10.1111/j.1348-0421.1983.tb00644.x
   Hajishengallis G, 1998, INFECT IMMUN, V66, P1740, DOI 10.1128/IAI.66.4.1740-1743.1998
   HAMADA S, 1980, MICROBIOL REV, V44, P331, DOI 10.1128/MMBR.44.2.331-384.1980
   KATZ J, 1993, INFECT IMMUN, V61, P1964, DOI 10.1128/IAI.61.5.1964-1971.1993
   KEYES PAUL H., 1958, JOUR DENTAL RES, V37, P1088, DOI 10.1177/00220345580370060901
   LEE SF, 1989, INFECT IMMUN, V57, P3306, DOI 10.1128/IAI.57.11.3306-3313.1989
   LEHNER T, 1985, INFECT IMMUN, V50, P796, DOI 10.1128/IAI.50.3.796-799.1985
   LEHNER T, 1981, INFECT IMMUN, V34, P407, DOI 10.1128/IAI.34.2.407-415.1981
   LOESCHE WJ, 1979, INFECT IMMUN, V26, P498, DOI 10.1128/IAI.26.2.498-507.1979
   MCGHEE JR, 1983, ANN NY ACAD SCI, V409, P1
   MICHALEK SM, 1975, INFECT IMMUN, V12, P69, DOI 10.1128/IAI.12.1.69-75.1975
   MICHALEK SM, 1976, SCIENCE, V192, P1238, DOI 10.1126/science.1273589
   MICHALEK SM, 1983, INFECT IMMUN, V39, P645, DOI 10.1128/IAI.39.2.645-654.1983
   MORRIS EJ, 1987, J BACTERIOL, V169, P164, DOI 10.1128/jb.169.1.164-171.1987
   Navia J. M., 1977, Animal models in dental research., P257
   Perrone M, 1997, CLIN DIAGN LAB IMMUN, V4, P291, DOI 10.1128/CDLI.4.3.291-296.1997
   Ray CA, 1999, CLIN DIAGN LAB IMMUN, V6, P400, DOI 10.1128/CDLI.6.3.400-404.1999
   RUSSELL MW, 1991, INFECT IMMUN, V59, P4061, DOI 10.1128/IAI.59.11.4061-4070.1991
   Russell MW, 1996, INFECT IMMUN, V64, P1272, DOI 10.1128/IAI.64.4.1272-1283.1996
   Smith DJ, 1996, INFECT IMMUN, V64, P3069, DOI 10.1128/IAI.64.8.3069-3073.1996
   TAKAHASHI I, 1990, ARCH ORAL BIOL, V35, P475, DOI 10.1016/0003-9969(90)90211-R
   TAUBMAN MA, 1977, J IMMUNOL, V118, P710
   WU HY, 1993, INFECT IMMUN, V61, P314, DOI 10.1128/IAI.61.1.314-322.1993
NR 30
TC 15
Z9 15
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 USA
SN 1071-412X
J9 CLIN DIAGN LAB IMMUN
JI Clin. Diagn. Lab. Immunol.
PD MAY
PY 1999
VL 6
IS 3
BP 405
EP 409
DI 10.1128/CDLI.6.3.405-409.1999
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 193GD
UT WOS:000080126800025
PM 10225844
OA Green Published, gold
DA 2021-08-04
ER

PT J
AU Adamo, HL
   Buruiana, R
   Schertzer, L
   Boylan, RJ
AF Adamo, HL
   Buruiana, R
   Schertzer, L
   Boylan, RJ
TI A comparison of MTA, Super-EBA, composite and amalgam as root-end
   filling materials using a bacterial microleakage model
SO INTERNATIONAL ENDODONTIC JOURNAL
LA English
DT Article
DE bacterial microleakage; microleakage; root-end fillings
ID MINERAL TRIOXIDE AGGREGATE; SEALING ABILITY; PENETRATION; LEAKAGE
AB Aim The aim of this study was to compare traditional and newly developed root-end filling materials for resistance to bacterial microleakage.
   Methodology Sixty extracted single-rooted teeth were randomly divided into five groups for root-end filling with mineral trioxide aggregate, Super-EBA, TPH composite resin with ProBond dentine bonding agent, Dispersalloy amalgam with and without ProBond, and positive and negative control groups. Root canals were instrumented using the step-back technique and simulated root-end resections performed. Root-end filling materials were placed in 3 mm ultrasonic retro-preparations, Nail varnish was applied to all external root surfaces to the level of the resected root ends to prevent lateral microleakage. Samples were sterilized in an ethylene oxide sterilizer for 12 h. Using a newly designed model system, the apical 3-4 mm of the roots were immersed in BHI culture medium with phenol red indicator within culture chambers. The coronal access of each specimen was inoculated every 48 h with a suspension of Streptococcus salivarius. Culture media were observed every 24 h for colour change indicating bacterial contamination. Media demonstrating colour change were plated for S, salivarius. Samples were observed for 12 weeks.
   Results At 4 weeks 10 % of specimens from each experimental group had evidence of leakage. At 8 weeks 20 % of specimens filled with amalgam without dentine bonding agent, Super-EBA and MTA had evidence of leakage, At 12 weeks minor differences between materials were noted.
   Conclusions Under the conditions of the study, despite some variations, there were no statistically significant differences in rate of microleakage among the five groups tested at either 4, 8 or 12 weeks.
C1 NYU, Coll Dent, Dept Endodont, New York, NY 10010 USA.
RP Adamo, HL (corresponding author), NYU, Coll Dent, Dept Endodont, 345 E 24th St, New York, NY 10010 USA.
CR AHLBERG KMF, 1995, INT ENDOD J, V28, P30, DOI 10.1111/j.1365-2591.1995.tb00153.x
   ANDREASEN JO, 1989, DANISH DENT J, V93, P195
   Bates CF, 1996, J ENDODONT, V22, P575, DOI 10.1016/S0099-2399(96)80023-9
   DHARANANIDHIKUL A, 1995, J ENDODONT, V21, P225
   GARTNER A H, 1992, Dental Clinics of North America, V36, P357
   GISH SP, 1994, J AM DENT ASSOC, V125, P1369, DOI 10.14219/jada.archive.1994.0189
   LEE SJ, 1993, J ENDODONT, V19, P541, DOI 10.1016/S0099-2399(06)81282-3
   MUNKSGAARD EC, 1985, SCAND J DENT RES, V93, P463
   Oynick J, 1978, J Endod, V4, P203, DOI 10.1016/S0099-2399(78)80183-6
   PERDIGAO J, 1994, J DENT RES, V73, P44, DOI 10.1177/00220345940730010601
   RUD J, 1989, DANISH DENT J, V93, P273
   TORABINEJAD M, 1995, J ENDODONT, V21, P109, DOI 10.1016/S0099-2399(06)80433-4
   TORABINEJAD M, 1994, J ENDODONT, V20, P159, DOI 10.1016/S0099-2399(06)80326-2
   TORABINEJAD M, 1990, J ENDODONT, V16, P566, DOI 10.1016/S0099-2399(07)80198-1
   TORABINEJAD M, 1993, J ENDODONT, V19, P591, DOI 10.1016/S0099-2399(06)80271-2
NR 15
TC 73
Z9 78
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0143-2885
EI 1365-2591
J9 INT ENDOD J
JI Int. Endod. J.
PD MAY
PY 1999
VL 32
IS 3
BP 197
EP 203
DI 10.1046/j.1365-2591.1999.00214.x
PG 7
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 206BV
UT WOS:000080856900006
PM 10530207
DA 2021-08-04
ER

PT J
AU Anglade, F
   Chapouthier, G
   Dodd, RH
   Baudoin, C
AF Anglade, F
   Chapouthier, G
   Dodd, RH
   Baudoin, C
TI Olfactory memory in rats, cholinergic agents and benzodiazepine receptor
   ligands
SO JOURNAL OF PHYSIOLOGY-PARIS
LA English
DT Article
DE learning; olfactory model; conspecific odor; cholinergic agents;
   benzodiazepine ligands
ID MEDIODORSAL THALAMIC NUCLEUS; SOCIAL-INTERACTION TEST; NORWAY RATS; ODOR
   MEMORY; DISCRIMINATION; CONSPECIFICS; RECOGNITION; PREFERENCES;
   PERFORMANCE; MODULATION
AB Drugs and their effects on olfactory learning processes in rats were tested using a modified version of the runway apparatus developed by Ades. Rats were first exposed to a conspecific urine sample and 24 h later were exposed to the same stimulus in the runway. Observations recorded the time spent investigating the urine and the number of sniffs at the site, these being considered to be indices of memory. Diazepam-treated rats (4 or 6 mg/kg) and scopolamine-treated rats (0.5 or 1 mg/kg) showed increases for both parameters. When both drugs were administered simultaneously, the impairing effect was potentiated. However, no changes in learning responses were observed in rats treated with physostigmine (0.125, 0.25, 0.5 mg/kg) or methyl beta-carboline-3-carboxylate (0.3, 0.5, 1 mg/kg), although the administration of physostigmine or methyl beta-carboline-3-carboxylate was shown to antagonize the impairing effect of diazepam or scopolamine respectively. These observations support the hypothesis of interactions existing between cholinergic agents and benzodiazepine receptor ligands and of such interactions affecting olfactory acquisition processes. The runway apparatus appears to be a valid candidate model to be used for the assessment of pharmacological influences on olfactory learning in rats. (C) Elsevier, Paris.
C1 Grp Hosp Pitie Salpetriere, UMR CNRS 7593, F-75634 Paris 13, France.
   Ctr Etud Bouchet, Lab Pharmacol Comportement, F-91710 Vert Le Petit, France.
   CNRS, Inst Chim Subst Nat, F-91198 Gif Sur Yvette, France.
   Univ Paris 13, URA 667 CNRS, Lab Ethol Expt & Comparee, F-93430 Villetaneuse, France.
RP Chapouthier, G (corresponding author), Grp Hosp Pitie Salpetriere, UMR CNRS 7593, 91 Blvd Hop, F-75634 Paris 13, France.
CR ADES C, 1975, PSYCHOL REP, V37, P271, DOI 10.2466/pr0.1975.37.1.271
   ANGLADE F, 1994, NEUROSCI LETT, V182, P247, DOI 10.1016/0304-3940(94)90808-7
   ANGLADE F, 1993, CR ACAD SCI III-VIE, V316, P603
   BUSCHSBAUM MS, 1991, ARCH GEN PSYCHIAT, V48, P840
   CARR WJ, 1976, J COMP PHYSIOL PSYCH, V90, P821, DOI 10.1037/h0077266
   DANTZER R, 1987, PSYCHOPHARMACOLOGY, V91, P363, DOI 10.1007/BF00518192
   ELROD K, 1988, PHARMACOL BIOCHEM BE, V29, P15, DOI 10.1016/0091-3057(88)90267-5
   FILE SE, 1980, J NEUROSCI METH, V2, P219, DOI 10.1016/0165-0270(80)90012-6
   FILE SE, 1985, PHARMACOL BIOCHEM BE, V23, P33, DOI 10.1016/0091-3057(85)90126-1
   FILE SE, 1991, PSYCHOPHARMACOLOGY, V104, P62, DOI 10.1007/BF02244555
   Galef B.G. Jr, 1988, P3
   GALEF BG, 1985, BEHAV NEURAL BIOL, V43, P298, DOI 10.1016/S0163-1047(85)91645-0
   GAO YA, 1991, ANIM BEHAV, V42, P506, DOI 10.1016/S0003-3472(05)80054-5
   HUGHES RN, 1991, PSYCHOBIOLOGY, V19, P168
   KESSLAK JP, 1988, NEUROBIOL AGING, V9, P399, DOI 10.1016/S0197-4580(88)80087-3
   KOMISKEY HL, 1981, PSYCHOPHARMACOLOGY, V73, P304, DOI 10.1007/BF00422422
   KUFER AM, 1989, P ABSTR E PSYCH ASS
   LALAND KN, 1991, ANIM BEHAV, V41, P997, DOI 10.1016/S0003-3472(05)80638-4
   LATANE B, 1972, NEW HORIZONS PSYCHOL, V2
   LU XC, 1988, CHEM SENSES, V13, P749
   MICZEK KA, 1979, ADV BEHAV PHARMACOL, P88
   OSTREM JL, 1992, PHARMACOL BIOCHEM BE, V41, P581, DOI 10.1016/0091-3057(92)90376-Q
   PAZOS A J, 1989, Chemical Senses, V14, P737
   PEARSON RCA, 1985, P NATL ACAD SCI USA, V82, P4531, DOI 10.1073/pnas.82.13.4531
   PERIO A, 1989, PSYCHOPHARMACOLOGY, V97, P262, DOI 10.1007/BF00442261
   POPIK P, 1991, PHYSIOL BEHAV, V49, P1031, DOI 10.1016/0031-9384(91)90327-K
   RAVEL N, 1992, PSYCHOPHARMACOLOGY, V109, P439, DOI 10.1007/BF02247720
   RENNER MJ, 1990, PSYCHOBIOLOGY, V18, P16
   REZEK DL, 1987, ARCH NEUROL-CHICAGO, V44, P1030, DOI 10.1001/archneur.1987.00520220036012
   Rozin P., 1972, BIOL BOUNDARIES LEAR, P66
   SLOTNICK BM, 1991, PHYSIOL BEHAV, V50, P555, DOI 10.1016/0031-9384(91)90545-Y
   SLOTNICK BM, 1990, BRAIN RES, V529, P23, DOI 10.1016/0006-8993(90)90807-N
   SLOTNICK BM, 1981, SCIENCE, V214, P91, DOI 10.1126/science.7280684
   SLOTNICK BM, 1985, BEHAV NEUROSCI, V99, P956, DOI 10.1037/0735-7044.99.5.956
   SOFFIE M, 1988, BEHAV PROCESS, V17, P181, DOI 10.1016/0376-6357(88)90001-0
   SPRANGER EL, 1988, PHARM BIOCH BEHAV, V30, P949
   STAUBLI U, 1986, BEHAV NEURAL BIOL, V46, P432, DOI 10.1016/S0163-1047(86)90464-4
   STEVENS R, 1981, PHYSIOL BEHAV, V27, P385, DOI 10.1016/0031-9384(81)90285-7
   THIEBOT MH, 1985, NEUROSCI BIOBEHAV R, V9, P95, DOI 10.1016/0149-7634(85)90035-1
   THOR DH, 1982, J COMP PHYSIOL PSYCH, V96, P1000, DOI 10.1037/0735-7036.96.6.1000
   THOR DH, 1981, ANIM LEARN BEHAV, V9, P363, DOI 10.3758/BF03197844
   VENAULT P, 1986, NATURE, V321, P864, DOI 10.1038/321864a0
   VENAULT P, 1987, BRAIN RES BULL, V19, P365, DOI 10.1016/0361-9230(87)90105-5
NR 43
TC 12
Z9 13
U1 0
U2 2
PU EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS CEDEX 15
PA 23 RUE LINOIS, 75724 PARIS CEDEX 15, FRANCE
SN 0928-4257
J9 J PHYSIOLOGY-PARIS
JI J. Physiol.-Paris
PD MAY-JUN
PY 1999
VL 93
IS 3
BP 225
EP 232
DI 10.1016/S0928-4257(99)80155-7
PG 8
WC Neurosciences; Physiology
SC Neurosciences & Neurology; Physiology
GA 206XZ
UT WOS:000080907000005
PM 10399678
DA 2021-08-04
ER

PT J
AU Puri, UC
   Uomoto, T
AF Puri, UC
   Uomoto, T
TI Numerical modeling - A new tool for understanding shotcrete
SO MATERIALS AND STRUCTURES
LA English
DT Article
AB The analytical flow simulation of fresh concrete is a recent challenge to researchers. Due to its heterogeneity, the concrete mix shows neither a perfectly viscous nor perfectly particulate behavior. However, the particulate behavior of fresh concrete flow like arching and blocking in pipes and in complex boundary conditions, is very common. This is further magnified due to high pressure in the case of shotcreting. For the first time in shotcrete research, authors propose the application of the Distinct Element Method [1] (DEM) to predict particle behavior and amount of rebound loss, and to assess the quality of the shotcrete analytically. Also, the effect of an accelerating agent, the way its effect is modeled, effects of gradual change in shooting pressure, the resulting rebound is shown. The void of the attached concrete is also compared with that of normal cast concrete in an analytical way.
C1 Univ Tokyo, Dept Civil Engn, Tokyo, Japan.
   Univ Tokyo, Inst Ind Sci, Tokyo, Japan.
RP Puri, UC (corresponding author), Univ Tokyo, Dept Civil Engn, Tokyo, Japan.
CR Beaupre D., 1994, THESIS U BRIT COLUMB
   CUNDALL PA, 1979, GEOTECHNIQUE, V29, P47, DOI 10.1680/geot.1979.29.1.47
   de Larrard F, 1997, ACI MATER J, V94, P234
   GHIO V, 1993, THESIS U CALIFORNIA
   GJORV OE, 1992, ADVANCES IN CONCRETE TECHNOLOGY, P21
   JIRO M, 1992, ACI MATER J, V89, P230
   MEGURO K, 1991, THESIS U TOKYO
   PHILIP TS, 1976, SHOTCRETE GROUND SUP, P29
   PURI UC, 1998, P 6 E AS PAC C STRUC, P1911
   Tattersall GH, 1983, RHEOLOGY FRESH CONCR
   WARD WH, 1976, SHOTCRETE GROUND SUP, P475
NR 11
TC 6
Z9 7
U1 1
U2 4
PU R I L E M Publications
PI cachan cedex
PA 61 ave president wilson, 94235 cachan cedex, FRANCE
SN 0025-5432
J9 MATER STRUCT
JI Mater. Struct.
PD MAY
PY 1999
VL 32
IS 218
BP 266
EP 272
DI 10.1007/BF02479596
PG 7
WC Construction & Building Technology; Engineering, Civil; Materials
   Science, Multidisciplinary
SC Construction & Building Technology; Engineering; Materials Science
GA 215VR
UT WOS:000081404600005
DA 2021-08-04
ER

PT J
AU Anderson, P
AF Anderson, P
TI Complexity theory and organization science
SO ORGANIZATION SCIENCE
LA English
DT Review
DE complexity theory; organizational evolution; strategic management
ID PUNCTUATED EQUILIBRIUM; NOISE COLOR; EXTINCTIONS; EVOLUTION; MODEL; FIRM
AB Complex organizations exhibit surprising, nonlinear behavior. Although organization scientists have studied complex organizations for many years, a developing set of conceptual and computational tools makes possible new approaches to modeling nonlinear interactions within and between organizations. Complex adaptive system models represent a genuinely new way of simplifying the complex. They are characterized by four key elements: agents with schemata, self-organizing networks sustained by importing energy, coevolution to the edge of chaos, and system evolution based on recombination. New types of models that incorporate these elements will push organization science forward by merging empirical observation with computational agent-based simulation. Applying complex adaptive systems models to strategic management leads to an emphasis on building systems that can rapidly evolve effective adaptive solutions. Strategic direction of complex organizations consists of establishing and modifying environments within which effective, improvised, self-organized solutions can evolve. Managers influence strategic behavior by altering the fitness landscape for local agents and reconfiguring the organizational architecture within which agents adapt.
C1 Dartmouth Coll, Amos Tuck Sch, Hanover, NH 03755 USA.
RP Anderson, P (corresponding author), Dartmouth Coll, Amos Tuck Sch, Hanover, NH 03755 USA.
EM Philip.C.Anderson@Dartmouth.EDU
RI Holman, B.J./E-8868-2010; Anderson, Philip/B-4364-2010
CR Allison M. A, 1999, COMPLEXITY ADVANTAGE
   Anderson J.A., 1995, INTRO NEURAL NETWORK
   ANDERSON P, 1999, IN PRSS BIOL BUSINES
   ARTHUR WB, 1990, SCI AM, V262, P92, DOI 10.1038/scientificamerican0290-92
   ASHBY R, 1981, MECH INTELLIGENCE AS
   Ashby R.W, 1956, INTRO CYBERNETICS
   Bak P., 1996, NATURE WORKS SCI SEL
   Bar-Yam Y., 1997, DYNAMICS COMPLEX SYS
   Barnard Chester I., 1938, FUNCTIONS EXECUTIVE
   Beniger JamesR., 1986, CONTROL REVOLUTION T
   BOULDING KE, 1956, MANAGE SCI, V2, P197, DOI 10.1287/mnsc.2.3.197
   Brown S.L., 1998, COMPETING EDGE STRAT
   BROWNING LD, 1995, ACAD MANAGE J, V38, P113, DOI 10.2307/256730
   Bruderer E, 1996, ACAD MANAGE J, V39, P1322, DOI 10.2307/257001
   BURGELMAN RA, 1994, ADMIN SCI QUART, V39, P24, DOI 10.2307/2393493
   Burgelman RA, 1991, ORGAN SCI, V2, P239, DOI 10.1287/orsc.2.3.239
   Burkhart R., 1996, EMBRACING COMPLEXITY
   BURT RS, 1980, AM J SOCIOL, V85, P892, DOI 10.1086/227093
   Burton R.M., 1998, STRATEGIC ORG DIAGNO
   CAPRA F, 1996, WEB LIFE NEW SCI UND
   Carley K.M., 1995, COMPUTATIONAL MATH O, V1, P39
   Casti J.L., 1994, COMPLEXIFICATION EXP
   Cohen J., 1994, COLLAPSE CHAOS DISCO
   Coveney P., 1995, FRONTIERS COMPLEXITY
   COWAN GA, 1994, COMPLEXITY METAPHORS, P17
   Cyert R.M., 1963, BEHAV THEORY FIRM
   Daft R.L., 1992, ORG THEORY DESIGN
   DAFT RL, 1990, ORG SCI, V1
   DAveni R. A., 1994, HYPERCOMPETITION MAN
   Dobzhansky, 1974, STUDIES PHILOS BIOL, P179, DOI DOI 10.1007/978-1-349-01892-5_11
   DRAZIN R, 1992, ORGAN SCI, V3, P230, DOI 10.1287/orsc.3.2.230
   Epstein J. M., 1997, NONLINEAR DYNAMICS M
   FLEMING L, 1998, THESIS STANFORD U
   Fontana W., 1999, COMPLEXITY, V4, P14, DOI DOI 10.1002/(SICI)1099-0526(199901/02)4:3<14::AID-CPLX3>3.3.CO;2-F
   Forrester J., 1961, IND DYNAMICS, V1st ed.
   FRIEDLANDER F, 1968, ADMIN SCI QUART, V13, P289, DOI 10.2307/2391456
   GALBRAITH JR, 1982, DESIGNING COMPLEX OR
   GELLMANN M, 1994, SFI S SCI C, V19, P17
   GELLMANN M, 1994, QUARK JAGUAR ADVENTU
   GERSICK CJG, 1991, ACAD MANAGE REV, V16, P10, DOI 10.2307/258605
   GRESOV C, 1993, ORGAN SCI, V4, P181, DOI 10.1287/orsc.4.2.181
   GUTOWITZ H, 1991, CELLULAR AUTOMATA TH
   HABERSTROH CJ, 1965, HDB ORG, P1171
   Heino M, 1998, OIKOS, V83, P368, DOI 10.2307/3546851
   HEYDEBRAND WV, 1989, WORK OCCUPATION, V16, P323, DOI 10.1177/0730888489016003004
   Heylighen F., 1997, COMPLEXITY, V2, P31
   Holland J.H., 1995, HIDDEN ORDER ADAPTAT
   HOLLAND JH, 1991, AM ECON REV, V81, P365
   HORGAN J, 1995, SCI AM, V272, P104, DOI 10.1038/scientificamerican0695-104
   Illinitch A.Y., 1998, MANAGING TIMES DISOR, pxxi
   Jorgensen SE, 1998, ECOL MODEL, V111, P261, DOI 10.1016/S0304-3800(98)00104-5
   Katz D., 1978, SOCIAL PSYCHOL ORG, V2nd ed.
   Kauffman S. A., 1995, HOME UNIVERSE SEARCH
   Kauffman S. A., 1993, ORIGINS ORDER SELF O
   KOGUT B, 1992, ORGAN SCI, V3, P383, DOI 10.1287/orsc.3.3.383
   Koput KW, 1997, ORGAN SCI, V8, P528, DOI 10.1287/orsc.8.5.528
   Lawrence BS, 1997, ORGAN SCI, V8, P1, DOI 10.1287/orsc.8.1.1
   Lee Marshall H., 1990, Annals of Epidemiology, V1, P1
   Levinthal DA, 1997, MANAGE SCI, V43, P934, DOI 10.1287/mnsc.43.7.934
   Lewin A. Y., 1999, COEVOLUTION NEW ORG
   Lewin R., 1998, Complexity, V3, P36, DOI 10.1002/(SICI)1099-0526(199803/04)3:4<36::AID-CPLX7>3.0.CO;2-I
   Lomi A., 1997, Computational & Mathematical Organization Theory, V3, P219
   Mainzer K., 1994, THINKING COMPLEXITY
   March J.G., 1958, ORGANIZATIONS
   March JG, 1991, ORGAN SCI, V2, P71, DOI 10.1287/orsc.2.1.71
   March James G., 1976, AMBIGUITY CHOICE ORG
   McKelvey B, 1997, ORGAN SCI, V8, P352
   MCPHERSON JM, 1991, SOC FORCES, V70, P19, DOI 10.2307/2580060
   Mead G.H., 1934, MIND SELF SOC STANDP
   Meyer A, 1998, ORGAN SCI, V9, P569, DOI 10.1287/orsc.9.5.569
   MEYER JW, 1977, AM J SOCIOL, V83, P340, DOI 10.1086/226550
   MINTZBERG H, 1982, ACAD MANAGE J, V25, P465, DOI 10.2307/256075
   MIZRUCHI MS, 1994, ACTA SOCIOL, V37, P329, DOI 10.1177/000169939403700403
   Moss S., 1998, Computational & Mathematical Organization Theory, V4, P43, DOI 10.1023/A:1009600530279
   Nowak A, 1998, CONNECTIONIST MODELS OF SOCIAL REASONING AND SOCIAL BEHAVIOR, P277
   Ott E., 1993, CHAOS DYNAMICAL SYST
   PALMER D, 1983, ADMIN SCI QUART, V28, P40, DOI 10.2307/2392384
   Paul D. L., 1996, COMPUTATIONAL MATH O, V2, P301
   PERROW C, 1961, AM SOCIOL REV, V26, P854, DOI 10.2307/2090570
   Prigogine l., 1984, ORDER OUT CHAOS MANS
   READ SJ, 1998, CONNECTIONIST MODELS
   Ripa J, 1996, P ROY SOC B-BIOL SCI, V263, P1751, DOI 10.1098/rspb.1996.0256
   Robertson D. S., 1996, Complexity, V2, P10, DOI 10.1002/(SICI)1099-0526(199609/10)2:1<10::AID-CPLX4>3.3.CO;2-S
   ROMANELLI E, 1994, ACAD MANAGE J, V37, P1141, DOI 10.2307/256669
   Rousseau D., 1994, J ORGAN BEHAV, V1986-1998, P13
   Roy B., 1998, Complexity, V3, P31, DOI 10.1002/(SICI)1099-0526(199803/04)3:4<31::AID-CPLX6>3.0.CO;2-N
   Rumelhart D., 1984, HDB SOCIAL COGNITION, P161
   Samuel Y., 1997, Computational & Mathematical Organization Theory, V3, P151, DOI 10.1023/A:1009664618421
   Scott W.R., 1992, ORG RATIONAL NATURAL, V3rd ed.
   SEGEL LA, 1995, COMPLEXITY, V1, P18
   Selznick P., 1957, LEADERSHIP ADM SOCIO
   Simon H.A., 1996, SCI ARTIFICIAL
   STEARNS LB, 1986, ADMIN SCI QUART, V31, P522, DOI 10.2307/2392962
   THIETART RA, 1995, ORGAN SCI, V6, P19, DOI 10.1287/orsc.6.1.19
   Thom R., 1975, STRUCTURAL STABILITY
   THOMPSON D, 1967, ORG ACTION
   VAKASDUONG D, 1998, J ARTIFICIAL SOC SOC, V1
   Von Bertalanffy L., 1968, GEN SYSTEM THEORY FD
   Waldrop M. M., 1992, COMPLEXITY EMERGING
   Wasserman S., 1994, SOCIAL NETWORK ANAL
   Weibull JW., 1995, EVOLUTIONARY GAME TH
   Weick, 1979, SOCIAL PSYCHOL ORG
   Weisbuch G., 1991, COMPLEX SYSTEMS DYNA
   Wright S, 1931, GENETICS, V16, P0097
   ZEGGELINK EPH, 1996, COMPUT MATH ORGAN TH, V2, P115
NR 105
TC 868
Z9 892
U1 15
U2 331
PU INFORMS
PI HANOVER
PA 7240 PARKWAY DR, STE 310, HANOVER, MD 21076-1344 USA
SN 1047-7039
J9 ORGAN SCI
JI Organ Sci.
PD MAY-JUN
PY 1999
VL 10
IS 3
BP 216
EP 232
DI 10.1287/orsc.10.3.216
PG 17
WC Management
SC Business & Economics
GA 231XX
UT WOS:000082337600002
DA 2021-08-04
ER

PT J
AU McKelvey, B
AF McKelvey, B
TI Avoiding complexity catastrophe in coevolutionary pockets: Strategies
   for rugged landscapes
SO ORGANIZATION SCIENCE
LA English
DT Review
DE coevolution; complexity; interdependencies, value chain; competitive
   advantage; networks; microstates; agent-based modeling; rugged
   landscapes
ID HIGH-VELOCITY ENVIRONMENTS; COLLECTIVE ACTION; CRITICAL MASS;
   ORGANIZATIONAL CHOICE; DECISION-PROCESSES; SOCIAL NETWORKS; CHAOS
   THEORY; PERFORMANCE; COMPETITION; DYNAMICS
AB Can firms and coevolutionary groups suffer from too much interdependent complexity? Is complexity theory an alternative explanation to competitive selection for the emergent order apparent in coevolutionary industry groups? The biologist Stewart Kauffman suggests a theory of complexity catastrophe offering universal principles explaining phenomena normally attributed to Darwinian natural selection theory. Kauffman's complexity theory seems to apply equally well to firms in coevolutionary pockets. Based on complexity theory, four kinds of complexity are identified. Kauffman's "NK[C] model" is positioned "at the edge of chaos" between complexity driven by "Newtonian" simple rules and rule-driven deterministic chaos. Kauffman's insight, which is the basis of the findings in this paper, is that complexity is both a consequence and a cause. Multicoevolutionary complexity in firms is defined by moving natural selection processes inside firms and down to a "parts" level of analysis, in this instance Porter's value chain level, to focus on microstate activities by agents. The assumptions of stochastically idiosyncratic microstates and coevolution in firms are analyzed. Competitive advantage, as a dependent variable, is defined in terms of Nash equilibrium fitness levels. This allows a translation of Kauffman's theory to firms, paying particular attention to (1) how value chain landscapes might be modeled, (2) assumptions underlying Kauffman's models makings them amenable to firms, and (3) a delineation of seven of Kauffman's computational experiments. As part of the translation, possible parallels between the application of complexity catastrophe theory to coevolutionary pockets and studies by institutional theorists and social network analysts are discussed. The models derive from spin-glass microstate models resulting in Boolean games. Kauffman's Boolean statistical mechanics is introduced in developing the logic underlying the somewhat simplified NK[C] model. The model allows the use of computational experiments to better understand how the dependent variable-value chain fitness-is affected by changes in the number of internal interdependencies K, the number of coevolutionary links with opponents C, the size of the coevolutionary pocket S, and the number of simultaneous adaptive changes, among other things. Various computational experiments are presented that suggest strategic organizing approaches most likely to foster competitive advantage. High or low Nash equilibrium fitness levels an shown to result from internal and external coevolutionary densities as a function of links among value chain competencies within a firm and between a firm and an opponent. Complexity phenomena appear to suggest a number of expected land thus validating) and surprising strategies with respect to complex organizational interdependencies. For example, moderate complexity fares best and external coevolutionary complexity sets an upper bound to advantages likely to be gained from internal complexity. Various complexity "lessons" are discussed. Models such as the NK[C] could offer insights into strategic organizing.
C1 Univ Calif Los Angeles, Anderson Sch, Los Angeles, CA 90095 USA.
RP McKelvey, B (corresponding author), Univ Calif Los Angeles, Anderson Sch, 110 Westwood Pl, Los Angeles, CA 90095 USA.
CR Alchian AA, 1950, J POLIT ECON, V58, P211, DOI 10.1086/256940
   ALDRICH H., 1979, ORG ENV
   ASTLEY WG, 1985, ADMIN SCI QUART, V30, P224, DOI 10.2307/2393106
   BADENFULLER C, 1994, REJUVENATING MATURE
   BAKER WE, 1990, AM J SOCIOL, V96, P589, DOI 10.1086/229573
   BARNETT WP, 1994, EVOLUTIONARY DYNAMIC, P337
   BARNEY J, 1991, J MANAGE, V17, P99, DOI 10.1177/014920639101700108
   BARNEY JB, 1994, FUNDAMENTAL ISSUES S, P55
   Barrow JD., 1991, THEORIES EVERYTHING
   Baum J., 1999, VARIATIONS ORG SCI H
   Baum J. A. C., 1994, EVOLUTIONARY DYNAMIC
   Baum J. A. C., 1994, EVOLUTIONARY DYNAMIC, P379
   BOGNER WC, 1993, 930172 U ILL
   BOURGEOIS LJ, 1988, MANAGE SCI, V34, P816, DOI 10.1287/mnsc.34.7.816
   Brittain J., 1980, ORG LIFE CYCLE, P291
   BURGELMAN RA, 1983, MANAGE SCI, V29, P1349, DOI 10.1287/mnsc.29.12.1349
   Burns T., 1961, MANAGEMENT INNOVATIO
   Burt R. S, 1992, STRUCTURAL HOLES
   Burt R. S., 1982, STRUCTURAL THEORY AC
   CAMERER C, 1994, FUNDAMENTAL ISSUES S, P195
   CARLEY K, 1994, J MATH SOCIOL, V19, P221, DOI 10.1080/0022250X.1994.9990145
   CARLEY K, 1991, AM SOCIOL REV, V56, P331, DOI 10.2307/2096108
   CARLEY K, 1992, ORGAN SCI, V3, P20, DOI 10.1287/orsc.3.1.20
   Carley K, 1994, COMPUTATIONAL ORG TH
   CARLEY KM, 1995, IEEE T SYST MAN CYB, V25, P221, DOI 10.1109/21.364841
   Carley KM, 1996, SOCIOL METHOD RES, V25, P138, DOI 10.1177/0049124196025001005
   Carley KM, 1997, MANAGE SCI, V43, P976, DOI 10.1287/mnsc.43.7.976
   CARLEY KM, 1997, ORG ADAPTATION VOLAT
   CARLEY KM, 1997, DYNAMIC ORG ORG ADAP
   CAVES RE, 1977, Q J ECON, V91, P241, DOI 10.2307/1885416
   Chandler AlfredD., 1977, VISIBLE HAND
   Chia R., 1996, ORG ANAL DECONSTRUCT
   CHILD J, 1972, SOCIOLOGY, V6, P1, DOI 10.1177/003803857200600101
   CHO S, 1996, RESOURCE GRADIENT TH
   Cohen J., 1994, COLLAPSE CHAOS DISCO
   COHEN MD, 1972, ADMIN SCI QUART, V17, P1, DOI 10.2307/2392088
   COHEN MD, 1996, LOGIC ORG DISORDERS, P183
   Cramer F., 1993, CHAOS ORDER COMPLEX
   DAveni R. A., 1994, HYPERCOMPETITION MAN
   Depew D.J., 1995, DARWINISM EVOLVING S
   DIMAGGIO P, 1992, NETWORKS AND ORGANIZATIONS : STRUCTURE, FORM, AND ACTION, P118
   DiMaggio P.J., 1988, I PATTERNS ORG CULTU, P3
   DIMAGGIO PJ, 1983, AM SOCIOL REV, V48, P147, DOI 10.2307/2095101
   Dimancescu D, 1992, SEAMLESS ENTERPRISE
   DURFEE EH, 1988, COORDINATION DISTRIB
   Eigen M., 1979, HYPERCYCLE PRINCIPLE
   EISENHARDT KM, 1989, ACAD MANAGE J, V32, P543, DOI 10.2307/256434
   EISENHARDT KM, 1995, ORG SCI WINT C JAN S
   Eldredge N., 1995, REINVENTING DARWIN
   ETZIONI A, 1961, COMP ANAL COMPLEX OR
   Fischer K. H., 1993, SPIN GLASSES
   FREEMAN C, 1991, RES POLICY, V20, P499, DOI 10.1016/0048-7333(91)90072-X
   Freeman JA, 1992, NEURAL NETWORKS ALGO
   Friedman M., 1953, ESSAYS POSITIVE EC
   FROST PJ, 1985, ORG CULTURE
   GALASKIEWICZ J, IN PRESS RES SOCIOLO
   GALBRAITH JR, 1993, ORG FUTURE NEW LOGIC
   Galunic DC, 1996, ORGAN SCI, V7, P255, DOI 10.1287/orsc.7.3.255
   Garzon M, 1995, MODELS MASSIVE PARAL
   Gelfand A., 1984, ENSEMBLE MODELING
   Gell-Mann M., 1994, QUARK JAGUAR
   Gibbs J.W., 1902, ELEMENTARY PRINCIPLE
   GLANCE NS, 1994, COMPUTATIONAL ORG TH, P217
   Gleick J., 1987, CHAOS MAKING NEW SCI
   GOULD RV, 1993, AM SOCIOL REV, V58, P182, DOI 10.2307/2095965
   GRAHAM M, 1994, HORIZONTAL REVOLUTIO
   GRANOVETTER M, 1978, AM J SOCIOL, V83, P1420, DOI 10.1086/226707
   GROENEWEGEN J, 1996, T COST EC
   Haas J.E. Jr, 1973, COMPLEX ORG SOCIOLOG
   HAGEDOORN J, 1995, RES POLICY, V24, P207, DOI 10.1016/0048-7333(94)00763-W
   Hall RH, 1977, ORG STRUCTURE PROCES
   Hannan MichaelT., 1992, DYNAMICS ORG POPULAT
   Hannan MichaelT., 1989, ORG ECOLOGY
   HANNAN MT, 1977, AM J SOCIOL, V82, P929, DOI 10.1086/226424
   Heene A, 1997, COMPETENCE BASED STR
   HIRSHLEIFER J, 1977, J LAW ECON, V20, P1, DOI 10.1086/466891
   Hogarth R. M., 1987, RATIONAL CHOICE CONT
   HOLLAND PW, 1981, J AM STAT ASSOC, V76, P33, DOI 10.2307/2287037
   Ingram P., 1999, VARIATIONS ORG SCI H
   JOHANN B, 1995, DESIGNING CROSS FUNC
   Jones T., 1995, THESIS U NEW MEXICO
   KAHNEMAN D, 1982, JUDGEMENT UNCERTAINT
   KAUFFMAN S, 1974, J THEOR BIOL, V44, P167, DOI 10.1016/S0022-5193(74)80037-8
   Kauffman S. A., 1993, ORIGINS ORDER SELF O
   KAUFFMAN SA, 1994, 9406031 SANT FE I
   Kerwin K, 1998, BUS WEEK, P26
   Kim HJ, 1997, AM SOCIOL REV, V62, P70, DOI 10.2307/2657453
   Krackhardt D, 1997, J MATH SOCIOL, V22, P177, DOI 10.1080/0022250X.1997.9990200
   KRACKHARDT D, 1992, NETWORKS AND ORGANIZATIONS : STRUCTURE, FORM, AND ACTION, P216
   KRACKHARDT D, 1990, ADMIN SCI QUART, V35, P342, DOI 10.2307/2393394
   KRACKHARDT D, 1985, ADMIN SCI QUART, V30, P242, DOI 10.2307/2393107
   Kreps D., 1990, GAME THEORY EC MODEL
   Levinthal DA, 1997, MANAGE SCI, V43, P934, DOI 10.1287/mnsc.43.7.934
   LEVINTHAL DA, 1993, STRATEGIC MANAGE J, V14, P95, DOI 10.1002/smj.4250141009
   LEVITAN IB, 1991, NEURON CELL MOL BIOL
   Levitt R.E., 1994, COMPUTATIONAL ORG TH, P1
   LEVY D, 1994, STRATEGIC MANAGE J, V15, P167
   Liebeskind JP, 1996, ORGAN SCI, V7, P428, DOI 10.1287/orsc.7.4.428
   Lin Z, 1995, J MATH SOCIOL, V20, P193, DOI 10.1080/0022250X.1995.9990162
   Lincoln J. R., 1982, RES SOCIOLOGY ORG, P1
   Lincoln JR, 1996, AM SOCIOL REV, V61, P67, DOI 10.2307/2096407
   Lincoln YS, 1985, ORG THEORY INQUIRY
   LIPPMAN SA, 1982, BELL J ECON, V13, P418, DOI 10.2307/3003464
   LOOMIS CJ, 1993, FORTUNE         0503, P36
   Mackenzie K.D., 1986, ORG DESIGN ORG AUDIT
   MACY MW, 1990, AM SOCIOL REV, V55, P809, DOI 10.2307/2095747
   MACY MW, 1991, AM SOCIOL REV, V56, P730, DOI 10.2307/2096252
   March JG, 1991, ORGAN SCI, V2, P71, DOI 10.1287/orsc.2.1.71
   MARTINEZ AC, 1997, SEARS TURNAROUND
   MARWELL G, 1988, AM J SOCIOL, V94, P502, DOI 10.1086/229028
   Marwell G., 1993, CRITICAL MASS COLLEC
   MASUCH M, 1989, ADMIN SCI QUART, V34, P38, DOI 10.2307/2392985
   MASUCH M, 1992, ARTIFICIAL INTELLIGE
   McKelvey B., 1982, ORG SYSTEMATICS TAXO
   MCKELVEY B, 1997, COMPLEXITY VS SELECT
   McKelvey B., 1999, VARIATIONS ORG SCI H
   MCKELVEY B, 1997, ORGAN SCI, V8, P351
   MCKELVEY B, 1999, MESO C DUK U APR 30
   McKelvey B., 1994, EVOLUTIONARY DYNAMIC, P314
   MCPHERSON JM, 1992, AM SOCIOL REV, V57, P153, DOI 10.2307/2096202
   MEYER M, 1989, PERMANENTLY FAILING
   MINTZBERG H, 1976, ADMIN SCI QUART, V21, P246, DOI 10.2307/2392045
   MINTZBERG H, 1985, STRATEGIC MANAGE J, V6, P257, DOI 10.1002/smj.4250060306
   Morgan G., 1997, IMAGES ORG
   Morrison F, 1991, ART MODELING DYNAMIC
   Mosakowski E, 1997, ORGAN SCI, V8, P414, DOI 10.1287/orsc.8.4.414
   MOSAKOWSKI E, 1997, COMPETENCE BASED STR, P65
   Nash J, 1951, ANN MATH, V54, P289, DOI DOI 10.2307/1969529
   Nei M., 1987, MOL EVOLUTIONARY GEN
   Nelson R.R., 1982, EVOLUTIONARY THEORY
   Nicolis G, 1989, EXPLORING COMPLEXITY
   Nohria N, 1992, NETWORKS ORG STRUCTU
   Nord W, 1996, HDB ORG STUDIES, P77
   OLIVER P, 1985, AM J SOCIOL, V91, P522, DOI 10.1086/228313
   PADGETT JF, 1997, EC EVOLVING COMPLEX, V27, P199
   PALMER D, 1995, AM SOCIOL REV, V60, P469, DOI 10.2307/2096288
   Pattison P., 1993, ALGEBRAIC MODELS SOC
   PERROW C, 1961, AM SOCIOL REV, V26, P859
   Podolny JM, 1996, AM J SOCIOL, V102, P659, DOI 10.1086/230994
   Podolny JM, 1998, ANNU REV SOCIOL, V24, P57, DOI 10.1146/annurev.soc.24.1.57
   Porter M.E., 1985, COMPETITIVE ADVANTAG
   Porter M.E, 1990, COMPETITIVE ADVANTAG
   PORTER ME, 1991, STRATEGIC MANAGE J, V12, P95, DOI 10.1002/smj.4250121008
   Porter ME, 1996, HARVARD BUS REV, V74, P61
   POSTREL S, 1998, UNPUB COMBINING KNOW
   POWELL WW, 1992, NETWORKS AND ORGANIZATIONS : STRUCTURE, FORM, AND ACTION, P366
   POWELL WW, 1990, RES ORGAN BEHAV, V12, P295
   Powell WW, 1996, ADMIN SCI QUART, V41, P116, DOI 10.2307/2393988
   PRAHALAD CK, 1990, HARVARD BUS REV, V68, P78
   Prigogine I, 1962, NONEQUILIBRIUM STAT
   Prigogine Ilya, 1980, BEING BECOMING TIME
   Prigogine l., 1984, ORDER OUT CHAOS MANS
   RANDLE YE, 1990, THESIS U CALIFORNIA
   RASMUSEN E, 1994, GAMES INFORMATION IN
   REEVISCONNER K, 1991, J MANAGE, V17, P121
   RIVKIN J, 1997, AC MAN M BOST MA
   ROMMEL G, 1995, SIMPLICITY WINS
   Rosenkopf L., 1994, EVOLUTIONARY DYNAMIC, P403
   ROSENKOPF L, 1999, VARIATIONS ORG SCI H
   Rosenkopf L., 1998, IND CORP CHANGE, V7, P311, DOI DOI 10.1093/ICC/7.2.311
   ROUGHGARDEN J, 1976, THEOR POPUL BIOL, V9, P388, DOI 10.1016/0040-5809(76)90054-X
   Rumelt R.P., 1987, COMPETITIVE CHALLENG, P137
   RUMELT RP, 1994, FUNDAMENTALS ISSUES
   Saloner G., 1994, FUNDAMENTAL ISSUES S, P155
   SCHRODINGER E, 1944, WHAT IS LIFE PHYSICA
   SCHWAB JJ, 1960, BEHAV SCI, V5, P1
   Scott W.R., 1998, ORG RATIONAL NATURAL, V4th
   Scott W.R., 1995, I ORG
   SCOTT WR, 1964, HDB MODERN SOCIOLOGY, P485
   Selznick P., 1949, TVA GRASS ROOTS
   Simmonds J., 1992, CHEM BIOMOLECULES
   SORENSON O, 1997, THESIS STANFORD U ST
   Soulie F. F, 1987, AUTOMATA NETWORKS CO
   Stacey R.D., 1996, COMPLEXITY CREATIVIT
   STACEY RD, 1995, STRATEGIC MANAGE J, V16, P477, DOI 10.1002/smj.4250160606
   Stacey RD., 1991, CHAOS FRONTIER CREAT
   STAUFFER D, 1987, J STAT PHYS, V46, P789, DOI 10.1007/BF01013386
   STAUFFER D, 1987, PHILOS MAG B, V56, P901, DOI 10.1080/13642818708215325
   Stinchcombe A., 1968, CONSTRUCTING SOCIAL
   TEECE DJ, 1984, CALIF MANAGE REV, V26, P87, DOI 10.2307/41165082
   TEECE DJ, 1994, 949 CCC U CAL CTR RE
   THIETART RA, 1995, ORGAN SCI, V6, P19, DOI 10.1287/orsc.6.1.19
   Thomas LG, 1996, ORGAN SCI, V7, P221, DOI 10.1287/orsc.7.3.221
   Thompson J.D., 1967, ORG ACTION ORG ACTION
   Toffoli T., 1987, CELLULAR AUTOMATA MA
   ULANOWICZ RE, 1989, SYST RES, V6, P209, DOI 10.1002/sres.3850060304
   Uzzi B, 1996, AM SOCIOL REV, V61, P674, DOI 10.2307/2096399
   van de Ven A. H., 1994, EVOLUTIONARY DYNAMIC, P425
   VANDEVEN AH, 1999, VARIATIONS ORG SCI H
   WARGLIEN M, 1996, LOGIC ORG DISORDER, P163
   Wasserman P. D., 1993, ADV METHODS NEURAL C
   WASSERMAN PD, 1989, NEURAL COMPUTING THE
   Wasserman S., 1994, SOCIAL NETWORK ANAL
   Weick K. E., 1995, SENSEMAKING ORG
   Weisbuch G., 1991, COMPLEX SYSTEMS DYNA
   WERNERFELT B, 1984, STRATEGIC MANAGE J, V5, P171, DOI 10.1002/smj.4250050207
   Westhoff FH, 1996, J ECON BEHAV ORGAN, V29, P1, DOI 10.1016/0167-2681(95)00049-6
   Williamson O.E., 1975, MARKETS HIERARCHIES
   Wright S, 1931, GENETICS, V16, P0097
   WRIGHT SEWALL, 1932, PROC SIXTH INTERNAT CONGR GENETICS ITHACA NEW YORK, V1, P356
   Ye M, 1995, J MATH SOCIOL, V20, P219, DOI 10.1080/0022250X.1995.9990163
   YOSHINO M. Y., 1995, STRATEGIC ALLIANCES
NR 203
TC 214
Z9 226
U1 2
U2 73
PU INST OPERATIONS RESEARCH  MANAGEMENT SCIENCES
PI LINTHICUM HTS
PA 901 ELKRIDGE LANDING RD, STE 400, LINTHICUM HTS, MD 21090-2909 USA
SN 1047-7039
J9 ORGAN SCI
JI Organ Sci.
PD MAY-JUN
PY 1999
VL 10
IS 3
BP 294
EP 321
DI 10.1287/orsc.10.3.294
PG 28
WC Management
SC Business & Economics
GA 231XX
UT WOS:000082337600007
DA 2021-08-04
ER

PT J
AU Crescenza, A
   Botta, M
   Corelli, F
   Santini, A
   Tafi, A
AF Crescenza, A
   Botta, M
   Corelli, F
   Santini, A
   Tafi, A
TI Cyclic dipeptides. 3. Synthesis of methyl
   (R)-6-[(tert-butoxycarbonyl)amino]-4,5,6,7-tetrahydro-2-methyl-5-oxo-1,4
   -thiazepine-3-carboxylate and its hexahydro analogues: Elaboration of a
   novel dual ACE NEP inhibitor
SO JOURNAL OF ORGANIC CHEMISTRY
LA English
DT Article
ID ANGIOTENSIN-CONVERTING ENZYME; NEUTRAL ENDOPEPTIDASE INHIBITOR;
   VERBESINA-CARACASANA; RENAL-FUNCTION; HEART-FAILURE;
   EXPERIMENTAL-HYPERTENSION; HYPOTENSIVE AGENT; BLOOD-PRESSURE;
   BREVETOXIN-B; CYCLIZATION
AB Synthetic routes to highly functionalized 1,4-thiazepinones 2 and 3 have been developed. S-Ac-N-Boc-L-Cys-D(L)-ThrOMe 7a,b have been prepared and, after transformation into the corresponding mesylates, used as the cyclization substrates. Treatment of these compounds with LiAlH(OMe)(3) in THF results in mesylate elimination and thiolacetate reduction, giving rise to both a Michael acceptor (a,P-unsaturated ester) and Michael donor (thiol anion), which undergo in situ intramolecular conjugate addition leading to the stereoselective formation of only two of the four possible stereoisomers of 2. On the other hand, PCC/CaCO3 oxidation of 7a gave in 80% yield the corresponding ketone 11, which was in turn transformed into the enol triflate 15. Cleavage of the thiolacetate moiety, simultaneous elimination of trifluoromethanesulfonic acid to generate an allene system, and addition of the thiol group to the central carbon of the allene to provide the enantiomerically pure cyclic compound 3 in 85% yield was effected via a one-pot reaction by means of MeONa/MeOH. Thiazepinone 3 is an interesting intermediate for the preparation of conformationally restricted dipeptide mime tics, and its elaboration into the dual ACE/NEP inhibitor 4 is reported.
C1 Univ Siena, Dipartimento Farmaco Chim Tecnol, I-53100 Siena, Italy.
   Univ Naples Federico II, Dipartimento Sci Alimentari, I-80055 Naples, Italy.
RP Botta, M (corresponding author), Univ Siena, Dipartimento Farmaco Chim Tecnol, Banchi di Sotto 55, I-53100 Siena, Italy.
EM botta@unisi.it; corelli@unisi.it
RI Santini, Antonello/J-4923-2019
OI SANTINI, Antonello/0000-0001-5505-3327
CR ALLRED EL, 1965, J AM CHEM SOC, V87, P673, DOI 10.1021/ja01081a063
   ALTOMARE A, 1994, J APPL CRYSTALLOGR, V27, P435, DOI 10.1107/S002188989400021X
   BLUMENKOPF TA, 1986, CHEM REV, V86, P857, DOI 10.1021/cr00075a009
   Botta B, 1997, GAZZ CHIM ITAL, V127, P305
   Botta M, 1997, TETRAHEDRON LETT, V38, P2775, DOI 10.1016/S0040-4039(97)00468-1
   BRENNER BM, 1990, PHYSIOL REV, V70, P665
   BRIGGS MT, 1979, J CHEM SOC PERK T 1, P2138, DOI 10.1039/p19790002138
   Casey M., 1990, ADV PRACTICAL ORGANI
   CASTANEDA A, 1989, J ORG CHEM, V54, P5695, DOI 10.1021/jo00285a016
   CHENG YS, 1980, SYNTHESIS-STUTTGART, P223
   CLARKE TC, 1972, J AM CHEM SOC, V94, P3626, DOI 10.1021/ja00765a061
   COCKERILL GS, 1985, J CHEM SOC PERK T 1, P2093, DOI 10.1039/p19850002093
   CONWAY TT, 1978, CAN J CHEM, V56, P1335, DOI 10.1139/v78-221
   COPPI L, 1988, J ORG CHEM, V53, P911, DOI 10.1021/jo00239a053
   Corelli F, 1997, J MED CHEM, V40, P125, DOI 10.1021/jm9605647
   CORELLI F, 1994, TETRAHEDRON-ASYMMETR, V5, P1469, DOI 10.1016/0957-4166(94)80115-0
   Corelli F, 1996, BIOORG MED CHEM LETT, V6, P653, DOI 10.1016/0960-894X(96)00079-0
   CRESCENZA A, 1998, THESIS U SIENA
   DELLEMONACHE G, 1992, BIOORG MED CHEM LETT, V2, P415
   DelleMonache G, 1996, BIOORG MED CHEM LETT, V6, P233, DOI 10.1016/0960-894X(96)00007-8
   DELLEMONACHE G, 1993, J MED CHEM, V36, P2956, DOI 10.1021/jm00072a016
   ERICKSON GW, 1980, J ORG CHEM, V45, P970, DOI 10.1021/jo01294a011
   FLYNN GA, 1993, J MED CHEM, V36, P2420, DOI 10.1021/jm00068a022
   FRENCH JF, 1995, J CARDIOVASC PHARM, V26, P107, DOI 10.1097/00005344-199507000-00017
   HANSEN RL, 1965, J ORG CHEM, V30, P4322, DOI 10.1021/jo01023a511
   HELSIN JC, 1988, J CHEM SOC P1, P1417
   ILLUMINATI G, 1981, ACCOUNTS CHEM RES, V14, P95, DOI 10.1021/ar00064a001
   KANT J, 1994, J ORG CHEM, V59, P4956, DOI 10.1021/jo00096a045
   KENNY AJ, 1988, FEBS LETT, V232, P1, DOI 10.1016/0014-5793(88)80375-2
   KOCIENSKI PJ, 1989, TETRAHEDRON, V45, P3839, DOI 10.1016/S0040-4020(01)89243-7
   KOTSUKI H, 1989, J ORG CHEM, V54, P5153, DOI 10.1021/jo00282a037
   LAWTON G, 1992, ADV DRUG RES, V23, P161
   LEY SV, 1994, SYNTHESIS-STUTTGART, P639
   Lien E J, 1994, Prog Drug Res, V43, P43
   LIU WG, 1995, J CHEM SOC PERK T 1, P553, DOI 10.1039/p19950000553
   MANCUSO AJ, 1978, J ORG CHEM, V43, P2480, DOI 10.1021/jo00406a041
   MARSHALL GR, 1993, TETRAHEDRON, V49, P3547, DOI 10.1016/S0040-4020(01)90214-5
   MASSA S, 1985, HETEROCYCLES, V23, P1417
   MEYERS AI, 1974, J ORG CHEM, V39, P2778, DOI 10.1021/jo00932a022
   NICOLAOU KC, 1989, J AM CHEM SOC, V111, P4136, DOI 10.1021/ja00193a076
   NICOLAOU KC, 1995, J AM CHEM SOC, V117, P10227, DOI 10.1021/ja00146a008
   NORTHRIDGE DB, 1990, AM J HYPERTENS, V3, P682, DOI 10.1093/ajh/3.9.682
   PARISH EJ, 1992, SYNTHETIC COMMUN, V22, P2839, DOI 10.1080/00397919208021550
   Perrin D. D., 1988, PURIFICATION LAB CHE
   PHAM I, 1993, J PHARMACOL EXP THER, V265, P1339
   PHAM I, 1992, J CARDIOVASC PHARM, V20, P847, DOI 10.1097/00005344-199212000-00001
   RITTER K, 1993, SYNTHESIS-STUTTGART, P735
   Robl JA, 1997, J MED CHEM, V40, P1570, DOI 10.1021/jm970041e
   SCHUSTER HF, 1984, ALLENES ORGANIC SYNT, pCH6
   *SDP, 1982, STRUCT DET PACK
   SEYMOUR AA, 1991, J CARDIOVASC PHARM, V17, P296, DOI 10.1097/00005344-199102000-00016
   SEYMOUR AA, 1993, J PHARMACOL EXP THER, V266, P872
   STANG PJ, 1975, J ORG CHEM, V40, P657, DOI 10.1021/jo00893a026
   STREITWI.A, 1968, J AM CHEM SOC, V90, P1598
   STRIJTVEEN B, 1986, J ORG CHEM, V51, P3664, DOI 10.1021/jo00369a020
   SUMMERVILLE RH, 1972, J AM CHEM SOC, V94, P3629, DOI 10.1021/ja00765a063
   TRIPPODO NC, 1995, J PHARMACOL EXP THER, V275, P745
   URA N, 1987, KIDNEY INT, V32, P507, DOI 10.1038/ki.1987.239
   VERA WG, 1995, J PHARMACOL EXP THER, V272, P343
   WAESHAWSKY AM, 1996, BIOORG MED CHEM LETT, V6, P957
   WIELAND T, 1962, LIEBIGS ANN CHEM, V658, P181
   WINQUIST RJ, 1990, PHARMACOL THERAPEUT, V48, P417, DOI 10.1016/0163-7258(90)90058-A
   YAMAMOTO Y, 1991, TETRAHEDRON LETT, V32, P7069, DOI 10.1016/0040-4039(91)85042-4
   ZAHN H, 1969, CHEM BER-RECL, V102, P1048, DOI 10.1002/cber.19691020340
NR 64
TC 37
Z9 37
U1 0
U2 7
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-3263
J9 J ORG CHEM
JI J. Org. Chem.
PD APR 30
PY 1999
VL 64
IS 9
BP 3019
EP 3025
DI 10.1021/jo981425v
PG 7
WC Chemistry, Organic
SC Chemistry
GA 194BA
UT WOS:000080171200017
PM 11674397
DA 2021-08-04
ER

PT J
AU Gogova, K
   Zuskova, I
   Tesarova, E
   Gas, B
AF Gogova, K
   Zuskova, I
   Tesarova, E
   Gas, B
TI Electromigration behavior of metal ions in the presence of complexing
   polymer
SO JOURNAL OF CHROMATOGRAPHY A
LA English
DT Article; Proceedings Paper
CT 11th International Symposium on Capillary Electrophoresis Techniques
   (ITP 98)
CY OCT 04-07, 1998
CL VENICE, ITALY
DE stability constants; metal cations; poly(ethylene glycol); metal
   complexes
ID ALKALINE-EARTH METAL; ISOTACHOPHORETIC SEPARATION BEHAVIOR; CAPILLARY
   ZONE ELECTROPHORESIS; X-RAY-EMISSION; AMMONIUM CATIONS; ACID
AB Electromigration behavior of metal ions in the presence of high concentrations of polyethylene glycol as a complexing agent was investigated under acidic non-buffered conditions. Simulation of the isotachophoretic steady state of the system containing the neutral polymer was performed. Both the complexation and the influence of viscosity on the electrophoretic mobility were taken into account. Good agreement between the calculated results and the experimentally obtained values was achieved. Based on the theoretical model, a new approach for the estimation of polymer-metal stability constants from experimental isotachophoretic data was proposed. Stability constants of Li+, Na+, Cs+, Mg2+, Sr2+, Mn2+, Co2+, Ni2+, Zn2+, Pb2+, Lu3+ and Y3+ ions with polyethylene glycol were determined. (C) 1999 Elsevier Science B.V. All rights reserved.
C1 Charles Univ Prague, Fac Sci, Dept Phys & macromol Chem, CZ-12840 Prague 2, Czech Republic.
RP Gogova, K (corresponding author), Charles Univ Prague, Fac Sci, Dept Phys & macromol Chem, Albertov 2030, CZ-12840 Prague 2, Czech Republic.
RI Zuskova, Iva/F-4250-2014; Tesarova, Eva/M-6234-2017; Gas,
   Bohuslav/P-2707-2017
OI Zuskova, Iva/0000-0002-4722-9879; Tesarova, Eva/0000-0002-4372-8494;
   Gas, Bohuslav/0000-0001-7425-0721
CR ERDEYGRUZ T, 1974, TRANSPORT PHENOMENA, P352
   EVERAERTS FM, 1985, J CHROMATOGR, V320, P263, DOI 10.1016/S0021-9673(01)90504-7
   GAS B, 1989, J CHROMATOGR, V470, P69, DOI 10.1016/S0021-9673(00)94200-6
   HIRAHARA T, 1997, THESIS
   HIROKAWA T, 1993, J CHROMATOGR, V633, P261, DOI 10.1016/0021-9673(93)83162-L
   HIROKAWA T, 1991, J CHROMATOGR, V538, P413, DOI 10.1016/S0021-9673(01)88862-2
   Ito K, 1996, J CHROMATOGR A, V742, P281, DOI 10.1016/0021-9673(96)00224-5
   KANIANSKY D, 1990, J CHROMATOGR, V502, P143, DOI 10.1016/S0021-9673(01)89571-6
   Macka M, 1997, ELECTROPHORESIS, V18, P2482, DOI 10.1002/elps.1150181237
   MARTELL AE, 1977, CRITICAL STABILITY C, P266
   NUKATSUKA I, 1981, J CHROMATOGR, V205, P95, DOI 10.1016/S0021-9673(00)81817-8
   Rundlett KL, 1997, ELECTROPHORESIS, V18, P2194, DOI 10.1002/elps.1150181210
   SalimiMoosavi H, 1996, J CHROMATOGR A, V749, P279, DOI 10.1016/0021-9673(96)00415-3
   Sarmini K, 1998, J CHROMATOGR A, V811, P201, DOI 10.1016/S0021-9673(98)00256-8
   SHI YC, 1994, J CHROMATOGR A, V671, P429, DOI 10.1016/0021-9673(94)80270-X
   SIMUNICOVA E, 1994, J CHROMATOGR A, V665, P203, DOI 10.1016/0021-9673(94)87050-0
   Stathakis C, 1996, ANALYST, V121, P839, DOI 10.1039/an9962100839
   Walden P, 1926, Z PHYS CHEM-STOCH VE, V123, P429
NR 18
TC 4
Z9 4
U1 0
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0021-9673
EI 1873-3778
J9 J CHROMATOGR A
JI J. Chromatogr. A
PD APR 9
PY 1999
VL 838
IS 1-2
BP 101
EP 109
DI 10.1016/S0021-9673(99)00116-8
PG 9
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 189DW
UT WOS:000079889700011
DA 2021-08-04
ER

PT J
AU Shouji, E
   Buttry, DA
AF Shouji, E
   Buttry, DA
TI A mechanistic study of the influence of proton transfer processes on the
   behavior of thiol/disulfide redox couples
SO JOURNAL OF PHYSICAL CHEMISTRY B
LA English
DT Article
ID PLASMA-POLYMERIZED VINYLFERROCENE; CHEMICALLY MODIFIED ELECTRODES;
   DIMETHYL-SULFOXIDE SOLUTION; RADICAL-CATION ACIDITIES; LITHIUM
   BATTERIES; POLYANILINE; BOND; 2,5-DIMERCAPTO-1,3,4-THIADIAZOLE;
   EQUILIBRIUM; REACTIVITY
AB The mechanism of the oxidation of 2-mercapto-5-methyl-1,3,4-thiadiazole (McMT) to its disulfide dimer and its subsequent reduction has been examined with a combined approach employing experimental data and digital simulation. In order to elucidate the influence of proton transfers on these redox processes, special attention has been paid to the influence of various bases, including triethylamine, pyridine, 3-chloropyridine, lutidine and 2,6-di-tert-butylpyridine, and proton donors, including methanesulfonic acid and trifluoromethanesulfonic acid, on both the oxidation and reduction reactions. On the basis of detailed comparisons of the experimental data with simulations of several mechanistic models, it is found that proton transfer pathways have a pronounced influence on both the oxidative and reductive pathways. In particular, McMT oxidation is facilitated by a rapid bimolecular proton transfer from McMT to weak bases such as Py that produces McMT(-), the thiolate form, which is then oxidized. There is no such facilitation in the presence of the sterically hindered base 2,6-di-tert-butylpyridine, suggesting that the facilitation occurs through the formation of a discrete hydrogen-bonded complex. The overall kinetic scheme by which these redox processes proceed both in the presence and absence of proton transfer agents is discussed, especially with regard to the potential use of a related dithiolate compound as a cathode material in Li secondary batteries.
C1 Univ Wyoming, Dept Chem, Laramie, WY 82071 USA.
RP Buttry, DA (corresponding author), Univ Wyoming, Dept Chem, Laramie, WY 82071 USA.
CR Andrieux CP, 1997, J AM CHEM SOC, V119, P2420, DOI 10.1021/ja963674b
   BARD AJ, 1980, ELECTROCHEMICAL METH, P450
   Barnett J, 1944, J CHEM SOC, P5, DOI 10.1039/jr9440000005
   BERNASCONI CF, 1979, J AM CHEM SOC, V101, P2707, DOI 10.1021/ja00504a035
   BORDWELL FG, 1986, J AM CHEM SOC, V108, P2473, DOI 10.1021/ja00269a071
   BORDWELL FG, 1988, ACCOUNTS CHEM RES, V21, P456, DOI 10.1021/ar00156a004
   BORDWELL FG, 1989, J AM CHEM SOC, V111, P1792, DOI 10.1021/ja00187a036
   BORDWELL FG, 1994, J AM CHEM SOC, V116, P6605, DOI 10.1021/ja00094a015
   DAUM P, 1979, J ELECTROANAL CHEM, V103, P289, DOI 10.1016/S0022-0728(79)80452-0
   DAUM P, 1981, J PHYS CHEM-US, V85, P389, DOI 10.1021/j150604a017
   FRY AJ, 1986, TOPICS ORGANIC ELECT, P1
   Gabriel S, 1912, BER DTSCH CHEM GES, V45, P1643, DOI 10.1002/cber.19120450231
   GILMAN H, 1945, J AM CHEM SOC, V67, P1845, DOI 10.1021/ja01226a065
   HOFFMAN MZ, 1972, J AM CHEM SOC, V94, P7950, DOI 10.1021/ja00778a002
   IUPAC, 1979, ION CONST ORG AC AQ
   KAMINAGA A, 1995, J ELECTROCHEM SOC, V142, P47
   KOLTHOFF IM, 1968, J AM CHEM SOC, V90, P23, DOI 10.1021/ja01003a005
   LAVIRON E, 1986, J ELECTROANAL CHEM, V208, P357, DOI 10.1016/0022-0728(86)80543-5
   LIU ML, 1990, J ELECTROCHEM SOC, V137, P750, DOI 10.1149/1.2086549
   LUO WF, 1994, J ELECTROANAL CHEM, V368, P109, DOI 10.1016/0022-0728(93)03083-2
   March J., 1992, ADV ORG CHEM, P250
   MURRAY RW, 1984, ELECTROANALYTICAL CH, V13, P206
   NICHOLAS AMD, 1982, CAN J CHEM, V60, P2165, DOI 10.1139/v82-310
   OYAMA N, 1995, NATURE, V373, P598, DOI 10.1038/373598a0
   PARKER VD, 1991, J AM CHEM SOC, V113, P2336, DOI 10.1021/ja00006a081
   PARKER VD, 1991, J AM CHEM SOC, V113, P7493, DOI 10.1021/ja00020a007
   PARKER VD, 1988, J AM CHEM SOC, V110, P1649, DOI 10.1021/ja00213a062
   RUDOLPH M, 1994, PHYSICAL ELECTROCHEM, P81
   SCHLESENER CJ, 1984, J AM CHEM SOC, V106, P7472, DOI 10.1021/ja00336a029
   Shouji E, 1996, J ELECTROANAL CHEM, V410, P229, DOI 10.1016/0022-0728(96)04555-X
   Shouji E, 1996, J ELECTROANAL CHEM, V417, P17, DOI 10.1016/S0022-0728(96)04757-2
   Shouji E, 1999, LANGMUIR, V15, P669, DOI 10.1021/la980775+
   Shouji E, 1997, J PHYS CHEM B, V101, P2861, DOI 10.1021/jp962704u
   SIMIC M, 1970, J AM CHEM SOC, V92, P6096, DOI 10.1021/ja00723a067
   Tatsuma T, 1996, J PHYS CHEM-US, V100, P14016, DOI 10.1021/jp960774v
   TATSUMA T, 1995, J ELECTROCHEM SOC, V142, pL182, DOI 10.1149/1.2050037
NR 36
TC 23
Z9 23
U1 0
U2 24
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1089-5647
J9 J PHYS CHEM B
JI J. Phys. Chem. B
PD MAR 25
PY 1999
VL 103
IS 12
BP 2239
EP 2247
DI 10.1021/jp984591f
PG 9
WC Chemistry, Physical
SC Chemistry
GA 182JU
UT WOS:000079496500027
DA 2021-08-04
ER

PT J
AU Knepper, TP
   Kirschhofer, F
   Lichter, I
   Maes, A
   Wilken, RD
AF Knepper, TP
   Kirschhofer, F
   Lichter, I
   Maes, A
   Wilken, RD
TI Metabolism studies of phenylsulfonamides relevant for water works
SO ENVIRONMENTAL SCIENCE & TECHNOLOGY
LA English
DT Article
AB Polar organic contaminants in surface water for drinking water purposes are relevant if they are poorly degradable, and analyses of such compounds are challenging because they are extremely water soluble. The problem is enhanced with more polar and unknown metabolites such as Sarkosin-N-(phenylsulfonyl) (SPS) which was detected in the Rhine river constantly in concentrations between 0.5 and 2 mu g/L. The ubiquitous presence of SPS in the water was initially hypothesized to be due to the microbial degradation in sewage plants of 6-[methyl(phenylsulfonyl)amino]hexanoic acid (HPS) which is extensively used in Germany as a corrosion inhibiting agent. Soil suspension as well as closed-bottle degradation experiments with sewage water confirmed this hypothesis. Immobilized cell systems simulated the behavior in underground passage. HPS was totally degraded within hours; while SPS and other metabolites such as 4-[methyl(phenylsulfonyl)amino]butanoic acid (BPS) and methyl(phenylsulfonyI)amide (MPS) were identified. These studies revealed that phenylsulfonamides should be included in the group of drinking water relevant compounds because of their positive identification in drinking water itself. Even if the toxic effects of the investigated phenylsulfonamides have not yet been substantiated possibly also due to their inadequate biodegradability, their presence in the environment is a concern in general and therefore should be minimized.
C1 ESWE Inst Water Res & Water Technol, D-65201 Wiesbaden, Germany.
RP Knepper, TP (corresponding author), ESWE Inst Water Res & Water Technol, Soehnleinstr 158, D-65201 Wiesbaden, Germany.
EM knepper@goofy.zdv.uni-mainz.de
CR BANDER A, 1972, SCHWEIZER APOTHEKER, V110, P791
   BASTIAN B, 1995, VOM WASSER, V84, P369
   DERUITER J, 1987, J PHARM SCI, V76, P149, DOI 10.1002/jps.2600760213
   DIERY H, 1979, Patent No. 2840112
   FORTH W, 1992, ALLGEIMEINE SPEZIELL, P619
   GEKE J, 1984, Patent No. 3316724
   HABERER K, 1993, GAS WASSERFACH WASSE, V134, P526
   HEBERER T, 1994, FRESEN ENVIRON BULL, V3, P639
   KARRENBROCK F, 1999, IN PRESS VOM WASSER, V92
   KNEPPER TP, 1995, VOM WASSER, V85, P271
   KNEPPER TP, 1996, VOM WASSER, V86, P263
   KORPIEN H, 1998, ARW JAHRESBRICHT 199, V54, P149
   LINDNER K, 1996, IAWR RHEINTHEMEN, V1, P106
   OSHIO H, 1975, Patent No. 93578
   SIEBERS J, 1995, COMMUNICATION
   TERNES TA, 1995, VOM WASSER, V85, P321
   Thomas K, 1919, H-S Z PHYSIOL CHEM, V104, P141, DOI 10.1515/bchm2.1919.104.4.141
NR 17
TC 27
Z9 29
U1 0
U2 14
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0013-936X
J9 ENVIRON SCI TECHNOL
JI Environ. Sci. Technol.
PD MAR 15
PY 1999
VL 33
IS 6
BP 945
EP 950
DI 10.1021/es980712d
PG 6
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA 175VV
UT WOS:000079117100019
DA 2021-08-04
ER

PT J
AU Hochster, H
   Speyer, JL
   Mandeli, JP
   Runowicz, C
   Wadler, S
   Berk, G
   Wallach, R
   Holland, JF
AF Hochster, H
   Speyer, JL
   Mandeli, JP
   Runowicz, C
   Wadler, S
   Berk, G
   Wallach, R
   Holland, JF
CA New York Gynecol Oncol Grp
TI A phase II double-blind randomized study of the simultaneous
   administration of recombinant human interleukin-6 and recombinant human
   granulocyte colony-stimulating factor following paclitaxel and
   carboplatin chemotherapy in patients with advanced epithelial ovarian
   cancer
SO GYNECOLOGIC ONCOLOGY
LA English
DT Article
ID CYCLOPHOSPHAMIDE
AB Purpose. Recombinant human interleukin-6 (rhuIL-6) is a glycosylated cytokine with hematopoietic stimulatory effects. In particular, preclinical studies suggest the agent can stimulate thrombopoiesis, even in conjunction with chemotherapy. We attempted to determine whether higher dose chemotherapy for ovarian cancer was possible given the pharmacologic use of this important growth factor.
   Methods. We conducted a randomized, double-blind phase II study of IL-6 plus granulocyte colony-stimulating factor (G-CSF) versus placebo plus G-CSF in combination with a standard chemotherapy regimen. Patients with epithelial ovarian cancer, stages Ic to IV, were eligible. All patients were previously untreated with chemotherapy and had Karnofsky performance status greater than or equal to 60. rhuIL-B (Escherichia coli, SDZ ILS 969) 1.0 mu g/kg or placebo was given subcutaneously on days 2-8 every cycle together with G-CSF 5.0 mu g/kg subcutaneously days 2-15, following administration of paclitaxel 175 mg/m(2) as a 3-h infusion and carboplatin given to a desired AUC of 7.5 on day 1 every 21 days.
   Results. Fifty patients were entered in this study, although the study was temporarily suspended by the FDA in midstudy over manufacturing concerns. Therefore, 37 patients were evaluable for efficacy of growth factor; 19 patients received placebo plus G-CSF and 18 rhIL-6 plus G-CSF, There was no difference in prognostic variables between these two groups. Platelet nadirs were lower in the first cycle for the placebo group (P = 0.004, Wilcoxon sum-rank test) but not in other cycles. There was no statistically significant difference in cycle treatment delays, carboplatin dose delivered, number of patients with grade 4 thrombocytopenia, or platelet transfusion. Nonetheless, the trend of the data favored IL-6 in all cases.
   Conclusions. This study demonstrated a minimal effect (statistically significant in the first cycle only) on thrombopoiesis in women undergoing paclitaxel and carboplatin therapy of ovarian cancer. No clinically significant effect on actual chemotherapy delivery was demonstrated, however, Future studies, if warranted, to ameliorate thrombocytopenia should be carried out with regimens producing even greater thrombocytopenia than the current regimen in the control arm. (C) 1999 Academic Press.
C1 NYU Med Ctr, Kaplan Comprehensive Canc Ctr, New York, NY 10016 USA.
   NYU, Sch Med, New York, NY USA.
   Mt Sinai Med Ctr, New York, NY 10029 USA.
   Cornell Univ, Med Ctr, New York Hosp, New York, NY 10021 USA.
   Albert Einstein Coll Med, Bronx, NY 10467 USA.
   NYU Med Ctr, Dept Med, New York, NY 10016 USA.
RP Hochster, H (corresponding author), NYU Med Ctr, Dept Med, 530 1st Ave, New York, NY 10016 USA.
OI Runowicz, Carolyn D./0000-0002-6246-3743
CR ALBERTS D, 1989, P AN M AM SOC CLIN, V8, P151
   ASANO S, 1990, BLOOD, V75, P1602
   CALVERT AH, 1989, J CLIN ONCOL, V7, P1748, DOI 10.1200/JCO.1989.7.11.1748
   CARACCIOLO D, 1989, BLOOD, V73, P666
   DEMETRI GD, 1995, CANC INVEST S1, V13, P5
   EDMONSON JH, 1985, CANCER TREAT REP, V69, P1243
   HILL RJ, 1991, BLOOD, V77, P42
   MANGIONI C, 1985, P AM SOC CLIN ONCOL, V1, P617
   McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101
   MUGGIA FM, 1997, P AN M AM SOC CLIN, V16, pA352
   National Cancer Institute, 1988, GUID REP ADV DRUG RE
   NAVARRO S, 1991, BLOOD, V77, P461
   Obasaju CK, 1996, CLIN CANCER RES, V2, P549
   OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014
   PATCHEN ML, 1991, BLOOD, V77, P472
   PAUL WE, 1989, ANN NY ACAD SCI, V557, P579
   PICCART MJ, 1997, P AN M AM SOC CLIN, V16, pA352
   Runowicz CD, 1996, AM J OBSTET GYNECOL, V174, P1151, DOI 10.1016/S0002-9378(96)70657-9
   SPEYER JL, 1995, GYNECOL ONCOL, V56, P387, DOI 10.1006/gyno.1995.1068
   TAKATSUKI F, 1990, CANCER RES, V50, P2885
   WONG GG, 1988, J IMMUNOL, V140, P3040
NR 21
TC 3
Z9 3
U1 0
U2 2
PU ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0090-8258
J9 GYNECOL ONCOL
JI Gynecol. Oncol.
PD MAR
PY 1999
VL 72
IS 3
BP 292
EP 297
DI 10.1006/gyno.1998.5261
PG 6
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA 174CE
UT WOS:000079015900005
PM 10053098
DA 2021-08-04
ER

PT J
AU Kaufman, DB
   Leventhal, JR
   Stuart, J
   Abecassis, MM
   Fryer, JP
   Stuart, FP
AF Kaufman, DB
   Leventhal, JR
   Stuart, J
   Abecassis, MM
   Fryer, JP
   Stuart, FP
TI Mycophenolate mofetil and tacrolimus as primary maintenance
   immunosuppression in simultaneous pancreas-kidney transplantation -
   Initial experience in 50 consecutive cases
SO TRANSPLANTATION
LA English
DT Article
ID MULTICENTER ANALYSIS; RECIPIENTS; DRAINAGE
AB Background. The current study examines the use of mycophenolate mofetil (MMF) and tacrolimus as primary immunosuppression in simultaneous pancreas-kidney (SPK) transplantation. In addition, analyses of the rates of conversion from one immunosuppressive agent to another, and its subsequent consequences with respect to outcomes were determined. Quality of graft function, infections, and effect on preexisting essential hypertension are also described.
   Methods. Immunosuppression consisted of quadruple therapy with antithymocyte globulin induction, tacrolimus, MMF, and prednisone. Patient and graft survival and rejection rates in 50 consecutive SPK recipients, followed for a minimum of 3 months and a mean of 14 months (range: 3-34 months), are described.
   Results. Thirty-nine of 50 (78%) patients tolerated the MMF/tacrolimus combination long-term (mean duration of follow-up: 14+/-7 months). Nine of 50 patients (18%) were converted to Neoral(R), and 4 patients were converted to azathioprine as a substitute for MMF. The 2-year actuarial patient, kidney, and pancreas survival rates were 97.7%, 93.3%, and 90.0%, respectively. At 6 months after transplant, the overall incidence of acute rejection was 16%. There was a statistically significant (P less than or equal to 0.04, Cox-Mantel test) difference in the rate of rejection associated with conversion to Neoral(R). The incidence of rejection 6 months after transplant in the group maintained on MMF/tacrolimus was 10.2% vs. 44.4% in the group converted to Neoral(R) (P less than or equal to 0.04, Cox-Mantel test). Overall, the 1-year actuarial cumulative incidence of tissue-invasive cytomegalovirus disease was 6.6%. There were no cases of fungal infections or post-transplant lymphoproliferative disorders. One patient developed Kaposi's sarcoma 10 months after transplant. With respect to hypertensive disease, 60% (12/20) of the patients who required pharmacologic control of blood pressure before transplant were off all antihypertensive medications at 1 year after transplant. An additional 20% (4/20) of patients had a reduction in the number of medications required to control blood pressure at 1 year after transplant.
   Conclusions. We conclude that the combination of MMF and tacrolimus as primary immunosuppression for SPK transplantation results in excellent patient and graft survival rates, a very low rate of acute rejection, and low rates of infection and malignancy.
C1 Northwestern Univ, Sch Med, Dept Surg, Div Transplantat, Chicago, IL 60611 USA.
RP Kaufman, DB (corresponding author), Northwestern Univ, Sch Med, Dept Surg, Div Transplantat, 303 E Super St,Passavant Pavil,Suite 535, Chicago, IL 60611 USA.
EM d-kaufman2@nwu.edu
RI Abecassis, Michael/F-7977-2011; Kaufman, Dixon B/E-4524-2016
CR *AM DIAB ASS, 1998, DIABETES CARE S1, V21, pS79
   Bartlett ST, 1996, ANN SURG, V224, P440, DOI 10.1097/00000658-199610000-00003
   Benedetti E, 1996, J AM COLL SURGEONS, V183, P307
   Bruce D. S., 1997, Acta Diabetologica, V34, P161
   BUSING M, 1997, ACTA DIABETOL, V34, P126
   Corry R. J., 1997, Acta Diabetologica, V34, P125
   Demirbas A, 1997, TRANSPLANT P, V29, P2903, DOI 10.1016/S0041-1345(97)00723-9
   DUNN DL, 1991, TRANSPLANTATION, V51, P150, DOI 10.1097/00007890-199101000-00023
   GRUESSNER A, 1997, CLIN TRANSPLANTS 199, P47
   GRUESSNER AC, 1998, CLIN TRANS, P45
   Gruessner RWG, 1998, TRANSPLANTATION, V66, P318, DOI 10.1097/00007890-199808150-00007
   Gruessner RWG, 1997, CLIN TRANSPLANT, V11, P299
   Gruessner RWG, 1996, TRANSPLANTATION, V61, P261, DOI 10.1097/00007890-199601270-00018
   GRUESSNER RWG, 1994, SURG ROUNDS, V17, P311
   GRUESSNER RWG, 1994, SURG ROUNDS, V17, P383
   Kaufman D. B., 1997, Acta Diabetologica, V34, P120
   La Rocca E, 1998, TRANSPLANTATION, V65, P390, DOI 10.1097/00007890-199802150-00016
   NGHIEM DD, 1987, AM J SURG, V153, P405, DOI 10.1016/0002-9610(87)90588-5
   Ryan EA, 1998, LANCET, V351, P1072, DOI 10.1016/S0140-6736(98)22015-0
   Segondy M, 1996, TRANSPLANT P, V28, P2810
   SOLLINGER HW, 1995, TRANSPLANTATION, V60, P225, DOI 10.1097/00007890-199508000-00003
   SOLLINGER HW, 1993, SURGERY, V114, P736
   Sollinger HW, 1998, ANN SURG, V228, P284, DOI 10.1097/00000658-199809000-00002
   Stegall MD, 1997, TRANSPLANTATION, V64, P1695, DOI 10.1097/00007890-199712270-00011
   Stratta RJ, 1997, TRANSPL P, V29, P654, DOI 10.1016/S0041-1345(96)00383-1
NR 25
TC 51
Z9 52
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0041-1337
EI 1534-6080
J9 TRANSPLANTATION
JI Transplantation
PD FEB 27
PY 1999
VL 67
IS 4
BP 586
EP 593
DI 10.1097/00007890-199902270-00017
PG 8
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 172XL
UT WOS:000078950900017
PM 10071032
DA 2021-08-04
ER

PT J
AU Jacobs, K
AF Jacobs, K
TI Incomplete markets and security prices: Do asset-pricing puzzles result
   from aggregation problems?
SO JOURNAL OF FINANCE
LA English
DT Article
ID EQUITY PREMIUM PUZZLE; TEMPORAL BEHAVIOR; HABIT FORMATION;
   RISK-AVERSION; LIQUIDITY CONSTRAINTS; CONSUMPTION GROWTH;
   GENERALIZED-METHOD; PANEL DATA; SUBSTITUTION; RETURNS
AB This paper investigates Euler equations involving security prices and household-level consumption data. It provides a useful complement to many existing studies of consumption-based asset pricing models that use a representative-agent framework, because the Euler equations under investigation hold even if markets are incomplete. It also provides a useful complement to simulation-based studies of market incompleteness. The empirical evidence indicates that the theory is rejected by the data along several dimensions. The results therefore indicate that some well-documented asset-pricing puzzles do not result from aggregation problems for the preferences under investigation.
C1 McGill Univ, Fac Management, Montreal, PQ H3A 2T5, Canada.
RP Jacobs, K (corresponding author), McGill Univ, Fac Management, Montreal, PQ H3A 2T5, Canada.
CR ABEL AB, 1990, AM ECON REV, V80, P38
   ALTUG S, 1990, ECONOMETRICA, V58, P543, DOI 10.2307/2938190
   ALTUG S, 1994, DYNAMIC CHOICE ASSET
   Attanasio O, 1996, J POLIT ECON, V104, P1227, DOI 10.1086/262058
   ATTANASIO OP, 1993, REV ECON STUD, V60, P631, DOI 10.2307/2298128
   ATTANASIO OP, 1995, J POLIT ECON, V103, P1121, DOI 10.1086/601443
   Attanasio OP, 1995, AM ECON REV, V85, P1118
   BRAV A, 1996, EMPIRICAL RESURRECTI
   BURNSIDE C, 1994, J BUS ECON STAT, V12, P57, DOI 10.2307/1391924
   Campbell J. Y., 1995, 4995 NBER
   CECCHETTI SG, 1994, J FINANC, V49, P123, DOI 10.2307/2329138
   Chamberlain G, 1984, HDB ECONOMETRICS, V2
   COCHRANE JH, 1991, J POLIT ECON, V99, P957, DOI 10.1086/261785
   COCHRANE JH, 1992, 1992 NBER MACROECONO
   Constantinides GM, 1996, J POLIT ECON, V104, P219, DOI 10.1086/262023
   CONSTANTINIDES GM, 1990, J POLIT ECON, V98, P519, DOI 10.1086/261693
   Deaton A., 1992, UNDERSTANDING CONSUM
   DETEMPLE JB, 1991, ECONOMETRICA, V59, P1633, DOI 10.2307/2938283
   DUNN KB, 1986, J FINANC ECON, V17, P27, DOI 10.1016/0304-405X(86)90005-X
   EICHENBAUM MS, 1988, Q J ECON, V103, P51, DOI 10.2307/1882642
   EPSTEIN LG, 1990, J MONETARY ECON, V26, P387, DOI 10.1016/0304-3932(90)90004-N
   EPSTEIN LG, 1991, J POLIT ECON, V99, P263, DOI 10.1086/261750
   EPSTEIN LG, 1989, ECONOMETRICA, V57, P937, DOI 10.2307/1913778
   GROSSMAN SJ, 1981, AM ECON REV, V71, P222
   GROSSMAN SJ, 1982, J FINANC ECON, V10, P195, DOI 10.1016/0304-405X(82)90013-7
   GROSSMAN SJ, 1987, J BUS ECON STAT, V5, P315, DOI 10.2307/1391605
   HALL RE, 1982, ECONOMETRICA, V50, P461, DOI 10.2307/1912638
   HANSEN LP, 1982, ECONOMETRICA, V50, P1029, DOI 10.2307/1912775
   HANSEN LP, 1984, ECONOMETRICA, V52, P267, DOI 10.2307/1911486
   HANSEN LP, 1983, J POLIT ECON, V91, P249, DOI 10.1086/261141
   HANSEN LP, 1991, J POLIT ECON, V99, P225, DOI 10.1086/261749
   HANSEN LP, 1982, ECONOMETRICA, V50, P1269, DOI 10.2307/1911873
   HAYASHI F, 1995, UNPUB RISK SHARING F
   HEATON J, 1993, ECONOMETRICA, V61, P353, DOI 10.2307/2951555
   Heaton J, 1996, J POLIT ECON, V104, P443, DOI 10.1086/262030
   HOTZ VJ, 1988, ECONOMETRICA, V56, P335, DOI 10.2307/1911075
   Kocherlakota NR, 1996, J ECON LIT, V34, P42
   LUCAS DJ, 1994, J MONETARY ECON, V34, P325, DOI 10.1016/0304-3932(94)90022-1
   Luttmer EGJ, 1996, ECONOMETRICA, V64, P1439, DOI 10.2307/2171838
   MACE BJ, 1991, J POLIT ECON, V99, P928, DOI 10.1086/261784
   MANKIW N, 1991, J FINANC ECON, V29, P113
   MANKIW NG, 1985, Q J ECON, V100, P225, DOI 10.2307/1885743
   MANKIW NG, 1990, 3402 NBER
   MEHRA R, 1985, J MONETARY ECON, V15, P145, DOI 10.1016/0304-3932(85)90061-3
   NEWEY WK, 1985, J ECONOMETRICS, V29, P229
   RIOSRULL JV, 1994, J MONETARY ECON, V34, P463, DOI 10.1016/0304-3932(94)90029-9
   RUNKLE DE, 1991, J MONETARY ECON, V27, P73, DOI 10.1016/0304-3932(91)90005-9
   SHILLER RJ, 1982, CARNEGIE-ROCHESTER C, V17, P203, DOI DOI 10.1016/0167-2231(82)90046-X
   TELMER CI, 1993, J FINANC, V48, P1803, DOI 10.2307/2329068
   WEIL P, 1989, J MONETARY ECON, V24, P401, DOI 10.1016/0304-3932(89)90028-7
   WEIL P, 1990, Q J ECON, V105, P28
   ZELDES SP, 1989, J POLIT ECON, V97, P305, DOI 10.1086/261605
NR 52
TC 21
Z9 21
U1 0
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-1082
EI 1540-6261
J9 J FINANC
JI J. Financ.
PD FEB
PY 1999
VL 54
IS 1
BP 123
EP 163
DI 10.1111/0022-1082.00100
PG 41
WC Business, Finance; Economics
SC Business & Economics
GA 164HP
UT WOS:000078457800004
DA 2021-08-04
ER

PT S
AU Aharonov-Barki, R
   Beker, T
   Ruppin, E
AF Aharonov-Barki, R
   Beker, T
   Ruppin, E
BE Floreano, D
   Nicoud, JD
   Mondada, F
TI Spontaneous evolution of command neurons, place cells and memory
   mechanisms in autonomous agents
SO ADVANCES IN ARTIFICIAL LIFE, PROCEEDINGS
SE LECTURE NOTES IN ARTIFICIAL INTELLIGENCE
LA English
DT Article; Proceedings Paper
CT 5th European Conference on Artificial Life (ECAL)
CY SEP 13-17, 1999
CL LAUSANNE, SWITZERLAND
SP Latsis Fdn, Swissair, K Team S A, Cyberbotics Ltd, Aarhus Univ, LEGO Lab, Cyberlife Technol Ltd
AB Using evolutionary simulations, we develop autonomous agents controlled by artificial neural networks (ANNs). In simple life-like tasks of foraging and navigation, high performance levels are attained by agents equipped with fully-recurrent ANN controllers. Examining several experimental settings, differing in the sensory input available to the agents, we find a common structure of a "command neuron" switching the dynamics of the network between radically different behavioural modes. In some of the models the command neuron reflects a map of the environment, acting as a "place cell". In others it is based on a spontaneously evolving short-term memory mechanism. The resemblance to known findings from neurobiology places Evolved ANNs as an excellent candidate model for the study of structure and function relation in complex nervous systems.
C1 Hebrew Univ Jerusalem, Ctr Computat Neurosci, Jerusalem, Israel.
   Tel Aviv Univ, Sch Med, IL-69978 Tel Aviv, Israel.
   Tel Aviv Univ, Sch Mat Sci, IL-69978 Tel Aviv, Israel.
RP Aharonov-Barki, R (corresponding author), Hebrew Univ Jerusalem, Ctr Computat Neurosci, Jerusalem, Israel.
RI Ruppin, Eytan/R-9698-2017
OI Ruppin, Eytan/0000-0002-7862-3940
CR Amit D. J., 1989, MODELING BRAIN FUNCT
   CANGELOSI A, 1994, NETWORK, P497
   Floreano D, 1996, IEEE T SYST MAN CY B, V26, P396, DOI 10.1109/3477.499791
   Fogel DB., 1995, EVOLUTIONARY COMPUTA
   Harrald P. G., 1997, IEEE Transactions on Evolutionary Computation, V1, P40, DOI 10.1109/4235.585891
   Hertz J., 1991, INTRO THEORY NEURAL
   Jakobi N, 1997, ADAPT BEHAV, V6, P325, DOI 10.1177/105971239700600205
   Kitano H., 1990, Complex Systems, V4, P461
   Martin PD, 1998, BRAIN RES, V783, P249, DOI 10.1016/S0006-8993(97)01369-3
   MITCHELL M, 1996, INTRO GENETIC ALGORI
   Scheier C, 1998, NEURAL NETWORKS, V11, P1551, DOI 10.1016/S0893-6080(98)00084-7
   TEYKE T, 1990, SCIENCE, V247, P85, DOI 10.1126/science.2294596
NR 12
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 0302-9743
BN 3-540-66452-1
J9 LECT NOTES ARTIF INT
PY 1999
VL 1674
BP 246
EP 255
PG 10
WC Computer Science, Artificial Intelligence
SC Computer Science
GA BS52B
UT WOS:000170202200031
DA 2021-08-04
ER

PT S
AU Berrah, AR
   Laboissiere, R
AF Berrah, AR
   Laboissiere, R
BE Floreano, D
   Nicoud, JD
   Mondada, F
TI SPECIES: An evolutionary model for the emergence of phonetic structures
   in an artificial society of speech agents
SO ADVANCES IN ARTIFICIAL LIFE, PROCEEDINGS
SE LECTURE NOTES IN ARTIFICIAL INTELLIGENCE
LA English
DT Article; Proceedings Paper
CT 5th European Conference on Artificial Life (ECAL)
CY SEP 13-17, 1999
CL LAUSANNE, SWITZERLAND
SP Latsis Fdn, Swissair, K Team S A, Cyberbotics Ltd, Aarhus Univ, LEGO Lab, Cyberlife Technol Ltd
ID VOWEL SYSTEMS
AB This paper addresses the emergence of a common phonetic code in a society of communicating speech agents using evolutionary techniques. Predictions for the large vowel systems of the world's languages using the Maximum Use of Available distinctive Features (MUAF) principle are discussed. Simulations of the use of supplementary phonetic features in large vowel systems axe presented. These experimental results show how simple local rules of interaction between speaking agents are sufficient to explain some of the universal characteristics of the phonological structure of the world's languages.
C1 LORIA, F-54506 Vandoeuvre Les Nancy, France.
   INPG, Inst Commun Parlee, F-38031 Grenoble, France.
RP Berrah, AR (corresponding author), LORIA, BP 239, F-54506 Vandoeuvre Les Nancy, France.
RI Laboissiere, Rafael/E-9814-2013
OI Laboissiere, Rafael/0000-0002-2180-9250
CR BERRAH AR, 1998, THESIS I NATL POLYTE
   Chomsky Noam., 1968, SOUND PATTERN ENGLIS
   de Boer B., 1997, P 4 EUR C ART LIF, P503
   Fant G., 1960, ACOUSTIC THEORY SPEE
   GLOTIN H, 1996, COLLECTIF SOCIAL ACT, P113
   LILJENCRANTS J, 1972, LANGUAGE, V48, P839, DOI 10.2307/411991
   LINDBLOM B, 1997, EVOLUTION HUMAN LANG
   MADDIESON I, 1986, PATTERNS SOUNDS
   MADDIESON I, 1990, UCLA WORKING PAPERS, V74, P104
   OHALA JJ, 1980, 9 INT C PHON SCI, V3, P181
   Schwartz JL, 1997, J PHONETICS, V25, P255, DOI 10.1006/jpho.1997.0043
   STEELS L, 1997, EVOLUTION HUMAN LANG
   VALLEE N, 1994, THESIS U STENDHAL GR
NR 13
TC 3
Z9 4
U1 0
U2 1
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 0302-9743
BN 3-540-66452-1
J9 LECT NOTES ARTIF INT
PY 1999
VL 1674
BP 674
EP 678
PG 5
WC Computer Science, Artificial Intelligence
SC Computer Science
GA BS52B
UT WOS:000170202200088
DA 2021-08-04
ER

PT J
AU Kroep, JR
   Pinedo, HM
   van Groeningen, CJ
   Peters, GJ
AF Kroep, JR
   Pinedo, HM
   van Groeningen, CJ
   Peters, GJ
TI Experimental drugs and drug combinations in pancreatic cancer
SO ANNALS OF ONCOLOGY
LA English
DT Article; Proceedings Paper
CT Conference on Biliopancreatic Malignancy - From Gene to Cure
CY FEB 04-06, 1999
CL AMSTERDAM, NETHERLANDS
SP Byk Nederland BV, Astra Pharmaceutica, Janssen Res Fdn
DE chemotherapy; 5-fluorouracil; gemcitabine; pancreatic carcinoma
ID PHASE-II TRIAL; PREVIOUSLY UNTREATED PATIENTS; HIGH-DOSE LEUCOVORIN;
   METASTATIC ADENOCARCINOMA; POTENTIAL APPLICATION; FLUOROURACIL;
   5-FLUOROURACIL; GEMCITABINE; ADENOVIRUS; TOPOTECAN
AB The current role of chemotherapy in pancreatic cancer is limited. Chemotherapy usually consists of 5-fluorouracil (5FU) and gemcitabine either as a single agent or in combinations. However, response rates are below 15% with minor effects on overall survival. Due to the aggressive behavior of the disease, current emphasis of new experimental chemotherapy is also focusing on clinical benefit: improvement of pain, performance status or weight. The results with gemcitabine indicated that evaluation of new chemotherapeutic agents in pancreatic cancer should not be limited to the evaluation of response rates; single agent gemcitabine not only showed higher response rates than 5FU, but also resulted in clinical benefit for the patients. Several new agents have been introduced into the clinic for treatment of various,oastro-intestinal malignancies, whereas novel agents with different types of targets, such as marimastat deserve further attention. Several oral formulations of 5FU, such as capecitabine, UFT, and eniluracil with 5FU, aim to simulate long-term continuous infusion. Response rates of these formulations are comparable to those of 5FU continuous infusion and 5FU bolus injections. However, the convenience of oral administration with reliable plasma drug concentrations makes these agents very attractive as a replacement of traditional 5FU administration. Since 5FU acts by inhibition of thymidylate synthase (TS), resulting in inhibition of DNA synthesis, several new antifolates, directed towards TS, have been developed. However, these agents, such as ZD1694 (Tomudex, Raltitrexed) and LY231514 (MTA, multitargetted antifolate) showed only limited efficacy. Other new agents active in colorectal cancer, e.g. the topoisomerase I inhibitors topotecan and CPT-11, showed only minor activity. The same was observed for the taxanes. Combinations of gemcitabine (cisplatin, 5FU, epirubicin, marimastat) show promising activities, not only regarding response but also with respect to clinical benefit. The effects were better than that for each agent separately. Thus, despite limited activity of single agents, novel combinations especially with gemcitabine are promising, with emphasis on improvement of the clinical benefit of patients.
C1 Free Univ Amsterdam Hosp, Dept Med Oncol, NL-1007 MB Amsterdam, Netherlands.
RP Peters, GJ (corresponding author), Free Univ Amsterdam Hosp, Dept Med Oncol, PO Box 7057, NL-1007 MB Amsterdam, Netherlands.
EM gj.peters@azvu.nl
OI Kroep, Judith/0000-0003-2671-1903
CR Aapro MS, 1998, ANTI-CANCER DRUG, V9, P191, DOI 10.1097/00001813-199803000-00001
   Abad A, 1998, ANN ONCOL, V9, P53
   AHLGREN JD, 1996, CANCER, V78, P653
   ALGREN JD, 1992, GASTROINTESTINAL ONC, P227
   Androulakis N, 1998, ANN ONCOL, V9, P54
   Baker SD, 1996, J CLIN ONCOL, V14, P3085, DOI 10.1200/JCO.1996.14.12.3085
   BLACKSTOCK AW, 1998, P AN M AM SOC CLIN, V17, pA264
   Borner MM, 1998, ANN ONCOL, V9, P51
   Bramhall SR, 1997, INT J PANCREATOL, V21, P1
   Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403
   CARMICHAEL J, 1998, P AN M AM SOC CLIN, V17, pA232
   CASCINU S, 1998, P AN M AM SOC CLIN, V17, pA264
   CASPER ES, 1994, INVEST NEW DRUG, V12, P29, DOI 10.1007/BF00873232
   COLUCCI G, 1998, P AN M AM SOC CLIN, V17, pA289
   CROWN J, 1991, J CLIN ONCOL, V9, P1682, DOI 10.1200/JCO.1991.9.9.1682
   De Gusmao CBRA, 1998, P AN M AM SOC CLIN, V17, p290a
   DECAPRIO JA, 1991, J CLIN ONCOL, V9, P2128, DOI 10.1200/JCO.1991.9.12.2128
   Dergham ST, 1997, INT J PANCREATOL, V21, P127
   Diasio RB, 1998, ONCOLOGY-NY, V12, P23
   ETIENNE MC, 1995, J CLIN ONCOL, V13, P1663, DOI 10.1200/JCO.1995.13.7.1663
   FINDLAY M, 1997, P AN M AM SOC CLIN, V16, P227
   Freytag SO, 1998, HUM GENE THER, V9, P1323, DOI 10.1089/hum.1998.9.9-1323
   Hall AR, 1998, NAT MED, V4, P1068, DOI 10.1038/2057
   HEINEMANN V, 1997, EUR J CANC S8, V33, P274
   Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639
   HOFFMAN JP, 1998, P AN M AM SOC CLIN, V17, pA283
   HUANG P, 1992, ANAL BIOCHEM, V207, P163, DOI 10.1016/0003-2697(92)90518-C
   HUANG P, 1991, CANCER RES, V51, P6110
   KELSEN D, 1991, CANCER, V68, P965, DOI 10.1002/1097-0142(19910901)68:5<965::AID-CNCR2820680509>3.0.CO;2-2
   LUCEK A, 1998, ANN ONCOL         S4, V9, P52
   Lutz MP, 1998, ANN ONCOL, V9, P54
   McGinn C, 1998, P AN M AM SOC CLIN, V17, p264a
   Miller KD, 1998, ANN ONCOL, V9, P46
   Mohammad RM, 1998, CLIN CANCER RES, V4, P887
   Mohammad RM, 1998, PANCREAS, V16, P19, DOI 10.1097/00006676-199801000-00004
   MULVIHILL SJ, 1998, P AN M AM SOC CLIN, V17, P211
   OReilly S, 1996, ANTI-CANCER DRUG, V7, P410, DOI 10.1097/00001813-199606000-00006
   OSTER MW, 1986, CANCER, V57, P29, DOI 10.1002/1097-0142(19860101)57:1<29::AID-CNCR2820570108>3.0.CO;2-L
   PAZDUR R, 1992, CANCER, V70, P2073, DOI 10.1002/1097-0142(19921015)70:8<2073::AID-CNCR2820700810>3.0.CO;2-A
   Pazdur R, 1995, INVEST NEW DRUG, V13, P355, DOI 10.1007/BF00873144
   Peters G. J., 1996, PRINCIPLES ANTINEOPL
   PETERS GJ, 1994, J CLIN ONCOL, V12, P2035, DOI 10.1200/JCO.1994.12.10.2035
   PETERS GJ, 1996, EXPERT OPIN INV DRUG, V5, P637
   Pettit GR, 1995, ANTI-CANCER DRUG DES, V10, P529
   Pinedo, 1997, ONCOLOGIST, V2, P127
   Plunkett W, 1995, ANTI-CANCER DRUG, V6, P7, DOI 10.1097/00001813-199512006-00002
   Polyzos A, 1998, ANN ONCOL, V9, P55
   Raderer M, 1998, ANN ONCOL, V9, P169
   ROSVOLD E, 1992, CANCER CHEMOTH PHARM, V29, P305
   Rothenberg ML, 1996, ANN ONCOL, V7, P347
   Rothmann T, 1998, J VIROL, V72, P9470, DOI 10.1128/JVI.72.12.9470-9478.1998
   Ruiz van Haperen V W, 1993, Biochem Pharmacol, V46, P762, DOI 10.1016/0006-2952(93)90566-F
   SCHEITHAUER W, 1992, CANCER, V70, P1864, DOI 10.1002/1097-0142(19921001)70:7<1864::AID-CNCR2820700709>3.0.CO;2-D
   Scher RM, 1995, INVEST NEW DRUG, V13, P347, DOI 10.1007/BF00873143
   Schilsky RL, 1998, ONCOLOGY-NY, V12, P13
   Schilsky RL, 1998, J CLIN ONCOL, V16, P1450, DOI 10.1200/JCO.1998.16.4.1450
   Stevenson JP, 1998, EUR J CANCER, V34, P1358, DOI 10.1016/S0959-8049(98)00053-7
   TOLIS C, 1999, IN PRESS EUR J CANC
   TWELVES C, 1996, P AN M AM SOC CLIN, V15, P476
   WAGENER DJT, 1995, ANN ONCOL, V6, P129, DOI 10.1093/oxfordjournals.annonc.a059107
   Whitehead RP, 1997, J CLIN ONCOL, V15, P2414, DOI 10.1200/JCO.1997.15.6.2414
   Wilki N, 1998, ANN ONCOL, V9, P46
   WOLFF RA, 1998, P AN M AM SOC CLIN, V17, pA283
NR 63
TC 28
Z9 28
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PY 1999
VL 10
SU 4
BP 234
EP 238
DI 10.1023/A:1008399927983
PG 5
WC Oncology
SC Oncology
GA 222RT
UT WOS:000081799100059
PM 10436830
DA 2021-08-04
ER

PT S
AU Cozien, RF
   Colautti, A
AF Cozien, RF
   Colautti, A
BE Bosacchi, B
   Fogel, DB
   Bezdek, JC
TI Project DANA: multi-agents simulations and fuzzy rules for international
   crisis detection: can we forestall wars?
SO APPLICATIONS AND SCIENCE OF NEURAL NETWORKS, FUZZY SYSTEMS, AND
   EVOLUTIONARY COMPUTATION II
SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
   (SPIE)
LA English
DT Proceedings Paper
CT Conference on Applications and Science of Neural Networks, Fuzzy
   Systems, and Evolutionary Computation II
CY JUL 19-20, 1999
CL DENVER, CO
DE agents; fuzzy logic; simulation; international crisis; war
AB Assessing the conflicting potential of an international situation is very important in the exercise of Defence duty. Mastering a formal method allowing the detection of risky situations is a necessity. Our aim was to develop a highly operational method twinned with a computer simulation tool which can explore a huge number of potential war zones, and can test many hypotheses with high accuracy within reasonable time. We use a multi-agents system to describe an international situation. The agent coding allows us to give computer existence to very abstract concepts such as: a government, the economy, the armed forces, the foreign policy. We give to these agents fuzzy rules of behavior, those rules represent human expertise. In order to yardstick our model we used the Falklands war to make our first simulations. The main distortion between the historical reality and our simulations comes from our fuzzy controller which causes a great loss of information. We are going to change it to a more efficient one in order to fit the historical reality. Agent coding with fuzzy rules allows human experts to keep close to their statements and expertise, and they can handle this kind of tool quite easily.
C1 Ctr Rech St Cyr, Ecoles Mil Coetquidan, French Dept Def, F-56381 Guer, France.
RP Cozien, RF (corresponding author), Ctr Rech St Cyr, Ecoles Mil Coetquidan, French Dept Def, F-56381 Guer, France.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 0-8194-3298-9
J9 P SOC PHOTO-OPT INS
PY 1999
VL 3812
BP 94
EP 105
DI 10.1117/12.367686
PG 12
WC Computer Science, Artificial Intelligence; Computer Science,
   Interdisciplinary Applications; Computer Science, Theory & Methods;
   Optics
SC Computer Science; Optics
GA BP12P
UT WOS:000084198700010
DA 2021-08-04
ER

PT S
AU Liu, J
   Shragowitz, E
AF Liu, J
   Shragowitz, E
BE Bosacchi, B
   Fogel, DB
   Bezdek, JC
TI Application of fuzzy logic in intelligent software agents for IP
   selection
SO APPLICATIONS AND SCIENCE OF NEURAL NETWORKS, FUZZY SYSTEMS, AND
   EVOLUTIONARY COMPUTATION II
SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
   (SPIE)
LA English
DT Proceedings Paper
CT Conference on Applications and Science of Neural Networks, Fuzzy
   Systems, and Evolutionary Computation II
CY JUL 19-20, 1999
CL DENVER, CO
DE Intellectual Property; hardware design; hardware/software codesign;
   software agent; Internet; fuzzy logic; framework
AB IPs (Intellectual Properties) are becoming increasingly essential in today's electronic system design. One of important issues in design reuse is the IP selection, i.e. finding an existing solution that matches the user's expectations best. This paper describes the Internet-based intelligent software system (Software Agent) that helps the user to pick out the optimal designs among those marketed by the IP vendors. The Software Agent For IP Selection (SAFIPS) conducts dialogues with both the IP users and IP vendors, narrowing the choices after evaluating general characteristics first, followed by matching behavioral, RTL, logic, and physical levels. The SAFIPS system conducts reasoning based on fuzzy logic rules derived in the process of dialogues of the software agent with the IP users and vendors. in addition to the dialogue system and fuzzy logic inference system, the SAFIPS includes a HDL simulator and fuzzy logic evaluator that are used to measure the level of matching of the user's behavioral model with the IP vendor's model.
C1 Univ Minnesota, Dept Comp Engn & Sci, Minneapolis, MN 55455 USA.
RP Shragowitz, E (corresponding author), Univ Minnesota, Dept Comp Engn & Sci, 4-192 EE-CS Bldg 200 Union St SE, Minneapolis, MN 55455 USA.
CR CAMPBELL M, 1994, MICROSOFT ACCESS HDB
   DALPASSO ABM, 1999, P DAC, P50
   DOORENBOS RB, 1996, SCALABLE COMP SHOPPI
   KEATING M, 1998, REUSE METHODOLOGY MA
   OEHLER P, 1998, P IP C FRANKF, P229
   VOLLRATH I, 1998, P 4 EUR WORKSH ADV C
   YAGER R, 1977, INT J MAN MACH STUD, V9, P378
   YAGER R, 1995, THEORETICAL ASPECTS, P1
NR 8
TC 2
Z9 2
U1 0
U2 0
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 0-8194-3298-9
J9 P SOC PHOTO-OPT INS
PY 1999
VL 3812
BP 168
EP 175
DI 10.1117/12.367693
PG 8
WC Computer Science, Artificial Intelligence; Computer Science,
   Interdisciplinary Applications; Computer Science, Theory & Methods;
   Optics
SC Computer Science; Optics
GA BP12P
UT WOS:000084198700016
DA 2021-08-04
ER

PT S
AU Finch, S
   Cumming, G
   Les, J
AF Finch, S
   Cumming, G
   Les, J
BE Lajoie, SP
   Vivet, M
TI Agents for diversity in statistics education
SO ARTIFICIAL INTELLIGENCE IN EDUCATION: OPEN LEARNING ENVIRONMENTS: NEW
   COMPUTATIONAL TECHNOLOGIES TO SUPPORT LEARNING, EXPLORATION AND
   COLLABORATION
SE Frontiers in Artificial Intelligence and Applications
LA English
DT Proceedings Paper
CT 9th International Conference on Artificial Intelligence in Education
   (AI-ED 99)
CY JUL 19-23, 1999
CL LE MANS, FRANCE
SP Int Artificial Intelligence Educ Soc, Univ Main & Lium Lab, City of Le Mans & Urban Community, Gen Council Sarthe, Council Reg Pays Loire & ATLANTECH, Chamber Commerce & Ind Le Mans, CNRS
AB Working with multiple representations can help students overcome the notorious difficulties of understanding statistics, but does raise difficulties. StatPlay, our simulation environment for beginning statistics, includes Sam, a voice-demonstration recording and playback facility. Sam provides students with 'demos' that give guidance, feedback and explanations based on StatPlay's multiple representations. Multiple situated agents are identified with the many different representations of a statistical concept. They monitor user behaviour and provide access to a rich resource of multiple explanations in a Sam database.
C1 La Trobe Univ, Sch Psychol Sci, Bundoora, Vic 3083, Australia.
RP Finch, S (corresponding author), La Trobe Univ, Sch Psychol Sci, Bundoora, Vic 3083, Australia.
EM s.finch@latrobe.edu.au; g.cumming@latrobe.edu.au; j.les@latrobe.edu.au
CR FALK R, 1995, THEOR PSYCHOL, V5, P75, DOI 10.1177/0959354395051004
   FINCH S, 1998, STAT ED EXPANDING NE
   Les J, 1997, FR ART INT, V39, P466
   LES J, 1997, P ASCILITE97 14 ANN
   THOMASON N, 1994, INTERACTIVE MUTLIMED
NR 5
TC 0
Z9 0
U1 0
U2 0
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 0922-6389
BN 90-5199-452-4
J9 FRONT ARTIF INTEL AP
PY 1999
VL 50
BP 670
EP 672
PG 3
WC Computer Science, Artificial Intelligence; Computer Science,
   Interdisciplinary Applications
SC Computer Science
GA BP25X
UT WOS:000084508300090
DA 2021-08-04
ER

PT J
AU Neuhaus, SJ
   Ellis, TS
   Barrett, MW
   Rofe, AM
   Jamieson, GG
   Watson, DI
AF Neuhaus, SJ
   Ellis, TS
   Barrett, MW
   Rofe, AM
   Jamieson, GG
   Watson, DI
TI In vitro inhibition of tumour growth in a helium-rich environment:
   Implications for laparoscopic surgery
SO AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY
LA English
DT Article
DE cancer; carbon dioxide; helium; laparoscopy; tumour growth; insufflation
   gas
ID CARBON-DIOXIDE; PNEUMOPERITONEUM; CHOLECYSTECTOMY; INSUFFLATION; MODEL;
   CACHEXIA; CELLS
AB Background: The recent results of several experimental studies have suggested that tumour implantation after laparoscopic surgery for intra-abdominal malignancy may be partly related to the chemical composition of the insufflation gas used during surgery. These studies have demonstrated that the use of helium as a laparoscopic insufflation agent for cancer surgery results in less tumour implantation and growth at port sites. To further investigate these findings, the present study was performed to compare the growth of cultured tumour cells after exposure to simulated laparoscopic environments, rich in helium, carbon dioxide (CO2), or air.
   Methods: A rat mammary adenocarcinoma cell suspension was exposed to a simulated laparoscopic environment for 40 min in one of the following groups: (i) control (atmospheric air. equivalent to a 'gasless' laparoscopic environment): (ii) a CO2-rich environment; and (iii) a helium-rich environment. Cells were then cultured for 18 h and optical density readings wore used to assess the number of viable tumour cells at the end of this period. The experiment was performed twice using an identical protocol to ensure consistency in the results. In a further study, pH was continuously measured using an antimony probe during a 40 min insufflation period and for 10 min after insufflation.
   Results: Cell growth was significantly lower after incubation in the helium-rich environment compared to both the CO2 and control groups (P < 0.001). There was a significant decrease in pH in the CO2 group which was not observed during exposure to either air or helium.
   Conclusions: The inhibition of tumour growth in a helium-rich environment demonstrated by this study, and the reduced incidence of port-site metastases seen in other experimental studies. suggests that the clinical use of helium as an insufflation gas may have important advantages ol er CO2.
C1 Univ Adelaide, Royal Adelaide Hosp, Dept Surg, Royal Adelaide Ctr Endoscop Surg, Adelaide, SA 5000, Australia.
   Inst Med & Vet Sci, Adelaide, SA 5000, Australia.
RP Watson, DI (corresponding author), Univ Adelaide, Royal Adelaide Hosp, Dept Surg, Royal Adelaide Ctr Endoscop Surg, Adelaide, SA 5000, Australia.
OI Watson, David/0000-0002-7683-2693
CR BONGARD FS, 1993, SURG GYNECOL OBSTET, V177, P140
   BONGARD FS, 1991, JAMA-J AM MED ASSOC, V266, P3131, DOI 10.1001/jama.266.22.3131
   COYLE P, 1990, IMMUNOL CELL BIOL, V68, P147, DOI 10.1038/icb.1990.21
   CRUZ LF, 1994, ENDOSC SURG ALLIED T, V2, P300
   Gandara V, 1997, SURG ENDOSC, V11, P707, DOI 10.1007/s004649900432
   Jacobi CA, 1997, SURGERY, V121, P72, DOI 10.1016/S0039-6060(97)90185-9
   Junghans T, 1997, ARCH SURG-CHICAGO, V132, P272
   LEIGHTON T, 1992, AM SURGEON, V58, P717
   LEIGHTON TA, 1993, SURGERY, V113, P527
   LOWIK CWGM, 1993, ANAL BIOCHEM, V213, P426, DOI 10.1006/abio.1993.1442
   Mathew G, 1997, AUST NZ J SURG, V67, P289, DOI 10.1111/j.1445-2197.1997.tb01965.x
   Mathew G, 1996, BRIT J SURG, V83, P1087, DOI 10.1002/bjs.1800830815
   MCDERMOTT JP, 1995, ARCH SURG-CHICAGO, V130, P984
   MCMAHON AJ, 1994, BRIT J SURG, V81, P1033, DOI 10.1002/bjs.1800810736
   Naude G P, 1995, Endosc Surg Allied Technol, V3, P183
   Neuberger TJ, 1996, GASTROINTEST ENDOSC, V43, P38, DOI 10.1016/S0016-5107(06)80079-9
   Neuhaus SJ, 1998, ARCH SURG-CHICAGO, V133, P762, DOI 10.1001/archsurg.133.7.762
   Neuhaus SJ, 1998, SURGERY, V123, P579, DOI 10.1067/msy.1998.88089
   RADEMAKER BMP, 1995, J LAPAROENDOSC SURG, V5, P15, DOI 10.1089/lps.1995.5.15
   STOCKDALE AD, 1985, EUR J SURG ONCOL, V11, P373
   STOVROFF MC, 1989, J SURG RES, V46, P462, DOI 10.1016/0022-4804(89)90161-3
   Uchikoshi F, 1997, SURG LAPAROSC ENDOSC, V7, P196, DOI 10.1097/00019509-199706000-00003
   Volz J, 1996, AM J OBSTET GYNECOL, V174, P132, DOI 10.1016/S0002-9378(96)70385-X
   Watson DI, 1997, ARCH SURG-CHICAGO, V132, P166
   WOLF JS, 1994, J LAPAROENDOSC SURG, V4, P173, DOI 10.1089/lps.1994.4.173
NR 25
TC 31
Z9 33
U1 0
U2 0
PU BLACKWELL SCIENCE ASIA
PI CARLTON
PA 54 UNIVERSITY ST, P O BOX 378, CARLTON, VICTORIA 3053, AUSTRALIA
SN 0004-8682
J9 AUST NZ J SURG
JI Aust. N. Z. J. Surg.
PD JAN
PY 1999
VL 69
IS 1
BP 52
EP 55
DI 10.1046/j.1440-1622.1999.01495.x
PG 4
WC Surgery
SC Surgery
GA 157QA
UT WOS:000078072100015
PM 9932923
DA 2021-08-04
ER

PT J
AU Koedel, U
   Pfister, HW
AF Koedel, U
   Pfister, HW
TI Oxidative stress in bacterial meningitis
SO BRAIN PATHOLOGY
LA English
DT Review
ID EXPERIMENTAL PNEUMOCOCCAL MENINGITIS; NITRIC-OXIDE SYNTHASE; GROUP-B
   STREPTOCOCCI; SUPEROXIDE ANION RELEASE; OXYGEN FREE-RADICALS; CEREBRAL
   BLOOD-FLOW; HYDROGEN-PEROXIDE; ESCHERICHIA-COLI; HAEMOPHILUS-INFLUENZAE;
   ENDOTHELIAL-CELLS
AB Fifty years after the advent of antibiotics for clinical use, the rates of morbidity and mortality associated with bacterial meningitis remain high, The unfavourable clinical outcome is often due to intracranial complications including cerebrovascular insults, raised intracranial pressure, hydrocephalus, and brain edema, Reactive oxygen species (ROS) are known effector molecules in the antimicrobial armature of polymorphonuclear and mononuclear phagocytes. However, over the last decade, there has been a substantial body of work implicating a central role of ROS in the development of intracranial complications and brain damage in bacterial meningitis, Recently, it also became evident that reactive nitrogen species (RNS), especially nitric oxide, are important mediators of meningitis-associated pathophysiological changes, at least during the early phase of the disease, There is now substantial evidence that much of the oxidative injury associated by simultaneous production of superoxide and nitric oxide is mediated by the strong oxidant peroxynitrite, ROS and peroxynitrite can be cytotoxic via a number of independent mechanisms, Their cytotoxic effects include initiation of lipid peroxidation and induction of DNA single strand breakage. Damaged DNA activates poly(ADP-ribose) polymerase (PARP), Recent experimental data propose a role of lipid peroxidation and PARP activation in the development of meningitis-associated intracranial complications and brain injury. Agents which interfere with the production of ROS and peroxynitrite, as well as with PARR activation and lipid peroxidation may represent novel, therapeutic strategies to limit meningitis-associated brain damage, and, thus, to improve the outcome of this serious disease.
C1 Univ Munich, Klinikum Grosshadern, Dept Neurol, D-81377 Munich, Germany.
RP Pfister, HW (corresponding author), Univ Munich, Klinikum Grosshadern, Dept Neurol, Marchioninistr 15, D-81377 Munich, Germany.
EM Pfister.Imuneuro@nefo.med.uni-muenchen.de
CR ANACHKOVA B, 1989, CYTOBIOS, V59, P19
   Archibald F S, 1983, Acta Med Port, V4, P101
   ARCHIBALD FS, 1986, INFECT IMMUN, V51, P631, DOI 10.1128/IAI.51.2.631-641.1986
   BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205
   BAUTISTA AP, 1995, HEPATOLOGY, V21, P855, DOI 10.1002/hep.1840210336
   BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620
   Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424
   BECKMAN JS, 1990, NATURE, V345, P27, DOI 10.1038/345027b0
   BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299
   BERGER NA, 1995, BIOCHIMIE, V77, P364, DOI 10.1016/0300-9084(96)88147-8
   BERKOWITZ ID, 1993, FASEB J, V7, pA530
   BERNATOWICZ A, 1995, J NEUROIMMUNOL, V60, P53, DOI 10.1016/0165-5728(95)00053-5
   BERNHARDT LL, 1981, INFECT IMMUN, V32, P411, DOI 10.1128/IAI.32.1.411-413.1981
   BILLE MB, 1998, 38 INT C ANT AG CHEM
   BISHAI WR, 1994, J BACTERIOL, V176, P2914, DOI 10.1128/JB.176.10.2914-2921.1994
   BOHR V, 1984, ARCH NEUROL-CHICAGO, V41, P1045, DOI 10.1001/archneur.1984.04050210043012
   BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X
   BOJE KMK, 1995, J PHARMACOL EXP THER, V274, P1199
   Boje KMK, 1996, BRAIN RES, V720, P75, DOI 10.1016/0006-8993(96)00142-4
   BRACONIER JH, 1982, J LAB CLIN MED, V100, P279
   BRANDI G, 1989, FREE RADICAL RES COM, V6, P47, DOI 10.3109/10715768909073427
   BRIAN JE, 1995, AM J PHYSIOL-HEART C, V269, pH783
   BROWN EJ, 1995, BIOESSAYS, V17, P109, DOI 10.1002/bies.950170206
   BUSTER BL, 1995, INFECT IMMUN, V63, P3835, DOI 10.1128/IAI.63.10.3835-3839.1995
   CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253
   CHAO CC, 1995, J LEUKOCYTE BIOL, V58, P65
   COCHRANE CG, 1991, MOL ASPECTS MED, V12, P137, DOI 10.1016/0098-2997(91)90009-B
   COLTON CA, 1994, ANN NY ACAD SCI, V738, P54
   DANTONIO D, 1992, BONE MARROW TRANSPL, V9, P299
   DarleyUsmar V, 1996, PHARM RES-DORDR, V13, P649, DOI 10.1023/A:1016079012214
   DARLEYUSMAR V, 1995, FEBS LETT, V369, P131, DOI 10.1016/0014-5793(95)00764-Z
   DAWSON VL, 1994, NEUROPHARMACOLOGY, V33, P1425, DOI 10.1016/0028-3908(94)90045-0
   DAWSON VL, 1995, CLIN EXP PHARMACOL P, V22, P305, DOI 10.1111/j.1440-1681.1995.tb02005.x
   DEGROOTE MA, 1995, CLIN INFECT DIS, V21, pS162, DOI 10.1093/clinids/21.Supplement_2.S162
   DODGE PR, 1965, NEW ENGL J MED, V272, P954, DOI 10.1056/NEJM196505062721806
   DODGE PR, 1986, PEDIATR INFECT DIS J, V5, P618, DOI 10.1097/00006454-198611000-00002
   DUANE PG, 1993, INFECT IMMUN, V61, P4392, DOI 10.1128/IAI.61.10.4392-4397.1993
   DURAND ML, 1993, NEW ENGL J MED, V328, P21, DOI 10.1056/NEJM199301073280104
   ESPOSITO AL, 1990, APMIS, V98, P812, DOI 10.1111/j.1699-0463.1990.tb05001.x
   FREI K, 1993, J EXP MED, V178, P1255, DOI 10.1084/jem.178.4.1255
   Freyer D, 1996, GLIA, V16, P1, DOI 10.1002/(SICI)1098-1136(199601)16:1<1::AID-GLIA1>3.0.CO;2-8
   GONZALEZFLECHA B, 1995, J BIOL CHEM, V270, P13681, DOI 10.1074/jbc.270.23.13681
   GOROG P, 1988, ATHEROSCLEROSIS, V72, P19, DOI 10.1016/0021-9150(88)90058-5
   GRAMMAS P, 1993, FREE RADICAL BIO MED, V14, P553, DOI 10.1016/0891-5849(93)90113-9
   GUTTERIDGE JMC, 1995, CLIN CHEM, V41, P1819
   HABERL RL, 1994, NEUROL RES, V16, P108
   HALLIWELL B, 1994, LANCET, V344, P721, DOI 10.1016/S0140-6736(94)92211-X
   HALLIWELL B, 1992, ANN NEUROL, V32, pS10, DOI 10.1002/ana.410320704
   HASSETT DJ, 1989, FASEB J, V3, P2574
   HASSETT DJ, 1990, J BACTERIOL, V172, P7293, DOI 10.1128/jb.172.12.7293-7296.1990
   HELLER B, 1995, J BIOL CHEM, V270, P11176, DOI 10.1074/jbc.270.19.11176
   Hu SX, 1996, CLIN IMMUNOL IMMUNOP, V78, P93, DOI 10.1006/clin.1996.0015
   HYSLOP PA, 1995, FREE RADICAL BIO MED, V19, P31, DOI 10.1016/0891-5849(95)00005-I
   IKEDA Y, 1990, NEUROSURGERY, V27, P1
   ISMAIL G, 1977, P SOC EXP BIOL MED, V155, P264
   KIM YS, 1995, J INFECT DIS, V171, P1363, DOI 10.1093/infdis/171.5.1363
   Kim YS, 1996, INFECT IMMUN, V64, P3148, DOI 10.1128/IAI.64.8.3148-3153.1996
   Koedel U, 1997, NEUROSCI LETT, V225, P33, DOI 10.1016/S0304-3940(97)00177-8
   KOEDEL U, 1995, ANN NEUROL, V37, P313, DOI 10.1002/ana.410370307
   KOEDEL U, 1998, AKTUEL NEUROL, V25, pS99
   Kornelisse RF, 1996, J INFECT DIS, V174, P120, DOI 10.1093/infdis/174.1.120
   Korytko PJ, 1996, NEUROPHARMACOLOGY, V35, P231, DOI 10.1016/0028-3908(95)00162-X
   KROLL JS, 1991, J BACTERIOL, V173, P7449, DOI 10.1128/jb.173.23.7449-7457.1991
   Leib SL, 1998, J INFECT DIS, V177, P692, DOI 10.1086/514226
   Leib SL, 1996, J INFECT DIS, V173, P166, DOI 10.1093/infdis/173.1.166
   Leib SL, 1996, J CLIN INVEST, V98, P2632, DOI 10.1172/JCI119084
   LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1
   Lorenzl S, 1996, CRIT CARE MED, V24, P1874, DOI 10.1097/00003246-199611000-00018
   LORENZL S, 1995, J INFECT DIS, V172, P113, DOI 10.1093/infdis/172.1.113
   MacMicking JD, 1997, P NATL ACAD SCI USA, V94, P5243, DOI 10.1073/pnas.94.10.5243
   MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3
   MATSUBARA T, 1986, J IMMUNOL, V137, P3295
   MCCORD JM, 1995, P SOC EXP BIOL MED, V209, P112
   MCKNIGHT AA, 1992, PEDIATR RES, V31, P640, DOI 10.1203/00006450-199206000-00020
   MURPHY S, 1993, TRENDS NEUROSCI, V16, P323, DOI 10.1016/0166-2236(93)90109-Y
   NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6
   PACELLI R, 1995, J EXP MED, V182, P1469, DOI 10.1084/jem.182.5.1469
   Paul R, 1997, J CEREBR BLOOD F MET, V17, P985, DOI 10.1097/00004647-199709000-00008
   PFISTER HW, 1993, ARCH NEUROL-CHICAGO, V50, P575, DOI 10.1001/archneur.1993.00540060015010
   PFISTER HW, 1990, J CEREBR BLOOD F MET, V10, P914, DOI 10.1038/jcbfm.1990.148
   PFISTER HW, 1992, STROKE, V23, P1798, DOI 10.1161/01.STR.23.12.1798
   PFISTER HW, 1992, NEUROLOGY, V42, P1497, DOI 10.1212/WNL.42.8.1497
   PFISTER HW, 1992, J INFECT DIS, V166, P1442, DOI 10.1093/infdis/166.6.1442
   POMEROY SL, 1990, NEW ENGL J MED, V323, P1651, DOI 10.1056/NEJM199012133232402
   POYART C, 1995, FEMS MICROBIOL LETT, V131, P41, DOI 10.1016/0378-1097(95)00232-T
   QUAGLIARELLO V, 1992, NEW ENGL J MED, V327, P864, DOI 10.1056/NEJM199209173271208
   Quagliarello VJ, 1997, NEW ENGL J MED, V336, P708, DOI 10.1056/NEJM199703063361007
   RODENAS J, 1995, FREE RADICAL BIO MED, V18, P869, DOI 10.1016/0891-5849(94)00215-6
   Rupalla K, 1995, EUR J PHARMACOL, V294, P469, DOI 10.1016/0014-2999(95)00570-6
   SANCHEZRINCON DA, 1991, J BACTERIOL, V173, P6632, DOI 10.1128/jb.173.20.6632-6634.1991
   Schuchat A, 1997, NEW ENGL J MED, V337, P970, DOI 10.1056/NEJM199710023371404
   SCHWARTZ CE, 1983, J BIOL CHEM, V258, P6277
   SHALL S, 1994, MOL CELL BIOCHEM, V138, P71, DOI 10.1007/BF00928445
   Sigurdardottir B, 1997, ARCH INTERN MED, V157, P425, DOI 10.1001/archinte.157.4.425
   SIMBERKOFF MS, 1980, J LAB CLIN MED, V95, P362
   SKAPER SD, 1995, J NEUROCHEM, V64, P266
   SMITH AL, 1988, NEW ENGL J MED, V319, P1012, DOI 10.1056/NEJM198810133191510
   SMITH PG, 1977, LANCET, V2, P59
   Stahel PF, 1997, AM J PATHOL, V151, P897
   SYNNOTT MB, 1994, ARCH DIS CHILD-FETAL, V71, pF75, DOI 10.1136/fn.71.2.F75
   Szabo C, 1997, J CLIN INVEST, V100, P723, DOI 10.1172/JCI119585
   Szabo C, 1998, EUR J PHARMACOL, V350, P1, DOI 10.1016/S0014-2999(98)00249-0
   Szabo C, 1998, P NATL ACAD SCI USA, V95, P3867, DOI 10.1073/pnas.95.7.3867
   TOMASZ A, 1995, NEW ENGL J MED, V333, P514, DOI 10.1056/NEJM199508243330810
   Tomasz A, 1997, CLIN INFECT DIS, V24, pS85, DOI 10.1093/clinids/24.Supplement_1.S85
   TUREEN JH, 1998, 38 INT C ANT AG CHEM
   vanFurth AM, 1996, CLIN INFECT DIS, V22, P876, DOI 10.1093/clinids/22.5.876
   VISSER JJ, 1994, ANN INTERN MED, V120, P345, DOI 10.7326/0003-4819-120-4-199402150-00023
   WILSON CB, 1985, J INFECT DIS, V152, P323, DOI 10.1093/infdis/152.2.323
   ZAHRADKA P, 1994, MOL CELL BIOCHEM, V138, P91, DOI 10.1007/BF00928448
   ZHANG J, 1995, J NEUROCHEM, V65, P1411
   ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500
   ZHU L, 1992, ARCH BIOCHEM BIOPHYS, V298, P452, DOI 10.1016/0003-9861(92)90434-X
   Zingarelli B, 1998, CIRC RES, V83, P85, DOI 10.1161/01.RES.83.1.85
   ZWAHLEN A, 1982, J INFECT DIS, V145, P635, DOI 10.1093/infdis/145.2.635
   ZWEIER JL, 1994, J BIOL CHEM, V269, P24156
NR 116
TC 78
Z9 78
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1015-6305
EI 1750-3639
J9 BRAIN PATHOL
JI Brain Pathol.
PD JAN
PY 1999
VL 9
IS 1
BP 57
EP 67
PG 11
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA 164TG
UT WOS:000078479200007
PM 9989452
DA 2021-08-04
ER

PT J
AU Park, JM
   Shin, WG
   Yoon, DJ
AF Park, JM
   Shin, WG
   Yoon, DJ
TI A study of interfacial aspects of epoxy-based composites reinforced with
   dual basalt and SiC fibres by means of the fragmentation and acoustic
   emission techniques
SO COMPOSITES SCIENCE AND TECHNOLOGY
LA English
DT Article
DE acoustic emission; interfacial shear strength; amino-silane coupling
   agent; fragmentation test; one-to-one correspondence
ID SHEAR-STRENGTH; DURABILITY IMPROVEMENT; WEIBULL DISTRIBUTION; GRAPHITE
   FIBERS; FAILURE MODES; ADHESION; SIMULATION; SPECIMENS; NICALON; SILANES
AB Fibre/matrix interfacial properties and interfacial shear strengths (IFSS) in epoxy composites reinforced by dual basalt and SiC fibres (DFC) were investigated by the fragmentation method combined with acoustic emission (AE) analysis. Statistical analysis of fibre tensile strength was performed in terms of statistical parameters. The tensile strength and elongation of basalt and SIC fibres decreased with increasing gauge length because of the size effect. Fibre tensile strengths above an optimum concentration decreased because of the stress concentrations at lumps in the coating. When an amino-silane coupling agent was used, the IFSS showed significant improvements of more than three times under dry conditions. The IFSS was also considerably improved under wet conditions. This environmental effect is probably due to chemical and hydrogen bonds as well as to interdiffusion effects in two different interphases in the fibre/silane-coupling-agent/epoxy-matrix system. In situ monitoring of AE during the straining of DFC specimens showed the sequential occurrence of two distinct groups of AE data. The first group may have come from fibre breakages, and the second mainly from cracking of the epoxy matrix. Characteristic frequencies coming from the different failure modes of the fibres and epoxy matrix were investigated by fast Fourier transform (FFT) analysis. By setting an appropriate threshold level, a one-to-one correspondence between the number of AE events and fibre breakages was established. This AE method could be correlated well with the fragmentation technique of obtaining the IFSS value. It can be also be applied to semi- or non-transparent composites where visual observation is not possible. (C) 1999 Elsevier Science Ltd. All rights reserved.
C1 Gyeongsang Natl Univ, Reg Res Ctr Aircraft Technol, Dept Polymer Sci & Engn, Chinju 660701, South Korea.
   Korea Res Inst Stand & Sci, Failure Prevent Res Ctr, Taejon 305600, South Korea.
RP Park, JM (corresponding author), Gyeongsang Natl Univ, Reg Res Ctr Aircraft Technol, Dept Polymer Sci & Engn, Chinju 660701, South Korea.
CR DRZAL LT, 1983, J ADHESION, V16, P133, DOI 10.1080/00218468308074911
   GODA K, 1986, J MATER SCI, V21, P4475, DOI 10.1007/BF01106574
   GUTTMAN I, 1982, INTRO ENG STAT, P330
   HENSTENBURG RB, 1989, POLYM COMPOSITE, V10, P389, DOI 10.1002/pc.750100603
   ISHIKAWA T, 1994, COMPOS SCI TECHNOL, V51, P135, DOI 10.1016/0266-3538(94)90184-8
   JUNG T, 1993, J MATER SCI, V28, P4489, DOI 10.1007/BF01154961
   Kelly A, 1965, MECH PHYS SOLIDS, V13, P329, DOI DOI 10.1016/0022-5096(65)90035-9
   KING JA, 1993, POLYM COMPOSITE, V14, P301, DOI 10.1002/pc.750140405
   KLINE R, 1983, ACOUSTIC EMISSION
   MA BT, 1990, POLYM COMPOSITE, V11, P211, DOI 10.1002/pc.750110403
   NETRAVALI AN, 1989, COMPOS SCI TECHNOL, V34, P289, DOI 10.1016/0266-3538(89)90001-8
   NETRAVALI AN, 1989, POLYM COMPOSITE, V10, P226, DOI 10.1002/pc.750100405
   PARK JM, 1994, J ADHES SCI TECHNOL, V8, P133, DOI 10.1163/156856194X00113
   Park JM, 1996, POLYM COMPOSITE, V17, P375, DOI 10.1002/pc.10624
   PARK JM, 1991, J ADHES SCI TECHNOL, V5, P459, DOI 10.1163/156856191X00602
   PARK JM, 1995, P 10 INT C COMP MAT, V6, P573
   PATANKAR SN, 1991, J MATER SCI LETT, V10, P1176, DOI 10.1007/BF00727897
   PISANOVA EV, 1994, POLYM COMPOSITE, V15, P147, DOI 10.1002/pc.750150208
   SACHSE W, 1993, J NONDESTRUC EVAL, V11, P251
   SANADI AR, 1985, J MATER SCI, V20, P431, DOI 10.1007/BF01026511
   WIMOLKIATISAK AS, 1989, POLYM COMPOSITE, V10, P162, DOI 10.1002/pc.750100304
   WU HF, 1992, J MATER SCI, V27, P3318, DOI 10.1007/BF01116031
NR 22
TC 83
Z9 85
U1 0
U2 25
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0266-3538
J9 COMPOS SCI TECHNOL
JI Compos. Sci. Technol.
PY 1999
VL 59
IS 3
BP 355
EP 370
DI 10.1016/S0266-3538(98)00085-2
PG 16
WC Materials Science, Composites
SC Materials Science
GA 177KM
UT WOS:000079209200004
DA 2021-08-04
ER

PT S
AU Sullivan, DG
   Glass, A
   Grosz, BJ
   Kraus, S
AF Sullivan, DG
   Glass, A
   Grosz, BJ
   Kraus, S
BE Klusch, M
   Shehory, OM
   Weiss, G
TI Intention reconciliation in the context of teamwork: An initial
   empirical investigation
SO COOPERATIVE INFORMATION AGENTS III, PROCEEDINGS
SE Lecture Notes in Artificial Intelligence
LA English
DT Article; Proceedings Paper
CT 3rd International Workshop on Cooperative Information Agents
CY JUL 31-AUG 02, 1999
CL UPPSALA, SWEDEN
SP Deutsch Telekom AG, Berkom GmbH, Berlin, George Mason Univ, Fairfax, Daimler Chrysler AG, Res & Technol, Berlin, Active Online Syst Ltd, London, AgentLink ESPRIT Network Excellence Agent Based Comp, German Comp Soc, Uppsala Univ, Comp Sci Dept
AB With growing opportunities for individually motivated agents to work collaboratively to satisfy shared goals, it becomes increasingly important to design agents that can make intelligent decisions in the context of commitments to group activities. In particular, agents need to be able to reconcile their intentions to do team-related actions with other, conflicting intentions. We present the SPIRE experimental system that allows the process of intention reconciliation in team contexts to be simulated and studied. SPIRE enables us to examine the influence of team norms and environmental factors on team members faced with conflicting intentions, as well as the effectiveness of different intention-reconciliation on strategies. We discuss results from pilot experiments that confirm the reasonableness of our model of the problem and illustrate some of the issues involved, and we lay the groundwork for future experiments that will allow us to derive principles for designers of collaboration-capable agents.
C1 Harvard Univ, Cambridge, MA 02138 USA.
   Bar Ilan Univ, IL-52900 Ramat Gan, Israel.
   Univ Maryland, Inst Adv Comp Studies, College Pk, MD 20712 USA.
RP Sullivan, DG (corresponding author), Harvard Univ, Cambridge, MA 02138 USA.
EM sullivan@eecs.harvard.edu; glass@eecs.harvard.edu;
   grosz@eecs.harvard.edu; sarit@cs.biu.ac.il
CR BRATMAN MICHAEL, 1987, INTENTION PLANS PRAC
   Decker K, 1998, INTERNATIONAL CONFERENCE ON MULTI-AGENT SYSTEMS, PROCEEDINGS, P104, DOI 10.1109/ICMAS.1998.699038
   DOYLE J, 1991, PRINCIPLES OF KNOWLEDGE REPRESENTATION AND REASONING, P163
   GLASS A, 1999, UNPUB BAR ILAN S FDN
   Grosz BJ, 1999, APPL LOG SER, V14, P227
   Grosz BJ, 1996, ARTIF INTELL, V86, P269, DOI 10.1016/0004-3702(95)00103-4
   GROSZ BJ, 1999, IN PRESS AI MAGAZINE
   HADAD M, 1999, INTELLIGENT INFORMAT
   HOLLANDER H, 1990, AM ECON REV, V80, P1157
   HORTY J, 1998, P 7 C THEOR ASP RAT, P249
   IANNACCONE LR, 1992, J POLIT ECON, V100, P271, DOI 10.1086/261818
   KALENKA S, 1999, P 5 INT C COGN SCI, P153
   KINNY D, 1994, LECT NOTES ARTIF INT, V830, P227
   LEVESQUE HJ, 1990, PROCEEDINGS : EIGHTH NATIONAL CONFERENCE ON ARTIFICIAL INTELLIGENCE, VOLS 1 AND 2, P94
   ROSENSCHEEIN JS, 1994, RULES ENCOUNTER DESI
   Sen S, 1997, INT J HUM-COMPUT ST, V47, P407, DOI 10.1006/ijhc.1997.0139
   SEN S, 1996, P 2 INT C MULT SYST, P322
   Shoham Y, 1992, P AAAI 92, P276
   Sycara K, 1996, INT J COOP INF SYST, V5, P181, DOI 10.1142/S0218843096000087
   Tambe M, 1997, J ARTIF INTELL RES, V7, P83, DOI 10.1613/jair.433
NR 20
TC 7
Z9 7
U1 0
U2 1
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 0302-9743
EI 1611-3349
BN 3-540-66325-8
J9 LECT NOTES ARTIF INT
PY 1999
VL 1652
BP 149
EP 162
PG 14
WC Computer Science, Artificial Intelligence; Computer Science, Information
   Systems
SC Computer Science
GA BQ61U
UT WOS:000088970300010
OA Green Submitted
DA 2021-08-04
ER

PT B
AU Bonarini, A
AF Bonarini, A
BE Banzhaf, W
   Daida, J
   Eiben, AE
   Garzon, MH
   Honavar, V
   Jakiela, M
   Smith, RE
TI Comparing Reinforcement Learning algorithms applied to crisp and fuzzy
   Learning Classifier Systems
SO GECCO-99: PROCEEDINGS OF THE GENETIC AND EVOLUTIONARY COMPUTATION
   CONFERENCE
LA English
DT Proceedings Paper
CT Genetic and Evolutionary Computation Conference (GECCO-99) at the 8th
   International Conference on Genetic Algorithms/4th Annual Genetic
   Programming Conference
CY JUL 13-17, 1999
CL ORLANDO, FL
SP European Network Excellence Evolutionary Comp, Evolut Artificielle, ICES, Int Soc Adapt Behav, Amer Assoc Artificial Intelligence
ID BEHAVIORS
AB We have implemented a tool to compare different modules of Reinforcement Learning algorithms applied to Learning Classifier Systems (LCS). We focus on three main classes of modules: credit assignment modules, exploration policies, and evolutionary strategies. For each class we have implemented many of the proposals we can find in literature and also some new algorithms that we have designed. In this paper, we present the results of the application of our tool to both fuzzy and crisp LCSs that learn behaviors for simulated autonomous agents. Fuzzy LCSs can be considered a successful approach to cope with real-valued input and output in a real environment. A lot of investigations can be done with this tool in this experimental setting. This paper is focused on the comparison among-different credit assignment algorithms and on their performance in learning both crisp and fuzzy models. Our experiments show that the more complex credit assignment algorithms (such as, for instance, the TD(lambda) generally have better performances than the more basic (such as Q-learning or Bucket Brigade) also when applied to LCSs. Moreover, fuzzy LCSs seem to require a larger computational effort, but also show more robustness.
C1 Politecn Milan, Dipartimento Elettron & Informaz, Politecn Milano AI & Robot Project, I-20133 Milan, Italy.
RP Bonarini, A (corresponding author), Politecn Milan, Dipartimento Elettron & Informaz, Politecn Milano AI & Robot Project, Piazza Leonardo da Vinci 32, I-20133 Milan, Italy.
RI Bonarini, Andrea/I-2984-2017
OI Bonarini, Andrea/0000-0002-4880-4521
CR Bonarini A, 1997, ADAPT BEHAV, V5, P281, DOI 10.1177/105971239700500304
   Bonarini A, 1997, INT J APPROX REASON, V17, P409, DOI 10.1016/S0888-613X(97)00002-9
   BONARINI A, 1996, FUZZY MODELLING PARA, P265
   BONARINI A, 1998, IEEE INT C EV COMP W, V1, P51
   Cordon O, 1997, FUZZY EVOLUTIONARY COMPUTATION, P33
   KLIR GJ, 1997, FUZZY SET THEORY F A, V49
NR 6
TC 11
Z9 11
U1 0
U2 2
PU MORGAN KAUFMANN PUB INC
PI SAN FRANCISCO
PA 340 PINE STR, 6TH FLR, SAN FRANCISCO, CA 94104-3205 USA
BN 1-55860-611-4
PY 1999
BP 52
EP 59
PG 8
WC Computer Science, Theory & Methods
SC Computer Science
GA BQ96Q
UT WOS:000165164700007
DA 2021-08-04
ER

PT S
AU Buss, D
   Brunner, G
AF Buss, D
   Brunner, G
BE Dahmen, N
   Dinjus, E
TI Countercurrent extraction with supercritical carbon dioxide: Behavior of
   a complex natural mixture
SO HIGH PRESSURE CHEMICAL ENGINEERING
SE FORSCHUNGSZENTRUM KARLSRUHE - TECHNIK UND UMWELT, WISSENSCHAFTLICHE
   BERICHTE (FZKA)
LA English
DT Proceedings Paper
CT International Meeting of the GVC-Fachausschuss
CY MAR 03-05, 1999
CL KARLSRUHE, GERMANY
SP GVC, Fachausschuss
ID SQUALENE; CHOLESTYRAMINE; CHOLESTEROL; RAT
AB Squalene (2,6, 10,15,19,23-hexamethyl-2,6, 10,14, 18,20-tetracosahexaene), known as spinacene, is a naturally occurring triterpenoid hydrocarbon, usually used in its natural form in health foods or in its hydrogenated form (squalane) in cosmetic preparations as a moisturizing or emollient agent, Academic interest arises because of its role as an precursor in the biosynthesis of sterols and of the naturally occurring tetracyclic and pentacyclic triterpenes [5, 11, 12, 13]. Olive oil deodorizer distillate (OODD), a by-product of the olive oil industry, contains squalene in a concentration range of 10 to 30 Ma-%. Other components are: 34 Ma-% free fatty acids, 24 Ma-% fatty acid esters (methyl and ethyl), 5.6 Ma.-% sterols, and 6.4 Ma.-% others (glycerides, tocopherols, hydrocarbons, etc.). To investigate the possibility of separating squalene from OODD by means of supercritical carbon dioxide extraction, VLE measurements and a theoretical separation analysis were carried out. VLE data provide information about the operating parameters of the process. The object of the theoretical separation analysis is the simulation of the separation process and the determination of data for a scale-up. Experimental results have to be correlated with results of the VLE measurements. Extraction experiments were Nn on a 7 m laboratory plant in countercurrent mode. Results show, that changing composition in the column has a major effect on the distribution coefficients K-i and on the separation factors alpha(ij). As a consequence, the concentration of squalene in the extract was limited and the concentration of FFA could not be reduced to a desired level.
C1 Tech Univ Hamburg Harburg, D-21073 Hamburg, Germany.
RP Buss, D (corresponding author), Tech Univ Hamburg Harburg, Eissendorfer Str 38, D-21073 Hamburg, Germany.
CR ADACHI Y, 1983, FLUID PHASE EQUILIBR, V14, P147, DOI 10.1016/0378-3812(83)80120-4
   BONDIOLI P, 1993, J AM OIL CHEM SOC, V70, P763, DOI 10.1007/BF02542597
   BRUNNER G, 1994, GAS EXTRACTION
   BUDICH M, IN PRESS J SUPERCRIT
   CERUTI M, 1988, EUR J MED CHEM, V23, P533, DOI 10.1016/0223-5234(88)90096-7
   GOPAKUMAR K, 1986, SEAFOOD EXPORT J MAR, P17
   RIHA V, 1994, THESIS TU HAMBRUG HA
   SAURE C, 1996, THESIS TU HAMBURG HA
   Stoldt J, 1996, FLUID PHASE EQUILIBR, V116, P399, DOI 10.1016/0378-3812(95)02911-7
   STRANDBERG TE, 1990, J LIPID RES, V31, P1637
   STRANDBERG TE, 1989, BIOCHIM BIOPHYS ACTA, V1001, P150, DOI 10.1016/0005-2760(89)90141-0
   STRANDBERG TE, 1989, LIPIDS, V24, P705, DOI 10.1007/BF02535208
   1949, NIPPON OIL TECNOL SO, V2, P48
NR 13
TC 1
Z9 1
U1 0
U2 2
PU FORSCHUNGSZENTRUM KARLSRUHE TECHNIK & UMWELT
PI KARLSRUHE
PA POSTFACH 3640, D-76021 KARLSRUHE, GERMANY
SN 0947-8620
J9 FZKA TECH UMW WIS B
PY 1999
VL 6271
BP 197
EP 200
PG 4
WC Engineering, Chemical
SC Engineering
GA BN63G
UT WOS:000082418900042
DA 2021-08-04
ER

PT B
AU Dorer, K
AF Dorer, K
GP IJCAII
   IJCAII
   IJCAII
TI Behavior networks for continuous domains using situation-dependent
   motivations
SO IJCAI-99: PROCEEDINGS OF THE SIXTEENTH INTERNATIONAL JOINT CONFERENCE ON
   ARTIFICIAL INTELLIGENCE, VOLS 1 & 2
LA English
DT Proceedings Paper
CT 16th International Joint Conference on Artificial Intelligence (IJCAI
   99)
CY JUL 31-AUG 06, 1999
CL STOCKHOLM, SWEDEN
SP Int Joint Conference Artificial Intelligence Inc, Scandinavian Al Soc
AB The problem of action selection by autonomous agents becomes increasingly difficult when acting in continuous, non-deterministic and dynamic environments pursuing multiple and possibly conflicting goals. We propose a method that exploits additional information gained from continuous states, is able to deal with unexpected situations, and takes multiple and conflicting goals into account including additional motivational aspects such as dynamic goals, which allow for situation-dependent motivational influence on the agent. Further we show some domain independent properties of this algorithm along with empirical results gained using the RoboCup simulated soccer environment.
C1 Univ Freiburg, Inst Comp Sci & Social Res, Ctr Cognit Sci, Freiburg, Germany.
RP Dorer, K (corresponding author), Univ Freiburg, Inst Comp Sci & Social Res, Ctr Cognit Sci, Hugstetter Str 55, Freiburg, Germany.
CR Decugis V., 1998, Proceedings of the Second International Conference on Autonomous Agents, P354, DOI 10.1145/280765.280859
   GOETZ P, 1997, THESIS STATE U NEW Y
   GOPHER D, 1986, HDB PERCEPTION HUMAN, V2, pCH41
   Maes P., 1990, Robotics and Autonomous Systems, V6, P49, DOI 10.1016/S0921-8890(05)80028-4
   MAES P, 1989, P INT JOINT C ART IN
   MAES P, 1992, P 1 EUR C ART LIF, P48
   Noda I., 1995, P AI S 95 JAP SOC AR, P29
   SAFFIOTTI A, 1995, ARTIF INTELL, V76, P481, DOI 10.1016/0004-3702(94)00088-I
   Tyrrell Toby, 1994, Adaptive Behavior, V2, P307, DOI 10.1177/105971239400200401
NR 9
TC 18
Z9 18
U1 0
U2 0
PU MORGAN KAUFMANN PUB INC
PI SAN FRANCISCO
PA 340 PINE STR, 6TH FLR, SAN FRANCISCO, CA 94104-3205 USA
BN 1-55860-613-0
PY 1999
BP 1233
EP 1238
PG 6
WC Computer Science, Artificial Intelligence
SC Computer Science
GA BR27X
UT WOS:000165996800175
DA 2021-08-04
ER

PT J
AU Killam, AL
   Mehlhaff, PM
   Zavorskas, PA
   Greener, Y
   McFerran, BA
   Miller, JJ
   Burrascano, C
   Jablonski, EG
   Anderson, L
   Dittrich, HC
AF Killam, AL
   Mehlhaff, PM
   Zavorskas, PA
   Greener, Y
   McFerran, BA
   Miller, JJ
   Burrascano, C
   Jablonski, EG
   Anderson, L
   Dittrich, HC
TI Tissue distribution of I-125-labeled albumin in rats, and whole blood
   and exhaled elimination kinetics of octafluoropropane in anesthetized
   canines, following intravenous administration of OPTISON (R) (FS069)
SO INTERNATIONAL JOURNAL OF TOXICOLOGY
LA English
DT Article
DE ultrasound contrast; fluorocarbon; pharmacokinetics
ID ECHOCARDIOGRAPHIC CONTRAST AGENT; MICROSPHERES; TIME
AB OPTISON, an agent being developed as an intravenous (IV) ultrasound contrast agent, consists of a suspension of octafluoropropane (OFP)-containing albumin microspheres. The distribution and elimination of the albumin component and the elimination kinetics of the OFF component of OPTISON (FS069) were studied in the conscious rat and anesthetized canine models, respectively. Radioiodinated OPTISON at 0.25 ml/kg (average dose 5.4 x 10(7) DPM/rat) and nonradioactive OPTISON, at dosages of 0.3, 0.6, and 1.0 ml/kg, was administered intravenously to conscious rats or to sodium pentobarbital-anesthetized and ventilated canines, respectively, A separate group of rats was housed in metabolism cages for 24 hours to capture excreted radioactivity. The tissue distribution data for the radiolabeled albumin in rats showed that the I-125 activity recovered in the liver was the highest of all the tissues at each timepoint (peak liver radioactivity at 5 minutes with 50.4 % of the dose), suggesting that the major route of uptake and metabolism of the radiolabeled albumin shell and its fragments occurred in the liver. The I-125 activity was excreted in the urine, where most of the recovered radioactivity (58.3%) was found at the end of 24 hours. In the anesthetized canine study, simultaneous venous blood samples and exhaled air samples plus additional exhaled air samples were analyzed by gas chromatography, OFF was rapidly exhaled through the lungs after an IV injection such that a maximum of less than 10% of the total dose appeared in the venous blood samples. Statistical moment analysis showed rapid OFF elimination with mean residence times of 46, 41, and 38 seconds for the three dosages, and mean total recoveries for the exhaled OFP were 111%,100.5%,and 121.6%, respectively. OFF was rapidly exhaled through the lungs after OPTISON injection with short mean residence times from statistical moment analysis. Exhaled OFF displayed one-compartment model kinetics with a measurable distribution phase in the blood using classical pharmacokinetic modeling. The albumin component appeared to be cleared primarily by the liver and radioactivity was excreted in the urine.
C1 Mol Biosyst Inc, San Diego, CA 92121 USA.
   Primed Corp, Worcester, MA USA.
   Univ Calif San Diego, Med Ctr, San Diego, CA 92103 USA.
RP Killam, AL (corresponding author), Mol Biosyst Inc, 10070 Barnes Canyon Rd, San Diego, CA 92121 USA.
EM akillam@mobi.com
CR CHANG S, 1985, OPHTHALMOLOGY, V92, P651
   CHORTKOFF BS, 1994, ANESTH ANALG, V79, P234
   CLAYTON JW, 1967, FLUORINE CHEM REV, V1, P197
   Cohen J., 1997, Journal of the American College of Cardiology, V29, p519A
   Dittrich H C, 1995, J Am Soc Echocardiogr, V8, P465, DOI 10.1016/S0894-7317(05)80333-5
   EGER EI, 1994, ANESTH ANALG, V79, P245
   EHRENREICH BA, 1967, J EXP MED, V126, P941, DOI 10.1084/jem.126.5.941
   Firschke C, 1997, CIRCULATION, V96, P959
   Forsberg F, 1996, J ULTRAS MED, V15, P853, DOI 10.7863/jum.1996.15.12.853
   GIBALDI M, 1982, PHARMACOKINETICS
   Kono Y, 1997, ULTRASOUND MED BIOL, V23, P719, DOI 10.1016/S0301-5629(97)00007-0
   MARSHALL BE, 1996, GOODMAN GILMANS PHAR, P315
   MAYERSOHN M, 1993, DRUG METAB DISPOS, V21, P1172
   Meza M, 1996, AM HEART J, V132, P871, DOI 10.1016/S0002-8703(96)90324-5
   NADA T, 1997, J ULTRAS MED, V16, P4852
   Rowland M, 1995, CLIN PHARMACOKINETIC
   SCHNOY N, 1980, VIRCHOWS ARCH B, V34, P269, DOI 10.1007/BF02892424
   TSUDA Y, 1988, BIOMATER ARTIF CELL, V16, P473, DOI 10.3109/10731198809132602
   Vorbrodt AW, 1996, J NEUROCYTOL, V25, P645, DOI 10.1007/BF02284831
   WALDAY P, 1994, BIOCHEM J, V299, P437, DOI 10.1042/bj2990437
   WEN WY, 1979, J SOLUTION CHEM, V8, P225, DOI 10.1007/BF00648882
   WONG RF, 1988, OPHTHALMOLOGY, V95, P609
NR 22
TC 13
Z9 15
U1 0
U2 3
PU TAYLOR & FRANCIS LTD
PI LONDON
PA ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND
SN 1091-5818
J9 INT J TOXICOL
JI Int. J. Toxicol.
PD JAN-FEB
PY 1999
VL 18
IS 1
BP 49
EP 63
DI 10.1080/109158199225800
PG 15
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA 158AC
UT WOS:000078093000007
DA 2021-08-04
ER

PT S
AU Takadama, K
   Kasahara, H
   Huang, LC
   Watabe, M
   Ii, H
   Shimohara, K
   Nakasuka, S
AF Takadama, K
   Kasahara, H
   Huang, LC
   Watabe, M
   Ii, H
   Shimohara, K
   Nakasuka, S
BE Perry, M
TI Organizational learning agents for task scheduling in space crew and
   robot operations
SO ISAIRAS '99: FIFTH INTERNATIONAL SYMPOSIUM ON ARTIFICIAL INTELLIGENCE,
   ROBOTICS AND AUTOMATION IN SPACE
SE ESA SPECIAL PUBLICATIONS
LA English
DT Proceedings Paper
CT 5th International Symposium on Artificial Intelligence, Robotics and
   Automation in Space (ISAIRAS 99)
CY JUN 01-03, 1999
CL NOORDWIJK, NETHERLANDS
SP European Space Agcy, Italian Space Agcy, Italy, French Natl Space Agcy, France, Inst Space & Astronaut Sci, Japan, Natl Aerosp Lab, Japan, NASA, US, Natl Space Dev Agcy, Japan, Netherlands Agcy Aerosp Programs, Netherlands
DE crew task scheduling; planning for multiple space robots; multiagent
   system; organizational learning; learning classifier system
AB This paper explores rescheduling and reorganization abilities of our organizational learning model in the following two important applications in space: crew task scheduling in a space shuttle/station and task planning for truss construction with multiple space robots. Through intensive simulations of the above two tasks, the following experimental results have been obtained: (1) Our model provides good feasible schedules quickly in the case of rescheduling, and it keeps the computational cost for rescheduling low; (2) Plans generated by our model keep or recover efficiency in tasks when robots are added, removed, or exchanged among robot groups; and (3) The integration of(a) learning mechanisms, (b) rule based systems with evolutionary approaches, and (c) multiagent approaches is effective in rescheduling/replanning problems.
C1 ATR, Human Informat Proc Res Labs, Seika, Kyoto 6190288, Japan.
RP Takadama, K (corresponding author), ATR, Human Informat Proc Res Labs, 2-2 Hikaridai, Seika, Kyoto 6190288, Japan.
CR AARTS EHL, 1989, SIMULATED ANNEALING
   Argyris C., 1978, ORG LEARNING
   COHEN MD, 1995, ORG LEARNING
   FUJITA S, 1996, 2 INT C MULT SYST IC, P95
   Goldberg D., 1989, GENETIC ALGORITHMS S
   Grefenstette J. J., 1988, Machine Learning, V3, P225, DOI 10.1023/A:1022614421909
   Holland J. H., 1978, PATTERN DIRECTED INF
   IIMA H, 1999, 4 INT S AUT DEC SYST, P366
   March JG, 1991, ORGAN SCI, V2, P1, DOI 10.1287/orsc.2.1.1
   Osman I. H., 1996, METAHEURISTICS THEOR
   Russell S. J., 2010, ARTIFICIAL INTELLIGE
   Takadama K, 1998, IEEE C EVOL COMPUTAT, P63, DOI 10.1109/ICEC.1998.699138
   Takadama K, 1998, APPL INTELL, V9, P25, DOI 10.1023/A:1008295030359
   TAKADAMA K, 1999, IN PRESS COMPUTATION
   TAKADAMA K, 1999, 16 INT JOINT C ART I
   Tamaki H., 1999, Transactions of the Society of Instrument and Control Engineers, V35, P428
   ZHANG W, 1995, 1995 INT JOINT C ART, P1114
   ZWEBEN M, 1994, INTELLIGENT SCHEDULI, P241
NR 18
TC 0
Z9 0
U1 0
U2 2
PU EUROPEAN SPACE AGENCY
PI PARIS
PA 8-10 RUE MARIO NIKIS, 75738 PARIS, FRANCE
SN 0379-6566
BN 92-9092-760-7
J9 ESA SP PUBL
PY 1999
VL 440
BP 561
EP 568
PG 8
WC Automation & Control Systems; Engineering, Aerospace; Computer Science,
   Artificial Intelligence; Computer Science, Interdisciplinary
   Applications
SC Automation & Control Systems; Engineering; Computer Science
GA BN59B
UT WOS:000082313700075
DA 2021-08-04
ER

PT J
AU Dibike, YB
   Abbott, MB
AF Dibike, YB
   Abbott, MB
TI Application of artificial neural networks to the simulation of a two
   dimensional flow
SO JOURNAL OF HYDRAULIC RESEARCH
LA English
DT Article
AB The practice of numerical simulation of flows and other processes occurring in water has now matured into an established and efficient part of hydraulics. At the same time, however, the models themselves often become very extended. In many situations, given the divergence between the response-time requirements and the computational-time requirements of numerical models, the need arises to reduce the time needed to simulate the impact of given input events on hydraulics systems. In this study the possibility of using systems composed of agents consisting only of artificial neural networks (ANNs) as modelling tools for the simulation of tidal flow in a two-dimensional flow field is investigated. In particular this involves the modelling of a process that evolves in time and the ANNs themselves function as non-linear dynamic systems that effectively reproduce the behaviour of the fluid at any one place and any one time from the behavior at other places at earlier times. Different types of ANN-agent architectures are investigated in order to asses their ability and relative performance in encapsulating the site-specific knowledge and data necessary to reproduce the temporal sequence of states observed in a modelled area.
C1 Int Inst Infrastruct Hydraul & Environm Engn, NL-2601 DA Delft, Netherlands.
RP Dibike, YB (corresponding author), Int Inst Infrastruct Hydraul & Environm Engn, POB 3015, NL-2601 DA Delft, Netherlands.
OI Dibike, Yonas/0000-0003-2138-9708
CR Abbott M B, 1966, INTRO METHOD CHARACT
   ABBOTT MB, 1997, P 2M C INT ASS HYDR, V2
   ABBOTT MB, 1998, P 3 INT C HYDR
   ABBOTT MB, 1997, J HYDRAULIC ENG, V123
   ABBOTT MB, 1994, P 1 INT C HYDR, V1, P3
   BOOGAARD HFP, 1998, P 3 INT C HYDR
   DIBIKE YB, 1999, UNPUB J HYDRAULIC RE
   DIBIKE YB, 1999, J HYDRAULIC RES, VPP
   Hertz J., 1991, INTRO THEORY NEURAL
   MASOODUIHASSAN K, 1995, ADV INTELLIGENT DATA, P114
   1996, HYDRODYNAMIC MODULE
NR 11
TC 16
Z9 18
U1 0
U2 4
PU INT ASSN HYDRAULIC RESEARCH
PI DELFT
PA PO BOX 177, 2600 DELFT, NETHERLANDS
SN 0022-1686
J9 J HYDRAUL RES
JI J. Hydraul. Res.
PY 1999
VL 37
IS 4
BP 435
EP 446
DI 10.1080/00221686.1999.9628261
PG 12
WC Engineering, Civil; Water Resources
SC Engineering; Water Resources
GA 230CV
UT WOS:000082235000001
DA 2021-08-04
ER

PT J
AU Furhang, EE
   Larson, SM
   Buranapong, P
   Humm, JL
AF Furhang, EE
   Larson, SM
   Buranapong, P
   Humm, JL
TI Thyroid cancer dosimetry using clearance fitting
SO JOURNAL OF NUCLEAR MEDICINE
LA English
DT Article
DE radioiodine; thyroid cancer; dosimetry; lesion uptake
ID THERAPY
AB Since 1962, Memorial Sloan Kettering Cancer Center has used an individually optimized dosimetry method for patients with thyroid carcinoma undergoing radioiodine therapy. This traditional dosimetry method involves a determination of the maximum tolerated activity or the activity that will deliver 2 Gy to the blood (A,,), and the corresponding ablative lesion dose (D-lesion) However, the traditional calculations of A,,, and Dlesion were based on empirical assumptions. The objective of this work was to develop a dosimetry method that eliminates these assumptions by incorporating patient kinetics and that is not restricted to I-131 as a tracer and therapeutic agent. Methods: Patient kinetics were incorporated into the dosimetry algorithm by fitting parameters to patient clearance measurements. The radioiodines I-123, I-124, I-125, and I-131 were accommodated as tracers and therapeutic agents by incorporating their physical half lives and by precalculating photon-absorbed fractions for these radionuclides for several thousand patient geometries using Monte Carlo simulations. Results: A(max) and D-lesion have been calculated using the traditional and new method for a group of patients, and errors associated with each of the above assumptions were examined. Assuming that the initial blood activity is distributed instantaneously in 5 L was found to introduce an error in A(max) of up to 30%, whereas assuming physical decay beyond the last data point introduced an error of up to 50%. Conclusion: individualized fitting of clearance data is a practical method to accurately account for inter-patient kinetics variations. The substitution of standard kinetics beyond measured data might lead to substantial errors in estimating A(max) and D-lesion. in addition, gamma camera images, rather than neck probe readings, should be used to determine lesion uptakes for thyroid cancer patients.
C1 Mem Sloan Kettering Canc Ctr, Dept Med Phys, New York, NY 10021 USA.
   Mem Sloan Kettering Canc Ctr, Dept Nucl Med, New York, NY 10021 USA.
   Mahidol Univ, Siriraj Hosp, Dept Radiol, Div Nucl Med, Bangkok 10700, Thailand.
RP Furhang, EE (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med Phys, 1275 York Ave, New York, NY 10021 USA.
CR BENUA RS, 1962, AMER J ROENTGENOL RA, V87, P171
   Brownell GL, 1968, J NUCL MED        S1, V9, P27
   BUSH F, 1949, BRIT J RADIOL, V22, P96, DOI 10.1259/0007-1285-22-254-96
   ERDI YE, 1997, MED PHYS, V24, P970
   Harbert JC, 1987, NUCL MED THERAPY
   HINE JG, 1956, RAD DOSIMETRY, P858
   IMBRIACO M, 1997, J NUCL MED, V38
   MAXON HR, 1992, J NUCL MED, V33, P1132
   MAXON HR, 1993, THYROID TODAY, V2, P1
   MAZZAFERRI EL, 1994, AM J MED, V97, P418, DOI 10.1016/0002-9343(94)90321-2
   NELSON WR, 1985, 26S SLAC NAT TECHN I
   SAMUEL AM, 1994, J NUCL MED, V35, P1944
   SNYDER WS, 1978, MIRD PAMPHLET 5 ESTI
   Storm L, 1970, NUCLEAR DATA TABLE A, V7, P565, DOI 10.1016/s0092-640x(70)80017-1
   Weber DA, 1989, MIRD RADIONUCLIDE DA
   ZANZONICO BPB, 1995, PRINCIPLES NUCL MED, P106
NR 16
TC 45
Z9 46
U1 0
U2 3
PU SOC NUCLEAR MEDICINE INC
PI RESTON
PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA
SN 0161-5505
J9 J NUCL MED
JI J. Nucl. Med.
PD JAN
PY 1999
VL 40
IS 1
BP 131
EP 136
PG 6
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 158KM
UT WOS:000078114700036
PM 9935068
DA 2021-08-04
ER

PT S
AU Aarnink, RG
   Sedelaar, JPM
   de la Rosette, JJMCH
   Debruyne, FMJ
   Wijkstra, H
AF Aarnink, RG
   Sedelaar, JPM
   de la Rosette, JJMCH
   Debruyne, FMJ
   Wijkstra, H
BE Mun, SK
   Kim, Y
TI Simulations of enhancement effects in ultrasound images after
   administration of ultrasound contrast agent; comparison with in vivo
   results of the heart and the prostate.
SO MEDICAL IMAGING 1999: IMAGE DISPLAY
SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
   (SPIE)
LA English
DT Proceedings Paper
CT Conference on Image Display at Medical Imaging 1999
CY FEB 21-23, 1999
CL SAN DIEGO, CA
SP SPIE, Amer Assoc Physicists Med, Amer Physiol Soc, FDA Ctr Devices & Radiol Hlth, Soc Imaging Sci & Technol, NEMA, Diagnost Imaging & Therapy Syst Div, Radiol Soc N Amer, Soc Comp Appl Radiol
DE ultrasound; contrast agents; prostate; mathematical model; Doppler
   ultrasound
ID TRANSRECTAL ULTRASOUND
AB The availability of contrast agents to enhance ultrasound imaging of blood flow has resulted in applications not only in echocardiography but in peripheral organs such as the prostate as well. Especially the association of tumor development with changes in blood flow patterns has a potential to improve differential diagnosis. Theoretical modeling of the behavior of contrast bubbles after injection can be used to increase the understanding of the images of prostatic blood supply resulting after enhancement. This knowledge might assist in the development of sophisticated software for objective interpretation of the improved blood flow display.
   The physical concepts of ultrasound contrast enhancement have been covered by a number of publications in the literature, and the behavior of the microbubbles in sound waves has been studied in theory. Front-end studies indicated the desired properties of ultrasound contrast agents needed to achieve the best possible image quality. also the theory of changes in ultrasound images over time after administration of the contrast agent has been covered recently. The results of these modeling studies are used to predict the in vivo behavior of contrast agents when applied for prostate enhancement.
   In vivo studies are needed to identify the real clinical value of contrast agents in displaying the local blood supply. Ln this paper, we present clinical data of cardiac and prostatic applications. We evaluated prostatic blood supply in dogs and humans and compared expected behavior to in vivo enhancement of prostatic blood flow. In dogs, grayscale imaging and color Doppler imaging using contrast enhancement have been evaluated and images have been processed to identify enhancement patterns. In humans, only Doppler imaging has been applied to obtain blood flow enhancement patterns over time. The recorded imaging video data after contrast administration was processed using video-capturing software and results were presented in individual bitmap files. These files were processed by inhouse developed software to identify changes in signals due to the administration of contrast agent. Tn gray scale video images, the increase in gray scale intensities were obtained in local windows over the prostate, in Doppler images the number of pixels showing a color signal over time were obtained. Results of the in vivo studies were correlated to the modeling study.
   Evaluation of contrast enhanced gray scale imaging of the prostate of the dog indicated that contrast administration did not result in a significant increase in gray scale intensity of prostate tissue. In Doppler imaging, the presence of micro airbubbles resulted in a strong increase of number of pixels showing a flow signal; comparison to theoretical behavior of concentration distribution of the contrast fluid over time indicated that a relation exists between the recorded signal and the predicted concentration over time. This relation can be used to describe the flow pattern numerically and to evaluate enhanced ultrasound imaging for differential diagnosis in organs based on flow pattern descriptions.
C1 Univ Nijmegen Hosp, Dept Urol, NL-6500 HB Nijmegen, Netherlands.
RP Aarnink, RG (corresponding author), Univ Nijmegen Hosp, Dept Urol, POB 9101, NL-6500 HB Nijmegen, Netherlands.
RI Wijkstra, Hessel/AAD-4475-2019; Sedelaar, J.P.M./L-4643-2015
OI Wijkstra, Hessel/0000-0002-4127-4169; 
CR AARNICK RG, 1999, EUR UROL, V35
   Aarnink RG, 1998, J UROLOGY, V159, P1568, DOI 10.1097/00005392-199805000-00045
   BOGERS JA, 1999, IN PRESS UROLOGY
   Burns P N, 1994, Radiol Med, V87, P71
   HUYNEN AL, 1994, ULTRASOUND MED BIOL, V20, P1, DOI 10.1016/0301-5629(94)90011-6
   Ragde H, 1997, PROSTATE, V32, P279, DOI 10.1002/(SICI)1097-0045(19970901)32:4<279::AID-PROS8>3.0.CO;2-E
   Sehgal CM, 1997, J ULTRAS MED, V16, P471
   Sehgal CM, 1998, J ULTRAS MED, V17, P751, DOI 10.7863/jum.1998.17.12.751
   UHLENDORF V, 1994, IEEE T ULTRASON FERR, V41, P70, DOI 10.1109/58.265823
NR 9
TC 0
Z9 0
U1 0
U2 1
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 0-8194-3130-3
J9 P SOC PHOTO-OPT INS
PY 1999
VL 3658
BP 580
EP 594
DI 10.1117/12.349470
PG 15
WC Optics; Radiology, Nuclear Medicine & Medical Imaging
SC Optics; Radiology, Nuclear Medicine & Medical Imaging
GA BN20B
UT WOS:000081058400057
DA 2021-08-04
ER

PT J
AU Brenizer, JS
   Hosticka, B
   Berger, H
   Gillies, GT
AF Brenizer, JS
   Hosticka, B
   Berger, H
   Gillies, GT
TI The use of contrast agents to enhance crack detection via neutron
   radiography
SO NDT & E INTERNATIONAL
LA English
DT Article
DE contrast agents; contrast; gadolinium; cadmium; neutron radiography
ID REFRACTION CONTRAST
AB Contrast agents have been used in a wide variety of neutron radiographic and radioscopic examinations. Useful contrast agents range from simple hydrogenous materials such as water and oil to exotic compounds such as gadolinium chelates. The properties of the contrast agents also vary widely. Considerations such as the ability to penetrate into cracks, the ability to be removed, the neutron cross-section, or the neutron attenuation mechanism, often steer the investigator to select a particular contrast agent. We have quantified the behavior of the following substances as contrast agents: an aqueous liquid penetrant, a solvent-based liquid penetrant, water, a GdCl3 aqueous solution, and a solution of gadolinium beta-diketonate (2,2,6,6-tetramethyl-3,5-heptanedione) (TMHD) dissolved in acetone and methylene chloride. The experimental tests were carried out using wedge-shaped gaps that simulated cracks, and in actual cracks in Inconel tubing. The experimental results showed that an aqueous solution of GdCl3 used with a wetting agent provided the best performance, but was difficult to remove completely from the crack. (C) 1998 Elsevier Science Ltd. All rights reserved.
C1 Univ Virginia, Dept Mech Aerosp & Nucl Engn, Charlottesville, VA 22903 USA.
   Ind Qual Inc, Gaithersburg, MD 20877 USA.
RP Gillies, GT (corresponding author), Univ Virginia, Dept Mech Aerosp & Nucl Engn, Charlottesville, VA 22903 USA.
CR BERGER H, 1987, P 2 WORLD C NEUTR RA, P563
   BRENIZER JS, 1987, P 2 WORLD C NEUTR RA, P813
   Edenborough N.B., 1976, ASTM STP, V586, P152
   HOLLAND BG, 1983, P 1 WORLD C NEUTR RA, P333
   JOHNSTON SC, 1978, REV SCI INSTRUM, V49, P242, DOI 10.1063/1.1135376
   LIU JH, 1995, ANGEW MAKROMOL CHEM, V224, P133, DOI 10.1002/apmc.1995.052240114
   MUKHERJEE D, 1995, GRAPH MODEL IM PROC, V57, P254, DOI 10.1006/gmip.1995.1024
   PODURETS KM, 1995, ZH TEKH FIZ+, V65, P167
   PODURETS KM, 1989, PHYSICA B, V156, P694, DOI 10.1016/0921-4526(89)90766-7
   PODURETS KM, 1989, PHYSICA B, V156, P691, DOI 10.1016/0921-4526(89)90765-5
   Poeth DF, 1996, RES NONDESTRUCT EVAL, V8, P67, DOI 10.1080/09349849608968107
   RANT J, 1987, P 2 WORLD C NEUTR RA, P455
   TSUKIMURA RR, 1987, P 2 WORLD C NEUTR RA, P329
   TYUFYAKOV ND, 1979, PRINCIPLES NEUTRON R
   VANOVERVELD IMCJ, 1995, J DIGIT IMAGING, V8, P168, DOI 10.1007/BF03168716
   WATT HV, 1962, 116427 ARF
   ZAWISKY M, 1994, PHYS REV A, V50, P5000, DOI 10.1103/PhysRevA.50.5000
NR 17
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0963-8695
J9 NDT&E INT
JI NDT E Int.
PD JAN
PY 1999
VL 32
IS 1
BP 37
EP 42
DI 10.1016/S0963-8695(98)00024-3
PG 6
WC Materials Science, Characterization & Testing
SC Materials Science
GA 157EB
UT WOS:000078046200005
DA 2021-08-04
ER

PT J
AU Agah, A
   Tanie, K
AF Agah, A
   Tanie, K
TI Interactions of an anthropomorphic simulated human with a simulated
   service robot
SO SIMULATION
LA English
DT Article
DE simulated humans; robot simulation; human-robot interaction;
   anthropomorphic movement modeling; service robotics
AB It is expected that robots of the future will coexist and interact with humans in places such as homes and offices. In order to make the interaction of service robots with humans safe and effective, new technologies must be developed, ranging from physical material design for robot bodies, to intelligent controllers. Simulation provides a convenient and efficient research environment for design, testing and implementation of service robots. This paper presents a simulated world that includes a realistic simulated human and a simulated robot which delivers and hands over an object to the human. The human is made realistic by being modeled using physiological data and anthropomorphic equations of motion. The robot's design is also based upon realistic specifications. The robot's intelligence is achieved through a number of independent software agents that contend for the robot's behavior production, named Contention Architecture. The proposed actions of the autonomous agents are evaluated based on a number of criteria so as to select one action to be taken by the robot. The experimental results of the interaction between human and robot through the task of handover is presented. It is shown that the robot is not only capable of performing the task effectively, but is also able to compensate for the unexpected movements of the human, while allowing no harm to come to the person through physical contact.
C1 Univ Kansas, Dept Elect Engn & Comp Sci, Lawrence, KS 66045 USA.
   AIST, Agcy Ind Sci & Technol, Robot Dept, Mech Engn Lab, Tsukuba, Ibaraki 305, Japan.
RP Agah, A (corresponding author), Univ Kansas, Dept Elect Engn & Comp Sci, Lawrence, KS 66045 USA.
EM agah@eecs.ukans.edu; m1750@melcy.mel.go.jp
CR AGAH A, 1996, DISTRIBUTED AUTONOMO, V2, P326
   Andersson R. L, 1993, PRESENCE-TELEOP VIRT, V2, P16
   BAERVELDT AJ, 1992, IEEE INTERNATIONAL WORKSHOP ON ROBOT AND HUMAN COMMUNICATION : PROCEEDINGS, P183, DOI 10.1109/ROMAN.1992.253891
   BOMAN DK, 1995, COMPUTER, V28, P57, DOI 10.1109/2.386986
   FUJISAWA Y, 1992, IEEE INTERNATIONAL WORKSHOP ON ROBOT AND HUMAN COMMUNICATION : PROCEEDINGS, P188, DOI 10.1109/ROMAN.1992.253890
   Ikeura R., 1994, Proceedings. 3rd IEEE International Workshop on Robot and Human Communication. RO-MAN '94 Nagoya (Cat. No.94TH0679-1), P112, DOI 10.1109/ROMAN.1994.365946
   Ishii M., 1994, PRESENCE, V3, P351
   KAJIKAWA S, 1995, P IEEE RSJ INT C INT, V1, P193
   *KNOWL REV INC, 1995, WORK MOD 3 0 US MAN
   MAES P, 1995, COMMUN ACM, V38, P108, DOI 10.1145/219717.219808
   MASSIMINO MJ, 1993, PRESENCE-TELEOP VIRT, V2, P344
   NEMIRE K, 1994, HUM FACTORS, V36, P79
   SCARBOROUGH E, 1992, PRESENCE-TELEOP VIRT, V1, P459
   Shibata S, 1995, RO-MAN'95 TOKYO: 4TH IEEE INTERNATIONAL WORKSHOP ON ROBOT AND HUMAN COMMUNICATION, PROCEEDINGS, P59, DOI 10.1109/ROMAN.1995.531935
   Shibata S, 1995, RO-MAN'95 TOKYO: 4TH IEEE INTERNATIONAL WORKSHOP ON ROBOT AND HUMAN COMMUNICATION, PROCEEDINGS, P53, DOI 10.1109/ROMAN.1995.531934
   STANSFIELD S, 1995, IEEE COMPUT GRAPH, V15, P12, DOI 10.1109/38.403821
   THALMANN D, 1995, P INT C VIRT SYST MU, P48
   YOSHIKAWA T, 1985, INT J ROBOT RES, V4, P3, DOI 10.1177/027836498500400201
NR 18
TC 1
Z9 1
U1 0
U2 6
PU SIMULATION COUNCILS INC
PI SAN DIEGO
PA PO BOX 17900, SAN DIEGO, CA 92117 USA
SN 0037-5497
J9 SIMULATION
JI Simulation
PD JAN
PY 1999
VL 72
IS 1
BP 12
EP 19
DI 10.1177/003754979907200102
PG 8
WC Computer Science, Interdisciplinary Applications; Computer Science,
   Software Engineering
SC Computer Science
GA 165BJ
UT WOS:000078498600002
DA 2021-08-04
ER

PT B
AU Nolan, F
   Wilkiewicz, J
   Dasgupta, D
   Franklin, S
AF Nolan, F
   Wilkiewicz, J
   Dasgupta, D
   Franklin, S
GP AAAI
   AAAI
TI Evolutionary economic agents
SO SIXTEENTH NATIONAL CONFERENCE ON ARTIFICIAL INTELLIGENCE
   (AAAI-99)/ELEVENTH INNOVATIVE APPLICATIONS OF ARTIFICIAL INTELLIGENCE
   (IAAI-99)
LA English
DT Proceedings Paper
CT 16th National Conference on Artificial Intelligence (AAAI-99)/11th
   Conference on Innovative Applications of Artificial Intelligence
   (IAAI-99)
CY JUL 18-22, 1999
CL ORLANDO, FL
SP Amer Assoc Artificial Intelligence, ACM,SIGART, US Def, Adv Res Projects Agcy, Microsoft Corp, USN, Res Lab, USN, Off Naval Res, NASA, Ames Res Ctr, NSF, Rent Comp
AB An empirical work is described which compares the optimization levels produced by a group of economic agents versus those of a similar group of economic agents which additionally employ a genetic algorithm (GA) to attain a higher level of optimization. The problem domain is multimodal. It incorporates multiple hard and soft constraints and dynamical behaviors. It also has areas of infeasibility and non-linear behaviors. The simulated model environment provides several types of sensors, actuators and opportunities for inter-agent resource mediation. Evidence is offered to support the theory that multiple weak methods operating in concert, on a shared problem, can produce better results than the individual weak methods acting alone. The problem area is resistant to the use of strong methods.
C1 Univ Memphis, Memphis, TN 38107 USA.
RP Nolan, F (corresponding author), Univ Memphis, 758 N McLean Blvd, Memphis, TN 38107 USA.
RI Franklin, Stan/AAI-5506-2020
CR AGRE PE, 1990, DESIGNING AUTONOMOUS, P17
   ANDERSON PW, 1997, EC EVOLVING COMPLEX, V27
   Arthur W.B., 1988, EC EVOLVING COMPLEX
   Baars B.J., 1997, THEATRE CONSCIOUSNES
   Baars B. J, 1990, COGNITIVE THEORY CON
   Bates E, 1997, LANG COGNITIVE PROC, V12, P507
   Cantu-Paz E., 1997, SURVEY PARALLEL GENE
   CANTUPAZ E, 1998, 98009 ILLIGAL
   DOLAN A, 1997, GA PLAYGROUND
   FRANKLIN S, 1997, P 3 INT WORKSH AG TH, P21
   Franklin S., 1995, ARTIFICIAL MINDS
   Holland J.H., 1996, HIDDEN ORDER ADAPTAT
   HORN J, 1994, P IEEE ICEC
   Kauffman S. A., 1993, ORIGINS ORDER SELF O
   KOLLMAN K, 1996, COMPUTATIONAL POLITI
   Krugman P., 1996, SELF ORG EC
   LOBO FG, 1996, 96009 ILLIGAL
   Moriarty D., 1998, EVOLUTIONARY COMPUTA, P5
   MULLEN T, 1996, INTELLIGENT AGENTS 2
   STEELS L, 1990, EXPLOITING ANALOGICA, V71, P88
   TOMASELLO M, 1998, NEW PSYCHOL LANTUAGE
   Wellman M.P., 1996, MARKET BASED CONTROL, P74
   WILSON SW, 1994, ZEROTH LEVEL CLASSIF
NR 23
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC ARTIFICIAL INTELLIGENCE
PI MENLO PK
PA 445 BURGESS DR, MENLO PK, CA 94025 USA
BN 0-262-51106-1
PY 1999
BP 38
EP 43
PG 6
WC Computer Science, Artificial Intelligence
SC Computer Science
GA BQ85T
UT WOS:000089853000006
DA 2021-08-04
ER

PT J
AU Okada, I
   Ishida, K
   Ohta, T
AF Okada, I
   Ishida, K
   Ohta, T
TI A reorganizing process on attitude fluctuations - A simulation study
SO SOCIOLOGICAL THEORY AND METHODS
LA English
DT Article
DE personality; reorganizing process; attitude fluctuation; computer
   simulation; operational organization orientation
AB According to the hypothesis of bounded rationality, there is no best approach for a reorganizing process due to the cognitive limit of organizational members. However, the reorganizing process can be successfully described in our model employing their attitude changes, in that the attitude change of personalistic agent causes a change of organizational behavioral pattern due to the attitude fluctuation.
   A multi-agent model based on a personalistic agent is developed to describe the reorganizing process in an organization with respect to an organizational performance and its environmental adaptation. A computer simulation is to employ to describe the reorganizing process, because the process must be difficult to deal with an empirical method due to the complexity. We also propose the approach as an operational organizational oriented approach, and discuss a methodological possibility of our approach.
   The attitude fluctuations in the reorganizing process are formulated in the model employing a concept of achievement motivation theory in psychology and of a differential engine proposed by Minsky. The personalistic agent consists of a task stickness, an emotion of interpersonal attractiveness, and of a conservativeness as variables.
   In conclusion, we may provide a mechanism of reorganizing and organizational rigidity as a mechanism of a positive and negative feedback loop mediated by the personality and the attitude fluctuations of organizational members.
C1 Univ Electrocommun, Grad Sch Informat Syst, Chofu, Tokyo 1828585, Japan.
   Matsue Natl Coll Technol, Dept Informat Engn, Matsue, Shimane 6900865, Japan.
RP Okada, I (corresponding author), Univ Electrocommun, Grad Sch Informat Syst, 1-5-1 Chofu Gaoka, Chofu, Tokyo 1828585, Japan.
CR ATKINSON JW, 1957, PSYCHOL REV, V64, P359, DOI 10.1037/h0043445
   CASTI JL, 1996, WOULD BE WORLDS
   CATTELL RB, 1980, MANKIND QUART, V21, P35
   CHIAKEN S, 1980, J PERS SOC PSYCHOL, V47, P1218
   Galbraith J., 1977, ORG DESIGN
   MICHAELS M, 1995, CHAOS SOC, P15
   Milgrom Paul, 1992, EC ORG MANAGEMENT
   Minsky ML., 1986, SOC MIND
   Pervin L. A., 1993, PERSONALITY THEORY R
   Prietula M. J., 1994, Journal of Organizational Computing, V4, P41
   Simon H., 1982, SCI ARTIFICIAL
NR 11
TC 1
Z9 1
U1 0
U2 3
PU JAPANESE ASSOC MATHEMATICAL SOCIOLOGY
PI SENDAI
PA C/O J A M S EXECUTIVE OFFICE, TOHOKU UNIV, DEPT BEHAVIORAL SCIENCE,
   SENDAI, 980-8576, JAPAN
SN 0913-1442
J9 SOCIOL THEOR METHOD
JI Sociol. Theor. Methods
PY 1999
VL 14
IS 2
BP 33
EP 52
PG 20
WC Social Sciences, Mathematical Methods; Sociology
SC Mathematical Methods In Social Sciences; Sociology
GA 254UP
UT WOS:000083630800003
DA 2021-08-04
ER

PT J
AU Platzek, T
   Schwabe, R
AF Platzek, T
   Schwabe, R
TI Combined prenatal toxicity of 6-mercaptopurine riboside and hydroxyurea
   in mice
SO TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS
LA English
DT Article
DE 6-mercaptopurine riboside; hydroxyurea; teratogenicity; dose response;
   DNA incorporation; mice
ID DNA-SYNTHESIS; RAT EMBRYOS; CELL DEATH; TERATOGENESIS; EMBRYOTOXICITY;
   6-THIOGUANINE; CONSEQUENCES; LIMB
AB Hydroxyurea (HU) and 6-mercaptopurine riboside (6-MPr) are used as cytostatic chemotherapeutics. Their teratogenic potential in experimental animals has been well known for several decades. Generally, it is assumed that the toxicity of both agents is due to an interference with enzymes of DNA synthesis. In the case of 6-MPr, it was speculated that the teratogenicity in rodents might be paralleled by or even correlated to an incorporation of 6-thioguanine into the DNA of the embryos, in this study, the interaction between these two compounds with regard to teratogenicity in NMRI mice was investigated. Dose-response data of 6-MPr (s.c.-treatment) were published earlier. First, a dose-response study with HU alone (i.p.-treatment) was performed. From these data, the doses for the combination study were derived: HU 250 mg/kg (NOAEL dose) and 6-MPr 16 mg/kg (strongly teratogenic dose). In all experimental groups the substances were administered to the dams once on day 11 of gestation. Combination effects were investigated applying various dosing regimens. In group I treatment was simultaneous, in group II HU was administered 2 h before 6-MPr, in group LU 2 h after 6-MPr. The differences in the overall frequency of gross structural abnormalities were moderate. However, when analysing the effects in more detail (single abnormalities), group III exhibited great differences: 1) 6-MPr co-treatment increased the frequency of HU effects (skull defects) and 2) HU co-treatment decreased the frequency of 6-MPr effects (limb defects) when compared to the findings of the dose-response studies. In addition, the influence of HU on the 6-MPr-induced DNA modification was determined by measuring the incorporation of 6-thioguanine into the DNA of day-ii embryos. As expected, the HU co-treatment corresponding to the group III dosing regimen of the teratogenicity experiment decreased the incorporation rate by ca. 40%. This was in parallel to the decrease in the frequency of 6-MPr effects in the teratogenicity III group. This finding may be considered as a further indication that in the case of 6-MPr, DNA modification is accompanying teratogenicity. Teratogenesis Carcinog. Mutagen. 19:223-232, 1999. (C) 1999 Wiley-Liss, Inc.
C1 Fed Inst Hlth Protect Consumers & Vet Med, Berlin, Germany.
   Free Univ Berlin, Inst Clin Pharmacol & Toxicol, Berlin, Germany.
RP Platzek, T (corresponding author), Bundesinst Gesundheitlichen Verbraucherschutz & V, Postfach 330013, D-14191 Berlin, Germany.
CR BARR M, 1981, TERATOLOGY, V24, P163, DOI 10.1002/tera.1420240207
   BELILES RP, 1991, J AM COLL TOXICOL, V10, P269, DOI 10.3109/10915819109078636
   BIANCHI V, 1986, J BIOL CHEM, V261, P6037
   Chahoud I., 1977, Methods in prenatal toxicology. Evaluation of embryotoxic effects in experimental animals. Teratology workshop April 1977, Berlin., P78
   CHAHOUD I, 1997, ATLAS EXTERNAL ANOMA
   CHAUBE S, 1966, CANCER RES, V26, P1448
   CHAUBE S, 1973, TERATOLOGY, V7, P79, DOI 10.1002/tera.1420070112
   COLLINS A, 1987, EUR J BIOCHEM, V169, P299, DOI 10.1111/j.1432-1033.1987.tb13612.x
   Dawson AB, 1926, STAIN TECHNOL, V1, P123, DOI 10.3109/10520292609115636
   DESESSO JM, 1981, TERATOLOGY, V24, P19, DOI 10.1002/tera.1420240104
   HANSEN DK, 1995, TOXICOL IN VITRO, V9, P11, DOI 10.1016/0887-2333(94)00192-W
   KWASIGROCH TE, 1985, FUND APPL TOXICOL, V5, P1161, DOI 10.1016/0272-0590(85)90153-8
   LENNARD L, 1992, EUR J CLIN PHARMACOL, V43, P329, DOI 10.1007/BF02220605
   LING YH, 1992, MOL PHARMACOL, V42, P802
   NELSON BK, 1994, TERATOLOGY, V49, P33, DOI 10.1002/tera.1420490107
   NEUBERT D, 1987, Congenital Anomalies, V27, P275, DOI 10.1111/j.1741-4520.1987.tb00711.x
   NEUBERT D, 1977, N-S ARCH PHARMACOL, V298, P93, DOI 10.1007/BF00508616
   PLATZEK T, 1994, CHEM-BIOL INTERACT, V93, P59, DOI 10.1016/0009-2797(94)90086-8
   Platzek T, 1996, TERATOGEN CARCIN MUT, V16, P169
   RAJEWSKY MF, 1971, EXP CELL RES, V66, P489, DOI 10.1016/0014-4827(71)90706-3
   RITTER EJ, 1982, TERATOLOGY, V25, P95, DOI 10.1002/tera.1420250113
   RITTER EJ, 1984, FUND APPL TOXICOL, V4, P352, DOI 10.1016/0272-0590(84)90192-1
   RITTER EJ, 1973, TERATOLOGY, V7, P219, DOI 10.1002/tera.1420070302
   SAS Institute Inc., 1988, SAS STAT US GUID REL SAS STAT US GUID REL
   SCOTT WJ, 1971, DEV BIOL, V26, P306, DOI 10.1016/0012-1606(71)90129-1
   SKALKO RG, 1978, ROLE PHARMACOKINETIC, P549
   THIERSCH JOHN B., 1954, ANN NEW YORK ACAD SCI, V60, P220
   UribeLuna S, 1997, BIOCHEM PHARMACOL, V54, P419, DOI 10.1016/S0006-2952(97)00200-1
   WILSON JG, 1975, TERATOLOGY, V11, P169, DOI 10.1002/tera.1420110205
   WISE LD, 1997, TERMINOLOGY DEV ABNO, V5, P249
NR 30
TC 7
Z9 7
U1 0
U2 0
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0270-3211
J9 TERATOGEN CARCIN MUT
JI Teratogenesis Carcinog. Mutagen.
PY 1999
VL 19
IS 3
BP 223
EP 232
DI 10.1002/(SICI)1520-6866(1999)19:3<223::AID-TCM5>3.0.CO;2-C
PG 10
WC Oncology; Genetics & Heredity; Toxicology
SC Oncology; Genetics & Heredity; Toxicology
GA 202BU
UT WOS:000080632900005
PM 10379846
DA 2021-08-04
ER

PT J
AU Palm, K
   Luthman, K
   Ungell, AL
   Strandlund, G
   Beigi, F
   Lundahl, P
   Artursson, P
AF Palm, K
   Luthman, K
   Ungell, AL
   Strandlund, G
   Beigi, F
   Lundahl, P
   Artursson, P
TI Evaluation of dynamic polar molecular surface area as predictor of drug
   absorption: Comparison with other computational and experimental
   predictors
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID EPITHELIAL CACO-2 CELLS; HYDROGEN-BONDING CAPACITY; BRAIN PENETRATION;
   PERMEABILITY COEFFICIENTS; PARTITION-COEFFICIENTS;
   INTESTINAL-ABSORPTION; PEPTIDE STRUCTURE; IN-VITRO; LOG-P; TRANSPORT
AB The relationship between various molecular descriptors and transport of drugs across the intestinal epithelium was evaluated. The monolayer permeability (P-c) of human intestinal Caco-2 cells to a series of nine beta-receptor-blocking agents was investigated in vitro. The dynamic polar molecular surface area (PSA(d)) of the compounds was calculated from all low-energy conformations identified in molecular mechanics calculations in vacuum and in simulated chloroform and water environments. For most of the investigated drugs, the effects of the different environments on PSA(d) were small. The exception was H 216/44, which is a large flexible compound containing several functional groups capable of hydrogen bonding (PSA(d,chloroform) = 70.8 Angstrom(2) and PSA(d,water) = 116.6 Angstrom(2)). The relationship between P-c and PSA(d) was stronger than those between P-c and the calculated octanol/water distribution coefficients (log D-calc) or the experimentally determined immobilized liposome chromatography (ILC) retention. P-c values for two new practolol analogues and H 216/44 were predicted from the structure-permeability relationships of a subset of the nine compounds and compared with experimental values. The P-c values of the two practolol analogues were predicted well from both PSA(d) calculations and ILC retention studies. The P-c value of H 216/44 was reasonably well-predicted only from the PSA(d) of conformations preferred in vacuum and in water. The other descriptors overestimated the P-c of H 216/44 100-500-fold.
C1 Uppsala Univ, Dept Pharm, BME, SE-75123 Uppsala, Sweden.
   Uppsala Univ, Dept Organ Pharmaceut Chem, BME, SE-75123 Uppsala, Sweden.
   Uppsala Univ, Dept Biochem, BME, SE-75123 Uppsala, Sweden.
   Astra Hassle AB, Pharmacokinet & Drug Metab, SE-43183 Molndal, Sweden.
   Astra Hassle AB, Med Chem, SE-43183 Molndal, Sweden.
RP Luthman, K (corresponding author), Univ Tromso, Inst Pharm, N-9037 Tromso, Norway.
RI Luthman, Kristina/A-7600-2010
OI Luthman, Kristina/0000-0003-4344-8609
CR AMIDON GL, 1975, J PHYS CHEM-US, V79, P2239, DOI 10.1021/j100588a008
   ANDERBERG EK, 1992, J PHARM SCI, V81, P879, DOI 10.1002/jps.2600810908
   ARTURSSON P, 1991, BIOCHEM BIOPH RES CO, V175, P880, DOI 10.1016/0006-291X(91)91647-U
   ARTURSSON P, 1993, PHARMACEUT RES, V10, P1123, DOI 10.1023/A:1018903931777
   ARTURSSON P, 1990, J PHARM SCI-US, V79, P476, DOI 10.1002/jps.2600790604
   ARTURSSON P, 1996, CELL CULTURE MODELS, P111
   AVDEEF A, 1992, QUANT STRUCT-ACT REL, V11, P510, DOI 10.1002/qsar.2660110408
   Avdeef A, 1998, PHARMACEUT RES, V15, P209, DOI 10.1023/A:1011954332221
   Barbato F, 1997, PHARMACEUT RES, V14, P1699, DOI 10.1023/A:1012119527214
   BARLOW D, 1994, J CONTROL RELEASE, V29, P283, DOI 10.1016/0168-3659(94)90074-4
   Basak SC, 1996, PHARMACEUT RES, V13, P775, DOI 10.1023/A:1016064003554
   BEIGI F, 1995, J CHROMATOGR A, V704, P315, DOI 10.1016/0021-9673(95)00214-8
   Beigi F, 1998, INT J PHARM, V164, P129, DOI 10.1016/S0378-5173(97)00398-0
   BREKKAN E, 1997, METH BIOTEC, V1, P193
   Burton PS, 1996, J PHARM SCI, V85, P1336, DOI 10.1021/js960067d
   CONRADI RA, 1991, PHARMACEUT RES, V8, P1453, DOI 10.1023/A:1015825912542
   CONRADI RA, 1992, PHARMACEUT RES, V9, P435, DOI 10.1023/A:1015867608405
   Craig P, 1990, CUMULATIVE SUBJECT I, P237
   DUNN WJ, 1987, J MED CHEM, V30, P1121, DOI 10.1021/jm00390a002
   ELTAYAR N, 1991, J PHARM SCI, V80, P590
   JACOBS RE, 1989, BIOCHEMISTRY-US, V28, P3421, DOI 10.1021/bi00434a042
   KARLSSON J, 1993, BRIT J PHARMACOL, V110, P1009, DOI 10.1111/j.1476-5381.1993.tb13914.x
   KARLSSON J, 1991, INT J PHARM, V71, P55, DOI 10.1016/0378-5173(91)90067-X
   LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X
   Lennernas H, 1996, INT J PHARM, V127, P103, DOI 10.1016/0378-5173(95)04204-0
   LEO A, 1975, J MED CHEM, V18, P865, DOI 10.1021/jm00243a001
   LIPINSKI CA, 1996, ADV DRUG DELIV REV, V23, P3
   LIPKOWITZ KB, 1989, J AM CHEM SOC, V111, P7750, DOI 10.1021/ja00202a014
   LUNDQVIST A, IN PRESS FREEZE THAW
   MANNHOLD R, 1990, QUANT STRUCT-ACT REL, V9, P21, DOI 10.1002/qsar.19900090105
   MARTIN YC, 1981, J MED CHEM, V24, P229, DOI 10.1021/jm00135a001
   MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405
   NORINDER U, 1997, PHARMACEUT RES, V14, P1785
   ONG SW, 1994, J PHYS CHEM-US, V98, P10189, DOI 10.1021/j100091a039
   OOI T, 1987, P NATL ACAD SCI USA, V84, P3086, DOI 10.1073/pnas.84.10.3086
   Palm K, 1997, PHARMACEUT RES, V14, P568, DOI 10.1023/A:1012188625088
   Palm K, 1996, J PHARM SCI, V85, P32, DOI 10.1021/js950285r
   PIDGEON C, 1995, J MED CHEM, V38, P590, DOI 10.1021/jm00004a004
   RUBAS W, 1994, MATER RES SOC SYMP P, V331, P179
   Salminen T, 1997, J PHARMACEUT BIOMED, V15, P469, DOI 10.1016/S0731-7085(96)01883-3
   SCHOENWALD RD, 1983, J PHARM SCI-US, V72, P1266, DOI 10.1002/jps.2600721108
   STEIN WD, 1967, MOVEMENT MOL CELL ME
   VANDEWATERBEEMD H, 1992, CHIMIA, V46, P299
   vandeWaterbeemd H, 1996, QUANT STRUCT-ACT REL, V15, P480, DOI 10.1002/qsar.19960150604
   WILS P, 1994, J PHARMACOL EXP THER, V269, P654
   XIANG TX, 1994, J MEMBRANE BIOL, V140, P111
   YOUNG RC, 1988, J MED CHEM, V31, P656, DOI 10.1021/jm00398a028
NR 47
TC 180
Z9 186
U1 0
U2 10
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD DEC 31
PY 1998
VL 41
IS 27
BP 5382
EP 5392
DI 10.1021/jm980313t
PG 11
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 155AQ
UT WOS:000077924000005
PM 9876108
DA 2021-08-04
ER

PT J
AU Helbing, D
   Huberman, BA
AF Helbing, D
   Huberman, BA
TI Coherent moving states in highway traffic
SO NATURE
LA English
DT Article
ID PHASE-TRANSITIONS; COOPERATION; SIMULATIONS; EVOLUTION; SYSTEMS; FLOW
AB Advances in multiagent simulation techniques(1-3) have made possible the study of realistic highway traffic patterns and have allowed theories(3-6) based on driver behaviour to be tested. Such simulations display various empirical features of traffic flows(7), and are used to design traffic controls that maximize the throughput of vehicles on busy highways. In addition to its intrinsic economic values, vehicular traffic is of interest because it may be relevant to social phenomena in which diverse individuals compete with each other under certain constraintsg(9,10). Here we report simulations of heterogeneous traffic which demonstrate that cooperative, coherent states can arise from competitive interactions between vehicles. As the density of vehicles increases, their interactions cause a transition into a highly correlated state in which all vehicles move with approximately the same speed, analogous to the motion of a solid block. This state is safer because it has a reduced lane-changing rate, and the traffic flow is high and stable. The coherent state disappears when the vehicle density exceeds a critical value. We observe the effect also in real Dutch traffic data.
C1 Univ Stuttgart, Inst Theoret Phys, D-70550 Stuttgart, Germany.
   Xerox Corp, Palo Alto Res Ctr, Palo Alto, CA 94304 USA.
RP Helbing, D (corresponding author), Univ Stuttgart, Inst Theoret Phys, Pfaffenwaldring 57-III, D-70550 Stuttgart, Germany.
RI Helbing, Dirk/C-6114-2008
CR AXELROD R, 1988, SCIENCE, V242, P1385, DOI 10.1126/science.242.4884.1385
   BANDO M, 1995, J PHYS I, V5, P1389, DOI 10.1051/jp1:1995206
   BENJACOB E, 1994, NATURE, V368, P46, DOI 10.1038/368046a0
   DAGANZO CF, 1975, TRANSPORT RES, V9, P339, DOI 10.1016/0041-1647(75)90004-0
   Faieta B., 1993, SSL42 XER PARC
   GAZIS DC, 1961, OPER RES, V9, P545, DOI 10.1287/opre.9.4.545
   GLANCE NS, 1994, SCI AM, V270, P76, DOI 10.1038/scientificamerican0394-76
   HALL FL, 1988, TRANSPORT RES A-POL, V22, P45, DOI 10.1016/0191-2607(88)90062-3
   Helbing D, 1998, PHYS REV LETT, V81, P3042, DOI 10.1103/PhysRevLett.81.3042
   Helbing D, 1997, NATURE, V388, P47, DOI 10.1038/40353
   Helbing D., 1997, VERKEHRSDYNAMIK
   HELBING D, UNPUB PHYS REV
   Helbing D., 1995, QUANTITATIVE SOCIODY
   HUBERMAN BA, 1993, P NATL ACAD SCI USA, V90, P7716, DOI 10.1073/pnas.90.16.7716
   Kerner BS, 1996, PHYS REV E, V53, pR1297, DOI 10.1103/PhysRevE.53.R1297
   Kerner BS, 1997, PHYS REV LETT, V79, P4030, DOI 10.1103/PhysRevLett.79.4030
   Krug J, 1996, J PHYS A-MATH GEN, V29, pL465, DOI 10.1088/0305-4470/29/18/004
   LAVE CA, 1985, AM ECON REV, V75, P1159
   Leutzbach W., 1988, INTRO THEORY TRAFFIC
   May A.D., 1990, TRAFFIC FLOW FUNDAME
   Nagel K, 1998, PHYS REV E, V58, P1425, DOI 10.1103/PhysRevE.58.1425
   Prigogine I., 1971, KINETIC THEORY VEHIC
   Rickert M, 1996, PHYSICA A, V231, P534, DOI 10.1016/0378-4371(95)00442-4
   SCHRECKENBERG M, 1995, PHYS REV E, V51, P2939, DOI 10.1103/PhysRevE.51.2939
   Schreckenberg M., 1998, TRAFFIC GRANULAR FLO
   Small K.A., 1992, URBAN TRANSPORTATION
   VICSEK T, 1995, PHYS REV LETT, V75, P1226, DOI 10.1103/PhysRevLett.75.1226
NR 27
TC 147
Z9 155
U1 1
U2 31
PU MACMILLAN MAGAZINES LTD
PI LONDON
PA PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD DEC 31
PY 1998
VL 396
IS 6713
BP 738
EP 740
DI 10.1038/25499
PG 3
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 151WC
UT WOS:000077742800028
OA Green Submitted
DA 2021-08-04
ER

PT J
AU Penney, RW
AF Penney, RW
TI Analytic determination of gradients of intervisibility over continuous
   randomly-generated topography
SO IMA JOURNAL OF APPLIED MATHEMATICS
LA English
DT Article
DE intervisibility; line of sight; synthetic terrain; computer-generated
   forces; autonomous agents
AB Determination of the existence of intervisibility between pairs of points above realistically undulating terrain is a fundamental operation within land-based military simulations. However, transitions between regions where an intelligently piloted vehicle is respectively exposed and concealed are of particular importance, yet are often very difficult to identify a priori. Tn this paper we show how a meaningful gradient of intervisibility can be directly calculated, and we argue that this provides a valuable indication of the direction to the nearest point of opposite visibility. Moreover, direct methods for evaluating such gradients are also relevant to some classes of behavioural models for vehicles moving over such terrain. Numerical simulation results are presented in support of the theoretical analyses.
   We will also outline how. simple randomized, yet differentiable topography, exhibiting realistic undulations, can be conveniently generated as a thermalized elastic manifold. The availability of such an ensemble of different topographies provides a powerful test of the adaptability of any terrain-dependent algorithm, and forms an integral part of the validation of our analysis.
C1 Def Evaluat & Res Agcy, Malvern WR14 3PS, Worcs, England.
RP Penney, RW (corresponding author), Def Evaluat & Res Agcy, St Andrews Rd, Malvern WR14 3PS, Worcs, England.
CR Dirac P.A.M., 1958, PRINCIPLES QUANTUM M, V4th ed.
   *GEOFORM, 1996, NEW SCI         0907
   LATOMBE JC, 1991, ROBOT MOTION PLANNIN
   Mandelbrot BB., 1982, FRACTAL GEOMETRY NAT
   METROPOLIS N, 1953, J CHEM PHYS, V21, P1087, DOI 10.1063/1.1699114
   PENNEY RW, 1996, P 6 C COMP GEN FORC, P519
   PETTY MD, 1997, P SIM INT WORKSH
NR 7
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0272-4960
J9 IMA J APPL MATH
JI IMA J. Appl. Math.
PD DEC
PY 1998
VL 61
IS 3
BP 291
EP 303
DI 10.1093/imamat/61.3.291
PG 13
WC Mathematics, Applied
SC Mathematics
GA 171KV
UT WOS:000078863600004
DA 2021-08-04
ER

PT J
AU Nilsen, J
   Mor, G
   Naftolin, F
AF Nilsen, J
   Mor, G
   Naftolin, F
TI Raloxifene induces neurite outgrowth in estrogen receptor positive PC12
   cells
SO MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
LA English
DT Article
DE estrogen replacement therapy; estrogen receptor (ER) ligands; menopause;
   brain; antiestrogen
ID DEMENTIA-ALZHEIMERS TYPE; ARCUATE NUCLEUS; NERVOUS-SYSTEM; RAT;
   ESTRADIOL; NEURONS; RISK; PHARMACOLOGY; PROGESTERONE; CULTURE
AB Objective: It is well established that gonadal steroids have direct in vivo and in vitro effects on neurons. To further study these effects, we used rat PC12 cells to examine the effects of estrogen receptor (ER) ligands on neuronal morphology.
   Design: PC12 cells constitutively express ER beta, but only strongly express ER alpha after long-term priming with nerve growth factor (NGF). We therefore primed PC12 cells with NGF for 14 days before testing them for estradiol (10(-9) M)- and/or raloxifene (10(-7) M)-induced neurite growth. Neurite growth was assessed by quantitative light microscopy. As control, ER status of the PC12 cells was assessed by reverse transcription-polymerase chain reaction (RT-PCR).
   Results: In this study, both estradiol and raloxifene induced the outgrowth of neurites in NGF-treated PC12 cells (p < 0.05). The combination of estradiol- and raloxifene-induced neurite growth was statistically greater than the effects of either agent alone. RT-PCR confirms that NGF-treated PC12 cells express both ER alpha and ER beta.
   Conclusions: This report is the first on the neurotrophic effect of raloxifene. At 10(-7) M, raloxifene's effect equaled that of estradiol; moreover, raloxifene did not block the neurite growth of simultaneously estradiol-treated PC12 cells, despite its functional antiestrogenic effects in vivo. We conclude that raloxifene is estrogen agonistic in this animal model and therefore studies are warranted to delineate the relationship between steroidal estrogen and raloxifene. (Menopause 1998;5:211-216, (C) 1998, The North American Menopause Society.).
C1 Yale Univ, Sch Med, Dept Obstet & Gynecol, New Haven, CT 06520 USA.
   Yale Univ, Sch Med, Ctr Reprod Biol, New Haven, CT 06520 USA.
   Yale Univ, Dept Biol, New Haven, CT USA.
RP Naftolin, F (corresponding author), Yale Univ, Sch Med, Dept Obstet & Gynecol, 333 Cedar St, New Haven, CT 06520 USA.
RI Nilsen, Jon/A-3082-2008
CR Anderson JJB, 1998, P SOC EXP BIOL MED, V217, P345, DOI 10.3181/00379727-217-44243
   Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645
   DIAZ H, 1992, J NEUROSCI RES, V33, P266, DOI 10.1002/jnr.490330210
   Draper MW, 1996, J BONE MINER RES, V11, P835
   FILLIT H, 1986, PSYCHONEUROENDOCRINO, V11, P337, DOI 10.1016/0306-4530(86)90019-3
   FUCHSYOUNG R, 1995, ANN NY ACAD SCI, V761, P355, DOI 10.1111/j.1749-6632.1995.tb31392.x
   Gustafsson JA, 1998, NAT MED, V4, P152, DOI 10.1038/nm0298-152
   HONJO H, 1989, J STEROID BIOCHEM, V34, P521
   JORDAN VC, 1984, PHARMACOL REV, V36, P245
   JORDAN VC, 1990, ENDOCR REV, V11, P578, DOI 10.1210/edrv-11-4-578
   KOIKE S, 1987, NUCLEIC ACIDS RES, V15, P2499, DOI 10.1093/nar/15.6.2499
   Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925
   Levy A, 1996, J NEUROSCI RES, V43, P719
   LOBO RA, 1994, TREATMENT POSTMENOPA
   LORENZO A, 1992, J NEUROSCI RES, V33, P418, DOI 10.1002/jnr.490330308
   LUSTIG RH, 1994, J NEUROSCI, V14, P3945
   MATSUMOTO A, 1979, CELL TISSUE RES, V198, P427
   Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508
   PAGANINIHILL A, 1994, AM J EPIDEMIOL, V140, P256, DOI 10.1093/oxfordjournals.aje.a117244
   PEREZ J, 1993, BRAIN RES, V608, P38, DOI 10.1016/0006-8993(93)90771-E
   SAITO Y, 1985, AM J OBSTET GYNECOL, V151, P805, DOI 10.1016/0002-9378(85)90525-3
   Sherwin BB, 1998, P SOC EXP BIOL MED, V217, P17
   SIEFER DB, 1994, MENOPAUSE, V1, P83
   SOHRABJI F, 1994, J NEUROBIOL, V25, P974, DOI 10.1002/neu.480250807
   Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9
   TORANALLERAND CD, 1994, NEW BIOL STEROID HOR, P311
   ZIEL HK, 1975, NEW ENGL J MED, V293, P1167, DOI 10.1056/NEJM197512042932303
NR 27
TC 81
Z9 81
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1072-3714
J9 MENOPAUSE
JI Menopause-J. N. Am. Menopause Soc.
PD WIN
PY 1998
VL 5
IS 4
BP 211
EP 216
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 151MH
UT WOS:000077723600005
PM 9872486
DA 2021-08-04
ER

PT J
AU Gallese, V
   Goldman, A
AF Gallese, V
   Goldman, A
TI Mirror neurons and the simulation theory of mind-reading
SO TRENDS IN COGNITIVE SCIENCES
LA English
DT Editorial Material
ID VENTRAL PREMOTOR CORTEX; MACAQUE MONKEY; INFERIOR AREA-6;
   FUNCTIONAL-ORGANIZATION; GRASP REPRESENTATIONS; INFEROTEMPORAL CORTEX;
   MACACA-MULATTA; VISUAL ANGLE; FRONTAL-LOBE; MOTOR
AB A new class of visuomotor neuron has been recently discovered in the monkey's premotor cortex: mirror neurons. These neurons respond both when a particular action is performed by the recorded monkey acid when the same action, performed by another individual, is observed. Mirror neurons appear to form a cortical system matching observation and execution of goal-related motor actions. Experimental evidence suggests that a similar matching system also exists in humans. What might be the functional role of this matching system? One possible function is to enable an organism to detect certain mental states of observed conspecifics. This function might be part of, or a precursor to, a more general mind-reading ability. Two different accounts of minding reading have been suggested. According to 'theory theory', mental states are represented as inferred posits of a naive theory. According to 'simulation theory', other people's mental states are represented by adopting their perspective: by tracking or matching their states with resonant states of one's own. The activity of mirror neurons, and the fact that observers undergo motor facilitation in the same muscular groups as those utilized by target agents, are findings that accord well with simulation theory but would not be predicted by theory theory.
RI Galantucci, Bruno/E-5770-2010
CR Astington JW, 1988, DEV THEORIES MIND
   Baron-Cohen S., 1995, MINDBLINDNESS
   Barresi J, 1996, BEHAV BRAIN SCI, V19, P107, DOI 10.1017/S0140525X00041790
   BROTHERS L, 1990, BEHAV BRAIN RES, V41, P199, DOI 10.1016/0166-4328(90)90108-Q
   Byrne RW., 1988, MACHIAVELLIAN INTELL
   BYRNE RW, IN PRESS BEHAV BRAIN
   Byrne RW, 1995, THINKING APE EVOLUTI
   CARRUTHERS P, 1996, THEORIES THEORIES MI
   Cheney D. L., 1990, MONKEYS SEE WORLD
   Churchland P, 1988, MATTER CONSCIOUSNESS
   Currie G, 1997, PHILOS SCI, V64, P161, DOI 10.1086/392541
   DAVIES M, 1995, MENTAL SIMULATION
   DAVIES M, 1995, FOLK PSYCHOL
   DECETY J, 1991, BEHAV BRAIN RES, V42, P1, DOI 10.1016/S0166-4328(05)80033-6
   FADIGA L, 1995, J NEUROPHYSIOL, V73, P2608
   FARAH MJ, 1992, J EXP PSYCHOL HUMAN, V18, P241, DOI 10.1037/0096-1523.18.1.241
   Fodor J., 1987, PSYCHOSEMANTICS
   Gallese V, 1996, BRAIN, V119, P593, DOI 10.1093/brain/119.2.593
   GENTILUCCI M, 1988, EXP BRAIN RES, V71, P475, DOI 10.1007/BF00248741
   GOLDMAN A, IN PRESS METAREPRESE
   Goldman A. I., 1989, MIND LANG, V4, P161, DOI DOI 10.1111/J.1468-0017.1989.TB00249.X
   Goldman A.I, 1992, MIND LANG, V7, P104, DOI [DOI 10.1111/J.1468-0017.1992.TB00200.X, 10.1111/j.1468-0017.1992.tb00200.x]
   GOPNIK A, 1993, BEHAV BRAIN SCI, V16, P1, DOI 10.1017/S0140525X00028636
   Gopnik A., 1997, WORDS THOUGHTS THEOR
   Gordon RM., 1986, MIND LANGUAGE, V1, P158, DOI [10.1111/j.1468-0017.1986.tb00324.x, DOI 10.1111/J.1468-0017.1986.TB00324.X]
   Grafton ST, 1996, EXP BRAIN RES, V112, P103
   GROSS CG, 1972, J NEUROPHYSIOL, V35, P96
   GROSS CG, 1985, PATTERN RECOGNITION
   HAUSER MD, 1993, BEHAV ECOL, V4, P206, DOI 10.1093/beheco/4.3.206
   HAUSER MD, 1992, P NATL ACAD SCI USA, V89, P12137, DOI 10.1073/pnas.89.24.12137
   HE SQ, 1993, J NEUROSCI, V13, P952
   HEAL J., 1986, LANGUAGE MIND LOGIC, P135
   HEPPREYMOND MC, 1994, CAN J PHYSIOL PHARM, V72, P571, DOI 10.1139/y94-081
   Heyes CM, 1998, BEHAV BRAIN SCI, V21, P101, DOI 10.1017/S0140525X98000703
   JEANNEROD M, 1994, BEHAV BRAIN SCI, V17, P187, DOI 10.1017/S0140525X00034026
   KOSSLYN SM, 1978, COGNITIVE PSYCHOL, V10, P356, DOI 10.1016/0010-0285(78)90004-X
   LESLIE AM, 1994, COGNITION, V50, P211, DOI 10.1016/0010-0277(94)90029-9
   Lewis D, 1972, AUSTRALAS J PHILOS, V50, P207, DOI [10.1080/00048407212341301, DOI 10.1080/00048407212341301]
   LHERMITTE F, 1986, ANN NEUROL, V19, P326, DOI 10.1002/ana.410190404
   Liberman A. M., 1996, SPEECH SPECIAL CODE
   Machiavelli NiccolO, 1979, PRINCE
   MATELLI M, 1986, J COMP NEUROL, V251, P281, DOI 10.1002/cne.902510302
   MATELLI M, 1985, BEHAV BRAIN RES, V18, P125, DOI 10.1016/0166-4328(85)90068-3
   MATELLI M, 1997, HANDB NEUR, V11, P9
   MATSUMURA M, 1979, NEUROSCI LETT, V11, P241, DOI 10.1016/0304-3940(79)90001-6
   Meltzoff A. N., 1995, BODY SELF, P43
   MUAKKASSA KF, 1979, BRAIN RES, V177, P176, DOI 10.1016/0006-8993(79)90928-4
   Murata A, 1997, J NEUROPHYSIOL, V78, P2226
   OKANO K, 1987, EXP BRAIN RES, V66, P155
   Perner J., 1991, UNDERSTANDING REPRES
   PERRETT DI, 1989, J EXP BIOL, V146, P87
   PERRETT DI, 1982, EXP BRAIN RES, V47, P329
   Perrett DI, 1990, VISION ACTION CONTRO, P163
   RIZZOLATTI G, 1988, EXP BRAIN RES, V71, P491, DOI 10.1007/BF00248742
   Rizzolatti G, 1998, TRENDS NEUROSCI, V21, P188, DOI 10.1016/S0166-2236(98)01260-0
   RIZZOLATTI G, 1981, BEHAV BRAIN RES, V2, P147, DOI 10.1016/0166-4328(81)90053-X
   Rizzolatti G, 1996, EXP BRAIN RES, V111, P246
   Rizzolatti G, 1996, COGNITIVE BRAIN RES, V3, P131, DOI 10.1016/0926-6410(95)00038-0
   Rizzolatti G., 1988, NEUROBIOLOGY NEOCORT, P269
   Sellars W., 1963, SCI PERCEPTION REALI, P127
   STAMMBACH E, 1988, BEHAVIOUR, V107, P241, DOI 10.1163/156853988X00368
   Stich S, 1992, MIND LANG, V7, P29
   TANAKA K, 1991, J NEUROPHYSIOL, V66, P170
   TOMASELLO M, 1993, BEHAV BRAIN SCI, V16, P495, DOI 10.1017/S0140525X0003123X
   Tversky, 1982, JUDGMENT UNCERTAINTY, P201, DOI [DOI 10.1017/CBO9780511809477, DOI 10.1017/CBO9780511809477.015]
   Wellman H, 1990, CHILDS THEORY MIND
   Wellman H. M., 1992, MIND LANG, V7, P145, DOI DOI 10.1111/J.1468-0017.1992.TB00202.X
   YUE G, 1992, J NEUROPHYSIOL, V67, P1114
NR 68
TC 1621
Z9 1651
U1 4
U2 311
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 1364-6613
J9 TRENDS COGN SCI
JI TRENDS COGN. SCI.
PD DEC
PY 1998
VL 2
IS 12
BP 493
EP 501
DI 10.1016/S1364-6613(98)01262-5
PG 11
WC Behavioral Sciences; Neurosciences; Psychology, Experimental
SC Behavioral Sciences; Neurosciences & Neurology; Psychology
GA 171PR
UT WOS:000078873000006
PM 21227300
DA 2021-08-04
ER

PT J
AU Hua, FJ
   Li, J
   Hu, CP
   Liu, HL
   Hu, Y
AF Hua, FJ
   Li, J
   Hu, CP
   Liu, HL
   Hu, Y
TI Diffusion behavior of ethanol in epoxy/urethane acrylate resin
   interpenetrating polymer networks (I) - Homogeneous transport model and
   correlation with experimental sorption curves
SO CHEMICAL JOURNAL OF CHINESE UNIVERSITIES-CHINESE
LA Chinese
DT Article
DE ethanol; transport; epoxy resin; urethane acrylate resin;
   interpenetrating polymer network; diffusion
ID VINYL-ESTER RESIN; INJECTION-MOLDING PROCESS; REACTION-KINETICS;
   POLYURETHANE
AB A transport-complex model has been established to correlate the experimental absorption curves of epoxy resin (epoxy) and urethane acrylate resin(UAR) simultaneous interpenetrating networks (SINs) with ethanol as the diffusion agent, The experimental results show that the simulative curves calculated can be correlated by using the complex model well enough with the experimental data in general and the physical meaning of correlating coefficient omega(r) is expressed as the ability of migration of ethanol through the networks after it makes hydrogen bond with urethane, ester or ether groups existing in the networks, Consequently it directly responds to the structures and morphologies of the SINs, The parameters measured including the solubility constant S, average diffusion coefficient D and penetrating weight P are all related to the composition of such SINs. It clearly exhibits that ethanol mainly transports through the UAR phase.
C1 E China Univ Sci & Technol, Inst Mat Sci & Engn, Shanghai 200237, Peoples R China.
   E China Univ Sci & Technol, Dept Chem, Shanghai 200237, Peoples R China.
RP Hu, CP (corresponding author), E China Univ Sci & Technol, Inst Mat Sci & Engn, Shanghai 200237, Peoples R China.
CR BARTON AFM, 1991, CRC HDB SOLUBILITY O, P442
   CHEN NP, 1992, J APPL POLYM SCI, V46, P2075, DOI 10.1002/app.1992.070461202
   CHEN SA, 1980, J APPL POLYM SCI, V25, P1105, DOI 10.1002/app.1980.070250613
   CRANK J, 1975, MATH DIFFUSION POLYM
   Fan LH, 1996, J APPL POLYM SCI, V59, P1417, DOI 10.1002/(SICI)1097-4628(19960228)59:9<1417::AID-APP9>3.3.CO;2-X
   Fan LH, 1997, POLYMER, V38, P3609, DOI 10.1016/S0032-3861(96)00919-6
   Fan LH, 1997, POLYM ENG SCI, V37, P338, DOI 10.1002/pen.11676
   FRISCH HL, 1979, POLYM ENG SCI, V19, P294, DOI 10.1002/pen.760190411
   FRISCH HL, 1974, POLYM ENG SCI, V14, P646, DOI 10.1002/pen.760140910
   FRISCH HL, 1977, POLYM ALLOYS, P97
   Fukuda M, 1996, POLYM ENG SCI, V36, P558, DOI 10.1002/pen.10442
   HSU TJ, 1985, J POLYM ENG SCI, V25, P951
   HUA FJ, 1998, IN PRESS EUR POLYM J
   HUA FJ, 1997, J FUNCTIONAL POLYM, V10, P513
   KIM JH, 1987, POLYM ENG SCI, V27, P1234
   LEE SS, 1991, POLYM ENG SCI, V31, P1182, DOI 10.1002/pen.760311605
   LI J, 1997, J CHEM IND ENG, V48, P517
   PERINCE R, 1982, J CELL PLAST     MAR, P121
   TSHUDY JA, 1973, J POLYM SCI POL PHYS, V11, P2027, DOI 10.1002/pol.1973.180111012
   YANG YS, 1987, MACROMOLECULES, V20, P1490, DOI 10.1021/ma00173a008
NR 20
TC 4
Z9 4
U1 0
U2 1
PU HIGHER EDUCATION PRESS
PI BEIJING
PA SHATANHOU ST 55, BEIJING 100009, PEOPLES R CHINA
SN 0251-0790
J9 CHEM J CHINESE U
JI Chem. J. Chin. Univ.-Chin.
PD NOV
PY 1998
VL 19
IS 11
BP 1807
EP 1812
PG 6
WC Chemistry, Multidisciplinary
SC Chemistry
GA 160YV
UT WOS:000078261700028
DA 2021-08-04
ER

PT J
AU Teles, V
   de Marsily, G
   Perrier, E
AF Teles, V
   de Marsily, G
   Perrier, E
TI A new approach for modelling sediment deposition in an alluvial plain in
   order to display its heterogeneity
SO COMPTES RENDUS DE L ACADEMIE DES SCIENCES SERIE II FASCICULE A-SCIENCES
   DE LA TERRE ET DES PLANETES
LA French
DT Article
DE modelling; heterogeneity; alluvial plain; multi-agent; meander
ID SIMULATION
AB This article proposes a multi-agent approach to modelling the genesis of alluvial sediments. The aim is to generate a set of sedimentary structures such as channels, point-bars and oxbow lakes by means of sedimentary process simulations. These structures will later be used to study groundwater flow. The major deposition-erosion processes are represented in an approximate and stochastic manner. The behaviour of sedimentary entities is defined by empirical rules derived from the local geometry of the flume. The emphasis of this paper is on the capacity of the model to reproduce stream evolution. The model was tested on the West Fork white River (Indiana), and shows the main tl end in the evolution of a meandering system despite the simplicity of imposed rules. Expected future developments of this approach are outlined. ((C) Academie des Sciences/Elsevier, Paris.).
C1 Univ Paris 06, Lab Geol Appl, UMR Sisyphe, CNRS UPMC 7619, F-75252 Paris 05, France.
   ORSTOM, Lab Informat Appl, F-93143 Bondy, France.
RP Teles, V (corresponding author), Univ Paris 06, Lab Geol Appl, UMR Sisyphe, CNRS UPMC 7619, 4 Pl Jussieu,Boite 123, F-75252 Paris 05, France.
CR BEGIN ZB, 1981, J GEOL, V89, P497, DOI 10.1086/628610
   BOGGS, 1995, PRINCIPLES SEDIMENTO, P306
   BRAVARD JP, 1997, COURS DYNAMIQUE SYST
   BRAVARD JP, 1993, HYDROSYSTEMES FLUVIA, V5, P83
   BRICE J, 1973, 4 ANN GEOMORPHOLOGY, P178
   de Marsily G, 1998, HYDROGEOL J, V6, P115, DOI 10.1007/s100400050138
   DEMARSILY G, 1993, HYDROGEOLOGIE, V4, P259
   FAYERS FJ, 1992, MATH MODELING WATER, V2, P3
   Ferber J., 1995, SYSTEMES MULTIAGENTS
   HERVOUET JM, 1994, J HYDRAUL RES, V32, P45
   HOWARD AD, 1984, WATER RESOUR RES, V20, P1659, DOI 10.1029/WR020i011p01659
   Koltermann CE, 1996, WATER RESOUR RES, V32, P2617, DOI 10.1029/96WR00025
   KOLTERMANN CE, 1992, SCIENCE, V256, P1775, DOI 10.1126/science.256.5065.1775
   Miall A. D., 1992, FACIES MODELS RESPON, V7, P119
   PERRIER E, 1995, ETUDES PHENOMENES SP, P215
   PERRIER E, 1997, TENDANCES NOUVELLES, P233
   REINECK HE, 1980, DEPOSITIONAL SEDIMEN, P257
   SCHUMM SA, 1987, EXPT FLUVIAL GEOMORP, P129
   Sun T, 1996, WATER RESOUR RES, V32, P2937, DOI 10.1029/96WR00998
   Tetzlaff D.M., 1989, SIMULATING CLASTIC S
   Treuil J. P, 1997, TENDANCES NOUVELLES, P425
   TREUIL JP, 1997, INTELLIGENCE ARTIFIC, P211
   Webb EK, 1996, WATER RESOUR RES, V32, P533, DOI 10.1029/95WR03399
   Wen XH, 1998, J CONTAM HYDROL, V30, P129, DOI 10.1016/S0169-7722(97)00035-1
NR 24
TC 12
Z9 12
U1 0
U2 8
PU EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS CEDEX 15
PA 23 RUE LINOIS, 75724 PARIS CEDEX 15, FRANCE
SN 1251-8050
J9 CR ACAD SCI II A
JI Comptes Rendus Acad. Sci. Ser II-A
PD NOV
PY 1998
VL 327
IS 9
BP 597
EP 606
DI 10.1016/S1251-8050(99)80113-X
PG 10
WC Geosciences, Multidisciplinary
SC Geology
GA 152AN
UT WOS:000077753300004
DA 2021-08-04
ER

PT J
AU Briones, R
   Lapidus, GT
AF Briones, R
   Lapidus, GT
TI The leaching of silver sulfide with the thiosulfate-ammonia-cupric ion
   system
SO HYDROMETALLURGY
LA English
DT Article
DE leaching; silver sulfide; thiosulfartl-ammonia-cupric ion system
AB In recent years, then has been renewed interest in the use of thiosulfate as a substitute for cyanide in gold and silver leaching. Copper has been recognized to act as a catalyst in the process, and ammonia to stabilize the system. However, discrepancies exist in the literature concerning the oxidizing agent and, specifically in the case of silver sulfide (argentite), whether the leaching is oxidative or by substitution. The distinct mechanisms have implications concerning the feasibility of the process. The present study elucidates the chemistry of the leach through calculation of the species distribution and experiments on pure phase argentite, and also determines the role of the ammonia/thiosulfate concentration ratio. The experimental results on the pure phase show that the cupric ion reacts with thiosulfate to form the tetrathionate ion and a cuprous thiosulfate or ammonia complex, which liberates the silver by substitution in the solid phase. The results of leaching studies from a mineral concentrate indicate that, in addition to the cuprous ion concentration, the ammonia/thiosulfate ratio influences the silver extraction velocity: silver solubility and extraction are favored at low values of this quantity. A mathematical model for silver leaching in this system, which considers redox and complex equilibria, was developed. The experimental extractions were similar to those predicted by the model for low ammonia concentrations. Divergence from the simulated behavior was probably due to the slow reduction of the cupric ion at the high ammonia concentration (I M). (C) 1998 Published by Elsevier Science B.V. All rights reserved.
C1 Univ Autonoma Metropolitana Iztapalapa, Mexico City 09340, DF, Mexico.
RP Lapidus, GT (corresponding author), Univ Autonoma Metropolitana Iztapalapa, Av Purisima & Michoacn S-N,Apdo Postal 55-532, Mexico City 09340, DF, Mexico.
RI Briones, Roberto/E-8129-2012; Lapidus, Gretchen T/AAF-9730-2021
OI Briones, Roberto/0000-0001-8093-2526; Lapidus, Gretchen
   T/0000-0002-1792-8513
CR BYERLEY JJ, 1973, J CHEM SOC DALTON, P889, DOI 10.1039/dt9730000889
   COTTON FA, 1980, ADV INORG CHEM, P799
   DURRANT PJ, 1970, INTRO ADV INORGANIC, P1108
   Finkelstein NP, 1976, FLOTATION AM GAUDIN, P414
   FLEMING CA, 1992, HYDROMETALLURGY, V30, P127, DOI 10.1016/0304-386X(92)90081-A
   FLETT DS, 1983, T I MIN METALL C, V92, pC216
   KERLEY BJ, 1981, Patent No. 4269622
   LAPIDUS G, 1992, CHEM ENG SCI, V47, P1933, DOI 10.1016/0009-2509(92)80311-Y
   LI J, 1995, P 19 INT MIN PROC C, V7, P37
   LI J, UNPUB CATALYZED AMMO
   Smith R. M., 1976, CRITICAL STABILITY C, V4
   TAYLOR PR, 1983, METALL TRANS B, V14, P49, DOI 10.1007/BF02654050
   TOZAWA K, 1981, 110 AIME ANN M CHIC
   VOGEL AI, 1978, TXB QUANTITATIVE INO, P155
   WEAST RC, 1967, HDB CHEM PHYSICS, pB174
NR 15
TC 43
Z9 44
U1 0
U2 15
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-386X
J9 HYDROMETALLURGY
JI Hydrometallurgy
PD NOV
PY 1998
VL 50
IS 3
BP 243
EP 260
DI 10.1016/S0304-386X(98)00056-5
PG 18
WC Metallurgy & Metallurgical Engineering
SC Metallurgy & Metallurgical Engineering
GA 164XL
UT WOS:000078488800004
DA 2021-08-04
ER

PT J
AU Reihsner, R
   Menzel, EJ
AF Reihsner, R
   Menzel, EJ
TI Two-dimensional stress-relaxation behavior of human skin as influenced
   by non-enzymatic glycation and the inhibitory agent aminoguanidine
SO JOURNAL OF BIOMECHANICS
LA English
DT Article
DE skin rheology; multiaxial tests; non-enzymatic glycation;
   aminoguanidine; diabetes mellitus
ID RAT TAIL TENDONS; 2-DIMENSIONAL MECHANICAL-PROPERTIES; I
   DIABETES-MELLITUS; NONENZYMATIC GLYCATION; CONNECTIVE TISSUES;
   THERMAL-STABILITY; CROSS-LINKING; RABBIT SKIN; COLLAGEN; GLYCOSYLATION
AB In order to simulate the in vivo stress alterations of diabetic skin in an in vitro model, we examined the viscoelastic properties of long-term glycated human skin samples. Since skin is subjected to biaxial tension, we used two-dimensional multiaxial testing which better reflects the in vivo situation than the uniaxial testing mode. For native skin samples from the abdominal region we found a direction-dependent elastic stress-strain behavior. The viscous stress component was separated from the elastic stress component by relaxation tests at consecutive incremental steps of radial strains. We hypothesize that glycation-induced changes in the tissue stiffness are generated in a direction-dependent mode. A marked increase of the direction-dependent stiffness was found upon long-term incubation with glucose-6-phosphate. This increase was statistically significant for the maximum principal elastic stress component which was highly correlated with the degree of non-enzymatic collagen modification. The viscous fractions obtained from two-dimensional relaxation tests at consecutive radial strains were inversely correlated with non-enzymatic modification. Only at 30% radial strain a significant decrease of the viscous fraction engendered by glucose-6-phosphate was observed together with a direction-dependent significant increase of the expectation value of the time constant. The biomechanical and biochemical effects of long-term glycation could be partially reversed by aminoguanidine, a potential therapeutic agent for patients with diabetes mellitus. Our findings suggest that additional cross-links generated by long-term glycation cause two-dimensional biomechanical alterations in human skin, which can be unequivocally detected by multiaxial testing. (C) 1998 Elsevier Science Ltd. All rights reserved.
C1 Univ Vienna, Inst Immunol, A-1090 Vienna, Austria.
   Ludwig Boltzmann Inst Expt Plast Chirurg, Vienna, Austria.
   Tech Univ Vienna, Inst Festigkeitslehre, A-1060 Vienna, Austria.
RP Menzel, EJ (corresponding author), Univ Vienna, Inst Immunol, Borschkegasse 8A, A-1090 Vienna, Austria.
EM ernst.johannes.menzel@univie.ac.at
CR ANDREASSEN TT, 1988, CONNECT TISSUE RES, V17, P1, DOI 10.3109/03008208808992789
   ANDREASSEN TT, 1981, BIOCHIM BIOPHYS ACTA, V677, P313, DOI 10.1016/0304-4165(81)90101-X
   BAI PM, 1992, CONNECT TISSUE RES, V28, P1, DOI 10.3109/03008209209014224
   BAILEY AJ, 1993, BIOCHEM J, V296, P489, DOI 10.1042/bj2960489
   BROWNLEE M, 1986, SCIENCE, V232, P1629, DOI 10.1126/science.3487117
   BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315
   CERAMI A, 1986, TRENDS BIOCHEM SCI, V11, P311, DOI 10.1016/0968-0004(86)90281-1
   COX NH, 1987, CLIN EXP DERMATOL, V12, P250, DOI 10.1111/j.1365-2230.1987.tb01913.x
   DOMINICZAK MH, 1991, DIABETIC MED, V8, P505, DOI 10.1111/j.1464-5491.1991.tb01643.x
   DUNN MG, 1983, CONNECT TISSUE RES, V12, P59, DOI 10.3109/03008208309005612
   EBERHARDSTEINER J, 1991, OSTERREICHISCHE INGE, V6, P265
   EGAN JM, 1987, J BIOMECH, V20, P681, DOI 10.1016/0021-9290(87)90034-0
   Fung Y., 1981, BIOMECHANICS MECH PR
   GALESKI A, 1977, J BIOMECH, V10, P775, DOI 10.1016/0021-9290(77)90091-4
   GIBSON T, 1969, J BIOMECH, V2, P201, DOI 10.1016/0021-9290(69)90032-3
   Gibson T., 1970, DERMIS, P19
   GOODFIELD MJD, 1988, DIABETOLOGIA, V31, P567, DOI 10.1007/BF00264762
   HANNA W, 1987, J AM ACAD DERMATOL, V16, P546, DOI 10.1016/S0190-9622(87)70072-3
   KELLY SB, 1989, J INVEST DERMATOL, V93, P327, DOI 10.1111/1523-1747.ep12280239
   LANGER K, 1978, BRIT J PLAST SURG, V31, P93, DOI 10.1016/0007-1226(78)90056-5
   LANGER K, 1861, SITZUNGSBERICHTE MAT, V45, P133
   LANIR Y, 1974, J BIOMECH, V7, P29, DOI 10.1016/0021-9290(74)90067-0
   LANIR Y, 1974, J BIOMECH, V7, P171, DOI 10.1016/0021-9290(74)90058-X
   LANIR Y, 1979, BIORHEOLOGY, V16, P191
   LANIR Y, 1979, J BIOMECH, V12, P423, DOI 10.1016/0021-9290(79)90027-7
   Lockett F.J., 1972, NONLINEAR VISCOELAST
   Manschot J, 1982, BIOMECHANICS, VI
   MANSCHOT JFM, 1986, J BIOMECH, V19, P511, DOI 10.1016/0021-9290(86)90124-7
   MANSOUR JM, 1991, ASME BIOMECHANICS S, V120, P299
   MENZEL EJ, 1991, DIABETOLOGIA, V34, P12, DOI 10.1007/BF00404018
   Menzel EJ, 1996, ANN CLIN BIOCHEM, V33, P241, DOI 10.1177/000456329603300311
   MONNIER VM, 1986, NEW ENGL J MED, V314, P403, DOI 10.1056/NEJM198602133140702
   OXLUND H, 1992, DIABETOLOGIA, V35, P19, DOI 10.1007/BF00400847
   OXLUND H, 1988, J BIOMECH, V21, P213, DOI 10.1016/0021-9290(88)90172-8
   PARTINGTON FR, 1963, BIOCHIM BIOPHYS ACTA, V69, P485, DOI 10.1016/0006-3002(63)91298-8
   Reihsner R, 1996, CONNECT TISSUE RES, V34, P145, DOI 10.3109/03008209609021498
   REIHSNER R, 1995, MED ENG PHYS, V17, P304, DOI 10.1016/1350-4533(95)90856-7
   RIDGE MD, 1965, BIOMECHANICS RELATED, P159
   SCHNIDER SL, 1982, EXP GERONTOL, V17, P185, DOI 10.1016/0531-5565(82)90024-9
   SCOTT JE, 1981, BIOCHEM J, V195, P573, DOI 10.1042/bj1950573
   SCOTT JE, 1980, BIOCHEM J, V187, P887, DOI 10.1042/bj1870887
   SERAFINIFRACASS.A, 1974, STRUCTURE BIOCH CART
   STEGEMAN.H, 1967, CLIN CHIM ACTA, V18, P267, DOI 10.1016/0009-8981(67)90167-2
   UITTO J, 1986, DERMATOL CLIN, V4, P433, DOI 10.1016/S0733-8635(18)30806-4
   Viidik A., 1979, Progress in biomechanics, P75
   VISHWANATH V, 1986, DIABETES, V35, P916, DOI 10.2337/diabetes.35.8.916
   WEINSTEIN GD, 1960, J INVEST DERMATOL, V12, P5
   YUE DK, 1983, DIABETOLOGIA, V24, P282
NR 48
TC 44
Z9 47
U1 0
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0021-9290
J9 J BIOMECH
JI J. Biomech.
PD NOV
PY 1998
VL 31
IS 11
BP 985
EP 993
DI 10.1016/S0021-9290(98)00088-8
PG 9
WC Biophysics; Engineering, Biomedical
SC Biophysics; Engineering
GA 151CY
UT WOS:000077704200003
PM 9880055
DA 2021-08-04
ER

PT J
AU Baleux, B
   Caro, A
   Lesne, J
   Got, P
   Binard, S
   Delpeuch, B
AF Baleux, B
   Caro, A
   Lesne, J
   Got, P
   Binard, S
   Delpeuch, B
TI Survival and virulence changes in the VNC state of Salmonella
   Typhimurium in relation to simultaneous UV radiation, salinity and
   nutrient deprivation exposure.
SO OCEANOLOGICA ACTA
LA French
DT Article; Proceedings Paper
CT Annual Meeting of the National-Coastal-Oceanography-Programme - National
   Research Project on Coastal Zones
CY JUN 24-26, 1996
CL NANTES, FRANCE
SP Natl Coastal Oceanog Programme, Inst Francais Rech Exploitat Mer, Inst Natl Sci Univ, Ctr Nato Rech Sci
DE Salmonella; survival; virulence; VNC; stress
ID NONCULTURABLE ESCHERICHIA-COLI; SHIGELLA-DYSENTERIAE TYPE-1;
   COPPER-INDUCED INJURY; VIBRIO-VULNIFICUS; INDICATOR MICROORGANISMS;
   PATHOGENIC BACTERIA; MARINE-ENVIRONMENT; VISIBLE-LIGHT; WASTE-WATER;
   VIABILITY
AB The release of enteric pathogenic bacteria in aquatic environments poses the problem of the fate of these bacteria under the effects of environmental factors (solar radiation, salt concentration, temperature, nutrient level, pH, competition). Frequently, these bacterial cells, potentially pathogenic, enter into a non-culturable state on routine bacteriological plating media. However, the use of direct detection methods (DAPI stained cells) allows the visualization of these Viable but Non Culturable cells (VNC). But, beyond the characterization of the viability of the cells (electron transport activity, metabolic activity, membrane integrity, structure and/or quantity of DNA), what happens with the virulence of these cells? This problem was experimentally investigated according to the bacterial model Salmonella Typhimurium. The virulence of this strain, which is the agent of the murine typhoid, was evaluated on a mouse model. Experimentally, the effects of some environmental factors on the survival and on the maintenance of virulence of Salmonella Typhimurium were measured in microcosms exposed to UV radiation (four germicidal lamps 8 mW s(-1) cm(-2), wave length: 254 nm), salt concentration (Sea Salt Sigma, 37), nutrient starvation. The microcosms were simultaneously submitted to these three factors, with variable exposure times. For each of those times, the viability of the nonculturable cells (which became nonculturable because of the exposure to the three factors) was measured through different physiological states notable in the cells, after using different fluorescent dyes. The stained cells were observed by epifluorescence microscopy and analysed by image cytometry. So, the cellular populations are characterised by enumeration of respiring bacteria (CTC, [39]), metabolising bacteria (YEK, [22] modified), bacteria owning an undamaged cytoplasmic membrane (LD, Live/Dead BacLight Viability Kit. Molecular Probes Inc.); we also determined the quantity and/or structure of DNA of the cells (fluorescence level of DAPI stained cells).
   After exposure to the three factors for one hour (13.56 J cm(-2)), while the plate count cell density rapidly decreased from #10(7) cells mL(-1) to < 0.1 cell mL(-1), physiological states of these viable but non-culturable cells are similar to those of nonexposed cells. On the other hand, after exposure for three hours, only 10 % of the cells deposit a CTC formazan-crystal and 20 % are substrate responsive cells (enlarged cells in presence of Yeast Extract and Cephalexin: YEC). Half of the cellular population presents an undamaged cytoplasmic membrane and the level of fluorecence of DAPI stained cells is close to 85 %, which shows that the DNA of these cells is weakly damaged. After exposure to the three experimental factors for 24 hours (315 J cm(-2)), weak replies to the physiological tests used in this study to characterize the viability of the non-culturable cellular population are observed (CTC: 4 %; YEC: 2 %; LD: 11.8 %) while the fluorescence level of DAPI stained cells remains firm at 80 %. At the same time, the virulence expression of VNC cells of Salmonella Typhimurium, evaluated by intraperitoneal injection to the mouse (route which excludes uncontrolled parameters, unlike the per os route) does not seem to be correlated with the cellular viability such as it has been evaluated in this study. A 30 min exposure (6.73 J cm(-2)) to the three environmental factors, leading to the non-culturability of almost the entire exposed cell population (0.08 culturable cell mL(-1)) whereas the level of viability of those culturable cells is closed to the one of non-exposed cells. The injection of 1000 of those cells (<0.001 culturable cells in 100 mu L inoculated) into the mouse (a group of ten mice) does not cause any mortality four weeks post-inoculation, whereas the injection of the same dose of nonexposed cells leads to the death of all mice in the group one week post-inoculation. According to our preliminary experiments on Salmonella Typhimurium, the loss of the state of culturability and the loss of virulence towards mice by intraperitoneal route, because of the exposure to associated effects of UV irradiation (254 nm), salinity (37) and nutrient starvation, seem to be concomitant. (C) Elsevier, Paris.
C1 Univ Montpellier 2, Lab Hydrobiol, F-34095 Montpellier 05, France.
   Univ Montpellier 2, CNRS, UMR UM II 5556, F-34095 Montpellier, France.
   Ecole Natl Sante Publ, Lab Etudes & Rech Environ & Sante, F-35043 Rennes, France.
RP Baleux, B (corresponding author), Univ Montpellier 2, Lab Hydrobiol, F-34095 Montpellier 05, France.
CR ALLENAUSTIN D, 1984, FEMS MICROBIOL LETT, V21, P143, DOI 10.1111/j.1574-6968.1984.tb00200.x
   BALEUX B, 1996, TSM, V6, P430
   BARCINA I, 1989, APPL ENVIRON MICROB, V55, P246, DOI 10.1128/AEM.55.1.246-251.1989
   BRAUNS LA, 1991, APPL ENVIRON MICROB, V57, P2651, DOI 10.1128/AEM.57.9.2651-2655.1991
   BYRD JJ, 1990, APPL ENVIRON MICROB, V56, P2104, DOI 10.1128/AEM.56.7.2104-2107.1990
   CHANG JCH, 1985, APPL ENVIRON MICROB, V49, P1361, DOI 10.1128/AEM.49.6.1361-1365.1985
   COLWELL RR, 1985, BIO-TECHNOL, V3, P817, DOI 10.1038/nbt0985-817
   COLWELL RR, 1988, ADV RES CHOLERA RELA
   CORNAX R, 1990, CURR MICROBIOL, V20, P293, DOI 10.1007/BF02091908
   CSONKA LN, 1991, ANNU REV MICROBIOL, V45, P569, DOI 10.1146/annurev.mi.45.100191.003033
   DAOUST JY, 1991, INT J FOOD MICROBIOL, V12, P17, DOI 10.1016/0168-1605(91)90045-Q
   DESMONTS C, 1990, APPL ENVIRON MICROB, V56, P1448, DOI 10.1128/AEM.56.5.1448-1452.1990
   FIERER J, 1992, J INFECT DIS, V166, P639, DOI 10.1093/infdis/166.3.639
   GALES P, 1994, THESIS USTL 2 MONTPE
   Got P., 1993, Revue des Sciences de l'Eau, V6, P269
   GOURMELON M, 1994, J APPL BACTERIOL, V77, P105, DOI 10.1111/j.1365-2672.1994.tb03051.x
   GRIMES DJ, 1986, FEMS MICROBIOL LETT, V34, P161
   GRIMES DJ, 1986, MICROBIOL SCI, V3, P324
   GULIG PA, 1993, INFECT IMMUN, V61, P504, DOI 10.1128/IAI.61.2.504-511.1993
   GULIG PA, 1990, MICROB PATHOGENESIS, V8, P3, DOI 10.1016/0882-4010(90)90003-9
   JONES DM, 1991, J GEN MICROBIOL, V25, P415
   KOGURE K, 1979, CAN J MICROBIOL, V25, P415, DOI 10.1139/m79-063
   LECHEVALLIER MW, 1985, APPL ENVIRON MICROB, V50, P412, DOI 10.1128/AEM.50.2.412-419.1985
   LERUDULIER D, 1993, B SOC FR MICROBIOL, V8, P167
   LINDENAUER KG, 1994, WATER RES, V28, P805, DOI 10.1016/0043-1354(94)90087-6
   LINDER K, 1989, APPL ENVIRON MICROB, V55, P2837, DOI 10.1128/AEM.55.11.2837-2842.1989
   MCKAY AM, 1992, LETT APPL MICROBIOL, V14, P129, DOI 10.1111/j.1472-765X.1992.tb00667.x
   MORINIGO MA, 1990, ANTON LEEUW INT J G, V57, P109, DOI 10.1007/BF00403162
   MORINIGO MA, 1989, CURR MICROBIOL, V18, P267, DOI 10.1007/BF01570304
   NOREL F, 1989, MOL MICROBIOL, V3, P733, DOI 10.1111/j.1365-2958.1989.tb00222.x
   Oliver JD, 1993, TRENDS IN MICROBIAL ECOLOGY, P187
   OLIVER JD, 1995, APPL ENVIRON MICROB, V61, P2620, DOI 10.1128/AEM.61.7.2620-2623.1995
   OLIVER JD, 1995, APPL ENVIRON MICROB, V61, P2624, DOI 10.1128/AEM.61.7.2624-2630.1995
   PALMER LM, 1984, FEMS MICROBIOL LETT, V21, P169
   PARDON P, 1986, ANN INST PASTEUR MIC, V137B, P47, DOI 10.1016/S0769-2609(86)80093-X
   PORTER KG, 1980, LIMNOL OCEANOGR, V25, P943, DOI 10.4319/lo.1980.25.5.0943
   Rahman I, 1996, APPL ENVIRON MICROB, V62, P115, DOI 10.1128/AEM.62.1.115-120.1996
   RAHMAN I, 1994, APPL ENVIRON MICROB, V60, P3573, DOI 10.1128/AEM.60.10.3573-3578.1994
   RODRIGUEZ GG, 1992, APPL ENVIRON MICROB, V58, P1801, DOI 10.1128/AEM.58.6.1801-1808.1992
   ROLLINS DM, 1986, APPL ENVIRON MICROB, V52, P531, DOI 10.1128/AEM.52.3.531-538.1986
   ROSZAK DB, 1984, CAN J MICROBIOL, V30, P334, DOI 10.1139/m84-049
   ROSZAK DB, 1987, APPL ENVIRON MICROB, V53, P2889, DOI 10.1128/AEM.53.12.2889-2893.1987
   ROSZAK DB, 1987, MICROBIOL REV, V51, P365, DOI 10.1128/MMBR.51.3.365-379.1987
   SINGH A, 1986, APPL ENVIRON MICROB, V51, P738, DOI 10.1128/AEM.51.4.738-742.1986
   SINGH A, 1986, APPL ENVIRON MICROB, V52, P832, DOI 10.1128/AEM.52.4.832-837.1986
   SINGH A, 1985, APPL ENVIRON MICROB, V50, P406, DOI 10.1128/AEM.50.2.406-411.1985
   WALSH SM, 1983, APPL ENVIRON MICROB, V45, P1060, DOI 10.1128/AEM.45.3.1060-1065.1983
   XU HS, 1982, MICROBIAL ECOL, V8, P313, DOI 10.1007/BF02010671
NR 48
TC 12
Z9 12
U1 1
U2 16
PU GAUTHIER-VILLARS/EDITIONS ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75015 PARIS, FRANCE
SN 0399-1784
J9 OCEANOL ACTA
JI Oceanol. Acta
PD NOV-DEC
PY 1998
VL 21
IS 6
BP 939
EP 950
DI 10.1016/S0399-1784(99)80017-6
PG 12
WC Oceanography
SC Oceanography
GA 156FY
UT WOS:000077992000017
OA Green Submitted
DA 2021-08-04
ER

PT J
AU Westin, SN
   Winter, S
   Karlsson, E
   Hin, A
   Oeseburg, F
AF Westin, SN
   Winter, S
   Karlsson, E
   Hin, A
   Oeseburg, F
TI On modeling of the evaporation of chemical warfare agents on the ground
SO JOURNAL OF HAZARDOUS MATERIALS
LA English
DT Article
DE evaporation; chemical warfare; vapour concentration
ID POROUS-MEDIA; SOIL; INFILTRATION; DIFFUSIVITY; TRANSPORT; BEHAVIOR;
   DROPLET; SURFACE; LIQUID; VAPOR
AB A model for evaporation of chemical warfare agents on the ground has been developed. The process of evaporation is described in three steps: (1) the immediate drop enlargement due to impact momentum is modeled using an empirical correlation from technical literature; (2) further enlargement caused by capillary spreading upon the surface and the simultaneous sorption into the substrate, modeled in three dimensions; (3) subsequent drying and redistribution of the sorbed material is described as a one-dimensional (vertical) process, The formulation of the flux in the soil takes into account vapour, liquid, solute, and adsorbed phases. The evaporation from the surface is determined by the vapour concentration at the surface and the conditions in the atmospheric viscous sub-layer close to the droplet spots on the surface.,Model results agree with the limited experimental data found in the literature. The model shows a very rapid sorption and redistribution of chemical warfare droplets on sand. This effect gives a rapid decrease of the evaporation, except for a shorter initial period. However, a small residual evaporation exists for a rather long time from liquid, which has penetrated down into the soil. (C) 1998 Elsevier Science B.V. All rights reserved.
C1 NBC Def, Def Res Estab, SE-90182 Umea, Sweden.
   TNO, Prins Maurits Lab, NL-2280 AA Rijswijk, Netherlands.
RP Winter, S (corresponding author), NBC Def, Def Res Estab, SE-90182 Umea, Sweden.
EM winter@ume.foa.se
CR AARNINK WAM, 1993, 1993IN25 TNO PML
   BAINES WD, 1994, IND ENG CHEM RES, V33, P411, DOI 10.1021/ie00026a036
   BLUMBERG W, 1993, DRY TECHNOL, V11, P41, DOI 10.1080/07373939308916802
   BRUTSAERT W, 1979, WATER RESOUR RES, V15, P481, DOI 10.1029/WR015i002p00481
   CAZABAT AM, 1986, J PHYS CHEM-US, V90, P5845, DOI 10.1021/j100280a075
   Chinn K. S. K, 1981, DPGTR401
   CRANK J, 1975, MATH DIFFUSION, P144
   FARMER WJ, 1980, SOIL SCI SOC AM J, V44, P676, DOI 10.2136/sssaj1980.03615995004400040002x
   JURY WA, 1983, J ENVIRON QUAL, V12, P558, DOI 10.2134/jeq1983.00472425001200040025x
   MEDEMA J, 1986, CALCULATION VAPOUR D
   MENDOZA CA, 1990, WATER RESOUR RES, V26, P388, DOI 10.1029/WR026i003p00388
   MILLER RD, 1977, SOIL SCI SOC AM J, V41, P1021
   MILLINGTON RJ, 1959, SCIENCE, V130, P100, DOI 10.1126/science.130.3367.100-a
   MONAGHAN J, 1971, MATH MODEL PREDICTIN
   PEL L, 1993, INT J HEAT MASS TRAN, V36, P1261, DOI 10.1016/S0017-9310(05)80095-X
   PHILIP JR, 1991, WATER RESOUR RES, V27, P1459, DOI 10.1029/91WR00780
   REICHARDT K, 1972, SOIL SCI SOC AM PRO, V36, P241, DOI 10.2136/sssaj1972.03615995003600020014x
   REICHMAN R, 1989, SOIL SCI, V148, P191, DOI 10.1097/00010694-198909000-00006
   REICHMAN R, 1995, P 5 INT S PROT CHEM, P393
   REINHARDT HW, 1995, MATER STRUCT, V28, P43, DOI 10.1007/BF02473290
   RICHARD TG, 1990, HDB CHEM PROPERTY ES
   RIIKONEN K, IN PRESS EXTENSION C
   ROBERTS LD, 1994, 2044002CBDE
   ROUSE H, 1978, ELEMENTARY MECH FLUI, P214
   SHELLER BL, 1995, AICHE J, V41, P1357
   THANING L, 1996, FOAR960026046
   WINTER S, 1997, P 1996 ERDEC SCI C C, P41
   YOUNGS EG, 1981, WATER RESOUR RES, V17, P1065, DOI 10.1029/WR017i004p01065
NR 28
TC 16
Z9 17
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-3894
J9 J HAZARD MATER
JI J. Hazard. Mater.
PD OCT 23
PY 1998
VL 63
IS 1
BP 5
EP 24
DI 10.1016/S0304-3894(98)00174-5
PG 20
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA 145JR
UT WOS:000077368100001
DA 2021-08-04
ER

PT J
AU Simoes, PN
   Pedroso, LM
   Portugal, AA
   Campos, JL
AF Simoes, PN
   Pedroso, LM
   Portugal, AA
   Campos, JL
TI Study of the decomposition of phase stabilized ammonium nitrate (PSAN)
   by simultaneous thermal analysis: determination of kinetic parameters
SO THERMOCHIMICA ACTA
LA English
DT Article
DE ammonium nitrate (AN); phase stabilized ammonium nitrate (PSAN); kinetic
   parameters; simultaneous thermal analysis; thermal decomposition
ID MASS-LOSS PROCESS; ENERGETIC MATERIALS; MOLTEN NH4NO3; BURNING-RATE;
   SAMPLE MASS; TEMPERATURE
AB Ammonium nitrate (AN) has been extensively used both in explosive and propellant formulations. Unlike AN, there is a lack of information about the thermal decomposition and related kinetic analysis of phase stabilized ammonium nitrate (PSAN), Simultaneous thermal analysis (DSC-TG) has been used in the thermal characterisation of a specific type of PSAN containing 1.0% of NiO (stabilizing agent) and 0.5% of Petro (anti-caking agent) as additives. Repeated runs covering the nominal heating rates range from 2.5 to 20 K min(-1) allowed to conclude on the good reproducibility of the main features of the thermal behavior of PSAN, i.e., two phase transitions, melting and decomposition. Non-isothermal kinetic analysis has been used to estimated the Arrhenius parameters of the decomposition process by applying both a single curve method and two isoconversion methods to the TG data. The results are discussed considering the range of applicability of the methods as well as the influence of the experimental conditions and/or techniques in the kinetic analysis results in a broader sense. A systematic approach based on the isoconversion methods results and statistical tools has been adopted to obtain reliable estimates of the Arrhenius parameters for the thermal decomposition of PSAN. Under the condition of study, the values of 81.4+/-3.5 kJ mol(-1) for the activation energy and (5.63+/-0.01)x10(5) s(-1) for the pre-exponential factor were found as describing the process over a wide range of the kinetic analysis. (C) 1998 Elsevier Science B.V.
C1 Univ Coimbra, Fac Ciencias & Tecnol, Dept Engn Quim, Lab Energet & Deton, P-3000 Coimbra, Portugal.
   Univ Coimbra, Fac Ciencias & Tecnol, Dept Engn Mecan, Lab Energet & Deton, P-3000 Coimbra, Portugal.
RP Simoes, PN (corresponding author), Univ Coimbra, Fac Ciencias & Tecnol, Dept Engn Quim, Lab Energet & Deton, Largo Marques Pombal, P-3000 Coimbra, Portugal.
RI Simoes, Pedro Nuno NL/M-3388-2019; Simoes, Pedro Nuno N. L./A-3967-2012;
   Portugal, Antonio A/F-9024-2015
OI Simoes, Pedro Nuno NL/0000-0002-5068-950X; Simoes, Pedro Nuno N.
   L./0000-0002-5068-950X; Portugal, Antonio A/0000-0002-7520-4767;
   Pedroso, Laurentina/0000-0002-5194-9422
CR BRILL TB, 1993, COMBUST FLAME, V92, P178, DOI 10.1016/0010-2180(93)90206-I
   BROWER KR, 1989, J PHYS CHEM-US, V93, P4029, DOI 10.1021/j100347a033
   CAMPBELL D, 1995, AGARD C P, V559
   CAMPOS J, 1995, AGARD C P, V559
   Carvalheira P, 1995, THERMOCHIM ACTA, V269, P273, DOI 10.1016/0040-6031(95)02366-6
   CHAN ML, 1995, AGARD C P, V559
   COATS AW, 1964, NATURE, V201, P68, DOI 10.1038/201068a0
   COOK MA, 1951, IND ENG CHEM, V43, P1098, DOI 10.1021/ie50497a029
   Doyle C.D., 1962, J APPL POLYM SCI, V6, P639, DOI DOI 10.1002/APP.1962.070062406
   Draper N. R., 1981, APPL REGRESSION ANAL
   FEICK G, 1954, J AM CHEM SOC, V76, P5860, DOI 10.1021/ja01651a096
   FLYNN JH, 1966, J RES NBS A PHYS CH, VA 70, P487, DOI 10.6028/jres.070A.043
   GUIOCHON G, 1957, CR HEBD ACAD SCI, V244, P771
   INGMAN JS, 1982, J CHEM SOC FARADAY T, V178, P1817
   KESTILA E, 1993, THERMOCHIM ACTA, V214, P305, DOI 10.1016/0040-6031(93)80067-K
   Kim JH, 1997, J CHEM ENG JPN, V30, P336, DOI 10.1252/jcej.30.336
   KOGA N, 1994, THERMOCHIM ACTA, V244, P1, DOI 10.1016/0040-6031(94)80202-5
   KOGA N, 1993, THERMOCHIM ACTA, V224, P141, DOI 10.1016/0040-6031(93)80164-6
   KOGA N, 1992, THERMOCHIM ACTA, V209, P127, DOI 10.1016/0040-6031(92)80190-8
   KOGA N, 1994, THERMOCHIM ACTA, V240, P141, DOI 10.1016/0040-6031(94)87036-5
   KOROBAN VA, 1994, PROPELL EXPLOS PYROT, V19, P307, DOI 10.1002/prep.19940190608
   Menke K, 1996, PROPELL EXPLOS PYROT, V21, P139, DOI 10.1002/prep.19960210306
   MENKE K, 1995, AGARD C P, V559
   Oyumi Y, 1996, PROPELL EXPLOS PYROT, V21, P271, DOI 10.1002/prep.19960210511
   OZAWA T, 1992, THERMOCHIM ACTA, V203, P159, DOI 10.1016/0040-6031(92)85192-X
   OZAWA T, 1965, B CHEM SOC JPN, V38, P1881, DOI 10.1246/bcsj.38.1881
   OZAWA T, 1986, THERMOCHIM ACTA, V100, P109, DOI 10.1016/0040-6031(86)87053-8
   PARK BS, 1993, 24 INT ANN C ICT KAR
   Patil D. G., 1992, PROPELL EXPLOS PYROT, V17, P99
   ROBERTSON AJB, 1948, J SOC CHEM IND-L, V67, P221, DOI 10.1002/jctb.5000670603
   RUSSELL TP, 1989, COMBUST FLAME, V76, P393, DOI 10.1016/0010-2180(89)90120-X
   Sestak J., 1984, THERMOPHYSICAL PROPE
   STOWE RA, 1995, AGARD C P, V559
   WOOD BJ, 1955, J CHEM PHYS, V23, P693, DOI 10.1063/1.1742078
NR 34
TC 31
Z9 34
U1 1
U2 21
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0040-6031
J9 THERMOCHIM ACTA
JI Thermochim. Acta
PD OCT 5
PY 1998
VL 319
IS 1-2
BP 55
EP 65
DI 10.1016/S0040-6031(98)00386-4
PG 11
WC Thermodynamics; Chemistry, Analytical; Chemistry, Physical
SC Thermodynamics; Chemistry
GA 130MJ
UT WOS:000076523600009
OA Green Published
DA 2021-08-04
ER

PT J
AU Bischoff, G
   Bischoff, R
   Birch-Hirschfeld, E
   Gromann, U
   Lindau, S
   Meister, WV
   Bambirra, SD
   Bohley, C
   Hoffmann, S
AF Bischoff, G
   Bischoff, R
   Birch-Hirschfeld, E
   Gromann, U
   Lindau, S
   Meister, WV
   Bambirra, SD
   Bohley, C
   Hoffmann, S
TI DNA-drug interaction measurements using surface plasmon resonance
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article
ID ELECTRIC LINEAR DICHROISM; SCANNING FORCE MICROSCOPY; CALF THYMUS DNA;
   NUCLEIC-ACIDS; BINDING DRUGS; HOECHST-33258; PORPHYRIN; LIGANDS; AGENTS;
   KINDS
AB The interactions of the drugs 2,7-bis[(diethylamino)-ethoxy]-fluoren-9-one dihydrochloride (<(Tilorone)under bar>), 2,7-bis[(dipropylamino)-acetamido]-fluoren-9-one dihydrochloride (<(FA-2)under bar>), 2'-(4-hydroxyphenyl)-5-(4-methyl-1-piperazinyl)-2,5'-bi-1H-benzimidazole trihydrochloride (<(Hoechst 33258)under bar>), and hematoporphyrin IX derivative (<(HPD)under bar>) with synthetic self-complementary DNA (36-b.p.; 5'-biotin-spacer-[d(CGCTATATAGCG)](3)-3') were studied by SPR (Surface Plasmon Resonance). Monolayers of biotinylated DNA were immobilized on a streptavidin-dextran-gold triple-layer. Small portions of the drugs (approximately 30 pmol/ml) were injected in continuous flow. The mass corresponded to the amount of the bound molecules. Injections of 50 mM sodium hydroxide pulses separated the DNA double strands, releasing the effector molecules. Subsequent treatments with the effecters gave reproducible results. The maximum interaction between drug and DNA was observed in the case of Tilorone. 41 molecules could bind to the 36-b.p. DNA duplex.
   To investigate the microscopic behavior in condensed nucleic acid phases, SFM (Scanning Force Microscopy)-imaging and polarizing microscopic observations of DNA-effector complexes were carried out. Supplementary UV-absorption thermal denaturation curves of DNA with the above-mentioned effecters in dilute solutions were measured. As an additional aid to understand the geometries of DNA-drug interactions, computer simulations were performed and compared with the experimental data.
C1 Univ Halle Wittenberg, Inst Biochem, D-06120 Halle, Saale, Germany.
   Dept Otorhinolaryngol Face & Neck Surg, D-06110 Halle, Saale, Germany.
   Univ Jena, Inst Virol, D-07745 Jena, Germany.
RP Bischoff, G (corresponding author), Univ Halle Wittenberg, Inst Biochem, D-06120 Halle, Saale, Germany.
EM bischoff@fu-berlin.de
CR BAILLY C, 1994, J BIOMOL STRUCT DYN, V12, P173, DOI 10.1080/07391102.1994.10508095
   Bailly C, 1996, NUCLEIC ACIDS RES, V24, P1460, DOI 10.1093/nar/24.8.1460
   Balbi A, 1997, BIOORGAN MED CHEM, V5, P1903, DOI 10.1016/S0968-0896(97)00127-2
   BISCHOFF G, 1997, J MOL MED, V75, pB130
   Bohley C, 1997, NUCLEOS NUCLEOT, V16, P2013, DOI 10.1080/07328319708002551
   Bohley C, 1997, SURF INTERFACE ANAL, V25, P614
   CARVLIN MJ, 1983, NUCLEIC ACIDS RES, V11, P6121, DOI 10.1093/nar/11.17.6121
   CHANDRA P, 1976, BIOCHEM PHARMACOL, V25, P877, DOI 10.1016/0006-2952(76)90306-3
   Clark GR, 1996, NUCLEIC ACIDS RES, V24, P4882, DOI 10.1093/nar/24.24.4882
   Colson P, 1996, BIOPHYS CHEM, V58, P125, DOI 10.1016/0301-4622(95)00092-5
   DICIOCCIO RA, 1978, J NATL CANCER I, V60, P533, DOI 10.1093/jnci/60.3.533
   DOUGHERTY TJ, 1987, PHOTOCHEM PHOTOBIOL, V46, P569, DOI 10.1111/j.1751-1097.1987.tb04815.x
   Frau S, 1996, B SOC CHIM FR, V133, P1053
   FRAU S, 1995, NEW J CHEM, V19, P873
   Hansma HG, 1996, NUCLEIC ACIDS RES, V24, P713, DOI 10.1093/nar/24.4.713
   HOFFMANN S, 1989, Z CHEM, V29, P173
   HOFFMANN S, 1983, Wissenschaftliche Zeitschrift Martin-Luther-Universitaet Halle-Wittenberg Mathematisch-Naturwissenschaftliche Reihe, V32, P51
   HOFFMANN S, 1977, Z CHEM, V17, P291
   HOFFMANN S, 1978, NUCL ACDIS RES SPEC, V4, P221
   HOFFMANN S, 1978, ACS SYM SER, V74, P178
   HOFFMANN S, 1975, WIRKMECHANISMEN HERB, P306
   Holmlin R.E., 1997, ANGEW CHEM, V109, P2830, DOI [10.1002/ange.19971092404, DOI 10.1002/ANGE.19971092404]
   HOLMLIN RE, 1997, ANGEW CHEM INT EDIT, V36, P2714
   KENNARD O, 1991, ANGEW CHEM, V103, P1280
   KRUEGER RF, 1970, SCIENCE, V169, P1213, DOI 10.1126/science.169.3951.1213
   LERMAN LS, 1961, J MOL BIOL, V3, P18, DOI 10.1016/S0022-2836(61)80004-1
   LIVOLANT F, 1992, MOL CRYST LIQ CRYST, V215, P47, DOI 10.1080/10587259208038510
   LOEWE H, 1974, ARZNEIMITTELFORSCH, V24, P1927
   LOFAS S, 1990, J CHEM SOC CHEM COMM, P1526, DOI 10.1039/c39900001526
   LOONTIENS FG, 1990, BIOCHEMISTRY-US, V29, P9029, DOI 10.1021/bi00490a021
   MAEDA Y, 1990, J MOL BIOL, V215, P321, DOI 10.1016/S0022-2836(05)80350-X
   McClure JE, 1997, BIOPOLYMERS, V42, P203, DOI 10.1002/(SICI)1097-0282(199708)42:2<203::AID-BIP9>3.0.CO;2-R
   Nakamura J, 1996, ANAL LETT, V29, P2453
   PASTERNACK RF, 1983, BIOCHEMISTRY-US, V22, P2406, DOI 10.1021/bi00279a016
   PATTERSON LH, 1994, ONCOL RES, V6, P533
   SCHELLER FW, 1997, ACS SYM SER, V613, P68
   Shao ZF, 1995, ANNU REV CELL DEV BI, V11, P241, DOI 10.1146/annurev.cb.11.110195.001325
   STIER E, 1942, Z PHYSL CHEM, V273, P47
   SUSSMAN JL, 1978, P NATL ACAD SCI USA, V75, P103, DOI 10.1073/pnas.75.1.103
   VANHILLEGERSBERG R, 1994, DRUGS, V48, P510, DOI 10.2165/00003495-199448040-00003
   VECKENSTEDT A, 1979, ACTA VIROL, V23, P153
   VECKENSTEDT A, 1979, ACTA BIOL MED GER, V38, P745
   Wheeler G, 1998, J BIOMOL STRUCT DYN, V15, P967, DOI 10.1080/07391102.1998.10508217
   Wheeler GV, 1997, J BIOMOL STRUCT DYN, V15, P107, DOI 10.1080/07391102.1997.10508950
   WITKOWSKI W, 1979, ACTA BIOL MED GER, V38, P733
   WITKOWSKI W, 1981, WISSENSCHAFTSPUBL N, V10, P11
   WOOTEN RS, 1989, CANCER, V64, P1569, DOI 10.1002/1097-0142(19891015)64:8<1569::AID-CNCR2820640802>3.0.CO;2-G
   YOON C, 1988, P NATL ACAD SCI USA, V85, P6332, DOI 10.1073/pnas.85.17.6332
   YUAN H, 1992, BIOCHEMISTRY-US, V31, P8009, DOI 10.1021/bi00149a035
   Yun BH, 1998, BIOPHYS CHEM, V70, P1, DOI 10.1016/S0301-4622(97)00031-8
NR 50
TC 23
Z9 23
U1 0
U2 9
PU ADENINE PRESS INC
PI GUILDERLAND
PA PO BOX 355/340, GUILDERLAND, NY 12084 USA
SN 0739-1102
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
PD OCT
PY 1998
VL 16
IS 2
BP 187
EP 203
DI 10.1080/07391102.1998.10508239
PG 17
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 136HJ
UT WOS:000076853100001
PM 9833660
DA 2021-08-04
ER

PT J
AU Nof, D
   Borisov, S
AF Nof, D
   Borisov, S
TI Inter-hemispheric oceanic exchange
SO QUARTERLY JOURNAL OF THE ROYAL METEOROLOGICAL SOCIETY
LA English
DT Article
DE abyssal circulation; frictional processes; potential-vorticity
   alteration
ID ANTARCTIC BOTTOM WATER; EQUATORIAL ATLANTIC-OCEAN; FLUX-CORRECTED
   TRANSPORT; WESTERN BOUNDARY CURRENT; NORTH-ATLANTIC; DEEP; CIRCULATION;
   PACIFIC; DRIVEN; MODEL
AB The exchange of water between hemispheres is examined theoretically by looking at the behaviour of continuous (double frontal) abyssal currents situated on the bottom of a (parabolic) meridional channel. We used a reduced-gravity (fluid) model with an active lower layer on the bottom of the channel, and a passive infinitely deep upper layer on the top. The topography is the agent responsible for forcing the current across the equator. We first examined analytically the nonlinear, steady, frictionless case and, as a second step, we considered a nonlinear numerical simulation (of the Bleck and Boudra type). We then compared the results of these two (fluid) models to each other and to the solid-balls model of Borisov and Nof which examined the migration of particles in the same cross-equatorial channel.
   All three models show that, in general, the current (or a 'cloud' of solid particles) advances gradually toward the equator without much change to its structure. Upon reaching the vicinity of the equator, the current width (or the distance between neighbouring balls) decreases dramatically. The current (or cloud) then turns eastward, flows rapidly downslope, and rises on the eastern side. The now (or cloud) ultimately splits into two parts, one progressing northward and the other recirculating and advancing southward.
   Remarkably good agreement is found between the detailed solid-particles analysis and the new numerical fluid simulations, indicating that the inter-hemispheric exchange is primarily an inertial process that depends mainly on the channel geometry. It is shown that the partition of mass flux between the two hemispheres depends on the way that the solid particles, or the current-jet, impinge on the eastern flank of the channel. In contrast to the very good agreement between the solid balls and the fluid simulations, poor agreement was found between the detailed analytical prediction for the cross-equatorial transport and the numerical solution (even when the viscosity was as small as we could use for numerical stability). However, the analytical solution does give the correct prediction for the position of the resulting currents and their general behaviour. It is argued that the disagreement between the analytically calculated fluid mass transports (which, in contrast to the balls, is subject to a potential-vorticity constraint) and the numerical computations is due to the alteration of potential vorticity. Specifically, the friction alters the potential vorticity of the flow and prevents it from acting as a constraint to the crossing. Though crucial to the crossing, the role of friction is, therefore, passive. It merely allows the fluid to alter its potential vorticity in such a manner that the flow can adapt to the crossing pattern imposed by the geometry.
   It is suggested that the observed recirculation of Antarctic Bottom Water in the vicinity of the equatorial Atlantic may be a result of our splitting process.
C1 Florida State Univ, Dept Oceanog 4320, Tallahassee, FL 32306 USA.
RP Nof, D (corresponding author), Florida State Univ, Dept Oceanog 4320, Tallahassee, FL 32306 USA.
CR ANDERSON DLT, 1976, MON WEATHER REV, V104, P907, DOI 10.1175/1520-0493(1976)104<0907:TLLJAA>2.0.CO;2
   ANDERSON DLT, 1979, DEEP-SEA RES, V26, P1, DOI 10.1016/0198-0149(79)90082-7
   Arakawa A., 1966, Journal of Computational Physics, V1, P119, DOI 10.1016/0021-9991(66)90015-5
   BLECK R, 1981, J PHYS OCEANOGR, V11, P755, DOI 10.1175/1520-0485(1981)011<0755:ITOANO>2.0.CO;2
   BLECK R, 1986, J GEOPHYS RES-OCEANS, V91, P7611, DOI 10.1029/JC091iC06p07611
   BLECK R, 1990, J GEOPHYS RES-OCEANS, V95, P3273, DOI 10.1029/JC095iC03p03273
   BORIS JP, 1973, J COMPUT PHYS, V11, P38, DOI 10.1016/0021-9991(73)90147-2
   Borisov S, 1998, GEOPHYS ASTRO FLUID, V87, P273, DOI 10.1080/03091929808221150
   BORISOV S, 1996, THESIS FLORIDA STATE
   DEMADRON XD, 1994, J MAR RES, V52, P583
   EMERY WJ, 1986, OCEANOL ACTA, V9, P383
   FIRING E, 1989, J GEOPHYS RES-OCEANS, V94, P2023, DOI 10.1029/JC094iC02p02023
   Goldsbrough GR, 1933, P R SOC LOND A-CONTA, V141, P512, DOI 10.1098/rspa.1933.0135
   GRIFFITHS RW, 1982, J FLUID MECH, V117, P343, DOI 10.1017/S0022112082001669
   Hall MM, 1997, J PHYS OCEANOGR, V27, P1903, DOI 10.1175/1520-0485(1997)027<1903:ABWFIT>2.0.CO;2
   Hallock ZR, 1996, J GEOPHYS RES-OCEANS, V101, P6617, DOI 10.1029/95JC03714
   Hogg N, 1982, J MAR RES, V40, P231
   JOHNSON GC, 1991, DEEP-SEA RES, V38, P637, DOI 10.1016/0198-0149(91)90003-X
   JOHNSON GC, 1993, DEEP-SEA RES PT I, V40, P371, DOI 10.1016/0967-0637(93)90009-R
   JOHNSON GC, 1993, DEEP-SEA RES PT I, V40, P1781, DOI 10.1016/0967-0637(93)90032-X
   JOHNSON GC, 1994, J MAR RES, V52, P177, DOI 10.1357/0022240943077118
   KAWASE M, 1987, J PHYS OCEANOGR, V17, P2294, DOI 10.1175/1520-0485(1987)017<2294:EODOCD>2.0.CO;2
   KAWASE M, 1992, J GEOPHYS RES-OCEANS, V97, P5447, DOI 10.1029/91JC03163
   KILLWORTH PD, 1991, J PHYS OCEANOGR, V21, P1581, DOI 10.1175/1520-0485(1991)021<1581:CEGA>2.0.CO;2
   MANTYLA AW, 1975, J MAR RES, V33, P341
   MANTYLA AW, 1983, DEEP-SEA RES, V30, P805, DOI 10.1016/0198-0149(83)90002-X
   MCCARTNEY MS, 1993, J PHYS OCEANOGR, V23, P1264, DOI 10.1175/1520-0485(1993)023<1264:TFOABW>2.0.CO;2
   MERZ A, 1922, Z GESELLSCHAFT ERDKU, P1
   NOF D, 1990, J PHYS OCEANOGR, V20, P880, DOI 10.1175/1520-0485(1990)020<0880:TBODF>2.0.CO;2
   NOF D, 1993, DEEP-SEA RES PT I, V40, P235, DOI 10.1016/0967-0637(93)90002-K
   NOF D, 1991, GEOPHYS ASTRO FLUID, V58, P173, DOI 10.1080/03091929108227338
   Polzin KL, 1996, NATURE, V380, P54, DOI 10.1038/380054a0
   ROED LP, 1980, J FLUID MECH, V96, P395, DOI 10.1017/S0022112080002182
   Rudnick DL, 1997, J GEOPHYS RES-OCEANS, V102, P3293, DOI 10.1029/96JC03286
   Schopp R, 1997, GEOPHYS ASTRO FLUID, V86, P43, DOI 10.1080/03091929708245456
   Sokov A. V., 1991, Oceanology, V31, P412
   SOKOV AV, 1992, OKEANOLOGIYA+, V32, P851
   SPEER K, 1993, J GEOPHYS RES-OCEANS, V98, P8547, DOI 10.1029/92JC03018
   SPEER KG, 1992, J PHYS OCEANOGR, V22, P83, DOI 10.1175/1520-0485(1992)022<0083:BWCITW>2.0.CO;2
   SPRINGER SR, 1993, J GEOPHYS RES-OCEANS, V98, P12511, DOI 10.1029/93JC00941
   STOMMEL H, 1960, DEEP-SEA RES, V6, P140
   STOMMEL H, 1960, DEEP-SEA RES, V6, P217
   STOMMEL H, 1958, DEEP-SEA RES, V5, P80, DOI 10.1016/S0146-6291(58)80014-4
   STOMMEL H, 1972, DEEP-SEA RES, V19, P707, DOI 10.1016/0011-7471(72)90062-9
   STRAUB DN, 1993, J PHYS OCEANOGR, V23, P1454, DOI 10.1175/1520-0485(1993)023<1454:ASMOMD>2.0.CO;2
   Tsuchiya M, 1996, J MAR RES, V54, P541, DOI 10.1357/0022240963213583
   Warren BA., 1981, EVOLUTION PHYSICAL O, P6
   WHITEHEAD JA, 1982, J GEOPHYS RES-OCEANS, V87, P7903, DOI 10.1029/JC087iC10p07903
   WHITEHEAD JA, 1985, J FLUID MECH, V157, P79, DOI 10.1017/S0022112085002312
   WHITEHEAD JA, 1989, J PHYS OCEANOGR, V19, P853, DOI 10.1175/1520-0485(1989)019<0853:SOABWI>2.0.CO;2
   WIJFFELS SE, 1993, WHOI9342 MIT
   WRIGHT WR, 1970, DEEP-SEA RES, V17, P367, DOI 10.1016/0011-7471(70)90028-8
   ZALESAK ST, 1979, J COMPUT PHYS, V31, P335, DOI 10.1016/0021-9991(79)90051-2
NR 53
TC 13
Z9 13
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0035-9009
EI 1477-870X
J9 Q J ROY METEOR SOC
JI Q. J. R. Meteorol. Soc.
PD OCT
PY 1998
VL 124
IS 552
BP 2829
EP 2866
DI 10.1256/smsqj.55214
PN B
PG 38
WC Meteorology & Atmospheric Sciences
SC Meteorology & Atmospheric Sciences
GA 157HW
UT WOS:000078052700014
DA 2021-08-04
ER

PT J
AU Mavri, J
AF Mavri, J
TI Irreversible inhibition of the HIV-1 protease: A theoretical study
SO INTERNATIONAL JOURNAL OF QUANTUM CHEMISTRY
LA English
DT Article
DE HIV-1 protease; irreversible inhibition; ab initio; DFT; solvent
   reaction field
ID IMMUNODEFICIENCY VIRUS-1 PROTEASE; ASPARTIC PROTEASE; MECHANISM;
   SIMULATIONS; POTENTIALS; EXCHANGE; BINDING; ENZYME
AB Reaction coordinate for the irreversible inhibition of the HIV-1 protease by epoxy alkylating agent has been examined by ab initio HF/6-31G(d) calculations, semiempirical molecular orbital (MO) calculations, while the effect of polar macromolecular environment was included on the solvent reaction field level. The calculations, show that inhibition is specific: activation (free) energy is low when two carboxylic groups that are models for Asp-25 and Asp-125 in the HIV-1 protease active center are involved and is considerably higher when only one formate or CH3S- is present. The latter two mimick any single carboxylate side chain and cysteine side chain, respectively. inclusion of solvent reaction field slightly changes the activation free energy. The calculations confirm experimental data concerning the necessity of two-aspartate motif of the protease active center to activate the alkylating agent [Yu et al., J. Am. Chem. Sec. 118, 5856 (1996)]. The results are discussed in the context of design of nonirreversible inhibitors. (C) 1998 John Wiley & Sons, Inc.
C1 Natl Inst Chem, Ljubljana 1115, Slovenia.
RP Mavri, J (corresponding author), Natl Inst Chem, POB 30,Hajdrihova 19, Ljubljana 1115, Slovenia.
CR BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913
   BERENDSEN HJC, 1997, THEORETICAL TREATMEN, P119
   CHATFIELD DC, 1995, J AM CHEM SOC, V117, P5561, DOI 10.1021/ja00125a018
   DECLERCQ E, 1995, J MED CHEM, V38, P2491, DOI 10.1021/jm00014a001
   Eurenius KP, 1996, INT J QUANTUM CHEM, V60, P1189, DOI 10.1002/(SICI)1097-461X(1996)60:6<1189::AID-QUA7>3.0.CO;2-W
   Frisch MJ, 1995, GAUSSIAN 94 REVISION
   HARRISON RW, 1994, PROTEIN ENG, V7, P1353, DOI 10.1093/protein/7.11.1353
   HOLDER A, 1996, AMPAC VERSION 5 0
   HYLAND LJ, 1991, BIOCHEMISTRY-US, V30, P8454, DOI 10.1021/bi00098a024
   HYLAND LJ, 1991, BIOCHEMISTRY-US, V30, P8441, DOI 10.1021/bi00098a023
   KIM EE, 1995, J AM CHEM SOC, V117, P1181, DOI 10.1021/ja00108a056
   LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785
   LENSINK MF, IN PRESS J PHYS CHEM
   MAVRI J, IN PRESS J PHYS CHEM
   MIERTUS S, 1993, BIOORG MED CHEM LETT, V3, P2105, DOI 10.1016/S0960-894X(01)81026-X
   MIERTUS S, 1981, CHEM PHYS, V55, P117, DOI 10.1016/0301-0104(81)85090-2
   RAO BG, 1994, J COMPUT CHEM, V15, P1241, DOI 10.1002/jcc.540151106
   Silva AM, 1996, J MOL BIOL, V255, P321, DOI 10.1006/jmbi.1996.0026
   TROPSHA A, 1992, PROTEIN ENG, V5, P29, DOI 10.1093/protein/5.1.29
   Yu ZH, 1996, J AM CHEM SOC, V118, P5846, DOI 10.1021/ja954069w
NR 20
TC 10
Z9 10
U1 0
U2 3
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0020-7608
J9 INT J QUANTUM CHEM
JI Int. J. Quantum Chem.
PD SEP 20
PY 1998
VL 69
IS 6
BP 753
EP 759
PG 7
WC Chemistry, Physical; Mathematics, Interdisciplinary Applications;
   Quantum Science & Technology; Physics, Atomic, Molecular & Chemical
SC Chemistry; Mathematics; Physics
GA 111VB
UT WOS:000075458000006
DA 2021-08-04
ER

PT J
AU Deaton, A
   Ng, S
AF Deaton, A
   Ng, S
TI Parametric and nonparametric approaches to price and tax reform
SO JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION
LA English
DT Article
DE average derivative estimator; demand systems; nonparametric; parametric;
   TNX reform; welfare
ID REGRESSION; COEFFICIENTS
AB In many public policy problems, we need to estimate the way in which policy changes affect people's behavior. In the analysis of tax and subsidy reform-the topic of this article-we need to know how tax-induced price changes affect the amounts that people buy of the taxed goods. We present various economic and statistical approaches to obtaining the required estimates. We consider the standard structural methods in economics, where the behavior and welfare of individual agents are captured simultaneously by the specification of utility functions whose parameters are to be estimated. We argue that these methods are less useful than alternatives that directly consider the derivatives of the re,regression function of average behavior. We consider both parametric and nonparametric estimators of these derivatives in the context of price reform For foods in Pakistan, focussing on the advantages and disadvantages of "average derivative estimation" (ADE). ADE is attractive in principle, because it directly estimates the statistics required for policy analysis. In the practical case considered here, neither technique is a clear winner; each has strengths and weaknesses.
C1 Princeton Univ, Princeton, NJ 08544 USA.
   Boston Coll, Chestnut Hill, MA 02167 USA.
RP Deaton, A (corresponding author), Princeton Univ, Princeton, NJ 08544 USA.
EM serena.ng@bc.edu
RI Deaton, Angus S/C-3334-2008; Ng, Serena/AAA-1003-2020
OI Ng, Serena/0000-0003-2684-364X
CR AHMAD SE, 1991, THEORY PRACTICE TAX
   Atkinson A. B., 1980, LECT PUBLIC EC
   ATKINSON AB, 1977, CAN J ECON, V10, P590, DOI 10.2307/134292
   DEATON A, 1989, WORLD BANK ECON REV, V3, P183, DOI 10.1093/wber/3.2.183
   DEATON A, 1988, AM ECON REV, V78, P418
   Deaton A, 1997, ANAL HOUSEHOLD SURVE
   Deaton A., 1987, THEORY TAXATION DEV, P92
   DEATON AS, IN PRESS J POLITICAL, P106
   DIXIT AK, 1976, J PUBLIC ECON, V4, P103
   HARDLE W, 1989, J AM STAT ASSOC, V84, P986, DOI 10.2307/2290074
   Hardle W., 1994, HDB ECONOMETRICS, V4
   HECKMAN J, 1974, ECONOMETRICA, V42, P679, DOI 10.2307/1913937
   HOROWITZ JL, 1994, UNPUB DIRECT SEMIPAR
   KLOEK T, 1981, ECONOMETRICA, V49, P205, DOI 10.2307/1911134
   LEE LF, 1986, ECONOMETRICA, V54, P1237, DOI 10.2307/1912330
   NEWEY WK, 1995, 9513 RIC U
   PFEFFERMANN D, 1985, INT STAT REV, V53, P37, DOI 10.2307/1402879
   PINKSE J, 1996, 1596 CRDE U MONTR
   POWELL JL, 1984, J ECONOMETRICS, V25, P303, DOI 10.1016/0304-4076(84)90004-6
   POWELL JL, 1989, ECONOMETRICA, V57, P1403, DOI 10.2307/1913713
   Powell JL, 1996, J ECONOMETRICS, V75, P291, DOI 10.1016/0304-4076(95)01761-5
   Prais S., 1955, ANAL FAMILY BUDGETS
   Silverman B.W., 1986, MONOGRAPHS STAT APPL
   STOKER TM, 1986, ECONOMETRICA, V54, P1461, DOI 10.2307/1914309
   STOKER TM, 1991, LECT SEMIPARAMETRIC
   Stone R, 1954, ECON J, V64, P511, DOI 10.2307/2227743
   TIMMER CP, 1981, REV ECON STAT, V63, P395, DOI 10.2307/1924357
   TIMMER CP, 1979, AM J AGR ECON, V61, P982, DOI 10.2307/3180361
NR 29
TC 10
Z9 10
U1 0
U2 1
PU AMER STATISTICAL ASSOC
PI ALEXANDRIA
PA 732 N WASHINGTON ST, ALEXANDRIA, VA 22314-1943 USA
SN 0162-1459
EI 1537-274X
J9 J AM STAT ASSOC
JI J. Am. Stat. Assoc.
PD SEP
PY 1998
VL 93
IS 443
BP 900
EP 909
DI 10.2307/2669828
PG 10
WC Statistics & Probability
SC Mathematics
GA 123BG
UT WOS:000076105500010
OA Green Submitted
DA 2021-08-04
ER

PT J
AU Cho, BC
   Lee, MS
   Lee, JH
   Byun, JS
   Baik, BS
AF Cho, BC
   Lee, MS
   Lee, JH
   Byun, JS
   Baik, BS
TI The effects of surgical and chemical delay procedures on the survival of
   arterialized venous flaps in rabbits
SO PLASTIC AND RECONSTRUCTIVE SURGERY
LA English
DT Article
ID SKIN DEFECTS; BLOOD-FLOW; ISLAND FLAPS; CLINICAL-APPLICATIONS; INFLOW;
   TISSUE; VEIN; AUGMENTATION; SYSTEM; NITROGLYCERIN
AB The aim of this study was to investigate the efficacy of a surgical delay procedure and a combined surgical and chemical delay procedure on the survival of arterialized venous flaps.
   Experimental groups included (1) a control group, (2) a surgical delay (4-day and 7-day delay) group, and (3) a combined surgical and chemical (doxazosin mesylate, nitroglycerine patch) delay group. These groups were further divided into subgroups (n = 10) depending on the delay period and the chemical agents. An arterialized venous flap was created on one ear of each rabbit. In the arterialized venous flap, arterial inflow was provided by anastomosis of the central auricular artery to the anterior branch of the central auricular vein and a venous outflow through the anterior marginal vein.
   In the control group, the arterialized venous flaps without any delay procedure shelved complete necrosis of all flaps, in the surgical delay group, the mean percentage survival of arterialized venous flaps was 36.6 percent in the 4-day delay group and,59.7 percent in the 7-day delay group. In the combined surgical and chemical delay group a S-day chemical delay followed by a 4-day: simultaneous surgical and chemical delay resulted in mean percentage survival of the arterialized venous flaps of 81.1 percent in the doxazosin mesylate group, 72.8 percent in the nitroglycerine patch group, and 92.9 percent in a combination group of doxazosin mesylate and nitroglycerine patch. A 3-day chemical delay followed by a ii-day simultaneous surgical and chemical delay resulted in mean percentage survival of the arterialized venous flaps of 94 percent in the doxazosin mesylate group, 90.2 percent in the nitroglycerine patch group, and 99 percent ill a combination group of doxazosin mesylate and nitroglycerine patch.
   In conclusion, the surgical delay procedure increased the percentage survival of the arterialized venous flaps in proportion to the delay period. The combination group of surgical and chemical delay procedures had a significantly greater percentage survival than that of the surgical delay group (p < 0.001), and the delay period could be shortened.
C1 Kyungpook Natl Univ Hosp, Dept Plast & Reconstruct Surg, Taegu 700412, South Korea.
RP Cho, BC (corresponding author), Kyungpook Natl Univ Hosp, Dept Plast & Reconstruct Surg, Samduk 2 Ga,50, Taegu 700412, South Korea.
CR AMARANTE J, 1988, BRIT J PLAST SURG, V41, P132, DOI 10.1016/0007-1226(88)90038-0
   BAEK SM, 1985, PLAST RECONSTR SURG, V75, P88, DOI 10.1097/00006534-198501000-00020
   Barthe Garcia P, 1991, Br J Plast Surg, V44, P285
   BRAITHWAITE F, 1951, BRIT J PLAST SURG, V4, P28, DOI 10.1016/S0007-1226(51)80004-3
   BYUN JS, 1995, PLAST RECONSTR SURG, V96, P1650, DOI 10.1097/00006534-199512000-00019
   CHAVOIN JP, 1987, BRIT J PLAST SURG, V40, P149, DOI 10.1016/0007-1226(87)90187-1
   CHIA SL, 1988, PLAST RECONSTR SURG, V82, P892, DOI 10.1097/00006534-198811000-00028
   Cho BC, 1997, ANN PLAS SURG, V39, P145, DOI 10.1097/00000637-199708000-00007
   CHOW SP, 1993, PLAST RECONSTR SURG, V91, P713, DOI 10.1097/00006534-199304000-00023
   CUTTING C, 1982, PLAST RECONSTR SURG, V69, P652, DOI 10.1097/00006534-198204000-00014
   ERIKSSON E, 1978, BRIT J PLAST SURG, V31, P238, DOI 10.1016/S0007-1226(78)90092-9
   FINSETH F, 1978, PLAST RECONSTR SURG, V61, P738, DOI 10.1097/00006534-197805000-00013
   FORREST CR, 1990, J SURG RES, V48, P237, DOI 10.1016/0022-4804(90)90219-R
   FOUCHER G, 1988, BRIT J PLAST SURG, V41, P337, DOI 10.1016/0007-1226(88)90069-0
   FUKUI A, 1991, J RECONSTR MICROSURG, V7, P217, DOI 10.1055/s-2007-1006782
   GALUMBECK MA, 1994, PLAST RECONSTR SURG, V94, P997, DOI 10.1097/00006534-199412000-00013
   German W, 1933, ARCH SURG-CHICAGO, V26, P27, DOI 10.1001/archsurg.1933.01170010030003
   GILMAN AG, 1988, PHARMACOL BASIS THER, P806
   GUBA AM, 1979, PLAST RECONSTR SURG, V63, P550, DOI 10.1097/00006534-197904000-00018
   HENDEL PM, 1983, PLAST RECONSTR SURG, V71, P399, DOI 10.1097/00006534-198303000-00019
   HONDA T, 1984, BRIT J PLAST SURG, V37, P607, DOI 10.1016/0007-1226(84)90158-9
   HYNES W, 1969, BR J PLAST SURG, V44, P52
   INADA Y, 1990, Journal of Reconstructive Microsurgery, V6, P123, DOI 10.1055/s-2007-1006811
   INADA Y, 1992, J RECONSTR MICROSURG, V8, P297, DOI 10.1055/s-2007-1006711
   INADA Y, 1991, BRIT J PLAST SURG, V44, P368, DOI 10.1016/0007-1226(91)90151-9
   INADA Y, 1993, BRIT J PLAST SURG, V46, P61, DOI 10.1016/0007-1226(93)90067-L
   INOUE G, 1990, BRIT J PLAST SURG, V43, P135, DOI 10.1016/0007-1226(90)90150-X
   INOUE G, 1988, Journal of Reconstructive Microsurgery, V4, P259, DOI 10.1055/s-2007-1006929
   INOUE G, 1993, PLAST RECONSTR SURG, V91, P299, DOI 10.1097/00006534-199302000-00014
   INOUE G, 1993, PLAST RECONSTR SURG, V91, P303, DOI 10.1097/00006534-199302000-00015
   Ji S Y, 1984, Microsurgery, V5, P151, DOI 10.1002/micr.1920050311
   JURELL G, 1986, ANN PLAS SURG, V17, P493, DOI 10.1097/00000637-198612000-00010
   KOSHIMA I, 1991, BRIT J PLAST SURG, V44, P23, DOI 10.1016/0007-1226(91)90171-F
   LEE JH, 1994, J KOREAN SOC PLAST R, V21, P865
   MATSUSHITA K, 1993, PLAST RECONSTR SURG, V91, P127, DOI 10.1097/00006534-199301000-00019
   MATSUSHITA K, 1991, J RECONSTR MICROSURG, V7, P146
   MORRIS SF, 1995, PLAST RECONSTR SURG, V95, P526, DOI 10.1097/00006534-199503000-00014
   MUNDY JC, 1984, ARCH OTOLARYNGOL, V110, P221
   MYERS MB, 1969, PLAST RECONSTR SURG, V44, P52, DOI 10.1097/00006534-196907000-00008
   NAKAYAMA Y, 1990, PLAST RECONSTR SURG, V85, P239, DOI 10.1097/00006534-199002000-00012
   NAKAYAMA Y, 1981, PLAST RECONSTR SURG, V67, P328, DOI 10.1097/00006534-198103000-00009
   NICHTER LS, 1985, PLAST RECONSTR SURG, V75, P686, DOI 10.1097/00006534-198505000-00012
   NICHTER LS, 1985, AM J SURG, V150, P191, DOI 10.1016/0002-9610(85)90117-5
   NORELDIN AA, 1992, BRIT J PLAST SURG, V45, P18, DOI 10.1016/0007-1226(92)90108-A
   OHTSUKA H, 1992, PLAST RECONSTR SURG, V89, P965, DOI 10.1097/00006534-199205000-00033
   PANG CY, 1986, PLAST RECONSTR SURG, V78, P68, DOI 10.1097/00006534-198607000-00010
   PANG CY, 1989, ANN PLAS SURG, V22, P293, DOI 10.1097/00000637-198904000-00003
   Pearl R M, 1981, Ann Plast Surg, V7, P102, DOI 10.1097/00000637-198108000-00005
   REICHEK N, 1974, CIRCULATION, V50, P348, DOI 10.1161/01.CIR.50.2.348
   REID KB, 1991, MATH SOC SCI, V21, P1, DOI 10.1016/0165-4896(91)90036-Q
   REINISCH JF, 1974, PLAST RECONSTR SURG, V54, P585, DOI 10.1097/00006534-197411000-00010
   RYU HH, 1996, J KOREAN SOC PLAST R, V23, P942
   SASA M, 1988, PLAST RECONSTR SURG, V82, P319, DOI 10.1097/00006534-198808000-00018
   STARK R B, 1959, Plast Reconstr Surg Transplant Bull, V24, P19, DOI 10.1097/00006534-195907000-00003
   THATTE MR, 1989, BRIT J PLAST SURG, V42, P193, DOI 10.1016/0007-1226(89)90203-8
   THATTE RL, 1987, BRIT J PLAST SURG, V40, P16, DOI 10.1016/0007-1226(87)90004-X
   THATTE RL, 1987, BRIT J PLAST SURG, V40, P11, DOI 10.1016/0007-1226(87)90003-8
   TOOMEY JM, 1979, OTOLARYNG HEAD NECK, V87, P757, DOI 10.1177/019459987908700609
   UEDA K, 1993, BRIT J PLAST SURG, V46, P56, DOI 10.1016/0007-1226(93)90066-K
   VOUKIDIS T, 1982, BRIT J PLAST SURG, V35, P524, DOI 10.1016/0007-1226(82)90057-1
   WRAY RC, 1984, PLAST RECONSTR SURG, V73, P939, DOI 10.1097/00006534-198406000-00015
   XIU ZF, 1995, ANN PLAS SURG, V34, P518, DOI 10.1097/00000637-199505000-00011
   YILMAZ M, 1995, ANN PLAS SURG, V34, P88, DOI 10.1097/00000637-199501000-00019
   YOSHIMURA M, 1987, PLAST RECONSTR SURG, V79, P243, DOI 10.1097/00006534-198702000-00016
   YOUNG RA, 1988, DRUGS, V35, P525, DOI 10.2165/00003495-198835050-00003
   YUEN QM, 1991, MICROSURG, V12, P60, DOI 10.1002/micr.1920120112
   ZELIS R, 1975, JAMA-J AM MED ASSOC, V234, P166, DOI 10.1001/jama.234.2.166
NR 67
TC 32
Z9 33
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA
SN 0032-1052
J9 PLAST RECONSTR SURG
JI Plast. Reconstr. Surg.
PD SEP
PY 1998
VL 102
IS 4
BP 1134
EP 1143
DI 10.1097/00006534-199809040-00033
PG 10
WC Surgery
SC Surgery
GA 116ET
UT WOS:000075711300033
PM 9734433
DA 2021-08-04
ER

PT J
AU Walker, VA
   Peremans, H
   Hallam, JCT
AF Walker, VA
   Peremans, H
   Hallam, JCT
TI Good vibrations: Exploiting reflector motion to partition an acoustic
   environment
SO ROBOTICS AND AUTONOMOUS SYSTEMS
LA English
DT Article
DE active sensing; echolocation; Doppler; agent-environment interaction
AB Much of Artificial Intelligence studies agent perception by exploring architectures for Linking (often abstract) sensors and actuators so as to give rise to particular behaviour. By contrast, the approach presented here proposes that perceptual investigations should begin with a characterisation of the underlying physical laws which govern the specific interaction of a sensor (or actuator) with its environment throughout the execution of a task. Moreover, it demonstrates that, through an understanding of task and environment physics, problems for which architectural solutions or explanations are often proposed may be solved more simply at the sensory interface - thereby minimising subsequent computation.
   As an example of this approach, we isolate the relevant physics governing an agent-environment interaction by reverse-engineering an echolocation system from existing ethological descriptions. The biological reference for this work includes several species of tone emitting insectivorous bats which hunt moving targets (i.e. fluttering insects) in acoustically cluttered environments (e.g. under the forest canopy). The simple perceptual mechanism that we hypothesise underlies this behaviour involves a binaural comparison of the spectral sideband energy contained in echoes reflected by targets with periodic motion. This perceptual mechanism can be exploited by any echolocator (with sufficiently narrow acoustical filters) to disambiguate the location of moving targets in the presence of strong stationary reflectors. When this localisation strategy is made to operate on energy in the particular sidebands reflected by targets with particular motions, target selective localisation behaviour emerges.
   The echolocation sensor designed to investigate this hypothesis is demonstrated via computer simulation and tested aboard a mobile robot. (C) 1998 Elsevier Science B.V. All rights reserved.
C1 Univ Edinburgh, Dept Artificial Intelligence, Edinburgh EH1 2QL, Midlothian, Scotland.
RP Walker, VA (corresponding author), Univ Edinburgh, Dept Artificial Intelligence, 5 Forrest Hill, Edinburgh EH1 2QL, Midlothian, Scotland.
CR Biber C, 1980, 67 CONV AUD ENG SOC
   Braitenberg, 1984, VEHICLES EXPT SYNTHE
   Everett H. R., 1989, Robotics and Autonomous Systems, V5, P5
   FORSTER P, 1991, 6 DAI U ED
   Gibson J.J., 1966, SENSES CONSIDERED PE
   Griffin D. R., 1958, LISTENING DARK
   HORSWILL I, 1995, ARTIF INTELL, V73, P1, DOI 10.1016/0004-3702(94)00057-8
   Kuc R, 1997, J ACOUST SOC AM, V102, P689, DOI 10.1121/1.419658
   MOSS C, 1996, HEARING BATS, P87
   NEUWEILER G, 1980, NATO ASI SER, P519
   Panter, 1965, MODULATION NOISE SPE
   PEREMANS H, 1993, IEEE T ROBOTIC AUTOM, V9, P36, DOI 10.1109/70.210793
   PEREMANS H, 1977, 44 DAI U ED
   ROEDER KD, 1963, BIOL BULL, V124, P200, DOI 10.2307/1539496
   SCHNITZLER HU, 1978, VERH DTSCH ZOOL GES, P16
   SCHULLER G, 1979, J COMP PHYSIOL, V132, P47, DOI 10.1007/BF00617731
   SHAMMA SA, 1986, J ACOUST SOC AM, V80, P133, DOI 10.1121/1.394173
   Varela F. J., 1991, EMBODIED MIND COGNIT
   WALKER VA, 1997, THESIS U EDINBURGH
   WEBB B, 1993, THESIS U EDINBURGH
NR 20
TC 1
Z9 1
U1 1
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-8890
J9 ROBOT AUTON SYST
JI Robot. Auton. Syst.
PD AUG 31
PY 1998
VL 24
IS 1-2
BP 43
EP 55
DI 10.1016/S0921-8890(98)00021-9
PG 13
WC Automation & Control Systems; Computer Science, Artificial Intelligence;
   Robotics
SC Automation & Control Systems; Computer Science; Robotics
GA 141AK
UT WOS:000077120300005
DA 2021-08-04
ER

PT J
AU Ching, LM
   Browne, WL
   Tchernegovski, R
   Gregory, T
   Baguley, BC
   Palmer, BD
AF Ching, LM
   Browne, WL
   Tchernegovski, R
   Gregory, T
   Baguley, BC
   Palmer, BD
TI Interaction of thalidomide, phthalimide analogues of thalidomide and
   pentoxifylline with the anti-tumour agent
   5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum
   tumour necrosis factor-alpha and enhancement of anti-tumour activity
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE 5,6-dimethylxanthenone-4-acetic acid; thalidomide; phthalimide;
   pentoxifylline; tumour necrosis factor; anti-tumour activity; Colon 38
ID FLAVONE ACETIC-ACID; POTENTIAL ANTITUMOR AGENTS; INDUCTION; INVIVO;
   CELLS
AB DMXAA (5,6-dimethylxanthenone-4-acetic acid), a novel anti-tumour agent currently undergoing clinical evaluation, appears to mediate its anti-tumour effects through immune modulation and the production of the cytokine tumour necrosis factor-alpha (TNF). Our previous studies have shown that thalidomide, a potent inhibitor of TNF biosynthesis that has numerous biological effects, including inhibition of tumour angiogenesis, unexpectedly augments the anti-tumour response in mice to DMXAA. We show here that thalidomide (100 mg kg(-1)) has no effect when administered with inactive doses of DMXAA, and that it must be given simultaneously with an active dose of DMXAA to have its maximum potentiating effect on the growth of the murine Colon 38 adenocarcinoma. To address the issue of whether inhibition of serum TNF production is important for potentiation of anti-tumour activity, we have tested three potent analogues of thalidomide. All three analogues, when cc-administered with DMXAA to mice at doses lower than those used with thalidomide, inhibited TNF production and were effective in potentiating the anti-tumour activity of DMXAA against transplanted Colon 38 tumours. One of the analogues, N-phenethyltetrafluorophthalimide, was 1000-fold more potent than thalidomide and at a dose of 0.1 mg kg(-1) in combination with DMXAA (30 mg kg(-1)) cured 100% of mice, compared with 67% for the group treated with DMXAA alone. We also tested pentoxifylline and found it to suppress TNF production in response to DMXAA and to potentiate the anti-tumour effect of DMXAA. The results are compatible with the hypothesis that pharmacological reduction of serum TNF levels might benefit the anti-tumour effects of DMXAA and suggest new strategies for therapy using this agent.
C1 Univ Auckland, Sch Med, Auckland Canc Soc, Res Ctr, Auckland, New Zealand.
RP Ching, LM (corresponding author), Univ Auckland, Sch Med, Auckland Canc Soc, Res Ctr, Private Bag 92019, Auckland, New Zealand.
RI Ching, Lai-Ming/H-6735-2016
OI Ching, Lai-Ming/0000-0002-9745-2868
CR BAGULEY BC, 1989, EUR J CANCER CLIN ON, V25, P263, DOI 10.1016/0277-5379(89)90018-7
   CASINI G, 1964, Farmaco Sci, V19, P563
   CHING LM, 1995, BRIT J CANCER, V72, P339, DOI 10.1038/bjc.1995.335
   CHING LM, 1991, EUR J CANCER, V27, P79, DOI 10.1016/0277-5379(91)90067-N
   CHING LM, 1987, EUR J CANCER CLIN ON, V23, P1047, DOI 10.1016/0277-5379(87)90357-9
   DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082
   FABRO S, 1967, NATURE, V215, P296, DOI 10.1038/215296a0
   FUTAMI H, 1992, J IMMUNOTHER, V12, P247, DOI 10.1097/00002371-199211000-00005
   HAN J, 1990, J EXP MED, V172, P391, DOI 10.1084/jem.172.1.391
   MACE KF, 1990, CANCER RES, V50, P1742
   MAHADEVAN V, 1990, CANCER RES, V50, P5537
   MOREIRA AL, 1993, J EXP MED, V177, P1675, DOI 10.1084/jem.177.6.1675
   NISHIMURA K, 1994, BIOCHEM BIOPH RES CO, V199, P455, DOI 10.1006/bbrc.1994.1250
   NOEL P, 1990, LIFE SCI, V47, P1023, DOI 10.1016/0024-3205(90)90474-6
   Philpott M, 1995, CANCER CHEMOTH PHARM, V36, P143
   PRATESI G, 1990, EUR J CANCER, V26, P1079, DOI 10.1016/0277-5379(90)90056-Y
   REWCASTLE GW, 1991, J MED CHEM, V34, P217, DOI 10.1021/jm00105a034
   REWCASTLE GW, 1989, J MED CHEM, V32, P793, DOI 10.1021/jm00124a012
   SAMPAIO EP, 1991, J EXP MED, V173, P699, DOI 10.1084/jem.173.3.699
   SASAKI K, 1995, BIOL PHARM BULL, V18, P1228
   Shannon EJ, 1996, IMMUNOPHARM IMMUNOT, V18, P59, DOI 10.3109/08923979609007110
   TEICHER BA, 1993, ANTICANCER RES, V13, P2101
   ZWI LJ, 1994, ONCOL RES, V6, P79
   ZWI LJ, 1989, JNCI-J NATL CANCER I, V81, P1005, DOI 10.1093/jnci/81.13.1005
NR 24
TC 45
Z9 45
U1 0
U2 3
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0007-0920
J9 BRIT J CANCER
JI Br. J. Cancer
PD AUG
PY 1998
VL 78
IS 3
BP 336
EP 343
DI 10.1038/bjc.1998.495
PG 8
WC Oncology
SC Oncology
GA 103GV
UT WOS:000075150400011
PM 9703279
OA Green Published, Bronze
DA 2021-08-04
ER

PT J
AU Irwin, RS
   Boulet, LP
   Cloutier, MM
   Fuller, R
   Gold, PM
   Hoffstein, V
   Ing, AJ
   McCool, FD
   O'Byrne, P
   Poe, RH
   Prakash, UBS
   Pratter, MR
   Rubin, BK
AF Irwin, RS
   Boulet, LP
   Cloutier, MM
   Fuller, R
   Gold, PM
   Hoffstein, V
   Ing, AJ
   McCool, FD
   O'Byrne, P
   Poe, RH
   Prakash, UBS
   Pratter, MR
   Rubin, BK
TI Managing cough as a defense mechanism and as a symptom - A consensus
   panel report of the American College of Chest Physicians
SO CHEST
LA English
DT Review
ID ANGIOTENSIN-CONVERTING-ENZYME; POSITIVE EXPIRATORY PRESSURE; CHRONIC
   PERSISTENT COUGH; OBSTRUCTIVE PULMONARY-DISEASE; GASTRO-ESOPHAGEAL
   REFLUX; AIR-FLOW OBSTRUCTION; RESPIRATORY-TRACT INFECTION; REGIONAL LUNG
   CLEARANCE; GASTROESOPHAGEAL REFLUX; CYSTIC-FIBROSIS
AB 1. Cough can (a) be an important defense mechanism to help clear excessive secretions and foreign material from airways; (b) be an important factor in the spread of infection; (c) maintain consciousness during potentially lethal arrhythmias and/or convert arrhythmias to more normal cardiac rhythms; and (d) present as one of the most common symptoms for which patients seek medical attention and spend health-care dollars.
   2. Cough involves a complex reflex are that begins with the stimulation of an irritant receptor. Most receptors are probably located in the respiratory system; the existence of a discrete central cough center has not been demonstrated. Evidence to date suggests that the cough center is diffusely located in the medulla. An effective cough depends on the ability to achieve high gas flows and intrathoracic pressures, enhancing the removal of mucus adhering to the airway wall. Cough ineffectiveness may occur when respiratory muscles are weakened or when the surface adhesive properties of mucus are altered. While a variety of nonpharmacologic protussive treatment modalities may improve cough mechanics, clinical studies documenting improvement in patient morbidity and mortality are lacking.
   3. It is the complications of cough that lead patients to seek medical attention. The most common complications are subjective perceptions of exhaustion and self-consciousness, and symptoms of insomnia, hoarseness, musculoskeletal pain: sweating, and urinary incontinence. The pressures produced during vigorous coughing can cause a variety of complications in nearly all organ systems.
   4. The two categories of cough, are acute, lasting less than 3 weeks, and chronic, lasting 3 to 8 weeks or longer; they are not mutually exclusive (Grade II-2, III-3). Acute cough is most frequently due to the common cold (Grade III). Chronic cough is often simultaneously due to more than one condition (Grade II-2, II-3), but can be the sole clinical manifestation of asthma and gastroesophageal reflux disease (GERD) (Grade II-2). The most common causes of chronic cough in nonsmokers are postnasal drip syndrome (PNDS), asthma, and/or GERD (Grade II-2, II-3), whether or not the cough is described as dry or productive (Grade II-2). PNDS, asthma, and/or GERD are likely to be causes(s) of chronic cough approximately 100% of the time in nonsmokers who are not taking angiotensin-converting enzyme inhibitor (ACEI) drugs and who have normal or nearly normal chest radiographs showing no more than stable inconsequential scars (Grade II-2).
   5. PNDS, either singly or in combination with other conditions, is the single most common cause of chronic cough for which patients seek medical attention (Grade II-2). The symptoms and signs of PNDS are nonspecific (Grade II-2); therefore, a definitive diagnosis of PNDS-induced cough cannot be made from history and physical examination alone. A favorable response to specific therapy for PNDS, with resolution of cough, is a crucial step in confirming that PNDS is present and is the etiology of cough. The combination of a first-generation antihistamine and a decongestant is considered to be the most consistently effective sole form of therapy in treating most patients with PNDS-induced cough not due to sinusitis (Grade II-2). In most patients, some improvement in cough will be seen within 1 week of initiation of therapy. Newer generation, relatively nonsedating antihistamines have been found ineffective in treating acute cough associated with the common cold (Grade I) and are not as effective as first-generation antihistamines in treating PNDS secondary to nonallergic conditions. The first-generation antihistamines should be used preferentially to treat PNDS-induced cough that is nonhistamine-mediated (Grade I, II-2).
   6. Asthma is a common cause of chronic cough. A diagnosis of cough-variant asthma is suggested by the presence of airway hyperresponsiveness, and confirmed only when the cough resolves with asthma medications. The treatment of cough-variant asthma is the same as for asthma presenting with other symptoms. Inhaled medications prescribed for asthma may worsen the cough.
   7. GERD can cause cough by aspiration, but it most likely causes chronic cough in patients with normal radiographs by a vagally mediated reflex mechanism (Grade II, II-2). When GERD is the cause of chronic cough, GI symptoms are often absent (Grade II-2). Twenty-four-hour esophageal pH monitoring is the most sensitive and specific test For GERD. In interpreting the test, it is important to assess the duration and frequency of reflux episodes, and the temporal relationship between reflux and cough episodes. Patients with normal standard reflux parameters may still have reflux as a cause of cough if a temporal relationship exists (Grade II-2). When 24-h esophageal pH monitoring cannot be done, an empiric trial of antireflux medication is appropriate when GERD is suspected as a cause of cough. However, if empiric treatment fails, GERD cannot be ruled out until objective studies are conducted (Grade III) because the empiric therapy may not have been intensive enough or medical therapy may have failed. Because minimum consistently effective therapy for GERD-induced chronic cough is not known, initial treatment should include diet and lifestyle changes in addition to drugs. Cough due to GERD has been reported to resolve with medical therapy in 70 to 100% of patients; mean time to recovery may take as long as 169 to 179 days (Grade II-2). Antireflux surgery may be considered after intensive medical therapy has been documented to have failed.
   8. Cough is a principal feature of chronic bronchitis (CB) and its treatment should chiefly be directed to reduction of sputum production and airway inflammation (eg, by smoking cessation and removal of environmental irritants) (Grade II-2). While CB is among tie most frequent causes of chronic cough in the community, it is the cause in only about 5% in series of patients who Seek medical attention for cough. Ipratropium can decrease sputum production and cough (Grade I). Nonspecific cough suppressants should be avoided, and mucolytics are of uncertain benefit. Although the effectiveness systemic corticosteroids and antibiotics on cough have not been specifically studied, they are likely to be helpful in decreasing cough during exacerbations of COPD (Grade III).
   9. Bronchiectasis is a cause of chronic cough in a relatively small number of patients: the diagnosis is established by clinical history, chest radiograph, high-resolution CT scan of the thorax, and cough disappearance with specific therapy. Cough associated with flares of the disease can be treated with a combination of chest physiotherapy, drugs to stimulate mucociliary clearance, and systemic antibiotics (Grade II-2). Inhaled antibiotics are recommended only in cystic fibrosis (CF) patients with bronchiectasis (Grade I).
   10. Postinfectious cough is a diagnosis of exclusion; it should be considered when a patient complains only of cough after a respiratory tract infection and has normal chest radiograph. Postinfectious cough ultimately resolves over time; oral corticosteroids (Grade II-3), inhaled corticosteroids (Grade III), or ipratropium bromide (Grade II may attenuate the cough.
   11. Coughs that develop for the first time and last for months in susceptible groups are suggestive of bronchogenic cat-cinema. Bronchogenic carcinoma is not a common cause of chronic cough (Grade II-2), and is very unlikely in never-smokers (Grade II-2). Present or prior cigarette smoking or occupational exposures increase the risk. Chest radiographs, sputum cytology, and flexible bronchoscopy are the most important initial tests for evaluating bronchogenic carcinoma as a cause of chronic cough.
   12. Cough due to ACEIs is a class effect of these drugs and is not dose-related. The cough is typically nonproductive and is associated with an irritating, tickling, or scratchy sensation in the throat. ACEI-induced cough may appear hours to weeks or months after ACEI is started (Grade Iii. Because no laboratory test predicts who will have ACEI-induced cough, the diagnosis should be considered in any patient who has a cough while taking an ACEI (Grade IIII. Cough due to ACEIs will disappear or substantially improve within 4 weeks of discontinuing the drug (Grade I); definitive treatment of ACEI-induced cough is discontinuation of the drug.
   13. Habit cough and psychogenic cough are diagnoses of exclusion (Grade III). The character of the cough (eg; honking or barking) is not diagnostically helpful in adults (Grade II-2). However, the pediatric literature suggests that honking and barking coughs are consistent with psychogenic cough (Grade III). After exclusion of other causes, psychological counseling and short-term antitussive therapy may be appropriate for psychogenic cough (Grade III).
   14. Chronic interstitial pulmonary disease is an uncommon cause of cough; treatment of such cough is based on treatment of the underlying condition. If this treatment fails to resolve the cough, the cough may still be treatable with specific therapy for other comet-bid conditions. The most common causes of chronic cough should be investigated before antitussives are prescribed (Grade III).
   15. In children, asthma, upper and lower respiratory tract infections, and GERD are the most common causes of acute and chronic cough. Less common causes of cough in children are congenital anomalies, aspiration and environmental exposures. The approach to managing chronic cough in children is similar to the approach in adults (Grade III). Diagnostic testing may be limited because many children are unable to cooperate in testing, and positive tests do not necessarily establish diagnosis or predict a favorable response to specific therapy (Grade III). A chest radiograph should be obtained in nearly all children with chronic cough to rule out lower respiratory tract and cardiac pathology (Grade III). A sweat test for CF may be considered when no clear etiology for cough is established. The recommended diagnostic approach to cough in children is history, physical examination, and determination of a most likely etiology (Grade III).
   16. The cause of chronic cough can be determined in most patients; specific therapy will be successful in the majority of patients when chronic cough is evaluated in a systematic manner. Guidelines and algorithms for evaluating acute and chronic cough in immunocompetent and immunocompromised adults, and children, with diagnostic caveats, are presented in the body of this report.
   17. Pharmacologic treatment of cough is either (a) antitussive, to prevent, control, or eliminate cough, or (b) protussive, to make cough more effective. Antitussive therapy is indicated when cough serves no useful function such as clearing the airways. Specific antitussive therapy is directed at the etiology or mechanism causing cough leg, cigarette smoking, postnasal drip). Nonspecific antitussive therapy is directed at the symptom rather than the etiology or mechanism. Because of the high probability of being able to determine the causes of cough and prescribe specific treatment that can be successful, there is a limited role for nonspecific antitussive treatment (Grade II-2, II-3). It is indicated (Grade III) when specific therapy has not had a chance to work or will not work leg, inoperable lung cancer). Protussive therapy is indicated when cough performs a useful function and needs to be encouraged leg, in bronchiectasis, CF). Although hypertonic saline, amiloride, and terbutaline by aerosol following chest physiotherapy have been shown to increase cough clearance (Grade I), or cough clearability in the case of amiloride, their clinical utility remains to be determined in future studies that assess short-term and long-term effects of these agents on the patient's condition. Hypertonic saline in CF appears promising.
OI Ing, Alvin/0000-0002-6391-020X
CR *ADH COMM ASS CLIN, 1997, AM J RESP CRIT CARE, V156, P320
   AGARWAL M, 1989, BIORHEOLOGY, V26, P977
   AGNEW JE, 1986, THORAX, V41, P524, DOI 10.1136/thx.41.7.524
   Albers GM, 1996, J APPL PHYSIOL, V81, P2690
   ANDERSON LI, 1996, CHEST, V90, P358
   [Anonymous], 1986, PEDIATRICS, V77, P755
   [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202
   ANTHONISEN NR, 1987, ANN INTERN MED, V106, P196, DOI 10.7326/0003-4819-106-2-196
   ARORA NS, 1981, J APPL PHYSIOL, V51, P494
   BACH JR, 1993, ARCH PHYS MED REHAB, V74, P170
   BALDI F, 1985, GUT, V26, P336, DOI 10.1136/gut.26.4.336
   BANYAI AL, 1947, CHEST, V13, P1
   BARKER AF, 1988, AM REV RESPIR DIS, V137, P969, DOI 10.1164/ajrccm/137.4.969
   BATEMAN JRM, 1979, LANCET, V1, P294
   BEEM MO, 1977, NEW ENGL J MED, V296, P306, DOI 10.1056/NEJM197702102960604
   BENNETT WD, 1993, CHEST, V103, P488, DOI 10.1378/chest.103.2.488
   BENNETT WD, 1992, CHEST, V102, P412, DOI 10.1378/chest.102.2.412
   BENNETT WD, 1990, J APPL PHYSIOL, V69, P1670
   BERKIN KE, 1988, BMJ-BRIT MED J, V296, P1279, DOI 10.1136/bmj.296.6632.1279
   BERKIN KE, 1989, EUR RESPIR J, V2, P198
   BERKOWITZ RB, 1991, ANN ALLERGY, V67, P593
   BERKOWITZ RB, 1989, ANN ALLERGY, V63, P336
   BICKERMAN HA, 1960, CLIN CARDIOPULMONARY, P494
   BLAZER S, 1980, AM J DIS CHILD, V134, P68, DOI 10.1001/archpedi.1980.02130130050015
   BOOTH DJ, 1968, ARCH SURG-CHICAGO, V96, P731
   BORISON HL, 1948, AM J PHYSIOL, V154, P55
   BOUCOT KR, 1966, JAMA-J AM MED ASSOC, V196, P167
   BOUROS D, 1995, THORAX, P1335
   BOWTON DL, 1984, CHEST, V86, P150, DOI 10.1378/chest.86.1.150
   BOYLE JT, 1985, AM REV RESPIR DIS, V131, pS16
   BRAMAN SS, 1987, CLIN CHEST MED, V8, P177
   BRAUN SR, 1984, AM J PHYS MED REHAB, V63, P1
   BRONSKY EA, 1995, J ALLERGY CLIN IMMUN, V95, P1117, DOI 10.1016/S0091-6749(95)70215-6
   BROWN TCK, 1983, MED J AUSTRALIA, V2, P322, DOI 10.5694/j.1326-5377.1983.tb122489.x
   BUCHER K, 1958, PHARMACOL REV, V10, P43
   BURROWS B, 1991, AM REV RESPIR DIS, V143, P1452, DOI 10.1164/ajrccm/143.6.1452
   CAMNER P, 1973, SCAND J RESPIR DIS, V54, P272
   CANMER P, 1979, SCAND J RESP, V60, P562
   CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77
   CHAKRAVARTY NK, 1956, J PHARMACOL EXP THER, V117, P127
   CHERIYAN S, 1994, ANN ALLERGY, V73, P478
   CHRISTENSEN EF, 1990, CHEST, V97, P645, DOI 10.1378/chest.97.3.645
   CHRISTENSEN HR, 1990, EUR RESPIR J, V3, P267
   CLARKE SW, 1970, J APPL PHYSIOL, V29, P464
   CLERF LH, 1947, MED CLIN N AM, P1393
   CLOUGH JB, 1994, AM J RESP CRIT CARE, V150, P48, DOI 10.1164/ajrccm.150.1.8025771
   CLOUTIER MM, 1994, DIAGNOSIS MANAGEMENT, P175
   COCHRANE GM, 1977, BRIT MED J, V2, P1181, DOI 10.1136/bmj.2.6096.1181
   COCKCROFT DW, 1983, CHEST, V83, P751, DOI 10.1378/chest.83.5.751
   COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x
   COHLAN SQ, 1984, PEDIATRICS, V74, P11
   COLE PJ, 1986, EUR J RESPIR DIS, V69, P6
   Coleridge H M, 1978, Adv Exp Med Biol, V99, P291
   Coleridge J, 1986, HDB PHYSL RESPIRAT 1, V2, P395
   COLLEY JRT, 1974, LANCET, V2, P1031
   Comroe JH, 1974, PHYSL RESPIRATION IN, P230
   CORAZZIARI E, 1984, GUT, V25, P7, DOI 10.1136/gut.25.1.7
   COUCH RB, 1984, J INFECT DIS, V150, P167, DOI 10.1093/infdis/150.2.167
   CRAUSAZ FM, 1988, CHEST, V93, P376, DOI 10.1378/chest.93.2.376
   CRYSTAL RG, 1976, ANN INTERN MED, V85, P769, DOI 10.7326/0003-4819-85-6-769
   CURLEY FJ, 1988, AM REV RESPIR DIS, V138, P305, DOI 10.1164/ajrccm/138.2.305
   CURRIE DC, 1990, Q J MED, V76, P799
   DALES RE, 1994, INT J EPIDEMIOL, V23, P775, DOI 10.1093/ije/23.4.775
   DAS RM, 1978, J ANAT, V126, P123
   DAVIS AL, 1991, CHRONIC OBSTRUCTIVE, P316
   DAVIS B, 1982, J APPL PHYSIOL, V53, P985
   DAVIS JN, 1972, EXP NEUROL, V34, P78, DOI 10.1016/0014-4886(72)90189-6
   DAVIS SF, 1995, CLIN INFECT DIS, V20, P621, DOI 10.1093/clinids/20.3.621
   DAYMAN H, 1951, J CLIN INVEST, V30, P1175, DOI 10.1172/JCI102537
   DEBENEDICTIS FM, 1986, J ASTHMA, V23, P303, DOI 10.3109/02770908609073177
   DELATTRE JF, 1985, ANAT CLIN, V7, P271, DOI 10.1007/BF01784644
   DEMEESTER TR, 1976, SURG CLIN N AM, V56, P39
   DEMEESTER TR, 1990, ANN SURG, V211, P337, DOI 10.1097/00000658-199003000-00005
   DENT J, 1987, BAILLIERE CLIN GASTR, V1, P727, DOI 10.1016/0950-3528(87)90016-9
   DENT J, 1980, J CLIN INVEST, V65, P256, DOI 10.1172/JCI109667
   DENT J, 1988, GUT, V29, P1020, DOI 10.1136/gut.29.8.1020
   DIEHR P, 1984, J CHRON DIS, V37, P215, DOI 10.1016/0021-9681(84)90149-8
   DIMARCO AF, 1995, AM J RESP CRIT CARE, V151, P1466, DOI 10.1164/ajrccm.151.5.7735601
   DINGLE JH, 1964, ILLNESS HOME STUDY 2, P293
   DOAN T, 1992, ANN ALLERGY, V69, P505
   DODDS WJ, 1982, NEW ENGL J MED, V307, P1547, DOI 10.1056/NEJM198212163072503
   DOGAN R, 1989, THORAC CARDIOV SURG, V37, P183, DOI 10.1055/s-2007-1020314
   Dordal M T, 1994, Allerg Immunol (Paris), V26, P53
   DUCOLONE A, 1987, AM REV RESPIR DIS, V135, P327
   DUPONT C, 1989, ANN PEDIATR-PARIS, V36, P148
   EKSTROM T, 1989, CHEST, V96, P995, DOI 10.1378/chest.96.5.995
   EKWO EE, 1983, CHEST, V84, P662, DOI 10.1378/chest.84.6.662
   ELBORN JS, 1992, RESP MED, V86, P121, DOI 10.1016/S0954-6111(06)80227-1
   Elftman AG, 1943, AM J ANAT, V72, P1, DOI 10.1002/aja.1000720102
   EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131
   Eng PA, 1996, PEDIATR PULM, V21, P77, DOI 10.1002/(SICI)1099-0496(199602)21:2<77::AID-PPUL3>3.3.CO;2-R
   ESTENNE M, 1994, AM J RESP CRIT CARE, V150, P1081, DOI 10.1164/ajrccm.150.4.7921440
   ESTENNE M, 1989, AM REV RESPIR DIS, V112, P22
   FAISON EP, 1991, AM J HYPERTENS S, V4, pA28
   FALK M, 1984, EUR J RESPIR DIS, V65, P423
   FITZGERALD JM, 1989, CAN MED ASSOC J, V140, P520
   FOGARI R, 1992, J CARDIOVASC PHARM, V19, P670
   FOSTER WM, 1985, AM REV RESPIR DIS, V132, P633
   FRIEBEL H., 1962, ARCH EXPTL PATHOL U PHARMAKOL, V243, P162
   FUCHS KH, 1987, SURGERY, V102, P575
   FULLER RW, 1991, RESP MED, V85, P31, DOI 10.1016/S0954-6111(06)80251-9
   FULLER RW, 1989, J HUM HYPERTENS, V3, P159
   FULLER RW, 1987, BMJ-BRIT MED J, V295, P1025, DOI 10.1136/bmj.295.6605.1025-a
   FURSTENBERG AC, 1948, ANN OTO RHINOL LARYN, V57, P298
   GAFFEY MJ, 1988, PEDIATR INFECT DIS J, V7, P223, DOI 10.1097/00006454-198803000-00032
   *GALL ORG, 1988, GALL SURV HEARTB AM
   GALLON A, 1991, RESP MED, V85, P45, DOI 10.1016/S0954-6111(06)80209-X
   GASTAL OL, 1994, CHEST, V106, P1793, DOI 10.1378/chest.106.6.1793
   Gaylor JB, 1934, BRAIN, V57, P143, DOI 10.1093/brain/57.2.143
   GHAFOURI MA, 1984, CHEST, V86, P387, DOI 10.1378/chest.86.3.387
   GIBSON PG, 1989, LANCET, V1, P1346
   GIBSON PG, 1995, CLIN EXP ALLERGY, V25, P127, DOI 10.1111/j.1365-2222.1995.tb01017.x
   GIUDICELLI R, 1990, ANN CHIR, V44, P552
   GOLDMAN J, 1988, LANCET, V2, P493, DOI 10.1016/S0140-6736(88)90132-8
   GONZALEZ ER, 1988, AM FAM PHYSICIAN, V37, P169
   GRAHAM DY, 1983, AM J GASTROENTEROL, V78, P257
   HARGREAVE FE, 1985, AIRWAY RESPONSIVENES, P122
   HARGREAVES MR, 1995, LANCET, V345, P13, DOI 10.1016/S0140-6736(95)91151-0
   HARRIS RS, 1968, CLIN SCI, V34, P569
   HASANI A, 1994, THORAX, V49, P557, DOI 10.1136/thx.49.6.557
   HASANI A, 1991, RESP MED, V85, P23, DOI 10.1016/S0954-6111(06)80249-0
   HERWALDT LA, 1991, ARCH INTERN MED, V151, P1510, DOI 10.1001/archinte.151.8.1510
   HIGENBOTTAM T, 1989, AM REV RESPIR DIS, V140, P58, DOI 10.1164/ajrccm/140.1.58
   HILL SL, 1986, THORAX, V41, P559, DOI 10.1136/thx.41.7.559
   HILL SL, 1988, Q J MED, V66, P163
   HOFFSTEIN V, 1994, CAN RESPIR J, V1, P40
   HOFMEYR JL, 1986, THORAX, V41, P951, DOI 10.1136/thx.41.12.951
   HOGG JC, 1992, AM REV RESPIR DIS, V145, P57
   HOLINGER LD, 1991, LARYNGOSCOPE, V101, P596
   HOLMES PW, 1992, RESP MED, V86, P425, DOI 10.1016/S0954-6111(06)80010-7
   HONICKY RE, 1983, PEDIATRICS, V71, P126
   HONJIN R, 1956, J COMP NEUROL, V105, P587, DOI 10.1002/cne.901050308
   HUDSON LD, 1990, MED CLIN N AM, V74, P661, DOI 10.1016/S0025-7125(16)30544-2
   HYDE L, 1974, CHEST, V65, P299, DOI 10.1378/chest.65.3.299
   ING A J, 1992, American Review of Respiratory Disease, V145, pA11
   ING AJ, 1992, CHEST, V102, P1668, DOI 10.1378/chest.102.6.1668
   ING AJ, 1994, AM J RESP CRIT CARE, V149, P160, DOI 10.1164/ajrccm.149.1.8111576
   ING AJ, 1992, AM REV RESPIR DIS, V144, pA11
   Ing AJ, 1993, MOD MED AUST, V36, P58
   IRAVANI J, 1974, RESPIRATION, V31, P358
   IRWIN RS, 1993, DRUGS, V46, P80, DOI 10.2165/00003495-199346010-00006
   IRWIN RS, 1993, CHEST, V104, P1511, DOI 10.1378/chest.104.5.1511
   IRWIN RS, 1990, AM REV RESPIR DIS, V141, P640, DOI 10.1164/ajrccm/141.3.640
   IRWIN RS, 1989, AM REV RESPIR DIS, V140, P1294, DOI 10.1164/ajrccm/140.5.1294
   IRWIN RS, 1977, ARCH INTERN MED, V137, P1186, DOI 10.1001/archinte.137.9.1186
   IRWIN RS, 1981, AM REV RESPIR DIS, V123, P413
   IRWIN RS, 1991, CHEST, V99, P1477, DOI 10.1378/chest.99.6.1477
   IRWIN RS, 1997, DIAGNOSIS TREATMENT, P1
   ISAWA T, 1984, J NUCL MED, V25, P352
   ISHRATHUSAIN S, 1967, CAN MED ASSOC J, V97, P540
   ISRAILI ZH, 1992, ANN INTERN MED, V117, P234, DOI 10.7326/0003-4819-117-3-234
   JAEGER RJ, 1993, ARCH PHYS MED REHAB, V74, P1358, DOI 10.1016/0003-9993(93)90093-P
   Jauma R, 1992, Aten Primaria, V9, P375
   JOHNSON D, 1991, J ASTHMA, V28, P85, DOI 10.3109/02770909109082732
   JOHNSON DA, 1989, ARCH INTERN MED, V149, P589, DOI 10.1001/archinte.149.3.589
   JUNIPER EF, 1981, THORAX, V36, P575, DOI 10.1136/thx.36.8.575
   KAMEI RK, 1991, PEDIATR CLIN N AM, V38, P593
   KARLSSON JA, 1988, J APPL PHYSIOL, V65, P1007
   KASE Y, 1970, LIFE SCI, V9, P49, DOI 10.1016/0024-3205(70)90009-3
   KASIAN GF, 1989, PEDIATR PULM, V7, P128, DOI 10.1002/ppul.1950070303
   KIM CS, 1983, J APPL PHYSIOL, V55, P154
   KING M, 1987, BIORHEOLOGY, V24, P589
   KING M, 1980, BIORHEOLOGY, V17, P249
   Kirilloff LH, 1988, CHEST, V103, P436
   KIRSCH CM, 1988, OTOLARYNG CLIN N AM, V21, P677
   KNUDSON RJ, 1974, J APPL PHYSIOL, V36, P653
   KONSTAN MW, 1994, J PEDIATR-US, V124, P689, DOI 10.1016/S0022-3476(05)81356-3
   Korpas J, 1979, COUGH OTHER RESP REF
   KREITZER SM, 1978, AM REV RESPIR DIS, V117, P437
   LACOURCIERE Y, 1994, J HYPERTENS, V12, P1387
   LANGLANDS J, 1967, THORAX, V22, P88, DOI 10.1136/thx.22.1.88
   Larsell O, 1924, AM J PHYSIOL, V70, P311
   Laube BL, 1996, AM J RESP CRIT CARE, V153, P752, DOI 10.1164/ajrccm.153.2.8564129
   LAUKKA MA, 1994, J CLIN GASTROENTEROL, V19, P100, DOI 10.1097/00004836-199409000-00004
   LAWSON TV, 1967, CLIN SCI, V33, P209
   Leith D E, 1968, Phys Ther, V48, P439
   LEITH DE, 1976, J APPL PHYSIOL, V41, P508
   LEITH DE, 1977, RESPIRATORY DEFENCE, V2, P545
   Leith DE, 1986, HDB PHYSL, VIII, P315
   LEROUX BT, 1986, CURRENT SURG PROBLEM, P94
   LIFSCHITZ MI, 1970, AM REV RESPIR DIS, V102, P456
   LILLIE HI, 1944, ANN OTO RHINOL LARYN, V53, P770
   LINDER SH, 1993, CHEST, V103, P166, DOI 10.1378/chest.103.1.166
   LITTLE JW, 1978, AM REV RESPIR DIS, V118, P295
   Lokshin B, 1993, AM J ASTHMA ALLERGY, V7, P11
   LOURENCO RV, 1971, J CLIN INVEST, V50, P1411, DOI 10.1172/JCI106624
   Malini PL, 1997, LANCET, V350, P15, DOI 10.1016/S0140-6736(96)12045-6
   MANSFIELD LE, 1978, ANN ALLERGY, V41, P224
   MANSFIELD LE, 1989, ANN ALLERGY, V62, P158
   MARMON LM, 1984, J PEDIATR SURG, V19, P683, DOI 10.1016/S0022-3468(84)80353-X
   MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223
   MAZZOCCO MC, 1985, CHEST, V88, P360, DOI 10.1378/chest.88.3.360
   MCARTHUR MS, 1986, AM J SURG, V151, P296, DOI 10.1016/0002-9610(86)90091-7
   MCCLUSKEY I, 1990, DISORDERS RESP TRACT, P692
   MCCOOL FD, 1989, AM REV RESPIR DIS, V139, P275, DOI 10.1164/ajrccm/139.1.275
   MCCOOL FD, 1987, CLIN CHEST MED, V8, P189
   MCEWAN JR, 1990, J PHARMACOL EXP THER, V255, P161
   MCGUINNESS G, 1994, CHEST, V105, P1155, DOI 10.1378/chest.105.4.1155
   MCKAY SE, 1993, THORAX, V48, P227, DOI 10.1136/thx.48.3.227
   MCLEMORE T, 1987, VITAL HLTH STAT
   Mello CJ, 1996, ARCH INTERN MED, V156, P997, DOI 10.1001/archinte.156.9.997
   MITTAL RK, 1987, AM J PHYSIOL, V252, pG636
   MITTAL RK, 1988, GASTROENTEROLOGY, V95, P593, DOI 10.1016/S0016-5085(88)80003-9
   MITTAL RK, 1990, GASTROENTEROL CLIN N, V19, P501
   MITTAL RK, 1989, AM J PHYSIOL, V256, pG139
   MORGAN WJ, 1987, PEDIAT REV, V8, P49
   MORI M, 1972, JPN J PHARMACOL, V22, P635, DOI 10.1254/jjp.22.635
   MORICE AH, 1987, LANCET, V2, P1116
   MORTENSEN J, 1991, CHEST, V100, P1350, DOI 10.1378/chest.100.5.1350
   MOSER KM, 1977, AM REV RESPIR DIS, V115, P829
   *N AM TIL STUD GRO, 1990, CHEST, V97, P299
   NEMIR RL, 1990, DISORDERS RESPIRATOR, P827
   Nicotra M B, 1994, Semin Respir Infect, V9, P31
   NIEDERMAN M, 1986, GERIATR CLIN N AM, V2, P241
   NIMMO WS, 1985, BRIT J HOSP MED, V34, P176
   O'Byrne P, 1996, CAN RESPIR J, V3, P169
   OCONNELL F, 1994, AM J RESP CRIT CARE, V150, P374, DOI 10.1164/ajrccm.150.2.8049818
   OCONNELL F, 1955, AM J RESP DIS, V152, P2068
   OLDENBURG FA, 1979, AM REV RESPIR DIS, V120, P739
   OLIVIERI D, 1991, RESPIRATION, V58, P117
   OLSON LC, 1975, MEDICINE, V54, P427, DOI 10.1097/00005792-197511000-00001
   ORENSTEIN SR, 1992, J PEDIATR-US, V121, P913, DOI 10.1016/S0022-3476(05)80339-7
   ORENSTEIN SR, 1988, J PEDIATR-US, V112, P847, DOI 10.1016/S0022-3476(88)80204-X
   PARKS DP, 1989, J PEDIATR-US, V115, P856, DOI 10.1016/S0022-3476(89)80123-4
   PATERSON WG, 1994, DIGEST DIS SCI, V39, P1117, DOI 10.1007/BF02087567
   PAVIA D, 1990, LUNG, V168, P614, DOI 10.1007/BF02718185
   PAVIA D, 1985, EUR J RESPIR DIS, V67, P177
   PELLEGRINI CA, 1979, SURGERY, V86, P110
   PETTY TL, 1990, CHEST, V97, P75, DOI 10.1378/chest.97.1.75
   POE RH, 1989, CHEST, V95, P723, DOI 10.1378/chest.95.4.723
   POE RH, 1982, AM REV RESPIR DIS, V126, P160
   POE RH, 1990, J RESPIR DIS, V11, P297
   POWNER JT, 1984, AM REV RESPIR DIS, V130, P999
   PRATTER MR, 1993, ANN INTERN MED, V119, P977, DOI 10.7326/0003-4819-119-10-199311150-00003
   PRYOR JA, 1979, BRIT MED J, V2, P417, DOI 10.1136/bmj.2.6187.417
   Puchala M, 1990, Vnitr Lek, V36, P1177
   PUCHELLE E, 1980, EUR J RESPIR DIS, V61, P254
   Pujol JL, 1996, AM J RESP CRIT CARE, V153, P243, DOI 10.1164/ajrccm.153.1.8542123
   PUOLIJOKI H, 1989, ANN MED, V21, P425, DOI 10.3109/07853898909149233
   PUTNAM PE, 1992, ACTA PAEDIATR, V81, P635, DOI 10.1111/j.1651-2227.1992.tb12319.x
   Rachelefsky GS, 1998, J ALLERGY CLIN IMMUN, V101, pS367, DOI 10.1016/S0091-6749(98)70222-2
   RAMSEY BW, 1993, NEW ENGL J MED, V328, P1740, DOI 10.1056/NEJM199306173282403
   RAVITCH MM, 1986, PEDIATR SURG, P602
   REISMAN JJ, 1988, ANN ALLERGY, V61, P163
   RICHTER JE, 1982, ANN INTERN MED, V97, P93, DOI 10.7326/0003-4819-97-1-93
   RIEGEL B, 1995, AM J PHYS MED REHAB, V74, P155
   ROBERTSON PW, 1987, MED J AUSTRALIA, V146, P522, DOI 10.5694/j.1326-5377.1987.tb120392.x
   ROSS BB, 1955, J APPL PHYSIOL, V8, P264
   ROSSMAN CM, 1982, AM REV RESPIR DIS, V126, P131
   Rubin BK, 1996, J AEROSOL MED, V9, P123, DOI 10.1089/jam.1996.9.123
   Rubin BK, 1996, CHEST, V109, P348, DOI 10.1378/chest.109.2.348
   SANT'AMBROGIO G, 1987, Clinical Respiratory Physiology, V23, p19S
   SCADDING KG, 1957, BMJ-BRIT MED J, V2, P225
   SCHAPPERT SM, 1993, VITA HLTH STAT, P1
   SCHENKER MB, 1983, AM REV RESPIR DIS, V128, P1038
   SCHERER PW, 1978, J BIOMECH, V11, P183, DOI 10.1016/0021-9290(78)90011-8
   SCHERER PW, 1981, CHEST, V80, P830, DOI 10.1378/chest.80.6.830
   SCHOEMAN MN, 1992, MECHANISMS REFLUX AM, P48
   SCHULTZ DD, 1986, HEART LUNG, V15, P273
   SCHWARZ MI, 1992, INTERSTITIAL LUNG DI, P1
   Schwarz Ml, 1994, TXB RESP DIS, P1803
   SEARS MR, 1986, THORAX, V41, P283, DOI 10.1136/thx.41.4.283
   SEBASTIAN JL, 1991, CHEST, V99, P36, DOI 10.1378/chest.99.1.36
   SESOKO S, 1985, ARCH INTERN MED, V145, P1524, DOI 10.1001/archinte.145.8.1524
   SHARPEYSCHAFER EP, 1953, BRIT MED J, V2, P860, DOI 10.1136/bmj.2.4841.860
   SHEPHERD RW, 1987, CLIN PEDIATR, V26, P55, DOI 10.1177/000992288702600201
   SHERRILL DL, 1990, CLIN CHEST MED, V11, P375
   SHIH CK, 1977, AM REV RESPIR DIS, V115, P989
   SIEBENS AA, 1974, ARCH PHYS MED REHAB, V45, P1
   SIMONSSON BG, 1967, J CLIN INVEST, V46, P1812, DOI 10.1172/JCI105671
   SMITH DE, 1988, LANCET, V2, P1049
   SMYRNIOS NA, 1995, CHEST, V108, P991, DOI 10.1378/chest.108.4.991
   SOMERVILLE SM, 1988, J EPIDEMIOL COMMUN H, V42, P105, DOI 10.1136/jech.42.2.105
   SONDHEIMER JM, 1989, GASTROENTEROLOGY, V97, P821, DOI 10.1016/0016-5085(89)91484-4
   SONTAG S, 1987, AM J GASTROENTEROL, V82, P119
   SONTAG SJ, 1990, GASTROENTEROLOGY, V99, P613, DOI 10.1016/0016-5085(90)90945-W
   SPEIRS CJ, 1988, BMJ-BRIT MED J, V297, P830, DOI 10.1136/bmj.297.6652.830
   STAGNO S, 1981, PEDIATRICS, V68, P322
   STANCIU C, 1974, GUT, V15, P852, DOI 10.1136/gut.15.11.852
   STANCIU C, 1977, GUT, V18, P536, DOI 10.1136/gut.18.7.536
   STCYR JA, 1989, AM J SURG, V157, P400, DOI 10.1016/0002-9610(89)90584-9
   STOVER DE, 1989, AM REV RESPIR DIS, V139, P1343, DOI 10.1164/ajrccm/139.6.1343
   STRANGER P, 1969, PEDIATRICS, V43, P760
   SUTPHEN JL, 1990, GASTROENTEROL CLIN N, V19, P617
   SUTTON PP, 1988, THORAX, V43, P57, DOI 10.1136/thx.43.1.57
   SUTTON PP, 1988, BRIT J DIS CHEST, V82, P127, DOI 10.1016/0007-0971(88)90032-0
   SUTTON PP, 1985, EUR J RESPIR DIS, V66, P147
   SUTTON PP, 1983, EUR J RESPIR DIS, V64, P62
   SUTTON PP, 1982, EUR J RESPIR DIS, V63, P188
   TATAR M, 1994, J APPL PHYSIOL, V76, P2672
   THOMAS J, 1995, AM J RESP CRIT CARE, V151, P846
   THOMPSON BJ, 1973, NZ J PHYSIOTHER, V4, P11
   TONNESEN P, 1984, EUR J RESPIR DIS, V65, P419
   Trucksis M, 1991, Curr Clin Top Infect Dis, V11, P170
   TSIMOYIANIS GV, 1987, PEDIATRICS, V80, P32
   TZELEPIS GE, 1994, J APPL PHYSIOL, V77, P795
   *US PHS, 1984, HLTH CONS SMOK REP S
   VANASPEREN PP, 1987, AUST PAEDIATR J, V23, P283
   VANDERSCHANS CP, 1986, THORAX, V41, P448, DOI 10.1136/thx.41.6.448
   VANHENGSTUM M, 1988, SCAND J GASTROENTERO, V23, P114, DOI 10.3109/00365528809090229
   VONLEDEN H, 1965, ARCHIV OTOLARYNGOL, V81, P616
   WANNER A, 1977, AM REV RESPIR DIS, V116, P73
   WARING JP, 1995, DIGEST DIS SCI, V40, P1093
   WEBB WR, 1994, RADIOL CLIN N AM, V32, P745
   WEI JY, 1980, AM J CARDIOL, V45, P174, DOI 10.1016/0002-9149(80)90235-0
   WEISS W, 1978, CHEST, V73, P57, DOI 10.1378/chest.73.1.57
   WESTRA SJ, 1994, J PEDIATR GASTR NUTR, V19, P58, DOI 10.1097/00005176-199407000-00009
   WHITTENBERGER JL, 1952, T 48 M NAT TUB ASS N, P414
   WIDDICOMBE JG, 1952, J PHYSIOL-LONDON, V118, pP46
   WIDDICOMBE JG, 1954, J PHYSIOL-LONDON, V123, P71, DOI 10.1113/jphysiol.1954.sp005034
   WIDDICOMBE JG, 1986, HDB PHYSL RESPIRATOR, V2, P363
   Widdicombe JG, 1964, HANDBOOK PHYSIOLOG 3, P585
   WILLIAMS JW, 1993, JAMA-J AM MED ASSOC, V270, P1242, DOI 10.1001/jama.270.10.1242
   WOLFF AP, 1973, JAMA-J AM MED ASSOC, V223, P1269
   WOOD RE, 1990, J PEDIATR-US, V116, P404, DOI 10.1016/S0022-3476(05)82833-1
   WOOLCOCK AJ, 1984, AM REV RESPIR DIS, V130, P71
   WRIGHT SW, 1995, JAMA-J AM MED ASSOC, V273, P1044, DOI 10.1001/jama.273.13.1044
   WYNDER EL, 1965, AM REV RESPIR DIS, V91, P679
   WYNDER EL, 1967, AM REV RESPIR DIS, V96, P645
   WYNNE JW, 1977, ANN INTERN MED, V87, P466, DOI 10.7326/0003-4819-87-4-466
   Yanagihara N, 1966, Acta Otolaryngol, V61, P495, DOI 10.3109/00016486609127088
   YEATES DB, 1975, J APPL PHYSIOL, V39, P487
   YEOMANS ND, 1992, AUST PRESCR, V15, P34
   YU J, 1989, J APPL PHYSIOL, V67, P682
   ZISKIND MM, 1964, ARCH INTERN MED, V114, P108, DOI 10.1001/archinte.1964.03860070154020
   ZOUMBOULAKIS D, 1973, ARCH DIS CHILD, V48, P51, DOI 10.1136/adc.48.1.51
NR 326
TC 400
Z9 426
U1 6
U2 64
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0012-3692
EI 1931-3543
J9 CHEST
JI Chest
PD AUG
PY 1998
VL 114
IS 2
SU S
BP 133S
EP 181S
DI 10.1378/chest.114.2_Supplement.133S
PG 49
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 110WB
UT WOS:000075403600001
PM 9725800
DA 2021-08-04
ER

PT J
AU Thakkar, MM
   Strecker, RE
   McCarley, RW
AF Thakkar, MM
   Strecker, RE
   McCarley, RW
TI Behavioral state control through differential serotonergic inhibition in
   the mesopontine cholinergic nuclei: A simultaneous unit recording and
   microdialysis study
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE REM sleep; serotonin; laterodorsal tegmental nucleus; pedunculopontine
   tegmental nucleus; mesopontine cholinergic neurons; microdialysis;
   single-unit recording
ID LATERODORSAL TEGMENTAL NUCLEUS; RETICULAR-FORMATION NEURONS; DORSAL
   RAPHE NUCLEUS; SLEEP-WAKING STATES; FREELY MOVING CAT; REM-SLEEP; PGO
   WAVES; PONTOMESENCEPHALIC TEGMENTUM; CYCLE CONTROL; IN-VITRO
AB Cholinergic neurons of the mesopontine nuclei are strongly implicated in behavioral state regulation. One population of neurons in the cholinergic zone of the laterodorsal tegmentum and the pedunculopontine nuclei, referred to as rapid eye movement (REM)-on neurons, shows preferential discharge activity during REM sleep, and extensive data indicate a key role in production of this state. Another neuronal group present in the same cholinergic zone of the laterodorsal tegmentum and the pedunculopontine nuclei, referred to as Wake/REM-on neurons, shows preferential discharge activity during both wakefulness and REM sleep and is implicated in the production of electroencephalographic activation in both of these states. To test the hypothesis of differential serotonergic inhibition as an explanation of the different state-related discharge activity, we developed a novel methodology that enabled, in freely behaving animals, simultaneous unit recording and local perfusion of neuropharmacological agents using a microdialysis probe adjacent to the recording electrodes. Discharge activity of REM-on neurons was almost completely suppressed by local microdialysis perfusion of the selective 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), although this agonist had minimal or no effect on the Wake/REM-on neurons. We conclude that selective serotonergic inhibition is a basis of differential state regulation in the mesopontine cholinergic nuclei, and that the novel methodology combining neurophysiological and neuropharmacological information from the freely behaving animal shows great promise for further insight into the neural basis of behavioral control.
C1 Harvard Univ, Sch Med, Brockton Vet Adm Med Ctr, Dept Psychiat, Brockton, MA 02401 USA.
RP McCarley, RW (corresponding author), Harvard Univ, Sch Med, Brockton Vet Adm Med Ctr, Dept Psychiat, 116-A,940 Belmont St, Brockton, MA 02401 USA.
RI Shenton, Martha/V-8780-2019; Oka, Yoshitaka/C-9670-2010; McCarley,
   Robert W/N-5562-2014
OI Oka, Yoshitaka/0000-0002-3482-3051; McCarley, Robert
   W/0000-0001-5705-7495
FU NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Mental Health (NIMH) [R01MH039683, R37MH039683] Funding
   Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Mental Health (NIMH) [R01 MH039683, R37 MH039683, MH39683]
   Funding Source: Medline
CR AMATRUDA TT, 1975, BRAIN RES, V98, P501, DOI 10.1016/0006-8993(75)90369-8
   Berman A., 1968, BRAINSTEM CAT
   ELMANSARI M, 1989, EXP BRAIN RES, V76, P519, DOI 10.1007/BF00248908
   FOOTE SL, 1983, PHYSIOL REV, V252, P117
   GEORGE R, 1964, INT J NEUROPHARMACOL, V3, P541
   GREENE RW, 1989, BRAIN RES, V476, P154, DOI 10.1016/0006-8993(89)91549-7
   HOBSON JA, 1975, SCIENCE, V189, P55, DOI 10.1126/science.1094539
   HONDA T, 1994, BRAIN RES, V647, P299, DOI 10.1016/0006-8993(94)91329-3
   Horner RL, 1997, J NEUROSCI, V17, P7541
   ITO K, 1984, BRAIN RES, V292, P169, DOI 10.1016/0006-8993(84)90903-X
   JACOBS BL, 1991, PHARMACOL REV, V43, P563
   JONES BE, 1993, PROG BRAIN RES, V98, P61
   JOUVET M, 1962, Arch Ital Biol, V100, P125
   KAYAMA Y, 1992, BRAIN RES, V569, P210, DOI 10.1016/0006-8993(92)90632-J
   Kia HK, 1996, NEUROSCIENCE, V74, P143, DOI 10.1016/0306-4522(96)00087-5
   KODAMA T, 1992, BRAIN RES, V580, P348, DOI 10.1016/0006-8993(92)90967-E
   LEONARD CS, 1994, NEUROSCIENCE, V59, P309, DOI 10.1016/0306-4522(94)90599-1
   Leonard TO, 1997, J NEUROSCI, V17, P774
   LUEBKE JI, 1992, P NATL ACAD SCI USA, V89, P743, DOI 10.1073/pnas.89.2.743
   LYDIC R, 1987, ARCH ITAL BIOL, V125, P317
   MCCARLEY RW, 1975, SCIENCE, V189, P58, DOI 10.1126/science.1135627
   MCCARLEY RW, 1992, J SLEEP RES, V1, P132, DOI 10.1111/j.1365-2869.1992.tb00026.x
   MCCARLEY RW, 1995, SEMIN NEUROSCI, V7, P341, DOI 10.1006/smns.1995.0037
   MCGINTY DJ, 1976, BRAIN RES, V101, P569, DOI 10.1016/0006-8993(76)90480-7
   MITANI A, 1988, BRAIN RES, V451, P397, DOI 10.1016/0006-8993(88)90792-5
   MORILAK DA, 1993, BRAIN RES, V627, P49, DOI 10.1016/0006-8993(93)90747-B
   MUHLETHALER M, 1990, DIENCEPHALON AND SLEEP, P367
   Nitz D, 1997, AM J PHYSIOL-REG I, V273, pR451
   PORKKAHEISKANEN T, 1997, SLEEP RES, V26, P35
   PORTAS CM, 1994, BRAIN RES, V648, P306, DOI 10.1016/0006-8993(94)91132-0
   Portas CM, 1996, J NEUROSCI, V16, P2820
   Sakai K, 1996, NEUROREPORT, V7, P2449, DOI 10.1097/00001756-199611040-00009
   SANFORD LD, 1994, PHARMACOL BIOCHEM BE, V49, P93, DOI 10.1016/0091-3057(94)90461-8
   Sanford LD, 1996, PHARMACOL BIOCHEM BE, V53, P323, DOI 10.1016/0091-3057(95)02029-2
   SEMBA K, 1992, J COMP NEUROL, V323, P387, DOI 10.1002/cne.903230307
   SIEGEL JM, 1977, EXP NEUROL, V56, P553, DOI 10.1016/0014-4886(77)90321-1
   Steininger TL, 1997, J COMP NEUROL, V382, P302, DOI 10.1002/(SICI)1096-9861(19970609)382:3<302::AID-CNE2>3.0.CO;2-7
   STERIADE M, 1990, J NEUROSCI, V10, P2541
   STRECKER RE, 1998, SLEEP S, V21, P22
   THAKKAR M, 1991, PHARMACOL BIOCHEM BE, V39, P211, DOI 10.1016/0091-3057(91)90424-Z
   Thakkar M, 1996, BRAIN RES, V723, P223, DOI 10.1016/0006-8993(96)00256-9
   THAKKAR M, 1997, SLEEP RES, V26, P52
   THAKKAR M, 1998, SLEEP S, V21, P3
   THAKKAR M, 1995, SOC NEUR ABSTR, V2, P957
   URSIN R, 1981, MANUAL STANDARDIZED, P1
   WEBSTER HH, 1988, BRAIN RES, V458, P285, DOI 10.1016/0006-8993(88)90471-4
   WILLIAMS JA, 1993, J NEUROSCI, V13, P3878
NR 47
TC 143
Z9 146
U1 0
U2 1
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD JUL 15
PY 1998
VL 18
IS 14
BP 5490
EP 5497
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA ZY294
UT WOS:000074605700037
PM 9651229
DA 2021-08-04
ER

PT J
AU Liu, WP
   Lee, HK
AF Liu, WP
   Lee, HK
TI Use of triethylenetetraminehexaacetic acid combined with field amplified
   sample injection in speciation analysis by capillary electrophoresis
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID MICELLAR ELECTROKINETIC CHROMATOGRAPHY; ZONE ELECTROPHORESIS;
   LIQUID-CHROMATOGRAPHY; ORGANOTIN COMPOUNDS; PEAK RESOLUTION; MODEL;
   OPTIMIZATION; ENANTIOMERS; SEPARATION; ORGANOLEAD
AB Simultaneous speciation of lead, mercury, and selenium was carried out by capillary electrophoresis. The method used a polyaminocarboxylic acid, triethylenetetraminehexaacetic acid (TTHA), as an off-column complexing agent to form W-absorbing complexes with the analytes for direct UV detection. TTHA was also added to the background electrolyte for the on-column complexations of the analytes, as well as for improving resolution and detection. To describe the migration behavior of the complexes, a theoretical model, considerating pH value and the concentrations of TTHA and SDS, was proposed. The parameters in the model were calculated on the basis of the experimental data, by nonlinear regression. The results were in good agreement with those from the literature. The model can be used for the prediction of migration behavior and for the optimization of the separation conditions. Field-amplified stacking injection was performed because the complexes were charged. Up to 1500-fold on-line enrichment and down to sub-nanogram-per-milliliter detection limits were obtained for the analytes under the optimal stacking conditions. Finally, the applicability of the method was evaluated on seawater samples.
C1 Natl Univ Singapore, Dept Chem, Singapore 119260, Singapore.
RP Lee, HK (corresponding author), Natl Univ Singapore, Dept Chem, Kent Ridge, Singapore 119260, Singapore.
EM chmleehk@nus.edu.sg
RI Lee, Hian Kee/B-3993-2018; Liu, Weiping/E-9208-2010
OI Lee, Hian Kee/0000-0002-5664-9509; Liu, Weiping/0000-0002-1173-892X
CR Albert M, 1997, J CHROMATOGR A, V757, P281, DOI 10.1016/S0021-9673(96)00783-2
   BETTMER J, 1993, J CHROMATOGR A, V654, P177, DOI 10.1016/0021-9673(93)83078-7
   BOSWERMT, 1997, ELECTROPHORESIS, V18, P82
   BURGI DS, 1991, ANAL CHEM, V63, P2042, DOI 10.1021/ac00018a028
   Ceulemans M, 1996, J ANAL ATOM SPECTROM, V11, P201, DOI 10.1039/ja9961100201
   CHENG KL, 1982, HDB ORGANIC ANAL REA, pCH3
   CHIEN RL, 1991, J CHROMATOGR, V559, P141, DOI 10.1016/0021-9673(91)80066-P
   CHIEN RL, 1992, ANAL CHEM, V64, pA489, DOI 10.1021/ac00032a002
   CRAIG PJ, 1986, ORGANOMETALLIC COMPO, pCH1
   ERIM FB, 1994, ANAL CHIM ACTA, V294, P155, DOI 10.1016/0003-2670(94)80190-8
   EVANS DF, 1994, COLLOIDAL DOMAIN WHE, P160
   FLORENCE TM, 1982, TALANTA, V29, P345, DOI 10.1016/0039-9140(82)80169-0
   FU XT, 1993, ANAL CHIM ACTA, V272, P221, DOI 10.1016/0003-2670(93)80572-3
   GOODALL DM, 1991, TRAC-TREND ANAL CHEM, V10, P272, DOI 10.1016/0165-9936(91)85004-B
   HAN F, 1995, J CHROMATOGR B, V669, P103, DOI 10.1016/0378-4347(95)00122-Y
   HARJU L, 1970, ANAL CHIM ACTA, V50, P475, DOI 10.1016/0003-2670(70)80045-9
   HOGFELDT E, 1982, STABILITY CONSTANTS, P49
   JANDIK P, 1991, J CHROMATOGR, V546, P431, DOI 10.1016/S0021-9673(01)93042-0
   LI K, 1995, J LIQ CHROMATOGR, V18, P1325, DOI 10.1080/10826079508010416
   LIU Y, 1994, J HIGH RES CHROMATOG, V17, P527
   Myers D., 1992, SURFACTANT SCI TECHN, P81
   NG CL, 1993, J CHROMATOGR A, V652, P547, DOI 10.1016/0021-9673(93)83277-Y
   NIELEN MWF, 1993, J CHROMATOGR, V637, P81, DOI 10.1016/0021-9673(93)83101-W
   NIELEN MWF, 1993, TRAC-TREND ANAL CHEM, V12, P345
   PANELI M, 1993, MIKROCHIM ACTA, V110, P205, DOI 10.1007/BF01245105
   PENGX, 1997, ELECTROPHORESIS, V18, P706
   PENN SG, 1995, J PHYS CHEM-US, V99, P3875, DOI 10.1021/j100011a065
   RAWJEE YY, 1994, ANAL CHEM, V66, P619, DOI 10.1021/ac00077a007
   RAWJEE YY, 1994, J CHROMATOGR A, V688, P273, DOI 10.1016/0021-9673(94)00888-4
   RINGBOM A, 1963, COMPLEXATION ANAL 2
   ROBARDS K, 1991, ANALYST, V116, P1247, DOI 10.1039/an9911601247
   Sillen L. G., 1964, SPECIAL PUBLICATI I, P64
   SILLEN LG, 1971, STABILITY CONSTA 1 S, V1, P27
   TERABE S, 1985, ANAL CHEM, V57, P834, DOI 10.1021/ac00281a014
   TOLGYESSY J, 1993, CHEM BIOL WATER AIR, P66
   Vazquez MJ, 1997, ANAL CHEM, V69, P221, DOI 10.1021/ac960513h
   VINTHER A, 1991, J CHROMATOGR, V559, P3, DOI 10.1016/0021-9673(91)80055-L
   WILLIAMS RL, 1995, J CHROMATOGR A, V716, P197, DOI 10.1016/0021-9673(95)00720-8
   YANG Q, 1995, J CHROMATOGR A, V706, P503, DOI 10.1016/0021-9673(94)01242-7
NR 39
TC 55
Z9 58
U1 0
U2 8
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
J9 ANAL CHEM
JI Anal. Chem.
PD JUL 1
PY 1998
VL 70
IS 13
BP 2666
EP 2675
DI 10.1021/ac971368q
PG 10
WC Chemistry, Analytical
SC Chemistry
GA ZY081
UT WOS:000074584700064
PM 21644787
DA 2021-08-04
ER

PT J
AU Bala, V
   Goyal, S
AF Bala, V
   Goyal, S
TI Learning from neighbours
SO REVIEW OF ECONOMIC STUDIES
LA English
DT Article
AB When payoffs from different actions are unknown, agents use their own past experience as well as the experience of their neighbours to guide their decision making. In this paper, we develop a general framework to study the relationship between the structure of these neighbourhoods and the process of social learning.
   We show that, in a connected society, local learning ensures that all agents obtain the same payoffs in the long run. Thus, if actions have different payoffs, then all agents choose the same action, and social conformism obtains. We develop conditions on the distribution of prior beliefs, the structure of neighbourhoods and the informativeness of actions under which this action is optimal. In particular, we identify a property of neighbourhood structures-local independence-which greatly facilitates social learning. Simulations of the model generate spatial and temporal patterns of adoption that are consistent with empirical work.
C1 McGill Univ, Montreal, PQ H3A 2T5, Canada.
   Erasmus Univ, NL-3000 DR Rotterdam, Netherlands.
RP Bala, V (corresponding author), McGill Univ, Montreal, PQ H3A 2T5, Canada.
CR AGHION P, 1991, REV ECON STUD, V58, P621, DOI 10.2307/2297825
   Aghion P., 1993, ECON THEOR, V3, P517
   ALLEN B, 1982, J MATH SOCIOL, V8, P265, DOI 10.1080/0022250X.1982.9989925
   ALLEN B, 1982, INT ECON REV, V23, P595, DOI 10.2307/2526377
   AN M, 1992, 9206 CAE CORN U
   ARTHUR WB, 1989, ECON J, V99, P116, DOI 10.2307/2234208
   BALA V, 1995, INT ECON REV, V36, P303, DOI 10.2307/2527198
   BALA V, 1994, ECON J, V104, P282, DOI 10.2307/2234749
   BIKHCHANDANI S, 1992, J POLIT ECON, V100, P992, DOI 10.1086/261849
   Billingsley P., 1985, PROBABILITY MEASURE
   BLUME LE, 1992, UNPUB RATIONAL EXPEC
   BOLTON P, 1992, UNPUB STRATEGIC EXPT
   Chung K. L., 1974, COURSE PROBABILITY T
   Coleman J. S., 1966, MED INNOVATION DIFFU
   DeGroot MH, 1970, OPTIMAL STAT DECISIO
   EASLEY D, 1988, ECONOMETRICA, V56, P1045, DOI 10.2307/1911358
   ELLISON G, 1993, J POLIT ECON, V101, P612, DOI 10.1086/261890
   ELLISON G, 1995, Q J ECON, V110, P93, DOI 10.2307/2118512
   FEDER G, 1985, ECON DEV CULT CHANGE, V33, P255, DOI 10.1086/451461
   GRILICHES Z, 1957, ECONOMETRICA, V25, P501, DOI 10.2307/1905380
   Hagerstrand T., 1969, INNOVATION DIFFUSION
   KOTLER P, 1986, PRINCIPLES MARKETING
   Rogers E.M., 1962, DIFFUSION INNOVATION, V1st ed.
   Ryan B, 1943, RURAL SOCIOL, V8, P15
   VIVES X, 1995, 30595 CSIC
   WATKINS S, 1991, PROVINCES NATIONS
NR 26
TC 294
Z9 301
U1 1
U2 22
PU REVIEW OF ECONOMIC STUDIES LTD
PI OXFORD
PA C/O BASIL BLACKWELL LTD, 108 COWLEY RD, PO BOX 805, OXFORD, OXON,
   ENGLAND OX4 1JF
SN 0034-6527
J9 REV ECON STUD
JI Rev. Econ. Stud.
PD JUL
PY 1998
VL 65
IS 3
BP 595
EP 621
DI 10.1111/1467-937X.00059
PG 27
WC Economics
SC Business & Economics
GA 110HE
UT WOS:000075374700010
DA 2021-08-04
ER

PT J
AU Adamietz, IA
   Rahn, R
   Bottcher, HD
   Schafer, V
   Reimer, K
   Fleischer, W
AF Adamietz, IA
   Rahn, R
   Bottcher, HD
   Schafer, V
   Reimer, K
   Fleischer, W
TI Prophylaxis with povidone-iodine against induction of oral mucositis by
   radiochemotherapy
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article; Proceedings Paper
CT 9th International Symposium on Supportive Care in Cancer
CY FEB 26-MAR 01, 1997
CL ST GALLEN, SWITZERLAND
DE oral mucositis; povidone-iodine; radiochemotherapy; supportive treatment
ID RADIATION-THERAPY; HEAD; NECK; CANCER; COMPLICATIONS; CHEMOTHERAPY;
   IRRADIATION; MOUTH; RADIOTHERAPY; MANAGEMENT
AB Oral mucositis is a frequent complication of radiochemotherapy. The origin of radiation-induced mucosal lesions is iatrogenic in nature, although further development of mucositis is essentially influenced by infection. It can be assumed that disinfection measures should decrease the severity of mucositis induced by radiochemotherapy, Therefore, in a prospective randomised study the efficacy of prophylactic oral rinsing with a disinfection agent was investigated. A randomised, prospective comparative trial was conducted with 40 patients undergoing radiochemotherapy of the head and neck region because of malignant disease. The treatment scheme consisted of irradiation to the tumour region and adjacent lymph nodes, with a total dose of 71.3 Gy, and simultaneous chemotherapy with carboplatin (60 mg/m(2)) on days 1-5 and 29-34. In all patients mucositis prophylaxis with nystatin, rutosides, panthenol and immunoglobulin was undertaken. In addition, 20 patients rinsed the oral cavity 4 times daily with povidone-iodine solution, while the group for comparison rinsed with sterile water, Clinical examination of the oral mucosa was performed weekly, Onset, grading and duration of mucositis were used as the main variables. Clinically manifest oral mucositis was observed in 14 patients in the iodine group (mean grading: 1.0) and in all 20 patients in the control group (mean grading: 3,0), The total duration (mean) of clinically observed mucositis was 2.75 weeks in treatment patients and 9.25 weeks in control patients. Median AUC (area under curve for grade vs duration) was 2.5 in the iodine rinsing patients and 15.75 in control patients. All differences found between the two groups were statistically significant, Increased iodine incorporation was not observed. A pathologic rise in thyroid hormone levels was not found in the iodine group. The results obtained indicate that in and duration of radiochemotherapy-induced mucositis can be significantly reduced by oral rinsing with povidone-iodine in addition to the standard prophylaxis scheme, It can be concluded that rinsing with povidone-iodine is an easy, cheap and safe prophylactic method and can be recommended as a supportive treatment during antineoplastic treatment of the head and neck region.
C1 Univ Frankfurt, Dept Radiotherapy, D-60590 Frankfurt, Germany.
   Univ Frankfurt, Dept Dent, D-60590 Frankfurt, Germany.
   Univ Frankfurt, Inst Microbiol, D-60590 Frankfurt, Germany.
   Mundipharma, Limburg, Germany.
RP Adamietz, IA (corresponding author), Univ Frankfurt, Dept Radiotherapy, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.
OI Adamietz, Irenaeus/0000-0002-7747-7259
CR ABDELAAL AS, 1989, LANCET, V1, P97
   ALBERS KH, 1992, ZAHNARZTL WELT, V101, P492
   ANDERSON PM, 1993, P AM ASS PEDIAT HEMA, V2, P32
   Belka C., 1997, Strahlentherapie und Onkologie, V173, P247
   BROWN LR, 1975, J DENT RES, V54, P740, DOI 10.1177/00220345750540040801
   CARL W, 1980, J SURG ONCOL, V15, P265, DOI 10.1002/jso.2930150311
   CHAMBERS MS, 1995, SUPPORT CARE CANCER, V3, P168, DOI 10.1007/BF00368886
   De Conno F, 1989, J Pain Symptom Manage, V4, P20
   DIETZ A, 1995, HNO, V43, P403
   DORR W, 1997, STRAHLENTHER ONKOL, V173, P153
   DREIZEN S, 1977, POSTGRAD MED, V6, P185
   DUDJAK LA, 1987, CANCER NURS, V10, P131
   ENGELMEIER RL, 1983, J PROSTHET DENT, V49, P514, DOI 10.1016/0022-3913(83)90314-1
   EPSTEIN JB, 1989, INT J RADIAT ONCOL, V16, P1571, DOI 10.1016/0360-3016(89)90964-4
   Exner M, 1990, HYG MED, V15, P148
   FERRETTI G, 1987, P ASCO, V6, P268
   FINE A, 1975, NOUS, V9, P17, DOI 10.2307/2214339
   FRITZNIGGLI H, 1978, OBETAHYDROXYETHYL RU, P169
   GLOBEL B, 1984, DEUT MED WOCHENSCHR, V109, P1401, DOI 10.1055/s-2008-1069385
   HAMMANS P, 1993, DTSCH ZAHNARZTL Z, V48, P55
   HASENAU C, 1988, LARYNGO RHINO OTOL, V67, P576, DOI 10.1055/s-2007-998565
   Herrmann T., 1994, Strahlentherapie und Onkologie, V170, P545
   HINGST V, 1995, ZBL HYG UMWELTMED, V197, P232
   Kaufmann M, 1980, SSO Schweiz Monatsschr Zahnheilkd, V90, P633
   King G E, 1988, Tex Dent J, V105, P10
   KRAMER A, 1993, KLIN ANTISEPTIK, P23
   LARSON DL, 1989, SURG CLIN N AM, V66, P169
   LEVEQUE FG, 1992, J CLIN ONCOL, V10, P1963, DOI 10.1200/JCO.1992.10.12.1963
   MARTIN MV, 1981, J MED MICROBIOL, V14, P457, DOI 10.1099/00222615-14-4-457
   MCLURE AR, 1992, J HOSP INFECT, V21, P291, DOI 10.1016/0195-6701(92)90139-D
   Mose S., 1995, Strahlentherapie und Onkologie, V171, P415
   PFEIFFER P, 1990, ACTA ONCOL, V29, P171, DOI 10.3109/02841869009126540
   PILLSBURY HC, 1986, ARCH OTOLARYNGOL, V112, P552
   Rahn R, 1994, HYG MED, V19, P128
   RAHN R, 1992, ZAHNARZTL WELT, V101, P936
   REIMER K, 1996, HYG MED S1, V21, P54
   RICE DH, 1979, LARYNGOSCOPE, V89, P1839
   SAMARANAYAKE LP, 1988, CLIN RADIOL, V39, P291, DOI 10.1016/S0009-9260(88)80538-5
   SONIS ST, 1978, J AM DENT ASSOC, V97, P468, DOI 10.14219/jada.archive.1978.0304
   Toth B., 1990, HIGHLIGHTS ANTINEOPL, V8, P27
   TOTH B B, 1983, Current Problems in Cancer, V7, P7, DOI 10.1016/S0147-0272(83)80011-7
   TOTH B B, 1991, Cancer Bulletin (Houston), V43, P397
   TOWBRIDGE J, 1975, AM J NURS, V75, P2146
   TSUZURA Y, 1992, JPN J CANC CHEMOTHER, V19, P817
   Werner HP, 1992, HYG MED, V17, P51
   ZINNER DD, 1961, ORAL SURG, V14, P1377
NR 46
TC 52
Z9 55
U1 0
U2 3
PU SPRINGER VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010 USA
SN 0941-4355
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD JUL
PY 1998
VL 6
IS 4
BP 373
EP 377
DI 10.1007/s005200050179
PG 5
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA 101HL
UT WOS:000074863500007
PM 9695205
DA 2021-08-04
ER

PT J
AU Zhang, WR
AF Zhang, WR
TI Nesting, safety, layering, and autonomy: A reorganizable multiagent
   cerebellar architecture for intelligent control with application in
   legged robot locomotion and gymnastics
SO IEEE TRANSACTIONS ON SYSTEMS MAN AND CYBERNETICS PART B-CYBERNETICS
LA English
DT Article
ID DECISION-ANALYSIS; FUZZY; SYSTEM
AB The learning and control space of real-world autonomous agents are often many-dimensional, growing, and unbounded in nature. Such agents exhibit adaptive, incremental, exploratory, and sometimes explosive learning behaviors, Learning in adaptive neurofuzzy control, however, is often referred to as global training with a large set of random examples and a very low learning rate. This type of controller is not reorganizable; it cannot explain exploratory learning behaviors as exhibited by human and animal species. A theory of coordinated computational intelligence (CCI) is proposed in this paper which leads to a reorganizable: multiagent cerebellar architecture for intelligent control, The architecture is based on the hypotheses that 1) a cerebellar system consists of a school of relatively simple and cognitively identifiable semiautonomous neurofuzzy agents; 2) autonomous control is the result of cerebellar agent fine-tuning and coordination rather than complicate computation; and 3) learning is accomplished via individual cerebellar agent learning and coordinated discovery in a leaning-tuning-brainstorming process. Agent-oriented decomposition and coordination algorithms are introduced; necessary and sufficient conditions are established for cerebellar agent discovery and common Sense cerebellar motion law discovery. Nesting, safety, layering, and autonomy-four principles are analytically formulated for the reorganization of neurofuzzy agents, The four Principles extend Saridis' principle of "increasing intelligence with decreasing precision" for hierarchical control to multiagent neurofuzzy control, and bridge a gap between neurofuzzy control and PID control, adaptive learning and exploratory learning, numerical learning and symbolic learning. Basic ideas are illustrated in legged locomotion and gymnastics. It is shown that, with agent-oriented decomposition, a single near-miss example can enable the cerebellar agents of a 3-link or 4-link uniped simulation to learn gymnastic jumps; a small number of fine-tuned agents can form a kernel community which can discover common sense cerebellar motion laws; and a kernel governed by the laws can grow with a geometrical learning rate. Implications of this work to human and animal locomotion control are discussed. Potential applications and extensions of the findings are outlined.
C1 Lamar Univ, Dept Comp Sci, Beaumont, TX 77710 USA.
RP Zhang, WR (corresponding author), Lamar Univ, Dept Comp Sci, Beaumont, TX 77710 USA.
EM zhang@hal.lamar.edu
CR Albus J. S., 1990, Robotics and Autonomous Systems, V6, P199, DOI 10.1016/0921-8890(90)90014-R
   ALBUS JS, 1975, ASME, V97, P220, DOI DOI 10.1115/1.3426922
   Bezdek J. C., 1992, International Journal of Approximate Reasoning, V6, P85, DOI 10.1016/0888-613X(92)90013-P
   BOND AH, READINGS DISTRIBUTED, P3
   BROOKS RA, 1986, IEEE T ROBOTIC AUTOM, V2, P14, DOI 10.1109/JRA.1986.1087032
   BROWN M, 1994, NEUROFUZZY ADAPTIVE
   GROSSBERG S, 1988, NEURAL NETWORKS NEUR
   KOHONEN T, 1984, SELF ORG ASS MEMORY
   MAMDANI EH, 1974, P I ELECTR ENG, V121, P1585, DOI 10.1049/piee.1974.0328
   MILLER WT, 1994, P IEEE INT C NEUR NE, P2771
   Rumelhart D. E., 1986, PARALLEL DISTRIBUTED, V1
   SARIDIS GN, 1989, AUTOMATICA, V25, P461, DOI 10.1016/0005-1098(89)90016-2
   WANG H, 1992, IEEE T SYST MAN CYB, V22, P164, DOI 10.1109/21.141321
   WANG LX, 1992, IEEE T SYST MAN CYB, V22, P1414, DOI 10.1109/21.199466
   YING H, 1993, AUTOMATICA, V29, P1139, DOI 10.1016/0005-1098(93)90115-A
   YING H, 1996, INT J INTELL CONTR S, V1, P327
   Zhang W, 1996, FUZZ-IEEE '96 - PROCEEDINGS OF THE FIFTH IEEE INTERNATIONAL CONFERENCE ON FUZZY SYSTEMS, VOLS 1-3, P239, DOI 10.1109/FUZZY.1996.551748
   ZHANG W, 1997, P IEEE INT C NEUR NE
   ZHANG W, 1996, P IEEE INT C FUZZ SY, V1, P78
   ZHANG W, 1995, J ORG COMPUT, V4, P127
   ZHANG W, 1996, INT J INTELLIGENT CO, V1, P339
   Zhang WR, 1996, PROCEEDINGS OF THE 1996 IEEE INTERNATIONAL SYMPOSIUM ON INTELLIGENT CONTROL, P524, DOI 10.1109/ISIC.1996.556256
   Zhang WR, 1996, IEEE T SYST MAN CY B, V26, P561, DOI 10.1109/3477.517031
   ZHANG WR, 1992, IEEE T SYST MAN CYB, V22, P103, DOI 10.1109/21.141315
   ZHANG WR, 1989, IEEE T SYST MAN CYB, V19, P31, DOI 10.1109/21.24529
NR 25
TC 8
Z9 8
U1 0
U2 0
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 1083-4419
EI 1941-0492
J9 IEEE T SYST MAN CY B
JI IEEE Trans. Syst. Man Cybern. Part B-Cybern.
PD JUN
PY 1998
VL 28
IS 3
BP 357
EP 375
DI 10.1109/3477.678631
PG 19
WC Automation & Control Systems; Computer Science, Artificial Intelligence;
   Computer Science, Cybernetics
SC Automation & Control Systems; Computer Science
GA ZP219
UT WOS:000073729800005
PM 18255953
DA 2021-08-04
ER

PT J
AU Chel-Guerrero, L
   Betancur, AD
AF Chel-Guerrero, L
   Betancur, AD
TI Cross-linkage of Canavalia ensiformis starch with adipic acid: Chemical
   and functional properties
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article
DE cross-linked; starch; Canavalia ensiformis; adipic acid; functional
   properties
ID AMYLOSE; AMYLOPECTIN; LOCATION; GRANULES
AB Adipic acid behavior was studied as a cross-linkage agent for Canavalia ensiformis native starch. A 2(3) factorial design with two replicates of each treatment was utilized. Acid concentration (1 and 2%) and the chemical agent incorporation method (direct incorporation with an initial pH adjustment, direct addition with pH readjustment, and 3% NaOH simultaneous addition) were the factors utilized. Gel firmness and syneresis were used as response variables. Main factors and their interactions showed statistical influence (P < 0.05) over the cross-linkage level achieved; the most effective modification was obtained by reactant direct incorporation. Cross-linkage increased gel firmness (11.25 mm penetration) compared to native starch (14.75 mm penetration), diminished syneresis to 7.15 mL/50 mL, and reduced solubilization and swelling power to 18% and 28.04 g/g levels, respectively.
C1 Univ Autonoma Yucatan, Fac Ingn Quim, Merida, Yucatan, Venezuela.
RP Chel-Guerrero, L (corresponding author), Univ Autonoma Yucatan, Fac Ingn Quim, Ave Juarez 421,Cd Ind,CP 97288,AP 1266-A, Merida, Yucatan, Venezuela.
RI Chel-Guerrero, Luis/ABH-1458-2020
OI Chel-Guerrero, Luis/0000-0001-9748-3704
CR *AACC, 1983, APPR METH AACC, P74
   AGBOOLA SO, 1991, STARCH-STARKE, V43, P62, DOI 10.1002/star.19910430207
   AN Y, 1993, CEREAL CHEM, V70, P596
   Betancur AD, 1997, J AGR FOOD CHEM, V45, P378, DOI 10.1021/jf960272e
   BETANCUR AD, 1996, THESIS U AUTONOMA YU
   BILIADERIS CG, 1981, CEREAL CHEM, V58, P496
   CANIZARES HE, 1994, UTILIZACION RACIONAL, P115
   CANIZARES HE, 1993, REV FAC ING QUIM U A, V22, P43
   Fleche G., 1985, STARCH CONVERSION TE, P73
   GILBERT GA, 1964, METHODS CARBOHYDRATE, V4, P156
   GUJSKA E, 1994, J FOOD SCI, V59, P634, DOI 10.1111/j.1365-2621.1994.tb05580.x
   Horwitz W., 1990, OFFICIAL METHODS ANA
   Hoseney C.R., 1986, PRINCIPLES CEREAL SC
   JANE J, 1992, CEREAL CHEM, V69, P405
   KASEMSUWAN T, 1994, CEREAL CHEM, V71, P282
   KESSLER M, 1990, TROP AGR, V67, P16
   LUALLEN TE, 1985, FOOD TECHNOL-CHICAGO, V39, P59
   MOGUEL OY, 1996, TECNOL ALIMENT MEXIC, V31, P11
   Montgomery DC, 1991, DISENO ANAL EXPT, P175
   NATELSON S, 1984, MICROCHEM J, V29, P26, DOI 10.1016/0026-265X(84)90084-5
   NIETO LM, 1993, THESIS U AUTONOMA YU
   Pomeranz Y, 1991, FUNCTIONAL PROPERTIE, P24
   RADLEY JA, 1976, EXAMINATION ANAL STA, P498
   RAMIREZ SM, 1985, THESIS U AUTONOMA ME
   SATHE SK, 1981, J FOOD SCI, V46, P617, DOI 10.1111/j.1365-2621.1981.tb04924.x
   Schoch T.J., 1964, METHODS CARBOHYDRATE, P106
   SIVOLIRODRIGUEZ L, 1996, TECNOL ALIMENT, V31, P5
   SMITH R. L, 1964, METHODS CARBOHYDRATE, V4, P240
   Swinkels J., 1985, STARCH CONVERSION TE, P15
   THOMPSON LU, 1986, J FOOD SCI, V51, P150, DOI 10.1111/j.1365-2621.1986.tb10857.x
   TJAHJADI C, 1984, J FOOD SCI, V49, P558, DOI 10.1111/j.1365-2621.1984.tb12467.x
   WHISTLER R, 1990, FOOD ADDITIVES, P399
   WIESENBORN DP, 1994, J FOOD SCI, V59, P644, DOI 10.1111/j.1365-2621.1994.tb05583.x
   Wurzburg O.B., 1986, MODIFIED STARCHES PR, P17
   YOOK C, 1993, J FOOD SCI, V58, P405, DOI 10.1111/j.1365-2621.1993.tb04285.x
   ZAJAC P, 1989, ALMIDON MAIZ OBTENCI
NR 36
TC 6
Z9 6
U1 1
U2 8
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021-8561
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD JUN
PY 1998
VL 46
IS 6
BP 2087
EP 2091
DI 10.1021/jf970828d
PG 5
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
   Technology
SC Agriculture; Chemistry; Food Science & Technology
GA ZV177
UT WOS:000074277800005
DA 2021-08-04
ER

PT J
AU Malaivijitnond, S
   Takenaka, O
   Sankai, T
   Yoshida, T
   Cho, F
   Yoshikawa, Y
AF Malaivijitnond, S
   Takenaka, O
   Sankai, T
   Yoshida, T
   Cho, F
   Yoshikawa, Y
TI Effects of single and multiple injections of ketamine hydrochloride on
   serum hormone concentrations in male cynomolgus monkeys
SO LABORATORY ANIMAL SCIENCE
LA English
DT Article
ID RHESUS-MONKEYS; LUTEINIZING-HORMONE; MACACA-MULATTA; GONADOTROPINS;
   RESTRAINT; CORTISOL; ANESTHETICS; PROLACTIN; SECRETION; STEROIDS
AB Using simulated short- and long-term effect studies, we evaluated the effect of ketamine anesthesia on serum cortisol, testosterone, and immunoreactive luteinizing hormone (ILH) and bioactive LH (BioLH) concentrations in adult male cynomolgus monkeys. Cortisol, testosterone, and ILH were measured by use of radioimmunoassay, and BioLH was measured by use of a radioreceptor assay method, For the acute effect, the first group (eight monkeys) was given four successive intramuscular injections of ketamine (10, 5, 5, and 5 mg/kg of body weight at 0, 30, 60, and 110 min respectively), Blood samples were taken at 0, 15, 30, 45, 60, and 120 min. For the long-term effect, the second group (10 monkeys) was given a single injection of ketamine (10 mg/kg) once a week for 4 consecutive weeks. Blood samples were taken 5 to 10 min after each injection, then were used to determine the variation in hormone concentrations among the monkeys (inter-individual variation) and within each monkey (intra-individual variation), There were no statistically significant differences in serum cortisol, testosterone, ILH, and BioLH values between the first blood sample (before the ketamine injection) and sequential blood samples in monkeys of the first group. Although intra-individual variation in the hormones (i.e., hormonal change within each monkey) was not statistically significant, inter-individual variation (among the monkeys) was significantly (0.00001 < P < 0.033) different in monkeys of the second group. These results indicate that an adequate number of animals must be used to minimize animal-to-animal variability. Our results confirm that ketamine is a suitable anesthetic agent to immobilize male cynomolgus monkeys in experimental studies (short- and long-term studies) aimed at elucidating hormonal changes.
C1 Natl Inst Infect Dis, Tsukuba Primate Ctr, Ibaraki 305, Japan.
   Chulalongkorn Univ, Fac Sci, Dept Biol, Primate Res Unit, Bangkok, Thailand.
   Kyoto Univ, Primate Res Inst, Aichi, Japan.
RP Yoshida, T (corresponding author), Natl Inst Infect Dis, Tsukuba Primate Ctr, 1 Hachimandai, Ibaraki 305, Japan.
CR CASTRO MI, 1981, P SOC EXP BIOL MED, V168, P389
   DOMINO EF, 1984, CLIN PHARMACOL THER, V36, P645, DOI 10.1038/clpt.1984.235
   ELVIDGE H, 1976, J ENDOCRINOL, V70, P325, DOI 10.1677/joe.0.0700325
   FULLER GB, 1984, P SOC EXP BIOL MED, V175, P487
   GOSSELIN RE, 1983, ENDOCRINOLOGY, V112, P2168, DOI 10.1210/endo-112-6-2168
   HATTORI M, 1983, ENDOCRINOL JAPON, V30, P289
   MALAIVIJITNOND S, 1997, P 13 INT C COMP END, P729
   Malaivijitnond S, 1996, J CLIN ENDOCR METAB, V22, P285
   MATZEN S, 1987, ACTA ENDOCRINOL-COP, V115, P528, DOI 10.1530/acta.0.1150528
   NAZIAN SJ, 1988, P SOC EXP BIOL MED, V187, P482, DOI 10.3181/00379727-187-42692
   NORMAN RL, 1994, BIOL REPROD, V50, P16, DOI 10.1095/biolreprod50.1.16
   OCHSNER AJ, 1977, LAB ANIM SCI, V27, P69
   OYAMA T, 1977, BRIT J ANAESTH, V49, P983, DOI 10.1093/bja/49.10.983
   PURI CP, 1981, ACTA ENDOCRINOL-COP, V97, P118, DOI 10.1530/acta.0.0970118
   SCHENKEN RS, 1985, J CLIN ENDOCR METAB, V60, P886, DOI 10.1210/jcem-60-5-886
   SUFI SB, 1986, WORLD HLTH ORG COLLA
   WALKER ML, 1987, AM J PRIMATOL, V13, P325, DOI 10.1002/ajp.1350130309
   WATANABE G, 1990, BIOL REPROD, V43, P196, DOI 10.1095/biolreprod43.2.196
   WICKINGS EJ, 1980, ACTA ENDOCRINOL-COP, V93, P2287
   YOSHIDA T, 1984, ENDOCRINOL JAPON, V31, P665
   Yoshida Takashi, 1992, Journal of Reproduction and Development, V38, P191
NR 21
TC 16
Z9 17
U1 0
U2 1
PU AMER ASSOC LABORATORY ANIMAL SCIENCE
PI CORDOVA
PA 70 TIMBERCREEK DR, SUITE 5, CORDOVA, TN 38018 USA
SN 0023-6764
J9 LAB ANIM SCI
JI Lab. Anim. Sci.
PD JUN
PY 1998
VL 48
IS 3
BP 270
EP 274
PG 5
WC Veterinary Sciences; Zoology
SC Veterinary Sciences; Zoology
GA 123ZZ
UT WOS:000076157000011
PM 10090027
DA 2021-08-04
ER

PT J
AU Soucek, B
AF Soucek, B
TI Quantum mind-evoked potential link
SO PERIODICUM BIOLOGORUM
LA English
DT Article
DE mind; quantum mind; brain; mind-brain link; evoked potential;
   neurodiagnoses; quantum mind theory; mind-computer interface; mind
   reading machines; primary oscillator; primary waveform; intelligent
   agent
ID BRAIN POTENTIALS; MEMORY
AB background and purpose: This work explains the link between Quantum Mind and the networks of oscillators in the brain. Through Primary Waveforms neural networks and brain component processes are linked to the mind and the behavioral integral processes.
   Material and methods: Generation of Evoked Potentials through interaction of flocks of Primary Oscillators is explained. Computer simulated flock's responses are matched with experimental EP records, N400, triggered by verbal stimuli
   Results: Primary Waveforms have been recognized and extracted from EP records. Each Primary Waveform is directly related to the flock of Primary Oscillators in neural structure. EP record is related to a bundle of mental sequences, composed of overlapped Primary Waveforms. Critical parameter in Primary Waveforms is the amplitude of Sensation Elements. Dominant, quantal amplitudes lead to the clustering of Primary Waveforms.
   Conclusion: Menial process is generated by the dynamics of flocks of agents or oscillators in neural structure and regulated by the Quantum Mind barrier Experimental data as well as the computer model point to the nested levels in the barrier Each level is composed of about 7 nested waves. The resulting EP is not just a filtered sum of the activity of a large set of individual agents or oscillators. Instead the self-organization of agents space leads to dominant modes, binding the underlying oscillators. These dominant modes produce the dominant components, Primary Waveforms. Although Primary Waveforms are overlapped, it is possible to recognize them, in human and in rodent EP record.
   Applications: New research and clinical methods, based on mind-brain links, through Primary Waveforms, Mind-body cross data banks and related drug testing Direct mind-computer interfaces; mind reading machines; thinking machines.
C1 IRIS, I-70125 Bari, Italy.
RP Soucek, B (corresponding author), IRIS, Via Michele Troisi 18, I-70125 Bari, Italy.
CR Hebb DO, 1949, ORG BEHAV NEUROPSYCH
   KIHLSTROM JF, 1993, CONSCIOUS COGN, V2, P334, DOI 10.1006/ccog.1993.1028
   KNOWLTON BJ, 1993, SCIENCE, V262, P1747, DOI 10.1126/science.8259522
   Koch C, 1994, SOME FURTHER IDEAS R
   KUTAS M, 1994, ELECTROEN CLIN NEURO, V92, P126, DOI 10.1016/0168-5597(94)90053-1
   KUTAS M, 1984, NATURE, V307, P161, DOI 10.1038/307161a0
   LISMAN JE, 1995, SCIENCE, V267, P1512, DOI 10.1126/science.7878473
   MILLER GA, 1956, PSYCHOL REV, V63, P81, DOI 10.1037/h0043158
   SOUCEK B, 1986, J THEOR BIOL, V119, P47, DOI 10.1016/S0022-5193(86)80050-9
   SOUCEK B, 1987, J THEOR BIOL, V125, P93, DOI 10.1016/S0022-5193(87)80182-0
   SOUCEK B, 1971, BIOPHYS J, V11, P127
   SOUCEK B, 1998, PERIOD BIOL, V100, P2
   SOUCEK B, 1997, QUANTUM MIND NETWORK
   Soucek Branko, 1996, Periodicum Biologorum, V98, P67
   Soucek Branko, 1997, Periodicum Biologorum, V99, P3
   SQUIRE LR, 1993, ANNU REV PSYCHOL, V44, P453, DOI 10.1146/annurev.ps.44.020193.002321
   STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652
   STUSS DT, 1983, MONOGR NEW YORK ACAD, V12
NR 18
TC 8
Z9 8
U1 0
U2 0
PU PERIODICUM BIOLOGORUM
PI ZAGREB
PA HRVATSKO PRIRODOSLOVNO DRUSTVO ILICA 16/111, 41000 ZAGREB, CROATIA
SN 0031-5362
J9 PERIOD BIOL
JI Period. Biol.
PD JUN
PY 1998
VL 100
IS 2
BP 129
EP 139
PG 11
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA 159BV
UT WOS:000078152700002
DA 2021-08-04
ER

PT J
AU Markou, CP
   Lutostansky, EM
   Ku, DN
   Hanson, SR
AF Markou, CP
   Lutostansky, EM
   Ku, DN
   Hanson, SR
TI A novel method for efficient drug delivery
SO ANNALS OF BIOMEDICAL ENGINEERING
LA English
DT Article
DE local drug delivery; mass transfer; blood-materials interactions
ID INTIMAL HYPERPLASIA; THROMBOSIS; HEPARIN; INFUSION; ANGIOPLASTY;
   CATHETER; GRAFTS
AB Local delivery of anti-thrombotic and anti-restenotic drugs is desired to achieve high concentrations of agents which may be rapidly degraded systemically or which exhibit very short half-lives in vivo. In this article, the operating characteristics of a novel local drug delivery method are described and its effectiveness demonstrated computationally and experimentally. Computational models used a finite volume method to determine the concentration field. Optical dye density measurements of Evans blue in saline were performed in an in vitro steady flow system. Modeling parameters were kept in the physiologic range. Experimental how visualization studies demonstrated high concentrations of infusate near the vessel wall. Computational studies predicted high, clinically significant drug concentrations along the wall downstream of the infusion device. When the radial infusion velocity is large (infusion flow rate, Q(inf)>0.5% of the main flow rate, Q), the wall concentration of the infused drug remains high, e.g., levels are greater than 80% of the infusate concentration 5 cm downstream of the infusion device. At lower infusion rates (Q(inf)<0.001Q), the drug concentration at the wall decreases exponentially with axial distance to less than 25% of the infusate concentration 5 cm downstream of the infusion device, although therapeutic drug levels are still readily maintained. The near wall drug concentration is a function of flow conditions, infusion rate, and the drug diffusivity. Good agreement was obtained between computational and experimental concentration measurements. Flow simulation and experimental results indicate that the technique can effectively sustain high local drug concentrations for inhibition of thrombosis and vascular lesion formation. (C) 1998 Biomedical Engineering Society.
C1 Emory Univ, Sch Med, Dept Med, Div Hematol Oncol, Atlanta, GA 30322 USA.
   Georgia Inst Technol, George W Woodruff Sch Mech Engn, Atlanta, GA 30332 USA.
RP Hanson, SR (corresponding author), Emory Univ, Sch Med, Dept Med, Div Hematol Oncol, 1639 Pierce Dr,Room 1129, Atlanta, GA 30322 USA.
RI Ku, David N./X-5216-2019
OI Ku, David N./0000-0002-6034-8004
FU NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [R01HL031469, P01HL048667,
   R29HL039437, R01HL039437] Funding Source: NIH RePORTER; NHLBI NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [HL 31469, HL 48667, HL 39437-07] Funding Source:
   Medline
CR BIRD RB, 1960, TRANSPORT PHENOMENA, P42
   Chen CY, 1997, J SURG RES, V69, P300, DOI 10.1006/jsre.1997.5052
   Chen CY, 1996, CIRCULATION, V94, P1989, DOI 10.1161/01.CIR.94.8.1989
   CHEN CY, 1995, J VASC SURG, V22, P237, DOI 10.1016/S0741-5214(95)70136-2
   Chen CY, 1996, ANN VASC SURG, V10, P147, DOI 10.1007/BF02000759
   Chen CY, 1997, J SURG RES, V67, P26, DOI 10.1006/jsre.1996.4915
   CUMBERLAND DC, 1994, J AM COLL CARDIOL, V23, pA186
   CUSSLER EL, 1984, DIFFUSION
   Hanson S R, 1995, Adv Pharmacol, V34, P383
   HONG MK, 1993, CORONARY ARTERY DIS, V4, P1023, DOI 10.1097/00019501-199311000-00011
   LAMBERT CR, 1993, CORONARY ARTERY DIS, V4, P469, DOI 10.1097/00019501-199305000-00011
   LINCOFF AM, 1994, CIRCULATION, V90, P2070, DOI 10.1161/01.CIR.90.4.2070
   LOVICH MA, 1995, CIRC RES, V77, P1143, DOI 10.1161/01.RES.77.6.1143
   MA PP, 1994, INT J HEAT MASS TRAN, V37, P2723, DOI 10.1016/0017-9310(94)90389-1
   Markou CP, 1996, CIRCULATION, V94, P1563
   Mattar SG, 1996, J SURG RES, V60, P339, DOI 10.1006/jsre.1996.0054
   MULLER DWM, 1990, CORONARY ARTERY DIS, V1, P438, DOI 10.1097/00019501-199007000-00005
   NATHAN A, 1995, MOL INTERVENTIONS LO, P29
   PINCHAK AC, 1975, J APPL PHYSIOL, V41, P646
   ROGERS C, 1995, MOL INTERVENTIONS LO, P131
   Saavedra JE, 1996, J MED CHEM, V39, P4361, DOI 10.1021/jm960616s
   SCOTT NA, 1994, CIRCULATION, V90, P1951, DOI 10.1161/01.CIR.90.4.1951
   WOLINSKY H, 1990, J AM COLL CARDIOL, V15, P475, DOI 10.1016/S0735-1097(10)80079-8
NR 23
TC 20
Z9 20
U1 0
U2 4
PU BLACKWELL SCIENCE INC
PI MALDEN
PA 350 MAIN ST, MALDEN, MA 02148 USA
SN 0090-6964
J9 ANN BIOMED ENG
JI Ann. Biomed. Eng.
PD MAY-JUN
PY 1998
VL 26
IS 3
BP 502
EP 511
DI 10.1114/1.97
PG 10
WC Engineering, Biomedical
SC Engineering
GA ZH211
UT WOS:000073084100016
PM 9570232
DA 2021-08-04
ER

PT J
AU Endres-Niggemeyer, B
   Neugebauer, E
AF Endres-Niggemeyer, B
   Neugebauer, E
TI Professional summarizing: No cognitive simulation without observation
SO JOURNAL OF THE AMERICAN SOCIETY FOR INFORMATION SCIENCE
LA English
DT Article
ID INFORMATION-RETRIEVAL; MODEL; ABSTRACTS
AB Professional summarizing includes the cognitive processes of abstracting, indexing, and classifying as performed by expert summarizers who prepare records for bibliographic information systems. In order to simulate their skilled performance, a "grounded" (or "naturalistic") cognitive model of expert summarization has been developed, using 54 working processes of 6 experts recorded by thinking-aloud protocols. The working processes comprise up to 140 working steps. The model is explained in the following using the abstracting step Trueby-2 executed by the expert Marliese. Components of the model are a toolbox of empirically founded strategies, principles of process organization, and interpreted working steps where the interaction of cognitive strategies can be investigated. In the computerized simulation, the SimSum (Simulation of Summarizing) system, cognitive strategies are represented by object-oriented agents grouped around dedicated blackboards. While the main scientific goal of the system is to check and improve the cognitive model, the system also serves practical presentation purposes. It will be distributed on CD-ROM as part of a textbook and thus help to explain the cognitive task of summarizing.
C1 Polytech Hanover, Dept Informat & Commun, D-30449 Hannover, Germany.
RP Endres-Niggemeyer, B (corresponding author), Polytech Hanover, Dept Informat & Commun, Hanomagstr 8, D-30449 Hannover, Germany.
EM ben@iks.ik.fh-hannover.de
CR ALTERMAN R, 1992, ENCY ARTIFICIAL INTE, P1579
   [Anonymous], 1988, 1426 DIN
   [Anonymous], 1985, 59631985 ISO
   *ANSI, Z3914 ANSI, P79
   BEGHTOL C, 1986, J DOC, V42, P84, DOI 10.1108/eb026788
   BELKIN NJ, 1992, COMMUN ACM, V35, P29, DOI 10.1145/138859.138861
   BEREITER C, 1987, PSCHOL WRITTEN COMPO
   BORKO H, 1977, INFORM PROCESS MANAG, V13, P355, DOI 10.1016/0306-4573(77)90055-3
   BORKO H., 1978, INDEXING CONCEPTS ME
   BORKO H, 1968, AUTOMATED LANGUAGE P
   Borko H, 1975, ABSTRACTING CONCEPTS
   CARVER N, 1994, EXPERT SYST APPL, V7, P1, DOI 10.1016/0957-4174(94)90023-X
   Cleveland D.B., 1983, INTRO INDEXING ABSTR
   CREMMINS ET, 1996, ART ABSTRACTING
   Diesing P., 1971, PATTERNS DISCOVERY S
   ENDRESNIGGEMEYE.B, 1997, SUMMARIZING INFORMAT
   ENDRESNIGGEMEYE.B, 1995, SUMMARIZING TEXT INT
   ENDRESNIGGEMEYER B, 1995, INFORM PROCESS MANAG, V31, P631, DOI 10.1016/0306-4573(95)00028-F
   Engelmore R. S., 1988, BLACKBOARD SYSTEMS
   ERICSSON KA, 1980, PSYCHOL REV, V87, P215, DOI 10.1037/0033-295X.87.3.215
   Ericsson KA., 1984, PROTOCOL ANAL VERBAL
   FARROW JF, 1991, J DOC, V47, P149, DOI 10.1108/eb026875
   FIDEL R, 1993, LIBR INFORM SCI RES, V15, P219
   Flavell J.H., 1981, CHILDRENS ORAL COMMU, P35
   Fum D., 1984, Computational models of natural language processing, P121
   FUM D, 1985, IJCAI, P840
   FUM D, 1982, P 9 INT C COMP LING, P83
   Garner R., 1987, METACOGNITION READIN
   GLASER BG, 1980, DISCOVERY GROUNDED T
   Hayes J. R., 1980, COGNITIVE PROCESS, P3, DOI DOI 10.4324/9781315630274
   HOVI I, 1989, INFORMATION KNOWLEDG, P121
   HOVY EH, 1993, ARTIF INTELL, V63, P341, DOI 10.1016/0004-3702(93)90021-3
   HUTCHINS WJ, 1987, INFORMATICS 9, P151
   JACOBS PS, 1990, COMMUN ACM, V33, P88, DOI 10.1145/92755.92769
   Kintsch W., 1983, STRATEGIES DISCOURSE
   KUHLEN R, 1989, COMPUTATIONAL LINGUS, P688
   Langridge Derek Wilton, 1989, SUBJECT ANAL PRINCIP
   LIDDY ED, 1991, INFORM PROCESS MANAG, V27, P55, DOI 10.1016/0306-4573(91)90031-G
   Lincoln Y.S., 1985, NATURALISTIC INQUIRY
   MANN WC, 1987, STRUCTURE DISCOURSE
   MAYRING P, 1990, EINFUEHRUNG QUALITAT
   MCCLELLAND JL, 1981, PSYCHOL REV, V88, P375, DOI 10.1037/0033-295X.88.5.375
   MCKEOWN KR, 1985, TEXT GENERATION USIN
   MOLINA MP, 1995, J AM SOC INFORM SCI, V46, P225, DOI 10.1002/(SICI)1097-4571(199504)46:3<225::AID-ASI6>3.0.CO;2-N
   MOLINA MP, 1994, J DOC, V50, P111, DOI 10.1108/eb026927
   NORMAN DA, 1983, MENTAL MODELS, P74
   PAICE CD, 1990, INFORM PROCESS MANAG, V26, P171, DOI 10.1016/0306-4573(90)90014-S
   PARIS SG, 1983, CONTEMP EDUC PSYCHOL, V8, P293, DOI 10.1016/0361-476X(83)90018-8
   *PENM PROJ, 1989, PENMAN DOC PRIM US G
   Pugh A., 1978, SILENT READING INTRO
   ROWLEY J, 1988, ABSTRACTING INDEXING
   RUDA S, 1992, NACHR DOK, V43, P283
   Rumelhart D., 1984, HDB SOCIAL COGNITION, P161
   SCHREIBER G, 1993, KADS PRINCIPLED APPR
   Selfridge O.G., 1959, S MECH THOUGHT PROC, P511
   STEELS L, 1990, AI MAG, V11, P29
   STROHNER H, 1988, LINGUISTISCHE BERICH, V118, P481
   THORNDYKE PW, 1979, COGNITIVE PSYCHOL, V11, P82, DOI 10.1016/0010-0285(79)90005-7
   TRABASSO T, 1985, J MEM LANG, V24, P595, DOI 10.1016/0749-596X(85)90048-8
   WELLISCH HH, 1980, INDEXING ABSTRACTING
NR 60
TC 10
Z9 10
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0002-8231
J9 J AM SOC INFORM SCI
JI J. Am. Soc. Inf. Sci.
PD MAY 1
PY 1998
VL 49
IS 6
BP 486
EP 506
DI 10.1002/(SICI)1097-4571(19980501)49:6<486::AID-ASI2>3.0.CO;2-Y
PG 21
WC Computer Science, Information Systems; Information Science & Library
   Science
SC Computer Science; Information Science & Library Science
GA ZG613
UT WOS:000073021400001
DA 2021-08-04
ER

PT J
AU Ivezic, N
   Garrett, JH
AF Ivezic, N
   Garrett, JH
TI Machine learning for simulation-based support of early collaborative
   design
SO AI EDAM-ARTIFICIAL INTELLIGENCE FOR ENGINEERING DESIGN ANALYSIS AND
   MANUFACTURING
LA English
DT Article
DE collaborative design; constraint satisfaction; real-time decision
   support; simulations; statistical neural networks
AB The research and development of a simulation-based decision support system (SB-DSS) capable of assisting early collaborative design processes is presented. The requirements for such a system are included. Existing collaborative DSSs are shown to lack the capability to manipulate complex simulation-based relationships. On the other hand, advances within the machine learning in design community are shown to have a potential for providing, but have not yet addressed, simulation-based support for collaborative design processes. The developed SB-DSS is described in terms of its four principal components. First, the behavior-evaluation (BE) model is used to both structure individual, domain-specific decision models and organize these models into a collaborative decision model. Second, a probabilistic framework for the BE model enables management of the uncertainty inherent in learning and using simulation-based knowledge. Significantly, this framework provides a constraint satisfaction environment in which simulation-based knowledge is used. Third, a statistical neural network approach is used to capture simulation-based knowledge and build the probabilistic behavior models based on this knowledge. Fourth, since a probability distribution theory does not exist for the nonlinear neural network approaches, Monte Carlo simulation is introduced as a method to sample the trained neural networks and approximate the likelihoods of design variable values. Consequently, constraint satisfaction problem-solving capability is obtained. In addition, a mapping of the SB-DSS architecture onto a collaborative design agent framework is provided. Experimental evaluation of a prototype SB-DSS system is summarized, and performance of the SB-DSS with respect to search and usability metrics is documented. Initial results in developing the simulation-based support for collaborative design are encouraging. Lastly, a categorization of the machine learning approach and a critique of the proposed categorization scheme is presented.
C1 Oak Ridge Natl Lab, Div Math & Comp Sci, Oak Ridge, TN 37831 USA.
   Carnegie Mellon Univ, Dept Civil & Environm Engn, Pittsburgh, PA 15213 USA.
OI Garrett, James/0000-0002-8408-2407
CR BERKE L, 1994, COMPUT SYST ENG, V5, P55, DOI 10.1016/0956-0521(94)90037-X
   BISHOP CM, 1994, NCRG4288 ASTO U DEP
   DARR TP, 1994, IEEE EXPERT, V9, P35, DOI 10.1109/64.331486
   GERO J, 1995, P 2 C COMP CIV ENG, P525
   GRECU DL, 1996, P WORKSH MACH LEARN
   IVEZIC N, 1995, THESIS CARNEGIE MELL
   JAFFAR J, 1990, CMUCS90181 CARN MELL
   KUOKKA D, 1994, P 12 NAT C ART INT
   MACKAY DJC, 1993, MAXIMUM ENTROPY BAYE
   Myers R., 1990, CLASSICAL MODERN REG, V2nd
   NEAL RM, 1994, CRGTR931 U TOR DEP C
   Pearl Judea, 1988, PROBABILISTIC REASON
   RAO RB, 1993, PROCEEDINGS OF THE ELEVENTH NATIONAL CONFERENCE ON ARTIFICIAL INTELLIGENCE, P277
   WHITE H, 1989, J AM STAT ASSOC, V84, P1008
   Yerramareddy S., 1993, Research in Engineering Design, V4, P227
NR 15
TC 8
Z9 8
U1 0
U2 4
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 40 WEST 20TH STREET, NEW YORK, NY 10011-4211 USA
SN 0890-0604
J9 AI EDAM
JI AI EDAM-Artif. Intell. Eng. Des. Anal. Manuf.
PD APR
PY 1998
VL 12
IS 2
BP 123
EP 139
DI 10.1017/S0890060498122059
PG 17
WC Computer Science, Artificial Intelligence; Computer Science,
   Interdisciplinary Applications; Engineering, Multidisciplinary;
   Engineering, Manufacturing
SC Computer Science; Engineering
GA ZJ820
UT WOS:000073256800005
DA 2021-08-04
ER

PT J
AU Freeman, JR
   Houser, D
AF Freeman, JR
   Houser, D
TI A computable equilibrium model for the study of political economy
SO AMERICAN JOURNAL OF POLITICAL SCIENCE
LA English
DT Article; Proceedings Paper
CT 91st Annual Meeting of the American-Political-Science-Association
CY AUG 30-SEP 03, 1995
CL CHICAGO, ILLINOIS
SP Amer Polit Sci Assoc
ID UNITED-STATES-ECONOMY; MACROECONOMIC POLICY; BUSINESS-CYCLE; OUTCOMES
AB Theory: The need for the development and use of a concept of joint, political-economic equilibrium is increasingly recognized by students of democracy and markets. Yet, to date, no adequate theoretical and methodological synthesis of this kind has been produced. The few works which have attempted it suffer from a lack of theoretical balance between economic and political theory; unrealistic, temporally aggregated conceptions of political-economic equilibrium; failure to incorporate theoretically meaningful stochastic elements of economic and political processes; and the absence of a coherent methodology for gauging the empirical power of political-economic models.
   Methods: In the spirit of the AJPS workshop, it is shown how these problems can be solved. An improved model is built, one which fuses a branch of real business cycle theory and the theory of presidential approval. This model produces a notion of computable political-economic equilibrium that provides for market clearing and simultaneous stochastic optimization by economic and political agents. Then, using data analysis techniques developed in parallel by real business cycle theorists (Hansen and Heckman 1996; Kydland and Prescott 1990, 1996; Lucas 1987; Prescott 1986a, 1986b, 1991; Sims 1996) and political methodologists (Brady 1996; Jackson 1995), the model is parameterized for the United States. More specifically, on the basis of estimates from economics and political science and some numerical experimentation, certain of its parameters are set so that, when simulated, the model mimics the United States political economy in the 1980s.
   Results: The parameterized model is used to study some important counterfactuals. The first is the impact of increased approval volatility on political-economic equilibration. Such volatility is expected in view of America's likely involvement in the post Cold War era's increasing number of "low intensity" international conflicts. The second is the impact of presidents pursuing relatively high-nonminimum winning-levels of approval. This kind of behavior is attributed to certain presidents along with the claim that it has harmful effects on markets and hence on various facets of social welfare. The former analysis shows how "business cycle phenomena" (Lucas 1987) can be traced, in part, to government approval management in an increasingly volatile international polity, management which is associated with a slight drop in social welfare. The latter investigation demonstrates that the president's pursuit of a consensual approval target is not necessarily socially harmful.
C1 Univ Minnesota, Minneapolis, MN 55455 USA.
RP Freeman, JR (corresponding author), Univ Minnesota, Minneapolis, MN 55455 USA.
OI Houser, Daniel/0000-0003-3583-8201
CR ALESINA A, 1987, Q J ECON, V102, P651, DOI 10.2307/1884222
   ALESINA A, 1993, AM POLIT SCI REV, V87, P12, DOI 10.2307/2938953
   ALESINA A, 1988, NBER MACROECONOMIC A
   BACKUS D, 1992, J POLITICAL EC, V10, P745
   BACKUS D, 1993, Q REV, V17, P14
   BARNETT W, 1993, POLITICAL EC I COMPE
   BARTELS LM, 1993, POLITICAL SCI STATE
   BRADY HE, 1989, AM POLIT SCI REV, V83, P143, DOI 10.2307/1956438
   BRADY HE, 1996, POLITICAL ANAL
   Brody R.A., 1991, ASSESSING PRESIDENT
   CHAPPELL HW, 1985, AM POLIT SCI REV, V79, P10, DOI 10.2307/1956116
   CHAPPELL HW, 1983, AM POLIT SCI REV, V77, P75, DOI 10.2307/1956012
   CHARI VV, 1991, J MONEY CREDIT BANK, V23, P519, DOI 10.2307/1992686
   CHARI VV, 1990, UNPUB OPTIMAL FISCAL
   CHRISTIANO L, 1990, 24 I EMP MACR FED RE
   COUGHLIN P, 1981, J PUBLIC ECON, V15, P113, DOI 10.1016/0047-2727(81)90056-6
   DRISSEN E, 1993, POLITICAL EC
   DURR R, 1993, POLITICAL ANAL
   FREEMAN JR, 1993, ANN SUMM M POL METH
   FREEMAN JR, 1995, ANN M AM POL SCI ASS
   FREEMAN JR, 1994, ANN SUMM M POL METH
   GANTZEL K, 1994, KRIEGE NACH ZWEITEN
   HANSEN GD, 1985, J MONETARY ECON, V16, P309, DOI 10.1016/0304-3932(85)90039-X
   Hansen LP, 1996, J ECON PERSPECT, V10, P87, DOI 10.1257/jep.10.1.87
   HIBBS DA, 1977, AM POLIT SCI REV, V71, P1467, DOI 10.2307/1961490
   HINICH MJ, 1977, J ECON THEORY, V16, P208, DOI 10.1016/0022-0531(77)90005-9
   Hodrick R.J., 1980, POSTWAR US BUSINESS
   Jackman S., 1995, 12 ANN POL METH SUMM
   JACKSON J, 1995, NEW HDB POLITICAL SC
   JUNG D, 1994, UNPUB ONGOING WARS T
   Krusell P, 1996, REV ECON STUD, V63, P301, DOI 10.2307/2297854
   KRUSELL P, 1994, 9441 CARESS U PENNS
   KRUSELL P, 1996, J MONETARY ECON, V37, P375
   Kydland F.E., 1990, FEDERAL RESERVE BANK, V14, P3
   KYDLAND FE, 1982, ECONOMETRICA, V50, P1345, DOI 10.2307/1913386
   Kydland FE, 1996, J ECON PERSPECT, V10, P69, DOI 10.1257/jep.10.1.69
   Lalman D., 1993, POLITICAL SCI STATE
   LUCAS RE, 1980, J MONEY CREDIT BANK, V12, P696, DOI 10.2307/1992030
   Lucas Robert E., 1987, MODELS BUSINESS CYCL
   LUCUS RE, 1983, J MONETARY EC, V12
   MACKUEN MB, 1992, AM POLIT SCI REV, V86, P597, DOI 10.2307/1964124
   MCGRATTEN ER, 1994, Q REV            FAL, P2
   MILLER P, 1987, 109 FED RES BANK MIN
   NICKELL S, 1985, OXFORD B ECON STAT, V47, P119
   NORDHAUS WD, 1975, REV ECON STUD, V42, P169, DOI 10.2307/2296528
   OSTROM CW, 1993, POLITICAL ANAL
   Prescott E. C., 1986, FEDERAL RESERVE BANK, V25, P11, DOI DOI 10.1016/0167-2231(86)90035-7
   Prescott E.C., 1991, REV ANAL ECON, V6, P3
   PRESCOTT EC, 1986, Q REV FEDERAL RESERV, V10, P28
   ROGOFF K, 1988, REV ECON STUD, V55, P1, DOI 10.2307/2297526
   SCHULTZ KA, 1995, BRIT J POLIT SCI, V25, P79, DOI 10.1017/S0007123400007079
   Sims CA, 1996, J ECON PERSPECT, V10, P105, DOI 10.1257/jep.10.1.105
   Stokey N.L., 1989, RECURSIVE METHODS EC
   Tufte Edward R., 1978, POLITICAL CONTROL EC
   Van Creveld Martin, 1991, TRANSFORMATION WAR
   VANDERPLOEG F, 1987, INT ECON REV, V28, P469
   VANDERPLOEG F, 1984, OXFORD ECON PAP, V36, P213, DOI 10.1093/oxfordjournals.oep.a041632
   WILLIAMS JT, 1990, AM POLIT SCI REV, V84, P767, DOI 10.2307/1962766
NR 58
TC 10
Z9 10
U1 0
U2 3
PU UNIV WISCONSIN PRESS
PI MADISON
PA JOURNAL DIVISION, 2537 DANIELS ST, MADISON, WI 53718 USA
SN 0092-5853
J9 AM J POLIT SCI
JI Am. J. Polit. Sci.
PD APR
PY 1998
VL 42
IS 2
BP 628
EP 660
DI 10.2307/2991773
PG 33
WC Political Science
SC Government & Law
GA ZB198
UT WOS:000072446200012
OA Green Submitted
DA 2021-08-04
ER

PT J
AU Heymann, D
   Sanguinetti, P
AF Heymann, D
   Sanguinetti, P
TI Changes in trends, expectations and economic fluctuations
SO DESARROLLO ECONOMICO-REVISTA DE CIENCIAS SOCIALES
LA Spanish
DT Article; Proceedings Paper
CT 2nd Conference on Economics
CY JUN 23-24, 1997
CL BUENOS AIRES, ARGENTINA
AB This paper deals with an old theme in macroeconomic analysis: the link between aggregate fluctuations and intertemporal coordination problems. We start with the observation that. sometimes, economic growth processes show signs of discontinuity (in either direction), forcing agents to learn abet a new environment. In turn, changes in expectations about future growth influence current decisions on spending, production and the supply of credit. In some conditions, revisions of beliefs induced by news about growth prospects can bring about macroeconomic oscillations. This is illustrated with a simple model, with points in common with those typical in the literature on real cycles in intertemporally coordinated open economies. However, rye do not postulate that agents automatically know the processes generating the relevant variables. Instead, we try to represent the learning dynamics, through schemes where agents revise adaptively their estimates of the parameters of a functions describing the trend behavior of output. The simulations of the model show that, after a permanent upward shock to the productivity of the economy, the transitional dynamics can indeed be cyclical, and in some cases there can be an over-expansion in aggregate demand, which must eventually be corrected. We also discuss extensions that incorporate the evolution of the real exchange rate and the supply of credit. In an empirical section, we analyze a recursive estimation of the growth in the output of traded goods in Argentina, The results indicate that the forecasts of future output based on that estimation have changed considerably in recent years (with an upward shift in 1991), suggesting that large movements in wealth perceptions took place in the period.
C1 CEPAL, Oficina Buenos Aires, Inst Torcuato Di Tella, RA-1067 Buenos Aires, DF, Argentina.
   Univ Buenos Aires, RA-1053 Buenos Aires, DF, Argentina.
   UTDT, RA-1428 Buenos Aires, DF, Argentina.
RP Heymann, D (corresponding author), CEPAL, Oficina Buenos Aires, Inst Torcuato Di Tella, Paraguay 1178,2 P, RA-1067 Buenos Aires, DF, Argentina.
CR EVANS M, 1995, LEARNING RATIONALITY
   GREENSPAN A, 1997, INFORME AL C ESTADOS
   HEYMANN D, 1996, UNPUB BUSINESS CYCLE
   HEYMANN D, 1997, UNPUB LEARNING TREND
   HEYMANN D, 1994, DESARROLLO EC
   HEYMANN D, 1984, ENSAYOS EC       MAR
   JAFFE F, 1990, HDB MONETARY EC, V2
   LEIJONHUFVUD A, 1968, KEYNESIAN EC EC KEYN
   LEIJONHUFVUD A, 1981, INFORMATION COORDINA
   Minsky H.P., 1975, JM KEYNES
   Sargent T., 1993, BOUNDED RATIONALITY
NR 11
TC 0
Z9 0
U1 0
U2 0
PU INST DESAROLLO ECON SOCIAL
PI BUENOS AIRES
PA AROAZ 2838, 1425 BUENOS AIRES, ARGENTINA
SN 0046-001X
J9 DESARROLLO ECON
JI Desarro. Econ.-Rev. Cienc. Soc.
PD APR-JUN
PY 1998
VL 38
IS 149
BP 365
EP 386
DI 10.2307/3467384
PG 22
WC Economics
SC Business & Economics
GA 104DV
UT WOS:000074998400002
DA 2021-08-04
ER

PT J
AU Kawachi, S
   Kawase, Y
AF Kawachi, S
   Kawase, Y
TI Evaluation of bubble removing performance in a TV glass furnace - Part
   1. Mathematical formulation
SO GLASTECHNISCHE BERICHTE-GLASS SCIENCE AND TECHNOLOGY
LA English
DT Article
ID NUMERICAL-SIMULATION; MELTING TANKS; HEAT-TRANSFER; BEHAVIOR; GAS;
   DISSOLUTION; CIRCULATION
AB The bubble evolution and dissolution process in a glass furnace is an extremely complicated physico-chemical phenomenon. Most of the huge number of bubbles, generated in molten glass during the decomposition of the glass batch, are removed during the trajectory from the charging end to the forming section, but some remain in final products. On the basis of the two mechanisms, flotation and absorption, in the bubble removing process, a numerical simulator was developed to evaluate the influence of first, glass and batch composition, including refining agents, second, geometrical tank design and third, furnace operating conditions upon the bubble quality in products. In particular, the simulator enabled the estimation of the effect of refining gases which are caused by decomposition of the refining agents. Furthermore, an index was devised to synthetically assess the numbers of bubbles in final products. In part 1, the principles of the model which composes the simulator are described in mathematical formulation. The basic equations with boundary conditions and calculation procedures for thermal flow of molten glass, gas concentration in glass melt and gas evolvement from the refining agents are presented. The calculation strategy of the bubble removing process is also described.
C1 Nippon Elect Glass Co Ltd, Dept Technol, Otsu, Shiga 520, Japan.
   Toyo Univ, Fac Engn, Dept Appl Chem, Kawagoe, Saitama 350, Japan.
RP Kawachi, S (corresponding author), Nippon Elect Glass Co Ltd, Dept Technol, 7-1 Seiran,2 Chome, Otsu, Shiga 520, Japan.
OI Kawase, Yoshinori/0000-0001-8483-6419
CR ABRAMZON BM, 1976, INZ FIZ ZH, V30, P73
   ARAKAWA C, 1994, COMPUTATIONAL FLUID, P157
   Balkanli B, 1996, GLASS TECHNOL, V37, P137
   Balkanli B, 1996, GLASS TECHNOL, V37, P101
   Balkanli B, 1996, GLASS TECHNOL, V37, P29
   Balkanli B, 1996, GLASS TECHNOL, V37, P164
   Beerkens RGC, 1995, GLASTECH BER-GLASS, V68, P369
   CABLE M, 1987, GLASTECH BER-GLASS, V60, P355
   CHMELAR J, 1992, 16 INT C GLASS MADR, V6, P45
   CHMELAR J, 1992, B SOC ESP CERAM VI C, V31, P6
   CLOMBURG L, 1971, THESIS MIT CAMBRIDGE
   de Waal H., 1990, GLASTECH BER, V63K, P1
   Jebsen-Marwedel H., 1980, GLASTECHNISCHE FABRI, P222
   KAWACHI S, 1989, Patent No. 197327
   Kramer F., 1979, GLASTECH BER, V52, P43
   MASE H, 1980, J NON-CRYST SOLIDS, V38-9, P807, DOI 10.1016/0022-3093(80)90536-0
   MASE H, 1995, GLASS, P24
   MASE H, 1985, J NONCRYST SOLIDS, V39, P807
   MASE H, 1973, REP RES LAB ASAHI GL, V23, P101
   NEMEC L, 1980, GLASS TECHNOL, V21, P139
   NEMEC L, 1980, GLASS TECHNOL, V21, P134
   ONORATO PIK, 1981, J AM CERAM SOC, V64, P676, DOI 10.1111/j.1151-2916.1981.tb15869.x
   PATANKAR SV, 1980, NUMERICAL HEAT TRANS, P118
   SCHILL P, 1990, 2 INT C ADV FUS PROC, P45
   SMITH GD, 1985, NUMERICAL SOLUTION P, P230
   UNGAN A, 1987, GLASTECH BER-GLASS, V60, P71
   UNGAN A, 1987, GLASTECH BER-GLASS, V60, P115
   Ungan A., 1990, GLASTECH BER, V63, P19
   UNGAN A, 1985, THESIS PURDUE U W LA
   WEINBERG MC, 1980, J AM CERAM SOC, V63, P175, DOI 10.1111/j.1151-2916.1980.tb10686.x
   WEINBERG MC, 1980, J AM CERAM SOC, V63, P435, DOI 10.1111/j.1151-2916.1980.tb10207.x
NR 31
TC 15
Z9 15
U1 0
U2 6
PU DEUTSCHEN GLASTECHNISCHEN GES
PI FRANKFURT 1
PA MENDELSSOHNSTR 75-77, W-6000 FRANKFURT 1, GERMANY
SN 0946-7475
J9 GLASTECH BER-GLASS
JI Glastech. Ber.-Glass Sci. Technol.
PD APR
PY 1998
VL 71
IS 4
BP 83
EP 91
PG 9
WC Materials Science, Ceramics
SC Materials Science
GA ZN963
UT WOS:000073701600001
DA 2021-08-04
ER

PT J
AU Soriguer, FJ
   Lillo, JA
   Tinahones, FJ
   Gonzalez-Molina, M
   Cabello, M
   Burgos, D
   de Antonio, IE
   Garcia-Arnes, J
   Garriga, MJ
   Olveira, G
   Pareja, A
AF Soriguer, FJ
   Lillo, JA
   Tinahones, FJ
   Gonzalez-Molina, M
   Cabello, M
   Burgos, D
   de Antonio, IE
   Garcia-Arnes, J
   Garriga, MJ
   Olveira, G
   Pareja, A
TI Cardiovascular risk profile in kidney transplant recipients with well
   controlled hypertension
SO NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
LA English
DT Article
DE hypertension; kidney transplantation; lipoproteins; syndrome X
ID DENSITY-LIPOPROTEIN CHOLESTEROL; INSULIN RESISTANCE; CYCLOSPORINE;
   HYPERLIPIDEMIA; ABNORMALITIES; METABOLISM; ADIPOSITY; WOMEN; MEN
AB Background and Aim: To study the alterations of carbohydrate and lipid metabolism in a group of renal-transplant recipients.
   Methods and Results: A case-control study was carried out on 44 renal-transplant recipients with normal kidney function and oral glucose tolerance, and a control group of 37 healthy subjects. The following variables were studied: a) anthropometric and clinical, b) diet, c) composition of the adipose tissue fatty acids d) glycemia, insulin, and C peptide at baseline and after oral glucose tolerance rest (OGTT), e) cholesterol, triglycerides, and Apo B in total plasma and in high density lipoprotein (HDL), very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low density lipoprotein (LDL) separated by ultracentrifugation, Apo A-I, Apo CII, and Apo CIII in plasma. The renal-transplant recipients had a greater waist to hip ratio (0.89+/-0.09 vs 0.69+/-0.07, p=0.0008) compared to controls. Calorie intake was similar but the transplant recipients had a lower intake of saturated fat per day (31.4+/-9.6 vs 37.4+/-10.98 g/day, p=0.05). The composition of fatty acids in adipose tissue was the same in cases and controls, except for a greater proportion of lauric acid in the transplant recipients (p=0.05). The transplant recipients had significantly higher levels of cholesterol, triglycerides, and Apo B both in plasma and in VLDL, LDL, and IDL. The Apo A-I, Apo CII, and Apo CIII were significantly raised in the transplant recipients, but the Apo CII/Apo CIII ratio was significantly reduced (p=0.005). The HDL levels were similar in the transplant recipients and controls except for the HDL triglycerides, which were significantly higher (p=0.0002). Insulin values in serum were higher in the transplant recipients over the whole glucose curve with statistically significant differences at minute 90 of the curve (p=0.05). C peptide was higher in the transplant recipients at baseline (3.83+/-5.31 ng/ml VS 1.70+/-0.61 ng/ml, p=0.0001) and at minute 180 of the curve (p=0.03). The C peptide/insulin ratio was also significantly raised at these same times. Transplant recipients with hypertension had higher levels of blood glucose at minutes 30 (p=0.04) and 90 (p=0.01) of the curve, as well as a larger area under the glucose curve (p=0.03). They also had significantly higher levels of insulin at minute 90 (p=0.03), total Apo B (p=0.05), Apo B in LDL (p=0.03) and LDL-cholesterol (p=0.05).
   Conclusions: The rise in cholesterol and plasma triglycerides, rite apolipoprotein distribution pattern, the redistribution of the body fat, the changes in carbohydrate and insulin metabolism, are all the expression in renal-transplant recipients of a plurimetabolic syndrome, probably secondary to the simultaneous action of steroids, cyclosporine and hypotensive agents. (C) 1998, Medikal Press.
C1 Hosp Reg Carlos Haya, Secc Endocrinol, Serv Nefrol, Malaga, Spain.
RP Soriguer, FJ (corresponding author), C Chopera 6, Malaga 29018, Spain.
RI Biguzzi, Felipe A/E-4724-2015; Tinahones, Francisco Jose/AAB-2882-2020
OI OLVEIRA, GABRIEL/0000-0002-7646-2899
CR BIANCHI S, 1994, HYPERTENSION, V23, P681, DOI 10.1161/01.HYP.23.6.681
   BITTAR AE, 1990, TRANSPLANTATION, V50, P987, DOI 10.1097/00007890-199012000-00018
   BRUNNER FP, 1988, NEPHROL DIAL TRANSPL, V2, P109
   CASSADER M, 1991, METABOLISM, V40, P922, DOI 10.1016/0026-0495(91)90067-7
   CSORIGUER FS, 1992, NUTR HOSPITALARIS, V12, P33
   DERFLER K, 1991, KIDNEY INT, V40, P720, DOI 10.1038/ki.1991.266
   DIVAKAR D, 1991, NEPHRON, V59, P423, DOI 10.1159/000186602
   EKSTRAND AV, 1992, TRANSPLANTATION, V53, P563, DOI 10.1097/00007890-199203000-00014
   FERRANNINI E, 1990, J HYPERTENS, V8, pS169
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   FRUTOS MA, 1985, NEFROLOGIA, V5, P233
   GALLA JH, 1978, J LAB CLIN MED, V91, P123
   GEORGE V, 1990, INT J OBESITY, V14, P1085
   HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182
   HRICK DE, 1994, AM J KIDNEY DIS, V5, P776
   IBELS LS, 1981, Q J MED, V50, P149
   JEVNIKAR AM, 1988, TRANSPLANTATION, V46, P722, DOI 10.1097/00007890-198811000-00018
   JUNG K, 1982, CLIN NEPHROL, V17, P191
   KAPLAN NM, 1989, ARCH INTERN MED, V149, P1514, DOI 10.1001/archinte.149.7.1514
   KOBAYASHI N, 1983, NEPHRON, V35, P237, DOI 10.1159/000183088
   KWITEROWICH PO, 1991, PRIMARY HYPERLIPOPRO, P239
   LE NA, 1988, J LIPID RES, V29, P669
   LEFEBRE PJ, 1994, DIABETES METAB REV, V10, P7
   LOPEZMIRANDA J, 1993, METABOLISM, V42, P678, DOI 10.1016/0026-0495(93)90232-D
   MOLINA MG, 1993, NEPHROL DIAL TRANSPL, V8, P1040
   MOORE RA, 1990, TRANSPLANTATION, V49, P60, DOI 10.1097/00007890-199001000-00013
   NEUMANITIS J, 1986, LANCET, V2, P744
   OST L, 1988, TRANSPLANTATION, V46, P370
   REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595
   SRINIVASAN SR, 1993, METABOLISM, V42, P170, DOI 10.1016/0026-0495(93)90031-I
   VATHSALA A, 1989, TRANSPLANTATION, V48, P37, DOI 10.1097/00007890-198907000-00009
   VERLUIS DJ, 1986, BRIT MED J, V292, P272
   VRIES P, 1991, AM J CLIN NUTR, V53, P469
   WHO, 1980, WHO TECHN REP SER, V646
   *WHO DOC, 1988, 125 EURICPNUT WHO RE
   WINOCOUR PH, 1992, ARTERIOSCLER THROMB, V12, P393, DOI 10.1161/01.ATV.12.3.393
   ZINMMERMAN J, 1984, METABOLISM, V33, P521
NR 37
TC 1
Z9 1
U1 0
U2 1
PU MEDIKAL PRESS S R L
PI MILAN
PA VIA LUIGI ZOJA, 30, 20153 MILAN, ITALY
SN 0939-4753
J9 NUTR METAB CARDIOVAS
JI Nutr. Metab. Carbiovasc. Dis.
PD APR
PY 1998
VL 8
IS 2
BP 107
EP 116
PG 10
WC Cardiac & Cardiovascular Systems; Endocrinology & Metabolism; Nutrition
   & Dietetics
SC Cardiovascular System & Cardiology; Endocrinology & Metabolism;
   Nutrition & Dietetics
GA ZW057
UT WOS:000074369600008
DA 2021-08-04
ER

PT J
AU Antelman, SM
   Caggiula, AR
   Kucinski, BJ
   Fowler, H
   Gershon, S
   Edwards, DJ
   Austin, MC
   Stiller, R
   Kiss, S
   Kocan, D
AF Antelman, SM
   Caggiula, AR
   Kucinski, BJ
   Fowler, H
   Gershon, S
   Edwards, DJ
   Austin, MC
   Stiller, R
   Kiss, S
   Kocan, D
TI The effects of lithium on a potential cycling model of bipolar disorder
SO PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
LA English
DT Review
DE bipolar disorder; cocaine; cyclicity; dopamine; lithium; oscillation;
   nucleus accumbens; stress; striatum
ID LIFE EVENTS; DOPAMINE; STRESS; SENSITIZATION; TRANSDUCTION; AMPHETAMINE;
   OSCILLATE; FOOTSHOCK; EFFLUX; DRUGS
AB 1. Although bipolar disorder constitutes a major public health problem, with a high risk of suicide and an economic cost exceeding that of unipolar depression, it has received comparatively little attention, particularly at the basic science level. Perhaps as a result of this neglect, there is currently no animal model able to simulate the cyclicity which is its defining characteristic.
   2. Consequently, drug development in this area is meager and has proceeded serendipitously rather than empirically.
   3. The authors have recently reported that repeated exposure to cocaine and other stressors can induce an oscillation or cycling in a host of neurochemical and physiological systems.
   4. In order to test whether such cycling might be of potential relevance to bipolar disorder, the authors examined whether cocaine-induced cyclicity of amphetamine-evoked efflux of dopamine from slices of rat nucleus accumbens and striatum and/or cocaine induced oscillation of a behavior, stress-induced hypoalgesia, could be prevented by lithium, the agent of choice in treating this disease.
   5. The authors report that prophylactic treatment with lithium, completely and specifically prevented oscillations in each instance. This may represent an important initial step toward the development of the first cycling model of bipolar disorder.
C1 Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA 15213 USA.
   Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15213 USA.
   Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15213 USA.
   Univ Pittsburgh, Dept Pharmaceut Sci, Sch Pharm, Pittsburgh, PA 15213 USA.
   Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA.
RP Antelman, SM (corresponding author), Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Dept Psychiat, 3811 OHara St, Pittsburgh, PA 15213 USA.
FU NIDA NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Drug Abuse
   (NIDA) [DA09163] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG
   ABUSEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Drug Abuse
   (NIDA)European Commission [R01DA009163] Funding Source: NIH RePORTER
CR Antelman SM, 1997, ANN NY ACAD SCI, V821, P296, DOI 10.1111/j.1749-6632.1997.tb48288.x
   Antelman SM, 1996, CRIT REV NEUROBIOL, V10, P101, DOI 10.1615/CritRevNeurobiol.v10.i1.50
   ANTELMAN SM, 1995, NEUROPSYCHOPHARMACOL, V12, P297, DOI 10.1016/0893-133X(94)00094-G
   ANTELMAN SM, 1988, DRUG DEVELOP RES, V14, P1, DOI 10.1002/ddr.430140102
   ANTELMAN SM, 1992, PSYCHOPHARMACOLOGY, V107, P331, DOI 10.1007/BF02245157
   Caggiula AR, 1996, NEUROPSYCHOPHARMACOL, V15, P125, DOI 10.1016/0893-133X(95)00174-C
   COPPEN A, 1986, NEW RESULTS DEPRESSI, P126
   ELLICOTT A, 1990, AM J PSYCHIAT, V147, P1194
   GESSA GL, 1995, DEPRESSION MANIA NEU, P43
   GLASSNER B, 1983, AM J PSYCHIAT, V140, P215
   Goodwin FK, 1990, MANIC DEPRESSIVE ILL
   HIRSCHFELD RMA, 1982, ARCH GEN PSYCHIAT, V39, P35
   KOOB GF, 1989, ANIMAL MODELS DEPRES
   KORNETSKY C, 1989, ANIMAL MODELS DEPRES, P18
   Lenox Robert H., 1995, P303
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MANJI HK, 1995, ARCH GEN PSYCHIAT, V52, P531
   McKinney W.T., 1989, ANIMAL MODELS DEPRES, P3
   MULE SJ, 1977, COCAINE OTHER STIMUL, P215
   *NIH, 1993, NIH GUID, V22
   POST R M, 1990, International Review of Psychiatry, V2, P277, DOI 10.3109/09540269009026602
   POST RM, 1992, AM J PSYCHIAT, V149, P999
   POST RM, 1990, REV PSYCHIATRY, V9, P170
   POST RM, 1984, NEUROBIOLOGY MOOD DI
   PRIEN RF, 1990, PSYCHOPHARMACOL BULL, V26, P409
   PRIEN RF, 1989, AM J PSYCHIAT, V146, P840
   Robbins T.W., 1980, MANIA EVOLVING CONCE, P143
   ROBINSON TE, 1987, NEUROPHARMACOLOGY, V26, P679, DOI 10.1016/0028-3908(87)90228-0
   ROSS RT, 1984, J EXP PSYCHOL ANIM B, V10, P127
   SNYDER GL, 1990, J PHARMACOL EXP THER, V253, P867
   Weiss Jay M., 1995, P81
   WEISS SRB, 1994, TOXICOL IND HEALTH, V10, P421
   Weissman MM, 1991, PSYCHIAT DISORDERS A, P53
   ZAHNISER NR, 1992, COCAINE PHARM PHYSL, P229
NR 34
TC 30
Z9 32
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0278-5846
J9 PROG NEURO-PSYCHOPH
JI Prog. Neuro-Psychopharmacol. Biol. Psychiatry
PD APR
PY 1998
VL 22
IS 3
BP 495
EP 510
DI 10.1016/S0278-5846(98)00020-7
PG 16
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA ZJ095
UT WOS:000073179000005
PM 9612846
DA 2021-08-04
ER

PT J
AU Tambe, M
AF Tambe, M
TI Implementing agent teams in dynamic multiagent environments
SO APPLIED ARTIFICIAL INTELLIGENCE
LA English
DT Article
AB Teamwork is becoming increasingly critical in multiagent environments ranging from virtual environments for training and education, to information integration of the internet, to potential multirobotic space missions. Teamwork in such complex, dynamic environments is more than a simple union of simultaneous individual activity, even if supplemented with preplanned coordination. Indeed, in these dynamic environments, unanticipated events can easily cause a breakdown in such preplanned coordination. The central hypothesis in this article is that for effective teamwork, agents should be provided explicit representation of team goals and plans, as well as an explicit representation of a model of teamwork to support the execution of team plans. In our work, this model of teamwork takes thr form of a set of domain independent rules that clearly outline an agent's commitments and responsibilities as a participant in team activities, and thus guide the agent's social activities while executing team plans. This article describes two implementations of agent-teams based on the above principles, one for a real-world helicopter combat simulation, and one for the RoboCup soccer simulation. The article also provides a preliminary comparison of the two agent-teams to illustrate some of the strengths and weaknesses of RoboCup as a common test bed for multiagent systems.
C1 Univ So Calif, Inst Informat Sci, Marina Del Rey, CA 90292 USA.
   Univ So Calif, Dept Comp Sci, Marina Del Rey, CA 90292 USA.
RP Tambe, M (corresponding author), Univ So Calif, Inst Informat Sci, 4676 Admiralty Way, Marina Del Rey, CA 90292 USA.
EM tambe@isi.edu
CR BATES J, 1992, CMUCS92142 SCH COMP
   CALDER RB, 1993, C COMP GEN FORC BEH
   Cohen P., 1991, NOUS, V35
   DAVIS R, 1982, AI MAGAZINE, V3
   DIS Steering Committee, 1994, ISTSP9401 DIS STEER
   FIRBY J, 1987, P NAT C ART INT AAAI
   GROSZ BJ, 1990, SYS DEV FDN, P417
   HAYESROTH B, 1995, INT C MULT SYST ICMA
   HUBER M, 1995, P AAAI SPRING S REAS
   INGRAND F, 1992, IEEE EXPERT, V7
   JENNINGS N, 1994, KNOWLEDGE ENG REV, V8
   JENNINGS NR, 1995, ARTIFICIAL INTELLIGE, V75
   KINNY D, 1992, LECT NOTES AI, V830
   KITANO H, 1995, IJCAI 95 WORKSH ENT
   KUNIYOSHI Y, 1994, IEEE INT C ROB AUT M
   Levesque HJ, 1990, P NAT C ART INT
   MATSUBARA H, 1996, AAAI SPRING S AD COE
   Newell A., 1990, UNIFIED THEORIES COG
   Pimentel K., 1994, VIRTUAL REALITY NEW
   RAJPUT S, 1995, ISTCR9535 U CENTR FL
   RAO AS, 1993, 42 AUSTR ART INT I
   ROBSON B, 1992, SOCCER SKILLS
   ROSENBLOOM PS, 1991, ARTIF INTELL, V47, P289, DOI 10.1016/0004-3702(91)90057-Q
   STONE P, 1996, AAAI SPRING S AD COE
   Tambe M, 1997, P NAT C ART INT AAAI
   TAMBE M, 1995, AI MAGAZINE, V16
   TAMBE M, 1995, INT JOINT C ART INT
   TAMBE M, 1995, 5 C COMP GEN FORC BE
   TAMBE M, 1996, P NAT C ART INT AAAI
   TIDHAR G, 1995, 60 AUSTR ART INT I
NR 30
TC 16
Z9 17
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 0883-9514
J9 APPL ARTIF INTELL
JI Appl. Artif. Intell.
PD MAR-MAY
PY 1998
VL 12
IS 2-3
BP 189
EP 210
DI 10.1080/088395198117820
PG 22
WC Computer Science, Artificial Intelligence; Engineering, Electrical &
   Electronic
SC Computer Science; Engineering
GA ZE069
UT WOS:000072754600005
DA 2021-08-04
ER

PT J
AU Lee, J
   Gruninger, M
   Jin, Y
   Malone, T
   Tate, A
   Yost, G
AF Lee, J
   Gruninger, M
   Jin, Y
   Malone, T
   Tate, A
   Yost, G
CA PIF Working Grp
TI The Process Interchange Format and framework
SO KNOWLEDGE ENGINEERING REVIEW
LA English
DT Review
AB This document provides the specification of the Process Interchange Format (PIF) version 1.2. The goal of this work is to develop an interchange format to help automatically exchange process descriptions among a wide variety of business process modelling and support systems such as workflow software, flow charting tools, planners, process simulation systems and process repositories. Instead of having to write ad hoc translators for each pair of such systems each system will only need to have a single translator for converting process descriptions in that system into and out of the common PIF format. Then any system will be able to automatically exchange basic process descriptions with any other system. This document describes the PIE-CORE 1.2, i.e. the core set of object types (such as activities, agents and prerequisite relations) that can be used to describe the basic elements of any process. The document also describes a framework for extending the core set of object types to include additional information needed in specific applications. These extended descriptions are exchanged in such a way that the common elements are interpretable by any PIF translator, and the additional elements are interpretable by any translator that knows about the extensions. The PIF format was developed by a working group including representatives from several universities and companies, and has been used for experimental automatic translations among systems developed independently at three of these sites. This document is being distributed in the hopes that other groups will comment upon the interchange format proposed here, and that this format (or future versions of it) may be useful to other groups as well. The PIF Document 1.0 was released in December 1994, and the current document reports the revised PIF that incorporate the feedback received since then.
C1 Univ Hawaii, Dept Decis Sci, Honolulu, HI 96822 USA.
   Univ Toronto, Dept Ind Engn, Toronto, ON, Canada.
   Stanford Univ, Dept Civil Engn, Stanford, CA 94305 USA.
   MIT, Ctr Coordinat Sci, Cambridge, MA 02139 USA.
   Univ Edinburgh, Artificial Intelligence Applicat Inst, Edinburgh EH8 9YL, Midlothian, Scotland.
   Digital Equipment Corp, Maynard, MA 01754 USA.
RP Lee, J (corresponding author), Univ Hawaii, Dept Decis Sci, 2401 Maile Way, Honolulu, HI 96822 USA.
CR CHAN FY, 1995, THESIS MIT
   Fikes R., 1992, KNOWLEDGE INTERCHANG
   GRUBER TR, 1993, KNOWL ACQUIS, V5, P199, DOI 10.1006/knac.1993.1008
   LEE JT, 1990, ACM T INFORM SYST, V8, P1, DOI 10.1145/78915.78916
   MALONE T, 1993, P 2 IEEE WORKSH EN T
   NECHES R, 1991, AI MAG, V12, P36
   STEELE GL, 1990, COMMON LISP LANGUAGE
   TATE A, 1995, ACM SIGART B, V6
   USCHOLD M, 1995, ENTERPRISE ONTOLOGY
NR 9
TC 22
Z9 25
U1 0
U2 1
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 40 WEST 20TH STREET, NEW YORK, NY 10011-4211 USA
SN 0269-8889
J9 KNOWL ENG REV
JI Knowl. Eng. Rev.
PD MAR
PY 1998
VL 13
IS 1
BP 91
EP 120
DI 10.1017/S0269888998001015
PG 30
WC Computer Science, Artificial Intelligence
SC Computer Science
GA 112DJ
UT WOS:000075478600004
DA 2021-08-04
ER

PT J
AU Adamietz, IA
   Rahn, R
   Bottcher, HD
   Schafer, V
   Reimer, K
   Fleischer, W
AF Adamietz, IA
   Rahn, R
   Bottcher, HD
   Schafer, V
   Reimer, K
   Fleischer, W
TI Prophylaxis of radiochemotherapy-induced mucositis. Efficacy of the
   prophylactic oral rinsing with povidone-iodine solution
SO STRAHLENTHERAPIE UND ONKOLOGIE
LA German
DT Article
DE PVP-iodine solution; mucositis prophylaxis; radiochemotherapy
ID RADIATION-THERAPY; NECK-CANCER; HEAD; RADIOTHERAPY; IRRADIATION;
   COMPLICATIONS; MOUTH; FLORA; SKIN
AB Background: Oral mucositis is a frequent complication of radiochemotherapy. The origin of radiation-induced mucosa lesions is of iatrogenic nature although further development of mucositis is essentially influenced by infection. It can be assumed that disinfection measures should decrease the severity of mucositis induced by radiochemotherapy. Therefore, in a prospective randomised study the efficacy of prophylactic oral rinsing with a disinfection agent was investigated.
   Patients and Method: An open, randomised, prospective comparative trial was conducted with 40 patients undergoing radiochemotherapy of head and neck region due to malignant disease. The treatment scheme consisted of irradiation to tumor region and adjacent lymph nodes with a total dose of 71.3 Gy and simultaneous chemotherapy with carboplatin (60 mg/m(2)) on days 1 to 5 and 29 to 34. In all patients, a prophylaxis of mucositis with nystatine, rutosides, panthenol and immunoglobulin was undertaken. In addition, 20 patients rinsed oral cavity 4 times daily with povidone-iodine-solution, the comparative group rinsed with sterile water. Clinical examination of the oral mucosa was performed weekly. Onset, grading and duration of mucositis were used as main variables.
   Results: Clinically manifested oral mucositis was observed in 14 patients of the iodine group (mean grading: 1.0) and all 20 patients of the control group (mean grading: 3.0). Total duration (mean) of clinically observed mucositis was 2.75 weeks in treatment patients and 9.25 in control patients. Median AUC (area under curve for grade vs duration) was 2.5 in iodine rinsing patients and 15.75 in control patients. All differences found between the 2 groups were statistically significant. Increased iodine incorporation was not observed. A pathological increase of thyroid hormone levels in the iodine group was not found.
   Conclusions: The gained results indicate that incidence, severity and duration of radiochemotherapy-induced mucositis can be significantly reduced by oral rinsing with povidone-iodine performed additionally to the standard prophylaxis scheme.
C1 Univ Frankfurt Klinikum, Klin Strahlentherapie, D-6000 Frankfurt, Germany.
   Univ Frankfurt Klinikum, Zentrum Zahn Mund & Kieferheilkunde, D-6000 Frankfurt, Germany.
   Univ Frankfurt Klinikum, Inst Med Bakteriol, D-6000 Frankfurt, Germany.
   Mundipharma GmbH, Limburg, Germany.
RP Adamietz, IA (corresponding author), Univ Bochum, Marienhosp, Klin Strahlentherapie & Radioonkol, Holkeskampring 40, D-44625 Herne, Germany.
OI Adamietz, Irenaeus/0000-0002-7747-7259
CR ABDELAAL AS, 1989, LANCET, V1, P97
   Belka C., 1997, Strahlentherapie und Onkologie, V173, P247
   De Conno F, 1989, J Pain Symptom Manage, V4, P20
   DIETZ A, 1995, HNO, V43, P403
   DORR W, 1995, RADIOTHER ONCOL, V37, P100, DOI 10.1016/0167-8140(95)01610-S
   Dorr W, 1997, Strahlenther Onkol, V173, P183
   DOVE J, 1989, J AM DENT ASSOC, V119, P179
   DREIZEN S, 1977, POSTGRAD MED, V61, P85, DOI 10.1080/00325481.1977.11712115
   DUDJAK LA, 1987, CANCER NURS, V10, P131
   ENGELMEIER RL, 1983, J PROSTHET DENT, V49, P514, DOI 10.1016/0022-3913(83)90314-1
   EPSTEIN JB, 1989, INT J RADIAT ONCOL, V16, P1571, DOI 10.1016/0360-3016(89)90964-4
   Exner M, 1990, HYG MED, V15, P148
   FERRETTI G, 1987, P ASCO, V6, P268
   FITZNIGGLI H, 1978, EXPT KLIN ERGEBNISSE, P169
   GLOBEL B, 1984, DEUT MED WOCHENSCHR, V109, P1401, DOI 10.1055/s-2008-1069385
   HAMMANS P, 1993, DTSCH ZAHNARZTL Z, V48, P55
   HASENAU C, 1988, LARYNGO RHINO OTOL, V67, P576, DOI 10.1055/s-2007-998565
   Herrmann T., 1994, Strahlentherapie und Onkologie, V170, P545
   Kaufmann M, 1980, SSO Schweiz Monatsschr Zahnheilkd, V90, P633
   LARSON DL, 1989, SURG CLIN N AM, V66, P169
   MACIEJEWSKI B, 1990, INT J RADIAT ONCOL, V18, P101, DOI 10.1016/0360-3016(90)90273-M
   Maeglin B, 1984, Schweiz Monatsschr Zahnmed (1984), V94 Spec No, P880
   MARTIN MV, 1981, J MED MICROBIOL, V14, P457, DOI 10.1099/00222615-14-4-457
   Mose S., 1995, Strahlentherapie und Onkologie, V171, P415
   PILLSBURY HC, 1986, ARCH OTOLARYNGOL, V112, P552
   PORTEDER H, 1988, PROSTAGLANDINE, V16, P4
   RAHN R, 1992, ZAHNARZTL WELT, V101, P936
   REIMER K, 1996, HYG MED S1, V21, P54
   RICE DH, 1979, LARYNGOSCOPE, V89, P1839
   SAMARANAYAKE LP, 1988, CLIN RADIOL, V39, P291, DOI 10.1016/S0009-9260(88)80538-5
   SONIS ST, 1978, J AM DENT ASSOC, V97, P468, DOI 10.14219/jada.archive.1978.0304
   SPIJKERVET FKL, 1989, J ORAL PATHOL MED, V18, P167, DOI 10.1111/j.1600-0714.1989.tb00756.x
   TSUZURA Y, 1992, JPN J CANC CHEMOTHER, V19, P817
   VANDERSCHUEREN E, 1990, INT J RADIAT ONCOL, V19, P301, DOI 10.1016/0360-3016(90)90538-U
   WANEBO HJ, 1975, AM J SURG, V130, P445, DOI 10.1016/0002-9610(75)90482-1
   WERNER HP, 1992, ANTISEPTIKA HYG MED, V17, P51
   ZINNER DD, 1961, ORAL SURG, V14, P1377
NR 37
TC 17
Z9 16
U1 0
U2 0
PU URBAN & VOGEL
PI MUNICH
PA LINDWURMSTRASSE 95, D-80337 MUNICH, GERMANY
SN 0179-7158
J9 STRAHLENTHER ONKOL
JI Strahlenther. Onkol.
PD MAR
PY 1998
VL 174
IS 3
BP 149
EP 155
DI 10.1007/BF03038498
PG 7
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 129RX
UT WOS:000076477700006
PM 9524624
DA 2021-08-04
ER

PT J
AU Francotte, E
   Richert, P
   Mazzotti, M
   Morbidelli, M
AF Francotte, E
   Richert, P
   Mazzotti, M
   Morbidelli, M
TI Simulated moving bed chromatographic resolution of a chiral antitussive
SO JOURNAL OF CHROMATOGRAPHY A
LA English
DT Article
DE enantiomer separation; simulated moving bed chromatography; preparative
   chromatography; guaifenesin
ID ADSORPTION TECHNOLOGY; ENANTIOSEPARATION; COUNTERCURRENT; EPOXIDE
AB The behavior of a laboratory simulated moving bed (SMB) unit for continuous chromatographic separation of enantiomers has been considered, This was applied to the resolution of a chiral antitussive agent, guaifenesin, on Chiralcel OD, during an experimental campaign involving nineteen runs. The application of recently developed criteria for the design and optimization of SMB units allows us to understand and rationalize the experimental results, as well as to indicate how to optimize the separation performances. A three-step procedure to determine the adsorption isotherms needed to apply these criteria is proposed: it is reliable and may be applied also where pure components are not available. (C) 1998 Elsevier Science B.V.
C1 ETH Zurich, Tech Chem Lab, CH-8092 Zurich, Switzerland.
   Novartis Pharma AG, Pharmaceut Res, CH-4002 Basel, Switzerland.
   ETH Zurich, Tech Chem Lab, CH-8092 Zurich, Switzerland.
RP Morbidelli, M (corresponding author), ETH Zurich, Tech Chem Lab, Univ Str 6, CH-8092 Zurich, Switzerland.
RI Mazzotti, Marco/M-1725-2016
CR CHARTON F, 1995, J CHROMATOGR A, V702, P97, DOI 10.1016/0021-9673(94)01026-B
   CHING CB, 1993, J CHROMATOGR, V634, P215, DOI 10.1016/0021-9673(93)83007-F
   Francotte ER, 1997, J CHROMATOGR A, V769, P101, DOI 10.1016/S0021-9673(97)00172-6
   Gattuso M. J., 1996, Chemical Technology Europe, V3, P27
   GENTILINI A, UNPUB J CHROMATOGR A
   Guest DW, 1997, J CHROMATOGR A, V760, P159, DOI 10.1016/S0021-9673(96)00903-X
   Guiochon G., 1994, FUNDAMENTALS PREPARA
   Kinkel J.N., 1995, P CHIR EUR 95 S SPRI, P121
   KUSTERS E, 1995, CHROMATOGRAPHIA, V40, P387, DOI 10.1007/BF02269900
   Mazzotti M, 1997, J CHROMATOGR A, V769, P3, DOI 10.1016/S0021-9673(97)00048-4
   MAZZOTTI M, 1996, P CHIR EUR 96 S SPRI, P103
   NAGAMATSU S, 1996, P CHIR EUR 96 S SPRI, P97
   NEGAWA M, 1992, J CHROMATOGR, V590, P113, DOI 10.1016/0021-9673(92)87011-V
   NICOUD RM, 1993, CHIRALITY, V5, P267, DOI 10.1002/chir.530050415
   Pais LS, 1997, CHEM ENG SCI, V52, P245, DOI 10.1016/S0009-2509(96)00398-3
   Priegnitz J. W., 1995, Patent No. [5470464, US 5470464 A]
   RUTHVEN DM, 1989, CHEM ENG SCI, V44, P1011, DOI 10.1016/0009-2509(89)87002-2
NR 17
TC 70
Z9 72
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0021-9673
J9 J CHROMATOGR A
JI J. Chromatogr. A
PD FEB 20
PY 1998
VL 796
IS 2
BP 239
EP 248
DI 10.1016/S0021-9673(97)01005-4
PG 10
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA ZC782
UT WOS:000072617500003
PM 9540209
DA 2021-08-04
ER

PT J
AU Liu, W
   Lee, HK
AF Liu, W
   Lee, HK
TI Simultaneous analysis of inorganic and organic lead, mercury and
   selenium by capillary electrophoresis with nitrilotriacetic acid as
   derivatization agent
SO JOURNAL OF CHROMATOGRAPHY A
LA English
DT Article
DE complexation; derivatization; electrophoresis; injection methods;
   migration behaviour; lead; mercury; selenium; nitrilotriacetic acid;
   metal cations; organolead compounds; organomercury compounds;
   organoselenium compounds
ID MICELLAR ELECTROKINETIC CHROMATOGRAPHY; ZONE ELECTROPHORESIS; ION
   ELECTROPHORESIS; SPECIATION ANALYSIS; ORGANOTIN COMPOUNDS; ORGANOLEAD;
   SAMPLES; SPECTROMETRY; COMPLEXES; WATER
AB A capillary electrophoresis (CE) method for the simultaneous speciation of three elements in organic and inorganic species was developed. Nitrilotriacetic acid (NTA) was used as the off-column derivatization agent to form UV-absorbing complexes with the analytes. It was also added to the running electrolyte for the separation and detection. Besides, micellar electrokinetic chromatography (MEKC) was performed with sodium dodecyl sulfate (SDS) for the adjustment of electrophoretic mobility. A theoretical model, with the consideration of pH, SDS and NTA in the electrolyte buffer, was designed to describe the migration behavior of the analytes. Good agreement was obtained when the model was used to explain the experimental results. The aspect of improvement in detection was also evaluated, and SDS was found capable of enhancing the detection sensitivity for the or organometallic compounds. Further improvement of determination was achieved by amplified field sample injection. It permitted a 40 to 600 fold on-line enrichment for five analytes. Detection limits down to 0.2 ng/ml were obtained. (C) 1998 Elsevier Science B.V.
C1 Natl Univ Singapore, Dept Chem, Singapore 119260, Singapore.
RP Lee, HK (corresponding author), Natl Univ Singapore, Dept Chem, Kent Ridge, Singapore 119260, Singapore.
RI Lee, Hian Kee/B-3993-2018
OI Lee, Hian Kee/0000-0002-5664-9509
CR AGUILAR M, 1989, J CHROMATOGR, V480, P427, DOI 10.1016/S0021-9673(01)84312-0
   Albert M, 1997, J CHROMATOGR A, V757, P281, DOI 10.1016/S0021-9673(96)00783-2
   Albert M, 1997, J CHROMATOGR A, V757, P291, DOI 10.1016/S0021-9673(96)00782-0
   BETTMER J, 1993, J CHROMATOGR A, V654, P177, DOI 10.1016/0021-9673(93)83078-7
   BURGI DS, 1991, ANAL CHEM, V63, P2042, DOI 10.1021/ac00018a028
   CHAKRABORTI D, 1984, ANAL CHEM, V56, P2692, DOI 10.1021/ac00278a016
   CHENG KL, 1982, HDB ORG ANAL REAGENT
   CHIEN RL, 1992, ANAL CHEM, V64, pA489, DOI 10.1021/ac00032a002
   CRAIG PJ, 1986, ORGANOMETALLIC COMPO
   HAN F, 1995, J CHROMATOGR B, V669, P103, DOI 10.1016/0378-4347(95)00122-Y
   HUANG XH, 1988, ANAL CHEM, V60, P375, DOI 10.1021/ac00155a023
   LI K, 1995, J LIQ CHROMATOGR, V18, P1325, DOI 10.1080/10826079508010416
   LIU Y, 1994, J HIGH RES CHROMATOG, V17, P527
   LOBINSKI R, 1993, J AOAC INT, V76, P1262
   MEDINA I, 1993, TALANTA, V40, P1631, DOI 10.1016/0039-9140(93)80077-5
   NG CL, 1993, J CHROMATOGR A, V652, P547, DOI 10.1016/0021-9673(93)83277-Y
   NIELEN MWF, 1993, TRAC-TREND ANAL CHEM, V12, P345
   OKEEFFE M, 1995, ANAL CHIM ACTA, V306, P91, DOI 10.1016/0003-2670(94)00667-B
   RINGBOM A., 1963, COMPLEXATION ANAL CH
   SALOMON DR, 1992, J CHROMATOGR, V602, P219, DOI 10.1016/0021-9673(92)80084-8
   Sillen L. G., 1964, STABILITY CONSTANTS
   YANG Q, 1995, J CHROMATOGR A, V706, P503, DOI 10.1016/0021-9673(94)01242-7
NR 22
TC 43
Z9 45
U1 0
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0021-9673
J9 J CHROMATOGR A
JI J. Chromatogr. A
PD FEB 20
PY 1998
VL 796
IS 2
BP 385
EP 395
DI 10.1016/S0021-9673(97)01012-1
PG 11
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA ZC782
UT WOS:000072617500019
DA 2021-08-04
ER

PT J
AU Tuomi, J
   Rantamaki, LK
   Tanskanen, R
AF Tuomi, J
   Rantamaki, LK
   Tanskanen, R
TI Experimental infection of cattle with several Borrelia burgdorferi sensu
   lato strains; immunological heterogeneity of strains as revealed in
   serological tests
SO VETERINARY MICROBIOLOGY
LA English
DT Article
DE Borrelia burgdorferi; cattle; bacteria; immune response; immunological
   heterogeneity; ELISA; IFA
ID LYME BORRELIOSIS; SEROPROTECTIVE GROUPS; ANTIBODY-RESPONSE; LABORATORY
   MICE; DAIRY-COWS; DISEASE; ARTHRITIS; ASSOCIATION; WISCONSIN; ANTIGENS
AB Twenty-three experimental cattle, mainly calves, were each inoculated 1-3 times with one of ten Finnish Borrelia burgdorferi sensu late strains. All three genospecies were represented. Borreliae were administered mainly by both intravenous (about 10(6) to 10(9) spirochaetes) and intradermal (10(4)) routes, and on six occasions subcutaneously (10(3)) only. For infectivity control and comparison purposes mice and rabbits were inoculated simultaneously. Immune responses in cattle were monitored both with whole-cell sonicate enzyme-linked immunosorbent assay (IgG-ELISA) and indirect immunofluorescent assay (IgM-IgG-IFA). Five Finnish strains and the American strain B31 were used as antigens. No clinical signs of borreliosis were observed. Of the strains, 7/10 were interpreted by the immune responses to have caused relatively short-term subclinical infections of varying intensity. Borreliae could not be isolated from blood or other organ specimens of cattle. A rough estimate of the mean infectious dose in the conditions of experiments is 10(6) to 10(7) organisms. In conclusion, the overall result appears to argue a low susceptibility of cattle to clinical borreliosis, at least when infected by Finnish strains of the agent. Significant antigen-specific differences were observed both by ELISA and LFA in detection and quantification of immune responses. As a rule, the homologous antigen was found to be the most sensitive. Genospecies differences were mostly distinct. Antigens of two Borrelia garinii isolates proved practically equal in sensitivity, whereas major differences were displayed between two Borrelia afzelii antigens. In an IFA study, an American (B31) and a Finnish B. burgdorferi sensu stricto strain proved equally sensitive as antigens. In two relatively strong primary immune responses the antigen-specific measurement differences were such that diagnostically in a cross-sectional study only the homologous antigen or an antigen of the same genospecies would have been sufficiently sensitive to show a positive result. (C) 1998 Elsevier Science B.V.
C1 Univ Helsinki, Fac Vet Med, Dept Vet Basic Sci, Div Microbiol & Epidemiol, FIN-00014 Helsinki, Finland.
RP Tuomi, J (corresponding author), Univ Helsinki, Fac Vet Med, Dept Vet Basic Sci, Div Microbiol & Epidemiol, POB 57, FIN-00014 Helsinki, Finland.
EM jaakko.tuomi@helsinki.fi
CR APPEL MJG, 1993, J INFECT DIS, V167, P651, DOI 10.1093/infdis/167.3.651
   ASSOUS MV, 1993, EUR J CLIN MICROBIOL, V12, P261, DOI 10.1007/BF01967256
   BARTHOLD SW, 1988, ANN NY ACAD SCI, V539, P264, DOI 10.1111/j.1749-6632.1988.tb31860.x
   BARTHOLD SW, 1991, J INFECT DIS, V163, P419, DOI 10.1093/infdis/163.2.419
   BARTHOLD SW, 1990, J INFECT DIS, V162, P133, DOI 10.1093/infdis/162.1.133
   BARTHOLD SW, 1995, INFECT IMMUN, V63, P2255, DOI 10.1128/IAI.63.6.2255-2261.1995
   BARTHOLD SW, 1990, AM J TROP MED HYG, V42, P596, DOI 10.4269/ajtmh.1990.42.596
   BERGER BW, 1988, J AM ACAD DERMATOL, V18, P1243, DOI 10.1016/S0190-9622(88)70129-2
   BLOWEY RW, 1994, VET REC, V135, P577
   Bos E S, 1981, J Immunoassay, V2, P187, DOI 10.1080/15321818108056977
   BUNIKIS J, 1995, J CLIN MICROBIOL, V33, P1473, DOI 10.1128/JCM.33.6.1473-1478.1995
   BURGESS EC, 1986, ZBL BAKT-INT J MED M, V263, P49
   BURGESS EC, 1988, ANN NY ACAD SCI, V539, P235, DOI 10.1111/j.1749-6632.1988.tb31857.x
   BURGESS EC, 1987, J AM VET MED ASSOC, V191, P1468
   BURGESS EC, 1993, VET MICROBIOL, V35, P61, DOI 10.1016/0378-1135(93)90116-O
   DRESSLER F, 1994, J INFECT DIS, V169, P313, DOI 10.1093/infdis/169.2.313
   GREENE RT, 1988, AM J VET RES, V49, P752
   HOVMARK A, 1986, ACTA VET SCAND, V27, P479
   JI BX, 1994, AM J VET RES, V55, P1228
   JOHNSON RC, 1984, J CLIN MICROBIOL, V20, P1099, DOI 10.1128/JCM.20.6.1099-1101.1984
   JUNTTILA J, 1994, SCAND J INFECT DIS, V26, P349, DOI 10.3109/00365549409011805
   KARLSSON M, 1991, EUR J CLIN MICROBIOL, V10, P742, DOI 10.1007/BF01972499
   LOVRICH SD, 1994, J INFECT DIS, V170, P115, DOI 10.1093/infdis/170.1.115
   LOVRICH SD, 1995, INFECT IMMUN, V63, P2113, DOI 10.1128/IAI.63.6.2113-2119.1995
   LOVRICH SD, 1993, INFECT IMMUN, V61, P4367, DOI 10.1128/IAI.61.10.4367-4374.1993
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MAGNARELLI LA, 1994, J CLIN MICROBIOL, V32, P1154, DOI 10.1128/JCM.32.5.1154-1158.1994
   MCKENNA P, 1995, VET REC, V136, P244, DOI 10.1136/vr.136.10.244
   Norman GL, 1996, J CLIN MICROBIOL, V34, P1732, DOI 10.1128/JCM.34.7.1732-1738.1996
   PACHNER AR, 1993, REG IMMUNOL, V4, P345
   ROEHRIG JT, 1992, J IMMUNOL, V149, P3648
   SCHAIBLE UE, 1990, AM J PATHOL, V137, P811
   SCHAIBLE UE, 1991, EUR J IMMUNOL, V21, P2397, DOI 10.1002/eji.1830211016
   SCHMITZ JL, 1988, INFECT IMMUN, V56, P2336, DOI 10.1128/IAI.56.9.2336-2342.1988
   SCHWAN TG, 1988, J CLIN MICROBIOL, V26, P893, DOI 10.1128/JCM.26.5.893-895.1988
   SCHWAN TG, 1989, INFECT IMMUN, V57, P3445, DOI 10.1128/IAI.57.11.3445-3451.1989
   SIMPSON WJ, 1991, J CLIN MICROBIOL, V29, P236, DOI 10.1128/JCM.29.2.236-243.1991
   SINSKY RJ, 1989, J CLIN MICROBIOL, V27, P1723, DOI 10.1128/JCM.27.8.1723-1727.1989
   STOENNER HG, 1974, APPL MICROBIOL, V28, P540, DOI 10.1128/AEM.28.4.540-543.1974
   TUOMI J, 1995, J CLIN MICROBIOL, V33, P1989, DOI 10.1128/JCM.33.8.1989-1996.1995
   Uilenberg G., 1967, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V20, P563
   WELLS SJ, 1993, AM J VET RES, V54, P398
   WIENECKE R, 1993, LANCET, V342, P435, DOI 10.1016/0140-6736(93)92848-N
   WILSKE B, 1994, MED MICROBIOL IMMUN, V183, P43, DOI 10.1007/BF00193630
   WILSKE B, 1989, ZBL BAKT P, V18, P299
   Wilson M.B., 1978, IMMUNOFLUORESCENCE R, P215
NR 46
TC 15
Z9 15
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1135
EI 1873-2542
J9 VET MICROBIOL
JI Vet. Microbiol.
PD FEB 15
PY 1998
VL 60
IS 1
BP 27
EP 43
DI 10.1016/S0378-1135(97)00200-9
PG 17
WC Microbiology; Veterinary Sciences
SC Microbiology; Veterinary Sciences
GA ZJ352
UT WOS:000073205400003
PM 9595625
DA 2021-08-04
ER

PT J
AU Sibani, P
   Brandt, M
   Alstrom, P
AF Sibani, P
   Brandt, M
   Alstrom, P
TI Evolution and extinction dynamics in rugged fitness landscapes
SO INTERNATIONAL JOURNAL OF MODERN PHYSICS B
LA English
DT Review
ID PERIODICITY; HISTORY
AB After an introductory section summarizing the paleontological data and some of their theoretical descriptions, we describe the "reset" model and its (in part analytically soluble) mean field version, which have been briefly introduced in Letters.(1,2) Macroevolution is considered as a problem of stochastic dynamics in a system with many competing agents. Evolutionary events (speciations and extinctions) are triggered by fitness records found by random exploration of the agents' fitness landscapes. As a consequence, the average fitness in the system increases logarithmically with time, while the rate of extinction steadily decreases. This non-stationary dynamics is studied by numerical simulations and, in a simpler mean field version, analytically. We also consider the effect of externally added "mass" extinctions. The predictions for various quantities of paleontological interest (life-time distribution, distribution of event sizes and behavior of the rate of extinction) are robust and in good agreement with available data.
C1 Odense Univ, Inst Fys, DK-5230 Odense M, Denmark.
   Kobenhavns Univ, Niels Bohr Inst, DK-2100 Kobenhavn, Denmark.
RP Sibani, P (corresponding author), Odense Univ, Inst Fys, Campusvej 55, DK-5230 Odense M, Denmark.
CR ALVAREZ LW, 1980, SCIENCE, V208, P1095, DOI 10.1126/science.208.4448.1095
   BAK P, 1993, PHYS REV LETT, V71, P4083, DOI 10.1103/PhysRevLett.71.4083
   Kauffman S.A., 1995, HOME UNIVERSE
   KIMURA M., 1983, NEUTRAL THEORY MOL E
   LENSKI RE, 1994, P NATL ACAD SCI USA, V91, P6808, DOI 10.1073/pnas.91.15.6808
   LENSKI RE, 1995, TEMPO MODE EVOLUTION
   MANRUBIA SC, CONDMAT9607066
   NEWMAN MEJ, 1995, P ROY SOC B-BIOL SCI, V260, P31, DOI 10.1098/rspb.1995.0055
   NEWMAN MEJ, IN PRESS J THEOR BIO
   Raup D. M., 1991, EXTINCTION BAD GENES
   RAUP DM, 1986, SCIENCE, V231, P1528, DOI 10.1126/science.11542058
   RAUP DM, 1984, P NATL ACAD SCI-BIOL, V81, P801, DOI 10.1073/pnas.81.3.801
   RAUP DM, 1982, SCIENCE, V215, P1501, DOI 10.1126/science.215.4539.1501
   RAUP DM, 1991, PALEOBIOLOGY, V17, P37, DOI 10.1017/S0094837300010332
   RAUP DM, 1978, PALEOBIOLOGY, V4, P42
   RUAP DM, 1995, TEMPO MODE EVOLUTION
   Rudin W, 1966, REAL COMPLEX ANAL
   SCHMIDT M, 1995, THESIS ODENSE U
   SEPKOSKI JJ, 1993, PALEOBIOLOGY, V19, P43, DOI 10.1017/S0094837300012306
   SEPKOSKI JJ, 1989, J GEOL SOC LONDON, V146, P7, DOI 10.1144/gsjgs.146.1.0007
   SIBANI P, 1995, PHYS REV LETT, V75, P2055, DOI 10.1103/PhysRevLett.75.2055
   Sibani P, 1997, PHYS REV LETT, V79, P1413, DOI 10.1103/PhysRevLett.79.1413
   SIBANI P, 1993, PHYS REV LETT, V71, P1485
   SNEPPEN K, 1995, P NATL ACAD SCI USA, V92, P5209, DOI 10.1073/pnas.92.11.5209
   SNEPPEN K, IN PRESS PHYSICA D
   Sole RV, 1996, P ROY SOC B-BIOL SCI, V263, P1407, DOI 10.1098/rspb.1996.0206
   Valentine J.W., 1995, TEMPO MODE EVOLUTION
   WEISBUCH G, 1992, SPIN GLASSES BIOL, P141
   WRIGHT S, 1982, EVOLUTION, V36, P427, DOI 10.1111/j.1558-5646.1982.tb05065.x
NR 29
TC 26
Z9 26
U1 0
U2 7
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA JOURNAL DEPT PO BOX 128 FARRER ROAD, SINGAPORE 9128, SINGAPORE
SN 0217-9792
J9 INT J MOD PHYS B
JI Int. J. Mod. Phys. B
PD FEB 10
PY 1998
VL 12
IS 4
BP 361
EP 391
DI 10.1142/S0217979298000259
PG 31
WC Physics, Applied; Physics, Condensed Matter; Physics, Mathematical
SC Physics
GA ZE206
UT WOS:000072768700001
OA Green Submitted
DA 2021-08-04
ER

PT J
AU Wolf, J
   Schmezer, P
   Fengel, D
   Schroeder, HG
   Scheithauer, H
   Woeste, P
AF Wolf, J
   Schmezer, P
   Fengel, D
   Schroeder, HG
   Scheithauer, H
   Woeste, P
TI The role of combination effects on the etiology of malignant nasal
   tumours in the wood-working industry - Most recent findings and analysis
   of 147 indemnified cases of adenocarcinomas
SO ACTA OTO-LARYNGOLOGICA
LA English
DT Article
DE adenocarcinomas of the nose in the wood-working industry; genotoxicity;
   wood components; wood additives
ID LINDANE; SAMPLES
AB Adenocarcinomas of the nose are regarded as an occupational disease in Germany and other European countries, and workers exposed to oak or beech wood-dust in the course of their work receive compensation if they incur adenocarcinoma of the nose. This has prompted a joint research project to record the functional and morphological changes of the nasal mucosa and/or paranasal sinus of 149 exposed subjects and 33 controls in accordance with a defined occupational exposure. To ensure the quantitative and qualitative reliability of the exposure data, 1,349 measurements at the company workplace were taken and analyses of 614 wood samples performed; parallel to this, the genotoxic effects of the most important substances used in the wood-working industry were tested. Apart from this, latency periods and morbidity rates in Germany were investigated. Partial findings of this research projects have been evaluated by the International Agency for Research on Cancer (IARC). According to these evaluations and the findings presented here, the following points can be made: i) Morphological changes in the nasal mucosa after exposure to wood-dust resulted in an increase in cylindrocellular hyperplasias and, in functional terms, a tendency towards improved nasal clearance was observed. Chromium and Formaldehyde, on the other hand, tended to give rise to an increase in the number of squamous metaplasias. This might explain the preference for the histological types of adenocarcinoma among subjects exposed to wood-dust. ii) In tissue samples more dysplasias were found among those exposed to oak and beech wood-dust. Subjects exposed to wood preserving agents had dysplasias only if they were simultaneously exposed to oak and beech wood-dust. The latter effect did not quite reach the level of significance (p = 0.07) on account of the low numbers of cases, iii) The investigation of genotoxic effects showed that oak and beech contain genotoxic substances that can be dissolved by means of ethanol and cyclohexane; they also showed that 3 out of 8 wood preservatives, 5 out of 16 stains, and 2 out of 11 paints from the wood-working industry are genotoxic too. Apart from this, lindane and PCP have proved to be genotoxic in the nasal cells of rats and human beings. Analysis of 614 wood samples from wood-preserving agents showed that almost 73% contained agents of this type, even in woods described by the companies as being guaranteed free of wood preservatives. iv) According to an analysis of 147 cases accepted since 1985 as a pensionable occupational illness by the Holz-Berufsgenossenschaft (an industrial compensation society for employees in the wood-working industry), the disease was much more apparent in small companies where there is multi-factorial exposure, than in large companies where the exposure factor tends to have a single component. This points to the combined effects of hardwood dusts and chemicals as being the cause, v) According to published findings, the incidence of the disease in England seems to be on the decline. In Germany, increasing latency; periods also point to a decline in the number of cases, although both countries have only very recently introduced effective prevention measures against exposure to wood-dust. This also leads to the assumption that wood-dusts cannot be the only cause of this type of cancer. vi) These findings tally with the evaluation by the IARC confirming the special part that hardwood dusts play in the development of nasal cancer. The findings presented here also indicate combined effects as being the cause of this type of cancer.
   This hypothesis cannot be confirmed until the conclusion of long-term animal experiments, currently being conducted, to test how the effects of chemicals such as lindane, PCP, and chromate compare with use of oak wood-dust.
C1 Stadt Klinikum, HNO Klin, D-38118 Braunschweig, Germany.
   Deutsch Krebsforschungszentrum, D-6900 Heidelberg, Germany.
   Tech Univ Munich, Inst Holzchem, D-8000 Munich, Germany.
   Inst Holzforsch, Dresden, Germany.
   Holz Berufsgenossenschaft, Munchen, Germany.
RP Wolf, J (corresponding author), Stadt Klinikum, HNO Klin, D-38118 Braunschweig, Germany.
RI Wolf, Jean-Pierre/B-8315-2012
OI Wolf, Jean-Pierre/0000-0003-3729-958X
CR ACHESON ED, 1982, NATURE, V299, P263, DOI 10.1038/299263a0
   [Anonymous], TECHNISCHE REGELN GE
   HARDELL L, 1982, American Journal of Industrial Medicine, V3, P247, DOI 10.1002/ajim.4700030304
   HERNBERG S, 1983, SCAND J WORK ENV HEA, V9, P97
   *IARC, 1995, IARC MON EV CARC RIS, V62
   KAUPPINEN TP, 1986, BRIT J IND MED, V43, P84
   KOCH D, WERKSTOFFE GEFAHRDUN
   NYLANDER LA, 1993, AM J IND MED, V24, P619, DOI 10.1002/ajim.4700240511
   POOLZOBEL BL, 1993, FOOD CHEM TOXICOL, V31, P271, DOI 10.1016/0278-6915(93)90077-C
   POOLZOBEL BL, 1994, ENVIRON MOL MUTAGEN, V24, P23, DOI 10.1002/em.2850240105
   POTT F, 1987, EXP PATHOL-JENA, V32, P129, DOI 10.1016/S0232-1513(87)80044-0
   SCHEITHAUER M, ABSCHLUSSBERICHT FOR
   SCHMEZER P, 1977, IARC SCI PUBL, V84, P270
   WILHELMSSON B, 1982, EFFECTS WOOD DUST NA
   WILLEITNER H, 1986, HOLZ ROH WERKST, V44, P1, DOI 10.1007/BF02616305
   WOLF J, 1990, STAUB REINHALT LUFT, V50, P23
   WOLF J, 1994, HOLZWIRTSCHAFT ASU S, V21, P1
   ANERKANNTE ANALYSENV
   1989, NN BIA ARBEITSMAPPE
NR 19
TC 5
Z9 5
U1 0
U2 4
PU SCANDINAVIAN UNIVERSITY PRESS
PI OSLO
PA PO BOX 2959 TOYEN, JOURNAL DIVISION CUSTOMER SERVICE, N-0608 OSLO,
   NORWAY
SN 0001-6489
J9 ACTA OTO-LARYNGOL
JI Acta Oto-Laryngol.
PY 1998
SU 535
BP 3
EP 16
PG 14
WC Otorhinolaryngology
SC Otorhinolaryngology
GA 110BJ
UT WOS:000075359100001
DA 2021-08-04
ER

PT S
AU Kramer, FW
AF Kramer, FW
BE Clare, AG
   Jones, LE
TI Simulation of fining in specialty glass
SO ADVANCES IN FUSION AND PROCESSING OF GLASS II
SE CERAMIC TRANSACTIONS
LA English
DT Proceedings Paper
CT 5th International Symposium on the Advances in Fusion and Processing of
   Glass
CY JUL 17-31, 1997
CL TORONTO, CANADA
AB Fining is one of the most important processes in the melting of specialty glass. To understand and improve this process simulations of fining outside the melting tanks must be done. Fining behavior of glasses can be studied in the laboratory with fining tests, including analysis of gases evolved from a batch, and determination of partial pressure of oxygen, an important analysis when the glass is fined with multivalent ions. These tests can determine the temperature at which fining will occur, what fining agent to use, and what raw material at what grain size distribution should be used.
   In addition to this experimental data, mathematical simulation of processes in melting tanks is available. Temperature distribution, flow current velocities, and redox reactions and the fining process can be calculated if the thermodynamic data of redox reactions are known. The behavior of bubbles in the melt during fining can be simulated by combining tank models with a bubble change model. The influence of water on fining in an oxy-fuel fired tank is described.
C1 Schott Glaswerke, D-55014 Mainz, Germany.
RP Kramer, FW (corresponding author), Schott Glaswerke, D-55014 Mainz, Germany.
NR 0
TC 3
Z9 3
U1 0
U2 0
PU AMER CERAMIC SOC
PI WESTERVILLE
PA 735 CERAMIC PLACE, WESTERVILLE, OH 43081-8720 USA
SN 1042-1122
BN 1-57498-045-9
J9 CERAM TRANS
PY 1998
VL 82
BP 7
EP 17
PG 11
WC Materials Science, Ceramics
SC Materials Science
GA BL05U
UT WOS:000074134200002
DA 2021-08-04
ER

PT B
AU Stefanovic, MM
   Stakic, MB
AF Stefanovic, MM
   Stakic, MB
BE Kozai, T
   Murase, H
   Hoshi, T
TI Simulation of the computer controlled dehydrator for raw vegetable mass
SO ARTIFICIAL INTELLIGENCE IN AGRICULTURE 1998
LA English
DT Proceedings Paper
CT 3rd IFAC/CIGR Workshop on Artificial Intelligence in Agriculture
CY APR 24-26, 1998
CL MAKUHARI, JAPAN
SP Int Federat Automat Control, Int Commiss Agr Engn, Japanese Soc High Technol Agr, Japanese Soc Environm Control Biol, Japan Assoc Int Commiss Agr Engn
DE simulation; process control; drying; energy consumption; dehydrator
AB During investigating the behavior of a dehydrator for raw vegetable mass (under different operational conditions, with various input parameters combined with different control parameters) experimental data obtained while plant is in operation can not give the sufficient results. Some of the unsuitable working conditions can cause losses during production, while some input parameters (like moisture of the raw material) are influenced by the atmospheric conditions or other factors beyond the authority of the explorer. This is the main reason for investigating the different regimes of the dehydrator operation using simulation program which includes model of the drying process, model describing behavior of the different parts in a dehydrator (encountering inertia of the system), simulation of the control of the drying agent temperature as a function of a fuel flow rate, thus enabling obtaining the most optimal regime during dehydrator operation. Copyright (C) 1998 IFAC.
C1 Inst Nucl Sci Vinca, Lab Thermal Engn & Energy, YU-11001 Belgrade, Yugoslavia.
RP Stefanovic, MM (corresponding author), Inst Nucl Sci Vinca, Lab Thermal Engn & Energy, POB 522, YU-11001 Belgrade, Yugoslavia.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU PERGAMON PRESS LTD
PI OXFORD
PA THE BOULEVARD LANGFORD LANE KIDLINGTON, OXFORD OX5 1GB, ENGLAND
BN 0-08-043030-9
PY 1998
BP 187
EP 192
PG 6
WC Agronomy; Computer Science, Interdisciplinary Applications
SC Agriculture; Computer Science
GA BM21X
UT WOS:000078047400031
DA 2021-08-04
ER

PT J
AU Roy, S
   Laerum, F
   Brosstad, F
AF Roy, S
   Laerum, F
   Brosstad, F
TI Quantitative evaluation of selective thrombolysis techniques: Influence
   of catheter characteristics and delivery parameters
SO CATHETERIZATION AND CARDIOVASCULAR DIAGNOSIS
LA English
DT Article
DE thrombolysis; catheters and catheterization; interventional procedures,
   experimental studies; thrombosis, experimental; blood vessels, stenosis
   or obstruction
ID TISSUE-PLASMINOGEN ACTIVATOR; INTRAARTERIAL THROMBOLYSIS; HEMODIALYSIS
   GRAFTS; BYPASS GRAFTS; INFUSION; FIBRINOLYSIS; UROKINASE; DIFFUSION;
   THERAPY; THROMBECTOMY
AB Here, we evaluate in vitro the site-specific delivery ability of thrombolysis catheters and compare continuous infusion (CI) and periodic injection (PI) protocols with reference to this parameter. Thrombotic occlusion was simulated by placing a porcine blood clot proximal to an eccentric stenosis in a flow phantom, Iodinated contrast agent was used as the marker. Part I-Evaluation of thrombolysis catheters: four CI and three PI catheters were tested. The marker was delivered as an infusion at 1 ml/min for 1 min (CI), or as two 0.25 ml boluses 30 sec apart (PI), Iodine content of the clot was then estimated with x-ray fluorescence spectrometry, This value as a ratio of the delivered dose was defined as the targeting efficiency. Part II-Evaluation of thrombolysis protocols: CI and PI were compared. The marker was delivered for 3 or 5 min using one of seven protocols. The iodine content of both clot and effluent were estimated. Among PI catheters, the Jet-Lysis catheter proved to be the best (P = 0.02). The EDM catheter had the lowest targeting efficiency in the CI group (P = 0.01). With CI, median iodine recovery dropped from 0.21 (95% confidence interval: 0.08, 0.25) for 1 min to 0.13 (0.05, 0.16) for 3 min and 0.07 (0.03, 0.10) for 5 min; for PI the values remained unchanged. The fraction lost in the effluent increased with the duration of regimen with both CI (P = 0.014) and PI (P = 0.004). Reducing the rate of infusion or the bolus frequency resulted in major improvements with respect to this parameter (P = 0.005). For CI, the targeting efficiency increased as well (P = 0.03), We conclude that currently used thrombolysis protocols do not fully exploit the delivery advantage offered by CI or PI. Fortunately, simple modifications offer the possibility of overcoming these drawbacks. (C) 1998 Wiley-Liss, Inc.
C1 Natl Hosp Norway, Inst Surg Res, N-0027 Oslo, Norway.
   Natl Hosp Norway, Internal Med Res Inst, N-0027 Oslo, Norway.
RP Roy, S (corresponding author), Natl Hosp Norway, Inst Surg Res, N-0027 Oslo, Norway.
CR BLINC A, 1992, THROMB HAEMOSTASIS, V68, P667
   BLINC A, 1994, THROMB HAEMOSTASIS, V71, P230
   BOOKSTEIN JJ, 1994, RADIOLOGY, V193, P318, DOI 10.1148/radiology.193.2.7972734
   Braithwaite BD, 1996, BRIT J SURG, V83, P1390, DOI 10.1002/bjs.1800831020
   BRAUNWALD E, 1987, J AM COLL CARDIOL, V10, P970, DOI 10.1016/S0735-1097(87)80296-6
   Brunner M C, 1991, J Vasc Interv Radiol, V2, P503, DOI 10.1016/S1051-0443(91)72232-X
   Busch U. W., 1993, European Heart Journal, V14, P247
   Comerota AJ, 1996, AM J SURG, V172, P105, DOI 10.1016/S0002-9610(96)00129-8
   DIAMOND SL, 1993, BIOPHYS J, V65, P2622, DOI 10.1016/S0006-3495(93)81314-6
   *EDM, EDM INF CATH
   Froelich JJ, 1996, CARDIOVASC INTER RAD, V19, P423
   FROHLICH JJ, 1993, CARDIOVASC INTERVENT, V16, pS20
   GRAOR RA, 1994, ANN SURG, V220, P251
   HUETTL EA, 1995, RADIOLOGY, V197, P141, DOI 10.1148/radiology.197.1.7568812
   KANDARPA K, 1993, RADIOLOGY, V188, P861, DOI 10.1148/radiology.188.3.8351363
   KANDARPA K, 1988, RADIOLOGY, V168, P739, DOI 10.1148/radiology.168.3.3406403
   KAUFMAN SL, 1991, CARDIOVASC INTER RAD, V14, P334, DOI 10.1007/BF02577891
   KHILNAMI N, 1996, ACAD RADIOL, V8, P121
   LIGHTFOOT EN, 1995, BIOMEDICAL ENG HDB, P1656
   LIPTON MJ, 1978, RADIOLOGY, V129, P363, DOI 10.1148/129.2.363
   Mruk JS, 1996, CIRCULATION, V93, P792
   OURIEL K, 1995, J VASC SURG, V22, P593, DOI 10.1016/S0741-5214(95)70045-5
   RIGGS P, 1995, SURG CLIN N AM, V75, P633, DOI 10.1016/S0039-6109(16)46687-9
   ROY S, 1994, RADIOLOGY, V191, P23, DOI 10.1148/radiology.191.1.8134577
   SCHILLING JJ, 1987, AM J KIDNEY DIS, V10, P92, DOI 10.1016/S0272-6386(87)80038-0
   SCHUMAN E, 1994, AM J SURG, V167, P473, DOI 10.1016/0002-9610(94)90237-2
   SUMMERS S, 1993, SURG GYNECOL OBSTET, V176, P534
   TREROTOLA SO, 1995, AM J ROENTGENOL, V164, P1501
   UNDERWOOD MJ, 1993, J VASC RES, V30, P323, DOI 10.1159/000159013
   VALJI K, 1993, RADIOLOGY, V188, P389, DOI 10.1148/radiology.188.2.8327683
   Vesely TM, 1996, J VASC INTERV RADIOL, V7, P507, DOI 10.1016/S1051-0443(96)70791-1
   WARD AS, 1994, J VASC SURG, V19, P503, DOI 10.1016/S0741-5214(94)70078-8
   WU JH, 1995, J CLIN INVEST, V95, P2483, DOI 10.1172/JCI117949
   WU JH, 1994, THROMB HAEMOSTASIS, V72, P105
   ZOLLIKOFER CL, 1995, CARDIOVASC INTER RAD, V18, pS66
NR 35
TC 7
Z9 7
U1 0
U2 3
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0098-6569
J9 CATHETER CARDIO DIAG
JI Catheter. Cardiovasc. Diagn.
PD JAN
PY 1998
VL 43
IS 1
BP 111
EP 119
DI 10.1002/(SICI)1097-0304(199801)43:1<111::AID-CCD32>3.0.CO;2-Q
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA YP911
UT WOS:000071328400032
PM 9473207
DA 2021-08-04
ER

PT J
AU Bachmann, S
   Hellwig, J
   Jackh, R
   Christian, MS
AF Bachmann, S
   Hellwig, J
   Jackh, R
   Christian, MS
TI Uterotrophic assay of two concentrations of migrates from each of 23
   polystyrenes administered orally (by gavage) to immature female Wistar
   rats
SO DRUG AND CHEMICAL TOXICOLOGY
LA English
DT Article
AB The Styrene Steering Committee (SSC) of the European Chemical Industry Council (CEFIC) sponsored this work to address any concern that styrene dimers and trimers that might migrate from polystyrene containers into food could possess some estrogenic activity and thus possibly affect human health. All phases of the study were conducted in conformance with GLP regulations and without knowledge of the oligomer migrates tested. All activities were managed and audited under a third-party contract between the SSC and Argus International.
   Low and high doses of the styrene oligomer migrates of 23 polystyrene samples [i.e. 9 general purpose polystyrenes (GPPS), 8 high impact polystyrenes (HIPS) and 6 expandable polystyrenes (EPS)] were tested for estrogenicity in an in vivo uterotrophic assay (immature female rat model). This model is considered to be the "gold standard" for use in screening for estrogenic effects because it evaluates both direct and indirect potential effects. The two concentrations of migrates of each of the 23 polystyrenes tested were selected to simulate daily human consumption of a low anal high amount of food. Representative dimer and trimer concentrations were obtained in conformance with EEC Council Directives and calculated to be at levels simulating human consumption of 0.5 or 5 kg of food for the GPPS and the HIPS samples and of 0.5 or 3.15 kg of food for the EPS samples, respectively.
   The study was conducted in a series of three blocks. Each block included concurrent untreated control (negative control), vehicle control (25% ethanol, 20 ml/kg/day) and positive control (diethylstilbestral-dipropionate, DES-DP, 5 mu g/kg/day) groups, and low and high doses of each of 7 (1 block) or 8 (2 blocks) polystyrene oligomer migrates. Each group in each black consisted of 10 immature Wistar (Chbb: THOM-SPF)female rats. Beginning when the rats were 22 +/- 1 days of age, each rat was appropriately handled (untreated control group) or administered twice daily oral (gavage) dosages of the vehicle, positive control agent or one of the two doses of the migrates of each polystyrene for 4 consecutive days and then sacrificed at 26 +/- 1 days of age. The uterus of each rat was weighed, and the uterine weight was compared with the terminal body weight.
   The positive control agent (DES-DP, 5 mu g/kg/day) significantly increased both absolute and relative (to terminal body weight) uterine weights, as compared to the untreated and vehicle control group values in each block, demonstrating sensitivity and response of the animals to an estrogenic agent. None of the 23 polystyrene oligomer migrates tested at low and high doses demonstrated biologically important or statistically significant differences from the untreated or vehicle control group values for absolute or relative (to body weight) uterine weights. Based an these data, it is concluded that low and high doses of the 23 polystyrene oligomer migrates tested did not induce an estrogenic response.
C1 Argus Int Inc, Horsham, PA 19044 USA.
   BASF Aktiengesell, Ludwigshafen, Germany.
   Argus Res Labs, Horsham, PA USA.
RP Christian, MS (corresponding author), Argus Int Inc, 933 Horsham Rd, Horsham, PA 19044 USA.
CR Allaben WT, 1996, TOXICOL PATHOL, V24, P776, DOI 10.1177/019262339602400622
   Astwood EB, 1939, AM J PHYSIOL, V126, P162
   CHRISTIAN MS, 1998, DRUG CHEM TOXICOL, V21
   DUNNETT CW, 1955, J AM STAT ASSOC, V50, P1096
   DUNNETT CW, 1964, BIOMETRICS, V20, P482, DOI 10.2307/2528490
   KLARNER P, 1998, DRUG CHEM TOXICOL S1, V21
   Nijenhuis A., 1978, COMBINATORIAL ALGORI, P62
   OConnor JC, 1996, FUND APPL TOXICOL, V33, P182, DOI 10.1006/faat.1996.0156
   Odum J, 1997, REGUL TOXICOL PHARM, V25, P176, DOI 10.1006/rtph.1997.1100
   *ORG ED COOP DEV, 1992, OECD PRINC GOOD LAB, V45
   Prinsen MK., 1996, V96160 TNO
   Reel JR, 1996, FUND APPL TOXICOL, V34, P288, DOI 10.1006/faat.1996.0198
   Stevens JT, 1997, J TOXICOL ENV HEALTH, V50, P415, DOI 10.1080/00984109708983999
   Weisbroth S.H., 1979, LAB ANIMAL, V8, P24
   1979, FED REG         0509, V44, P27354
NR 15
TC 12
Z9 15
U1 1
U2 4
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016 USA
SN 0148-0545
J9 DRUG CHEM TOXICOL
JI Drug Chem. Toxicol.
PY 1998
VL 21
SU 1
BP 1
EP 30
DI 10.3109/01480549809007402
PG 30
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy; Toxicology
SC Chemistry; Pharmacology & Pharmacy; Toxicology
GA 168AN
UT WOS:000078668100003
PM 10028402
DA 2021-08-04
ER

PT J
AU Nasir, A
   McGuire, J
AF Nasir, A
   McGuire, J
TI Sequential and competitive adsorption of bovine serum albumin and
   beta-lactoglobulin, and their resistance to exchange with
   alpha-lactalbumin and beta-casein
SO FOOD HYDROCOLLOIDS
LA English
DT Article
ID AIR-WATER-INTERFACE; SILICA SURFACES; LISTERIA-MONOCYTOGENES; BINARY
   MIXTURE; PROTEINS; LYSOZYME; ADHESION; KINETICS; COADSORPTION
AB The sequential and competitive adsorption of bovine serum albumin (BSA) and beta-lactoglobulin at silanized silica surfaces were investigated using protein radiolabeling and in situ ellipsometry. Simultaneous adsorption of C-14-labeled BSA and beta-lactoglobulin revealed an initial dominance of the surface by beta-lactoglobulin, with subsequent replacement by BSA. In sequential adsorption experiments, where the surface was contacted with C-14-labeled BSA followed by contact with protein-free buffer and addition of beta-lactoglobulin, most of the adsorbed BSA was not removed. The effect of adding alpha-lactalbumin, beta-casein and beta-lactoglobulin to adsorbed BSA, and the effect of adding alpha-lactalbumin, beta-casein and BSA to adsorbed beta-lactoglobulin, were investigated using in situ ellipsometry. beta-Casein was the most effective eluting agent, while alpha-lactalbumin was the least effective. The abilities of alpha-lactalbumin and beta-casein to exchange with adsorbed BSA and beta-lactoglobulin were evaluated with reference to a simple kinetic model for protein adsorption and exchange. The model is based on a mechanism allowing for reversible adsorption followed by either a surface-induced conformational change yielding an irreversibly adsorbed form, or exchange with a dissimilar protein from the solution. Differences in exchange behavior were generally found to be explainable with reference to the rate constant for surface-induced conversion of the adsorbed protein as opposed to that describing exchange of adsorbed protein with a dissimilar protein. This suggests that under these experimental conditions exchange was mediated by a protein-surface interaction, i.e. a displacement mechanism, where protein-protein associations were of minor significance. (C) 1998 Elsevier Science Ltd. All rights reserved.
C1 Oregon State Univ, Dept Bioresource Engn, Corvallis, OR 97331 USA.
   Oregon State Univ, Dept Chem Engn, Corvallis, OR 97331 USA.
   Oregon State Univ, Dept Food Sci & Technol, Corvallis, OR 97331 USA.
   Oregon State Univ, Ctr Gene Res & Biotechnol, Corvallis, OR 97331 USA.
RP McGuire, J (corresponding author), Oregon State Univ, Dept Bioresource Engn, Corvallis, OR 97331 USA.
CR ALMAKHLAFI H, 1995, APPL ENVIRON MICROB, V61, P2013, DOI 10.1128/AEM.61.5.2013-2015.1995
   ALMAKHLAFI H, 1994, APPL ENVIRON MICROB, V60, P3560, DOI 10.1128/AEM.60.10.3560-3565.1994
   ANAND K, 1995, J COLLOID INTERF SCI, V176, P63, DOI 10.1006/jcis.1995.0008
   Anand K, 1996, J AGR FOOD CHEM, V44, P1022, DOI 10.1021/jf950212t
   ANDRADE JD, 1990, CROAT CHEM ACTA, V63, P527
   ARNEBRANT T, 1986, J COLLOID INTERF SCI, V111, P529, DOI 10.1016/0021-9797(86)90055-X
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Brash J. L., 1995, ACS SYM SER, V602, P1
   CAO YH, 1995, J AGR FOOD CHEM, V43, P2567, DOI 10.1021/jf00058a003
   CUYPERS PA, 1983, J BIOL CHEM, V258, P2426
   DALGLEISH DG, 1996, INTERFACIAL PHENOMEN, P447
   DICKINSON E, 1987, FOOD EMULSIONS FOAMS, P40
   Dickinson E, 1988, FOOD HYDROCOLLOID, V2, P397, DOI 10.1016/S0268-005X(88)80004-3
   ELGERSMA AV, 1992, J COLLOID INTERF SCI, V152, P410, DOI 10.1016/0021-9797(92)90043-L
   ELWING H, 1988, J COLLOID INTERF SCI, V123, P306, DOI 10.1016/0021-9797(88)90249-4
   HORBETT TA, 1994, COLLOID SURFACE B, V2, P225, DOI 10.1016/0927-7765(94)80037-5
   HUNTER JR, 1990, J COLLOID INTERF SCI, V137, P462, DOI 10.1016/0021-9797(90)90421-J
   HUNTER JR, 1991, J COLLOID INTERF SCI, V143, P37, DOI 10.1016/0021-9797(91)90435-B
   HUNTER JR, 1991, J COLLOID INTERF SCI, V142, P429, DOI 10.1016/0021-9797(91)90074-I
   JENTOFT N, 1979, J BIOL CHEM, V254, P4359
   KRISDHASIMA V, 1993, J COLLOID INTERF SCI, V161, P325, DOI 10.1006/jcis.1993.1474
   KRISDHASIMA V, 1992, J COLLOID INTERF SCI, V154, P337, DOI 10.1016/0021-9797(92)90148-F
   LUNDSTROM I, 1990, J COLLOID INTERF SCI, V136, P68, DOI 10.1016/0021-9797(90)90079-4
   MEANS G, 1971, CHEM MODIFICATION PR
   NYLANDER T, 1994, J COLLOID INTERF SCI, V162, P151, DOI 10.1006/jcis.1994.1020
   Pethig R., 1979, DIELECTRIC ELECT PRO
   RUZGAS TA, 1992, J COLLOID INTERF SCI, V151, P136, DOI 10.1016/0021-9797(92)90244-G
   SUTTIPRASIT P, 1992, J COLLOID INTERF SCI, V154, P316, DOI 10.1016/0021-9797(92)90146-D
   VANWACHEM PB, 1987, J BIOMED MATER RES, V21, P701, DOI 10.1002/jbm.820210603
   WAHLGREN MC, 1993, J COLLOID INTERF SCI, V158, P46, DOI 10.1006/jcis.1993.1227
NR 30
TC 12
Z9 12
U1 1
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0268-005X
J9 FOOD HYDROCOLLOID
JI Food Hydrocolloids
PD JAN
PY 1998
VL 12
IS 1
BP 95
EP 103
DI 10.1016/S0268-005X(98)00050-2
PG 9
WC Chemistry, Applied; Food Science & Technology
SC Chemistry; Food Science & Technology
GA ZY037
UT WOS:000074580300012
DA 2021-08-04
ER

PT S
AU Huber, SA
   Bulthoff, HH
AF Huber, SA
   Bulthoff, HH
BE Pfeifer, R
   Blumberg, B
   Meyer, JA
   Wilson, SW
TI Simulation and robot implementation of visual orientation behaviors of
   flies
SO FROM ANIMALS TO ANIMATS 5
SE FROM ANIMALS TO ANIMATS SERIES
LA English
DT Proceedings Paper
CT 5th International Conference on Simulation of Adaptive Behavior
CY AUG 17-21, 1998
CL UNIV ZURICH, ZURICH, SWITZERLAND
HO UNIV ZURICH
AB Flies have developed visuomotor programs for tasks like course stabilization, fixation and approach towards stationary objects, tracking of moving objects, and landing, which are based on the analysis of visual motion information. Theoretical and experimental results suggest that the visuomotor control for course stabilization as well as fixation and approach towards stationary objects may be realized at least partially by one common sensory circuit In order to test this hypothesis we designed simulated agents, with a control architecture that is based on results from fly research. We present agents with a visuomotor controller that regulates the two behaviors of course stabilization and object fixation. To test this controller under real world conditions, we implemented it on a miniature robot. We can show that besides course stabilization and object fixation, the robot additionally approaches stationary objects.
C1 Max Planck Inst Biol Kybernet, D-72076 Tubingen, Germany.
RP Huber, SA (corresponding author), Max Planck Inst Biol Kybernet, Spemannstr 38, D-72076 Tubingen, Germany.
RI Bulthoff, Heinrich H/J-6579-2012; Bulthoff, Heinrich/AAC-8818-2019
OI Bulthoff, Heinrich H/0000-0003-2568-0607; 
NR 0
TC 9
Z9 9
U1 0
U2 0
PU M I T PRESS
PI CAMBRIDGE
PA FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA
SN 1089-4365
BN 0-262-66144-6
J9 FROM ANIM ANIMAT
PY 1998
BP 77
EP 85
PG 9
WC Automation & Control Systems; Behavioral Sciences; Computer Science,
   Artificial Intelligence; Multidisciplinary Sciences; Psychology;
   Psychology, Experimental
SC Automation & Control Systems; Behavioral Sciences; Computer Science;
   Science & Technology - Other Topics; Psychology
GA BL45G
UT WOS:000075557600010
DA 2021-08-04
ER

PT S
AU Sharpe, T
   Webb, B
AF Sharpe, T
   Webb, B
BE Pfeifer, R
   Blumberg, B
   Meyer, JA
   Wilson, SW
TI Simulated and situated models of chemical trail following in ants
SO FROM ANIMALS TO ANIMATS 5
SE FROM ANIMALS TO ANIMATS SERIES
LA English
DT Proceedings Paper
CT 5th International Conference on Simulation of Adaptive Behavior
CY AUG 17-21, 1998
CL UNIV ZURICH, ZURICH, SWITZERLAND
HO UNIV ZURICH
AB A simple neural network model for ant chemical trail following is proposed. It performs temporal differencing and comparison to control an osmotropotaxis response. The mechanism was first tested by implementing it in a virtual simulation, and using a genetic algorithm to find appropriate connection strengths. Resulting behavioural measures show strong similarity to data from ants and previous algorithmic models, including: non-linear effects of varying chemical strength; failure to follow trails crossed at large angles; worse trail following at faster speeds and better trail following with longer antennae. In a real-world implementation using chemical sensors on a robot following an alcohol-based trail, it was found necessary to use a somewhat different set of weightings to cope with the inherent unreliability of detecting chemical concentrations. It was still possible to show qualitatively similar behaviour under the same experimental conditions as the simulation model. We argue that these results may illustrate the nature of the agent-environment task space rather than proving the model 'correct'; but that the model nevertheless provides useful pointers to further investigation of this biological system.
C1 Univ Nottingham, Dept Psychol, Nottingham NG7 2RD, England.
RP Sharpe, T (corresponding author), Univ Nottingham, Dept Psychol, Nottingham NG7 2RD, England.
NR 0
TC 11
Z9 11
U1 0
U2 2
PU M I T PRESS
PI CAMBRIDGE
PA FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA
SN 1089-4365
BN 0-262-66144-6
J9 FROM ANIM ANIMAT
PY 1998
BP 195
EP 204
PG 10
WC Automation & Control Systems; Behavioral Sciences; Computer Science,
   Artificial Intelligence; Multidisciplinary Sciences; Psychology;
   Psychology, Experimental
SC Automation & Control Systems; Behavioral Sciences; Computer Science;
   Science & Technology - Other Topics; Psychology
GA BL45G
UT WOS:000075557600026
DA 2021-08-04
ER

PT S
AU Gadanho, SC
   Hallam, J
AF Gadanho, SC
   Hallam, J
BE Pfeifer, R
   Blumberg, B
   Meyer, JA
   Wilson, SW
TI Emotion-driven learning for animat control
SO FROM ANIMALS TO ANIMATS 5
SE FROM ANIMALS TO ANIMATS SERIES
LA English
DT Proceedings Paper
CT 5th International Conference on Simulation of Adaptive Behavior
CY AUG 17-21, 1998
CL UNIV ZURICH, ZURICH, SWITZERLAND
HO UNIV ZURICH
AB Models of emotion are often suggested as a way of providing an evaluation of the current behaviour of an agent. In this work, we investigate whether emotions can actually provide suitable reinforcement signals for a Q-learning system to learn adaptive policies. For this purpose a recurrent network model of emotion consistent with the somatic somatic marker hypothesis of Damasio was developed. Experimental work was done in a realistic mobile robot simulator in a simple foraging-like task. Experiments revealed that having emotions providing a context evaluation for direct use as a reinforcement signal does not work, but using them as modifiers for learning system parameters could be fruitful.
C1 Univ Edinburgh, Dept Artificial Intelligence, Edinburgh EH1 2QL, Midlothian, Scotland.
RP Gadanho, SC (corresponding author), Univ Edinburgh, Dept Artificial Intelligence, 5 Forest Hill, Edinburgh EH1 2QL, Midlothian, Scotland.
NR 0
TC 3
Z9 3
U1 0
U2 0
PU M I T PRESS
PI CAMBRIDGE
PA FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA
SN 1089-4365
BN 0-262-66144-6
J9 FROM ANIM ANIMAT
PY 1998
BP 354
EP 359
PG 6
WC Automation & Control Systems; Behavioral Sciences; Computer Science,
   Artificial Intelligence; Multidisciplinary Sciences; Psychology;
   Psychology, Experimental
SC Automation & Control Systems; Behavioral Sciences; Computer Science;
   Science & Technology - Other Topics; Psychology
GA BL45G
UT WOS:000075557600047
DA 2021-08-04
ER

PT S
AU Cliff, D
   Bruten, J
AF Cliff, D
   Bruten, J
BE Pfeifer, R
   Blumberg, B
   Meyer, JA
   Wilson, SW
TI Market trading interactions as collective adaptive behavior
SO FROM ANIMALS TO ANIMATS 5
SE FROM ANIMALS TO ANIMATS SERIES
LA English
DT Proceedings Paper
CT 5th International Conference on Simulation of Adaptive Behavior
CY AUG 17-21, 1998
CL UNIV ZURICH, ZURICH, SWITZERLAND
HO UNIV ZURICH
AB We argue that human economic interactions, particularly bargaining and trading in market environments, can be considered as adaptive behaviors. Moreover, the tools and techniques of adaptive behavior research could be profitably employed to build predictive models of existing or planned market systems. In addition to applications in economic modeling, "trading animals" could find use in market-based resource-allocation and control, and in internet-based commerce. After a brief overview of core concepts in experimental economics (where human trading behavior is studied under laboratory conditions), we propose that such experiments could and should be used as 'benchmarks' for evaluating and comparing different architectures and strategies for trading animats. We then present empirical results from simulations that invite a Braitenberg-style eliminative materialism perspective on the dynamics of experimental retail markets. In these experiments, an elementary machine learning technique endows simple software animats with the capability to adapt while interacting via price-bargaining in market environments. The environments are based on artificial retail markets used in experimental economics research. We demonstrate that groups of simple agents can exhibit human-like collective market behaviors, and discuss the implications.
C1 MIT, Artificial Intelligence Lab, Cambridge, MA 02139 USA.
RP Cliff, D (corresponding author), MIT, Artificial Intelligence Lab, Cambridge, MA 02139 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU M I T PRESS
PI CAMBRIDGE
PA FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA
SN 1089-4365
BN 0-262-66144-6
J9 FROM ANIM ANIMAT
PY 1998
BP 417
EP 426
PG 10
WC Automation & Control Systems; Behavioral Sciences; Computer Science,
   Artificial Intelligence; Multidisciplinary Sciences; Psychology;
   Psychology, Experimental
SC Automation & Control Systems; Behavioral Sciences; Computer Science;
   Science & Technology - Other Topics; Psychology
GA BL45G
UT WOS:000075557600055
DA 2021-08-04
ER

PT B
AU Bakam, I
   Takforyan, A
   Proton, H
   Bousquet, F
   Weber, J
AF Bakam, I
   Takforyan, A
   Proton, H
   Bousquet, F
   Weber, J
BE Tachker, Y
TI Spatial-temporal simulations of interactions between hunters and
   resources by means of a Multi-Agent System (MAS): A case of hunting in
   East-Cameroun
SO GIBIER FANE SAUVAGE - GAME AND WILDLIFE, VOL 15 (SPECIAL NUMBER PTS 2
   AND 3) 1998
LA French
DT Proceedings Paper
CT IUGB XXIIIrd Congress
CY SEP 01-06, 1997
CL LYON, FRANCE
SP Int Union Game Biologists, Conseil Reg Rhone Alpes, Conseil Gen Rhone, Conseil Gen Ain, Rhone Poulec Agro France, Rhone Merieux, Bayer, Novartis, Force Limagrain, Jouffray Drillaud, Conseil Int Chasse, Fdn Int Sauvegarde Faune, Federat Assoc Chasseurs Union Europeenne, Union Natl Federat Dept Chasseurs, Federat Interdepartementale Chasseurs Paris HSV, Federat Departementale chasseurs Rhone, Federat Departementale Chasseurs Ain, Union Industries Protect Plantes, Union Nationale cooperat Agricoled Approvisionnement, Credit Agricole, Fdn Pierre Verots, Air Inter, Renault, Dist Inject
DE blue duiker; Cephalophus monticola; model; simulation; Multi Agent
   System; GIS; hunting; resource economics
AB Multi Agent Systems (MAS) offer powerful as well as congenial tools for interaction simulations between the dynamics of resources and hunter behaviours. Based on the data collected for a Ph.D., we built a spatio-temporal simulation the purpose of which is to suggest the usefulness of such modelling approaches to obtain a spatial simulation of a scientific set of hypotheses over time; and to observe changes in both resources and social behaviours in interactions. The case study relates to the exploitation of the blue duiker, Cephalophus monticol, in an Eastern Cameroon village. Combining Geographical Information Systems (GIS) and MAS it is possible to observe the seasonal evolution of the resources and the hunters on a moving map. The purpose of the communication is to inform the participants of the existence and availability of such tools and receive their comments for improvement.
C1 Univ Yaounde, Yaounde, Cameroon.
RP Bakam, I (corresponding author), Univ Yaounde, Yaounde, Cameroon.
RI Bousquet, Francois/Y-7904-2019; Bousquet, Francois/G-3605-2010
OI Bousquet, Francois/0000-0002-4552-3724; 
CR BAURINI R, 1993, BASES DONNEES GEOMAT
   BOUSQUET F, 1994, THESIS ORSTOM
   BOUSQUET F, 1996, ACT C EC SOC EC QUEL
   DUBOST G, 1980, J COMP ETHOLOGY
   Ferber J, 1995, SYSTEMES MULTI AGENT
   GREEN, 1997, ETUDE EC ECOSYSTEME, V1
   TAKFORYAN A, 1996, GESTION LOCALE FAUNE
   Weber J., 1996, C PAN GEST COMM RESS
NR 8
TC 0
Z9 0
U1 0
U2 1
PU OFFICE NATIONAL CHASSE
PI PARIS
PA 85 BIS, AVENUE WAGRAM, PARIS, FRANCE
PY 1998
BP 1111
EP 1120
PG 10
WC Ecology; Forestry; Zoology
SC Environmental Sciences & Ecology; Forestry; Zoology
GA BM94Z
UT WOS:000080237300082
DA 2021-08-04
ER

PT B
AU Armstrong, AA
   Durfee, EH
AF Armstrong, AA
   Durfee, EH
GP IEEE
TI Mixing and memory: Emergent cooperation in an information marketplace
SO INTERNATIONAL CONFERENCE ON MULTI-AGENT SYSTEMS, PROCEEDINGS
LA English
DT Proceedings Paper
CT 3rd International Conference on Multi-Agent Systems (ICMAS'98)
CY JUL 03-07, 1998
CL PARIS, FRANCE
AB An information marketplace consists of a group of agents buying and selling information content and services. Self-interested agents may find it rational to cheat others in the market. We have modeled federations of digital libraries selling information to one another. In our model, cooperation emerges through endogenous incentives. We had hypothesized that a number of factors would encourage cooperation. greater familiarity with trading partners, more memory for modeling others, fewer initially misbehaving agents, lower rates of strategy exploration, smaller world sizes, and more rapidly evolving measures of the likelihood of other agents to cooperate. Our simulations confirmed many of our hypotheses. However; the benefits of a small world size are dependent on memory size, and the usefulness of rapidly evolving estimates of cooperation is dependent on the types of strategies employed by the agents. We suggest that it will become increasingly important to allow agents conceptually to carve their networked environment into subcommunities where familiarity and trust can emerge, as opposed to promoting indiscriminate interactions within a large society of digital agents.
C1 Univ Michigan, Artificial Intelligence Lab, Ann Arbor, MI 48109 USA.
RP Armstrong, AA (corresponding author), Univ Michigan, Artificial Intelligence Lab, Ann Arbor, MI 48109 USA.
RI Durfee, Edmund/AAG-8185-2019
NR 0
TC 3
Z9 3
U1 0
U2 0
PU IEEE COMPUTER SOC
PI LOS ALAMITOS
PA 10662 LOS VAQUEROS CIRCLE, PO BOX 3014, LOS ALAMITOS, CA 90720-1264 USA
BN 0-8186-8500-X
PY 1998
BP 34
EP 41
DI 10.1109/ICMAS.1998.699029
PG 8
WC Computer Science, Artificial Intelligence; Computer Science, Software
   Engineering; Computer Science, Theory & Methods
SC Computer Science
GA BL32K
UT WOS:000075130800010
DA 2021-08-04
ER

PT J
AU Van der Bruggen, B
   Vogels, G
   Van Herck, P
   Vandecasteele, C
AF Van der Bruggen, B
   Vogels, G
   Van Herck, P
   Vandecasteele, C
TI Simulation of acid washing of municipal solid waste incineration fly
   ashes in order to remove heavy metals
SO JOURNAL OF HAZARDOUS MATERIALS
LA English
DT Article
DE heavy metals; leaching; fly ash; modelling; MINTEQA2
ID BEHAVIOR
AB Fly ash from municipal waste incinerators constitutes an environmental problem, as it is polluted with heavy metals. By extracting the heavy metals from fly ashes with an acid solution, they can be partly removed and possibly recovered. The remaining fly ash can be landfilled or used as construction material. In this paper, the results of experimental leaching tests of fly ash are compared with computer calculations of the thermodynamic equilibrium of the leaching solution - fly ash system. The computer program MINTEQA2, used for this purpose, allows to predict the metal concentrations in the leaching solution, the minerals that precipitate, and the pH of the leaching solution at equilibrium. A calculation approach was chosen, whereby the simulation of the complex leaching process was divided into five subproblems. A leaching diagram with linear scales was introduced to visualise the equilibria as a function of pH. The computer simulation was used in two applications: calculation of the impact of addition of a complexing agent on the leaching behaviour of lead, and optimisation of the volume of liquid to be used in the leaching process for a given amount of fly ash. (C) 1998 Elsevier Science B.V.
C1 Univ Leuven, Dept Chem Engn, B-3001 Heverlee, Belgium.
RP Van der Bruggen, B (corresponding author), Univ Leuven, Dept Chem Engn, De Croylaan 46, B-3001 Heverlee, Belgium.
RI Van der Bruggen, Bart/AAR-3676-2020
CR Allison J.D., 1991, MINTEQA2 PRODEFA2 GE
   CLESCERI LS, 1989, STANDARD METHODS EXA, P177
   COMANS RNJ, 1994, P INT C ENV IMPL CON, P103
   DERIE R, 1993, STRUCT REACTIVITE CH, V10, P1091
   EIGHMY TT, 1995, ENVIRON SCI TECHNOL, V29, P629, DOI 10.1021/es00003a010
   FELMY AR, 1994, 600384032 US EPA
   GONG Y, 1994, J HAZARD MATER, V36, P249, DOI 10.1016/0304-3894(94)85018-6
   *INT ASH WORK GROU, 1994, INT PERSP CHAR MAN R
   KIRBY CS, 1993, ENVIRON SCI TECHNOL, V27, P652, DOI 10.1021/es00041a008
   Knacke O, 1991, THERMOCHEMICAL PROPE
   Mulder E, 1996, WASTE MANAGE, V16, P181, DOI 10.1016/S0956-053X(96)00040-2
   SENELLE R, 1995, VLAREM 2
   *US EPA, MINTEQA2 VERS 3 11
   VANDERHOEK EE, 1994, P INT C ENV IMPL CON, P467
   VANHERCK P, 1995, P SOL WAST MAN THERM, P723
   VEHLOW J, 1990, WASTE MANAGE RES, V8, P461, DOI 10.1177/0734242X9000800172
   WILLE D, 1996, INVENTARISATIE HUISH
NR 17
TC 49
Z9 50
U1 1
U2 23
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-3894
J9 J HAZARD MATER
JI J. Hazard. Mater.
PD JAN
PY 1998
VL 57
IS 1-3
BP 127
EP 144
DI 10.1016/S0304-3894(97)00078-2
PG 18
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA ZB365
UT WOS:000072464400009
DA 2021-08-04
ER

PT S
AU Webster, C
AF Webster, C
BE Cesnik, B
   McCray, AT
   Scherrer, JR
TI Medical affective computing: Medical informatics meets affective
   computing
SO MEDINFO '98 - 9TH WORLD CONGRESS ON MEDICAL INFORMATICS, PTS 1 AND 2
SE STUDIES IN HEALTH TECHNOLOGY AND INFORMATICS
LA English
DT Proceedings Paper
CT 9th World Congress on Medical Informatics: Global Health Networking - A
   Vision for the Next Millennium (MEDINFO 98)
CY 1998
CL SEOUL, SOUTH KOREA
SP Int Med Informat Assoc
DE affective computing; medical informatics; depression; psychiatry;
   neurology; simulation
AB From advisory systems that understand emotional attitudes toward medical outcomes, to wearable computers that compensate for communication disability to computer simulations of emotions and their disorders, the research agendas of medical informatics and affective computing-how and why to create computers that detect convey, and even have emotions-increasingly overlap. Same psychiatric and neurological researchers slate their theories in terms of actual or hypothetical computer programs. Adaptive intelligent systems will increasingly rely on emotions to compensate for their own conflicting goals and limited resources-emotional reactions about which psychiatrists and neurologists have special insights. DEP2 (Depression Emulation Program 2) is a computer simulation of adaptive depression-learning from explainable patterns of failure in autobiographical memory-that simulates many depressive behaviors. In the terminology of fault-tolerant computing adaptive depression involves fault detection (triggered by failure), fault location (strategic retreat and failure diagnosis), and fault recovery (return to on-line operation). DEP2 relies on subsystems whose structures and behaviors are based on popular hypotheses about left and right brain hemispheric function during depression and emotion. DEP2 and its predecessors, DEP and DEPlanner, are relevant to psychiatric and neurological informatics, and to the design of adaptive autonomous robots and software agents.
C1 Duquesne Univ, Dept Hlth Management Syst, Pittsburgh, PA 15282 USA.
RP Webster, C (corresponding author), Duquesne Univ, Dept Hlth Management Syst, Pittsburgh, PA 15282 USA.
NR 0
TC 1
Z9 1
U1 0
U2 4
PU I O S PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 0926-9630
BN 90-5199-407-9
J9 ST HEAL T
PY 1998
VL 52
BP 1209
EP 1212
PG 4
WC Medical Informatics
SC Medical Informatics
GA BM09G
UT WOS:000077613500237
PM 10384652
DA 2021-08-04
ER

PT S
AU Rouchier, J
   Bousquet, F
AF Rouchier, J
   Bousquet, F
BE Sichman, JS
   Conte, R
   Gilert, N
TI Non-merchant economy and multi-agent system: An analysis of structuring
   exchanges
SO MULTI-AGENT SYSTEMS AND AGENT-BASED SIMULATION
SE Lecture Notes in Artificial Intelligence
LA English
DT Article; Proceedings Paper
CT 1st Workshop on Multi-Agent Systems and Agent-Base Simulation
CY JUL 04-06, 1998
CL PARIS, FRANCE
SP SimSoc
AB The hypothesis is that the exchanges of goods structure the society, and especially the non-merchant exchanges. Their aim is to express unselfishness, but also to generate a moral debt that builds strong reciprocal links. A multi-agent system was built with 100 agents and a resource, the interactions being only gifts. For the simulations, the agents have different rules to perform gifts and to organize their memory. The results are analyzed by the agent as well as by the modeller, with different points of view: either local or global and with different time length.
C1 CIRAD, TERA, F-34032 Montpellier, France.
RP Rouchier, J (corresponding author), CIRAD, TERA, Campus de Baillarguet,BP 5035, F-34032 Montpellier, France.
EM rouchier@cirad.fr; bousquet@cirad.fr
RI Bousquet, Francois/G-3605-2010; Bousquet, Francois/Y-7904-2019
OI Bousquet, Francois/0000-0002-4552-3724
CR BOAS F, 1966, KWAKIUTL ETHNOGRAPHY
   BOUSQUET F, 1998, LECT NOTES ARTIF INT, V1416, P826, DOI DOI 10.1007/3-540-64574-8
   DORAN J, 1994, MEMOIRE COLLECTIVE D
   DROGOUL A, 1994, MEMOIRE COLLECTIVE S
   Epstein J.M., 1996, GROWING ARTIFICIAL S
   FERBER J, 1996, COOPERATION INTENTIO
   FERBER J, 1994, KENETIQUE SYSTEMS MU, V8
   GILBERT N, 1993, EMERGENCE SOCIAL SIM
   GODELIER M, 1996, ENIGME
   LAHIRE B, 1992, PRECISIONS MANIERE S, V59
   MAUSS M, 1968, SOCIOLOGIE ANTRO
   WEBER J, 1985, REV MAUSS, V13
   WELLMAN B, 1996, DUMPTARIAN RECONSIDE, V18
NR 13
TC 4
Z9 4
U1 0
U2 1
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 0302-9743
EI 1611-3349
BN 3-540-65476-3
J9 LECT NOTES ARTIF INT
PY 1998
VL 1534
BP 111
EP 123
PG 13
WC Computer Science, Artificial Intelligence
SC Computer Science
GA BN94Y
UT WOS:000083636800008
DA 2021-08-04
ER

PT S
AU Garrido, L
   Brena, R
   Sycara, K
AF Garrido, L
   Brena, R
   Sycara, K
BE Sichman, JS
   Conte, R
   Gilert, N
TI Towards modeling other agents: A simulation-based study
SO MULTI-AGENT SYSTEMS AND AGENT-BASED SIMULATION
SE LECTURE NOTES IN ARTIFICIAL INTELLIGENCE
LA English
DT Article; Proceedings Paper
CT 1st Workshop on Mult-Agent Systems and Agent-Base Simulation
CY JUL 04-06, 1998
CL PARIS, FRANCE
SP SimSoc
AB In this paper, we present some of our ongoing experimental research towards investigating advantages of modeling other agents in multiagent environments. We attempt to quantify the value or utility of building models about other agents using no more than the observation of others' behavior. We are interested in empirically showing that a modeler agent can take advantage of building and updating its beliefs about other agents. This advantage can make it perform better than an agent without modeling capabilities. We have been conducting a simulataion-based study using a competitive game called Meeting Scheduling Game as a testbed. First, we briefly describe our multiagent simultaion testbed. Then, we describe in detail our experimental study. We explore a range of strategies from least- to most-informed, and present some of our preliminary results on the relative performance of these strategies. Decreasing the a priori knowledge about the others and increasing the modeling capabilities we are able to define a series of "modeler" agents. Finally, we present a method for using probabilistic models about the others in such a way that the expected utility is maximized.
C1 Ctr Inteligencia Artificial Tecnol Monterrey, Monterrey 64849, Nuevo Leon, Mexico.
   Carnegie Mellon Univ, Inst Robot, Pittsburgh, PA 15213 USA.
RP Garrido, L (corresponding author), Ctr Inteligencia Artificial Tecnol Monterrey, Monterrey 64849, Nuevo Leon, Mexico.
RI Brena, Ramon/D-4294-2009; Garrido, Leonardo/R-1173-2019
OI Brena, Ramon/0000-0002-0995-2273; Garrido, Leonardo/0000-0002-0951-2358
CR BRENA R, 1996, CIARI026 ITESM CAMP
   CARMEL D, 1996, LECT NOTE AI, V1042
   DAVIS R, 1983, ARTIF INTELL, V20, P63, DOI 10.1016/0004-3702(83)90015-2
   DECKER K, 1996, AAAI 9L WORKSH AG MO
   GARRIDO L, 1996, 2 INT C MULT SYST, P95
   GARRIDO L, 1996, 1 IB WORKSH DISTR AR, P55
   GARRIDO L, 1998, UNPUB M SCHEDULING G
   GMYTRASIEWICZ PJ, 1996, LECT NOTES ARTIFICIA, V1037
   KAUTZ A, 1985, P NAT C ART INT, P32
   MOR Y, 1996, LECT NOTE AI, V1042
   NADELLA R, 1997, LECT NOTES ARTIF INT, P137
   PETRIE CJ, 1996, IEEE EXPERT      DEC
   RAO AS, 1991, 12 INT JOINT C ART I
   ROSENSCHEIN JS, 1988, 9 INT JOINT C ART IN
   ROSENSCHEIN JS, 1994, ARTIFICIAL INTELLIGE
   SICHMAN J, 1992, 11 EUR C ART INT ECA, P188
   *STANF U CTR DES R, JATL JAV AG TEMPL LI
   STONE CJ, 1996, COURSE PROBABILITY S
   *SUN MICR INC, SOURC JAV TECHN
   TAMBE M, 1996, LNAI, V1037
   VIDAL J, 1996, LNAI, V1037
   ZENG D, 1997, 14 NAT C AI, P36
NR 22
TC 3
Z9 3
U1 0
U2 1
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 0302-9743
BN 3-540-65476-3
J9 LECT NOTES ARTIF INT
PY 1998
VL 1534
BP 210
EP 225
PG 16
WC Computer Science, Artificial Intelligence
SC Computer Science
GA BN94Y
UT WOS:000083636800015
DA 2021-08-04
ER

PT B
AU Gonzalez, M
   Uriarte, A
   Motos, L
   Borja, A
   Uriarte, A
AF Gonzalez, M
   Uriarte, A
   Motos, L
   Borja, A
   Uriarte, A
GP IEEE
   IEEE
TI Validation of a numerical model for the study of anchovy recruitment in
   the Bay of Biscay
SO OCEANS'98 - CONFERENCE PROCEEDINGS, VOLS 1-3
LA English
DT Proceedings Paper
CT IEEE OCEANS Conference and Exhibition on Engineering for Sustainable Use
   of the Oceans (OCEANS 98)
CY SEP 28-OCT 01, 1998
CL NICE, FRANCE
SP IEEE, IEEE Ocean Engn Soc
AB Some responses of the sea to the forcing agents actuating on it can be represented as differential equations in partial derivatives Equations most frequently used to describe sea currents are the Shallow Water Equations (SWE). These SWE are derived from the equations for the conservation of momentum and continuity making the assumptions that the pressure distribution is hydrostatic and that the terms referring to the vertical velocity are negligible.
   Unfortunately, the analytical resolution of the SWE is impossible and requires of the use of numerical approximation algorithms The method herein used for the calculation of currents induced by the wind and by the astronomical tide in the area of the Bay of Biscay is the quasi-3D approximation using Finite Elements.
   Anchovy is a species of high economic interest for the Basque Country's fleet. Eggs and larvae of this species behave as passive particles and are drifted around close to the surface (first 50m) by sea currents The behaviour of these particles can be represented by means of the general convection/diffusion equation, and by adding a source-decay term, the mortality of larvae can be represented The Taylor-Galerkin technique adequate for problems in which convection dominates, allows the application of the Finite Element method to solve the dispersion in the marine environment
   In this paper the preliminary results are presented concerning the numerical simulation of the drifting process of anchovy eggs and larvae from spawning areas, towards areas where they are fished Results will be compared with survey data.
C1 AZTI Fundazioa, Inst Tecnol Pesquero & Alimentario, San Sebastian 20008, Gipuzkoa, Spain.
RP Gonzalez, M (corresponding author), AZTI Fundazioa, Inst Tecnol Pesquero & Alimentario, Av Satrustegui, San Sebastian 20008, Gipuzkoa, Spain.
RI Motos, Lorenzo/C-5496-2008; Uriarte, Ainhize/AAF-5750-2021; Borja,
   Angel/I-3665-2018
OI Motos, Lorenzo/0000-0002-4858-3618; Uriarte,
   Ainhize/0000-0002-9596-6451; Borja, Angel/0000-0003-1601-2025
CR DONNEA J, 1985, INT J NUMER METH ENG, V20, P817
   ESPINO M, 1994, THESIS U POLITECNICA
   FORTIN M, 1985, COMMUN APPL NUMER M, V1, P205, DOI 10.1002/cnm.1630010504
   GODIN G, 1991, TIDES
   GONZALEZ M, 1994, THESIS U POLIECNICA
   HERMOSILLA F, 1996, THESIS U POLIECNICA
   *I HIDR ARM, 1992, AN MAR
   Peraire J., 1986, THESIS
   WALTERS RA, 1986, COMMUN APPL NUMER M, V2, P393, DOI 10.1002/cnm.1630020410
   ZIENKIEWICZ OC, 1979, COMPUT METHOD APPL M, V17-8, P673, DOI 10.1016/0045-7825(79)90050-1
NR 10
TC 0
Z9 0
U1 0
U2 1
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
BN 0-7803-5045-6
PY 1998
BP 1313
EP 1318
PG 6
WC Acoustics; Engineering, Marine; Engineering, Electrical & Electronic;
   Instruments & Instrumentation
SC Acoustics; Engineering; Instruments & Instrumentation
GA BM30T
UT WOS:000078340800261
DA 2021-08-04
ER

PT S
AU Stein, RM
   Bernard, RN
AF Stein, RM
   Bernard, RN
GP IEEE
TI Data mining the future: Genetic discovery of good trading rules in
   agent-based financial market simulations
SO PROCEEDINGS OF THE IEEE/IAFE/INFORMS 1998 CONFERENCE ON COMPUTATIONAL
   INTELLIGENCE FOR FINANCIAL ENGINEERING (CIFER)
SE IEEE Conference on Computational Intelligence for Financial Engineering
   and Economics CIFEr
LA English
DT Proceedings Paper
CT IEEE/IAFE/INFORMS 1998 Conference on Computational Intelligence for
   Financial Engineering (CIFE)
CY MAR 29-31, 1998
CL NEW YORK, NY
SP IEEE, Int Assoc Financial Engineers, Inst Operat Res & Management Sci
AB The field of agent-based simulation of financial markets has grown considerably in the last decade. However, the interpretation of simulation results has received far less attention. Typically, the output of a large number of simulations is reduced to one or two summary statistics, such as sample moments. While such summarization is useful, it overlooks a vast amount of additional information that might be revealed by examining patterns of behavior that emerge at lower levels. In this paper, we propose an approach to interpreting simulation results that involves the use of so-called data mining techniques to identify the rules of behavior that govern computer simulations of a complex systems. We demonstrate the approach by analyzing data from runs of two different agent-based financial market simulations. In each case we derive rules that describe characteristics of the underlying structure of the simulated markets. In one case we are able to recover evidence of known dynamics of the simulation, and in the second case we find evidence of emergent behavior not explicitly a part of the simulation design.
C1 NYU, Dept Informat Syst, Leonard N Stern Sch Business, New York, NY 10007 USA.
RP Stein, RM (corresponding author), NYU, Dept Informat Syst, Leonard N Stern Sch Business, 99 Church St, New York, NY 10007 USA.
EM rstein@stern.nyu.edu; minusone@walrus.com
NR 0
TC 1
Z9 1
U1 0
U2 3
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
SN 2380-8454
EI 2640-7701
BN 0-7803-4930-X
J9 IEEE C COMP INTEL FI
PY 1998
BP 171
EP 179
DI 10.1109/CIFER.1998.690081
PG 9
WC Business, Finance; Computer Science, Interdisciplinary Applications;
   Engineering, Electrical & Electronic; Operations Research & Management
   Science
SC Business & Economics; Computer Science; Engineering; Operations Research
   & Management Science
GA BL23K
UT WOS:000074777000011
DA 2021-08-04
ER

PT J
AU Cekic, O
   Batman, C
   Yasar, U
   Basci, NE
   Bozkurt, A
   Kayaalp, O
AF Cekic, O
   Batman, C
   Yasar, U
   Basci, NE
   Bozkurt, A
   Kayaalp, O
TI Penetration of ofloxacin in human aqueous and vitreous humors following
   oral and topical administration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE aqueous humor; ofloxacin; oral; topical; vitreous humor
ID APPLIED CIPROFLOXACIN; ANTIMICROBIAL AGENTS; INVITRO ACTIVITY;
   NORFLOXACIN
AB Purpose: To determine aqueous and vitreous humor ofloxacin levels following oral and topical application of ofloxacin in patients with noninflamed cornea and intact crystalline lens, and to compare the drug levels provided by each route.
   Materials and Methods: Twenty-six patients undergoing pars plana vitrectomy for various ocular pathologies were divided into two groups. Fourteen patients received two drops of 0.3% ophthalmic solution of ofloxacin every 30 minutes for 3 hours and every 60 minutes for the next 3 hours, and 12 patients received a single oral dose of 400 mg ofloxacin 8 hours before surgery. The aqueous and vitreous humor samples were simultaneously collected after oral or topical administration during pars plana vitrectomy to assess penetration of the drug. Samples were assayed for ofloxacin concentrations by a previously described method using high-performance liquid chromatography.
   Results: The aqueous and vitreous humor levels of ofloxacin were 1.54 +/- 0.27 mu g/mL (mean +/- standard error) and 1.77 +/- 0.24 mu g/mL after oral and 1.44 +/- 0.24 mu g/mL and 0.37 +/- 0.05 mu g/mL after topical ofloxacin administration, respectively. Aqueous humor levels were not statistically different following oral or topical administration (P > 0.8). However, vitreous level of the drug after oral administration was significantly higher than that after topical administration (P < 0.001).
   Conclusion: Ocular bioavailability of ofloxacin in aqueous humor after oral and topical administration is similar when the drug is applied as described. Penetration of ofloxacin into vitreous humor is less than that into aqueous humor following topical application. The aqueous humor levels of ofloxacin via both routes and the Vitreous level of the drug after oral route exceed the minimum inhibitory concentrations for certain bacterial species that frequently cause intraocular infection.
C1 SSK Ankara Eye Hosp, Dept Vitreoretinal Surg, Ankara, Turkey.
   Univ Hacettepe, Fac Med, Dept Pharmacol, TR-06100 Ankara, Turkey.
RP Cekic, O (corresponding author), Basak Sokak,54-7, TR-06660 Ankara, Turkey.
RI Bozkurt, Atilla/A-7963-2010; Yasar, Umit/A-1602-2008; Cekic,
   Osman/H-3027-2019
OI Bozkurt, Atilla/0000-0001-8146-5296; Yasar, Umit/0000-0001-6758-0335;
   Cekic, Osman/0000-0003-0911-8649
CR Akkan AG, 1997, J CHEMOTHERAPY, V9, P257, DOI 10.1179/joc.1997.9.4.257
   Basci NE, 1997, J PHARMACEUT BIOMED, V15, P663, DOI 10.1016/S0731-7085(96)01889-4
   BORRMANN L, 1992, CORNEA, V11, P226
   Bouchard CS, 1996, CORNEA, V15, P72
   DONNENFELD ED, 1994, OPHTHALMOLOGY, V101, P902
   Donnenfeld ED, 1997, ARCH OPHTHALMOL-CHIC, V115, P173, DOI 10.1001/archopht.1997.01100150175004
   DURMAZ B, 1997, DRUG RES, V4, P413
   Fiscella RG, 1997, RETINA-J RET VIT DIS, V17, P535
   Fitton A, 1992, Clin Pharmacokinet, V22 Suppl 1, P1
   JUST PM, 1993, PHARMACOTHERAPY S2, V13, P4
   KUMADA T, 1985, J ANTIMICROB CHEMOTH, V16, P563, DOI 10.1093/jac/16.5.563
   MATSUMOTO SS, 1993, DRUG INVEST, V6, P96, DOI 10.1007/BF03258459
   MATSUMURA K, 1991, FOLIA OPHTHALMOL JPN, V42, P662
   MITSUI Y, 1986, Folia Ophthalmologica Japonica, V37, P1115
   OSATO MS, 1989, AM J OPHTHALMOL, V108, P380, DOI 10.1016/S0002-9394(14)73305-7
   ROSS DL, 1990, INT J PHARM, V63, P237, DOI 10.1016/0378-5173(90)90130-V
   TODD PA, 1991, DRUGS, V42, P825, DOI 10.2165/00003495-199142050-00008
   Verbraeken H, 1996, GRAEF ARCH CLIN EXP, V234, pS59, DOI 10.1007/BF02343049
   WOLFSON JS, 1985, ANTIMICROB AGENTS CH, V28, P581, DOI 10.1128/AAC.28.4.581
NR 19
TC 27
Z9 27
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PY 1998
VL 18
IS 6
BP 521
EP 525
DI 10.1097/00006982-199806000-00005
PG 5
WC Ophthalmology
SC Ophthalmology
GA 147MU
UT WOS:000077571900005
PM 9869460
DA 2021-08-04
ER

PT J
AU Chiarizia, R
   Horwitz, EP
   Beauvais, RA
   Alexandratos, SD
AF Chiarizia, R
   Horwitz, EP
   Beauvais, RA
   Alexandratos, SD
TI Diphonix-CS: A novel combined cesium and strontium selective ion
   exchange resin
SO SOLVENT EXTRACTION AND ION EXCHANGE
LA English
DT Article
ID METAL-IONS
AB The recently developed Diphonix(R) resin contains the geminally substituted diphosphonic acid ligand chemically bonded to a styrene-divinylbenzene copolymer. The resin exhibits an extraordinarily strong affinity for actinides, especially in the tetra-and hexavalent oxidation states. Therefore the resin has potential for application in TRU removal from nuclear wastes. The Diphonix-CS resin is a Diphonix-type resin that contains also phenolic groups chemically attached to the polymeric matrix. The phenolic groups exhibit high affinity for Cs' ions from highly alkaline media. Thanks to the combined action of the diphosphonic acid and the phenolic groups, the Diphonix-CS resin can simultaneously remove actinide species, Cs and Sr from alkaline media. In this paper the results obtained in the characterization of the new resin are reported, with regard to the uptake equilibrium and kinetics of Cs+ and Sr+2 removal from NaOH solutions and from synthetic alkaline wastes. The chemical and radiolytic stability of the resin has been investigated. The results have indicated that the Diphonix-CS resin is remarkably stable under the experimental conditions of this work (up to 35 days in 1 to 4 M NaOH, and up to 200 MRad gamma ray absorbed dose). The possibility of stripping the Cs+ and Sr+2 from the resin has been investigated in column experiments by using 1 M HNO3 as the stripping agent. Some problems encountered in the stripping of Sr+2 and possible ways to improve the stripping performance are discussed.
C1 Argonne Natl Lab, Div Chem, Argonne, IL 60439 USA.
   Univ Tennessee, Dept Chem, Knoxville, TN 37996 USA.
RP Chiarizia, R (corresponding author), Argonne Natl Lab, Div Chem, 9700 S Cass Ave, Argonne, IL 60439 USA.
CR ALEXANDRATOS SD, 1977, UNPUB J POLYM SCI
   BIBLER JP, 1990, WASTE MANAGE, V2, P747
   BIBLER JP, 1987, DPST87847 SAV RIV LA
   BORTUM AI, 1997, IN PRESS SOLVENT EXT, V15
   BROWN GN, 1995, PNL10486
   BRUNSON RR, 1994, ORNLTM12708
   Chiarizia R, 1997, SEPAR SCI TECHNOL, V32, P1, DOI 10.1080/01496399708003184
   CHIARIZIA R, 1995, SOLVENT EXTR ION EXC, V13, P1063, DOI 10.1080/07366299508918318
   CHIARIZIA R, 1994, SOLVENT EXTR ION EXC, V12, P211, DOI 10.1080/07366299408918209
   COLTON NG, COMMUNICATION
   Dumont N, 1996, SEPAR SCI TECHNOL, V31, P1001, DOI 10.1080/01496399608002501
   HELFFERICH F, 1966, ION EXCHANGE, V1, pCH2
   HORWITZ EP, 1993, SOLVENT EXTR ION EXC, V11, P943, DOI 10.1080/07366299308918195
   HORWITZ EP, 1977, J CHROMATOGR SCI, V15, P41, DOI 10.1093/chromsci/15.2.41
   Knop A, 1979, CHEM APPL PHENOLIC R
   Korkish J., 1989, HDB ION EXCHANGE RES
   MARSH SF, 1994, LA12654 LOS AL NAT L
   NASH KL, 1994, SOLVENT EXTR ION EXC, V12, P193, DOI 10.1080/07366299408918208
   SIMON GP, 1979, STABILITY ION EXCHAN, V1
NR 19
TC 19
Z9 19
U1 2
U2 16
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016 USA
SN 0736-6299
J9 SOLVENT EXTR ION EXC
JI Solvent Extr. Ion Exch.
PY 1998
VL 16
IS 3
BP 875
EP 898
DI 10.1080/07366299808934558
PG 24
WC Chemistry, Multidisciplinary
SC Chemistry
GA ZN729
UT WOS:000073676100011
DA 2021-08-04
ER

PT S
AU Addison, MB
   Petry, TM
AF Addison, MB
   Petry, TM
GP NATL RES COUNCIL
TI Optimizing multiagent, multi-injected swell modifier
SO STABILIZATION AND GEOSYNTHETICS
SE TRANSPORTATION RESEARCH RECORD
LA English
DT Article; Proceedings Paper
CT 77th Annual Meeting of the Transportation-Research-Board
CY JAN, 1998
CL WASHINGTON, D.C.
SP Transportat Res Board
AB Interactions of expansive clay soils with transportation facilities have caused billions of dollars of damage. In the process of determining agents and methodologies to overcome expansive clay behavior, multiple injections of chemical agents into the subgrade to modify clay behavior are most promising. A study was conducted to optimize a potassium-rich solution of four parts. The modifying solution has been injected into expansive clay subgrades with success since the early 1970s. A laboratory methodology was developed to inject specimens multiple times and to conduct swell tests. Screening tests were conducted to evaluate linear effects that each of the four constituents had on swell response through interpretation of a factorial design. Analysis of replicated tests, randomly arranged in blocks, revealed that one constituent had no effect on swell behavior. A central composite experimental design then was used to optimize the remaining constituents. The resulting response surface equation led to an optimal combination for swell abatement, confirmed during short- and long-term verification testing. The optimal blend of constituents was determined to reduce swell from 7.2 percent to 0.84 percent under injection situations simulating the field, and it was found to improve the reduction in swell by 2.6 percent compared with the original blend. In addition, XRD confirmed that modification of clay occurred. This study was unique in its use of laboratory simulation of multiple field injections and in its use of statistical analysis to minimize the number of tests needed to ensure confidence in the optimization sought.
C1 Univ Missouri, Dept Civil Engn, Rolla, MO 65401 USA.
RP Addison, MB (corresponding author), POB 173908, Arlington, TX 76003 USA.
CR Barker TB., 1985, QUALITY EXPT DESIGN
   Bayne C. K., 1986, PRACTICAL EXPT DESIG
   BOX GEP, 1951, J ROYAL STAT SOC B, V13
   Box GEP., 1978, STAT EXPT
   GOLDMAN L J., 1990, CLAY LINERS WASTE MA
   JOHNSON LD, 1993, 3 INT C CAS HIST GEO
   MEYERS RH, 1989, TECHNOMETRICS, V31, P137
   MEYERS RH, 1990, STAT DESIGN ANAL IND, P211
   Mitchell, 1993, FUNDAMENTALS SOIL BE
   VANMALE HO, 1983, NP832052 COL SCH MIN
NR 10
TC 6
Z9 6
U1 0
U2 2
PU NATL ACAD SCI
PI WASHINGTON
PA 2101 CONSTITUTION AVE, WASHINGTON, DC 20418 USA
SN 0361-1981
BN 0-309-06456-2
J9 TRANSPORT RES REC
PY 1998
IS 1611
BP 38
EP 45
PG 8
WC Engineering, Civil; Engineering, Geological; Transportation
SC Engineering; Transportation
GA BN47L
UT WOS:000081980800005
DA 2021-08-04
ER

PT J
AU Pisani, A
   Calabresi, P
   Tozzi, A
   D'Angelo, V
   Bernardi, G
AF Pisani, A
   Calabresi, P
   Tozzi, A
   D'Angelo, V
   Bernardi, G
TI L-type Ca2+ channel blockers attenuate electrical changes and Ca2+ rise
   induced by oxygen/glucose deprivation in cortical neurons
SO STROKE
LA English
DT Article
DE calcium channels; electrophysiology; fura 2; glucose; ischemia; oxygen
ID FOCAL CEREBRAL-ISCHEMIA; CYTOSOLIC FREE CALCIUM; IN-VITRO ISCHEMIA;
   GLUCOSE DEPRIVATION; NEOCORTICAL NEURONS; HIPPOCAMPAL SLICES; O-2
   DEPRIVATION; ADULT-RAT; INJURY; BRAIN
AB Background and Purpose-Experimental evidence supports a major role of increased intracellular calcium [Ca2+](i) levels in the induction of neuronal damage during cerebral ischemia. However, the source of Ca2+ rise has trot been fully elucidated. To clarify further the role and the origin of Ca2+ in cerebral ischemia, we have studied the effects of various pharmacological agents in an in vitro model of oxygen (O-2)/glucose deprivation.
   Methods-Pyramidal cortical neurons were intracellularly recorded from a slice preparation. Electrophysiological recordings and microfluorometric measurements of [Ca2+](i) were performed simultaneously in slices perfused with a glucose-free physiological medium equilibrated with a 95% N-2/5% CO2 gas mixture.
   Results-Eight to twelve minutes of O-2/glucose deprivation induced all initial membrane hyperpolarization, followed by a delayed, large but reversible membrane depolarization. The depolarization phase was accompanied by a transient increase in [Ca2+](i) levels. When O-2/glucose deprivation exceeded 13 to 15 minutes, both membrane depolarization and [Ca2+](i) rise became irreversible. The dihydropyridines nifedipine and nimodipine significantly reduced either the membrane depolarization or the [Ca2+](i) elevation. In contrast, tetrodotoxin had no effect on either of these parameters. Likewise, antagonists of ionotropic and group I and II metabotropic glutamate receptors failed to reduce the depolarization of the cell membrane and the [Ca2+](i) accumulation. Finally, dantrolene, blocker of intracellular Ca2+ release, did not reduce both electrical and [Ca2+](i) changes caused by O-2/glucose depletion.
   Conclusions-This work supports a role of L-type Ca2+ channels both in the electrical and ionic changes occurring during the early phases of O-2/glucose deprivation.
C1 Univ Roma Tor Vergata, Dipartimento Sanita, I-00133 Rome, Italy.
   Univ Roma Tor Vergata, Neurol Clin, I-00133 Rome, Italy.
   Osped S Lucia, IRCCS, Rome, Italy.
RP Pisani, A (corresponding author), Univ Roma Tor Vergata, Dipartimento Sanita, Via Tor Vergata 135, I-00133 Rome, Italy.
EM pisani@utovrm.it
RI Pisani, Antonio/G-2492-2012; Calabresi, Paolo/G-8496-2011; Tozzi,
   Alessandro/G-7254-2011
OI Pisani, Antonio/0000-0002-8432-594X; D'Angelo,
   Vincenza/0000-0002-7720-8913; Tozzi, Alessandro/0000-0003-3153-2424
CR ABE K, 1988, J CEREBR BLOOD F MET, V8, P436, DOI 10.1038/jcbfm.1988.81
   BICKLER PE, 1994, BRAIN RES, V665, P269, DOI 10.1016/0006-8993(94)91347-1
   BLOCK GA, 1987, CEREBROVASC DIS, P23
   Brott T, 1996, ARCH NEUROL-CHICAGO, V53, P1305, DOI 10.1001/archneur.1996.00550120117025
   CALABRESI P, 1995, BRAIN, V118, P1027, DOI 10.1093/brain/118.4.1027
   Calabresi P, 1997, J NEUROSCI, V17, P1940
   CHOI DW, 1987, J NEUROSCI, V7, P369
   CONNORS BW, 1982, J NEUROPHYSIOL, V48, P1302
   Davis SM, 1997, LANCET, V349, P32, DOI 10.1016/S0140-6736(05)62166-6
   del Zoppo G J, 1995, Neurologia, V10 Suppl 2, P37
   DUBINSKY JM, 1991, J NEUROSCI, V11, P2545
   FISHER M, 1995, EUR NEUROL, V35, P3, DOI 10.1159/000117082
   FRIEDMAN JE, 1993, J NEUROSCI, V13, P63
   GOLDBERG MP, 1987, J PHARMACOL EXP THER, V243, P784
   GOLDBERG MP, 1993, J NEUROSCI, V13, P3510
   GROTTA JC, 1991, CLIN NEUROPHARMACOL, V14, P373, DOI 10.1097/00002826-199110000-00001
   HADDAD GG, 1993, PROG NEUROBIOL, V40, P277, DOI 10.1016/0301-0082(93)90014-J
   HADDAD GG, 1993, BRAIN RES, V625, P261, DOI 10.1016/0006-8993(93)91067-3
   HOEHNER PJ, 1992, J CEREBR BLOOD F MET, V12, P418, DOI 10.1038/jcbfm.1992.59
   HORIKAWA K, 1988, J NEUROSCI METH, V25, P1, DOI 10.1016/0165-0270(88)90114-8
   HOSSMANN KA, 1994, BRAIN PATHOL, V4, P23
   JIANG C, 1992, J NEUROPHYSIOL, V68, P2165
   KATSUTA K, 1995, J CEREBR BLOOD F MET, V15, P345, DOI 10.1038/jcbfm.1995.40
   KAWAGUCHI Y, 1993, J NEUROSCI, V13, P4908
   KRNJEVIC K, 1989, J NEUROPHYSIOL, V62, P15
   LEVRAM V, 1992, J NEUROPHYSIOL, V68, P1167
   LIPTON P, 1988, J NEUROSCI METH, V24, P198
   LOBNER D, 1993, J NEUROSCI, V13, P4861
   LUST WD, 1985, CEREBRAL ENERGY META, P79
   MARCOUX FW, 1989, CEREBROVASC DIS, P135
   MARTIN RL, 1994, TRENDS NEUROSCI, V17, P251, DOI 10.1016/0166-2236(94)90008-6
   MCCORMICK DA, 1985, J NEUROPHYSIOL, V54, P782
   MERCURI NB, 1994, J NEUROPHYSIOL, V71, P1165
   MITANI A, 1993, BRAIN RES, V601, P103, DOI 10.1016/0006-8993(93)91700-3
   MITANI A, 1995, ACTA NEUROPATHOL, V89, P2, DOI 10.1007/BF00294252
   MOHR JP, 1994, CEREBROVASC DIS, V14, P373
   MURI R, 1994, J NEUROPHYSIOL, V71, P420
   NISHIKAWA T, 1994, STROKE, V25, P2258, DOI 10.1161/01.STR.25.11.2258
   Pisani A, 1997, NEUROREPORT, V8, P1143, DOI 10.1097/00001756-199703240-00017
   Pringle AK, 1996, STROKE, V27, P2124, DOI 10.1161/01.STR.27.11.2124
   SIESJO BK, 1988, ANN NY ACAD SCI, V522, P638
   SILVER IA, 1990, J GEN PHYSIOL, V95, P837, DOI 10.1085/jgp.95.5.837
   STEEN PA, 1985, ANESTHESIOLOGY, V62, P406, DOI 10.1097/00000542-198504000-00007
   UEMATSU D, 1989, STROKE, V20, P1531, DOI 10.1161/01.STR.20.11.1531
   UEMATSU D, 1988, ANN NEUROL, V24, P420, DOI 10.1002/ana.410240311
   WARD A, 1986, DRUGS, V32, P130, DOI 10.2165/00003495-198632020-00003
   WIELOCH T, 1988, NEUROL NEUR, V46, P715
NR 47
TC 60
Z9 65
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD JAN
PY 1998
VL 29
IS 1
BP 196
EP 201
DI 10.1161/01.STR.29.1.196
PG 6
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA YQ726
UT WOS:000071417100040
PM 9445351
OA Bronze, Green Published
DA 2021-08-04
ER

PT S
AU Ruvini, JD
   Fagot, C
AF Ruvini, JD
   Fagot, C
GP IEEE
   IEEE
TI IBHYS: A new approach to learn users habits
SO TENTH IEEE INTERNATIONAL CONFERENCE ON TOOLS WITH ARTIFICIAL
   INTELLIGENCE, PROCEEDINGS
SE PROCEEDINGS - INTERNATIONAL CONFERENCE ON TOOLS WITH ARTIFICIAL
   INTELLIGENCE
LA English
DT Proceedings Paper
CT 10th International Conference on Tools with Artificial Intelligence
CY NOV 10-12, 1998
CL TAIPEI, TAIWAN
SP IEEE Comp Soc, IEEE Taipei Sect, Natl Cheng kung Univ, Res Ctr Comp Syst Tech, Natl Tsing Hua Univ, Comp Commmun Red Ctr, Natl Taiwan Univ, Ctr Excellence Res Comp Sci, Natl Sci Council, Acer Sertek Inc
ID INTERFACE; AGENTS
AB Learning interface agents search regularities in the user behavior and use them to predict user's actions. We propose a new inductive concept learning approach, called IBHYS, to learn such regularities. This approach limits the hypothesis search to a small portion of the hypothesis space by letting each training example build a local approximation of rite global target function. It allows to simultaneously search several hypothesis spaces and to simultaneously handle hypotheses described in different languages. This approach is particularly suited for learning interface agents because it provides an incremental algorithm with low training time and decision time, which does not require, from the designer of the interface agent, to describe in advance and quite carefully the repetitive patterns searched. We illustrate our approach with two autonomous software agents, the Apprentice and the Assistant, devoted to assist users of interactive programming environments and implemented in Objectworks-Smalltalk-80. The Apprentice learns user's work habits using an IBHYS algorithm and the Assistant, based on what has been learnt, proposes to the programmer sequences of actions the user might want to redo. We show, with experimental results on real data, that IBHYS outperforms ID3 both in computing time and predictive accuracy.
C1 UMII, UMR 5506 CNRS, LIRMM, F-34392 Montpellier 5, France.
RP Ruvini, JD (corresponding author), UMII, UMR 5506 CNRS, LIRMM, 161 Rue Ada, F-34392 Montpellier 5, France.
CR ARMSTRONG R, 1995, AAAI SPRING S INF GA
   Caglayan A., 1996, PAAM 96. Proceedings of the First International Conference on the Practical Application of Intelligent Agents and Multi-Agent Technology, P61
   CYPHER A, 1991, P CHI 91, P33
   Duda R.O, 1973, PATTERN CLASSIFICATI
   GASCUEL O, 1992, PATTERN RECOGN LETT, V13, P757, DOI 10.1016/0167-8655(92)90125-J
   Hertz J., 1991, LECT NOTES, V1
   HOLLAND J, 1975, ADAPTATION NATURAL A
   HOLTE RC, 1994, SOFTW AG SPRING S MA
   Karp RM, 1972, 4TH P ANN ACM S THEO, P125, DOI DOI 10.1145/800152.804905
   LASHKARI Y, 1994, PROCEEDINGS OF THE TWELFTH NATIONAL CONFERENCE ON ARTIFICIAL INTELLIGENCE, VOLS 1 AND 2, P444
   MAES P, 1993, PROCEEDINGS OF THE ELEVENTH NATIONAL CONFERENCE ON ARTIFICIAL INTELLIGENCE, P459
   Maes P., 1994, Software Agents. Papers from the 1994 AAAI Spring Symposium, P71
   MAES P, 1994, COMMUN ACM, V37, P31
   MITCHELL T, 1994, COMMUN ACM, V37, P81, DOI 10.1145/176789.176798
   MITCHELL TM, 1979, THESIS STANFORD U
   ORWANT J, 1995, USER MODEL USER-ADAP, V4, P107
   Payne TR, 1997, APPL ARTIF INTELL, V11, P1, DOI 10.1080/088395197118325
   POHL W, 1996, ICML 96 WORKSH MACH, P29
   Powell M., 1987, ALGORITHMS APPROXIMA, P143
   Quinlan J. R., 1986, Machine Learning, V1, P81, DOI 10.1007/BF00116251
   RICH C, 1988, COMPUTER, P11
   Schlimmer JC, 1993, J ARTIF INTELL RES, V1, P61
   WATERS RC, 1982, IEEE T SOFTWARE ENG, V8, P1, DOI 10.1109/TSE.1982.234769
   WU S, 1992, COMMUN ACM, V35, P83, DOI 10.1145/135239.135244
   Yoshida K, 1996, INT J HUM-COMPUT INT, V8, P237, DOI 10.1080/10447319609526151
NR 25
TC 0
Z9 0
U1 0
U2 0
PU IEEE COMPUTER SOC
PI LOS ALAMITOS
PA 10662 LOS VAQUEROS CIRCLE, PO BOX 3014, LOS ALAMITOS, CA 90720-1264 USA
SN 1082-3409
BN 0-7803-5214-9
J9 PROC INT C TOOLS ART
PY 1998
BP 200
EP 207
DI 10.1109/TAI.1998.744843
PG 8
WC Computer Science, Artificial Intelligence
SC Computer Science
GA BM70Q
UT WOS:000079563400025
DA 2021-08-04
ER

PT J
AU Spiazzi, E
   Mascheroni, R
AF Spiazzi, E
   Mascheroni, R
TI Mass transfer model for osmotic dehydration of fruits and vegetables -
   I. Development of the simulation model
SO JOURNAL OF FOOD ENGINEERING
LA English
DT Article
ID DRYING BEHAVIOR; QUALITY; AGENTS; APPLES; POTATO; RINGS; WATER
AB A mathematical model based on mass transfer in plant tissues was developed with the aim of finding a simple predictive model which was easy to use and yet had a broad application scope in the osmotic dehydration of foods. The model takes into account the capacity of each constituent to diffuse within tissue by using a diffusion coefficient and a transmembrane mass transfer coefficient. The model also depends on the mass ratio of osmotic solution to product, on the initial chemical composition of the product and solution, and on the product shape. The application of the model to apple dehydration with polyethyleneglycol (PEG) solutions allowed us to quantitatively simulate the time evolution of cellular and extracellular volumes which was observed previously in histological sections under the microscope. By using experimental data obtained during potato dehydration in mixed solutions of sucrose and salt, mass transfer and apparent diffusion coefficients were fitted in order to evaluate product behavior under different process conditions. A good quantitative agreement was obtained between the experimental and calculated results. The model presented in this paper allows the main variables of osmotic dehydration to be estimated using a low number of fitting parameters, and interprets, through a simple algorithm, the complex phenomena of the main mass transfer mechanisms in plant tissues. (C) 1998 Elsevier Science Limited. All rights reserved.
C1 Natl Univ La Plata, Fac Ciencias Exactas, Ctr Invest & Desarrolo Critecnol Alimentos, RA-1900 La Plata, Argentina.
   Natl Univ La Plata, Fac Ingn, Dept Ingn Quim, MODIAL, RA-1900 La Plata, Argentina.
RP Mascheroni, R (corresponding author), Natl Univ La Plata, Fac Ciencias Exactas, Ctr Invest & Desarrolo Critecnol Alimentos, 47y 116, RA-1900 La Plata, Argentina.
CR Andreotti R., 1983, Industria Conserve, V58, P90
   BERISTAIN CI, 1990, INT J FOOD SCI TECH, V25, P576
   BISWAL R N, 1989, Journal of Food Process Engineering, V11, P159, DOI 10.1111/j.1745-4530.1989.tb00027.x
   BISWAL RN, 1991, J FOOD SCI, V56, P1008, DOI 10.1111/j.1365-2621.1991.tb14628.x
   BISWAL RN, 1992, T ASAE, V35, P257
   BOLIN HR, 1983, J FOOD SCI, V48, P202, DOI 10.1111/j.1365-2621.1983.tb14823.x
   BONGIRWAR DR, 1977, J FOOD SCI TECH MYS, V14, P104
   CAMIRAND WM, 1968, J SCI FOOD AGR, V19, P472, DOI 10.1002/jsfa.2740190813
   CONTRERAS JE, 1981, CAN I FOOD SC TECH J, V14, P310, DOI 10.1016/S0315-5463(81)72932-8
   CONWAY J, 1983, CAN I FOOD SC TECH J, V16, P25, DOI 10.1016/S0315-5463(83)72014-6
   Crank J., 1979, MATH DIFFUSION
   Dalla Rosa M., 1982, Industria Conserve, V57, P3
   FARKAS DF, 1969, FOOD TECHNOL-CHICAGO, V23, P688
   FITO P, 1994, J FOOD ENG, V21, P513, DOI 10.1016/0260-8774(94)90070-1
   FLICK D, 1990, JOURN MIT CIRAD PROC
   FLINK JM, 1975, J AGR FOOD CHEM, V23, P1019, DOI 10.1021/jf60202a018
   FORNI E, 1986, CARBOHYD POLYM, V6, P379, DOI 10.1016/0144-8617(86)90027-5
   Garcia R, 1974, P INT C FOOD SCI TEC, V4, P32
   GEURTS TJ, 1974, NETH MILK DAIRY J, V28, P102
   GIANGIACOMO R, 1987, J FOOD PROCESS PRES, V11, P183, DOI 10.1111/j.1745-4549.1987.tb00046.x
   GIROD JF, 1990, P INT AGR ENG C BANG, V4, P1345
   GUILBERT S, 1990, Patent No. 4634
   HARTAL D, 1967, THESIS U ILLINOIS
   Hawkes J., 1978, Journal of Food Processing and Preservation, V2, P265, DOI 10.1111/j.1745-4549.1978.tb00562.x
   HOUGH G, 1993, FOOD SCI TECHNOL-LEB, V26, P151, DOI 10.1006/fstl.1993.1031
   ISLAM MN, 1982, J FOOD TECHNOL, V17, P387, DOI 10.1127/0935-1221/2005/0017-0387
   Isse M.G., 1991, 4 WORLD C CHEM ENG K
   KAREL M, 1975, PRINCIPLES FOOD SC 2, P348
   KHAN AA, 1990, J SCI FOOD AGR, V52, P455, DOI 10.1002/jsfa.2740520404
   KIM MH, 1987, J FOOD SCI, V52, P980, DOI 10.1111/j.1365-2621.1987.tb14256.x
   LENART A, 1984, J FOOD TECHNOL, V19, P45
   Lenart A., 1988, In 'Preconcentration and drying of food materials', edited by Bruin, S. Conference. Eindhoven, Netherlands. 5-6 Nov. 1987. 1000 AE Amsterdam, Netherlands; Elsevier Science Publishers BV. ISBN 0-444-42968-9 [see FSTA (1989) 21 5E22]., P307
   LERICI C R, 1986, Industria Conserve (Parma), V61, P223
   LERICI CR, 1985, J FOOD SCI, V50, P1217, DOI 10.1111/j.1365-2621.1985.tb10445.x
   Lerici CR, 1983, IND ALIMENTARI, V3, P184
   LEVI A, 1983, J FOOD TECHNOL, V18, P667
   LEWICKI PP, 1980, PRZEMSYL FERMENTACYJ, V8, P24
   MAGEE TRA, 1983, IRISH J FOOD SCI TEC, V7, P147
   MARCELIN O, 1970, PHYSL VEG, V8, P173
   MARCOTTE M, 1991, Journal of Food Engineering, V13, P199, DOI 10.1016/0260-8774(91)90027-P
   Marcotte M., 1988, THESIS U ALBERTA
   MOLZ FJ, 1979, PLANT PHYSIOL, V64, P712, DOI 10.1104/pp.64.5.712
   MOY J H, 1978, Journal of Food Processing and Preservation, V2, P131, DOI 10.1111/j.1745-4549.1978.tb00553.x
   NUR MA, 1976, THESIS U MADISON
   PAVASCOVIC V, 1986, DRYING 89, P761
   PHILIP JR, 1958, PLANT PHYSIOL, V33, P275, DOI 10.1104/pp.33.4.275
   PHILIP JR, 1958, PLANT PHYSIOL, V33, P271, DOI 10.1104/pp.33.4.271
   PHILIP JR, 1958, PLANT PHYSIOL, V33, P264, DOI 10.1104/pp.33.4.264
   PONTING J. D., 1966, FOOD TECHNOL, V20, P125
   PONTING JD, 1973, PROCESS BIOCHEM, V8, P18
   RAHMAN MS, 1990, J FOOD SCI TECH MYS, V27, P150
   Raoult-Wack AL, 1990, CAHIERS ENSBANA EAU, V7, P171
   RAOULTWACK AL, 1991, DRY TECHNOL, V9, P589, DOI 10.1080/07373939108916698
   ROTSTEIN E, 1988, 6 INT DRYING S, V1, P63
   Saurel R., 1995, THESIS U MONTPELLIER
   Tomasicchio M., 1986, Industria Conserve, V61, P108
   TORREGGIANI D, 1986, Industria Conserve (Parma), V61, P226
   Torreggiani D., 1986, Industria Conserve, V61, P101
   Torregiani D., 1988, P INT S PROGR FOOD P, VI, P71
   TORREGIANI D, 1988, IND CONSERVE, V63, P223
   TOUPIN C J, 1989, Journal of Food Engineering, V10, P13, DOI 10.1016/0260-8774(89)90018-6
   ZOZULEVICH BV, 1969, KONSER VN OVOSHCHENS, V7, P32
NR 62
TC 69
Z9 73
U1 1
U2 12
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0260-8774
J9 J FOOD ENG
JI J. Food Eng.
PD DEC
PY 1997
VL 34
IS 4
BP 387
EP 410
DI 10.1016/S0260-8774(97)00102-7
PG 24
WC Engineering, Chemical; Food Science & Technology
SC Engineering; Food Science & Technology
GA ZN426
UT WOS:000073644700003
DA 2021-08-04
ER

PT J
AU Wang, MW
   Lee, CT
   Lin, MS
AF Wang, MW
   Lee, CT
   Lin, MS
TI Curing behaviour of compatible interpenetrating polymer networks based
   on epoxy and methacrylated epoxy
SO POLYMER INTERNATIONAL
LA English
DT Article
DE IPN; compatibility; network interlock; cure; viscosity increase
AB Compatible interpenetrating polymer networks (IPNs) based on diglycidyl ether of bisphenol A (DGEBA) and methacrylated diglycidyl ether of bisphenol A (MADGEBA) in weight ratios of 100/0, 75/25, 50/50, 25/75 and 0/100 were blended and cured simultaneously by using dicumyl peroxide (DICUP) and hexahydrophthalic anhydride (HHPA) as curing agents. Fourier transform infrared spectroscopy (FTIR) was employed to investigate the intermolecular interactions and functional group changes. Viscosity increases during crosslinking were examined with a Brookfield viscometer. Curing exothermic peaks were studied with differential scanning calorimetry (DSC). The gel fractions of various IPN compositions were measured with a Soxhlet extractor. Samples thus prepared were checked for their compatibility by measuring glass transitions with DSC and damping peaks with rheometric dynamic spectroscopy (RDS). Experimental results revealed that good compatibility between components induced a network interlock, which subsequently resulted in incomplete cure of the IPN materials.
C1 Natl Chiao Tung Univ, Dept Appl Chem, Hsinchu 30050, Taiwan.
RP Lin, MS (corresponding author), Natl Chiao Tung Univ, Dept Appl Chem, Hsinchu 30050, Taiwan.
CR Frisch K.C., 1983, MATER DESIGN, V4, P855
   HOURSTON DJ, 1984, J APPL POLYM SCI, V29, P2969, DOI 10.1002/app.1984.070291003
   HOURSTON DJ, 1987, J APPL POLYM SCI, V39, P215
   JIN SR, 1986, POLYMER, V27, P592, DOI 10.1016/0032-3861(86)90245-4
   Lin M. - S., 1996, J POLYM RES, V3, P165
   LIN MS, 1993, J POLYM SCI POL CHEM, V31, P3317, DOI 10.1002/pola.1993.080311320
   LIN MS, 1995, POLYMER, V36, P4567, DOI 10.1016/0032-3861(95)96825-S
   LIN MS, 1994, POLYMER, V35, P594, DOI 10.1016/0032-3861(94)90517-7
   LIN MS, UNPUB J POLYM SCI PP
   MACKNIGHT WJ, 1978, POLYM BLENDS, V1, P188
   NISHI S, 1985, MACROMOLECULES, V18, P1519, DOI 10.1021/ma00150a001
   SIEFRIED DL, 1981, POLYM ENG SCI, V21, P39
   Sperling L. H., 1981, INTERPENETRATING POL
   XUE SC, 1989, POLYMER, V30, P1271
NR 14
TC 11
Z9 12
U1 5
U2 6
PU JOHN WILEY & SONS LTD
PI W SUSSEX
PA BAFFINS LANE CHICHESTER, W SUSSEX PO19 1UD, ENGLAND
SN 0959-8103
J9 POLYM INT
JI Polym. Int.
PD DEC
PY 1997
VL 44
IS 4
BP 503
EP 509
DI 10.1002/(SICI)1097-0126(199712)44:4<503::AID-PI860>3.0.CO;2-E
PG 7
WC Polymer Science
SC Polymer Science
GA YP647
UT WOS:000071299900014
DA 2021-08-04
ER

PT J
AU Kovscek, AR
   Patzek, TW
   Radke, CJ
AF Kovscek, Anthony R.
   Patzek, Tadeusz W.
   Radke, Clayton J.
TI Mechanistic Foam Flow Simulation in Heterogeneous and Multidimensional
   Porous Media
SO SPE JOURNAL
LA English
DT Article
AB Gases typically display large flow mobilities in porous media relative to oil or water, thereby impairing their effectiveness as displacing fluids. Foamed gas, though, is a promising agent for achieving mobility control in porous media. Because reservoir-scale simulation is a vital component of the engineering and economic evaluation of any enhanced oil recovery (EOR) or aquifer remediation project, efficient application of foam as a displacement fluid requires a predictive numerical model. Unfortunately, no such model is currently available for foam injection in the field where flow is multidimensional and the porous medium is heterogeneous.
   We have incorporated a conservation equation for the number density of foam bubbles into a fully implicit, three-dimensional, compositional, and thermal reservoir simulator and created a fully functional, mechanistic foam simulator. Because foam mobility is a strong function of bubble texture, the bubble population balance is necessary to make accurate predictions of foam-flow behavior. Foam generation and destruction are included through rate expressions that depend on saturations and surfactant concentration. Gas relative permeability and effective viscosity are modified according to the texture of foam bubbles. In this paper, we explore foam flow in radial, layered, and heterogeneous porous media. Simulations in radial geometries indicate that foam can be formed deep within rock formations, but that the rate of propagation is slow. Foam proves effective in controlling gas mobility in layered porous media. Significant flow diversion and sweep improvement by foam are predicted, regardless of whether the layers are communicating or isolated.
C1 [Kovscek, Anthony R.] Stanford Univ, Dept Petr Engn, Stanford, CA 94305 USA.
   [Patzek, Tadeusz W.] Univ Calif Berkeley, Dept Mat Sci & Mineral Engn, Petr Engn, Berkeley, CA 94720 USA.
   [Radke, Clayton J.] Univ Calif Berkeley, Dept Chem Engn, Chem Engn, Berkeley, CA 94720 USA.
RP Kovscek, AR (corresponding author), Stanford Univ, Dept Petr Engn, Stanford, CA 94305 USA.
EM kovscek@pangea.stanford.edu; patzek@patzek.berkeley.edu;
   radke@cchem.berkeley.edu
FU Assistant Secretary for Fossil Energy, Office of Oil, Gas, and Shale
   Technologies of the U.S. Department of Energy [DEAC03-76FS00098,
   DE-FG22-96BCI4994]
FX This work was supported by the Assistant Secretary for Fossil Energy,
   Office of Oil, Gas, and Shale Technologies of the U.S. Department of
   Energy, under contract No. DEAC03-76FS00098 to the Lawrence Berkeley
   National Laboratory of the University of California and under contract
   No. DE-FG22-96BCI4994 to Stanford University.
CR Aare M.G., 1995, P 8 EUR IOR S VIENN
   ADENEKAN AE, 1993, WATER RESOUR RES, V29, P3727, DOI 10.1029/93WR01957
   ARONSON AS, 1994, COLLOID SURFACE A, V83, P109, DOI 10.1016/0927-7757(94)80094-4
   Bernard G. G., 1965, SPE J, V5, P295, DOI [http://dx.doi.org/10.2118/1204-pa, DOI 10.2118/1204-PA]
   BRETHERTON FP, 1961, J FLUID MECH, V10, P166, DOI 10.1017/S0022112061000160
   Chambers K.T., 1991, INTERFACIAL PHENOM P, V36, P191
   Chang S.H., 1990, P SPE DOE 7 S ENH OI
   Chou S.I., 1990, P 7 SPE DOE S ENH OI
   de Vries A.S., 1990, SPE RESERVOIR ENG, V5, P185, DOI DOI 10.2118/18075-PA
   Djabbarah N.F., 1990, P 60 CAL REG M VENT
   Ettinger R.A., 1989, THESIS
   Ettinger R.A., 1992, SPE RESERVOIR ENG, V7, P83, DOI DOI 10.2118/19688-PA
   Falls A.H., 1988, SPE RESERVOIR ENG, V3, P884, DOI DOI 10.2118/14961-PA
   Falls A.H., 1989, SPE RESERVOIR ENG, V4, P155, DOI DOI 10.2118/16048-PA
   Fergui A., 1995, P 8 EUR IOR S VIENN
   Fisher A.W., 1990, P 7 SPE DOE S ENH OI
   FRIEDMANN F, 1994, SPE RESERVOIR ENG, V9, P297, DOI 10.2118/21780-PA
   Friedmann F., 1991, SPE RESERVOIR ENG, V6, P37, DOI DOI 10.2118/17357-PA
   Friedmann F., 1986, P SPE CAL REG M OAKL
   Gillis J.V., 1990, P 65 SPE ANN TECHN C
   HIRASAKI GJ, 1985, SOC PETROL ENG J, V25, P176, DOI 10.2118/12129-PA
   HOLM LW, 1968, SOC PETROL ENG J, V8, P359, DOI 10.2118/1848-PA
   Huh D. G., 1989, SPE RESERVOIR ENG, V4, P77, DOI DOI 10.2118/15078-PA
   International Formulation Committee, 1967, FORM THERM PROP ORD
   JIMENEZ AI, 1989, ACS SYM SER, V396, P460
   Khatib Z.I., 1988, SPE RESERVOIR ENG, V3, P919, DOI [10.2118/15442-PA, DOI 10.2118/15442-PA, 10.2118/15442-PA.]
   Kovscek A.R., 1993, P 68 ANN TECHN C SPE
   Kovscek AR, 1996, COLLOID SURFACE A, V117, P55, DOI 10.1016/0927-7757(96)03637-0
   KOVSCEK AR, 1995, CHEM ENG SCI, V50, P3783, DOI 10.1016/0009-2509(95)00199-F
   KOVSCEK AR, 1994, ADV CHEM SER, V242, P115
   Leverett MC, 1941, T AM I MIN MET ENG, V142, P152, DOI 10.2118/941152-G
   Liu D., 1992, 1460019 DOEBC
   Mahmood S.M., 1986, P SPE CAL REG M OAKL
   Marfoe C.H., 1987, P 62 SPE ANN M DALL
   Mohammadi S.S., 1989, SPE RESERVOIR ENG, V4, P7, DOI DOI 10.2118/16736-PA
   Mohammadi S.S., 1992, P SPE CAL REG M BAK
   MOHAMMADI SS, 1993, J CAN PETROL TECHNOL, V32, P49, DOI 10.2118/93-10-06
   NARASIMHAN TN, 1976, WATER RESOUR RES, V12, P57, DOI 10.1029/WR012i001p00057
   Patzek T.W., 1988, SURFACTANT BASED MOB, P326
   Patzek T.W., 1989, P SPE CAL REG M BAK
   PATZEK TW, 1990, J PETROL TECHNOL, V42, P496, DOI 10.2118/17380-PA
   Patzek TW, 1996, SPE RESERVOIR ENG, V11, P79, DOI 10.2118/29612-PA
   PERSOFF P., 1991, SPE RESERVOIR ENG, V6, P365, DOI DOI 10.2118/18781-PA
   Pruess K., 1987, NUREGCR4645 NUCL REG
   Pruess K., 1991, LBL29400 LBL29400
   Rossen W. R., 1991, P 66 SPE ANN TECHN C
   ROSSEN WR, 1990, J COLLOID INTERF SCI, V136, P1, DOI 10.1016/0021-9797(90)90074-X
   ROSSEN WR, 1990, J COLLOID INTERF SCI, V136, P38, DOI 10.1016/0021-9797(90)90076-Z
   ROSSEN WR, 1990, J COLLOID INTERF SCI, V136, P17, DOI 10.1016/0021-9797(90)90075-Y
   ROSSEN WR, 1990, AICHE J, V36, P1176, DOI 10.1002/aic.690360807
   Sanchez J. M., 1986, P 61 SPE ANN TECHN C
   STONE HL, 1970, J PETROL TECHNOL, V22, P214, DOI 10.2118/2116-PA
   Svorstol I., 1996, P SPE DOE 10 S IMPR
   WONG H, 1995, J FLUID MECH, V292, P71, DOI 10.1017/S0022112095001443
   WONG H, 1995, J FLUID MECH, V292, P95, DOI 10.1017/S0022112095001455
   Zhou Z., 1992, P SPE DOE 8 S ENH OI
NR 56
TC 71
Z9 73
U1 0
U2 0
PU SOC PETROLEUM ENG
PI RICHARDSON
PA 222 PALISADES CREEK DR,, RICHARDSON, TX 75080 USA
SN 1086-055X
EI 1930-0220
J9 SPE J
JI SPE J.
PD DEC
PY 1997
VL 2
IS 4
BP 511
EP 526
DI 10.2118/39102-PA
PG 16
WC Engineering, Petroleum
SC Engineering
GA VJ6WY
UT WOS:000618242200013
DA 2021-08-04
ER

PT J
AU Hraber, PT
   Milne, BT
AF Hraber, PT
   Milne, BT
TI Community assembly in a model ecosystem
SO ECOLOGICAL MODELLING
LA English
DT Article
DE adaptive agents; community ecology; genetic algorithms; invasion;
   neutral evolution
ID SPATIAL MODELS; ORGANIZATION; LANDSCAPES; DYNAMICS; PATTERNS
AB Environmental and biotic factors regulate species abundance and the composition of ecological communities. However, it is difficult to demonstrate principles of community assembly in nature due to observational limitations and historical effects. Numerical simulation can be used to evaluate whether hypothesized mechanisms produce a pattern seen in natural communities. Most models of many-species communities assume similar behavior by all individuals in a population. Here we describe an agent-based model of many-species communities in which interactions among individual agents are subjected to Darwinian selection (Holland's Echo model). To evaluate the response of the model to evolutionary mechanisms, we present a simple version of the model, and describe an experiment which evaluated community assembly patterns with and without selection for genome-mediated interactions, at various levels of invasion. Increased invasion rates decreased population size, but increased species richness and evenness. Interactions acted upon by natural selection resulted in greater population sizes and lower species richness and evenness than random interactions. Genotype abundances deviated from the expectation of equal abundances, and were affected by both the invasion rate and nature of inter-agent interactions. Species abundance patterns indicate that communities formed by random and selective interactions follow different assembly rules, and communities formed under high invasion rates showed no coherent community-level pattern of genotype abundances. Thus, both invasion rate and type of interspecific interaction regulate the assembly of species into communities. (C) 1997 Elsevier Science B.V.
RP Hraber, PT (corresponding author), UNIV NEW MEXICO, DEPT BIOL, ALBUQUERQUE, NM 87131 USA.
OI Hraber, Peter/0000-0002-2920-4897
CR ALDOUS D, 1995, J APPL PROBAB, V32, P279, DOI 10.2307/3215288
   Brown J.H., 1995, MACROECOLOGY
   BROWN JH, 1981, AM ZOOL, V21, P877
   BROWN JH, 1994, SFI S SCI C, V19, P419, DOI 10.1109/ICIPRM.1994.328259
   CASWELL H, 1976, ECOL MONOGR, V46, P327, DOI 10.2307/1942257
   CONNOR EF, 1979, ECOLOGY, V60, P1132, DOI 10.2307/1936961
   DEANGELIS DL, 1992, INDIVIDUAL BASED MOD
   Diamond J.M., 1975, P342
   DRAKE JA, 1991, AM NAT, V137, P1, DOI 10.1086/285143
   Durrett R, 1996, J THEOR BIOL, V179, P119, DOI 10.1006/jtbi.1996.0053
   DURRETT R, 1994, THEOR POPUL BIOL, V46, P363, DOI 10.1006/tpbi.1994.1032
   DURRETT R, 1994, PHILOS T ROY SOC B, V343, P329, DOI 10.1098/rstb.1994.0028
   FORREST S, 1994, COMPLEX SYSTEMS MECH, P3
   GARDNER RG, 1991, QUANTITATIVE METHODS, P209
   Gause GF, 1934, STRUGGLE EXISTENCE
   GILPIN ME, 1974, AM NAT, V108, P859
   Green D. G., 1993, Complex systems: from biology to computation, P24
   Green David G., 1994, Journal of Biological Systems, V2, P91, DOI 10.1142/S0218339094000088
   Hartvigsen Gregg, 1995, Artificial Life, V2, P239, DOI 10.1162/artl.1995.2.2.239
   Hiebeler D., 1994, 9412065 SANT FE I
   Holland J.H., 1995, HIDDEN ORDER ADAPTAT
   Holland J.H., 1992, ADAPTATION NATURAL A
   HOLLAND JH, 1994, SFI S SCI C, V19, P309
   HOLLAND JH, 1986, INDUCTION PROCESSES
   HRABER PT, IN PRESS ARTIFICIAL
   HUFFAKER C. B., 1958, HILGARDIA, V27, P343
   HUTCHINSON GE, 1959, AM NAT, V93, P145, DOI 10.1086/282070
   JONES T, 1993, 9312074 SANT FE I
   KAREIVA P, 1990, PHILOS T ROY SOC B, V330, P175, DOI 10.1098/rstb.1990.0191
   Kauffman S., 1993, ORIGINS ORDER
   KEITT TH, 1995, J THEOR BIOL, V172, P127, DOI 10.1006/jtbi.1995.0010
   KODRICBROWN A, 1984, ECOLOGY, V65, P1358, DOI 10.2307/1939116
   KOLASA J, 1989, P NATL ACAD SCI USA, V86, P8837, DOI 10.1073/pnas.86.22.8837
   Langton C.G., 1989, SANTA FE I STUDIES S, V6
   LANGTON CG, 1990, PHYSICA D, V42, P12, DOI 10.1016/0167-2789(90)90064-V
   LANGTON CG, 1994, SANTA FE I STUDIES S, V17
   LEVIN SA, 1992, ECOLOGY, V73, P1943, DOI 10.2307/1941447
   LEVINS RICHARD, 1968
   MAC ARTHUR ROBERT H., 1967
   MAY RM, 1986, ECOLOGY, V67, P1115, DOI 10.2307/1938668
   MAY RM, 1973, MONOGRAPHS POPULATIO, V6, P235
   Mayr E., 1963, ANIMAL SPECIES EVOLU
   MILNE BT, 1992, AM NAT, V139, P32, DOI 10.1086/285312
   Milne BT, 1996, ECOLOGY, V77, P805, DOI 10.2307/2265503
   MILNE BT, 1992, THEOR POPUL BIOL, V41, P337, DOI 10.1016/0040-5809(92)90033-P
   MITCHELL M, 1996, INTRO GENETIC ALGORI
   Nicolas G, 1989, EXPLORING COMPLEXITY
   NITECKI MH, 1987, NEUTRAL MEDELS BIOL
   OLSON RL, 1995, ECOL MODEL, V79, P95, DOI 10.1016/0304-3800(93)E0124-L
   PAINE RT, 1974, OECOLOGIA, V15, P93, DOI 10.1007/BF00345739
   PALMER R, 1989, SANTA FE I LECT SCI, V2, P275
   PIELOU E C, 1969, P286
   PIMM SL, 1984, NATURE, V307, P321, DOI 10.1038/307321a0
   Ricklefs Robert E., 1993, P350
   ROSEN R, 1991, LIFE ITSELF
   ROUGHGARDEN J, 1976, THEOR POPUL BIOL, V9, P388, DOI 10.1016/0040-5809(76)90054-X
   *SAS I INC, 1990, SAS STAT US GUID VER
   SCHMITZ OJ, IN PRESS EVOLUT ECOL
   SUTHERLAND JP, 1974, NATURE, V261, P40
   Tilman D, 1996, ECOLOGY, V77, P350, DOI 10.2307/2265614
   Tilman David, 1993, P13
   TURNER MG, 1989, ANNU REV ECOL SYST, V20, P171, DOI 10.1146/annurev.es.20.110189.001131
   Urban Dean L., 1992, V11, P249
   Wiens J. A., 1986, COMMUNITY ECOLOGY, P145
NR 64
TC 33
Z9 34
U1 0
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-3800
EI 1872-7026
J9 ECOL MODEL
JI Ecol. Model.
PD NOV 17
PY 1997
VL 103
IS 2-3
BP 267
EP 285
DI 10.1016/S0304-3800(97)00111-7
PG 19
WC Ecology
SC Environmental Sciences & Ecology
GA YJ453
UT WOS:A1997YJ45300011
DA 2021-08-04
ER

PT J
AU Wetzstein, HG
   Schmeer, N
   Karl, W
AF Wetzstein, HG
   Schmeer, N
   Karl, W
TI Degradation of the fluoroquinolone enrofloxacin by the brown rot fungus
   Gloeophyllum striatum: Identification of metabolites
SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY
LA English
DT Article
ID WOOD-ROTTING FUNGI; WHITE ROT; CELLULOSE; AGENTS; LIGNIN; ACID
AB The degradation of enrofloxacin, a fluoroquinolone antibacterial drug used in veterinary medicine, was investigated with the brown rot fungus Gloeophyllum striatum. After 8 weeks, mycelia suspended in a defined liquid medium had produced 273, 18.5, and 6.7% (CO2)-C-14 from [C-14] enrofloxacin labeled either at position C-2, at position C-4, or in the piperazinyl moiety, respectively. Enrofloxacin, applied at 10 ppm, was transformed into metabolites already after about 1-week The most stable intermediates present in 2-day old supernatants were analyzed by high-performance liquid chromatography combined with electrospray ionization mass spectrometry. Eight of 11 proposed molecular structures could be confirmed by H-1 nuclear magnetic resonance spectroscopy or by cochromatography with reference compounds. We identified (i) 3-, 6-, and 8-hydroxylated congeners of enrofloxacin, which have no or only very little residual antibacterial activity; (ii) 5,6-(or 6,8-), 5,8-, and 7,8-dihydroxylated congeners, which were prone to autoxidative transformation; (iii) an isatin-type compound as well as an anthranilic acid derivative, directly demonstrating cleavage of the heterocyclic core of enrofloxacin; and (iv) 1-ethylpiperazine, the 7-amino congener, and desethglene-enrofloxacin, representing both elimination and degradation of the piperazinyl moiety. The pattern of metabolites implies four principle routes of degradation which might be simultaneously employed. Each route, initiated by either oxidative decarboxylation, defluorination, hydroxylation at C-8, or oxidation of the piperazinyl moiety, may reflect an initial attack by hydroxyl radicals at a different site of the drug. During chemical degradation of [4-C-14]enrofloxacin with Fenton's reagent, five confirmatory metabolites, contained in groups i and iv, were identified. These findings provide new evidence in support of the hypothesis that brown rot fungi may be capable of producing hydroxyl radicals, which could be utilized to degrade wood and certain xenobiotics.
C1 BAYER AG,CENT RES,D-51368 LEVERKUSEN,GERMANY.
RP Wetzstein, HG (corresponding author), BAYER AG,ANIM HLTH RES,D-51368 LEVERKUSEN,GERMANY.
CR ALEF K, 1991, METHODENHANDBUCH BOD, P89
   ANDREONI V, 1995, PROG IND M, V32, P1
   BACKA S, 1992, HOLZFORSCHUNG, V46, P61, DOI 10.1515/hfsg.1992.46.1.61
   BARR DP, 1994, REV ENVIRON CONTAM T, V138, P49
   BAUER I, 1994, FEMS MICROBIOL LETT, V117, P299, DOI 10.1111/j.1574-6968.1994.tb06783.x
   BOOMINATHAN K, 1992, HDB APPLIED MYCOLOGY, V4, P763
   BOOTHE DM, 1994, VET MED-US, V89, P744
   BUMPUS JA, 1985, SCIENCE, V228, P1434, DOI 10.1126/science.3925550
   BUMPUS JA, 1993, SOIL BIOCH, V8, P65
   Buswell JA, 1992, HDB APPLIED MYCOLOGY, V1, P425
   COLLETT O, 1992, MATER ORGANISMEN, V27, P67
   DOMAGALA JM, 1994, J ANTIMICROB CHEMOTH, V33, P685, DOI 10.1093/jac/33.4.685
   EDLUND C, 1988, ANTIMICROB AGENTS CH, V32, P1869, DOI 10.1128/AAC.32.12.1869
   Eggert C, 1996, FEBS LETT, V391, P144, DOI 10.1016/0014-5793(96)00719-3
   EVANS CS, 1994, FEMS MICROBIOL REV, V13, P235, DOI 10.1016/0168-6445(94)90081-7
   FREER SN, 1982, MYCOLOGIA, V74, P943, DOI 10.2307/3792724
   Frost A. J., 1991, Microbiology of animals and animal products. World Animal Science, A6.., P181
   Greene Craig E., 1993, P473
   Halliwell B., 1989, FREE RADICALS BIOL M
   HARPER DB, 1994, NAT PROD REP, V11, P123, DOI 10.1039/np9941100123
   HEKTOEN H, 1995, AQUACULTURE, V133, P175, DOI 10.1016/0044-8486(94)00310-K
   HIRANO T, 1995, MOKUZAI GAKKAISHI, V41, P334
   HOLZMAN D, 1995, ASM NEWS, V61, P445
   Hyde SM, 1996, FEMS MICROBIOL LETT, V145, P439, DOI 10.1016/S0378-1097(96)00448-X
   JOSELEAU JP, 1994, FEMS MICROBIOL REV, V13, P255, DOI 10.1016/0168-6445(94)90083-3
   Kaiser JP, 1996, MICROBIOL REV, V60, P483, DOI 10.1128/MMBR.60.3.483-498.1996
   Karabalut Nigahus, 1993, P195
   KIRK TK, 1991, HOLZFORSCHUNG, V45, P239, DOI 10.1515/hfsg.1991.45.4.239
   KLEMANLEYER K, 1992, APPL ENVIRON MICROB, V58, P1266, DOI 10.1128/AEM.58.4.1266-1270.1992
   Koenigs J. W., 1974, Wood and Fiber, V6, P66
   Marengo JR, 1997, ENVIRON TOXICOL CHEM, V16, P462, DOI [10.1897/1551-5028(1997)016&lt;0462:ABOCSH&gt;2.3.CO;2, 10.1002/etc.5620160311]
   MARKHAM P, 1991, HDB APPL MYCOLOGY, V1, P379
   Martens R, 1996, APPL ENVIRON MICROB, V62, P4206, DOI 10.1128/AEM.62.11.4206-4209.1996
   Nowara A, 1997, J AGR FOOD CHEM, V45, P1459, DOI 10.1021/jf960215l
   Orth A.B., 1995, MYCOTA, P287, DOI 10.1007/978-3-662-10364-7_17
   RIBBONS DW, 1987, J FLUORINE CHEM, V37, P299, DOI 10.1016/S0022-1139(00)81968-5
   RITSCHKOFF AC, 1995, J BIOTECHNOL, V40, P179, DOI 10.1016/0168-1656(95)00044-Q
   Schlosser D, 1997, APPL MICROBIOL BIOT, V47, P412, DOI 10.1007/s002530050949
   Schwarz Gerhild, 1994, P459
   Stalpers JAJM, 1978, STUDIES MYCOLOGY, V16
   THRN GR, 1996, APPL ENVIRON MICROB, V62, P4288
   VANCUTSEM PM, 1990, CORNELL VET, V80, P173
   WETZSTEIN HG, UNPUB
   WETZSTEIN HG, 1996, 96 GEN M AM SOC MICR, P414
   WETZSTEIN HG, 1996, COMPEND CONTIN ED S, V18, pS22
   WETZSTEIN HG, 1997, 97 GEN M AM SOC MICR, P519
   *WHO, 1995, WHO TECH REP SER, V855, P17
   WICKLOW DT, 1980, APPL ENVIRON MICROB, V40, P169, DOI 10.1128/AEM.40.1.169-170.1980
   WICKLOW DT, 1992, FUNGAL COMMUNITY ITS, P715
   WOLFSON JS, 1989, CLIN MICROBIOL REV, V2, P378, DOI 10.1128/CMR.2.4.378-424.1989
   WOOD PM, 1994, FEMS MICROBIOL REV, V13, P313, DOI 10.1111/j.1574-6976.1994.tb00051.x
NR 51
TC 102
Z9 111
U1 1
U2 19
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171
SN 0099-2240
J9 APPL ENVIRON MICROB
JI Appl. Environ. Microbiol.
PD NOV
PY 1997
VL 63
IS 11
BP 4272
EP 4281
DI 10.1128/AEM.63.11.4272-4281.1997
PG 10
WC Biotechnology & Applied Microbiology; Microbiology
SC Biotechnology & Applied Microbiology; Microbiology
GA YE281
UT WOS:A1997YE28100021
PM 9361414
OA Green Published, Bronze
DA 2021-08-04
ER

PT J
AU Zuniga, MA
   Neureuther, AR
AF Zuniga, MA
   Neureuther, AR
TI Stress dependent silylation model and two-dimensional profile simulation
SO JOURNAL OF VACUUM SCIENCE & TECHNOLOGY B
LA English
DT Article; Proceedings Paper
CT 41st International Conference on Electron, Ion, and Photon Beam
   Technology and Nanofabrication (EIBPN)
CY MAY 27-30, 1997
CL DANA POINT, CALIFORNIA
SP Amer Vacuum Soc, IEEE, Electron Device Soc, Optical Soc Amer
ID LITHOGRAPHY
AB A new model for polymer silylation is proposed that takes into account three mechanisms: The relaxation of the polymer during silylation, a diffusivity of the silylating agent which increases with resist matrix expansion, as well as a local reaction rate retardation due to stress induced by resist swelling. These mechanisms capture changes in profile shape during silylation. The resulting nonlinear differential equations are solved two-dimensional (2D) using the finite element method and the influence of the main parameters is studied as a function of feature size and feature type, illustrating the effects of initial aerial image and processing conditions on the final resist image. The simulation profiles reproduce the silylation depth reduction with feature size and abrupt encroachment heretofore unexplained in various experimental studies. (C) 1997 American Vacuum Society.
C1 Univ Calif Berkeley, Elect Res Lab, Berkeley, CA 94720 USA.
RP Zuniga, MA (corresponding author), Univ Calif Berkeley, Elect Res Lab, Berkeley, CA 94720 USA.
CR ARIALI J, 1989, J SOC IND APPL MATH, V10, P165
   BABUSKA I, 1986, ACCURACY ESTIMATES A
   Crank J., 1975, MATH DIFFUSION
   DAVIS A, 1983, APPL SCI
   HARTNEY MA, 1993, J VAC SCI TECHNOL B, V11, P681, DOI 10.1116/1.586818
   Horn MW, 1996, J VAC SCI TECHNOL B, V14, P4207, DOI 10.1116/1.588576
   JAGHOLD U, 1995, P SOC PHOTO-OPT INS, V2438, P884
   LATULIPE DC, 1994, P SOC PHOTO-OPT INS, V2195, P372, DOI 10.1117/12.175353
   MATHUR BP, 1994, P SOC PHOTO-OPT INS, V2195, P497, DOI 10.1117/12.175364
   MCDONAGH D, 1996, OPT LETT, V277
   NEALEY PF, 1995, POLYMER, V36, P3687, DOI 10.1016/0032-3861(95)93771-D
   NICHOLAU D, 1992, P SOC PHOTO-OPT INS, V1672, P461
   ODONNELL B, 1994, J MATER SCI, V29, P3955, DOI 10.1007/BF00355954
   Ohfuji T, 1996, J VAC SCI TECHNOL B, V14, P4203, DOI 10.1116/1.588575
   PIERRAT C, 1992, J VAC SCI TECHNOL B, V10, P2581, DOI 10.1116/1.586331
   SHEWCHUK JR, 1996, 1 WORKSH APPL COMP G
   SUTARDJA P, 1988, THESIS U CALIFORNIA
   WEIB M, 1996, MICROELECTRON ENGG, V30, P313
   WONG A, 1994, THESIS U CALIFORNIA
NR 19
TC 1
Z9 1
U1 0
U2 0
PU AMER INST PHYSICS
PI WOODBURY
PA CIRCULATION FULFILLMENT DIV, 500 SUNNYSIDE BLVD, WOODBURY, NY 11797-2999
   USA
SN 1071-1023
J9 J VAC SCI TECHNOL B
JI J. Vac. Sci. Technol. B
PD NOV-DEC
PY 1997
VL 15
IS 6
BP 2565
EP 2569
DI 10.1116/1.589686
PG 5
WC Engineering, Electrical & Electronic; Nanoscience & Nanotechnology;
   Physics, Applied
SC Engineering; Science & Technology - Other Topics; Physics
GA YM807
UT WOS:000071103100133
DA 2021-08-04
ER

PT J
AU Blasco, G
   Traversa, U
   Drago, F
AF Blasco, G
   Traversa, U
   Drago, F
TI Effects of nicergoline on rabbit electroretinogram during recovery after
   ischaemia in light and dark
SO PHARMACOLOGICAL RESEARCH
LA English
DT Article
DE nicergoline; electroretinogram; b-wave; ischaemia; reperfusion
ID ISCHEMIC-INJURY; BRAIN DAMAGES; RETINA; ANIMALS; DEXTROMETHORPHAN;
   AGGREGATION; PROTECTION; CATALASE; HYPOXIA
AB Nicergoline is an ergot alkaloid derivative acting as a neuroprotective agent. In the present investigation, b-wave time-course recovery profiles under both light-and dark-adapted conditions, were studied in order to evaluate the possible effectiveness of nicergoline in the protection of the rabbit retina. Retinal ischaemia was induced by bilateral occlusion of common carotid artery in male rabbit of the Dutch strain. Groups of animals were subjected to 15-, 30- and 60-min periods of ischaemia under pentobarbital anaesthesia. Electroretinogram recordings were simultaneously obtained from both eyes, using, as the stimulus, the brightest flash from a stimulator positioned 15 cm in front of each eye. The treatment with nicergoline, administered immediately before the carotid occlusion, induced a significant protection only when the ischaemia seemed to cause retinal damage that the reperfusion alone was not able to recover completely. Nicergoline did not modify the recovery rate after 15-min or 30-min light-adapted and 15-min dark-adapted ischaemia; in these conditions the controls showed a full recovery. After 30-min dark-adapted ischaemia, the maximum recovery of the controls was 82%, and nicergoline significantly improved b-wave amplitude at all time points of reperfusion up to the complete recovery. Rabbit retina was irreversibly damaged by a 60-min ischaemia. In these conditions nicergoline significantly increased the percentage of b-wave recovery both in light-and dark-adapted ERG. Nicergoline, probably on the basis of its metabolic actions, seems to be effective in severe conditions of hypoxia and is more potent in dark than in light-adapted conditions. Its effectiveness in these experimental conditions could be justified by the different oxygen consumption of the photoreceptors in light and dark and the different sensitivity of cones and rods to the ischaemia. (C) 1997 The Italian Pharmacological Society.
C1 Univ Catania, Sch Med, Inst Pharmacol, Fac Med, I-95125 Catania, Italy.
   Univ Trieste, Sch Med, Osped Maggiore, Inst Ophthalmol, Trieste, Italy.
   Univ Trieste, Sch Med, Dept Biomed Sci, Trieste, Italy.
RP Drago, F (corresponding author), Univ Catania, Sch Med, Inst Pharmacol, Fac Med, Viale A Doria 6, I-95125 Catania, Italy.
RI Drago, Francesco/H-7563-2019; Drago, Filippo/K-5619-2018
OI Drago, Filippo/0000-0003-2887-5223
CR Ames A 3rd, 1983, Am J Emerg Med, V1, P139, DOI 10.1016/0735-6757(83)90081-5
   ARCARI G, 1968, BRIT J PHARMACOL, V34, pP700
   BATTAGLIA A, 1989, J AM GERIATR SOC, V37, P295
   Bock J, 1971, Trans Ophthalmol Soc U K, V91, P399
   BRUNETTE JR, 1986, CAN J OPHTHALMOL, V21, P13
   BRUNETTE JR, 1986, DOC OPHTHALMOL, V63, P359
   CHISHOLM IA, 1974, T OPHTHAL SOC UK, V94, P335
   DEGAETANO G, 1976, I RIC FARM M NEGRI, P19
   DIKOVA M, 1989, BIOMED BIOCHIM ACTA, V48, pS227
   FEKE GT, 1983, INVEST OPHTH VIS SCI, V24, P136
   GARA II, 1993, ZH NEVROPATOL PSIKH, V93, P28
   GUPTA LY, 1993, ARCH OPHTHALMOL-CHIC, V111, P384, DOI 10.1001/archopht.1993.01090030104049
   Johnson N F, 1974, Trans Ophthalmol Soc U K, V94, P394
   JOHNSON NF, 1976, ACTA OPHTHALMOL, V54, P517
   JOHNSON NF, 1978, EXP EYE RES, V27, P45, DOI 10.1016/0014-4835(78)90052-0
   KIM SY, 1994, INVEST OPHTH VIS SCI, V35, P664
   LANZA F, 1986, AGENTS ACTIONS, V18, P586, DOI 10.1007/BF01964968
   LINSENMEIER RA, 1986, J GEN PHYSIOL, V88, P521, DOI 10.1085/jgp.88.4.521
   LINSENMEIER RA, 1990, GRAEF ARCH CLIN EXP, V228, P143, DOI 10.1007/BF00935724
   MAFFEI L, 1990, RES P ARNMD, V67, P289
   Morisaki H, 1994, Nihon Jibiinkoka Gakkai Kaiho, V97, P1393
   NAGAKAWA Y, 1990, ARZNEIMITTEL-FORSCH, V40-2, P862
   NAYAK MS, 1993, INVEST OPHTH VIS SCI, V34, P2018
   PELLEGRINIGIAMPIETRO DE, 1990, J NEUROSCI, V10, P1035, DOI 10.1523/jneurosci.10-03-01035.1990
   SALETU B, 1990, J NEURAL TRANSM-PARK, V2, P305, DOI 10.1007/BF02252925
   SHINTOMI K, 1991, ARZNEIMITTEL-FORSCH, V41-2, P885
   SHINTOMI K, 1986, FOLIA PHARMACOL JPN, V87, P445, DOI 10.1254/fpj.87.445
   SHINTOMI K, 1986, FOLIA PHARMACOL JPN, V87, P537, DOI 10.1254/fpj.87.537
   SHINTOMI K, 1986, FOLIA PHARMACOL JPN, V87, P427, DOI 10.1254/fpj.87.427
   TOKAR AV, 1990, VRACHEBNOE DELO, V2, P27
   Ueda T, 1992, No To Shinkei, V44, P1095
   ULRICH WD, 1986, DOC OPHTHALMOL, V63, P91, DOI 10.1007/BF00153016
   YOON YH, 1989, ARCH OPHTHALMOL-CHIC, V107, P409, DOI 10.1001/archopht.1989.01070010419037
   ZUCKERMAN R, 1980, EXP EYE RES, V30, P117, DOI 10.1016/0014-4835(80)90106-2
NR 34
TC 3
Z9 3
U1 0
U2 0
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-6618
J9 PHARMACOL RES
JI Pharmacol. Res.
PD NOV
PY 1997
VL 36
IS 5
BP 363
EP 368
DI 10.1006/phrs.1997.0240
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA YP189
UT WOS:000071251500003
PM 9441726
DA 2021-08-04
ER

PT J
AU Wang, QA
   He, TB
   Xia, P
   Chen, TL
   Huang, BT
AF Wang, QA
   He, TB
   Xia, P
   Chen, TL
   Huang, BT
TI Cure processing modeling and cure cycle simulation of epoxy-terminated
   poly(phenylene ether ketone) .1. DSC characterization of curing reaction
SO JOURNAL OF APPLIED POLYMER SCIENCE
LA English
DT Article
DE epoxy resin; poly(phenylene ether ketone); curing reaction kinetics;
   model and simulation; differential scanning calorimetry
ID KINETICS; COMPOSITES; BEHAVIOR; PREPREG; RESINS
AB The curing reaction process of epoxy-terminated poly(phenylene ether ketone) (E-PEK) with 4,4'-diaminodiphenyl sulfone (DDS) and hexahydrophthalic acid anhydride (Nadic) as curing agents was investigated using isothermal differential scanning calorimetry (IDSC) and nonisothermal differential scanning calorimetry (DDSC) techniques. It was found that the curing reactions of E-PEK/DDS and E-PEK/Nadic are nth-order reactions but not autoaccelerating. The experimental results revealed that the curing reaction kinetics parameters measured from IDSC and DDSC are not equivalent. This means that, in the curing reaction kinetics model for our E-PEK system, both isothermal and nonisothermal reaction kinetics parameters are needed to describe isothermal and nonisothermal curing processes, The isothermal and nonisothermal curing processes were successfully simulated using this model. A new extrapolation method was suggested. On the basis of this method the maximum extent of the curing reaction (A(ult)) that is able to reach a certain temperature can be predicted. The A(ult) for the E-PEK system estimated by the new method agrees well with the results obtained from another procedure reported in the literature. (C) 1997 John Wiley & Sons, Inc.
C1 CHINESE ACAD SCI,CHANGCHUN INST APPL CHEM,STATE KEY LAB POLYMER MAT & ENGN,POLYMER PHYS LAB,CHANGCHUN 130022,PEOPLES R CHINA.
   HEBEI UNIV TECHNOL,DEPT CHEM ENGN,TIANJIN 300130,PEOPLES R CHINA.
CR BARRETT KEJ, 1967, J APPL POLYM SCI, V11, P1617, DOI 10.1002/app.1967.070110901
   BARTON JM, 1974, J MACROMOL SCI CHEM, V171, P247
   BARTON JM, 1974, POLYM CHARACTERIZATI, P25
   COLE KC, 1989, POLYM COMPOSITE, V10, P150, DOI 10.1002/pc.750100303
   CRANE LW, 1973, J POLYM SCI POL LETT, V11, P533, DOI 10.1002/pol.1973.130110808
   DUSI MR, 1983, ACS SYM SER, V227, P301
   ENNS JB, 1983, J APPL POLYM SCI, V28, P2567, DOI 10.1002/app.1983.070280810
   FREEMAN ES, 1958, J PHYS CHEM-US, V62, P394, DOI 10.1021/j150562a003
   GOLUB MA, 1986, J APPL POLYM SCI, V32, P215
   HAGNAUER GL, 1983, ACS SYM SER, V221, P229
   HINRICHS RJ, 1983, ACS SYM SER, V227, P187
   KAY R, 1975, EUR POLYM J, V11, P25, DOI 10.1016/0014-3057(75)90170-6
   KENNY JM, 1994, J APPL POLYM SCI, V51, P761, DOI 10.1002/app.1994.070510424
   KENNY JM, 1991, POLYM ENG SCI, V31, P1426, DOI 10.1002/pen.760311909
   LOOS AC, 1983, J COMPOS MATER, V17, P135, DOI 10.1177/002199838301700204
   MIJOVIC J, 1986, J APPL POLYM SCI, V31, P1177, DOI 10.1002/app.1986.070310503
   MOACANIN J, 1983, ACS SYM SER, V227, P83
   PRIME RB, 1982, THERMAL CHARACTERIST, pCH5
   RICCARDI CC, 1984, J APPL POLYM SCI, V29, P2481, DOI 10.1002/app.1984.070290805
   SCHNEIDER NS, 1979, POLYM ENG SCI, V19, P304, DOI 10.1002/pen.760190413
   SCOTT EP, 1993, POLYM ENG SCI, V18, P1157
   SUE HJ, 1995, POLYM PREP-ACS, V36, P769
   WANG Q, IN PRESS J APPL POLY
NR 23
TC 11
Z9 11
U1 0
U2 4
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-8995
J9 J APPL POLYM SCI
JI J. Appl. Polym. Sci.
PD OCT 24
PY 1997
VL 66
IS 4
BP 789
EP 797
DI 10.1002/(SICI)1097-4628(19971024)66:4<789::AID-APP19>3.3.CO;2-E
PG 9
WC Polymer Science
SC Polymer Science
GA XX810
UT WOS:A1997XX81000019
DA 2021-08-04
ER

PT J
AU Chambers, LK
   Singleton, GR
   Hood, GM
AF Chambers, LK
   Singleton, GR
   Hood, GM
TI Immunocontraception as a potential control method of wild rodent
   populations
SO BELGIAN JOURNAL OF ZOOLOGY
LA English
DT Article; Proceedings Paper
CT International Workshop on Rodent Biology and Integrated Pest Management
   in Africa
CY OCT 21-25, 1996
CL MOROGORO, TANZANIA
DE fertility reduction; rodents; immunocontraception; mouse plagues; Mus
   domesticus; computer simulation; experimental design
ID MICE MUS-DOMESTICUS; HOUSE MICE; SOUTHEASTERN AUSTRALIA; MURINE
   CYTOMEGALOVIRUS; FERTILITY-CONTROL; PREDATION; VIRUSES
AB Rodents have the capacity to periodically reach very high numbers in agricultural landscapes, reducing agricultural production, and causing considerable environmental and social problems for farmers and their families. Such rodent problems occur worldwide and have a long history. Currently mortality enhancing agents (mainly poisons) are the principal method of rodent control. This approach raises environmental, ethical and humane issues, and ignores the inherent high capacity for increase in these species. We argue that it is more appropriate to reduce reproduction than increase mortality. This paper uses house mice in Australia as a case study to explore fertility reduc tion as a potential alternative to conventional methods of control. In particular, the question of what level of fertility control is required to have a significant effect on population growth is discussed. A computer simulation, based on the life-history strategies of house mice, examined the effect of different levels of fertility control on mouse population dynamics. This simulation provides a reference for future studies of confined populations of mice used to test the effects of fertility control, refines the design of these experiments and identifies the type of data needed to be collected. Immunocontraception, the process of inducing the body's immune system to attack its own reproductive cells, is suggested as a method for reducing fertility in rodent populations. The advantages and disadvantages of immunocontraception over mortality-enhancing agents are discussed, as are the potential impacts of social structure on the efficacy of immunocontraception and the possible application of this control method to other rodent pest situations, particularly rodent pest problems in Africa.
RP Chambers, LK (corresponding author), CSIRO,DIV WILDLIFE & ECOL,CRC BIOL CONTROL VERTEBRATE PEST POPULAT,POB 84,LYNEHAM,ACT 2602,AUSTRALIA.
RI Singleton, Grant/B-6230-2013; Akison, Lisa/M-8104-2013
OI Singleton, Grant/0000-0002-2154-1223; Akison, Lisa/0000-0002-2667-3743
CR ANDERSSON M, 1977, OIKOS, V29, P591, DOI 10.2307/3543597
   BARKER SC, 1991, PARASITOLOGY, V103, P439, DOI 10.1017/S0031182000059965
   BOMFORD M, 1990, BUREAU RURAL RESOURC, V7, P1
   BOOTH TWM, 1993, ARCH VIROL, V132, P209, DOI 10.1007/BF01309855
   BUCKLE A.L., 1994, RODENT PESTS THEIR C
   CAUGHLEY G, 1992, WILDLIFE RES, V19, P623, DOI 10.1071/WR9920623
   CAUGHLEY J, 1994, OCCASIONAL PAPER SER, V7
   Childs J.E., 1994, P 16 VERT PEST C, P188
   Cowan PE, 1997, REPROD FERT DEVELOP, V9, P27, DOI 10.1071/R96058
   CROWCROFT P, 1966, MICE OVER
   GEDDES AMW, 1992, 47 NAT RES I B
   Gratz N. G., 1994, P85
   JAKSIC FM, 1992, OECOLOGIA, V89, P90, DOI 10.1007/BF00319020
   Key G, 1994, P 16 VERT PEST C U C, P118
   KORPIMAKI E, 1989, OIKOS, V54, P154, DOI 10.2307/3565261
   Leirs H, 1997, BELG J ZOOL, V127, P29
   MILLAR SE, 1989, SCIENCE, V246, P935, DOI 10.1126/science.2479101
   Moors P.J., 1992, Bird Conservation International, V2, P93
   Oogjes G, 1997, REPROD FERT DEVELOP, V9, P163, DOI 10.1071/R96061
   Prakash I., 1988, RODENT PEST MANAGEME
   REDHEAD TD, 1987, CAPILLARIA HEPATICA, P6
   REDHEAD TD, 1982, THESIS AUSTR NATL U
   SAINSBURY AW, 1995, ANIM WELFARE, V4, P183
   SAUNDERS G, 1981, EMU, V82, P227
   SHELLAM GR, 1994, REPROD FERT DEVELOP, V6, P401, DOI 10.1071/RD9940401
   Sinclair ARE, 1997, REPROD FERT DEVELOP, V9, P1, DOI 10.1071/R96057
   SINCLAIR ARE, 1991, OIKOS, V59, P382
   SINGLETON G. R., 1994, 30 ACIAR
   SINGLETON GR, 1983, BEHAV ECOL SOCIOBIOL, V12, P49, DOI 10.1007/BF00296932
   SINGLETON GR, 1990, BIOL J LINN SOC, V41, P285, DOI 10.1111/j.1095-8312.1990.tb00837.x
   SINGLETON GR, 1989, J ZOOL, V219, P495, DOI 10.1111/j.1469-7998.1989.tb02596.x
   SINGLETON GR, 1987, ACTA THERIOL, V32, P245, DOI 10.4098/AT.arch.87-17
   SINGLETON GR, 1993, EPIDEMIOL INFECT, V110, P399, DOI 10.1017/S0950268800068345
   SINGLETON GR, 1994, P 16 VERT PEST C U C, P301
   SINGLETON GR, 1989, MEDITERRANEAN LANDSC, P418
   SMITH AL, 1993, J WILDLIFE DIS, V29, P219, DOI 10.7589/0090-3558-29.2.219
   SOUTHWOOD TRE, 1977, J ANIM ECOL, V46, P337
   Thompson DW, 1910, WORKS ARISTOTLE, VIV
   TYNDALEBISCOE CH, 1994, REPROD FERT DEVELOP, V6, P281, DOI 10.1071/RD9940281
   TYNDALEBISCOE CH, 1991, REPROD FERT DEVELOP, V3, P339, DOI 10.1071/RD9910339
   TYNDALEBISCOE CH, 1997, REPROD FERT DEVELOP, V9, P183
   TYNDALEBISCOE H, 1995, SEARCH, V26, P239
   Wace N.M., 1986, Oryx, V20, P79
   WHITTEN WK, 1966, ADV REPROD PHYSIOL, V1, P155
   WHITTINGHAM DG, 1983, MOUSE BIOMEDICAL RES, V3, P137
   Williams CK, 1996, FRONTIERS OF POPULATION ECOLOGY, P547
   Williams CK, 1997, REPROD FERT DEVELOP, V9, P169, DOI 10.1071/R96063
NR 47
TC 28
Z9 32
U1 0
U2 9
PU SOCIETE ROYALE ZOOLOGIQUE DE BELGIQUE
PI DIEPENBEEK
PA C/O PROF DR E SCHOCKAERT, DEPT SBG, LIMBURGS UNIVERSITAIR CENTRUM,
   B-3590 DIEPENBEEK, BELGIUM
SN 0777-6276
J9 BELG J ZOOL
JI Belg. J. Zool.
PD OCT
PY 1997
VL 127
SU 1
BP 145
EP 156
PG 12
WC Zoology
SC Zoology
GA YF238
UT WOS:A1997YF23800018
DA 2021-08-04
ER

PT J
AU McElwee, KJ
   Rushton, DH
   Trachy, R
   Oliver, RF
AF McElwee, KJ
   Rushton, DH
   Trachy, R
   Oliver, RF
TI Topical FK506: a potent immunotherapy for alopecia areata? Studies using
   the Dundee experimental bald rat model
SO BRITISH JOURNAL OF DERMATOLOGY
LA English
DT Article
ID RESTORES HAIR-GROWTH; CYCLOSPORINE-A; DEBR RAT; IMMUNOHISTOCHEMICAL
   ANALYSIS; ORAL CYCLOSPORINE; FK-506; IMMUNOSUPPRESSANT; CALCINEURIN;
   RAPAMYCIN; SKIN
AB We elected to examine the efficacy of the topically applied immunosuppressive agent FK506 (Prograf(R)) in the treatment of alopecia areata (AA) using the Dundee experimental bald rat (DEER) model, Thirty lesional DEER rats were allocated to five groups of six, Group I rats received 0.1 mL of a 0.25% solution of FK506 within a 2 x 2 cm marked area on one bald flank twice a week (125 mu g FK506/cm(2) per week) for 8 weeks, while the contralateral flank was left untreated, In group II, 0.05 mL of a 0.1% solution of FK506 was applied 5 days per week on one flank (62.5 mu g FK506/cm(2) per week) and control vehicle to the opposite flank for 8 weeks. Group III rats were treated as in group II except that drug and vehicle were applied twice a week (25 mu g FK506/cm(2) per week) for 4 weeks. A positive control group received orally administered cyclosporin A (CsA) (10 mg/kg daily) for 8 weeks and a further group was left untreated, Rats were regularly examined and photographed with skin biopsies taken from groups II and III. All FK506-treated rats regrew hair at the site of drug application within 14-21 days. Growth continued for 3 weeks beyond termination of treatment after which gradual hair loss was observed, No hair growth was seen as a result of vehicle application and hair loss continued on untreated areas and in the untreated control group, Immunohistology revealed a drastic reduction in the follicular inflammatory infiltrate at the site of the FK506 application, The oral CsA group responded by simultaneous regrowth of hair over the whole body. Our findings suggest that FK506 may have considerable potential as a topical treatment for AA.
C1 UNIV DUNDEE, DEPT BIOL SCI, DUNDEE DD1 4HN, SCOTLAND.
   UNIV PORTSMOUTH, SCH PHARM, PORTSMOUTH PO1 2UP, HANTS, ENGLAND.
   PROCYTE CORP, KIRKLAND, WA USA.
RI Rushton, D Hugh/AAE-8491-2020
OI McElwee, Kevin/0000-0003-1020-3832
CR CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0
   COULSON IH, 1989, BR J DERMATOL S34, V121, P53
   DUNCAN JI, 1994, J INVEST DERMATOL, V102, P84, DOI 10.1111/1523-1747.ep12371737
   GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5
   GUPTA AK, 1990, J AM ACAD DERMATOL, V22, P242, DOI 10.1016/0190-9622(90)70032-D
   JIANG H, 1995, J INVEST DERMATOL, V104, P523, DOI 10.1111/1523-1747.ep12606018
   LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H
   McElwee KJ, 1996, BRIT J DERMATOL, V135, P211, DOI 10.1046/j.1365-2133.1996.d01-977.x
   McElwee KJ, 1996, INT CONGR SER, V1111, P253
   McElwee KJ, 1996, BRIT J DERMATOL, V134, P55, DOI 10.1111/j.1365-2133.1996.tb07840.x
   McElwee KJ, 1996, INT CONGR SER, V1111, P259
   MCELWEE KJ, 1996, THESIS U DUNDEE
   MCELWEE KJ, 1995, J INVEST DERMATOL S, V104, P34
   MEINGASSNER JG, 1992, J INVEST DERMATOL, V98, P851, DOI 10.1111/1523-1747.ep12456939
   MICHIE HJ, 1990, BRIT J DERMATOL, V123, P557, DOI 10.1111/j.1365-2133.1990.tb01471.x
   MICHIE HJ, 1991, BRIT J DERMATOL, V125, P94, DOI 10.1111/j.1365-2133.1991.tb06054.x
   MICHIE HJ, 1989, DEBR RAT ANIMAL MODE
   OLIVER RF, 1995, CLIN EXP DERMATOL, V20, P127, DOI 10.1111/j.1365-2230.1995.tb02669.x
   OLIVER RF, 1991, J INVEST DERMATOL, V96, pS97, DOI 10.1111/1523-1747.ep12472251
   PARODI A, 1987, ARCH DERMATOL, V123, P135
   PERRET C, 1984, ACTA DERM-VENEREOL, V64, P26
   Perret CM, 1990, HAIR HAIR DISEASES, P571
   PRICE VH, 1991, PROG DERMATOL, V25, P1
   SAINSBURY TSL, 1991, TRANSPLANT P, V23, P3332
   SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511
   SUNDBERG JP, 1995, J INVEST DERMATOL, V104, P33
   THOMSON AW, 1993, SPRINGER SEMIN IMMUN, V14, P323, DOI 10.1007/BF00192307
   YAMAMOTO S, 1994, J INVEST DERMATOL, V102, P160, DOI 10.1111/1523-1747.ep12371755
   YAMAMOTO S, 1994, J DERMATOL SCI S, V7, P547
   ZHANG JG, 1994, BRIT J DERMATOL, V130, P405, DOI 10.1111/j.1365-2133.1994.tb03371.x
   1984, LANCET, V1, P1335
NR 31
TC 59
Z9 64
U1 1
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0007-0963
J9 BRIT J DERMATOL
JI Br. J. Dermatol.
PD OCT
PY 1997
VL 137
IS 4
BP 491
EP 497
DI 10.1111/j.1365-2133.1997.tb03777.x
PG 7
WC Dermatology
SC Dermatology
GA YD862
UT WOS:A1997YD86200002
PM 9390322
DA 2021-08-04
ER

PT J
AU Kunnev, D
   Tsvetkov, L
   Anachkova, B
   Russev, G
AF Kunnev, D
   Tsvetkov, L
   Anachkova, B
   Russev, G
TI Clusters of replicons that fire simultaneously may be organized into
   superloops
SO DNA AND CELL BIOLOGY
LA English
DT Article
ID MAMMALIAN DNA-REPLICATION; XENOPUS EGG EXTRACT; IONIZING-RADIATION;
   HUMAN-CELLS; S-PHASE; INITIATION; SITES; IDENTIFICATION; CHROMOSOMES;
   INHIBITION
AB To study the relation between replicon initiation and nuclear organization of DNA, mouse erythroleukemia F4N cells were irradiated with Co-60 source and the rates of initiation of DNA synthesis were determined by a sensitive assay based on the introduction of Trioxsalen cross-links in DNA in vivo and determination of the amount of short nascent DNA fragments synthesized between the cross-links, In parallel, nuclear organization of DNA was monitored using the nucleoid sedimentation technique, The results show that DNA initiation rate and relative nucleoid sedimentation change sharply and simultaneously at doses of about 1 Gy, which suggests the existence of relationship between them, This suggestion was supported by the finding, that during the after-irradiation period, first DNA organization was restored and only after this process had been completed, the restoration of replicon initiation commenced, When cells were treated with novobiocin, an agent that is known to slow down the recovery of nucleoid sedimentation rate, initiation of DNA synthesis was also postponed, A hypothesis is put forward that replicon clusters represent groups of adjacent DNA loops organized in superloop domains and that the intact superloop domain structure is necessary for activation of the cluster.
C1 BULGARIAN ACAD SCI,INST MOL BIOL,BU-1113 SOFIA,BULGARIA.
CR ANACHKOVA B, 1984, EUR J BIOCHEM, V141, P105, DOI 10.1111/j.1432-1033.1984.tb08163.x
   ANACHKOVA B, 1985, BIOCHEM BIOPH RES CO, V128, P101, DOI 10.1016/0006-291X(85)91650-X
   ANACHKOVA B, 1989, MOL CELL BIOL, V9, P532, DOI 10.1128/MCB.9.2.532
   BLOW JJ, 1990, J CELL SCI, V95, P383
   BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0
   BURHANS WC, 1990, CELL, V62, P955, DOI 10.1016/0092-8674(90)90270-O
   CLEAVER JE, 1990, RADIAT RES, V124, P294, DOI 10.2307/3577842
   COOK PR, 1991, CELL, V66, P627, DOI 10.1016/0092-8674(91)90109-C
   COOK PR, 1975, J CELL SCI, V19, P261
   DROUIN R, 1990, CHROMOSOMA, V99, P273, DOI 10.1007/BF01731703
   DUBE SK, 1975, P NATL ACAD SCI USA, V72, P1863, DOI 10.1073/pnas.72.5.1863
   Gencheva M, 1996, J BIOL CHEM, V271, P2608, DOI 10.1074/jbc.271.5.2608
   GILBERT DM, 1995, MOL CELL BIOL, V15, P2942
   GOODHEAD DT, 1994, INT J RADIAT BIOL, V65, P7, DOI 10.1080/09553009414550021
   HAND R, 1978, CELL, V15, P317, DOI 10.1016/0092-8674(78)90001-6
   HOZAK P, 1994, J CELL SCI, V107, P2191
   HUBERMAN JA, 1968, J MOL BIOL, V32, P327, DOI 10.1016/0022-2836(68)90013-2
   JACKSON DA, 1995, EXP CELL RES, V220, P62, DOI 10.1006/excr.1995.1292
   KITSBERG D, 1993, NATURE, V366, P588, DOI 10.1038/366588a0
   LALLEV A, 1993, EUR J BIOCHEM, V216, P177, DOI 10.1111/j.1432-1033.1993.tb18130.x
   LAMB JR, 1989, INT J RADIAT BIOL, V56, P125, DOI 10.1080/09553008914551271
   MATTERN MR, 1979, BIOCHIM BIOPHYS ACTA, V563, P306, DOI 10.1016/0005-2787(79)90049-2
   MATTERN MR, 1983, BIOCHEM BIOPH RES CO, V112, P1077, DOI 10.1016/0006-291X(83)91728-X
   MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835
   PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315
   PAINTER RB, 1986, INT J RADIAT BIOL, V49, P771
   PAULSON JR, 1977, CELL, V12, P817, DOI 10.1016/0092-8674(77)90280-X
   POVIRK LF, 1976, BIOCHIM BIOPHYS ACTA, V432, P267, DOI 10.1016/0005-2787(76)90135-0
   RUSSEV G, 1982, J MOL BIOL, V161, P77, DOI 10.1016/0022-2836(82)90279-0
   Tsvetkov L, 1996, EUR J BIOCHEM, V237, P489, DOI 10.1111/j.1432-1033.1996.0489k.x
   VASSILEV L, 1987, BIOCHIM BIOPHYS ACTA, V949, P138
   WALICKA M, 1989, INT J RADIAT BIOL, V55, P953, DOI 10.1080/09553008914550991
   YOKOTA H, 1995, J CELL BIOL, V130, P1239, DOI 10.1083/jcb.130.6.1239
   YOON Y, 1995, MOL CELL BIOL, V15, P2482
   ZLATANOVA J S, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P211
NR 35
TC 9
Z9 9
U1 0
U2 1
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538
SN 1044-5498
J9 DNA CELL BIOL
JI DNA Cell Biol.
PD SEP
PY 1997
VL 16
IS 9
BP 1059
EP 1065
DI 10.1089/dna.1997.16.1059
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
GA YA934
UT WOS:A1997YA93400005
PM 9324308
DA 2021-08-04
ER

PT J
AU RodriguezArias, M
   Minarro, J
   Simon, VM
AF RodriguezArias, M
   Minarro, J
   Simon, VM
TI Interaction of morphine and haloperidol on agonistic and motor behaviors
   of male mice
SO PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
LA English
DT Article
DE aggression; morphine; haloperidol; motor activity; reward; mice
   dopamine; opiates
ID MESOLIMBIC DOPAMINE SYSTEM; D-2 RECEPTOR ANTAGONISTS; VENTRAL TEGMENTAL
   AREA; NUCLEUS-ACCUMBENS; INDUCED HYPERACTIVITY; AGGRESSIVE-BEHAVIOR;
   LOCOMOTOR-ACTIVITY; OPIATE; RATS; OPIOIDS
AB To further clarify the interaction between opioid and dopaminergic systems, the effects of simultaneous administration of morphine hydrochloride (1.25 or 2.5 mg/kg) and haloperidol (0.1 mg/kg) on aggressive behavior of male mice were explored. Isolated male mice (experimental animals)were confronted in a neutral area with anosmic, group-housed conspecifics (standard opponents) 30 min after injection of both compounds, and aggression was evaluated by estimation of times allocated to II different behavioral categories. In the first experiment (which functioned as a pilot study), the two doses of morphine were explored. In the second one, incorporating a more complete experimental design, only the lowest morphine dose was used and the animals were preselected by a previous aggression test. In attack behavior, morphine added to haloperidol counteracted, at least partially, the antiaggressive effect of the neuroleptic. In contrast, the impairing effects of haloperidol on motor activity were increased by the addition of morphine. These results show that the behavioral effects of dopaminergic antagonists are modulated by opioid influences and that opiates and dopaminergic agents interact in a different manner on motor and on aggressive behaviors. (C) 1997 Elsevier Science Inc.
C1 UNIV VALENCIA,FAC PSICOL,AREA PSICOBIOL,VALENCIA 46071,SPAIN.
RI Rodriguez-Arias, Marta/B-5163-2011; Minarro, Jose/B-4414-2011
OI Minarro, Jose/0000-0002-5731-7821
CR ACQUAS E, 1989, PSYCHOPHARMACOLOGY, V99, P151, DOI 10.1007/BF00442800
   AGUILAR MA, 1994, PHARMACOL BIOCHEM BE, V47, P753, DOI 10.1016/0091-3057(94)90185-6
   AXON DIR, 1987, PHARMACOL BIOCHEM BE, V26, P45, DOI 10.1016/0091-3057(87)90531-4
   BALSARA JJ, 1984, PSYCHOPHARMACOLOGY, V82, P237, DOI 10.1007/BF00427781
   BOZARTH MA, 1983, PROG NEURO-PSYCHOPH, V7, P569, DOI 10.1016/0278-5846(83)90027-1
   BOZARTH MA, 1988, ENDORPHINS OPIATES B, P53
   BRAIN PF, 1981, BEHAV PROCESS, V6, P319, DOI 10.1016/0376-6357(81)90049-8
   BRAIN PF, 1989, NEUROMETHODS, P687
   CAMBELL A, 1982, PSYCHOPHARMACOLOGY, V77, P150
   COOPER SJ, 1991, MESOLIMBIC DOPAMINE SYSTEM : FROM MOTIVATION TO ACTION, P331
   CUNNINGHAM ST, 1992, BRAIN RES, V588, P104
   DICHIARA G, 1988, J PHARMACOL EXP THER, V244, P1067
   ESPERT R, 1993, AGGRESSIVE BEHAV, V19, P377, DOI 10.1002/1098-2337(1993)19:5<377::AID-AB2480190507>3.0.CO;2-Y
   GERRITS MAFM, 1994, PSYCHOPHARMACOLOGY, V114, P486, DOI 10.1007/BF02249340
   Gianutsos G, 1978, Mod Probl Pharmacopsychiatry, V13, P114
   IWAMOTO ET, 1981, J PHARMACOL EXP THER, V217, P451
   JOHNSON SW, 1992, J NEUROSCI, V12, P483
   JOYCE EM, 1979, NEUROSCI LETT, V14, P207, DOI 10.1016/0304-3940(79)96149-4
   JOYCE EM, 1981, BRAIN RES, V221, P359, DOI 10.1016/0006-8993(81)90784-8
   KALIVAS PW, 1983, J PHARMACOL EXP THER, V227, P229
   KANTAK KM, 1988, PSYCHOPHARMACOLOGY, V96, P468, DOI 10.1007/BF02180026
   KIRITSYROY JA, 1989, PHARMACOL BIOCHEM BE, V32, P717, DOI 10.1016/0091-3057(89)90023-3
   LAL H, 1975, LIFE SCI, V17, P29, DOI 10.1016/0024-3205(75)90229-5
   LAYER RT, 1991, PHARMACOL BIOCHEM BE, V40, P21, DOI 10.1016/0091-3057(91)90315-S
   LONGONI R, 1987, PSYCHOPHARMACOLOGY, V93, P401, DOI 10.1007/BF00187265
   MAGNUSELLENBROEK B, 1993, N-S ARCH PHARMACOL, V347, P635, DOI 10.1007/BF00166947
   MARTINEZ M, 1991, PSICOLOGICA, V12, P1
   MINARRO J, 1990, PHYSIOL BEHAV, V47, P281, DOI 10.1016/0031-9384(90)90143-R
   NAVARRO JF, 1993, PHYSIOL BEHAV, V53, P1055, DOI 10.1016/0031-9384(93)90359-N
   OLSON GA, 1991, PEPTIDES, V12, P1407, DOI 10.1016/0196-9781(91)90227-G
   PLANETA CD, 1994, PHARM BIOCH BEHAV, V50, P35
   POTEGAL M, 1979, AGGRESSIVE BEHAV, V5, P353, DOI 10.1002/1098-2337(1979)5:4<353::AID-AB2480050404>3.0.CO;2-7
   REDOLAT R, 1991, PSICOTHEMA, V3, P79
   SELF DW, 1995, ANNU REV NEUROSCI, V18, P463, DOI 10.1146/annurev.neuro.18.1.463
   SHIPPENBERG TS, 1993, J PHARMACOL EXP THER, V265, P53
   SHIPPENBERG TS, 1988, EUR J PHARMACOL, V151, P233, DOI 10.1016/0014-2999(88)90803-5
   SMOOTHY R, 1986, PHYSIOL BEHAV, V37, P689, DOI 10.1016/0031-9384(86)90173-3
   SPANAGEL R, 1994, NEUROSCIENCE, V63, P797, DOI 10.1016/0306-4522(94)90524-X
   SPANAGEL R, 1991, PSYCHOPHARMACOLOGY, V104, P51, DOI 10.1007/BF02244553
   SPYRAKI C, 1983, PSYCHOPHARMACOLOGY, V79, P278, DOI 10.1007/BF00427827
   STINUS L, 1980, P NATL ACAD SCI-BIOL, V77, P2323, DOI 10.1073/pnas.77.4.2323
   STINUS L, 1989, BIOL PSYCHIAT, V26, P363, DOI 10.1016/0006-3223(89)90052-8
   STINUS L, 1992, ANN NY ACAD SCI, V654, P254, DOI 10.1111/j.1749-6632.1992.tb25972.x
   TIDEY JW, 1992, PSYCHOPHARMACOLOGY, V108, P177, DOI 10.1007/BF02245304
   VACCARINO FJ, 1986, PHARMACOL BIOCHEM BE, V24, P61, DOI 10.1016/0091-3057(86)90045-6
   VERMEULEN RJ, 1995, PSYCHOPHARMACOLOGY, V118, P451, DOI 10.1007/BF02245946
   WINSLOW JT, 1988, PSYCHOPHARMACOLOGY, V96, P493, DOI 10.1007/BF02180030
   WISE RA, 1989, ANNU REV PSYCHOL, V40, P191, DOI 10.1146/annurev.ps.40.020189.001203
NR 48
TC 13
Z9 13
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0091-3057
J9 PHARMACOL BIOCHEM BE
JI Pharmacol. Biochem. Behav.
PD SEP
PY 1997
VL 58
IS 1
BP 153
EP 158
DI 10.1016/S0091-3057(96)00403-0
PG 6
WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy
SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy
GA XP135
UT WOS:A1997XP13500023
PM 9264084
DA 2021-08-04
ER

PT J
AU Levine, RA
   Ohman, PA
AF Levine, RA
   Ohman, PA
TI Repeated challenge studies: A comparison of union-intersection testing
   with linear modeling
SO PSYCHOMETRIKA
LA English
DT Article
DE hypothesis testing; multiple tests; power analysis; population
   prevalence; Kolmogorov tests; application
ID SUGAR; HYPERSENSITIVITY; BEHAVIOR
AB Challenge studies are often implemented for assessing whether a subject is sensitive to a certain agent or allergen. In particular, researchers test groups of subjects to determine if there really exists a causal relationship between some agent of interest and a response. To answer such a question, we need to detect the presence of the phenomenon in just one individual. Typically, however, there are a large number of unknown risk factors associated with the response and a potentially small population prevalence. Hence, standard statistical techniques, by averaging the treatment effect across the group, may miss a significant response of a single individual and lead to inconclusive results. We develop an alternative approach based on union-intersection testing that will allow a practitioner to correctly examine observations on an individual apart from the other subjects and test the hypothesis of interest: Does the phenomenon exist in the population? More specifically, we show how this technique adjusts for the multiple number of tests encountered when analyzing data for each individual subject separately. Furthermore, we demonstrate power calculations for the determination of sample size prior to performing the study. The performance of the union-intersection approach in comparison to linear models and semiparametric techniques is considered through sample size calculations and simulations. The union-intersection testing methodology out performs the Kolmogorov tests. However, the nested linear model performs as well if not better than the union-intersection tests. To illustrate the ideas presented in the paper, we provide an application in which we analyze psychological data collected by way of a challenge study design.
C1 CORNELL UNIV, ITHACA, NY 14853 USA.
RP Levine, RA (corresponding author), UNIV CALIF DAVIS, DIV STAT, DAVIS, CA 95616 USA.
CR *APTECH SYST, 1992, GAUSS GAUSS SYST VER
   Bayer L. E., 1994, Society for Neuroscience Abstracts, V20, P153
   BEHAR D, 1984, Nutrition and Behavior, V1, P277
   Casella G., 1990, STAT INFERENCE
   CONOVER WJ, 1980, PRACTICAL NONPARAMET
   Feingold B F, 1975, Am J Nurs, V75, P797, DOI 10.2307/3423460
   KINDERMAN AJ, 1976, J AM STAT ASSOC, V71, P893, DOI 10.2307/2286857
   METCALFE DD, 1990, J ALLERGY CLIN IMMUN, V86, P421, DOI 10.1016/S0091-6749(05)80252-0
   MILICH R, 1986, CLIN PSYCHOL REV, V6, P493, DOI 10.1016/0272-7358(86)90034-6
   Neter J., 1990, APPL LINEAR STAT MOD
   PEARSON DJ, 1985, J ROY COLL PHYS LOND, V19, P154
   POLLOCK I, 1990, ARCH DIS CHILD, V65, P74, DOI 10.1136/adc.65.1.74
   Press S.J., 1982, APPL MULTIVARIATE AN
   PRINZ RJ, 1985, ADV LEARNING BEHAV D, V4, P181
   ROSEN LA, 1988, J CONSULT CLIN PSYCH, V56, P583, DOI 10.1037/0022-006X.56.4.583
   ROSHON MS, 1989, J ABNORM CHILD PSYCH, V17, P349, DOI 10.1007/BF00917404
   ROWE KS, 1988, AUST PAEDIATR J, V24, P143
   Roy S. N, 1957, SOME ASPECTS MULTIVA
   SAMPSON HA, 1992, FOOD TECHNOL-CHICAGO, V46, P141
   SCHARDT D, 1994, NUTR ACTION HEALTHLE, V21, P12
   SEARLE SR, 1994, VARIANCE COMPONENTS
   SEARLE SR, 1971, LINEAR MODELS
   VANDUSSELDORP M, 1989, VOEDING HAGUE, V50, P2
   WARNER JO, 1987, FOOD INTOLERANCE, P133
NR 24
TC 2
Z9 2
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0033-3123
EI 1860-0980
J9 PSYCHOMETRIKA
JI Psychometrika
PD SEP
PY 1997
VL 62
IS 3
BP 435
EP 455
DI 10.1007/BF02294560
PG 21
WC Mathematics, Interdisciplinary Applications; Social Sciences,
   Mathematical Methods; Psychology, Mathematical
SC Mathematics; Mathematical Methods In Social Sciences; Psychology
GA XU460
UT WOS:A1997XU46000007
OA Green Submitted
DA 2021-08-04
ER

PT J
AU Cary, R
   Clarke, S
   Delic, J
AF Cary, R
   Clarke, S
   Delic, J
TI Effects of combined exposure to noise and toxic substances - Critical
   review of the literature
SO ANNALS OF OCCUPATIONAL HYGIENE
LA English
DT Article
ID OCCUPATIONAL EXPOSURE; AUDITORY-SENSITIVITY; ORGANIC-SOLVENTS; RAT;
   CADMIUM; STYRENE; HEARING
AB A number of studies have been conducted in recent years investigating the potential effects on various health endpoints of the combination of noise and a variety of different industrial substances. This review indicates that the information available in both animals and humans on this subject is limited particularly with respect to assessing occupational risk. Most studies have focused on auditory effects in animals, although investigations have been performed for other toxicological endpoints. For some substances, notably toluene, the information from animals studies does suggest an interaction but these were performed only al exposure levels to both noise and chemicals which were each individually ototoxic. Single simultaneous exposure to noise and styrene did not result in any enhancement of auditory impairment above that produced by noise or styrene alone. Single simultaneous exposure to noise and carbon monoxide (GO), however, showed some evidence of enhancement of ototoxicity beyond that produced by noise or carbon monoxide alone, although only at high atmospheric concentrations of CO. When 1,3-dinitrobenzene was administered parentally at neurotoxic dose levels with continuous noise exposure, there was an increased severity of effects in the brain stem. Combined exposure to noise and lead and/or cadmium resulted in histopathological heart lesions of undefined severity, a finding which was not observed for either of those agents in isolation. Dermal exposure to dimethylformamide and noise or inhalation exposure to xylene and noise resulted in some biochemical changes in cardiac muscle which were of doubtful toxicological significance. In developing mice, there was evidence that combined exposure to cadmium sulphate and noise caused an increased incidence of external and skeletal malformations but only at dose levels of cadmium which would have induced developmental effects. Overall, for each of these chemicals and endpoints observed there is a suggestion of some interaction with noise exposure. From the data that are currently available, however, inferences cannot be drawn on whether or not interactions would have occurred at lower, more occupationally relevant, levels of exposure. A number of studies have investigated human populations exposed to both noise and industrial chemicals. Due to confounding factors, however, it was concluded that these data were inadequate for assessing the combined effects of noise and chemical exposure on hearing. (C) 1997 British Occupational Hygiene Society. Published by Elsevier Science Ltd.
RP Cary, R (corresponding author), HLTH & SAFETY EXECUT,MAGDALEN HOUSE,BOOTLE L20 2QZ,MERSEYSIDE,ENGLAND.
CR BARREGARD L, 1984, SCAND AUDIOL, V13, P151, DOI 10.3109/01050398409043054
   BELL G, 1989, HSE TOXICITY REV, V20
   BERSTROM B, 1986, SCANDINAVIAN AUDIOLO, V15, P227
   CONETTA JA, 1993, J ENVIRON SCI HEAL A, V28, P403, DOI 10.1080/10934529309375886
   FECHTER L, 1988, P 5 INT C NOIS PUBL, P117
   FECHTER LD, 1993, NEUROTOXICOL TERATOL, V15, P151, DOI 10.1016/0892-0362(93)90010-L
   IRION H, 1988, P 5 INT C NOIS PUBL, P131
   IVANOVA NO, 1985, IZV VUZ FIZ+, V28, P105
   IVANOVICH E, 1983, INT ARCH OCC ENV HEA, V51, P319, DOI 10.1007/BF00378344
   JOHNSON AC, 1988, ACTA OTO-LARYNGOL, V105, P56, DOI 10.3109/00016488809119446
   JOHNSON AC, 1990, ACTA OTO-LARYNGOL, V109, P34, DOI 10.3109/00016489009107412
   KELLY JB, 1977, J COMP PHYSIOL PSYCH, V91, P930, DOI 10.1037/h0077356
   MORATA TC, 1989, SCAND AUDIOL, V18, P53, DOI 10.3109/01050398909070723
   MORATA TC, 1993, SCAND J WORK ENV HEA, V19, P245, DOI 10.5271/sjweh.1477
   MORATA TC, 1994, ARCH ENVIRON HEALTH, V49, P359, DOI 10.1080/00039896.1994.9954988
   MURATA M, 1993, J TOXICOL ENV HEALTH, V39, P237, DOI 10.1080/15287399309531748
   RAY DE, 1992, NEUROTOXICOLOGY, V13, P379
   YANO BL, 1992, TOXICOL PATHOL, V20, P1, DOI 10.1177/019262339202000101
   YOUNG JS, 1987, HEARING RES, V26, P37, DOI 10.1016/0378-5955(87)90034-7
NR 19
TC 37
Z9 42
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0003-4878
J9 ANN OCCUP HYG
JI Ann. Occup. Hyg.
PD AUG
PY 1997
VL 41
IS 4
BP 455
EP 465
DI 10.1016/S0003-4878(97)00006-9
PG 11
WC Public, Environmental & Occupational Health; Toxicology
SC Public, Environmental & Occupational Health; Toxicology
GA XV242
UT WOS:A1997XV24200006
PM 9284647
DA 2021-08-04
ER

PT J
AU Sunnetcioglu, MM
   Dadayli, D
   Sungur, R
   Bingol, G
AF Sunnetcioglu, MM
   Dadayli, D
   Sungur, R
   Bingol, G
TI An EPR study of wheat seeds by the use of nitroxide spin probes
SO JOURNAL OF PLANT PHYSIOLOGY
LA English
DT Article
DE wheat seed; EPR; nitroxide spin probes; simulation of EPR spectra
ID IMBIBITION; LABELS
AB The viability of a variety of wheat seeds Mas investigated by use of the EPR technique, Three different types of spin probes (4-Hydroxy-TEMPO (TANOL), 3-Carbamoyl-2,2,5,5-tetramethyl-3-pyrrolin-1-yloxy, 3-Carbamoyl-PROXYL) were utilized in examining the viability of embryo cells. The penetration of the spin probe across the membrane was observed via the change in signal intensity against time for dry embryos of the variety of wheat seeds soaked in aqueous solutions of spin probe and line broadening agent. From the analysis of the signal intensity-time curves (i.e. rehydration curves) it was observed that the two kinds having different genetic roots (Bezostaya, Kunduru) exhibit similar saturation behaviour whereas Gerek saturates much more easily. The rehydration curves for naturally aged seeds indicates that aging causes rapid saturation and an important decrease in the signal intensity. In order to get better insight on the effect of the signals from polar and nonpolar regions on the experimental spectra, these spectra were simulated by the use of the theoretical models developed.
C1 ZONGULDAK KARAELMAS UNIV,FAC ART & SCI,DEPT PHYS,TR-67100 ZONGULDAK,TURKEY.
RP Sunnetcioglu, MM (corresponding author), HACETTEPE UNIV,DEPT ENGN PHYS,TR-06532 BEYTEPE,ANKARA,TURKEY.
RI SUNNETCIOGLU, MUBERRA/G-6080-2013
CR AKSYONOV SI, 1986, STUD BIOPHYS, V111, P169
   BERLINER LJ, 1989, BIOL MAGNETIC RESONA, V8
   BEWLEY JD, 1983, PHYSL BIOCH SEEDS, V1, P115
   BURCHFIELD J, 1994, J MAGN RESON SER B, V104, P69, DOI 10.1006/jmrb.1994.1054
   EATON SS, 1978, COORDIN CHEM REV, V26, P207, DOI 10.1016/S0010-8545(00)80348-3
   GOLOVINA EA, 1994, BBA-BIOMEMBRANES, V1190, P385, DOI 10.1016/0005-2736(94)90098-1
   KUTCHER J, 1986, STUD BIOPHYS, V111, P105
   NELDER JA, 1965, COMPUT J, V7, P308, DOI 10.1093/comjnl/7.4.308
   SMIRNOV AI, 1992, J PLANT PHYSIOL, V140, P447, DOI 10.1016/S0176-1617(11)80823-0
   SMIRNOV AI, 1988, SOV PLANT PHYSIOL+, V35, P516
   Volwerk J. J., 1988, Magnetic Resonance Review, V13, P135
   WERTHEIM GK, 1974, REV SCI INSTRUM, V45, P1369, DOI 10.1063/1.1686503
NR 12
TC 7
Z9 7
U1 0
U2 3
PU GUSTAV FISCHER VERLAG
PI JENA
PA VILLENGANG 2, D-07745 JENA, GERMANY
SN 0176-1617
J9 J PLANT PHYSIOL
JI J. Plant Physiol.
PD AUG
PY 1997
VL 151
IS 2
BP 196
EP 200
PG 5
WC Plant Sciences
SC Plant Sciences
GA XT591
UT WOS:A1997XT59100009
DA 2021-08-04
ER

PT J
AU Lotsch, J
   Hummel, T
   Kraetsch, H
   Kobal, G
AF Lotsch, J
   Hummel, T
   Kraetsch, H
   Kobal, G
TI The negative mucosal potential: Separating central and peripheral
   effects of NSAIDs in man
SO EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Article
DE ibuprofen; tonic pain; phasic pain; peripheral nociception; trigeminal
   nociception; carbon dioxide; chemo-somato sensory event-related
   potential; non-steroidal anti-inflammatory drug (NSAID)
ID ASPIRIN-LIKE DRUGS; HUMAN NASAL-MUCOSA; ANTIINFLAMMATORY AGENTS;
   ANTINOCICEPTIVE ACTIONS; EVOKED-POTENTIALS; ANALGESIC ACTION; FORMALIN
   TEST; PAIN; RATS; PROSTAGLANDINS
AB Objective: We wanted to test whether assessment of both a central pain-related signal (chemo-somatosensory evoked potential, CSSEP) and a concomitantly recorded peripheral signal (negative mucosal potential, NMP) allows for separation of central and peripheral effects of NSAIDs. For this purpose, experimental conditions were created in which NSAIDs had previously been observed to produce effects on phasic and tonic pain by either central or peripheral mechanisms.
   Methods: According to a double-blind, randomised, controlled, threefold cross-over design, 18 healthy subjects (11 males, 7 females; mean age 26 years) received either placebo, 400 mg ibuprofen. or 800 mg ibuprofen. Phasic pain was applied by means of short pulses of CO2 to the nasal mucosa (stimulus duration 500 ms, interval approximately 60 s), and tonic pain was induced in the nasal cavity by means of dry air of controlled temperature, humidity and flow rate (22 degrees C, 0% relative humidity, 145 ml s(-1)). Both CSSEPs as central and NMPs as peripheral correlates of pain were obtained in response to the CO2 stimuli. Additionally, the subjects rated the intensity of both phasic and tonic pain by means of visual analogue scales.
   Results: As described earlier, administration of ibuprofen was followed by a decrease in tonic pain but - relative to placebo - an increase in correlates of phasic pain, indicating a specific effect of ibuprofen on the interaction between the pain stimuli under these spacial experimental conditions. Based on the similar behaviour of CSSEP and NMP, it was concluded that the pharmacological process underlying this phenomenon was localised in the periphery. By means of the simultaneous recording of interrelated peripheral and central electrophysiologic correlates of nociception, it was possible to separate central and peripheral effects of an NSAID. The major advantage of this pain model is the possibility of obtaining peripheral pain-related activity directly using a non-invasive technique in humans.
RP Lotsch, J (corresponding author), UNIV ERLANGEN NURNBERG,DEPT EXPT & CLIN PHARMACOL & TOXICOL,UNIV STR 22,D-91054 ERLANGEN,GERMANY.
OI Lotsch, Jorn/0000-0002-5818-6958
CR CHEN ACN, 1980, EXP BRAIN RES, V39, P359
   DUBAS TC, 1971, ARCH INT PHARMACOD T, V194, P117
   FERREIRA SH, 1973, BRIT J PHARMACOL, V49, P86, DOI 10.1111/j.1476-5381.1973.tb08270.x
   FERREIRA SH, 1972, NATURE-NEW BIOL, V240, P200
   FERREIRA SH, 1978, EUR J PHARMACOL, V53, P39, DOI 10.1016/0014-2999(78)90265-0
   GEISSLINGER G, 1994, LIFE SCI, V54, pPL173, DOI 10.1016/0024-3205(94)00555-9
   GEISSLINGER G, 1990, BRAIN RES, V629, P293
   HUMMEL T, 1995, EUR J CLIN PHARMACOL, V49, P7
   Hummel T, 1996, NEUROSCI LETT, V212, P37, DOI 10.1016/0304-3940(96)12767-1
   HUMMEL T, 1995, PHARM COMM, V5, P101
   JURNA I, 1990, PAIN, V41, P71, DOI 10.1016/0304-3959(90)91111-U
   KOBAL G, 1985, PAIN, V22, P151, DOI 10.1016/0304-3959(85)90175-7
   KOBAL G, 1990, AGENTS ACTIONS, V29, P342, DOI 10.1007/BF01966467
   KOBAL G, 1994, BRIT J CLIN PHARMACO, V37, P445, DOI 10.1111/j.1365-2125.1994.tb05712.x
   KOBAL G, 1989, ADV PAIN RES THER, P95
   LOTSCH J, 1995, BRIT J CLIN PHARMACO, V40, P339, DOI 10.1111/j.1365-2125.1995.tb04556.x
   Lotsch J, 1995, BRIT J CLIN PHARMACO, V40, P545, DOI 10.1111/j.1365-2125.1995.tb05799.x
   MACKENZIE RA, 1975, J NEUROL NEUROSUR PS, V38, P865, DOI 10.1136/jnnp.38.9.865
   MALMBERG AB, 1992, J PHARMACOL EXP THER, V263, P136
   MOHAMMADIAN P, 1996, CHEM SENSES, V21, P492
   OKUYAMA S, 1984, JPN J PHARMACOL, V35, P95, DOI 10.1254/jjp.35.95
   PICTON TW, 1988, HDB ELECTROENCEPHALO, V3, P361
   SHYU KW, 1985, J NEURAL TRANSM, V62, P285, DOI 10.1007/BF01252242
   STEEN K H, 1990, Pfluegers Archiv European Journal of Physiology, V415, pR106
   THURAUF N, 1991, NEUROSCI LETT, V128, P297, DOI 10.1016/0304-3940(91)90283-Y
   THURAUF N, 1993, BRAIN RES, V629, P293, DOI 10.1016/0006-8993(93)91333-N
   TJOLSEN A, 1992, PAIN, V51, P5, DOI 10.1016/0304-3959(92)90003-T
   TOREBJORK HE, 1973, EXP BRAIN RES, V16, P321
NR 28
TC 21
Z9 21
U1 0
U2 1
PU SPRINGER VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010
SN 0031-6970
J9 EUR J CLIN PHARMACOL
JI Eur. J. Clin. Pharmacol.
PD JUL
PY 1997
VL 52
IS 5
BP 359
EP 364
DI 10.1007/s002280050301
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA XQ359
UT WOS:A1997XQ35900005
PM 9272404
DA 2021-08-04
ER

PT J
AU Munoz, JF
   Rengifo, P
   Vauclin, M
AF Munoz, JF
   Rengifo, P
   Vauclin, M
TI Acid leaching of copper in a saturated porous material: Parameter
   identification and experimental validation of a two-dimensional
   transport model
SO JOURNAL OF CONTAMINANT HYDROLOGY
LA English
DT Article
DE in situ leaching of copper; transport model; parameter identification;
   tailings ponds
ID DISPERSION; SOIL
AB In this study, a two-dimensional mathematical solute transport model is proposed to simulate the leaching of copper ore tailings using sulfuric acid as the leaching agent, injection wells to introduce the leaching agent, and pumping wells to retrieve the pregnant copper leach solution. To calibrate the model, a tracer experiment and a leaching experiment were performed, both under conditions of a single-direction flow pattern established between two boundaries of constant height. These experiments enabled the model hydraulic, dispersion and reaction parameters to be determined. Validation of the model was performed by comparison of the numerical results given by the model with experimental results obtained from a second leaching experiment, performed under conditions of a radial flow pattern established through the use of four injection wells and one pumping well and making use of the parameters estimated previously during the calibration process, The comparison between predicted and measured leaching behavior was good (20-22% error). The study has significant implications for applications related to the use of the proposed numerical model for predicting the performance of in-situ soil washing alternatives. (C) 1997 Elsevier Science B.V.
C1 UNIV GRENOBLE 1,INPG,CNRS,UMR 5564,LTHE,F-38041 GRENOBLE 9,FRANCE.
RP Munoz, JF (corresponding author), PONTIFICIA UNIV CATOLICA CHILE,DEPT INGN HIDRAUL & AMBIENTAL,CASILLA 306,CORREO 22,SANTIAGO,CHILE.
RI Munoz, Jose/D-1739-2014
OI Munoz, Jose/0000-0002-4745-8313
CR BADILLAOHLBAUM R, 1989, HYDROMETALLURGY, V22, P193
   Bear J, 1990, INTRO MODELING TRANS
   Bear J., 1972, DYNAMICS FLUIDS PORO
   BOX JC, 1986, HYDROMETALLURGY, V16, P77, DOI 10.1016/0304-386X(86)90053-8
   BRAUN RL, 1974, SOLUTION MINING S AI, P295
   Brusseau ML, 1996, GROUND WATER, V34, P19, DOI 10.1111/j.1745-6584.1996.tb01860.x
   DOMENICO PA, 1990, PHYSICAL CHEM HYDROG
   GARDER AO, 1964, SOC PETROL ENG J, V4, P26, DOI 10.2118/683-PA
   GAUDET JP, 1977, SOIL SCI SOC AM J, V41, P665, DOI 10.2136/sssaj1977.03615995004100040009x
   GELHAR LW, 1992, WATER RESOUR RES, V28, P1955, DOI 10.1029/92WR00607
   KONIKOW LF, 1978, TECHNIQUES WATER RES, pCHC2
   LEIJ FJ, 1990, WATER RESOUR RES, V26, P1475, DOI 10.1029/WR026i007p01475
   MONTERO JP, 1994, SOIL SCI SOC AM J, V58, P678, DOI 10.2136/sssaj1994.03615995005800030007x
   MUNOZ JF, 1996, MODEL CARE 96 CALIBR
   REMSON I, 1971, NUMERICAL METHODS SU
   ROSENBROCK HH, 1960, COMPUT J, V3, P175, DOI 10.1093/comjnl/3.3.175
   SAEZ PB, 1992, WATER RES, V26, P789, DOI 10.1016/0043-1354(92)90010-2
   SILLIMAN SE, 1987, WATER RESOUR RES, V23, P1667, DOI 10.1029/WR023i008p01667
   SUDICKY EA, 1983, J HYDROL, V63, P81, DOI 10.1016/0022-1694(83)90224-X
   TOUMA J, 1986, TRANSPORT POROUS MED, V1, P27, DOI 10.1007/BF01036524
   VANGENUCHTEN MT, 1976, SOIL SCI SOC AM J, V41, P665
   Vauclin M., 1994, Revue des Sciences de l'Eau, V7, P81
NR 22
TC 17
Z9 17
U1 1
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-7722
J9 J CONTAM HYDROL
JI J. Contam. Hydrol.
PD JUL
PY 1997
VL 27
IS 1-2
BP 1
EP 24
DI 10.1016/S0169-7722(96)00050-2
PG 24
WC Environmental Sciences; Geosciences, Multidisciplinary; Water Resources
SC Environmental Sciences & Ecology; Geology; Water Resources
GA XK435
UT WOS:A1997XK43500001
DA 2021-08-04
ER

PT J
AU Fleming, RA
   Adams, RM
AF Fleming, RA
   Adams, RM
TI The importance of site-specific information in the design of policies to
   control pollution
SO JOURNAL OF ENVIRONMENTAL ECONOMICS AND MANAGEMENT
LA English
DT Article
ID WATER-QUALITY
AB The presence and concentration of pollutants in groundwater are influenced by geophysical processes and the behavior of economic agents. The purpose of this paper is to assess the importance of spatial variability in physical parameters in the design of efficient pollution regulations. Alternative tax policies are evaluated in terms of effects on farm profit utilizing a spatially distributed, dynamic simulation model which links economic behavior with the geophysical processes that determine groundwater quality. The empirical focus is the control of groundwater nitrates arising from irrigated agriculture in Malheur County, Oregon. Results indicate that a detailed accounting of spatial variance in physical parameters had little effect on selection of a cost-minimizing tax policy to control groundwater nitrate concentration. This result implies that relatively simple tax schemes and models to evaluate these tax schemes may be adequate in some settings. (C) 1997 Academic Press.
C1 OREGON STATE UNIV,DEPT AGR & RESOURCE ECON,CORVALLIS,OR 97331.
RP Fleming, RA (corresponding author), UNIV KENTUCKY,DEPT AGR ECON,LEXINGTON,KY 40546, USA.
CR ALBER DG, 1994, AM AGR EC ASS ANN M, P7
   Bower H., 1978, GROUNDWATER HYDROLOG
   BRADEN JB, 1989, AM J AGR ECON, V71, P404, DOI 10.2307/1241598
   Chowdhury ME, 1996, J AGR RESOUR ECON, V21, P82
   DOSI C, 1993, THOERY MODELING EXPE
   ENGLISH M, 1995, COMMUNICATION
   GRIFFIN RC, 1987, J ENVIRON ECON MANAG, V14, P41, DOI 10.1016/0095-0696(87)90004-0
   HELFAND GE, 1995, AM J AGR ECON, V77, P1024, DOI 10.2307/1243825
   JOHNSON SL, 1991, AM J AGR ECON, V73, P1064
   LAFRANCE JT, 1995, AM J AGR ECON, V77, P447, DOI 10.2307/1243215
   Larson DM, 1996, AM J AGR ECON, V78, P1108, DOI 10.2307/1243867
   LEE DJ, 1993, WATER RESOUR RES, V29, P3917, DOI 10.1029/93WR02464
   MAPP HP, 1994, AM J AGR ECON, V76, P889, DOI 10.2307/1243749
   *MCES, 1992, MALH COUNT AGR 1992
   *MCGMC, 1991, GWWH47605 MCGMC
   MILTZ D, 1988, J AGR ECON, V39, P360, DOI 10.1111/j.1477-9552.1988.tb00595.x
   Pigou A. C., 1932, EC WELFARE
   SEGERSON K, 1988, J ENVIRON ECON MANAG, V15, P87, DOI 10.1016/0095-0696(88)90030-7
   SHORTLE J, 1994, NONPOINT SOURCE POLL
   SHORTLE JS, 1986, AM J AGR ECON, V68, P668, DOI 10.2307/1241551
   TIETENBERG TH, 1974, J ENVIRON ECON MANAG, V1, P3, DOI 10.1016/0095-0696(74)90014-X
   *USAGO, 1995, GAORCED95200BR
   WALKER DS, 1989, THESIS OREGON STATE
   Xepapadeas A., 1992, NAT RESOUR MODEL, V6, P139
NR 24
TC 43
Z9 44
U1 0
U2 6
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0095-0696
J9 J ENVIRON ECON MANAG
JI J.Environ.Econ.Manage.
PD JUL
PY 1997
VL 33
IS 3
BP 347
EP 358
DI 10.1006/jeem.1997.0990
PG 12
WC Business; Economics; Environmental Studies
SC Business & Economics; Environmental Sciences & Ecology
GA XN379
UT WOS:A1997XN37900009
DA 2021-08-04
ER

PT J
AU Dresner, LS
   Wang, SP
   West, MW
   Ponomarenko, IN
   Mueller, CM
   Wait, RB
AF Dresner, LS
   Wang, SP
   West, MW
   Ponomarenko, IN
   Mueller, CM
   Wait, RB
TI Nitric oxide inhibition simulates the enhancement of alpha(1)
   agonist-induced vasoconstriction in diabetes
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article
ID RESISTANCE ARTERIES; RAT AORTA; ENDOTHELIUM; RESPONSES; MELLITUS;
   NORADRENALINE; CONTRACTION; SENSITIVITY
AB We have previously reported that endothelium-dependent, nitric oxide (NO)-mediated vasorelaxation is impaired in diabetic mesenteric arteries. We hypothesized that vasoconstrictor responses should therefore be enhanced. The purpose of this study was to determine whether diabetic mesenteric arteries exhibit in creased vasoconstrictor responses, and to investigate if these changes are receptor and/or NO mediated. Thirty age-matched male Sprague-Dawley rats were divided into control (C) and diabetic (D, streptozotocin: 60 mg/kg) groups and studied after 4 weeks, Terminal branches of ileal mesenteric arteries (300 +/- 9 mu m) were isolated, pressurized, and superfused with modified Krebs solution. Changes in vessel internal diameter were measured and dose-response curves (DRC) for each vasoactive agent were determined. Each vessel was initially constricted with 40 mM of KCl to determine maximal vasoconstriction. Phenylephrine (Phe, 10(-8)-10(-4) M) and UK14304 (10(-9)-10(-5) M) were used to determine alpha(1)- and alpha(2)-receptor responses, respectively. Similar studies were performed in the presence of N-omega-nitro-L-arginine methyl ester (L-NAME, 10(-4) M), a competitive inhibitor of NO synthase. Maximal response (Max), area under the curve (AUG), and vessel sensitivity (ED50) for each DRC were calculated. Comparisons among groups were made using analysis of variance and Student's t test with Bonferroni correction. There were no differences in vasoconstrictor responses induced by KCI (C: 82 +/- 2% vs D: 80 +/- 1%). alpha(1)-vasoconstrictor responses to Phe were enhanced in diabetes with significantly higher Max (96 +/- 2% vs 83 +/- 3%), and AUC (1.92 +/- 0.09 vs 1.56 +/- 0.08), but no difference in ED50. The addition of L-NAME enhanced only Phe-induced vasoconstrictor response significantly in control rats, Thus, differences in Phe-induced vasoconstrictor responses between C and D were abolished in the presence of L-NAME. alpha(2)-vasodilator responses induced by UK14304 were similar between C and D and unaffected by L-NAME. alpha(1)-, but not alpha(2)- vasoconstrictor responses are enhanced in streptozotocin-induced diabetic rats. These enhanced responses can be duplicated by treatment of control vessels with L-NAME. (C) 1997 Academic Press.
RP Dresner, LS (corresponding author), SUNY HLTH SCI CTR,DEPT SURG,BOX 40,450 CLARKSON AVE,BROOKLYN,NY 11203, USA.
OI Dresner, Lisa/0000-0001-7059-720X
CR AGRAWAL DK, 1987, CAN J PHYSIOL PHARM, V65, P1484, DOI 10.1139/y87-232
   BUCALA R, 1991, J CLIN INVEST, V87, P432, DOI 10.1172/JCI115014
   CHANG KSK, 1992, BRIT J PHARMACOL, V107, P983, DOI 10.1111/j.1476-5381.1992.tb13395.x
   DAVIES MG, 1993, ANN SURG, V218, P593, DOI 10.1097/00000658-199321850-00003
   GEBREMEDHIN D, 1987, ARCH INT PHARMACOD T, V288, P100
   GIBBONS GF, 1986, CLIN SCI, V71, P477, DOI 10.1042/cs0710477
   HALPERN W, 1991, BLOOD VESSELS, V28, P245
   Hendriks M G, 1993, Blood Press, V2, P69, DOI 10.3109/08037059309077530
   KARASU C, 1994, GEN PHARMACOL, V25, P795, DOI 10.1016/0306-3623(94)90262-3
   LANDIN L, 1994, CHEST, V106, P250, DOI 10.1378/chest.106.1.250
   LASH JM, 1991, CIRC RES, V69, P1259, DOI 10.1161/01.RES.69.5.1259
   MARTIN W, 1986, J PHARMACOL EXP THER, V237, P529
   MAYHAN WG, 1991, AM J PHYSIOL, V260, pH319
   MORRIS SM, 1994, AM J PHYSIOL, V266, pE829
   PFAFFMAN MA, 1982, AM J PHYSIOL, V242, pH490
   PIEPER GM, 1989, AM J PHYSIOL, V257, pH1327
   POSTON L, 1995, CLIN SCI, V88, P245, DOI 10.1042/cs0880245
   RONGEN GA, 1994, NETH J MED, V44, P26
   RUFFOLO RR, 1984, J CARDIOVASC PHARM, V6, P1011
   SCARBOROUGH NL, 1984, J PHARMACOL EXP THER, V231, P597
   TAYLOR PD, 1992, BRIT J PHARMACOL, V107, P393, DOI 10.1111/j.1476-5381.1992.tb12757.x
   TESFAMARIAM B, 1989, AM J PHYSIOL, V257, pH1327
   TESFAMARIAM B, 1985, BLOOD VESSELS, V22, P301
   TILTON RG, 1993, DIABETES, V42, P221, DOI 10.2337/diabetes.42.2.221
   TOMLINSON KC, 1992, PHARMACOL REV, V44, P103
   Wang SP, 1996, SURGERY, V120, P328, DOI 10.1016/S0039-6060(96)80306-0
NR 26
TC 18
Z9 21
U1 0
U2 0
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0022-4804
J9 J SURG RES
JI J. Surg. Res.
PD JUL 1
PY 1997
VL 70
IS 2
BP 119
EP 123
DI 10.1006/jsre.1997.5106
PG 5
WC Surgery
SC Surgery
GA XM960
UT WOS:A1997XM96000004
PM 9245559
DA 2021-08-04
ER

PT J
AU Desrayaud, S
   Guntz, P
   Scherrmann, JM
   Lemaire, M
AF Desrayaud, S
   Guntz, P
   Scherrmann, JM
   Lemaire, M
TI Effect of the P-glycoprotein inhibitor, SDZ PSC 833, on the blood and
   brain pharmacokinetics of colchicine
SO LIFE SCIENCES
LA English
DT Article
DE colchicine; SDZ PSC 833; P-glycoprotein; blood/brain pharmacokinetics;
   microdialysis
ID MEDIATED MULTIDRUG RESISTANCE; TRANSPORTER STUDIED INVIVO; FREELY-MOVING
   RATS; NONIMMUNOSUPPRESSIVE CYCLOSPORINE; MICRODIALYSIS; SECRETION;
   PSC-833; PERMEABILITY; CELLS; TUMOR
AB The effect of the multidrug resistance-reversing agent, SDZ PSC 833, on blood and brain pharmacokinetics of a P-glycoprotein substrate, colchicine, was investigated using simultaneous blood and brain microdialysis in freely moving rats. The use of microdialysis for pharmacokinetic studies was validated by comparing the blood concentrations of colchicine obtained by microdialysis with those obtained by direct blood sampling. The rats received either SDZ PSC 833 (2.3 mg/kg i.v. bolus followed by 16.7 mu g/min/kg i.v. infusion during all the experiment) and colchicine (1 mg/kg i.v. bolus followed by 12.5 mu g/min/kg i.v. infusion during 2 hours) or colchicine alone (the same dosage with SDZ PSC 833 vehicle). The SDZ PSC 833 treatment resulted in important modifications of colchicine blood pharmacokinetics: the unbound colchicine blood concentration at steady-state was enhanced from 149.6 +/- 9.9 to 333.5 +/- 81.7 ng/ml indicating a two-fold decrease in colchicine clearance. Moreover the coadministration of SDZ PSC 833 increased the brain penetration of colchicine by a factor of 10, at least. This enhancement could not be exactly assessed because the brain dialysate concentrations of control group were below the limit of detection. Nevertheless, the large increase of colchicine brain penetration is consistent with the hypothesis that SDZ PSC 833 is able to inhibit the P-glycoprotein pump present at the blood-brain barrier.
C1 HOP FERNAND WIDAL,INSERM U26,F-75010 PARIS,FRANCE.
RP Desrayaud, S (corresponding author), NOVARTIS PHARMA INC,DRUG METAB & PHARMACOKINET,CH-4002 BASEL,SWITZERLAND.
RI Scherrmann, Jean-Michel/I-1865-2017
CR ALONSO MJ, 1995, PHARMACEUT RES, V12, P291, DOI 10.1023/A:1016247413935
   BENVENISTE H, 1990, PROG NEUROBIOL, V35, P195, DOI 10.1016/0301-0082(90)90027-E
   BOEKHORST PAW, 1992, CANCER CHEMOTHER PHA, V30, P238
   BOESCH D, 1991, CANCER RES, V51, P4226
   ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033
   FRICHE E, 1992, CANCER CHEMOTH PHARM, V30, P235, DOI 10.1007/BF00686321
   GAVERIAUX C, 1991, J CELL PHARM, V2, P225
   GONZALEZ O, 1995, CANCER CHEMOTH PHARM, V36, P335, DOI 10.1007/BF00689051
   GORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695
   GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125
   KELLER RP, 1992, INT J CANCER, V50, P593, DOI 10.1002/ijc.2910500418
   LEIGHTON JA, 1990, HEPATOLOGY, V11, P210, DOI 10.1002/hep.1840110209
   LEVIN VA, 1980, J MED CHEM, V23, P682, DOI 10.1021/jm00180a022
   LING V, 1974, J CELL PHYSIOL, V83, P103, DOI 10.1002/jcp.1040830114
   LONNROTH P, 1987, AM J PHYSIOL, V253, P228
   Paxinos G., 1986, RAT BRAIN STEREOTAXI RAT BRAIN STEREOTAXI, V2nd
   SARRE S, 1993, TRAC-TREND ANAL CHEM, V12, P67, DOI 10.1016/0165-9936(93)87053-Z
   SCHERRMANN JM, 1980, J PHARM PHARMACOL, V32, P800, DOI 10.1111/j.2042-7158.1980.tb13076.x
   SCOTT DO, 1991, PHARMACEUT RES, V8, P389, DOI 10.1023/A:1015862003147
   SHEINER LB, 1983, ELSFIT VERSION 3 1
   SHIRAI A, 1994, BBA-MOL CELL RES, V1222, P400, DOI 10.1016/0167-4889(94)90047-7
   SPEEG KV, 1992, J PHARMACOL EXP THER, V261, P50
   SPEEG KV, 1992, HEPATOLOGY, V15, P899, DOI 10.1002/hep.1840150524
   SPEEG KV, 1994, CANCER CHEMOTH PHARM, V34, P133
   SUGAWARA I, 1988, CANCER RES, V48, P1926
   TELTINGDIAZ M, 1993, PHARMACEUT RES, V10, P44, DOI 10.1023/A:1018964727833
   THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735
   UNGERSTEDT U, 1984, MEASUREMENT NEUROTRA
   VANAMSTERDAM C, 1996, IN PRESS EUR J PHARM
NR 29
TC 46
Z9 50
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0024-3205
J9 LIFE SCI
JI Life Sci.
PD JUN 6
PY 1997
VL 61
IS 2
BP 153
EP 163
DI 10.1016/S0024-3205(97)00370-6
PG 11
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA XE884
UT WOS:A1997XE88400008
PM 9217274
DA 2021-08-04
ER

PT J
AU Ram, A
   Arkin, RC
   Moorman, K
   Clark, RJ
AF Ram, A
   Arkin, RC
   Moorman, K
   Clark, RJ
TI Case-based reactive navigation: A method for on-line selection and
   adaptation of reactive robotic control parameters
SO IEEE TRANSACTIONS ON SYSTEMS MAN AND CYBERNETICS PART B-CYBERNETICS
LA English
DT Article
DE case-based reasoning; reactive control; robot navigation
ID MOBILE ROBOT
AB This article presents a new line of research investigating on-line adaptive reactive control mechanisms for autonomous intelligent agents, We discuss a case-based method for dynamic selection and modification of behavior assemblages for a navigational system, The case-based reasoning module is designed as an addition to a traditional reactive control system, and provides more flexible performance in novel environments without extensive high-level reasoning that would otherwise slow the system down, The method is implemented in the ACBARR (A Case-BAsed Reactive Robotic) system and evaluated through empirical simulation of the system on several different environments, including ''box canyon'' environments known to be problematic for reactive control systems in general.
C1 UNIV DAYTON, DEPT COMP SCI, DAYTON, OH 45420 USA.
RP Ram, A (corresponding author), GEORGIA INST TECHNOL, COLL COMP, ATLANTA, GA 30332 USA.
CR Agre P., 1987, P AAAI 87 SEATTLE, P268
   AMAREL S, 1968, MACH INTELL, V3
   Arkin R. C., 1990, Robotics and Autonomous Systems, V6, P105, DOI 10.1016/S0921-8890(05)80031-4
   ARKIN RC, 1989, INT J ROBOT RES, V8, P92, DOI 10.1177/027836498900800406
   ARKIN RC, 1993, P IEEE INT C ROB AUT, V1
   ARKIN RC, 1989, P IEEE INT WORKSH IN
   ARKIN RC, 1993, P INT C INT AUT SYST
   BALCH T, 1993, P IEEE INT C ROB AUT
   BENNETT SW, 1990, P 7 INT C MACH LEARN, P226
   Brooks R. A., 1988, INTELLIGENCE REPRESE
   BROOKS RA, 1989, PROCEEDINGS - 1989 IEEE INTERNATIONAL CONFERENCE ON ROBOTICS AND AUTOMATION, VOL 1-3, P692, DOI 10.1109/ROBOT.1989.100065
   BROOKS RA, 1986, IEEE T ROBOTIC AUTOM, V2, P14, DOI 10.1109/JRA.1986.1087032
   CHIEN SA, 1991, P 8 INT WORKSH MACH, P288
   CLARK RJ, 1992, 1992 IEEE INTERNATIONAL CONF ON ROBOTICS AND AUTOMATION : PROCEEDINGS, VOLS 1-3, P111, DOI 10.1109/ROBOT.1992.220326
   COHEN PR, 1988, AI MAG, V9, P35
   FIRBY RJ, 1989, YALEUCSDRR673 YAL U
   HAMMOND KJ, 1989, CASE BASED PLANNING
   KADANOFF M, 1986, P SOC PHOTO-OPT INS, V727, P77
   Kaelbling L. P., 1991, Robotics and Autonomous Systems, V8, P131, DOI 10.1016/0921-8890(91)90018-G
   KAELBLING LP, 1986, 400 SRI INT
   KOLODNER J., 1993, CASE BASED REASONING
   KOLODNER JL, 1990, GITICS9019 GEORG I T
   KOPEIKINA L, 1988, P CASE BASED REASONI, P250
   Kuipers B., 1991, Robotics and Autonomous Systems, V8, P47, DOI 10.1016/0921-8890(91)90014-C
   Lin L. J., 1993, P 10 INT C INT C MAC, P182
   MACKENZIE DC, 1993, WORK NOT AAAI FALL S
   MAES P, 1990, 8TH P NAT C ART INT, P796
   MAHADEVAN S, 1992, P 9 INT C MACH LEARN, P290
   MITCHELL TM, 1990, PROCEEDINGS : EIGHTH NATIONAL CONFERENCE ON ARTIFICIAL INTELLIGENCE, VOLS 1 AND 2, P1051
   PAYTON DW, 1986, IEEE T ROBOTIC AUTOM, P1838
   RAM A, 1993, MACH LEARN, V10, P201, DOI 10.1023/A:1022634926452
   RAM A, 1992, GITCC9257 GEORG I TE
   RAM A, 1993, INFORMATICA, V17, P347
   RAM A, 1993, P AAAI CAS BAS REAS, P86
   Ram Ashwin, 1994, Adaptive Behavior, V2, P277, DOI 10.1177/105971239400200303
   RAMSEY CL, 1994, P AAAI WORKSH CAS BA
   SEGRE AM, 1988, MACHINE LEARNING ROB
   Skinner B.F., 1974, ABOUT BEHAV
   VELOSO MM, 1993, MACH LEARN, V10, P249, DOI 10.1023/A:1022686910523
NR 39
TC 24
Z9 25
U1 0
U2 0
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 1083-4419
EI 1941-0492
J9 IEEE T SYST MAN CY B
JI IEEE Trans. Syst. Man Cybern. Part B-Cybern.
PD JUN
PY 1997
VL 27
IS 3
BP 376
EP 394
DI 10.1109/3477.584946
PG 19
WC Automation & Control Systems; Computer Science, Artificial Intelligence;
   Computer Science, Cybernetics
SC Automation & Control Systems; Computer Science
GA WY939
UT WOS:A1997WY93900002
PM 18255878
DA 2021-08-04
ER

PT J
AU Garcia, JIL
   Alonso, E
   GonzalezUriarte, J
   Romano, DR
AF Garcia, JIL
   Alonso, E
   GonzalezUriarte, J
   Romano, DR
TI Evaluation of scolicidal agents in an experimental hydatid disease model
SO EUROPEAN SURGICAL RESEARCH
LA English
DT Article
DE hydatid cyst; scolicidal agents; hydatid relapse
ID EXPERIMENTAL PERITONEAL HYDATIDOSIS; SURGICAL-TREATMENT;
   POVIDONE-IODINE; HEPATIC HYDATIDOSIS
AB Introduction: The treatment of hydatid disease is largely surgical, with medical treatment being reserved as coadjuvant treatment, The scolicidal agents have been,and are being used mainly during surgical manipulation of the cysts, with the object of avoiding relapses and peritoneal dissemination. Objective: Evaluation of the scolicidal agents used in surgery in a hydatid disease model in the mouse. Material and Methods: We have used 85 Swiss OF1 mice, weighing more than 30 g, of 90 +/- 10 days of age,in which a picture of hydatid sowing was reproduced by means of intra-peritoneal inoculation with 0.2 mi of a suspension which contained approximately 1,200 viable protoscolex of Echinococcus granulosus which came from the livers of parasite-infested sheep. 24 h after the inoculation, the mice were subjected to a median laparotomy for the introduction of 1 mi of the scolicidal solution to be evaluated: physiologic saline (n = 10); 10% povidone iodine (n = 15) praziquantel (n = 15); 10% hydrogen peroxide (n = 15) 10% hypertonic saline (a = 15); simulated operation (a = 15), After 7 months of follow-up, the mice were sacrificed and the following was evaluated: number of isolated cysts, cyst masses, and total cysts, Results: The number of isolated cysts which developed was significantly lower in the hydrogen peroxide group (tF 2.14 < RC 3.29). The number of cyst masses was significantly reduced in the hydrogen peroxide group (tF 2.14 < RC 2.18), in the povidone iodine group (tF 2.17 < RC 3), and in the hypertonic saline group (tF 2.11 < RC 2.77). The total number of cysts which developed decreased significantly in the hydrogen peroxide (tF 2.14 < RC 2.84) and the povidone iodine (tF 2.17 < RC 3.79) groups. Conclusions: Hydrogen peroxide and povidone iodine shaw a greater protoscolicidal effect than simple cleansing with physiological saline, hypertonic saline, or praziquantel.
C1 DOCE OCTUBRE UNIV HOSP,INST SURG RES,MADRID,SPAIN.
CR ALVAREZ C, 1991, 15 EXTR C CEL 50 YEA, P599
   BARQUET N, 1989, MED CLIN-BARCELONA, V92, P121
   BEHRNS KE, 1991, MAYO CLIN PROC, V66, P1193, DOI 10.1016/S0025-6196(12)62469-0
   BELGHITI J, 1986, PRESSE MED, V15, P536
   BOLTON JS, 1979, AM J SURG, V137, P780, DOI 10.1016/0002-9610(79)90093-X
   DERMICI S, 1989, WORLD J SURG, V13, P88
   DJILALI G, 1983, PRESSE MED, V12, P235
   GALLARDO MP, 1991, EXTR C CEL 50 YEARS, P225
   GALLARDO MP, 1991, INT C PAR VAL, P333
   GOKCE O, 1991, BRIT J SURG, V78, P495, DOI 10.1002/bjs.1800780434
   GOMEZ R, 1992, REV ESP ENFERM DIG, V82, P100
   GONZALEZ EM, 1991, WORLD J SURG, V15, P254, DOI 10.1007/BF01659061
   HEATH DD, 1970, PARASITOLOGY, V60, P449, DOI 10.1017/S0031182000078252
   KOLBAKIR F, 1992, BRIT J SURG, V79, P373, DOI 10.1002/bjs.1800790433
   MAGISTRELLI P, 1991, ARCH SURG-CHICAGO, V126, P518, DOI 10.1001/archsurg.1991.01410280122020
   MOMPEAN JAL, 1993, BR J SURG ED ESP, V10, P291
   MOTTAGHIAN H, 1978, BRIT J SURG, V65, P237, DOI 10.1002/bjs.1800650407
   PASCUAL MH, 1987, REV ESP ENFERM APAR, V71, P103
   PERALTA CAM, 1989, SURGERY, V105, P570
   ROGIERS X, 1995, BR J SURG ED ESP, V14, P363
   SAIDI F, 1971, NEW ENGL J MED, V284, P1346, DOI 10.1056/NEJM197106172842403
   SMYTH JD, 1980, T ROY SOC TROP MED H, V74, P649, DOI 10.1016/0035-9203(80)90157-1
   TAYLOR DH, 1989, BRIT J SURG, V76, P954, DOI 10.1002/bjs.1800760927
NR 23
TC 35
Z9 37
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0014-312X
J9 EUR SURG RES
JI Eur. Surg. Res.
PD MAY-JUN
PY 1997
VL 29
IS 3
BP 202
EP 208
PG 7
WC Surgery
SC Surgery
GA WY439
UT WOS:A1997WY43900006
PM 9161837
DA 2021-08-04
ER

PT J
AU Garcia, R
   Lusardi, A
   Ng, S
AF Garcia, R
   Lusardi, A
   Ng, S
TI Excess sensitivity and asymmetries in consumption: An empirical
   investigation
SO JOURNAL OF MONEY CREDIT AND BANKING
LA English
DT Article; Proceedings Paper
CT 1994 National-Bureau-of-Economic-Research Summer Institute
CY 1994
CL UNIV TOULOUSE, TOULOUSE, FRANCE
SP Natl Bur Econ Res
HO UNIV TOULOUSE
ID PERMANENT-INCOME HYPOTHESIS; CONSUMER EXPENDITURE SURVEY; LIQUIDITY
   CONSTRAINTS; PANEL DATA; VARIABLES; AVERSION; MODEL
AB Most empirical studies on liquidity constraints classify a consumer as being constrained on the basis of a single indicator such as the asset-to-income ratio. In this analysis. we model the probability that a consumer faces liquidity constraints as a function of multiple social and economic factors. This probability function is estimated simultaneously with the degree of excess sensitivity of consumption to income in a switching regressions framework. The switching regressions apply optimal weights to the densities for the Euler equations in the two states and are less susceptible to sample misclassification. Our results based on data from the CEX confirm that liquidity-constrained consumers are excessively sensitive to variables already known to economic agents. However. there is also evidence that the unconstrained consumers exhibit behavior that is inconsistent with the theoretical predictions. Further analysis suggests that such behavior could be explained by time-nonseparable preferences.
C1 DARTMOUTH COLL,HANOVER,NH 03755.
   BOSTON COLL,CHESTNUT HILL,MA 02167.
RP Garcia, R (corresponding author), UNIV MONTREAL,MONTREAL,PQ H3C 3J7,CANADA.
OI Ng, Serena/0000-0003-2684-364X
CR ABEL AB, 1990, AM ECON REV, V80, P38
   ALTONJI JG, 1987, Q J ECON, V102, P293, DOI 10.2307/1885065
   ALTUG S, 1990, ECONOMETRICA, V58, P543, DOI 10.2307/2938190
   ANGRIST JD, 1992, J AM STAT ASSOC, V87, P328
   Attanasio O.P., 1995, CARNEGIE ROCHESTER C, VVol. 42, P39
   ATTANASIO OP, 1995, J POLIT ECON, V103, P1121, DOI 10.1086/601443
   Attanasio OP, 1995, AM ECON REV, V85, P1118
   BOWMAN D, 1993, UNPUB LOSS AVERSION
   Browning M, 1996, J ECON LIT, V34, P1797
   Chamberlain G., 1984, HDB ECONOMETRICS, V2, P1247, DOI DOI 10.1016/S1573-4412(84)02014-6
   Deaton A., 1992, UNDERSTANDING CONSUM
   DYNAN KE, 1993, J POLIT ECON, V101, P1104, DOI 10.1086/261916
   EBERLY JC, 1994, J POLIT ECON, V102, P403, DOI 10.1086/261940
   EPSTEIN L, 1991, 109 NAT BUR EC RES
   GUL F, 1991, ECONOMETRICA, V59, P667, DOI 10.2307/2938223
   HAJIVASSILIOU VA, 1990, UNPUB DYNAMIC SWITCH
   HALL RE, 1982, ECONOMETRICA, V50, P461, DOI 10.2307/1912638
   HALL RE, 1978, J POLIT ECON, V86, P971, DOI 10.1086/260724
   HU XQ, 1994, INVESTMENT FINANCING
   JAPPELLI T, 1990, Q J ECON, V105, P219, DOI 10.2307/2937826
   JAPPELLI T, 1994, UNPUB TESTING LIQUID
   KUEHLWEIN M, 1991, ECON LETT, V37, P471, DOI 10.1016/0165-1765(91)90089-4
   LEE LF, 1984, ECONOMETRICA, V52, P391, DOI 10.2307/1911495
   LEE LF, 1978, INT ECON REV, V19, P415, DOI 10.2307/2526310
   Lusardi A, 1996, J BUS ECON STAT, V14, P81, DOI 10.2307/1392101
   LUSARDI A, 1992, THESIS PRINCETON U
   Maddala G. S., 1986, LTD DEPENDENT QUALIT, V3
   MANKIW NG, 1982, J MONETARY ECON, V10, P417, DOI 10.1016/0304-3932(82)90036-8
   NELSON JA, 1994, J POLIT ECON, V102, P384, DOI 10.1086/261937
   RUNKLE DE, 1991, J MONETARY ECON, V27, P73, DOI 10.1016/0304-3932(91)90005-9
   SHEA J, 1995, AM ECON REV, V85, P186
   SHEA J, 1995, J MONEY CREDIT BANK, V27, P798, DOI 10.2307/2077751
   TVERSKY A, 1991, Q J ECON, V106, P1039, DOI 10.2307/2937956
   ZELDES SP, 1989, J POLIT ECON, V97, P305, DOI 10.1086/261605
NR 34
TC 40
Z9 40
U1 0
U2 3
PU OHIO STATE UNIV PRESS
PI COLUMBUS
PA 1050 CARMACK RD, COLUMBUS, OH 43210
SN 0022-2879
J9 J MONEY CREDIT BANK
JI J. Money Credit Bank.
PD MAY
PY 1997
VL 29
IS 2
BP 154
EP 176
DI 10.2307/2953673
PG 23
WC Business, Finance; Economics
SC Business & Economics
GA WY096
UT WOS:A1997WY09600002
OA Green Submitted
DA 2021-08-04
ER

PT J
AU Uno, T
   Yamaguchi, T
   Li, XK
   Suzuki, Y
   Hashimoto, H
   Harada, Y
   Kimura, T
   Kazui, T
AF Uno, T
   Yamaguchi, T
   Li, XK
   Suzuki, Y
   Hashimoto, H
   Harada, Y
   Kimura, T
   Kazui, T
TI The pharmacokinetics of water-in-oil-in-water-type multiple emulsion of
   a new tacrolimus formulation
SO LIPIDS
LA English
DT Article
ID LIVER-TRANSPLANTATION; FK-506; SURVIVAL; EFFICACY; LIPOSOME; RELEASE;
   FK506; RATS
AB We developed a water-in-oil-in-water (W/O/W)-type multiple emulsion of a new tacrolimus formulation. A potential approach to avoid the complications of systemic immunosuppression and simultaneously enhance immunosuppressive efficacy is to deliver immunosuppressive agents locally to the site of the target organs. The W/O/W emulsion is dispersed oil drops containing smaller water droplets that allow the delivery of drugs preferentially to the reticuloendothelial system (RES). Since the liver and the spleen are primary components of the RES, and the brain and the kidney have a poor RES, we hypothesized that a W/O/W emulsion of tacrolimus would possess the pharmacokinetic benefits of local immunosuppression. We evaluated this hypothesis in a rat model. The tacrolimus levels of whole blood, the liver, spleen, brain, and kidney in rats given intravenous emulsions of tacrolimus (W/O/W group) were compared with a group administered tacrolimus alone (T group). There were no significant differences between the pharmacokinetic parameters of W/O/W group and T group based on whole blood data. However, the W/O/W group had significantly decreased tacrolimus levels in the brain and kidney, and significantly increased levels in the liver and spleen compared with the T group. These data suggest that the W/O/W emulsion is applicable as an intravenous drug carrier for local immunosuppression.
C1 HAMAMATSU UNIV SCH MED, DIV PHARM, HAMAMATSU, SHIZUOKA 43131, JAPAN.
RP Uno, T (corresponding author), HAMAMATSU UNIV SCH MED, DEPT SURG 1, 3600 HANDA CHO, HAMAMATSU, SHIZUOKA 43131, JAPAN.
CR AEBISCHER P, 1991, DIABETES, V40, P482, DOI 10.2337/diabetes.40.4.482
   BENOY CH, 1972, BRIT J PHARMACOL, V45, P135
   BOLLING SF, 1991, J HEART LUNG TRANSPL, V10, P577
   BRODIN AF, 1978, ACTA PHARM SUEC, V15, P1
   BUSUTTIL RW, 1994, NEW ENGL J MED, V331, P1110
   FREISE CE, 1994, TRANSPLANTATION, V57, P928, DOI 10.1097/00007890-199403270-00027
   GRUBER SA, 1992, TRANSPLANTATION, V54, P1, DOI 10.1097/00007890-199207000-00001
   HERBERT WJ, 1965, LANCET, V2, P771
   KINO T, 1987, J ANTIBIOT, V40, P1256, DOI 10.7164/antibiotics.40.1256
   KO S, 1995, TRANSPLANTATION, V59, P1384, DOI 10.1097/00007890-199505270-00004
   KO S, 1994, TRANSPLANTATION, V58, P1142
   LEE MJ, 1995, PHARM RES-DORDR, V12, P1055, DOI 10.1023/A:1016222817860
   MCCAULEY J, 1991, TRANSPLANT P, V23, P3143
   Ohta S, 1985, JPN J CLIN HEMATOL, V26, P555
   OKABE S, 1981, JPN J DERMATOL, V91, P759
   STEINER JP, 1992, NATURE, V358, P584, DOI 10.1038/358584a0
   TAKAHASHI T, 1976, CANCER, V38, P1507, DOI 10.1002/1097-0142(197610)38:4<1507::AID-CNCR2820380411>3.0.CO;2-V
   TAMURA K, 1987, TRANSPLANT P, V19, P23
   TODO S, 1990, ANN SURG, V212, P295, DOI 10.1097/00000658-199009000-00008
NR 19
TC 21
Z9 21
U1 0
U2 5
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0024-4201
J9 LIPIDS
JI Lipids
PD MAY
PY 1997
VL 32
IS 5
BP 543
EP 548
DI 10.1007/s11745-997-0069-1
PG 6
WC Biochemistry & Molecular Biology; Nutrition & Dietetics
SC Biochemistry & Molecular Biology; Nutrition & Dietetics
GA XF045
UT WOS:A1997XF04500010
PM 9168461
DA 2021-08-04
ER

PT J
AU McComb, ME
   Gesser, HD
AF McComb, ME
   Gesser, HD
TI Passive monitoring of trace metals in water by in situ sample
   preconcentration via chelation on a textile based solid sorbent
SO ANALYTICA CHIMICA ACTA
LA English
DT Article
DE X-ray fluorescence spectrometry; passive monitor; trace metals; sample
   preconcentration; water analysis
ID AMIDOXIME GROUPS; SEA-WATER; URANIUM; RECOVERY; SEAWATER; FIBER;
   ADSORPTION; RESIN; POLYMER; GOLD
AB A simple, inexpensive, passive monitor, based on a textile-bound polyacryloamidoxime chelating agent (polyacryloamidoxime cloth), was evaluated for the analysis of selected trace heavy metals in water using both Energy Dispersive X-Ray Fluorescence (EDXRF) Spectroscopy and Wavelength Dispersive X-Ray Fluorescence (WDXRF) Spectroscopy as a means of analysis. Acid leaching of the sorbed metals followed by Graphite Furnace Atomic Absorption (GFAA) Spectroscopy was also carried out. It was shown that, in controlled in vitro experiments using a flow chamber, the sorption profiles of Pb and Cu by the cloth used were similar to those of chelating resins and fibres containing the amidoxime group. The rate of uptake of metals by the cloth was found to be dependent on the percent surface area converted to amidoxime groups, the concentration and type of metal being tested for, the time of exposure, the flow rate of solution and the temperature of solution. Distribution coefficients of 3.5 x 10(6) and 1.5 x 10(6) for Cu(II) and Pb(II) were observed and indicate a high degree of sample preconcentration. The average rates of uptake for Cu and Pb per gram of cloth were 600 and 200 mg per day respectively from dilute solution ([Cu]=5.9 mg l(-1), [Pb]=2.8 mg l(-1)). From replicate samples, a relative error of <10% was observed for the sorption of Cu and Pb. Experimental results of field tests involving the passive monitoring of river water and lake water under various conditions suggest that a number of ions can be identified and monitored simultaneously. The deployment of the monitors by the general public and the use of a mailing program was tested and shown to be practical. These results indicate the feasibility of using polyacryloamidoxime cloth as a passive monitor for trace metals in water.
C1 UNIV MANITOBA,DEPT CHEM,WINNIPEG,MB R3T 2N2,CANADA.
RI McComb, Mark E/I-3193-2014
OI /0000-0002-4249-485X
CR COLELLA MB, 1980, ANAL CHEM, V52, P2347, DOI 10.1021/ac50064a024
   COLELLA MB, 1980, ANAL CHEM, V52, P967, DOI 10.1021/ac50056a044
   EGAWA H, 1993, IND ENG CHEM RES, V32, P709, DOI 10.1021/ie00016a018
   FISCHER HJ, 1993, FRESEN J ANAL CHEM, V346, P934, DOI 10.1007/BF00322754
   GILLER E, 1994, THESIS U MANITOBA
   GILLER E, 1995, ENVIRON INT, V21, P839
   HIROTSU T, 1986, SEPAR SCI TECHNOL, V21, P1101, DOI 10.1080/01496398608058400
   HIROTSU T, 1987, IND ENG CHEM RES, V26, P1970, DOI 10.1021/ie00070a006
   HIROTSU T, 1988, J APPL POLYM SCI, V36, P1741, DOI 10.1002/app.1988.070360803
   KABAY N, 1993, SEPAR SCI TECHNOL, V28, P1985, DOI 10.1080/01496399308016728
   KABAY N, 1993, J APPL POLYM SCI, V49, P599, DOI 10.1002/app.1993.070490406
   KABAY N, 1993, TURK J CHEM, V17, P62
   KATOH S, 1982, B SOC SEA WATER SCI, V9, P1155
   KOBUKE Y, 1990, IND ENG CHEM RES, V29, P1662, DOI 10.1021/ie00104a014
   KYFFIN TW, 1976, THESIS U SALFOR
   LIN WP, 1993, J APPL POLYM SCI, V47, P45, DOI 10.1002/app.1993.070470107
   LIN WP, 1993, J APPL POLYM SCI, V49, P1635, DOI 10.1002/app.1993.070490915
   LIN WP, 1992, REACT POLYM, V17, P255
   LUTTRELL GH, 1971, ANAL CHEM, V43, P1370, DOI 10.1021/ac60305a048
   MCCOMB ME, 1996, IN PRESS J APPL POLY
   MCCOMB ME, UNPUB
   MCCOMB ME, 1995, THESIS U MANITOBA
   Schmuckler G., 1965, TALANTA, V1, P281, DOI [10.1016/0039-9140(65)80249-1, DOI 10.1016/0039-9140(65)80249-1]
   SUGASAKA K, 1981, SEPAR SCI TECHNOL, V16, P971, DOI 10.1080/01496398108057594
   *TEST FABR INC, 1992, TECHN CAT TEST FABR
   VULFSON KME, 1991, ZH PRIKL KHIM, V64, P1263
NR 26
TC 19
Z9 21
U1 0
U2 13
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0003-2670
J9 ANAL CHIM ACTA
JI Anal. Chim. Acta
PD APR 10
PY 1997
VL 341
IS 2-3
BP 229
EP 239
DI 10.1016/S0003-2670(96)00491-6
PG 11
WC Chemistry, Analytical
SC Chemistry
GA WW545
UT WOS:A1997WW54500014
DA 2021-08-04
ER

PT J
AU Walsh, GC
   Cordo, HA
AF Walsh, GC
   Cordo, HA
TI Coprophilous arthropod community from Argentina with species of
   potential use as biocontrol agents against pest flies.
SO ENVIRONMENTAL ENTOMOLOGY
LA English
DT Article
DE Philonthini; manure ecology; biocontrol of pest flies; dung beetles; fly
   parasitoids; fly predators
ID VETUSTISSIMA WALKER DIPTERA; DUNG BEETLES COLEOPTERA; EAST CENTRAL
   TEXAS; SIMULATION-MODEL; CENTRAL MISSOURI; BOVINE DUNG; FLY DIPTERA;
   HORN FLY; MUSCIDAE; PARASITES
AB Dung-inhabiting pest flies are one of the main problems associated with the accumulation of cattle dung. This work analyzes the diversity and dynamics of a coprophilous community from northern Buenos Aires, Argentina, in a search for potential biocontrol agents. Thirty-six dung pads of 3 age categories and 4 microhabitats were collected on each sampling date and examined for their arthropod fauna. Some of the species with undefined feeding behavior were subjected to feeding trials in the laboratory. We found 34 coprophagous species, 47 predators, and 13 parasitoids. The combination of the results of the feeding trials, co-occurrence and abundance data of the prey and predator populations, and direct field observations were used to put together a trophic web and hypothesis on the dynamics of the community. Dung scarabs cause significant reductions in immature dung fly survival by burying and desiccating large amounts of dung. The Philonthini (Coleoptera: Staphylinidae) are the most abundant and rich predator group, although they are slow to respond to variations in fly populations. However, predatory flies show the same abundance curves as their prey flies. Predatory beetles and flies, dung scarabs, and pupal parasitoids cause additive mortality to the fly population, whereas larval parasitoids cause some compensatory mortality. Four species of staphylinids, 1 predatory muscid, and a coprophagous scarab could have potential as biocontrol agents. The perspectives of success and convenience of a horn fly biocontrol scheme in southern South America are discussed.
RP Walsh, GC (corresponding author), US EMBASSY BUENOS AIRES, USDA ARS, S AMER BIOL CONTROL LAB, AMER RES SERV LAB, UNIT 4325, APO, AA 34034 USA.
CR ATKINSON WD, 1981, J ANIM ECOL, V50, P461, DOI 10.2307/4067
   Begon M, 1986, POPULATION ECOLOGY U
   BLUME RR, 1986, SOUTHWEST ENTOMOL, V11, P215
   Boero J. J., 1976, PARASITOSIS ANIMALES
   BORNEMISSZA G. F., 1960, JOUR AUSTRALIAN INST AGRIC SCI, V26, P54
   BORNEMISSZA GE, 1976, AUST MEAT RES COMM R, V30
   DESANTIS L, 1988, AN ACAD NAC CIENC BU
   DOUBE BM, 1987, J ENTOMOL SOC S AFR, V50, P475
   DOUBE BM, 1987, S AFR J SCI, V83, P187
   DREA JJ, 1966, J ECON ENTOMOL, V59, P1368, DOI 10.1093/jee/59.6.1368
   Drummond R. O., 1988, CONTROL ARTHROPOD PE
   FAY HAC, 1983, Z ANGEW ENTOMOL, V95, P460
   FIGG DE, 1983, ENVIRON ENTOMOL, V12, P961, DOI 10.1093/ee/12.3.961
   FIGG DE, 1983, ENVIRON ENTOMOL, V12, P993, DOI 10.1093/ee/12.3.993
   FINCHER GT, 1981, J GEORGIA ENTOMOL SO, V16, P316
   FINCHER GT, 1973, J PARASITOL, V59, P396, DOI 10.2307/3278842
   GEDEN CJ, 1990, ENVIRON ENTOMOL, V19, P578, DOI 10.1093/ee/19.3.578
   GILLARD P., 1967, Journal of the Australian Institute of Agricultural Science, V33, P30
   HANSKI I, 1977, Annales Entomologici Fennici, V43, P108
   HARRIS RL, 1984, SOUTHWEST ENTOMOL, V9, P169
   HOLTER P, 1982, OIKOS, V39, P213, DOI 10.2307/3544488
   HUGHES RD, 1978, B ENTOMOL RES, V68, P361, DOI 10.1017/S0007485300009342
   HUNTER JS, 1986, SOUTHWEST ENTOMOL, V11, P83
   KESSLER H, 1970, THESIS U S DAKOTA BR
   LEGNER EF, 1986, ENTOMOL SOC AM MISC, V62, P120
   MacLUSKY D. S., 1960, JOUR BRIT GRASSLAND SOC, V15, P181
   MCKINNEY GT, 1975, J APPL ECOL, V12, P831
   MORGAN PB, 1977, J ECON ENTOMOL, V70, P450, DOI 10.1093/jee/70.4.450
   PAINE RT, 1979, SCIENCE, V205, P685, DOI 10.1126/science.205.4407.685
   PETERSEN R. G., 1956, AGRON JOUR, V48, P440
   PICKENS LG, 1981, CAN ENTOMOL, V113, P523, DOI 10.4039/Ent113523-6
   Pont A.C., 1973, P251
   ROTH JP, 1988, ENVIRON ENTOMOL, V17, P603, DOI 10.1093/ee/17.3.603
   ROTH JP, 1983, ENVIRON ENTOMOL, V12, P124, DOI 10.1093/ee/12.1.124
   ROTH JP, 1991, ENVIRON ENTOMOL, V20, P909, DOI 10.1093/ee/20.3.909
   RUEDA LM, 1985, AGR RES SERV TECH B, V278
   SMITH TJR, 1984, B ENTOMOL RES, V74, P191, DOI 10.1017/S0007485300011330
   SMITH TJR, 1988, B ENTOMOL RES, V78, P633
   Sokal RR, 1981, BIOMETRY
   SUMMERLIN JW, 1984, ANN ENTOMOL SOC AM, V77, P543, DOI 10.1093/aesa/77.5.543
   *SYSTAT, 1992, SYSTAT WIND VERS 5 S
   VALIELA I, 1974, AM MIDL NAT, V92, P370, DOI 10.2307/2424302
   WHARTON RA, 1979, PAN-PAC ENTOMOL, V53, P181
NR 43
TC 7
Z9 8
U1 2
U2 12
PU ENTOMOLOGICAL SOC AMER
PI LANHAM
PA 10001 DEREKWOOD LANE, STE 100, LANHAM, MD 20706-4876 USA
SN 0046-225X
EI 1938-2936
J9 ENVIRON ENTOMOL
JI Environ. Entomol.
PD APR
PY 1997
VL 26
IS 2
BP 191
EP 200
DI 10.1093/ee/26.2.191
PG 10
WC Entomology
SC Entomology
GA WZ118
UT WOS:A1997WZ11800007
DA 2021-08-04
ER

PT J
AU Capasso, V
   Wilson, RE
AF Capasso, V
   Wilson, RE
TI Analysis of a reaction-diffusion system modeling man-environment-man
   epidemics
SO SIAM JOURNAL ON APPLIED MATHEMATICS
LA English
DT Article
DE qualitative properties of solutions; reaction-diffusion systems;
   epidemiology
ID DISEASES
AB In this paper an old model for the temporal and spatial evolution of orofecal transmitted disease is reexamined. It consists of a system of two coupled reaction-diffusion equations for the concentration of bacteria and infective humans, under the assumptions that the total population of humans is unaffected by the disease and only a small proportion of the population is affected at any one time. The force of infection on healthy humans is assumed to be a sigmoidal function of bacterial concentration tending to some finite limit, and with zero gradient at zero. (This last feature models an immune response to low concentrations of the infectious agent.) In practice the diffusion coefficient for infective humans is much smaller than that of bacteria and is therefore set to zero; a detailed analysis of the steady-state bifurcation pattern is then performed for the case of homogeneous Dirichlet boundary conditions applied at the endpoints of a one-dimensional interval. Particular attention is paid to the limiting case of small bacterial diffusivity.
   A partial analysis of the dynamical behavior of the system, based on monotone techniques, is carried out. It is speculated that the system, subject to homogeneous Dirichlet boundary conditions, has saddle point structure in the natural function space of the problem, similar to the ODE case in which the diffusivity of bacteria is also set to zero. This conjecture is supported by some numerical simulation on both one- and two-dimensional space domains.
C1 UNIV OXFORD,INST MATH,OXFORD OX1 3LB,ENGLAND.
RP Capasso, V (corresponding author), UNIV MILAN,DIPARTIMENTO MATEMAT,VIA SAKLINI 50,I-20133 MILAN,ITALY.
CR Arnold V.I., 1973, ORDINARY DIFFERENTIA
   CAPASSO V, 1988, Q APPL MATH, V46, P431, DOI 10.1090/qam/963580
   CAPASSO V, 1981, J MATH BIOL, V13, P173, DOI 10.1007/BF00275212
   CAPASSO V, 1982, MATH COMPUT SIMULAT, V24, P540, DOI 10.1016/0378-4754(82)90656-5
   CAPASSO V, 1979, REV EPIDEMIOL SANTE, V27, P121
   Capasso V., 1993, MATH STRUCTURES EPID, V97
   Hale J.K., 1969, ORDINARY DIFFERENTIA
   *ISS, 1974, P INT SEM DIFF TREAT
   JORDAN DW, 1987, NONLINEAR ORDINARY D
   LIONS PL, 1982, SIAM REV, V24, P441, DOI 10.1137/1024101
   Matano H., 1979, PUBL RES I MATH SCI, V15, P401, DOI [10.2977/prims/1195188180, DOI 10.2977/PRIMS/1195188180.MR555661]
   MIRENGHI E, 1987, NONLINEAR ANAL-THEOR, V11, P393, DOI 10.1016/0362-546X(87)90054-X
   Morton K.W., 1994, NUMERICAL SOLUTION P
   NASELL I, 1973, COMMUN PUR APPL MATH, V26, P395, DOI 10.1002/cpa.3160260402
   SMOLLER J, 1981, J DIFFER EQUATIONS, V39, P269, DOI 10.1016/0022-0396(81)90077-2
   Smoller J., 1983, SHOCK WAVES REACTION
   WILSON RE, 1995, THESIS U OXFORD
NR 17
TC 74
Z9 75
U1 0
U2 9
PU SIAM PUBLICATIONS
PI PHILADELPHIA
PA 3600 UNIV CITY SCIENCE CENTER, PHILADELPHIA, PA 19104-2688
SN 0036-1399
J9 SIAM J APPL MATH
JI SIAM J. Appl. Math.
PD APR
PY 1997
VL 57
IS 2
BP 327
EP 346
DI 10.1137/S0036139995284681
PG 20
WC Mathematics, Applied
SC Mathematics
GA WR388
UT WOS:A1997WR38800002
OA Green Submitted
DA 2021-08-04
ER

PT J
AU Shen, V
   Watanabe, K
   Bell, AT
AF Shen, V
   Watanabe, K
   Bell, AT
TI Theoretical analysis of the thermodynamics of ZSM-11 zeolite synthesis
SO JOURNAL OF PHYSICAL CHEMISTRY B
LA English
DT Article
ID EFFECTIVE PAIR POTENTIALS; MICROPOROUS MATERIALS; STRUCTURE DIRECTION;
   SILICA ZEOLITES; MECHANISM; CRYSTALLIZATION; SIMULATIONS; FRAMEWORK;
   TEMPLATES; NMR
AB Theoretical methods are used to analyze the thermodynamics of ZSM-11 synthesis from amorphous silica and an aqueous solution of tetraalkylammonium hydroxide (TAAOH). The overall process is represented by the reaction 96SiO(2)(a) + n(TAA(+)/OH-/200H(2)O) = (nTAA(+)/Z(n-)) + 200nH(2)O. Both tetrapropylammonium (TPA(+)) and tetrabutylammonium (TBA(+)) cations are considered as the structure-directing agents, and calculations are performed for occlusion of either three or four TAA(+) cations per unit cell of the zeolite. Both estimates of the change in internal energy and Gibbs free energy reveal that the synthesis of ZSM-11 should be favored by the occlusion of three TBA(+) cations per unit cell, consistent with experimental observation. The present analysis also demonstrates the importance of energy and entropy changes associated with the dehydration of TAA(+) and OH- ions and with the occlusion of TAA(+) cations into the zeolite. The interactions of OH- anions with the zeolite framework to form defects in the form of siloxy (=SiO-) groups are also considered.
C1 UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,DIV MAT SCI,BERKELEY,CA 94720.
   UNIV CALIF BERKELEY,DEPT CHEM ENGN,BERKELEY,CA 94720.
RI VIEILLARD, Philippe/B-8544-2008
OI VIEILLARD, Philippe/0000-0003-0394-7999; Watanabe,
   Karen/0000-0002-3572-6667; Bell, Alexis/0000-0002-5738-4645
CR BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913
   BELL RG, 1994, STUD SURF SCI CATAL, V84, P2075
   BERENDSEN HJC, 1987, J PHYS CHEM-US, V91, P6269, DOI 10.1021/j100308a038
   *BIOS MSI, 1995, DISC 2 9 7 MOL SIM S
   BOXHOORN G, 1983, J CHEM SOC CHEM COMM, P1416, DOI 10.1039/c39830001416
   BURKETT SL, 1994, J PHYS CHEM-US, V98, P4647, DOI 10.1021/j100068a027
   BURKETT SL, 1995, CHEM MATER, V7, P920, DOI 10.1021/cm00053a017
   BURKETT SL, 1995, CHEM MATER, V7, P1440
   CHANG CD, 1991, CATAL LETT, V8, P305, DOI 10.1007/BF00764192
   CODATA, 1978, J CHEM THERMODYN, V10, P903
   DAVIS ME, 1992, CHEM MATER, V4, P756, DOI 10.1021/cm00022a005
   DEROUANE EG, 1981, APPL CATAL, P1
   DORSEY NE, 1940, PROPERTIES ORDINARY, P583
   DUTTA PK, 1987, J PHYS CHEM-US, V91, P4329, DOI 10.1021/j100300a025
   FEIJEN EJP, 1994, STUD SURF SCI CATAL, V84, P3
   FLANIGEN EM, 1980, PURE APPL CHEM, V53, P2191
   FRANK HS, 1945, J CHEM PHYS, V13, P507, DOI 10.1063/1.1723985
   FRANK HS, 1957, DISCUSS FARADAY SOC, P133, DOI 10.1039/df9572400133
   FYFE CA, 1989, J AM CHEM SOC, V111, P2470, DOI 10.1021/ja00189a016
   GIES H, 1992, ZEOLITES, V12, P42, DOI 10.1016/0144-2449(92)90008-D
   GILSON JP, 1992, NATO ADV SCI I C-MAT, V352, P19
   GITTLEMAN CS, 1994, MICROPOROUS MATER, V2, P145, DOI 10.1016/0927-6513(93)E0047-K
   GITTLEMAN CS, 1995, MICROPOROUS MATER, V3, P511, DOI 10.1016/0927-6513(94)00062-Z
   HARRIS TV, 1994, STUD SURF SCI CATAL, V84, P29
   HELMKAMP MM, 1995, ANNU REV MATER SCI, V25, P161
   HILL JR, 1995, J PHYS CHEM-US, V99, P9536, DOI 10.1021/j100023a036
   ITON LE, 1992, LANGMUIR, V8, P1045, DOI 10.1021/la00040a005
   JACOBS PA, 1992, NATO ADV SCI I C-MAT, V352, P3
   JANSEN JC, 1991, INTRO ZEOLITE SCI PR, P77
   JOHNSON GK, 1987, J CHEM THERMODYN, V19, P617, DOI 10.1016/0021-9614(87)90068-1
   KARASAWA N, 1989, J PHYS CHEM-US, V93, P7320, DOI 10.1021/j100358a012
   LEWIS DW, 1995, J PHYS CHEM-US, V99, P11194, DOI 10.1021/j100028a022
   MAYO SL, 1990, J PHYS CHEM-US, V94, P8897, DOI 10.1021/j100389a010
   MCCORMICK AV, 1989, CATAL REV, V31, P97, DOI 10.1080/01614948909351349
   *MOL SIM INC, 1995, CER 2 1 6 COMP CHEM
   MULLER N, 1990, ACCOUNTS CHEM RES, V23, P23, DOI 10.1021/ar00169a005
   NAGY JB, 1983, ZEOLITES, V3, P43, DOI 10.1016/0144-2449(83)90084-2
   PETROVIC I, 1993, CHEM MATER, V5, P1805, DOI 10.1021/cm00036a019
   RAPPE AK, 1991, J PHYS CHEM-US, V95, P3358, DOI 10.1021/j100161a070
   RINGNALDA MN, 1996, PS GVB V2 3
   SCHOLLE KFMGJ, 1985, APPL CATAL, V17, P233, DOI 10.1016/S0166-9834(00)83208-X
   Shen V, 1996, MICROPOROUS MATER, V7, P187, DOI 10.1016/0927-6513(95)00093-3
   VANKONINGSVELD H, 1987, ACTA CRYSTALLOGR B, V43, P127, DOI 10.1107/S0108768187098173
   WATANABE K, 1989, CHEM PHYS, V131, P157, DOI 10.1016/0301-0104(89)80166-1
NR 44
TC 9
Z9 9
U1 0
U2 18
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 1089-5647
J9 J PHYS CHEM B
JI J. Phys. Chem. B
PD MAR 20
PY 1997
VL 101
IS 12
BP 2207
EP 2212
DI 10.1021/jp9631341
PG 6
WC Chemistry, Physical
SC Chemistry
GA WP413
UT WOS:A1997WP41300017
DA 2021-08-04
ER

PT J
AU Narula, J
   Petrov, A
   Pak, KY
   Lister, BC
   Khaw, BA
AF Narula, J
   Petrov, A
   Pak, KY
   Lister, BC
   Khaw, BA
TI Very early noninvasive detection of acute experimental nonreperfused
   myocardial infarction with Tc-99m-labeled glucarate
SO CIRCULATION
LA English
DT Article; Proceedings Paper
CT 41st Annual Meeting of the Society-of-Nuclear-Medicine
CY JUN 05-09, 1994
CL ORLANDO, FL
SP Soc Nucl Med
DE myocardial infarction; imaging; antibodies; coronary disease; myosin;
   reperfusion
ID HEART-MITOCHONDRIA; ANTIMYOSIN FAB; ANTIBODY; DOGS;
   TECHNETIUM-99M-GLUCARATE; PYROPHOSPHATE; GLUCONATE; NECROSIS; BINDING;
   MYOSIN
AB Background Tc-99m glucarate has recently been reported to be an infarct-avid agent. The feasibility of imaging with (TC)-T-99m glucarate was evaluated for the early diagnosis of nonreperfused and reperfused myocardial infarction and compared with localization of simultaneously administered In-111 anti-myosin.
   Methods and Results Four groups of six rabbits each were studied. The left anterior descending coronary artery (LAD) was kept persistently occluded (n = 6) or reperfused after 40 minutes (n = 6) in rabbits. After confirmation of LAD occlusion by Tl-201 scintigraphy, a mixture of Tc-99m glucarate (15.7+/-1.6 mCi) and In-111 anti-myosin (0.53 +/- 0.03 mCi) was administered intravenously. Another group of rabbits (n = 6) with 5 or 15 minutes of LAD occlusion were used to assess the affinity of Tc-99m glucarate for the ischemic myocardium. The remaining 6 rabbits with reperfused myocardial infarction were used for the assessment of subcellular localization of Tc-99m glucarate. Tc-99m glucarate cleared rapidly from circulation (elimination t(1/2), 36 minutes). Infarcts were visualized within 10 minutes in reperfused and within 30 minutes in nonreperfused coronary territories after intravenous administration. In-111 anti-myosin delineated reperfused infarcts within 1 to 3 hours, but no uptake was seen in persistently occluded rabbits. Tc-99m glucarate uptake in reperfused and nonreperfused infarct centers was 28 and 12 times greater, respectively, than that in normal myocardium (P = .0001). A direct correlation between glucarate and antimyosin localization (r = .60 for nonreperfused; 0.76 for reperfused; P < .0001) was observed. Ischemic hearts showed no glucarate uptake. Subcellularly, Tc-99m glucarate localized predominantly in the nuclear fraction of the infarct, with lesser extents in the mitochondrial and cytoplasmic fractions.
   Conclusions Noninvasive imaging of myocardial infarcts with Tc-99m glucarate is possible within minutes in persistently occluded or reperfused myocardial infarcts. Early detectability results from the rapid blood clearance and high avidity of glucarate for the acutely necrotic myocardial tissue.
C1 NORTHEASTERN UNIV,CTR DRUG TARGETING & ANAL,BOSTON,MA 02115.
   MASSACHUSETTS GEN HOSP,CARDIAC UNIT,BOSTON,MA 02114.
   HARVARD UNIV,SCH MED,BOSTON,MA.
   MOL TARGETING TECHNOL INC,MALVERN,PA.
FU NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [R43HL054410] Funding
   Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Heart Lung & Blood Institute (NHLBI) [1R43-HL-54410-01] Funding Source:
   Medline
CR AHLBERG NE, 1981, ACTA RADIOL ONCOL, V20, P357, DOI 10.3109/02841868109130223
   BEANLANDS RS, 1994, CIRCULATION, V90, P76
   BHATTACHARYA S, 1991, AM HEART J, V122, P1583, DOI 10.1016/0002-8703(91)90274-L
   BONTE FJ, 1974, RADIOLOGY, V110, P473, DOI 10.1148/110.2.473
   BUJA LM, 1977, J CLIN INVEST, V60, P724, DOI 10.1172/JCI108825
   CONSTANTINI C, 1975, AM J CARDIOL, V36, P368
   GALARIS D, 1983, EUR J NUCL MED, V8, P4
   HNATOWICH DJ, 1983, SCIENCE, V220, P613, DOI 10.1126/science.6836304
   ISHIDATE M, 1965, ANAL BIOCHEM, V11, P176, DOI 10.1016/0003-2697(65)90004-7
   JOHNSON LL, 1989, J AM COLL CARDIOL, V13, P27, DOI 10.1016/0735-1097(89)90544-5
   KHAW BA, 1984, HYBRIDOMA, V3, P11, DOI 10.1089/hyb.1984.3.11
   KHAW BA, 1987, J NUCL MED, V28, P76
   KHAW BA, 1986, CIRCULATION, V74, P501, DOI 10.1161/01.CIR.74.3.501
   KHAW BA, 1987, J NUCL MED, V28, P1671
   MAROKO PR, 1972, J CLIN INVEST, V51, P2710, DOI 10.1172/JCI107090
   NARULA J, 1993, NEW ENGL J MED, V328, P100, DOI 10.1056/NEJM199301143280205
   NARULA J, 1995, J AM COLL CARDIOL, V24, pA218
   OHTANI H, 1992, J NUCL MED, V33, P1988
   ORLANDI C, 1991, J NUCL MED, V32, P263
   PAK K Y, 1989, Journal of Nuclear Medicine, V30, P906
   REIMER KA, 1977, CIRCULATION, V56, P786, DOI 10.1161/01.CIR.56.5.786
   STRAUSS HW, 1994, MONOCLONAL ANTIBODIE, P30
   Tyler D. D., 1967, METHOD ENZYMOL, V10, P75, DOI DOI 10.1016/0076-6879(67)10014-1
   VERCESI A, 1978, J BIOL CHEM, V253, P6379
   WILLERSON JT, 1991, J NUCL MED, V32, P269
   WILLERSON JT, 1975, CIRCULATION, V51, P1046, DOI 10.1161/01.CIR.51.6.1046
   YAOITA H, 1993, J NUCL MED, V34, P1303
NR 27
TC 62
Z9 62
U1 0
U2 1
PU AMER HEART ASSOC
PI DALLAS
PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD MAR 18
PY 1997
VL 95
IS 6
BP 1577
EP 1584
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA WN577
UT WOS:A1997WN57700035
PM 9118528
DA 2021-08-04
ER

PT J
AU Landowski, TH
   GleasonGuzman, MC
   Dalton, WS
AF Landowski, TH
   GleasonGuzman, MC
   Dalton, WS
TI Selection for drug resistance results in resistance to Fas-mediated
   apoptosis
SO BLOOD
LA English
DT Article
ID CANCER CELL-LINE; P-GLYCOPROTEIN; MULTIDRUG-RESISTANCE;
   MULTIPLE-MYELOMA; TUMOR-CELLS; DEATH; EXPRESSION; APO-1; RECEPTOR;
   PROTEIN
AB Recent evidence has supported the hypothesis that chemotherapeutic drugs and radiation induce an apoptotic pathway that requires the active participation of the cell. One pathway of apoptosis in malignant lymphoid cells is mediated by the Fas antigen. We studied the human myeloma (8226) and T-cell leukemia (GEM) cell lines selected for resistance to the anthracenes, doxorubicin or mitoxantrone, by continuous culture in the presence of either agent, We found that these drug-resistant cell lines were also resistant to Fas-mediated apoptosis in a dose-dependent manner, The degree of resistance to Fas-mediated apoptosis correlated directly with the level of resistance to chemotherapeutic drugs. These observations indicate that, as cancer cell lines develop mechanisms of drug resistance, they may also develop mechanisms of resistance to physiologic signals of apoptosis, Two mechanisms of resistance to Fas-mediated apoptosis were observed in these cell lines, One mechanism was associated with a dose-dependent reduction in the surface expression of Fas antigen. Analysis of RNA by reverse transcriptase-polymerase chain reaction assays showed that the reduction of Fas antigen expression occurred at the level of transcription, A second mechanism of drug resistance showed no decrease of Fas antigen expression; however, the apoptotic response was diminished, In this situation, removal of the chemotherapeutic agent resulted in a partial reversion to chemosensitivity and re-expression of the Fas antigen, but these cell lines did not regain the ability to undergo apoptosis in response to cross-linking by anti-fas antibody. These findings support the hypothesis that apoptosis mediated by both chemotherapeutic agents and physiologic stimuli may share a common downstream effector, The demonstration that selection for drug resistance in hematopoietic cell lines results in a simultaneous resistance to Fas-mediated apoptosis may have clinical implications in the development of strategies for the treatment of resistant disease, Further analysis of the molecular mechanisms of Fas expression and function will facilitate the design of biological response modifying agents for the treatment of malignancy. (C) 1997 by The American Society of Hematology.
C1 UNIV ARIZONA,ARIZONA CANC CTR,DEPT MED,TUCSON,AZ.
   UNIV ARIZONA,ARIZONA CANC CTR,DEPT PHARMACOL & TOXICOL,TUCSON,AZ.
CR Baker SJ, 1996, ONCOGENE, V12, P1
   BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387
   Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9
   BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8
   CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3
   COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704
   DALTON WS, 1986, CANCER RES, V46, P5125
   DALTON WS, 1989, J CLIN ONCOL, V7, P415, DOI 10.1200/JCO.1989.7.4.415
   DAMICO AV, 1994, RADIOTHER ONCOL, V33, P3, DOI 10.1016/0167-8140(94)90079-5
   DANIEL PT, 1994, J IMMUNOL, V152, P5624
   DARZYNKIEWICZ Z, 1995, J CELL BIOCHEM, V58, P151, DOI 10.1002/jcb.240580204
   ELKHATIB M, 1995, CELL IMMUNOL, V163, P237, DOI 10.1006/cimm.1995.1122
   FALK MH, 1992, BLOOD, V79, P3300
   FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265
   Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574
   FUTSCHER BW, 1994, BIOCHEM PHARMACOL, V47, P1601, DOI 10.1016/0006-2952(94)90538-X
   GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125
   GREEN DR, 1995, CURR OPIN IMMUNOL, V7, P694, DOI 10.1016/0952-7915(95)80079-4
   ITOH N, 1993, J BIOL CHEM, V268, P10932
   ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5
   Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x
   JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0
   KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J
   KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x
   LEITHAUSER F, 1993, LAB INVEST, V69, P415
   LYNCH DH, 1995, IMMUNOL TODAY, V16, P569, DOI 10.1016/0167-5699(95)80079-4
   MASSAIA M, 1995, LEUKEMIA LYMPHOMA, V17, P63, DOI 10.3109/10428199509051704
   MONTEL AH, 1995, CELL IMMUNOL, V166, P236, DOI 10.1006/cimm.1995.9974
   Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0
   NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326
   PODACK ER, 1995, J LEUKOCYTE BIOL, V57, P548
   PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7
   SCHATTNER EJ, 1995, J EXP MED, V182, P1557, DOI 10.1084/jem.182.5.1557
   SCHEFFER GL, 1995, NAT MED, V1, P578, DOI 10.1038/nm0695-578
   SHIMA Y, 1995, BLOOD, V85, P757, DOI 10.1182/blood.V85.3.757.bloodjournal853757
   SHUSTIK C, 1995, MOL ASPECTS MED, V16, P1, DOI 10.1016/0098-2997(94)00040-A
   TAYLOR CW, 1991, BRIT J CANCER, V63, P923, DOI 10.1038/bjc.1991.202
   TEW KD, 1994, CANCER RES, V54, P4313
   THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464
   TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530
   Tricot G, 1996, BLOOD, V87, P1196, DOI 10.1182/blood.V87.3.1196.bloodjournal8731196
   UEDA K, 1986, BIOCHEM BIOPH RES CO, V141, P956, DOI 10.1016/S0006-291X(86)80136-X
   WESTENDORF JJ, 1995, BLOOD, V12, P3466
   Zhang J, 1996, MOL CELL BIOL, V16, P2756
NR 44
TC 150
Z9 151
U1 0
U2 1
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0006-4971
J9 BLOOD
JI Blood
PD MAR 15
PY 1997
VL 89
IS 6
BP 1854
EP 1861
DI 10.1182/blood.V89.6.1854
PG 8
WC Hematology
SC Hematology
GA WP231
UT WOS:A1997WP23100002
PM 9058704
OA Bronze
DA 2021-08-04
ER

PT J
AU Humayun, MU
   Rader, RS
   Pieramici, DJ
   Awh, CC
   deJuan, E
AF Humayun, MU
   Rader, RS
   Pieramici, DJ
   Awh, CC
   deJuan, E
TI Quantitative measurement of the effects of caffeine and propranolol on
   surgeon hand tremor
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article; Proceedings Paper
CT Association for Vision and Research in Ophthalmology Annual Meeting
CY MAY 14-19, 1995
CL FT LAUDERDALE, FL
SP Assoc Vis Res Ophthalmol
ID PERFORMANCE; EXERCISE
AB Objective: To quantitatively measure the effects of caffeine and propranolol, a nonselective beta-blocking agent, on surgeon hand tremor during simulated vitreoretinal microsurgery.
   Methods: Seventeen ophthalmic surgeons were tested on 3 separate days. On each day, subjects ingested 200 mg of caffeine, 10 mg of,propranolol hydrochloride, or gelatin placebo. The drugs were administered as part of a double-masked, placebo-controlled trial. Hand tremor was measured using the Microsurgery Advanced Design Laboratory Stability, Activation, and Maneuverability tester (MADSAM), a high-resolution, noncontact position tracking system.
   Results: The average percent magnitude changes from baseline tremor measurements were +15%, +31%, and -22% for placebo, caffeine, and propranolol groups, respectively. Analysis of variance techniques accounting for effects of individuals, drugs, and day order demonstrated that only drug effects on percent magnitude change of tremor were statistically significant (P=.01, F test). Detailed comparisons of the 2 drug groups with the placebo group revealed that, after adjusting for individual and order effects, only the mean decrease in tremor due to ingestion of propranolol was a statistically significant trend (P=.03, F test). Although caffeine caused a larger mean increase in percent magnitude change in tremor than placebo, this trend was not statistically significant (P=.34, F test). The evaluation of systemic physiologic measurements showed that there were statistically significant drug effects on percent change in systolic (P<.001, F test) and diastolic (P=.002, F test) blood pressure and pulse rate (P=.002, F test). Individual and day order effects were not significant. No adverse side effects were observed or reported in our test subjects.
   Conclusion: Physiologic surgeon hand tremor can be decreased by the oral intake of a low dose of propranolol.
C1 JOHNS HOPKINS UNIV HOSP, WILMER OPHTHALMOL INST, MICROSURG ADV DESIGN LAB, BALTIMORE, MD 21287 USA.
   RETINA VITREOUS ASSOCIATES, NASHVILLE, TN USA.
FU NATIONAL EYE INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Eye
   Institute (NEI) [P30EY001765] Funding Source: NIH RePORTER; NEI NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Eye Institute (NEI)
   [EY01765] Funding Source: Medline
CR ABILA B, 1986, BRIT J CLIN PHARMACO, V22, P104
   ARNOLD RW, 1993, ANN OPHTHALMOL, V25, P250
   CALZETTI S, 1983, ANN NEUROL, V13, P165, DOI 10.1002/ana.410130210
   Evans D R, 1978, Ophthalmology, V85, P878
   FINDLEY LJ, 1985, J NEUROL NEUROSUR PS, V48, P911, DOI 10.1136/jnnp.48.9.911
   Gillespie M M, 1991, J Neurosci Nurs, V23, P170
   HOLMES JM, 1992, ANN OPHTHALMOL, V24, P156
   HUMAYUN MU, 1994, INVEST OPHTH VIS SCI, V35, P1261
   JACOBSON BH, 1992, PERCEPT MOTOR SKILL, V74, P151, DOI 10.2466/PMS.74.1.151-157
   JACOBSON BH, 1991, PERCEPT MOTOR SKILL, V72, P1175, DOI 10.2466/PMS.72.4.1175-1181
   Kirby T J, 1979, Trans Am Ophthalmol Soc, V77, P294
   KRUSE P, 1986, J APPL PHYSIOL, V61, P417
   SHIFFMAN SM, 1983, CLIN PHARMACOL THER, V33, P800, DOI 10.1038/clpt.1983.109
   WADE P, 1982, ARCH NEUROL-CHICAGO, V39, P358, DOI 10.1001/archneur.1982.00510180036009
NR 14
TC 40
Z9 42
U1 0
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD MAR
PY 1997
VL 115
IS 3
BP 371
EP 374
DI 10.1001/archopht.1997.01100150373010
PG 4
WC Ophthalmology
SC Ophthalmology
GA WN485
UT WOS:A1997WN48500010
PM 9076210
DA 2021-08-04
ER

PT J
AU Gao, J
   McManus, NT
   Penlidis, A
AF Gao, J
   McManus, NT
   Penlidis, A
TI Experimental and simulation studies on ethyl acrylate polymerization
SO MACROMOLECULAR CHEMISTRY AND PHYSICS
LA English
DT Article
ID FREE-RADICAL POLYMERIZATION; CONTROLLED VINYL POLYMERIZATION;
   METHYL-METHACRYLATE; TRANSITION BEHAVIOR; RATE COEFFICIENTS;
   TERMINATION; PROPAGATION; KINETICS
AB An experimental study of the bulk free radical polymerization of ethyl acrylate (EA) initiated by 2,2'-azoisobutyronitrile (AIBN) was conducted. The experiments were carried out based on a factorial design with replicates. The reaction variables investigated were initiator concentration, temperature and chain transfer agent (CTA) concentration (primary octanethiol). The results obtained were used to develop and test a simulation model for EA homopolymerization.
C1 UNIV WATERLOO,DEPT CHEM ENGN,WATERLOO,ON N2L 3G1,CANADA.
OI Penlidis, Alexander/0000-0003-1826-1818
CR ADHIKARI MS, 1987, J APPL POLYM SCI, V34, P109, DOI 10.1002/app.1987.070340110
   Anseth K. S., 1993, POLYM REACT ENG, V1, P499
   BALAKRISHNAN T, 1988, J POLYM SCI POL CHEM, V26, P355, DOI 10.1002/pola.1988.080260202
   BALLARD MJ, 1986, J POLYM SCI POL CHEM, V24, P1027, DOI 10.1002/pola.1986.080240518
   BAMFORD CH, 1969, POLYMER, V10, P885, DOI 10.1016/0032-3861(69)90120-7
   BRANDRUP A, 1989, POLYM HDB
   BRESSERS HJL, 1980, POLYM BULL, V2, P201, DOI 10.1007/BF00254585
   FEHERVARI A, 1981, J MACROMOL SCI CHEM, VA16, P993, DOI 10.1080/00222338108056455
   FEHERVARI A, 1982, J MACROMOL SCI CHEM, VA18, P347, DOI 10.1080/00222338208056505
   FEHERVARI A, 1982, J MACROMOL SCI CHEM, VA18, P337, DOI 10.1080/00222338208056504
   FEHERVARI A, 1980, EUR POLYM J, V16, P185, DOI 10.1016/0014-3057(80)90068-3
   FEHERVARI A, 1980, J MACROMOL SCI CHEM, VA14, P1071, DOI 10.1080/00222338008056731
   FEHERVARI A, 1982, J MACROMOL SCI CHEM, VA18, P431, DOI 10.1080/00222338208056513
   Gao J, 1996, J MACROMOL SCI R M C, VC36, P199
   GAO J, 1992, THESIS U WATERLOO
   GARRETT RW, 1989, POLYM BULL, V22, P611
   HAYASHI K, 1988, J APPL POLYM SCI, V36, P295, DOI 10.1002/app.1988.070360204
   HOURSTON DJ, 1980, J APPL POLYM SCI, V25, P959, DOI 10.1002/app.1980.070250523
   HUTCHINSON RA, 1993, MACROMOLECULES, V26, P6410, DOI 10.1021/ma00076a017
   KATIME J, 1983, THERMOCHIM ACTA, V70, P1
   KLOOSTERBOER JG, 1980, POLYM BULL, V2, P205, DOI 10.1007/BF00254586
   KOLARIK J, 1979, J APPL POLYM SCI, V24, P1565, DOI 10.1002/app.1979.070240617
   LENKA S, 1981, J POLYM SCI POL CHEM, V19, P2671, DOI 10.1002/pol.1981.170191102
   MA YD, 1994, POLYMER, V35, P1375, DOI 10.1016/0032-3861(94)90336-0
   MADRUGA EL, 1982, EUR POLYM J, V18, P1011, DOI 10.1016/0014-3057(82)90091-X
   MALAVASIC T, 1983, J MACROMOL SCI CHEM, V19, P7
   MANGARAJ D, 1967, MAKROMOLEKUL CHEM, V104, P125
   MCISAAC S, 1994, THESIS U WATERLOO
   NANDI US, 1982, MAKROMOL CHEM, V183, P1467
   NAYAK PS, 1981, J POLYM SCI POL CHEM, V19, P2671
   PITTMAN CU, 1981, J APPL POLYM SCI, V26, P2403, DOI 10.1002/app.1981.070260726
   RAAVE A, 1979, J MACROMOL SCI CHEM, V13, P285
   RAGHURAM PV, 1969, J POLYM SCI A1, V7, P2379, DOI 10.1002/pol.1969.150070832
   RAGHURAM PV, 1970, J POLYM SCI A1, V8, P3079, DOI 10.1002/pol.1970.150081104
   RAGHURAM PV, 1967, J POLYM SCI A1, V5, P2005, DOI 10.1002/pol.1967.150050817
   REDDY VA, 1984, J MACROMOL SCI CHEM, V21, P487
   REID CG, 1990, J APPL POLYM SCI, V39, P995, DOI 10.1002/app.1990.070390417
   SACK R, 1988, MACROMOLECULES, V21, P3345, DOI 10.1021/ma00190a001
   SOH SK, 1982, J POLYM SCI POL CHEM, V20, P1331, DOI 10.1002/pol.1982.170200515
   SOH SK, 1982, J POLYM SCI POL CHEM, V20, P1345, DOI 10.1002/pol.1982.170200516
   SPERLING LH, 1970, J APPL POLYM SCI, V14, P73, DOI 10.1002/app.1970.070140108
   SUBRAHMANYAM B, 1992, J POLYM SCI POL CHEM, V30, P2531, DOI 10.1002/pola.1992.080301207
   TUDOS F, 1991, ANGEW MAKROMOL CHEM, V185, P303, DOI 10.1002/apmc.1991.051850129
   TUDOS F, 1965, ACTA CHIM HUNG, V44, P403
   TUDOS F, 1965, ACTA CHIM HUNG, V43, P397
   ZHU S, 1990, MACROMOLECULES, V23, P1144, DOI 10.1021/ma00206a037
   ZHU S, 1991, POLYMER, V32, P3021, DOI 10.1016/0032-3861(91)90204-V
NR 47
TC 3
Z9 3
U1 0
U2 3
PU HUTHIG & WEPF VERLAG
PI BASEL
PA AUF DEM WOLF 4, CH-4052 BASEL, SWITZERLAND
SN 1022-1352
J9 MACROMOL CHEM PHYSIC
JI Macromol. Chem. Phys.
PD MAR
PY 1997
VL 198
IS 3
BP 843
EP 859
DI 10.1002/macp.1997.021980315
PG 17
WC Polymer Science
SC Polymer Science
GA WN901
UT WOS:A1997WN90100017
DA 2021-08-04
ER

PT J
AU Grassberger, P
   Chate, H
   Rousseau, G
AF Grassberger, P
   Chate, H
   Rousseau, G
TI Spreading in media with long-time memory
SO PHYSICAL REVIEW E
LA English
DT Article
ID SURFACE-REACTION MODEL; REGGEON FIELD-THEORY; DIRECTED PERCOLATION;
   PHASE-TRANSITIONS; STATISTICAL-MECHANICS; CRITICAL EXPONENTS;
   CRITICAL-BEHAVIOR; DIMENSIONS; SYSTEMS
AB We study the spreading of an agent in a medium whose susceptibility changes irreversibly at the first encounter with the agent. This can model epidemics with partial immunization or population growth with incomplete replenishment of food (in both cases the susceptibility for growth decreases after the first attack) or epidemics in which the resistance is weakened by the first infection (increased susceptibility). In such models one can have no growth at all, compact growth, or annular growth. We delineate the phase diagram and study the scaling behavior at the phase boundaries. Our arguments are supported by simulations in one and two dimensions. Although our model does not involve multiple absorbing states, we claim that our results explain the ''nonuniversal'' behavior seen in models with such states.
C1 CEA,CTR ETUD SACLAY,SERV PHYS ETAT CONDENSE,F-91191 GIF SUR YVETTE,FRANCE.
   DAEC,OBSERV MEUDON,F-92195 MEUDON,FRANCE.
RP Grassberger, P (corresponding author), UNIV GESAMTHSCH WUPPERTAL,DEPT PHYS,D-42097 WUPPERTAL,GERMANY.
RI rousseau, guillaume/B-9945-2019; Chate, Hugues/D-2156-2015
OI Chate, Hugues/0000-0002-6098-4094
CR BENAVRAHAM D, 1992, J STAT PHYS, V65, P839
   Broadbent S.R., 1957, Proceedings of the Cambridge Philosophical Society, V53, P629
   CARDY JL, 1985, J PHYS A-MATH GEN, V18, pL267, DOI 10.1088/0305-4470/18/6/001
   CHATE H, 1988, PHYS REV A, V38, P4351, DOI 10.1103/PhysRevA.38.4351
   Dickman R, 1996, PHYS REV E, V53, P2223, DOI 10.1103/PhysRevE.53.2223
   Diehl H. W., 1986, PHASE TRANSITIONS CR
   DURRETT R, 1988, LECT PARTICLE SYSTEM
   ESSAM JW, 1988, J PHYS A-MATH GEN, V21, P3815, DOI 10.1088/0305-4470/21/19/018
   GRASSBERGER P, 1995, J STAT PHYS, V79, P13, DOI 10.1007/BF02179381
   GRASSBERGER P, 1979, ANN PHYS-NEW YORK, V122, P373, DOI 10.1016/0003-4916(79)90207-0
   GRASSBERGER P, 1978, PHYS LETT B, V77, P220, DOI 10.1016/0370-2693(78)90626-3
   GRASSBERGER P, 1992, J PHYS A-MATH GEN, V25, P5867, DOI 10.1088/0305-4470/25/22/015
   GRASSBERGER P, 1989, J PHYS A-MATH GEN, V22, P3673, DOI 10.1088/0305-4470/22/17/032
   GRASSBERGER P, 1982, Z PHYS B CON MAT, V47, P365, DOI 10.1007/BF01313803
   Grassberger P, 1996, PHYSICA A, V224, P169, DOI 10.1016/0378-4371(95)00321-5
   GRASSBERGER P, 1983, MATH BIOSCI, V62, P157
   GRASSBERGER P, 1996, J PHYS A, V224, P169
   HALPINHEALY T, 1995, PHYS REP, V254, P215, DOI 10.1016/0370-1573(94)00087-J
   JANSSEN HK, 1985, Z PHYS B CON MAT, V58, P311, DOI 10.1007/BF01303673
   JANSSEN HK, 1981, Z PHYS B CON MAT, V42, P151, DOI 10.1007/BF01319549
   JENSEN I, 1993, PHYS REV LETT, V70, P1465, DOI 10.1103/PhysRevLett.70.1465
   JENSEN I, 1993, PHYS REV E, V48, P1710, DOI 10.1103/PhysRevE.48.1710
   JENSEN I, 1990, PHYS REV A, V41, P3411, DOI 10.1103/PhysRevA.41.3411
   KINZEL W, 1985, Z PHYS B CON MAT, V58, P229, DOI 10.1007/BF01309255
   Liggett T.M., 1985, INTERACTING PARTICLE
   Mendes JFF, 1996, PHYS REV E, V54, pR3071, DOI 10.1103/PhysRevE.54.R3071
   MENDES JFF, 1994, J PHYS A-MATH GEN, V27, P3019, DOI 10.1088/0305-4470/27/9/017
   MOLLISON D, 1977, J ROY STAT SOC B MET, V39, P283
   MOSHE M, 1978, PHYS REP, V37, P255, DOI 10.1016/0370-1573(78)90098-4
   Munoz MA, 1996, PHYS REV LETT, V76, P451, DOI 10.1103/PhysRevLett.76.451
   SCHULMAN LS, 1978, J STAT PHYS, V19, P293, DOI 10.1007/BF01011727
   Stauffer D., 1992, INTRO PERCOLATION TH
   YALDRAM K, 1993, J PHYS A-MATH GEN, V26, pL801, DOI 10.1088/0305-4470/26/17/009
   ZIFF RM, 1986, PHYS REV LETT, V56, P2553, DOI 10.1103/PhysRevLett.56.2553
NR 34
TC 68
Z9 70
U1 0
U2 3
PU AMERICAN PHYSICAL SOC
PI COLLEGE PK
PA ONE PHYSICS ELLIPSE, COLLEGE PK, MD 20740-3844 USA
SN 1063-651X
J9 PHYS REV E
JI Phys. Rev. E
PD MAR
PY 1997
VL 55
IS 3
BP 2488
EP 2495
DI 10.1103/PhysRevE.55.2488
PN A
PG 8
WC Physics, Fluids & Plasmas; Physics, Mathematical
SC Physics
GA WN934
UT WOS:A1997WN93400053
DA 2021-08-04
ER

PT J
AU Bansal, VK
   Beto, JA
AF Bansal, VK
   Beto, JA
TI Treatment of lupus nephritis: A meta-analysis of clinical trials
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Article
DE lupus nephritis; renal function; meta-analysis
ID COMBINED PREDNISONE; IMMUNOSUPPRESSIVE DRUGS; PULSE CYCLOPHOSPHAMIDE;
   RENAL-FUNCTION; AZATHIOPRINE; ERYTHEMATOSUS; THERAPY;
   GLOMERULONEPHRITIS; CLASSIFICATION
AB The best therapeutic choice in lupus nephritis remains shrouded in a body of controversial literature. The purpose of this review was to assess and compare by meta-analysis the efficacy of therapeutic agents used in the treatment of lupus nephritis using outcomes of end-stage renal disease (ESRD) and total mortality, An exhaustive search was performed using MEDLlNE (1970 to 1995) and manual search of bibliographic notations and nonindexed sources, Twenty prospective controlled trials with treatment allocation by random assignment or consecutive enrollment were identified using diagnostic evidence of systemic lupus erythematosus based on American Rheumatism Association (ARA) criteria and clinical/biopsy evidence of lupus nephritis. One trial was excluded, resulting in 19 trials (n = 440) using treatment groups of oral prednisone alone, azathioprine with and without concomitant prednisone, oral cyclophosphamide with prednisone, azathioprine and oral cyclophosphamide with prednisone, and intravenous cyclophosphamide with prednisone. Crude risk data was pooled. An adjusted pooled risk was calculated using the random effects model of DerSimonian and Laird, Two measures of clinical effectiveness were used to compare treatments: absolute risk differences and number needed to treat, Analysis was completed between treatment groups as follows: oral prednisone compared with all immunosuppressive agents with prednisone and all treatment groups compared with one another, When compared with oral prednisone alone, immunosuppressive agents used in conjunction with oral prednisone were found to be statistically more effective for both total mortality and ESRD (absolute risk differences, 13.2% and 12.9%, respectively). When treatment groups were compared, intravenous cyclophosphamide in conjunction with oral prednisone was found to be statistically more effective than oral prednisone alone for both total mortality and ESRD (absolute risk differences, 19.9% and 16.2%, respectively), The simultaneous use of azathioprine and oral cyclophosphamide concomitant with oral prednisone was found to be 16.9% more effective than oral prednisone alone in reducing incidence of ESRD, No difference was seen in total mortality and data represented only two studies (n = 30). No immunosuppressive agent was found to be statistically more effective than another for either total mortality or ESRD, Future prospective studies are needed to control for numerous variables and renal function changes to provide more definitive answers. (C) 1997 by the National Kidney Foundation, Inc.
RP Bansal, VK (corresponding author), LOYOLA UNIV,MED CTR,DIV RENAL DIS & HYPERTENS,2160 S 1ST AVE,BLDG 102,ROOM 3668,MAYWOOD,IL 60153, USA.
CR AUSTIN HA, 1994, KIDNEY INT, V45, P544, DOI 10.1038/ki.1994.70
   AUSTIN HA, 1986, NEW ENGL J MED, V314, P614, DOI 10.1056/NEJM198603063141004
   BOUMPAS DT, 1992, LANCET, V340, P741, DOI 10.1016/0140-6736(92)92292-N
   CADE R, 1973, NEPHRON, V10, P37, DOI 10.1159/000180176
   CAMERON JS, 1993, J NEPHROL, V6, P172
   CARETTE S, 1983, ANN INTERN MED, V99, P1, DOI 10.7326/0003-4819-99-1-1
   DECKER JL, 1975, ANN INTERN MED, V83, P606, DOI 10.7326/0003-4819-83-5-606
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   DINANT HJ, 1989, ANN INTERN MED, V96, P728
   DONADIO JV, 1978, NEW ENGL J MED, V299, P1151, DOI 10.1056/NEJM197811232992102
   DONADIO JV, 1972, ANN INTERN MED, V77, P829, DOI 10.7326/0003-4819-77-6-829
   DONADIO JV, 1993, AM J KIDNEY DIS, V21, P239, DOI 10.1016/S0272-6386(12)80741-4
   DONADIO JV, 1974, ARTHRITIS RHEUM, V17, P573, DOI 10.1002/art.1780170511
   DONADIO JV, 1976, MAYO CLIN PROC, V51, P484
   FELSON DT, 1984, NEW ENGL J MED, V311, P1528, DOI 10.1056/NEJM198412133112402
   GINZLER E, 1976, ARTHRITIS RHEUM, V19, P693, DOI 10.1002/1529-0131(197607/08)19:4<693::AID-ART1780190406>3.0.CO;2-2
   GOLBUS J, 1994, RHEUM DIS CLIN N AM, V20, P213
   Gourley MF, 1996, ANN INTERN MED, V125, P549, DOI 10.7326/0003-4819-125-7-199610010-00003
   HAHN BH, 1975, ANN INTERN MED, V83, P597, DOI 10.7326/0003-4819-83-5-597
   Hedges LV, 1985, STAT METHODS METAANA, P153
   IMPERIALE TF, 1994, JAMA-J AM MED ASSOC, V271, P1780, DOI 10.1001/jama.271.22.1780
   Laird N M, 1990, Int J Technol Assess Health Care, V6, P5
   LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605
   LEVEY AS, 1992, ANN INTERN MED, V116, P114, DOI 10.7326/0003-4819-116-2-114
   LEWIS EJ, 1992, NEW ENGL J MED, V326, P1373, DOI 10.1056/NEJM199205213262101
   PIERUCCI A, 1989, NEW ENGL J MED, V320, P421, DOI 10.1056/NEJM198902163200703
   SCHWARTZ MM, 1993, AM J KIDNEY DIS, V21, P374, DOI 10.1016/S0272-6386(12)80263-0
   STEINBER.AD, 1971, ANN INTERN MED, V75, P165, DOI 10.7326/0003-4819-75-2-165
   STEINBERG AD, 1991, ARTHRITIS RHEUM-US, V34, P945, DOI 10.1002/art.1780340803
   STEINBERG AD, 1974, ARTHRITIS RHEUM, V17, P923, DOI 10.1002/art.1780170602
   SZTEJNBOK M, 1971, ARTHRITIS RHEUM-US, V14, P639, DOI 10.1002/art.1780140511
   TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101
   VALERI A, 1994, CLIN NEPHROL, V42, P71
NR 33
TC 137
Z9 145
U1 0
U2 4
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0272-6386
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD FEB
PY 1997
VL 29
IS 2
BP 193
EP 199
DI 10.1016/S0272-6386(97)90029-9
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA WH364
UT WOS:A1997WH36400003
PM 9016889
DA 2021-08-04
ER

PT J
AU deSouza, PL
   Cooper, MR
   Imondi, AR
   Myers, CE
AF deSouza, PL
   Cooper, MR
   Imondi, AR
   Myers, CE
TI 9-aminocamptothecin: A topoisomerase I inhibitor with preclinical
   activity in prostate cancer
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID CARCINOMA CELL-LINE; BIOLOGICAL-ACTIVITY; LACTONE FORM; HUMAN-TUMORS;
   NUDE-MICE; CAMPTOTHECIN; XENOGRAFTS; CHEMOTHERAPY; DRUG;
   PHARMACOKINETICS
AB 9-Aminocamptothecin (9-AC) is a topoisomerase I inhibitor currently being developed as an antineoplastic agent, The aim of these preclinical studies was to assess the activity of 9-AC against prostate cancer, a malignancy notoriously insensitive to most cytotoxic agents in the clinic, The activity of 9-AC was first tested in vitro against one hormone-sensitive (LNCaP) and three hormone-resistant (PC-3, PC-3M, and DU145) human prostate cancer cell lines, After 96 h of drug exposure, concentrations required to inhibit cell viability to 50% of control values (IC(50)s) were 34.1, 10, 6.5, and 8.9 nhr for PC-3, PC-3M, DU145, and LNCaP, respectively. Because 9-AC is known to undergo rapid hydrolysis, we assayed lactone levels in tissue culture medium over 24 h and found that the half-life was 20 min, with only 15% of the drug remaining as lactone at steady state, Consequently, the IC(50)s calculated from a single dose of the drug may represent overestimates, Subsequently, we tested the activity of a colloidal dispersion formulation of 9-AC against PC-3 implanted into flanks of nude mice, 9-AC was given for a total of 3 weeks by daily oral gavage (excluding weekends) or by twice weekly s.c. injections. 9-AC inhibited tumor growth at the lowest oral dose (0.35 mg/kg/day), whereas higher oral doses (0.75 and 1 mg/kg/day) and s.c. administration (4 mg/kg/week) caused tumor regression, 9-AC was well tolerated at all doses, with no toxic death or weight loss of more than 10% observed in any group. Finally, we considered that the activity of 9-AC seen in the mouse xenograft model might he explained, in part, by the relatively acidic tumor microenvironment, which would favor the formation of the more potent lactone, Simultaneous determination of plasma and tumor 9-AC lactone concentrations confirmed this hypothesis. Taken together, these studies suggest that 9-AC should be submitted for clinical trials in patients with prostate cancer.
C1 UNIV VIRGINIA,HLTH SCI CTR,DIV HEMATOL & ONCOL,CHARLOTTESVILLE,VA 22908.
   PHARMACIA & UPJOHN INC,COLUMBUS,OH 43216.
RI de Souza, Paul/P-5069-2019
CR BURKE TG, 1994, J MED CHEM, V37, P40, DOI 10.1021/jm00027a005
   BUTTKE TM, 1993, J IMMUNOL METHODS, V157, P233, DOI 10.1016/0022-1759(93)90092-L
   CARTER HB, 1992, CANCER RES, V52, P3323
   FASSBERG J, 1992, J PHARM SCI, V81, P676, DOI 10.1002/jps.2600810718
   GIBBONS RP, 1987, CANCER, V60, P586, DOI 10.1002/1097-0142(19870801)60:3+<586::AID-CNCR2820601525>3.0.CO;2-2
   GIOVANELLA BC, 1989, SCIENCE, V246, P1046, DOI 10.1126/science.2555920
   GIOVANELLA BC, 1991, CANCER RES, V51, P3052
   HERTZBERG RP, 1989, J MED CHEM, V32, P715, DOI 10.1021/jm00123a038
   HERTZBERG RP, 1991, DNA TOPOISOMERASES C, P103
   HINZ HR, 1994, CANCER RES, V54, P3096
   HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809
   HUSAIN I, 1994, CANCER RES, V54, P539
   KAIGHN ME, 1979, INVEST UROL, V17, P16
   KOZLOWSKI JM, 1984, CANCER RES, V44, P3522
   MEYER JS, 1982, J UROLOGY, V128, P1353, DOI 10.1016/S0022-5347(17)53506-5
   PANTAZIS P, 1992, CANCER RES, V52, P3980
   PANTAZIS P, 1993, ONCOL RES, V5, P273
   PRETLOW TG, 1991, CANCER RES, V51, P3814
   SCHMID HP, 1993, CANCER-AM CANCER SOC, V71, P2031, DOI 10.1002/1097-0142(19930315)71:6<2031::AID-CNCR2820710618>3.0.CO;2-Q
   STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305
   SUFFNESS M, 1985, ALKALOIDS CHEM PHARM, V25, P73
   SUPKO JG, 1991, J LIQ CHROMATOGR, V14, P1779, DOI 10.1080/01483919108049653
   SUPKO JG, 1993, CANCER RES, V53, P3062
   TAKIMOTO CH, 1994, J CHROMATOGR B, V655, P97, DOI 10.1016/0378-4347(94)00051-4
   TAKIMOTO CH, 1996, P AN M AM SOC CLIN, V15, P488
   TAKIMOTO CH, 1996, CANC CHEMOTHERAPY BI, P463
   THEYER G, 1993, J UROLOGY, V150, P1544, DOI 10.1016/S0022-5347(17)35838-X
   VAUPEL P, 1989, CANCER RES, V49, P6449
   WANI MC, 1980, J MED CHEM, V23, P554, DOI 10.1021/jm00179a016
NR 29
TC 19
Z9 19
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA PUBLIC LEDGER BLDG, SUITE 816, 150 S. INDEPENDENCE MALL W.,
   PHILADELPHIA, PA 19106
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD FEB
PY 1997
VL 3
IS 2
BP 287
EP 294
PG 8
WC Oncology
SC Oncology
GA WY366
UT WOS:A1997WY36600021
PM 9815685
DA 2021-08-04
ER

PT J
AU Hall, CS
   Marsh, JN
   Hughes, MS
   Mobley, J
   Wallace, KD
   Miller, JG
   Brandenburger, GH
AF Hall, CS
   Marsh, JN
   Hughes, MS
   Mobley, J
   Wallace, KD
   Miller, JG
   Brandenburger, GH
TI Broadband measurements of the attenuation coefficient and backscatter
   coefficient for suspensions: A potential calibration tool
SO JOURNAL OF THE ACOUSTICAL SOCIETY OF AMERICA
LA English
DT Article
ID ULTRASOUND CONTRAST AGENTS; SOUND SCATTERING; ACOUSTIC BACKSCATTER;
   AQUEOUS SUSPENSIONS; ELASTIC SPHERE; RANDOM-MEDIA; TISSUES;
   MICROSPHERES; ABSORPTION; ALBUNEX
AB Tissue characterization would be facilitated by improved methods of calibration with which to make absolute measurements of the backscatter and attenuation of tissue or contrast agents, In this paper, the use of polystyrene microspheres is examined as a potential broadband in vitro calibration tool by employing an experimental system designed to characterize ultrasonic contrast agents. The frequency-dependent attenuation coefficient and backscatter coefficient were measured for a series of microsphere size distributions with a broadband ultrasound system using a custom-built specimen chamber and a novel suspension mixing technique. The measurements were used in a broadband reduction method to yield the backscatter coefficient. The range of ka spanned in this study is from ka = 0.5 to ka = 12. The broadband nature of the pulses permitted simultaneous measurement of different regimes of scattering of the microspheres (specifically, the transition region from Rayleigh to short-wavelength asymptotic scattering). Experimental results were compared with corresponding theoretical predictions for the attenuation and backscatter of solid elastic spheres in liquid and yielded good quantitative agreement. Discussion of some possible applications of this technique to the fields of tissue characterization and contrast is presented. (C) 1997 Acoustical Society of America.
C1 MALLINCKRODT INC,HAZELWOOD,MO 63042.
RP Hall, CS (corresponding author), WASHINGTON UNIV,DEPT PHYS,LAB ULTRASON,ST LOUIS,MO 63130, USA.
OI Mobley, Joel/0000-0003-4568-0348
CR ALLEGRA JR, 1972, J ACOUST SOC AM, V51, P1545, DOI 10.1121/1.1912999
   BLEEKER HJ, 1990, J ACOUST SOC AM, V87, P1792, DOI 10.1121/1.399428
   Bridal SL, 1996, J ACOUST SOC AM, V100, P1841, DOI 10.1121/1.416003
   BRILL D, 1987, J ACOUST SOC AM, V81, P1, DOI 10.1121/1.394983
   CAMPBELL JA, 1984, J ACOUST SOC AM, V75, P1879, DOI 10.1121/1.390989
   CAMPBELL JA, 1983, J ACOUST SOC AM, V74, P393, DOI 10.1121/1.389832
   CHEN JF, 1993, IEEE T ULTRASON FERR, V40, P603, DOI 10.1109/58.238114
   CHRISTY DH, 1995, P IEEE ULTR S, P1125
   CHURCH CC, 1995, J ACOUST SOC AM, V97, P1510, DOI 10.1121/1.412091
   COMMANDER KW, 1989, J ACOUST SOC AM, V85, P732, DOI 10.1121/1.397599
   DEJONG N, 1993, ULTRASONICS, V31, P175, DOI 10.1016/0041-624X(93)90004-J
   DEJONG N, 1992, ULTRASONICS, V30, P95, DOI 10.1016/0041-624X(92)90041-J
   DEJONG N, 1991, ULTRASONICS, V29, P324, DOI 10.1016/0041-624X(91)90030-C
   ELSLEY RK, 1980, ACCURATE ULTRASONIC, P311
   FARAN JJ, 1951, J ACOUST SOC AM, V23, P405, DOI 10.1121/1.1906780
   Feleppa E. J., 1986, IEEE T ULTRASON FERR, V33, P319
   FLAX L, 1978, J ACOUST SOC AM, V63, P723, DOI 10.1121/1.381780
   GAUNAURD GC, 1983, J ACOUST SOC AM, V73, P1, DOI 10.1121/1.388839
   GOLDBERG BB, 1994, ULTRASOUND MED BIOL, V20, P319, DOI 10.1016/0301-5629(94)90001-9
   HAY AE, 1982, J ACOUST SOC AM, V72, P950, DOI 10.1121/1.388176
   HAY AE, 1989, J ACOUST SOC AM, V85, P1124, DOI 10.1121/1.397442
   HAY AE, 1985, J ACOUST SOC AM, V78, P1761, DOI 10.1121/1.392762
   HICKLING R, 1962, J ACOUST SOC AM, V34, P1582, DOI 10.1121/1.1909055
   HSU DK, 1992, J ACOUST SOC AM, V92, P669, DOI 10.1121/1.405279
   INSANA MF, 1995, J ACOUST SOC AM, V97, P649, DOI 10.1121/1.412287
   INSANA MF, 1990, J ACOUST SOC AM, V87, P179, DOI 10.1121/1.399283
   INSANA MF, 1986, J ACOUST SOC AM, V79, P1230, DOI 10.1121/1.393702
   LANDINI L, 1986, ULTRASOUND MED BIOL, V12, P397, DOI 10.1016/0301-5629(86)90197-3
   Linker D T, 1991, Int J Card Imaging, V6, P255, DOI 10.1007/BF01797857
   LOCKWOOD GR, 1991, ULTRASOUND MED BIOL, V17, P653, DOI 10.1016/0301-5629(91)90096-F
   Marsh JN, 1997, J ACOUST SOC AM, V101, P1155, DOI 10.1121/1.418270
   MERZBACHER E, 1977, AM J PHYS, V45, P964, DOI 10.1119/1.10860
   Morse P. M., 1968, THEORETICAL ACOUSTIC
   MOTTLEY JG, 1990, J ACOUST SOC AM, V88, P1203, DOI 10.1121/1.399751
   NEUBAUER WG, 1974, J ACOUST SOC AM, V55, P1123, DOI 10.1121/1.1914676
   ODONNELL M, 1981, J APPL PHYS, V52, P1056, DOI 10.1063/1.328803
   ODONNELL M, 1981, J ACOUST SOC AM, V69, P580, DOI 10.1121/1.385433
   RHYNE TL, 1986, ULTRASONIC IMAGING, V8, P107, DOI 10.1016/0161-7346(86)90003-9
   SHENG JY, 1988, J ACOUST SOC AM, V83, P598, DOI 10.1121/1.396153
   SOLLISH BD, 1979, VOL SPEC PUBL, V525
   THORNE PD, 1992, J ACOUST SOC AM, V92, P978, DOI 10.1121/1.403967
   THORNE PD, 1992, ULTRASONICS, V30, P15, DOI 10.1016/0041-624X(92)90026-I
   VILLANUEVA FS, 1995, CORONARY ARTERY DIS, V6, P18, DOI 10.1097/00019501-199501000-00004
   VOGT RH, 1976, J ACOUST SOC AM, V60, P15, DOI 10.1121/1.381058
   WALLER BF, 1992, CIRCULATION, V85, P2305, DOI 10.1161/01.CIR.85.6.2305
   WATERMAN PC, 1961, J MATH PHYS, V2, P512, DOI 10.1063/1.1703737
   WEAR KA, 1995, J ACOUST SOC AM, V98, P1852, DOI 10.1121/1.413372
   WONG AK, 1993, ULTRASOUND MED BIOL, V19, P365, DOI 10.1016/0301-5629(93)90055-S
NR 48
TC 32
Z9 32
U1 0
U2 1
PU AMER INST PHYSICS
PI WOODBURY
PA CIRCULATION FULFILLMENT DIV, 500 SUNNYSIDE BLVD, WOODBURY, NY 11797-2999
SN 0001-4966
J9 J ACOUST SOC AM
JI J. Acoust. Soc. Am.
PD FEB
PY 1997
VL 101
IS 2
BP 1162
EP 1171
DI 10.1121/1.418020
PG 10
WC Acoustics; Audiology & Speech-Language Pathology
SC Acoustics; Audiology & Speech-Language Pathology
GA WH323
UT WOS:A1997WH32300053
DA 2021-08-04
ER

PT J
AU Mok, YS
   Lee, WK
   Lee, YK
AF Mok, YS
   Lee, WK
   Lee, YK
TI Modeling of liquid emulsion membranes facilitated by two carriers
SO CHEMICAL ENGINEERING JOURNAL
LA English
DT Article
DE polyamine-type surfactant; advancing front model; axial dispersion model
ID SURFACTANT MEMBRANE; ORGANIC-ACIDS; MASS-TRANSFER; PENICILLIN-G;
   LACTIC-ACID; EXTRACTION; SIMULATION; DIFFUSION
AB A mathematical model was proposed to describe the behavior of liquid emulsion membranes for the extraction of penicillin G in a continuous countercurrent mixing column. A polyamine-type surfactant acts not only as a carrier but also as a surface-stabilizing agent; thus the influence of surfactant on extraction should be considered in mathematical modeling when its effect is significant. The proposed model takes into account the influence of surfactant on mass transfer. The advancing front model was employed for deriving the overall mass transfer coefficient in the emulsion globule, and the axial dispersion model was applied to the external feed phase. The experimental data were compared with the proposed model, the calculations without considering the contribution of the surfactant to extraction, and the calculations without considering diffusion in the emulsion phase.
C1 POHANG IRON & STEEL CO LTD,TECH RES LABS,ENVIRONM & ENERGY RES TEAM,KYUNGBUK 790785,SOUTH KOREA.
   KOREA ADV INST SCI & TECHNOL,DEPT CHEM ENGN,TAEJON 305701,SOUTH KOREA.
OI Mok, Young Sun/0000-0002-6694-2135
CR BIBAUD RE, 1966, AICHE J, V12, P472, DOI 10.1002/aic.690120315
   CHAUDHURI JB, 1992, CHEM ENG SCI, V47, P41, DOI 10.1016/0009-2509(92)80198-L
   CUSSLER EL, 1992, MASS TRANSFER FLUID, pCH7
   Dean J., 1985, LANGES HDB CHEM
   HANO T, 1993, J MEMBRANE SCI, V84, P271, DOI 10.1016/0376-7388(93)80022-P
   HANO T, 1990, J CHEM ENG JPN, V23, P772, DOI 10.1252/jcej.23.772
   HATTON TA, 1984, AICHE J, V30, P934, DOI 10.1002/aic.690300608
   HO WS, 1982, AICHE J, V28, P662, DOI 10.1002/aic.690280419
   KATAOKA T, 1987, J CHEM ENG JPN, V20, P410, DOI 10.1252/jcej.20.410
   KIM KS, 1983, IND ENG CHEM FUND, V22, P167, DOI 10.1021/i100010a003
   LEE CJ, 1990, IND ENG CHEM RES, V29, P101, DOI 10.1021/ie00097a015
   MARR R, 1983, GER CHEM ENG, V6, P365
   MATSUMOTO M, 1990, J CHEM ENG JPN, V23, P402, DOI 10.1252/jcej.23.402
   RAUTENBACH R, 1988, J MEMBRANE SCI, V36, P425, DOI 10.1016/0376-7388(88)80034-6
   REISINGER H, 1993, J MEMBRANE SCI, V80, P85, DOI 10.1016/0376-7388(93)85134-I
   Reisinger H., 1992, CHEM ENG TECHNOL, V15, P363
   RESCHKE M, 1984, CHEM ENG J BIOCH ENG, V28, pB1, DOI 10.1016/0300-9467(84)85015-7
   SKELLAND AHP, 1981, AICHE J, V27, P99, DOI 10.1002/aic.690270115
   TERAMOTO M, 1991, J MEMBRANE SCI, V58, P11, DOI 10.1016/S0376-7388(00)80634-1
   WANG CC, 1990, J MEMBRANE SCI, V53, P105
   WILKE CR, 1955, AICHE J, V1, P264, DOI 10.1002/aic.690010222
NR 21
TC 6
Z9 6
U1 0
U2 2
PU ELSEVIER SCIENCE SA LAUSANNE
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0923-0467
J9 CHEM ENG J
JI Chem. Eng. J.
PD JAN 31
PY 1997
VL 66
IS 1
BP 11
EP 20
DI 10.1016/S1385-8947(96)03147-6
PG 10
WC Engineering, Environmental; Engineering, Chemical
SC Engineering
GA XA796
UT WOS:A1997XA79600002
DA 2021-08-04
ER

PT J
AU Carley, KM
AF Carley, KM
TI Organizational adaptation
SO ANNALS OF OPERATIONS RESEARCH
LA English
DT Article
ID PERFORMANCE; EVOLUTION; BEHAVIOR; DESIGN; TEAMS
AB A computational model of organizational adaptation in which change occurs at both the strategic and the operational level is presented. In this model, simulated annealing is used to alter the organization's structure even as the agents within the organization learn. Using this model a virtual experiment is run to generate hypotheses which can be tested in multiple venues. The results suggest that, although it may not be possible for organizations of complex adaptive agents to locate the optimal form, they can improve their performance by altering their structure. Moreover, organizations that most successfully adapt over time come to be larger, less dense, with fewer isolated agents, and fewer overlooked decision factors. These results have implications for organizations of both humans and non-humans. For example, they suggest that organizational learning resides not just in the minds of the personnel within the organization, but in the connections among personnel, and among personnel and tasks. These results suggest that collections of non-humans may come to seem more intelligent (i.e., show improved performance) even if the agents remain unchanged if the system simply develops duplicate copies of some of the artificial agents and if the connections among agents are dynamically altered.
C1 Carnegie Mellon Univ, Dept Social & Decis Sci, Pittsburgh, PA 15213 USA.
OI Carley, Kathleen M./0000-0002-6356-0238
CR Allison G. T., 1971, ESSENCE DECISION
   AXELROD R, 1988, SCIENCE, V242, P1385, DOI 10.1126/science.242.4884.1385
   Axelrod R., 1987, GENETIC ALGORITHMS S, P32
   Axelrod R., 1976, STRUCTURE DECISION C
   BRUDERL J, 1990, ADMIN SCI QUART, V35, P530, DOI 10.2307/2393316
   BUSH RR, 1955, STOCHASTIC MODELS LE
   BUTLER R, 1993, PUBLIC ADMIN, V71, P395, DOI 10.1111/j.1467-9299.1993.tb00981.x
   CARLEY K, 1994, J MATH SOCIOL, V19, P221, DOI 10.1080/0022250X.1994.9990145
   CARLEY K, 1992, ORGAN SCI, V3, P20, DOI 10.1287/orsc.3.1.20
   CARLEY K, IN PRESS MANAGEMENT
   CARLEY KM, 1995, IEEE T SYST MAN CYB, V25, P221, DOI 10.1109/21.364841
   CARLEY KM, IN PRESS SOCIOLOGICA
   CARLEY KM, IN PRESS J EC BEHAV
   CARLEY KM, 1996, WEBBOTS TRUST ORG SC
   CASTELFRANCHI C, 1992, ARTIFICIAL SOCIAL SY
   Cohen M., 1974, LEADERSHIP AMBIGUITY
   CROWSTON K, IN PRESS COMPUTATION
   CROWSTON K, 1994, COMPUTATIONAL ORG TH, P19
   DIMAGGIO PJ, 1983, AM SOCIOL REV, V48, P147, DOI 10.2307/2095101
   DURFEE EH, 1991, IEEE T SYST MAN CYB, V21, P1363, DOI 10.1109/21.135682
   Eccles R., 1988, DOING DEALS INVESTME
   ELOFSON GS, 1993, DECIS SUPPORT SYST, V10, P109, DOI 10.1016/0167-9236(93)90033-Y
   GASSER L, 1994, ADV DES MAN, V4, P133
   HANNAN MT, 1977, AM J SOCIOL, V82, P929, DOI 10.1086/226424
   HOLLAND J, 1975, ADAPTATION NATURAL A
   HOLLAND JH, 1991, AM ECON REV, V81, P365
   HOLLENBECK JR, 1995, J APPL PSYCHOL, V80, P292, DOI 10.1037/0021-9010.80.2.292
   HOLLENBECK JR, 1995, J APPL PSYCHOL, V80, P685, DOI 10.1037/0021-9010.80.6.685
   Hutchins E., 1990, INTELLECTUAL TEAMWOR, P191
   HUTCHINS E, 1991, PERSPECTIVES SOCIALL, P238
   ISHIDA T, 1992, IEEE T KNOWL DATA EN, V4, P123, DOI 10.1109/69.134249
   KILMANN RH, 1988, CORPORATE TRANSFORMA, V1
   Kim D, 1993, SLOAN MANAGEMENT FAL, P37
   KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671
   LANT TK, 1994, COMPUTATIONAL ORG TH, P195
   Lawrence P.R., 1967, ORG ENV MANAGING DIF
   LEVITT B, 1988, ANNU REV SOCIOL, V14, P319, DOI 10.1146/annurev.so.14.080188.001535
   Levitt R.E., 1994, COMPUTATIONAL ORG TH, P1
   LIN Z, IN PRESS MANAGEMENT
   LIN Z, 1994, UNPUB ORG PERFORMANC
   March J.G., 1958, ORGANIZATIONS
   MARCH JG, 1981, ADMIN SCI QUART, V26, P563, DOI 10.2307/2392340
   MIHAVICS K, 1996, COMPUTATIONAL MATH O, V1, P143
   Minsky M., 1988, SOC MIND
   OUKSEL A, 1995, IDS951 U ILL CHIC CO
   PADGETT JF, IN PRESS EC COMPLEX
   PETE A, 1993, IEEE T SYST MAN CYB, V23, P1626, DOI 10.1109/21.257759
   PRIETULA MJ, 1994, J ORG COMPUTING, V41, P41
   ROMANELLI E, 1991, ANNU REV SOCIOL, V17, P79
   RUTENBAR RA, 1989, IEEE CIRCUITS DEVICE, V5, P12
   SIMON HA, 1956, PSYCHOL REV, V63, P129, DOI 10.1037/h0042769
   Simon HA, 1955, Q J ECON, V69, P99, DOI 10.2307/1884852
   Simon HA, 1944, PUBLIC ADMIN REV, V4, P16, DOI 10.2307/972435
   STAW BM, 1981, ADMIN SCI QUART, V26, P501, DOI 10.2307/2392337
   STINCHCOMBE A, 1965, TRANS-ACT-SOC SCI MO, V2, P34
   Stinchcombe A. L., 1965, HDB ORG, P153, DOI DOI 10.1016/S0742-3322(00)17019-6
   TANG ZB, 1992, IEEE T AUTOMAT CONTR, V37, P1042, DOI 10.1109/9.148368
   VERHAGEN H, 1994, COMPUTATIONAL ORG TH, P39
NR 58
TC 28
Z9 29
U1 1
U2 9
PU BALTZER SCI PUBL BV
PI BUSSUM
PA PO BOX 221, 1400 AE BUSSUM, NETHERLANDS
SN 0254-5330
J9 ANN OPER RES
JI Ann. Oper. Res.
PY 1997
VL 75
BP 25
EP 47
DI 10.1023/A:1018963630536
PG 23
WC Operations Research & Management Science
SC Operations Research & Management Science
GA YW682
UT WOS:000071962000003
DA 2021-08-04
ER

PT J
AU Gatesoupe, FJ
AF Gatesoupe, FJ
TI Siderophore production and probiotic effect of Vibrio sp. associated
   with turbot larvae, Scophthalmus maximus
SO AQUATIC LIVING RESOURCES
LA English
DT Article
DE bacteria; pathogenic Vibrio; probiotic Vibrio; experimental infection;
   siderophore; turbot; larva
ID PATHOGENIC VIBRIO; BACTERIA; ANGUILLARUM; GROWTH; FISH; ALGINOLYTICUS;
   INHIBITION; ORDALII; STRAIN
AB The proportion of vibrio E, dominant in healthy turbot larvae, was artificially increased in the rotifer enrichment medium. The maid effect of this vibrio enrichment was to improve the resistance of larval turbot challenged with a pathogenic strain of Vibrio splendidus, vibrio P. The improvement of the survival rates was significant with 1.5 x 10(6) CFU of vibrio E added per mi of enrichment medium, and it was still maximum at the hi hest dose tested (5 x 10(7) CFU.ml(-1); 80 +/- 2% of survivors after 48 h of challenge, versus 50 +/- 2 % for the control group).
   Further in vitro characterisation showed that vibrio E was able to grow in the presence of the chelating agents EDDHA and EDTA, while producing siderophore, as revealed by chrome azurol S dyeing. The pathogenic vibrio P did not grow on iron-depleted medium, and it did not seem to produce siderophore. Consequently, a second experiment attempted to appraise the role of iron availability in the interaction between the pathogenic and probiotic vibrios. To this end, turbot larvae were fed with rotifers treated by the bacterial siderophore deferoxamine. This treatment significantly increased the resistance of larvae challenged with vibrio P in comparison with the control group, but to a lesser extent than the group enriched with vibrio E. There was also an increase of the growth rate due to either the siderophore treatment or the vibrio enrichment, as well. No further improvement was observed when the rotifers were simultaneously both treated and enriched. It was concluded that the probiotic effect of vibrio E may be at least partly due to competition for iron with the pathogen.
RP Gatesoupe, FJ (corresponding author), IFREMER,CTR BREST,INRA,UNITE MIXTE NUTR POISSONS,BP 70,F-29280 PLOUZANE,FRANCE.
RI Gatesoupe, Francois-Joel/F-9731-2010
OI Gatesoupe, Francois-Joel/0000-0001-5894-6243
CR ALSINA M, 1994, J APPL BACTERIOL, V76, P79, DOI 10.1111/j.1365-2672.1994.tb04419.x
   AUSTIN B, 1995, J FISH DIS, V18, P93, DOI 10.1111/j.1365-2761.1995.tb01271.x
   BERGH O, 1995, J FISH DIS, V18, P31, DOI 10.1111/j.1365-2761.1995.tb01263.x
   BORREGO JL, 1996, RUDITAPES PHILIPPINA, V9, P125
   BROWN C, 1988, AQUACULTURE, V74, P195, DOI 10.1016/0044-8486(88)90363-8
   DOPAZO CP, 1988, J APPL BACTERIOL, V65, P97, DOI 10.1111/j.1365-2672.1988.tb01497.x
   FOUZ B, 1994, FEMS MICROBIOL LETT, V121, P181, DOI 10.1111/j.1574-6968.1994.tb07097.x
   Gatesoupe F.J., 1995, Aquaculture International, V3, P150, DOI 10.1007/BF00117882
   GATESOUPE F J, 1986, Oceanis, V12, P207
   GATESOUPE FJ, 1994, AQUAT LIVING RESOUR, V7, P277, DOI 10.1051/alr:1994030
   GATESOUPE FJ, 1990, AQUACULTURE, V89, P139, DOI 10.1016/0044-8486(90)90306-8
   Gram L, 1996, J MICROBIOL METH, V25, P199, DOI 10.1016/0167-7012(95)00079-8
   IMADA C, 1985, CAN J MICROBIOL, V31, P1089, DOI 10.1139/m85-206
   MUNRO PD, 1995, APPL ENVIRON MICROB, V61, P4425, DOI 10.1128/AEM.61.12.4425-4428.1995
   NAIR S, 1985, B JPN SOC SCI FISH, V51, P1469
   Nicolas JL, 1996, DIS AQUAT ORGAN, V27, P67, DOI 10.3354/dao027067
   Owens L, 1996, DIS AQUAT ORGAN, V27, P157, DOI 10.3354/dao027157
   PLANAS M, 1994, EUROPEAN AQUACULTURE, V22, P54
   PYBUS V, 1994, J FISH DIS, V17, P311, DOI 10.1111/j.1365-2761.1994.tb00227.x
   Ringo E, 1996, J APPL BACTERIOL, V81, P207, DOI 10.1111/j.1365-2672.1996.tb04502.x
   SCHWYN B, 1987, ANAL BIOCHEM, V160, P47, DOI 10.1016/0003-2697(87)90612-9
   Skjermo J, 1997, AQUACULT INT, V5, P13, DOI 10.1007/BF02764784
   Sokal R. R., 1969, BIOMETRY
   WESTERDAHL A, 1991, APPL ENVIRON MICROB, V57, P2223, DOI 10.1128/AEM.57.8.2223-2228.1991
NR 24
TC 68
Z9 77
U1 0
U2 13
PU GAUTHIER-VILLARS
PI PARIS
PA 120 BLVD SAINT-GERMAIN, 75280 PARIS, FRANCE
SN 0990-7440
J9 AQUAT LIVING RESOUR
JI Aquat. Living Resour.
PY 1997
VL 10
IS 4
BP 239
EP 246
DI 10.1051/alr:1997026
PG 8
WC Fisheries; Marine & Freshwater Biology
SC Fisheries; Marine & Freshwater Biology
GA XQ185
UT WOS:A1997XQ18500006
OA Green Submitted
DA 2021-08-04
ER

PT J
AU Agah, A
   Bekey, GA
AF Agah, A
   Bekey, GA
TI Phylogenetic and ontogenetic learning in a colony of interacting robots
SO AUTONOMOUS ROBOTS
LA English
DT Article
DE robot colony; ontogenetic learning; phylogenetic learning; multi-agent
   systems; cognitive architecture; distributed systems
AB The objective of this paper is to describe the development of a specific theory of interactions and learning among multiple robots performing certain tasks. One of the primary objectives of the research was to study the feasibility of a robot colony in achieving global objectives, when each individual robot is provided only with local goals and local information. In order to achieve this objective the paper introduces a novel cognitive architecture for the individual behavior of robots in a colony. Experimental investigation of the properties of the colony demonstrates its ability to achieve global goals, such as the gathering of objects, and to improve its performance as a result of learning, without explicit instructions for cooperation. Since this architecture is based on representation of the ''likes'' and ''dislikes'' of the robots, it is called the Tropism System Cognitive Architecture. This paper addresses learning in the framework of the cognitive architecture, specifically, phylogenetic and ontogenetic learning by the robots. The results show that learning is indeed possible with the Tropism Architecture, that the ability of a simulated robot colony to perform a gathering task improves with practice and that it can further improve with evolution over successive generations. Experimental results also show that the variability of the results decreases over successive generations.
C1 UNIV SO CALIF, DEPT COMP SCI, INST ROBOT & INTELLIGENT SYST, LOS ANGELES, CA 90089 USA.
RP Agah, A (corresponding author), MINIST INT TRADE & IND, MECH ENGN LAB, BIOROBOT DIV, TSUKUBA, IBARAKI 305, JAPAN.
CR AGAH A, 1995, 1995 IEEE INTERNATIONAL CONFERENCE ON SYSTEMS, MAN AND CYBERNETICS, VOLS 1-5, P3800, DOI 10.1109/ICSMC.1995.538380
   AGAH A, 1994, THESIS U SO CALIFORN
   Arkin R, 1987, P IEEE INT C ROB AUT
   ARKIN RC, 1993, P IEEE INT C ROB AUT, V3, P588
   ASADA M, 1995, IEEE INT CONF ROBOT, P146, DOI 10.1109/ROBOT.1995.525277
   BARTO AG, 1992, HDB INTELLIGENT CONT, P469
   BENI G, 1990, PRACTICE AUTONOMOUS, P153
   BROOKS R, 1986, IEEE J ROBOTICS AUTO
   Brooks RA, 1989, NEURAL COMPUT, V1, P253, DOI 10.1162/neco.1989.1.2.253
   DENEUBOURG JL, 1991, FROM ANIMALS TO ANIMATS, P356
   FUKUDA T, 1992, IFAC SYMP SERIES, V4, P177
   GASSER L, 1989, ANNU REV COMPUT SCI, V4, P203
   Goldberg D., 1989, GENETIC ALGORITHMS S
   Grey Walter William, 1950, SCI AM, V182, P42, DOI DOI 10.1038/SCIENTIFICAMERICAN0550-42
   GRIFFIN DR, 1992, ANIMALS MINDS
   Hackman, 1990, GROUPS WORK THOSE DO
   ICHIKAWA S, 1993, P IEEE RSJ INT C INT, P1149
   ISHIDA T, 1993, P IEEE INT C ROB AUT, V3, P839
   ISHIDA Y, 1992, IFAC SYMP SERIES, V4, P189
   KAELBLING LP, 1993, P IJCAI 93, P1094
   KAWAUCHI Y, 1992, 1992 IEEE INTERNATIONAL CONF ON ROBOTICS AND AUTOMATION : PROCEEDINGS, VOLS 1-3, P813, DOI 10.1109/ROBOT.1992.220269
   Kube C. Ronald, 1993, Adaptive Behavior, V2, P189, DOI 10.1177/105971239300200204
   MAES P, 1991, AUTONOMOUS MOBILE RO, P224
   MAJCHRZAK A, 1992, INT J COMP INTEG M, V5, P118, DOI 10.1080/09511929208944521
   MATARIC MJ, 1992, 1992 IEEE INTERNATIONAL CONF ON ROBOTICS AND AUTOMATION : PROCEEDINGS, VOLS 1-3, P830, DOI 10.1109/ROBOT.1992.220192
   NOREILS FR, 1993, INT J ROBOT RES, V12, P79, DOI 10.1177/027836499301200106
   Walter W. G., 1953, LIVING BRAIN
   Wang J., 1988, P IEEE INT S INT CON, P63
   WIENER Norbert, 1961, CYBERNETICS
   Wilson E. O., 1980, SOCIOBIOLOGY ABRIDGE
   WILSON EO, 1971, INSECT SOCIETIES
NR 31
TC 16
Z9 16
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0929-5593
EI 1573-7527
J9 AUTON ROBOT
JI Auton. Robot.
PY 1997
VL 4
IS 1
BP 85
EP 100
DI 10.1023/A:1008811203902
PG 16
WC Computer Science, Artificial Intelligence; Robotics
SC Computer Science; Robotics
GA WV846
UT WOS:A1997WV84600006
DA 2021-08-04
ER

PT J
AU Bloomfield, VA
AF Bloomfield, VA
TI DNA condensation by multivalent cations
SO BIOPOLYMERS
LA English
DT Review
DE DNA condensation; multivalent cations; torsoids; statistical mechanics;
   DNA morphology; DNA kinetics; DNA reversibility
ID TO-COIL TRANSITION; MONTE-CARLO SIMULATION; CONCENTRATED ISOTROPIC
   SOLUTIONS; HEXAGONALLY ORIENTED DNA; DOUBLE HELICES; QUANTITATIVE
   THEORY; HYDRATION FORCES; COMPACT FORM; MULTIMOLECULAR AGGREGATION;
   INTERMOLECULAR FORCES
AB In the presence of multivalent cations, high molecular weight DNA undergoes a dramatic condensation to a compact, usually highly ordered toroidal structure. This review begins with an overview of DNA condensation : condensing agents, morphology, kinetics, and reversibility, and the minimum size required to form orderly condensates. It then summarizes the statistical mechanics of the collapse of stiff polymers, which shows why DNA condensation is abrupt and why toroids are favored structures. Various ways to estimate or measure intermolecular forces ii? DNA condensation are discussed all of them agreeing that the free energy change per base pair is very small, on the order of 1% of thermal energy. Experimental evidence is surveyed showing that DNA condensation occurs when about 90% of its charge is neutralized by counterions. The various intermolecular forces whose interplay gives rise to DNA condensation are then reviewed. The entropy loss upon collapse of the expanded wormlike coil costs free energy, and stiffness sets limits on tight curvature. However, the dominant contributions seem to come from ions and water Electrostatic repulsions must be overcome by high salt concentrations or by the correlated fluctuations of territorially bound multivalent cations. Hydration must be adjusted to allow a cooperative accommodation of the water structure surrounding surface groups on the DNA helices as they approach. Undulations of the DNA in its confined surroundings extend the range of the electrostatic forces. The condensing ions may also subtly modify the local structure of the double helix. (C) 1998 John Wiley & Sons, Inc.
C1 Univ Minnesota, Dept Biochem, St Paul, MN 55108 USA.
RP Bloomfield, VA (corresponding author), Univ Minnesota, Dept Biochem, 1479 Gortner Ave, St Paul, MN 55108 USA.
FU NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [R01GM028093]
   Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [GM28093] Funding
   Source: Medline
CR ARSCOTT PG, 1990, BIOPOLYMERS, V30, P619, DOI 10.1002/bip.360300514
   ARSCOTT PG, 1995, BIOPOLYMERS, V36, P345, DOI 10.1002/bip.360360309
   Baumann CG, 1997, P NATL ACAD SCI USA, V94, P6185, DOI 10.1073/pnas.94.12.6185
   BAUMANN CG, 1997, UNPUB
   BENBASAT JA, 1984, BIOCHEMISTRY-US, V23, P3609, DOI 10.1021/bi00311a007
   BLOOMFIELD VA, 1991, BIOPOLYMERS, V31, P1471, DOI 10.1002/bip.360311305
   Bloomfield VA, 1996, CURR OPIN STRUC BIOL, V6, P334, DOI 10.1016/S0959-440X(96)80052-2
   BLOOMFIELD VA, 1980, BIOPHYS CHEM, V11, P339, DOI 10.1016/0301-4622(80)87006-2
   BLOOMFIELD VA, 1994, MACROION CHARACTERIZ, P195
   BLOOMFIELD VA, 1988, NUCL ACIDS STRUCTURE
   BRAUNLIN WH, 1992, BIOPOLYMERS, V32, P1703, DOI 10.1002/bip.360321212
   CHATTORAJ DK, 1978, J MOL BIOL, V121, P327, DOI 10.1016/0022-2836(78)90367-4
   DREW HR, 1981, J MOL BIOL, V151, P535, DOI 10.1016/0022-2836(81)90009-7
   DUZGUNES N, 1993, METHOD ENZYMOL, V221, P303, DOI 10.1016/0076-6879(93)21025-4
   EICKBUSH TH, 1978, CELL, V13, P295, DOI 10.1016/0092-8674(78)90198-8
   FEUERSTEIN BG, 1986, P NATL ACAD SCI USA, V83, P5948, DOI 10.1073/pnas.83.16.5948
   FEUERSTEIN BG, 1990, NUCLEIC ACIDS RES, V18, P1271, DOI 10.1093/nar/18.5.1271
   Flock S, 1996, BIOPHYS J, V70, P1456, DOI 10.1016/S0006-3495(96)79705-9
   FLOCK S, 1995, J BIOMOL STRUCT DYN, V13, P87, DOI 10.1080/07391102.1995.10508823
   GARCIARAMIREZ M, 1994, BIOPOLYMERS, V34, P285, DOI 10.1002/bip.360340214
   GOSULE LC, 1978, J MOL BIOL, V121, P311, DOI 10.1016/0022-2836(78)90366-2
   GOSULE LC, 1976, NATURE, V259, P333, DOI 10.1038/259333a0
   Grosberg A. Y., 1994, STAT PHYS MACROMOLEC, P1
   GROSBERG AY, 1985, J BIOMOL STRUCT DYN, V3, P515, DOI 10.1080/07391102.1985.10508438
   GROSBERG AY, 1992, MACROMOLECULES, V25, P1991, DOI 10.1021/ma00033a024
   GROSBERG AY, 1992, MACROMOLECULES, V25, P1970, DOI 10.1021/ma00033a022
   GROSBERG AY, 1993, MACROMOLECULES, V26, P4249, DOI 10.1021/ma00068a027
   GROSBERG AY, 1992, MACROMOLECULES, V25, P1996, DOI 10.1021/ma00033a025
   GROSBERG AY, 1992, MACROMOLECULES, V25, P1980, DOI 10.1021/ma00033a023
   GROSBERG AY, 1986, J BIOMOL STRUCT DYN, V3, P859, DOI 10.1080/07391102.1986.10508469
   GULDBRAND L, 1986, J CHEM PHYS, V85, P6686, DOI 10.1063/1.451450
   GUO PX, 1987, J MOL BIOL, V197, P229, DOI 10.1016/0022-2836(87)90121-5
   HE S, 1992, KINETICS DNA CONDENS, P1
   HSIANG MW, 1977, P NATL ACAD SCI USA, V74, P4852, DOI 10.1073/pnas.74.11.4852
   Huang L., 1993, J LIPOSOME RES, V3, P505
   KLIMENKO SM, 1967, J MOL BIOL, V23, P523, DOI 10.1016/S0022-2836(67)80122-0
   LAEMMLI U K, 1974, Journal of Supramolecular Structure, V2, P276, DOI 10.1002/jss.400020219
   LAEMMLI UK, 1975, P NATL ACAD SCI USA, V72, P4288, DOI 10.1073/pnas.72.11.4288
   LANG D, 1976, J MOL BIOL, V106, P97, DOI 10.1016/0022-2836(76)90302-8
   LANG D, 1973, J MOL BIOL, V78, P247, DOI 10.1016/0022-2836(73)90113-7
   LASIC DD, 1997, LIPOSOMES GENE DELIV
   LEIKIN S, 1991, PHYS REV A, V44, P5272, DOI 10.1103/PhysRevA.44.5272
   LEIKIN S, 1993, ANNU REV PHYS CHEM, V44, P369, DOI 10.1146/annurev.pc.44.100193.002101
   LERMAN LS, 1971, P NATL ACAD SCI USA, V68, P1886, DOI 10.1073/pnas.68.8.1886
   LevinZaidman S, 1996, BIOCHEMISTRY-US, V35, P2985, DOI 10.1021/bi9525482
   LIFSHITZ IM, 1978, REV MOD PHYS, V50, P683, DOI 10.1103/RevModPhys.50.683
   LIQUORI AM, 1967, J MOL BIOL, V24, P113, DOI 10.1016/0022-2836(67)90094-0
   LYUBARTSEV AP, 1995, J PHYS CHEM-US, V99, P10373, DOI 10.1021/j100025a046
   MA CL, 1994, BIOPHYS J, V67, P1678, DOI 10.1016/S0006-3495(94)80641-1
   MA CL, 1995, BIOPOLYMERS, V35, P211, DOI 10.1002/bip.360350209
   MANNING GS, 1989, J BIOMOL STRUCT DYN, V6, P877, DOI 10.1080/07391102.1989.10506519
   MANNING GS, 1978, Q REV BIOPHYS, V11, P179, DOI 10.1017/S0033583500002031
   MARQUET R, 1988, J BIOMOL STRUCT DYN, V6, P235, DOI 10.1080/07391102.1988.10507710
   MARQUET R, 1985, BIOCHIM BIOPHYS ACTA, V825, P365, DOI 10.1016/0167-4781(85)90063-6
   MARQUET R, 1991, J BIOMOL STRUCT DYN, V9, P159, DOI 10.1080/07391102.1991.10507900
   MARQUET R, 1987, BIOCHIM BIOPHYS ACTA, V909, P165, DOI 10.1016/0167-4781(87)90074-1
   MARX KA, 1983, NUCLEIC ACIDS RES, V11, P1839, DOI 10.1093/nar/11.6.1839
   MORITA M, 1993, VIROLOGY, V193, P748, DOI 10.1006/viro.1993.1183
   NILSSON LG, 1991, MOL PHYS, V72, P177, DOI 10.1080/00268979100100121
   ODIJK T, 1993, MACROMOLECULES, V26, P6897, DOI 10.1021/ma00077a029
   ODIJK T, 1993, BIOPHYS CHEM, V46, P69, DOI 10.1016/0301-4622(93)87008-K
   OOSAWA F, 1968, BIOPOLYMERS, V6, P1633, DOI 10.1002/bip.1968.360061108
   Oosawa F., 1971, POLYELECTROLYTES
   PARSEGIAN VA, 1986, METHOD ENZYMOL, V127, P400
   PLUM GE, 1988, BIOPOLYMERS, V27, P1045, DOI 10.1002/bip.360270611
   PLUM GE, 1990, BIOPOLYMERS, V30, P631, DOI 10.1002/bip.360300515
   PODGORNIK R, 1989, MACROMOLECULES, V22, P1780, DOI 10.1021/ma00194a048
   PODGORNIK R, 1994, BIOPHYS J, V66, P962, DOI 10.1016/S0006-3495(94)80877-X
   PORSCHKE D, 1984, BIOCHEMISTRY-US, V23, P4821, DOI 10.1021/bi00316a002
   PORSCHKE D, 1986, J BIOMOL STRUCT DYN, V4, P373, DOI 10.1080/07391102.1986.10506356
   POST CB, 1982, BIOPOLYMERS, V21, P2139, DOI 10.1002/bip.360211105
   POST CB, 1979, BIOPOLYMERS, V18, P1487, DOI 10.1002/bip.1979.360180612
   POST CB, 1982, BIOPOLYMERS, V21, P2123, DOI 10.1002/bip.360211104
   RAU DC, 1992, BIOPHYS J, V61, P246, DOI 10.1016/S0006-3495(92)81831-3
   RAU DC, 1992, BIOPHYS J, V61, P260, DOI 10.1016/S0006-3495(92)81832-5
   RAU DC, 1984, P NATL ACAD SCI-BIOL, V81, P2621, DOI 10.1073/pnas.81.9.2621
   RAY J, 1994, LANGMUIR, V10, P2450, DOI 10.1021/la00019a071
   REICH Z, 1995, J BIOL CHEM, V270, P7045, DOI 10.1074/jbc.270.13.7045
   REICH Z, 1992, J BIOMOL STRUCT DYN, V9, P1097, DOI 10.1080/07391102.1992.10507981
   RIEMER SC, 1978, BIOPOLYMERS, V17, P785, DOI 10.1002/bip.1978.360170317
   ROSS PD, 1974, BIOPOLYMERS, V13, P415, DOI 10.1002/bip.1974.360130218
   Rouzina I, 1996, J PHYS CHEM-US, V100, P9977, DOI 10.1021/jp960458g
   ROUZINA I, 1998, IN PRESS BIOPHYS J
   SCHELLMAN JA, 1984, J MOL BIOL, V175, P313, DOI 10.1016/0022-2836(84)90351-6
   SCHELLMAN JA, 1995, BIOPHYS CHEM, V55, P95, DOI 10.1016/0301-4622(94)00144-9
   STRAUSS JK, 1994, SCIENCE, V266, P1829, DOI 10.1126/science.7997878
   Strauss JK, 1996, P NATL ACAD SCI USA, V93, P9515, DOI 10.1073/pnas.93.18.9515
   SUWALSKY M, 1969, J MOL BIOL, V42, P363, DOI 10.1016/0022-2836(69)90049-7
   TRIFONOV EN, 1987, STRUCTURE EXPRESSION, V3, P243
   Ubbink J, 1996, EUROPHYS LETT, V33, P353, DOI 10.1209/epl/i1996-00346-7
   UBBINK J, 1995, BIOPHYS J, V68, P54, DOI 10.1016/S0006-3495(95)80158-X
   Vasilevskaya VV, 1997, BIOPOLYMERS, V41, P51
   VOTAVOVA H, 1986, J BIOMOL STRUCT DYN, V4, P477, DOI 10.1080/07391102.1986.10506363
   Wang MD, 1997, BIOPHYS J, V72, P1335, DOI 10.1016/S0006-3495(97)78780-0
   WEMMER DE, 1985, J MOL BIOL, V185, P457, DOI 10.1016/0022-2836(85)90418-8
   WIDOM J, 1983, BIOPOLYMERS, V22, P1595, DOI 10.1002/bip.360220612
   WIDOM J, 1980, J MOL BIOL, V144, P431, DOI 10.1016/0022-2836(80)90330-7
   WILSON RW, 1979, BIOCHEMISTRY-US, V18, P2192, DOI 10.1021/bi00578a009
   WISSENBURG P, 1995, MACROMOLECULES, V28, P2315, DOI 10.1021/ma00111a027
   WISSENBURG P, 1994, MACROMOLECULES, V27, P306, DOI 10.1021/ma00079a047
   XU QW, 1993, BIOCHEMISTRY-US, V32, P11754, DOI 10.1021/bi00095a002
   XU QW, 1993, BIOPHYS J, V65, P1039, DOI 10.1016/S0006-3495(93)81163-9
   YEN WS, 1982, BIOPHYS J, V37, pA291
   Yoshikawa K, 1996, BER BUNSEN PHYS CHEM, V100, P876, DOI 10.1002/bbpc.19961000631
   Yoshikawa K, 1996, PHYS REV LETT, V76, P3029, DOI 10.1103/PhysRevLett.76.3029
NR 105
TC 947
Z9 958
U1 17
U2 218
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0006-3525
J9 BIOPOLYMERS
JI Biopolymers
PY 1997
VL 44
IS 3
BP 269
EP 282
DI 10.1002/(SICI)1097-0282(1997)44:3<269::AID-BIP6>3.0.CO;2-T
PG 14
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA ZL352
UT WOS:000073424300006
PM 9591479
DA 2021-08-04
ER

PT J
AU Dias, MAFS
   Machado, AJ
AF Dias, MAFS
   Machado, AJ
TI The role of local circulations in summertime convective development and
   nocturnal fog in Sao Paulo, Brazil
SO BOUNDARY-LAYER METEOROLOGY
LA English
DT Article
DE local circulation; convection; fog; Brazil
ID COORDINATE TRANSFORMATION; BOUNDARY-CONDITION; MODEL; SIMULATION; FLUXES
AB A non-hydrostatic, fully compressible, regional-scale numerical model of the atmosphere that includes parameterization of cloud microphysics is run in a two-dimensional mode. It uses two different observed vertical profiles of temperature, relative humidity and wind to simulate the local circulation evolution and impact on convection and nocturnal fog occurrence in Sao Paulo, Brazil. The atmospheric behaviour generated by the model is similar to the observations of the two summer days with and without sea breeze progression over the plateau. The convective development occurs in the afternoon of the two experiments but with different features and intensities. In the experiment with sea-breeze progression, there is fog formation over the plateau during the following night, in accordance with the observations. A strong northwesterly flow acting in the lower troposphere, with intensity varying between 7 and 10 m s(-1), appears as an inhibiting agent of the sea-breeze progression over the plateau and of convective development in the afternoon and of the nocturnal fog occurrence. In this case, observed gusts during the night are well simulated and appear to be related to the topography.
RP Dias, MAFS (corresponding author), UNIV SAO PAULO,DEPT ATMOSPHER SCI,INST ASTRON & GEOPHYS,RUA MATAO 1226,BR-05508900 SAO PAULO,BRAZIL.
CR CARDENAS LD, 1990, P 6 BRAZ MET C SALV, P567
   CHEN C, 1983, BOUND-LAY METEOROL, V25, P289, DOI DOI 10.1007/BF00119541
   CLARK TL, 1977, J COMPUT PHYS, V24, P186, DOI 10.1016/0021-9991(77)90057-2
   Cotton W. R., 1982, Journal de Recherches Atmospheriques, V16, P295
   DIAS MAFS, 1995, BOUND-LAY METEOROL, V74, P371, DOI 10.1007/BF00712378
   Durran D.R, 1986, MESOSCALE METEOROLOG, P472
   GALCHEN T, 1975, J COMPUT PHYS, V17, P276, DOI 10.1016/0021-9991(75)90054-6
   GALCHEN T, 1975, J COMPUT PHYS, V17, P209, DOI 10.1016/0021-9991(75)90037-6
   KLEMP JB, 1983, MON WEATHER REV, V111, P430, DOI 10.1175/1520-0493(1983)111<0430:AUBCPI>2.0.CO;2
   LOUIS JF, 1979, BOUND-LAY METEOROL, V17, P187, DOI 10.1007/BF00117978
   MCCUMBER MC, 1981, J GEOPHYS RES-OCEANS, V86, P9929, DOI 10.1029/JC086iC10p09929
   ORLANSKI I, 1976, J COMPUT PHYS, V21, P251, DOI 10.1016/0021-9991(76)90023-1
   SCHEMENAUER RS, 1992, J APPL METEOROL, V31, P275, DOI 10.1175/1520-0450(1992)031&lt;0275:TQOFWC&gt;2.0.CO;2
   Smagorinsky J., 1963, MON WEATHER REV, V91, P99, DOI [DOI 10.1175/1520-0493(1963)0912.3.CO;2, DOI 10.1175/1520-0493(1963)091<0099:GCEWTP>2.3.CO;2, 10.1175/1520-0493(1963)091<0099:gcewtp>2.3.co;2]
   Tripoli G. J., 1982, Journal de Recherches Atmospheriques, V16, P185
   WHITEMAN CD, 1986, J CLIM APPL METEOROL, V25, P1205, DOI 10.1175/1520-0450(1986)025<1205:AMTBAV>2.0.CO;2
NR 16
TC 28
Z9 30
U1 0
U2 2
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 0006-8314
J9 BOUND-LAY METEOROL
JI Bound.-Layer Meteor.
PD JAN
PY 1997
VL 82
IS 1
BP 135
EP 157
DI 10.1023/A:1000241602661
PG 23
WC Meteorology & Atmospheric Sciences
SC Meteorology & Atmospheric Sciences
GA WN543
UT WOS:A1997WN54300007
DA 2021-08-04
ER

PT J
AU Villa, AEP
   Lorenzana, VMB
AF Villa, AEP
   Lorenzana, VMB
TI Ketamine modulation of the temporal pattern of discharges and spike
   train interactions in the rat substantia nigra pars reticulata
SO BRAIN RESEARCH BULLETIN
LA English
DT Article
DE substantia nigra pars reticulata; extracellular single unit recordings;
   ketamine; firing properties; crosscorrelation analysis; bursting;
   noncompetitive NMDA antagonist
ID DOPAMINE CELL-ACTIVITY; METHYL-D-ASPARTATE; BASAL GANGLIA; SUBTHALAMIC
   NUCLEUS; FIRING PATTERN; EXTRACELLULAR ELECTROPHYSIOLOGY; EFFERENT
   CONNECTIONS; SYNAPTIC CONNECTIONS; CORRELATED ACTIVITY;
   FUNCTIONAL-ANATOMY
AB This study compares the temporal pattern of discharges of extracellularly recorded substantia nigra pars reticulata (SNr) single units in two experimental conditions: Equithesin- and ketamine-induced anesthesia. The analysis of the statistical properties of the spike trains recorded in the Equithesin group of animals showed that this experimental condition could be considered as a control condition with respect to previous data reported in the literature. We investigated the glutamatergic modulation of SNr activity at spike train level in a steady-state condition by using the anesthetic agent ketamine, which is a noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) glutamatergic receptors. The most relevant effect of ketamine at single unit level was to induce burst discharges, with an intraburst frequency rate near 50 Hz, specifically in units characterized by an initial long refractoriness in the Equithesin condition. The other classes of single units tended to discharge at a higher rate without any significant change in their temporal pattern of firing. Simultaneous recording of the spike trains of 108 SNr pairs (46 and 62 during Equithesin and ketamine condition, respectively) were equally distributed between pairs of units simultaneously recorded from the same electrode and from distinct electrodes at a distance up to 400 mu m in the same hemisphere. Ketamine induced a significant increase in the number of pairs with synchronous firing (from 4 to 49%), which was strongly, but not exclusively, associated with an increased tendency to fire in bursts. Neighboring cells tended to fire with a similar pattern in either condition of recording, whereas synchronous firing between distant cells was observed only during ketamine condition. (C) 1997 Elsevier Science Inc.
C1 UNIV SALAMANCA, DEPT BIOL CELULAR & PATOL, LAB NEUROBIOL AUDIC, SALAMANCA 37007, SPAIN.
RP Villa, AEP (corresponding author), UNIV LAUSANNE, INST PHYSIOL, LAB NEUROHEURIST, RUE BUGNON 7, CH-1005 LAUSANNE, SWITZERLAND.
RI Villa, Alessandro E.P./G-6220-2011
OI Villa, Alessandro E.P./0000-0002-4684-0027; Bajo,
   Victoria/0000-0002-3612-2048
CR ABELES M, 1982, J NEUROSCI METH, V5, P317, DOI 10.1016/0165-0270(82)90002-4
   AHISSAR E, 1992, SCIENCE, V257, P1412, DOI 10.1126/science.1529342
   ALBIN RL, 1992, NEUROSCIENCE, V46, P35, DOI 10.1016/0306-4522(92)90006-N
   ALEXANDER GE, 1990, PROG BRAIN RES, V85, P119
   BECKSTEAD RM, 1979, BRAIN RES, V175, P191, DOI 10.1016/0006-8993(79)91001-1
   BENTIVOGLIO M, 1979, BRAIN RES, V174, P1, DOI 10.1016/0006-8993(79)90800-X
   BIANCHI L, 1994, NEUROREPORT, V5, P1233, DOI 10.1097/00001756-199406020-00019
   BUNNEY BS, 1976, BRAIN RES, V117, P423, DOI 10.1016/0006-8993(76)90751-4
   BUNNEY BS, 1973, J PHARMACOL EXP THER, V185, P560
   CARLSON JH, 1992, SYNAPSE, V11, P229, DOI 10.1002/syn.890110308
   CARTER CJ, 1982, NEUROPHARMACOLOGY, V21, P379, DOI 10.1016/0028-3908(82)90019-3
   CHERGUI K, 1994, NEUROREPORT, V5, P1185, DOI 10.1097/00001756-199406020-00006
   CHRISTOFFERSEN CL, 1995, NEUROSCIENCE, V67, P373, DOI 10.1016/0306-4522(95)00047-M
   COLLARD C, 1973, ANESTH ANALG REANIM, V30, P1039
   CONDI M, 1972, ANESTH ANALG REANIM, V29, P377
   DeLong M, 1981, HDB PHYSL, P1017
   DENIAU JM, 1992, NEUROSCIENCE, V46, P361, DOI 10.1016/0306-4522(92)90058-A
   FREEMAN AS, 1985, LIFE SCI, V36, P1983, DOI 10.1016/0024-3205(85)90448-5
   GANDIA JA, 1993, BRAIN RES BULL, V32, P351, DOI 10.1016/0361-9230(93)90199-L
   GERFEN CR, 1985, J COMP NEUROL, V236, P454, DOI 10.1002/cne.902360404
   GIANNINI AJ, 1985, PSYCHIAT MED, V33, P197
   GONZALEZVEGAS JA, 1981, BRAIN RES, V207, P170, DOI 10.1016/0006-8993(81)90688-0
   GRACE AA, 1991, NEUROSCIENCE, V41, P1, DOI 10.1016/0306-4522(91)90196-U
   GRACE AA, 1984, J NEUROSCI, V4, P2877
   GRACE AA, 1983, NEUROSCIENCE, V10, P301, DOI 10.1016/0306-4522(83)90135-5
   GRACE AA, 1984, J NEUROSCI, V4, P2866
   GRACE AA, 1983, NEUROSCIENCE, V10, P333, DOI 10.1016/0306-4522(83)90137-9
   GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209
   GREEN CJ, 1981, LAB ANIM, V15, P163, DOI 10.1258/002367781780959107
   HAJOS M, 1993, NEUROSCIENCE, V55, P919, DOI 10.1016/0306-4522(93)90308-3
   HAJOS M, 1994, BRAIN RES, V660, P216, DOI 10.1016/0006-8993(94)91292-0
   HALL P, 1992, BOOSTRAP EDGEWORTH E
   HAMMOND C, 1978, BRAIN RES, V151, P235, DOI 10.1016/0006-8993(78)90881-8
   HUANG KX, 1992, J PHARMACOL EXP THER, V260, P409
   IVARSSON C, 1988, J NEUROPHYSIOL, V59, P586
   JAVITT DC, 1991, AM J PSYCHIAT, V148, P1301
   KARABELAS AB, 1985, J COMP NEUROL, V239, P309, DOI 10.1002/cne.902390305
   KHORRAMZADEH E, 1973, PSYCHOSOMATICS, V14, P344
   KITA H, 1987, J COMP NEUROL, V260, P435, DOI 10.1002/cne.902600309
   KORNHUBER J, 1984, BRAIN RES, V322, P124, DOI 10.1016/0006-8993(84)91189-2
   KUCERA P, 1970, BRAIN RES, V17, P499, DOI 10.1016/0006-8993(70)90256-8
   LI L, 1992, HEARING RES, V61, P73, DOI 10.1016/0378-5955(92)90038-O
   LOSCHER W, 1995, BRAIN RES, V702, P133, DOI 10.1016/0006-8993(95)01030-4
   MIYASAKA M, 1968, INT J NEUROPHARMACOL, V7, P557
   MURASE S, 1993, J NEURAL TRANSM-GEN, V91, P13, DOI 10.1007/BF01244915
   NINI A, 1995, J NEUROPHYSIOL, V74, P1800
   OERTEL WH, 1984, NEUROSCI LETT, V47, P233, DOI 10.1016/0304-3940(84)90519-6
   PARE D, 1990, BRAIN RES, V535, P139, DOI 10.1016/0006-8993(90)91832-2
   PARENT A, 1995, BRAIN RES REV, V20, P91, DOI 10.1016/0165-0173(94)00007-C
   PARENT A, 1995, BRAIN RES REV, V20, P128, DOI 10.1016/0165-0173(94)00008-D
   RICARDO JA, 1980, BRAIN RES, V202, P257, DOI 10.1016/0006-8993(80)90140-7
   ROSALES MG, 1994, BRAIN RES, V645, P335, DOI 10.1016/0006-8993(94)91669-1
   SAPPINGTON AA, 1979, J CLIN PSYCHOL, V35, P425, DOI 10.1002/1097-4679(197904)35:2<425::AID-JCLP2270350240>3.0.CO;2-9
   SMITH AD, 1990, TRENDS NEUROSCI, V13, P259
   SOMOGYI P, 1981, BRAIN RES, V217, P245, DOI 10.1016/0006-8993(81)90002-0
   SVENSSON TH, 1975, BRAIN RES, V92, P291, DOI 10.1016/0006-8993(75)90276-0
   SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111
   UEKI A, 1977, EXPERIENTIA, V33, P1480, DOI 10.1007/BF01918820
   VAADIA E, 1995, NATURE, V373, P515, DOI 10.1038/373515a0
   VILLA AEP, 1990, BRAIN RES REV, V15, P25, DOI 10.1016/0165-0173(90)90010-L
   Villa AEP, 1996, BRAIN RES BULL, V39, P139, DOI 10.1016/0361-9230(95)02085-3
   VIRTANEN R, 1985, J VET PHARMACOL THER, V8, P30, DOI 10.1111/j.1365-2885.1985.tb00921.x
   VIRTANEN R, 1986, ACTA PHARMACOL TOX, V58, P348
   WHITE PF, 1982, ANESTHESIOLOGY, V56, P119, DOI 10.1097/00000542-198202000-00007
   WILSON CJ, 1977, BRAIN RES, V136, P243, DOI 10.1016/0006-8993(77)90801-0
   ZHANG J, 1994, J PHARMACOL EXP THER, V269, P313
   ZURITA P, 1994, NEUROSCI RES, V19, P303, DOI 10.1016/0168-0102(94)90043-4
NR 67
TC 11
Z9 12
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0361-9230
EI 1873-2747
J9 BRAIN RES BULL
JI Brain Res. Bull.
PY 1997
VL 43
IS 6
BP 525
EP 535
DI 10.1016/S0361-9230(96)00337-1
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA XN344
UT WOS:A1997XN34400002
PM 9254023
DA 2021-08-04
ER

PT B
AU Penney, RW
AF Penney, RW
BE Warwick, K
   Karny, M
TI Statistical physics and the optimization of autonomous behaviour in
   complex virtual worlds
SO COMPUTER-INTENSIVE METHODS IN CONTROL AND SIGNAL PROCESSING: THE CURSE
   OF DIMENSIONALITY
LA English
DT Proceedings Paper
CT 2nd IEEE European Workshop on Computer-Intensive Methods in Control and
   Signal Processing - Can We Beat the Curse of Dimensionality
CY AUG 28-30, 1996
CL PRAGUE, CZECH REPUBLIC
SP Acad Sci Czech Republic, Inst Informat Theory & Automat, Univ Reading, Sch Engn & Informat Sci, UK, IEEE Control Syst Soc
DE optimization theory; statistical mechanics; autonomous agents
AB Motivated by the demands of creating artificial intelligent entities that are able to interact with humans in complex, time-dependent, environments, we will outline how flexible and adaptive decision-making can be formulated as an optimization problem. We will discuss how this problem, when expressed mathematically, relates to well-understood phenomena and concepts in statistical physics. By analogy with physical paradigms, we will then consider how this optimization can be effected by combining gradient-descent and thermal processes in a form of simulated annealing, but one intended to avoid some of the potential hazards of canonical simulated annealing. Thereafter, we will briefly present an example application of our approach to a simple battlefield simulation.
RP Penney, RW (corresponding author), DEF RES AGCY,MALVERN WR14 3PS,WORCS,ENGLAND.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BIRKHAUSER BOSTON
PI CAMBRIDGE
PA 675 MASSACHUSETTS AVE, CAMBRIDGE, MA 02139-2333
BN 0-8176-3989-6
PY 1997
BP 49
EP 61
PG 13
WC Computer Science, Artificial Intelligence; Computer Science,
   Cybernetics; Engineering, Multidisciplinary; Engineering, Electrical &
   Electronic; Mathematics, Applied
SC Computer Science; Engineering; Mathematics
GA BH53W
UT WOS:A1997BH53W00002
DA 2021-08-04
ER

PT J
AU Schembecker, G
   Simmrock, KH
AF Schembecker, G
   Simmrock, KH
TI Heuristic-numeric design of separation processes for azeotropic mixtures
SO COMPUTERS & CHEMICAL ENGINEERING
LA English
DT Article; Proceedings Paper
CT Joint 6th International Symposium on Process Systems Engineering/30th
   European Symposium on Computer Aided Process Engineering (PSE
   97-ESCAPE-7)
CY MAY 25-29, 1997
CL TRONDHEIM, NORWAY
AB The paper presents the results of a cooperation between the University of Dortmund and GHN, Gesellschaft fur Heuristisch-Numerische Beratungssysteme mbH, in the field of heuristic-numeric systems for the distillation of close boiling and azeotropic mixtures. The described software TEAGPERT designs such separation processes by using heuristic rules for the selection and the design of flowsheet elements as well as numeric programs and databases. Based on an analysis of the boiling behavior of tie mixture TEAGPERT selects thermodynamically proven separation units. In addition, a first mass balance is calculated which serves as a starting point for further detailed simulations with common flowsheet simulators. The paper describes in detail the use of the software for the prediction of separating cuts. In addition, a design procedure for heteroazeotropic distillation processes with mass agents is presented.
C1 GESELL HEURIST NUMER BERATUNGSSYST MBH,GHN,D-44227 DORTMUND,GERMANY.
RP Schembecker, G (corresponding author), UNIV DORTMUND,FACHBEREICH CHEM TECH,D-44221 DORTMUND,GERMANY.
CR BIEKER T, 1994, COMPUT CHEM ENG, V18, pS25, DOI 10.1016/0098-1354(94)80005-7
   FIDKOWSKI ZT, 1993, COMPUT CHEM ENG, V17, P1141, DOI 10.1016/0098-1354(93)80095-5
   FIEN GJAF, 1994, IND ENG CHEM RES, V33, P2505, DOI 10.1021/ie00035a001
   FRIED A, 1991, CHEM-ING-TECH, V63, P593
   Kim YJ, 1997, COMPUT CHEM ENG, V21, P93, DOI 10.1016/0098-1354(95)00249-9
   MALONE MF, 1995, AICHE S SERIES, V304, P9
   SCHEMBECKER G, 1995, COMPUT CHEM ENG, V19, pS253, DOI 10.1016/0098-1354(95)00081-C
   Schembecker G, 1996, CHEM-ING-TECH, V68, P1307, DOI 10.1002/cite.330681014
   SCHEMBECKER G, 1996, AICHE S SERIES, V312, P275
NR 9
TC 9
Z9 9
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0098-1354
J9 COMPUT CHEM ENG
JI Comput. Chem. Eng.
PY 1997
VL 21
SU S
BP S231
EP S236
PG 6
WC Computer Science, Interdisciplinary Applications; Engineering, Chemical
SC Computer Science; Engineering
GA XD313
UT WOS:A1997XD31300039
DA 2021-08-04
ER

PT J
AU Camps, J
   Tardieu, C
   Dejou, J
   Franquin, JC
   Ladaique, P
   Rieu, R
AF Camps, J
   Tardieu, C
   Dejou, J
   Franquin, JC
   Ladaique, P
   Rieu, R
TI In vitro cytotoxicity of dental adhesive systems under simulated pulpal
   pressure
SO DENTAL MATERIALS
LA English
DT Article
ID IN-VITRO; RESTORATIVE MATERIALS; LEACHABLE COMPONENTS; BONDING AGENTS;
   PERMEABILITY; CRYOPRESERVATION; COMPOSITES; FLUID; TRANSPLANTATION;
   REPLANTATION
AB Objectives. Most of the devices used to evaluate the cytotoxicity of resin-based composites in vitro use a dentin barrier test. However, it is difficult to obtain the number of freshly extracted teeth, all on the same day, that is necessary for powerful statistical analysis. Tooth cryopreservation provides a way to build up a supply of teeth. This in vitro study compared cryopreserved teeth and freshly extracted teeth in an evaluation of the cytotoxicity of resin-based composites. In addition, this study also evaluated the effects of pulsatile pressure and the importance of dentin permeability on the cytotoxic response to bonding resins.
   Methods. Forty freshly extracted and forty cryopreserved third molars were used. A standardized Class I cavity was prepared within the dentin. The hydraulic conductance of each tooth was recorded. The cavities were filled either with Scotchbond Multi-Purpose Plus and Z 100 (3M Dental Products) or with Optibond and Herculite (Kerr). A plexiglas device was designed to permit 24 h long contact between culture medium and the roof of the pulp chamber while a pulsatile pulpal pressure was simulated. The viability of L 929 cells cultured with a control medium and evaluated by an MTT assay was compared to that of L 929 cells cultured with medium which remained for 24 h in contact with the pulp chamber of restored teeth. A three-way ANOVA was used to compare the cytotoxicity among the different groups. A simple least-squares linear regression was used to seek a relationship between the hydraulic conductance of dentin and the cytotoxicity of composite restorative materials.
   Results. No significant differences in cytotoxicity were found between the freshly extracted teeth and the cryopreserved teeth (p = 0.53). The cytotoxicity of the resin adhesives was statistically higher when a pulsatile pulpal pressure was simulated (p = 0.04). A significant relationship was found between the hydraulic conductance of dentin and the cytotoxicity of resin-based composites (p = 0.02).
   Significance. Cryopreserved teeth can be used for in vitro evaluation of the cytotoxicity of resin adhesives. Pulsatile pulpal pressure simulations increased the in vitro cytotoxicity of the tested materials.
C1 INST J PAOLI I CALMETTES, F-13009 MARSEILLE, FRANCE.
   CNRS UM 138, MARSEILLE, FRANCE.
RP Camps, J (corresponding author), FAC ODONTOL, UNITE IMEB, LAB RECH, 27 BLVD JEAN MOULIN, F-13385 MARSEILLE 5, FRANCE.
CR BEITZ J, 1985, BIOMED BIOCHIM ACTA, V44, P1681
   BERGENHOLTZ G, 1982, J ORAL PATHOL MED, V11, P439, DOI 10.1111/j.1600-0714.1982.tb00188.x
   Bouillaguet S, 1996, J ENDODONT, V22, P244, DOI 10.1016/S0099-2399(06)80141-X
   BROWNE R M, 1986, Endodontics and Dental Traumatology, V2, P177
   CAMPS J, 1994, DENT MATER, V10, P210, DOI 10.1016/0109-5641(94)90034-5
   Camps J, 1996, ARCH ORAL BIOL, V41, P837, DOI 10.1016/S0003-9969(96)00037-4
   Camps J, 1996, DENT MATER, V12, P121, DOI 10.1016/S0109-5641(96)80079-0
   CAMPS J, 1995, DENT MATER, V11, P177, DOI 10.1016/0109-5641(95)80014-X
   Elbaum R, 1992, Quintessence Int, V23, P773
   FERRACANE JL, 1994, J ORAL REHABIL, V21, P441, DOI 10.1111/j.1365-2842.1994.tb01158.x
   FERRACANE JL, 1990, DENT MATER, V6, P282, DOI 10.1016/S0109-5641(05)80012-0
   Fujitani M, 1992, Int Dent J, V42, P3
   Fusayama T, 1993, SIMPLE PAIN FREE ADH
   GERZINA TM, 1994, J ORAL REHABIL, V21, P463, DOI 10.1111/j.1365-2842.1994.tb01160.x
   GERZINA TM, 1995, J DENT RES, V74, P369, DOI 10.1177/00220345950740011301
   HANKS CT, 1989, J ORAL PATHOL MED, V18, P97, DOI 10.1111/j.1600-0714.1989.tb00744.x
   HANKS CT, 1988, J ORAL PATHOL MED, V17, P396, DOI 10.1111/j.1600-0714.1988.tb01304.x
   HANKS CT, 1991, J DENT RES, V70, P1450, DOI 10.1177/00220345910700111201
   HANKS CT, 1994, J ORAL REHABIL, V21, P475, DOI 10.1111/j.1365-2842.1994.tb01162.x
   HANKS CT, 1992, J ENDODONT, V18, P589, DOI 10.1016/S0099-2399(06)81328-2
   HEYERAAS KJ, 1994, MICROVASC RES, V47, P329, DOI 10.1006/mvre.1994.1026
   HUME WR, 1985, J DENT RES, V64, P1322, DOI 10.1177/00220345850640111501
   JAMES V E, 1955, Oral Surg Oral Med Oral Pathol, V8, P1305, DOI 10.1016/0030-4220(55)90435-7
   KREJCI I, 1993, J DENT RES, V72, P490, DOI 10.1177/00220345930720020401
   KRISTERSON L, 1976, J ORAL SURG, V34, P13
   LAFOREST P, 1991, REV CHIR ORTHOP, V77, P389
   LUNDQVIST C, 1974, SWED DENT J, V67, P13
   MITCHEM JC, 1988, DENT MATER, V4, P351, DOI 10.1016/S0109-5641(88)80048-4
   Noblett WC, 1996, J ENDODONT, V22, P1, DOI 10.1016/S0099-2399(96)80226-3
   OGATA T, 1960, ARCH JAP CHIR, V29, P59
   Olgart L, 1996, CRIT REV ORAL BIOL M, V7, P159, DOI 10.1177/10454411960070020401
   OUTHWAITE WC, 1976, ARCH ORAL BIOL, V21, P599, DOI 10.1016/0003-9969(76)90029-7
   PASHLEY DH, 1979, ARCH ORAL BIOL, V24, P455, DOI 10.1016/0003-9969(79)90008-6
   PASHLEY DH, 1988, INT ENDOD J, V21, P143
   PAUL SJ, 1994, J ESTHET DENT, V5, P179
   Prati C, 1992, Am J Dent, V5, P33
   PRATI C, 1991, DENT MATER, V7, P268, DOI 10.1016/S0109-5641(05)80027-2
   RATHBUN MA, 1991, J BIOMED MATER RES, V25, P443
   REEDER OW, 1978, J DENT RES, V57, P187, DOI 10.1177/00220345780570020601
   SCHACHAR N, 1992, J ORTHOPAED RES, V10, P603, DOI 10.1002/jor.1100100502
   SCHMALZ G, 1994, J ENDODONT, V20, P592, DOI 10.1016/S0099-2399(06)80083-X
   SCHNETTLER JM, 1991, J ENDODONT, V17, P488, DOI 10.1016/S0099-2399(06)81795-4
   SCHWARTZ O, 1983, INT J ORAL MAXILLOF, V12, P425, DOI 10.1016/S0300-9785(83)80034-9
   SCHWARTZ O, 1986, INT J ORAL MAX SURG, V15, P30, DOI 10.1016/S0300-9785(86)80008-4
   STANLEY HR, 1993, J AM DENT ASSOC, V124, P76, DOI 10.14219/jada.archive.1993.0199
   TAO L, 1989, DENT MATER, V5, P181, DOI 10.1016/0109-5641(89)90010-9
   Tao L, 1991, Am J Dent, V4, P73
   TYLER MW, 1994, OPER DENT, V19, P116
   WATAHA JC, 1994, J ORAL REHABIL, V21, P453, DOI 10.1111/j.1365-2842.1994.tb01159.x
NR 49
TC 32
Z9 32
U1 2
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0109-5641
EI 1879-0097
J9 DENT MATER
JI Dent. Mater.
PD JAN
PY 1997
VL 13
IS 1
BP 34
EP 42
DI 10.1016/S0109-5641(97)80006-1
PG 9
WC Dentistry, Oral Surgery & Medicine; Materials Science, Biomaterials
SC Dentistry, Oral Surgery & Medicine; Materials Science
GA XD943
UT WOS:A1997XD94300006
PM 9467321
DA 2021-08-04
ER

PT B
AU Nadella, R
   Sen, S
AF Nadella, R
   Sen, S
BE Weiss, G
TI Correlating internal parameters and external performance: Learning
   soccer agents
SO DISTRIBUTED ARTIFICIAL INTELLIGENCE MEETS MACHINE LEARNING: LEARNING IN
   MULTI-AGENT ENVIRONMENTS
SE LECTURE NOTES IN ARTIFICIAL INTELLIGENCE
LA English
DT Article; Proceedings Paper
CT 2nd International Conference on Multiagent Systems (ICMAS 96)
CY DEC 09-13, 1996
CL KYOTO, JAPAN
AB We have developed a Soccer simulator in Java, which allows us to evaluate agent behavioral strategies for effectively collaborating with other team members while countering threats posed by the opposing team. Whereas action selection mechanisms to decide when to shoot, pass, dribble, guard opponent, tackle, etc. are important from a player's viewpoint, learning the capabilities of individual opponents from repeated encounters can provide critical information for the success of a team. Each agent is described by a set of skill levels for different soccer skills. A soccer agent uses its incomplete perceptions, model of the changing environment, knowledge of the skill levels of its own team players, and estimated skill levels of the opponent team players to select the most prudent action. In this paper, we identify learning opportunities for soccer agents, and investigate some of these possibilities in detail. Initial experimental results demonstrate the advantage of learning agents.
C1 Univ Tulsa, Dept Math & Comp Sci, Tulsa, OK 74104 USA.
RP Nadella, R (corresponding author), Univ Tulsa, Dept Math & Comp Sci, Tulsa, OK 74104 USA.
CR ASADA M, 1994, P IEEE RSJ GI INT C, P917
   Banks J., 1984, DISCRETE EVENT SYSTE, V5th edition
   COLLINOT A, 1996, P 2 INT C MULT SYST, P41
   FLANAGAN D, 1996, JAVA NUTSHELL
   HANKS S, 1993, AI MAG, V14, P17
   Hines W.W., 1980, PROBABILITY STAT ENG
   KAEBLING LP, 1996, J ARTIFICIAL INTELLI, V4, P237
   KITANO H, 1995, IJCAI 95 WORKSH AD L
   Matsubara H., 1996, Adaptation, Coevolution and Learning in Multiagent Systems. Papers from the 1996 AAAI Symposium (TR SS-96-01), P63
   PHILIP D, 1980, TOPICS THEORY VOTING
   Rumelhart D. E., 1986, PARALLEL DISTRIBUTED, V1
   Stone P., 1996, Adaptation, Coevolution and Learning in Multiagent Systems. Papers from the 1996 AAAI Symposium (TR SS-96-01), P88
NR 12
TC 2
Z9 4
U1 0
U2 0
PU SPRINGER-VERLAG BERLIN
PI BERLIN 33
PA HEIDELBERGER PLATZ 3, W-1000 BERLIN 33, GERMANY
BN 3-540-62934-3
J9 LECT NOTES ARTIF INT
PY 1997
VL 1221
BP 137
EP 150
PG 14
WC Computer Science, Artificial Intelligence; Computer Science, Theory &
   Methods
SC Computer Science
GA BK99B
UT WOS:000074016000010
DA 2021-08-04
ER

PT B
AU Dragoni, AF
   Giorgini, P
AF Dragoni, AF
   Giorgini, P
BE Weiss, G
TI Learning agents' reliability through Bayesian conditioning: A simulation
   experiment
SO DISTRIBUTED ARTIFICIAL INTELLIGENCE MEETS MACHINE LEARNING: LEARNING IN
   MULTI-AGENT ENVIRONMENTS
SE LECTURE NOTES IN ARTIFICIAL INTELLIGENCE
LA English
DT Article; Proceedings Paper
CT 2nd International Conference on Multiagent Systems (ICMAS 96)
CY DEC 09-13, 1996
CL KYOTO, JAPAN
ID REVISION
AB This paper reports the first results of a simulation experiment. There are two databases, one containing true propositions and the other containing their respective negations. Five agents in turn access one of them. Each agent has a "capacity" that will be used as the frequency with which the agent accesses (unconsciously) the database with the correct knowledge. Agents randomly exchange information with the others. Since they have limited degrees of capacity, their "cognitive state" quickly becomes inconsistent. Each agent is equipped with the same belief revision mechanism to detect and solve these contradictions. This adopts the Dempster's Rule of Combination to evaluate the credibility of the various pieces of information and Bayesian Conditioning to estimate the relative degrees of reliability of the agents (itself included). The purpose of the experiments was that of evaluating on a statistical basis, the emergent cognitive behavior of the group.
C1 Univ Ancona, Ist Informat, I-60131 Ancona, Italy.
RP Dragoni, AF (corresponding author), Univ Ancona, Ist Informat, Via Brecce Bianche, I-60131 Ancona, Italy.
RI Dragoni, Aldo Franco F/B-1662-2012; Dragoni, Aldo Franco/N-3434-2019;
   Giorgini, Paolo/G-7886-2012
OI Dragoni, Aldo Franco F/0000-0002-3013-3424; Dragoni, Aldo
   Franco/0000-0002-3013-3424; 
CR ALCHOURRON CE, 1985, J SYMBOLIC LOGIC, V50, P510, DOI 10.2307/2274239
   BENFERHAT S, 1995, P 14 INT JOINT C ART, P1449
   BENFERHAT S, 1993, P 13 INT JOINT C ART, P640
   DEKLEER J, 1986, ARTIF INTELL, V28, P127, DOI 10.1016/0004-3702(86)90080-9
   DRAGONI AF, 1994, P 6 IEEE C TOOLS AI
   DRAGONI AF, 1995, LNAI, V992
   DRAGONI AF, 1996, P 5 C IB DER INF LA
   DRAGONI AF, 1997, IN PRESS KNOWLEDGE E
   DRAGONI AF, 1997, LNAI SERIES
   DUBOIS D, 1994, INT J INTELL SYST, V9, P61, DOI 10.1002/int.4550090105
   GARDENFORS P, 1988, FLUX MODELING DYNAMI
   GARDENFORS P, 1992, BELIEF REVISION
   NEBEL W, 1994, P 11 EUR C ART INT
   REITER R, 1987, ARTIFICIAL INTELLIGE, V53
   SHAFER G, 1990, READING UNCERTAIN RE
   Shafer G, 1976, MATH THEORY EVIDENCE, DOI 10.1515/9780691211696
   Shafer G., 1990, READINGS UNCERTAIN R
   WILLIAMS MA, 1995, P 14 INT JOINT C ART, P1541
NR 18
TC 3
Z9 3
U1 0
U2 1
PU SPRINGER-VERLAG BERLIN
PI BERLIN 33
PA HEIDELBERGER PLATZ 3, W-1000 BERLIN 33, GERMANY
BN 3-540-62934-3
J9 LECT NOTES ARTIF INT
PY 1997
VL 1221
BP 151
EP 167
PG 17
WC Computer Science, Artificial Intelligence; Computer Science, Theory &
   Methods
SC Computer Science
GA BK99B
UT WOS:000074016000011
DA 2021-08-04
ER

PT J
AU Alvarez, L
   Hurtt, ME
   Kennedy, GL
AF Alvarez, L
   Hurtt, ME
   Kennedy, GL
TI Developmental toxicity of dimethyl sulfate by inhalation in the rat
SO DRUG AND CHEMICAL TOXICOLOGY
LA English
DT Article
ID ALKYLATING-AGENTS; METHYL METHANESULFONATE; MOUSE; INDUCTION; MUTAGENS;
   DNA; ABERRATIONS; SUBSTANCES; ZYGOTES; EMBRYOS
AB Dimethyl sulfate (DMS; CAS No. 77-78) is a colorless, oily liquid which is used as a chemical intermediate and as a reactant in producing polyurethane resins. In this study, groups of pregnant Cr1:CD(R)BR rats were exposed, nose-only, to either 0.1, 0.7 or 1.5 ppm DMS by inhalation for 6 hr/day from Days 7 through 16 of gestation (day in which copulation plug was detected was designated Day 1G). A control group of pregnant rats was exposed simultaneously to air only. All female rats were euthanized on Day 22G and the fetuses were examined. A suppression of both food consumption and the rate of body weight gain was seen in the 0.7 and 1.5 ppm groups. No unusual clinical signs were seen in rats exposed to DMS. None of the reproductive parameters was altered in any of the groups and no statistically significant fetal effects were detected. DMS is not a developmental toxin in the rat following inhalation exposures up to 1.5 ppm during the period of major organogenesis.
C1 DUPONT CO INC,HASKELL LAB TOXICOL & IND MED,NEWARK,DE 19714.
CR ALDERSON T, 1969, MUTAT RES, V8
   BARROW MV, 1969, J MORPHOL, V127, P291, DOI 10.1002/jmor.1051270303
   BRADLEY MO, 1987, MUTAT RES, V189, P69, DOI 10.1016/0165-1218(87)90034-6
   BRAUN R, 1984, TERATOGEN CARCIN MUT, V4, P449, DOI 10.1002/tcm.1770040507
   Connell J R, 1984, Basic Life Sci, V29 Pt A, P343
   CONNELL JR, 1982, CARCINOGENESIS, V3, P385, DOI 10.1093/carcin/3.4.385
   DIXON WJ, 1969, INTRO STATISTICAL AN, P308
   DRUCKREY H, 1970, Z KREBSFORSCH KLIN O, V74, P241, DOI 10.1007/BF00525457
   DRUCKREY H, 1973, IARC SCI PUBL, V4, P45
   EPSTEIN SS, 1972, TOXICOL APPL PHARM, V23, P288, DOI 10.1016/0041-008X(72)90192-5
   EVENSON DP, 1993, ENVIRON MOL MUTAGEN, V21, P144, DOI 10.1002/em.2850210208
   FAUSTMAN EM, 1989, TERATOLOGY, V40, P199, DOI 10.1002/tera.1420400303
   FAUSTMAN EM, 1995, FUNDAM APPL TOXICOL, V26, P136
   GENEROSO WM, 1991, MUTAT RES, V250, P439, DOI 10.1016/0027-5107(91)90200-8
   GUILLOT JP, 1982, FOOD CHEM TOXICOL, V20, P573, DOI 10.1016/S0278-6915(82)80066-5
   HASEMAN JK, 1975, TERATOLOGY, V12, P167
   HOFFMANN GR, 1988, ENVIRON MOL MUTAGEN, V11, P545, DOI 10.1002/em.2850110414
   *IARC, 1974, MON EV CARC RISK CHE, V7, P253
   IARC, 1974, MON EV CARC RISK CHE, V4, P271
   JELINEK R, 1985, INDIAN J EXP BIOL, V23, P588
   JONCKHEERE AR, 1954, BIOMETRIKA, V41, P133, DOI 10.1093/biomet/41.1-2.133
   KLEIHUES P, 1974, Z KREBSFORSCH KLIN O, V81, P273, DOI 10.1007/BF00305030
   LEHMANN AR, 1984, CARCINOGENESIS, V5, P117, DOI 10.1093/carcin/5.1.117
   Little S. A., 1994, Teratology, V49, P400
   MANN HB, 1947, ANN MATH STAT, V18, P50, DOI 10.1214/aoms/1177730491
   MOHR U, 1980, INVEST CELL PATHOL, V3, P209
   RAPPORT IA, 1947, DOKLADY VSES AKAD SK, V12, P12
   RUTLEDGE JC, 1992, MUTAT RES, V296, P167, DOI 10.1016/0165-1110(92)90040-G
   SALEWSKL E., 1964, ARCH EXP PATHOL PHARMAKOL [NAUNYN SCHMEEDEBERGS], V247, P367
   SCHLOGEL FA, 1970, N-S ARCH PHARMAKOL, V266, P441
   Siegel S., 1956, NONPARAMETRIC STAT, P96
   SMYTH HF, 1951, AMA ARCH IND HYG OCC, V4, P119
   SNEDECOR GW, 1967, STATISTICAL METHODS, P246
   SOLOMON FP, 1987, ENVIRON TOXICOL CHEM, V264, P747
   STAPLES RE, 1974, TERATOLOGY, V9, pA37
   STAPLES RE, 1964, STAIN TECHNOL, V39, P62
   STEEL RGD, 1980, PRINCIPLES PROCEDURE, P188
   SUGIYAMA C, 1992, MUTAT RES, V278, P117, DOI 10.1016/0165-1218(92)90220-T
   TATES AD, 1992, MUTAGENESIS, V7, P441
   WESTERGAARD M, 1957, EXPERIENTIA, V13, P224, DOI 10.1007/BF02157427
   WOO DC, 1972, TERATOLOGY, V6, P191, DOI 10.1002/tera.1420060210
NR 41
TC 2
Z9 2
U1 0
U2 1
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016
SN 0148-0545
J9 DRUG CHEM TOXICOL
JI Drug Chem. Toxicol.
PY 1997
VL 20
IS 1-2
BP 99
EP 114
DI 10.3109/01480549709011081
PG 16
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy; Toxicology
SC Chemistry; Pharmacology & Pharmacy; Toxicology
GA XC895
UT WOS:A1997XC89500008
PM 9183565
DA 2021-08-04
ER

PT B
AU Meylan, M
   Rings, DM
   Shulaw, WP
   Bech-Nielsen, S
   Kowalski, JJ
   Hoffsis, GF
AF Meylan, M
   Rings, DM
   Shulaw, WP
   Bech-Nielsen, S
   Kowalski, JJ
   Hoffsis, GF
BE Chiodini, RJ
   Hines, ME
   Collins, MT
TI Survival of Mycobacterium paratuberculosis and preservation of
   immunoglobulin G in bovine colostrum under conditions simulating
   pasteurization
SO FIFTH INTERNATIONAL COLLOQUIUM ON PARATUBERCULOSIS: MEETING OF THE
   INTERNATIONAL ASSOCIATION FOR PARATUBERCULOSIS
LA English
DT Proceedings Paper
CT 5th International Colloquium on Paratuberculosis of the
   International-Association-for-Paratuberculosis
CY SEP 29-OCT 04, 1996
CL MADISON, WI
SP Int Assoc Paratuberculosis
AB Mycobacterium paratuberculosis is the agent of a chronic, fatal, granulomatous enterocolitis in ruminants. Most susceptible to infection are animals in their first month of life, although clinical disease becomes apparent only several years later. The main way of infection is the fecal-oral route, but since excretion of M. paratuberculosis has been demonstrated in colostrum as well as in milk of infected cows, there is concern about feeding infected colostrum to highly susceptible neonate calves. We! investigated the effects of colostrum pasteurization under laboratory conditions, i.e. elimination of the mycobacteria and preservation of immunoglobulins through hear treatment. Colostrum samples were spiked with M. paratuberculosis (strain ATCC 19698) in concentrations of 10(4), 10(3) and 10(2) CFU/ml each, and split into two groups, pasteurized and unpasteurized The pasteurized samples were held for 30 minutes - exclusive of come-up time - at 63 degrees C in a waterbath, then cooled on ice. Both groups of samples (pasteurized and unpasteurized) were subsequently handled similarly. IgG content was measured by single radial immunodiffusion on agarose gel and the samples were cultured on Herrold's Egg Yolk Medium (HEYM) supplemented with mycobactin J. The mean value for colostral IgG was 44.4 g/l in the unpasteurized samples and 37.2 g/l in the pasteurized samples with a mean decrease in IgG concentration of 12.3%, a statistically significant difference (p=0.005). The observed reduction in immunoglobulin concentrations can be managed by accordingly increasing the amount of colostrum fed. The pasteurization procedure did significantly reduce (p<0.0001), but did nor completely eliminate M. paratuberculosis from the pasteurized colostrum samples. Although not sufficient by itself to prevent potential infection of neonate calves by feeding (otherwise mandatory) colostrum front infected and shedding cows, colostrum pasteurization may be advisable, along with other control measures (such as identification and elimination of infected adult animals, and careful selection of colostrum for pooling) to reduce the infection pressure in infected herds.
C1 Ohio State Univ, Columbus, OH 43210 USA.
RP Meylan, M (corresponding author), Ohio State Univ, Columbus, OH 43210 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU INT ASSOC PARATUBERCULOSIS INC
PI PROVIDENCE
PA SWP 526, RI HOSPITAL 593 EDDY STREET, PROVIDENCE, RI 02903 USA
BN 0-963304-33-X
PY 1997
BP 339
EP 346
PG 8
WC Veterinary Sciences
SC Veterinary Sciences
GA BK83Z
UT WOS:000073607200074
DA 2021-08-04
ER

PT B
AU Yamaguchi, T
   Kohata, N
   Wakamatsu, Y
   Baba, T
AF Yamaguchi, T
   Kohata, N
   Wakamatsu, Y
   Baba, T
BE Jain, LC
TI Evolutionary parallel computation on welfare intelligent agent
SO FIRST INTERNATIONAL CONFERENCE ON KNOWLEDGE-BASED INTELLIGENT ELECTRONIC
   SYSTEMS, PROCEEDINGS 1997 - KES '97, VOLS 1 AND 2
LA English
DT Proceedings Paper
CT 1st International Conference on Knowledge-Based Intelligent Electronic
   Systems (KES 97)
CY MAY 21-23, 1997
CL ADELAIDE, AUSTRALIA
SP Austr Electr Engn, Austr, IEEE S Austr Sect, S Austr, Gerard Ind Pty Ltd, S Austr, Mitsubishi Motors, Austr Ltd
DE evolutionary computation; chaotic retrieval; parallel processing;
   associative memories
AB This paper proposes the realization of evolutionary computation on an intelligent agent using knowledge creation based on chaotic retrieval and parallel processing. This intelligent agent has the ability to self-organize knowledge, and we intend to introduce a kind of evolutionary computation into intelligent agents to make use of the flexibility in a group of various agents. This agent model consists of hierarchical parts which memorize fuzzy knowledge. Each hierarchical part retrieves the knowledge based on fuzzy associative inference on associative memories. Essentially, this inference in each part is parallel processing, and these hierarchical parts also work in parallel. Furthermore, a large number of agents work in parallel on the multi-agent model and its evolutionary computation, We realize parallel processing according to these parallel properties in the brain and in nature. When we realize a welfare intelligent robot, robots have to move in a suitable formation, in cooperation with the outer environment. Therefore, we apply the knowledge creation method to multi-agent robots which move abreast and simulate parallel processing of the multiagent model as the basis for realizing evolutionary computation. We implement a parallel processing algorithm on an A-NET(Actors NETwork) parallel object-oriented computer, and show eke usefulness of parallel processing for future evolutionary computation.
RP Yamaguchi, T (corresponding author), UTSUNOMIYA UNIV,FAC ENGN,DEPT INFORMAT SCI,2753 ISHII CHO,UTSUNOMIYA,TOCHIGI 321,JAPAN.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU I E E E
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017
PY 1997
BP 118
EP 125
PG 8
WC Computer Science, Artificial Intelligence; Engineering, Electrical &
   Electronic
SC Computer Science; Engineering
GA BJ47T
UT WOS:A1997BJ47T00015
DA 2021-08-04
ER

PT S
AU Bisset, DL
   Vandenbergh, RC
AF Bisset, DL
   Vandenbergh, RC
BE Husbands, P
   Harvey, I
TI The dynamics of photo-taxis: Applying the agent environment interaction
   system to a simple Braitenberg robot
SO FOURTH EUROPEAN CONFERENCE ON ARTIFICIAL LIFE
SE FROM ANIMALS TO ANIMATS SERIES
LA English
DT Proceedings Paper
CT 4th European Conference on Artificial Life (ECAL97)
CY JUL 28-31, 1997
CL BRIGHTON, ENGLAND
SP BT, Cyberlife Technol, Brighton & Hove Council, Times Higher Educ Supplement
AB This paper describes a dynamic system used to model the behaviour of a-Photon, a simple Braitenberg robot designed to achieve photo-taxis with a single, stationary light source.
   The model is based on the Agent Environment Interaction System described in [Smithers 1994]. The equations detailed in this paper model both the robot and the environment so as to allow a full analysis of the completed agent-environment interaction system.
   Finally, a numeric simulation system is developed and used to solve the coupled agent-environment interaction system. Graphical simulation results are presented in the form of the agent's absolute track in a 2D Cartesian space.
C1 Univ Kent, Canterbury CT2 7NT, Kent, England.
RP Bisset, DL (corresponding author), Univ Kent, Canterbury CT2 7NT, Kent, England.
RI van den Bergh, Roderick/AAP-7811-2021
NR 0
TC 0
Z9 0
U1 0
U2 0
PU M I T PRESS
PI CAMBRIDGE
PA FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA
SN 1089-4365
BN 0-262-58157-4
J9 FROM ANIM ANIMAT
PY 1997
BP 327
EP 336
PG 10
WC Computer Science, Artificial Intelligence; Multidisciplinary Sciences
SC Computer Science; Science & Technology - Other Topics
GA BK05M
UT WOS:000071005100037
DA 2021-08-04
ER

PT J
AU Chung, LLWK
   Zhau, HYE
   Wu, TT
AF Chung, LLWK
   Zhau, HYE
   Wu, TT
TI Development of human prostate cancer models for chemoprevention and
   experimental therapeutics studies
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article; Proceedings Paper
CT International Cancer Chemoprevention Conference
CY OCT 13-16, 1996
CL BEIJING, PEOPLES R CHINA
DE prostate cancer progression; stromal-epithelial interaction;
   three-dimensional growth models; prostate cancer bone metastasis
ID BONE FIBROBLASTS; GROWTH-INVIVO; LNCAP MODEL; ANDROGEN; METASTASIS;
   CARCINOMA; CELLS
AB The progression of human prostate cancer from histomorphologic to clinical expression often requires several decades. This study emphasizes the importance of developing relevant human prostate cancer models to study the molecular events leading to prostate cancer progression. These models will provide a rational basis for chemopreventive and treatment strategies to retard the progression of human prostate cancer from its localized to its metastatic state. In our laboratory, we have established the LNCaP progression and ARCaP models and the in vitro three-dimensional growth models involving prostate cancer and bone stroma to study the progression of prostate cancer. We propose that prostate cancer may progress from an androgen-dependent to an androgen-independent stale. While existing as androgen-independent tumors (defined as tumors capable of growing in castrated hosts and secreting PSA in serum), prostate cancer may assume three different phenotypes as it progresses: androgen-independent while remaining androgen-responsive; androgen-independent and unresponsive to androgen stimulation; and androgen-independent but suppressed by androgen. It is conceivable that any androgen-independent human prostate cancer may contain variable proportions of cells that exhibit these three phenotypes. This concept may have important implications in determining strategies for chemopreventive and therapeutic trials. We have established three-dimensional growth models of prostate cancer cells either in collagen gel or microgravity-simulated growth conditions to form viable and functional organoids which contain prostate cancer epithelial cells admired with prostate or bone stromal cells. These in vitro models combined with the in vivo models described above will enhance our understanding of the regulatory mechanism of prostate cancer growth and progression, and hence could improve efficiency in screening chemopreventive and therapeutic agents which alter the biologic behaviors of human prostate cancer. (C) 1998 Wiley-Liss, Inc.
C1 Univ Virginia, Hlth Sci Ctr, Dept Urol, Mol Urol & Therapeut Program, Charlottesville, VA 22908 USA.
RP Chung, LLWK (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Urol, Mol Urol & Therapeut Program, Charlottesville, VA 22908 USA.
CR BOSLAND MC, 1995, CARCINOGENESIS, V16, P1311, DOI 10.1093/carcin/16.6.1311
   CHANG SM, 1989, ENDOCRINOLOGY, V125, P2719, DOI 10.1210/endo-125-5-2719
   DUNNING WF, 1963, MONOGR NATL CANC I, V12, P351
   GLEAVE M, 1991, CANCER RES, V51, P3753
   GLEAVE ME, 1992, J UROLOGY, V147, P1151, DOI 10.1016/S0022-5347(17)37506-7
   GLEAVE ME, 1992, CANCER RES, V52, P1598
   GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439
   HOEHN W, 1980, Prostate, V1, P95, DOI 10.1002/pros.2990010113
   Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115
   HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809
   Hyytinen ER, 1997, BRIT J CANCER, V75, P190, DOI 10.1038/bjc.1997.32
   NOBLE RL, 1980, CANCER RES, V40, P3550
   Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5
   Pathak S, 1997, BRIT J CANCER, V76, P1134, DOI 10.1038/bjc.1997.524
   PEEHL DM, 1992, CULTURE EPITHELIAL C, P159
   THALMANN GN, 1994, CANCER RES, V54, P2577
   THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9
   WU HC, 1994, INT J CANCER, V57, P406, DOI 10.1002/ijc.2910570319
   Zhau HE, 1997, IN VITRO CELL DEV-AN, V33, P375
   Zhau HYE, 1996, P NATL ACAD SCI USA, V93, P15152, DOI 10.1073/pnas.93.26.15152
NR 20
TC 20
Z9 21
U1 0
U2 4
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PY 1997
SU 28-29
BP 174
EP 181
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA ZL634
UT WOS:000073454800021
PM 9589364
DA 2021-08-04
ER

PT J
AU Allen, DS
AF Allen, DS
TI A multi-sector inventory model
SO JOURNAL OF ECONOMIC BEHAVIOR & ORGANIZATION
LA English
DT Article
DE inventory investment; production; business cycles
ID PRODUCTION SMOOTHING HYPOTHESIS; AGGREGATION; SHOCKS
AB Two competing paradigms for firm-level inventory behavior are production smoothing and (S,s). Empirical evidence that aggregate production varies more than sales, and inventory investment is positively correlated with sales, appears to contradict the buffer-stock/production-smoothing motivation. Work by Blinder and Maccini suggests that an (S,s) model better explains these stylized facts. I simulate a multi-sector model with sequential interaction of heterogeneous agents (representing manufacturing, wholesale and retail agents) who use either smoothing or (S,s) inventory decision rules. The results demonstrate that the stylized facts can be explained by a model of this type.
RP Allen, DS (corresponding author), FED RESERVE BANK,POB 442,ST LOUIS,MO 63166, USA.
CR Blinder A.S., 1991, J ECON SURV, V5, P291, DOI DOI 10.1111/J.1467-6419.1991.TB00138.X
   BLINDER AS, 1991, J ECON PERSPECT, V5, P73, DOI 10.1257/jep.5.1.73
   BLINDER AS, 1990, INVENTORY THEORY CON
   CABALLERO RJ, 1991, ECONOMETRICA, V59, P1659, DOI 10.2307/2938284
   CAPLIN AS, 1985, ECONOMETRICA, V53, P1395, DOI 10.2307/1913214
   CARPENTER R, 1994, BROOKINGS PAPERS EC, V2, P75, DOI DOI 10.2307/2534655
   Christiano L., 1987, CARNEGIE-ROCHESTER C, V26, P63, DOI [10.1016/0167-2231(87)90022-4, DOI 10.1016/0167-2231(87)90022-4]
   COOPER R, 1990, AM ECON REV, V80, P170
   EICHENBAUM M, 1989, AM ECON REV, V79, P853
   FAIR RC, 1989, J MONETARY ECON, V24, P370
   GHALI MA, 1987, AM ECON REV, V77, P464
   Hamilton J.D., 1994, TIME SERIES ANAL
   HAY D, 1991, INVESTMENT INVENTORI
   Holt CC, 1960, PLANNING PRODUCTION
   KAHN JA, 1987, AM ECON REV, V77, P667
   KRANE SD, 1991, J POLITICAL EC, V99, P81
   LAI KS, 1991, INT ECON REV, V32, P391, DOI 10.2307/2526882
   LONG JB, 1987, AM ECON REV, V77, P333
   LOVELL MC, 1993, J ECON BEHAV ORGAN, P147
   LUNDBERG E, 1937, STUDIES THEORY EC EX, pCH9
   Metzler LA, 1941, REV ECON STATISTICS, V23, P113, DOI 10.2307/1927555
   MOSSR PC, 1991, Q J ECON, P1267
   RAMEY VA, 1991, J POLIT ECON, V99, P306, DOI 10.1086/261752
   Scarf H., 1959, OPTIMALITY S S POLIC
NR 24
TC 2
Z9 2
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-2681
J9 J ECON BEHAV ORGAN
JI J. Econ. Behav. Organ.
PD JAN
PY 1997
VL 32
IS 1
BP 55
EP 87
DI 10.1016/S0167-2681(96)00019-4
PG 33
WC Economics
SC Business & Economics
GA XC945
UT WOS:A1997XC94500004
DA 2021-08-04
ER

PT J
AU Saincher, A
   Sitar, DS
   Tenenbein, M
AF Saincher, A
   Sitar, DS
   Tenenbein, M
TI Efficacy of ipecac during the first hour after drug ingestion in human
   volunteers
SO JOURNAL OF TOXICOLOGY-CLINICAL TOXICOLOGY
LA English
DT Article
ID INDUCED EMESIS; ACTIVATED-CHARCOAL; GASTRIC LAVAGE; SIMULATED OVERDOSE;
   ACETAMINOPHEN; SYRUP; PREVENTION; ABSORPTION; ADULTS; PHARMACOKINETICS
AB Objective: To determine the decrease of drug absorption when syrup of ipecac is administered at various times within one hour of drug ingestion. Methods: Ten healthy human volunteers were recruited for a four-limbed randomized crossover study. The three experimental limbs consisted of administration of 30 mt syrup of ipecac, at 5, 30, or 60 minutes after ingestion of 3900 mg acetaminophen as 12 x 325 mg tablets with 250 mt room temperature water. The fourth limb served as control. Blood samples were drawn at 0, 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, and 8.0 hours after analgesic ingestion for serum acetaminophen concentration determination by high-performance liquid chromatography. Repeated measures ANOVA and Tukey's HSD tests were used for group comparisons. Results: The area under the serum concentration vs time curve was (mean +/- SD) 206 +/- 48, 67 +/- 37, 183 +/- 78, and 162 +/- 47 mg/L for control, 5, 30, and 60 minutes, respectively. This corresponds to decreases in bioavailability of 67, 11, and 21%. Only the 5-minunte group differed significantly from control (p < 0.05). Sedation was observed as a significant adverse effect of ipecac administration. Conclusions: Our data do not support benefit from ipecac administration at 30 minutes and beyond. Our data suggest that benefit is lost at some point between 5 and 30 minutes. The sedative effect of ipecac may confound the observation of patients who have ingested sedative hypnotic agents.
C1 UNIV MANITOBA,WINNIPEG,MB,CANADA.
RI Sitar, Daniel/T-8777-2018
OI Sitar, Daniel/0000-0003-4294-7940
CR ALAM SN, 1977, J PEDIATR-US, V90, P130, DOI 10.1016/S0022-3476(77)80787-7
   AMITAI Y, 1987, PEDIATRICS, V80, P364
   AOKI FY, 1992, J CLIN PHARMACOL, V32, P24, DOI 10.1002/j.1552-4604.1992.tb03782.x
   AUERBACH PS, 1986, ANN EMERG MED, V15, P692, DOI 10.1016/S0196-0644(86)80427-9
   BOND GR, 1993, ANN EMERG MED, V22, P1403, DOI 10.1016/S0196-0644(05)81986-9
   CORBY DG, 1968, PEDIATRICS, V42, P361
   CURTIS RA, 1984, ARCH INTERN MED, V144, P48, DOI 10.1001/archinte.144.1.48
   CZAJKA PA, 1985, PEDIATRICS, V75, P1101
   EDWARDS DA, 1986, ANN EMERG MED, V15, P1314, DOI 10.1016/S0196-0644(86)80618-7
   EPPERSON EL, 1984, CLIN PHARM, V3, P627
   FORREST JAH, 1982, CLIN PHARMACOKINET, V7, P93, DOI 10.2165/00003088-198207020-00001
   GIBALDI M, 1982, PHARMACOKINETICS, P33
   LITOVITZ TL, 1986, AM J EMERG MED, V4, P427, DOI 10.1016/0735-6757(86)90220-2
   Litovitz TL, 1996, AM J EMERG MED, V14, P487, DOI 10.1016/S0735-6757(96)90160-6
   MCNAMARA RM, 1989, ANN EMERG MED, V18, P934, DOI 10.1016/S0196-0644(89)80456-1
   MICELI JN, 1979, CLIN CHEM, V25, P1002
   MILLER RP, 1976, CLIN PHARMACOL THER, V19, P284
   NEUVONEN PJ, 1984, J TOXICOL-CLIN TOXIC, V22, P103, DOI 10.3109/15563658408992547
   NEUVONEN PJ, 1983, EUR J CLIN PHARMACOL, V24, P557, DOI 10.1007/BF00609903
   ROBERTSON WO, 1962, AM J DIS CHILD, V103, P136, DOI 10.1001/archpedi.1962.02080020142005
   SAETTA JP, 1991, J ROY SOC MED, V84, P274
   TANDBERG D, 1986, AM J EMERG MED, V4, P205, DOI 10.1016/0735-6757(86)90066-5
   TENENBEIN M, 1987, ANN EMERG MED, V16, P838, DOI 10.1016/S0196-0644(87)80518-8
   TENENBEIN M, 1997, PEDIAT EMERGENCY MED, P527
   VASQUEZ TE, 1988, CLIN NUCL MED, V13, P638, DOI 10.1097/00003072-198809000-00004
   WILKINSON L, 1986, SYSTAT SYSTEM STAT
   YOUNG WF, 1993, ANN EMERG MED, V22, P1423, DOI 10.1016/S0196-0644(05)81990-0
NR 27
TC 22
Z9 22
U1 0
U2 1
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016
SN 0731-3810
J9 J TOXICOL-CLIN TOXIC
JI J. Toxicol.-Clin. Toxicol.
PY 1997
VL 35
IS 6
BP 609
EP 615
DI 10.3109/15563659709001241
PG 7
WC Toxicology
SC Toxicology
GA YE756
UT WOS:A1997YE75600006
PM 9365428
DA 2021-08-04
ER

PT B
AU Nguyen, TS
   Selvadurai, APS
AF Nguyen, TS
   Selvadurai, APS
BE Pietruszczak, S
   Pande, GN
TI Coupled thermal-hydraulic-mechanical processes in a cylindrical cavity
   in rock
SO NUMERICAL MODELS IN GEOMECHANICS - NUMOG VI
LA English
DT Proceedings Paper
CT 6th International Symposium on Numerical Models in Geomechanics (NUMOG
   VI)
CY JUL 02-04, 1997
CL MONTREAL, CANADA
AB The concept of geological disposal of heat emitting nuclear fuel wastes being considered by many countries consists of burying the wastes in a geological formations at depths ranging from hundreds to thousands of metres. The only credible agent which could transport contaminants from the stored wastes to the ground surface is the groundwater. It is generally recognized that the groundwater regime might be significantly influenced by thermal and mechanical processes occurring in the host geological medium. In order to further our understanding of the coupled thermal-hydraulic-mechanical processes occuring in both intact and jointed rock, a research program consisting of computational and experimental modelling is being conducted by the Atomic Energy Control Board and McGill University. In this paper we present the results of experimental and computational simulations of pressure pulse and heating tests performed with cylindrical samples of intact saturated granite. The samples contain a central water-filled cavity, where the water pressure transients are continually monitored during a test. The time-varying water pressure in the cavity bears the signature of the coupled T-H-M behaviour of the rock.
RP Nguyen, TS (corresponding author), ATOM ENERGY CONTROL BOARD,OTTAWA,ON,CANADA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU A A BALKEMA
PI ROTTERDAM
PA PO BOX 1675, 3000 BR ROTTERDAM, NETHERLANDS
BN 90-5410-886-X
PY 1997
BP 315
EP 324
PG 10
WC Engineering, Civil; Mathematics, Applied; Mechanics
SC Engineering; Mathematics; Mechanics
GA BJ34L
UT WOS:A1997BJ34L00051
DA 2021-08-04
ER

PT B
AU Iba, H
   Nozoe, T
   Ueda, K
AF Iba, H
   Nozoe, T
   Ueda, K
GP IEEE
TI Evolving communicating agents based on genetic programming
SO PROCEEDINGS OF 1997 IEEE INTERNATIONAL CONFERENCE ON EVOLUTIONARY
   COMPUTATION (ICEC '97)
LA English
DT Proceedings Paper
CT 1997 IEEE International Conference on Evolutionary Computation (ICEC 97)
CY APR 13-16, 1997
CL INDIANAPOLIS, IN
SP IEEE, IEEE Neural Network Council, Evolut Programming Soc
AB This paper presents the emergence of the cooperative behavior for the communicating agents by means of Genetic Programming (GP). Our experimental domain is the pursuit game, a multi-agent test bed. The world consists of simulated robot agents and a simulated environment which is both dynamic and unpredictable. For the purpose of evolving the cooperative behavior, we use the co-revolutionary breeding strategy. We confirm the emergence of cooperation via communication. The effectiveness of GP-based multi-agent learning is discussed with comparative experiments.
RP Iba, H (corresponding author), ELECTROTECH LAB,MACHINE INFERENCE SECT,1-4 UMEZONO,TSUKUBA,IBARAKI 305,JAPAN.
NR 0
TC 3
Z9 3
U1 0
U2 0
PU I E E E
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017
BN 0-7803-3949-5
PY 1997
BP 297
EP 302
DI 10.1109/ICEC.1997.592321
PG 6
WC Computer Science, Artificial Intelligence
SC Computer Science
GA BH58Y
UT WOS:A1997BH58Y00054
DA 2021-08-04
ER

PT B
AU Calenbuhr, V
   Varela, FJ
   Bersini, H
AF Calenbuhr, V
   Varela, FJ
   Bersini, H
BE PerezMunuzuri, V
   PerezVillar, V
   Chua, LO
   Markus, M
TI Natural tolerance as a function of network connectivity
SO PROCEEDINGS OF THE WORKSHOP ON DISCRETELY-COUPLED DYNAMICAL SYSTEMS
SE WORLD SCIENTIFIC SERIES ON NONLINEAR SCIENCE, SERIES B
LA English
DT Proceedings Paper
CT Workshop on Discretely-Coupled Dynamical Systems
CY JUN 24-28, 1995
CL UNIV SANTIAGO COMPOSTELA, FAC PHYS, SANTIAGO COMPOSTE, SPAIN
SP Univ Santiago Compostela, Grp Nonlinear Phys
HO UNIV SANTIAGO COMPOSTELA, FAC PHYS
ID IMMUNE NETWORK; IDIOTYPIC NETWORK; STATIONARY STATES; SHAPE-SPACE;
   DYNAMICS; OSCILLATIONS; BEHAVIOR; SYSTEM; CHAOS; MODEL
AB This article investigates the following basic question: in the relatively stable molecular environment of a vertebrate body, can a dynamic idiotypic immune network develop a natural tolerance to endogenous components? Our approach is based on stability analysis and computer simulation using a model that takes into account the dynamics of two agents of the immune system, namely, B-lymphocytes and antibodies. We investigate the behavior of simple immune networks in interaction with an Ag whose concentration is being held constant as a function of the connectivity matrix of the network. The latter is characterized by the total number of clones, N, and the number of clones, C, with which each clone interacts. The idiotypic network models typically become unstable in the presence of this type of Ag. We show that idiotypic networks that can be found in particular connected regions of NC-space show tolerance towards auto-Ag without the need for ad hoc mechanisms that prevent an immune response. These tolerant network structures provide dynamical regimes in which the clone which interacts with the auto-Ag is suppressed instead of being excited such that an unbounded immune response does not occur. Possible implications for the future treatment of auto-immune disease such as IvIg-treatment are discussed in the light of these results. Moreover, we propose an experimental approach to verify the results of the present theoretical study.
C1 Univ Leipzig, Inst Med Informat Stat & Epidemiol, D-04103 Leipzig, Germany.
RP Calenbuhr, V (corresponding author), Univ Leipzig, Inst Med Informat Stat & Epidemiol, Liebigstr 27, D-04103 Leipzig, Germany.
CR Atiya A., 1989, International Journal of Neural Systems, V1, P103, DOI 10.1142/S0129065789000025
   BERSINI H, 1995, CHAOS SOLITON FRACT, V5, P1533, DOI 10.1016/0960-0779(94)00176-Q
   BERSINI H, 1992, ARTIFICIAL LIFE, V3
   Calenbuhr V, 1995, J THEOR BIOL, V177, P199, DOI 10.1006/jtbi.1995.0239
   CALENBUHR V, 1993, FRUSTRATION INDUCED
   CALENBUHR V, 1993, P 1 COP S COMP SIM B
   DEBOER R, 1990, J THEOR BIOL, V149, P381
   DEBOER RJ, 1993, B MATH BIOL, V55, P781, DOI 10.1016/S0092-8240(05)80189-2
   DEBOER RJ, 1989, B MATH BIOL, V51, P381, DOI 10.1016/S0092-8240(89)80083-7
   DEBOER RJ, 1993, B MATH BIOL, V55, P745, DOI 10.1016/S0092-8240(05)80188-0
   DETOURS V, 1994, J THEOR BIOL, V170, P401, DOI 10.1006/jtbi.1994.1201
   DETOURS V, 1995, UNPUB CLUSTERING PHE
   DIETRICH G, 1993, EUR J IMMUNOL, V23, P2945, DOI 10.1002/eji.1830231133
   KAVERI SV, 1991, CLIN EXP IMMUNOL, V86, P192
   MATTHEWS PC, 1991, PHYSICA D, V52, P293, DOI 10.1016/0167-2789(91)90129-W
   NEUMANN AU, 1992, B MATH BIOL, V54, P699, DOI 10.1007/BF02459926
   NEUMANN AU, 1992, B MATH BIOL, V54, P21, DOI 10.1007/BF02458618
   STEWART J, 1989, IMMUNOL REV, V110, P37, DOI 10.1111/j.1600-065X.1989.tb00026.x
   STEWART J, 1991, J THEOR BIOL, V153, P477, DOI 10.1016/S0022-5193(05)80152-3
   STEWART J, 1990, J THEOR BIOL, V144, P103, DOI 10.1016/S0022-5193(05)80302-9
   TAUBER F, 1994, IMMUNE SELF THEORY M
   TOULOUSE G, 1977, COMMUN PHYS, V2, P115
   TSANG KY, 1991, PHYSICA D, V48, P102, DOI 10.1016/0167-2789(91)90054-D
   Varela F. J., 1988, THEORETICAL IMMUNOLO, V2, P359
   VARELA FJ, 1991, IMMUNOL TODAY, V12, P159, DOI 10.1016/0167-5699(91)90081-4
   VARELA FJ, 1990, J THEOR BIOL, V144, P93, DOI 10.1016/S0022-5193(05)80301-7
   VARELA FJ, 1993, THINKING BIOL
   WEISBUCH G, 1993, J THEOR BIOL, V163, P237, DOI 10.1006/jtbi.1993.1119
NR 28
TC 0
Z9 0
U1 0
U2 0
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA PO BOX 128 FARRER RD, SINGAPORE 9128, SINGAPORE
BN 981-02-2912-7
J9 WSS NONLIN SCI SER B
PY 1997
VL 9
BP 87
EP 98
PG 12
WC Biophysics; Mathematics, Applied
SC Biophysics; Mathematics
GA BM49G
UT WOS:000078896300008
DA 2021-08-04
ER

PT S
AU Perram, JW
   Demazeau, Y
AF Perram, JW
   Demazeau, Y
BE Grahne, G
TI A multi-agent architecture for distributed constrained optimization and
   control
SO SIXTH SCANDINAVIAN CONFERENCE ON ARTIFICIAL INTELLIGENCE
SE FRONTIERS IN ARTIFICIAL INTELLIGENCE AND APPLICATIONS
LA English
DT Proceedings Paper
CT 6th Scandinavian Conference on Artificial Intelligence (SCAI 97)
CY AUG 18-20, 1997
CL UNIV HELSINKI, HELSINKI, FINLAND
SP Finnish Artificial Intelligence Soc, Nord Inst Adv Study, Acad Finland, IBM, Omron
HO UNIV HELSINKI
AB This article is meant as a contribution to the debate about the meaning and the prediction of emergent behaviour. By means of a number of examples, we show that reactive multi-agent systems have much in common with the statistical mechanical systems studied by physicists.
   The PHAMUS (PHysics-based Approaches to MUltiple computing Systems) model of an agent is an entity which possesses a number of internal states about which it can communicate with other agents. PHAMUS agents pass through a sequence of time frames, at each one being able to update their internal states as a result of interaction with other agents or with the external environment.
   By showing that societies of such agents are generalizations of statistical mechanical systems, we demonstrate the extreme difficulty of being able to reason about and to prove the collective behaviour of multi-agent systems from the only knowledge of the agents and their interactions. Simulation must be the main tool for assessing whether a particular agent design will lead to a multi-agent system capable of solving a particular application efficiently.
   This rather negative result is balanced by our promotion in this paper of a revisited methodology far studying reactive multi-agent systems that is close to the one used by physicists in statistical mechanics. Lu particular, and given our previous experience, this analogy suggests to us that the problem of simulating the behaviour of large collections of agents can be efficiently executed on multi-processor computing systems.
RP Perram, JW (corresponding author), ODENSE UNIV,MAERSK MCKINNEY MOLLER INST PROD TECHNOL,LCAM,FORSKERPK 10,DK-5230 ODENSE M,DENMARK.
RI Demazeau, Yves R/M-7113-2018
OI Demazeau, Yves R/0000-0003-4059-9284
NR 0
TC 1
Z9 1
U1 0
U2 0
PU I O S PRESS
PI AMSTERDAM
PA VAN DIEMENSTRAAT 94, 1013 CN AMSTERDAM, NETHERLANDS
SN 0922-6389
BN 90-5199-354-4
J9 FR ART INT
PY 1997
VL 40
BP 162
EP 175
PG 14
WC Computer Science, Artificial Intelligence
SC Computer Science
GA BJ73Z
UT WOS:A1997BJ73Z00019
DA 2021-08-04
ER

PT S
AU Ballet, P
   Tisseau, J
   Harrouet, F
AF Ballet, P
   Tisseau, J
   Harrouet, F
GP IEEE
TI A multiagent system to model an human humoral response
SO SMC '97 CONFERENCE PROCEEDINGS - 1997 IEEE INTERNATIONAL CONFERENCE ON
   SYSTEMS, MAN, AND CYBERNETICS, VOLS 1-5: CONFERENCE THEME: COMPUTATIONAL
   CYBERNETICS AND SIMULATION
SE IEEE INTERNATIONAL CONFERENCE ON SYSTEMS, MAN, AND CYBERNATICS,
   CONFERENCE PROCEEDINGS
LA English
DT Proceedings Paper
CT 1997 IEEE International Conference on Systems, Man, and Cybernetics -
   Computational Cybernetics and Simulation (SMC 97)
CY OCT 12-15, 1997
CL ORLANDO, FL
SP IEEE Syst Man & Cybernet Soc
AB The immune system mechanisms are very complex and the number of parameters is extremely important. Moreover, the interactions beetween the different cells during an immune response induce chaotics and non linear phenomena. Our approach consists in using the cooperative models, established by the immunologists, to build a multi-agent model. Like this, we avoid the problem of non-determinism by only encoding the basic behaviors of the agents, and the global chaotic phenomena are induced by the interactions between the agents. The advantages, face to the mathematical models, are that each agent could be viewed, modified, removed from the model or added to the model very easily. That is not the case in mathematics where a modification of an assumption generaly involves the rewriting of the model. This approach is possible because the behaviors of several immune system cells are known in their principal lines and some qualitative models of immune cell cooperations have been developped by immunologists. These models have already demonstrated their validity localy in time and in space, i.e they have not a global approach. With the multi-agent system, we can, thanks to the simulation, analyse the global consequences from the local behaviors and observe a, qualitative striking resemblance to statistical results coming from a real experimentation. We have chosen to simulate a human secondary humoral response with a multi-agent system to study the cinetic of the antibody proliferation with severals type of antigenic substances.
RP Ballet, P (corresponding author), ECOLE NATL INGENIEURS BREST,LAB INFORMAT IND,TECHNOPOLE BREST IROISE,SITE POINTE DIABLE,CP 15,F-29608 BREST,FRANCE.
NR 0
TC 5
Z9 5
U1 0
U2 0
PU I E E E
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017
SN 1062-922X
BN 0-7803-4054-X
J9 IEEE SYS MAN CYBERN
PY 1997
BP 357
EP 362
PG 6
WC Computer Science, Cybernetics; Computer Science, Interdisciplinary
   Applications
SC Computer Science
GA BJ80Y
UT WOS:A1997BJ80Y00063
DA 2021-08-04
ER

PT J
AU Kreuzer, J
   Denger, S
   Jahn, L
   Bader, J
   Ritter, K
   vonHodenberg, E
   Kubler, W
AF Kreuzer, J
   Denger, S
   Jahn, L
   Bader, J
   Ritter, K
   vonHodenberg, E
   Kubler, W
TI LDL stimulates chemotaxis of human monocytes through a
   cyclooxygenase-dependent pathway
SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
LA English
DT Article
DE chemotaxis; U937 cells; LDL; arachidonic acid; cyclooxygenase
ID LOW-DENSITY-LIPOPROTEIN; CELL-LINE U937; PLATELET-ACTIVATING-FACTOR;
   ARACHIDONIC-ACID; PHORBOL ESTERS; GROWTH-FACTOR; CHOLESTEROL; RELEASE;
   DIFFERENTIATION; QUANTITATION
AB Monocyte migration into the vessel wall is an early step in atherogenesis. Even though a number of chemotactic factors have been identified, the regulation of the chemotactic response is not clearly understood. As the release of arachidonic acid has been implicated in monocyte chemotaxis, we studied the influence of LDL, which can supply this fatty acid to cells, on the chemotactic mobility of monocytes. Migration of human monocytic U937 cells was abolished by a 30-hour incubation in medium containing lipoprotein-depleted 10% fetal calf serum. Thereafter, human VLDL, LDL, acetyl LDL, methyl LDL, HDL, free cholesterol, linoleic acid, oleic acid, or arachidonic acid was added. At the end of varying incubation periods (0.5 to 8 hours), chemotaxis, viability, and cellular cholesterol content were measured. In the same experimental setting we also studied the effects of the pharmacological agents chloroquine, indomethacin, and acetylsalicylic acid on LDL-mediated chemotaxis. Chemotaxis was restored by LDL in a dose- and time-dependent manner starting at concentrations as low as 5 mu g/mL and at incubations;as brief as 30 minutes. The other lipoproteins tested (VLDL, HDL, acetyl LDL, and methyl LDL) as well as free cholesterol had no comparable effect on chemotaxis. Viability and total cholesterol content did not differ among the groups. Simultaneous incubation of cells with chloroquine, indomethacin, and acetylsalicylic acid reduced restitution of chemotaxis by LDL by 71%, 82%, and 68%, respectively. In contrast, the agents had only slight inhibitory effects on the chemotactic mobility of serum-fed control cells. Incubation with linoleic acid showed a 60% restoration of chemotaxis, whereas arachidonic acid stimulated chemotaxis by 140% compared with the positive control. Preincubation of LDL with the monoclonal antibody MB47 directed against LDL resulted in a significantly reduced migratory response. The data suggest a novel cyclooxygenase-dependent regulatory mechanism of chemotaxis by LDL.
RP Kreuzer, J (corresponding author), UNIV HEIDELBERG,BERGHEIMER STR 58,D-69115 HEIDELBERG,GERMANY.
CR BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178
   BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311
   CATERINA MJ, 1991, FASEB J, V5, P3078
   CHAIT A, 1988, BIOCHIM BIOPHYS ACTA, V960, P183, DOI 10.1016/0005-2760(88)90063-X
   COBB MA, 1983, J RETICULOENDOTH SOC, V33, P197
   CORNELL RB, 1980, J CELL BIOL, V86, P820, DOI 10.1083/jcb.86.3.820
   DEPACE DM, 1987, ANAT REC, V219, P135, DOI 10.1002/ar.1092190205
   ESFAHANI M, 1986, BIOCHIM BIOPHYS ACTA, V889, P287, DOI 10.1016/0167-4889(86)90191-6
   ESFAHANI M, 1984, J CELL BIOCHEM, V25, P87, DOI 10.1002/jcb.240250204
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   FROSTEGARD J, 1990, P NATL ACAD SCI USA, V87, P904, DOI 10.1073/pnas.87.3.904
   HABENICHT AJR, 1990, NATURE, V345, P634, DOI 10.1038/345634a0
   HABERLAND ME, 1992, J BIOL CHEM, V267, P4143
   HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407
   HARVATH L, 1980, J IMMUNOL METHODS, V37, P39, DOI 10.1016/0022-1759(80)90179-9
   HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182
   Havel RJ, 1989, METABOLIC BASIS INHE, P1129
   HIDAKA Y, 1992, ATHEROSCLEROSIS, V95, P87, DOI 10.1016/0021-9150(92)90179-K
   HRBOTICKY N, 1994, J CLIN INVEST, V93, P195, DOI 10.1172/JCI116945
   KELLEY JL, 1988, AM J PATHOL, V130, P223
   KREUZER J, 1991, ATHEROSCLEROSIS, V90, P203, DOI 10.1016/0021-9150(91)90116-K
   LEFKOWITH JB, 1992, J IMMUNOL, V149, P1729
   LOCATI M, 1994, J BIOL CHEM, V269, P4746
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MADDEN MC, 1992, J LEUKOCYTE BIOL, V51, P118
   MCDONALDGIBSON RG, 1987, PROSTAGLANDINS RELAT, P259
   NOLFO R, 1990, PROSTAGLANDINS, V39, P157, DOI 10.1016/0090-6980(90)90072-4
   NORTHOFF H, 1987, REV INFECT DIS, V9, P599
   PIKE MC, 1980, J IMMUNOL, V124, P1963
   ROLLINS BJ, 1991, CANC CELLS, V3, P1517
   ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0
   ROUIS M, 1984, J CELL PHYSIOL, V121, P540, DOI 10.1002/jcp.1041210313
   RZIGALINSKI BA, 1994, BBA-MOL CELL RES, V1223, P219, DOI 10.1016/0167-4889(94)90229-1
   SALBACH PB, 1992, P NATL ACAD SCI USA, V89, P2439, DOI 10.1073/pnas.89.6.2439
   SCHMITZ G, 1984, J CHROMATOGR, V307, P65, DOI 10.1016/S0378-4347(00)84073-6
   SHETH B, 1988, IMMUNOLOGY, V63, P483
   SOZZANI S, 1994, BIOCHEM BIOPH RES CO, V199, P761, DOI 10.1006/bbrc.1994.1294
   TOKORO A, 1988, MICROBIOL IMMUNOL, V32, P387, DOI 10.1111/j.1348-0421.1988.tb01398.x
   VANLENTEN BJ, 1990, J LIPID RES, V31, P1455
   WEISGRABER KH, 1978, J BIOL CHEM, V253, P9053
NR 40
TC 28
Z9 34
U1 0
U2 1
PU AMER HEART ASSOC
PI DALLAS
PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596
SN 1079-5642
J9 ARTERIOSCL THROM VAS
JI Arterioscler. Thromb. Vasc. Biol.
PD DEC
PY 1996
VL 16
IS 12
BP 1481
EP 1487
DI 10.1161/01.ATV.16.12.1481
PG 7
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA WA769
UT WOS:A1996WA76900010
PM 8977452
OA Bronze
DA 2021-08-04
ER

PT J
AU Sundaram, R
   Venkataranganna, MV
   Gopumadhavan, S
   Mitra, SK
AF Sundaram, R
   Venkataranganna, MV
   Gopumadhavan, S
   Mitra, SK
TI Interaction of a herbomineral preparation D-400, with oral hypoglycaemic
   drugs
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE D-400; tolbutamide; glibenclamide; drug interaction
ID PERFORMANCE LIQUID-CHROMATOGRAPHY; PLASMA
AB D-400, a herbomineral preparation has proven antidiabetic activity in experimental models as well as in clinical trials. The possibility of concomitant use of this drug with sulphonylureas was explored in animal models. D-400 has been investigated for its interaction with oral hypoglycaemic agents namely, tolbutamide and glibenclamide in alloxan-induced diabetic rabbits. Administration of D-400 at a dose of 1 g/kg for 15 days significantly elevated plasma tolbutamide and glibenclamide concentrations with simultaneous reduction of blood glucose. Plasma tolbutamide and glibenclamide concentrations were significantly lowered after withdrawal of D-400 treatment. Elevation of plasma concentration of tolbutamide was observed only for the first 4 h after which it declined towards normal levels and no significant difference between D-400 treated and control group was observed at the end of 8 h. Significant elevation of plasma glibenclamide levels was observed at 2, 4 and 8 h with D-400 treatment. Incubation, of D-400 with tolbutamide in plasma resulted in a significant increase in free tolbutamide levels.
C1 HIMALAYA DRUG CO, CTR RES & DEV, BANGALORE 562123, KARNATAKA, INDIA.
RI Marikunte, Venkataranganna V/K-5709-2013; Sundaram, Raman/L-5294-2019
OI Marikunte, Venkataranganna V/0000-0002-0188-7243; 
CR Anturlikar S. D., 1995, Indian Journal of Physiology and Pharmacology, V39, P95
   BALODIMOS MC, 1966, METABOLIS, V15, P957, DOI 10.1016/0026-0495(66)90044-8
   BERHHARD H, 1965, DIABETES, V1, P59
   CERVANTE.A, 1965, J AMER MED ASSOC, V193, P759, DOI 10.1001/jama.1965.03090100005001
   Dubey G. P., 1994, Indian Journal of Pharmacology, V26, P225
   GROOP LC, 1986, DIABETES CARE, V9, P129, DOI 10.2337/diacare.9.2.129
   KEAL J, 1986, J CHROMATOGR, V378, P237, DOI 10.1016/S0378-4347(00)80719-7
   MILLER AK, 1978, J PHARM SCI, V67, P1192, DOI 10.1002/jps.2600670852
   Mitra S. K., 1995, Indian Journal of Experimental Biology, V33, P798
   Mitra SK, 1996, PHYTOTHER RES, V10, P433, DOI 10.1002/(SICI)1099-1573(199608)10:5&lt;433::AID-PTR864&gt;3.0.CO;2-D
   MULLER R, 1969, HORM METABOL RES   S, V1, P88
   NADKARNI AK, 1992, KM NADKARNIS INDIAN, V1
   NADKARNI AK, 1992, KM NADKARNIS INDIAN, V2
   POTTER H, 1983, J CHROMATOGR, V273, P217, DOI 10.1016/S0378-4347(00)80942-1
   POWELL T, 1966, DIABETES, V15, P269, DOI 10.2337/diab.15.4.269
   TURNER RC, 1989, NONINSULIN DEPENDENT, P52
NR 16
TC 6
Z9 6
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378-8741
EI 1872-7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD DEC
PY 1996
VL 55
IS 1
BP 55
EP 61
DI 10.1016/S0378-8741(96)01474-2
PG 7
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA WE673
UT WOS:A1996WE67300008
PM 9121168
DA 2021-08-04
ER

PT J
AU Kuzel, RJ
AF Kuzel, RJ
TI Treating comorbid depression and anxiety
SO JOURNAL OF FAMILY PRACTICE
LA English
DT Article
DE depression; anxiety; drug therapy; comorbidity
ID SEROTONIN REUPTAKE INHIBITORS; 5-YEAR FOLLOW-UP; PANIC DISORDER;
   TRICYCLIC ANTIDEPRESSANTS; ATYPICAL DEPRESSION; PRIMARY-CARE; MAJOR
   DEPRESSION; MIXED ANXIETY; SECONDARY DEPRESSION; ATTEMPTED-SUICIDE
AB Depression and anxiety disorders are distinct illnesses that often coexist. Patients suffering from both disorders have more psychological, physical, and social impairment than do patients suffering from either illness alone. Mixed anxiety-depression is gaining recognition as a separate diagnosis and has been included in the International Classification of Diseases, 10th edition, and in the appendix of the Diagnostic and Statistical Manual of Mental Disorders, 4th edition. Current treatment recommendations for comorbid depression and anxiety are based on clinical experience with the treatment of anxiety and depressive disorders when they occur independently. Tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), and selective serotonin reuptake inhibitors (SSRIs) have been shown to be effective for simultaneously occurring anxiety and depression, but the side-effect profiles of the MAOIs and TCAs limit their use for this condition. Benzodiazepines are useful for the acute treatment of anxiety symptoms and buspirone for chronic generalized anxiety, but neither agent is effective for the long-term treatment of depression. The recently available antidepressants nefazodone and venlafaxine may also be useful for this patient population. When possible, psychotherapy should be used in conjunction with pharmacotherapy to improve treatment outcomes.
RP Kuzel, RJ (corresponding author), DAKOTA CLIN W ACRES,I-29 & 13TH AVE S,FARGO,ND 58103, USA.
CR *AM PSYCH ASS, 1994, DSM 4 CRIT SETS AX P, P703
   AMSTERDAM JD, 1994, J CLIN PSYCHIAT, V55, P394
   ANDREWS JM, 1994, AM J MED S6A, V67, P24
   ARANOW RB, 1989, AM J PSYCHIAT, V146, P911
   ARONSON TA, 1987, AM J PSYCHIAT, V144, P1014
   BARRETT JE, 1988, ARCH GEN PSYCHIAT, V45, P1100
   BARROS J, 1993, AM J PSYCHIAT, V150, P1751
   BAUGHMAN OL, 1994, J FAM PRACTICE, V39, P373
   BEASLEY CM, 1992, J CLIN PSYCHOPHARM, V12, P328
   BECK AT, 1988, PANIC PSYCHOL PERSPE, P23
   BELL IR, 1988, J CLIN PSYCHOPHARM, V8, P447, DOI 10.1097/00004714-198812000-00025
   BLACK DW, 1993, ARCH GEN PSYCHIAT, V50, P44
   BLAZER D, 1988, ARCH GEN PSYCHIAT, V45, P1078
   BOYER WF, 1991, SELECTIVE SEROTONIN, P119
   Cesura A M, 1992, Prog Drug Res, V38, P171
   CLANCY J, 1978, J NERV MENT DIS, V166, P846, DOI 10.1097/00005053-197812000-00003
   CLAYTON PJ, 1987, ANXIOUS DEPRESSION A, P1
   CREWE HK, 1992, BRIT J CLIN PHARMACO, V34, P262, DOI 10.1111/j.1365-2125.1992.tb04134.x
   CULLBERG J, 1988, ACTA PSYCHIAT SCAND, V77, P598, DOI 10.1111/j.1600-0447.1988.tb05173.x
   DEVANE CL, 1994, AM J MED, V97, pS13, DOI 10.1016/0002-9343(94)90359-X
   DEWILDE J, 1993, ACTA PSYCHIAT SCAND, V87, P141
   EISON MS, 1989, FAM PRACT RECERT, V11, P1
   FAWCETT J, 1988, J CLIN PSYCHIAT, V49, P7
   FAWCETT J, 1983, J CLIN PSYCHIAT, V44, P8
   FAWCETT J, 1990, AM J PSYCHIAT, V147, P1189
   FAWCETT J, 1990, J CLIN PSYCHIAT, V51, P40
   FAWCETT J, 1995, J CLIN PSYCHIAT, V56, P37
   FINLEY PR, 1994, ANN PHARMACOTHER, V28, P1359, DOI 10.1177/106002809402801207
   FLEISCHHACKER WW, 1991, BIOL PSYCHIAT, V30, P531
   GITLIN MJ, 1994, J CLIN PSYCHIAT, V55, P406
   GOODNICK PJ, 1989, AM J PSYCHIAT, V146, P552
   GRIMSLEY SR, 1992, CLIN PHARMACY, V11, P930
   GRUNHAUS L, 1988, CLIN NEUROPHARMACOL, V11, P454, DOI 10.1097/00002826-198810000-00006
   HILLER W, IN PRESS ICDL INT DI
   HONIG PK, 1993, JAMA-J AM MED ASSOC, V269, P1513, DOI 10.1001/jama.269.12.1513
   HSU JH, 1995, INT J PSYCHIAT MED, V25, P191, DOI 10.2190/1DHU-Y7L7-9GKG-V7WV
   JOHNSON J, 1990, ARCH GEN PSYCHIAT, V47, P805
   KATON W, 1992, GEN HOSP PSYCHIAT, V14, P237, DOI 10.1016/0163-8343(92)90094-Q
   KATON W, 1991, J ABNORM PSYCHOL, V100, P337, DOI 10.1037/0021-843X.100.3.337
   KELLER MB, 1995, J CLIN PSYCHIAT, V56, P22
   KOSTEN TR, 1991, J NERV MENT DIS, V179, P366, DOI 10.1097/00005053-199106000-00011
   LESSER IM, 1988, ARCH GEN PSYCHIAT, V45, P437
   LIEBOWITZ MR, 1992, ARCH GEN PSYCHIAT, V49, P290
   LIEBOWITZ MR, 1988, ARCH GEN PSYCHIAT, V45, P129
   LIEBOWITZ MR, 1984, ARCH GEN PSYCHIAT, V41, P669
   LITOVITZ TL, 1994, AM J EMERG MED, V12, P546, DOI 10.1016/0735-6757(94)90276-3
   LYDIARD RB, 1987, AM J PSYCHIAT, V144, P664
   LYDIARD RB, 1993, AM J PSYCHIAT, V150, P1125
   MCELROY SL, 1995, J CLIN PSYCHIAT, V56, P49
   MCGLYNN TJ, 1989, DIAGNOSIS TREATMENT, P8
   MICHELS R, 1993, NEW ENGL J MED, V329, P628, DOI 10.1056/NEJM199308263290908
   MURPHY JM, 1986, PSYCHOL MED, V16, P117, DOI 10.1017/S0033291700057809
   NEMEROFF CB, 1994, J CLIN PSYCHIAT, V55, P3
   NIELSEN B, 1990, ACTA PSYCHIAT SCAND, V81, P250, DOI 10.1111/j.1600-0447.1990.tb06490.x
   POHL R, 1988, J CLIN PSYCHIAT, V49, P100
   PRESKORN SH, 1993, J CLIN PSYCHIAT, V54, P24
   PRESKORN SH, 1990, AM J PSYCHIAT, V147, P532
   QUITKIN FM, 1990, ARCH GEN PSYCHIAT, V47, P935
   RICKELS K, 1991, J CLIN PSYCHIAT, V52, P34
   ROTHSCHILD AJ, 1991, J CLIN PSYCHIAT, V52, P491
   SCHATZBERG AF, 1995, J CLIN PSYCHIAT, V13, P2
   SCHWEIZER EE, 1986, PSYCHOPHARMACOL BULL, V22, P183
   *SCOTT LEV ASS, 1994, PHYS DRUG DIAGN AUD
   SHEAR MK, 1995, B MENNINGER CLIN, V59, pA73
   SHEEHAN D, 1992, PSYCHOPHARMACOL BULL, V28, P139
   *SOLV PHARM, 1995, LUV PRESCR INF
   SPROULE BA, 1995, CLIN PHARMACOL THER, V57, P151
   STAHL SM, 1993, J CLIN PSYCHIAT, V54, P33
   SUOKAS J, 1991, ACTA PSYCHIAT SCAND, V84, P545, DOI 10.1111/j.1600-0447.1991.tb03191.x
   TOLLEFSON GD, 1994, J CLIN PSYCHIAT, V55, P50
   VANVALKENBURG C, 1984, J AFFECT DISORDERS, V6, P67, DOI 10.1016/0165-0327(84)90009-0
   VAUGHAN DA, 1988, AM J PSYCHIAT, V145, P1478
   ZISOOK S, 1985, J CLIN PSYCHOPHARM, V5, P131
   ZUBENKO GS, 1987, J CLIN PSYCHOPHARM, V7, P254
   ZUSSMAN BD, 1995, BR J CLIN PHARM, V39, P550
NR 75
TC 21
Z9 21
U1 0
U2 5
PU APPLETON & LANGE
PI E NORWALK
PA 25 VAN ZANT ST, E NORWALK, CT 06855
SN 0094-3509
J9 J FAM PRACTICE
JI J. Fam. Pract.
PD DEC
PY 1996
VL 43
IS 6
SU S
BP S45
EP S53
PG 9
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA VZ587
UT WOS:A1996VZ58700010
PM 8969712
DA 2021-08-04
ER

PT J
AU Schmitt, N
   Pulakos, ED
   Nason, E
   Whitney, DJ
AF Schmitt, N
   Pulakos, ED
   Nason, E
   Whitney, DJ
TI Likability and similarity as potential sources of predictor-related
   criterion bias in validation research
SO ORGANIZATIONAL BEHAVIOR AND HUMAN DECISION PROCESSES
LA English
DT Article
ID MANAGER-SUBORDINATE DYADS; PERFORMANCE RATINGS; WORK; VALIDITY; BEHAVIOR
AB Previous research on the effects of bias in criterion-related validation research has typically involved the use of statistical corrections for halo, leniency, and/or central tendency. We present arguments that likability and similarity of raters to ratees may constitute a form of predictor-related criterion bias. One cannot investigate this form of bias without clear understanding of method, predictor, and criterion constructs and careful direct measurement of each. Measurement and theorizing of method constructs is rarely, if ever, undertaken in criterion-related validation work. The results of a criterion-related validation of the use of quantitative and verbal ability and interview and role-play simulations to predict the performance of 372 federal investigative agents are reported. Using the all-Y LISREL model (Williams & Anderson, 1994), we found that likability and similarity factors were related to interview and role play measures. However, none of these potential ''biases'' affected both predictor and criterion constructs, hence there was no effect on the estimates of the relationships between the predictors and criteria. Limitations with respect to the generalizability of these results to criterion-related research in which performance data are not as carefully collected as well as advantages and disadvantages of more traditional regression and correlational analyses are discussed. (C) 1996 Academic Press.
C1 PERSONNEL DECIS RES INST, MINNEAPOLIS, MN USA.
RP Schmitt, N (corresponding author), MICHIGAN STATE UNIV, DEPT PSYCHOL, PSYCHOL RES BLDG, E LANSING, MI 48824 USA.
CR AUSTIN JT, 1992, J APPL PSYCHOL, V77, P836, DOI 10.1037/0021-9010.77.6.836
   BARRICK MR, 1991, PERS PSYCHOL, V44, P1, DOI 10.1111/j.1744-6570.1991.tb00688.x
   BENTLER PM, 1980, PSYCHOL BULL, V88, P588, DOI 10.1037/0033-2909.107.2.238
   Blum M., 1968, IND PSYCHOL ITS THEO
   Bollen K.A., 1993, TESTING STRUCTURAL E
   Borman W.C., 1991, HDB IND ORG PSYCHOL, P271
   Brogden HE, 1950, PERS PSYCHOL, V3, P133, DOI 10.1111/j.1744-6570.1950.tb01691.x
   BYRNE D, 1968, J PERS, V36, P259, DOI 10.1111/j.1467-6494.1968.tb01473.x
   Byrne D., 1971, ATTRACTION PARADIGM
   CARDY RL, 1986, J APPL PSYCHOL, V71, P672, DOI 10.1037/0021-9010.71.4.672
   DIPBOYE RL, 1985, ACAD MANAGE REV, V10, P116, DOI 10.2307/258218
   Guion R. M., 1991, HDB IND ORG PSYCHOL, V2, P327
   HUNT D, 1976, J ASSOC STUD PERCEPT, V11, P9
   Joreskog K.G., 1989, LISREL
   KLIMOSKI R, 1987, PERS PSYCHOL, V40, P243, DOI 10.1111/j.1744-6570.1987.tb00603.x
   KLIMOSKI RJ, 1977, PERS PSYCHOL, V30, P353, DOI 10.1111/j.1744-6570.1977.tb00428.x
   MACKENZIE SB, 1991, ORGAN BEHAV HUM DEC, V50, P123, DOI 10.1016/0749-5978(91)90037-T
   OPPLER SH, 1992, J APPL PSYCHOL, V77, P201, DOI 10.1037/0021-9010.77.2.201
   PAULLAY IM, 1994, J APPL PSYCHOL, V79, P224, DOI 10.1037/0021-9010.79.2.224
   PULAKOS ED, 1983, ACAD MANAGE J, V26, P129, DOI 10.2307/256139
   PULAKOS ED, 1995, PERS PSYCHOL, V48, P289, DOI 10.1111/j.1744-6570.1995.tb01758.x
   ROBBINS TL, 1994, J APPL PSYCHOL, V79, P341, DOI 10.1037/0021-9010.79.3.341
   ROSS J, 1981, ADMIN SCI QUART, V26, P617, DOI 10.2307/2392343
   SCHAUBROECK J, 1992, J APPL PSYCHOL, V77, P322, DOI 10.1037/0021-9010.77.3.322
   SCHMITT N, 1994, J ORGAN BEHAV, V15, P393, DOI 10.1002/job.4030150504
   SCHMITT N, 1995, J MANAGE, V21, P159, DOI 10.1177/014920639502100110
   SCHNEIDER B, 1987, PERS PSYCHOL, V40, P437, DOI 10.1111/j.1744-6570.1987.tb00609.x
   SKINNER J, 1987, AIR FORCE OFFICER QU
   Thorndike R. L., 1949, PERSONNEL SELECTION
   TSUI AS, 1989, ACAD MANAGE J, V32, P402, DOI 10.2307/256368
   TUCKER LR, 1973, PSYCHOMETRIKA, V38, P1, DOI 10.1007/bf02291170
   TURBAN DB, 1988, J APPL PSYCHOL, V73, P228, DOI 10.1037/0021-9010.73.2.228
   WEINER JM, 1994, J APPL PSYCHOL, V79, P98
   WEXLEY KN, 1980, ACAD MANAGE J, V23, P320, DOI 10.2307/255434
   WEXLEY KN, 1974, J SOCIAL BEHAVIORAL, V20, P66
   WILLIAMS LJ, 1994, J APPL PSYCHOL, V79, P323, DOI 10.1037/0021-9010.79.3.323
   ZALESNY MD, 1989, HUM RELAT, V42, P81, DOI 10.1177/001872678904200105
NR 37
TC 14
Z9 14
U1 0
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0749-5978
EI 1095-9920
J9 ORGAN BEHAV HUM DEC
JI Organ. Behav. Hum. Decis. Process.
PD DEC
PY 1996
VL 68
IS 3
BP 272
EP 286
DI 10.1006/obhd.1996.0105
PG 15
WC Psychology, Applied; Management; Psychology, Social
SC Psychology; Business & Economics
GA WF085
UT WOS:A1996WF08500008
DA 2021-08-04
ER

PT J
AU Hammer, LB
   StoneRomero, EF
AF Hammer, LB
   StoneRomero, EF
TI Effects of mood state and favorability of feedback on reactions to
   performance feedback
SO PERCEPTUAL AND MOTOR SKILLS
LA English
DT Article
ID PERCEIVED TASK COMPETENCE; ACCURACY; INFORMATION; APPRAISAL; BEHAVIOR;
   MEMORY
AB An experimental simulation involving 55 women assessed the main and interactive effects of experimentally induced mood state (positive vs negative) and favorability of performance feedback (positive vs negative) on the perceived accuracy of feedback. The study was conducted in two sessions. During Session I the subjects role-played the position of an advertising agent and worked on an advertising task. In Session II they were administered either a positive or negative mood induction, given positive or negative feedback on the advertising task, and completed a measure of the perceived accuracy of feedback. Regression analyses indicated support for hypothesized main and interactive effects, suggesting that mood state and favorability of feedback interactively affect the perceived accuracy of received feedback.
C1 SUNY ALBANY, DEPT PSYCHOL, ALBANY, NY 12222 USA.
RP Hammer, LB (corresponding author), PORTLAND STATE UNIV, DEPT PSYCHOL, PORTLAND, OR 97207 USA.
CR AGUINIS HA, IN PRESS J APPL PSYC
   ANSHEL MH, 1988, J GEN PSYCHOL, V115, P117, DOI 10.1080/00221309.1988.9711095
   Aronson E., 1990, METHODS RES SOCIAL P
   BANNISTER BD, 1986, J APPL PSYCHOL, V71, P203, DOI 10.1037/0021-9010.71.2.203
   BARON RA, 1987, J APPL SOC PSYCHOL, V17, P911, DOI 10.1111/j.1559-1816.1987.tb00298.x
   BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004
   BOWER GH, 1981, AM PSYCHOL, V36, P129, DOI 10.1037/0003-066X.36.2.129
   CARDY RL, 1986, J APPL PSYCHOL, V71, P672, DOI 10.1037/0021-9010.71.4.672
   Clark M. S., 1982, COGNITIVE SOCIAL PSY, P73, DOI DOI 10.2307/3033676
   Cohen J., 1969, STAT POWER ANAL BEHA
   Cook T.D., 1979, QUASIEXPERIMENTATION, VVolume 351
   FROST RO, 1982, PERS SOC PSYCHOL B, V8, P341, DOI 10.1177/0146167282082024
   GEORGE JM, 1989, J APPL PSYCHOL, V74, P317, DOI 10.1037/0021-9010.74.2.317
   GEORGE JM, 1992, PSYCHOL BULL, V112, P310, DOI 10.1037/0033-2909.112.2.310
   ILGEN DR, 1979, J APPL PSYCHOL, V64, P349, DOI 10.1037/0021-9010.64.4.349
   INGRAM RE, 1984, COGNITIVE THER RES, V8, P371, DOI 10.1007/BF01173312
   ISEN AM, 1982, SOC PSYCHOL QUART, V45, P58, DOI 10.2307/3033676
   ISEN AM, 1991, RES ORGAN BEHAV, V13, P1
   ISEN AM, 1978, J PERS SOC PSYCHOL, V36, P1, DOI 10.1037/0022-3514.36.1.1
   ISEN AM, 1983, PERS SOC PSYCHOL B, V9, P136, DOI 10.1177/0146167283091019
   Isen AM., 1984, HDB SOCIAL COGNITION, P179
   KERLINGER FN, 1986, F BEHAVIORAL RES
   Locke E.A., 1986, GEN LAB FIELD SETTIN
   MAYER JD, 1992, J PERS SOC PSYCHOL, V63, P119, DOI 10.1037/0022-3514.63.1.119
   NATALE M, 1978, J PSYCHOL, V100, P315
   Pedhazur EJ, 1982, MULTIPLE REGRESSION
   SINCLAIR RC, 1988, ORGAN BEHAV HUM DEC, V42, P22, DOI 10.1016/0749-5978(88)90018-0
   STONE DL, 1985, ORGAN BEHAV HUM DEC, V36, P167, DOI 10.1016/0749-5978(85)90011-1
   STONE DL, 1984, PERS PSYCHOL, V37, P487, DOI 10.1111/j.1744-6570.1984.tb00525.x
   Stone E., 1978, RES METHODS ORG BEHA
   STONE EF, 1984, J MANAGE, V10, P371, DOI 10.1177/014920638401000311
   STONE EF, 1987, M SOC IND ORG PSYCH
   STONEROMERO EF, 1994, J APPL PSYCHOL, V79, P354, DOI 10.1037/0021-9010.79.3.354
   TSUI AS, 1986, ACAD MANAGE J, V29, P586, DOI 10.2307/256225
   VELTEN E, 1968, BEHAV RES THER, V6, P473, DOI 10.1016/0005-7967(68)90028-4
   VELTEN E, 1967, DISS ABSTR INT, V28, P1700
   WEITZENHOFFER A, 1953, HYPNOTISM OBJECTIVE
   WILLIAMS KJ, 1994, ACAD MANAGE J, V37, P837, DOI 10.2307/256602
   WILLIAMS KJ, 1988, M SOC IND ORG PSYCH
   Zuckerman M, 1985, MANUAL MULTIPLE AFFE
NR 40
TC 7
Z9 7
U1 0
U2 6
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0031-5125
EI 1558-688X
J9 PERCEPT MOTOR SKILL
JI Percept. Mot. Skills
PD DEC
PY 1996
VL 83
IS 3
BP 923
EP 934
DI 10.2466/pms.1996.83.3.923
PN 1
PG 12
WC Psychology, Experimental
SC Psychology
GA VW967
UT WOS:A1996VW96700036
PM 8961330
DA 2021-08-04
ER

PT J
AU Moad, G
   Moad, CL
AF Moad, G
   Moad, CL
TI Use of chain length distributions in determining chain transfer
   constants and termination mechanisms
SO MACROMOLECULES
LA English
DT Article
ID MOLECULAR-WEIGHT DISTRIBUTIONS; FREE-RADICAL POLYMERIZATION;
   ADDITION-FRAGMENTATION REACTION; DEPENDENT TERMINATION; RATE
   COEFFICIENTS; END GROUP; EXPRESSIONS; COPOLYMERS
AB A new method for determining transfer constants based on an analysis of the In chain length (Or molecular weight) distributions has recently been reported. In this paper, the basis of this method is examined in terms of classical statistics and with the aid of simulated chain length distributions. The advantages, limitations and sources of error in the method are considered with reference to conventional analysis. We show that one major benefit is that the requisite information can be obtained by analysis of a small segment of the chain length distribution. This means that it may be applied under circumstances where there may be overlap between the distributions of the new polymer being formed and the transfer agent (i.e. transfer constants to polymeric species can be determined). The method also has general application since it is less sensitive to experimental noise, poor baseline selection, or the presence of artifacts in gel permeation chromatograms. Finally we look at the scope for obtaining additional mechanistic information on termination mechanisms by analysis of chain length distributions of low-conversion polymers by considering the effects of combination:disproportionation ratios and chain length dependent propagation and termination.
RP Moad, G (corresponding author), CSIRO,DIV CHEM & POLYMERS,PRIVATE BAG 10,CLAYTON,VIC 3169,AUSTRALIA.
RI Moad, Graeme/A-1984-2008
OI Moad, Graeme/0000-0002-4375-5580
CR BALLARD MJ, 1983, THESIS U SYDNEY
   BAMFORD CH, 1990, EUR POLYM J, V26, P1245, DOI 10.1016/0014-3057(90)90035-3
   BAMFORD CH, 1958, KINETICS VINYL POLYM, P267
   BARSON CA, 1989, COMPREHENSIVE POLYM, V3, P171
   BILLINGHAM NC, 1989, COMPREHENSIVE POLYM, V3, P43
   Christie DI, 1996, MACROMOL CHEM PHYSIC, V197, P403, DOI 10.1002/macp.1996.021970131
   CLAY PA, 1995, MACROMOLECULES, V28, P552, DOI 10.1021/ma00106a021
   CORNER T, 1984, ADV POLYM SCI, V62, P95
   FARINA M, 1987, MAKROMOL CHEM-M SYMP, V10, P255, DOI 10.1002/masy.19870100114
   FLORY PJ, 1953, PRINCIPLES POLYM CHE, P317
   GRESZTA D, 1994, MACROMOLECULES, V27, P638, DOI 10.1021/ma00081a002
   HUTCHINSON RA, 1993, MACROMOLECULES, V26, P6410, DOI 10.1021/ma00076a017
   HUTCHINSON RA, 1995, MACROMOLECULES, V28, P5655, DOI 10.1021/ma00120a035
   KRSTINA J, 1995, MACROMOLECULES, V28, P5381, DOI 10.1021/ma00119a034
   Mayo FR, 1943, J AM CHEM SOC, V65, P2324, DOI 10.1021/ja01252a021
   MOAD G, 1996, MACROMOLECULES, V29, P7717
   Moad G., 1995, CHEM FREE RADICAL PO
   MOAD G, 1989, COMPREHENSIVE POLYM, V3, P147
   OLAJ OF, 1987, MACROMOLECULES, V20, P839, DOI 10.1021/ma00170a024
   OSHAUGHNESSY B, 1994, MACROMOLECULES, V27, P5079, DOI 10.1021/ma00096a033
   PALIT SR, 1966, ENCY POLYM SCI TECHN, V3, P575
   RUDIN A, 1989, COMPREHENSIVE POLYM, V3, P239
   Schulz GV, 1939, Z PHYS CHEM B-CHEM E, V43, P25
   SHORTT DW, 1993, J LIQ CHROMATOGR, V16, P3371, DOI 10.1080/10826079308019695
   Starks C.M., 1974, FREE RADICAL TELOMER
   WHANG BCY, 1991, AUST J CHEM, V44, P1133, DOI 10.1071/CH9911133
   YAMADA B, 1993, POLYM BULL, V31, P263, DOI 10.1007/BF00692950
   YAMADA B, 1994, MACROMOL CHEM PHYSIC, V195, P581, DOI 10.1002/macp.1994.021950215
   YAMADA B, 1992, POLYM J, V24, P281, DOI 10.1295/polymj.24.281
NR 29
TC 77
Z9 78
U1 0
U2 11
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0024-9297
J9 MACROMOLECULES
JI Macromolecules
PD NOV 18
PY 1996
VL 29
IS 24
BP 7727
EP 7733
DI 10.1021/ma960851k
PG 7
WC Polymer Science
SC Polymer Science
GA VU066
UT WOS:A1996VU06600013
DA 2021-08-04
ER

PT J
AU Yamaguchi, T
   Koval, CA
   Noble, RD
   Bowman, CN
AF Yamaguchi, T
   Koval, CA
   Noble, RD
   Bowman, CN
TI Transport mechanism of carbon dioxide through perfluorosulfonate ionomer
   membranes containing an amine carrier
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE carrier transport; facilitated transport; membrane separation; carbon
   dioxide; amine; gas separation
ID ION-EXCHANGE MEMBRANES; FACILITATED TRANSPORT; PORE MODEL; ACID GASES;
   CO2
AB A new facilitated transport model for CO2 through ion-exchange membranes containing a diamine complexing agent was developed. The diamine ion behaves as a mobile carrier for CO2. Although the morphology of the ion-exchange membrane affects carrier transport, the effect of morphology on ionic carrier transport is not clear. The Nernst-Planck equation and the penetration model were employed in this modeling study. The electrical double layer effect and friction effect in the ion-exchange membrane was also considered. In the membrane, there are two kinds of counter ions (NH3+-R-NH2 and NH3+-R-NH3+), CO2 and NH3+-R-NHCOO- (carbamate ion). The carbamate ion can be treated as a neutral molecule because it has both plus and minus charge. Commercial Nafion117 (N117) and heat treated Nafion117 (HN117) were used as ion-exchange membranes. The water content of N117 and HN117 was 16 and 45%, respectively. Nafion has cluster channels which were filled with water, and HN117 has a larger cluster channel size than N117. Monoprotonated ethylenediamine was used as a carrier. Mobile counter ion diffusivities were measured by membrane conductivity. Carbon dioxide diffusivity was determined from transport measurements in a nonreactive Nafion membrane. The diffusivity ratio of carbamate ion to CO2 was estimated by the group contribution method which is effective in aqueous solutions. We estimated a friction effect for the carbamate ion which reduces the carbamate ion diffusivity ratio in the cluster channel. For the HN117 membrane case, experimental results and simulations were in good agreement when we used the diffusivity ratio which was estimated from the group contribution method The counter ion diffusivities, which are restricted by electrical forces, are the rate limiting step for CO2 transport through large clusters. For the N117 case, we must consider the friction effect, and when we use a small carbamate diffusivity ratio, simulations and experimental results agreed well. The diffusivity of the carbamate ion, which is the largest molecule in the membrane, is the rate limiting step for transport through small cluster channels. This model can explain the permeate-side CO2 pressure effect as the permeate-side CO2 pressure seriously reduces the facilitation effect. Copyright (C) 1996 Elsevier Science Ltd
C1 UNIV COLORADO,DEPT CHEM ENGN,BOULDER,CO 80309.
   UNIV COLORADO,DEPT CHEM & BIOCHEM,BOULDER,CO 80309.
RI Bowman, Christopher N/B-1490-2008; Yamaguchi, Takeo/H-1607-2011
OI Bowman, Christopher N/0000-0001-8458-7723; Yamaguchi,
   Takeo/0000-0001-9043-4408
CR CORNELISSE R, 1980, CHEM ENG SCI, V35, P1240
   CWIRKO EH, 1992, J MEMBRANE SCI, V67, P227, DOI 10.1016/0376-7388(92)80027-H
   CWIRKO EH, 1992, J MEMBRANE SCI, V67, P211, DOI 10.1016/0376-7388(92)80026-G
   Danckwerts PV, 1970, GAS LIQUID REACTIONS
   Gierke T. D., 1982, PERFLUORINATED IONOM
   HEANEY MD, 1989, J MEMBRANE SCI, V47, P143, DOI 10.1016/S0376-7388(00)80865-0
   Helfferich F., 1962, ION EXCHANGE
   HIKITA H, 1977, CHEM ENG J, V14, P27
   JEMAA N, 1992, J MEMBRANE SCI, V70, P289, DOI 10.1016/0376-7388(92)80115-Z
   Kohl A, 1979, GAS PURIFICATION
   KOVAL CA, 1992, IND ENG CHEM RES, V31, P1116, DOI 10.1021/ie00004a021
   LANGEVIN D, 1993, J MEMBRANE SCI, V82, P51, DOI 10.1016/0376-7388(93)85092-B
   LEBLANC OH, 1980, J MEMBRANE SCI, V6, P339, DOI 10.1016/S0376-7388(00)82175-4
   LITTEL RJ, 1991, CHEN ENG SCI, V46, P2302
   NOBLE RD, 1986, IND ENG CHEM FUND, V25, P450, DOI 10.1021/i100023a025
   Pellegrino J.J., 1988, GAS SEP PURIF, V2, P126, DOI [10.1016/0950-4214(88)80028-8, DOI 10.1016/0950-4214(88)80028-8]
   Perry R.H., 1973, CHEM ENG HDB
   VERSTEEG GF, 1988, J CHEM ENG DATA, V33, P29, DOI 10.1021/je00051a011
   WAY JD, 1989, J MEMBRANE SCI, V46, P309, DOI 10.1016/S0376-7388(00)80342-7
   WAY JD, 1987, AICHE J, V33, P480, DOI 10.1002/aic.690330313
   YAMAGUCHI T, 1995, IND ENG CHEM RES, V34, P4071, DOI 10.1021/ie00038a049
NR 21
TC 52
Z9 54
U1 2
U2 19
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0009-2509
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD NOV
PY 1996
VL 51
IS 21
BP 4781
EP 4789
DI 10.1016/0009-2509(96)00324-7
PG 9
WC Engineering, Chemical
SC Engineering
GA VM905
UT WOS:A1996VM90500004
DA 2021-08-04
ER

PT J
AU Stamler, A
   Wang, SY
   Aguirre, DE
   Sellke, FW
   Johnson, RG
AF Stamler, A
   Wang, SY
   Aguirre, DE
   Sellke, FW
   Johnson, RG
TI Effects of pentastarch-deferoxamine conjugate on lung injury after
   cardiopulmonary bypass
SO CIRCULATION
LA English
DT Article
DE cardiopulmonary; bypass; lung; deferoxamine; pentastarch; edema
ID FREE-RADICAL GENERATION; PULMONARY INJURY; HYDROXYETHYL STARCH;
   LIPID-PEROXIDATION; PRIMING SOLUTION; REPERFUSION; PENTAFRACTION;
   CARDIOPLEGIA; FILTRATION; RECOVERY
AB Background Oxygen-derived free radicals have been implicated in the pathogenesis of lung injury and endothelial dysfunction after cardiopulmonary bypass (CPB). We examined the effects of priming the CPB pump with a low-molecular-weight hydroxyethyl starch pentastarch (PS) solution, PS conjugated to the iron chelator deferoxamine (DFO), or lactated Ringer's solution done (LR) on lung injury parameters and skeletal microvessel relaxation responses.
   Methods and Results Sheep were placed on hypothermic CPB with a prime of PS (n=8), PS-DFO (n=8), or LR (n=8). A 60-minute period of cardioplegia-ischemia was followed by rewarming, separation from CPB, and 2 hours of post-CPB monitoring. Hemodynamics, oxygenation, pulmonary lymph flow, lymph protein clearance, and total body weight were measured. Right and left atrial blood samples were obtained simultaneously for white blood cell and platelet counts. No statistically significant hemodynamic or oxygenation differences were found between groups. Lymph flow was increased after CPB but significantly more in the LR group (264.6 +/- 45%, P<.05) compared with PS-DFO (126.6 +/- 22%) or PS (120.9 +/- 25%). Increases in lymph protein clearance and weight gain were significantly less with PS and PS-DFO compared with LR (P<.05).
   Conclusions The oncotic agent PS ameliorates lung derangements seen after CPB compared with that seen with an LR prime, and no significant additional pulmonary benefit was demonstrated with PS conjugated to the oxygen-derived free radical scavenger DFO.
C1 HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT SURG,DIV CARDIOTHORAC SURG,BOSTON,MA 02215.
CR BANDO K, 1990, J THORAC CARDIOV SUR, V99, P873
   BOLLI R, 1990, AM J PHYSIOL, V259, pH1901
   BRAZEAL BA, 1995, CRIT CARE MED, V23, P332, DOI 10.1097/00003246-199502000-00020
   CHENOWETH DE, 1981, NEW ENGL J MED, V304, P479
   FANTINI GA, 1993, AM J PHYSIOL, V264, pH1953
   FREEMAN BA, 1982, LAB INVEST, V47, P412
   FRIEDMAN M, 1995, ANN THORAC SURG, V59, P598, DOI 10.1016/0003-4975(94)00919-8
   FRIEDMAN M, 1994, CIRCULATION, V90, P262
   HALLAWAY PE, 1989, P NATL ACAD SCI USA, V86, P10108, DOI 10.1073/pnas.86.24.10108
   KOIKE K, 1986, J APPL PHYSIOL, V60, P80
   LONDON MJ, 1992, J THORAC CARDIOV SUR, V104, P284
   MARUYAMA M, 1991, J CARDIOVASC PHARM, V17, P166, DOI 10.1097/00005344-199101000-00024
   MENASCHE P, 1990, CIRCULATION, V82, P390
   MENASCHE P, 1987, CIRCULATION, V76, P180
   MORITA K, 1995, J THORAC CARDIOV SUR, V110, P1190, DOI 10.1016/S0022-5223(95)70005-6
   MYERS GA, 1995, SURGERY, V117, P340, DOI 10.1016/S0039-6060(05)80211-9
   OHQVIST G, 1981, SCAND J THORAC CARD, V15, P257, DOI 10.3109/14017438109100583
   RATLIFF NB, 1973, J THORAC CARDIOV SUR, V65, P425
   ROYSTON D, 1986, J THORAC CARDIOV SUR, V91, P759
   SADE RM, 1985, J THORAC CARDIOV SUR, V89, P713
   SELLKE FW, 1993, CIRCULATION, V88, P395
   SELLKE FW, 1994, AM J PHYSIOL-HEART C, V267, pH1303
   TATE RM, 1983, AM REV RESPIR DIS, V128, P552, DOI 10.1164/arrd.1983.128.3.552
   VANDERMEER TJ, 1994, J APPL PHYSIOL, V76, P2006
   WILLIAMS RE, 1991, CIRCULATION, V83, P1006, DOI 10.1161/01.CIR.83.3.1006
   ZWEIER JL, 1988, P NATL ACAD SCI USA, V85, P4046, DOI 10.1073/pnas.85.11.4046
NR 26
TC 10
Z9 10
U1 0
U2 1
PU AMER HEART ASSOC
PI DALLAS
PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD NOV 1
PY 1996
VL 94
IS 9
SU S
BP 358
EP 363
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA VP690
UT WOS:A1996VP69000066
DA 2021-08-04
ER

PT J
AU Jenck, F
   Martin, JR
   Moreau, JL
AF Jenck, F
   Martin, JR
   Moreau, JL
TI Behavioral effects of CCKB receptor ligands in a validated simulation of
   panic anxiety in rats
SO EUROPEAN NEUROPSYCHOPHARMACOLOGY
LA English
DT Article
DE anxiety; panic; animal model; CCK; brain stimulation
ID CHOLECYSTOKININ-TETRAPEPTIDE; HEALTHY-VOLUNTEERS; ANTAGONIST; DISORDER;
   BRAIN; L-365,260; CI-988; STIMULATION
AB Animals or human subjects receiving brain stimulation in the dorsal periaqueductal gray matter (dPAG) show sudden fear-suggestive behavioral reactions and physical signs of autonomic activation which are reminiscent of the symptom profile characterizing a panic attack. An experimental situation in rats measuring dPAG stimulation self-interruption thresholds has been validated as realistically simulating several aspects of panic anxiety with objective signs of symptomatic and predictive validity using established antipanic and panicogenic agents; it was utilized here to evaluate the effects of various cholecystokinin B receptor ligands. A dose-dependent increase in self-interruption thresholds (antipanic-like effect) was recorded following injection of L-365,260 (3.2, 10 and 32 mg/kg i.p.), a CCKB receptor antagonist with good brain penetration, whereas no significant changes in thresholds were recorded following CI-988 (3.2, 10 and 32 mg/kg i.p.), a dipeptoid CCKB receptor antagonist with poor brain penetration. Latencies for self-interruption were not modified, suggesting that motor functions remained intact. No significant changes in self-interruption thresholds were recorded following peripheral administration of the CCKB receptor agonists CCK4 (0.03 to 0.32 mg/kg i.v.; 0.01 to 3.2 mg/kg i.p.) or the metabolically stabilized analog Boc-CCK4 (0.1 to 10 mg/kg i.p.). Systemic administration of the panicogenic compounds caffeine and yohimbine enhance acute anxiety in this model. These data indicate that, in the dPAG simulation of panic anxiety, central CCKB receptor blockade by L-365,260 induces antiaversive effects analogous to those observed following benzodiazepine receptor activation by clonazepam or alprazolam. Potency and efficacy of L-365,260 were lower than those of clonazepam or alprazolam, suggesting modest, but nonetheless authentic, antiaversive properties for this CCKB receptor antagonist. Lack of effects observed following peripheral administration of the agonists CCK4 and Boc-CCK4 or of the dipeptoid antagonist CI-988 is likely to reflect restricted brain penetration of those compounds in rats; it furthermore excludes a contribution of peripheral gastrin and CCKA receptors to the antipanic-like properties of selective CCKB receptor antagonists such as L-365,260.
RP Jenck, F (corresponding author), F HOFFMANN LA ROCHE & CO LTD,PRECLIN CNS RES,DIV PHARMA,CH-4070 BASEL,SWITZERLAND.
CR BODEN PR, 1994, BRIT J PHARMACOL, V112, P429, DOI 10.1111/j.1476-5381.1994.tb13090.x
   BOURIN M, 1995, EUR NEUROPSYCHOPHA S, V5, P183
   BRADWEJN J, 1991, ARCH GEN PSYCHIAT, V48, P603
   BRADWEJN J, 1994, ARCH GEN PSYCHIAT, V51, P486
   BRADWEJN J, 1995, BIOL PSYCHIAT, V38, P742, DOI 10.1016/0006-3223(95)00081-X
   BRADWEJN J, 1992, AM J PSYCHIAT, V149, P962
   BRADWEJN J, 1991, J PSYCHIATRY NEUROSC, V16, P260
   BRODIN K, 1994, EUR J PHARMACOL, V263, P175, DOI 10.1016/0014-2999(94)90538-X
   CHARRIER D, 1995, PSYCHOPHARMACOLOGY, V121, P127, DOI 10.1007/BF02245599
   CHOPIN P, 1993, PSYCHOPHARMACOLOGY, V110, P409, DOI 10.1007/BF02244646
   DAWSON GR, 1995, PSYCHOPHARMACOLOGY, V121, P109, DOI 10.1007/BF02245597
   DELGADO JMR, 1954, AM J PHYSIOL, V179, P587
   DEMONTIGNY C, 1989, ARCH GEN PSYCHIAT, V46, P511
   DERRIEN M, 1994, PHARMACOL BIOCHEM BE, V49, P133, DOI 10.1016/0091-3057(94)90467-7
   DOOLEY DJ, 1993, PSYCHOPHARMACOLOGY, V112, P452, DOI 10.1007/BF02244893
   FEKETE M, 1984, EUR J PHARMACOL, V98, P79, DOI 10.1016/0014-2999(84)90111-0
   FENG R, 1993, PHARM RES, V10
   HARRO J, 1991, NEUROSCI BIOBEHAV R, V15, P473, DOI 10.1016/S0149-7634(05)80134-4
   HARRO J, 1993, TRENDS PHARMACOL SCI, V14, P224
   HUGHES J, 1990, P NATL ACAD SCI USA, V87, P6728, DOI 10.1073/pnas.87.17.6728
   INNIS RB, 1980, P NATL ACAD SCI-BIOL, V77, P6917, DOI 10.1073/pnas.77.11.6917
   JENCK F, 1990, EUR J PHARMACOL, V177, P201, DOI 10.1016/0014-2999(90)90271-7
   JENCK F, 1995, PSYCHIAT RES, V57, P181, DOI 10.1016/0165-1781(95)02673-K
   JOHNSON MR, 1995, DRUGS, V49, P328, DOI 10.2165/00003495-199549030-00002
   KRAMER MS, 1995, BIOL PSYCHIAT, V37, P462, DOI 10.1016/0006-3223(94)00190-E
   LOTTI VJ, 1989, EUR J PHARMACOL, V162, P273, DOI 10.1016/0014-2999(89)90290-2
   Makovec Francesco, 1993, Drugs of the Future, V18, P919
   MONGEAU R, 1995, BRIT J PHARMACOL, V116, pP351
   NASHOLD BS, 1969, J NEUROSURG, V30, P14, DOI 10.3171/jns.1969.30.1.0014
   PATEL S, 1994, EUR J PHARMACOL, V253, P237, DOI 10.1016/0014-2999(94)90197-X
   Paxinos G., 1982, RAT BRAIN STEREOTAXI
   PISEGNA JR, 1992, BIOCHEM BIOPH RES CO, V189, P296, DOI 10.1016/0006-291X(92)91557-7
   POWELL KR, 1991, NEUROPEPTIDES, V19, P75, DOI 10.1016/0143-4179(91)90085-W
   RAVARD S, 1990, TRENDS PHARMACOL SCI, V11, P271, DOI 10.1016/0165-6147(90)90004-R
   SCHMITT P, 1981, BEHAV BRAIN RES, V2, P49, DOI 10.1016/0166-4328(81)90038-3
   Schmitt P., 1984, MODULATION SENSORIMO, P393
   SINGH L, 1991, BRIT J PHARMACOL, V104, P239, DOI 10.1111/j.1476-5381.1991.tb12413.x
   *SWISS AC SCI SWIS, 1995, WEST, V51, P1
   Westernberg H. G. M., 1993, Pharmacopsychiatry, V26, P30, DOI 10.1055/s-2007-1021803
   WETTSTEIN JG, 1994, PHARMACOL THERAPEUT, V62, P267, DOI 10.1016/0163-7258(94)90047-7
NR 40
TC 26
Z9 26
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0924-977X
J9 EUR NEUROPSYCHOPHARM
JI Eur. Neuropsychopharmacol.
PD NOV
PY 1996
VL 6
IS 4
BP 291
EP 298
DI 10.1016/S0924-977X(96)00033-8
PG 8
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA VY999
UT WOS:A1996VY99900004
PM 8985712
DA 2021-08-04
ER

PT J
AU Carley, KM
AF Carley, KM
TI A comparison of artificial and human organizations
SO JOURNAL OF ECONOMIC BEHAVIOR & ORGANIZATION
LA English
DT Article
DE simulation; organizational performance; adaptive agents; organizational
   design; computational organization theory
ID GARBAGE; MODEL; CHOICE
AB Formal models can facilitate the development of organizational theory. The complex, adaptive, non-linear nature of human endeavor makes computational models a particularly useful type of formal model for exploring organizational behavior. Researchers, however, rarely contrast such models with empirical data. Further, researchers tend not to contrast such models with other such models. This paper presents results from the artificial organization project and demonstrates how contrasting models with each other and with empirical data can facilitate the development of more veridical organizational models. Specifically, this paper examines whether certain organizational models, differing only with respect to the cognitive limitations of, and adaptability or general intelligence of the agents are better or worse predictors of the behavior of similar organizations composed of humans. It is shown that, not only do different agent models predict different levels of organizational performance, they also predict different relative standings for different organizational structures. Finally, the adequacy of organizations composed of simple computational agents for predicting the behavior of organizations composed of humans appears to increase as the complexity of the organizational structure increases.
RP Carley, KM (corresponding author), CARNEGIE MELLON UNIV,DEPT SOCIAL & DECIS SCI,PITTSBURGH,PA 15213, USA.
OI Carley, Kathleen M./0000-0002-6356-0238
CR BALIGH HH, 1994, COMPUTATIONAL ORG TH
   BALIGH HH, 1990, ORG MANAGEMENT EXPER, P35
   Bond AH., 1988, READINGS DISTRIBUTED
   BUSH RR, 1955, STOCHASTIC MODELS LE
   CARLEY K, 1994, J MATH SOCIOL, V19, P221, DOI 10.1080/0022250X.1994.9990145
   Carley K, 1994, COMPUTATIONAL ORG TH
   CARLEY K, 1993, P 1993 COORD THEOR C
   Carley KM., 1991, IND CRISIS Q, V5, P19
   CARLEY KM, 1992, P 1992 COORD THEOR C
   CARLEY KM, 1995, IEEE SYSTEMS MAN CYB, V25
   CARLEY KM, 1992, ORGAN SCI, V3, P2
   COHEN MD, 1972, ADMIN SCI QUART, V17, P1, DOI 10.2307/2392088
   CYERT RM, 1992, BEHAVIORAL THEORY FI
   HARRISON JR, 1991, ADMIN SCI QUART, V36, P552, DOI 10.2307/2393274
   HOLLENBECK JR, 1991, 911 MICH STAT U DEP
   Ilgen D.R., 1991, 912 MICH STAT U DEP
   LANT TK, 1990, STRATEGIC MANAGE J, V11, P147
   MASUCH M, 1989, ADMIN SCI QUART, V34, P38, DOI 10.2307/2392985
   MASUCH M, 1994, 94120 CCSOM
   PADGETT JF, 1980, ADMIN SCI QUART, V25, P583, DOI 10.2307/2392282
   Prietula M. J., 1994, Journal of Organizational Computing, V4, P41
   SALANCIK GR, 1988, RES SOCIOLOGY ORG, V6, P1
   Scott W., 1987, **DROPPED REF**
   TANG Z, 1992, IEEE T AUTOMATIC CON, P632
   Zhiang Lin, 1993, International Journal of Intelligent Systems in Accounting, Finance and Management, V2, P271
NR 25
TC 29
Z9 32
U1 0
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-2681
J9 J ECON BEHAV ORGAN
JI J. Econ. Behav. Organ.
PD NOV
PY 1996
VL 31
IS 2
BP 175
EP 191
DI 10.1016/S0167-2681(96)00896-7
PG 17
WC Economics
SC Business & Economics
GA WL434
UT WOS:A1996WL43400004
DA 2021-08-04
ER

PT J
AU Kurz, M
   Schneider, M
AF Kurz, M
   Schneider, M
TI Coordination and correlation in Markov rational belief equilibria
SO ECONOMIC THEORY
LA English
DT Article
AB This paper studies the effect of correlation in the rational beliefs of agents on the volatility of asset prices. We use the technique of generating variables to study stable and non-stationary processes needed to characterize rational beliefs. We then examine how the stochastic interaction among such variables affects the behavior of a wide class of Rational Belief Equilibria (RBE). The paper demonstrates how to construct a consistent price state space and then shows the existence of RBE for any economy for which such price state space is constructed. Next, the results are used to study the volatility of asset prices via numerical simulation of a two agents model. If beliefs of agents are uniformly dispersed and independent, we would expect heterogeneity of beliefs to have a limited impact on the fluctuations of asset prices. On the other hand, our results show that correlation across agents can have a complex and dramatic effect on the volatility of prices and thus can be the dominant factor in the fluctuation of asset prices. The mechanism generating this effect works through the clustering of beliefs in states of different levels of agreement. In states of agreement the conditional forecasts of the agents tend to fluctuate together inducing more volatile asset prices. In states of disagreement the conditional forecasts fluctuate in diverse directions tending to cancel each other's effect on market demand and resulting in reduced price volatility.
RP Kurz, M (corresponding author), STANFORD UNIV,DEPT ECON,SERRA ST & GALVEZ,STANFORD,CA 94305, USA.
CR Ash R. B., 1972, REAL ANAL PROBABILIT
   GOTTARDI P, 1990, STATIONARY MONETARY
   GRAY RM, 1987, PROBABILITY RANDOM P
   Hamilton J.D., 1994, TIME SERIES ANAL
   Kurz M, 1996, ECON THEORY, V8, P461, DOI 10.1007/BF01213505
   KURZ M, 1974, ECONOMETRICA, V42, P1, DOI 10.2307/1913681
   Kurz M., 1994, EC THEORY COMMUN, V4, P877, DOI DOI 10.1007/BF01213817
   KURZ M, 1997, IN PRESS SPRINGER SE
   Kurz M., 1994, EC THEORY, V4, P859
   KURZ M, 1974, ESSAYS EC BEHAV UNCE, P389
   KURZ M, 1996, UNPUB COORDINATION C
   LUCAS RE, 1978, ECONOMETRICA, V46, P1429, DOI 10.2307/1913837
   Nielsen CK, 1996, ECON THEORY, V8, P399, DOI 10.1007/BF01213503
   NIELSEN CK, 1994, THESIS STANFORD U
NR 14
TC 20
Z9 21
U1 0
U2 2
PU SPRINGER VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010
SN 0938-2259
J9 ECON THEORY
JI Econ. Theory
PD OCT
PY 1996
VL 8
IS 3
BP 489
EP 520
DI 10.1007/s001990050102
PG 32
WC Economics
SC Business & Economics
GA VQ189
UT WOS:A1996VQ18900005
DA 2021-08-04
ER

PT J
AU Leon, R
   Santamaria, JM
   Alpizar, L
   Escamilla, JA
   Oropeza, C
AF Leon, R
   Santamaria, JM
   Alpizar, L
   Escamilla, JA
   Oropeza, C
TI Physiological and biochemical changes in shoots of coconut palms
   affected by lethal yellowing
SO NEW PHYTOLOGIST
LA English
DT Article
DE lethal yellowing; Cocos nucifera L (coconut); physiology; biochemistry
ID INFECTED TOBACCO-LEAVES; ETHYLENE BIOSYNTHESIS; ABSCISIC-ACID;
   MYCOPLASMALIKE ORGANISMS; PLANTS; RESPONSES; DISEASE; GROWTH
AB Noon stomatal conductance of lethal-yellowing (LY) affected coconut palms (Cocos nucifera L. Atlantic Tall ecotype) decreased progressively as the disease developed. In the early stages of the disease and before leaf yellowing started, stomatal conductance decreased to a minimum in leaves at both the top, the middle and the base of the crown. Since altered stomatal behaviour might affect gas exchange and related processes in the plant, such as water movement and photosynthesis, these results support the hypothesis that LY-induced stomatal closure is central to the development of LY symptoms in coconut palms, and therefore to the mode of pathogenicity of the LY mycoplasma-like organism. Leaf yellowing occurred simultaneously with a decrease in photosynthetic rates and a decrease in protein, chlorophyll and carotenoid contents. Based on these biochemical changes a second hypothesis is proposed, that LY-associated leaf yellowing is part of a leaf senescence process. The concentration of abscisic acid in the leaves and the capacity of leaf tissue to form ethylene increased in diseased palms, suggesting that a hormonal imbalance occurs in LY-affected palms. Furthermore, treatment of symptomless palms with an ethylene-releasing agent (ethephon) resulted in symptoms that mimicked some of the LY symptoms. A third hypothesis is therefore proposed, that a hormonal imbalance might be related to LY symptom development, at least with respect to nutfall and leaf senescence.
C1 CTR INVEST CIENT YUCATAN, CORDEMEX 97310, YUCATAN, MEXICO.
CR AHARONI N, 1989, J PLANT GROWTH REGUL, V8, P309, DOI 10.1007/BF02021824
   ALEJAR AA, 1988, PLANT PHYSIOL, V88, P329, DOI 10.1104/pp.88.2.329
   Andrews TJ, 1987, BIOCH PLANTS, V10, P131
   BEAKBANE AB, 1972, J HORTIC SCI BIOTECH, V47, P265
   CARDENA R, 1991, CAN J PLANT PATHOL, V13, P135, DOI 10.1080/07060669109500948
   DABEK A J, 1974, Phytopathologische Zeitschrift, V81, P346
   DABEK AJ, 1976, TROP AGR, V53, P115
   DABEK AJ, 1975, PHYTOPATHOLOGIE Z, V84, P2
   DAVEY JE, 1981, PHYSIOL PLANT PATHOL, V19, P193
   DAVIES WJ, 1991, ANNU REV PLANT PHYS, V42, P55, DOI 10.1146/annurev.pp.42.060191.000415
   DAVIES WJ, 1991, ABSCISIC ACID PHYSL
   DELAAT AMM, 1983, PHYSIOL PLANT PATHOL, V22, P261
   DELAAT AMM, 1982, PLANT PHYSIOL, V69, P240, DOI 10.1104/pp.69.1.240
   Ellis R. J., 1978, Plant proteins., P25
   Escamilla JA, 1995, DEV PLANT PATHOL, V5, P93
   ESCAMILLA JA, 1993, ADV COCONUT RES DEV, P597
   ESKAFI FM, 1986, TROP AGR, V63, P225
   GRYLLS N. E., 1971, Oleagineux, V26, P543
   Harrison NA, 1995, DEV PLANT PATHOL, V5, P79
   HEINZE K, 1972, PHYTOPATHOLOGY, V64, P307
   HENDERSON J, 1994, J EXP BOT, V45, P943, DOI 10.1093/jxb/45.7.943
   HUNT P, 1974, PHYTOPATHOLOGY, V63, P307
   Incoll L. D., 1987, Stomatal function, P281
   JONES RJ, 1970, J EXP BOT, V21, P714, DOI 10.1093/jxb/21.3.714
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9
   MATOO AK, 1988, SENESCENCE AGING PLA, P241
   MATTEONI JA, 1983, PHYTOPATHOLOGY, V73, P398, DOI 10.1094/Phyto-73-398
   MCCOY RE, 1972, PLANT DIS REP, V56, P1019
   MCCOY RE, 1983, TECHNICAL B U FLORID, V834
   Nooden L.D., 1988, SENESCENCE AGING PLA, P329, DOI DOI 10.1016/B978-0-12-520920-5.50016-X.
   PEMADASA MA, 1982, NEW PHYTOL, V90, P209, DOI 10.1111/j.1469-8137.1982.tb03253.x
   PLAVSICBANJAC B, 1972, PHYTOPATHOLOGY, V62, P298, DOI 10.1094/Phyto-62-298
   QUARRIE SA, 1988, PLANTA, V173, P330, DOI 10.1007/BF00401020
   Sexton R., 1985, Ethylene and plant development, P173
   SNAITH PJ, 1982, J EXP BOT, V33, P360, DOI 10.1093/jxb/33.2.360
   SPANU P, 1989, J PLANT PHYSIOL, V134, P533, DOI 10.1016/S0176-1617(89)80143-9
   Thimann K. V., 1980, Senescence in plants., P85
   THIMANN KV, 1979, P NATL ACAD SCI USA, V76, P2295, DOI 10.1073/pnas.76.5.2295
   THIMANN KV, 1979, P NATL ACAD SCI USA, V76, P2770, DOI 10.1073/pnas.76.6.2770
   YANG SF, 1984, ANNU REV PLANT PHYS, V35, P155, DOI 10.1146/annurev.pp.35.060184.001103
   ZHANG JH, 1987, J EXP BOT, V38, P1174, DOI 10.1093/jxb/38.7.1174
   Zimmermann M. H., 1979, NSC Symposium Series, P37
NR 43
TC 27
Z9 28
U1 1
U2 13
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0028-646X
J9 NEW PHYTOL
JI New Phytol.
PD OCT
PY 1996
VL 134
IS 2
BP 227
EP 234
DI 10.1111/j.1469-8137.1996.tb04627.x
PG 8
WC Plant Sciences
SC Plant Sciences
GA VQ988
UT WOS:A1996VQ98800004
OA Bronze
DA 2021-08-04
ER

PT J
AU Venkatesh, S
   Li, JM
   Xu, YH
   Vishnuvajjala, R
   Anderson, BD
AF Venkatesh, S
   Li, JM
   Xu, YH
   Vishnuvajjala, R
   Anderson, BD
TI Intrinsic solubility estimation and pH-solubility behavior of cosalane
   (NSC 658586), an extremely hydrophobic diprotic acid
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE cosalane; solubility; facilitated dissolution; partition coefficient;
   group contribution approach; pH-solubility behavior
ID ANTI-HIV AGENT; INHIBITION; PROTEASE; DESIGN
AB Purpose. The selection of cosalane (NSC 658586) by the National Cancer Institute for further development as a potential drug candidate for the treatment of AIDS led to the exploration of the solubility behavior of this extremely hydrophobic drug, which has an intrinsic solubility (S-0) approaching 1 ng/ml. This study describes attempts to reliably measure the intrinsic solubility of cosalane and examine its pH-solubility behavior.
   Methods. S-0 was estimated by 5 different strategies: (a) direct determination in an aqueous suspension; (b) facilitated dissolution; (c) estimation from the octanol/water partition coefficient and octanol solubility; (d) application of an empirical equation based on melting point and partition coefficient; and (e) estimation from the hydrocarbon solubility and functional group contributions for transfer from hydrocarbon to water.
   Results. S-0 estimates using these five methods varied over a 5 x 10(9)-fold range. Method (a) yielded the highest values, two-orders of magnitude greater than those obtained by method (b) (facilitated dissolution, 1.4 +/- 0.5 ng/ml). Method (c) gave a value 20-fold higher while that from method (d) was in fair agreement with that from facilitated dissolution. Method (e) yielded a value several orders-of-magnitude lower than other methods. A molecular dynamics simulation suggests that folded conformations not accounted for by group contributions may reduce cosalane's effective hydrophobicity. Ionic equilibria calculations for this weak diprotic acid suggested a 100-fold increase in solubility per pH unit increase. The pH-solubility profile of cosalane at 25 degrees C agreed closely with theory.
   Conclusions. These studies highlight the difficulty in determining solubility of very poorly soluble compounds and the possible advantage of the facilitated dissolution method. The diprotic nature of cosalane enabled a solubility enhancement of > 10(7)-fold by simple pH adjustment.
C1 UNIV UTAH,DEPT PHARMACEUT & PHARMACEUT CHEM,SALT LAKE CITY,UT 84112.
   NCI,NIH,BETHESDA,MD 20892.
FU NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [N0I-CM-27720] Funding Source: Medline; DIVISION OF CANCER
   TREATMENTUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH
   National Cancer Institute- Division of Cancer Treatment & Diagnosis
   [N01CM027720] Funding Source: NIH RePORTER
CR ANDERSON BD, 1980, J PHARM SCI, V69, P424, DOI 10.1002/jps.2600690417
   CHOU JT, 1980, PHYSICAL CHEM PROPER, P141
   CUSHMAN M, 1995, J MED CHEM, V38, P443, DOI 10.1021/jm00003a007
   CUSHMAN M, 1994, J MED CHEM, V37, P3040, DOI 10.1021/jm00045a008
   Davis S S, 1974, Adv Pharm Sci, V4, P73
   FRIEDMAN SH, 1993, J AM CHEM SOC, V115, P6506, DOI 10.1021/ja00068a005
   GOLEBIEWSKI WM, 1993, BIOORG MED CHEM LETT, V3, P1739, DOI 10.1016/S0960-894X(00)80053-0
   Grant D. J. W., 1990, TECHNIQUES CHEM, VXXI
   HIGUCHI T, 1979, J PHARM SCI, V68, P1267, DOI 10.1002/jps.2600681019
   LEVINE IN, 1988, PHYSICAL CHEM
   MADAN DK, 1973, J PHARM SCI-US, V62, P1567, DOI 10.1002/jps.2600620947
   NELSON KG, 1968, RECL TRAV CHIM PAY B, V87, P623
   Noyes A.A., 1897, J AM CHEM SOC, V19, P930, DOI [DOI 10.1021/JA02086A003, 10.1021/ja02086a003]
   SAAD HY, 1965, J PHARM SCI, V54, P1205, DOI 10.1002/jps.2600540826
   Seidell A., 1940, SOLUBILITIES ORGANIC
   SIJBESMA R, 1993, J AM CHEM SOC, V115, P6510, DOI 10.1021/ja00068a006
   Valvani S. C., 1980, PHYSICAL CHEM PROPER, P201
   YALKOWSKY SH, 1980, J PHARM SCI, V69, P912, DOI 10.1002/jps.2600690814
NR 18
TC 21
Z9 22
U1 0
U2 2
PU PLENUM PUBL CORP
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013
SN 0724-8741
J9 PHARMACEUT RES
JI Pharm. Res.
PD OCT
PY 1996
VL 13
IS 10
BP 1453
EP 1459
DI 10.1023/A:1016059008464
PG 7
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA VN257
UT WOS:A1996VN25700005
PM 8899834
DA 2021-08-04
ER

PT J
AU Dees, C
   Garrett, S
   Henley, D
   Travis, C
AF Dees, C
   Garrett, S
   Henley, D
   Travis, C
TI Effects of 60-Hz fields, estradiol and xenoestrogens on human breast
   cancer cells
SO RADIATION RESEARCH
LA English
DT Article
ID DNA-BINDING; ELECTROMAGNETIC-FIELDS; RETINOBLASTOMA PROTEIN;
   MAGNETIC-FIELDS; P53 PROTEIN; HYPOTHESIS; HYPERPHOSPHORYLATION;
   ACTIVATION; EXPRESSION; HEALTH
AB If exposure to xenoestrogens or electromagnetic fields (EMFs) such as 60 Hz contributes to the etiology of breast cancer, it is likely that they must stimulate the growth of breast cells, damage genetic material or enhance the effects of other mitogenic or mutagenic agents (co-promotion). Therefore, the ability of xenoestrogens or exposure to 60-Hz fields to stimulate the entry of growth-arrested human breast cancer cells into the cell cycle was determined using cyclin-dependent kinase 2 (Cdk2) activity, synthesis of cyclin D1 and cdc2 activity. Exposure of estrogen receptor-positive MCF-7 or T-47D cells to estrogen and xenoestrogens (DDT and Red No. 3) increased Cdk2 and cyclin B1-cdc2 activity and cyclin D1 synthesis. Exposure of breast cancer cells to 12 mG or 1 or 9 G electromagnetic fields at 60 Hz failed to stimulate Cdk2 or cyclin B1-cdc2 activity or cyclin D1 synthesis. Simultaneous co-exposure of cells to 60-Hz fields and chemical promoters did not enhance Cdk2 activation above the levels produced by the chemical promoter alone. Estrogen and xenoestrogens also stimulated binding of the estrogen receptor to the estrogen receptor element but the EMF did not. Phorbol 12-myristate 13-acetate (PMA) induced phosphorylation of p53 and pRb105 in MCF-7 cells, but EMF exposure had no effect. DNA-damaging chemotherapeutic agents and Red Dye No. 3 were found to increase p53 site-specific DNA binding in breast cancer cells, but EMF exposure did not. Differential display analysis failed to detect any effect of EMF exposure on gene expression in MCF-7 cells, whereas the effects of estradiol were detected. These studies suggest that estrogen and xenoestrogens stimulate growth-arrested breast cancer cells to enter the growth cycle, but EMF exposure does not. Site-specific p53-DNA binding was increased in MCF-7 cells treated with DNA-damaging agents, but not by EMF exposure. EMF exposure does not appear to act as a promoter or DNA-damaging agent for human breast cancer cells in vitro. (C) 1996 by Radiation Research Society
C1 OAK RIDGE INST SCI & EDUC, OAK RIDGE, TN 37831 USA.
   UNIV TENNESSEE, KNOXVILLE, TN 37916 USA.
RP Dees, C (corresponding author), OAK RIDGE NATL LAB, RISK ANAL SECT, HLTH SCI RES DIV, OAK RIDGE, TN 37831 USA.
CR AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900
   ALDRICH TE, 1987, ENVIRON HEALTH PERSP, V75, P159, DOI 10.2307/3430588
   AYALA M, 1995, BIOTECHNIQUES, V18, P832
   BISHOFF JR, 1988, P NATL ACAD SCI USA, V87, P4766
   DAVIS DL, 1993, ENVIRON HEALTH PERSP, V101, P372, DOI 10.2307/3431889
   DEES C, 1994, CANCER LETT, V84, P117, DOI 10.1016/0304-3835(94)90365-4
   DEES C, 1995, CANCER LETT, V96, P225, DOI 10.1016/0304-3835(95)03936-Q
   DEES C, IN PRESS ENV HLTH PE
   EASTERLY CE, 1981, AM J EPIDEMIOL, V114, P169, DOI 10.1093/oxfordjournals.aje.a113179
   Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488
   FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866
   GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264
   HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505
   JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8
   KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7
   LACYHULBERT A, 1995, RADIAT RES, V144, P9, DOI 10.2307/3579230
   LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6
   LIBURDY RP, 1993, J PINEAL RES, V14, P89, DOI 10.1111/j.1600-079X.1993.tb00491.x
   LIPPMAN ME, 1989, RECENT PROG HORM RES, V45, P383
   LOSCHER W, 1995, CANCER LETT, V96, P175, DOI 10.1016/0304-3835(95)03926-N
   MARSHALL E, 1993, SCIENCE, V259, P618, DOI 10.1126/science.8430308
   MATSUMOTO H, 1994, CANCER LETT, V87, P39, DOI 10.1016/0304-3835(94)90407-3
   PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101
   REGAZZI R, 1986, INT J CANCER, V37, P731, DOI 10.1002/ijc.2910370514
   SAFFER JD, 1995, RADIAT RES, V144, P18, DOI 10.2307/3579231
   SAFFER JD, 1995, NATURE, V375, P22, DOI 10.1038/375022a0
   SDAFE SH, 1995, HUM ECOL RISK ASSESS, V1, P17
   SOTO AM, 1994, ENVIRON HEALTH PERSP, V102, P380, DOI 10.2307/3431626
   STEVENS RG, 1987, AM J EPIDEMIOL, V125, P556, DOI 10.1093/oxfordjournals.aje.a114569
   TAUBES G, 1995, SCIENCE, V269, P1816, DOI 10.1126/science.269.5232.1816-a
   TISHLER RB, 1993, CANCER RES, V53, P2212
   VONSAAL FS, 1995, HUM ECOL RISK ASSESS, V1, P3
   WILLETT WC, 1994, SCIENCE, V264, P532, DOI 10.1126/science.8160011
   YATSUNAMI J, 1993, CANCER RES, V53, P239
NR 34
TC 19
Z9 20
U1 0
U2 0
PU RADIATION RESEARCH SOC
PI LAWRENCE
PA 810 E TENTH STREET, LAWRENCE, KS 66044 USA
SN 0033-7587
EI 1938-5404
J9 RADIAT RES
JI Radiat. Res.
PD OCT
PY 1996
VL 146
IS 4
BP 444
EP 452
DI 10.2307/3579306
PG 9
WC Biology; Biophysics; Radiology, Nuclear Medicine & Medical Imaging
SC Life Sciences & Biomedicine - Other Topics; Biophysics; Radiology,
   Nuclear Medicine & Medical Imaging
GA VK984
UT WOS:A1996VK98400010
PM 8927716
DA 2021-08-04
ER

PT J
AU Schob, OM
   Allen, DC
   Benzel, E
   Curet, MJ
   Adams, MS
   Baldwin, NG
   Largiader, F
   Zucker, KA
AF Schob, OM
   Allen, DC
   Benzel, E
   Curet, MJ
   Adams, MS
   Baldwin, NG
   Largiader, F
   Zucker, KA
TI A comparison of the pathophysiologic effects of carbon dioxide, nitrous
   oxide, and helium pneumoperitoneum on intracranial pressure
SO AMERICAN JOURNAL OF SURGERY
LA English
DT Article
AB BACKGROUND: Previous studies have suggested that diagnostic laparoscopy may be contraindicated in multiple trauma patients with closed head injuries because of the detrimental effects of carbon dioxide (CO2) pneumoperitoneum on intracranial pressure (ICP). In this study we compared the effects of two alternative inflation gases, helium (He) and nitrous oxide (N2O), against the standard agent used in most hospitals, CO2. ICP was monitored in experimental animals both with and without a space occupying intracranial lesion designed to simulate a closed head injury.
   METHODS: Twenty-four domestic pigs (mean, 30 kg) were divided into four groups (6 CO2, 6 He, 6 N2O, and 6 control animals without insufflation). All animals were monitored for ICP, intraabdominal pressure, mean arterial pressure, end-tidal CO2 (ETCO(2)), and arterial blood gases. These parameters were measured for 30 minutes prior to introducing a pneumoperitoneum and then for 80 minutes thereafter. The measurements were repeated after artificially elevating the ICP with a balloon placed in the epidural space.
   RESULTS: The mean ICP increased significantly in all groups during peritoneal insufflation compared with the control group (P <0.005). The CO2-insufflated animals also showed a significant increase in PaCO2 (P <0.05) and ETCO(2) (P <0.05), as well as a decrease in pH (P <0.05). After inflating the epidural balloon the ICP remained significantly higher in animals inflated with CO2 as compared with the He and N2O groups (P <0.05).
   CONCLUSIONS: Peritoneal insufflation with He and N2O resulted in a significantly less increase in ICP as compared with CO2. That difference was most likely due to a metabolically mediated increase in cerebral perfusion (PaCO2) in the CO2 group. Further studies need to be conducted to determine the safety and efficacy of using He and N2O as inflation agents prior to attempting diagnostic or therapeutic laparoscopy in patients with potential closed head injuries.
C1 UNIV NEW MEXICO,SCH MED,DEPT SURG,ALBUQUERQUE,NM 87131.
   UNIV ZURICH HOSP,DEPT SURG,CH-8091 ZURICH,SWITZERLAND.
NR 0
TC 50
Z9 51
U1 0
U2 4
PU CAHNERS PUBL CO
PI NEW YORK
PA 249 WEST 17 STREET, NEW YORK, NY 10011
SN 0002-9610
J9 AM J SURG
JI Am. J. Surg.
PD SEP
PY 1996
VL 172
IS 3
BP 248
EP 252
DI 10.1016/S0002-9610(96)00101-8
PG 5
WC Surgery
SC Surgery
GA VK095
UT WOS:A1996VK09500008
PM 8862077
DA 2021-08-04
ER

PT J
AU Elcock, AH
   Rodger, A
   Richards, WG
AF Elcock, AH
   Rodger, A
   Richards, WG
TI Theoretical studies of the intercalation of 9-hydroxyellipticine in DNA
SO BIOPOLYMERS
LA English
DT Article
ID MOLECULAR-DYNAMICS; B-DNA; NUCLEIC-ACIDS; ELLIPTICINE SERIES; SEQUENCE
   SPECIFICITY; CIRCULAR-DICHROISM; ATOMIC RESOLUTION; ANTITUMOR AGENTS;
   FORCE-FIELD; BINDING
AB Extensive molecular dynamics (MD) simulations have been used to investigate the intercalative binding of 9-hydroxyellipticine to the DNA oligonucleotide d(ATATATATATAT)2. Four independent simulations differing in the initial orientation of the drug at the intercalation site were carried out, and compared both with each other and a control simulation of the free DNA sequence. The structure of the latter was compared with structures obtained from x-ray crystallography and nmr spectroscopy, as well as the theoretically derived ''alternating B-DNA'' model [A. Klug et al. (1979), Journal of Molecular Biology, Vol. 131. p. 669]. The alternation of twist angles observed in experimental structures was reproduced in the simulation. All four independent simulations of the drug-DNA intercalation complex converged in placing the pyridine ring of the ellipticine chromophore in the major groove; in one case this involved a 180 degrees rotation of the drug at the intercalation site. At a more detailed level, the drug is seen to be capable of adopting several distinct orientations, each stable over a period of hundreds of pico-seconds. Despite the presence of several polar groups in the drug, however, no direct hydrogen bonding to the DNA occurs; instead, interactions between the methyl groups of the drug and the thymine bases at the intercalation site appear important in determining the orientational preferences of the drug. Comparison of the intercalation complexes with the free DNA sequence shows a degree of unwinding resulting from intercalation, in good agreement with experimental results, but spread over the three central base-pair steps, not confined to the intercalation site itself. Measurements of torsional rigidity indicate only a slight stiffening of the DNA restricted to the immediate site of intercalation. The structures obtained from the MD simulations were used to calculate theoretical CD spectra, with separate simulations giving very different results. This appears to indicate that given an accurate assignment of the main electronic transition dipole moment of the ellipticine chromophore, discrimination of the more realistic binding geometries may be possible. The relative merits of the various drug orientations observed in the simulations are discussed and a perpendicular orientation of the drug at the intercalation site is considered to be the most consistent with experimental data. While the simulations themselves represent a total of over 2 ns, however, the differences apparent between independent runs indicate that longer simulation times will be required before a complete, unequivocal view of DNA intercalation is obtained. (C) 1996 John Wiley & Sons, Inc.
C1 UNIV OXFORD,PHYS & THEORET CHEM LAB,OXFORD OX1 3QZ,ENGLAND.
RI Rodger, Alison/A-1063-2009; Elcock, Adrian H./F-4799-2010
OI Rodger, Alison/0000-0002-7111-3024; Elcock, Adrian/0000-0003-2820-1376
CR ARNOTT S, 1972, BIOCHEM BIOPH RES CO, V47, P1504, DOI 10.1016/0006-291X(72)90243-4
   AUBARD J, 1992, J RAMAN SPECTROSC, V23, P373, DOI 10.1002/jrs.1250230702
   AUCLAIR C, 1987, ARCH BIOCHEM BIOPHYS, V259, P1, DOI 10.1016/0003-9861(87)90463-2
   BAGULEY BC, 1991, ANTI-CANCER DRUG DES, V6, P1
   BAYLEY PM, 1969, J PHYS CHEM-US, V73, P228, DOI 10.1021/j100721a038
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   BEVERIDGE DL, 1993, WATER BIOL MOL
   CAPRANICO G, 1994, J MOL BIOL, V235, P1218, DOI 10.1006/jmbi.1994.1075
   CECH CL, 1977, BIOPOLYMERS, V16, P43, DOI 10.1002/bip.1977.360160105
   CHENG JW, 1992, J MOL BIOL, V228, P118, DOI 10.1016/0022-2836(92)90496-7
   CHIRLIAN LE, 1987, J COMPUT CHEM, V8, P894, DOI 10.1002/jcc.540080616
   CHOU PJ, 1993, J AM CHEM SOC, V115, P1205, DOI 10.1021/ja00057a001
   COURSEILLE C, 1974, ACTA CRYSTALLOGR B, V30, P2628, DOI 10.1107/S0567740874007692
   DENNY WA, 1989, ANTI-CANCER DRUG DES, V4, P241
   DEWAR MJS, 1985, J AM CHEM SOC, V107, P3905
   ELCOCK AH, 1994, THESIS U OXFORD OXFO
   FEIGON J, 1984, J MED CHEM, V27, P450, DOI 10.1021/jm00370a007
   FENNELL GC, 1994, THESIS U OXFORD OXFO
   FORESTER TR, 1991, MOL PHYS, V72, P643, DOI 10.1080/00268979100100481
   FOSSE P, 1991, NUCLEIC ACIDS RES, V19, P2861, DOI 10.1093/nar/19.11.2861
   GILSON MK, 1987, J COMPUT CHEM, V12, P435
   HEHRE WJ, 1969, J CHEM PHYS, V51, P2657, DOI 10.1063/1.1672392
   HERZYK P, 1992, J BIOMOL STRUCT DYN, V10, P97, DOI 10.1080/07391102.1992.10508633
   JAIN SC, 1979, J MOL BIOL, V135, P813, DOI 10.1016/0022-2836(79)90514-X
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   KAMITORI S, 1992, J MOL BIOL, V225, P445, DOI 10.1016/0022-2836(92)90931-9
   KLUG A, 1979, J MOL BIOL, V131, P669, DOI 10.1016/0022-2836(79)90196-7
   KOHN KW, 1975, CANCER RES, V35, P71
   LAHM A, 1991, J MOL BIOL, V221, P645
   LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728
   LAVERY R, 1990, CURVES3 1
   LEPECQ JB, 1974, P NATL ACAD SCI USA, V71, P5078, DOI 10.1073/pnas.71.12.5078
   LONG EC, 1990, ACCOUNTS CHEM RES, V23, P371
   LYNG R, 1987, BIOPOLYMERS, V26, P1327, DOI 10.1002/bip.360260809
   LYNG R, 1992, BIOPOLYMERS, V32, P1201, DOI 10.1002/bip.360320910
   LYNG R, 1991, BIOPOLYMERS, V31, P1709
   MAUFFRET O, 1991, BIOPOLYMERS, V31, P1325, DOI 10.1002/bip.360311110
   MCCAMMON JA, 1987, DYNAMICS PROTEINS NU
   MOHAN V, 1993, J PHYS CHEM-US, V97, P12984, DOI 10.1021/j100151a055
   *MOL SIM, 1993, QUANTA
   MONNOT M, 1991, J BIOL CHEM, V266, P1820
   MONNOT M, 1990, FEBS LETT, V273, P71, DOI 10.1016/0014-5793(90)81053-Q
   MONNOT M, 1992, EUR J BIOCHEM, V204, P1035, DOI 10.1111/j.1432-1033.1992.tb16725.x
   NEIDLE S, 1992, DESIGN DRUGS MACROMO
   NICHOLLS A, 1990, DELPHI3 0
   PATEL N, 1991, EUR J BIOCHEM, V197, P597, DOI 10.1111/j.1432-1033.1991.tb15949.x
   PEARLMAN DA, 1991, AMBER4 0
   PRABHAKARAN M, 1985, J PHYS CHEM-US, V89, P5767, DOI 10.1021/j100272a038
   RIZZO V, 1984, BIOPOLYMERS, V23, P435, DOI 10.1002/bip.360230305
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5
   Saenger W., 1989, J MOL BIOL, V205, P787
   SAENGER W, 1987, PRINCIPLES NUCLEIC A
   SATYANARAYANA S, 1992, BIOCHEMISTRY-US, V31, P9319, DOI 10.1021/bi00154a001
   SCHWALLER MA, 1991, BIOPOLYMERS, V31, P519, DOI 10.1002/bip.360310507
   SCHWALLER MA, 1990, ANTI-CANCER DRUG DES, V5, P77
   SCHWALLER MA, 1989, EUR J BIOCHEM, V181, P129, DOI 10.1111/j.1432-1033.1989.tb14703.x
   SHARP KA, 1990, J PHYS CHEM-US, V94, P7684, DOI 10.1021/j100382a068
   SINGH UC, 1985, P NATL ACAD SCI USA, V82, P755, DOI 10.1073/pnas.82.3.755
   STEWART JJP, 1990, J COMPUT AID MOL DES, V4, P1, DOI 10.1007/BF00128336
   VISWAMITRA MA, 1978, NATURE, V273, P687, DOI 10.1038/273687a0
   Wang A.H., 1992, CURR OPIN STRUC BIOL, V2, P361
   WEERASINGHE S, 1995, J AM CHEM SOC, V117, P2147, DOI 10.1021/ja00113a004
   WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216
   WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051
   WESTON SA, 1992, J MOL BIOL, V226, P1237, DOI 10.1016/0022-2836(92)91064-V
   YOON C, 1988, P NATL ACAD SCI USA, V85, P6332, DOI 10.1073/pnas.85.17.6332
   YUAN H, 1992, BIOCHEMISTRY-US, V31, P8009, DOI 10.1021/bi00149a035
NR 67
TC 25
Z9 25
U1 0
U2 6
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0006-3525
J9 BIOPOLYMERS
JI Biopolymers
PD SEP
PY 1996
VL 39
IS 3
BP 309
EP 326
DI 10.1002/(SICI)1097-0282(199609)39:3<309::AID-BIP4>3.3.CO;2-O
PG 18
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA VC347
UT WOS:A1996VC34700004
PM 8756512
DA 2021-08-04
ER

PT J
AU Calenbuhr, V
   Varela, FJ
   Bersini, H
AF Calenbuhr, V
   Varela, FJ
   Bersini, H
TI Natural tolerance as a function of network connectivity
SO INTERNATIONAL JOURNAL OF BIFURCATION AND CHAOS
LA English
DT Article; Proceedings Paper
CT Workshop on Discretely-Coupled Dynamical Systems
CY JUN 24-28, 1995
CL UNIV SANTIAGO COMPOSTELA, FAC PHYS, SANTIAGO COMPOSTELA, SPAIN
SP Univ Santiago Compostela, Grp Nonlinear Phys
HO UNIV SANTIAGO COMPOSTELA, FAC PHYS
ID IMMUNE NETWORK; IDIOTYPIC NETWORK; STATIONARY STATES; SHAPE-SPACE;
   DYNAMICS; OSCILLATIONS; BEHAVIOR; SYSTEM; CHAOS; MODEL
AB This article investigates the following basic question: in the relatively stable molecular environment of a vertebrate body, can a dynamic idiotypic immune network develop a natural tolerance to endogenous components? Our approach is based on stability analysis and computer simulation using a model that takes into account the dynamics of two agents of the immune system, namely, B-lymphocytes and antibodies. We investigate the behavior of simple immune networks in interaction with an Ag whose concentration is being held constant as a function of the connectivity matrix of the network. The latter is characterized by the total number of clones, N, and the number of clones, C, with which each clone interacts. The idiotypic network models typically become unstable in the presence of this type of Ag. We show that idiotypic networks that can be found in particular connected regions of NO-space show tolerance towards auto-Ag without the need for ad hoc mechanisms that prevent an immune response. These tolerant network structures provide dynamical regimes in which the clone which interacts with the auto-dg is suppressed instead of being excited such that an unbounded immune response does not occur. Possible implications for the future treatment of auto-immune disease such as IvIg-treatment are discussed in the light of these results. Moreover, we propose an experimental approach to verify the results of the present theoretical study.
C1 ECOLE POLYTECH,CREA,F-75005 PARIS,FRANCE.
   FREE UNIV BRUSSELS,IRIDIA,B-1050 BRUSSELS,BELGIUM.
CR Atiya A., 1989, International Journal of Neural Systems, V1, P103, DOI 10.1142/S0129065789000025
   BERSINI H, 1995, CHAOS SOLITON FRACT, V5, P1533, DOI 10.1016/0960-0779(94)00176-Q
   BERSINI H, 1992, ARTIFICIAL LIFE, V3
   Calenbuhr V, 1995, J THEOR BIOL, V177, P199, DOI 10.1006/jtbi.1995.0239
   CALENBUHR V, 1993, UNPUB FRUSTRATION IN
   CALENBUHR V, 1993, P 1 COP S COMP SIM B
   DEBOER R, 1990, J THEOR BIOL, V149, P381
   DEBOER RJ, 1993, B MATH BIOL, V55, P781, DOI 10.1016/S0092-8240(05)80189-2
   DEBOER RJ, 1989, B MATH BIOL, V51, P381, DOI 10.1016/S0092-8240(89)80083-7
   DEBOER RJ, 1993, B MATH BIOL, V55, P745, DOI 10.1016/S0092-8240(05)80188-0
   DETOURS V, 1994, J THEOR BIOL, V170, P401, DOI 10.1006/jtbi.1994.1201
   DETOURS V, 1995, CLUSTERING PHENOMENA
   DIETRICH G, 1993, EUR J IMMUNOL, V23, P2945, DOI 10.1002/eji.1830231133
   KAVERI SV, 1991, CLIN EXP IMMUNOL, V86, P192
   MATTHEWS PC, 1991, PHYSICA D, V52, P293, DOI 10.1016/0167-2789(91)90129-W
   NEUMANN AU, 1992, B MATH BIOL, V54, P699, DOI 10.1007/BF02459926
   NEUMANN AU, 1992, B MATH BIOL, V54, P21, DOI 10.1007/BF02458618
   STEWART J, 1989, IMMUNOL REV, V110, P37, DOI 10.1111/j.1600-065X.1989.tb00026.x
   STEWART J, 1991, J THEOR BIOL, V153, P477, DOI 10.1016/S0022-5193(05)80152-3
   STEWART J, 1990, J THEOR BIOL, V144, P103, DOI 10.1016/S0022-5193(05)80302-9
   TAUBER F, 1994, IMMUNE SELF THEORY M
   TOULOUSE G, 1977, COMMUN PHYS, V2, P115
   TSANG KY, 1991, PHYSICA D, V48, P102, DOI 10.1016/0167-2789(91)90054-D
   VARELA FJ, 1991, IMMUNOL TODAY, V12, P159, DOI 10.1016/0167-5699(91)90081-4
   VARELA FJ, 1990, J THEOR BIOL, V144, P93, DOI 10.1016/S0022-5193(05)80301-7
   VARELA FJ, 1988, THEORETICAL IMMUNO 2, P359
   VARELA FJ, 1993, SFI SERIES
   WEISBUCH G, 1993, J THEOR BIOL, V163, P237, DOI 10.1006/jtbi.1993.1119
NR 28
TC 5
Z9 5
U1 0
U2 0
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA JOURNAL DEPT PO BOX 128 FARRER ROAD, SINGAPORE 9128, SINGAPORE
SN 0218-1274
J9 INT J BIFURCAT CHAOS
JI Int. J. Bifurcation Chaos
PD SEP
PY 1996
VL 6
IS 9
BP 1691
EP 1702
DI 10.1142/S0218127496001041
PG 12
WC Mathematics, Interdisciplinary Applications; Multidisciplinary Sciences
SC Mathematics; Science & Technology - Other Topics
GA WB436
UT WOS:A1996WB43600010
DA 2021-08-04
ER

PT J
AU Schwartz, BF
   Swanzy, S
   Thrasher, JB
AF Schwartz, BF
   Swanzy, S
   Thrasher, JB
TI A randomized prospective comparison of antibiotic tissue levels in the
   corpora cavernosa of patients undergoing penile prosthesis implantation
   using gentamicin plus cefazolin versus an oral fluoroquinolone for
   prophylaxis
SO JOURNAL OF UROLOGY
LA English
DT Article
DE penis; impotence; anti-infective agents, fluoroquinolone; penile
   prosthesis
ID PERIPROSTHETIC INFECTIONS; COMPLICATIONS; SURGERY; INVITRO;
   AMINOGLYCOSIDE; EXPERIENCE
AB Purpose: We performed a prospective randomized trial comparing the efficacy, safety and cost of parenteral antibiotics and oral fluoroquinolones for prophylaxis in penile prosthesis surgery.
   Materials and Methods: We prospectively randomized 20 consecutive patients undergoing penile prosthesis surgery to receive ofloxacin orally or gentamicin and cefazolin parenterally followed by cephradine orally. Intraoperatively corpora cavernosa tissue and simultaneous peripheral serum samples were evaluated for antibiotic levels. Median followup was 16 months (range 8 to 21, mean 15.35).
   Results: There were no implant losses or reoperations and complications were comparable in the 2 groups. The difference in mean serum-to-tissue ratios of ofloxacin versus the combination of cefazolin and gentamicin was statistically significant (p <0.03). The minimum inhibitory concentrations of ofloxacin met or exceeded those of the 2 most common offending organisms, Staphylococcus epidermidis and Escherichia coli, in 80% of patients, which was comparable to the results of the parenteral regimen. Cost savings of the medications alone were more than $250,000 in the ofloxacin group. By eliminating a hospital stay of the 25,000 cases of penile prosthesis placement in the United States yearly a total cost savings of more than $36 million would be realized.
   Conclusions: When oral ofloxacin is given for prophylaxis in penile implant surgery, the procedure may be performed on an outpatient basis and health care dollars are saved.
C1 UNIV WASHINGTON, DEPT LAB MED, SEATTLE, WA 98195 USA.
RP Schwartz, BF (corresponding author), MADIGAN ARMY MED CTR, DEPT UROL, MCHJ SU UROL, TACOMA, WA 98431 USA.
CR BENNETT JV, 1966, APPL MICROBIOL, V14, P170, DOI 10.1128/AEM.14.2.170-177.1966
   BISHOP JR, 1992, J UROLOGY, V147, P386, DOI 10.1016/S0022-5347(17)37244-0
   CARSON CC, 1983, SOUTHERN MED J, V76, P1139, DOI 10.1097/00007611-198309000-00019
   DALY JS, 1988, J ANTIMICROB CHEMOTH, V21, P721, DOI 10.1093/jac/21.6.721
   DAN M, 1986, ANTIMICROB AGENTS CH, V30, P88, DOI 10.1128/AAC.30.1.88
   EDBERG SC, 1975, AM J MED TECHNOL, V41, P99
   ENGEL RME, 1987, UROLOGY, V29, P498, DOI 10.1016/0090-4295(87)90036-7
   FISHMAN IJ, 1984, UROLOGY, V23, P86, DOI 10.1016/0090-4295(84)90249-8
   GUNDERSON TJ, 1994, PIPER JAFFRAY R 0925
   Halkin H, 1988, Rev Infect Dis, V10 Suppl 1, pS258
   JOLLEY ME, 1981, CLIN CHEM, V27, P1190
   KABALIN JN, 1988, J UROLOGY, V139, P953, DOI 10.1016/S0022-5347(17)42727-3
   KAUFMAN JJ, 1982, J UROLOGY, V128, P1192, DOI 10.1016/S0022-5347(17)53418-7
   KESSLER R, 1981, UROLOGY, V18, P470, DOI 10.1016/0090-4295(81)90292-2
   MATSUMOTO T, 1991, CHEMOTHERAPY, V37, P60, DOI 10.1159/000238908
   MONTAGUE DK, 1987, J UROLOGY, V138, P68, DOI 10.1016/S0022-5347(17)42992-2
   SMALL MP, 1978, J UROLOGY, V119, P365, DOI 10.1016/S0022-5347(17)57492-3
   TAKAHATA M, 1988, J ANTIMICROB CHEMOTH, V22, P143, DOI 10.1093/jac/22.2.143
   THOMALLA JV, 1987, J UROLOGY, V138, P65, DOI 10.1016/S0022-5347(17)42991-0
   WALKER RC, 1991, MAYO CLIN PROC, V66, P1249, DOI 10.1016/S0025-6196(12)62477-X
   WALTERS FP, 1992, J UROLOGY, V147, P1282, DOI 10.1016/S0022-5347(17)37543-2
   WATANABE NA, 1988, ANTIMICROB AGENTS CH, V32, P693, DOI 10.1128/AAC.32.5.693
   WISE R, 1988, ANTIMICROB AGENTS CH, V32, P1251, DOI 10.1128/AAC.32.8.1251
NR 23
TC 16
Z9 16
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5347
EI 1527-3792
J9 J UROLOGY
JI J. Urol.
PD SEP
PY 1996
VL 156
IS 3
BP 991
EP 994
DI 10.1016/S0022-5347(01)65680-5
PG 4
WC Urology & Nephrology
SC Urology & Nephrology
GA VB453
UT WOS:A1996VB45300038
PM 8709381
DA 2021-08-04
ER

PT J
AU Feng, CG
   Zeng, QX
   Wang, LQ
   Fang, X
AF Feng, CG
   Zeng, QX
   Wang, LQ
   Fang, X
TI Study of the mechanism of oscillatory solid-phase combustion by a
   non-linear chemical kinetic model
SO JOURNAL OF THE CHEMICAL SOCIETY-FARADAY TRANSACTIONS
LA English
DT Article
AB Oscillatory solid-phase pyrotechnic combustion in the following system
   NH4ClO4 + Mg (powder) + K2Cr2O7
   is studied, where NH4ClO4, Mg and K2Cr2O7 are the oxidant, reducing agent and frequency-modulating species, respectively, in order to elucidate a more detailed description of the oscillatory mechanism. The simplicity of this pyrotechnic system serves our purposes very well.
   It is shown that the combustion of the above system is highly oscillatory in nature. Once ignited, the mixture exhibits 'pulsed burning', the intensity of the combustion varying periodically between flash combustion (deflagration) and smokeless smouldering. A number of experiments were carried out which confirmed that the phenomenon is intrinsic and that the controlling process chemical in nature.
   According to the results of the experiments and the observed combustion phenomena, the following chemical kinetic mechanism for the oscillatory process is suggested
   [GRAPHICS]
   It is considered that the competiting reactions between the three phases of Mg with the oxidizable gases produced by the decomposition of NH4ClO4 control the oscillatory burning process. Based on this analysis, the following simplified qualitative chemical kinetical model is proposed
   [GRAPHICS]
   and kinetic equations are deduced. The results of the simulation of the autocatalytic model using non-linear numerical methods are reported and discussed. Steady-state solution and oscillatory behaviour is obtained, in good agreement with experimental phenomena.
RP Feng, CG (corresponding author), BEIJING INST TECHNOL,DEPT MECH & ENGN,POB 327,BEIJING 100081,PEOPLES R CHINA.
CR Conkling J. A., 1985, CHEM PYROTECHNICS BA
   Donoho D. W., 1982, patent USP, Patent No. 4341573
   GOLDBINDER AI, 1961, RUSS J PHYS CHEM, V35, P889
   GRAY P, 1990, CHEM OSCILLATIONS IN
   KUBICEK EM, 1983, COMPUTATIONAL METHOD
   KULKARNI AK, 1982, AIAA J, V20, P243, DOI 10.2514/3.51071
   Marek M., 1991, CHAOTIC BEHAV DETERM
   reng C., 1988, THERMAL EXPLOSION TH
   Scott S.K., 1991, CHEM CHAOS
   SEYDEL R, 1988, EQUILIBRIUM CHAOS PR
   Sidorov A.I., 1969, Soviet Union Patent, Patent No. [SU237041, 237041]
   SIDOROV AI, 1969, Patent No. 247828
   SIDOROV AI, 1969, Patent No. 237039
   Wasmann F, 1976, P 5 INT PYR SEM VAIL, P643
   XU Y, COMMUNICATION
   ZENG QX, 1993, THESIS BEIJING I TEC
NR 16
TC 9
Z9 11
U1 0
U2 7
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK MILTON ROAD, CAMBRIDGE, CAMBS, ENGLAND
   CB4 4WF
SN 0956-5000
J9 J CHEM SOC FARADAY T
JI J. Chem. Soc.-Faraday Trans.
PD AUG 21
PY 1996
VL 92
IS 16
BP 2971
EP 2975
DI 10.1039/ft9969202971
PG 5
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA VD334
UT WOS:A1996VD33400021
DA 2021-08-04
ER

PT J
AU Wachsmuth, I
   Jung, B
AF Wachsmuth, I
   Jung, B
TI Dynamic conceptualization in a mechanical-object assembly environment
SO ARTIFICIAL INTELLIGENCE REVIEW
LA English
DT Article
DE knowledge representation; hybrid structural and spatial representations;
   situated communication
AB In an experimental setting of mechanical-object assembly, the CODY (''Concept Dynamics'') project is concerned with the development of knowledge representations and inference methods that are able to dynamically conceptualize the situation in the task environment. A central aim is to enable an artificial agent to understand and process natural-language instructions of a human partner. Instructions may build on the current perception of the assembly environment on the one hand, and on the other on the knowledge-based understanding of grouped structures in the developing construct. To this end, a dynamic conceptualization must integrate information not only describing the types of the objects involved, but also their changing functional roles when becoming part of structured assemblies.
   We have developed an operational knowledge representation formalism, COAR (''Concepts for Objects, Assemblies, and Roles''), by which processes of dynamic conceptualization in sequences of assembly steps can be formally reconstructed. Inferences concern the assertion or retraction of aggregate representations in a dynamic knowledge base, as well as the computation of role changes for individual objects associated herewith. The structural representations integrate situated spatial features and relations, such as position, size, distance, or orthogonality, which are inferred on need from a geometry description of the task environment. The capacity of our approach has been evaluated in a 3D computergraphics simulation environment.
RP Wachsmuth, I (corresponding author), UNIV BIELEFELD, FAC TECHNOL, D-33501 BIELEFELD, GERMANY.
OI Wachsmuth, Ipke/0000-0002-4786-5189
CR CAO Y, 1995, P 14 INT JOINT C ART, P2061
   FINK GA, 1994, INT C SPOK LANG PROC, V4, P2183
   GENESERETH MR, 1987, LOGICAL FDN ARTIFICA
   GRUBER TR, 1994, MOR KAUF R, P258
   GUARINO N, 1994, MOR KAUF R, P270
   JUNG B, 1994, 949 SFB U BIEL
   JUNG B, 1995, KL 95 ACT WORKSH POS, P103
   JUNG B, 1995, 956 SFB U BIEL
   LIN PH, 1994, MOR KAUF R, P485
   MORATZ R, 1995, 1995 AAAI FALL S COM
   NIEMANN H, 1990, IEEE T PATTERN ANAL, V12, P883, DOI 10.1109/34.57683
   RICKHEIT G, 1994, SPRACHE KOGNITION PE, P73
   SAGERER G, 1990, AUTOMATISCHES VERSTE
   SOWA J, 1988, RELATIONAL MODELS LE, P112
   THOMAS F, 1995, IJCAI 95 WORKSH REPR, P93
   Way E. C, 1991, KNOWLEDGE REPRESENTA
NR 16
TC 7
Z9 7
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0269-2821
EI 1573-7462
J9 ARTIF INTELL REV
JI Artif. Intell. Rev.
PD AUG
PY 1996
VL 10
IS 3-4
BP 345
EP 368
DI 10.1007/BF00127686
PG 24
WC Computer Science, Artificial Intelligence
SC Computer Science
GA VG078
UT WOS:A1996VG07800011
OA Green Submitted
DA 2021-08-04
ER

PT J
AU Mok, YS
   Lee, WK
   Lee, YK
AF Mok, YS
   Lee, WK
   Lee, YK
TI Modeling of liquid emulsion membranes facilitated by two carriers
SO CHEMICAL ENGINEERING JOURNAL
LA English
DT Article
DE polyamine-type surfactant; advancing front model; axial dispersion model
ID SURFACTANT MEMBRANE; ORGANIC-ACIDS; MASS-TRANSFER; PENICILLIN-G;
   LACTIC-ACID; EXTRACTION; SIMULATION; DIFFUSION
AB A mathematical model was proposed to describe the behavior of liquid emulsion membranes for the extraction of penicillin G in a continuous countercurrent mixing column. A polyamine-type surfactant acts not only as carrier but also as surface-stabilizing agent; thus the influence of surfactant on extraction should be considered in mathematical modeling when its effect is significant. The proposed model takes into account the influence of surfactant on mass transfer. The advancing front model was employed for deriving the overall mass transfer coefficient in the emulsion globule, and the axial dispersion model was applied to the external feed phase. The experimental data were compared with the proposed model, the calculations without considering the contribution of the surfactant to extraction, and the calculations without considering diffusion in the emulsion phase.
C1 KOREA ADV INST SCI & TECHNOL,DEPT CHEM ENGN,TAEJON 305701,SOUTH KOREA.
RP Mok, YS (corresponding author), POHANG IRON & STEEL CO LTD,TECH RES LABS,ENVIRONM & ENERGY RES TEAM,POB 36,1 KOEDONG DONG,NAM KU,POHANG 790785,KYUUNGBUK,SOUTH KOREA.
CR BIBAUD RE, 1966, AICHE J, V12, P472, DOI 10.1002/aic.690120315
   CHAUDHURI JB, 1992, CHEM ENG SCI, V47, P41, DOI 10.1016/0009-2509(92)80198-L
   CUSSLER EL, 1992, MASS TRANSFER FLUID, pCH7
   Dean J., 1985, LANGES HDB CHEM
   HANO T, 1993, J MEMBRANE SCI, V84, P271, DOI 10.1016/0376-7388(93)80022-P
   HANO T, 1990, J CHEM ENG JPN, V23, P772, DOI 10.1252/jcej.23.772
   HATTON TA, 1984, AICHE J, V30, P934, DOI 10.1002/aic.690300608
   HO WS, 1982, AICHE J, V28, P662, DOI 10.1002/aic.690280419
   KATAOKA T, 1987, J CHEM ENG JPN, V20, P410, DOI 10.1252/jcej.20.410
   KIM KS, 1983, IND ENG CHEM FUND, V22, P167, DOI 10.1021/i100010a003
   LEE CJ, 1990, IND ENG CHEM RES, V29, P101, DOI 10.1021/ie00097a015
   MARR R, 1983, GER CHEM ENG, V6, P365
   MATSUMOTO M, 1990, J CHEM ENG JPN, V23, P402, DOI 10.1252/jcej.23.402
   RAUTENBACH R, 1988, J MEMBRANE SCI, V36, P425, DOI 10.1016/0376-7388(88)80034-6
   REISINGER H, 1993, J MEMBRANE SCI, V80, P85, DOI 10.1016/0376-7388(93)85134-I
   Reisinger H., 1992, CHEM ENG TECHNOL, V15, P363
   RESCHKE M, 1984, CHEM ENG J BIOCH ENG, V28, pB1, DOI 10.1016/0300-9467(84)85015-7
   SKELLAND AHP, 1981, AICHE J, V27, P99, DOI 10.1002/aic.690270115
   TERAMOTO M, 1991, J MEMBRANE SCI, V58, P11, DOI 10.1016/S0376-7388(00)80634-1
   WANG CC, 1990, J MEMBRANE SCI, V53, P105
   WILKE CR, 1955, AICHE J, V1, P264, DOI 10.1002/aic.690010222
NR 21
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE SA LAUSANNE
PI LAUSANNE 1
PA PO BOX 564, 1001 LAUSANNE 1, SWITZERLAND
SN 0923-0467
J9 CHEM ENG J
JI Chem. Eng. J.
PD AUG
PY 1996
VL 63
IS 2
BP 127
EP 137
DI 10.1016/0923-0467(96)03097-7
PG 11
WC Engineering, Environmental; Engineering, Chemical
SC Engineering
GA VR763
UT WOS:A1996VR76300007
DA 2021-08-04
ER

PT J
AU Wyser, C
   Walzl, G
   Smedema, JP
   Swart, F
   vanSchalkwyk, EM
   vandeWal, BW
AF Wyser, C
   Walzl, G
   Smedema, JP
   Swart, F
   vanSchalkwyk, EM
   vandeWal, BW
TI Corticosteroids in the treatment of tuberculous pleurisy - A
   double-blind, placebo-controlled, randomized study
SO CHEST
LA English
DT Article
DE computed tomography; lung function testing; prednisone; therapeutic
   aspiration; thoracoscopy; tuberculous pleurisy
ID PULMONARY
AB Although several studies on tuberculous (TB) pleurisy suggest that the addition of corticosteroids to anti-TB therapy may have beneficial effects, these agents are not used routinely. To assess the effects of short-term oral prednisone therapy in TB pleurisy, 74 patients were randomly assigned in a double-blind fashion to treatment with either placebo or prednisone at a dose of 0.75 mg/kg/d for up to 4 weeks with gradual reduction over an additional 2 weeks, All subjects received a standard 3-drug anti-TB chemotherapy regimen for 6 months. TB pleurisy was diagnosed by histologic study and/or culture of pleural biopsy specimens obtained at thoracoscopy, Complete drainage of the effusion was performed simultaneously. Outcome measures were assessed periodically for 24 weeks, including indexes of morbidity and pleural thickening, After randomization, four patients were excluded fi om the final analysis, Of the 70 patients analyzed, 34 received prednisone and 36 received placebo, Demographic and clinical characteristics of the treatment groups were comparable at the time of hospital admission, Although a statistically significant improvement in symptoms occurred earlier in the prednisone group (8 weeks) than in the placebo group (12 weeks), between-group comparison showed no significant differences at any of the follow-up evaluations. The proportion of subjects in the prednisone group (53.1%) with residual pleural thickening at 6 months did not differ significantly from that of the placebo group (60%), Pleural effusions did not recur in any of the patients. Initial complete drainage of the effusion was associated with greater symptomatic improvement than any subsequent therapy, We conclude that standard anti-TB therapy and early complete drainage is adequate for the treatment of TB pleurisy. The addition of short-term oral prednisone therapy neither results in clinically relevant earlier symptom relief nor confers a beneficial effect on residual pleural thickening.
C1 UNIV STELLENBOSCH, STELLENBOSCH UNIV PULM UNIT RES, ZA-7600 STELLENBOSCH, SOUTH AFRICA.
RP Wyser, C (corresponding author), KANTONSSPITAL, DEPT INTERNAL MED, DIV PULM, PETERSGRABEN 4, CH-4031 BASEL, SWITZERLAND.
RI Smedema, Jan-Peter/S-3687-2017; Walzl, Gerhard/N-6371-2016
OI Walzl, Gerhard/0000-0003-2487-125X
CR [Anonymous], 1979, AM REV RESPIR DIS, V119, P831
   ASPIN J, 1958, BRIT J TUBERC DIS CH, V52, P81, DOI 10.1016/S0366-0869(58)80064-7
   BARBAS CSV, 1991, CHEST, V100, P1264, DOI 10.1378/chest.100.5.1264
   BERGQVIST S, 1966, SCAND J RESPIR DIS, V47, P64
   BOUTIN C, 1993, TUBERCLE LUNG DIS, V74, P225, DOI 10.1016/0962-8479(93)90048-3
   DAMANY S J, 1968, J. Inst. Metals Met. Abstr., V51, P391
   FILLER J, 1963, AM REV RESPIR DIS, V88, P181
   GOLDMAN HI, 1959, AM REV TUBERC PULM, V79, P457
   GOLDSTEIN RA, 1990, AM REV RESPIR DIS, V142, P481
   Grewal K S, 1969, J Indian Med Assoc, V52, P514
   HOUGHTON LE, 1954, LANCET, V1, P595
   HULNICK DH, 1983, RADIOLOGY, V149, P759, DOI 10.1148/radiology.149.3.6647852
   IM JG, 1989, RADIOLOGY, V171, P125, DOI 10.1148/radiology.171.1.2928515
   LEE CH, 1988, CHEST, V94, P1256, DOI 10.1378/chest.94.6.1256
   MATHUR KS, 1965, DIS CHEST, V47, P83, DOI 10.1378/chest.47.1.83
   MATHUR KS, 1960, TUBERCLE, V40, P358
   MCCORMACK HM, 1988, PSYCHOL MED, V18, P1007, DOI 10.1017/S0033291700009934
   MENON N K, 1964, Tubercle, V45, P17, DOI 10.1016/S0041-3879(64)80082-9
   MUTHUSWAMY P, 1995, CHEST, V107, P1621, DOI 10.1378/chest.107.6.1621
   PALEY SS, 1959, AM REV TUBERC PULM, V79, P307
   SCHOENBERG JB, 1978, RESP PHYSIOL, V33, P367, DOI 10.1016/0034-5687(78)90063-4
   SMITH MHD, 1958, PEDIATRICS, V22, P1074
   TANI P, 1964, ACTA TUBERC PNEUM SC, V44, P303
NR 23
TC 76
Z9 85
U1 0
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0012-3692
EI 1931-3543
J9 CHEST
JI Chest
PD AUG
PY 1996
VL 110
IS 2
BP 333
EP 338
DI 10.1378/chest.110.2.333
PG 6
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA VB923
UT WOS:A1996VB92300011
PM 8697829
DA 2021-08-04
ER

PT J
AU Maestrini, C
   Callaioli, A
   Rossi, M
   Bertani, R
AF Maestrini, C
   Callaioli, A
   Rossi, M
   Bertani, R
TI Styrenics materials and cyclopentane: Problems and perspectives
SO JOURNAL OF MATERIALS SCIENCE
LA English
DT Article
ID STRESS DUCTILE FRACTURE; HIGH-IMPACT POLYSTYRENE; ESSENTIAL WORK;
   POLYMERS
AB The use of chlorofluorocarbons (CFC) and hydrochlorofluorocarbons (HCFC) has been greatly limited in recent years because of their high ozone depletion potential (ODP) (Montreal protocol). The manufacturers of refrigerators have tried various new blowing agents for polyurethane (PU) foams used as insulating panels, and currently the chosen organic compound in Europe seems to be cyclopentane (CP), due to its acceptable insulating power and null ODP and toxicity. Unfortunately the interaction of CP with high impact polystyrene (HIPS) panels of the refrigerators produces blisters and can possibly induce environmental stress cracking (ESC). The aim of this work is, then, to explain the growth of blisters with a theoretical calculation and also to investigate the mechanical behaviour of HIPS in contact with gaseous and liquid CP, in comparison with usually used Freon(R) 11 (F11).
   By means of the group contribution one can calculate with the Flory-Huggins equation an isothermal adsorption curve for the polystyrene (PS) matrix/organic system and with the Chow equation calculate the lowering of T-g. From the calculation it is evident that the lower CP vapour pressure causes a considerable absorption, and this is simultaneous to the lesser CP amount needed to reach a 23 degrees C T-g for the PS matrix: it is then possible to state that the blisters form from a sort of micro blow-moulding, induced in the plasticized PS by the thermal treatments that are introduced in the refrigerator production cycle. The use of small amounts of acrylonitrile (AN) in the PS matrix may be sufficient to avoid this inconvenience, as it has been confirmed by lab and industrial experiences.
   From a mechanical point of view two experimental set-ups were designed in order to evaluate the ESC resistance in gaseous and liquid environment: for the first case slow crack propagation (SCP) experiments were performed in controlled atmospheres on compact tension (CT) specimens, while in the second case the essential work of fracture (EWF) technique was applied to double edge notch (DEN) specimens fully immersed in the considered liquids at different temperatures. In the first case it can be immediately concluded that the ESC produced in the presence of the same pressure of the two different agents (CP and F11) is very different, the CP one being much more aggressive than the F11. However, if the data are plotted versus the thermodynamic activity, there is no meaningful difference between CP and F11, suggesting that this parameter controls the ESC in gaseous environment for the considered blowing agents. In the case of ESC in the presence of a liquid, that could have a practical relevance in refrigerators if condensation phenomena take place, one observes that ordinary HIPS becomes rapidly brittle, while an AN modified HIPS maintains an appreciable ductility also in the presence of the liquid solvents.
RP Maestrini, C (corresponding author), ENICHEM RES CTR,VIA TALIERCIO 14,I-46100 MANTOVA,ITALY.
CR ANZALDI S, 1994, J MATER SCI LETT, V13, P1555, DOI 10.1007/BF00626507
   Barton A. F. M., 1983, CRC HDB SOLUBILITY P
   Broberg KB, 1968, INT J FRAC MECH, V4, P11
   BROWN G, 1965, P C PHYSICS NONCR SO, P303
   BROWN N, 1981, J MACROMOL SCI PHYS, VB19, P387, DOI 10.1080/00222348108015310
   BUBECK RA, 1981, POLYM ENG SCI, V21, P624, DOI 10.1002/pen.760211009
   CHOW TS, 1980, MACROMOLECULES, V13, P362, DOI 10.1021/ma60074a029
   CIGNA G, 1982, 6882 MONT
   COTTERELL B, 1977, INT J FRACTURE, V13, P267
   Flory P.J, 1953, PRINCIPLES POLYM CHE
   Hertzberg R.W., 1980, FATIGUE ENG PLASTICS
   HERTZBERG RW, 1985, ENCY POLYM SCI ENG, V10
   HOA SV, 1980, POLYM ENG SCI, V20, P1157, DOI 10.1002/pen.760201707
   Kato K., 1967, POLYM ENG SCI, V7, P38
   KRAMER EJ, 1979, DEV POLYM FRACTURE
   LEMONICK MD, 1994, TIME INT, V45, P61
   MAESTRINI C, 1992, J MATER SCI, V27, P5994, DOI 10.1007/BF01133742
   MAESTRINI C, IN PRESS POLYM
   MAI YW, 1991, J POLYM SCI POL PHYS, V29, P785, DOI 10.1002/polb.1991.090290702
   MAI YW, 1986, J MATER SCI, V21, P904, DOI 10.1007/BF01117371
   MAI YW, 1987, POLYM ENG SCI, V27, P804, DOI 10.1002/pen.760271106
   MAI YW, 1986, INT J FRACTURE, V32, P105, DOI 10.1007/BF00019787
   MAREGA C, COMMUNICATION
   OLF HG, 1974, J POLYM SCI POL PHYS, V12, P2209, DOI 10.1002/pol.1974.180121104
   PARIS PC, 1964, P 10 SAG C 1964 SYR
   PATON CA, 1992, J MATER SCI, V27, P2279, DOI 10.1007/BF01105033
   SAVADORI A, 1987, POLYM TEST, V7, P59, DOI 10.1016/0142-9418(87)90038-9
   SMITHS GF, 1993, J CELL PLAST, V29, P57
   VULF MA, 1988, INT POLYM SCI TECH, V15, pT62
   Williams J.G., 1984, FRACTURE MECH POLYM
   WILLIAMS JG, 1990, POLYM TEST, V9, P15, DOI 10.1016/0142-9418(90)90045-F
   1979, Patent No. 2951117
   1980, Patent No. 19220
   1970, PRUF THERMOPLAST KUN, V31
   1986, EGF NEWSLETT, V1
   1979, Patent No. 2946761
NR 36
TC 4
Z9 4
U1 0
U2 7
PU CHAPMAN HALL LTD
PI LONDON
PA 2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8HN
SN 0022-2461
J9 J MATER SCI
JI J. Mater. Sci.
PD JUL 15
PY 1996
VL 31
IS 14
BP 3747
EP 3761
DI 10.1007/BF00352790
PG 15
WC Materials Science, Multidisciplinary
SC Materials Science
GA UZ305
UT WOS:A1996UZ30500023
DA 2021-08-04
ER

PT J
AU Ivy, SP
   Olshefski, RS
   Taylor, BJ
   Patel, KM
   Reaman, GH
AF Ivy, SP
   Olshefski, RS
   Taylor, BJ
   Patel, KM
   Reaman, GH
TI Correlation of P-glycoprotein expression and function in childhood acute
   leukemia: A children's cancer group study
SO BLOOD
LA English
DT Article
ID MEDIATED MULTIDRUG RESISTANCE; ACUTE LYMPHOBLASTIC-LEUKEMIA; BACTERIAL
   TRANSPORT PROTEINS; ACUTE MYELOID-LEUKEMIA; TUMOR-CELL-LINES;
   DNA-SEQUENCES; MONOCLONAL-ANTIBODY; DRUG-RESISTANCE; CYCLOSPORINE-A;
   HAMSTER-CELLS
AB Clinical drug resistance may be attributed to the simultaneous selection and expression of genes modulating the uptake and metabolism of chemotherapeutic agents, P-glycoprotein (P-gp) functions as a membrane-associated drug efflux pump whose increased expression results in resistance to anthracyclines, epipodophyllotoxins, vinca alkaloids, and some alkylating agents. This type of resistance occurs as both de novo and acquired resistance to therapy for leukemia. We have studied P-gp expression and function in childhood acute leukemias by developing a series of doxorubicin- and vincristine-selected GEM, T-cell lymphoblastoid cell lines that recapitulate the low levels of expression and resistance seen clinically. These cell lines have been used to develop flow cytometric assays for the semiquantitative measurements of P-gp expression with the MRK16 monoclonal antibody and P-gp function using the enhanced retention of rhodamine 123 in the presence of verapamil, a resistance modulator, Kolmogorov-Smirnov statistics, represented by the D measurement, are used to determine the difference in level of P-gp expression by comparing MRK16 staining to an IgG2a isotype control. When D is >0.09, there is an excellent correlation (R = 0.82) between P-gp expression and function. The evaluation of 107 bone marrow specimens from 84 children with lymphoblastic or myelogenous leukemia showed a statistically significant (P = .004) increase in P-gp function at relapse. P-gp expression at relapse, however, approached but did not reach a significant level (P = .097), Using this methodology, we can identify patients with levels of P-gp expression and function that we can define clinically, as well as children with discordant multidrug resistance phenotypes, This study supports the role of P-gp-mediated drug resistance in childhood leukemia and confirms that P-gp expression and function are measurable in their leukemic blasts. These assays provide the means for the in vitro testing of resistance modulators and the monitoring of in vivo response to treatment with these agents. (C) 1996 by The American Society of Hematology.
C1 CHILDRENS NATL MED CTR,CHILDRENS RES INST,DEPT HEMATOL ONCOL,WASHINGTON,DC 20010.
   CHILDRENS NATL MED CTR,CHILDRENS RES INST,CANC & TRANSPLANTAT RES CTR,WASHINGTON,DC 20010.
FU NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [CA
   02971, CA 13539, CA 17829] Funding Source: Medline; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [U10CA002971, U10CA013539, U10CA017829] Funding Source: NIH RePORTER
CR ALLEY MC, 1988, CANCER RES, V48, P589
   ARCECI RJ, 1993, BLOOD, V81, P2215
   ARMITAGE P, 1971, STAT METHODS MED RES
   AUTL KA, 1979, STAT METHODS MED RES, V300, P1401
   BOESCH D, 1991, CANCER RES, V51, P4226
   CAIRO MS, 1989, CANCER RES, V49, P1063
   CHAUDHARY PM, 1991, CELL, V66, P85, DOI 10.1016/0092-8674(91)90141-K
   CHAUDHARY PM, 1992, BLOOD, V80, P2735
   CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7
   COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704
   DALTON WS, 1989, J CLIN ONCOL, V7, P415, DOI 10.1200/JCO.1989.7.4.415
   DINNDORF PA, 1986, BLOOD, V68, P975
   ERLICHMAN C, 1993, CANCER RES, V53, P4837
   GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C
   GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5
   GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0
   GROS P, 1986, P NATL ACAD SCI USA, V83, P337, DOI 10.1073/pnas.83.2.337
   GRUBER A, 1992, BRIT J CANCER, V66, P266, DOI 10.1038/bjc.1992.255
   HAMADA H, 1990, CANCER RES, V50, P3167
   INO T, 1994, LEUKEMIA, V8, P1492
   IVY SP, 1992, P AM ASSOC CANC RES, V33, pA473
   KESSEL D, 1991, CANCER RES, V51, P4665
   LAMY T, 1995, LEUKEMIA, V9, P1549
   LEITH CP, 1995, BLOOD, V86, P2329, DOI 10.1182/blood.V86.6.2329.bloodjournal8662329
   LIST AF, 1993, J CLIN ONCOL, V11, P1652, DOI 10.1200/JCO.1993.11.9.1652
   LUDESCHER C, 1995, LEUKEMIA, V9, P350
   MECHETNER EB, 1992, P NATL ACAD SCI USA, V89, P5824, DOI 10.1073/pnas.89.13.5824
   MIWA H, 1993, BLOOD, V82, P3445
   OZOLS RF, 1987, J CLIN ONCOL, V5, P641, DOI 10.1200/JCO.1987.5.4.641
   POPLACK DG, 1988, PEDIATR CLIN N AM, V35, P903
   POPLACK DG, 1989, PRINCIPLES PRACTICE, P323
   PUI CH, 1995, NEW ENGL J MED, V332, P1618, DOI 10.1056/NEJM199506153322407
   RONINSON IB, 1984, NATURE, V309, P626, DOI 10.1038/309626a0
   RONINSON IB, 1983, NUCLEIC ACIDS RES, V11, P5413, DOI 10.1093/nar/11.16.5413
   ROSS DD, 1993, BLOOD, V82, P1288
   ROSS DD, 1989, CYTOMETRY, V10, P185, DOI 10.1002/cyto.990100209
   SALMON SE, 1991, BLOOD, V78, P44
   SCHEPER RJ, 1993, CANCER RES, V53, P1475
   SIEVERS EL, 1994, BLOOD, V84, pA303
   SONNEVELD P, 1993, LEUKEMIA, V7, P963
   TEBOEKHORST PAW, 1993, BLOOD, V82, P3157
   TSURUO T, 1987, JPN J CANCER RES, V78, P1415
   TSURUO T, 1983, CANCER RES, V43, P2267
   TSURUO T, 1981, CANCER RES, V41, P1967
   TWENTYMAN PR, 1991, EUR J CANCER, V27, P1639, DOI 10.1016/0277-5379(91)90435-G
   YOUNG IT, 1977, J HISTOCHEM CYTOCHEM, V25, P935, DOI 10.1177/25.7.894009
NR 46
TC 73
Z9 76
U1 0
U2 1
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0006-4971
J9 BLOOD
JI Blood
PD JUL 1
PY 1996
VL 88
IS 1
BP 309
EP 318
PG 10
WC Hematology
SC Hematology
GA UV297
UT WOS:A1996UV29700035
PM 8704189
DA 2021-08-04
ER

PT J
AU Pellegrini, PA
   Reader, S
AF Pellegrini, PA
   Reader, S
TI Duration modeling of spatial point patterns
SO GEOGRAPHICAL ANALYSIS
LA English
DT Article
ID URBAN SHOPPING BEHAVIOR; PANEL-DATA MODELS; RESIDENTIAL-MOBILITY;
   LONGITUDINAL DATA; HOUSING CAREERS; HETEROGENEITY; MIGRATION; VARIABLES;
   CHOICE; LIKELIHOOD
AB This paper attempts to further the research by Odland and Ellis (1992) in applying event history methodology to the analysis of spatial point patterns (that is, event patterns). Its empirical focus is the event pattern derived from the adoption of an agricultural innovation, the Harvestore, in southern. Ontario, Canada, from 1963 to 1986. Event history analysis involves the use of discrete-state, continuous-time stochastic models to investigate a tempos-al longitudinal record on discrete variables. Event history models are usually concerned with durations of time between events and the effects of intertemporal time dependencies on future event occurrences. As such, they are often referred to as duration models. Many of the methods used in event history analysis allow the use of other nonnegative interval measurements in place of standard temporal intervals to investigate a series of events. In particular, spatial intervals (or durations) of distances between events may also be accommodated by event history models. Our analysis extends the previous research of Odland and Ellis (1992) by using a wider range of parametric models to explore duration dependence, investigating the role of spatial censoring, and using a more extensive set of explanatory variables. In addition, simulation experiments and graphical tests are used to evaluate the empirical event pattern against one generated from Complete Spatial Randomness. Results indicate that the event pattern formed by the Harvestore adopter farms is clustered (that is, is described by positive duration dependency), the sales agent is a significant factor ist the distribution of adopters, and that contrasting results are obtained from the analysis using censored data versus uncensored data.
C1 MCMASTER UNIV,GIS LAB,HAMILTON,ON L8S 4L8,CANADA.
RP Pellegrini, PA (corresponding author), SUNY BUFFALO,DEPT GEOG,BUFFALO,NY, USA.
CR Allison PD, 1984, EVENT HIST ANAL REGR
   BLOSSFELD HP, 1989, EVENT HIST ANAL
   BROWN LA, 1981, INNOVATION DIFFUSION
   CLARK PJ, 1954, ECOLOGY, V35, P445, DOI 10.2307/1931034
   CLARK WAV, 1992, ENVIRON PLANN A, V24, P1291, DOI 10.1068/a241291
   COX D. R., 1984, ANAL SURVIVAL DATA
   COX DR, 1975, BIOMETRIKA, V62, P269, DOI 10.1093/biomet/62.2.269
   COX DR, 1962, J ROY STAT SOC B, V24, P406
   CROUCHLEY R, 1987, LONGITUDINAL DATA AN
   DAVIES RB, 1984, ENVIRON PLANN A, V16, P1375, DOI 10.1068/a161375
   DAVIES RB, 1984, REG SCI URBAN ECON, V14, P231, DOI 10.1016/0166-0462(84)90025-5
   DAVIES RB, 1985, ENVIRON PLANN A, V17, P1315, DOI 10.1068/a171315
   DAVIES RB, 1991, ENVIRON PLANN A, V23, P629, DOI 10.1068/a230629
   DAVIES RB, 1987, TRANSPORT RES A-POL, V21, P345, DOI 10.1016/0191-2607(87)90054-9
   DAVIES RB, 1982, SOCIOL METHOD RES, V10, P285, DOI 10.1177/0049124182010003003
   DAVIES RB, 1982, ENVIRON PLANN A, V14, P603, DOI 10.1068/a140603
   DAVIES RB, 1982, DEMOGRAPHY, V19, P291, DOI 10.2307/2060972
   DAVIES RB, 1983, GEOGR ANAL, V15, P305
   DAVIES RB, 1982, ENVIRON PLANN A, V15, P1475
   Dawson A.H., 1975, AREA, V7, P42
   DETEMPLE DJ, 1970, THESIS MICHIGAN STAT
   DETEMPLE DJ, 1971, GEOGRAPHIC MONOGRAPH
   DIGGLE PJ, 1983, STATISTICAL ANAL SPA
   EASTMAN RJ, 1991, IDRISI GRID BASED GE
   Fingleton B, 1985, SPATIAL DATA ANAL EX, V1
   FOTHERINGHAM AS, 1993, INT J GEOGR INF SYST, V7, P3, DOI 10.1080/02693799308901936
   FOTHERINGHAM AS, 1994, IN PRESS GEOGRAPHICA
   GETIS A, 1978, MODELS SPATIAL PROCE
   GREENE WH, 1990, LIMDEP VERSION 5 1
   HALPERIN WC, 1985, MEASURING UNMEASURAB, P561
   HECKMAN JJ, 1980, ECONOMICA, V47, P247, DOI 10.2307/2553150
   KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI
   KIEFER NM, 1988, J ECON LIT, V26, P646
   LAWLESS JF, 1982, STATISTICAL MODELS M
   MAYER K.U., 1990, EVENT HIST ANAL LIFE
   ODLAND J, 1992, GEOGR ANAL, V24, P97
   PELLEGRINI PA, 1993, THESIS MCMASTER U
   PICKLES A, 1985, J REGIONAL SCI, V25, P85, DOI 10.1111/j.1467-9787.1985.tb00295.x
   PICKLES AR, 1982, ENVIRON PLANN A, V14, P615, DOI 10.1068/a140615
   PICKLES AR, 1983, REG SCI URBAN ECON, V13, P271, DOI 10.1016/0166-0462(83)90017-0
   Pickles AR, 1984, SPATIAL STAT MODELS, P321
   READER S, 1993, ENVIRON PLANN A, V25, P495, DOI 10.1068/a250495
   READER S, 1988, LONDON PAPERS REGION, V18, P45
   READER S, 1988, THESIS U BRISTOL
   Rogers E.M., 1962, DIFFUSION INNOVATION, V1st ed.
   SCORGIE EK, 1992, THESIS U WATERLOO
   SCORGIE EK, 1973, THESIS U W ONTARIO
   Tuma N. B., 1984, SOCIAL DYNAMICS MODE
   TUMA NB, 1978, SOCIOL METHODOL, P209
   TUMA NB, 1982, SOCIOL METHODOL, P1
   Vincent P., 1976, AREA, V8, P161
   WRIGLEY N, 1984, ENVIRON PLANN A, V16, P629, DOI 10.1068/a160629
   WRIGLEY N, 1984, ENVIRON PLANN A, V16, P1221, DOI 10.1068/a161221
   WRIGLEY N, 1986, PROG HUM GEOG, V10, P84, DOI 10.1177/030913258601000105
   WRIGLEY N, 1984, ENVIRON PLANN A, V16, P759, DOI 10.1068/a160759
   WRIGLEY N, 1985, ENVIRON PLANN A, V17, P319, DOI 10.1068/a170319
NR 56
TC 14
Z9 14
U1 0
U2 7
PU OHIO STATE UNIV PRESS
PI COLUMBUS
PA 1050 CARMACK RD, COLUMBUS, OH 43210
SN 0016-7363
J9 GEOGR ANAL
JI Geogr. Anal.
PD JUL
PY 1996
VL 28
IS 3
BP 219
EP 243
PG 25
WC Geography
SC Geography
GA UU704
UT WOS:A1996UU70400003
DA 2021-08-04
ER

PT J
AU Reith, W
   Dardzinski, BJ
   Sotak, CH
   Fisher, M
AF Reith, W
   Dardzinski, BJ
   Sotak, CH
   Fisher, M
TI Monitoring of tissue plasminogen activator treatment with multislice
   diffusion mapping and perfusion imaging in a thromboembolic stroke model
SO INTERNATIONAL JOURNAL OF NEURORADIOLOGY
LA English
DT Article
DE diffusion mapping; perfusion imaging; tissue plasminogen activator;
   thromboembolic stroke model
ID CEREBRAL-ISCHEMIA; CONTRAST AGENTS; CANINE MODEL; RAT MODEL; HEPARIN
AB Purpose: Thromboembolic stroke models in animals closely simulate human embolic stroke, However, great intrinsic variability in the size of the ischemic lesions that are produced makes evaluation of the success of later therapies difficult. Diffusion and perfusion MRI can be employed to assess the size, and subsequent status, of experimental and clinical stroke subjects undergoing thrombolytic therapy,
   Methods: Beginning 30 minutes after embolization of the middle cerebral artery territory with autologous clot, 15 Sprague-Dawley rats were randomly assigned to treatment with a 30-minute infusion of either t-PA or saline, Serial, whole-brain, diffusion-weighted mapping studies were performed before, during, and after the t-PA (or saline) infusion to quantitatively identify the ischemic region. Bolus tracking perfusion imaging with gadolinium trimeglumine was performed before clot injection, just before treatment, and 30 minutes after the t-PA infusion, Infarction volume at 24 hours after embolization was calculated using 2, 3, 5-triphenyltetrazolium chloride staining, Animals with pre-treatment ischemic lesion volumes less than 100 mm(3) were excluded to reduce the variability of the model,
   Results: The volume of the ischemic lesion showed no statistically significant difference in the t-PA group as compared to controls (n = 7 per group), When one control animal with spontaneous reperfusion was excluded, the diffusion imaging studies showed a significantly smaller ischemic lesion volume in the t-PA group at 60, 90, and 120 minutes after embolization (P < .05). Perfusion imaging documented reduced flow before treatment in all animals, improvement after treatment in four of seven t-PA animals, and spontaneous reperfusion in one control animal,
   Conclusion: This pilot study demonstrates that diffusion and perfusion imaging can be used to evaluate thrombolytic therapy in a thromboembolic stroke model in vivo.
C1 UNIV HEIDELBERG,SCH MED,DEPT NEURORADIOL,D-69120 HEIDELBERG,GERMANY.
   UNIV MASSACHUSETTS,SCH MED,DEPT NEURORADIOL,WORCESTER,MA.
   UNIV MASSACHUSETTS,SCH MED,DEPT RADIOL,WORCESTER,MA.
   WORCESTER POLYTECH INST,DEPT BIOMED ENGN,WORCESTER,MA 01609.
   MED CTR CENT MASSACHUSETTS MEM,WORCESTER,MA.
CR DARDZINSKI BJ, 1993, MAGNET RESON MED, V30, P318, DOI 10.1002/mrm.1910300307
   DECRESPIGNY AJ, 1993, JMRI-J MAGN RESON IM, V3, P746, DOI 10.1002/jmri.1880030510
   FIESCHI C, 1989, J NEUROL SCI, V91, P311, DOI 10.1016/0022-510X(89)90060-9
   GARCIA JH, 1993, AM J PATHOL, V142, P623
   GORE JC, 1990, MAGNET RESON MED, V14, P242, DOI 10.1002/mrm.1910140210
   HEISS WD, 1983, ANN NEUROL, V14, P294, DOI 10.1002/ana.410140307
   LEBIHAN D, 1990, J MAGN RESON IMAGING, V1, P7
   MANSFIELD P, 1977, J PHYS C SOLID STATE, V10, pL55, DOI 10.1088/0022-3719/10/3/004
   MARTIN U, 1991, J CARDIOVASC PHARM, V18, P111, DOI 10.1097/00005344-199107000-00015
   MINEMATSU K, 1993, STROKE, V24, P2974
   MINEMATSU K, 1992, NEUROLOGY, V42, P1717
   OVERGAARD K, 1990, FIBRINOLYSIS, V4, P13, DOI 10.1016/0268-9499(90)90348-N
   OVERGAARD K, 1992, J CEREBR BLOOD F MET, V12, P484, DOI 10.1038/jcbfm.1992.66
   REITH W, 1995, NEUROLOGY, V45, P172, DOI 10.1212/WNL.45.1.172
   REITH W, 1995, AM J NEURORADIOL, V16, P53
   ROSEN BR, 1990, MAGNET RESON MED, V14, P249, DOI 10.1002/mrm.1910140211
   SAKAMURA T, 1994, STROKE, V25, P451
   SHEBUSKI RJ, 1990, CIRCULATION, V82, P169, DOI 10.1161/01.CIR.82.1.169
   VILLRINGER A, 1988, MAGNET RESON MED, V6, P164, DOI 10.1002/mrm.1910060205
   VONKUMMER R, 1992, STROKE, V23, P646, DOI 10.1161/01.STR.23.5.646
   WARDLAW JM, 1992, STROKE, V23, P1820
   ZIVIN JA, 1988, ARCH NEUROL-CHICAGO, V45, P387, DOI 10.1001/archneur.1988.00520280033012
NR 22
TC 2
Z9 2
U1 0
U2 1
PU LIPPINCOTT-RAVEN PUBL
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106
SN 1079-8110
J9 INT J NEURORADIOL
JI Int. J. Neuroradiol.
PD JUL-AUG
PY 1996
VL 2
IS 4
BP 397
EP 407
PG 11
WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical
   Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA VC485
UT WOS:A1996VC48500009
DA 2021-08-04
ER

PT J
AU Pitarresi, G
   Tomarchio, V
   Cavallaro, G
   Spadaro, G
   Giammona, G
AF Pitarresi, G
   Tomarchio, V
   Cavallaro, G
   Spadaro, G
   Giammona, G
TI Microparticles of a polyaspartamide cross-linked by gamma irradiation
   containing zidovudine and diflunisal as model drugs: Preparation,
   characterization and in vitro release behaviour
SO STP PHARMA SCIENCES
LA English
DT Article
DE alpha,beta-poly(N-hydroxyethyl)-DL-aspartamide; hydrogels; gamma
   radiation; zidovudine; diflunisal; drug release
ID ANTIVIRAL AGENT; DERIVATIVES; DELIVERY
AB alpha, beta-poly(N-hydroxyethyl)-DL-aspartamide was cross-linked by gamma radiations in order to obtain micromatrices capable of swelling in an aqueous medium. alpha, beta-poly(N-hydroxyethyl)-DL-aspartamide hydrogels were loaded by a soaking method with zidovudine, a water soluble drug, and diflunisal, a poorly water soluble drug. Samples containing two different loaded drug amounts (4.76 and 16.70 % m/m) were prepared. X-ray analysis revealed that both these drugs are dispersed into alpha, beta-poly(N-hydroxyethyl)-DL-aspartamide networks in an amorphous state. alpha, beta-poly(N-hydroxyethyl)-DL-aspartamide hydrogels loaned with zidovudine or diflunisal were also characterized by dimensional analysis and scanning electron microscopy, which showed the presence of quasi-spherical micro particles. The zidovudine release from alpha, beta-poly(N-hydroxyethyl)-DL-aspartamide hydrogels was studied in vitro at pH I and in pH 7.4 phosphate buffer solution. Experimental results indicated that zidovudine is released rapidly, regardless of the pH value or the amount of drug loaded. In vitro release tests of alpha, beta-poly(N-hydroxyethyl)-DL-aspartamide hydrogels loaded with diflunisal were performed in simulated gastro-intestinal fluids (pH 1/6.8) using the pH variation method, and in pH 7.4 phosphate buffer solution. Experimental data indicated that, particularly at a low pH, the delivery of diflunisal is more prolonged than that of zidovudine.
C1 UNIV PALERMO,DIPARTIMENTO CHIM & TECNOL FARMACEUT,I-90123 PALERMO,ITALY.
   UNIV PALERMO,DIPARTIMENTO INGN CHIM PROC & MAT,I-90128 PALERMO,ITALY.
CR ANTONI G, 1979, IL FARMACO, V34, P146
   BRODGEN RN, 1980, DRUGS, V19, P84
   BRONDSTED H, 1990, P INT S CONTROL REL, V17, P128
   CALDERARO E, 1980, QUADERNI I APPL IMPI, V3
   COUARRAZE G, 1989, INT J PHARM, V56, P197, DOI 10.1016/0378-5173(89)90015-X
   Dumitriu Severian, 1994, P3
   FILIPOVAVOPRSALOVA M, 1991, J CONTROL RELEASE, V17, P89, DOI 10.1016/0168-3659(91)90134-Y
   GIAMMONA G, 1995, J CONTROL RELEASE, V33, P261, DOI 10.1016/0168-3659(94)00091-8
   GIAMMONA G, 1987, J POLYM SCI POL CHEM, V25, P2813, DOI 10.1002/pola.1987.080251016
   GIAMMONA G, 1992, J CONTROL RELEASE, V22, P197, DOI 10.1016/0168-3659(92)90094-8
   GIAMMONA G, 1991, J BIOACT COMPAT POL, V6, P129, DOI 10.1177/088391159100600202
   GIAMMONA G, 1994, INT J PHARM, V104, P57
   KAKLAMANIS PH, 1990, CLIN THER, V1, P279
   LANGMAN MJS, 1994, LANCET, V343, P1075, DOI 10.1016/S0140-6736(94)90185-6
   MERKLI A, 1994, PHARMACEUT RES, V11, P1485, DOI 10.1023/A:1018964511053
   MIRCHANDANI H, 1993, INT J PHARM, V95, P1, DOI 10.1016/0378-5173(93)90385-S
   MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096
   NERI P, 1973, J MED CHEM, V16, P893, DOI 10.1021/jm00266a006
   RIDEIJOT JL, 1986, Patent No. 3608606
   ROBERT C C R, 1987, Journal of Controlled Release, V5, P151, DOI 10.1016/0168-3659(87)90006-X
   ROSIAK JM, 1995, RADIAT PHYS CHEM, V46, P161, DOI 10.1016/0969-806X(95)00007-K
   Spadaro G, 1996, BIOMATERIALS, V17, P953, DOI 10.1016/0142-9612(96)84668-0
NR 22
TC 7
Z9 7
U1 0
U2 0
PU EDITIONS SANTE
PI PARIS
PA 5 RUE LAS CASES, 75007 PARIS, FRANCE
SN 1157-1497
J9 STP PHARMA SCI
JI STP Pharma Sci.
PD JUL-AUG
PY 1996
VL 6
IS 4
BP 292
EP 297
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA VR062
UT WOS:A1996VR06200006
DA 2021-08-04
ER

PT J
AU Ravn, HB
   Vissinger, H
   Kristensen, SD
   Husted, SE
AF Ravn, HB
   Vissinger, H
   Kristensen, SD
   Husted, SE
TI Magnesium inhibits platelet activity - An in vitro study
SO THROMBOSIS AND HAEMOSTASIS
LA English
DT Article
ID ACUTE MYOCARDIAL-INFARCTION; INTRAVENOUS-MAGNESIUM; CALCIUM;
   ANTICOAGULANT; SULFATE; AGENTS; BLOOD; AGGREGOMETER; PROSTACYCLIN;
   BEHAVIOR
AB The in vitro effect of magnesium (Mg) on platelet aggregation and platelet release function was evaluated in healthy volunteers, Platelet aggregation was induced with collagen, ADP, or thrombin after incubation of the sample with saline or increasing concentrations of magnesium sulphate (MgSO4) (0.5-8.0 mM). Mg showed a dose-dependent inhibition of platelet aggregation in whole blood, platelet rich plasma and washed platelets, An antiaggregatory effect was also present with low Mg concentrations. Statistically significant inhibition of the mean aggregation response was obtained in 83% of the different media and agonists rested following the addition of 1.0 mM Mg, The remaining 17% were significantly inhibited with the addition of 2.0 mM Mg. The platelet synthesis of thromboxane A(2) and release of beta-thromboglobulin were also inhibited by Mg, in a dose-dependent manner. In order to evaluate if any of these effects were modified by conventional antithrombotic treatment with low-dose acetylsalicylic acid (ASA), volunteers were asked to meet on two consecutive days. On day 2 the participants were given 300 mg ASA orally, one hour prior to blood sampling. The Mg mediated effects were present independent of this pretreatment with ASA. Following stimulation with collagen a synergistic effect of Mg and ASA was demonstrated on platelet aggregation. The platelet inhibiting effect demonstrated in this study may in part explain the beneficial effect of Mg infusion in some patients with acute myocardial infarction, The effect of Mg infusion: given alone or administered simultaneously with ASA, should also be evaluated in other arterial thrombotic disease states.
C1 AARHUS UNIV HOSP, SKEJBY SYGEHUS, DEPT CARDIOL, DK-8000 AARHUS, DENMARK.
RP Ravn, HB (corresponding author), AARHUS UNIV, DEPT INTERNAL MED & CARDIOL, AARHUS KOMMUNE HOSP, DK-8000 AARHUS C, DENMARK.
CR ABBATE R, 1989, AM J CLIN PATHOL, V91, P159, DOI 10.1093/ajcp/91.2.159
   Acland R, 1972, Br J Plast Surg, V25, P292, DOI 10.1016/S0007-1226(72)80066-3
   ADAMS JH, 1979, THROMB HAEMOSTASIS, V42, P603
   ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81
   [Anonymous], 1988, LANCET, V2, P349
   BLACKWELL GJ, 1982, BIOCHIM BIOPHYS ACTA, V718, P60, DOI 10.1016/0304-4165(82)90009-5
   BORN GVR, 1962, NATURE, V194, P927, DOI 10.1038/194927b0
   CARDINAL DC, 1980, J PHARMACOL METHOD, V3, P135, DOI 10.1016/0160-5402(80)90024-8
   CHRONOS NAF, 1994, CLIN SCI, V87, P575, DOI 10.1042/cs0870575
   COLLINS R, 1995, LANCET, V345, P669
   FALK E, 1992, CIRCULATION, V86, P30
   FUSTER V, 1985, J AM COLL CARDIOL, V5, pB175, DOI 10.1016/S0735-1097(85)80552-0
   GAWAZ M, 1994, THROMB HAEMOSTASIS, V72, P912
   GERTZ SD, 1987, MAGNESIUM, V6, P225
   HARDY E, 1995, THROMB HAEMOSTASIS, V74, P1132
   HARDY E, 1995, PLATELETS, V6, P346, DOI 10.3109/09537109509078470
   HEPTINSTALL S, 1976, THROMB HAEMOSTASIS, V36, P208, DOI 10.1055/s-0038-1648026
   HUGHES A, 1966, NATURE, V210, P106, DOI 10.1038/210106a0
   HWANG DL, 1992, AM J HYPERTENS, V5, P700, DOI 10.1093/ajh/5.10.700
   ISERI LT, 1984, AM HEART J, V108, P188, DOI 10.1016/0002-8703(84)90572-6
   Kristensen S D, 1991, Platelets, V2, P11, DOI 10.3109/09537109109005497
   MARKI WE, 1990, THROMB HAEMOSTASIS, V64, P344
   MARKWARDT F, 1991, THROMB HAEMOSTASIS, V66, P141
   MARTIN JF, 1991, LANCET, V338, P1409, DOI 10.1016/0140-6736(91)92719-I
   NADLER JL, 1992, DIABETES CARE, V15, P835, DOI 10.2337/diacare.15.7.835
   PACKHAM MA, 1989, THROMB HAEMOSTASIS, V62, P968
   PACKHAM MA, 1987, BLOOD, V70, P647
   RADOMSKI M, 1983, THROMB RES, V30, P383, DOI 10.1016/0049-3848(83)90230-X
   RINDER CS, 1993, BLOOD, V82, P505
   SMYTH DW, 1993, EUR J CLIN INVEST, V23, P361, DOI 10.1111/j.1365-2362.1993.tb02037.x
   TEO KK, 1991, BMJ-BRIT MED J, V303, P1499, DOI 10.1136/bmj.303.6816.1499
   WALLEN NH, 1993, CLIN SCI, V85, P577, DOI 10.1042/cs0850577
   WALLENTIN L, 1990, LANCET, V336, P827
   WATSON KV, 1986, P NATL ACAD SCI USA, V83, P1075, DOI 10.1073/pnas.83.4.1075
   WOODS KL, 1992, LANCET, V339, P1553, DOI 10.1016/0140-6736(92)91828-V
   WOODS KL, 1991, BRIT J CLIN PHARMACO, V32, P3, DOI 10.1111/j.1365-2125.1991.tb05605.x
NR 36
TC 50
Z9 52
U1 0
U2 1
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0340-6245
EI 2567-689X
J9 THROMB HAEMOSTASIS
JI Thromb. Haemost.
PD JUL
PY 1996
VL 76
IS 1
BP 88
EP 93
PG 6
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA UX026
UT WOS:A1996UX02600018
PM 8819258
DA 2021-08-04
ER

PT J
AU Murciano, A
   Millan, JDR
AF Murciano, A
   Millan, JDR
TI Learning signaling behaviors and specialization in cooperative agents
SO ADAPTIVE BEHAVIOR
LA English
DT Article
DE reinforcement learning; multiagent systems; cooperation; specialization
ID REINFORCEMENT
AB In this article, we present a learning mechanism that allows a multiagent system to cooperate to achieve a gathering task efficiently in unknown and changing environments. The multiagent system is a team of autonomous behavior-based agents with limited communication capabilities. Cooperation is based on the acquisition of signaling behaviors and on the specialization of She agents into different types. Every agent has the same collection of built-in reactive behaviors. Some of she built-in behaviors are fixed, whereas others can be modified through reinforcement learning. The reinforcement signal is delayed until a trial is completed and assesses the collective performance of the ream. Each agent uses this common signal to learn what individual behaviors are more suitable for the team. Simulation results, and the corresponding statistical analysis, show that the multiagent system always achieves near-optimal performances.
C1 COMMISS EUROPEAN COMMUNITIES,JOINT RES CTR,INST SYST INFORMAT & SAFETY,I-21020 ISPRA,VA,ITALY.
RP Murciano, A (corresponding author), UNIV COMPLUTENSE MADRID,FAC BIOL,DEPT BIOMATEMAT,E-28040 MADRID,SPAIN.
RI del R. Millan, Jose/F-1696-2011
OI del R. Millan, Jose/0000-0001-5819-1522
CR ARKIN RC, 1989, INT J ROBOT RES, V8, P92, DOI 10.1177/027836498900800406
   BARTO AG, 1995, ARTIF INTELL, V72, P81, DOI 10.1016/0004-3702(94)00011-O
   BARTO AG, 1989, COINS8995 U MASS DEP
   DROGOUL A, 1993, ANIMALS ANIMATS, V2
   GOSS S, 1992, PRACTICE AUTONOMOUS
   KUBE CR, 1993, ADAPT BEHAV, V2, P189
   LIN LJ, 1992, MACH LEARN, V8, P293, DOI 10.1023/A:1022628806385
   MAHADEVAN S, 1992, ARTIF INTELL, V55, P311, DOI 10.1016/0004-3702(92)90058-6
   MATARIC M, 1994, ANIMALS ANIMATS, V3
   MATARIC MJ, 1994, MACHINE LEARNING
   MATARIC MJ, 1993, ANIMALS ANIMATS, V2
   MILLAN JDR, 1992, MACH LEARN, V8, P363, DOI 10.1023/A:1022684924132
   MILLAN JDR, 1994, ANIMALS ANIMATS, V3
   MITCHELL TM, 1993, ADV NEURAL INFORMATI, V5
   MURCIANO A, 1995, THESIS U COMPLUTENSE
   NUMAOKA C, 1993, ANIMALS ANIMATS, V2
   PRESCOTT TJ, 1992, ADV NEURAL INFORMATI, V4
   STEELS L, 1994, ANIMALS ANIMATS, V3
   Sutton, 1984, THESIS U MASSACHUSET
   SUTTON R, 1990, P 7 INT C MACH LEARN
   Tan Ming, 1993, P 10 INT C MACH LEAR
   WEISS G, 1993, ANIMALS ANIMATS, V2
   YANCO H, 1993, ANIMALS ANIMATS, V2
NR 23
TC 12
Z9 12
U1 0
U2 3
PU M I T PRESS
PI CAMBRIDGE
PA FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142
SN 1059-7123
J9 ADAPT BEHAV
JI Adapt. Behav.
PD SUM
PY 1996
VL 5
IS 1
BP 5
EP 28
DI 10.1177/105971239600500102
PG 24
WC Computer Science, Artificial Intelligence; Psychology, Experimental;
   Social Sciences, Interdisciplinary
SC Computer Science; Psychology; Social Sciences - Other Topics
GA WR155
UT WOS:A1996WR15500002
DA 2021-08-04
ER

PT J
AU Randitelli, S
   Baiocchi, C
   Pesi, R
   Allegrini, S
   Turriani, M
   Ipata, PL
   Camici, M
   Tozzi, MG
AF Randitelli, S
   Baiocchi, C
   Pesi, R
   Allegrini, S
   Turriani, M
   Ipata, PL
   Camici, M
   Tozzi, MG
TI The phosphotransferase activity of cytosolic 5'-nucleotidase; A purine
   analog phosphorylating enzyme
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
LA English
DT Article
DE 5'-nucleotidase; purine analogs; capillary electrophoresis;
   deoxycoformycin
ID NUCLEOSIDE PHOSPHOTRANSFERASE; CYTOPLASMIC 5'-NUCLEOTIDASE;
   2'-DEOXYCOFORMYCIN; METABOLISM; INHIBITION; DEAMINASE; ADENOSINE;
   PROTEIN; CELLS; RAT
AB Cytosolic 5'-nucleotidase is involved in the phosphorylation of several purine nucleoside analogs, used as antiviral and chemotherapeutic agents. In order to assess its role in the mechanisms of activation and inactivation of purine prodrugs, it is essential to study the regulation of both hydrolase and phosphotransferase activities of the enzyme. Using a zone capillary electrophoresis apparatus, we were able to separate substrates and products of the reactions catalyzed by cytosolic 5'-nucleotidase. The method overcomes the frequent unavailability of radiolabeled substrates, and allows the influence of possible effecters and/or experimental conditions on both enzyme activities to be evaluated simultaneously. Results showed that the enzyme was able to phosphorylate several nucleosides and nucleoside analogs with the following efficiency: inosine and 2'-deoxyinosine > 2',3'-dideoxyinosine > 6-chloropurineriboside > 6-hydroxylaminepurine riboside > 2,6-diaminopurine riboside > adenosine > cytidine > deoxycoformycin > 2'-deoxyadenosine. This is the first report of deoxycoformycin phosphorylation catalyzed by a 5'-nucleotidase purified from eukaryotic cells. The optimum pH for nucleoside monophosphate hydrolysis was 6.5, slightly more acidic than the optimum pH for the transfer of the phosphate, which was 7.2. Finally, the presence of a suitable substrate for the phosphotransferase activity of cytosolic 5'-nucleotidase caused a stimulation of the rate of formation of the nucleoside. The results suggest the requirements for phosphorylation of nucleoside analogs are a purine ring and the presence of an electronegative group in the 6-position. The stimulation of the rate of nucleoside monophosphate disappearance exerted by the phosphate acceptor suggests that the hydrolysis of the phosphoenzyme intermediate is the rate-limiting step of the process. (C) 1996 Elsevier Science Ltd
C1 UNIV SASSARI,FAC FARM,IST CHIM BIOL,I-07100 SASSARI,ITALY.
   UNIV PISA,DIPARTIMENTO FISIOL & BIOCHIM,BIOCHIM LAB,I-56100 PISA,ITALY.
RI Pesi, Rossana/AAQ-3102-2020; Tozzi, Maria Grazia/A-6018-2016; Allegrini,
   Simone/F-9192-2010
OI Tozzi, Maria Grazia/0000-0002-1075-7096; Allegrini,
   Simone/0000-0002-7005-654X; Pesi, Rossana/0000-0003-4785-7282
CR ALLEGRINI S, 1993, J BIOCHEM BIOPH METH, V27, P293, DOI 10.1016/0165-022X(93)90010-L
   BAIOCCHI C, 1993, INT J BIOCHEM, V25, P1625, DOI 10.1016/0020-711X(93)90521-F
   BONTEMPS F, 1988, PURIEN PYRIMIDINE ME, V6, P141
   BONTEMPS F, 1994, J BIOL CHEM, V269, P17820
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   CARRERAS J, 1986, CLIN BIOCHEM, V19, P348, DOI 10.1016/S0009-9120(86)80008-X
   CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4
   CIRRI P, 1993, EUR J BIOCHEM, V214, P647, DOI 10.1111/j.1432-1033.1993.tb17965.x
   FRIEDEN C, 1979, BIOCHEM BIOPH RES CO, V91, P278, DOI 10.1016/0006-291X(79)90614-4
   FUJITAKI JM, 1992, J BIOCHEM BIOPH METH, V25, P1, DOI 10.1016/0165-022X(92)90030-E
   GREVER MR, 1981, BLOOD, V57, P406
   HERSHFIELD MS, 1984, P NATL ACAD SCI-BIOL, V81, P253, DOI 10.1073/pnas.81.1.253
   ITOH R, 1993, COMP BIOCHEM PHYS B, V105, P13, DOI 10.1016/0305-0491(93)90163-Y
   ITOH R, 1991, INT J BIOCHEM, V23, P461
   JOHNSON MA, 1989, MOL PHARMACOL, V36, P291
   KELLER PM, 1985, J BIOL CHEM, V260, P8664
   KIRDASZUK B, 1992, BIOCHEM PHARMACOL, V43, P197
   MITSUGI K, 1964, AGR BIOL CHEM TOKYO, V28, P586
   PESI R, 1994, ARCH BIOCHEM BIOPHYS, V312, P75, DOI 10.1006/abbi.1994.1282
   SIAW MFE, 1984, J BIOL CHEM, V259, P9426
   SKLADANOWSKI AC, 1989, BIOCHEM J, V262, P203, DOI 10.1042/bj2620203
   STINSON RA, 1987, BIOCHIM BIOPHYS ACTA, V913, P272, DOI 10.1016/0167-4838(87)90135-X
   TESORIERE G, 1984, BIOCHIM BIOPHYS ACTA, V786, P231, DOI 10.1016/0167-4838(84)90093-1
   TOZZI MG, 1991, ARCH BIOCHEM BIOPHYS, V291, P212, DOI 10.1016/0003-9861(91)90125-3
   TOZZI MG, 1995, PURINE PYRIMIDINE ME, V8, P575
   TURRIANI M, 1994, J BIOCHEM TOXICOL, V9, P51, DOI 10.1002/jbt.2570090108
   WANG LY, 1993, J BIOL CHEM, V268, P22847
   WO JJP, 1992, BIOCHEMISTRY-US, V31, P1712
   WORKU Y, 1982, BIOCHEM J, V205, P503, DOI 10.1042/bj2050503
   ZIMMERMANN H, 1992, BIOCHEM J, V285, P345, DOI 10.1042/bj2850345
NR 30
TC 28
Z9 28
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 1357-2725
J9 INT J BIOCHEM CELL B
JI Int J. Biochem. Cell Biol.
PD JUN
PY 1996
VL 28
IS 6
BP 711
EP 720
DI 10.1016/1357-2725(95)00171-9
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA UQ420
UT WOS:A1996UQ42000011
PM 19927594
DA 2021-08-04
ER

PT J
AU Chen, JW
   Clarkson, RB
   Belford, RL
AF Chen, JW
   Clarkson, RB
   Belford, RL
TI Rotational dynamics of MRI paramagnetic contrast agents in viscous media
SO JOURNAL OF PHYSICAL CHEMISTRY
LA English
DT Article
ID ELECTRON-SPIN-RESONANCE; LIQUID-CRYSTALLINE SOLVENTS; RELAXATION
AB Electron paramagnetic resonance spectra of model magnetic resonance imaging contrast agents vanadyl ethylenediaminetetraacetate and vanadyl diethylenetriaminepentaacetate in 46% w/v sucrose solutions have been acquired from near physiological temperature to near freezing to study their rotational dynamics in a viscous environment. The sucrose solution simulates environments that may arise in vivo and also when the contrast agents are bound either covalently or noncovalently (e.g., via hydrogen bonds) to another molecule either by chance or by design to improve the relaxivity and the specificity. We report that an isotropic Brownian model, which described the rotational dynamics of these agents in water, does not fully portray the rotational dynamics in this environment, especially in the intermediate or slow tumbling regime. However, an axial anisotropic rotational model simulated the experimental spectra well and can account for the trends exhibited by the data. The dynamics results suggest that the motion deviates substantially from Stokes-Einstein behavior, and possible physical models to account for the behavior are discussed.
RP Chen, JW (corresponding author), UNIV ILLINOIS,DEPT CHEM,1209 W CALIF ST,URBANA,IL 61801, USA.
CR Allen M.P., 1993, ADV CHEM PHYS, V86, P1, DOI [10.1002/9780470141458.ch1, DOI 10.1002/9780470141458.CH1]
   ALLEN MP, 1990, PHYS REV LETT, V65, P2881, DOI 10.1103/PhysRevLett.65.2881
   BLOEMBERGEN N, 1957, J CHEM PHYS, V27, P572, DOI 10.1063/1.1743771
   Brent R. P., 1973, ALGORITHMS MINIMIZAT
   CAMPBELL RF, 1980, J PHYS CHEM-US, V84, P2666
   Chasteen N. D., 1981, BIOL MAGNETIC RESONA
   CHEN JW, 1994, J PHYS CHEM-US, V98, P13452, DOI 10.1021/j100102a005
   CHEN JW, 1994, 2 M SOC MAGN RES SAN
   EARLE KA, 1995, 37 ROCK MOUNT C AN C
   Einstein A., 1956, INVESTIGATIONS THEOR
   Freed J.H., 1989, BIOL MAGNETIC RESONA, V8
   FREED JH, 1976, SPIN LABELING THEORY, V1
   LAUFFER RB, 1987, CHEM REV, V87, P901, DOI 10.1021/cr00081a003
   LIN WJ, 1979, J PHYS CHEM-US, V83, P379, DOI 10.1021/j100466a018
   MEIROVITCH E, 1982, J CHEM PHYS, V77, P3915, DOI 10.1063/1.444346
   NELDER JA, 1965, COMPUT J, V7, P308, DOI 10.1093/comjnl/7.4.308
   NILGES MJ, 1979, THESIS U ILLINOIS
   POLIMENO A, 1995, J CHEM PHYS, V102, P8094, DOI 10.1063/1.469220
   POLNASZEK CF, 1975, J PHYS CHEM-US, V79, P2283, DOI 10.1021/j100588a015
   SOLOMON I, 1955, PHYS REV, V99, P559, DOI 10.1103/PhysRev.99.559
   VASAVADA KV, 1987, J CHEM PHYS, V86, P647, DOI 10.1063/1.452319
   WIENER EC, IN PRESS J AM CHEM S
   WOESSNER DE, 1962, J CHEM PHYS, V36, P1, DOI 10.1063/1.1732274
   WOESSNER DE, 1962, J CHEM PHYS, V37, P647, DOI 10.1063/1.1701390
NR 24
TC 8
Z9 8
U1 0
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0022-3654
J9 J PHYS CHEM-US
JI J. Phys. Chem.
PD MAY 16
PY 1996
VL 100
IS 20
BP 8093
EP 8100
DI 10.1021/jp953210k
PG 8
WC Chemistry, Physical
SC Chemistry
GA UL282
UT WOS:A1996UL28200011
DA 2021-08-04
ER

PT J
AU Kammel, U
   Schluter, S
   Steiff, A
   Weinspach, PM
AF Kammel, U
   Schluter, S
   Steiff, A
   Weinspach, PM
TI Control of runaway polymerization reactions by injection of inhibiting
   agents - A contribution to the safety of chemical reactors
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article; Proceedings Paper
CT 14th International Symposium on Chemical Reaction Engineering - From
   Fundamentals to Commercial Plants and Products
CY MAY 05-08, 1996
CL BRUGGE, BELGIUM
AB In case of a failure in the cooling or the electric supply and thus a stirrer break down, exothermic reactions can be self-accelerated caused by the heating-up of the reactor content, so that the danger of an unallowed rise in temperature and pressure occurs. In certain chemical processes (e. g. radical polymerization) a reaction-runaway can be stopped by the addition of inhibiting agents. With rapid and homogeneous distribution of the inhibiting agent by means of a fluid stored under pressure the endangered reactor can be controlled. In order to obtain design criteria for this safety device, the influence of relevant system parameters in the reaction and mixing behaviour has to be examined. Therefore experimental investigations and numerical simulations were made.
RP Kammel, U (corresponding author), UMSICHT,INST ENVIRONM SAFETY & ENERGY TECHNOL,OSTERFELDER STR 3,D-46047 OBERHAUSEN,GERMANY.
CR Brandrup J., 1975, POLYM HDB
   EASTMOND GC, 1976, COMP CHEM KINETICS A, V14
   Flory P.J, 1953, PRINCIPLES POLYM CHE
   HAARDE W, 1989, THESIS U HANNOVER GE
   HENRICIOLIVE G, 1969, POLYM KATALYSE KINET
   HUI AW, 1972, J APPL POLYM SCI, V16, P749, DOI 10.1002/app.1972.070160319
   KORNER HJ, 1994, THESIS U DORTMUND GE
   Odian G., 1970, PRINCIPLES POLYM
   RIESEN R, 1990, SWISS CHEM, V12, P37
   SCHULER H, 1984, CHEM ENG SCI, V50, P1891
NR 10
TC 12
Z9 13
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0009-2509
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY
PY 1996
VL 51
IS 10
BP 2253
EP 2259
DI 10.1016/0009-2509(96)00082-6
PG 7
WC Engineering, Chemical
SC Engineering
GA UK960
UT WOS:A1996UK96000066
DA 2021-08-04
ER

PT J
AU Fedorocko, P
   Mackova, NO
AF Fedorocko, P
   Mackova, NO
TI Combined modality radioprotection: Enhancement of survival and
   hematopoietic recovery in gamma-irradiated mice by the joint use of
   liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) and
   indomethacin
SO INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY
LA English
DT Article
DE radioprotection; hematopoiesis; liposomal muramyl tripeptide;
   indomethacin
ID TUMOR-NECROSIS-FACTOR; COLONY-STIMULATING FACTOR; MYELOID PROGENITOR
   CELLS; HUMAN-BLOOD MONOCYTES; CANCER-PATIENTS; TUMORICIDAL PROPERTIES;
   MACROPHAGE ACTIVATOR; FORMING-UNITS; PHASE-I; INTERLEUKIN-1
AB We have reported previously [Fedorocko, P.; Int. J. Ridiat. Biol. 65:465, 1994] that liposomal muramyl tripeptidephosphatidyl ethanolamine (MTP-PE/MLV) given prior to irradiation results in augmented hemopoietic recovery and enhanced animal survival as evidenced by increased pluripotent stem cells (CFU-S) and progenitor cells committed to granulocyte and/or macrophage development (GM-CFC) or white blood cells, neutrophil counts, as well as by survival rates of lethally irradiated mice.
   In this report the effects of liposomal MTP-PE (radioprotective immunomodulator; 10 mg/kg i.p., 24 h before irradiation) and indomethacin (inhibitor of prostaglandin production; 2 mg/kg i.m., 24 h and 3 h before irradiation) were studied. Both of the agents were administered either alone or in combination. The results included the assessment of preirradiation hemopoietic effects of drugs and postirradiation hemopoietic recovery in terms of bone marrow cellularity, number of bone marrow GM-CFC, endogenous spleen colony formation (endoCFU-S), and the determination of the survival of lethally irradiated mice.
   Experimental evidence elevated by the increased preirradiation numbers of GM-CFC and hydroxyurea kill of GM-CFC as well as a simultaneous significant diminution in bone marrow cellularity indicated that the beneficial action of the combined treatment could be a consequence of increased cell proliferation in the hemopoietic tissue and mobilization with redistribution of stem cells from bone marrow into the circulation. In the postirradiation period (3-14 days), combined pretreatment of mice accelerated myelopoietic regeneration in the bone marrow compared to treatment with MTP-PE/MLV alone or indomethacin alone.
   Combined administration of MTP-PE/MLV (10 mg/kg, -24 h, i.p.) and indomethacin (2 mg/kg, -24 h and -3 h, i.m.) to mice, prior to lethal irradiation, exerted an additional radioprotective effect and protected 100% of the C57B1/6 mice. Copyright (C) 1996 International Society for Immunopharmacology
RP Fedorocko, P (corresponding author), SAFARIK UNIV,FAC SCI,DEPT MOL & CELLULAR BIOL,MOYZESOVA 11,KOSICE 04164,SLOVAKIA.
RI Fedorocko, Peter/AAJ-1317-2021; Fedorocko, Peter/R-2433-2016
OI Fedorocko, Peter/0000-0002-1138-6282; Fedorocko,
   Peter/0000-0002-1138-6282
CR ADAM A, 1988, ISI ATLAS-IMMUNOL, V1, P205
   AGLIETTA M, 1989, HAEMATOLOGICA, V74, P121
   AINSWORTH EJ, 1988, PHARMACOL THERAPEUT, V39, P223
   BASCHANG G, 1989, TETRAHEDRON, V45, P6331, DOI 10.1016/S0040-4020(01)89512-0
   Behling UH, 1983, BENEFICIAL EFFECTS E, P127
   CAMPANILE F, 1992, INT J IMMUNOPHARMACO, V14, P655, DOI 10.1016/0192-0561(92)90127-7
   CREAVEN PJ, 1990, J BIOL RESP MODIF, V9, P492
   DENEKAMP J, 1986, INT J RADIAT BIOL, V49, P357, DOI 10.1080/09553008514552591
   FARADJI A, 1991, J CLIN ONCOL, V9, P1251, DOI 10.1200/JCO.1991.9.7.1251
   FEDOROCKO P, 1994, INT J RADIAT BIOL, V65, P465, DOI 10.1080/09553009414550541
   FIDLER IJ, 1985, CANCER RES, V45, P4714
   FIDLER IJ, 1990, LYMPHOKINE RES, V9, P449
   FIDLER IJ, 1986, SITE SPECIFIC DRUG D, P111
   FONTAGNE J, 1980, EXP HEMATOL, V8, P1157
   FROST H, 1990, J BIOL RESP MODIF, V9, P160
   KLEINERMAN ES, 1983, CANCER RES, V43, P2010
   KLEINERMAN ES, 1989, CANCER RES, V49, P4665
   KOFF WC, 1985, SCIENCE, V228, P295
   KOZUBIK A, 1987, FOLIA BIOL-PRAGUE, V33, P418
   KOZUBIK A, 1990, FOLIA BIOL-PRAGUE, V36, P291
   KUNKEL SL, 1986, J IMMUNOL, V136, P186
   KURLAND J, 1977, EXP HEMATOL, V5, P357
   KURLAND JI, 1978, BLOOD, V52, P388
   MACKOVA NO, 1993, NEOPLASMA, V40, P379
   MAEDA M, 1991, CANCER COMMUN, V3, P313
   MEIJNE EIM, 1991, EXP HEMATOL, V19, P617
   MELISSEN PMB, 1992, INFECT IMMUN, V60, P95, DOI 10.1128/IAI.60.1.95-101.1992
   MORRISSEY P, 1988, J IMMUNOL, V140, P4204
   MURRAY JL, 1989, J CLIN ONCOL, V7, P1915, DOI 10.1200/JCO.1989.7.12.1915
   Neta R, 1988, Biotherapy, V1, P41
   NETA R, 1986, J IMMUNOL, V136, P2483
   NETA R, 1988, J IMMUNOL, V140, P108
   NETA R, 1988, TUMOR NECROSIS FACTO, P246
   NETA R, 1986, PROGR IMMUNOLOGY, V6, P900
   NIKCEVICH DA, 1986, J IMMUNOPHARMACOL, V8, P299
   NISHIGUCHI I, 1990, RADIAT RES, V122, P188, DOI 10.2307/3577605
   PELUS LM, 1989, J IMMUNOL, V143, P4171
   PLOEMACHER RE, 1992, INT J RADIAT BIOL, V61, P489, DOI 10.1080/09553009214551251
   POSPISIL M, 1993, FOLIA BIOL-PRAGUE, V39, P178
   POSPISIL M, 1989, STRAHLENTHER ONKOL, V165, P627
   POSPISIL M, 1992, EXP HEMATOL, V20, P891
   RASSMUSEN LT, 1987, SCAND J IMMUNOL, V26, P731
   SCHWARTZ GN, 1987, IMMUNOPHARM IMMUNOT, V9, P371, DOI 10.3109/08923978709035220
   SCHWARTZ GN, 1989, RADIAT RES, V119, P101, DOI 10.2307/3577370
   SINCLAIR WK, 1966, RADIAT RES, V29, P450, DOI 10.2307/3572025
   SLORDAL L, 1989, J IMMUNOL, V142, P833
   SONE S, 1989, P125
   TILL JE, 1963, RADIAT RES, V18, P96, DOI 10.2307/3571429
   VACEK A, 1991, FOLIA BIOL-PRAGUE, V37, P35
   Van Hoogevest P., 1989, LIPOSOMES THERAPY IN, P453
NR 50
TC 14
Z9 14
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0192-0561
J9 INT J IMMUNOPHARMACO
JI Int. J. Immunopharmacol.
PD MAY
PY 1996
VL 18
IS 5
BP 329
EP 337
DI 10.1016/0192-0561(96)00023-9
PG 9
WC Immunology; Pharmacology & Pharmacy
SC Immunology; Pharmacology & Pharmacy
GA VT912
UT WOS:A1996VT91200007
PM 8933212
DA 2021-08-04
ER

PT J
AU Lefaix, JL
   Delanian, S
   Leplat, JJ
   Tricaud, Y
   Martin, M
   Nimrod, A
   Baillet, F
   Daburon, F
AF Lefaix, JL
   Delanian, S
   Leplat, JJ
   Tricaud, Y
   Martin, M
   Nimrod, A
   Baillet, F
   Daburon, F
TI Successful treatment of radiation-induced fibrosis using Cu/Zn-SOD and
   Mn-SOD: An experimental study
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Article
DE Cu/Zn-superoxide dismutase; Mn-superoxide dismutase; late radiation
   effects; fibrosis
ID IR-192 GAMMA-RAYS; SUPEROXIDE-DISMUTASE; MUSCULAR FIBROSIS; IATROGENIC
   FIBROSIS; PIG SKIN; TISSUE; IRRADIATION; NECROSIS; PENTOXIFYLLINE;
   MECHANISMS
AB Purpose: To establish how far liposomal copper/zinc superoxide dismutase (Cu/Zn-SOD) and manganese superoxide dismutase (Mn-SOD), respectively, reduce radiation-induced fibrosis (RIF), using a well-characterized pig model of RIF permitting the design of a controlled laboratory experiment.
   Methods and Materials: In this model of acute localized gamma irradiation simulating accidental overexposure in humans, three groups of five large white pigs were irradiated using a collimated Ir-192 source to deliver a single dose of 160 Gy onto the skin surface (100%) of the outer side of the thigh. A well-defined block of subcutaneous fibrosis involving skin and skeletal muscle developed 6 months after irradiation. One experimental group of five pigs was then injected i.m. with 10 mg/10 kg b.wt. of Cu/Zn-SOD, twice a week for 3 weeks, and another experimental group of five was infected with 10 mg/10 kg b.wt. of Mn-SOD, three times a week for 3 weeks. Five irradiated control pigs were injected with physiological serum. Animals were assessed for changes in the density of the palpated fibrotic block and in the dimensions of the projected cutaneous surface. Block depth was determined by ultrasound. Physical and sonographic findings were confirmed by autopsy 12-14 weeks after completing SOD injections. The density, length, width, and depth of the fibrotic block, and the areas and volume of its projected cutaneous surface were compared before treatment, 1, 3, and 6 weeks thereafter, and at autopsy, 12-14 weeks after treatment ended.
   Results: The experimental animals exhibited no change in behavior and no abnormal clinical or anatomic signs. Whether they were given Cu/Zn- dr Mn-SOD, significant and roughly equivalent softening and shrinking of the fibrotic block were noted in all treated animals between the first week after treatment ended and autopsy, when mean regression was 45% for length and width, 30% for depth, and 70% for area and volume. Histologic examination showed completely normal muscle and subcutaneous tissue surrounding the residual scar. This replacement of scar tissue by normal tissue in experimental animals and the 50% decrease in the linear dimensions of the scar were comparable to the results obtained in previous clinical studies and highly significant compared to the clinical and autopsy results for the control animals.
   Conclusions: Our results are striking and comparable to the results obtained in our previous clinical study after liposomal Cu/Zn-SOD treatment. To our knowledge, this is the first time that two agents have been shown to reverse the radiation-induced fibrotic process in experimental animals and to permit the regeneration of normal tissue in a zone of well-established postirradiation fibrosis.
C1 HOP NEKER ST LOUIS, DEPT RADIOTHERAPIE, PARIS, FRANCE.
   BIOTECHNOL GEN LTD, REHOVOT, ISRAEL.
   HOP LA PITIE SALPETRIERE, DEPT RADIOTHERAPIE, PARIS, FRANCE.
RP Lefaix, JL (corresponding author), CEA SACLAY, DRR, LAB RADIOBIOL APPL, DSV, F-91191 GIF SUR YVETTE, FRANCE.
RI Martin, Michele/AAC-4211-2021; Martin, Michele T/C-5554-2008
OI Martin, Michele/0000-0003-0530-6466; DELANIAN,
   Sylvie/0000-0003-1017-9502
CR Baillet F, 1986, Free Radic Res Commun, V1, P387
   CANNEY PA, 1990, BRIT J RADIOL, V63, P620, DOI 10.1259/0007-1285-63-752-620
   DELANIAN S, 1993, B CANCER, V80, P202
   DELANIAN S, 1993, B CANCER, V80, P192
   DELANIAN S, 1994, RADIOTHER ONCOL, V32, P12, DOI 10.1016/0167-8140(94)90444-8
   DELANIAN S, 1994, B CANC RADIOTHER, V81, P475
   Delanian S, 1992, BRIT J RADIOL, V65, P82
   DION MW, 1990, INT J RADIAT ONCOL, V19, P401, DOI 10.1016/0360-3016(90)90549-Y
   EDSMYR F, 1981, EUR J RHEUMATOL INFL, V4, P228
   EMAMI B, 1991, INT J RADIAT ONCOL, V21, P109, DOI 10.1016/0360-3016(91)90171-Y
   EMERIT J, 1983, SEM HOP PARIS, V59, P277
   GOLSTEIN P, 1991, IMMUNOL REV, V121, P29, DOI 10.1111/j.1600-065X.1991.tb00822.x
   GORECKI M, 1991, FREE RADICAL RES COM, V12-3, P401, DOI 10.3109/10715769109145810
   KOVACS EJ, 1991, IMMUNOL TODAY, V12, P17, DOI 10.1016/0167-5699(91)90107-5
   KRANE SM, 1985, CIBA F SYMP, V114, P97
   LEFAIX JL, 1992, HEALTH PHYS, V63, P692, DOI 10.1097/00004032-199212000-00011
   LEFAIX JL, 1993, BRIT J RADIOL, V66, P537, DOI 10.1259/0007-1285-66-786-537
   LORTAT-JACOB H, 1991, J CLIN INVEST, V87, P878, DOI 10.1172/JCI115093
   MARKLUND SL, 1982, CANCER RES, V42, P1955
   MARTIN M, 1993, RADIAT RES, V134, P63, DOI 10.2307/3578502
   MARTIN M, 1989, J INVEST DERMATOL, V93, P497, DOI 10.1111/1523-1747.ep12284053
   Michelson A M, 1986, Free Radic Res Commun, V2, P43, DOI 10.3109/10715768609088054
   MICHELSON AM, 1980, ACTA PHYSIOL SCAND, P67
   MICHELSON AM, 1987, LIFE CHEM REPORTS, V6, P1
   OYANAGUI Y, 1991, BIOCHEM PHARMACOL, V42, P991, DOI 10.1016/0006-2952(91)90280-I
   PARIZADA B, 1991, FREE RADICAL RES COM, V15, P297, DOI 10.3109/10715769109105225
   PERDEREAU B, 1994, B CANCER, V81, P659
   PETKAU A, 1986, CANCER TREAT REV, V13, P17, DOI 10.1016/0305-7372(86)90012-5
   REMY J, 1991, RADIAT RES, V125, P14, DOI 10.2307/3577976
   RUBIN P, 1992, INT J RADIAT ONCOL, V24, P93, DOI 10.1016/0360-3016(92)91027-K
   RUBIN P, 1986, INT J RAD ONCOL PHYS, V10, P5
   SAPPINO AP, 1990, LAB INVEST, V63, P144
   TURRENS JF, 1984, J CLIN INVEST, V73, P87, DOI 10.1172/JCI111210
   VAILLE A, 1990, BIOCHEM PHARMACOL, V39, P247, DOI 10.1016/0006-2952(90)90023-E
   WEGROWSKI J, 1992, INT J RADIAT BIOL, V61, P685, DOI 10.1080/09553009214551501
   WERNERWASKIK M, 1993, INT J RADIAT ONCOL, V25, P757, DOI 10.1016/0360-3016(93)90027-S
   WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6
NR 37
TC 129
Z9 143
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
EI 1879-355X
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD MAY 1
PY 1996
VL 35
IS 2
BP 305
EP 312
DI 10.1016/0360-3016(96)00061-2
PG 8
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA UM703
UT WOS:A1996UM70300014
PM 8635938
DA 2021-08-04
ER

PT J
AU Rotter, BA
   Prelusky, DB
   Pestka, JJ
AF Rotter, BA
   Prelusky, DB
   Pestka, JJ
TI Toxicology of deoxynivalenol (vomitoxin)
SO JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH
LA English
DT Review
ID EXPERIMENTAL T-2 TOXICOSIS; ESOPHAGEAL CANCER AREAS; WHITE LEGHORN HENS;
   PROTEIN-SYNTHESIS INHIBITION; CELL-MEDIATED RESISTANCE;
   FUSARIUM-INFECTED CORN; CEREBRAL SPINAL-FLUID; SPRAGUE-DAWLEY RATS;
   (VOMITOXIN)-CONTAMINATED WHEAT; TRICHOTHECENE VOMITOXIN
AB Trichothecene mycotoxins are a group of structurally similar fungal metabolites that are capable of producing a wide range of toxic effects. Deoxynivalenol (DON, vomitoxin), a trichothecene, is prevalent worldwide in crops used for food and feed production, including in Canada and the United States. Although DON is one of the least acutely toxic trichothecenes, it should be treated as an important food safety issue because it is a very common contaminant of grain. This review focuses on the ability of DON to induce toxicologic and immunotoxic effects in a variety of cell systems and animal species. At the cellular level, the main toxic effect is inhibition of protein synthesis via binding to the ribosome. In animals, moderate to low ingestion of toxin can cause a number of as yet poorly defined effects associated with reduced performance and immune function. The main overt effect at low dietary concentrations appears to be a reduction in food consumption (anorexia), while higher doses induce vomiting (emesis). DON is known to alter brain neurochemicals. The serotoninergic system appears to play a role in mediation of the feeding behavior and emetic response. Animals fed low to moderate doses are able to recover from initial weight losses, while higher doses induce more long-term changes in feeding behavior. At low dosages of DON, hematological, clinical, and immunological changes are also transitory and decrease as compensatory/adaptation mechanisms are established. Swine are more sensitive to DON than mice, poultry, and ruminants, in part because of differences in metabolism of DON, with males being more sensitive than females. The capacity of DON to alter normal immune function has been of particular interest. There is extensive evidence that DON can be immunosuppressive or immunostimulatory, depending upon the dose and duration of exposure. While immunosuppression can be explained by the inhibition of translation, immunostimulation can be related to interference with normal regulatory mechanisms. In vivo, DON suppresses normal immune response to pathogens and simultaneously induces autoimmune-like effects which are similar to human immunoglobulin A (IgA) nephropathy. Other effects include superinduction of cytokine production by T helper cells (in vitro) and activation of macrophages and T cells to produce a proinflammatory cytokine wave that is analogous to that found in lipopolysaccharide-induced shack (in vivo). To what extent the elevation of cytokines contributes to metabolic effects such as decreased feed intake remains to be established. Although these effects have been largely characterized in the mouse, several investigations with DON suggest that immunotoxic effects are also likely in domestic animals. Further toxicology studies and an assessment of the potential of DON to be an etiologic agent in human disease are warranted.
C1 MICHIGAN STATE UNIV, DEPT FOOD SCI & HUMAN NUTR, E LANSING, MI 48824 USA.
RP Rotter, BA (corresponding author), AGR & AGRI FOOD CANADA, CTR FOOD & ANIM RES, K W NEATBY BLDG, OTTAWA, ON K1A 0C6, CANADA.
CR ABBAS HK, 1986, APPL ENVIRON MICROB, V51, P841, DOI 10.1128/AEM.51.4.841-843.1986
   ABBAS HK, 1984, J ASSOC OFF ANA CHEM, V67, P607
   ABDELHAMID AM, 1990, ARCH TIERERNAHR, V40, P647, DOI 10.1080/17450399009428413
   ABOUZIED MM, 1991, APPL ENVIRON MICROB, V57, P672, DOI 10.1128/AEM.57.3.672-677.1991
   ANDREWS PLR, 1988, TRENDS PHARMACOL SCI, V9, P334, DOI 10.1016/0165-6147(88)90106-X
   ANDREWS PLR, 1988, BAILLIERE CLIN GASTR, V2, P141, DOI 10.1016/0950-3528(88)90025-5
   ARNOLD DL, 1986, FOOD CHEM TOXICOL, V24, P935, DOI 10.1016/0278-6915(86)90321-2
   ARNOLD DL, 1986, FUND APPL TOXICOL, V6, P691, DOI 10.1016/0272-0590(86)90182-X
   ATKINSON HAC, 1984, TOXICOL LETT, V23, P215, DOI 10.1016/0378-4274(84)90129-2
   ATROSHI F, 1994, J ANIM PHYSIOL AN N, V71, P223, DOI 10.1111/j.1439-0396.1994.tb00359.x
   AZCONAOLIVERA JI, 1995, TOXICOL APPL PHARM, V133, P109, DOI 10.1006/taap.1995.1132
   AZCONAOLIVERA JI, 1995, FOOD CHEM TOXICOL, V33, P433, DOI 10.1016/0278-6915(95)00012-Q
   BAMBURG JR, 1983, PROGR MOL SUBCELLULA, V8, P41
   Beardall J. M., 1994, P487
   BERGER J, 1969, TRANSPL P, V1, P939
   BETINA V, 1989, CHEM-BIOL INTERACT, V71, P105, DOI 10.1016/0009-2797(89)90030-6
   BLUNDELL JE, 1984, NEUROPHARMACOLOGY, V23, P1537, DOI 10.1016/0028-3908(84)90098-4
   BONDY GS, 1991, TOXICON, V29, P1107, DOI 10.1016/0041-0101(91)90208-9
   BONDY GS, 1991, TOXICOL APPL PHARM, V108, P520, DOI 10.1016/0041-008X(91)90098-Y
   BORISON HL, 1989, TOXICOL APPL PHARM, V101, P399, DOI 10.1016/0041-008X(89)90190-7
   BRADLAW JA, 1985, FOOD CHEM TOXICOL, V23, P1063, DOI 10.1016/0278-6915(85)90053-5
   BUNNER DL, 1988, TOXICOL APPL PHARM, V92, P113, DOI 10.1016/0041-008X(88)90233-5
   CAVAN KR, 1988, J NUTR, V118, P901
   CHAVEZ ER, 1986, CAN J ANIM SCI, V66, P277, DOI 10.4141/cjas86-028
   COPPOCK RW, 1985, AM J VET RES, V46, P169
   CORRIER DE, 1987, AM J VET RES, V48, P1304
   CORRIER DE, 1987, VET IMMUNOL IMMUNOP, V14, P11, DOI 10.1016/0165-2427(87)90071-7
   CORRIER DE, 1987, TOXICOL APPL PHARM, V89, P323, DOI 10.1016/0041-008X(87)90152-9
   CORRIER DE, 1986, AM J VET RES, V47, P856
   CORRIER DE, 1986, AM J VET RES, V47, P1956
   COTE LM, 1987, FOOD CHEM TOXICOL, V25, P291, DOI 10.1016/0278-6915(87)90125-6
   COTE LM, 1986, J DAIRY SCI, V69, P2416, DOI 10.3168/jds.S0022-0302(86)80681-6
   COTE LM, 1985, J ANIM SCI, V61, P942
   COTE LM, 1984, J AM VET MED ASSOC, V184, P189
   *COUNC AGR SCI TEC, 1989, 116 COUNC AGR SCI TE
   DAMICO G, 1987, Q J MED, V64, P709
   DONG WM, 1994, TOXICOL APPL PHARM, V127, P282, DOI 10.1006/taap.1994.1163
   DONG WM, 1993, FUND APPL TOXICOL, V20, P38, DOI 10.1006/faat.1993.1005
   DONG WM, 1991, FUND APPL TOXICOL, V17, P197, DOI 10.1016/0272-0590(91)90251-X
   DUNBAR AW, 1986, BRIT J PHARMACOL, V88, P319
   EHRLICH KC, 1987, BIOCHIM BIOPHYS ACTA, V923, P206, DOI 10.1016/0304-4165(87)90005-5
   ELBANNA AA, 1983, J AGR FOOD CHEM, V31, P1381, DOI 10.1021/jf00120a064
   FELDBERG W, 1953, J PHYSIOL-LONDON, V119, P352, DOI 10.1113/jphysiol.1953.sp004850
   FIORAMONTI J, 1993, J PHARMACOL EXP THER, V266, P1255
   FITZPATRICK DW, 1988, J ENVIRON SCI HEAL B, V23, P159, DOI 10.1080/03601238809372594
   FITZPATRICK DW, 1988, TOXICOL LETT, V40, P241, DOI 10.1016/0378-4274(88)90047-1
   FORSELL JH, 1987, FOOD CHEM TOXICOL, V25, P155, DOI 10.1016/0278-6915(87)90149-9
   FORSELL JH, 1985, APPL ENVIRON MICROB, V49, P1523, DOI 10.1128/AEM.49.6.1523-1526.1985
   FORSELL JH, 1985, APPL ENVIRON MICROB, V50, P1304, DOI 10.1128/AEM.50.5.1304-1307.1985
   FORSELL JH, 1986, FOOD CHEM TOXICOL, V24, P213, DOI 10.1016/0278-6915(86)90231-0
   FORSYTH DM, 1977, APPL ENVIRON MICROB, V34, P547, DOI 10.1128/AEM.34.5.547-552.1977
   FOSTER BC, 1986, CAN J ANIM SCI, V66, P1149, DOI 10.4141/cjas86-128
   FOZARD JR, 1984, NEUROPHARMACOLOGY, V23, P1473, DOI 10.1016/0028-3908(84)90091-1
   FRIEND DW, 1982, CAN J ANIM SCI, V62, P1211, DOI 10.4141/cjas82-141
   FRIEND DW, 1986, CAN J ANIM SCI, V66, P1075, DOI 10.4141/cjas86-118
   FRIEND DW, 1992, CAN J ANIM SCI, V72, P703, DOI 10.4141/cjas92-082
   FRIEND DW, 1986, CAN J ANIM SCI, V66, P765, DOI 10.4141/cjas86-083
   FRIEND SCE, 1983, TOXICOL APPL PHARM, V69, P234, DOI 10.1016/0041-008X(83)90304-6
   FROMENTIN H, 1981, SABOURAUDIA, V19, P311
   GANG L, 1988, P 7 INT IUPAC S MYC, P67
   Gareis M, 1987, Mycotoxin Res, V3, P25, DOI 10.1007/BF03191982
   Gauvreau HC, 1991, THESIS S FRASER U VA
   GERBERICK GF, 1983, ENVIRON RES, V32, P269, DOI 10.1016/0013-9351(83)90111-1
   GERBERICK GF, 1984, ENVIRON RES, V33, P246, DOI 10.1016/0013-9351(84)90021-5
   GILBERT J, 1989, J APPL BACTERIOL, V67, pS89, DOI 10.1111/j.1365-2672.1989.tb03773.x
   GREENE DM, 1994, J TOXICOL ENV HEALTH, V43, P37, DOI 10.1080/15287399409531902
   GREENE DM, 1995, FUND APPL TOXICOL, V26, P107, DOI 10.1006/faat.1995.1080
   GREENE DM, 1994, TOXICOLOGY, V92, P245, DOI 10.1016/0300-483X(94)90181-3
   GREENHALGH R, 1986, J AGR FOOD CHEM, V34, P98, DOI 10.1021/jf00067a027
   HAMILTON RMG, 1986, POULTRY SCI, V65, P288, DOI 10.3382/ps.0650288
   HAMILTON RMG, 1985, POULTRY SCI, V64, P273, DOI 10.3382/ps.0640273
   HAMILTON RMG, 1985, POULTRY SCI, V64, P1840, DOI 10.3382/ps.0641840
   Harvey R B, 1990, J Vet Diagn Invest, V2, P227
   HARVEY RB, 1989, AM J VET RES, V50, P602
   HARVEY RB, 1990, AM J VET RES, V51, P1688
   HARVEY RB, 1991, B ENVIRON CONTAM TOX, V46, P410, DOI 10.1007/BF01688940
   Hayes MA, 1982, J APPL TOXICOL, V2, P207, DOI 10.1002/jat.2550020407
   HE P, 1992, APPL ENVIRON MICROB, V58, P3857, DOI 10.1128/AEM.58.12.3857-3863.1992
   HESKETH PJ, 1991, J NATL CANCER I, V83, P613, DOI 10.1093/jnci/83.9.613
   HIETANIEMI V, 1991, FOOD ADDIT CONTAM, V8, P171, DOI 10.1080/02652039109373967
   HUFF WE, 1986, POULTRY SCI, V65, P1291, DOI 10.3382/ps.0651291
   HUNDER G, 1991, FOOD CHEM TOXICOL, V29, P809, DOI 10.1016/0278-6915(91)90107-I
   HUNT JN, 1980, AM J PHYSIOL, V239, pG1
   IVERSON F, 1985, TOXICOLOGIST, V5, P6
   JELINEK CF, 1989, J ASSOC OFF ANA CHEM, V72, P223
   JONE C, 1987, CELL BIOL TOXICOL, V3, P1, DOI 10.1007/BF00117821
   KANAI K, 1984, JPN J MED SCI BIOL, V37, P97, DOI 10.7883/yoken1952.37.97
   KARAVAEV OY, 1986, SOVIET AGR SCI, V8, P49
   KARPPANEN E, 1985, J AGR SCI FINLAND, V57, P195
   KIESSLING KH, 1984, APPL ENVIRON MICROB, V47, P1070, DOI 10.1128/AEM.47.5.1070-1073.1984
   KING RR, 1984, J AGR FOOD CHEM, V32, P1181, DOI 10.1021/jf00125a061
   KUBENA LF, 1985, POULTRY SCI, V64, P1649, DOI 10.3382/ps.0641649
   Kuiper-Goodman Tine, 1994, P439
   KUIPERGOODMAN T, 1985, MYCOTOXINS CANADIAN, P103
   LAKE BG, 1987, FOOD CHEM TOXICOL, V25, P589, DOI 10.1016/0278-6915(87)90019-6
   LEE US, 1986, FOOD ADDIT CONTAM, V3, P253, DOI 10.1080/02652038609373589
   LEIBOWITZ SF, 1986, FASEB J, V45, P1396
   Lew H, 1991, Mycotoxin Res, V7 Suppl 1, P71, DOI 10.1007/BF03192189
   LORENZANA RM, 1985, FUND APPL TOXICOL, V5, P879, DOI 10.1016/0272-0590(85)90170-8
   LORENZANA RM, 1985, FUND APPL TOXICOL, V5, P893, DOI 10.1016/0272-0590(85)90171-X
   LUN AK, 1985, J ANIM SCI, V61, P1178
   LUN AK, 1989, B ENVIRON CONTAM TOX, V42, P919, DOI 10.1007/BF01701636
   LUN AK, 1988, B ENVIRON CONTAM TOX, V40, P317, DOI 10.1007/BF01689086
   LUN AK, 1986, POULTRY SCI, V65, P1095, DOI 10.3382/ps.0651095
   Luo X. Y., 1988, Proceedings of the Japanese Association of Mycotoxicology, P97
   LUO Y, 1990, APPL ENVIRON MICROB, V56, P3723, DOI 10.1128/AEM.56.12.3723-3726.1990
   MACDONALD EJ, 1988, J ANIM SCI, V66, P434
   MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0
   MARASAS WFO, 1981, PHYTOPATHOLOGY, V71, P792, DOI 10.1094/Phyto-71-792
   MARASAS WFO, 1988, S AFR MED J, V74, P110
   MARASAS WFO, 1979, J AGR FOOD CHEM, V27, P1108, DOI 10.1021/jf60225a013
   MARPEGAN MR, 1988, J VET MED A, V35, P610
   MEKHANCHADAHEL C, 1990, FOOD ADDIT CONTAM, V7, pS94, DOI 10.1080/02652039009373855
   MILLER JD, 1991, MYCOLOGIA, V83, P121, DOI 10.2307/3759927
   MILLER JD, 1983, CAN J MICROBIOL, V29, P1171, DOI 10.1139/m83-179
   MILLER JD, 1995, J STORED PROD RES, V31, P1, DOI 10.1016/0022-474X(94)00039-V
   MILLER K, 1987, ARCH TOXICOL, P321
   MILLER K, 1986, FOOD CHEM TOXICOL, V24, P545, DOI 10.1016/0278-6915(86)90111-0
   MINERVINI F, 1993, MYCOPATHOLOGIA, V121, P33, DOI 10.1007/BF01103352
   MIZEL SB, 1981, J IMMUNOL, V126, P834
   MOROOKA N, 1972, Journal of the Food Hygienic Society of Japan, V13, P368
   MORRISSEY RE, 1985, FOOD CHEM TOXICOL, V23, P995, DOI 10.1016/0278-6915(85)90250-9
   MORRISSEY RE, 1984, FOOD CHEM TOXICOL, V22, P453, DOI 10.1016/0278-6915(84)90328-4
   MORRISSEY RE, 1985, APPL ENVIRON MICROB, V49, P1062, DOI 10.1128/AEM.49.5.1062-1066.1985
   MULLER HM, 1993, MYCOPATHOLOGIA, V121, P115, DOI 10.1007/BF01103579
   NAKANO N, 1979, JPN J MED SCI BIOL, V32, P269, DOI 10.7883/yoken1952.32.269
   NIYO KA, 1988, AM J VET RES, V49, P1766
   NORRED WP, 1994, J FOOD PROTECT, V57, P522, DOI 10.4315/0362-028X-57.6.522
   ONJI Y, 1989, J AGR FOOD CHEM, V37, P478, DOI 10.1021/jf00086a045
   OSSENKOPP KP, 1994, PHARMACOL BIOCHEM BE, V47, P363, DOI 10.1016/0091-3057(94)90024-8
   OSWEILER GD, 1990, J ANIM SCI S1, V68, pA403
   PANG VF, 1988, FUND APPL TOXICOL, V11, P100, DOI 10.1016/0272-0590(88)90274-6
   PANG VF, 1987, TOXICOL PATHOL, V15, P308, DOI 10.1177/019262338701500309
   PAUCOD JC, 1990, ACTA MICROBIOL HUNG, V37, P331
   PESTKA JJ, 1990, CAN J PHYSIOL PHARM, V68, P1009, DOI 10.1139/y90-154
   PESTKA JJ, 1988, TOXICOL LETT, V41, P215, DOI 10.1016/0378-4274(88)90057-4
   PESTKA JJ, 1994, FOOD CHEM TOXICOL, V32, P1125, DOI 10.1016/0278-6915(94)90128-7
   PESTKA JJ, 1987, FOOD CHEM TOXICOL, V25, P855, DOI 10.1016/0278-6915(87)90264-X
   PESTKA JJ, 1990, FOOD CHEM TOXICOL, V28, P693, DOI 10.1016/0278-6915(90)90145-D
   PESTKA JJ, 1990, TOXICOL LETT, V50, P75, DOI 10.1016/0378-4274(90)90254-J
   PESTKA JJ, 1994, FUND APPL TOXICOL, V22, P314, DOI 10.1006/faat.1994.1035
   PESTKA JJ, 1990, FOOD CHEM TOXICOL, V28, P409, DOI 10.1016/0278-6915(90)90087-4
   PESTKA JJ, 1987, FOOD CHEM TOXICOL, V25, P297, DOI 10.1016/0278-6915(87)90126-8
   PESTKA JJ, 1989, FOOD CHEM TOXICOL, V27, P361, DOI 10.1016/0278-6915(89)90141-5
   PESTKA JJ, 1986, FOOD CHEM TOXICOL, V24, P1309, DOI 10.1016/0278-6915(86)90063-3
   PESTKA JJ, 1994, IMMUNOTOXICOLOGY IMM, P163
   PIER AC, 1980, J AM VET MED ASSOC, V176, P719
   POLLOCK JD, 1981, PHARMACOL BIOCHEM BE, V15, P179, DOI 10.1016/0091-3057(81)90174-X
   Prelusky D. B., 1994, P359
   Prelusky Dan B., 1993, Natural Toxins, V1, P296, DOI 10.1002/nt.2620010508
   Prelusky Dan B., 1994, Natural Toxins, V2, P97, DOI 10.1002/nt.2620020302
   PRELUSKY DB, 1993, J ENVIRON SCI HEAL B, V28, P731, DOI 10.1080/03601239309372851
   PRELUSKY DB, 1994, J ENVIRON SCI HEAL B, V29, P1203, DOI 10.1080/03601239409372923
   PRELUSKY DB, 1991, J AGR FOOD CHEM, V39, P748, DOI 10.1021/jf00004a026
   PRELUSKY DB, 1990, J ENVIRON SCI HEAL B, V25, P395, DOI 10.1080/03601239009372697
   PRELUSKY DB, 1987, J ENVIRON SCI HEAL B, V22, P125, DOI 10.1080/03601238709372550
   PRELUSKY DB, 1984, J ENVIRON SCI HEAL B, V19, P593, DOI 10.1080/03601238409372453
   PRELUSKY DB, 1992, J FOOD SCI, V57, P801, DOI 10.1111/j.1365-2621.1992.tb14297.x
   PRELUSKY DB, 1988, FUND APPL TOXICOL, V10, P276, DOI 10.1016/0272-0590(88)90312-0
   PRELUSKY DB, 1986, FUND APPL TOXICOL, V7, P635, DOI 10.1016/0272-0590(86)90113-2
   PRELUSKY DB, 1986, FUND APPL TOXICOL, V6, P356, DOI 10.1016/0272-0590(86)90251-4
   PRELUSKY DB, 1985, J ENV SCI HLTH  B, V30, P603
   PRICE WD, 1993, J ANIM SCI, V71, P2556, DOI 10.2527/1993.7192556x
   RAMAKRISHNA Y, 1990, J AGR FOOD CHEM, V38, P1857, DOI 10.1021/jf00099a015
   RASOOLY L, 1992, FOOD CHEM TOXICOL, V30, P499, DOI 10.1016/0278-6915(92)90101-P
   RASOOLY L, 1994, FOOD CHEM TOXICOL, V32, P337, DOI 10.1016/0278-6915(94)90072-8
   RASOOLY L, 1994, FOOD CHEM TOXICOL, V32, P329, DOI 10.1016/0278-6915(94)90071-X
   RESNICK RH, 1961, GASTROENTEROLOGY, V41, P119
   RICHARD JL, 1978, TOXINS ANIMAL PLANT, P801
   RICHARDSON BP, 1986, TRENDS NEUROSCI, V9, P424, DOI 10.1016/0166-2236(86)90137-2
   RINGOLD GM, 1984, P NATL ACAD SCI-BIOL, V81, P3964, DOI 10.1073/pnas.81.13.3964
   ROBBANABARNAT S, 1987, FOOD ADDIT CONTAM, V4, P49, DOI 10.1080/02652038709373614
   ROBBANABARNAT S, 1988, TOXICOLOGY, V48, P155, DOI 10.1016/0300-483X(88)90097-2
   ROBISON TS, 1979, J AGR FOOD CHEM, V27, P1411, DOI 10.1021/jf60226a022
   ROSENSTEIN Y, 1979, IMMUNOLOGY, V36, P111
   ROTTER BA, 1994, FUND APPL TOXICOL, V23, P117, DOI 10.1006/faat.1994.1087
   ROTTER BA, 1992, J TOXICOL ENV HEALTH, V37, P329, DOI 10.1080/15287399209531673
   ROTTER BA, 1995, CAN J ANIM SCI, V75, P297, DOI 10.4141/cjas95-046
   Rotter Barbara A., 1993, Natural Toxins, V1, P303, DOI 10.1002/nt.2620010509
   Salazar M. S., 1980, Comptes Rendus Hebdomadaire des Seances de l'Academie des Sciences, D, V290, P877
   SARIBAN E, 1988, J CLIN INVEST, V81, P1506, DOI 10.1172/JCI113482
   SCHIEFER HB, 1987, FOOD CHEM TOXICOL, V25, P593, DOI 10.1016/0278-6915(87)90020-2
   SCHOBITZ B, 1994, PROG NEUROBIOL, V44, P397, DOI 10.1016/0301-0082(94)90034-5
   SCOTT P M, 1991, P529
   SCOTT PM, 1990, CEREAL FOOD WORLD, V35, P661
   SCOTT PM, 1989, TRICHOTHECENE MYCOTO, V1, P1
   SHAW J, 1988, J IMMUNOL, V140, P2243
   SHAW J, 1987, MOL IMMUNOL, V24, P409, DOI 10.1016/0161-5890(87)90014-9
   SHEU CW, 1988, FOOD CHEM TOXICOL, V26, P243, DOI 10.1016/0278-6915(88)90125-1
   SHORPOSNER G, 1986, BRAIN RES BULL, V17, P663, DOI 10.1016/0361-9230(86)90198-X
   SHOTWELL OL, 1985, J ASSOC OFF ANA CHEM, V68, P954
   SIGGENS KW, 1985, BIOCHEM BIOPH RES CO, V133, P274, DOI 10.1016/0006-291X(85)91871-6
   SILVERSTONE T, 1992, DRUGS, V43, P820, DOI 10.2165/00003495-199243060-00003
   SILVERSTONE T, 1986, APPETITE, V7, P85, DOI 10.1016/S0195-6663(86)80054-X
   SNIJDERS CHA, 1990, NETH J PLANT PATHOL, V96, P187, DOI 10.1007/BF01974256
   SORENSON WG, 1986, ENVIRON HEALTH PERSP, V66, P45, DOI 10.2307/3430213
   SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091
   SUNEJA SK, 1984, TOXICON, V22, P39, DOI 10.1016/0041-0101(84)90136-3
   TAI JH, 1990, MYCOPATHOLOGIA, V109, P149, DOI 10.1007/BF00436803
   TAI JH, 1988, FOOD CHEM TOXICOL, V26, P691, DOI 10.1016/0278-6915(88)90068-3
   TANAKA T, 1988, J AGR FOOD CHEM, V36, P979, DOI 10.1021/jf00083a019
   Taylor M. J., 1989, Trichothecene mycotoxicosis: pathophysiologic effects. Volume II., P1
   THIEL PG, 1982, 5 P INT IUPAC S MYC, P126
   THOMPSON WL, 1986, TOXICON, V24, P985, DOI 10.1016/0041-0101(86)90004-8
   Thurston J. R., 1986, Diagnosis of mycotoxicoses. A publication based on the symposium on the diagnosis of mycotoxicoses of importance in the United States and Japan, held at Ames, Iowa, October 11-13, 1984, P149
   TOBIN NF, 1988, AUST J EXP AGR, V28, P107, DOI 10.1071/EA9880107
   TOMAR RS, 1988, TOXICOL LETT, V40, P109, DOI 10.1016/0378-4274(88)90151-8
   TOMAR RS, 1986, INT J IMMUNOPHARMACO, V8, P125, DOI 10.1016/0192-0561(86)90051-2
   TOMAR RS, 1988, INT J IMMUNOPHARMACO, V10, P145, DOI 10.1016/0192-0561(88)90089-6
   TOMAR RS, 1987, FOOD CHEM TOXICOL, V25, P393, DOI 10.1016/0278-6915(87)90175-X
   Trenholm H. L., 1989, Trichothecene mycotoxicosis: pathophysiologic effects. Volume I., P107
   TRENHOLM HL, 1985, J DAIRY SCI, V68, P1000, DOI 10.3168/jds.S0022-0302(85)80921-8
   TRENHOLM HL, 1984, J AM VET MED ASSOC, V185, P527
   TRENHOLM HL, 1994, CAN J ANIM SCI, V74, P361, DOI 10.4141/cjas94-049
   TRUCKSESS MW, 1995, J AOAC INT, V78, P135
   TRYPHONAS H, 1984, TOXICOL LETT, V23, P17, DOI 10.1016/0378-4274(84)90004-3
   TRYPHONAS H, 1986, TOXICOL LETT, V30, P137, DOI 10.1016/0378-4274(86)90096-2
   UENO Y, 1973, J BIOCHEM-TOKYO, V74, P285
   Ueno Y., 1987, Mycotoxins in food, P123
   UENO Y, 1985, CRC CR REV TOXICOL, V14, P99, DOI 10.3109/10408448509089851
   UENO Y, 1983, DEV FOOD SCI, V4, P135
   VANEGMOND HP, 1989, FOOD ADDIT CONTAM, V6, P139, DOI 10.1080/02652038909373773
   VESONDER RF, 1973, APPL MICROBIOL, V26, P1008, DOI 10.1128/AEM.26.6.1008-1010.1973
   VESONDER RF, 1976, APPL ENVIRON MICROB, V31, P280, DOI 10.1128/AEM.31.2.280-285.1976
   VESONDER RF, 1978, APPL ENVIRON MICROB, V36, P885, DOI 10.1128/AEM.36.6.885-888.1978
   VESONDER RF, 1981, PROCESS BIOCH    JAN, P12
   VIDAL D, 1989, INFECT IMMUN, V57, P2260, DOI 10.1128/IAI.57.7.2260-2264.1989
   VIDAL DR, 1990, B I PASTEUR, V88, P159
   VISCONTI A, 1991, MYCOPATHOLOGIA, V113, P181, DOI 10.1007/BF00436128
   VOGEL SN, 1990, IMMUNOPHYSIOLOGY ROL, P238
   WANG E, 1991, J BIOL CHEM, V266, P14486
   WARNER RL, 1994, FOOD CHEM TOXICOL, V32, P617, DOI 10.1016/0278-6915(94)90005-1
   WEAVER GA, 1978, VET REC, V103, P531, DOI 10.1136/vr.103.24.531
   WELLMAN PJ, 1989, PHYSIOL BEHAV, V45, P501, DOI 10.1016/0031-9384(89)90065-6
   WHO, 1990, ENV HLTH CRIT, V105
   WORRELL NR, 1989, XENOBIOTICA, V19, P25, DOI 10.3109/00498258909034673
   YOSHIZAWA T, 1981, FOOD COSMET TOXICOL, V19, P31, DOI 10.1016/0015-6264(81)90300-X
   YOSHIZAWA T, 1973, AGR BIOL CHEM TOKYO, V37, P2933, DOI 10.1080/00021369.1973.10861103
   YOUNG JC, 1987, J AGR FOOD CHEM, V35, P259, DOI 10.1021/jf00074a023
   YOUNG LG, 1983, J ANIM SCI, V57, P655
   1993, IARC MONOGR EVAL CAR, V56, P397
NR 241
TC 782
Z9 822
U1 3
U2 215
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0098-4108
J9 J TOXICOL ENV HEALTH
JI J. Toxicol. Environ. Health
PD MAY
PY 1996
VL 48
IS 1
BP 1
EP 34
DI 10.1080/009841096161447
PG 34
WC Environmental Sciences; Public, Environmental & Occupational Health;
   Toxicology
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health; Toxicology
GA UM024
UT WOS:A1996UM02400001
PM 8637056
DA 2021-08-04
ER

PT J
AU Mak, CK
   Avalos, M
   Randall, PK
   Kwan, SW
   Abell, CW
   Neumeyer, JL
   Whisennand, R
   Wilcox, RE
AF Mak, CK
   Avalos, M
   Randall, PK
   Kwan, SW
   Abell, CW
   Neumeyer, JL
   Whisennand, R
   Wilcox, RE
TI Improved models for pharmacological null experiments: Calculation of
   drug efficacy at recombinant D1A dopamine receptors stably expressed in
   clonal cell lines
SO NEUROPHARMACOLOGY
LA English
DT Article
DE dopamine; recombinant receptor; cAMP; affinity; efficacy; cell culture;
   clonal cell line; stable expression
ID BETA-ADRENERGIC-RECEPTOR; MOLECULAR-CLONING; ADENYLYL-CYCLASE;
   DIFFERENTIAL EXPRESSION; AGONIST; DESENSITIZATION; GENE; AFFINITY;
   LIGANDS; BINDING
AB Modern drug discovery demands accurate knowledge of the drug properties of affinity and efficacy at specific receptor proteins. Furthermore, drugs with well defined properties make better tools with which to explore and understand receptor regulation. The use of clonal cell lines stably expressing a given recombinant receptor may provide a highly useful model in which drug effects may be studied on one receptor subtype at a time. The present report was designed to evaluate the utility of a general method in which a clonal cell line stably expressing a recombinant D1A dopamine receptor was used as a model system for studying drug actions by null models. The null model for receptor occlusion (to calculate agonist K-a) and the null model for relative efficacy (to calculate test agonist affinity and epsilon(r)) were evaluated in these studies. To initiate these studies, rat C6 glioma cells that do not normally express DA receptors have been modified by stable transfection with the primate D1A DA receptor [Machida et al., 1992 (Molec. Pharmacol. 41: 652-659)] to a density of approximate to 200 fmol/mg protein. The recombinant receptors show robust stimulation of cAMP in the stably transfected C6 cells.
   Calculation of agonist K-a from dose-response data requires that a portion of the cell's receptors be occluded in the absence of changes in post-receptor events leading to the response. Receptor reserve is typically reduced by alkylation, thereby lowering maximal response. Unfortunately, most of the currently available alkylating agents are not selective either for a particular receptor or for receptors vs other proteins within a signaling pathway. Short-term agonist treatment offers a possible complement to the use of non-selective or poorly characterized alkylating drugs for reducing maximum response in appropriate cell systems.
   The null method of receptor occlusion was used to determine the K-a for dopamine when maximum response was decreased by alkylation vs short-term agonist treatment. Direct non-linear curve fitting was used to analyze the data. In addition to DA, two other compounds were used to reduce receptor reserve to validate the method: fenoldopam (relatively high efficacy) and SKF38393 (low efficacy). Analyses indicated that the affinity of DA was similar whether calculated by alkylation (1.1 +/- 0.58 mu M), 75 min DA treatment (0.57 +/- 0.16 mu M) or 45 min treatment with DA (0.86 +/- 0.11 mu M). Short-term agonist treatment experiments using multiple concentrations of DA, fenoldopam, or SKF38393 to decrease receptor reserve provided additional support for the validity of the K-a determinations using this procedure.
   Other experiments were conducted according to the null model for relative efficacy in which the affinity for DA is calculated by comparing the DA response before and after receptor occlusion, and the affinity and relative intrinsic efficacy of the test agonist are determined as a function of its actions relative to DA. We used the following four test drugs: + Br-APB, a novel agent with potential dopamine agonist properties, and three high-affinity DA agonists, fenoldopam, R-(-)-apomorphine (APO), and SKF38393. Intrinsic efficacy values relative to that of DA (1.0) were as follows: fenoldopam, 0.46 +/- 0.11; APO, 0.19 +/- 0.13; SKF38393, 0.07 +/- 0.01; and +Br-APB, 0.26 +/- 0.40. The agonist affinities (K-a) were: fenoldopam, 0.018 +/- 0.008 mu M; APO, 0.80 +/- 0.18 mu M; SKF38393, 0.16 +/- 0.04 mu M; Br-APB, 0.43 +/- 0.29 mu M; and DA, 0.58 +/- 0.17 mu M EC(50)/K-a ratios were consistent with relative intrinsic efficacies and K-a values were similar to K-L values reported for membrane binding studies.
   Finally, Monte Carlo simulations were conducted to determine the precision of the parameter estimates. These simulations of 1000 experiments each, using the empirical variance of approximate to 3% of the maximum response, indicated a precision for the DA K-a of approximate to 16%, for the independently determined fenoldopam K-a of approximate to 24%, and of the fenoldopam epsilon(r) of approximate to 16% of the parameter values. To our knowledge, this represents the first report of agonist affinity plus relative intrinsic efficacy measurement at any recombinant receptor. The present results also provide the first report of the precision of these important drug parameter measurements using Monte Carlo methods. Together, these results suggest that clonal cell lines which stably express a recombinant receptor of interest may offer a unique system with which to determine essential drug properties. The method is able to accommodate agonists with very high potency and intrinsic activity, extremely low relative intrinsic efficacy, and can determine whether or not a drug is behaving as expected for a classical partial agonist. Copyright (C) 1996 Elsevier Science Ltd
C1 UNIV TEXAS,COLL PHARM,DIV PHARMACOL & TOXICOL,AUSTIN,TX 78712.
   UNIV TEXAS,INST NEUROSCI,AUSTIN,TX 78712.
   UNIV TEXAS,COLL PHARM,DIV MED CHEM,AUSTIN,TX 78712.
   RES BIOCHEM INT,NATICK,MA 01760.
   MCCALLUM HIGH SCH,DEPT BIOL,AUSTIN,MN.
OI Neumeyer, John/0000-0003-2287-9864
FU NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Research Resources (NCRR) [R03RR008579] Funding Source: NIH
   RePORTER; NCRR NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Research Resources (NCRR) [RR08579] Funding Source: Medline; NIMH NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH) [MH30003] Funding Source: Medline
CR AGARWAL A, 1993, J COMPUT CHEM, V14, P237, DOI 10.1002/jcc.540140211
   AUSUBEL F, 1992, SHORT PROTOCOLS MOL
   BATES MD, 1991, AM J PHYSIOL, V260, pF937
   BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797
   BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0
   CARON MG, 1993, RECENT PROG HORM RES, V48, P277
   CIVELLI O, 1993, ANN REV PHARM TOXICO, V32, P281
   COX BA, 1992, J NEUROCHEM, V59, P627, DOI 10.1111/j.1471-4159.1992.tb09416.x
   DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0
   DELEAN A, 1980, J BIOL CHEM, V255, P7108
   DELEAN A, 1978, AM J PHYSIOL, V235, pE97
   DELEAN A, 1992, USERS GUIDE ALLFIT S
   EGLEN RM, 1987, J PHARMACOL EXP THER, V240, P404
   EHLERT FJ, 1988, MOL PHARMACOL, V33, P187
   ENZ A, 1990, MOL PHARMACOL, V37, P560
   FARNDALE RW, 1992, SIGNAL TRANSDUCTION, P75
   Furchgott R.F., 1966, ADV DRUG RES, V3, P21
   GINGRICH JA, 1993, ANNU REV NEUROSCI, V16, P299, DOI 10.1146/annurev.ne.16.030193.001503
   GRENADER A, 1991, J PHARMACOL EXP THER, V258, P193
   HAMBLIN MW, 1982, MOL PHARMACOL, V21, P44
   Hartmann M., 1992, Society for Neuroscience Abstracts, V18, P275
   HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979
   HEREPATH ML, 1990, N-S ARCH PHARMACOL, V341, P525
   HERNDON H, 1988, EUR J PHARMACOL, V154, P115
   HORIUCHI A, 1993, MOL PHARMACOL, V43, P281
   IMAI S, 1991, NEUROCHEM INT, V18, P331, DOI 10.1016/0197-0186(91)90163-8
   JAMES MK, 1989, J PHARMACOL EXP THER, V249, P61
   JARVIE KR, 1993, J RECEPTOR RES, V13, P573, DOI 10.3109/10799899309073680
   KENAKIN T, 1993, PHARM ANAL DRUG RECE, P1
   KENAKIN TP, 1984, PHARMACOL REV, V36, P165
   KENAKIN TP, 1992, PHARMACOL REV, V44, P351
   Knuth D. E., 1981, ART COMPUTER PROGRAM, V2
   LOVENBERG TW, 1991, J NEUROCHEM, V57, P1563, DOI 10.1111/j.1471-4159.1991.tb06352.x
   MACHIDA C, 1992, MOL PHARMACOL, V1, P652
   MACKAY D, 1990, TRENDS PHARMACOL SCI, V11, P17, DOI 10.1016/0165-6147(90)90036-8
   Mak C. K., 1994, Society for Neuroscience Abstracts, V20, P520
   MINOWA MT, 1992, P NATL ACAD SCI USA, V89, P3045, DOI 10.1073/pnas.89.7.3045
   MISHELL BB, 1980, CELL IMMUNOL, P14
   MONSMA FJ, 1990, P NATL ACAD SCI USA, V87, P6723, DOI 10.1073/pnas.87.17.6723
   NANTEL F, 1994, J BIOL CHEM, V269, P13148
   NEUMEYER JL, 1992, J MED CHEM, V35, P1466, DOI 10.1021/jm00086a016
   NORUSIS MJ, 1990, SPSS STAT PACKAGE SO
   OBOYLE KM, 1988, BRIT J PHARMACOL, V82, pP132
   ODOWD BF, 1993, J NEUROCHEM, V60, P804, DOI 10.1111/j.1471-4159.1993.tb03224.x
   OLSON MF, 1992, MOL ENDOCRINOL, V6, P1095, DOI 10.1210/me.6.7.1095
   PARKER RB, 1971, J PHARMACOL EXP THER, V177, P1
   PRESS WH, 1988, NUMERICAL RECEIPES C
   RATKOWSKY DA, 1983, NON LINEAR REGRESSIO
   RUFFOLO RR, 1983, J PHARMACOL EXP THER, V224, P559
   RUFFOLO RR, 1982, J AUTON PHARMACOL, V2, P277, DOI 10.1111/j.1474-8673.1982.tb00520.x
   RUFFOLO RR, 1979, J PHARMACOL EXP THER, V209, P429
   SALLER CF, 1989, LIFE SCI, V45, P917, DOI 10.1016/0024-3205(89)90206-3
   SAMAMA P, 1993, J BIOL CHEM, V268, P4625
   SCHWINN DA, 1992, HEART CARDIOVASCULAR, P1657
   SEEMAN P, 1992, NEUROPSYCHOPHARMACOL, V7, P261
   SIBLEY DR, 1992, TRENDS PHARMACOL SCI, V13, P61, DOI 10.1016/0165-6147(92)90025-2
   SUNAHARA RK, 1990, NATURE, V347, P80, DOI 10.1038/347080a0
   SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0
   TALLARIDA RJ, 1988, LIFE SCI, V43, P2169, DOI 10.1016/0024-3205(88)90409-2
   TIBERI M, 1991, P NATL ACAD SCI USA, V88, P7491, DOI 10.1073/pnas.88.17.7491
   UNNERSTALL JR, 1990, METHODS NEUROTRANSMI, P37
   WHALEY BS, 1994, MOL PHARMACOL, V45, P481
   Wilcox R. E., 1994, Society for Neuroscience Abstracts, V20, P521
   Wilcox R. E., 1993, Society for Neuroscience Abstracts, V19, P75
   WILCOX RE, 1995, TXB PSYCHOPHARMACOLO, P1
   YU SS, 1993, J BIOL CHEM, V268, P337
   ZHONG HY, 1995, J PHARMACOL EXP THER, V272, P1088
   ZHOU QY, 1990, NATURE, V347, P76, DOI 10.1038/347076a0
NR 68
TC 14
Z9 14
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0028-3908
J9 NEUROPHARMACOLOGY
JI Neuropharmacology
PD MAY
PY 1996
VL 35
IS 5
BP 549
EP 570
DI 10.1016/0028-3908(96)84625-9
PG 22
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA VK792
UT WOS:A1996VK79200004
PM 8887963
DA 2021-08-04
ER

PT J
AU Frank, E
   Tu, XM
   Anderson, B
   Reynolds, CF
   Karp, JF
   Mayo, A
   Ritenour, A
   Kupfer, DJ
AF Frank, E
   Tu, XM
   Anderson, B
   Reynolds, CF
   Karp, JF
   Mayo, A
   Ritenour, A
   Kupfer, DJ
TI Effects of positive and negative life events on time to depression
   onset: An analysis of additivity and timing
SO PSYCHOLOGICAL MEDICINE
LA English
DT Article
ID AFFECTIVE-DISORDER; ANXIETY; STRESS
AB While the relationship of life events to depression onset has occupied researchers for almost a quarter of a century, few studies have attempted to account for either the temporal patterning of events relative to episode onset, or, the effect of multiple events in a study period. In this report, we attempt to address the issues of timing of events, multiple events (both positive and negative) and multiple aspects (both positivity and negativity) of single events on latency time to depression onset, while simultaneously accounting for possible decay in the effects of events over time. We use the proportional hazards approach to model the effects of life events and consider modelling the change in impact of events with the passage of time.
   After interviewing 142 recurrent unipolar patients using the Life Events and Difficulties Schedule, we rated severity and positivity of life events reported during the 6-month period prior to onset. As we hypothesized, additional life events occurring after an initial provoking agent level event significantly alter the risk of illness onset. Additional severely threatening events decrease the time to onset, but positive events do not appear to delay onset. Interestingly, seemingly neutral events had a highly significant effect in shortening the time to onset. We note the many limitations imposed on the interpretation of these findings related to the selected group of subjects studied and encourage those who have more generalizable data to apply these methods of analysis.
C1 UNIV PITTSBURGH,DEPT PSYCHIAT,PITTSBURGH,PA 15260.
   UNIV PITTSBURGH,DEPT MATH & STAT,PITTSBURGH,PA 15260.
RI mayo, avi/N-3756-2019
OI mayo, avi/0000-0002-4479-3423
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI36627] Funding Source: Medline; NIMH NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Mental Health
   (NIMH) [MH43832, MH30915] Funding Source: Medline; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [R29AI036627] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Mental Health (NIMH) [P50MH030915,
   P30MH030915, R37MH043832, R01MH043832] Funding Source: NIH RePORTER
CR BEBBINGTON P, 1993, BRIT J PSYCHIAT, V16, P358
   Brown G., 1989, LIFE EVENTS ILLNESS, P3
   BROWN GW, 1993, PSYCHOSOM MED, V55, P248, DOI 10.1097/00006842-199305000-00003
   BROWN GW, 1986, J AFFECT DISORDERS, V11, P1, DOI 10.1016/0165-0327(86)90054-6
   BROWN GW, 1987, BRIT J PSYCHIAT, V150, P30, DOI 10.1192/bjp.150.1.30
   BROWN GW, 1992, BRIT J PSYCHIAT, V161, P44, DOI 10.1192/bjp.161.1.44
   BROWN GW, 1994, ARCH GEN PSYCHIAT, V51, P525
   BROWN GW, 1973, PSYCHOL MED, V3, P74, DOI 10.1017/S0033291700046365
   BROWN GW, 1978, BEDFORD COLLEGE LIFE
   FINLAYJONES R, 1981, PSYCHOL MED, V11, P803, DOI 10.1017/S0033291700041301
   FRANK E, 1994, ARCH GEN PSYCHIAT, V51, P519
   HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56
   Harris TO., 1978, SOCIAL ORIGINS DEPRE
   KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI
   KARP JF, 1993, DEPRESSION, V1, P250
   Klerman G. L., 1984, INTERPERSONAL PSYCHO
   LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876
   *SAS I INC, 1991, P217 SAS I INC, P63
   Silver R.C., 1980, HUMAN HELPLESSNESS T, P279
   SURTEES PG, 1986, J AFFECT DISORDERS, V10, P37, DOI 10.1016/0165-0327(86)90047-9
   SURTEES PG, 1981, ACTA PSYCHIAT SCAND, V64, P177, DOI 10.1111/j.1600-0447.1981.tb00774.x
   SURTEES PG, 1980, SOC PSYCHIATR, V15, P21, DOI 10.1007/BF00577958
   Surtees PG, 1989, LIFE EVENTS ILLNESS, P161
   TENNANT C, 1981, BRIT J PSYCHIAT, V139, P213, DOI 10.1192/bjp.139.3.213
NR 24
TC 24
Z9 26
U1 0
U2 8
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 40 WEST 20TH STREET, NEW YORK, NY 10011-4211
SN 0033-2917
J9 PSYCHOL MED
JI Psychol. Med.
PD MAY
PY 1996
VL 26
IS 3
BP 613
EP 626
DI 10.1017/S0033291700035686
PG 14
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA UK259
UT WOS:A1996UK25900017
PM 8733219
DA 2021-08-04
ER

PT J
AU Abelson, JL
   Weg, JG
   Nesse, RM
   Curtis, GC
AF Abelson, JL
   Weg, JG
   Nesse, RM
   Curtis, GC
TI Neuroendocrine responses to laboratory panic: Cognitive intervention in
   the doxapram model
SO PSYCHONEUROENDOCRINOLOGY
LA English
DT Article
DE panic disorder; doxapram; cortisol; catecholamines; growth hormone;
   cognition
ID PITUITARY-ADRENOCORTICAL UNRESPONSIVENESS; PSYCHOLOGICAL STRESS;
   DISORDER PATIENTS; NEURO-ENDOCRINE; CORTISOL; ATTACKS; ANXIETY;
   YOHIMBINE; HORMONE; HYPOTHESIS
AB Doxapram is a respiratory stimulant that appears to be a potent and specific panicogenic agent. It also elicits an abnormal ventilatory response in patients with panic. A replication study confirmed these findings and demonstrated that behavioral and ventilatory responses to doxapram were significantly modified by a psychological intervention designed to cognitively block panic. The replication study provided an opportunity to simultaneously investigate the neuroendocrine effects of the illness, the drug, the drug-induced panic attacks, and the cognitive intervention. Epinephrine (EPI), norepinephrine (NE), growth hormone (GH), adrenocorticotropin (ACTH), and cortisol were studied in patients with panic and control subjects given placebo and doxapram injections after receiving either standard instructions or a brief cognitive intervention. Patients with panic had elevated levels of EPI, ACTH, and cortisol throughout the study. Doxapram had little or no detectable effects on plasma NE, GH, ACTH, and cortisol. Doxapram-induced panic attacks were not associated with elevations in NE, GH, ACTH, or cortisol. Doxapram led to a rapid and very brief rise in plasma EPI, which was small in subjects who did not panic and pronounced in patients who did panic. The cognitive intervention attenuated the EPI response to doxapram, perhaps through its effect on panic, and modified the temporal pattern of ACTH and cortisol secretion. These results suggest that: (1) further study of catecholamine responses within the first few minutes after panic induction is needed; (2) intense panic can occur without significant activation of the hypothalamic-pituitary-adrenal axis; and (3) cognitive factors can modulate neuroendocrine activity in laboratory studies of patients with panic. Copyright (C) 1996 Elsevier Science Ltd.
C1 UNIV MICHIGAN, DEPT INTERNAL MED, DIV PULM, ANN ARBOR, MI 48109 USA.
RP Abelson, JL (corresponding author), UNIV MICHIGAN, DEPT PSYCHIAT, ANXIETY DISORDERS PROGRAM, RM C435, MED INN BLDG 0840, ANN ARBOR, MI 48109 USA.
OI Nesse, Randolph/0000-0003-1768-0949
FU NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Research Resources (NCRR) [M01RR000042] Funding Source: NIH
   RePORTER; NCRR NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Research Resources (NCRR) [M01RR00042] Funding Source: Medline
CR Abelson JL, 1996, ARCH GEN PSYCHIAT, V53, P323
   ABELSON JL, 1994, BIOL PSYCHIAT, V36, P84, DOI 10.1016/0006-3223(94)91188-6
   ABELSON JL, IN PRESS PSYCHOSOM M
   ALBUS M, 1992, EUR ARCH PSY CLIN N, V241, P337, DOI 10.1007/BF02191958
   ARONSON TA, 1989, BIOL PSYCHIAT, V26, P463, DOI 10.1016/0006-3223(89)90067-X
   BREIER A, 1987, AM J PSYCHIAT, V144, P1419
   BURKI NK, 1984, CHEST, V85, P600, DOI 10.1378/chest.85.5.600
   CALVERLEY PMA, 1983, CLIN SCI, V65, P65, DOI 10.1042/cs0650065
   CAMERON OG, 1987, PSYCHONEUROENDOCRINO, V12, P321, DOI 10.1016/0306-4530(87)90061-8
   CARR DB, 1986, AM J PSYCHIAT, V143, P483
   CHARNEY DS, 1984, ARCH GEN PSYCHIAT, V41, P751
   CLARK DM, 1993, ADV BEHAV RES THER, V15, P75, DOI 10.1016/0146-6402(93)90004-L
   CROES S, 1993, PSYCHONEUROENDOCRINO, V18, P23, DOI 10.1016/0306-4530(93)90052-M
   CURTIS GC, 1978, PSYCHOSOM MED, V40, P368, DOI 10.1097/00006842-197808000-00002
   DIMSDALE JE, 1980, PSYCHOSOM MED, V42, P493, DOI 10.1097/00006842-198009000-00003
   FOLGERING H, 1981, CLIN RES PROC, V17, P237
   GORMAN JM, 1988, ARCH GEN PSYCHIAT, V45, P31
   GURGUIS GNM, 1991, BIOL PSYCHIAT, V30, P502, DOI 10.1016/0006-3223(91)90312-A
   Holsboer F, 1987, Horm Metab Res Suppl, V16, P80
   INSEL TR, 1984, ARCH GEN PSYCHIAT, V41, P741
   KELLNER M, 1995, AM J PSYCHIAT, V152, P1365
   KELLNER M, 1992, LIFE SCI, V50, P1835, DOI 10.1016/0024-3205(92)90543-X
   KIRSCHBAUM C, 1992, PSYCHOSOM MED, V54, P648, DOI 10.1097/00006842-199211000-00004
   KLEIN DF, 1994, ANXIETY, V1, P1
   KLEIN DF, 1993, ARCH GEN PSYCHIAT, V50, P306
   LEE YJ, 1993, BIOL PSYCHIAT, V33, P295, DOI 10.1016/0006-3223(93)90299-S
   LEVIN AP, 1987, PSYCHIAT RES, V21, P23, DOI 10.1016/0165-1781(87)90058-8
   LEVINE S, 1993, ANN NY ACAD SCI, V697, P61, DOI 10.1111/j.1749-6632.1993.tb49923.x
   PAPP LA, 1993, AM J PSYCHIAT, V150, P1149
   ROYBYRNE PP, 1986, AM J PSYCHIAT, V143, P896
   SANDERSON WC, 1989, ARCH GEN PSYCHIAT, V46, P157
   SPITZER RL, 1986, STRUCTURED CLIN INTE
   TARGUM SD, 1992, PSYCHONEUROENDOCRINO, V17, P453, DOI 10.1016/0306-4530(92)90003-P
   UHDE TW, 1992, NEUROPSYCHOPHARMACOL, V6, P101
   UHDE TW, 1984, PSYCHOPHARMACOL BULL, V20, P426
   UHDE TW, 1987, RECEPTORS LIGANDS PS, P375
   VEITH RC, 1991, STRESS NEUROBIOLOGY, P395
   Weinberg J, 1980, COPING HLTH, P39
   WINNIE AP, 1973, ACTA ANAESTH SCAND, P1
   WOODS SW, 1987, ARCH GEN PSYCHIAT, V44, P365
NR 40
TC 29
Z9 29
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4530
J9 PSYCHONEUROENDOCRINO
JI Psychoneuroendocrinology
PD MAY
PY 1996
VL 21
IS 4
BP 375
EP 390
DI 10.1016/0306-4530(96)00005-4
PG 16
WC Endocrinology & Metabolism; Neurosciences; Psychiatry
SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry
GA VC377
UT WOS:A1996VC37700002
PM 8844876
DA 2021-08-04
ER

PT J
AU Brown, PM
AF Brown, PM
TI Experimental evidence on money as a medium of exchange
SO JOURNAL OF ECONOMIC DYNAMICS & CONTROL
LA English
DT Article
DE laboratory; individual behavior; statistical simulation methods; money
   and interest rates
ID AGENTS
AB This paper presents an experimental examination of Kiyotaki and Wright's (1989) model of how money can arise as a medium of exchange. While the results generally support the hypothesis that individuals are willing to utilize a good as a medium of exchange, the trading patterns of a portion of the individuals deviated from the predicted patterns. Simulation studies suggest that while these deviations may have initially been a rational response by these subjects, they persisted after they became less than optimal.
RP Brown, PM (corresponding author), UNIV MASSACHUSETTS,DEPT ECON,BOSTON,MA 02125, USA.
CR ANDREONI J, 1995, J GAMES EC BEHAV, V10, P1
   CAMERER C, 1987, UNPUB EXPT MARKETS I
   CLOWER R, 1967, WESTERN ECON J, V6, P1
   HOLLAND JH, 1991, AM ECON REV, V81, P365
   KEHOE T, 1993, J ECON THEORY, V3, P297
   KIYOTAKI N, 1989, J POLIT ECON, V97, P927, DOI 10.1086/261634
   LIAN P, 1993, UNPUB GENERAL EQUILI
   MARCET A, 1989, J ECON THEORY, V48, P337, DOI 10.1016/0022-0531(89)90032-X
   MARIMOM R, 1990, J ECON DYN CONTROL, V14, P329, DOI 10.1016/0165-1889(90)90025-C
   MARIMON R, 1989, UNPUB MONEY MEDIUM E
   MARIMON R, 1992, 199030 GSIA CARN MEL
   Patinkin D, 1965, MONEY INTEREST PRICE
   WARNERYD K, 1990, J ECON BEHAV ORGAN, V13, P117, DOI 10.1016/0167-2681(90)90056-J
   WILLIAMS AW, 1987, J MONEY CREDIT BANK, V19, P1, DOI 10.2307/1992241
NR 14
TC 41
Z9 42
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-1889
J9 J ECON DYN CONTROL
JI J. Econ. Dyn. Control
PD APR
PY 1996
VL 20
IS 4
BP 583
EP 600
DI 10.1016/0165-1889(95)00865-9
PG 18
WC Economics
SC Business & Economics
GA TY754
UT WOS:A1996TY75400003
DA 2021-08-04
ER

PT J
AU Dusek, K
   Somvarsky, J
AF Dusek, K
   Somvarsky, J
TI Topological nanoinhomogeneities in polymer networks
SO MACROMOLECULAR SYMPOSIA
LA English
DT Article; Proceedings Paper
CT International Conference on Nano-Structures and Self-Assemblies in
   Polymer Systems
CY MAY 18-26, 1995
CL ST PETERSBURG-MOSCOW, RUSSIA
SP Russian Acad Sci, Polym Council
ID ELASTICITY
AB Small-size topological inhomogeneities in polymer networks characterized by differences in composition are formed as a consequence of history-determined covalent linking of units differing in some property into chemical clusters (topological inhomogeneities). This process is possibly assisted by physical association (segregation) of units of different types. Evolution of hard clusters in mixtures of long and short chains crosslinked with a common crosslinking agent and multicomponent polyurethane networks have been treated as examples of evolution of topological inhomogeneities. Simple mean-field models based on the statistical theory of branching processes (TBP) have been developed for modelling of the topological inhomogeneities (molecular weight averages, functionality averages, percolation threshold, etc.) in dependence on initial composition, reactivities of the functional groups, or history of network formation. Such characterization was possible by distinguishing bonds between e.g. soft-soft, soft-hard, and hard-hard units. More sophisticated models view inhomogeneities formation as a kinetic process where effective reactivity of functional groups in reactions, by which inhomogeneities are formed, depends on the size and composition of a given chemical cluster. This model is based on Monte-Carlo simulations of the generalized Smoluchowski coagulation process.
RP Dusek, K (corresponding author), ACAD SCI CZECH REPUBL, INST MACROMOLEC CHEM, CR-16206 PRAGUE 6, CZECH REPUBLIC.
RI Dusek, Karel/I-5692-2014; Dusek, Karel/AAG-9314-2019; Somvarsky,
   Jan/I-1834-2013
OI Dusek, Karel/0000-0002-4597-5501; Somvarsky, Jan/0000-0003-0920-6390
CR BASTIDE J, IN PRESS STRUCTURE G, pCH5
   DUSEK K, 1979, POLYM ENG SCI, V19, P246, DOI 10.1002/pen.760190404
   Dusek K, 1982, DEV POLYM, V3, P143
   DUSEK K, 1995, IN PRESS FARADAY DIS, V101
   DUSEK K, 1974, FARADAY DISCUSS CHEM, V101
   Dusek K., 1989, TELECHELIC POLYM SYN, P289
   FLORY PJ, 1982, MACROMOLECULES, V15, P800, DOI 10.1021/ma00231a022
   ILAVSKY M, 1995, EUR C GELS BAL
   KRAKOVSKY I, 1993, POLYMER, V34, P3437, DOI 10.1016/0032-3861(93)90473-N
   MATEJKA L, 1995, EUR C GELS BAL
   NABETH B, 1994, THESIS INSA LYON
   NABETH B, UNPUB J POLYM SCI PP
   SCHAEFER DW, 1986, MATER RES SOC S P, V73, P277
   SOMVARSKY J, 1994, POLYM BULL, V33, P369, DOI 10.1007/BF00314276
   SOMVARSKY J, 1994, POLYM BULL, V33, P377, DOI 10.1007/BF00314277
NR 15
TC 15
Z9 15
U1 0
U2 4
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY
SN 1022-1360
J9 MACROMOL SYMP
JI Macromol. Symp.
PD APR
PY 1996
VL 106
BP 119
EP 136
DI 10.1002/masy.19961060113
PG 18
WC Polymer Science
SC Polymer Science
GA UN880
UT WOS:A1996UN88000012
DA 2021-08-04
ER

PT J
AU Westley, AM
   Westley, J
AF Westley, AM
   Westley, J
TI Enzyme inhibition in open systems - Superiority of uncompetitive agents
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID RHODANESE CATALYSIS; THIOSULFATE
AB Investigations of the open system behavior of reversible dead-end inhibitors were carried out by means of computer simulations and experimental studies. The results from both approaches indicate that substrate-competitive inhibition may often be an inappropriate basis for design of potential therapeutic agents. The use of uncompetitive (also called anticompetitive) inhibitors in this role is likely to be far more effective. Chemical analogs of pathogen-specific enzymic reaction products rather than analogs of substrates provide a promising basis for the systematic design of such uncompetitive inhibitors.
C1 UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637.
CR CHA S, 1968, J BIOL CHEM, V243, P820
   CHOW SF, 1985, J BIOL CHEM, V260, P2763
   CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6
   CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P188
   CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P173, DOI 10.1016/0926-6569(63)90226-8
   CORNISHBOWDEN A, 1986, FEBS LETT, V203, P3, DOI 10.1016/0014-5793(86)81424-7
   FRANCO R, 1984, INT J BIOMED COMPUT, V15, P419, DOI 10.1016/0020-7101(84)90013-8
   HOROWITZ PM, 1978, ANAL BIOCHEM, V86, P751, DOI 10.1016/0003-2697(78)90803-5
   JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219
   KING EL, 1956, J PHYS CHEM-US, V60, P1375, DOI 10.1021/j150544a010
   KOSHLAND DE, 1968, ANNU REV BIOCHEM, V37, P359, DOI 10.1146/annurev.bi.37.070168.002043
   LEININGER KR, 1968, J BIOL CHEM, V243, P1892
   MINTEL R, 1966, J BIOL CHEM, V241, P3381
   SCHLESINGER P, 1974, J BIOL CHEM, V249, P780
   WANG SF, 1973, J BIOL CHEM, V248, P7376
   WESTLEY A, 1984, ANAL BIOCHEM, V142, P161
   WESTLEY J, 1987, METHOD ENZYMOL, V143, P22
   WESTLEY J, 1971, J BIOL CHEM, V246, P1468
   Westley J, 1981, Methods Enzymol, V77, P285
   WESTLEY J, 1969, ENZYMIC CATALYSIS, P44
   WONG JTF, 1962, CAN J BIOCHEM PHYS, V40, P763
   WOOD JL, 1975, CHEM BIOCH THIOCYANI, P156
NR 22
TC 45
Z9 48
U1 0
U2 5
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAR 8
PY 1996
VL 271
IS 10
BP 5347
EP 5352
DI 10.1074/jbc.271.10.5347
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA TZ286
UT WOS:A1996TZ28600013
PM 8621387
OA hybrid
DA 2021-08-04
ER

PT J
AU Liu, CD
   Aloia, T
   Adrian, TE
   Newton, TR
   Bilchik, AJ
   Zinner, MJ
   Ashley, SW
   McFadden, DW
AF Liu, CD
   Aloia, T
   Adrian, TE
   Newton, TR
   Bilchik, AJ
   Zinner, MJ
   Ashley, SW
   McFadden, DW
TI Peptide YY: A potential proabsorptive hormone for the treatment of
   malabsorptive disorders
SO AMERICAN SURGEON
LA English
DT Article; Proceedings Paper
CT Annual Meeting of the Southern-California-Chapter of the
   American-College-of-Surgeons
CY JAN 20-22, 1995
CL INDIAN WELLS, CA
SP Amer Coll Surgeons, SO Calif Chapter
ID DISTAL COLON; RELEASE; DOG; TRANSPORT
AB Peptide YY (PYY) is a 36 amino acid peptide that is released from the endocrine cells of the distal ileum, colon, and rectum following a meal. PYY is strongly proabsorptive in the small intestine. We studied the effects of intravenous PYY on colonic water and electrolyte transport in awake dogs. Dogs had 20 cm neurovascularly intact colon Thiry-Vella fistulas (TVF) surgically constructed. Colonic transport was studied in three experimental groups. Group 1 animals received a standard mixed meal. Group 2 animals were unfed and received intravenous PYY at 100 pmol/kg/hr for two hours. This dose of PYY has previously been shown to simulate the plasma levels of PYY normally seen after a meal. Group 3 received intravenous PYY at the same dose in addition to a mixed meal. Our study shows an increase in colonic water, Na+, and Cl- absorption after a meal (P < 0.05). Infusion of PYY at a 100 pmol/kg/hr was significantly proabsorptive beginning at 60 minutes (P < 0.01). Infusion of PYY in addition to a meal further increased absorption (P < 0.05). PYY is a potent proabsorptive agent in the colon of the conscious dog. PYY, or its analogs, may be useful clinical agents in intestinal. malabsorptive disorders or after bowel resection.
C1 UNIV CALIF LOS ANGELES,MED CTR,DEPT SURG,LOS ANGELES,CA 90024.
   VET ADM MED CTR,LOS ANGELES,CA.
   CREIGHTON UNIV,DEPT PHYSIOL,OMAHA,NE 68178.
RI Adrian, Thomas E/D-8484-2012
OI Adrian, Thomas/0000-0002-5051-1111
FU NIDDK NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK) [R0I-DK 39879] Funding Source:
   Medline
CR ADRIAN TE, 1985, GASTROENTEROLOGY, V89, P1070, DOI 10.1016/0016-5085(85)90211-2
   ANNEGERS JH, 1961, AM J PHYSIOL, V200, P107
   BALLANTYNE GH, 1993, REGUL PEPTIDES, V47, P117, DOI 10.1016/0167-0115(93)90415-5
   BILCHIK AJ, 1993, GASTROENTEROLOGY, V105, P1441, DOI 10.1016/0016-5085(93)90149-7
   BILCHIK AJ, 1994, AM J SURG, V167, P570, DOI 10.1016/0002-9610(94)90100-7
   BUELL MG, 1989, REGUL PEPTIDES, V24, P195, DOI 10.1016/0167-0115(89)90238-3
   COX HM, 1988, J PHYSIOL-LONDON, V398, P65, DOI 10.1113/jphysiol.1988.sp017029
   FIELD M, 1989, NEW ENGL J MED, V321, P870
   GREELEY GH, 1989, ENDOCRINOLOGY, V125, P1761, DOI 10.1210/endo-125-4-1761
   GUAN D, 1993, REGUL PEPTIDES, V43, P169, DOI 10.1016/0167-0115(93)90151-W
   HARMASATHAPHOIN K, 1980, GASTROENTEROLOGY, V788, P1559
   LEVENS NR, 1981, AM J PHYSIOL, V240, P17
   MCFADDEN DW, 1984, SURG FORUM, V35, P174
   Opleta-Madsen K., 1991, AM J PHYSIOL, V260, P807
   PAPPAS T, 1985, AM J PHYSIOL, V248, P18
   PERRONE RD, 1984, PFLUG ARCH EUR J PHY, V400, P257, DOI 10.1007/BF00581556
   TAYLOR IL, 1985, GASTROENTEROLOGY, V88, P731, DOI 10.1016/0016-5085(85)90144-1
   YEO CJ, 1991, AM J PHYSIOL, V259, P402
NR 18
TC 41
Z9 43
U1 0
U2 3
PU SOUTHEASTERN SURGICAL CONGRESS
PI ATLANTA
PA 1776 PEACHTREE RD, NW., SUITE 410N, ATLANTA, GA 30309-2352
SN 0003-1348
J9 AM SURGEON
JI Am. Surg.
PD MAR
PY 1996
VL 62
IS 3
BP 232
EP 236
PG 5
WC Surgery
SC Surgery
GA TW980
UT WOS:A1996TW98000013
PM 8607584
DA 2021-08-04
ER

PT J
AU Stewart, PS
   Hamilton, MA
   Goldstein, BR
   Schneider, BT
AF Stewart, PS
   Hamilton, MA
   Goldstein, BR
   Schneider, BT
TI Modeling biocide action against biofilms
SO BIOTECHNOLOGY AND BIOENGINEERING
LA English
DT Article
DE biofilm; biocide; disinfection; reaction-diffusion
ID PSEUDOMONAS-AERUGINOSA; SENSITIVITY ANALYSIS; COMPUTER-MODELS;
   PENETRATION; CULTURE
AB A phenomenological model of biocide action against microbial biofilms was derived. Processes incorporated in the model include bulk flow in and out of a well-mixed reactor, transport of dissolved species into the biofilm, substrate consumption by bacterial metabolism, bacterial growth, advection of cell mass within the biofilm, cell detachment from the biofilm, cell death, and biocide concentration-dependent disinfection. Simulations were performed to analyze the general behavior of the model and to perform preliminary sensitivity analysis to identify key input parameters. The model captured several general features of antimicrobial agent action against biofilms that have been observed widely by experimenters and practitioners. These included (1) rapid disinfection followed by biofilm regrowth, (2) slower detachment than disinfection, and (3) reduced susceptibility of microorganisms in biofilms. The results support the plausibility of a mechanism of biofilm resistance in which the biocide is neutralized by reaction with biofilm constituents, leading to a reduction in the bulk biocide concentration and, more significantly, biocide concentration gradients within the biofilm. Sensitivity experiments and analyses identified which input parameters influence key response variables. Each of three response variables was sensitive to each of the five input parameters, but they were most sensitive to the initial biofilm thickness and next most sensitive to the biocide disinfection rate coefficient. Statistical regression modeling produced simple equations for approximating the response variables for situations within the range of conditions covered by the sensitivity experiment. The model should be useful as a tool for studying alternative biocide control strategies. For example, the simulations suggested that a good; interval between pulses of biocide is the time to minimum thickness. (C) 1996 John Wiley & Sons, Inc.
C1 MONTANA STATE UNIV, DEPT MATH SCI, BOZEMAN, MT 59717 USA.
RP Stewart, PS (corresponding author), MONTANA STATE UNIV, CTR BIOFILM ENGN, DEPT CHEM ENGN, BOZEMAN, MT 59717 USA.
OI Stewart, Philip/0000-0001-7773-8570
CR ALHO JM, 1990, INT J FORECASTING, V6, P521, DOI 10.1016/0169-2070(90)90030-F
   Bailey J.E., 1986, BIOCH ENG FUNDAMENTA
   BISWAS P, 1993, WATER RES, V27, P1715, DOI 10.1016/0043-1354(93)90108-T
   BOX GEP, 1978, STATISTICS EXPT
   BRANDSTETTER A, 1987, GEOSTATISTICAL SENSI, P96
   Camper AK, 1993, BIOFOULING BIOCORROS, P91
   CARPENTIER B, 1993, J APPL BACTERIOL, V75, P499, DOI 10.1111/j.1365-2672.1993.tb01587.x
   Characklis W.G., 1990, BIOFILMS, P585
   CHEN CI, 1993, BIOFOULING, V7, P241
   CHEN CI, 1993, BIOFOULING, V7, P241
   COSTERTON JW, 1987, ANNU REV MICROBIOL, V41, P435, DOI 10.1146/annurev.mi.41.100187.002251
   DEBEER D, 1994, APPL ENVIRON MICROB, V60, P4339, DOI 10.1128/AEM.60.12.4339-4344.1994
   EASTWOOD IM, 1994, BACTERIAL BIOFILMS T
   GRIEBE T, 1994, BIOFOULING AND BIOCORROSION IN INDUSTRIAL WATER SYSTEMS, P151
   HERBERT BN, 1994, BACTERIAL BIOFILMS T
   HOLT DM, 1987, BIODETERIORATION, V7, P493
   HUANG CT, 1995, APPL ENVIRON MICROB, V61, P2252, DOI 10.1128/AEM.61.6.2252-2256.1995
   IMAN RL, 1981, J QUAL TECHNOL, V13, P232
   IMAN RL, 1981, J QUAL TECHNOL, V13, P174
   KINNIMENT SL, 1992, Q J TECH PAPERS  OCT, P43
   KISSEL JC, 1984, J ENVIRON ENG-ASCE, V110, P393, DOI 10.1061/(ASCE)0733-9372(1984)110:2(393)
   Marsh P, 1984, ORAL MICROBIOLOGY
   NICHOLS WW, 1989, LIFE SCI R, V46, P321
   NICHOLS WW, 1989, J GEN MICROBIOL, V135, P1291
   NOVAK L, 1982, J HEAT TRANS-T ASME, V104, P663, DOI 10.1115/1.3245183
   Perry R.H., 1973, CHEM ENG HDB
   RIDGWAY HF, 1985, J AM WATER WORKS ASS, V77, P97
   ROBINSON JA, 1984, BIOTECHNOL BIOENG, V26, P1409, DOI 10.1002/bit.260261203
   ROSSMAN LA, 1994, J ENVIRON ENG-ASCE, V120, P803, DOI 10.1061/(ASCE)0733-9372(1994)120:4(803)
   SRINIVASAN R, 1995, BIOTECHNOL BIOENG, V46, P553, DOI 10.1002/bit.260460608
   STEWART PS, 1994, ANTIMICROB AGENTS CH, V38, P1052, DOI 10.1128/AAC.38.5.1052
   STEWART PS, 1994, APPL ENVIRON MICROB, V60, P1690, DOI 10.1128/AEM.60.5.1690-1692.1994
   STEWART PS, 1993, BIOTECHNOL BIOENG, V41, P111, DOI 10.1002/bit.260410115
   STRAUSS SD, 1984, POWER, V128, pS1
   TASHIRO H, 1991, WATER SCI TECHNOL, V23, P1395
   WANNER O, 1986, BIOTECHNOL BIOENG, V28, P314, DOI 10.1002/bit.260280304
   WESTRIN BA, 1991, BIOTECHNOL BIOENG, V38, P439, DOI 10.1002/bit.260380502
NR 37
TC 47
Z9 47
U1 0
U2 10
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0006-3592
J9 BIOTECHNOL BIOENG
JI Biotechnol. Bioeng.
PD FEB 20
PY 1996
VL 49
IS 4
BP 445
EP 455
DI 10.1002/(SICI)1097-0290(19960220)49:4<445::AID-BIT12>3.0.CO;2-9
PG 11
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA TR945
UT WOS:A1996TR94500012
PM 18623600
DA 2021-08-04
ER

PT J
AU Zaharescu, T
   Postolache, C
   Giurginca, M
AF Zaharescu, T
   Postolache, C
   Giurginca, M
TI The structural changes in butyl and halogenated butyl elastomers during
   gamma irradiation
SO JOURNAL OF APPLIED POLYMER SCIENCE
LA English
DT Article
ID MODEL-COMPOUND APPROACH; RADIATION; DEGRADATION; CHEMISTRY
AB Ionizing radiation induces various changes in the molecular structure of elastomers; consequently, the macroscopic properties of the irradiated elastomers will be modified. The newly formed products and the alteration of the initial chemical structure are the result of free-radical reactions which provide the crosslinking and/or the depolymerization of the tested materials and destructive simultaneous processes involving diffused aggressive agents. This paper describes the behavior of butyl and chlorinated and brominated butyl elastomers under the action of gamma radiation for total doses up to 0.5 MGy. The experimental data provided by several procedures emphasize a complex chemistry circumstance consisting of the simultaneous crosslinking and scission of the macromolecular chains and consecutive processes involving free radicals. Evaluation of the studied changes was via gel content, oxidation level, unsaturation, and halogen distribution as dependent on the total radiation dose. The mechanism of the degradation and a relationship between the crosslinking/scission ratio and the absorbed dose are discussed. (C) 1996 John Wiley & Sons, Inc.
C1 ICPE,R-79623 BUCHAREST,ROMANIA.
   IFA,R-76900 BUCHAREST,ROMANIA.
   CERELAST,R-79628 BUCHAREST,ROMANIA.
RI Zaharescu, Traian/C-4778-2011
CR BOHM GGA, 1982, RUBBER CHEM TECHNOL, V55, P575
   BOVEY FA, 1959, EFFECT IONIZING RAD, P413
   CARLSSON DJ, 1990, MACROMOLECULES, V23, P1934
   Chapiro A, 1962, RAD CHEM POLYM SYSTE
   CHARLESBY A, 1959, PROC R SOC LON SER-A, V249, P367, DOI 10.1098/rspa.1959.0030
   Clough R. L, 1988, ENCY POLYM SCI ENG, V13, P667
   CLOUGH RL, 1989, J POLYM SCI POL CHEM, V27, P2313, DOI 10.1002/pola.1989.080270715
   DEVER JA, 1991, NASA103711 TECH MEM
   Drozdovskii V. F., 1973, MANUFACTURE USE BUTY
   DROZDOVSKII VF, 1989, METHODS RECLAIM MANU
   GIURGINCA M, 1976, MATER PLAST BUCHARES, V13, P100
   LAGHARI JR, 1987, IEEE T NUCL SCI, V37, P1076
   MORAND JL, 1974, RUBBER CHEM TECHNOL, V47, P1094
   NAKANISHI K, 1962, INFRARED ABSORPTION, P42
   NENITESCU CD, 1956, ORGANIC CHEM, P102
   RANBY B, 1977, ESR SPECTROSCOPY POL, pCH5
   SCHNABEL E, ASPECT DEGRADATION S, P149
   VUKOV R, 1984, RUBBER CHEM TECHNOL, V57, P284, DOI 10.5254/1.3536008
   VUKOV R, 1984, RUBBER CHEM TECHNOL, V57, P275, DOI 10.5254/1.3536007
   WILSKI H, 1987, RADIAT PHYS CHEM, V29, P1
NR 20
TC 11
Z9 12
U1 0
U2 3
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012
SN 0021-8995
J9 J APPL POLYM SCI
JI J. Appl. Polym. Sci.
PD FEB 7
PY 1996
VL 59
IS 6
BP 969
EP 974
DI 10.1002/(SICI)1097-4628(19960207)59:6<969::AID-APP9>3.0.CO;2-N
PG 6
WC Polymer Science
SC Polymer Science
GA TQ346
UT WOS:A1996TQ34600009
DA 2021-08-04
ER

PT J
AU Khilnani, N
   Lee, M
   Winchester, P
   Zanzonico, P
   McCaffrey, T
   Trost, D
   Jagust, M
   Binkert, B
   Sos, T
AF Khilnani, N
   Lee, M
   Winchester, P
   Zanzonico, P
   McCaffrey, T
   Trost, D
   Jagust, M
   Binkert, B
   Sos, T
TI In vitro model to evaluate the relative efficacy of catheter-directed
   thrombolytic strategies
SO ACADEMIC RADIOLOGY
LA English
DT Article
DE thrombolysis; pulse spray; experimental thrombolysis; urokinase;
   peripheral arterial occlusion therapy
ID PULSE-SPRAY THROMBOLYSIS; LOW-DOSE STREPTOKINASE; PLASMINOGEN-ACTIVATOR;
   GRAFT OCCLUSIONS; THROMBOSIS; UROKINASE; ARTERIAL; INVITRO;
   FIBRINOLYSIS; ENHANCEMENT
AB Rationale and Objectives. Catheter-directed thrombolytic therapy has become an accepted treatment for many vascular occlusions, However, the relative rates of lysis of the different methods of drug administration have not been quantified. We developed an in vitro model to simulate and quantify local lyric therapy of a thrombotic vascular occlusion and tested it by evaluating three catheter-directed lytic strategies.
   Methods. Seven-centimeter-long segments of I-125-fibrinogen-labeled thrombus made from recently expired human blood from a blood bank were formed in plastic tubes and were placed in a flowing stream of saline. Using multisidehole catheters, the clots were ''treated'' with intrathrombic saline or urokinase administered by drip infusion or forced injection using identical total doses of drug and volumes of fluid. Using endhole catheters, saline or urokinase was drip infused into the leading edge of the thrombus using the same protocol, A collimated scintillation detector was used to quantify the amount of activity remaining in the thrombus during each experiment, and the resultant time-activity curves for the different trials were compared.
   Results. Forced-injection administration of urokinase using a multisidehole catheter produced the fastest lysis, resulting in a half-life of 42 min. The other infusion methods were slower, with half-lives of 153 min for multisidehole urokinase drip infusion, 365 min for endhole urokinase drip infusion, and more than 1,000 min for multisidehole catheter forced injection of saline and multisidehole and endhole saline drip infusion. The differences among these groups were reproducible and statistically significant.
   Conclusion. Results suggest that a simple and inexpensive in vitro model simulating lysis of a vascular occlusion can produce reproducible quantitative data, The data demonstrate that forced injection of lytic agents with a multisidehole catheter enhances the rate of thrombolysis and that the enhancement is not primarily attributable to the mechanical effect of this mode of administration.
C1 NEW YORK HOSP,CORNELL MED CTR,DEPT MED,NEW YORK,NY 10021.
RP Khilnani, N (corresponding author), NEW YORK HOSP,CORNELL MED CTR,DEPT RADIOL,ROOM L-515,525 E 68TH ST,NEW YORK,NY 10021, USA.
CR BECKER GJ, 1983, RADIOLOGY, V148, P663, DOI 10.1148/radiology.148.3.6878681
   BOOKSTEIN JJ, 1985, INVEST RADIOL, V20, P731, DOI 10.1097/00004424-198510000-00013
   CHANDLER AB, 1958, LAB INVEST, V7, P110
   CRAGG AH, 1991, RADIOLOGY, V178, P681, DOI 10.1148/radiology.178.3.1994402
   DOTTER CT, 1974, RADIOLOGY, V111, P31, DOI 10.1148/111.1.31
   FRANCIS CW, 1992, J CLIN INVEST, V90, P2063, DOI 10.1172/JCI116088
   HARPAZ D, 1993, J AM COLL CARDIOL, V21, P1507, DOI 10.1016/0735-1097(93)90331-T
   HOUGHIE C, 1983, HEMATOLOGY, P1662
   KANDARPA K, 1993, RADIOLOGY, V188, P861, DOI 10.1148/radiology.188.3.8351363
   KANDARPA K, 1988, RADIOLOGY, V168, P739, DOI 10.1148/radiology.168.3.3406403
   KATZEN BT, 1981, AM J ROENTGENOL, V136, P1171, DOI 10.2214/ajr.136.6.1171
   MEYEROVITZ MF, 1990, RADIOLOGY, V175, P75, DOI 10.1148/radiology.175.1.2107563
   OURIEL K, 1994, J VASC SURG, V19, P1021, DOI 10.1016/S0741-5214(94)70214-4
   STOUGHTON J, 1994, J VASC SURG, V19, P298, DOI 10.1016/S0741-5214(94)70105-9
   SULLIVAN KL, 1989, RADIOLOGY, V173, P805, DOI 10.1148/radiology.173.3.2813789
   Tachibana K, 1992, J Vasc Interv Radiol, V3, P299, DOI 10.1016/S1051-0443(92)72029-6
   VALJI K, 1987, INVEST RADIOL, V22, P23, DOI 10.1097/00004424-198701000-00003
   VALJI K, 1993, RADIOLOGY, V186, P873, DOI 10.1148/radiology.186.3.8430201
   VALJI K, 1992, INVEST RADIOL, V27, P912, DOI 10.1097/00004424-199211000-00007
   1994, ANN SURG, V220, P251
NR 20
TC 4
Z9 4
U1 0
U2 0
PU ASSOC UNIV RADIOLOGISTS
PI RESTON
PA 1891 PRESTON WHITE DR, RESTON, VA 22091
SN 1076-6332
J9 ACAD RADIOL
JI Acad. Radiol.
PD FEB
PY 1996
VL 3
IS 2
BP 121
EP 128
DI 10.1016/S1076-6332(05)80378-2
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA TT651
UT WOS:A1996TT65100005
PM 8796652
DA 2021-08-04
ER

PT J
AU Zsigmond, EK
   Kovacs, V
   Fekete, G
AF Zsigmond, EK
   Kovacs, V
   Fekete, G
TI A new route, jet-injection for anesthetic induction in children .2.
   Ketamine dose-range finding studies
SO INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
DE anesthesia induction; jet-injection; ketamine; new anesthetic method;
   pediatric anesthesia
ID PREMEDICATION; SURGERY
AB Ketamine (K) i.m. has been widely used for anesthetic induction in small children in the last decades, if mask induction has failed. In many instances, however, physical restraint was required. In order to eliminate the pain of i.m. injection and to prevent the psychological and physical trauma associated with restraint, we evaluated the utility of jet-injection (j.i.) of K for anesthetic induction in a dose-range finding study. Thirty children (age 1 - 6 years), whose parents gave a valid consent approved by the IRE and were scheduled for minor surgeries, were randomized into 3 equal groups: A/ketamine 6.0 mg/kg j.i., B/ketamine 3.5 mg/kg j.i., C/ketamine 2.5 mg/kg j.i. As a drying agent atropine 20 mu g/kg was also given i.v. The onset of full amnesic/sedative effect of K, the scoring of sedation and emotional state, the ease of placement of the i.v. catheter, the speed of recovery by Aldrete scores, and the time for safe discharge were evaluated. Although no demographic differences were observed among the groups the duration of surgery and anesthesia were longer in the B group (41 and 49 min) than in the A or C groups. The onset of sedation was significantly (p < 0.05) faster in group A (174 sec) than in group B (312 sec) or C (303 sec). However, no significant difference was observed in the onset of complete sedation among the groups. The sedation index was the lowest representing the best sedation in group A (4.2) while in group B and C were somewhat higher (4.6 and 4.4). There were no differences in the ease of i.v. cannulation among the groups. Recovery from anesthesia was the slowest in group A, although the differences among the 3 groups did not reach statistical significance. The mean discharge times ranged from 10 - 13 min with no differences among the groups. Laryngospasm occurred in 4 : 10 in group A and 1 : 10 in groups B and C. Evidently the high dose of K, 6.0 mg/kg caused a proneness to laryngospasm. Since no additional benefit was derived from this high dose, the lower doses (3.0 mg/kg) of K may be sufficient for routine use. None of the children experienced unpleasant recall or pain for the injection or the whole procedure. This new route of anesthetic induction with the jet-injector utilizing K may provide pain-free and stress-free induction as compared to its i.m. injection. This technique also prevents transmission of infection and cost effective since simultaneous and/or sequential injection can be given from a single vial of K.
C1 SEMMELWEIS UNIV MED,SCH MED,DEPT PEDIAT 2,BUDAPEST,HUNGARY.
RP Zsigmond, EK (corresponding author), UNIV ILLINOIS,SCH MED,DEPT ANESTHESIA,SUITE 3214B,1740 W TAYLOR ST,M-C 515,CHICAGO,IL 60612, USA.
CR ALDERSON PJ, 1994, CAN J ANAESTH, V41, P221, DOI 10.1007/BF03009834
   BEEBE DS, 1992, ANESTH ANALG, V75, P880
   BION JF, 1984, ANAESTHESIA, V39, P1023, DOI 10.1111/j.1365-2044.1984.tb08895.x
   COHN L, 1974, ALA J MED SCI, V11, P36
   DOMINO EF, 1982, ANESTH ANALG, V61, P87
   GUTSTEIN HB, 1992, ANESTHESIOLOGY, V76, P28, DOI 10.1097/00000542-199201000-00004
   HINGSON RA, 1947, ANESTH ANALG, V26, P221
   JANTZEN PP, 1990, STATUS KETAMINE ANES, P325
   KENTRUP H, 1994, INT J CLIN PHARM TH, V32, P82
   LOKKEN P, 1994, SCAND J DENT RES, V102, P274
   LUON A, 1994, ACTA ANAESTH SCAND, V28, P259
   STEWART KG, 1990, ANAESTH INTENS CARE, V18, P11, DOI 10.1177/0310057X9001800103
   TOBIAS JD, 1992, PEDIATRICS, V90, P537
   TSAI SK, 1988, ANESTH ANALG, V67, pS234
   WEKSLER N, 1993, CAN J ANAESTH, V40, P119, DOI 10.1007/BF03011307
   WHITE PF, 1990, STATUS OF KETAMINE IN ANESTHESIOLOGY, P343
   ZSIGMOND EK, 1995, INT J CLIN PHARM TH, V33, P580
   ZSIGMOND EK, 1982, REGION ANESTH, V7, P82
NR 18
TC 13
Z9 13
U1 0
U2 1
PU DUSTRI-VERLAG DR KARL FEISTLE
PI MUNCHEN-DEISENHOFEN
PA BAHNHOFSTRABE 9 POSTFACH 49, W-8024 MUNCHEN-DEISENHOFEN, GERMANY
SN 0946-1965
J9 INT J CLIN PHARM TH
JI Int. J. Clin. Pharmacol. Ther.
PD FEB
PY 1996
VL 34
IS 2
BP 84
EP 88
PG 5
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA TW533
UT WOS:A1996TW53300008
PM 8929752
DA 2021-08-04
ER

PT J
AU Tobita, H
AF Tobita, H
TI Random sampling technique to predict the molecular weight distribution
   in free-radical polymerization that involves polyfunctional chain
   transfer agents
SO MACROMOLECULES
LA English
DT Article
ID CROSS-LINKING COPOLYMERIZATION; NETWORK FORMATION; COMPUTER-SIMULATION;
   KINETICS; GELATION
AB A random sampling technique in which polymer molecules are sampled from an infinite number of polymer molecules in the reaction mixture is used to predict the molecular weight distribution (MWD) development during free-radical polymerization that involves polyfunctional chain transfer agents (P-CTAs). For an ideal ease where the chain transfer constant is unity and chain stoppage is dominated by chain transfer reactions, the analytical solutions for the full MWD as well as the average molecular weights can be derived in a straightforward manner. For more complex reaction systems where nonrandom history-dependent kinetics is important due to bimolecular termination reactions and the substitution effect of the P-CTAs, the Monte Carlo simulation on the basis of the random sampling technique enables one to estimate the statistical property development quite effectively. When bimolecular termination reactions and/or the substitution effects are involved, the MWD does not necessarily become narrower with polymerization in contrast with the ideal case. The decreased reactivity of the functional groups in a P-CTA due to the substitution effect may increase or decrease the average molecular weights depending on the magnitude of the chain transfer constant, concentration of P-CTA, the mode of bimolecular termination (disproportionation or combination), and the degree of the substitution effect.
RP Tobita, H (corresponding author), FUKUI UNIV, DEPT MAT SCI & ENGN, 3-9-1 BUNKYO, FUKUI 910, JAPAN.
CR BANSIL R, 1984, MACROMOLECULES, V17, P998, DOI 10.1021/ma00135a004
   BOWMAN CN, 1992, CHEM ENG SCI, V47, P1411, DOI 10.1016/0009-2509(92)80286-L
   DEMJANENKO M, 1980, MACROMOLECULES, V13, P571, DOI 10.1021/ma60075a019
   Flory P.J, 1953, PRINCIPLES POLYM CHE
   GORDON M, 1962, PROC R SOC LON SER-A, V268, P240, DOI 10.1098/rspa.1962.0136
   GREST GS, 1992, EUROPHYS LETT, V19, P195, DOI 10.1209/0295-5075/19/3/008
   GUAITA M, 1990, MACROMOLECULES, V23, P2087, DOI 10.1021/ma00209a035
   KIMURA T, 1962, J PHYS SOC JPN, V17, P1884, DOI 10.1143/JPSJ.17.1884
   LEUNG YK, 1984, J CHEM PHYS, V80, P3877, DOI 10.1063/1.447169
   MACOSKO CW, 1976, MACROMOLECULES, V9, P199, DOI 10.1021/ma60050a003
   MIKES J, 1982, MACROMOLECULES, V15, P93, DOI 10.1021/ma00229a018
   ODRISCOLL KF, 1994, MACROMOL THEOR SIMUL, V3, P469, DOI 10.1002/mats.1994.040030214
   ROLFES H, 1993, MAKROMOL CHEM-M SYMP, V65, P233, DOI 10.1002/masy.19930650126
   Saito O, 1972, RADIAT CHEM MACROMOL, P223, DOI [10.1016/B978-0-12-219801-4.50017-3, DOI 10.1016/B978-0-12-219801-4.50017-3]
   SCHAEFGEN JR, 1948, J AM CHEM SOC, V70, P2709, DOI 10.1021/ja01188a026
   Stockmayer WH, 1944, J CHEM PHYS, V12, P125, DOI 10.1063/1.1723922
   Stockmayer WH, 1943, J CHEM PHYS, V11, P45, DOI 10.1063/1.1723803
   THORN M, 1994, MACROMOL THEOR SIMUL, V3, P585, DOI 10.1002/mats.1994.040030306
   TOBITA H, 1993, J POLYM SCI POL PHYS, V31, P1363, DOI 10.1002/polb.1993.090311011
   TOBITA H, 1995, J POLYM SCI POL PHYS, V33, P841, DOI 10.1002/polb.1995.090330513
   TOBITA H, 1995, MACROMOLECULES, V28, P5119, DOI 10.1021/ma00118a046
   TOBITA H, 1993, MACROMOLECULES, V26, P836, DOI 10.1021/ma00056a039
   TOBITA H, 1994, POLYMER, V35, P3032, DOI 10.1016/0032-3861(94)90416-2
   TOBITA H, 1994, POLYMER, V35, P3023, DOI 10.1016/0032-3861(94)90415-4
   TOBITA H, 1994, J POLYM SCI POL PHYS, V32, P901, DOI 10.1002/polb.1994.090320513
   TOBITA H, 1993, MACROMOLECULES, V26, P5427, DOI 10.1021/ma00072a021
   TOBITA H, 1995, POLYMER, V36, P2585, DOI 10.1016/0032-3861(95)91205-L
   TOBITA H, 1994, J POLYM SCI POL PHYS, V32, P911, DOI 10.1002/polb.1994.090320514
   TOBITA H, 1994, MACROMOLECULES, V27, P5413, DOI 10.1021/ma00097a022
   TOBITA H, 1994, MACROMOL THEOR SIMUL, V3, P1033, DOI 10.1002/mats.1994.040030607
   TOBITA H, 1993, MAKROMOL CHEM-THEOR, V2, P761
   TOBITA H, 1995, J POLYM SCI POL PHYS, V33, P1191, DOI 10.1002/polb.1995.090330805
   TOBITA H, IN PRESS J POLYM PP
   TOBITA H, 1995, LECTURE NOTE FUKUI U
   ULLISCH B, 1977, MAKROMOL CHEM, V178, P1427
   ULLISCH B, 1977, MAKROMOL CHEM, V178, P1403
   YUAN CM, 1994, MACROMOL THEOR SIMUL, V3, P193, DOI 10.1002/mats.1994.040030116
   YUAN CM, 1994, MACROMOL THEOR SIMUL, V3, P203, DOI 10.1002/mats.1994.040030117
NR 38
TC 35
Z9 35
U1 0
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036
SN 0024-9297
J9 MACROMOLECULES
JI Macromolecules
PD JAN 15
PY 1996
VL 29
IS 2
BP 693
EP 704
DI 10.1021/ma950693h
PG 12
WC Polymer Science
SC Polymer Science
GA TQ379
UT WOS:A1996TQ37900025
DA 2021-08-04
ER

PT J
AU Bhatia, M
   Kirkland, JB
   MecklingGill, KA
AF Bhatia, M
   Kirkland, JB
   MecklingGill, KA
TI 1,25-dihydroxyvitamin D-3 primes acute promyelocytic cells for
   TPA-induced monocytic differentiation through both PKC and tyrosine
   phosphorylation cascades
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
ID PROTEIN-KINASE-C; T(15-17) TRANSLOCATION; LEUKEMIC-CELLS; HL-60 CELLS;
   MACROPHAGE; EXPRESSION; INDUCTION; D3; SENSITIVITY; MATURATION
AB NB4 cells are the only in vitro model of differentiation in acute promyelocytic leukemia (APL). Although these cells respond to all-trans-retinoic acid to form neutrophils, our group has recently shown that these cells are capable of terminal monocytic differentiation in response to combined treatment with 1,25-dihydroxyvitamin D-3 (1,25 D-3) and 12-O-tetradecanoylphorbol-13-acetate (TPA). We show here that the agents need not be present simultaneously, but may be added sequentially. TPA treatment prior to 1,25 D-3 Zed to the appearance of adherent cells; however, when 1,25 D-3 treatment preceded TPA treatment cells expressed all differentiation markers reflective of terminal differentiation. This priming effect of 1,25 D-3 was both dose and time dependent. Increasing the interval between 1,25 D-3 and TPA treatment caused a decrease in this priming potential indicative of limited commitment inducing capacity of 1,25 D-3. In Order to characterize the mechanism of action of 1,25 D-3 and TPA, chemical inhibitors of phosphorylation were used. Staurosporine and bisindolymaleimide GF 109203X treatment prior to and during 1,25 D-3 treatment or TPA treatment caused attenuation of the differentiation response. Experiments utilizing tyrosine kinase and phosphatase inhibitors supported the hypothesis that 1,25 D-3 Signaling was mediated by both serine/threonine and tyrosine phosphorylation cascades. Results from this study provide evidence to support the hypothesis that 1,25 D-3 signaling occurs via nongenomic mechanisms which when combined with the signaling effects of TPA, allow for the terminal differentiation of APL cells. This model should be used to develop new differentiation therapies for APL and other leukemias. (C) 1996 Academic Press, Inc.
C1 UNIV GUELPH,DEPT NUTR SCI,GUELPH,ON N1G 2W1,CANADA.
CR AIHARA H, 1991, P NATL ACAD SCI USA, V88, P11062, DOI 10.1073/pnas.88.24.11062
   AKIYAMA T, 1987, J BIOL CHEM, V262, P5592
   BHATIA M, 1994, LEUKEMIA, V8, P1744
   CARROLL MP, 1994, J BIOL CHEM, V269, P1249
   CASTAIGNE S, 1990, BLOOD, V76, P1704
   CLEMENS MJ, 1992, J CELL SCI, V103, P881
   Courage C., 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P442
   DELVA L, 1993, BLOOD, V82, P2175
   DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D
   DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0
   DODD RC, 1983, P NATL ACAD SCI-BIOL, V80, P7538, DOI 10.1073/pnas.80.24.7538
   GUPTAROY B, 1992, J BIOL CHEM, V267, P15326
   HASS R, 1993, CELL GROWTH DIFFER, V4, P657
   HAUSS P, 1993, CELL IMMUNOL, V150, P439, DOI 10.1006/cimm.1993.1211
   JARVIS WD, 1994, CANCER RES, V54, P1707
   KATZ EZ, 1985, CANCER RES, V45, P5159
   KAUSHANSKY K, 1993, BLOOD, V82, P3229
   KELSEY SM, 1992, LEUKEMIA RES, V16, P427, DOI 10.1016/0145-2126(92)90167-6
   KHARBANDA S, 1994, J BIOL CHEM, V269, P872
   KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0
   LANOTTE M, 1991, BLOOD, V77, P1080
   MACFARLANE DE, 1994, J BIOL CHEM, V269, P4327
   MARTELL RE, 1987, J BIOL CHEM, V262, P5570
   METCALF D, 1993, BLOOD, V82, P3515
   METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0
   MORELLI S, 1993, BIOCHEM J, V289, P675, DOI 10.1042/bj2890675
   NAKAMAKI T, 1992, ANTICANCER RES, V12, P1331
   NELSON R, 1992, MOL CELL BIOL, V4, P1003
   NISHIKAWA M, 1990, CANCER RES, V50, P621
   OBEID LM, 1990, J BIOL CHEM, V265, P2370
   OBERG F, 1993, J IMMUNOL, V150, P3487
   OKAZAKI T, 1994, J BIOL CHEM, V269, P4070
   OLSON EN, 1993, CELL GROWTH DIFFER, V4, P699
   SIMBOLICAMPBELL.M, 1993, CELL SIGNAL, V4, P99
   Studzinski George P., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P279
   STUDZINSKI GP, 1987, J NATL CANCER I, V79, P67
   STUDZINSKI GP, 1985, CANCER RES, V45, P3898
   STUDZINSKI GP, 1985, P SOC EXP BIOL MED, V179, P288
   SUDA T, 1989, P SOC EXP BIOL MED, V191, P214
   SYLVIA VL, 1993, J CELL PHYSIOL, V157, P271, DOI 10.1002/jcp.1041570209
   TESTA U, 1993, J IMMUNOL, V150, P2418
   TONETTI DA, 1994, J BIOL CHEM, V269, P23230
   TOULLEC D, 1991, J BIOL CHEM, V266, P15771
   VALETERI M, 1991, BLOOD, V77, P1804
   VANDERHEM KG, 1993, LEUKEMIA, V8, P266
   VANLEEUWEN JPTM, 1992, J BIOL CHEM, V267, P12562
   WALI RK, 1990, J CLIN INVEST, V85, P1296, DOI 10.1172/JCI114567
   WAYS DK, 1994, CELL GROWTH DIFFER, V5, P161
   WEISE RJ, 1992, J BIOL CHEM, V267, P20082
   XU HM, 1993, EXP CELL RES, V209, P367, DOI 10.1006/excr.1993.1322
   YANG KD, 1994, BLOOD, V83, P490
   YU XP, 1991, J BIOL CHEM, V266, P7588
   ZIPORI D, 1992, FASEB J, V6, P2691
NR 53
TC 41
Z9 42
U1 0
U2 1
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495
SN 0014-4827
J9 EXP CELL RES
JI Exp. Cell Res.
PD JAN 10
PY 1996
VL 222
IS 1
BP 61
EP 69
DI 10.1006/excr.1996.0008
PG 9
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA TQ829
UT WOS:A1996TQ82900008
PM 8549674
DA 2021-08-04
ER

PT J
AU Overgaard, L
   Petersen, HG
   Perram, JW
AF Overgaard, L
   Petersen, HG
   Perram, JW
TI Reactive motion planning: A multiagent approach
SO APPLIED ARTIFICIAL INTELLIGENCE
LA English
DT Article
ID REPRESENTATION; MANIPULATORS; ALGORITHM; BODIES; SPACE
AB We present an efficient approach to reactive robot motion planning and collision avoidance. Unlike the traditional methods, there is no centralized control; instead the links and the joints of the robot are autonomous agents. This is a completely new approach. A set of dynamic equations of motion for an arbitrary robot is derived Artificial forces are introduced to express and combine multiple, possibly conflicting objectives, such as avoiding obstacles while approaching a goal. The joint agents impose forces of constraint between the link agents, and these forces establish a flow of information among the agents. The emergent behavior of the multiagent system gives an impression of surprisingly intelligent overall control. The developed method is used in actual industrial applications to control welding robot installations for ship building with up to II degrees of freedom (DOF). Experimental results from the simulation of a 25-DOF snakelike robot operating in a complex three-dimensional structure are given. It is demonstrated that the time complexity is O(n(3)) for branched n-DOF robots, while for serial robots such as standard manipulators and the snake, it is O(n).
RP Overgaard, L (corresponding author), ODENSE UNIV,LINDO CTR APPL MATH,DK-5230 ODENSE M,DENMARK.
CR BARRAQUAND J, 1991, INT J ROBOT RES, V10, P628, DOI 10.1177/027836499101000604
   BRADY M, 1985, ARTIF INTELL, V26, P79, DOI 10.1016/0004-3702(85)90013-X
   BROOKS RA, 1983, IEEE T SYST MAN CYB, V13, P190, DOI 10.1109/TSMC.1983.6313112
   BROOKS RA, 1983, INT J ROBOT RES, V2, P19, DOI 10.1177/027836498300200402
   BROOKS RA, 1991, 12TH P INT JOINT C A, P569
   CHIRIKJIAN GS, 1993, IEEE T ROBOTIC AUTOM, P113
   DELEEUW SW, 1990, J STAT PHYS, V61, P1203, DOI 10.1007/BF01014372
   DONALD BR, 1987, ARTIF INTELL, V31, P295, DOI 10.1016/0004-3702(87)90069-5
   JACOBSEN NL, 1990, 2ND WORKSH P ESPR PA
   JACOBSEN NL, 1992, 23RD P INT S IND ROB, P363
   KEARNEY PJ, 1992, 4TH P EUR WORKSH MOD
   KHATIB O, 1986, INT J ROBOT RES, V5, P90, DOI 10.1177/027836498600500106
   KROGH B, 1984, WORLD C ROBOTICS RES
   LARSEN R, 1994, UNPUB INT J ROBOTICS
   LARSEN R, 1991, 3RD WORKSH P ESP PAR
   LIU JS, 1993, 5TH P EUR WORKSH MOD
   LOZANOPEREZ T, 1987, IEEE T ROBOTIC AUTOM, V3, P224, DOI 10.1109/JRA.1987.1087095
   LOZANOPEREZ T, 1981, IEEE T SYST MAN CYB, V11, P681, DOI 10.1109/TSMC.1981.4308589
   LOZANOPEREZ T, 1983, IEEE T COMPUT, V32, P108
   NAGAO K, 1993, 5TH P EUR WORKSH MOD
   OVERGAARD L, 1991, THESIS ODENSE U DENM
   PERAM JW, 1988, MOL SIMULAT, V1, P239
   PERRAM JW, 1988, MOL PHYS, V65, P861, DOI 10.1080/00268978800101461
   Press W.H., 1988, NUMERICAL RECIPES C
   SCHWARTZ JT, 1983, INT J ROBOT RES, V2, P46, DOI 10.1177/027836498300200304
   WERNER E, 1994, 6TH P EUR WORKSH MOD, P1
NR 26
TC 11
Z9 12
U1 0
U2 5
PU TAYLOR & FRANCIS
PI BRISTOL
PA 1900 FROST ROAD, SUITE 101, BRISTOL, PA 19007-1598
SN 0883-9514
J9 APPL ARTIF INTELL
JI Appl. Artif. Intell.
PD JAN-FEB
PY 1996
VL 10
IS 1
BP 35
EP 51
DI 10.1080/088395196118678
PG 17
WC Computer Science, Artificial Intelligence; Engineering, Electrical &
   Electronic
SC Computer Science; Engineering
GA TW760
UT WOS:A1996TW76000003
DA 2021-08-04
ER

PT J
AU Sun, WZ
   Shyu, BC
   Shieh, JY
AF Sun, WZ
   Shyu, BC
   Shieh, JY
TI Nitrous oxide or halothane, or both, fail to suppress c-fos expression
   in rat spinal cord dorsal horn neurones after subcutaneous formalin
SO BRITISH JOURNAL OF ANAESTHESIA
LA English
DT Article
DE analgesia,pre-emptive; anaesthetics gases, nitrous oxide; anaesthetics
   volatile, halothane; anaesthetics iv, fentanyl; rat; genetic factors,
   proto-oncogenes
ID ANESTHETIC REQUIREMENT; POSTOPERATIVE PAIN; MORPHINE; STIMULATION;
   PROTEIN; BRAIN; IMMUNOREACTIVITY; PLASTICITY; ANALGESIA; INDUCTION
AB In rats injected s.c. with formalin, behavioural correlates of the amount and pattern of Fos-like immunoreactivity (Fos-LI) (molecular responses to pain) were studied to test if early phase treatment with 75% nitrous oxide or 2% halothane, or both, suppressed subsequent spinal sensitization. Rats were allocated to four treatment groups: (1) 100% oxygen (control, n = 15), (2) 75% nitrous oxide (0.5 MAC, n = 12), (3) 2% halothane (1 MAC, n = 12), and (4) 75% nitrous oxide with 2% halothane (1.5 MAC, n = 18) for 20 min. Each rat then received a s.c. injection of 1% formalin 50 mu l into the left hindpaw and anaesthesia was maintained for another 5 min (early phase). A fifth group of rats receiving fentanyl 100 mu g kg(-1) (n = 12) 10 min before formalin injection were studied simultaneously as a positive control. Rats in all groups were killed 60 min after formalin injection and maximal counts of Fos-LI labelled neurones in the dorsal horn of the rat spinal cord were compared according to laminar distribution. Formalin-induced behavioural hyperalgesia during the early phase was suppressed completely by fentanyl, 75% nitrous oxide, or 2% halothane, or both. The late phase response was attenuated by all four anaesthetic regimens within 20 min after injection, whereas behavioural scores for the nitrous oxide, halothane, or both, groups were nearly identical to the control 20 min later. Fentanyl suppressed the late phase response until 30 min after formalin injection but failed to reduce it thereafter. The numbers of Fos-LI labelled neurones for groups given nitrous oxide, or halothane, or both, were identical to the control, whereas numbers for fentanyl were 47.2% less (P < 0.01). The decrease occurred predominantly in the neck of the dorsal horn (44.9% of control, P < 0.01) and also in the nucleus proprius and superficial laminae (54.4% and 56.2% of control, P < 0.05). In summary, we found that nitrous oxide, or halothane, or both, did not suppress subsequent spinal sensitization to noxious stimulation. This result supports the previous hypothesis that inhalation anaesthesia lacks pre-emptive analgesic action. Inhalation anaesthetic agents, unlike fentanyl, suppress the early and late phase response because of anaesthetic but not analgesic effects. Thus, we suggest that measuring the genetic product of c-fos proto-oncogene is a useful adjunct to pharmacological tests whenever behavioural hyperalgesia is questionable or unobtainable.
C1 NATL TAIWAN UNIV HOSP,COLL MED,DEPT ANAT,TAIPEI,TAIWAN.
   ACAD SINICA,INST BIOMED SCI,TAIPEI,TAIWAN.
RP Sun, WZ (corresponding author), NATL TAIWAN UNIV HOSP,COLL MED,DEPT ANAESTHESIOL,7 CHUNGSHAN S RD,TAIPEI,TAIWAN.
RI Shyu, Bai Chuang/Q-2622-2018
OI Shyu, Bai Chuang/0000-0001-5619-2281; SUN, WEI-ZEN/0000-0001-8543-2600
CR ABBADIE C, 1994, EUR J PHARMACOL, V258, P215, DOI 10.1016/0014-2999(94)90483-9
   ABBOTT FV, 1982, EXP NEUROL, V75, P644, DOI 10.1016/0014-4886(82)90031-0
   ABRAM SE, 1993, ANESTHESIOLOGY, V78, P713, DOI 10.1097/00000542-199304000-00015
   BERGE OG, 1991, PHARMACOL BIOCHEM BE, V40, P197, DOI 10.1016/0091-3057(91)90539-E
   BULLITT E, 1990, J COMP NEUROL, V296, P517, DOI 10.1002/cne.902960402
   CODERRE TJ, 1993, PAIN, V54, P43, DOI 10.1016/0304-3959(93)90098-A
   CODERRE TJ, 1990, BRAIN RES, V535, P155, DOI 10.1016/0006-8993(90)91835-5
   COLE DJ, 1990, ANESTHESIOLOGY, V73, P93, DOI 10.1097/00000542-199007000-00014
   DUBNER R, 1992, TRENDS NEUROSCI, V15, P96, DOI 10.1016/0166-2236(92)90019-5
   DUBUISSON D, 1977, PAIN, V4, P161, DOI 10.1016/0304-3959(77)90130-0
   GOTO T, 1994, ANESTHESIOLOGY, V80, P409, DOI 10.1097/00000542-199402000-00021
   HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0
   JASMIN L, 1994, NEUROSCIENCE, V58, P275, DOI 10.1016/0306-4522(94)90034-5
   JOHANSSON B, 1994, ANESTH ANALG, V78, P210, DOI 10.1213/00000539-199402000-00003
   MAROTA JJA, 1992, ANESTHESIOLOGY, V77, P365, DOI 10.1097/00000542-199208000-00021
   MOLANDER C, 1984, J COMP NEUROL, V230, P133, DOI 10.1002/cne.902300112
   OCONNOR TC, 1994, ANESTHESIOLOGY, V81, P1277, DOI 10.1097/00000542-199411000-00023
   PERTOVAARA A, 1993, NEUROSCIENCE, V54, P117, DOI 10.1016/0306-4522(93)90387-U
   PRESLEY RW, 1990, J NEUROSCI, V10, P323
   TAKAYAMA K, 1994, NEUROSCI LETT, V176, P59, DOI 10.1016/0304-3940(94)90871-0
   TJOLSEN A, 1992, PAIN, V51, P5, DOI 10.1016/0304-3959(92)90003-T
   TOLLE TR, 1994, NEUROSCIENCE, V58, P305, DOI 10.1016/0306-4522(94)90037-X
   TOLLE TR, 1994, PAIN, V56, P103, DOI 10.1016/0304-3959(94)90155-4
   WALL PD, 1988, PAIN, V33, P289, DOI 10.1016/0304-3959(88)90286-2
   WHEELERACETO H, 1991, PSYCHOPHARMACOLOGY, V104, P35, DOI 10.1007/BF02244551
   WHITE PF, 1974, ANESTHESIOLOGY, V40, P52, DOI 10.1097/00000542-197401000-00012
   WOOLF CJ, 1993, ANESTH ANALG, V77, P362, DOI 10.1213/00000539-199377020-00026
   YAO GL, 1992, BRAIN RES, V599, P333
NR 28
TC 47
Z9 51
U1 0
U2 4
PU PROF SCI PUBL
PI LONDON
PA TAVISTOCK HOUSE EAST, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR
SN 0007-0912
J9 BRIT J ANAESTH
JI Br. J. Anaesth.
PD JAN
PY 1996
VL 76
IS 1
BP 99
EP 105
PG 7
WC Anesthesiology
SC Anesthesiology
GA TP763
UT WOS:A1996TP76300020
PM 8672390
DA 2021-08-04
ER

PT J
AU Akdas, A
   Turkeri, LN
   Kullu, S
   Tarcan, T
   Sakr, W
   Grignon, DJ
AF Akdas, A
   Turkeri, LN
   Kullu, S
   Tarcan, T
   Sakr, W
   Grignon, DJ
TI Glutathione S-transferase and multidrug-resistant phenotype in
   transitional cell carcinoma of the bladder
SO EUROPEAN UROLOGY
LA English
DT Article
DE bladder neoplasm; drug resistance; immunohistochemistry
ID MULTIPLE-DRUG RESISTANCE; FOLLOW-UP; CANCER; LINES
AB Objective: To asses the role of expression of resistance phenotypes in treatment failure in patients with invasive transitional cell carcinoma of the urinary bladder, since P-glycoprotein and glutathione S-transferase pi (GST) expression are implicated in resistance to various chemotherapy agents in different tumors. Methods: Tumor samples from P-glycoprotein and GST-pi were analyzed by immunohistochemistry. Results: P-glycoprotein and GST-pi were found in 35.7 and 42.9% of the samples, respectively, In 21.4% of the samples there was simultaneous expression of both proteins, No significant impact on prediction of tumor behavior was evident on statistical analysis by any one of the protein expressions, Conclusion: Drug resistance in transitional cell carcinoma may be through different mechanisms. Although the small sample size of this study precludes firm conclusions, the assessment of P-glycoprotein or GST-pi expression appears to be of little value as a predictor of response to chemotherapy in this group of tumors.
C1 MARMARA UNIV,SCH MED,DEPT UROL,ISTANBUL,TURKEY.
   MARMARA UNIV,SCH MED,DEPT PATHOL,ISTANBUL,TURKEY.
   WAYNE STATE UNIV,SCH MED,DEPT PATHOL,DETROIT,MI.
RI Turkeri, Levent N./W-9283-2018
CR AHN HJ, 1994, J UROLOGY, V151, P263, DOI 10.1016/S0022-5347(17)34929-7
   ANDREWS PA, 1985, CANCER RES, V45, P6250
   AYALA AG, 1989, PATHOLOGY URINARY BL, P65
   BENSON MC, 1991, J UROLOGY, V146, P982, DOI 10.1016/S0022-5347(17)37981-8
   GIRALT M, 1993, J UROLOGY, V149, P1452, DOI 10.1016/S0022-5347(17)36413-3
   KAUFMAN DS, 1992, HEMATOL ONCOL CLIN N, V6, P179
   KRAMER RA, 1988, SCIENCE, V241, P694, DOI 10.1126/science.3399900
   Kurth KH, 1992, PROBL UROL, V6, P471
   MALMSTROM PU, 1987, SCAND J UROL NEPHROL, V21, P185, DOI 10.3109/00365598709180320
   MEIJER C, 1990, BRIT J CANCER, V62, P72, DOI 10.1038/bjc.1990.232
   MURPHY WM, 1986, J UROLOGY, V135, P694, DOI 10.1016/S0022-5347(17)45821-6
   PARK J, 1994, J UROLOGY, V151, P43, DOI 10.1016/S0022-5347(17)34868-1
   RICHON VM, 1987, CANCER RES, V47, P2056
   SAMUELS BL, 1991, CANCER RES, V51, P521
   SHINOHARA N, 1993, J UROLOGY, V150, P505, DOI 10.1016/S0022-5347(17)35536-2
   SINGH SV, 1991, BIOCHIM BIOPHYS ACTA, V1074, P363, DOI 10.1016/0304-4165(91)90086-V
   STEINBERG GD, 1992, UROL CLIN N AM, V19, P735
   THEYER G, 1993, J UROLOGY, V150, P1544, DOI 10.1016/S0022-5347(17)35838-X
   THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735
NR 19
TC 3
Z9 3
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0302-2838
J9 EUR UROL
JI Eur. Urol.
PY 1996
VL 29
IS 4
BP 483
EP 486
PG 4
WC Urology & Nephrology
SC Urology & Nephrology
GA UR568
UT WOS:A1996UR56800018
PM 8791059
DA 2021-08-04
ER

PT J
AU Erdem, T
   Keane, MP
AF Erdem, T
   Keane, MP
TI Decision-making under uncertainty: Capturing dynamic brand choice
   processes in turbulent consumer goods markets
SO MARKETING SCIENCE
LA English
DT Article
ID PANEL-DATA; PROBIT MODEL; SIMULATION; PURCHASE
AB We construct two models of the behavior of consumers in an environment where there is uncertainty about brand attributes. In our models, both usage experience and advertising exposure give consumers noisy signals about brand attributes. Consumers use these signals to update their expectations of brand attributes in a Bayesian manner. The two models are (1) a dynamic model with immediate utility maximization, and (2) a dynamic ''forward-looking'' model in which consumers maximize the expected present value of utility over a planning horizon. Given this theoretical framework, we derive from the Bayesian learning framework how brand choice probabilities depend on past usage experience and advertising exposures. We then form likelihood functions for the models and estimate them on Nielsen scanner data for detergent.
   We find that the functional forms for experience and advertising effects that we derive from the Bayesian learning framework fit the data very well relative to flexible ad hoc functional forms such as exponential smoothing, and also perform better at out-of-sample prediction. Another finding is that in the context of consumer learning of product attributes, although the forward-looking model fits the data statistically better at conventional significance levels, both models produce similar parameter estimates and policy implications. Our estimates indicate that consumers are risk-averse with respect to variation in brand attributes, which discourages them from buying unfamiliar brands.
   Using the estimated behavioral models, we perform various scenario evaluations to find how changes in marketing strategy affect brand choice both in the short and long run. A key finding obtained from the policy experiments is that advertising intensity has only weak short run effects, but a strong cumulative effect in the long Nn.
   The substantive content of the paper is potentially of interest to academics in marketing, economics and decision sciences, as well as product managers, marketing research managers and analysts interested in studying the effectiveness of marketing mix strategies. Our paper will be of particular interest to those interested in the long run effects of advertising.
   Note that our estimation strategy requires us to specify explicit behavioral models of consumer choice behavior, derive the implied relationships among choice probabilities, past purchases and marketing mix variables, and then estimate the behavioral parameters of each model. Such an estimation strategy is referred to as ''structural'' estimation, and econometric models that are based explicitly on the consumer's maximization problem and whose parameters are parameters of the consumers' utility functions or of their constraints are referred to as ''structural'' models.
   A key benefit of the structural approach is its potential usefulness for policy evaluation. The parameters of structural models are invariant to policy, that is, they do not change due to a change in the policy. In contrast, the parameters of reduced form brand choice models are, in general, functions of marketing strategy variables (e.g., consumer response to price may depend on pricing policy). As a result, the predictions of reduced form models for the outcomes of policy experiments may be unreliable, because in making the prediction one must assume that the model parameters are unaffected by the policy change.
   Since the agents in our models choose among many alternative brands, their choice probabilities take the form of higher-order integrals. We employ Monte-Carlo methods to approximate these integrals and estimate our models using simulated maximum likelihood. Estimation of the dynamic forward-looking model also requires that a dynamic programming problem be solved in order to form the likelihood function. For this we use a new approximation method based on simulation and interpolation techniques. These estimation techniques may be of interest to researchers and policy makers in many fields where dynamic choice among discrete alternatives is important, such as marketing, decision sciences, labor and health economics, and industrial organization.
C1 UNIV MINNESOTA,MINNEAPOLIS,MN 55455.
RP Erdem, T (corresponding author), UNIV CALIF BERKELEY,BERKELEY,CA 94720, USA.
RI Keane, Michael/R-6329-2019; Erdem, Tulin/ABH-6648-2020; Keane,
   Michael/O-2840-2013
OI Keane, Michael/0000-0002-3918-1377
CR Amemiya T., 1985, ADV ECONOMETRICS
   BAWA K, 1991, MARKET SCI, V3, P263
   Bellman R.E., 1957, DYNAMIC PROGRAMMING
   CARPENTER GS, 1985, J MARKETING RES, V22, P318, DOI 10.2307/3151428
   DEGROOT ML, 1970, OPTIMAL STATISTICAL
   Eckstein Z., 1988, 88 U ROCH
   ELROD T, 1988, MARKET SCI, V7, P21, DOI 10.1287/mksc.7.1.21
   ELROD T, 1995, J MARKETING RES, V32, P1, DOI 10.2307/3152106
   ELROD T, 1991, EMPIRICAL COMP MAPPI
   ERDEM T, 1993, THESIS U ALBERTA
   Fishbein M. E., 1967, READINGS ATTITUDE TH
   Guadagni P.M., 1983, MARKET SCI, V2, P203, DOI DOI 10.1287/MKSC.2.3.203
   HANNEMAN M, 1984, ECONOMETRICA, V52, P541
   Heckman J.J., 1981, STUDIES LABOR MARKET, P91
   HOFFMAN PJ, 1960, PSYCHOL BULL, V57, P116, DOI 10.1037/h0047807
   HOWARD JA, 1969, THEORY BUYER BEHAVIO
   Jeuland A. P., 1978, ED P SERIES, V43, P33
   KAHN BE, 1986, J MARKETING RES, V23, P89, DOI 10.2307/3151656
   KEANE MP, 1994, ECONOMETRICA, V62, P95, DOI 10.2307/2951477
   KEANE MP, 1994, REV ECON STAT, V76, P648, DOI 10.2307/2109768
   KEANE MP, 1993, HDB STAT
   LANCASTER KJ, 1966, J POLIT ECON, V74, P132, DOI 10.1086/259131
   LERMAN S, 1987, STRUCTURAL ANAL DISC
   Lucas RE, 1976, J MONETARY EC S
   MCFADDEN D, 1989, ECONOMETRICA, V57, P995, DOI 10.2307/1913621
   Meyer R. J., 1985, MARKET SCI, V4, DOI 10.1287/mksc.4.1.41
   PAKES A, 1986, ECONOMETRICA, V54, P755, DOI 10.2307/1912835
   PAKES A, 1989, ECONOMETRICA, V57, P1027, DOI 10.2307/1913622
   PAPATLA P, 1992, MARKET SCI, V11, P189, DOI 10.1287/mksc.11.2.189
   PEDRICK JH, 1991, MARKET SCI, V10, P111, DOI 10.1287/mksc.10.2.111
   PHILLIPS LD, 1966, J EXP PSYCHOL, V72, P346, DOI 10.1037/h0023653
   ROBERTS JH, 1988, MANAGE SCI, V34, P167, DOI 10.1287/mnsc.34.2.167
   RUST J, 1991, ESTIMATION DYNAMIC 1
   RUST J, 1987, ECONOMETRICA, V55, P993
   TELLIS GJ, 1988, J MARKETING RES, V25, P134, DOI 10.2307/3172645
   WOLPIN KI, 1987, ECONOMETRICA, V55, P801, DOI 10.2307/1911030
NR 36
TC 436
Z9 441
U1 10
U2 202
PU INST OPERATIONS RESEARCH  MANAGEMENT SCIENCES
PI LINTHICUM HTS
PA 901 ELKRIDGE LANDING RD, STE 400, LINTHICUM HTS, MD 21090-2909
SN 0732-2399
J9 MARKET SCI
JI Mark. Sci.
PY 1996
VL 15
IS 1
BP 1
EP 20
DI 10.1287/mksc.15.1.1
PG 20
WC Business
SC Business & Economics
GA VH139
UT WOS:A1996VH13900002
DA 2021-08-04
ER

PT B
AU Giroux, S
   Marcenac, P
   Quinqueton, J
   Grasso, JR
AF Giroux, S
   Marcenac, P
   Quinqueton, J
   Grasso, JR
BE Javor, A
   Lehmann, A
   Molnar, I
TI Modelling and simulating self-organised critical systems
SO MODELLING AND SIMULATION 1996
LA English
DT Proceedings Paper
CT 10th European Simulation Multiconference
CY JUN 02-06, 1996
CL BUDAPEST UNIV ECON SCI, BUDAPEST, HUNGARY
SP Soc Comp Simulat Int, Czech & Slovak Simulat Soc, Chinese Assoc Syst Simulat, EUROSIM, Federat European Simulat Soc, European Simulat council, Hungarian Simulat Soc, Japan Soc Simulat Technol, Latvian Simulat Soc, Polish Simulat Soc, Simulat In Europe ESPRIT Working Grp, Turkish Simulat Soc
HO BUDAPEST UNIV ECON SCI
DE simulation languages and programming environments; distributed AI-based
   simulation; object/agent-oriented simulation; natural sciences
   applications; reflection
AB Classical models and laws of mechanics have failed both to understand the underlying physical processes of most natural phenomena and to predict their complex macrobehaviours. A new approach to such complex systems is to consider them as self-organised critical systems. To get a better grasp on the mechanics behind self-organised critical systems, we designed and implemented GEOMAS, a simulation platform based on agents and reflection. The issue is to establish if the spatial and temporal complexity of natural phenomena emerges either from geometrical and material heterogeneity or from the chaotic behaviour related to the non-linear equations governing their behaviours at different levels. Using GEOMAS, we were able to express local microbehaviours, global macrobehaviours, the emergence of macrobehaviours out of microbehaviours, and macroconstraints coupled with the control of microbehaviours by macrobehaviours. As a concrete application of our platform, we explored the fitness of models based on statistical physics to the complexity of the eruptive behaviour of the Piton de la Foumaise volcano, which is located on La Reunion Island.
C1 Tele Univ, UER Sci & Technol, Ctr Rech LICEF, Montreal, PQ, Canada.
RP Giroux, S (corresponding author), Tele Univ, UER Sci & Technol, Ctr Rech LICEF, 1001 Sherbrooke Est, Montreal, PQ, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SOC COMPUTER SIMULATION
PI SAN DIEGO
PA PO BOX 17900, SAN DIEGO, CA 92177 USA
BN 1-56555-097-8
PY 1996
BP 1072
EP 1075
PG 4
WC Computer Science, Software Engineering
SC Computer Science
GA BQ56K
UT WOS:000088778200184
DA 2021-08-04
ER

PT J
AU Griebel, G
   Sanger, DJ
   Perrault, G
AF Griebel, G
   Sanger, DJ
   Perrault, G
TI Further evidence for differences between non-selective and BZ-1 (omega
   1) selective, benzodiazepine receptor ligands in murine models of
   ''state'' and ''trait'' anxiety
SO NEUROPHARMACOLOGY
LA English
DT Article
DE benzodiazepines; BZ (omega) receptor; light/dark choice task;
   free-exploration test; risk assessment; ''trait'' and ''state'' anxiety;
   BALB/c mice
ID PARTIAL AGONISTS; ANIMAL-MODELS; PENTYLENETETRAZOLE-CUE; A RECEPTOR;
   MICE; SUBTYPES; PHARMACOLOGY; BEHAVIOR; STRAINS; FEAR
AB The behavioural effects of several BZ (omega) receptor ligands were compared in mice using the light/dark choice task, an animal model of ''state'' anxiety, and the free-exploration test, which has been proposed as an experimental model of ''trait'' anxiety. The drugs used included non-selective full (alprazolam, clorazepate, chlordiazepoxide and diazepam), partial agonists (bretazenil, imidazenil and Ro 19-8022) and BZ-1 (omega 1) selective receptor ligands (abecarnil, CL 218,872 and zolpidem). In the light/dark choice task, non-selective full agonists elicited clear anxiolytic-like effects increasing time spent in the lit box and simultaneously reducing attempts at entry into the illuminated cage followed by withdrawal responses, a measure of risk assessment. With the exception of abecarnil, both non-selective partial agonists and BZ-1 (omega 1) selective receptor ligands displayed reduced efficacy compared to the full agonists as they decreased risk assessment responses without altering time in the lit box. In addition, the weak anxiolytic-like actions displayed by selective BZ-1 (omega 1) agents were evident only at doses which reduced locomotor activity, indicating that this effect may be non-specific. In the free-exploration test, non-selective BZ (omega) receptor agonists markedly increased the percentage of time spent in the novel compartment and reduced the number of attempts to enter, whereas selective BZ-1 (omega 1) receptor ligands displayed a weaker neophobia-reducing effect as they reduced risk assessment responses only. As was the case in the light/dark choice task, this latter effect was observed at locomotor depressant doses. These findings indicate that while both full and partial BZ (omega) receptor agonists are equally effective against ''trait'' anxiety, full agonists may be superior in reducing ''state'' anxiety. In addition, the lack of specific effects of selective BZ-1 (omega 1) receptor ligands in reducing both types of anxiety suggests that the BZ-1 (omega 1) receptor subtype cannot be considered as the primary target mediating the anxiolytic action of drugs interacting with the GABA(A)/benzodiazepine receptor complex. Copyright (C) 1996 Elsevier Science Ltd.
RP Griebel, G (corresponding author), CNS, RES DEPT, SYNTHELABO RECH, 31 AVE PAUL VAILLANT COUTURIER, F-92220 BAGNEUX, FRANCE.
RI Griebel, Guy/F-8752-2014
OI Griebel, Guy/0000-0002-6052-9438
CR BELZUNG C, 1987, PHARMACOL BIOCHEM BE, V28, P29, DOI 10.1016/0091-3057(87)90006-2
   BELZUNG C, 1994, PHYSIOL BEHAV, V56, P623, DOI 10.1016/0031-9384(94)90311-5
   BELZUNG C, 1989, PSYCHOPHARMACOLOGY, V97, P388, DOI 10.1007/BF00439456
   BELZUNG C, 1994, PHARMACOL BIOCHEM BE, V49, P433, DOI 10.1016/0091-3057(94)90445-6
   BELZUNG C, 1988, THESIS U L PASTEUR S
   BEUZEN A, 1995, PHYSIOL BEHAV, V58, P111, DOI 10.1016/0031-9384(95)00013-9
   BLANCHARD DC, 1991, ADV PHAR SC, P117
   COSTALL B, 1989, PHARMACOL BIOCHEM BE, V32, P777, DOI 10.1016/0091-3057(89)90033-6
   CRAWLEY J, 1980, PHARMACOL BIOCHEM BE, V13, P167, DOI 10.1016/0091-3057(80)90067-2
   DEACON RMJ, 1991, DRUG DEVELOP RES, V22, P321, DOI 10.1002/ddr.430220404
   DEPOORTERE H, 1986, J PHARMACOL EXP THER, V237, P649
   FAUREHALLEY C, 1993, EUR J PHARM-MOLEC PH, V246, P283, DOI 10.1016/0922-4106(93)90043-9
   GIUSTI P, 1993, J PHARMACOL EXP THER, V266, P1018
   GRIEBEL G, 1992, NEUROREPORT, V3, P84, DOI 10.1097/00001756-199201000-00022
   GRIEBEL G, 1993, BEHAV PHARMACOL, V4, P637
   Griebel G, 1996, PSYCHOPHARMACOLOGY, V124, P245, DOI 10.1007/BF02246664
   HAEFELY W, 1990, TRENDS PHARMACOL SCI, V11, P452, DOI 10.1016/0165-6147(90)90126-S
   JENCK F, 1992, J PHARMACOL EXP THER, V262, P1121
   JONES GH, 1994, PSYCHOPHARMACOLOGY, V114, P191, DOI 10.1007/BF02244836
   KNOFLACH F, 1993, J PHARMACOL EXP THER, V266, P285
   LANGER SZ, 1988, PHARMACOL BIOCHEM BE, V29, P763, DOI 10.1016/0091-3057(88)90202-X
   LISTER RG, 1990, PHARMACOL THERAPEUT, V46, P321, DOI 10.1016/0163-7258(90)90021-S
   MAKINO J, 1991, JPN PSYCHOL RES, V33, P145, DOI 10.4992/psycholres1954.33.145
   MARTIN JR, 1993, PSYCHOPHARMACOLOGY, V111, P415, DOI 10.1007/BF02253530
   MARTIN JR, 1988, PHARMACOPSYCHIATRY, V21, P360, DOI 10.1055/s-2007-1021947
   Misslin R, 1990, Neuroreport, V1, P267, DOI 10.1097/00001756-199011000-00025
   MISSLIN R, 1986, BEHAV PROCESS, V12, P45, DOI 10.1016/0376-6357(86)90069-0
   MISSLIN R, 1989, BEHAV PROCESS, V8, P119
   Pribilla I., 1993, ANXIOLYTIC BETA CARB, P50
   PRITCHETT DB, 1990, J NEUROCHEM, V54, P1802, DOI 10.1111/j.1471-4159.1990.tb01237.x
   PRITCHETT DB, 1989, SCIENCE, V245, P1389, DOI 10.1126/science.2551039
   PUIA G, 1992, P NATL ACAD SCI USA, V89, P3620, DOI 10.1073/pnas.89.8.3620
   RIJNDERS HJ, 1991, PHARMACOL BIOCHEM BE, V39, P129, DOI 10.1016/0091-3057(91)90409-U
   ROBERTSON HA, 1979, EUR J PHARMACOL, V56, P163, DOI 10.1016/0014-2999(79)90447-3
   RODGERS RJ, 1994, ETHOLOGY AND PSYCHOPHARMACOLOGY, P9
   SANGER DJ, 1995, BEHAV PHARMACOL, V6, P116
   SANGER DJ, 1988, NEUROPHARMACOLOGY, V27, P1125, DOI 10.1016/0028-3908(88)90007-X
   SANGER DJ, 1994, NEUROSCI BIOBEHAV R, V18, P355, DOI 10.1016/0149-7634(94)90049-3
   SANGER DJ, 1991, PROG NEURO-PSYCHOPH, V15, P205, DOI 10.1016/0278-5846(91)90082-C
   SANGER DJ, 1995, PSYCHOPHARMACOLOGY, V121, P104, DOI 10.1007/BF02245596
   SIEGHART W, 1984, BIOCHEM PHARMACOL, V33, P4033, DOI 10.1016/0006-2952(84)90017-0
   SIEGHART W, 1995, PHARMACOL REV, V47, P181
   SQUIRES RF, 1979, PHARMACOL BIOCHEM BE, V10, P825, DOI 10.1016/0091-3057(79)90341-1
   STEPHENS DN, 1990, J PHARMACOL EXP THER, V253, P334
   STEPHENS DN, 1994, BEHAV PHARMACOL, V5, P4, DOI 10.1097/00008877-199402000-00001
   TREIT D, 1985, NEUROSCI BIOBEHAV R, V9, P203, DOI 10.1016/0149-7634(85)90046-6
   TRULLAS R, 1993, PSYCHOPHARMACOLOGY, V111, P323, DOI 10.1007/BF02244948
   WAFFORD KA, 1993, MOL PHARMACOL, V43, P240
NR 48
TC 37
Z9 37
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0028-3908
J9 NEUROPHARMACOLOGY
JI Neuropharmacology
PY 1996
VL 35
IS 8
BP 1081
EP 1091
DI 10.1016/S0028-3908(96)00080-9
PG 11
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA WB756
UT WOS:A1996WB75600008
PM 9121611
DA 2021-08-04
ER

PT J
AU Bissoli, NS
   Vasquez, EC
   Cabral, AM
AF Bissoli, NS
   Vasquez, EC
   Cabral, AM
TI Chlorthalidone-modulated vascular responses to vasodilator stimuli in
   doca-salt hypertensive rats
SO PHARMACOLOGICAL RESEARCH
LA English
DT Article
DE ouabain; calcium; DOCA-salt hypertension; chlorthalidone; vascular
   reactivity; Na-Ca exchange; vasodilators; diuretic
ID TERM THIAZIDE THERAPY; SMOOTH-MUSCLE; BLOOD-PRESSURE; CALCIUM;
   HYPOTHESIS; DIGITALIS; PLASMA; SODIUM; RENIN
AB This study was carried out to test the effect of chlorthalidone (Chlor) treatment on the vascular responsiveness to acetylcholine (Ach) and adenosine disphosphate (ADP) under different extracellular calcium concentrations (Ca-e(2+)) in deoxycorticosterone acetate (DOCA)-salt hypertensive rats. Half of the DOCA-salt hypertensive rats were simultaneously given Chlor (8 mg day(-1), p.o.), after the twentieth day of DOCA, until the fortieth day. Mean arterial pressure (MAP) was reduced (P<0.01) in DOCA-salt-Chlor (121+/-3 mmHg) compared to DOCA-salt (175+/-3 mmHg) rats. Chlor reduced the high plasma sodium of DOCA-salt to levels of the normotensive groups. The basal perfusion pressure of the isolated mesenteric vascular bed (MVB) was not modified by Ca-e(2+) changing or previous addition of ouabain. At normal and low Ca-e(2+) the vasodilator effect of Ach in the MVB was reduced (P<0.01) in DOCA-salt and less (P<0.05) in the salt-control rats, Chlor shifted the curve of DOCA-salt backward to control group curves. In high Ca-e(2+) the vasodilator responses to Ach were reduced (P<0.01) both in normal-control and DOCA-salt+Chlor but not in salt-control and DOCA-salt group. The vasodilator effect of ADP to different Ca-e(2+) was similar in presence of normal and low Ca-e(2+) in normal-control rats and it was reduced (P<0.01) in presence of high Ca-e(2+) in the DOCA-salt group. Chlor restored the responses to ADP to normal-control level. Under ouabain-treatment, the vasodilatation duration was reduced (P<0.05) in all groups. It was shorter (P<0.01) in DOCA-salt than in the other ones. Chlor completely abolished this difference. The MAP reduction in DOCA-salt rats by chlor could also be associated with a restored normal responsiveness of endothelial cells to endogenous vasodilator, for example Ach and ADP, since sodium nitroprusside did not exhibit differences among the various treatments. This diuretic agent seems to elicit its effect through a reduction in plasma sodium content of DOCA-salt hypertensive rats. (C) 1996 The Italian Pharmacological Society
RP Bissoli, NS (corresponding author), UFES, BIOMED CTR, DEPT PHYSIOL SCI, AVE MARECHAL CAMPOS 1468, BR-29040090 VITORIA, ES, BRAZIL.
RI Vasquez, Elisardo C/D-5885-2012
OI Vasquez, Elisardo C/0000-0002-7169-5634
CR ANDERSON DE, 1984, ANNU REV PHYSIOL, V46, P143
   BEVAN JA, 1993, HYPERTENSION, V21, P16, DOI 10.1161/01.HYP.21.1.16
   BLAUSTEIN MP, 1977, AM J PHYSIOL, V232, pC165
   BOHR DF, 1984, AM J MED, V77, P3, DOI 10.1016/S0002-9343(84)80032-7
   BOHR DF, 1991, HYPERTENSION, V17, pI39, DOI 10.1161/01.HYP.17.1_Suppl.I39
   CABRAL AM, 1992, CLIN EXP HYPERTENS A, V14, P667, DOI 10.3109/10641969209036214
   CONWAY J, 1967, CIRCULATION, V22, P21
   CORDELLINI S, 1988, BRAZ J MED BIOL RES, V21, P845
   FORTES ZB, 1990, J HYPERTENS, V8, P1043, DOI 10.1097/00004872-199011000-00011
   FROHLICH ED, 1960, NEW ENGL J MED, V262, P1261, DOI 10.1056/NEJM196006232622502
   FURSPAN PB, 1989, HYPERTENSION, V13, P727, DOI 10.1161/01.HYP.13.6.727
   GAVRAS H, 1986, HYPERTENSION, V8, P83, DOI 10.1161/01.HYP.8.1.83
   GODFRAIND T, 1985, CLIN SCI, V68, pS65, DOI 10.1042/cs068s065
   GOTO A, 1991, LIFE SCI, V48, P2109, DOI 10.1016/0024-3205(91)90143-Y
   HAMLYN JM, 1989, J BIOL CHEM, V264, P7395
   HANSEN J, 1968, ACTA MED SCAND, V183, P317
   HOLLOWAY ET, 1973, CIRC RES, V33, P678, DOI 10.1161/01.RES.33.6.678
   JONES AW, 1975, CIRC RES, V37, P333, DOI 10.1161/01.RES.37.3.333
   LETH A, 1970, CIRCULATION, V42, P479, DOI 10.1161/01.CIR.42.3.479
   LOPEZJARAMILLO P, 1990, BRIT J PHARMACOL, V101, P489, DOI 10.1111/j.1476-5381.1990.tb12735.x
   LUNDJOHANSEN P, 1970, ACTA MED SCAND, V187, P509
   MARK AL, 1975, CIRC RES, V36, P194, DOI 10.1161/01.RES.36.6.194
   MONCADA S, 1990, INT CONGR SER, V897, P19
   ORLOV S, 1993, HYPERTENSION, V21, P195, DOI 10.1161/01.HYP.21.2.195
   REMBOLD CM, 1992, HYPERTENSION, V19, P308, DOI 10.1161/01.HYP.19.4.308
   SCIVOLETTO R, 1991, GEN PHARMACOL, V22, P133, DOI 10.1016/0306-3623(91)90323-X
   STORM DS, 1992, HYPERTENSION, V19, P734, DOI 10.1161/01.HYP.19.6.734
   TARAZI RC, 1970, CIRCULATION, V41, P709, DOI 10.1161/01.CIR.41.4.709
   TOBAIN L, 1976, ANNU REV PHARMACOL, V7, P399
   VANBRUMMELEN P, 1979, CLIN SCI, V56, P463, DOI 10.1042/cs0560463
   VANBRUMMELEN P, 1980, ACTA MED SCAND, V207, P259
   Zidek W, 1985, Klin Wochenschr, V63 Suppl 3, P147
NR 32
TC 8
Z9 8
U1 0
U2 1
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-6618
J9 PHARMACOL RES
JI Pharmacol. Res.
PD JAN
PY 1996
VL 33
IS 1
BP 47
EP 54
DI 10.1006/phrs.1996.0008
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA UV446
UT WOS:A1996UV44600008
PM 8817646
DA 2021-08-04
ER

PT J
AU Brandolin, A
   Lacunza, MH
   Ugrin, PE
   Capiati, NJ
AF Brandolin, A
   Lacunza, MH
   Ugrin, PE
   Capiati, NJ
TI High pressure polymerization of ethylene. An improved mathematical model
   for industrial tubular reactors
SO POLYMER REACTION ENGINEERING
LA English
DT Article
ID LOW-DENSITY POLYETHYLENE
AB This work presents an exhaustive mathematical model for the high pressure polymerization of ethylene in tubular reactors of configuration similar to that encountered in the industry. Multiple injection of monomer, mixtures of initiators and chain transfer agents are considered together with realistic flux configurations. Typical heat transfer coefficients are estimated from industrial plant data, The effects of pressure pulse on the reactor behavior are also analyzed. Instantaneous temperature profiles produced by such pressure pulse were recovered from stationary simulations showing a very good agreement with the corresponding experimental data. The model features are demonstrated by predictions of temperature, concentrations of reactants and products and molecular properties as a function of reactor length. Also, appropriate predictive capabilities are disclosed by comparison of model simulation results and experimental data. The generation of a high temperature initiator, derived from oxygen, is assessed by comparison of temperature profiles corresponding to runs with and without oxygen.
RP Brandolin, A (corresponding author), UNIV NACL SUR,CONICET,PLANTA PILOTO INGN QUIM,12 OCTUBRE 1842,RA-8000 BAHIA BLANCA,ARGENTINA.
CR AGRAWAL S, 1975, AICHE J, V21, P449, DOI 10.1002/aic.690210305
   ALLCOCK H, 1981, CONT POLYM CHEM, pCH3
   ANGUS S, 1974, INT THERMODYNAMIC TA
   BARD Y, 1974, NONLINEAR PARAMETER, pCH6
   BILLMEYER FW, 1971, TXB POLYM SCI, pCH9
   BRANDOLIN A, 1988, IND ENG CHEM RES, V27, P784, DOI 10.1021/ie00077a012
   BRANDOLIN A, 1987, THESIS U NATL SUR BA
   BROWN KM, 1972, NUMER MATH, V18, P289
   BUBACK M, 1980, MAKROMOL CHEM, V181, P373
   CHEN CH, 1976, AICHE J, V22, P463, DOI 10.1002/aic.690220308
   Curtis F.G., 1978, APPL NUMERICAL ANAL
   DONATI G, 1982, ACS SYM SER, V196, P579
   EHRLICH P, 1957, J POLYM SCI, V24, P283, DOI 10.1002/pol.1957.1202410609
   Ehrlich P., 1970, ADV POLYM SCI, V7, P386
   FOSTER GN, 1980, ACS SYM SER, V138, P131
   GALLANT AR, 1987, NONLINEAR STAT MODEL, pCH1
   GIERTH V, 1970, ANGEW MAKROMOL CHEM, V12, P9, DOI 10.1002/apmc.1970.050120102
   GOTO S, 1981, J APPL POLYM SCI APP, V36, P21
   GRUNIG H, 1983, J MACROMOL SCI CHEM, VA19, P723, DOI 10.1080/00222338308069454
   GUPTA SK, 1985, POLYM ENG SCI, V25, P37, DOI 10.1002/pen.760250108
   Hollar W, 1983, CHEM ENG COMMUN, V24, P57, DOI 10.1080/00986448308940073
   KATZ S, 1967, AICHE J, V13, P319, DOI 10.1002/aic.690130223
   Kern DQ., 1950, PROCESS HEAT TRANSFE
   KONSTADINIDIS K, 1992, POLYMER, V33, P5019, DOI 10.1016/0032-3861(92)90053-Y
   Lee K. H., 1979, ACS SYM SER, V104, P221
   LORENZINI P, 1992, CHEM ENG SCI, V47, P3981, DOI 10.1016/0009-2509(92)85147-4
   Mavridis H., 1985, POLYM P ENG, V3, P263
   METZLER DE, 1973, BIOCHEMISTRY-US, V12, P5377, DOI 10.1021/bi00750a022
   Ray W.H., 1977, CHEM REACTOR THEORY, P532
   Reid R.C., 1977, PROPERTIES GASES LIQ
   SAIDEL GM, 1968, J POLYM SCI A2, V6, P1149, DOI 10.1002/pol.1968.160060608
   SCHILDKNECHT CE, 1977, POLYM PROCESSES, P88
   SHIRODKAR PP, 1986, CHEM ENG SCI, V41, P1031, DOI 10.1016/0009-2509(86)87189-5
   TATSUKAMI Y, 1980, MAKROMOL CHEM, V181, P1107
   VANDERMOLEN T, 1982, QUAD ING CHIM ITAL, V18, P7
   WEAST RC, 1985, CRC HDB CHEM PHYSICS, pD171
   WYMAN CE, 1976, AICHE S SER 160, V72, P1
   YOON BJ, 1985, CHEM ENG COMMUN, V34, P253
   ZABISKY RCM, 1992, POLYMER, V33, P2243, DOI 10.1016/0032-3861(92)90514-W
NR 39
TC 43
Z9 44
U1 0
U2 5
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016
SN 1054-3414
J9 POLYM REACT ENG
JI Polym. React. Eng.
PY 1996
VL 4
IS 4
BP 193
EP 241
DI 10.1080/10543414.1996.10744475
PG 49
WC Engineering, Chemical; Polymer Science
SC Engineering; Polymer Science
GA VW498
UT WOS:A1996VW49800002
DA 2021-08-04
ER

PT S
AU McGregor, D
AF McGregor, D
BE Stewart, BW
   McGregor, D
   Kleihues, P
TI Tumour incidence reductions in carcinogenicity bioassays
SO PRINCIPLES OF CHEMOPREVENTION
SE IARC SCIENTIFIC PUBLICATIONS
LA English
DT Proceedings Paper
CT IARC Conference on Principles of Chemoprevention
CY NOV 10-16, 1995
CL LYON, FRANCE
SP Int Agcy Res Canc
AB Most experimental evidence for chemopreventive activity comes from studies in which animals are administered the suspect chemopreventive agent before, after or simultaneously with a carcinogen predicted to increase tumour incidence in a particular tissue. Such experimental designs have inherent mechanistic assumptions. Evidence of chemopreventive function is also theoretically derivable from carcinogenicity assays, which in principle involve exposure to a single agent in addition to all other factors experienced by the control group. in these assays, exposure is normally for a very large proportion of the animal's lifespan, so they could indicate chemopreventive activity with much greater facility than could human trials, in which exposure for 10% of the lifespan would be considered to be a long study. Site-specific tumour incidence reductions do occur in carcinogenicity assays, often in the same experiments in which increases occur at other sites. These reductions could be due to a carcinogenic response at another site which increases mortality within the group. They could also be secondary to a noncarcinogenic toxic effect that results in either a lifespan reduction (thereby reducing the chance of tumour development) or a reduced food intake (this being the dearest example of an experimental manipulation resulting in reduction in tumour incidence). Nevertheless, if chemoprevention is possible in humans, then it should also be experimentally demonstrable at nontoxic dose levels. Studies involving experimentally reduced tumour incidence are reviewed here, with the aim of describing special requirements for their evaluation and their significance in the field of chemoprevention.
RP McGregor, D (corresponding author), INT AGCY RES CANC,UNIT CARCINOGEN IDENTIFICAT & EVALUAT,150 COURS ALBERT THOMAS,F-69372 LYON 08,FRANCE.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU INT AGENCY RESEARCH CANCER
PI LYONS
PA 150, COURS ALBERT THOMAS, 69372 LYONS, FRANCE
SN 0300-5038
BN 92-832-2139-7
J9 IARC SCI PUBL
PY 1996
IS 139
BP 277
EP 290
PG 14
WC Oncology; Public, Environmental & Occupational Health; Nutrition &
   Dietetics
SC Oncology; Public, Environmental & Occupational Health; Nutrition &
   Dietetics
GA BJ53S
UT WOS:A1996BJ53S00024
PM 8923038
DA 2021-08-04
ER

PT J
AU Chaudhari, S
   Tare, V
AF Chaudhari, S
   Tare, V
TI Analysis and evaluation of heavy metal uptake and release by insoluble
   starch xanthate in aqueous environment
SO WATER SCIENCE AND TECHNOLOGY
LA English
DT Article; Proceedings Paper
CT 18th Biennial Conference of the
   International-Association-on-Water-Quality
CY JUN 23-28, 1996
CL SINGAPORE, SINGAPORE
SP Int Assoc Water Qual
DE heavy metals; metal removal; metal recovery; insoluble xanthates; starch
   xanthate; hazardous wastes
ID HYDROGEN-PEROXIDE; CARBON-DISULFIDE; HYDROLYSIS
AB This paper presents the finding of the investigation on the behaviour of metal removal and recovery using insoluble starch xanthate. It is hypothesized that metal-xanthate interaction is a net result of the two simultaneous reactions - (i) reversible complexation of metal with xanthate groups, and (ii) decomposition of the xanthates. The affinity, and also the selectivity sequence of metals for xanthate groups is postulated to follow the reverse order of metal-ethyl xanthate solubilities. Further decomposition of xanthates is viewed advantageous for metal recovery. Metal recovery is predicted to follow reverse order of metal selectivity for xanthates. Results of the laboratory experiments carried out on insoluble starch (corn) xanthate are used to test the hypothesis. The selectivity of metals for ISX follows the sequence Hg(II)>Cu(II)>Cd(II)>Ni(II) which correlates with metal-ethyl xanthate Ksp values. The recovery of metals from metal-ISX sludge is attempted by using mineral acids (hydrochloric, sulfuric and nitric), oxidizing agents (chlorine solution and hydrogen peroxide) and eluting agent (EDTA). The results of metal removal and recovery are in accordance with the proposed hypothesis. Copyright (C) 1996 IAWQ.
RP Chaudhari, S (corresponding author), INDIAN INST TECHNOL,DEPT CIVIL ENGN,ENVIRONM ENGN LAB,KANPUR 208016,UTTAR PRADESH,INDIA.
CR ADEWUYI YG, 1987, ENVIRON SCI TECHNOL, V21, P170, DOI 10.1021/es00156a602
   CHAUDHARI S, 1993, THESIS INDIAN I TECH
   ELLIOTT S, 1990, ENVIRON SCI TECHNOL, V24, P264, DOI 10.1021/es00072a017
   MACCHI G, 1985, ENVIRON TECHNOL LETT, V6, P369, DOI 10.1080/09593338509384354
   MARANI D, 1981, P INT C HEAV MET ENV, P92
   TARE V, 1992, WATER SCI TECHNOL, V26, P237
   TARE V, 1989, EVALUATION XANTHATE
   TIRAVANTI G, 1989, ENV PROT ENG, V15, P25
   WANGER CK, 1986, J APPL POLYM SCI, V31, P1797
   WING RE, 1978, STARKE, V30, P163, DOI 10.1002/star.19780300507
   ZHANG L, 1988, HUANJING HUAXUE, V7, P57
NR 11
TC 18
Z9 22
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0273-1223
J9 WATER SCI TECHNOL
JI Water Sci. Technol.
PY 1996
VL 34
IS 10
BP 161
EP 168
DI 10.1016/S0273-1223(96)00710-X
PG 8
WC Engineering, Environmental; Environmental Sciences; Water Resources
SC Engineering; Environmental Sciences & Ecology; Water Resources
GA WC230
UT WOS:A1996WC23000022
DA 2021-08-04
ER

PT J
AU Theraulaz, G
   Bonabeau, E
AF Theraulaz, G
   Bonabeau, E
TI Modelling the collective building of complex architectures in social
   insects with lattice swarms
SO JOURNAL OF THEORETICAL BIOLOGY
LA English
DT Article
ID MATHEMATICAL-MODEL; DECISION-MAKING; SELF-ORGANIZATION; NEST
   CONSTRUCTION; PATTERN-FORMATION; HONEY-BEES; PAPER WASP; COLONIES;
   POLISTES; BEHAVIOR
AB In this paper we present a formal model of distributed building inspired by wasp colonies. We characterize a set of distributed stigmergic algorithms that allow a swarm of simple agents to build coherent nest-like structures. The agents that constitute the swarm of builders move randomly on a 3D lattice and can deposit elementary bricks. The agents do not communicate, have no global representation of the architecture they are building, do not possess any plan or blueprint and can only perceive the local configuration of matter surrounding them. Only a few of these configurations are stimulating, that is, trigger a building action. The aim of this paper is not to prove that this model is an accurate model of how wasps behave, but rather to show (i) that such behavioural algorithms can produce coherent biological-like architectures, (ii) that these architectures, if they are to be generated with these behavioural algorithms, require algorithms with specific ''coordination'' properties, and (iii) finally that algorithms possessing these specific properties produce in turn only very specific, coherent architectures. In effect, we found an empirical one to one correspondence between biological-like architectures and ''coordinated algorithms''. Coordinated algorithms rely on a partition of the shape to be built into modular subshapes: if a swarm of agents is to build a given coherent architecture, the shape has to be decomposed into a finite number of building steps, with the necessary condition that the local stimulating configurations that are created at a given stage differ from those created at a previous or a forthcoming building stage so as to avoid disorganization of the whole building activity. Moreover, shapes generated with non-coordinated algorithms, for instance when stimulating configurations corresponding to the subshapes overlap and may subsequently affect the overall building process, are unstable, the same given rule table will produce very dissimilar architecture in different simulations. Finally, architectures generated under such conditions were found not to resemble any known biological architecture. We believe that our study constitutes a first step towards a deeper understanding of the origins of natural shapes in terms of the logical constraints that may have affected the evolutionary path. (C) 1995 Academic Press Limited.
C1 FRANCE TELECOM, CNET LANNION, B RIO, TNT, F-22307 LANNION, FRANCE.
RP Theraulaz, G (corresponding author), UNIV TOULOUSE 3, CNRS, URA 1837, LAB ETHOL & PSYCHOL ANIM, 118 ROUTE NARBONNE, F-31062 TOULOUSE, FRANCE.
RI Theraulaz, Guy/H-8464-2016
OI Theraulaz, Guy/0000-0002-3062-4215
CR Aron S., 1990, Lecture Notes in Biomathematics, V89, P533
   Beckers R., 1994, Artificial Life IV. Proceedings of the Fourth International Workshop on the Synthesis and Simulation of Living Systems, P181
   BECKERS R, 1990, INSECT SOC, V37, P258, DOI 10.1007/BF02224053
   BECKERS R, 1993, 2ND EUR C ART LIF BR
   BELIC MR, 1986, J MATH BIOL, V24, P437, DOI 10.1007/BF01236891
   BENI G, 1991, 1991 IEEE INTERNATIONAL CONFERENCE ON ROBOTICS AND AUTOMATION, VOLS 1-3, P1914, DOI 10.1109/ROBOT.1991.131906
   BENI G, 1989, 7 ANN M ROB SOC JAP, P425
   Benzecri J.-P., 1973, ANAL DONNEES
   BERLAND L, 1951, TRAITE ZOOL, V10, P1127
   Bonabeau E, 1994, INTELLIGENCE COLLECT
   BONABEAU E, 1994, ARTIF LIFE, V4, P307
   Bruinsma O. H., 1979, THESIS LANDBOUWHOGES
   CAMAZINE S, 1991, BEHAV ECOL SOCIOBIOL, V28, P61, DOI 10.1007/BF00172140
   CAMAZINE S, 1990, J THEOR BIOL, V147, P553, DOI 10.1016/S0022-5193(05)80264-4
   CAMAZINE S, 1991, J THEOR BIOL, V149, P547, DOI 10.1016/S0022-5193(05)80098-0
   Ceusters R., 1980, Biologie et Ecologie Mediterraneenne, V7, P187
   Corbara B., 1991, Actes des Colloques Insectes Sociaux, V7, P205
   DARCHEN R, 1959, THESIS U PARIS
   Deneubourg J.-L., 1991, P 1 INT C SIM AD BEH, P356
   DENEUBOURG JL, 1989, J INSECT BEHAV, V2, P719, DOI 10.1007/BF01065789
   DENEUBOURG JL, 1977, INSECT SOC, V24, P117, DOI 10.1007/BF02227166
   DENEUBOURG JL, 1989, ETHOL ECOL EVOL, V1, P295, DOI 10.1080/08927014.1989.9525500
   DENEUBOURG JL, 1992, PRACTICE AUTONOMOUS, P123
   DOWNING HA, 1988, ANIM BEHAV, V36, P1729, DOI 10.1016/S0003-3472(88)80112-X
   DOWNING HA, 1990, ANIM BEHAV, V39, P105, DOI 10.1016/S0003-3472(05)80731-6
   FRANKS NR, 1992, BEHAV ECOL SOCIOBIOL, V30, P109
   FRANKS NR, 1989, AM SCI, V77, P138
   FRANKS NR, 1992, ANIM BEHAV, V44, P357, DOI 10.1016/0003-3472(92)90041-7
   FREIMUTH RD, 1990, MODELING COMPLEX PHE, P302
   GALLAISHAMONNO FG, 1972, CR ACAD SCI D NAT, V275, P1275
   Gerardo Beni, 1988, P IEEE INT S INT CON, P57, DOI DOI 10.1109/ISIC.1988.65405
   GOODWIN BC, 1993, J THEOR BIOL, V163, P135, DOI 10.1006/jtbi.1993.1112
   GOSS S, 1990, NATO ADV SCI I G-ECO, V20, P661
   Grasse P. P., 1959, Insectes Sociaux Paris, V6, P41, DOI 10.1007/BF02223791
   GRASSE PP, 1984, TERMITOLOGIA, V2, P490
   Hansell M. H., 1984, ANIMAL ARCHITECTURE
   HELD LI, 1992, MONOGRAPHS DEV BIOL, V24
   JEANNE RL, 1975, Q REV BIOL, V50, P267, DOI 10.1086/408564
   KARSAI I, 1995, SOCIOBIOLOGY, V26, P83
   KARSAI I, 1993, J THEOR BIOL, V161, P505, DOI 10.1006/jtbi.1993.1070
   Kauffman S., 1993, ORIGINS ORDER
   KUGLER PN, 1990, PSYCHOL RES, V52
   Kugler PN, 1987, INFORMATION NATURAL
   LEFEBVRE J, 1980, INTRO AUX ANAL STATI
   Meinhardt H., 1982, MODELS BIOL PATTERN
   Murray JD., 1989, MATH BIOL, P109, DOI 10.1007/978-3-662-08539-4_5
   OSTER G, 1982, EVOLUTION, V36, P444, DOI 10.1111/j.1558-5646.1982.tb05066.x
   PASTEELS JM, 1987, INDIVIDUAL COLLECTIV, V54, P155
   RESNIK D, 1995, J THEOR BIOL, V173, P231, DOI 10.1006/jtbi.1995.0059
   SACHS T, 1994, J THEOR BIOL, V170, P423, DOI 10.1006/jtbi.1994.1203
   SEELEY TD, 1991, BEHAV ECOL SOCIOBIOL, V28, P277, DOI 10.1007/BF00175101
   SENDOVAFRANKS A, 1993, B MATH BIOL, V55, P75, DOI 10.1007/BF02460295
   SKARKA V, 1990, J THEOR BIOL, V147, P1, DOI 10.1016/S0022-5193(05)80249-8
   SUDD JH, 1975, INSECT SOC, V22, P225, DOI 10.1007/BF02223433
   THERAULAZ G, 1994, INTELLIGENCE COLLECT, P29
   THERAULAZ G, 1992, 1992 P IEEE INT S IN
   THERAULAZ G, 1994, P NATO ASI D, V78, P107
   THERAULAZ G, 1992, PSYCHOL FR, V37, P7
   THERAULAZ G, 1990, 1990 P IEEE INT S IN, P135
   THERAULAZ G, 1991, SIMULATION ANIMAL BE, P346
   THERAULAZ G, 1993, 2ND P EUR C SYST SCI, V3, P880
   Wenzel J.W., 1991, P480
   Wilson E.O., 1975, P1
   WILSON EO, 1971, INSECT SOCIETIES
NR 64
TC 93
Z9 96
U1 0
U2 12
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-5193
EI 1095-8541
J9 J THEOR BIOL
JI J. Theor. Biol.
PD DEC 21
PY 1995
VL 177
IS 4
BP 381
EP 400
DI 10.1006/jtbi.1995.0255
PG 20
WC Biology; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology
GA TT358
UT WOS:A1995TT35800006
DA 2021-08-04
ER

PT J
AU CHATTERJEE, A
   VETRIVEL, R
AF CHATTERJEE, A
   VETRIVEL, R
TI COMPUTER-SIMULATION STUDIES ON THE ROLE OF TEMPLATING ORGANIC-MOLECULES
   IN THE SYNTHESIS OF ZSM-5
SO JOURNAL OF THE CHEMICAL SOCIETY-FARADAY TRANSACTIONS
LA English
DT Article
ID ZEOLITE ZSM-5; SILICATE SOLUTIONS; TPA ZSM-5; CRYSTALLIZATION;
   FRAMEWORK; PRECURSORS; ALUMINUM; POSITION; AGENT; NMR
AB We report here the structure and electronic properties of a few typical representative molecules from a family containing more than 50 templating organic molecules which lead to the synthesis of zeolite ZSM-5. Force-field calculations were utilised to study the structural and conformational properties, while semi-empirical MNDO calculations were adopted to study the electronic properties. The conformational flexibility and the charge-compensating function were brought out as common features of these organic molecules. Furthermore, the interaction of various organic molecules with a suitable cluster model for the ZSM-5 framework was studied by MNDO calculations. The orientation of the template organic molecules and the actual conformation of the template-framework complex are derived, based on the X-ray crystal structure reports and the MNDO energetics. The influence of the nature of the functional group and the alkyl group on the electronic interaction is studied systematically. It has been shown that quantum-chemical calculations could be successfully utilised for the generalised description of the importance of several complex interactions which are mutually present.
C1 NATL CHEM LAB,DIV CATALYSIS,POONA 411008,MAHARASHTRA,INDIA.
CR ARAYA A, 1986, ZEOLITES, V6, P111, DOI 10.1016/S0144-2449(86)80007-0
   BELL RG, 1994, STUD SURF SCI CATAL, V84, P2075
   BELTRAME P, 1987, ZEOLITES, V7, P418, DOI 10.1016/0144-2449(87)90007-8
   BHAWAL BM, 1994, J PHYS ORG CHEM, V7, P377, DOI 10.1002/poc.610070708
   BOXHOORN G, 1982, J CHEM SOC CHEM COMM, P264, DOI 10.1039/c39820000264
   BRECK DW, 1974, ZEOLITE MOL SIEVES
   BURCHART ED, 1993, ZEOLITES, V13, P216
   Casci J. L, 1986, STUD SURF SCI CATAL, V28, P215
   CAVELL KJ, 1982, ZEOLITES, V2, P244, DOI 10.1016/S0144-2449(82)80063-8
   CHAO KJ, 1986, ZEOLITES, V6, P35, DOI 10.1016/0144-2449(86)90009-6
   CHATTERJEE A, 1994, MICROPOROUS MATER, V3, P211, DOI 10.1016/0927-6513(94)00032-8
   CHOUDHARY VR, 1989, J CATAL, V117, P542, DOI 10.1016/0021-9517(89)90363-1
   COX PA, 1994, STUD SURF SCI CATAL, V84, P2115
   DANIELS RH, 1978, J AM CHEM SOC, V100, P3097, DOI 10.1021/ja00478a024
   de Vos Burchart E., 1993, ZEOLITES, V13, P216
   DEROUANE EG, 1985, ZEOLITES, V5, P165, DOI 10.1016/0144-2449(85)90025-9
   DEROUANE EG, 1982, ZEOLITES, V2, P299, DOI 10.1016/S0144-2449(82)80074-2
   DEWAR MJS, 1977, J AM CHEM SOC, V99, P4899, DOI 10.1021/ja00457a004
   ENGLEHARDT G, 1987, HIGH RESOLUTION SOLI
   FLANIGEN EM, 1978, NATURE, V271, P212
   FRANKLIN KR, 1989, STUD SURF SCI CATAL, V49, P179
   FRIPIAT JG, 1983, ZEOLITES, V3, P306, DOI 10.1016/0144-2449(83)90174-4
   GATTI F, 1986, ZEOLITES, V6, P312, DOI 10.1016/0144-2449(86)90087-4
   GELIN BR, 1979, BIOCHEMISTRY-US, V18, P1256, DOI 10.1021/bi00574a022
   GIES H, 1992, ZEOLITES, V12, P42, DOI 10.1016/0144-2449(92)90008-D
   GIORDONO G, 1990, J THERM ANAL, V36, P2233
   GROENEN EJJ, 1986, ZEOLITES, V6, P403, DOI 10.1016/0144-2449(86)90070-9
   GUNAWARDANE RP, 1988, ZEOLITES, V8, P128
   HARRIS TV, 1994, STUD SURF SCI CATAL, V84, P29
   HOEBBEL D, 1975, Z ANORG ALLG CHEM, V418, P35, DOI 10.1002/zaac.19754180105
   HOWDEN MG, 1993, ZEOLITES, V13, P315, DOI 10.1016/0144-2449(93)90012-R
   KOTASTHANE AN, 1986, ZEOLITES, V6, P253, DOI 10.1016/0144-2449(86)90077-1
   KULKARNI SB, 1982, ZEOLITES, V2, P313, DOI 10.1016/S0144-2449(82)80077-8
   LOK BM, 1983, ZEOLITES, V3, P282, DOI 10.1016/0144-2449(83)90169-0
   MCCORMICK AV, 1989, CATAL REV, V31, P97, DOI 10.1080/01614948909351349
   MINTOVA S, 1993, ZEOLITES, V13, P299, DOI 10.1016/0144-2449(93)90009-R
   MINTOVA S, 1993, ZEOLITES, V13, P102, DOI 10.1016/0144-2449(93)90068-E
   NAGY JB, 1983, ZEOLITES, V3, P43, DOI 10.1016/0144-2449(83)90084-2
   NAGY JB, 1988, ZEOLITES, V8, P221
   NASTRO A, 1989, ZEOLITES, V9, P227
   NASTRO A, 1989, STUD SURF SCI CATAL, V44, P227
   OZIN GA, 1989, ANGEW CHEM INT EDIT, V28, P359, DOI 10.1002/anie.198903591
   PARKER LM, 1984, ZEOLITES, V4, P168, DOI 10.1016/0144-2449(84)90056-3
   Plank C.J., 1979, US Patent, Patent No. [4,151,189, 4151189]
   PRASAD S, 1992, J PHYS CHEM-US, V96, P3092, DOI 10.1021/j100186a058
   PRASAD S, 1991, RECENT DEV CATALYSIS, P175
   RAMANIKOV VM, 1983, ZEOLITES, V3, P311
   REDONDO A, 1993, J PHYS CHEM-US, V97, P11754, DOI 10.1021/j100147a031
   SCHOLLE KFMGJ, 1984, J PHYS CHEM-US, V88, P3395, DOI 10.1021/j150660a005
   SHIRALKAR VP, 1989, ZEOLITES, V9, P363, DOI 10.1016/0144-2449(89)90089-4
   SHIRALKAR VP, 1992, J INCLUSION PHENOM M, V13, P181
   SOLARD M, 1987, ZEOLITES, V7, P463
   SONG TY, 1990, J SOLID STATE CHEM, V88, P577
   SUZUKI K, 1986, ZEOLITES, V6, P290, DOI 10.1016/0144-2449(86)90083-7
   TESTA F, 1991, ZEOLITES, V11, P705, DOI 10.1016/S0144-2449(05)80176-9
   THOMPSON RW, 1991, MODELLING STRUCTURE, P231
   TWO J, 1991, ZEOLITES, V11, P672
   TWOMEY TAM, 1994, ZEOLITES, V14, P162, DOI 10.1016/0144-2449(94)90150-3
   Van Bekkum H., 1991, INTRO ZEOLITE SCI PR
   VANKONINGSVELD H, 1987, ACTA CRYSTALLOGR B, V43, P127, DOI 10.1107/S0108768187098173
   VOLYOCSIK W, 1985, ZEOLITES, V5, P123
   WILKOSZ J, 1993, ZEOLITES, V13, P581, DOI 10.1016/0144-2449(93)90237-W
   XU WY, 1992, ZEOLITES, V12, P299, DOI 10.1016/S0144-2449(05)80299-4
   1993, ZEOLITES, V13, P399
NR 64
TC 30
Z9 30
U1 0
U2 4
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE SCIENCE PARK MILTON ROAD, CAMBRIDGE, CAMBS, ENGLAND
   CB4 4WF
SN 0956-5000
J9 J CHEM SOC FARADAY T
JI J. Chem. Soc.-Faraday Trans.
PD DEC 7
PY 1995
VL 91
IS 23
BP 4313
EP 4319
DI 10.1039/ft9959104313
PG 7
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA TH656
UT WOS:A1995TH65600016
DA 2021-08-04
ER

PT J
AU Chitra, KR
   Gaikwad, AG
   Surender, GD
   Damodaran, AD
AF Chitra, KR
   Gaikwad, AG
   Surender, GD
   Damodaran, AD
TI Studies on kinetics of forward and backward extraction of neodymium by
   using phosphonic acid monoester as an acidic extractant
SO CHEMICAL ENGINEERING JOURNAL AND THE BIOCHEMICAL ENGINEERING JOURNAL
LA English
DT Article
DE extraction; kinetics; membrane; stripping; dynamic simulation
ID SUPPORTED LIQUID MEMBRANES; MEDIATED TRANSPORT; SOLVENT-EXTRACTION;
   MODEL
AB Studies on the kinetics of neodymium transport through a bulk liquid membrane, in apparatus consisting of a source, membrane and receiving phases, have been carried out. Different experimental variables, such as the pH, carrier, metal ion and stripping agent concentrations, have been explored. However, the kinetic and solvent extraction methods were compared to determine the equilibrium extraction constant. Complexation mechanism models have been developed. The kinetic behaviour of the ion transport based on forward and backward extraction processes with the consideration of controlled parameters was predicted. The ion transport of neodymium in the receiving or membrane phase envisages the determination of forward and backward extraction rate constants.
C1 CSIR,REG RES LAB,TRIVANDRUM 695019,KERALA,INDIA.
CR AKIBA K, 1983, SEPAR SCI TECHNOL, V18, P831, DOI 10.1080/01496398308060308
   BABCOCK WC, 1986, J MEMBRANE SCI, V26, P303, DOI 10.1016/S0376-7388(00)82114-6
   BEHR JP, 1985, J AM CHEM SOC, V107, P241, DOI 10.1021/ja00287a043
   BOKHARI AH, 1978, J CHEM ENG JPN, V11, P203, DOI 10.1252/jcej.11.203
   CHIARIZIA R, 1991, J MEMBRANE SCI, V55, P65, DOI 10.1016/S0376-7388(00)82327-3
   CUI FJ, 1985, J MEMBRANE SCI, V23, P137
   CUSSLER EL, 1974, SEPAR PURIF METHOD, V3, P399, DOI 10.1080/03602547408066031
   DANESI PR, 1984, J MEMBRANE SCI, V20, P231, DOI 10.1016/S0376-7388(00)82001-3
   FRANKENFELD JW, 1981, SEPAR SCI TECHNOL, V16, P385, DOI 10.1080/01496398108068528
   FRITZ JS, 1958, ANAL CHEM, V30, P111
   GAIKWAD AG, 1991, SEPAR SCI TECHNOL, V26, P853, DOI 10.1080/01496399108050501
   GAIKWAD AG, 1993, SEPAR SCI TECHNOL, V28, P1019, DOI 10.1080/01496399308029235
   IBANEZ JA, 1990, SEPAR SCI TECHNOL, V25, P739, DOI 10.1080/01496399008050363
   IZATT RM, 1986, J MEMBRANE SCI, V28, P69, DOI 10.1016/S0376-7388(00)82200-0
   KOLTHOFF IM, 1963, TREATISE ANALYTICA 2, V8, P57
   LEBLANC OH, 1980, J MEMBRANE SCI, V6, P339, DOI 10.1016/S0376-7388(00)82175-4
   LONSDALE HK, 1982, J MEMBRANE SCI, V10, P81, DOI 10.1016/S0376-7388(00)81408-8
   MARCUS Y, 1983, J PHYS CHEM-US, V87, P794, DOI 10.1021/j100228a019
   MUSCATELLO AC, 1987, SEPAR SCI TECHNOL, V22, P843, DOI 10.1080/01496398708068985
   PRESTON JS, 1985, HYDROMETALLURGY, V14, P171, DOI 10.1016/0304-386X(85)90032-5
   RICKELTON WA, 1988, SEPAR SCI TECHNOL, V23, P1227, DOI 10.1080/01496398808075627
   SUGIURA M, 1979, B CHEM SOC JPN, V52, P684, DOI 10.1246/bcsj.52.684
   TAKEUCHI H, 1979, WATER TREAT, V5, P222
   TERAMOTO M, 1986, SEPAR SCI TECHNOL, V21, P229, DOI 10.1080/01496398608058375
NR 24
TC 10
Z9 10
U1 0
U2 5
PU ELSEVIER SCIENCE SA LAUSANNE
PI LAUSANNE 1
PA PO BOX 564, 1001 LAUSANNE 1, SWITZERLAND
SN 0923-0467
J9 CHEM ENG J BIOCH ENG
JI Chem. Eng. J. Biochem. Eng. J.
PD DEC
PY 1995
VL 60
IS 1-3
BP 63
EP 73
DI 10.1016/0923-0467(95)02985-0
PG 11
WC Engineering, Chemical
SC Engineering
GA TP503
UT WOS:A1995TP50300006
DA 2021-08-04
ER

PT J
AU SU, JY
   STOREY, KB
AF SU, JY
   STOREY, KB
TI FISH MUSCLE PHOSPHOFRUCTOKINASE - INFLUENCES OF PROTEIN-CONCENTRATION ON
   ENZYME-KINETIC BEHAVIOR
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
LA English
DT Article
DE POLYETHYLENE GLYCOL CROWDING OF ENZYMES; GLYCOLYTIC REGULATION IN FISH
   MUSCLE; ONCORHYNCHUS MYKISS; ENZYME CONCENTRATION; ALLOSTERIC PROPERTIES
ID RAT-LIVER PHOSPHOFRUCTOKINASE; PHYSIOLOGICAL CONCENTRATION;
   POLY(ETHYLENE GLYCOL); ALLOSTERIC BEHAVIOR; POLYETHYLENE-GLYCOL; CELL
AB Phosphofructokinase (PFK) is regulated by multiple mechanisms, one of these being changes in the polymerization state of the enzyme which is influenced by enzyme concentration. To better understand the regulation of PFK in vivo, the present study monitored the effects of changing enzyme concentration and of protein crowding on enzyme activity and properties. Purified PFK from white muscle of rainbow trout (Oncorhynchus mykiss) was characterized under assay conditions that simulated the physiological state of resting muscle [pH 7.2, 7.5 mM MgATP, 0.2 mM fructose-6-phosphate (F6P)], and with experimental manipulation of enzyme concentration in two ways: (a) increasing the amount of PFK (0.1 or 0.6 mu g/ml) added, and (b) crowding the enzyme by the addition of polyethylene glycol (PEG) (or other agents) to the assay mixture. A marked decrease in ATP inhibition of the enzyme was observed when PFK was studied in buffer containing PEG, as well as when assays were carried out with the purified enzyme at a concentration of 0.6 mu g/ml, as compared with a 6-fold diluted enzyme. Enzyme concentration also altered the F6P saturation curve, S-0.5 values for F6P decreasing when PFK concentration was increased or crowding reagents were added. The inclusion of PEG in the assay mixture shifted the pH profile of PFK leftward with much higher enzyme activity observed as compared to that in the absence of PEG, especially at low pH values. These results provide evidence that the allosteric behaviour of fish muscle PFK is affected by enzyme concentration and support the proposal that the more aggregated forms of the enzyme have higher affinity for fructose 6-phosphate and are less inhibited by Mg.ATP.
C1 CARLETON UNIV,INST BIOCHEM,OTTAWA,ON K1S 5B6,CANADA.
   CARLETON UNIV,DEPT CHEM,OTTAWA,ON K1S 5B6,CANADA.
RI Storey, Kenneth B/G-9883-2011
OI Storey, Kenneth/0000-0002-7363-1853
CR ARAGON JJ, 1986, EUR J BIOCHEM, V161, P757, DOI 10.1111/j.1432-1033.1986.tb10504.x
   ARAGON JJ, 1991, FASEB J, V5, P2945
   ARAGON JJ, 1985, BIOCHEM BIOPH RES CO, V131, P849, DOI 10.1016/0006-291X(85)91317-8
   ARAGON JJ, 1988, P NATL ACAD SCI USA, V77, P6324
   ARAKAWA T, 1985, BIOCHEMISTRY-US, V24, P6756, DOI 10.1021/bi00345a005
   BAR J, 1990, BIOCHEM BIOPH RES CO, V167, P1214, DOI 10.1016/0006-291X(90)90653-5
   BAUMANN P, 1968, BIOCHEMISTRY-US, V7, P3653, DOI 10.1021/bi00850a044
   BOSCA L, 1985, J BIOL CHEM, V260, P2100
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   BROOKS SPJ, 1988, AM J PHYSIOL, V255, pR289
   BROOKS SPJ, 1992, BIOTECHNIQUES, V13, P906
   GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4677, DOI 10.1021/bi00519a024
   HELMERHORST E, 1980, ANAL BIOCHEM, V104, P130, DOI 10.1016/0003-2697(80)90287-0
   HOFER HW, 1975, FEBS LETT, V53, P217, DOI 10.1016/0014-5793(75)80023-8
   KNOLL D, 1983, J BIOL CHEM, V258, P5710
   LEE LLY, 1987, BIOCHEMISTRY-US, V26, P7813, DOI 10.1021/bi00398a042
   LING KH, 1965, J BIOL CHEM, V240, P1893
   MEDINA R, 1985, FEBS LETT, V180, P77, DOI 10.1016/0014-5793(85)80235-0
   MIDDAUGH CR, 1979, J BIOL CHEM, V254, P9724
   MIEKKA SI, 1978, ARCH BIOCHEM BIOPHYS, V191, P525, DOI 10.1016/0003-9861(78)90391-0
   MILLIGAN CL, 1987, PHYSIOL ZOOL, V60, P54, DOI 10.1086/physzool.60.1.30158628
   MORTBERG M, 1987, BIOCHEM BIOPH RES CO, V146, P41, DOI 10.1016/0006-291X(87)90687-5
   OVADI J, 1986, BIOCHEM BIOPH RES CO, V135, P852, DOI 10.1016/0006-291X(86)91006-5
   PAVELICH MJ, 1973, BIOCHEMISTRY-US, V12, P1408, DOI 10.1021/bi00731a022
   RAMADOSS CS, 1976, ARCH BIOCHEM BIOPHYS, V175, P487, DOI 10.1016/0003-9861(76)90536-1
   REINHART GD, 1980, J BIOL CHEM, V255, P576
   REINHART GD, 1987, ARCH BIOCHEM BIOPHYS, V258, P65, DOI 10.1016/0003-9861(87)90323-7
   REINHART GD, 1980, BIOCHEMISTRY-US, V19, P1491, DOI 10.1021/bi00548a036
   SOLS A, 1979, CURR TOP CELL REGUL, V2, P227
   SOLS A, 1981, METABOLIC INTERCONVE, P111
   SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513
   SRIVASTAVA DK, 1987, ANNU REV BIOPHYS BIO, V16, P175
   STOREY KB, 1987, J BIOL CHEM, V262, P1670
   SU JY, 1994, INT J BIOCHEM, V26, P519, DOI 10.1016/0020-711X(94)90009-4
   SU JY, 1992, BIOCHIM BIOPHYS ACTA, V1160, P301
   Uyeda K, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P193
NR 36
TC 7
Z9 9
U1 0
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 1357-2725
J9 INT J BIOCHEM CELL B
JI Int J. Biochem. Cell Biol.
PD DEC
PY 1995
VL 27
IS 12
BP 1277
EP 1283
DI 10.1016/1357-2725(95)00104-W
PG 7
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA TK346
UT WOS:A1995TK34600005
DA 2021-08-04
ER

PT J
AU SKORSKI, T
   NIEBOROWSKASKORSKA, M
   CAMPBELL, K
   IOZZO, RV
   ZON, G
   DARZYNKIEWICZ, Z
   CALABRETTA, B
AF SKORSKI, T
   NIEBOROWSKASKORSKA, M
   CAMPBELL, K
   IOZZO, RV
   ZON, G
   DARZYNKIEWICZ, Z
   CALABRETTA, B
TI LEUKEMIA TREATMENT IN SEVERE COMBINED IMMUNODEFICIENCY MICE BY ANTISENSE
   OLIGODEOXYNUCLEOTIDES TARGETING COOPERATING ONCOGENES
SO JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
ID NF-KAPPA-B; BCR-ABL; CELL-CYCLE; MYC; INHIBITION; SEQUENCE; TUMORS;
   TRANSFORMATION; CRISIS; GENE
AB Transformation of hematopoietic cells by the p210(bcr/abl) tyrosine kinase appears to require the expression of a functional MYC protein, suggesting that simultaneous targeting of BCR-ABL and c-myc might be a rational strategy for attempting treatment of Philadelphia(1) leukemia. To test this hypothesis, severe combined immunodeficiency mice injected with Philadelphia(1) leukemic cells were treated systemically with equal doses of bcr-abl or c-myc antisense oligodeoxynucleotides (ODNs) or with both ODNs in combination. Compared with the mice treated with individual agents, the disease process was much slower in the group treated with both ODNs, as revealed by now cytometry, clonogenic assay, and reverse transcriptase-polymerase chain reaction analysis to detect leukemic cells in mouse tissue cell suspensions, and by enumeration of liver metastases. The retardation of the disease process was positively correlated with a markedly increased survival of leukemic mice treated with both ODNs. These data demonstrate the therapeutic potential of targeting multiple cooperating oncogenes.
C1 THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, DEPT IMMUNOL & MICROBIOL, PHILADELPHIA, PA 19107 USA.
   THOMAS JEFFERSON UNIV, DEPT PATHOL & CELL BIOL, PHILADELPHIA, PA 19107 USA.
   LYNX THERAPEUT INC, HAYWARD, CA 94545 USA.
   NEW YORK MED COLL, CANC RES INST, ELMSFORD, NY 10523 USA.
RI Iozzo, Renato/AAS-1980-2020
OI Darzynkiewicz, Zbigniew/0000-0002-2040-7081; Iozzo,
   Renato/0000-0002-5908-5112
CR ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168
   AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630
   ALIMENA G, 1987, CANCER GENET CYTOGEN, V26, P39, DOI 10.1016/0165-4608(87)90131-2
   BEDI A, 1994, BLOOD, V83, P2038
   BERGAN R, 1994, NUCLEIC ACIDS RES, V22, P2150, DOI 10.1093/nar/22.11.2150
   CARACCIOLO D, 1990, J CLIN INVEST, V85, P55, DOI 10.1172/JCI114433
   COLOMBEL M, 1992, CANCER RES, V52, P4313
   DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   FOTI A, 1991, BLOOD, V77, P2441
   HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901
   HUIYA N, 1994, P NATL ACAD SCI USA, V31, P4499
   HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E
   KANTARJIAN HM, 1993, BLOOD, V82, P691
   KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224
   LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263
   MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179
   MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x
   MOJCIK CF, 1993, CLIN IMMUNOL IMMUNOP, V67, P130, DOI 10.1006/clin.1993.1055
   MURRAY MJ, 1983, CELL, V33, P749, DOI 10.1016/0092-8674(83)90017-X
   NIEBOROWSKASKORSKA M, 1994, FOLIA HISTOCHEM CYTO, V32, P231
   PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728
   RATAJCZAK MZ, 1992, P NATL ACAD SCI USA, V89, P11823, DOI 10.1073/pnas.89.24.11823
   ROSENBAUM H, 1990, EMBO J, V9, P897, DOI 10.1002/j.1460-2075.1990.tb08187.x
   SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4
   SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I
   SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2
   SKORSKI T, 1994, P NATL ACAD SCI USA, V91, P4504, DOI 10.1073/pnas.91.10.4504
   SKORSKI T, 1993, J CLIN INVEST, V92, P194, DOI 10.1172/JCI116549
   STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0
   SZCZYLIK C, 1991, SCIENCE, V253, P562, DOI 10.1126/science.1857987
   THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9
   WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0
   YAMAMOTO S, 1992, J IMMUNOL, V148, P4072
   Yaswen P, 1993, Antisense Res Dev, V3, P67
NR 35
TC 48
Z9 48
U1 0
U2 0
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA
SN 0022-1007
EI 1540-9538
J9 J EXP MED
JI J. Exp. Med.
PD DEC 1
PY 1995
VL 182
IS 6
BP 1645
EP 1653
DI 10.1084/jem.182.6.1645
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA TJ870
UT WOS:A1995TJ87000003
PM 7500009
OA Bronze, Green Published, Green Submitted
DA 2021-08-04
ER

PT J
AU NETTI, PA
   BAXTER, LT
   BOUCHER, Y
   SKALAK, R
   JAIN, RK
AF NETTI, PA
   BAXTER, LT
   BOUCHER, Y
   SKALAK, R
   JAIN, RK
TI TIME-DEPENDENT BEHAVIOR OF INTERSTITIAL FLUID PRESSURE IN SOLID TUMORS -
   IMPLICATIONS FOR DRUG-DELIVERY
SO CANCER RESEARCH
LA English
DT Article
ID HUMAN ADENOCARCINOMA LS174T; ANGIOTENSIN-II; BLOOD-FLOW; MICROVASCULAR
   PERMEABILITY; ARTICULAR-CARTILAGE; NEOPLASTIC TISSUES;
   THEORETICAL-MODEL; SURFACE-AREA; WATER FLUX; SCID MICE
AB Elevated interstitial fluid pressure (IFP) may constitute a significant physiological barrier to drug delivery in solid tumors. Strategies for overcoming this barrier have not been developed to date, To identify and characterize various mechanisms regulating IFP and to develop strategies for overcoming the IFP barrier, we modeled the tumor as a poroelastic solid, We used this model to simulate the effect of changes in microvascular pressure and tumor blood now (TBF) on IFP, To test model predictions, the effects of changes in arterial pressure and TBF on IFP were measured using a tissue-isolated tumor preparation. IFP in the center of an isolated tumor was predicted to follow variation of the arterial pressure with a time delay of the order of magnitude of 10 s, and this delay was found to be 11 +/- 6 s experimentally, Following a cessation of TBP, the time constant of the drop in IFP was predicted to be of the order of 1000 s and was found to be 1500 +/- 900 s experimentally, The former time scale is characteristic of transcapillary fluid exchange, and the latter of percolation of fluid through the interstitial matrix, Relying on the good agreement between theoretical predictions and experimental data, we estimated the effect of blood pressure modulation on macromolecular uptake in solid tumors, Our results show that no appreciable increase of macromolecular uptake should occur either by an acute or by a chronic increase of blood pressure. On the other hand, higher uptake would result from periodic modulation of blood pressure, Therefore, the effectiveness of a vasoconstrictor such as angiotensin II to increase macromolecular delivery should be significantly enhanced by periodic rather than bolus or continuous administration of the vasoactive agent.
C1 HARVARD UNIV, SCH MED, BOSTON, MA USA.
   UNIV CALIF SAN DIEGO, DEPT BIOENGN, SAN DIEGO, CA 92093 USA.
RP NETTI, PA (corresponding author), MASSACHUSETTS GEN HOSP, DEPT RADIAT ONCOL, BOSTON, MA 02114 USA.
RI Jain, Rakesh K/I-1384-2017
OI Jain, Rakesh K/0000-0001-7571-3548; NETTI, PAOLO/0000-0002-2435-7181
FU NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [R35CA056591] Funding Source: NIH RePORTER; NCI NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [R35-CA-56591] Funding Source: Medline
CR ABE I, 1988, JPN J CANCER RES, V79, P874, DOI 10.1111/j.1349-7006.1988.tb00050.x
   BASSER PJ, 1992, MICROVASC RES, V44, P143, DOI 10.1016/0026-2862(92)90077-3
   BAXTER LT, 1989, MICROVASC RES, V37, P77, DOI 10.1016/0026-2862(89)90074-5
   BAXTER LT, 1991, MICROVASC RES, V41, P5, DOI 10.1016/0026-2862(91)90003-T
   BIOT MA, 1955, J APPL PHYS, V26, P182, DOI 10.1063/1.1721956
   Biot MA, 1941, J APPL PHYS, V12, P155, DOI 10.1063/1.1712886
   BOUCHER Y, 1990, CANCER RES, V50, P4478
   BOUCHER Y, 1991, CANCER RES, V51, P6691
   BOUCHER Y, 1992, CANCER RES, V52, P5110
   BUTLER TP, 1975, CANCER RES, V35, P3084
   CURTI BD, 1993, CANCER RES, V53, P2204
   DIRESTA GR, 1993, MICROVASC RES, V46, P158, DOI 10.1006/mvre.1993.1044
   FLESSNER MF, 1994, CANCER RES, V54, P4376
   GERLOWSKI LE, 1986, MICROVASC RES, V31, P288, DOI 10.1016/0026-2862(86)90018-X
   GULLINO PM, 1964, CANCER RES, V24, P780
   GULLINO PM, 1961, J NATL CANCER I, V27, P679
   GUTMANN R, 1992, CANCER RES, V52, P1993
   HILMAS DE, 1974, CANCER, V33, P103, DOI 10.1002/1097-0142(197401)33:1<103::AID-CNCR2820330116>3.0.CO;2-7
   HORI K, 1985, J NATL CANCER I, V74, P453
   HORI K, 1993, CANCER RES, V53, P5528
   HORI K, 1993, INT J ONCOL, V2, P289
   INTAGLIETTA M, 1970, Microvascular Research, V2, P212, DOI 10.1016/0026-2862(70)90009-9
   JAIN R, 1987, J BIOMECH ENG-T ASME, V109, P311, DOI 10.1115/1.3138686
   JAIN RK, 1988, CANCER RES, V48, P7022
   JAIN RK, 1987, CANCER RES, V47, P3039
   KENYON DE, 1979, B MATH BIOL, V41, P79, DOI 10.1016/S0092-8240(79)80055-5
   KRISTJANSEN PEG, 1994, MICROVASC RES, V48, P389, DOI 10.1006/mvre.1994.1063
   LESS JR, 1992, CANCER RES, V52, P6371
   LEUNIG M, 1992, CANCER RES, V52, P6553
   LI CJ, 1993, BRIT J CANCER, V67, P975, DOI 10.1038/bjc.1993.179
   MOW VC, 1984, J BIOMECH, V17, P377, DOI 10.1016/0021-9290(84)90031-9
   MOW VC, 1980, J BIOMECH ENG-T ASME, V102, P73, DOI 10.1115/1.3138202
   MOW VC, 1979, ANN REV FLUID MECH, V11
   Nagashima T, 1990, Adv Neurol, V52, P317
   NAGASHIMA T, 1990, Neurologia Medico-Chirurgica, V30, P1, DOI 10.2176/nmc.30.1
   NAGASHIMA T, 1987, NEUROSURGERY, V21, P898, DOI 10.1227/00006123-198712000-00019
   NAGASHIMA T, 1990, ACT NEUR S, V51, P155
   NATHANSON SD, 1994, ANN SURG ONCOL, V1, P333, DOI 10.1007/BF03187139
   NICHOLSON C, 1981, J PHYSIOL-LONDON, V321, P225, DOI 10.1113/jphysiol.1981.sp013981
   PAPPENHEIMER JR, 1951, AM J PHYSIOL, V167, P13
   REED RK, 1992, CIRC RES, V71, P978, DOI 10.1161/01.RES.71.4.978
   RIPPE B, 1978, ACTA PHYSIOL SCAND, V104, P318, DOI 10.1111/j.1748-1716.1978.tb06284.x
   ROH HD, 1991, CANCER RES, V51, P6695
   SEVICK EM, 1991, CANCER RES, V51, P1352
   SPILKER RL, 1992, J BIOMECH ENG-T ASME, V114, P191, DOI 10.1115/1.2891371
   SPILKER RL, 1990, COMPUT STRUCT, V35, P425, DOI 10.1016/0045-7949(90)90067-C
   STOHRER M, 1995, 43RD ANN M RAD RES S, P187
   SUZUKI M, 1981, JNCI-J NATL CANCER I, V67, P663
   SWABB EA, 1974, CANCER RES, V34, P2814
   YOUNG JS, 1950, J PATHOL BACTERIOL, V62, P313, DOI 10.1002/path.1700620303
   YUAN F, 1993, MICROVASC RES, V45, P269, DOI 10.1006/mvre.1993.1024
   ZLOTECKI RA, 1993, CANCER RES, V53, P2466
   ZLOTECKI RA, 1995, IN PRESS MICROVASC R
NR 53
TC 215
Z9 219
U1 4
U2 29
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD NOV 15
PY 1995
VL 55
IS 22
BP 5451
EP 5458
PG 8
WC Oncology
SC Oncology
GA TD887
UT WOS:A1995TD88700057
PM 7585615
DA 2021-08-04
ER

PT J
AU AGBENORKU, PT
   KUS, H
   MYCZKOWSKI, T
AF AGBENORKU, PT
   KUS, H
   MYCZKOWSKI, T
TI THE KELOID TRIAD HYPOTHESIS (KTH) - A BASIS FOR KELOID ETIOPATHOGENESIS
   AND CLUES FOR PREVENTION
SO EUROPEAN JOURNAL OF PLASTIC SURGERY
LA English
DT Article
DE KELOID TRIAD HYPOTHESIS (KTH); MAJOR AND MINOR KELOID ETIOLOGIC FACTORS;
   KELOID PREVENTION; RESECTION
AB The basis of keloid formation and its subsequent behavior, the very high incidence of recurrence after resection, and other forms of treatment are not fully understood. Keloids still remain a dilemma in plastic surgery. Analyzing the etiopathogenesis of keloids in a large number of patients in Ghana and in Poland led to a concept of keloid triad hypothesis (KTH). This is defined as a group of three etiologic factors which must simultaneously coexist and interact for keloids to form. The etiological factors are: genetic Links; bacterial, viral or any type of infective agent; type of surgery - sutures, tension of suture lines, location of sutures in relationship to the body skin lines of tension; etc. At least three of these factors must be present, inter-correlate, in order to form a keloid. These factors have been sub-divided into two groups - major (or main) and minor (or auxiliary) and are analyzed in this paper. In each situation at least one major factor must be present in order for a keloid to form.
C1 STATE RAILWAY HOSP,DEPT PLAST SURG,WROCLAW,POLAND.
NR 0
TC 4
Z9 4
U1 0
U2 0
PU SPRINGER VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010
SN 0930-343X
J9 EUR J PLAST SURG
JI Eur. J. Plast. Surg.
PD NOV
PY 1995
VL 18
IS 6
BP 301
EP 303
PG 3
WC Surgery
SC Surgery
GA TH198
UT WOS:A1995TH19800010
DA 2021-08-04
ER

PT J
AU MEYER, D
   FOUCHET, MH
   PETTA, M
   CARRUPT, PA
   GAILLARD, P
   TESTA, B
AF MEYER, D
   FOUCHET, MH
   PETTA, M
   CARRUPT, PA
   GAILLARD, P
   TESTA, B
TI STABILIZATION OF THE HYDROPHILIC SPHERE OF IOBITRIDOL, AN IODINATED
   CONTRAST AGENT, AS REVEALED BY EXPERIMENTAL AND COMPUTATIONAL
   INVESTIGATIONS
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE CONTRAST AGENTS; MOLECULAR FLEXIBILITY; VARIABLE-TEMPERATURE NMR;
   MOLECULAR DYNAMICS SIMULATIONS; MOLECULAR ELECTROSTATIC POTENTIAL
ID KEY MODEL; LOCK; DYNAMICS; BINDING; MEDIA
AB Purpose. The regular distribution in space and the stability in time of the hydrophilic sphere surrounding iobitridol were investigated. This is a novel yet important concept in the design of polyiodinated contrast agents since such a sphere is meant to hide their hydrophobic core and thus prevent hydrophobic interactions with biomacromolecules and hence chemotoxicity.
   Methods. The methods used were experimental (HPLC, H-1- and C-13-NMR spectroscopy) and computational (calculation of conformational behavior and molecular electrostatic potentials).
   Results. Iobitridol exists as a mixture of stereoisomers due to hindered rotation around several bonds. High-temperature molecular dynamics established the existence between 0 and 15 kcal/mol of 238 conformers belonging to 14 classes. Most of these conformers have an inaccessible hydrophobic core, and variable temperature molecular dynamics confirmed that the hydrophilic sphere around iobitridol is stable against external disruption.
   Conclusions. This study has demonstrated that iobitridol fulfills the physicochemical and structural criteria believed to render a polyiodinated contrast agent inert toward interacting with biomacromolecules.
C1 UNIV LAUSANNE,BEP,INST CHIM THERAPEUT,CH-1015 LAUSANNE,SWITZERLAND.
RP MEYER, D (corresponding author), GUERBET GCA,POB 50400,F-95943 ROISSY CDG,FRANCE.
RI Carrupt, Pierre-Alain/C-4854-2008
CR ALKORTA I, 1994, J MED CHEM, V37, P210, DOI 10.1021/jm00027a028
   ALTOMARE C, 1994, J MED CHEM, V38, P170
   Berg A, 1987, Acta Radiol Suppl, V370, P13
   BLOKZIJL W, 1993, ANGEW CHEM INT EDIT, V32, P1545, DOI 10.1002/anie.199315451
   BONNEMAIN B, 1990, INVEST RADIOL, V25, pS104, DOI 10.1097/00004424-199009001-00048
   BRADAMANTE S, 1987, MAGN RESON CHEM, V25, P283, DOI 10.1002/mrc.1260250402
   CARRUPT PA, 1991, J MED CHEM, V34, P1272, DOI 10.1021/jm00108a005
   DEAN PM, 1992, J MOL STRUC-THEOCHEM, V256, P75
   ELOY R, 1991, Clinical Materials, V7, P89, DOI 10.1016/0267-6605(91)90045-H
   FOSTER SJ, 1988, INVEST RADIOL, V23, pS106, DOI 10.1097/00004424-198809001-00011
   GAILLARD P, 1994, BIOORG MED CHEM LETT, V4, P737, DOI 10.1016/S0960-894X(01)80191-8
   Hoey GB, 1984, RADIOCONTRAST AGENTS, P23
   JORGENSEN WL, 1991, SCIENCE, V254, P954, DOI 10.1126/science.1719636
   KESSLER H, 1970, ANGEW CHEM INT EDIT, V9, P219, DOI 10.1002/anie.197002191
   KHANNA NC, 1986, J BIOL CHEM, V261, P8883
   KLEBE G, 1994, J COMPUT AID MOL DES, V8, P583, DOI 10.1007/BF00123667
   MELKUMYANTS AM, 1990, CARDIOVASC RES, V24, P165, DOI 10.1093/cvr/24.2.165
   NAGY P, 1985, CAN J CHEM, V63, P1694, DOI 10.1139/v85-284
   NEUBIG RR, 1989, BIOESSAYS, V11, P136, DOI 10.1002/bies.950110506
   OCONNOR SD, 1992, J MED CHEM, V35, P2870, DOI 10.1021/jm00093a021
   PRANGE T, 1995, FEBS LETT, V357, P247, DOI 10.1016/0014-5793(94)01356-6
   SOVAK M, 1988, INVEST RADIOL, V23, pS79, DOI 10.1097/00004424-198809001-00003
   SOVAK M, 1978, ANN RADIOL, V21, P283
   STAAB HA, 1968, CHEM BER-RECL, V101, P864, DOI 10.1002/cber.19681010317
   STEWART JJP, 1990, J COMPUT AID MOL DES, V4, P1, DOI 10.1007/BF00128336
   UEDA J, 1992, ACTA RADIOL, V33, P596
   WALKINSHAW MD, 1992, MED RES REV, V12, P317, DOI 10.1002/med.2610120403
NR 27
TC 17
Z9 17
U1 0
U2 2
PU PLENUM PUBL CORP
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013
SN 0724-8741
J9 PHARMACEUT RES
JI Pharm. Res.
PD NOV
PY 1995
VL 12
IS 11
BP 1583
EP 1591
DI 10.1023/A:1016272412775
PG 9
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA TG802
UT WOS:A1995TG80200004
PM 8592654
DA 2021-08-04
ER

PT J
AU SCHILD, JH
   CLARK, JW
   CANAVIER, CC
   KUNZE, DL
   ANDRESEN, MC
AF SCHILD, JH
   CLARK, JW
   CANAVIER, CC
   KUNZE, DL
   ANDRESEN, MC
TI AFFERENT SYNAPTIC DRIVE OF RAT MEDIAL NUCLEUS-TRACTUS-SOLITARIUS NEURONS
   - DYNAMIC SIMULATION OF GRADED VESICULAR MOBILIZATION, RELEASE, AND
   NON-NMDA RECEPTOR KINETICS
SO JOURNAL OF NEUROPHYSIOLOGY
LA English
DT Article
ID AMPA KAINATE RECEPTORS; PROTEIN-KINASE-C; NEUROTRANSMITTER RELEASE;
   TRANSMITTER RELEASE; GLUTAMATE; VESICLE; DESENSITIZATION; TRANSMISSION;
   CURRENTS; MODEL
AB 1. We have developed a comprehensive mathematical model of an afferent synaptic connection to the soma of a medial nucleus tractus solitarius (mNTS) neuron. Model development is based on numerical fits to quantitative data recorded in our laboratory. This work is part of a continuing collaborative effort aimed at identifying and characterizing the mechanisms responsible for the nonlinear integrative properties of this first synapse in the baroreceptor reflex.
   2. The complete model consists of three major parts. 1) a Hodgkin-Huxley (HH)-type membrane model of the prejunctional sensory terminal bouton; 2) a multistage model describing vesicular storage, adenosine 3',5'-cyclic monophosphate (cAMP)- and Ca2+-dependent mobilization, release and recycling; and 3) a HH-type membrane model of the postjunctional mNTS cell that includes descriptions for a desensitizing non-N-methyl-D-aspartate (NMDA) ionic current that is responsible for the fast excitatory postsynaptic potentials (EPSPs) observed in mNTS cells. The membrane models for both the terminal bouton and the mNTS neuron are coupled to separate lumped fluid compartment models describing intracellular Ca2+ ion concentration dynamics.
   3. Our modeling strategy is twofold. The first is to validate model performance by reproducing a wide variety of experimental data both from our laboratory and from the literature. The second is to explore the functional aspects of the model in order to gain a greater appreciation for the balance between presynaptic mechanisms (e.g., terminal membrane properties and vesicular dynamics) and postsynaptic mechanisms (e.g., non-NMDA receptor kinetics and neuronal dynamics) that underlie the afferent synaptic drive of mNTS neurons.
   4. The model accurately reproduces EPSP dynamics recorded with the use of a wide range of stimulus protocols. The model can also mirror the unique pattern of graded frequency- and use-dependent reduction in peak EPSP magnitude observed experimentally through 60 s of constant, suprathreshold synaptic activation. We demonstrate how vesicular mobilization, recycling, and receptor kinetics can function synergistically in establishing synaptic transfer. Furthermore, we show that by allowing the aggregate rate of vesicle mobilization to respond in a use-dependent manner, it is possible to compensate for the attenuating affects of desensitization at elevated rates of stimulation.
   5. Our simulations indicate that the low-frequency characteristics of this synapse are dominated by vesicular dynamics, whereas the high-frequency properties arise from a combination of Ca2+-dependent vesicular mobilization and the kinetics of the non-NMDA receptor. Desensitization can influence the peak magnitude and decay time of the EPSP, thereby affecting synaptic throughput. However, we demonstrate that, as the time course of neurotransmitter in the synaptic cleft decreases, the influence of desensitization should be somewhat diminished. As a result, the effective bandwidth of the synapse increases and becomes limited by the gating characteristics of the non-NMDA channel.
   6. The model also includes a neuromodulatory aspect in that the frequency response of the synapse can be modulated by an adenylate cyclase-mediated regulatory mechanism. Although our simulations indicate the behavior of a limited number of possible neuromodulatory agents, the results demonstrate the pivotal role such agents could play in modifying synaptic transfer characteristics presynaptically.
   7. Both continuous and burst-mode tract stimulation evoke patterns of action potentials in spontaneously active mNTS neurons that are mimicked very well by our model. Our simulations demonstrate that, as the rate of stimulation increases beyond similar to 20-30 Hz, the inherent low-pass frequency-response characteristics of the synapse limit the overall dynamic range of the mNTS neuron, causing the postsynaptic cell to ''entrain'' at frequencies within its normal operating range. These results suggest that this first synapse in the baroreflex pathway is well suited for transmitting sustained low-frequency (i.e., less than or equal to 10 Hz) activity to mNTS neurons but cannot faithfully transmit high-frequency (i.e., greater than or equal to 20 Hz) activity.
C1 RICE UNIV,DEPT ELECT & COMP ENGN,HOUSTON,TX 77251.
   BAYLOR COLL MED,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030.
   UNIV TEXAS,SCH MED,DEPT ANAT & NEUROBIOL,HOUSTON,TX 77030.
   OREGON HLTH SCI UNIV,DEPT PHYSIOL,PORTLAND,OR 97201.
OI Andresen, Michael/0000-0003-0524-1172
FU NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [R01HL041119] Funding
   Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Heart Lung & Blood Institute (NHLBI) [HL-41119] Funding Source: Medline
CR ANDRESEN M, 1990, AM J PHYSL, V259
   ANDRESEN M, 1995, J NEUROPHYSIOL, V74, P1519
   Andresen M. C., 1994, Society for Neuroscience Abstracts, V20, P301
   ANDRESEN MC, 1994, ANNU REV PHYSIOL, V56, P93, DOI 10.1146/annurev.physiol.56.1.93
   BERTOLINO M, 1993, RECEPTOR CHANNEL, V1, P267
   BETZ WJ, 1993, J PHYSIOL-LONDON, V460, P287, DOI 10.1113/jphysiol.1993.sp019472
   BOURNE HR, 1993, CELL, V72, P65, DOI 10.1016/S0092-8674(05)80029-7
   BROWNING MD, 1992, SYNAPSE, V10, P62, DOI 10.1002/syn.890100109
   BUXBAUM JD, 1989, J BIOL CHEM, V264, P9344
   CARLSON MD, 1990, NEUROSCI LETT, V110, P325, DOI 10.1016/0304-3940(90)90868-A
   CLEMENTS JD, 1992, SCIENCE, V258, P1498, DOI 10.1126/science.1359647
   COLQUHOUN D, 1992, J PHYSIOL-LONDON, V458, P261, DOI 10.1113/jphysiol.1992.sp019417
   CURTIS DR, 1960, J PHYSIOL-LONDON, V150, P374, DOI 10.1113/jphysiol.1960.sp006393
   DESCHUTTER E, 1993, J NEUROPHYSIOL, V69, P1225
   DREWE JA, 1988, SCIENCE, V241, P1810, DOI 10.1126/science.2459774
   DREWE JA, 1990, AM J PHYSIOL, V259, pH1389
   ELIOT LS, 1994, J NEUROSCI, V14, P3280
   FONNUM F, 1993, PROG BIOPHYS MOL BIO, V60, P47, DOI 10.1016/0079-6107(93)90012-9
   GNEGY ME, 1993, ANNU REV PHARMACOL, V33, P45, DOI 10.1146/annurev.pharmtox.33.1.45
   GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330
   GRINGRICH K, 1987, J NEUROPHYSIOL, V57, P1705
   HAY M, 1994, J NEUROPHYSIOL, V72, P421
   Hay M., 1994, Society for Neuroscience Abstracts, V20, P107
   HEINEMANN C, 1993, PFLUG ARCH EUR J PHY, V424, P105, DOI 10.1007/BF00374600
   HESTRIN S, 1992, NEURON, V9, P991, DOI 10.1016/0896-6273(92)90250-H
   HIGASHI H, 1986, AUTONOMIC ENTERIC GA, P439
   Hille B., 1991, IONIC CHANNELS EXCIT
   HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764
   HU YH, 1993, NEURON, V10, P921, DOI 10.1016/0896-6273(93)90207-8
   ISAACSON JS, 1993, J NEUROPHYSIOL, V70, P2187
   JACK J, 1971, J PHYSIOL-LONDON, V349, P321
   JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.neuro.17.1.219
   KATZ B, 1957, J PHYSIOL-LONDON, V231, P549
   KELLY RB, 1993, NEURON S, V72, P43
   KOENIG JH, 1989, J NEUROSCI, V9, P3844
   KORN H, 1991, TRENDS NEUROSCI, V14, P4349
   KUNZE DL, 1987, AM J PHYSIOL, V252, pH867
   LILEY AW, 1953, J NEUROPHYSIOL, V16, P509
   LIVSEY CT, 1993, J NEUROSCI, V13, P5324
   LLINAS R, 1991, J PHYSIOL-LONDON, V436, P257, DOI 10.1113/jphysiol.1991.sp018549
   MENDELOWITZ D, 1995, J NEUROPHYSIOL, V73, P872
   MOSKOWITZ N, 1985, MOL MODULATION CHEM
   NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M
   NOVIKOV V, 1987, COMPUTATIONAL MATH, V2, P162
   PATNEAU DK, 1991, NEURON, V6, P785, DOI 10.1016/0896-6273(91)90175-Y
   PERKEL DH, 1964, SCIENCE, V145, P61, DOI 10.1126/science.145.3627.61
   Persson P.B., 1991, BARORECEPTOR REFLEXE
   ROBINSON PJ, 1994, TRENDS NEUROSCI, V17, P348, DOI 10.1016/0166-2236(94)90179-1
   ROBINSON PJ, 1991, MOL NEUROBIOL, V5, P87, DOI 10.1007/BF02935541
   RYAN TA, 1993, NEURON, V11, P713, DOI 10.1016/0896-6273(93)90081-2
   SAKMANN B, 1992, BIOSCIENCE REP, V12, P237, DOI 10.1007/BF01122797
   SCHILD JH, 1993, J PHYSIOL-LONDON, V469, P341, DOI 10.1113/jphysiol.1993.sp019817
   SCHILD JH, 1994, J NEUROPHYSIOL, V71, P2338
   SIHRA TS, 1993, NEUROCHEM RES, V18, P47, DOI 10.1007/BF00966922
   STANLEY E, 1991, CALCIUM ENTRY ACTION
   TRAVEN HGC, 1993, J NEUROPHYSIOL, V70, P695
   TRUSSELL LO, 1993, NEURON, V10, P1185, DOI 10.1016/0896-6273(93)90066-Z
   TRUSSELL LO, 1989, NEURON, V3, P209, DOI 10.1016/0896-6273(89)90034-2
   VYKLICKY L, 1991, NEURON, V7, P971, DOI 10.1016/0896-6273(91)90342-W
   WINSLOW JL, 1994, J NEUROPHYSIOL, V72, P1769
   WINTER HC, 1993, NEUROCHEM RES, V18, P79, DOI 10.1007/BF00966925
   WYLLIE DJA, 1994, J PHYSIOL-LONDON, V475, P95, DOI 10.1113/jphysiol.1994.sp020052
   ZORUMSKI CF, 1992, PROG NEUROBIOL, V39, P295, DOI 10.1016/0301-0082(92)90020-F
   ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13
NR 64
TC 24
Z9 25
U1 0
U2 0
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814
SN 0022-3077
J9 J NEUROPHYSIOL
JI J. Neurophysiol.
PD OCT
PY 1995
VL 74
IS 4
BP 1529
EP 1548
PG 20
WC Neurosciences; Physiology
SC Neurosciences & Neurology; Physiology
GA TA401
UT WOS:A1995TA40100015
PM 8989391
DA 2021-08-04
ER

PT J
AU ACTIS, AM
   CARUSO, SP
   LEVIN, E
AF ACTIS, AM
   CARUSO, SP
   LEVIN, E
TI OPPOSITE EFFECT OF A CAMP ANALOG ON TUMORAL GROWTH-RELATED TO HORMONE
   DEPENDENCE OF A MURINE MAMMARY-TUMOR
SO CANCER LETTERS
LA English
DT Article
DE PROGESTIN INDUCED TUMORS; MAMMARY TUMOR HORMONE DEPENDENCE; CAMP
   ANALOGS; MEDROXYPROGESTERONE ACETATE; TRANSCRIPTION FACTORS INTERACTION
ID BREAST-CANCER; TRANSCRIPTION; INDUCTION; RECEPTORS
AB Interactions among transcription factors are one of the mechanisms that regulate gene expression. Through protein-protein associations different signaling pathways become connected and the message triggered by each of the molecules involved can modify other related routes. In a murine mammary tumor induced by medroxyprogesterone acetate (MPA), further treatment with this agent showed a different response on tumor growth. In one group of tumors, growth rate was increased (hormone dependent, HD), whereas in the other group the progestin agent failed to modify the rate of tumor development (hormone autonomous, HA). Progesterone receptors (PgR) and estrogen receptors (ER) were expressed in both groups. Administration of 8-CI-cAMP, a cAMP analogue, stimulated tumor growth in the HD subline and inhibited growth in the HA subline. Simultaneous administration of 8-CI-cAMP and MPA resulted in suppression of inhibitory 8-CI-cAMP action in the HA tumor subline attributable to changes in molecular configuration of protagonic members of each signaling pathway, whereas in the HD subline growth was additive as if each of the pathways were acting separately. MPA induced down regulation of PgR in both tumor sublines and up regulation of ER in the C4-HD subline. The effect of 8-CI-cAMP alone or associated with MPA was more complex and variations in PgR and ER content by themselves are insufficient to explain changes in tumoral growth. A model consistent with our experimental findings is presented.
C1 UNIV BUENOS AIRES,FAC MED,DEPT BIOQUIM HUMANA,RA-1121 BUENOS AIRES,DF,ARGENTINA.
CR ACTIS AM, 1994, INT J CANCER, V58, P668, DOI 10.1002/ijc.2910580509
   BECK CA, 1993, P NATL ACAD SCI USA, V90, P4441, DOI 10.1073/pnas.90.10.4441
   CHOCHUNG YS, 1993, CANCER RES, V50, P7093
   DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P145, DOI 10.1210/me.7.2.145
   FUQUA SAW, 1993, J CELL BIOCHEM, V51, P135, DOI 10.1002/jcb.240510204
   LANARI C, 1986, CANCER LETT, V33, P215, DOI 10.1016/0304-3835(86)90027-3
   LEVIN E, 1990, J STEROID BIOCHEM, V37, P681, DOI 10.1016/0960-0760(90)90351-K
   LEVIN E, 1995, ENDOCR-RELAT CANCER, V2, P1
   MINER JN, 1991, TRENDS BIOCHEM SCI, V16, P423, DOI 10.1016/0968-0004(91)90168-U
   ROESLER WJ, 1988, J BIOL CHEM, V263, P9063
   SARTORIUS CA, 1993, J BIOL CHEM, V268, P9262
   SASSONECORSI P, 1994, EMBO J, V13, P4717, DOI 10.1002/j.1460-2075.1994.tb06797.x
   TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459
NR 13
TC 6
Z9 6
U1 0
U2 0
PU ELSEVIER SCI PUBL IRELAND LTD
PI CLARE
PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE,
   IRELAND
SN 0304-3835
J9 CANCER LETT
JI Cancer Lett.
PD SEP 4
PY 1995
VL 96
IS 1
BP 81
EP 85
DI 10.1016/0304-3835(95)03908-F
PG 5
WC Oncology
SC Oncology
GA RX300
UT WOS:A1995RX30000011
PM 7553611
DA 2021-08-04
ER

PT J
AU Notario, A
   Mazzucchelli, I
   Rolandi, ML
   Fossati, G
AF Notario, A
   Mazzucchelli, I
   Rolandi, ML
   Fossati, G
TI The in vitro activity of two urinary polypeptides respect to G- and
   GM-CSF and IL3 on the peripheral CFU of normal and leukemic subjects
SO INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY
LA English
DT Article
DE urinary polypeptides; G-CSF; GM-CSF and IL3; peripheral CFU
ID COLONY-STIMULATING FACTOR; PURIFICATION
AB We isolated two polypeptides on HPLC from the acetonic precipitate of the urine of normal subjects and of patients with untreated AML, APL and AMML. Before separation the quantity of the total urinary factor from leukemic patients was 50+/-10 mg/24h and from normal subjects was 10+/-5 mg. We tested the total polypeptidic extract and the two main fractions obtained on liquid cultures of the peripheral CFU of normal and leukemic subjects (AML, APL, CML and CMmL). Colony growth, cell morphology changes and the main cellular markers were examined at the beginning and at the 5th and 10th days of incubation in RPMI 1640 medium. Testing conditions were basal and as determined by the addition of the polypeptidic fractions, both alone and in association with trans-retinoic acid (t-RA) or thioproline (T). Simultaneously and under the same experimental conditions, we tested the activity of G- and GMCSF and IL3. The results obtained prove the colony stimulating activity of the two fractions and of crude extract; they also prove the ability of such agents to modify the behavior in vitro of peripheral CFU. The urinary extracts are also able to stimulate a moderate differentiation of the elements and an increase both in fibroblasts and in adhesion molecules. We conclude that the dosage of growth factors in urine may be usefull as important marker in several hemopoietic pathological conditions or as a possible source of growth factors.
RP Notario, A (corresponding author), UNIV PAVIA, IRCCS, POLICLIN S MATTEO, IST TERAPIA MED, DIPARTIMENTO INTERNA & TERAPIA MED, I-27100 PAVIA, ITALY.
RI Mazzucchelli, Iolanda/P-4499-2019; Mazzucchelli, Iolanda/K-4366-2012
OI Mazzucchelli, Iolanda/0000-0003-2715-0685; 
CR ABDERHALDEN R, 1948, EXPERIENTIA, V4, P114, DOI 10.1007/BF02164442
   ISHIZAKA Y, 1986, EXP HEMATOL, V14, P1
   METCALF D, 1971, BRIT J HAEMATOL, V21, P481
   METCALF D, 1988, EXP HEMATOL, V16, P794
   MOTOYOSHI K, 1978, BLOOD, V52, P1012
   ROBINSON WA, 1969, BLOOD-J HEMATOL, V33, P396, DOI 10.1182/blood.V33.3.396.396
   SHADDUCK RK, 1979, BLOOD, V54, P894
   SHERIDAN JW, 1973, P SOC EXP BIOL MED, V144, P785
   WANG FF, 1983, J CELL BIOCHEM, V21, P263, DOI 10.1002/jcb.240210403
NR 9
TC 1
Z9 1
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0394-6320
J9 INT J IMMUNOPATH PH
JI Int. J. Immunopathol. Pharmacol.
PD SEP-DEC
PY 1995
VL 8
IS 3
BP 173
EP 184
DI 10.1177/039463209500800304
PG 12
WC Immunology; Pathology; Pharmacology & Pharmacy
SC Immunology; Pathology; Pharmacology & Pharmacy
GA TN856
UT WOS:A1995TN85600004
DA 2021-08-04
ER

PT J
AU SEGALMAN, DJ
   WITKOWSKI, WR
AF SEGALMAN, DJ
   WITKOWSKI, WR
TI 2-DIMENSIONAL FINITE-ELEMENT ANALYSIS OF A POLYMER GEL DRUG-DELIVERY
   SYSTEM
SO MATERIALS SCIENCE & ENGINEERING C-BIOMIMETIC AND SUPRAMOLECULAR SYSTEMS
LA English
DT Article
DE DRUG DELIVERY SYSTEM; FINITE ELEMENT ANALYSIS; GELS; HYDROGELS
AB Hydrogels are being investigated as drug delivery mechanisms. Gels can be impregnated with a drug and then stimulated through various means to release it. Having the capability to predict the dynamic behaviour of the release process numerically would benefit the design and control of such a process. In this paper, a finite element analysis is used to simulate the dynamic behaviour of an eroding polyelectrolyte gel. The gel is impregnated in a collapsed state. It is then subjected to a higher pH environment, causing it to swell. When it has swollen to a specified extent, the gel erodes, thereby releasing the drug agent. Such gels are currently being investigated in drug delivery schemes to the colon.
C1 SANDIA NATL LABS, DIV 1425, DEPT STRUCT DYNAM & VIBRAT CONTROL, ALBUQUERQUE, NM 87185 USA.
CR BRONDSTED H, 1992, ACS SYM SER, V480, P285
   Flory PJ, 1969, STATISTICAL MECHANIC
   GRIMSHAW PE, 1990, J CHEM PHYS, V93, P4462, DOI 10.1063/1.458729
   HUGHES T, 1987, FINITE ELEMENT METHO, P208
   HUGHES TJR, 1986, COMPUT METHOD APPL M, V59, P85, DOI 10.1016/0045-7825(86)90025-3
   LODGE A, 1964, ELASTIC LIQUIDS, P62
   SEGALMAN D, 1992, 1ST P INT C INT MAT
   SEGALMAN D, 1993, SPIE C, V1916, P14
   Segalman D. J., 1992, Smart Materials and Structures, V1, P95, DOI 10.1088/0964-1726/1/1/015
NR 9
TC 9
Z9 9
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0928-4931
J9 MAT SCI ENG C-BIO S
JI Mater. Sci. Eng. C-Biomimetic Supramol. Syst.
PD SEP
PY 1995
VL 2
IS 4
BP 243
EP 249
DI 10.1016/0928-4931(95)00103-4
PG 7
WC Materials Science, Multidisciplinary
SC Materials Science
GA TG131
UT WOS:A1995TG13100011
OA Green Submitted
DA 2021-08-04
ER

PT J
AU KOWALL, T
   FOGLIA, F
   HELM, L
   MERBACH, AE
AF KOWALL, T
   FOGLIA, F
   HELM, L
   MERBACH, AE
TI MOLECULAR-DYNAMICS SIMULATION STUDY OF LANTHANIDE IONS LN(3+) IN
   AQUEOUS-SOLUTION - ANALYSIS OF THE STRUCTURE OF THE FIRST HYDRATION
   SHELL AND OF THE ORIGIN OF SYMMETRY FLUCTUATIONS
SO JOURNAL OF PHYSICAL CHEMISTRY
LA English
DT Article
ID CROWN ETHER COMPLEXES; CRYSTAL-STRUCTURE; VARIABLE-PRESSURE;
   WATER-EXCHANGE; LIQUID WATER; RELAXATION; COORDINATION; TERBIUM; GD3+
AB We have analyzed molecular dynamics simulations of tripositive lanthanide ions Ln(3+) in aqueous solution. Combining a variety of new approaches for the analysis and the visualization of the first hydration shells, we were able to extract in detail their angular structure and their dynamic behavior along the series of Ln(3+) ions. For a heavy lanthanide ion (Yb3+) the eight water molecules of the first hydration shell form a well-defined square antiprism, whereas for a nine-coordinate light lanthanide ion (Nd3+) the first hydration shell adopts the tricapped trigonal prism geometry. In the middle of the series both geometries coexist. Both the square antiprism and the tricapped trigonal prism rearrange via 90 degrees pseudorotations of the main symmetry axis. The pertaining transition state of lowered symmetry is a dodecahedron for the Yb3+ octaaqua complex and a capped square antiprism for the Nd3+ enneaaqua complex. The lifetime of a square antiprism between two pseudorotations is 11 ps but amounts to only 2 ps for a tricapped trigonal prism. The Lifetime of a square antiprism from the simulation of Yb3+ (CN = 8) is in quantitative agreement with the correlation time for the fluctuation of the zero-field splitting from experimental EPR spectra of the Gd3+ octaaqua complex. This correlation time, of relevance for the understanding of the mechanism of the H-1 relaxation of Gd3+-based MRI contrast agents, is linked to transient distorsions of the Gd3+ aqua complex from perfect symmetry that were so far assumed to be due to random impacts of solvent molecules. On the basis of our MD-simulations we can go beyond these general notions and propose a model with 90 degrees pseudorotations of the coordination polyhedron as the principal mechanism for distorsions of the first hydration shell.
C1 UNIV LAUSANNE,INST CHIM MINERALE & ANALYT,CH-1015 LAUSANNE,SWITZERLAND.
CR ALBERTSSON J, 1977, ACTA CRYSTALLOGR B, V33, P1460, DOI 10.1107/S0567740877006293
   BROACH RW, 1979, ACTA CRYSTALLOGR B, V35, P2317, DOI 10.1107/S0567740879009213
   CHATTERJEE A, 1988, ACTA CRYSTALLOGR B, V44, P381, DOI 10.1107/S0108768188001764
   COSSY C, 1989, INORG CHEM, V28, P2699, DOI 10.1021/ic00313a003
   COSSY C, 1989, J CHEM PHYS, V90, P3254, DOI 10.1063/1.455878
   COSSY C, 1995, NEW J CHEM, V19, P27
   COSSY C, 1988, PURE APPL CHEM, V60, P1785, DOI 10.1351/pac198860121785
   FITZWATER DR, 1959, Z KRISTALLOGR KRISTA, V112, P362
   GEIGER A, 1979, J CHEM PHYS, V70, P263, DOI 10.1063/1.437241
   GEIGER A, 1981, BER BUNSEN PHYS CHEM, V85, P52, DOI 10.1002/bbpc.19810850112
   HARROWFIELD JM, 1983, AUST J CHEM, V36, P483, DOI 10.1071/CH9830483
   HELM L, 1991, EUR J SOL STATE INOR, V28, P245
   Helmholz L, 1939, J AM CHEM SOC, V61, P1544, DOI 10.1021/ja01875a062
   HUBBARD CR, 1974, ACTA CRYSTALLOGR B, V30, P2613, DOI 10.1107/S0567740874007679
   IMPEY RW, 1983, J PHYS CHEM-US, V87, P5071, DOI 10.1021/j150643a008
   JOHANSSON G, 1985, INORG CHEM, V24, P3047, DOI 10.1021/ic00213a035
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   KELLER E, 1990, PROGRAM SCHAKAL 88
   Kepert D, 1982, INORGANIC STEREOCHEM
   KEPERT DL, 1965, J CHEM SOC, P4736, DOI 10.1039/jr9650004736
   KOENIG SH, 1975, J CHEM PHYS, V63, P2279, DOI 10.1063/1.431677
   KOENIG SH, 1990, PROG NUCL MAG RES SP, V22, P487, DOI 10.1016/0079-6565(90)80008-6
   KOWALL T, 1995, J AM CHEM SOC, V117, P3790, DOI 10.1021/ja00118a015
   KURIHARA LK, 1986, INORG CHIM ACTA, V116, P171
   KURIHARA LK, 1987, INORG CHIM ACTA, V130, P131
   MICSKEI K, 1993, MAGN RESON CHEM, V31, P1011, DOI 10.1002/mrc.1260311111
   MORET E, 1991, J LESS-COMMON MET, V171, P273, DOI 10.1016/0022-5088(91)90151-S
   NELDER JA, 1965, COMPUT J, V7, P308, DOI 10.1093/comjnl/7.4.308
   POWELL DH, 1994, MAGN RESON CHEM, V32, P739, DOI 10.1002/mrc.1260321207
   POWELL DH, 1993, HELV CHIM ACTA, V76, P2129, DOI 10.1002/hlca.19930760524
   Rahman A, 1971, J CHEM PHYS, V55, P3336, DOI 10.1063/1.1676585
   REUBEN J, 1971, J PHYS CHEM-US, V75, P3164, DOI 10.1021/j100689a023
   RIZKALLA EM, 1991, HDB PHYSICS CHEM RAR, V15
   RODE BM, 1992, J CHEM SOC FARADAY T, V88, P417, DOI 10.1039/ft9928800417
   ROGERS RD, 1988, J COORD CHEM, V16, P415, DOI 10.1080/00958978808081668
   ROGERS RD, 1987, INORG CHIM ACTA, V133, P347, DOI 10.1016/S0020-1693(00)87790-7
   ROGERS RD, 1987, INORG CHIM ACTA, V133, P181, DOI 10.1016/S0020-1693(00)84392-3
   SANTOS COP, 1985, INORG CHIM A-F-BLOCK, V110, P83
   SIKKA SK, 1969, ACTA CRYSTALL A-CRYS, VA 25, P621, DOI 10.1107/S0567739469001380
   TANAKA K, 1987, Z NATURFORSCH A, V42, P29, DOI 10.1515/zna-1987-0106
   VANGUNSTEREN WF, BIOMOS BIOMOLEULAR S
   WEBB S, 1986, CHEM PHYS LETT, V129, P310, DOI 10.1016/0009-2614(86)80218-4
   WEINRACH JB, 1990, J CHEM EDUC, V67, P995, DOI 10.1021/ed067p995
   WESTLUND PO, 1993, MOL PHYS, V78, P1365, DOI 10.1080/00268979300100911
NR 44
TC 91
Z9 93
U1 1
U2 21
PU AMER CHEMICAL SOC
PI WASHINGTON
PA PO BOX 57136, WASHINGTON, DC 20037-0136
SN 0022-3654
J9 J PHYS CHEM-US
JI J. Phys. Chem.
PD AUG 31
PY 1995
VL 99
IS 35
BP 13078
EP 13087
DI 10.1021/j100035a007
PG 10
WC Chemistry, Physical
SC Chemistry
GA RR846
UT WOS:A1995RR84600007
DA 2021-08-04
ER

PT J
AU MALTZMAN, F
AF MALTZMAN, F
TI MEETING COMPETING DEMANDS - COMMITTEE PERFORMANCE IN THE POSTREFORM
   HOUSE
SO AMERICAN JOURNAL OF POLITICAL SCIENCE
LA English
DT Article; Proceedings Paper
CT 1993 Meeting of the American-Political-Science-Association
CY 1993
CL WASHINGTON, DC
SP Amer Polit Sci Assoc
ID CONGRESSIONAL COMMITTEES; ORGANIZATION
AB Theory: A conditional model of committee behavior is proposed to explain variation in committee responsiveness to chamber and party principals.
   Hypotheses: Committee member behavior is consistent with the preferences of both the floor and the party caucuses; variation in salience explains differences in committee responsiveness to noncommittee colleagues.
   Methods: Committee-specific votes are scaled to produce spatial locations for committee, floor, party caucuses, and party committee delegations; a Monte Carlo simulation is used to assess the statistical significance of voting alignments.
   Results: Postreform House committees generally act in a manner acceptable to both the chamber and majority party; the Democratic caucus is frequently represented by extreme committee delegations; members of salient committees are more loyal agents of the chamber and majority party than are members of low salient committees.
RP MALTZMAN, F (corresponding author), GEORGE WASHINGTON UNIV,WASHINGTON,DC 20052, USA.
CR ALDRICH JH, 1994, LEGIS STUD QUART, V19, P313, DOI 10.2307/440135
   Aldrich John, 1994, DYNAMICS AM POLITICS
   BACH S, 1988, MANAGING UNCERTAINIT
   BARTELS LM, 1993, POLITICAL SCI STATE, V2
   Black D., 1958, THEORY COMMITTEES EL
   BRADY DW, 1973, C VOTING PARTISAN ER
   BRADY DW, 1988, CRITICAL ELECTIONS C
   BURGER T, 1993, ROLL CALL        JUN
   CLAUSEN A, 1973, HOW CONGRESS DECIDE
   COOPER J, 1970, ORIGINS STANDING COM
   Cox GaryW., 1993, LEGISLATIVE LEVIATHA
   COX GW, 1994, LEGIS STUD QUART, V19, P215, DOI 10.2307/440425
   DAVIDSON RH, 1986, LEGIS STUD QUART, V11, P19, DOI 10.2307/439906
   Deering Christopher J., 1990, COMMITTEES C
   FENNO RF, 1966, POWER PURSE
   Fenno Richard F., 1973, CONGRESSMEN COMMITTE
   FOWLER LL, 1982, LEGIS STUD QUART, V7, P401, DOI 10.2307/439365
   GILLIGAN TW, 1990, AM J POLIT SCI, V34, P531, DOI 10.2307/2111460
   GROSECLOSE T, 1994, J POLIT, V56, P440, DOI 10.2307/2132147
   HALL RL, 1990, AM POLIT SCI REV, V84, P1149, DOI 10.2307/1963257
   HASBROUCK PD, 1927, PARTY GOVT HOUSE REP
   KIEWET DR, 1991, LOGIC DELEGATION C P
   KRAMER GH, 1972, J MATH SOCIOL, V2, P165
   KREHBIEL K, 1990, AM POLIT SCI REV, V84, P149, DOI 10.2307/1963634
   KREHBIEL K, 1993, PUBLIC CHOICE, V76, P21, DOI 10.1007/BF01049341
   KREHBIEL K, 1994, LEGIS STUD QUART, V19, P61, DOI 10.2307/439800
   KREHBIEL K, 1993, BRIT J POLIT SCI, V23, P235, DOI 10.1017/S0007123400009741
   KREHBIEL K, 1991, INFORMATION LEGISLAT
   Maass arthur, 1983, C COMMON GOOD
   MALTZMAN F, 1994, LEGIS STUD QUART, V19, P457, DOI 10.2307/440168
   MALTZMAN F, 1993, THESIS U MINNESOTA
   MANLEY J, 1970, POLITICS FINANCE HOU
   MAYHEW D, C ELECTORAL CONNECTI
   MOE TM, 1984, AM J POLIT SCI, V28, P739, DOI 10.2307/2110997
   MUNGER MC, 1988, AM J POLIT SCI, V32, P317, DOI 10.2307/2111126
   NORUSIS MJ, 1990, SPSS BASE SYSTEM USE
   POOLE KT, 1985, AM J POLIT SCI, V29, P357, DOI 10.2307/2111172
   PRICE D, 1979, POLICYMAKING C COMMI
   PRICE DE, 1981, C RECONSIDERED
   RAY BA, 1980, LEGIS STUD QUART, V5, P501, DOI 10.2307/439571
   Rohde David W., 1991, PARTIES LEADERS POST
   ROHDE DW, 1994, LEGIS STUD QUART, V19, P341, DOI 10.2307/440136
   SCHICK A, 1980, C MONEY
   SINCLAIR B, 1993, ANN M AM POL SCI ASS
   Sinclair Barbara, 1989, C RECONSIDERED
   SINCLAIR BD, 1977, AM POLIT SCI REV, V71, P940, DOI 10.2307/1960099
   Smith S. S., 1984, COMMITTEES C
   Smith Steven, 1989, CALL ORDER FLOOR POL
   SNYDER JM, 1992, LEGIS STUD QUART, V17, P319, DOI 10.2307/439733
   SNYDER JM, 1992, AM J POLIT SCI, V36, P1, DOI 10.2307/2111421
   SNYDER JM, 1992, AM J POLIT SCI, V36, P36, DOI 10.2307/2111423
   UNEKIS JK, 1978, J POLIT, V40, P761, DOI 10.2307/2129865
   WEINGAST B, 1988, J POLITICAL EC, V91, P132
   WHITE J, 1993, C RESURGENT FOREIGN
   White Joseph, 1989, THESIS U CALIFORNIA
   WILCOX RR, 1986, J EDUC STAT, V11, P263, DOI 10.3102/10769986011004263
NR 56
TC 30
Z9 30
U1 0
U2 3
PU UNIV TEXAS PRESS
PI AUSTIN
PA BOX 7819, AUSTIN, TX 78713-7819
SN 0092-5853
J9 AM J POLIT SCI
JI Am. J. Polit. Sci.
PD AUG
PY 1995
VL 39
IS 3
BP 653
EP 682
DI 10.2307/2111649
PG 30
WC Political Science
SC Government & Law
GA RM584
UT WOS:A1995RM58400008
DA 2021-08-04
ER

PT J
AU EGNER, PA
   GANGE, SJ
   DOLAN, PM
   GROOPMAN, JD
   MUNOZ, A
   KENSLER, TW
AF EGNER, PA
   GANGE, SJ
   DOLAN, PM
   GROOPMAN, JD
   MUNOZ, A
   KENSLER, TW
TI LEVELS OF AFLATOXIN-ALBUMIN BIOMARKERS IN RAT PLASMA ARE MODULATED BY
   BOTH LONG-TERM AND TRANSIENT INTERVENTIONS WITH OLTIPRAZ
SO CARCINOGENESIS
LA English
DT Article
ID PERFORMANCE LIQUID-CHROMATOGRAPHY; MOLECULAR DOSIMETRY; F344 RATS;
   ADDUCTS; SERUM; AFLATOXIN-N7-GUANINE; CARCINOGENESIS; EXCRETION; URINE;
   DNA
AB The validation process for biomarkers to be used for monitoring the efficacy of preventive interventions in humans includes assessments of whether levels of the biomarker can be modulated in experimental models. From this perspective, the influence of two intervention protocols with the chemopreventive agent oltipraz on rates of formation and disappearance of aflatoxin-albumin adducts has been evaluated in rats chronically exposed to aflatoxin B-1. Male F344 rats were treated daily with 20 mu g aflatoxin B-1, p.o. for 35 days. The first strategy employed a standard, long-term intervention in which basal AIN-76A diet was supplemented with 0.05% oltipraz beginning one week before AFB(1) treatment and continuing throughout the period of carcinogen exposure. In this setting, treatment with oltipraz reduced the rate of formation of aflatoxin-albumin adducts such that steady-state levels were lowered by >50% from control values of 400 pmol aflatoxin adducts/mg albumin. The time-course for reaching respective steady-state levels was unchanged, with or without oltipraz intervention. The second intervention strategy utilized a delayed, transient protocol in which oltipraz was fed for 2 weeks beginning 1 week after AFB(1) dosing began and ending 2 weeks before AFB(1) dosing was completed. This second strategy, which models clinical interventions in chronically exposed individuals, produced a steady decline in aflatoxin-albumin adduct levels that approached a 50% reduction by the end of the AFB(1) exposure period. Development of smooth curve functions allowed for the estimation of the ratio of effects between the non-intervention and intervention groups as well as the simultaneous 90% confidence intervals for the aflatoxin-albumin adduct levels. These analyses indicated that long-term intervention with oltipraz produced a statistically significant reduction in levels of the aflatoxin-albumin biomarker at all times throughout aflatoxin exposure. By contrast, a statistically significant decrease in biomarker levels was not seen in the delayed, transient intervention protocol until the ninth day of the intervention. However, once achieved, significant differences from the control group were maintained for the remainder of the aflatoxin exposure period. These changes in aflatoxin biomarker levels are consistent with the cancer chemopreventive outcomes of these intervention protocols in rats. Collectively, these results support the utility of measuring this biomarker as a means for assessing the efficacy of chemopreventive interventions in individuals at high risk for aflatoxin exposure and development of hepatocellular carcinoma.
C1 JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT ENVIRONM HLTH SCI, BALTIMORE, MD 21205 USA.
   JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT EPIDEMIOL, BALTIMORE, MD 21205 USA.
RI Kensler, Thomas W/D-8686-2014; /X-4205-2019
OI Kensler, Thomas W/0000-0002-6676-261X; /0000-0003-4690-2133; Gange,
   Stephen/0000-0001-7842-512X
FU NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [CA39416] Funding Source: Medline; NIEHS NIH HHSUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Environmental Health Sciences (NIEHS) [ES06052,
   ES03819] Funding Source: Medline; NATIONAL CANCER INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [R01CA039416] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Environmental Health
   Sciences (NIEHS) [P01ES006052, P30ES003819] Funding Source: NIH RePORTER
CR BENNETT RA, 1981, CANCER RES, V41, P650
   BENSON AB, 1993, J CELL BIOCHEM, P278
   BOLTON MG, 1993, CANCER RES, V53, P3499
   BUSBY WF, 1984, CHEM CARCINOGENS, P945
   CHRISTENSEN RG, 1992, J CHROMATOGR-BIOMED, V584, P207, DOI 10.1016/0378-4347(92)80577-D
   Egner P. A., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P585
   GAN LS, 1988, CARCINOGENESIS, V9, P1323, DOI 10.1093/carcin/9.7.1323
   GROOPMAN JD, 1993, CHEM RES TOXICOL, V6, P764, DOI 10.1021/tx00036a004
   GROOPMAN JD, 1992, CARCINOGENESIS, V13, P101, DOI 10.1093/carcin/13.1.101
   GROOPMAN JD, 1992, CANCER RES, V52, P267
   GROOPMAN JD, 1992, CANCER RES, V52, P45
   HALL AJ, 1994, TOXICOLOGY AFLATOXIN, P233
   KENSLER TW, 1995, IN PRESS J CELL BIOC
   Kensler TW, 1994, TOXICOLOGY AFLATOXIN, P281
   QIAN GS, 1994, CANCER EPIDEM BIOMAR, V3, P3
   RAO CV, 1991, CARCINOGENESIS, V12, P1051, DOI 10.1093/carcin/12.6.1051
   ROEBUCK BD, 1984, J NATL CANCER I, V72, P1405
   ROEBUCK BD, 1991, CANCER RES, V51, P5501
   ROSS RK, 1992, LANCET, V339, P943, DOI 10.1016/0140-6736(92)91528-G
   SABBIONI G, 1987, CARCINOGENESIS, V8, P819, DOI 10.1093/carcin/8.6.819
   SKIPPER PL, 1990, CARCINOGENESIS, V11, P507, DOI 10.1093/carcin/11.4.507
   WILD CP, 1992, CANCER EPIDEM BIOMAR, V1, P229
   WILD CP, 1986, CARCINOGENESIS, V7, P853, DOI 10.1093/carcin/7.6.853
NR 23
TC 40
Z9 42
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD AUG
PY 1995
VL 16
IS 8
BP 1769
EP 1773
DI 10.1093/carcin/16.8.1769
PG 5
WC Oncology
SC Oncology
GA RP924
UT WOS:A1995RP92400015
PM 7634402
DA 2021-08-04
ER

PT J
AU CHATZI, EG
   KIPARISSIDES, C
AF CHATZI, EG
   KIPARISSIDES, C
TI STEADY-STATE DROP-SIZE DISTRIBUTIONS IN HIGH HOLDUP FRACTION
   DISPERSION-SYSTEMS
SO AICHE JOURNAL
LA English
DT Article
ID LIQUID-LIQUID DISPERSIONS; AGITATED VESSELS; SUSPENSION POLYMERIZATION;
   MODEL; COALESCENCE; BREAKAGE
AB Macroscopic phenomena in suspension polymerization reactors are extremely complex, and breakage and coalescence of polymerizing monomer droplets are not well understood, especially for high dispersed-phase volume fractions. Depending on the agitation, concentration and type of surface-active agent the droplet size call exhibit a U shape variation with respect to the impeller speed. This behavior has been confirmed experimentally and theoretically as the balance between breakage and coalescence rates of monomer drops. Both processes are related to the drop surface energy, which is proportional to the interfacial tension and its variation with time. In this study die most comprehensive models describing breakage and coalescence processes in a dispersion system were incorporated into a generalized numerical algorithm to predict the steady-state drop-size distributions in a high holdup (50%) liquid-liquid dispersion system. To assess the effectiveness of the theoretical model in simulating drop-size distributions in high holdup dispersion systems, experiments were carried out with a model system of 50% n-butyl chloride in water in the presence of a surface-active agent, poly(vinyl alcohol), at different concentrations and agitation rates. The theoretical model can predict reasonably well the drop-size distribution for all experimental conditions A systematic theoretical and experimental investigation elucidates the relationships between the changing structure of PVA molecules at the monomer/water interface and their effects on breakage and coalescence frequencies at different agitation times and rates.
C1 ARISTOTELIAN UNIV THESSALONIKI,DEPT CHEM ENGN,GR-54006 THESSALONIKI,GREECE.
   ARISTOTELIAN UNIV THESSALONIKI,CHEM PROC ENGN RES INST,GR-54006 THESSALONIKI,GREECE.
CR Burkholz A., 1984, PART CHARACT, P153
   CHATZI E, 1987, IND ENG CHEM RES, V26, P2263, DOI 10.1021/ie00071a016
   CHATZI EG, 1991, IND ENG CHEM RES, V30, P1307, DOI 10.1021/ie00054a035
   CHATZI EG, 1991, IND ENG CHEM RES, V30, P536, DOI 10.1021/ie00051a015
   CHATZI EG, 1989, IND ENG CHEM RES, V28, P1704, DOI 10.1021/ie00095a022
   CHATZI EG, 1992, CHEM ENG SCI, V47, P445, DOI 10.1016/0009-2509(92)80032-8
   COLLINS SB, 1970, AICHE J, V16, P1072, DOI 10.1002/aic.690160634
   COULALOGLOU CA, 1977, CHEM ENG SCI, V32, P1289, DOI 10.1016/0009-2509(77)85023-9
   HINZE JO, 1955, AICHE J, V1, P289, DOI 10.1002/aic.690010303
   HOWARTH WJ, 1964, CHEM ENG SCI, V19, P33, DOI 10.1016/0009-2509(64)85003-X
   JOHNSON GR, 1980, J VINYL TECHNOL, V2, P138
   KARAM HJ, 1968, IND ENG CHEM FUND, V7, P576, DOI 10.1021/i160028a009
   Kelsall D.G., 1983, POLYM REACTION ENG I
   LANKVELD JM, 1972, J COLLOID INTERF SCI, V41, P454, DOI 10.1016/0021-9797(72)90369-4
   MIKOS AG, 1986, J APPL POLYM SCI, V31, P2647, DOI 10.1002/app.1986.070310820
   MLYNEK Y, 1972, AICHE J, V18, P122, DOI 10.1002/aic.690180122
   NARSIMHAN G, 1980, AICHE J, V26, P991, DOI 10.1002/aic.690260614
   NARSIMHAN G, 1979, CHEM ENG SCI, V34, P257, DOI 10.1016/0009-2509(79)87013-X
   Nilsson H, 1985, J VINYL TECHNOL, V7, P112
   NISHIKAWA M, 1987, J CHEM ENG JPN, V20, P454, DOI 10.1252/jcej.20.454
   PARK JY, 1975, CHEM ENG SCI, V30, P1957
   PETER S, 1964, KOLLOID Z Z POLYM, V196, P125, DOI 10.1007/BF01499572
   SHINNAR R, 1960, IND ENG CHEM, V52, P253, DOI 10.1021/ie50603a036
   SHUICHI A, 1958, AICHE J, V4, P485
   SLEICHER CA, 1962, AICHE J, V8, P471, DOI 10.1002/aic.690080410
   SOVOVA H, 1981, CHEM ENG SCI, V36, P1567, DOI 10.1016/0009-2509(81)85117-2
   TANAKA M, 1990, J APPL POLYM SCI, V39, P955, DOI 10.1002/app.1990.070390414
   Taylor GI, 1932, P R SOC LOND A-CONTA, V138, P41, DOI 10.1098/rspa.1932.0169
   Taylor GI, 1934, P R SOC LOND A-CONTA, V146, P0501, DOI 10.1098/rspa.1934.0169
   VALENTAS KJ, 1966, IND ENG CHEM FUND, V5, P533, DOI 10.1021/i160020a018
   VALENTAS KJ, 1966, IND ENG CHEM FUND, V5, P271, DOI 10.1021/i160018a019
   VOUTETAKIS S, 1992, THESIS ARISTOTLE U T
   ZWICK MM, 1965, J APPL POLYM SCI, V9, P2393, DOI 10.1002/app.1965.070090706
NR 33
TC 63
Z9 63
U1 0
U2 10
PU AMER INST CHEMICAL ENGINEERS
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017
SN 0001-1541
J9 AICHE J
JI AICHE J.
PD JUL
PY 1995
VL 41
IS 7
BP 1640
EP 1652
DI 10.1002/aic.690410705
PG 13
WC Engineering, Chemical
SC Engineering
GA RH246
UT WOS:A1995RH24600004
DA 2021-08-04
ER

PT J
AU FERGUSON, IA
AF FERGUSON, IA
TI ON THE ROLE OF BDI MODELING FOR INTEGRATED CONTROL AND COORDINATED
   BEHAVIOR IN AUTONOMOUS AGENTS
SO APPLIED ARTIFICIAL INTELLIGENCE
LA English
DT Article
ID INTELLIGENCE
AB This paper describes an architecture for controlling and coordinating autonomous agents, building on previous work addressing reactive and deliberative control methods. The proposed multilayered hybrid architecture allows a rationally bounded, goal-directed agent to reason predictively about potential conflicts by constructing knowledge level models that explain other agents' observed behaviors and hypothesize their beliefs, desires, and intentions; at the same time, it enables the agent to operate autonomously, to react promptly to changes in its real-time environment, and to coordinate its actions effectively with other agents. A principal aim of this research is to understand the role different functional capabilities play in constraining apt agent's behavior under varying environmental conditions. To this end, an experimental test bed has been constructed comprising a simulated multi-agent world in which a variety of agent configurations and behaviors have been investigated. A number of experimental findings are reported.
RP FERGUSON, IA (corresponding author), NATL RES COUNCIL CANADA,INST INFORMAT TECHNOL,INTERACT INFORMAT GRP,BLDG M-50,OTTAWA,ON K1A 0R6,CANADA.
CR Agre P., 1987, P AAAI 87 SEATTLE, P268
   BACLACE PE, 1992, COMMUN ACM, V35, P50, DOI 10.1145/138859.138865
   Bond AH., 1988, READINGS DISTRIBUTED
   Bratman M. E., 1988, Computational Intelligence, V4, P349, DOI 10.1111/j.1467-8640.1988.tb00284.x
   BROOKS RA, 1991, ARTIF INTELL, V47, P139, DOI 10.1016/0004-3702(91)90053-M
   CARBERRY S, 1990, PLAN RECOGNITION NAT
   CHANDRASEKARAN B, 1994, FAL AAAI S CONTR PHY, P19
   COHEN PR, 1989, AI MAG, V10, P32
   COHEN PR, 1991, AI MAG, V12, P16
   COVRIGARU AA, 1991, AI MAG, V12, P110
   Davis Ernest, 1990, REPRESENTATIONS COMM
   Davis R., 1988, EXPLORING ARTIFICIAL, P297
   DURFEE EH, 1990, JUL P NAT C ART INT, P86
   FERGUSON I, 1992, THESIS U CAMBRIDGE C
   FERGUSON IA, 1995, SPR AAAI S LESS LEAR
   FERGUSON IA, 1994, FALL AAAI S CONTR PH, P46
   FININ T, 1992, OVERVIEW KQML KNOWLE
   GALLIERS JR, 1990, DECENTRALIZED AI
   GEORGEFF MP, 1990, READINGS PLANNING, P5
   HANKS S, 1990, NOV P WORKSH INN APP, P59
   KINNY DN, 1991, 17 AUSTR ART INT I T
   KIRSH D, 1991, ARTIF INTELL, V47, P161, DOI 10.1016/0004-3702(91)90054-N
   Langley P., 1988, Machine Learning, V3, P5, DOI 10.1007/BF00115008
   Maes P., 1990, Robotics and Autonomous Systems, V6, P49, DOI 10.1016/S0921-8890(05)80028-4
   Maes Pattie, 1994, Artificial Life, V1, P135
   Miller Mark S., 1988, ECOLOGY COMPUTATION, P133
   Minsky ML., 1986, SOC MIND
   MULLER JP, 1994, 13TH INT WORKSH DIST
   POLLACK ME, 1990, PROCEEDINGS : EIGHTH NATIONAL CONFERENCE ON ARTIFICIAL INTELLIGENCE, VOLS 1 AND 2, P183
   POOLE D, 1988, 5TH P INT C GEN COMP, P1282
   POOLE DL, 1986, CS8606 U WAT RES REP
   SCHOPPERS MJ, 1987, 10TH P INT JOINT C A, P1039
   SHOHAM Y, 1993, ARTIF INTELL, V60, P51, DOI 10.1016/0004-3702(93)90034-9
   SHOHAM Y, 1990, READINGS PLANNING, P581
   Vere S., 1990, Computational Intelligence, V6, P41, DOI 10.1111/j.1467-8640.1990.tb00128.x
NR 35
TC 4
Z9 4
U1 0
U2 1
PU TAYLOR & FRANCIS
PI BRISTOL
PA 1900 FROST ROAD, SUITE 101, BRISTOL, PA 19007-1598
SN 0883-9514
J9 APPL ARTIF INTELL
JI Appl. Artif. Intell.
PD JUL-AUG
PY 1995
VL 9
IS 4
BP 421
EP 447
DI 10.1080/08839519508945483
PG 27
WC Computer Science, Artificial Intelligence; Engineering, Electrical &
   Electronic
SC Computer Science; Engineering
GA RQ374
UT WOS:A1995RQ37400004
DA 2021-08-04
ER

PT J
AU ZENG, JL
   LAURITA, KR
   ROSENBAUM, DS
   RUDY, Y
AF ZENG, JL
   LAURITA, KR
   ROSENBAUM, DS
   RUDY, Y
TI 2 COMPONENTS OF THE DELAYED RECTIFIER K+ CURRENT IN VENTRICULAR MYOCYTES
   OF THE GUINEA-PIG TYPE - THEORETICAL FORMULATION AND THEIR ROLE IN
   REPOLARIZATION
SO CIRCULATION RESEARCH
LA English
DT Article
DE K+ CURRENT; ACTION POTENTIAL DURATION; REPOLARIZATION; SIMULATION;
   OPTICAL MAPPING
ID ACTION-POTENTIAL DURATION; III ANTIARRHYTHMIC AGENT; HUMAN ATRIAL
   MYOCYTES; OUTWARD CURRENT; POTASSIUM CHANNEL; ELECTRICAL RESTITUTION;
   HUMAN-HEART; CELLS; MUSCLE; SINGLE
AB Two distinct delayed rectifier K+ currents, I-Kr and I-Ks, were found recently in ventricular cells. We formulated these currents theoretically and investigated their roles in action potential repolarization and the restitution of action potential duration (APD). The Luo-Rudy (L-R) model of the ventricular action potential was used in the simulations. The single delayed rectifier K+ current in the model was replaced by I-Kr and I-Ks. Our results show that I-Ks is the major outward current during the plateau repolarization. A specific block of either I-Kr or I-Ks can effectively prolong APD to the same degree. Therefore, either channel provides a target for class III antiarrhythmic drugs. In the simulated guinea pig ventricular cell, complete block of I-Kr does not result in early afterdepolarizations (EADs). In contrast, >80% block of I-Ks results in abnormal repolarization and EADs. This behavior reflects the high I-Ks-to-I-Kr density ratio (similar to 8:1) in this cell and can be reversed (ie, I-Kr block can cause EADs) by reducing the ratio of I-ks to I-Kr. The computed APD restitution curve is consistent with the experimental behavior, displaying fast APD variation at short diastolic intervals (DIs) and downward shift at longer DIs with the decrease of basic drive cycle length (BCL). Examining the ionic currents and their underlying kinetic processes, we found that activation of both I-Kr and I-Ks is the primary determinant of the APD restitution at shorter DIs, with Ca2+ current through L-type channels (I-Ca) playing a minor role. The rate of APD change depends on the relative densities of I-Kr and I-Ks; it increases when the I-Kr-to-I-Ks density ratio is large. The BCL-dependent shift of restitution at longer DIs is primarily attributed to long-lasting changes in [Ca2+](i), This in turn causes different degrees of Ca2+-dependent inactivation of I-Ca and different degrees of Ca2+-dependent conductance of I-Ks at very long DIs (>5 s) fur different BCLs. This BCL dependence of I-Ca and I-Ks that is secondary to long-lasting changes in [Ca2+](i) is responsible for APD changes at long DIs and can be viewed as a ''memory property'' of cardiac cells.
C1 CASE WESTERN RESERVE UNIV, DEPT BIOMED ENGN, CTR CARDIAC BIOELECT RES & TRAINING, CLEVELAND, OH 44106 USA.
FU NHLBI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [HL-49054] Funding Source: Medline; NATIONAL HEART,
   LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [R01HL049054] Funding Source: NIH RePORTER
CR BACKX PH, 1993, CIRC RES, V72, P890, DOI 10.1161/01.RES.72.4.890
   BALKE CW, 1992, J PHYSIOL-LONDON, V456, P247, DOI 10.1113/jphysiol.1992.sp019335
   BALSER JR, 1990, J GEN PHYSIOL, V96, P835, DOI 10.1085/jgp.96.4.835
   BASS BG, 1975, AM J PHYSIOL, V228, P1717
   BEELER GW, 1977, J PHYSIOL-LONDON, V268, P177, DOI 10.1113/jphysiol.1977.sp011853
   BJORNSTAD H, 1993, CARDIOVASC RES, V27, P946, DOI 10.1093/cvr/27.6.946
   BOYETT MR, 1978, J PHYSIOL-LONDON, V285, P359, DOI 10.1113/jphysiol.1978.sp012576
   CARMELIET E, 1992, J PHARMACOL EXP THER, V262, P809
   CARMELIET E, 1990, CARDIAC ELECTROPHYSI, P55
   CHINN K, 1993, J PHARMACOL EXP THER, V264, P553
   Courtney K R, 1992, Proc West Pharmacol Soc, V35, P177
   DROOGMANS G, 1989, J PHYSIOL-LONDON, V419, P627, DOI 10.1113/jphysiol.1989.sp017890
   FOLLMER CH, 1990, CIRCULATION, V82, P289, DOI 10.1161/01.CIR.82.1.289
   FRANZ MR, 1983, CIRC RES, V53, P815, DOI 10.1161/01.RES.53.6.815
   GILES WR, 1988, J PHYSIOL-LONDON, V405, P123, DOI 10.1113/jphysiol.1988.sp017325
   GWILT M, 1991, J CARDIOVASC PHARM, V17, P376, DOI 10.1097/00005344-199103000-00004
   HORIE M, 1990, JPN J PHYSIOL, V40, P479, DOI 10.2170/jjphysiol.40.479
   IINUMA H, 1979, CIRC RES, V44, P624, DOI 10.1161/01.RES.44.5.624
   JURKIEWICZ NK, 1993, CIRC RES, V72, P75, DOI 10.1161/01.RES.72.1.75
   KOBAYASHI Y, 1992, CIRCULATION, V86, P955, DOI 10.1161/01.CIR.86.3.955
   LODGE NJ, 1990, BIOPHYS J, V57, pA506
   LUO CH, 1991, CIRC RES, V68, P1501, DOI 10.1161/01.RES.68.6.1501
   LUO CH, 1994, CIRC RES, V74, P1097, DOI 10.1161/01.RES.74.6.1097
   LUO CH, 1994, CIRC RES, V74, P1071, DOI 10.1161/01.RES.74.6.1071
   MARTIN CL, 1992, J CARDIOVASC PHARM, V19, P830, DOI 10.1097/00005344-199205000-00022
   MATSUURA H, 1987, PFLUG ARCH EUR J PHY, V410, P596, DOI 10.1007/BF00581319
   MORGAN JM, 1992, J AM COLL CARDIOL, V19, P1244, DOI 10.1016/0735-1097(92)90331-G
   MORGAN JM, 1992, BRIT HEART J, V67, P42
   PAULMICHL M, 1991, P NATL ACAD SCI USA, V88, P7892, DOI 10.1073/pnas.88.17.7892
   ROBINSON RB, 1987, AM J PHYSIOL, V253, pH1018
   ROSENBAUM DS, 1994, SPIE, V2132, P347
   SAKMANN B, 1984, J PHYSIOL-LONDON, V347, P641, DOI 10.1113/jphysiol.1984.sp015088
   SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195
   SANGUINETTI MC, 1991, AM J PHYSIOL, V260, pH393
   SANGUINETTI MC, 1993, PFLUGERS ARCH, V420, P180
   SHIBASAKI T, 1987, J PHYSIOL-LONDON, V387, P227, DOI 10.1113/jphysiol.1987.sp016571
   Singh BN, 1994, ELECTROPHARMACOLOGIC
   SNYDERS DJ, 1993, J GEN PHYSIOL, V101, P513, DOI 10.1085/jgp.101.4.513
   TANDE PM, 1990, J CARDIOVASC PHARM, V16, P401, DOI 10.1097/00005344-199009000-00008
   TODT H, 1994, J CARDIOVASC PHARM, V24, P1010, DOI 10.1097/00005344-199424060-00022
   TOHSE N, 1990, AM J PHYSIOL, V258, pH1200
   TURGEON J, 1994, CIRC RES, V75, P879, DOI 10.1161/01.RES.75.5.879
   VELDKAMP MW, 1993, CIRC RES, V72, P865, DOI 10.1161/01.RES.72.4.865
   WALSH KB, 1991, AM J PHYSIOL, V260, pH1390
   WANG ZG, 1993, CIRC RES, V73, P1061, DOI 10.1161/01.RES.73.6.1061
   WANG ZG, 1993, CIRC RES, V73, P276, DOI 10.1161/01.RES.73.2.276
   WATANABE M, 1995, CIRC RES, V76, P915, DOI 10.1161/01.RES.76.5.915
   WONG W, 1992, AM J CARDIOL, V69, P206, DOI 10.1016/0002-9149(92)91306-O
   YANG T, 1994, CIRC RES, V75, P870, DOI 10.1161/01.RES.75.5.870
   YUE DT, 1988, PFLUG ARCH EUR J PHY, V413, P127, DOI 10.1007/BF00582522
   ZENG JL, 1995, BIOPHYS J, V68, P949, DOI 10.1016/S0006-3495(95)80271-7
NR 51
TC 326
Z9 333
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7330
EI 1524-4571
J9 CIRC RES
JI Circ.Res.
PD JUL
PY 1995
VL 77
IS 1
BP 140
EP 152
DI 10.1161/01.RES.77.1.140
PG 13
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
   Disease
SC Cardiovascular System & Cardiology; Hematology
GA RG256
UT WOS:A1995RG25600018
PM 7788872
DA 2021-08-04
ER

PT J
AU RECCHIA, F
   SICA, G
   DEFILIPPIS, S
   DISCEPOLI, S
   REA, S
   TORCHIO, P
   FRATI, L
AF RECCHIA, F
   SICA, G
   DEFILIPPIS, S
   DISCEPOLI, S
   REA, S
   TORCHIO, P
   FRATI, L
TI INTERFERON-BETA, RETINOIDS, AND TAMOXIFEN IN THE TREATMENT OF METASTATIC
   BREAST-CANCER - A PHASE-II STUDY
SO JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
LA English
DT Article
ID THERAPEUTIC ANTICANCER AGENTS; VITAMIN-A; 13-CIS-RETINOIC ACID; RECEPTOR
   EXPRESSION; ESTROGEN-RECEPTORS; MALIGNANT-LYMPHOMA; ALPHA-INTERFERON;
   MULTIPLE-MYELOMA; CELL CARCINOMA; TRIAL
AB Based on the additive or synergistic antiproliferative effect of interferon and tamoxifen on breast cancer cell lines and on preclinical and clinical data on retinoids alone and incombination with antiestrogen or interferon, we designed a pilot phase II study to test the toxicity of simultaneous administration of interferon-beta (IFN-beta), retinoids (R), and tamoxifen (TAM) and the efficacy of this combination as salvage therapy in a group of patients with metastatic breast cancer (MBC), A total of 49 stage IV breast cancer patients, 11 pretreated with hormones, 26 with chemotherapy, and 12 with both, received 30 mg TAM and two dose levels of IFN-beta and retinyl palmitate, Among 49 evaluable patients, 27 achieved a clinical response (55%; 95% CI 41-69%), 10 had stable disease (20%), and in 12 (25%) the disease progressed, Toxicity with both dose levels was moderate and mainly hepatic, Median response duration, not statistically different in estrogen receptor-positive and negative patients, was 31.4 months (range 4.9-67), Median overall survival was 19.2 months (range 2-69), We have shown that long-term administration of TAM, IFN-beta, and retinyl palmitate is feasible with moderate toxicity, We have also demonstrated that this regimen is active in pretreated MBC patients and that responses are not influenced by receptor status.
C1 CIVIL HOSP, DIV INTERNAL MED, ONCOL UNIT, AVEZZANO, ITALY.
   MONTEROTONDO CTR RIFERIMENTO ONCOL FRANCO ITALIA, ROME, ITALY.
   UNIV CATTOLICA SACRO CUORE, DEPT HISTOL & EMBRYOL, I-00168 ROME, ITALY.
   CIVIL HOSP, DEPT PATHOL, AVEZZANO, ITALY.
   SURG ONCOL UNIV, LAQUILA, ITALY.
   UNIV LAQUILA, CTR INTERDIPARTIMENTALE EPIDEMIOL, I-67100 LAQUILA, ITALY.
   UNIV ROMA LA SAPIENZA, ROME, ITALY.
RI REA, Silvio/A-8001-2016
OI REA, Silvio/0000-0002-1439-2768
CR ABE O, 1992, LANCET, V339, P71
   BARRERAS L, 1988, INVEST NEW DRUGS, V2, P211
   BENDICH A, 1989, AM J CLIN NUTR, V49, P358
   BORDEN EC, 1982, ANN INTERN MED, V97, P1, DOI 10.7326/0003-4819-97-1-1
   BUDZAR AU, 1990, SEMIN SURG ONCOL, V16, P77
   BUTLER WB, 1992, CANCER RES, V61, P64
   BUTTA A, 1992, CANCER RES, V52, P4261
   BUZZI F, 1992, ANTICANCER RES, V12, P869
   CASSIDY J, 1982, EUR J CANCER CLIN ON, V18, P925, DOI 10.1016/0277-5379(82)90239-5
   CLARKE CL, 1990, J BIOL CHEM, V265, P12694
   CLARKE R, 1989, P NATL ACAD SCI USA, V86, P3649, DOI 10.1073/pnas.86.10.3649
   COBLEIGH MA, 1993, J CLIN ONCOL, V11, P474, DOI 10.1200/JCO.1993.11.3.474
   COX DR, 1972, J R STAT SOC B, V34, P187
   DIMITROV NV, 1984, ANN CLIN LAB SCI, V14, P32
   Early Breast Cancer Trialists collaborative Group, 1992, LANCET, V339, P1
   EVANS RM, 1988, SCIENCE, V240, P879
   FREY JR, 1991, CANCER LETT, V57, P223, DOI 10.1016/0304-3835(91)90161-A
   GALE RP, 1993, LEUKEMIA, V7, P653
   GOLDSTEIN D, 1989, CANCER RES, V49, P2698
   GUTTERMAN JU, 1980, ANN INTERN MED, V93, P399, DOI 10.7326/0003-4819-93-3-399
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   KERR DJ, 1988, BRIT J CANCER, V75, P229
   KOGA M, 1991, J STEROID BIOCHEM, V39, P455, DOI 10.1016/0960-0760(91)90238-Z
   Lama G., 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P88
   LINDNER DJ, 1994, P AM SOC CANCER RES, V35, P268
   LIPPMAN SM, 1987, CANCER TREAT REP, V71, P391
   LIPPMAN SM, 1987, CANCER TREAT REP, V71, P493
   LIPPMAN SM, 1992, JNCI-J NATL CANCER I, V84, P241, DOI 10.1093/jnci/84.4.241
   LIPPMAN SM, 1993, EUROP J CANC A, V29, P9
   MARTIN JHJ, 1991, EUR J CANCER, V27, P143, DOI 10.1016/0277-5379(91)90473-Q
   MASOOD S, 1992, CANCER, V70, P2109, DOI 10.1002/1097-0142(19921015)70:8<2109::AID-CNCR2820700817>3.0.CO;2-C
   PASTORINO U, 1991, ONCOLOGY-BASEL, V48, P131
   PORZSOLT F, 1989, J CANCER RES CLIN, V115, P465, DOI 10.1007/BF00393339
   POUILLART P, 1982, EUR J CANCER CLIN ON, V18, P929, DOI 10.1016/0277-5379(82)90240-1
   QUESADA JR, 1986, BLOOD, V68, P493, DOI 10.1182/blood.V68.2.493.493
   QUESADA JR, 1984, AM J MED, V77, P427, DOI 10.1016/0002-9343(84)90097-4
   RATKO TA, 1989, CANCER RES, V49, P4472
   RECCHIA F, 1991, P AN M AM SOC CLIN, V10, P88
   SEYMOUR L, 1993, BRIT J CANCER, V68, P352, DOI 10.1038/bjc.1993.339
   SICA G, 1993, EUR J CANCER, V29A, P329, DOI 10.1016/0959-8049(93)90378-S
   SICA G, 1987, CANCER, V60, P2419, DOI 10.1002/1097-0142(19871115)60:10<2419::AID-CNCR2820601011>3.0.CO;2-S
   SONDIK E, 1989, ANN CANCER STATISTIC
   SPIELMANN M, 1994, J CLIN ONCOL, V12, P1764, DOI 10.1200/JCO.1994.12.9.1764
   SPORN MB, 1983, CANCER RES, V43, P3034
   SUNDERLAND MC, 1991, J CLIN ONCOL, V9, P1283, DOI 10.1200/JCO.1991.9.7.1283
   TRUMP DL, 1987, CANCER TREAT REP, V71, P165
   VANDENBERG HW, 1987, BRIT J CANCER, V55, P255, DOI 10.1038/bjc.1987.49
NR 47
TC 31
Z9 31
U1 1
U2 3
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538
SN 1079-9907
J9 J INTERF CYTOK RES
JI J. Interferon Cytokine Res.
PD JUL
PY 1995
VL 15
IS 7
BP 605
EP 610
DI 10.1089/jir.1995.15.605
PG 6
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA RL132
UT WOS:A1995RL13200003
PM 7553230
DA 2021-08-04
ER

EF